PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	MELHEM, RF; ZHU, XX; HAILAT, N; STRAHLER, JR; HANASH, SM				MELHEM, RF; ZHU, XX; HAILAT, N; STRAHLER, JR; HANASH, SM			CHARACTERIZATION OF THE GENE FOR A PROLIFERATION-RELATED PHOSPHOPROTEIN (ONCOPROTEIN-18) EXPRESSED IN HIGH AMOUNTS IN ACUTE-LEUKEMIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURON-ENRICHED PHOSPHOPROTEIN; TRANSCRIPTION FACTOR; C-MYC; DNA; IDENTIFICATION; STATHMIN; PROMOTER; INTRON; RNA; PHOSPHORYLATION	The oncoprotein 18 (Op18) gene encodes a proliferation-related cytosolic phosphoprotein, which is induced in normal lymphocytes following mitogenic stimulation. Studies of the Op18 gene are of particular interest because of the proposed role of Op18 protein in signal transduction and because of its occurrence in markedly increased amounts in acute leukemia cells. We have recently reported the cloning and sequencing of two cDNA clones for Op18 (1 and 1.5 kilobases). Both clones code for the same 149-amino acid polypeptide; however, they differ in their 3'-region as a result of alternative polyadenylation. We report here the sequencing of the Op18 gene and describe its expression in leukemia. The Op18 gene, which is 6.3 kilobases in length, is comprised of five exons and four introns and exhibits features that are common to other genes involved in cellular growth and proliferation. The increase in Op18 polypeptide in leukemia is associated with increased RNA transcription without gene amplification or rearrangement. Treatment of K562 leukemia cell line with hemin that induces terminal differentiation resulted in decreased expression of Op18. Our findings suggest that the high amount of Op18 protein in acute leukemia results from increased expression of a structurally unaltered gene.	UNIV MICHIGAN,SCH MED,ANN ARBOR,MI 48104	University of Michigan System; University of Michigan				Zhu, Charles/0000-0003-2922-0042	NATIONAL CANCER INSTITUTE [R01CA032146, P01CA026803] Funding Source: NIH RePORTER; NCI NIH HHS [CA32146, CA26803] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Battey, 1986, BASIC METHODS MOL BI; BERETTA L, 1989, J BIOL CHEM, V264, P9932; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BISHOP JM, 1987, SCIENCE, V235, P305, DOI 10.1126/science.3541204; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER HL, 1990, J IMMUNOL, V145, P1205; COULOMBE B, 1988, MOL CELL BIOL, V8, P3227, DOI 10.1128/MCB.8.8.3227; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOYE V, 1989, J BIOL CHEM, V264, P12134; DYNAN WS, 1986, TRENDS GENET, V2, P196, DOI 10.1016/0168-9525(86)90226-X; EVANS MJ, 1989, J BIOL CHEM, V264, P14361; FEURSTEIN N, 1983, J BIOL CHEM, V258, P10786; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HAILAT N, 1990, ONCOGENE, V5, P1615; HANASH SM, 1988, J BIOL CHEM, V263, P12813; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; JASKULSKI D, 1988, SCIENCE, V240, P1544, DOI 10.1126/science.2897717; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KEIM D, 1990, BLOOD, V76, P985; LAWN RM, 1978, CELL, V15, P1157, DOI 10.1016/0092-8674(78)90043-0; LINIAL M, 1985, SCIENCE, V230, P1126, DOI 10.1126/science.2999973; MANIATIS T, 1985, MOL CLONING; MUDRYJ M, 1990, EMBO J, V9, P2179, DOI 10.1002/j.1460-2075.1990.tb07387.x; NEPVEU A, 1986, EMBO J, V5, P2859, DOI 10.1002/j.1460-2075.1986.tb04580.x; NEVINS JR, 1987, METHOD ENZYMOL, V152, P234; PASMANTIER R, 1986, ENDOCRINOLOGY, V7119, P1229; ROSSI P, 1987, P NATL ACAD SCI USA, V84, P5590, DOI 10.1073/pnas.84.16.5590; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SOBEL A, 1989, J BIOL CHEM, V264, P3765; STRAHLER JR, 1989, PROTEIN STRUCTURE PR, P65; WILLIAMS T, 1988, GENE DEV, V2, P1557, DOI 10.1101/gad.2.12a.1557; ZHU XX, 1989, J BIOL CHEM, V264, P14556	38	107	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17747	17753						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917919				2022-12-25	WOS:A1991GG55300008
J	HUANG, Y; FRIEDMAN, S				HUANG, Y; FRIEDMAN, S			INHIBITION OF RECA-MEDIATED STRAND EXCHANGE BY ADDUCTS OF AZACYTOSINE-CONTAINING DNA AND THE ECORII METHYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K-12; PLECTONEMIC JOINTS; 5-AZACYTIDINE; HYDROLYSIS; SURVIVAL; SEQUENCE; PROTEIN	Wild type Escherichia coli cells containing elevated levels of DNA (cytosine-5) methyltransferases have increased sensitivity to the toxic effects of 5-azacytidine. The methyltransferases form tight binding complexes with azacytosine in DNA which could interfere with the recA recBCD repair pathway which is largely responsible for cell survival after treatment with the drug. We therefore determined if these complexes interfered with recA-mediated strand exchange in vitro. P-32-Labeled DNA fragments containing a single EcoRII site, with cytosine in the (-) strand replaced by 5-azacytosine, were prepared. We investigated the effect of the EcoRII methyltransferase on recA-mediated strand exchange with homologous M13 DNA by electrophoresis in agarose gels. In the absence of the methylase the rate and extent of strand exchange of azacytosine-containing DNA is the same as control DNA. In the presence of the methyltransferase strand exchange is inhibited, but some incorporation of duplexes into recA-single-stranded DNA (ssDNA) complexes still occurs. The formation of these complexes is dependent on the length of the fragment 3' to the methylase binding site on the strand complementary to the ssDNA. The greater the length the greater the number of complexes that form. S-Adenosyl-L-methionine, which enhances binding of the methyltransferase to azacytosine-containing DNA, causes an increase in the inhibition of strand exchange and an increase in the number of inactive complexes formed. The complexes can be dissociated with guanidinium chloride which denatures the methyltransferase and leads to release of the (+) strand. The (-) strand remains associated with the ssDNA. This result implies that a plectonemic joint is formed between recA-ssDNA complexes and azacytosine-containing DNA-methyltransferase complexes. However, branch migration in these complexes is inhibited. Denaturation of the methyltransferase allows branch migration to proceed to completion, releasing the (+) strand.	SUNY HLTH SCI CTR,DEPT PHARMACOL,BOX 29,450 CLARKSON AVE,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center					PHS HHS [27787] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARBE J, 1986, MUTAT RES, V166, P9, DOI 10.1016/0167-8817(86)90035-0; BEISLER JA, 1978, J MED CHEM, V21, P204, DOI 10.1021/jm00200a012; BHAGWAT AS, 1987, J BACTERIOL, V169, P1537, DOI 10.1128/jb.169.4.1537-1546.1987; BOUCHARD J, 1983, MOL PHARMACOL, V24, P109; COX MM, 1983, J BIOL CHEM, V258, P2577; FRIEDMAN S, 1982, J BACTERIOL, V151, P262, DOI 10.1128/JB.151.1.262-268.1982; FRIEDMAN S, 1985, J BIOL CHEM, V260, P5689; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; LAL D, 1988, MUTAT RES, V193, P229, DOI 10.1016/0167-8817(88)90033-8; Maniatis T., 1982, MOL CLONING; MCINTOSH LP, 1985, BIOCHEMISTRY-US, V24, P4806, DOI 10.1021/bi00339a014; MOMPARLER RL, 1985, PHARMACOL THERAPEUT, V30, P287, DOI 10.1016/0163-7258(85)90053-1; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; RIDDLES PW, 1985, J BIOL CHEM, V260, P170; RIDDLES PW, 1985, J BIOL CHEM, V260, P165; SANTI DV, 1984, P NATL ACAD SCI-BIOL, V81, P6993, DOI 10.1073/pnas.81.22.6993; SOM S, 1987, NUCLEIC ACIDS RES, V15, P313, DOI 10.1093/nar/15.1.313; TOWNSEND AJ, 1987, MOL PHARMACOL, V32, P330; VESELY J, 1985, PHARMACOL THERAPEUT, V28, P227, DOI 10.1016/0163-7258(85)90012-9; WEST SC, 1981, NATURE, V290, P29, DOI 10.1038/290029a0	20	10	10	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17424	17429						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894630				2022-12-25	WOS:A1991GF44500068
J	BUCKLEY, BJ; KENT, RS; WHORTON, AR				BUCKLEY, BJ; KENT, RS; WHORTON, AR			REGULATION OF ENDOTHELIAL-CELL PROSTAGLANDIN SYNTHESIS BY GLUTATHIONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; HYDROGEN-PEROXIDE; H SYNTHASE; ALVEOLAR MACROPHAGE; VESICULAR GLAND; OXYGEN RADICALS; REDOX CYCLE; BIOSYNTHESIS; PROSTACYCLIN; MECHANISM	Prostaglandin synthesis in in vitro systems is dependent on glutathione and peroxide concentrations. We tested the effects of glutathione depletion and H2O2 exposure on prostaglandin synthesis in cultured porcine aortic endothelial cells. Depletion of glutathione using buthionine sulfoximine (BSO), diethylmaleate, and 2,4-chlorodinitrobenzene increased prostaglandin synthetic capacity. Production of prostacyclin, but not prostaglandin E2, from exogenous arachidonic acid was significantly greater than in controls. Glutathione depletion also resulted in enhanced production of prostacyclin from exogenous prostaglandin H-2. These responses were not due to direct effects of glutathione-depleting agents on prostaglandin synthetic enzymes. Exposure to H2O2 also altered prostaglandin synthetic capacity in endothelial cells. While 5-mu-M H2O2 Stimulated prostaglandin production from exogenous arachidonate, 25 and 50-mu-M were found to be inhibitory. Prostaglandin synthetic capacity was greater in BSO-treated cells which were exposed to 5 and 10-mu-M H202 than in cells exposed to H202 alone. However, prostaglandin synthetic capacity was greatly reduced in BSO-treated cells exposed to 50-mu-M H202. Thus, normal levels of cellular glutathione exert an inhibitory influence on prostaglandin synthesis. However, glutathione depletion increases the sensitivity of prostaglandin synthesis to inhibition by 50-mu-M H202.	DUKE UNIV,MED CTR,DEPT MED,DURHAM,NC 27710	Duke University	BUCKLEY, BJ (corresponding author), DUKE UNIV,MED CTR,DEPT PHARMACOL,DIV PULM MED,BOX 3177,DURHAM,NC 27710, USA.				NHLBI NIH HHS [P01HL42444] Funding Source: Medline; NIA NIH HHS [AG02868] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG002868] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADLER S, 1987, AM J PHYSIOL, V252, pF743, DOI 10.1152/ajprenal.1987.252.4.F743; BARCHOWSKY A, 1987, BIOCHIM BIOPHYS ACTA, V927, P372, DOI 10.1016/0167-4889(87)90102-9; BEERS KW, 1988, FASEB J, V2, pA742; Bergmeyer H. U., 1978, METHOD ENZYMAT AN, P574; BOTTJE WG, 1986, BIOCHEM PHARMACOL, V35, P1629, DOI 10.1016/0006-2952(86)90315-1; Bruning J. L., 1977, COMPUTATIONAL HDB ST; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; COOK HW, 1976, NATURE, V260, P630, DOI 10.1038/260630a0; COSTA LG, 1986, BIOCHEM PHARMACOL, V35, P3383, DOI 10.1016/0006-2952(86)90439-9; EGAN RW, 1976, J BIOL CHEM, V251, P7329; ELING TE, 1986, J BIOL CHEM, V261, P5023; FANTONE JC, 1983, BIOCHEM BIOPH RES CO, V113, P506, DOI 10.1016/0006-291X(83)91754-0; FLOHE L, 1979, CIBA F S, V65, P95; GERRITSEN ME, 1981, CIRC RES, V49, P1152, DOI 10.1161/01.RES.49.5.1152; GREEN K, 1978, ADV PROSTAGLANDIN TH, V5, P45; GRIFFITH OW, 1982, J BIOL CHEM, V257, P13704; GRUNDFEST CC, 1982, BIOCHIM BIOPHYS ACTA, V713, P149, DOI 10.1016/0005-2760(82)90177-1; GUIDI G, 1984, J LAB CLIN MED, V104, P574; HAJJAR DP, 1982, J CLIN INVEST, V70, P479, DOI 10.1172/JCI110639; HAM EA, 1979, J BIOL CHEM, V254, P2191; HARLAN JM, 1984, J CLIN INVEST, V74, P442, DOI 10.1172/JCI111440; HEMLER ME, 1979, ARCH BIOCHEM BIOPHYS, V193, P340, DOI 10.1016/0003-9861(79)90038-9; HEMLER ME, 1980, J BIOL CHEM, V255, P6253; Inoue M, 1987, Adv Prostaglandin Thromboxane Leukot Res, V17A, P29; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KAWAGUCHI H, 1982, LIPIDS, V17, P577, DOI 10.1007/BF02535362; KENT RS, 1983, J CLIN INVEST, V72, P455, DOI 10.1172/JCI110993; KULMACZ RJ, 1986, ARCH BIOCHEM BIOPHYS, V249, P273, DOI 10.1016/0003-9861(86)90003-2; Lands WE, 1984, FREE RADICAL BIO MED, P39; LITTLE C, 1970, J BIOL CHEM, V245, P3632; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADDEN MC, 1987, PROSTAGLANDINS, V34, P445, DOI 10.1016/0090-6980(87)90089-X; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARSHALL PJ, 1987, J BIOL CHEM, V262, P3510; MARSHALL PJ, 1986, J LAB CLIN MED, V108, P525; MCNAMARA DB, 1984, PROSTAGLANDINS LEUKO, P57; MIZUNOYAGYU Y, 1987, BIOCHEM PHARMACOL, V36, P3809; MONCADA S, 1982, ARTERIOSCLEROSIS, V2, P192; OGINO N, 1977, J BIOL CHEM, V252, P890; PAGANAMALA RV, 1986, PROSTAGLANDINS LEUKO, V22, P349; PETERSGOLDEN M, 1987, J BIOL CHEM, V262, P10594; PETERSGOLDEN M, 1989, AM REV RESPIR DIS, V140, P1210, DOI 10.1164/ajrccm/140.5.1210; ROUZER CA, 1982, P NATL ACAD SCI-BIOL, V79, P1621, DOI 10.1073/pnas.79.5.1621; SALMON JA, 1982, METHOD ENZYMOL, V86, P91; SEEGER W, 1986, AM REV RESPIR DIS, V133, P1029; SETTY BNY, 1984, PROSTA LEUKOTR MED, V14, P205; SMITH WL, 1972, BIOCHEMISTRY-US, V11, P3276, DOI 10.1021/bi00767a024; SPORN PHS, 1988, AM REV RESPIR DIS, V137, P49, DOI 10.1164/ajrccm/137.1.49; SUTTORP N, 1986, AM J PHYSIOL, V251, pC671, DOI 10.1152/ajpcell.1986.251.5.C671; TAYLOR L, 1983, J BIOL CHEM, V258, P6855; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WHORTON AR, 1982, BIOCHIM BIOPHYS ACTA, V712, P79, DOI 10.1016/0005-2760(82)90087-X; WHORTON AR, 1985, J CLIN INVEST, V76, P295, DOI 10.1172/JCI111960	53	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16659	16666						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885596				2022-12-25	WOS:A1991GD63500068
J	GENNITY, JM; INOUYE, M				GENNITY, JM; INOUYE, M			THE PROTEIN-SEQUENCE RESPONSIBLE FOR LIPOPROTEIN MEMBRANE LOCALIZATION IN ESCHERICHIA-COLI EXHIBITS REMARKABLE SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE; KLEBSIELLA-PNEUMONIAE; SALMONELLA-TYPHIMURIUM; CYTOPLASMIC MEMBRANE; GENE; PULLULANASE; EXPORT; TRANSLOCATION; EXPRESSION; MECHANISM	Structural information defining an N-terminal sequence required for the membrane sorting of bacterial lipoproteins has been previously garnered through the study of a hybrid outer membrane (OM) lipo-beta-lactamase (LL) (Ghrayeb and Inouye (1984) J. Biol. Chem. 259, 463-467). Introduction of an aspartate as the second residue of mature LL (D2 mutant) causes an inner membrane (IM) localization of this protein (Yamaguchi, K., Yu, F., and Inouye, M. (1988) Cell 53, 423-432). Introduction of as aspartate at the third residue of mature LL (D3) causes a weaker IM sorting signal and when present as the fourth residue (D4), normal OM sorting occurs. A positively charged residue at the second position (K2) has no effect on OM localization. Remarkably, glutamate substitution at either the second (E2) or third (E3) position does not interfere with OM sorting. Sorting of the mutant D2 LL can be partially suppressed by introduction of a positively charged histidine (D2H3) or lysine (D2K3) at residue 3 of the mature protein. These results indicate that both the negative charge of the aspartate residue and some structural feature not present in a glutamate residue are required for sorting to the IM. The suppression of IM localization of the D2H3 LL double mutant can be eliminated by growing Escherichia coli at pH 8.4 to reduce the histidine partial positive charge. This result supports the essentiality of a negative charge in IM localization and indicates that the committed step in lipoprotein sorting is made in a cellular compartment, the periplasm, at equilibrium with the external pH.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM019043, R01GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED S, 1983, J GEN MICROBIOL, V129, P2521; AITKEN JF, 1990, J BIOL CHEM, V265, P4711; ANDERSON BE, 1987, J BACTERIOL, V169, P2385, DOI 10.1128/jb.169.6.2385-2390.1987; Bayer M.E., 1979, BACTERIAL OUTER MEMB, P167; BENSON SA, 1984, P NATL ACAD SCI-BIOL, V81, P3830, DOI 10.1073/pnas.81.12.3830; BERGSTROM S, 1989, MOL MICROBIOL, V3, P479, DOI 10.1111/j.1365-2958.1989.tb00194.x; BOSCH D, 1986, J MOL BIOL, V189, P449, DOI 10.1016/0022-2836(86)90316-5; BOULAIN JC, 1986, MOL GEN GENET, V205, P339, DOI 10.1007/BF00430448; BRAUN V, 1969, EUR J BIOCHEM, V10, P426, DOI 10.1111/j.1432-1033.1969.tb00707.x; DENFERT C, 1987, MOL MICROBIOL, V1, P107, DOI 10.1111/j.1365-2958.1987.tb00534.x; DENFERT C, 1987, EMBO J, V6, P3531, DOI 10.1002/j.1460-2075.1987.tb02679.x; DENFERT C, 1989, J BACTERIOL, V171, P3673, DOI 10.1128/jb.171.7.3673-3679.1989; DUCHENE M, 1989, J BACTERIOL, V171, P4130; FANDL J, 1990, J BIOENERG BIOMEMBR, V22, P369, DOI 10.1007/BF00763173; FREUDL R, 1990, J BIOENERG BIOMEMBR, V22, P441, DOI 10.1007/BF00763176; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GHRAYEB J, 1984, J BIOL CHEM, V259, P463; HAYASHI S, 1990, J BIOENERG BIOMEMBR, V22, P451, DOI 10.1007/BF00763177; HELMKAMP GM, 1986, J BIOENERG BIOMEMBR, V18, P71, DOI 10.1007/BF00743477; HUANG JZ, 1990, J BIOL CHEM, V265, P11628; ICHIHARA S, 1981, J BIOL CHEM, V256, P3125; JANNATIPOUR M, 1987, J BACTERIOL, V169, P3785, DOI 10.1128/jb.169.8.3785-3791.1987; JONES NC, 1977, J BIOL CHEM, V252, P7405; JUNG JU, 1989, J BACTERIOL, V171, P511, DOI 10.1128/jb.171.1.511-520.1989; KASHKET ER, 1982, BIOCHEMISTRY-US, V21, P5534, DOI 10.1021/bi00265a024; KLOSE M, 1988, J BIOL CHEM, V263, P13291; KLOSE M, 1988, J BIOL CHEM, V263, P13297; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUIRINK J, 1989, THESIS VRIJE U AMSTE; Miller J.H., 1972, EXPT MOL GENETICS; NIKAIDO H, 1984, P NATL ACAD SCI-BIOL, V81, P1048, DOI 10.1073/pnas.81.4.1048; OSBORN MJ, 1972, J BIOL CHEM, V247, P3962; OUDEGA B, 1984, FEMS MICROBIOL LETT, V22, P101; PERUMAL NB, 1984, J BIOL CHEM, V259, P5357; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; PUGSLEY AP, 1990, MOL MICROBIOL, V4, P59, DOI 10.1111/j.1365-2958.1990.tb02015.x; PUGSLEY AP, 1988, MOL GEN GENET, V211, P335, DOI 10.1007/BF00330613; SAARILAHTI HT, 1990, FEMS MICROBIOL LETT, V69, P49, DOI 10.1016/0378-1097(90)90411-I; SARVAS MO, 1983, J BACTERIOL, V155, P657, DOI 10.1128/JB.155.2.657-663.1983; SCHNAITM.CA, 1970, J BACTERIOL, V104, P890, DOI 10.1128/JB.104.2.890-901.1970; WEYER KA, 1987, BIOCHEMISTRY-US, V26, P2909, DOI 10.1021/bi00384a036; YAMAGUCHI K, 1988, CELL, V53, P423, DOI 10.1016/0092-8674(88)90162-6; YU F, 1984, J BIOL CHEM, V259, P6013; YU F, 1986, J BIOL CHEM, V261, P2284	44	84	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16458	16464						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885579				2022-12-25	WOS:A1991GD63500038
J	WILKISON, WO; CHOY, L; SPIEGELMAN, BM				WILKISON, WO; CHOY, L; SPIEGELMAN, BM			BIOSYNTHETIC REGULATION OF MONOBUTYRIN, AN ADIPOCYTE-SECRETED LIPID WITH ANGIOGENIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIHYDROXYACETONE-PHOSPHATE; TRIACYLGLYCEROL SYNTHESIS; ADIPOSE CONVERSION; GLYCEROL KINASE; 3T3 ADIPOCYTES; CELLS; DIFFERENTIATION; ENZYMES; STIMULATION; SN-GLYCEROL-3-PHOSPHATE	1-Butyrylglycerol (monobutyrin) is a novel angiogenic compound that is synthesized and secreted during the differentiation of 3T3-F442A preadipocytes into adipocytes. To study the regulation of monobutyrin biosynthesis we have developed an assay utilizing the glycerol kinase enzyme from Cellulomonas to quantitate the levels of this compound in cell-conditioned medium. Analysis of several cultured cell types, including tumor cell lines, indicated that monobutyrin production is detectable only from adipocytes, reaching a steady-state concentration of approximately 1.0-mu-M in conditioned medium. Monobutyrin synthesis was demonstrated in vitro using [C-14]butyryl-CoA with total homogenate or particulate fractions from adipocytes. Similar fractions from non-adipocyte cell lines failed to synthesize monobutyrin. This biosynthetic activity was shown to be distinct by substrate competition studies from the microsomal sn-glycerol-3-phosphate acyltransferase, whose activity is known to increase during adipocyte differentiation. The production of monobutyrin was hormonally regulated, as the addition of epinephrine to adipocytes caused a 10-fold increase in the amount of monobutyrin secreted. These results indicate that monobutyrin synthesis is adipocyte specific, occurs through an apparently novel particulate enzyme system, and is regulated in a hormone-dependent manner. The implications of these results for adipose physiology and angiogenesis are discussed.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT BIOL CHEM & MOLEC PHARMACOL,44 BINNEY ST,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008277, R01DK042420] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK08277, DK42420] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AICHE M, 1982, J NATL CANCER I, V69, P475; ANDERSSON P, 1979, CELL, V16, P63, DOI 10.1016/0092-8674(79)90188-0; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BIRRER MJ, 1988, MOL CELL BIOL, V8, P2668, DOI 10.1128/MCB.8.6.2668; BRADLEY DC, 1989, ANAL BIOCHEM, V180, P11, DOI 10.1016/0003-2697(89)90081-X; CASTELLOT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P5597, DOI 10.1073/pnas.79.18.5597; CASTELLOT JJ, 1986, J CELL PHYSIOL, V127, P323, DOI 10.1002/jcp.1041270221; CASTELLOT JJ, 1980, P NATL ACAD SCI-BIOL, V77, P6007, DOI 10.1073/pnas.77.10.6007; CHANG YY, 1967, J LIPID RES, V8, P447; CHERNICK SS, 1986, J LIPID RES, V27, P286; COLEMAN RA, 1980, J BIOL CHEM, V255, P7681; COLLINS SJ, 1977, NATURE, V270, P3447; CONSTANTINIDES PP, 1985, J BIOL CHEM, V260, P7573; CRANDALL DL, 1990, FASEB J, V4, P141, DOI 10.1096/fasebj.4.2.2404816; CRANS DC, 1985, J AM CHEM SOC, V107, P7008, DOI 10.1021/ja00310a044; CRANS DC, 1985, J AM CHEM SOC, V107, P7019, DOI 10.1021/ja00310a045; DOBSON DE, 1990, CELL, V61, P223, DOI 10.1016/0092-8674(90)90803-M; DUNHAM LJ, 1953, JNCI-J NATL CANCER I, V13, P1299; EFRAT S, 1988, P NATL ACAD SCI USA, V85, P9037, DOI 10.1073/pnas.85.23.9037; FORM DM, 1983, P SOC EXP BIOL MED, V172, P214; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GRIMALDI P, 1978, EUR J BIOCHEM, V84, P369, DOI 10.1111/j.1432-1033.1978.tb12177.x; HOFFMAN BB, 1987, HORM METAB RES, V19, P358, DOI 10.1055/s-2007-1011823; HOPKINS NK, 1981, BIOCHIM BIOPHYS ACTA, V663, P457, DOI 10.1016/0005-2760(81)90174-0; KURIHARCUCH W, 1977, J BIOL CHEM, V252, P2158; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; MOSCATELLI D, 1986, P NATL ACAD SCI USA, V83, P2091, DOI 10.1073/pnas.83.7.2091; NEILSEN SL, 1968, SCAND J CLIN LAB INV, V22, P124; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; ROSELL S, 1979, PHYSIOL REV, V59, P1078, DOI 10.1152/physrev.1979.59.4.1078; SCHLOSSMAN DM, 1976, J BIOL CHEM, V251, P5738; SENGER DR, 1990, CANCER RES, V50, P1774; SIPPOLATHIELE M, 1989, MOL CELL BIOL, V9, P925, DOI 10.1128/MCB.9.3.925; STERN I, 1953, J CLIN PATHOL, V6, P158, DOI 10.1136/jcp.6.2.158; WASSERMANN F, 1965, HDB PHYSL 5, P87; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0	39	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16886	16891						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885616				2022-12-25	WOS:A1991GD63500101
J	CASEY, JR; REITHMEIER, RAF				CASEY, JR; REITHMEIER, RAF			ANALYSIS OF THE OLIGOMERIC STATE OF BAND-3, THE ANION TRANSPORT PROTEIN OF THE HUMAN ERYTHROCYTE-MEMBRANE, BY SIZE EXCLUSION HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY - OLIGOMERIC STABILITY AND ORIGIN OF HETEROGENEITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-CELL MEMBRANE; INTACT HUMAN-ERYTHROCYTES; NON-IONIC DETERGENTS; EXCHANGE PROTEIN; COVALENT DIMERS; MAJOR PROTEINS; BINDING-SITES; CROSS-LINKING; SPIN-LABEL; ASSOCIATION	The oligomeric state of human Band 3 (M(r) = 95,000), the erythrocyte membrane anion exchanger, was examined by size exclusion high performance liquid chromatography in solutions containing the nonionic detergent C12E8 (octaethylene glycol n-dodecyl monoether). Band 3 was heterogeneous with respect to oligomeric composition, the predominant (70%) species being a dimer that bound 0.57 Mg Of C12E8/mg of protein (Stokes radius = 78 angstrom, s20,w = 6.9 S). Variable amounts of larger oligomers were also present; however, no evidence for equilibration between oligomeric species was observed in detergent solution. Analytical and large zone size exclusion chromatography showed that Band 3 could not be dissociated to monomers, other than by protein denaturation. The membrane domain of Band 3 (M(r) = 52,000) was also dimeric, but without evidence for higher oligomeric forms, which implies that the interactions responsible for higher associations involve the cytoplasmic domain. Prelabeling of Band 3 with the anion exchange inhibitor 4,4'-diisothiocyanostilbene-2,2'-disulfonate had no effect upon the oligomeric state of either intact Band 3 or its 52-kDa membrane domain. Band 3 oligomeric state could be reversibly changed in the membrane by altering the pH of the solution. The fraction of Band 3 not associated with the cytoskeleton was almost entirely dimeric. Band 3 purified from erythrocytes separated by density gradient centrifugation revealed that older red cells contained a larger proportion of higher oligomers than did younger cells. We conclude that Band 3, in the membrane and in C12E8 solution, exists as a mixture of dimers and larger oligomers. The higher oligomers interact with the cytoskeleton, increase in amount with cell age, and are held together by interactions of the cytoplasmic domain.	UNIV TORONTO, DEPT MED,MRC,MEMBRANE BIOL GRP,RM 7307, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO M5S 1A8, ONTARIO, CANADA	University of Toronto; University of Toronto			Casey, Joseph/A-8888-2013	Casey, Joseph/0000-0002-9890-5056				ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ANDERSEN JP, 1986, BIOCHEMISTRY-US, V25, P6439, DOI 10.1021/bi00369a015; BENNETT GD, 1981, EXP HEMATOL, V9, P297; BENNETT V, 1982, BIOCHIM BIOPHYS ACTA, V689, P475, DOI 10.1016/0005-2736(82)90305-4; BEPPU M, 1990, J BIOL CHEM, V265, P3226; BETH AH, 1986, BIOCHEMISTRY-US, V25, P3824, DOI 10.1021/bi00361a013; BITTMAN R, 1984, BIOCHIM BIOPHYS ACTA, V769, P85, DOI 10.1016/0005-2736(84)90012-9; BOODHOO A, 1984, J BIOL CHEM, V259, P785; BOSMAN GJCGM, 1990, BIOCHEM CELL BIOL, V68, P1419, DOI 10.1139/o90-205; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABANTCHIK ZI, 1974, J MEMBRANE BIOL, V15, P207, DOI 10.1007/BF01870088; CASEY JR, 1989, METHOD ENZYMOL, V173, P494; CHANG HW, 1980, ANAL BIOCHEM, V104, P112, DOI 10.1016/0003-2697(80)90283-3; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; CLARKE S, 1975, J BIOL CHEM, V250, P5459; COX JV, 1988, MOL CELL BIOL, V8, P1327, DOI 10.1128/MCB.8.3.1327; CUPPOLETTI J, 1985, J BIOL CHEM, V260, P5714; DEISENHOFER J, 1985, NATURE, V318, P618, DOI 10.1038/318618a0; DEMPSEY CE, 1986, BIOCHEMISTRY-US, V25, P2180, DOI 10.1021/bi00356a049; DIXON HBF, 1968, BIOCHEM J, V109, P312, DOI 10.1042/bj1090312; FREITAG C, 1981, J BIOL CHEM, V256, P6102; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; GRINSTEIN S, 1978, BIOCHIM BIOPHYS ACTA, V507, P294, DOI 10.1016/0005-2736(78)90424-8; GUNN RB, 1975, J GEN PHYSIOL, V65, P731, DOI 10.1085/jgp.65.6.731; HELINIUS A, 1979, METHOD ENZYMOL, V56, P734; JAY D, 1986, ANNU REV BIOCHEM, V55, P511, DOI 10.1146/annurev.bi.55.070186.002455; JENNINGS ML, 1989, ANNU REV BIOPHYS BIO, V18, P397, DOI 10.1146/annurev.bb.18.060189.002145; JENNINGS ML, 1979, BIOCHIM BIOPHYS ACTA, V554, P498, DOI 10.1016/0005-2736(79)90387-0; JENNINGS ML, 1984, J MEMBRANE BIOL, V80, P105, DOI 10.1007/BF01868768; KAY MMB, 1984, P NATL ACAD SCI-BIOL, V81, P5753, DOI 10.1073/pnas.81.18.5753; KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; LIEBERMAN DM, 1983, BIOCHEMISTRY-US, V22, P4028, DOI 10.1021/bi00286a006; LOW PS, 1986, BIOCHIM BIOPHYS ACTA, V864, P145, DOI 10.1016/0304-4157(86)90009-2; LOW PS, 1985, SCIENCE, V227, P531, DOI 10.1126/science.2578228; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUCAKOVIC MF, 1981, BIOCHEMISTRY-US, V20, P3145; LUTZ HU, 1983, BIOMED BIOCHIM ACTA, V42, P117; LUTZ HU, 1987, BIOMED BIOCHIM ACTA, V46, P65; MACARA IG, 1983, CELL MEMBR METH REV, V1, P41; MACARA IG, 1981, BIOCHEMISTRY-US, V20, P5095, DOI 10.1021/bi00521a001; MUHELEBACH T, 1985, BIOCHEMISTRY-US, V24, P975; MULZER K, 1990, COLLOID POLYM SCI, V268, P60, DOI 10.1007/BF01410424; NAKASHIMA H, 1980, J BIOCHEM-TOKYO, V88, P933, DOI 10.1093/oxfordjournals.jbchem.a133081; NAKASHIMA H, 1980, J BIOCHEM, V87, P899, DOI 10.1093/oxfordjournals.jbchem.a132820; NIGG EA, 1980, P NATL ACAD SCI-BIOL, V77, P4702, DOI 10.1073/pnas.77.8.4702; OIKAWA K, 1985, BIOCHEMISTRY-US, V24, P2843, DOI 10.1021/bi00333a005; PAPPERT G, 1983, BIOCHIM BIOPHYS ACTA, V730, P32, DOI 10.1016/0005-2736(83)90313-9; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; RAMJEESINGH M, 1980, BIOCHIM BIOPHYS ACTA, V599, P127, DOI 10.1016/0005-2736(80)90062-0; Reithmeier R.A.F., 1989, ANION TRANSPORT PROT, P213; REITHMEIER RAF, 1979, J BIOL CHEM, V254, P3054; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SALHANY JM, 1989, BIOCHEM BIOPH RES CO, V159, P1337, DOI 10.1016/0006-291X(89)92257-2; SALHANY JM, 1990, J BIOL CHEM, V265, P17688; SALHANY JM, 1978, BIOCHEMISTRY-US, V17, P3354, DOI 10.1021/bi00609a028; SCHUBERT D, 1983, FEBS LETT, V163, P81, DOI 10.1016/0014-5793(83)81168-5; STAROS JV, 1982, BIOCHEMISTRY-US, V21, P3950, DOI 10.1021/bi00260a008; STECK TL, 1972, J MOL BIOL, V66, P295, DOI 10.1016/0022-2836(72)90481-0; STECK TL, 1976, BIOCHEMISTRY-US, V15, P1154, DOI 10.1021/bi00650a030; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; THEVENIN BJM, 1990, J BIOL CHEM, V265, P16166; TOMIDA M, 1988, BIOCHIM BIOPHYS ACTA, V943, P493, DOI 10.1016/0005-2736(88)90382-3; TSUJI A, 1988, BIOCHEMISTRY-US, V27, P7447, DOI 10.1021/bi00419a041; Valdes R Jr, 1979, Methods Enzymol, V61, P125; WAXMAN L, 1979, ARCH BIOCHEM BIOPHYS, V195, P300, DOI 10.1016/0003-9861(79)90356-4; YOON SC, 1984, BIOCHIM BIOPHYS ACTA, V778, P385, DOI 10.1016/0005-2736(84)90383-3; YU J, 1975, J BIOL CHEM, V250, P9176; YU J, 1976, P NATL ACAD SCI USA, V73, P3891, DOI 10.1073/pnas.73.11.3891	71	201	201	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15726	15737						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874731				2022-12-25	WOS:A1991GB97700035
J	MASHIYAMA, S; MURAKAMI, Y; YOSHIMOTO, T; SEKIYA, T; HAYASHI, K				MASHIYAMA, S; MURAKAMI, Y; YOSHIMOTO, T; SEKIYA, T; HAYASHI, K			DETECTION OF P53 GENE-MUTATIONS IN HUMAN BRAIN-TUMORS BY SINGLE-STRAND CONFORMATION POLYMORPHISM ANALYSIS OF POLYMERASE CHAIN-REACTION PRODUCTS	ONCOGENE			English	Article							POINT MUTATIONS; HUMAN GLIOMA; LUNG-CANCER; TRANSFORMATION; DNA; ONCOGENE; NEUROFIBROMATOSIS; RAS; ABNORMALITIES; AMPLIFICATION	Single-strand conformation polymorphism analysis of polymerase chain reaction products (PCR-SSCP analysis) was used for detection of mutations of the p53 gene in surgical specimens of human brain tumors. Six of 45 brain tumors showed mobility shifts in the analyses. These six tumors also showed loss of a normal allele. The samples were examined further by direct sequencing. Results showed that four of them had single-base substitutions and the other two had deletions of one and eight base pairs. Five of the six mutations detected were clustered in highly conserved regions of the p53 gene. The frequency of p53 gene mutations in primary brain tumors examined was 9.8%. We also found two new polymorphic markers in the p53 gene, one in intron 7 and the other in an Alu repeat in exon 11. Both markers could be detected by SSCP analysis. Using these two markers, we found two cases of loss of heterozygosity in other brain tumor specimens. Results suggested that aberrations of the p53 gene were not correlated with the malignancy of some types of brain tumors such as anaplastic astrocytoma and glioblastoma, contrary to previous observations on colorectal cancers.	NATL CANC CTR,RES INST,DIV ONCOGENE,1-1 TSUKIJI 5-CHOME,CHUO KU,TOKYO 104,JAPAN; TOHOKU UNIV,SCH MED,INST BRAIN DIS,DIV NEUROSURG,AOBA KU,SENDAI,MIYAGI 980,JAPAN	National Cancer Center - Japan; Tohoku University								BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; BIGNER SH, 1988, CANCER RES, V48, P405; BLIN N, 1976, NUCLEIC ACIDS RES, V3, P2303, DOI 10.1093/nar/3.9.2303; BUCHMAN VL, 1988, GENE, V70, P245, DOI 10.1016/0378-1119(88)90196-5; BURGER PC, 1985, CANCER, V56, P1106, DOI 10.1002/1097-0142(19850901)56:5<1106::AID-CNCR2820560525>3.0.CO;2-2; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; DEAN M, 1990, CELL, V61, P863, DOI 10.1016/0092-8674(90)90196-L; DUMANSKI JP, 1987, P NATL ACAD SCI USA, V84, P9275, DOI 10.1073/pnas.84.24.9275; ELIYAHU D, 1984, NATURE, V312, P646, DOI 10.1038/312646a0; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; HENN W, 1986, HUM GENET, V74, P104; HINDS P, 1989, J VIROL, V63, P739, DOI 10.1128/JVI.63.2.739-746.1989; HUMPHREY PA, 1988, CANCER RES, V48, P2231; IGGO R, 1990, LANCET, V335, P675, DOI 10.1016/0140-6736(90)90801-B; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; JAMES CD, 1988, CANCER RES, V48, P5546; JENKINS JR, 1984, NATURE, V312, P651, DOI 10.1038/312651a0; JENKINS JR, 1988, ONCOGENE HDB, P403; KINZLER KW, 1987, SCIENCE, V236, P70, DOI 10.1126/science.3563490; MACKAY J, 1988, LANCET, V2, P1384; MASHIYAMA S, 1990, Technique (Philadelphia), V2, P304; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; MULLIGAN LM, 1990, P NATL ACAD SCI USA, V87, P5863, DOI 10.1073/pnas.87.15.5863; MUNROE DG, 1988, ONCOGENE, V2, P621; MURAKAMI Y, 1991, ONCOGENE, V6, P37; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; ORITA M, 1990, GENOMICS, V8, P271, DOI 10.1016/0888-7543(90)90282-Y; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; PARADA LF, 1984, NATURE, V312, P649, DOI 10.1038/312649a0; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; ROHRINGER M, 1989, J NEUROSURG, V71, P665, DOI 10.3171/jns.1989.71.5.0665; RUSSELL DS, 1977, PATHOLOGY TUMORS NER; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEIZINGER BR, 1987, SCIENCE, V236, P317, DOI 10.1126/science.3105060; SOUSSI T, 1990, ONCOGENE, V5, P945; SUZUKI Y, 1991, ANAL BIOCHEM, V192, P82, DOI 10.1016/0003-2697(91)90188-Y; SUZUKI Y, 1990, ONCOGENE, V5, P1037; TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494; VOGELSTEIN B, 1989, SCIENCE, V244, P207, DOI 10.1126/science.2565047	41	217	219	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1313	1318						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886708				2022-12-25	WOS:A1991GX27200003
J	NAKAZATO, Y; SIMONSON, MS; HERMAN, WH; KONIECZKOWSKI, M; SEDOR, JR				NAKAZATO, Y; SIMONSON, MS; HERMAN, WH; KONIECZKOWSKI, M; SEDOR, JR			INTERLEUKIN-1-ALPHA STIMULATES PROSTAGLANDIN BIOSYNTHESIS IN SERUM-ACTIVATED MESANGIAL CELLS BY INDUCTION OF A NONPANCREATIC (TYPE-II) PHOSPHOLIPASE-A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-ASSOCIATED PHOSPHOLIPASE-A2; ARACHIDONIC-ACID; CYTOSOLIC PHOSPHOLIPASE-A2; POTASSIUM CHANNELS; ENDOTHELIAL-CELLS; ARISTOLOCHIC ACID; SYNOVIAL-FLUID; PHORBOL ESTER; MESSENGER-RNA; RAT	Enhanced prostaglandin (PG) biosynthesis is a hallmark of inflammation, and interleukin-1 (IL), a proinflammatory cytokine, is a potent stimulus of PG production. We investigated the mechanisms of IL-1-alpha-enhanced PG synthesis in serum-stimulated mesangial cells. The rIL-1-stimulated increase in PGE2 synthesis was dose- and time-dependent and inhibited by both cycloheximide and actinomycin D. Phospholipase (PL) activity was increased 5- to 10-fold in acid extracts of rIL-1-treated cells as measured by arachidonate release from exogenous [C-14]arachidonyl-phosphatidyl-ethanolamine. This induced phospholipase activity was Ca2+-dependent and inhibited by the PLA2 inhibitors, aristocholic acid, 7,7-dimethyl-5,8-eicosadienoic acid, and p-bromophenacylbromide, but not by the 1,2-diacylglycerol lipase inhibitor RHC 80267. The rIL-1-stimulated PLA2 had an alkaline pH optimum, and phosphatidylethanolamine was preferred over phosphatidylcholine as substrate. The PLA2 activity increased by rIL-1 was inhibited in cells coincubated with cycloheximide and was measurable after 6 h. A sensitive and specific solution hybridization assay demonstrated a coordinate time-dependent induction of non-pancreatic PLA2 mRNA expression which was increased at least 6-fold by 24 h. In whole cells, IL-1 had no effect on basal [H-3]arachidonic acid release but vasopressin (1-mu-m)-stimulated release was potentiated 2- to 3-fold, suggesting that IL-1 may prime cells for increased PG synthesis via increased PLA2 activity. Thus IL-1 directly stimulates, as well as primes cells for, enhanced PG synthesis, in part, by increasing PLA2 activity through new synthesis of a non-pancreatic (Type II) PLA2.	UNIV HOSP CLEVELAND, DEPT MED, DIV NEPHROL, 2074 ABINGTON RD, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, SCH MED, DEPT MED, CLEVELAND, OH 44106 USA	University Hospitals of Cleveland; Case Western Reserve University				Nakazato, Yuichi/0000-0001-7541-3799	NHLBI NIH HHS [HL-22563] Funding Source: Medline; NIDDK NIH HHS [DK-01404, DK-38558] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022563, R01HL022563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK001404, R01DK038558] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; BROOKS RC, 1989, J BIOL CHEM, V264, P20147; BURCH RM, 1988, P NATL ACAD SCI USA, V85, P6306, DOI 10.1073/pnas.85.17.6306; BURCH RM, 1988, J BIOL CHEM, V263, P4764; CHANG J, 1986, J IMMUNOL, V136, P1283; CHANNON JY, 1990, J BIOL CHEM, V265, P5409; CHIOU WJ, 1990, J IMMUNOL, V145, P2155; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DINARELLO CA, 1989, ADV IMMUNOL, V44, P153; FUSE I, 1989, J BIOL CHEM, V264, P3890; GAO G, 1990, J BIOL CHEM, V265, P2431; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; ISHIZAKI J, 1989, BIOCHEM BIOPH RES CO, V162, P1030, DOI 10.1016/0006-291X(89)90777-8; KESTER M, 1989, J CLIN INVEST, V83, P718, DOI 10.1172/JCI113937; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KNAUSS TC, 1989, AM J PHYSIOL, V257, pF478, DOI 10.1152/ajprenal.1989.257.3.F478; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; LIN AH, 1989, J BIOL CHEM, V264, P17379; LISTER MD, 1989, J BIOL CHEM, V264, P8520; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKI F, 1986, BIOCHIM BIOPHYS ACTA, V879, P149, DOI 10.1016/0005-2760(86)90097-4; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MOHRI M, 1990, J IMMUNOL, V144, P2678; NEWTON RC, 1987, CELL IMMUNOL, V110, P338, DOI 10.1016/0008-8749(87)90127-4; ONEILL LAJ, 1987, FEBS LETT, V212, P35, DOI 10.1016/0014-5793(87)81551-X; ONO T, 1988, J BIOL CHEM, V263, P5732; ORDWAY RW, 1989, SCIENCE, V244, P1176, DOI 10.1126/science.2471269; RAZ A, 1988, J BIOL CHEM, V263, P3022; ROSENTHAL MD, 1989, BIOCHIM BIOPHYS ACTA, V1001, P1, DOI 10.1016/0005-2760(89)90299-3; SAKATA T, 1989, BIOCHIM BIOPHYS ACTA, V1007, P124, DOI 10.1016/0167-4781(89)90141-3; SCHALKWIJK C, 1991, BIOCHEM BIOPH RES CO, V174, P268, DOI 10.1016/0006-291X(91)90515-9; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; SIMONSON MS, 1990, METHOD ENZYMOL, V187, P544; SIMONSON MS, 1990, J CLIN INVEST, V85, P790, DOI 10.1172/JCI114505; SIMONSON MS, 1991, MOL ENDOCRINOL, V5, P441, DOI 10.1210/mend-5-3-441; SOLING HD, 1989, J BIOL CHEM, V264, P10643; VISHWANATH BS, 1988, INFLAMMATION, V12, P549, DOI 10.1007/BF00914317; WERBER HI, 1987, J IMMUNOL, V138, P3207; WU KK, 1988, J BIOL CHEM, V263, P19043; ZAVOICO GB, 1989, J IMMUNOL, V142, P3993; ZHANG Y, 1988, J BIOL CHEM, V263, P9965	44	125	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					14119	14127						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906891				2022-12-25	WOS:A1991FY02700101
J	PINTO, M; MORANGE, M; BENSAUDE, O				PINTO, M; MORANGE, M; BENSAUDE, O			DENATURATION OF PROTEINS DURING HEAT-SHOCK - INVIVO RECOVERY OF SOLUBILITY AND ACTIVITY OF REPORTER ENZYMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHICKEN-EMBRYO FIBROBLASTS; MAMMALIAN-CELLS; DROSOPHILA-MELANOGASTER; CHINESE-HAMSTER; RNA-POLYMERASE; HELA-CELLS; C-MYC; STRESS; DEGRADATION; NUCLEAR	Using beta-galactosidase and luciferase as reporter enzymes, we have previously shown that enzymatic inactivation occurring during a heat shock is concomitant with protein insolubilization (Nguyen, V. T., Morange, M., and Bensaude, O. (1989) J. Biol. Chem. 264, 10487-10492). In this paper, we observe that pretreatment of cells with D20 and glycerol, compounds known to stabilize protein structure, leads to a parallel decrease of protein inactivation and insolubilization, suggesting that these two phenomena result most probably from heat-induced protein denaturation. We found that heat shock-promoted inactivation and insolubilization are not irreversible processes, since even in the absence of protein synthesis, beta-galactosidase solubility and luciferase solubility and activity are recovered in vivo after a heat treatment. Cognate heat shock proteins might be involved in this renaturation process.	INST PASTEUR,BIOL MOLEC STRESS GRP,F-75724 PARIS 15,FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris				Bensaude, Olivier/0000-0002-0259-6608				ANDERSON RL, 1985, RADIAT RES, V102, P314, DOI 10.2307/3576707; ARRIGO AP, 1980, DEV BIOL, V78, P86, DOI 10.1016/0012-1606(80)90320-6; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; BENSAUDE O, 1990, P89; CARLSON N, 1987, J CELL BIOL, V104, P547, DOI 10.1083/jcb.104.3.547; COLBEREGARAPIN F, 1979, P NATL ACAD SCI USA, V76, P3755, DOI 10.1073/pnas.76.8.3755; COLLIER NC, 1988, J CELL BIOL, V106, P1131, DOI 10.1083/jcb.106.4.1131; COLLIER NC, 1986, J CELL BIOL, V103, P1495, DOI 10.1083/jcb.103.4.1495; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DUBOIS MF, 1989, J BIOL CHEM, V264, P12165; EDINGTON BV, 1989, J CELL PHYSIOL, V139, P219, DOI 10.1002/jcp.1041390202; EVAN GI, 1985, CELL, V43, P253, DOI 10.1016/0092-8674(85)90030-3; FISHER PA, 1989, J BIOL CHEM, V264, P3464; GERLSMA SY, 1972, INT J PEPT PROT RES, V4, P377; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; KRESHECK GC, 1965, J PHYS CHEM-US, V69, P3132, DOI 10.1021/j100893a054; LEPOCK JR, 1988, J CELL PHYSIOL, V137, P14, DOI 10.1002/jcp.1041370103; LEWIS MJ, 1985, EMBO J, V4, P3137, DOI 10.1002/j.1460-2075.1985.tb04056.x; LITTLEWOOD TD, 1987, J CELL SCI, V88, P65; LUSCHER B, 1988, MOL CELL BIOL, V8, P2504; LUTZ Y, 1988, EXP CELL RES, V175, P109, DOI 10.1016/0014-4827(88)90259-5; MARIDONNEAUPARINI I, 1988, BIOCHEM BIOPH RES CO, V154, P179, DOI 10.1016/0006-291X(88)90667-5; NGUYEN VT, 1989, J BIOL CHEM, V264, P10487; NGUYEN VT, 1988, ANAL BIOCHEM, V171, P404, DOI 10.1016/0003-2697(88)90505-2; NICOLAS JF, 1983, COLD SPRING HARBOR C, V10, P469; NOLAN NL, 1982, RADIAT RES, V90, P187, DOI 10.2307/3575806; PARAG HA, 1987, EMBO J, V6, P55, DOI 10.1002/j.1460-2075.1987.tb04718.x; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; SPIRO IJ, 1982, RADIAT RES, V89, P134, DOI 10.2307/3575691; TANGUAY RM, 1982, CAN J BIOCHEM CELL B, V60, P306, DOI 10.1139/o82-037; VELAZQUEZ JM, 1984, CELL, V36, P655, DOI 10.1016/0092-8674(84)90345-3; WESTWOOD JT, 1989, J CELL PHYSIOL, V139, P196, DOI 10.1002/jcp.1041390127	33	73	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13941	13946						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906889				2022-12-25	WOS:A1991FY02700077
J	FISHER, KJ; ARONSON, NN				FISHER, KJ; ARONSON, NN			CHARACTERIZATION OF THE MUTATION RESPONSIBLE FOR ASPARTYLGLUCOSAMINURIA IN 3 FINNISH PATIENTS - AMINO-ACID SUBSTITUTION CYS163-]SER ABOLISHES THE ACTIVITY OF LYSOSOMAL GLYCOSYLASPARAGINASE AND ITS CONVERSION INTO SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NORMAL HUMAN-FIBROBLASTS; BETA-HEXOSAMINIDASE; SEQUENCE-ANALYSIS; ALPHA-SUBUNIT; EXPRESSION; CDNA; ENZYME; ASPARTYLGLYCOSAMINURIA; GALACTOSIDASE; TRANSPORT	The mutation that causes a deficiency of the lysosomal amidase, glycosylasparaginase, has been characterized in fibroblasts from three Finnish patients diagnosed with aspartylglucosaminuria (AGU). The polymerase chain reaction was used to amplify the glycosylasparaginase protein coding sequence from the three AGU patients in order to compare them to the normal sequence from a full-length human placenta cDNA clone HPAsn.6 (Fisher, K. J., Tollersrud, O. K., and Aronson, N. N., Jr. (1990) FEBS Lett. 269, 440-444). Two base changes were found to be common to all three Finnish AGU patients, a G482 --> A transition that results in an Arg161 --> Gln substitution and a G488 --> C transversion that causes Cysl63 --> Ser. Detection of both point mutations from PCR-amplified cDNA or genomic DNA was facilitated by their creation of new endonuclease restriction sites. Expression studies in COS-1 cells revealed only the Cys163 --> Ser mutation caused a deficiency of glycosylasparaginase activity. This same substitution also prevented the normal post-translational processing of the precusor glycosylasparaginase polypeptide into its alpha and beta-subunits. Cell-free expression of the single-chain glycosylasparaginase precursor did not produce an active enzyme, suggesting that post-translational generation of subunits may be required for catalytic activity.			FISHER, KJ (corresponding author), PENN STATE UNIV,DEPT MOLEC & CELL BIOL,ALTHOUSE LAB,UNIVERSITY PK,PA 16802, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK033314] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-33314] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON NN, 1989, FASEB J, V3, P2615, DOI 10.1096/fasebj.3.14.2531691; AULA P, 1986, J MENT DEFIC RES, V30, P365; AULA P, 1974, HUMANGENETIK, V25, P307, DOI 10.1007/BF00336906; BAUMANN M, 1989, BIOCHEM J, V262, P189, DOI 10.1042/bj2620189; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; FISHER KJ, 1990, FEBS LETT, V269, P440, DOI 10.1016/0014-5793(90)81211-6; FISHER KJ, 1989, BIOCHEM J, V264, P695, DOI 10.1042/bj2640695; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; HARLOW E, 1988, ANTIBODIES LABORATOR; HREIDARSSON S, 1983, CLIN GENET, V23, P427; IKONEN E, 1991, EMBO J, V10, P51, DOI 10.1002/j.1460-2075.1991.tb07920.x; JENNER FA, 1967, BIOCHEM J, V103, pP48; KINCAID RL, 1988, BIOTECHNIQUES, V6, P42; LAU MMH, 1989, J BIOL CHEM, V264, P21376; LEE CC, 1990, PCR PROTOCOLS GUIDE, P46; LITTLE LE, 1988, J BIOL CHEM, V263, P4288; MAHURAN DJ, 1988, J BIOL CHEM, V263, P4612; Maniatis T., 1982, MOL CLONING; MAURY CPJ, 1982, J INHERIT METAB DIS, V5, P192, DOI 10.1007/BF02179139; MITCHELL GA, 1989, P NATL ACAD SCI USA, V86, P197, DOI 10.1073/pnas.86.1.197; MONONEN I, 1988, SCAND J CLIN LAB INV, V48, P7; MORREAU H, 1989, J BIOL CHEM, V264, P20655; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; PALO J, 1973, CLIN CHIM ACTA, V47, P69, DOI 10.1016/0009-8981(73)90061-2; PAW BH, 1990, J BIOL CHEM, V265, P9452; POLLITT RJ, 1968, LANCET, V2, P253; QUON DVK, 1989, J BIOL CHEM, V264, P3380; REISSIG JL, 1955, J BIOL CHEM, V217, P959; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHEELE G, 1982, J BIOL CHEM, V257, P2277; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SONDERFELDRESKO S, 1988, J BIOL CHEM, V263, P13463; TOLLERSRUD OK, 1989, BIOCHEM J, V260, P101, DOI 10.1042/bj2600101; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466; YONEZAWA S, 1988, J BIOL CHEM, V263, P16504	37	44	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					12105	12113						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904874				2022-12-25	WOS:A1991FT76200103
J	GOMEZCAMBRONERO, J; WANG, E; JOHNSON, G; HUANG, CK; SHAAFI, RI				GOMEZCAMBRONERO, J; WANG, E; JOHNSON, G; HUANG, CK; SHAAFI, RI			PLATELET-ACTIVATING-FACTOR INDUCES TYROSINE PHOSPHORYLATION IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; ALKYL ETHER ANALOG; PROTEIN-KINASE; PAF-ACETHER; PHOSPHATIDYLCHOLINE; STIMULATION; ONCOGENES; MEDIATOR; MEMBRANE; CALCIUM	The addition of platelet-activating factor (PAF) to human neutrophils increases the levels of the tyrosine phosphorylation in several proteins. These proteins have molecular weights of 41 (pp41), 54 (pp54), 66 (pp66), 104 (pp104), and 116 (pp116) kDa. The effect of PAF was dose-dependent and could be seen at concentrations as low as 1 nM. The nonmetabolizable bioactive PAF analog, C-PAF, caused an increase in the level of phosphorylation of the same proteins in a time- and dose-dependent manner. On the contrary, lyso-PAF, enantio-PAF, and L-beta,gamma-dihexadecyl-alpha-lecithin failed to stimulate the phosphorylation of any of the aforementioned proteins. The response to PAF was prevented by the PAF antagonist BN-52021. The PAF-induced increases in tyrosine phosphorylation in pp66, pp116, and pp104 were selectively inhibited by pertussis toxin. In contrast, the level of pp41 phosphorylation remained unchanged after the pertussis toxin treatment. The calcium chelator EGTA significantly inhibited the PAF-produced phosphorylation of the pp41 protein. The intracellular calcium chelator 1,2-bis-(O-aminophenoxil)ethane-N,N,N',N' -tetraacetic acid (BAPTA) potentiated the PAF-enhanced levels of tyrosine phosphorylation on the pp41 protein. On the other hand, the PAF-induced phosphorylations of pp66, pp104, and pp116 were inhibited in BAPTA-treated cells. The calcium ionophore A23187 selectively potentiated the phosphorylation of the pp41 protein and reduced the phosphorylation in the pp54 protein. This phosphorylation was dependent on extracellular calcium and was inhibited in toxin-treated cells. The results suggest that PAF is able to affect either directly or indirectly tyrosine kinase and/or phosphotyrosine phosphatase activities. The phosphorylation of the high and low molecular weight proteins are mediated by two different sets of kinases and/or phosphatases.	UNIV CONNECTICUT,CTR HLTH,DEPT PHYSIOL,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06032; UNIV CONNECTICUT,CTR HLTH,DEPT PATHOL,FARMINGTON,CT 06032	University of Connecticut; University of Connecticut; University of Connecticut				Gomez-Cambronero, Julian/0000-0002-7581-9227	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024935] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037694] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-24935, AI-209423] Funding Source: Medline; NIGMS NIH HHS [GM-37694] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENVENISTE J, 1979, CR ACAD SCI D NAT, V289, P1037; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BLANK ML, 1979, BIOCHEM BIOPH RES CO, V90, P1194, DOI 10.1016/0006-291X(79)91163-X; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COHEN HJ, 1978, J CLIN INVEST, V61, P1081, DOI 10.1172/JCI109007; DEMOPOULOS CA, 1979, J BIOL CHEM, V254, P9355; DHAR A, 1990, MOL PHARMACOL, V37, P519; ELY CM, 1990, J CELL BIOL, V110, P731, DOI 10.1083/jcb.110.3.731; ENGLISH D, 1974, J IMMUNOL METHODS, V7, P2267; GLASER KB, 1990, J BIOL CHEM, V265, P8658; GOETZL EJ, 1980, BIOCHEM BIOPH RES CO, V94, P881, DOI 10.1016/0006-291X(80)91317-0; GOMEZCAMBRONERO J, 1989, BIOCHEM BIOPH RES CO, V162, P1478, DOI 10.1016/0006-291X(89)90841-3; GOMEZCAMBRONERO J, 1989, P NATL ACAD SCI USA, V86, P3569, DOI 10.1073/pnas.86.10.3569; GOMEZCAMBRONERO J, 1989, J BIOL CHEM, V264, P21699; GRINSTEIN S, 1990, J BIOL CHEM, V265, P318; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HUANG CK, 1988, BIOCHEM BIOPH RES CO, V151, P794, DOI 10.1016/S0006-291X(88)80351-6; INGRAHAM LM, 1982, BLOOD, V59, P1259; KATAN M, 1988, NATURE, V332, P203, DOI 10.1038/332203a0; KRAFT AS, 1987, BLOOD, V70, P356; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NACCACHE PH, 1985, BIOCHEM BIOPH RES CO, V130, P677, DOI 10.1016/0006-291X(85)90470-X; OFLAHERTY JT, 1986, J CLIN INVEST, V78, P381, DOI 10.1172/JCI112588; PAGE CP, 1984, TRENDS PHARMACOL SCI, V5, P239, DOI 10.1016/0165-6147(84)90431-0; PINCKARD RN, 1982, ADV INFLAMMAT RES, V4, P147; ROSSOMANDO AJ, 1989, P NATL ACAD SCI USA, V86, P6940, DOI 10.1073/pnas.86.18.6940; SALTZMAN EM, 1988, J BIOL CHEM, V263, P6956; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; TANIZAWA H, 1989, BIOCHEM PHARMACOL, V38, P2559; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; TOU J, 1985, BIOCHEM BIOPH RES CO, V127, P1045, DOI 10.1016/S0006-291X(85)80050-4; VALONE FH, 1983, IMMUNOLOGY, V48, P141	32	119	120	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6240	6245						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1901060				2022-12-25	WOS:A1991FE37300038
J	CROUCH, MF				CROUCH, MF			GROWTH FACTOR-INDUCED CELL-DIVISION IS PARALLELED BY TRANSLOCATION OF GI-ALPHA TO THE NUCLEUS	FASEB JOURNAL			English	Article						G PROTEIN; MYRISTOYLATION; ALPHA-SUBUNIT; GTP-BINDING PROTEIN; PERTUSSIS; MITOSIS	NUCLEOTIDE-BINDING-PROTEINS; RECEPTOR	Induction of mitosis by certain growth factors is inhibited by pertussis toxin, indicating that the GTP-binding protein, G(i), is involved in receptor signal transduction to initiate cell division. However, the substrates of receptor-activated G(i) that are involved in mitosis have not been determined. The present study has examined whether G(i) may directly modulate cell division by receptor-induced subcellular translocation of the alpha subunit of G(i) (G(i-alpha)). Insulin and EGF, particularly when added together or in combination with phorbol dibutyrate (PdBu), induced a rapid (1-4 h) redistribution of G(i-alpha) from the plasma membrane to perinuclear sites in the cell. After 2 days of stimulation, G(i-alpha) had translocated into the nucleus of dividing cells and bound specifically to the separating chromatin of dividing nuclei. Unstimulated cells did not display translocation of G(i-alpha). This demonstrates a direct involvement of G(i-alpha) in cell division, which provides an apparently uninterrupted link from growth factor receptor to nucleus.			CROUCH, MF (corresponding author), AUSTRALIAN NATL UNIV,JOHN CURTIN SCH MED RES,DIV NEUROSCI,CANBERRA,ACT 2601,AUSTRALIA.							BENDITT JO, 1989, J BIOL CHEM, V86, P9327; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CHAMBARD JC, 1987, NATURE, V326, P800, DOI 10.1038/326800a0; CROUCH MF, 1989, P NATL ACAD SCI USA, V86, P1776, DOI 10.1073/pnas.86.6.1776; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; CROUCH MF, 1990, BIOCHEM BIOPH RES CO, V167, P1369, DOI 10.1016/0006-291X(90)90674-C; FRANZE-FERNANDEZ M T, 1971, Proceedings of the National Academy of Sciences of the United States of America, V68, P3040, DOI 10.1073/pnas.68.12.3040; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MURAYAMA T, 1987, J BIOL CHEM, V262, P12463; NISHIMOTO I, 1989, J BIOL CHEM, V264, P14029; PETERS R, 1983, J BIOL CHEM, V258, P1427; SPIEGEL AM, 1987, MOL CELL ENDOCRINOL, V49, P1, DOI 10.1016/0303-7207(87)90058-X	15	80	80	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	FEB	1991	5	2					200	206		10.1096/fasebj.5.2.1900794	http://dx.doi.org/10.1096/fasebj.5.2.1900794			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	EZ002	1900794				2022-12-25	WOS:A1991EZ00200009
J	LEAH, R; TOMMERUP, H; SVENDSEN, I; MUNDY, J				LEAH, R; TOMMERUP, H; SVENDSEN, I; MUNDY, J			BIOCHEMICAL AND MOLECULAR CHARACTERIZATION OF 3 BARLEY SEED PROTEINS WITH ANTIFUNGAL PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEINS; N-GLYCOSIDASE ACTIVITY; NUCLEOTIDE-SEQUENCE; BIOLOGICAL FUNCTION; ALEURONE CELLS; IDENTIFICATION; ENDOCHITINASE; CHITINASE; TOBACCO; EXPRESSION	We have purified three proteins from barely (Hordeum vulgare L.) seeds which synergistically inhibit the growth of fungi measured in a microtiter well assay. The proteins are a 26-kDa chitinase, a 30-kDa ribosome-inactivating protein, and a 32-kDa (1-3)-beta-glucanase. Full-length cDNAs encoding them were isolated and sequenced to determine the complete primary structures of the proteins. Northern hybridizations with the cDNAs as probes showed that the corresponding mRNAs accumulate differentially during seed development and germination. Chitinase mRNA accumulates to high levels in aleurone cells during late seed development and early germination, while high levels of mRNA encoding the ribosome-inactivating protein accumulate only in the starchy endosperm during late seed development. The glucanase mRNA accumulates to low levels during seed development and to higher levels in aleurone and seedling tissues during germination. Southern hybridizations showed that the three proteins are encoded by small families of three to eight genes. Their biological roles and potential use in genetic engineering studies are discussed.	CARLSBERG RES LAB,GL CARLSBERG VEJ 10,DK-2500 COPENHAGEN,DENMARK; CARLSBERG LAB,DEPT CHEM,DK-2500 COPENHAGEN,DENMARK				mundy, john/A-2361-2013	mundy, john/0000-0001-7490-4588				AASTRUP S, 1984, CARLSBERG RES COMMUN, V49, P105, DOI 10.1007/BF02913969; ASANO K, 1986, CARLSBERG RES COMMUN, V51, P129, DOI 10.1007/BF02907320; BALLANCE GM, 1988, CARLSBERG RES COMMUN, V53, P619; BARTNICK.S, 1968, ANNU REV MICROBIOL, V22, P87, DOI 10.1146/annurev.mi.22.100168.000511; BENHAMOU N, 1990, PLANT PHYSIOL, V92, P1108, DOI 10.1104/pp.92.4.1108; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; Boller T., 1988, Oxford Surveys of Plant Molecular and Cell Biology, V5, P145; Boller T, 1985, CELLULAR MOL BIOL PL, P247; BROEKAERT WF, 1989, SCIENCE, V245, P1100, DOI 10.1126/science.245.4922.1100; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; CASSAB GI, 1987, J CELL BIOL, V105, P2581, DOI 10.1083/jcb.105.6.2581; COLEMAN WH, 1982, BIOCHIM BIOPHYS ACTA, V696, P239, DOI 10.1016/0167-4781(82)90053-7; DARVILL AG, 1984, ANN REV PLANT PHYSL, V35, P43; ENDO Y, 1988, BIOCHIM BIOPHYS ACTA, V954, P224, DOI 10.1016/0167-4838(88)90075-1; FINCHER GB, 1986, P NATL ACAD SCI USA, V83, P2081, DOI 10.1073/pnas.83.7.2081; HAHLBROCK K, 1979, ANNU REV PLANT PHYS, V30, P105, DOI 10.1146/annurev.pp.30.060179.000541; HOJ PB, 1989, PLANT MOL BIOL, V13, P31, DOI 10.1007/BF00027333; JOOSTEN MHAJ, 1989, PLANT PHYSIOL, V89, P945, DOI 10.1104/pp.89.3.945; KAUFFMANN S, 1987, EMBO J, V6, P3209, DOI 10.1002/j.1460-2075.1987.tb02637.x; LAMB FI, 1985, EUR J BIOCHEM, V148, P265, DOI 10.1111/j.1432-1033.1985.tb08834.x; LEAH R, 1987, CARLSBERG RES COMMUN, V52, P31, DOI 10.1007/BF02910425; LEAH R, 1989, PLANT MOL BIOL, V12, P673, DOI 10.1007/BF00044158; LEGRAND M, 1987, P NATL ACAD SCI USA, V84, P6750, DOI 10.1073/pnas.84.19.6750; LOTAN T, 1989, PLANT CELL, V1, P881, DOI 10.1105/tpc.1.9.881; LUCAS J, 1985, FEBS LETT, V193, P208, DOI 10.1016/0014-5793(85)80152-6; Maniatis T., 1982, MOL CLONING; MAUCH F, 1988, PLANT PHYSIOL, V88, P936, DOI 10.1104/pp.88.3.936; MOLANO J, 1977, ANAL BIOCHEM, V83, P648, DOI 10.1016/0003-2697(77)90069-0; MUNDY J, 1986, FEBS LETT, V198, P349, DOI 10.1016/0014-5793(86)80434-3; MUNDY J, 1986, PLANT PHYSIOL, V81, P630, DOI 10.1104/pp.81.2.630; RAIHKEL NV, 1989, PLANT MOL BIOL MAN B, V9, P1; ROBERTS WK, 1986, BIOCHIM BIOPHYS ACTA, V880, P161, DOI 10.1016/0304-4165(86)90076-0; ROGERS JC, 1985, J BIOL CHEM, V260, P3731; RYAN CA, 1987, ANNU REV CELL BIOL, V3, P295, DOI 10.1146/annurev.cellbio.3.1.295; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shewry P. R., 1985, Advances in Cereal Science and Technology, V7, P1; STIRPE F, 1989, BIOCHEM J, V262, P1001; Stoskopf N.C., 1985, CEREAL GRAIN CROPS; SWEGLE M, 1989, PLANT MOL BIOL, V12, P403, DOI 10.1007/BF00017580; VANLOON LC, 1985, PLANT MOL BIOL, V4, P111, DOI 10.1007/BF02418757; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	43	526	555	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1564	1573						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1899089				2022-12-25	WOS:A1991EU49700034
J	BIENER, Y; ZICK, Y				BIENER, Y; ZICK, Y			POLYLYSINE INCREASES THE NUMBER OF INSULIN BINDING-SITES IN SOLUBLE INSULIN-RECEPTOR PREPARATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; RADIATION INACTIVATION; BASIC POLYCATIONS; HUMAN-PLACENTA; PHOSPHORYLATION; ACTIVATION; CALMODULIN; AUTOPHOSPHORYLATION; REQUIREMENTS; POLYAMINES	The effects of cationic polyamino acids on insulin binding to soluble insulin receptor preparations were studied. Incubation of partially or fully purified receptor preparations with polylysine (pLys) increased by several-fold the amount of [I-125]insulin that remained associated with the receptor, as determined both by precipitation of receptor-insulin complexes by polyethylene glycol or by separation of the complexes from the free hormone by gel filtration. This elevation in the amount of bound insulin resulted from increased number of insulin binding sites, and could not be attributed to an increased affinity of the receptors to insulin. In fact, pLys reduced 2-3-fold the affinity of insulin binding to its receptor as determined by equilibrium binding studies, and by monitoring the rate of exchange of bound [I-125]insulin with unlabeled hormone. pLys induced specific interactions between insulin and its native receptor since other basic compounds such as histone, spermidine, polymixin B, compound 48/80, lysine, and arginine failed to reproduce its effects. pLys did not interact with the free ligand, nor did it promote interactions between insulin and denatured receptor forms. Furthermore, pLys did not induce binding of insulin to other proteins present in the partially purified receptor preparations. The effects of pLys were time and dose-dependent and were proportional to the pLys chain length. The longer the chain, the greater was the effect. Enhanced insulin binding and receptor beta-subunit autophosphorylation (in the presence of insulin) exhibited a similar dependency on the chain length of pLys. pLys effects on insulin binding were associated with formation of large protein aggregates that remained trapped at the top of Sephacryl S-300 columns. These aggregates contained substantial amounts of receptor-insulin complexes. Our results suggest that pLys induces formation of receptor clusters that create de novo insulin binding sites among adjacent receptor tetramers. Alternatively, formation of receptor aggregates might facilitate insulin binding to a soluble receptor subfraction that otherwise fails to bind the hormone.	WEIZMANN INST SCI,DEPT CHEM IMMUNOL,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science			Zick, Yehiel/K-1479-2012					ABDELGHANY M, 1987, P NATL ACAD SCI USA, V84, P8888, DOI 10.1073/pnas.84.24.8888; BIENER Y, 1990, EUR J BIOCHEM, V194, P243, DOI 10.1111/j.1432-1033.1990.tb19449.x; BONISCHNETZLER M, 1986, J BIOL CHEM, V261, P5281; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FUJITAYAMAGUCHI Y, 1988, BIOCHEMISTRY-US, V27, P3252, DOI 10.1021/bi00409a020; FUJITAYAMAGUCHI Y, 1989, BIOCHEMISTRY-US, V28, P4556, DOI 10.1021/bi00437a008; FUJITAYAMAGUCHI Y, 1989, BIOCHEM J, V263, P813, DOI 10.1042/bj2630813; FUJITAYAMAGUCHI Y, 1989, P NATL ACAD SCI USA, V86, P7306, DOI 10.1073/pnas.86.19.7306; FUJITAYAMAGUCHI Y, 1983, J BIOL CHEM, V258, P5045; GATICA M, 1987, P NATL ACAD SCI USA, V84, P324, DOI 10.1073/pnas.84.2.324; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HEDO JA, 1981, BIOCHEMISTRY-US, V20, P3385, DOI 10.1021/bi00515a013; HEFFETZ D, 1986, J BIOL CHEM, V261, P885; JARRETT L, 1974, J BIOL CHEM, V249, P7024; KAHN CR, 1988, J CLIN INVEST, V82, P1151, DOI 10.1172/JCI113711; KASUGA M, 1982, J BIOL CHEM, V257, P392; KATCHALSKY A, 1959, BIOCHIM BIOPHYS ACTA, V33, P120; KOHANSKI RA, 1989, J BIOL CHEM, V264, P20984; KORNGUTH SE, 1961, EXP CELL RES, V24, P484, DOI 10.1016/0014-4827(61)90448-7; KUBAR J, 1989, BIOCHEMISTRY-US, V28, P1086, DOI 10.1021/bi00429a024; MAMELAK M, 1969, J MEMBRANE BIOL, V1, P144, DOI 10.1007/BF01869779; MORRISON BD, 1989, J BIOL CHEM, V264, P9994; PELECH S, 1985, EUR J BIOCHEM, V148, P245, DOI 10.1111/j.1432-1033.1985.tb08832.x; QUINTON PM, 1973, J CELL BIOL, V56, P787, DOI 10.1083/jcb.56.3.787; ROSEN OM, 1988, FEBS LETT, V231, P397, DOI 10.1016/0014-5793(88)80858-5; ROSEN OM, 1987, SCIENCE, V237, P1452, DOI 10.1126/science.2442814; SACKS DB, 1988, J BIOL CHEM, V263, P2377; SACKS DB, 1989, BIOCHEM J, V263, P803, DOI 10.1042/bj2630803; SAKAI K, 1989, BIOCHEM BIOPH RES CO, V158, P1043, DOI 10.1016/0006-291X(89)92827-1; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGEL S, 1986, EUR J BIOCHEM, V154, P253, DOI 10.1111/j.1432-1033.1986.tb09390.x; ZICK Y, 1983, J BIOL CHEM, V258, P75; ZICK Y, 1989, CRIT REV BIOCHEM MOL, V24, P217, DOI 10.3109/10409238909082554	34	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17369	17375						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894624				2022-12-25	WOS:A1991GF44500060
J	HILLE, R; MASSEY, V				HILLE, R; MASSEY, V			THE KINETIC-BEHAVIOR OF XANTHINE-OXIDASE CONTAINING CHEMICALLY MODIFIED FLAVINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CENTERS; OXIDATION-REDUCTION POTENTIALS; MOLYBDENUM; ANALOGS; OXYGEN; EXAFS; PH	The steady-state and rapid kinetic properties of xanthine oxidase containing a series of FAD analogs of varying reduction potential have been investigated. From steady-state analysis, V(max) is found to exhibit a sigmoidal dependence on the flavin midpoint potential in the homologous series. This dependence is accurately described by a model in which the rate of catalysis is attenuated by the amount of partially reduced enzyme generated during turnover possessing an unfavorable distribution of reducing equivalents among the several redox-active centers of the protein. The model assumes that reducing equivalents equilibrate among these centers rapidly compared to the limiting rates for the reductive and oxidative half-reactions. This assumption is borne out by a quantitative analysis of the reductive and oxidative half-reactions of the several enzyme forms investigated in detail. It is demonstrated in these studies that xanthine oxidase containing low potential flavin derivatives such as 1-deaza, 6-hydroxy, or 8-hydroxy FAD exhibits low turnover not because of inherently slow rates of reduction by xanthine or oxidation by molecular oxygen, but because in partially reduced enzyme generated in the course of turnover reducing equivalents are distributed within the enzyme in such a way that the enzyme can participate in neither the reductive nor oxidative half-reactions. These results provide confirmation of the operation of a thermodynamic control mechanism in a simple electron-transferring system.	UNIV MICHIGAN,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan	HILLE, R (corresponding author), OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210, USA.							ANDERSON RF, 1986, J BIOL CHEM, V261, P5870; BARBER MJ, 1982, BIOCHEMISTRY-US, V21, P1638, DOI 10.1021/bi00536a026; BRAY RC, 1964, J BIOL CHEM, V239, P2667; BRAY RC, 1988, Q REV BIOPHYS, V21, P299, DOI 10.1017/S0033583500004479; Bray RC., 1975, ENZYMES, V12, P299, DOI DOI 10.1016/S1874-6047(08)60229-2; BURLEIGH BD, 1969, ANAL BIOCHEM, V27, P536, DOI 10.1016/0003-2697(69)90067-0; CAMMACK R, 1976, BIOCHEM J, V157, P469, DOI 10.1042/bj1570469; CRAMER SP, 1981, J AM CHEM SOC, V103, P7721, DOI 10.1021/ja00416a005; CRAMER SP, 1985, J AM CHEM SOC, V107, P8164, DOI 10.1021/ja00312a059; EDMONDSON DE, 1987, FLAVINS FLAVOPROTEIN, P403; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; Hille R., 1985, Metal Ions in Biology, V7, P443; HILLE R, 1984, J BIOL CHEM, V259, P1570; HILLE R, 1981, J BIOL CHEM, V256, P8933; HILLE R, 1981, J BIOL CHEM, V256, P9090; HILLE R, 1986, J BIOL CHEM, V261, P1241; KALCKAR HM, 1947, J BIOL CHEM, V167, P429; KOMAI H, 1969, J BIOL CHEM, V244, P1692; LIGHT DR, 1980, J BIOL CHEM, V255, P4264; MANSTEIN DJ, 1986, J BIOL CHEM, V261, P6169; MASSEY V, 1969, J BIOL CHEM, V244, P1682; MORRISON M, 1963, J BIOL CHEM, V238, P2847; OLSON JS, 1974, J BIOL CHEM, V249, P4350; OLSON JS, 1974, J BIOL CHEM, V249, P4363; PALMER G, 1980, MOLYBDENUM MOLYBDENU, P189; PORRAS AG, 1981, J BIOL CHEM, V256, P9096; PORRAS AG, 1982, J BIOL CHEM, V257, P1617; SCHWERT GW, 1969, J BIOL CHEM, V244, P1278; SPENCE JT, 1982, BIOCHEMISTRY-US, V21, P1656, DOI 10.1021/bi00536a028; WALKER MC, 1991, BIOCHEMISTRY-US, V30, P5912, DOI 10.1021/bi00238a015	30	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17401	17408						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894627				2022-12-25	WOS:A1991GF44500065
J	HOLDEN, JL; NUREKAMAL, MSA; FABRI, L; NICE, E; HAMMACHER, A; MARUTA, H				HOLDEN, JL; NUREKAMAL, MSA; FABRI, L; NICE, E; HAMMACHER, A; MARUTA, H			RSR1 AND RAP1 GTPASES ARE ACTIVATED BY THE SAME GTPASE-ACTIVATING PROTEIN AND REQUIRE THREONINE-65 FOR THEIR ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE BRAIN; RAS; BINDING; GENE; IDENTIFICATION; PURIFICATION; DOMAIN; P21; GAP	The Rsr1 protein of Saccharomyces cerevisiae has been shown to be essential for bud site selection (Bender, A., and Pringle, J. (1989) Proc. Natl. Acad. Sci. U.S.A. 86, 9976-9980). This protein of 272 amino acids shares approximately 50% sequence identity with both Ras and Rap GTPases. However, neither GTP binding nor GTPase activity of the Rsr1 protein has been reported. The Rsr1 protein shares with human Rap1 GTPases the four specific motifs, i.e. Gly12, residues 32-40, Ala-59, and residues 64-70, that are required for GAP3-dependent activation of the Rap1 GTPases. In this paper we demonstrate that the intrinsic GTPase activity of the Rsr1 protein is stimulated by GAP3 purified from bovine brain cytosol. The Rsr1 GTPase is not activated by either GAP1 or GAP2 which are specific for the Ras and Rho GTPases, respectively. Thus, it appears that the Rsr1 GTPase is a new member of the Rap1 GTPase family. Replacement of Gly-12 by Val in the Rsr1 GTPase completely abolishes the GAP3-dependent activation. The chimeric GTPases, Ras(1-60)/Rsr1(61-168) and Rsr1(1-65)/Ras(66-189), are activated by GAP3 but not by GAP1. Replacement of Thr-65 by Ser in the latter chimeric GTPase completely abolishes the GAP3-dependent activation, indicating that Thr-65 is required for distinguishing GAP3 from GAP1. We have previously shown that Gln-61 and Ser-65 are sufficient to determine the GAP1 specificity. Replacement of Thr-35 by Ala in the common effector domain (residues 32-40) of the chimeric Ras/Rsr1 GTPases completely abolishes GAP3-dependent activation.	LUDWIG INST CANC RES, MELBOURNE TUMOR BIOL BRANCH, MELBOURNE, VIC 3050, AUSTRALIA	Ludwig Institute for Cancer Research			Nice, Edouard C/B-1026-2011	fabri, louis/0000-0003-4033-3304				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BENDER A, 1989, P NATL ACAD SCI USA, V86, P9976, DOI 10.1073/pnas.86.24.9976; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANDT DR, 1983, BIOCHEMISTRY-US, V22, P4357, DOI 10.1021/bi00288a002; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; MARUTA H, 1989, NATO ADV SCI I A-LIF, V170, P255; MARUTA H, 1991, J BIOL CHEM, V266, P11661; MIYAMOTO S, 1987, GENE, V54, P125, DOI 10.1016/0378-1119(87)90354-4; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; YAMAMOTO J, 1990, IN PRESS MOL BRAIN R	21	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					16992	16995						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910037				2022-12-25	WOS:A1991GF44500008
J	PARKKINEN, J; RAUVALA, H				PARKKINEN, J; RAUVALA, H			INTERACTIONS OF PLASMINOGEN AND TISSUE PLASMINOGEN-ACTIVATOR (T-PA) WITH AMPHOTERIN - ENHANCEMENT OF T-PA-CATALYZED PLASMINOGEN ACTIVATION BY AMPHOTERIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURO-BLASTOMA CELLS; GROWTH CONE; FIBRINOGEN FRAGMENTS; BINDING; DOMAINS; LYSINE; OUTGROWTH; ADHESIVE; KINETICS; VARIANTS	The heparin-binding p30 protein amphoterin is proposed to mediate adhesive interactions of the advancing plasma membrane in migrating and differentiating cells. Since the NH2-terminal part of amphoterin is exceptionally rich in lysine residues, we have studied its interactions with plasminogen and tissue plasminogen activator (t-PA). On immunostaining of N18 neuroblastoma cells, amphoterin and t-PA showed a close co-localization in the filopodia of the leading membrane and in the substrate-attached material. In purified systems, both t-PA and plasminogen bound to immobilized amphoterin, and their binding was inhibited by the lysine analogue epsilon-aminocaproic acid. Plasminogen bound to immobilized amphoterin was activated by t-PA, and this resulted in effective degradation of the immobilized amphoterin. Correspondingly, amphoterin-bound t-PA activated plasminogen. In solution amphoterin accelerated t-PA-catalyzed plasminogen activation maximally 46-fold. The results indicate that t-PA and plasminogen form through their lysine-binding sites a complex with amphoterin, which results in acceleration of plasminogen activation and effective degradation of amphoterin. We suggest that local acceleration of t-PA-catalyzed plasminogen activation by amphoterin at the leading membrane enhances the penetration of growing cytoplasmic processes through extracellular materials during cell migration, differentiation and regeneration. The amphoterin-mediated adhesion at the leading membrane may be transient in nature, because the protein also enhances its own breakdown by accelerating t-PA-catalyzed plasminogen activation.	UNIV HELSINKI,DEPT OBSTET & GYNECOL,SF-00290 HELSINKI 29,FINLAND; UNIV HELSINKI,INST BIOTECHNOL,SF-00380 HELSINKI,FINLAND	University of Helsinki; University of Helsinki	PARKKINEN, J (corresponding author), UNIV HELSINKI,DEPT MED CHEM,SF-00170 HELSINKI 17,FINLAND.			Rauvala, Heikki/0000-0001-7809-9811				ANDRADEGORDON P, 1986, BIOCHEMISTRY-US, V25, P4033, DOI 10.1021/bi00362a007; BOSMA PJ, 1988, EUR J BIOCHEM, V172, P399, DOI 10.1111/j.1432-1033.1988.tb13900.x; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; CHMIELEWSKA J, 1983, THROMB RES, V31, P427, DOI 10.1016/0049-3848(83)90407-3; CHRISTENSEN U, 1985, FEBS LETT, V182, P43, DOI 10.1016/0014-5793(85)81150-9; DANO K, 1985, ADV CANCER RES, V44, P140; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; DEVRIES C, 1989, J BIOL CHEM, V264, P12604; DRAPIER JC, 1979, BIOCHIMIE, V61, P163; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; HEMMILA I, 1984, ANAL BIOCHEM, V137, P335, DOI 10.1016/0003-2697(84)90095-2; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; KRYSTOSEK A, 1986, EXP CELL RES, V166, P31, DOI 10.1016/0014-4827(86)90506-9; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; LERCH PG, 1980, EUR J BIOCHEM, V107, P7, DOI 10.1111/j.1432-1033.1980.tb04617.x; LETOURNEAU PC, 1988, J NEUROSCI RES, V21, P286, DOI 10.1002/jnr.490210221; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; MARKUS G, 1978, J BIOL CHEM, V253, P727; MERENMIES J, 1991, J BIOL CHEM, V266, P16722; MONARD D, 1988, TRENDS NEUROSCI, V11, P541, DOI 10.1016/0166-2236(88)90182-8; NEUMAN T, 1989, J NEUROSCI RES, V23, P274, DOI 10.1002/jnr.490230305; RANBY M, 1982, BIOCHIM BIOPHYS ACTA, V704, P461, DOI 10.1016/0167-4838(82)90068-1; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; RIJKEN DC, 1980, THROMB RES, V18, P815, DOI 10.1016/0049-3848(80)90204-2; VALI Z, 1982, J BIOL CHEM, V257, P2104; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; VERHEIJEN JH, 1982, THROMB RES, V27, P377, DOI 10.1016/0049-3848(82)90055-X; VONZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; WILSON EL, 1980, CANCER RES, V40, P933; WIMAN B, 1983, CLIN CHIM ACTA, V127, P279, DOI 10.1016/S0009-8981(83)80012-6; WIMAN B, 1977, THROMB RES, V1, P213	34	129	146	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16730	16735						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1909331				2022-12-25	WOS:A1991GD63500078
J	TSUJI, A; TORRESROSADO, A; ARAI, T; LEBEAU, MM; LEMONS, RS; CHOU, SH; KURACHI, K				TSUJI, A; TORRESROSADO, A; ARAI, T; LEBEAU, MM; LEMONS, RS; CHOU, SH; KURACHI, K			HEPSIN, A CELL MEMBRANE-ASSOCIATED PROTEASE - CHARACTERIZATION, TISSUE DISTRIBUTION, AND GENE LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; PLASMA-MEMBRANES; PROTEINS; ENZYME; SURFACE; TRYPSIN; PURIFICATION; PROTEOLYSIS; FIBROBLASTS; BINDING	Hepsin, a putative membrane-bound serine protease, was originally identified as a human liver cDNA clone (Leytus, S. P., Loeb, K. R., Hagen, F. S., Kurachi, K., and Davie, E. W. (1988) Biochemistry 27, 10671074). In the present study the human hepsin gene was localized to chromosome 19 at q11-13.2. The messenger RNA of hepsin is 1.85 kilobases in size and present in most tissues, with the highest level in liver. Hepsin is synthesized as a single polypeptide chain, and its mature form of 51 kDa was found in various mammalian cells including HepG2 cells and baby hamster kidney cells. It is present in the plasma-membrane in a molecular orientation of type II membrane-associated proteins, with its catalytic subunit (carboxyl-terminal half) at the cell surface, and its amino terminus facing the cytosol. Hepsin is found neither in cytosol nor in culture media. The results obtained suggest that hepsin has an important role(s) in cell growth and function.	UNIV MICHIGAN,SCH MED,DEPT HUMAN GENET,ANN ARBOR,MI 48109; UNIV CHICAGO,HEMATOL & ONCOL SECT,CHICAGO,IL 60637; UNIV UTAH,DEPT PEDIAT,SALT LAKE CITY,UT 84132; UNIV WASHINGTON,DEPT BIOCHEM,SEATTLE,WA 98195	University of Michigan System; University of Michigan; University of Chicago; Utah System of Higher Education; University of Utah; University of Washington; University of Washington Seattle				CHOU, Shan-Ho/0000-0002-5202-8238	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038644] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL38644] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AOYAMA A, 1990, P NATL ACAD SCI USA, V87, P8296, DOI 10.1073/pnas.87.21.8296; BELSHAM GJ, 1980, BIOCHEM J, V192, P457, DOI 10.1042/bj1920457; BILLINGS PC, 1987, P NATL ACAD SCI USA, V84, P4801, DOI 10.1073/pnas.84.14.4801; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BOND JS, 1987, ANNU REV BIOCHEM, V56, P333, DOI 10.1146/annurev.bi.56.070187.002001; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FLEMING PJ, 1977, J BIOL CHEM, V252, P1663; FRASER JD, 1984, MOL IMMUNOL, V21, P311, DOI 10.1016/0161-5890(84)90102-0; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HUARTE J, 1987, J CELL BIOL, V104, P1281, DOI 10.1083/jcb.104.5.1281; KALDERON N, 1986, DEV BRAIN RES, V25, P1, DOI 10.1016/0165-3806(86)90146-X; KATUNUMA N, 1989, INTRACELLULAR PROTEO; KURACHI K, 1989, INTRACELLULAR PROTEO, P144; KUSUMOTO H, 1988, P NATL ACAD SCI USA, V85, P7307, DOI 10.1073/pnas.85.19.7307; LEBEAU MM, 1984, NATURE, V312, P70, DOI 10.1038/312070a0; LEBEAU MM, 1986, COLD SPRING HARB SYM, V51, P899, DOI 10.1101/SQB.1986.051.01.103; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; NEURATH H, 1985, FED PROC, V44, P2907; PARKS GD, 1991, CELL, V64, P777, DOI 10.1016/0092-8674(91)90507-U; Reichlin M, 1980, Methods Enzymol, V70, P159; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SATOH M, 1988, J BIOCHEM-TOKYO, V103, P493, DOI 10.1093/oxfordjournals.jbchem.a122298; SCOTT GK, 1989, BIOCHIM BIOPHYS ACTA, V1010, P160, DOI 10.1016/0167-4889(89)90156-0; SCOTT GK, 1985, EXP CELL RES, V158, P41, DOI 10.1016/0014-4827(85)90429-X; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; STEVEN FS, 1988, BIOL CHEM H-S, V369, P137; STEVEN FS, 1986, J CHROMATOGR, V376, P211, DOI 10.1016/S0378-4347(00)80838-5; STEVEN FS, 1983, EUR J BIOCHEM, V130, P335, DOI 10.1111/j.1432-1033.1983.tb07157.x; TANAKA K, 1986, J BIOL CHEM, V261, P2610; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALINSKY JE, 1985, EMBO J, V4, P1403, DOI 10.1002/j.1460-2075.1985.tb03793.x; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WINDELL CC, 1968, P NATL ACAD SCI USA, V61, P1050	35	103	116	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16948	16953						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885621				2022-12-25	WOS:A1991GD63500111
J	CHAI, KX; MA, JX; MURRAY, SR; CHAO, J; CHAO, L				CHAI, KX; MA, JX; MURRAY, SR; CHAO, J; CHAO, L			MOLECULAR-CLONING AND ANALYSIS OF THE RAT KALLIKREIN-BINDING PROTEIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIRECTS SPECIFIC INITIATION; TISSUE-KALLIKREIN; CONTROL REGION; CDNA CLONING; ALPHA-1-ANTITRYPSIN; EXPRESSION; INHIBITOR; IDENTIFICATION; TRANSCRIPTION; SEQUENCES	The gene encoding rat kallikrein-binding protein (RKBP), a serine protease inhibitor, has been isolated and analyzed with the aid of the polymerase chain reaction. The gene is approximately 10 kilobases in length with four introns of approximately 2.2, 1.8, 0.9, and 0.84 kilobases. This gene is composed of five exons and encodes a polypeptide of 416 amino acid residues. The reactive center region of RKBP is encoded by the fifth exon with the putative P1-P1' residues being Lys-Ser. The organization of the RKBP gene is homologous to those of human alpha-1-antitrypsin and al-antichymotrypsin in size and arrangement of exons and introns, suggesting that they belong to the same subgroup of serpins. In the 5'-flanking region of the RKBP gene, a variant TATA box sequence, ATAAATA, is found 20 base pairs upstream from the transcription initiation site. The 5'-flanking region of the RKBP gene was able to direct transcription of the reporter gene chloramphenicol acetyltransferase when transfected into a rat hepatoma cell line. An internal promoter-like region was found in the first intron of the RKBP gene, downstream from the transcription initiation site and upstream from the translation initiation codon, however, it was unable to direct expression of the chloramphenicol acetyltransferase reporter gene in our experiments. The expression of RKBP in rat liver was induced by sex hormone treatment as indicated by dot-blot analysis. A genomic Southern blot using an RKBP cDNA probe revealed multiple bands suggesting that the RKBP gene belongs to a family of highly conserved genes.	MED UNIV S CAROLINA,DEPT BIOCHEM & MOLEC BIOL,171 ASHLEY AVE,CHARLESTON,SC 29425	Medical University of South Carolina					NHLBI NIH HHS [HL 44083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANDA MJ, 1988, J BIOL CHEM, V263, P4481; BAO JJ, 1987, BIOCHEMISTRY-US, V26, P7755, DOI 10.1021/bi00398a033; BENOIST C, 1980, NUCLEIC ACIDS RES, V8, P127, DOI 10.1093/nar/8.1.127; BOGENHAGEN DF, 1980, CELL, V19, P27, DOI 10.1016/0092-8674(80)90385-2; BUCHMAN TG, 1990, SURGERY, V108, P559; CHAO J, 1990, J BIOL CHEM, V265, P16394; CHAO J, 1988, J HYPERTENS, V6, P551, DOI 10.1097/00004872-198807000-00006; CHAO J, 1986, BIOCHEM J, V239, P325, DOI 10.1042/bj2390325; CHAO S, 1990, BIOCHEMISTRY-US, V29, P323, DOI 10.1021/bi00454a004; CHEN LM, 1990, BIOCHEM J, V267, P79, DOI 10.1042/bj2670079; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; LECAM A, 1987, EMBO J, V6, P1225, DOI 10.1002/j.1460-2075.1987.tb02358.x; Maniatis T, 1982, MOL CLONING LABORATO, P312; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MONTGOMERY KT, 1990, MOL CELL BIOL, V10, P2625, DOI 10.1128/MCB.10.6.2625; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURRAY SR, 1989, J CARDIOVASC PHARM, V6, pS7; PAGES G, 1990, EUR J BIOCHEM, V190, P385, DOI 10.1111/j.1432-1033.1990.tb15587.x; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; SAKONJU S, 1980, CELL, V19, P13, DOI 10.1016/0092-8674(80)90384-0; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TECCE MF, 1987, BIOCHEMISTRY-US, V25, P5831; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; YOON JB, 1987, J BIOL CHEM, V262, P4284	30	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16029	16036						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874745				2022-12-25	WOS:A1991GB97700076
J	HARMANN, B; ZANDER, NF; KILIMANN, MW				HARMANN, B; ZANDER, NF; KILIMANN, MW			ISOFORM DIVERSITY OF PHOSPHORYLASE-KINASE ALPHA-SUBUNITS AND BETA-SUBUNITS GENERATED BY ALTERNATIVE RNA SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; GLYCOGEN-PHOSPHORYLASE; CDNA CLONING; CARDIAC ISOENZYME; MESSENGER-RNAS; DEFICIENCY; PURIFICATION; ISOZYMES; LIVER; CHROMOSOME	We have sequenced rabbit cDNAs that encode one isoform of the alpha-subunit and two isoforms of the beta-subunit of phosphorylase kinase, in addition to the single isoform from fast skeletal muscle that has been characterized to date for each subunit. All these isoforms are generated by alternative RNA splicing. The a subunit sequence obtained from slow skeletal muscle (soleus) is characterized by an internal deletion of 59 amino acids. This deletion is predominant in mRNA from slow muscle, heart, and uterus and accounts for the smaller alpha-subunit variant (alpha') characteristic of phosphorylase kinase purified from slow muscle and heart. The beta-subunit mRNA can be differentially spliced at two sites. In all tissues (except skeletal muscle) that were analyzed, an internal segment encoding 28 amino acids of the muscle sequence is replaced by a homologous sequence of identical length, presumably through the use of mutually exclusive exons. In brain and some other tissues, the deduced N-terminal sequence of the beta-subunit is also changed. This is achieved by an insertion into the mRNA sequence that interrupts the initial reading frame after 25 codons and starts a new reading frame, encoding a different N terminus of 18 amino acids. This modification probably affects the major regulatory phosphorylation site of the beta-subunit.	RUHR UNIV BOCHUM,INST PHYSIOL CHEM,BIOCHEM SUPRAMOLEK SYST ABT,UNIV STR 150,W-4630 BOCHUM 1,GERMANY	Ruhr University Bochum								ABARBANEL JM, 1986, NEUROLOGY, V36, P560, DOI 10.1212/WNL.36.4.560; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; BARNARD PJ, 1990, CYTOGENET CELL GENET, V53, P91, DOI 10.1159/000132902; BENDER PK, 1989, P NATL ACAD SCI USA, V86, P9996, DOI 10.1073/pnas.86.24.9996; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHRISMAN TD, 1982, J BIOL CHEM, V257, P798; CLEMENS PR, 1990, ANN NEUROL, V28, P529, DOI 10.1002/ana.410280410; COHEN PTW, 1981, EUR J BIOCHEM, V115, P619; COOPER RH, 1981, J BIOL CHEM, V256, P8030; COOPER RH, 1980, J BIOL CHEM, V255, P1794; FRANCKE U, 1989, AM J HUM GENET, V45, P276; GROSS SR, 1974, J BIOL CHEM, V249, P6710; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; JENNISSEN HP, 1974, FEBS LETT, V42, P77, DOI 10.1016/0014-5793(74)80283-8; KILIMANN MW, 1990, J INHERIT METAB DIS, V13, P435, DOI 10.1007/BF01799500; KILIMANN MW, 1988, P NATL ACAD SCI USA, V85, P9381, DOI 10.1073/pnas.85.24.9381; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAWRENCE JC, 1986, J BIOL CHEM, V261, P8556; LEBO RV, 1984, SCIENCE, V225, P57, DOI 10.1126/science.6587566; NEWGARD CB, 1988, J BIOL CHEM, V263, P3850; NEWGARD CB, 1987, AM J HUM GENET, V40, P351; OHTANI Y, 1982, NEUROLOGY, V32, P833, DOI 10.1212/WNL.32.8.833; PROUX D, 1974, BIOCHIMIE, V56, P1559; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA RK, 1980, J BIOL CHEM, V255, P1102; TAIRA T, 1982, J BIOCHEM-TOKYO, V91, P883, DOI 10.1093/oxfordjournals.jbchem.a133776; WILLEMS PJ, 1991, GENOMICS, V9, P565, DOI 10.1016/0888-7543(91)90347-H; YEAMAN SJ, 1975, EUR J BIOCHEM, V51, P93, DOI 10.1111/j.1432-1033.1975.tb03910.x; ZANDER NF, 1988, P NATL ACAD SCI USA, V85, P2929, DOI 10.1073/pnas.85.9.2929	29	49	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15631	15637						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874721				2022-12-25	WOS:A1991GB97700018
J	SOPCHAK, L; THRUSH, GR; LERMAN, SP; KING, SR				SOPCHAK, L; THRUSH, GR; LERMAN, SP; KING, SR			LOSS OF MYB EXPRESSION IN AN AGGRESSIVE SJL/J B-CELL LYMPHOMA	ONCOGENE			English	Article							C-MYB; NUCLEOTIDE-SEQUENCE; ONCOGENE ACTIVATION; V-MYB; DNA; SARCOMAS; TUMORS; GENES; MICE; AMPLIFICATION	SJL mice spontaneously develop B-cell lymphomas that can be propagated by transplantation into syngeneic mice. These tumors usually have an indolent phenotype and require at least several weeks to produce morbidity following transplantation. However an aggressive lymphoma (RCS5) has been found that produces morbidity within days of transplantation. RCS5 cells fail to express the H-2D(s) class I major histocompatibility complex antigen, whereas indolent tumors express H-2D(s). To identify genetic factors that may contribute to the tumorigenicity of B-cell lymphomas in SJL mice, tumor genomes were analyzed for mutations in cellular oncogenes. No rearrangements were detected by Southern hybridization analysis in tumors at the abl, myc, mhcl-2, Ha-ras, Ki-ras and raf loci. Indolent tumors were not rearranged at the myb oncogene, however alterations were detected in both myb alleles in RCS5. Northern hybridization analysis on RNA from in vivo-derived tumor preparations failed to detect any myb transcripts in RCS5. The loss of normal myb expression could directly contribute to the aggressive phenotype of RCS5. Alternatively, expression of the RCS5 myb allele may have contributed to early stages of tumor development. The possibilities that the observed myb mutations affect tumor aggressiveness and H-2D(s) expression are discussed.	WAYNE STATE UNIV,SCH MED,DEPT IMMUNOL & MICROBIOL,DETROIT,MI 48201	Wayne State University			King, Steven/AAE-2526-2019		NCI NIH HHS [CA22453, CA52603] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA052603, P30CA022453] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1987, J IMMUNOL, V139, P3822; BENDER TP, 1986, P NATL ACAD SCI USA, V83, P3204, DOI 10.1073/pnas.83.10.3204; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BONAVIDA B, 1985, SURV IMMUNOL RES, V4, P271; BUTCH AW, 1986, 6TH INT C IMM, P397; CAVENEE W, 1989, RECESSIVE ONCOGENES; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; GRUNWALD DJ, 1982, J VIROL, V43, P92, DOI 10.1128/JVI.43.1.92-103.1982; KANTER MR, 1988, J VIROL, V62, P1423, DOI 10.1128/JVI.62.4.1423-1432.1988; KLEIN G, 1987, SCIENCE, V238, P1539, DOI 10.1126/science.3317834; KLEMPNAUER KH, 1983, CELL, V33, P345, DOI 10.1016/0092-8674(83)90416-6; KLEMPNAUER KH, 1986, MOL CELL BIOL, V6, P62, DOI 10.1128/MCB.6.1.62; LAVU S, 1986, NUCLEIC ACIDS RES, V14, P5309, DOI 10.1093/nar/14.13.5309; LUSCHER B, 1990, GENE DEV, V4, P2235, DOI 10.1101/gad.4.12b.2235; MURPHY ED, 1969, J NATL CANCER I, V42, P797; NAKAUCHI H, 1987, J IMMUNOL, V139, P2803; PELICCI PG, 1984, SCIENCE, V224, P1117, DOI 10.1126/science.6585957; PETERS CWB, 1987, EMBO J, V6, P3085, DOI 10.1002/j.1460-2075.1987.tb02616.x; PIZER E, 1989, J VIROL, V63, P1630, DOI 10.1128/JVI.63.4.1630-1640.1989; PONTE P, 1984, NUCLEIC ACIDS RES, V12, P1687, DOI 10.1093/nar/12.3.1687; Ponzio N M, 1986, Int Rev Immunol, V1, P273, DOI 10.3109/08830188609056610; PONZIO NM, 1977, CELL IMMUNOL, V32, P10, DOI 10.1016/0008-8749(77)90178-2; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; ROSLONIEC EF, 1984, J IMMUNOL, V132, P945; ROSSON D, 1987, P NATL ACAD SCI USA, V84, P3171, DOI 10.1073/pnas.84.10.3171; ROSSON D, 1986, NATURE, V319, P604, DOI 10.1038/319604a0; Sambrook J, 1989, MOL CLONING LABORATO; SHENONG GLC, 1990, BIOCHIM BIOPHYS ACTA, V1032, P39, DOI 10.1016/0304-419X(90)90011-O; SHENONG GLC, 1986, MOL CELL BIOL, V6, P380, DOI 10.1128/MCB.6.2.380; SOPCHAK L, 1989, CANCER RES, V49, P665; STAVNEZER J, 1989, EUR J IMMUNOL, V19, P1063, DOI 10.1002/eji.1830190616; WIRSCHUBSKY Z, 1984, INT J CANCER, V33, P477, DOI 10.1002/ijc.2910330410; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898	34	1	1	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1335	1338						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886709				2022-12-25	WOS:A1991GX27200006
J	DILIBERTO, PA; GORDON, G; HERMAN, B				DILIBERTO, PA; GORDON, G; HERMAN, B			REGIONAL AND MECHANISTIC DIFFERENCES IN PLATELET-DERIVED GROWTH-FACTOR ISOFORM-INDUCED ALTERATIONS IN CYTOSOLIC FREE CALCIUM IN PORCINE VASCULAR SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR FREE CALCIUM; CYTOPLASMIC FREE CA-2+; HUMAN-FIBROBLASTS; PDGF RECEPTOR; BALB/C-3T3 CELLS; MESSENGER SYSTEM; 3 ISOFORMS; 3T3 CELLS; OSCILLATIONS; EXPRESSION	Three specific platelet-derived growth factor (PDGF) isoforms are thought to bind with differing affinities to two distinct PDGF receptors which undergo activation following dimerization. Recent evidence has been presented that marked differences exist between the ability of PDGF-AA versus PDGF-AB and PDGF-BB to stimulate alterations in second messengers in cultures of vascular smooth muscle cells (VSMC), a result which was thought to be due to low numbers of the A-type receptor in this cell type (Sachinidis, A., Locker, R., Vetter, W., Tatje, D., and Hoppe, J. (1990) J. Biol. Chem. 265, 10238-10243, 1990). In particular, PDGF-BB and PDGF-AB but not PDGF-AA could elicit alterations in cytosolic free calcium (Ca2+i). However, because these studies were performed on large cell populations using biochemical assays of PDGF activity, a minor PDGF-AA-Ca2+-responsive population of cells might go undetected. To test this possibility, VSMC were isolated from either thoracic or abdominal pig aorta, and alterations in Ca2+i were monitored using Multiparameter Digitized Video Microscopy following stimulation with PDGF isoforms alone, or either before or after exposure of VSMC to 5 mM EGTA. PDGF-AA-responsive cells were found to exist only in cultures of thoracic VSMC, caused oscillations in Ca2+i, represented 20% of the PDGF-BB-responsive cells, and were subsequently responsive to PDGF-BB. PDGF-BB elicited monophasic alterations in Ca2+i in both thoracic and abdominal VSMC. Prior addition of EGTA inhibited PDGF-AA but not PDGF-BB-induced alterations in Ca2+i. Addition of EGTA during PDGF-AA-induced Ca2+i oscillations inhibited subsequent oscillations in Ca2+i, while addition of EGTA at the peak of the PDGF-BB Ca2+ response resulted in a more rapid return of Ca2+i to prestimulation levels. These data suggest that regional differences in the distribution of PDGF-A- and B-type receptor exists in vivo, and that activation of the A- and B-type PDGF receptors results in distinct alterations in Ca2+i.	UNIV N CAROLINA,DEPT CELL BIOL & ANAT,CELL BIOL LABS,CB 7090,232 TAYLOR BLDG,CHAPEL HILL,NC 27599; UNIV N CAROLINA,SCH MED,LINEBERGER CANC RES CTR,CANC CELL BIOL PROGRAM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NCI NIH HHS [2-P01-CA29589] Funding Source: Medline; NIA NIH HHS [AG10104, AG07218] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG007218, R01AG010104, R01AG007218] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AMBLER SK, 1988, J BIOL CHEM, V263, P1952; BERNACKI SH, 1990, OPTICAL MICROSCOPY FOR BIOLOGY, P307; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BLOCK LH, 1989, P NATL ACAD SCI USA, V86, P2388, DOI 10.1073/pnas.86.7.2388; BOWENPOPE DF, 1989, J BIOL CHEM, V264, P2502; CLAESSONWELSH L, 1989, P NATL ACAD SCI USA, V86, P4917, DOI 10.1073/pnas.86.13.4917; CLAESSONWELSH L, 1989, ACTA ONCOL, V28, P331, DOI 10.3109/02841868909111202; DILIBERTO P A, 1990, FASEB Journal, V4, pA489; FRACE AM, 1989, P NATL ACAD SCI USA, V86, P2511, DOI 10.1073/pnas.86.7.2511; FRANTZ CN, 1985, EXP CELL RES, V158, P287, DOI 10.1016/0014-4827(85)90454-9; HAMMACHER A, 1988, J BIOL CHEM, V263, P16493; HART CE, 1988, SCIENCE, V240, P1529, DOI 10.1126/science.2836952; HELDIN CH, 1988, EMBO J, V7, P1387, DOI 10.1002/j.1460-2075.1988.tb02955.x; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; HELDIN CH, 1986, NATURE, V319, P511, DOI 10.1038/319511a0; HELDIN CH, 1990, J CELL SCI, V96, P193; HEPLER JR, 1987, J BIOL CHEM, V262, P2951; HERMAN B, 1987, CELL MOTIL CYTOSKEL, V8, P91, DOI 10.1002/cm.970080202; HESKETH TR, 1983, J BIOL CHEM, V258, P4876; HOPPE J, 1990, EUR J BIOCHEM, V187, P207, DOI 10.1111/j.1432-1033.1990.tb15296.x; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; KHALIL R, 1987, J HYPERTENS, V5, pS5, DOI 10.1097/00004872-198712004-00003; MAJACK RA, 1990, J CELL BIOL, V111, P239, DOI 10.1083/jcb.111.1.239; MCNEIL PL, 1985, J CELL BIOL, V101, P372, DOI 10.1083/jcb.101.2.372; MIX LL, 1984, BIOCHEM BIOPH RES CO, V119, P69, DOI 10.1016/0006-291X(84)91619-X; MOOLENAAR WH, 1986, J EXP BIOL, V124, P359; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MOOLENAAR WH, 1979, J EXP BIOL, V279, P721; MORRIS JDH, 1984, FEBS LETT, V169, P189, DOI 10.1016/0014-5793(84)80316-6; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1094; RASMUSSEN H, 1986, NEW ENGL J MED, V314, P1164; ROE MW, 1989, J CELL PHYSIOL, V139, P100, DOI 10.1002/jcp.1041390115; ROE MW, 1990, CELL CALCIUM, V11, P63, DOI 10.1016/0143-4160(90)90060-8; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROTHENBERG P, 1982, P NATL ACAD SCI-BIOL, V79, P7783, DOI 10.1073/pnas.79.24.7783; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SADOSHIMA JI, 1988, AM J PHYSIOL, V255, pH754, DOI 10.1152/ajpheart.1988.255.4.H754; SAGE SO, 1989, J BIOL CHEM, V264, P6; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SJOHUND M, 1988, J CELL BIOL, V106, P403; SPERTI G, 1987, FED PROC, V46, P974; TACHER RW, 1986, EUR J CELL BIOL, V41, P347; TERRACIO L, 1988, J CELL BIOL, V107, P1947, DOI 10.1083/jcb.107.5.1947; TUCKER RW, 1990, EUR J CELL BIOL, V51, P120; TUCKER RW, 1989, J CELL BIOCHEM, V39, P139, DOI 10.1002/jcb.240390206; WESTERMARK B, 1986, P NATL ACAD SCI USA, V83, P7197, DOI 10.1073/pnas.83.19.7197; WOODS NM, 1987, CELL CALCIUM, V8, P79, DOI 10.1016/0143-4160(87)90038-8; ZAGARI M, 1989, J CELL PHYSIOL, V139, P167, DOI 10.1002/jcp.1041390123; ZAGARI M, 1988, BIOCHEM BIOPH RES CO, V150, P1207, DOI 10.1016/0006-291X(88)90757-7	52	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12612	12617						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905727				2022-12-25	WOS:A1991FV18000080
J	HIGASHIJIMA, T; ROSS, EM				HIGASHIJIMA, T; ROSS, EM			MAPPING OF THE MASTOPARAN-BINDING SITE ON G-PROTEINS - CROSS-LINKING OF [I-125] TYR3,CYS11]MASTOPARAN TO G0	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; GUANINE-NUCLEOTIDE-BINDING; ROD OUTER SEGMENTS; ADENYLATE-CYCLASE; GTPASE ACTIVITY; ALPHA-SUBUNITS; REGULATORY PROTEINS; LIMITED PROTEOLYSIS; ADP-RIBOSYLATION; TRANSDUCIN	Mastoparan (MP) activates GTP-binding regulatory proteins (G proteins) by promoting GDP/GTP exchange through a mechanism similar to that of G protein-coupled receptors (Higashijima, T., Burnier, J., and Ross, E. M. (1990) J. Biol. Chem. 265, 14176-14186). [Tyr3,Cys11]MP was synthesized and shown to have regulatory activity similar to that of mastoparan when assayed in the presence of dithiothreitol (DTT). Activation by [Tyr3,Cys11]MP in the absence of DTT was complex in its kinetics, concentration dependence, and dependence on detergents. [I-125-Tyr3, Cys11]MP bound covalently to the alpha-subunit of G proteins. Cross-linking was blocked by mastoparan or [Tyr3,Cys11]MP. Cross-linking was enhanced by the addition of beta-gamma-subunits, but no cross-linking to beta-gamma subunits was observed. Cross-linking was inhibited by incubation of G(o) with guanosine 5'-O-(thiotriphosphate) and Mg2+ and was reversed by incubation with DTT or 2-mercaptoethanol. Stoichiometry of labeling was consistent with the cross-linking of one molecule of [I-125-Tyr3,Cys11]MP/alpha-subunit, and CNBr hydrolysis of the [I-125-Tyr3,Cys11]MP-alpha-o. adduct yielded one major labeled peptide fragment of approximately 6 kDa. Amino acid sequencing of this CNBr fragment prepared from recombinant alpha-o showed that cross-linking occurred at Cys3. No alpha-o sequence was obtained from the same fragment prepared from bovine brain alpha-o, which is blocked by a myristoyl group at Gly2. Regulation of G(o) by MP was eliminated by tryptic proteolysis of the amino-terminal region. These observations suggest that the amino-terminal region of G protein alpha-subunits contributes to the mastoparan-binding site, which may also be the receptor-binding site, and is involved in regulation of nucleotide exchange.			HIGASHIJIMA, T (corresponding author), UNIV TEXAS,SW MED CTR,SW GRAD SCH BIOMED SCI,DEPT PHARMACOL,DALLAS,TX 75235, USA.				NIGMS NIH HHS [GM30355, GM40676] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030355, R37GM030355, R01GM040676] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CERIONE RA, 1988, J BIOL CHEM, V263, P9345; COTECCHIA S, 1990, P NATL ACAD SCI USA, V87, P2896, DOI 10.1073/pnas.87.8.2896; EDELHOCH H, 1962, J BIOL CHEM, V237, P2778; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAGA T, 1977, P NATL ACAD SCI USA, V74, P2016, DOI 10.1073/pnas.74.5.2016; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1988, J BIOL CHEM, V263, P6491; HIGASHIJIMA T, 1990, J BIOL CHEM, V265, P14176; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; KUBO T, 1988, FEBS LETT, V241, P119, DOI 10.1016/0014-5793(88)81043-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MALENCIK DA, 1983, BIOCHEM BIOPH RES CO, V114, P50, DOI 10.1016/0006-291X(83)91592-9; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; RUBENSTEIN RC, 1987, J BIOL CHEM, V262, P16655; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRADER CD, 1987, J BIOL CHEM, V262, P16439; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; VANDOP C, 1984, J BIOL CHEM, V259, P23; WAKAMATSU K, 1983, FEBS LETT, V162, P123, DOI 10.1016/0014-5793(83)81062-X; WEINGARTEN R, 1990, J BIOL CHEM, V265, P11044; WESS J, 1989, FEBS LETT, V258, P133, DOI 10.1016/0014-5793(89)81633-3; WEST RE, 1985, J BIOL CHEM, V260, P4428; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; WONG SKF, 1990, J BIOL CHEM, V265, P6219; WONG SKF, 1988, J BIOL CHEM, V263, P7925	42	95	97	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12655	12661						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905730				2022-12-25	WOS:A1991FV18000086
J	GRANDHEE, SK; MONNIER, VM				GRANDHEE, SK; MONNIER, VM			MECHANISM OF FORMATION OF THE MAILLARD PROTEIN CROSS-LINK PENTOSIDINE - GLUCOSE, FRUCTOSE, AND ASCORBATE AS PENTOSIDINE PRECURSORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LENS PROTEINS; ACID; COLLAGEN	Pentosidine is a recently discovered fluorescent protein cross-link from human extracellular matrix that involves lysyl and arginyl residues in an imidazo(4, 5b)pyridinium ring. Pentosidine could be synthesized in vitro by the reaction of ribose, lysine, and arginine. The potential biological significance of the molecule prompted us to investigate its mechanism of formation from D-ribose and key Maillard intermediates, as well as from other potential precursor sugars. The yield of pentosidine from N-alpha-t-Boc-lysine, N-alpha-t-Boc-arginine, and D-ribose was highest at pH 9.0 and 65-degrees-C, but was unaffected by reactant ratios at alkaline pH suggesting an important role for base catalysis. Ribated Boc-lysine on incubation with N-alpha-t-Boc-arginine afforded a fluorescent compound with UV, fluorescence, H-1 NMR, and MS properties identical with those from native or synthetic pentosidine. 3-Deoxypentosone, however, was not a major pentosidine precursor. Pentosidine became slowly detectable in bovine serum albumin incubated with 0.25 M and 1.0 M glucose and reached, at 30 days, 13.2 and 17 pmol/mg bovine serum albumin, respectively. Spectroscopical properties of glucose-derived pentosidine were identical with those from ribose-derived pentosidine. Pentosidine formed from glucated Boc-lysine with N-alpha-t-Boc-arginine in higher yields than from glucose under standard conditions. Fructose, and unexpectedly ascorbate, also formed pentosidine in similar yields as glucose. The discovery that pentosidine can form not only from pentoses but also from hexoses and ascorbate raises major new questions concerning biochemical pathways of the Maillard reaction in vivo.	CASE WESTERN RESERVE UNIV,INST PATHOL,CLEVELAND,OH 44106	Case Western Reserve University			Monnier, Vincent M/B-1371-2009		NATIONAL EYE INSTITUTE [R01EY007099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR039750] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG005601] Funding Source: NIH RePORTER; NEI NIH HHS [EY 07099] Funding Source: Medline; NIAMS NIH HHS [AR-39750] Funding Source: Medline; NIA NIH HHS [AG 05601] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		[Anonymous], CARBOHYDRATES CHEM B; BOAS NF, 1953, J BIOL CHEM, V204, P553; CHATTERJEE IB, 1979, ANAL BIOCHEM, V98, P368, DOI 10.1016/0003-2697(79)90155-6; Feather M.S., 1973, ADV CARBOHYDR CHEM B, V28, P161, DOI 10.1016/S0065-2318(08)60383-2; FINOT PA, 1969, HELV CHIM ACTA, V52, P1488, DOI 10.1002/hlca.19690520609; GREEN JW, 1980, CARBOHYDRATES CHEM B, P1101; HODGE JE, 1953, J AGR FOOD CHEM, V1, P928, DOI 10.1021/jf60015a004; KHADEM HE, 1971, CARBOHYD RES, V17, P183; ORTWERTH BJ, 1988, BIOCHIM BIOPHYS ACTA, V956, P10, DOI 10.1016/0167-4838(88)90292-0; SELL DR, 1989, J BIOL CHEM, V264, P21597; SELL DR, 1989, CONNECT TISSUE RES, V19, P77, DOI 10.3109/03008208909016816; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SLIGHT SH, 1990, BIOCHIM BIOPHYS ACTA, V1038, P367, DOI 10.1016/0167-4838(90)90250-J; STILL WC, 1978, J ORG CHEM, V43, P2923, DOI 10.1021/jo00408a041; WOLFF SP, 1987, BIOCHEM J, V245, P243, DOI 10.1042/bj2450243	15	418	432	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11649	11653						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904866				2022-12-25	WOS:A1991FT76200038
J	PHILIPS, MR; ABRAMSON, SB; KOLASINSKI, SL; HAINES, KA; WEISSMANN, G; ROSENFELD, MG				PHILIPS, MR; ABRAMSON, SB; KOLASINSKI, SL; HAINES, KA; WEISSMANN, G; ROSENFELD, MG			LOW-MOLECULAR-WEIGHT GTP-BINDING PROTEINS IN HUMAN NEUTROPHIL GRANULE MEMBRANES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM TOXIN; ADP-RIBOSYLATION; SUBCELLULAR-LOCALIZATION; POLYMORPHONUCLEAR LEUKOCYTES; GUANINE-NUCLEOTIDES; POLYACRYLAMIDE GELS; ADENYLATE-CYCLASE; PERTUSSIS TOXIN; CHOLERA-TOXIN; RAS	Degranulation of neutrophils involves the differential regulation of the exocytosis of at least two populations of granules. Low molecular weight GTP-binding proteins (LMW-GBPs) have been implicated in the regulation of vesicular traffic in the secretory pathways of several types of cells. In the present study we identify distinct subsets of LMW-GBPs associated with the membranes of neutrophil-specific and azurophilic granules. Ninety-four percent of total [S-35]guanosine 5'-(3-O-thio)triphosphate (GTP-gamma-S) binding activity was equally distributed between the plasma membrane and cytosol with the remaining 6% localized in the granules. In contrast, the cytosol contained only 10% of the total GTPase activity while the specific granules accounted for 13%. [alpha-32-P]GTP binding to proteins transferred to nitrocellulose revealed LMW-GBPs in all fractions except the azurophilic granules. The specific granules contained three out of four bands which were found in the plasma membrane; these ranged from 20 to 23 kDa and all were resistant to alkaline extraction. Photoaffinity labeling with [alpha-32-P]8-azido-GTP in the presence of micromolar Al3+ identified proteins of 25 and 26 kDa unique to azurophilic granules; these could not be labeled with [alpha-32-P]8-azido-ATP and could be extracted by acidic but not alkaline pH. Botulinum C3-mediated [P-32]ADP-ribosylation identified proteins of 16, 20, and 24 kDa both in plasma membranes and those of specific granules. An anti-ras monoclonal antibody, 142-24E5, recognized a 20-kDa protein localized to the plasma and specific granule membranes which could not be extracted by alkaline pH, was not a substrate for botulinum C3 ADP-ribosyltransferase, and was translocated from specific granules to plasma membrane after exposure of neutrophils to phorbol myristate acetate. We conclude that neutrophil-specific and azurophilic granules contain distinct subsets of LMW-GBPs which are uniquely situated to regulate the differential exocytosis of these two compartments.	NYU,SCH MED,DEPT MED,NEW YORK,NY 10016; NYU,SCH MED,DEPT CELL BIOL,NEW YORK,NY 10016	New York University; New York University			Weissmann, Gerald/N-5273-2015	Weissmann, Gerald/0000-0002-4285-4552; Abramson, Steven/0000-0002-0668-6344; Mark, Philips/0000-0002-1179-8156	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL019721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR011949, R37AR011949] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020277] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 19721-14] Funding Source: Medline; NIAMS NIH HHS [AR 11949-23] Funding Source: Medline; NIGMS NIH HHS [GM 20277] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMVIZI V, 1987, NATURE, V328, P581, DOI 10.1038/328581a0; ADAMVIZI V, 1988, FEBS LETT, V238, P277, DOI 10.1016/0014-5793(88)80496-4; BAINTON DF, 1973, J CELL BIOL, V58, P249, DOI 10.1083/jcb.58.2.249; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; BARSAGI D, 1988, ONCOGENE, V3, P463; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BLACK VH, 1989, ENDOCRINOLOGY, V124, P2480, DOI 10.1210/endo-124-5-2480; BOKOCH GM, 1988, FEBS LETT, V227, P66, DOI 10.1016/0014-5793(88)81415-7; BOKOCH GM, 1988, J BIOL CHEM, V263, P16744; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BOKOCH GM, 1990, CURR TOP MEMBR TRANS, V35, P65; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; BRANDT DR, 1985, J BIOL CHEM, V260, P266; BRITTINGER GR, 1968, J CELL BIOL, V60, P507; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; DECHATELET LR, 1970, BIOCHEM MED METAB B, V4, P61, DOI 10.1016/0006-2944(70)90103-1; DEXTER D, 1988, J CELL BIOL, V107, P774; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; EDDY A, 1984, CLIN IMMUNOL IMMUNOP, V31, P371, DOI 10.1016/0090-1229(84)90090-4; FISCHER, 1990, P NATL ACAD SCI USA, V87, P1988; FLETCHER MP, 1983, BLOOD, V62, P792; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOMPERTS BD, 1990, ANNU REV PHYSIOL, V52, P591; GOTTLIEB C, 1965, BLOOD-J HEMATOL, V25, P875, DOI 10.1182/blood.V25.6.875.875; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUERRERO I, 1985, P NATL ACAD SCI USA, V82, P7810, DOI 10.1073/pnas.82.23.7810; HEIPLE JM, 1986, J EXP MED, V164, P826, DOI 10.1084/jem.164.3.826; HENSON PM, 1988, INFLAMMATION BASIC P, P363; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KNIGHT DE, 1985, NATURE, V317, P719, DOI 10.1038/317719a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MEGE JL, 1988, BIOCHEM BIOPH RES CO, V152, P926, DOI 10.1016/S0006-291X(88)80129-3; MOLINA V, 1988, P NATL ACAD SCI USA, V85, P5899; MORII N, 1988, J BIOL CHEM, V263, P12420; NATH J, 1990, CLIN RES, V38, P369; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; O'SHEA JJ, 1985, J IMMUNOL, V134, P2580; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; QUILLIAM LA, 1989, FEBS LETT, V247, P221, DOI 10.1016/0014-5793(89)81339-0; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; ROSENER S, 1987, FEBS LETT, V224, P38, DOI 10.1016/0014-5793(87)80418-0; ROTROSEN D, 1988, J BIOL CHEM, V263, P10958; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SINGER II, 1989, J CELL BIOL, V109, P3169, DOI 10.1083/jcb.109.6.3169; SMOLEN JE, 1981, BIOCHIM BIOPHYS ACTA, V672, P197, DOI 10.1016/0304-4165(81)90393-7; STEVENSON KB, 1987, J IMMUNOL, V139, P3759; TEMELES GL, 1985, NATURE, V313, P700, DOI 10.1038/313700a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOLPP BD, 1989, J IMMUNOL, V142, P3206; WACKER WEC, 1956, NEW ENGL J MED, V255, P449, DOI 10.1056/NEJM195609062551001; WEST BC, 1974, AM J PATHOL, V77, P41; WILDE MW, 1989, J BIOL CHEM, V264, P190; WORTHINGTON CC, 1988, WORTHINGTON MANUAL E; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZURIER RB, 1973, J CELL BIOL, V58, P27, DOI 10.1083/jcb.58.1.27	68	63	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1289	1298						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898732				2022-12-25	WOS:A1991ET17700093
J	YOSHIHARA, E; YONEYAMA, H; NAKAE, T				YOSHIHARA, E; YONEYAMA, H; NAKAE, T			INVITRO ASSEMBLY OF THE FUNCTIONAL PORIN TRIMER FROM DISSOCIATED MONOMERS IN PSEUDOMONAS-AERUGINOSA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PERMEABILITY; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; DIMINISHED EXPRESSION; IMIPENEM RESISTANCE; POLYACRYLAMIDE GELS; DIFFUSION PORES; CROSS-LINKING; PROTEIN	The molecular weights of monomeric and oligomeric forms of the newly identified porins, protein D2, of the outer membrane of Pseudomonas aeruginosa appeared to be 47,000 and 137,000, respectively, as determined by the light scattering technique. Presence of the trimeric aggregates of the homologous subunits in the intact outer membrane, the liposome membrane, and the non-ionic surfactant were confirmed through cross-linking experiments and immunoblotting techniques. The protein D2 monomers prepared in 0.1% of sodium dodecyl sulfate at 23-degrees-C spontaneously reassembled into the trimeric aggregate when the surfactant dropped below critical concentration. The diffusion rates of saccharides and beta-lactam antibiotics through the liposome membranes reconstituted from the reassembled protein D2 trimers were indistinguishable from those of the native protein D2. This study shed some light on the porin trimer assembly as well as on the mechanism of carbapenem diffusion through the protein D2 pores.			YOSHIHARA, E (corresponding author), TOKAI UNIV,DEPT CELLULAR INFORMAT SCI,ISEHARA,KANAGAWA 25911,JAPAN.							ANGUS BL, 1982, ANTIMICROB AGENTS CH, V21, P299, DOI 10.1128/AAC.21.2.299; ANGUS BL, 1983, J BACTERIOL, V155, P1042, DOI 10.1128/JB.155.3.1042-1051.1983; BUSCHER KH, 1987, J INFECT DIS, V156, P681, DOI 10.1093/infdis/156.4.681; BUSCHER KH, 1987, ANTIMICROB AGENTS CH, V31, P703, DOI 10.1128/AAC.31.5.703; CAULCOTT CA, 1984, FEMS MICROBIOL LETT, V21, P119, DOI 10.1016/0378-1097(84)90189-7; EISELE JL, 1990, J BIOL CHEM, V265, P10217; HANCOCK REW, 1979, BIOCHIM BIOPHYS ACTA, V554, P323, DOI 10.1016/0005-2736(79)90373-0; HANCOCK REW, 1979, J BACTERIOL, V140, P902, DOI 10.1128/JB.140.3.902-910.1979; HANCOCK REW, 1978, J BACTERIOL, V136, P381, DOI 10.1128/JB.136.1.381-390.1978; KAMEYAMA K, 1982, BIOCHIM BIOPHYS ACTA, V706, P19, DOI 10.1016/0167-4838(82)90370-3; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH MJ, 1987, ANTIMICROB AGENTS CH, V31, P1892, DOI 10.1128/AAC.31.12.1892; MAEZAWA S, 1983, BIOCHIM BIOPHYS ACTA, V747, P291, DOI 10.1016/0167-4838(83)90108-5; MIZUNO T, 1978, J BIOCHEM, V84, P179, DOI 10.1093/oxfordjournals.jbchem.a132106; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NAKAE T, 1986, J BIOL CHEM, V261, P622; NAKAE T, 1986, CRC CR REV MICROBIOL, V13, P1, DOI 10.3109/10408418609108734; NAKAE T, 1979, J BIOL CHEM, V254, P1457; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; PALVA ET, 1978, J BACTERIOL, V133, P279, DOI 10.1128/JB.133.1.279-286.1978; PEDERSEN MM, 1970, AM J CLIN PATHOL, V54, P178; QUINN JP, 1986, J INFECT DIS, V154, P289, DOI 10.1093/infdis/154.2.289; ROSENBUSCH JP, 1974, J BIOL CHEM, V249, P8019; SCHINDLER M, 1984, FEBS LETT, V173, P85, DOI 10.1016/0014-5793(84)81022-4; STEVEN AC, 1977, J CELL BIOL, V72, P292, DOI 10.1083/jcb.72.2.292; TAE HJ, 1979, BIOCHIM BIOPHYS ACTA, V559, P39; Tanford C., 1961, PHYSICAL CHEM MACROM, P275; TOKUNAGA H, 1979, EUR J BIOCHEM, V95, P433, DOI 10.1111/j.1432-1033.1979.tb12982.x; TOKUNAGA M, 1979, EUR J BIOCHEM, V95, P441, DOI 10.1111/j.1432-1033.1979.tb12983.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIAS J, 1989, ANTIMICROB AGENTS CH, V33, P1201, DOI 10.1128/AAC.33.8.1202; TRIAS J, 1990, ANTIMICROB AGENTS CH, V34, P52, DOI 10.1128/AAC.34.1.52; YONEYAMA H, 1986, BIOCHEM BIOPH RES CO, V134, P106; YONEYAMA H, 1986, EUR J BIOCHEM, V157, P33, DOI 10.1111/j.1432-1033.1986.tb09634.x; YOSHIHARA E, 1989, J BIOL CHEM, V264, P6297; YOSHIHARA E, 1988, BIOCHEM BIOPH RES CO, V156, P470, DOI 10.1016/S0006-291X(88)80865-9	37	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					952	957						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898740				2022-12-25	WOS:A1991ET17700045
J	GILLECECASTRO, BL; PRAKOBPHOL, A; BURLINGAME, AL; LEFFLER, H; FISHER, SJ				GILLECECASTRO, BL; PRAKOBPHOL, A; BURLINGAME, AL; LEFFLER, H; FISHER, SJ			STRUCTURE AND BACTERIAL RECEPTOR ACTIVITY OF A HUMAN SALIVARY PROLINE-RICH GLYCOPROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; STREPTOCOCCUS-SANGUIS ATCC-10557; RESPIRATORY-MUCUS GLYCOPROTEINS; SUBMANDIBULAR-SUBLINGUAL SALIVA; BOMBARDMENT MASS-SPECTROMETRY; 500-MHZ H-1-NMR SPECTROSCOPY; QUANTITATIVE SUGAR ANALYSIS; HUMAN-PAROTID SALIVA; EPITHELIAL-CELLS; ESCHERICHIA-COLI	Using an overlay technique, we previously showed that the Gram-negative periodontal pathogen Fusobacterium nucleatum binds to a glycoprotein of M(r) 89,000 (Prakobphol, A., Murray, P., and Fisher, S. J. (1987) Anal. Biochem. 164, 5-11) in the parotid saliva of some individuals. We now show that deglycosylation of the purified glycoprotein results in loss of receptor activity. Amino acid analysis of the protein core showed predominantly proline, glycine, and glutamic acid/glutamine, a characteristic of proline-rich glycoproteins (PRG). The amino terminus contained repeating sequences of Ser-Gln-Gly-Pro-Pro-Pro-Arg-Pro-Gly-Lys-Pro-Glu-Gly-Pro-Pro-Pro-Gln-Gly tht had significant compositional and sequence homology to that encoded by exon 3 of the PRB3 gene. We analyzed the PRG oligosaccharides by a combination of mass spectrometry techniques and nuclear magnetic resonance spectroscopy. Twenty-seven highly fucosylated structures were identified. The most abundant was as follows (where Fuc is fucose). [GRAPHICS] To understand the structural basis of F. nucleatum binding, we screened glycolipids and neoglycolipids carrying carbohydrate structures related to those of the PRG for receptor activity; components with unsubstituted terminal lactosamine residues best supported adherence. Neoglycolipids constructed from PRG oligosaccharides were also receptors. Treatment with beta-galactosidase, but not alpha-fucosidase, abolished binding, suggesting that unsubstituted lactosamine units, including the 6-antenna of the major oligosaccharide, mediate F. nucleatum adherence.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT ANAT,HSW-604,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH MED,DEPT PSYCHIAT,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,SCH DENT,DIV ORAL BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco			Leffler, Hakon/A-2416-2019	Leffler, Hakon/0000-0003-4482-8945	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001614] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R37DE007244, R01DE007244] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 01614] Funding Source: Medline; NIDCR NIH HHS [DE 07244] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALHASHIMI I, 1989, ARCH ORAL BIOL, V34, P289, DOI 10.1016/0003-9969(89)90070-8; ANDERSSON B, 1983, J EXP MED, V158, P559, DOI 10.1084/jem.158.2.559; ANGSTROM J, 1982, BIOCHIM BIOPHYS ACTA, V712, P274, DOI 10.1016/0005-2760(82)90344-7; ANN DK, 1988, J BIOL CHEM, V263, P10887; AZEN EA, 1985, AM J HUM GENET, V37, P418; AZEN EA, 1990, AM J HUM GENET, V47, P686; BENNICK A, 1982, MOL CELL BIOCHEM, V45, P83; BENNICK A, 1981, J BIOL CHEM, V256, P4741; BERGEY EJ, 1986, BIOCHEM J, V234, P43, DOI 10.1042/bj2340043; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOCK K, 1985, J BIOL CHEM, V260, P8545; BRADWAY SD, 1989, BIOCHEM J, V261, P887, DOI 10.1042/bj2610887; BREG J, 1988, EUR J BIOCHEM, V171, P643, DOI 10.1111/j.1432-1033.1988.tb13835.x; BREIMER ME, 1983, BIOCHIM BIOPHYS ACTA, V755, P170, DOI 10.1016/0304-4165(83)90200-3; BREIMER ME, 1985, J BIOCHEM, V98, P1169, DOI 10.1093/oxfordjournals.jbchem.a135383; CARLSON DM, 1966, J BIOL CHEM, V241, P2984; CLARK WB, 1989, INFECT IMMUN, V57, P3003, DOI 10.1128/IAI.57.10.3003-3008.1989; CLEMENTS S, 1985, J BIOL CHEM, V260, P3471; DELL A, 1989, ANAL CARBOHYDRATES G, P217; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EGGE H, 1987, MASS SPECTROM REV, V6, P331, DOI 10.1002/mas.1280060302; ETO T, 1968, J BIOCHEM, V64, P205, DOI 10.1093/oxfordjournals.jbchem.a128881; FINNE J, 1989, J BIOL CHEM, V264, P5720; FISHER SJ, 1987, ARCH ORAL BIOL, V32, P509, DOI 10.1016/S0003-9969(87)80013-4; Gibbons RJ, 1980, BACTERIAL ADHERENC B, P61; GILLECECASTRO BL, 1990, METHOD ENZYMOL, V193, P689, DOI 10.1016/0076-6879(90)93445-Q; GILLECECASTRO BL, 1987, ARCH BIOCHEM BIOPHYS, V256, P194, DOI 10.1016/0003-9861(87)90437-1; GREEN ED, 1988, J BIOL CHEM, V263, P18253; GUNSOLLEY JC, 1990, J PERIODONTOL, V61, P412, DOI 10.1902/jop.1990.61.7.412; HANCOCK K, 1983, ANAL BIOCHEM, V133, P157, DOI 10.1016/0003-2697(83)90237-3; HANSSON GC, 1982, FEBS LETT, V139, P291, DOI 10.1016/0014-5793(82)80873-9; HATTON MN, 1985, BIOCHEM J, V230, P817, DOI 10.1042/bj2300817; HAY DI, 1979, J DENT RES, V58, P930, DOI 10.1177/00220345790580024701; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; KADABA PK, 1969, J PHARM SCI, V11, P1422; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; KARLSSON KA, 1981, J BIOL CHEM, V256, P3512; KAUFFMAN D, 1982, BIOCHEMISTRY-US, V21, P6558, DOI 10.1021/bi00268a036; KAUFFMAN DL, 1991, BIOCHEMISTRY-US, V30, P3351, DOI 10.1021/bi00228a001; KIM HS, 1990, GENOMICS, V6, P260, DOI 10.1016/0888-7543(90)90565-C; KLEIN A, 1988, EUR J BIOCHEM, V171, P631, DOI 10.1111/j.1432-1033.1988.tb13834.x; KRESAK M, 1981, J DENT RES, V60, P653; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFFLER H, 1980, FEMS MICROBIOL LETT, V8, P127, DOI 10.1111/j.1574-6968.1980.tb05064.x; LEFFLER H, 1990, AM J RESP CELL MOL, V2, P409, DOI 10.1165/ajrcmb/2.5.409; LEFFLER H, 1986, MICROBIAL LECTINS AG, P84; LEFFLER H, 1985, 5TH GLYC P INT S, P66; LEVINE MJ, 1987, J DENT RES, V66, P436, DOI 10.1177/00220345870660020901; LINDER H, 1988, INFECT IMMUN, V56, P1309, DOI 10.1128/IAI.56.5.1309-1313.1988; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYONS KM, 1988, GENETICS, V120, P255; MAEDA N, 1985, J BIOL CHEM, V260, P1123; MCKIBBIN JM, 1982, J BIOL CHEM, V257, P755; MINAGUCHI K, 1989, J DENT RES, V68, P2, DOI 10.1177/00220345890680010201; Mirelman D., 1986, MICROBIAL LECTINS AG; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MUENZER J, 1979, J BIOL CHEM, V254, P5623; MURRAY PA, 1988, INFECT IMMUN, V56, P1314, DOI 10.1128/IAI.56.5.1314-1319.1988; NAGATA K, 1983, J PERIODONTOL, V54, P163, DOI 10.1902/jop.1983.54.3.163; NEWMAN HN, 1990, J CLIN PERIODONTOL, V17, P533, DOI 10.1111/j.1600-051X.1990.tb01102.x; OHASHI M, 1973, J LIPID RES, V14, P698; PARKKINEN J, 1988, INFECT IMMUN, V56, P2623, DOI 10.1128/IAI.56.10.2623-2630.1988; POULTER L, 1990, METHOD ENZYMOL, V193, P661, DOI 10.1016/0076-6879(90)93444-P; POULTER L, 1991, ANAL BIOCHEM, V195, P1, DOI 10.1016/0003-2697(91)90286-3; PRAKOBPHOL A, 1987, ANAL BIOCHEM, V164, P5, DOI 10.1016/0003-2697(87)90359-9; PRAKOBPHOL A, 1982, CARBOHYD RES, V108, P111, DOI 10.1016/S0008-6215(00)81896-0; REDDY MS, 1982, BIOCHEM BIOPH RES CO, V104, P882, DOI 10.1016/0006-291X(82)91331-6; REINHOLD VN, 1987, METHOD ENZYMOL, V138, P59, DOI 10.1016/0076-6879(87)38007-3; ROBINSON R, 1989, BIOCHEM J, V263, P497, DOI 10.1042/bj2630497; SABATINI LM, 1989, J DENT RES, V68, P1138, DOI 10.1177/00220345890680070101; SHIBATA S, 1980, J PERIODONTOL, V51, P499, DOI 10.1902/jop.1980.51.9.499; SIMPSON RC, 1990, ANAL CHEM, V62, P248, DOI 10.1021/ac00202a005; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; SPELLMAN MW, 1991, BIOCHEMISTRY-US, V30, P2395, DOI 10.1021/bi00223a015; STOLL MS, 1988, BIOCHEM J, V256, P661, DOI 10.1042/bj2560661; STROMBERG N, 1990, J BIOL CHEM, V265, P11251; SWEELEY CC, 1964, ANAL CHEM, V36, P1461, DOI 10.1021/ac60214a014; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANHALBEEK H, 1985, BIOCHEM BIOPH RES CO, V131, P507, DOI 10.1016/0006-291X(85)91831-5; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WANG WT, 1984, ANAL BIOCHEM, V141, P366, DOI 10.1016/0003-2697(84)90057-5; WEBB JW, 1988, ANAL BIOCHEM, V169, P337, DOI 10.1016/0003-2697(88)90293-X	83	84	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17358	17368						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894623				2022-12-25	WOS:A1991GF44500059
J	SEETHARAM, S; CHAUDHARY, VK; FITZGERALD, D; PASTAN, I				SEETHARAM, S; CHAUDHARY, VK; FITZGERALD, D; PASTAN, I			INCREASED CYTOTOXIC ACTIVITY OF PSEUDOMONAS EXOTOXIN AND 2 CHIMERIC TOXINS ENDING IN KDEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ENDOPLASMIC-RETICULUM; BREFELDIN-A; INTRACELLULAR-TRANSPORT; SECRETORY PROTEINS; RAT HEPATOCYTES; FUSION PROTEIN; DOMAIN-II; CELLS; IMMUNOTOXIN	Pseudomonas exotoxin (PE) is a 66,000 molecular weight protein secreted by Pseudomonas aeruginosa. PE is made up of three domains, and PE40 is a form of PE which lacks domain Ia (amino acids 1-252) and has very low cytotoxicity because it cannot bind to target cells. The sequence Arg-Glu-Asp-Leu-Lys (REDLK) at the carboxyl terminus of Pseudomonas exotoxin has been shown to be important for its cytotoxic activity (Chaudhary, V. K., Jinno, Y., FitzGerald, D. J., and Pastan, I. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 308-312). In this study, we tested the effect of altering the carboxyl sequence of PE from REDLK to the characteristic endoplasmic reticulum retention sequence, KDEL, or to KDEL repeated three times (KDEL)3. We also made similar changes at the carboxyl terminus of two chimeric toxins in which domain I of PE (amino acids 1-252) was either replaced with transforming growth factor-alpha (TGF-alpha) to make TGF-alpha-PE40 or with a single chain antibody (anti-Tac) reacting with the human interleukin 2 receptor to make anti-Tac(Fv)-PE40. Statistical analyses of our results demonstrate that PE and its derivatives ending in KDEL or (KDEL)3 are significantly more active than PE or derivatives ending in REDLK. We have also found that brefeldin A, which is known to perturb the endoplasmic reticulum, inhibits the cytotoxic action of PE. Our results suggest that the altered carboxyl terminus may enable the toxin to interact more efficiently with a cellular component involved in translocation of the toxin to the cytosol.	NCI,DIV CANC BIOL DIAGNOSIS & CENTERS,MOLEC BIOL LAB,BLDG 37,RM 4E16,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270				ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ANDRES DA, 1990, J BIOL CHEM, V265, P5952; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P9491, DOI 10.1073/pnas.87.23.9491; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P308, DOI 10.1073/pnas.87.1.308; CHAUDHARY VK, 1988, NATURE, V335, P369, DOI 10.1038/335369a0; CHAUDHARY VK, 1987, P NATL ACAD SCI USA, V84, P4538, DOI 10.1073/pnas.84.13.4538; DEAN N, 1990, J CELL BIOL, V111, P369, DOI 10.1083/jcb.111.2.369; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GAMOU S, 1988, J BIOCHEM-TOKYO, V104, P388, DOI 10.1093/oxfordjournals.jbchem.a122478; HAIGLER HT, 1980, J BIOL CHEM, V255, P1239; HWANG J, 1987, CELL, V48, P126; JINNO Y, 1989, J BIOL CHEM, V264, P15953; KNIGHT M, 1989, J CHROMATOGR, V484, P299, DOI 10.1016/S0021-9673(01)88977-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NUCHTERN JG, 1989, NATURE, V339, P223, DOI 10.1038/339223a0; ODA K, 1987, FEBS LETT, V214, P135, DOI 10.1016/0014-5793(87)80028-5; OGATA M, 1990, J BIOL CHEM, V265, P20678; Olsnes S., 1988, IMMUNOTOXINS, P39; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; SIEGALL CB, 1989, FASEB J, V3, P2647, DOI 10.1096/fasebj.3.14.2556314; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TODARO GJ, 1980, P NATL ACAD SCI-BIOL, V77, P5258, DOI 10.1073/pnas.77.9.5258; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; YOSHIDA T, 1990, EXP CELL RES, V190, P11, DOI 10.1016/0014-4827(90)90137-Y	31	191	207	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17376	17381						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910044				2022-12-25	WOS:A1991GF44500061
J	TAKEUCHI, T; DICKINSON, CJ; TAYLOR, IL; YAMADA, T				TAKEUCHI, T; DICKINSON, CJ; TAYLOR, IL; YAMADA, T			EXPRESSION OF HUMAN PANCREATIC-POLYPEPTIDE IN HETEROLOGOUS CELL-LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE PITUITARY-CELLS; NERVE GROWTH-FACTOR; NEUROPEPTIDE-Y; MAMMALIAN-CELLS; INTRACELLULAR STORAGE; PROCESSING ENZYMES; ENDOCRINE-CELLS; NEURO-BLASTOMA; FUSION GENE; TUMOR-CELLS	Pancreatic polypeptide (PP) is initially synthesized as a larger precursor that requires post-translational processing to produce the biologically active hexatriacontapeptide. These steps include tryptic cleavage at paired basic residues, their subsequent removal by a carboxypeptidase B-like enzyme, and formation of a carboxyl-terminal amide moiety via the action of peptidyl-glycyl alpha-amidating monooxygenase. To examine these reactions further, we utilized the pZIPneo(SVX) retroviral vector to express a cDNA clone encoding human PP in several cell lines including a fibroblast line (psi-2), two endocrine cell lines known to produce amidated peptides (AtT-20 and PC12), and two lines that do not ordinarily produce amidated peptides (RIN5-f and GH3). Transfected psi-2 cells produced an unprocessed precursor of PP that appeared to be secreted constitutively with little remaining in intracellular stores. No post-translational processing of the PP precursor was evident in these cells. By contrast, all 4 endocrine-derived cell lines, regardless of the nature of their endogenous products, were capable of expressing fully processed and carboxyl-terminally amidated PP. Moreover, these lines had the ability to store the processed products. Our results support the notion that post-translational processing of peptide hormone precursors requires storage in secretory granules that contain the appropriate processing enzymes. Furthermore, enzymes such as peptidyl-glycyl alpha-amidating monooxygenase that are required for processing peptides may be a common feature of endocrine-derived cells regardless of the requirement for their activity to process endogenous products.	UNIV MICHIGAN, MED CTR, DEPT PEDIAT, ANN ARBOR, MI 48109 USA; DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA	University of Michigan System; University of Michigan; Duke University	TAKEUCHI, T (corresponding author), UNIV MICHIGAN, MED CTR, DEPT INTERNAL MED, ANN ARBOR, MI 48109 USA.				NIDDK NIH HHS [P3O-DK34933, R01 DK38216, R01-DK34306] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038216, R01DK034306, P30DK034933] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLEN JM, 1984, NEUROSCI LETT, V46, P291, DOI 10.1016/0304-3940(84)90114-9; CEPKO CL, 1984, CELL, V37, P1053, DOI 10.1016/0092-8674(84)90440-9; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; COMB M, 1985, EMBO J, V4, P3115, DOI 10.1002/j.1460-2075.1985.tb04053.x; CONE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6349, DOI 10.1073/pnas.81.20.6349; CULLEN EI, 1989, ENDOCRINOLOGY, V125, P1774, DOI 10.1210/endo-125-4-1774; CWIKEL BJ, 1987, J BIOL CHEM, V262, P14235; DICKERSON IM, 1987, J BIOL CHEM, V262, P13646; DICKERSON IM, 1990, J BIOL CHEM, V265, P2462; DICKERSON IM, 1990, ENDOCRINOLOGY, V127, P133, DOI 10.1210/endo-127-1-133; DICKINSON C, 1989, HDB PHYSL 6, V2, P63; DRUCKER DJ, 1986, J BIOL CHEM, V261, P9637; EDWARDS RH, 1988, MOL CELL BIOL, V8, P2456, DOI 10.1128/MCB.8.6.2456; EIPPER BA, 1986, J BIOL CHEM, V261, P8686; GAINER H, 1985, NEUROENDOCRINOLOGY, V40, P171, DOI 10.1159/000124070; GLEMBOTSKI CC, 1984, J BIOL CHEM, V259, P6385; GLOVER ID, 1984, EUR J BIOCHEM, V142, P379, DOI 10.1111/j.1432-1033.1984.tb08298.x; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; LANDENHEIM RG, 1984, FEBS LETT, V245, P70; LAPPS W, 1988, J BIOL CHEM, V263, P13456; LIN TM, 1977, AM J PHYSIOL, V232, pE311, DOI 10.1152/ajpendo.1977.232.3.E311; LOH YP, 1987, ANN NY ACAD SCI, V493, P292, DOI 10.1111/j.1749-6632.1987.tb27214.x; MANN R, 1983, CELL, V33, P153, DOI 10.1016/0092-8674(83)90344-6; MAY V, 1990, ENDOCRINOLOGY, V127, P358, DOI 10.1210/endo-127-1-358; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; OHARE MMT, 1985, CANCER, V55, P1895, DOI 10.1002/1097-0142(19850501)55:9<1895::AID-CNCR2820550910>3.0.CO;2-S; OHARE MMT, 1989, CANCER RES, V49, P7015; OHARE MMT, 1989, CANCER RES, V49, P7010; REHFELD JF, 1986, J BIOL CHEM, V261, P5841; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; SEVARINO KA, 1987, J BIOL CHEM, V262, P4987; SEVARINO KA, 1989, J BIOL CHEM, V264, P21529; SHIELDS PP, 1990, J BIOL CHEM, V265, P10905; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; STOLLER TJ, 1988, J CELL BIOL, V107, P2087, DOI 10.1083/jcb.107.6.2087; SUGANO K, 1985, J BIOL CHEM, V260, P1724; TAKEUCHI T, 1985, P NATL ACAD SCI USA, V82, P1536, DOI 10.1073/pnas.82.5.1536; TAYLOR IL, 1983, PEPTIDES, V4, P245, DOI 10.1016/0196-9781(83)90122-5; TAYLOR IL, 1989, HDB PHYSL 6, V2, P475; THORNE BA, 1989, J BIOL CHEM, V264, P3545; THORNE BA, 1990, J BIOL CHEM, V265, P8436; WIGLER M, 1978, CELL, V14, P725, DOI 10.1016/0092-8674(78)90254-4	43	10	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17409	17415						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894628				2022-12-25	WOS:A1991GF44500066
J	URATA, H; KINOSHITA, A; PEREZ, DM; MISONO, KS; BUMPUS, FM; GRAHAM, RM; HUSAIN, A				URATA, H; KINOSHITA, A; PEREZ, DM; MISONO, KS; BUMPUS, FM; GRAHAM, RM; HUSAIN, A			CLONING OF THE GENE AND CDNA FOR HUMAN HEART CHYMASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAST-CELL CHYMASE; HUMAN CATHEPSIN-G; VASOACTIVE INTESTINAL PEPTIDE; CHYMOTRYPSIN-LIKE PROTEINASE; FAILING HUMAN HEARTS; MOLECULAR-CLONING; SERINE PROTEASE; ANGIOTENSIN-II; SUBSTANCE-P; RMCP-II	We have recently identified and characterized a chymotrypsin-like serine proteinase in human heart (human heart chymase) that is the most catalytically efficient enzyme described, thus far, for the cleavage of angiotensin I to yield angiotensin II and the dipeptide His-Leu. Compared to other chymases, this enzyme also has an unusually high degree of specificity for the substrate angiotensin I. We report here the molecular cloning and nucleotide sequence of the gene and cDNA encoding human heart chymase, and determination of its entire deduced amino acid sequence. These data indicate that human heart chymase is highly homologous to other members of the chymase subfamily of chymotrypsin-like proteinases and, most likely, all evolved from a common ancestral gene. Potential regulatory elements found in the 5'-untranslated region of other chymases are also found in the human heart chymase gene. However, this gene lacks mast cell-specific sequences found in the 5'- and 3'-untranslated regions of the rat chymase II gene. In addition, human heart chymase contains clusters of unique amino acid sequences located at key positions likely involved in substrate binding, which may contribute to its high substrate specificity. These contrasting features of the human heart chymase gene and cDNA, and the potential determinants of its primary structure that underlie its unique functional characteristics are considered.	CLEVELAND CLIN FDN,RES INST,DEPT HEART & HYPERTENS RES,CLEVELAND,OH 44195	Cleveland Clinic Foundation			Husain, Ahsan/J-6861-2012	Husain, Ahsan/0000-0003-3426-3469	NHLBI NIH HHS [HL33713] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL033713] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVRAHAM S, 1989, P NATL ACAD SCI USA, V86, P3763, DOI 10.1073/pnas.86.10.3763; BELL GI, 1981, P NATL ACAD SCI-BIOL, V78, P5759, DOI 10.1073/pnas.78.9.5759; BELL GI, 1984, J BIOL CHEM, V259, P4265; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; BOULET AM, 1986, P NATL ACAD SCI USA, V83, P3599, DOI 10.1073/pnas.83.11.3599; BRAIN SD, 1988, NATURE, V335, P73, DOI 10.1038/335073a0; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARNE T, 1985, CELL BIOL SECRETORY, P73; CAUGHEY GH, 1990, BIOCHEMISTRY-US, V29, P5166, DOI 10.1021/bi00473a024; CAUGHEY GH, 1988, J PHARMACOL EXP THER, V244, P133; CAUGHEY GH, 1988, BIOCHIM BIOPHYS ACTA, V952, P142, DOI 10.1016/0167-4838(88)90109-4; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; CRAIK CS, 1984, J BIOL CHEM, V259, P4255; DAYHOFF MO, 1972, ATLAS PROTEIN SEQUEN, V0005; de Haen C, 1975, J Mol Biol, V92, P225, DOI 10.1016/0022-2836(75)90225-9; FRANCONI GM, 1989, J PHARMACOL EXP THER, V248, P947; HAGENBUCHLE O, 1978, CELL, V13, P551, DOI 10.1016/0092-8674(78)90328-8; HOHN PA, 1989, J BIOL CHEM, V264, P13412; JENNE DE, 1989, BIOCHEMISTRY-US, V28, P7953, DOI 10.1021/bi00445a060; KING SJ, 1984, IMMUNOLOGY, V51, P653; KINOSHITA A, 1991, IN PRESS J BIOL CHEM; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; LEWIN B, 1990, GENES, V4, P543; LOBE CG, 1986, SCIENCE, V232, P858, DOI 10.1126/science.3518058; Maniatis T., 1982, MOL CLONING; MEIER M, 1990, BIOCHEMISTRY-US, V29, P4042, DOI 10.1021/bi00469a003; MURPHY MEP, 1988, PROTEINS, V4, P190, DOI 10.1002/prot.340040306; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; REED R, 1985, CELL, V41, P95, DOI 10.1016/0092-8674(85)90064-9; REILLY CF, 1985, BIOCHEM BIOPH RES CO, V127, P443, DOI 10.1016/S0006-291X(85)80180-7; REILLY CF, 1982, J BIOL CHEM, V257, P8619; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; ROGERS J, 1985, NATURE, V315, P458, DOI 10.1038/315458a0; SALVESEN G, 1987, BIOCHEMISTRY-US, V26, P2289, DOI 10.1021/bi00382a032; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SARID J, 1989, J BIOL CHEM, V264, P1022; SAYAMA S, 1987, J BIOL CHEM, V262, P6808; SCHECHTER NM, 1983, J BIOL CHEM, V258, P2973; SCHECHTER NM, 1986, J IMMUNOL, V137, P962; SCHECHTER NM, 1990, J IMMUNOL, V145, P2652; SCHEDLICH LJ, 1987, DNA-J MOLEC CELL BIO, V6, P429, DOI 10.1089/dna.1987.6.429; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; Seppa H, 1979, Acta Histochem, V64, P64; SERAFIN WE, 1991, J BIOL CHEM, V266, P1934; SERAFIN WE, 1990, J BIOL CHEM, V265, P423; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; TAKAHASHI H, 1988, J BIOL CHEM, V263, P2543; Trong H Le, 1989, BIOCHEMISTRY-US, V28, P391, DOI 10.1021/BI00427A054; URATA H, 1989, J CLIN ENDOCR METAB, V69, P54, DOI 10.1210/jcem-69-1-54; URATA H, 1990, J BIOL CHEM, V265, P22348; URATA H, 1990, CIRC RES, V66, P883, DOI 10.1161/01.RES.66.4.883; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; VARTIO T, 1981, J BIOL CHEM, V256, P471; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WINTROUB BU, 1984, J INVEST DERMATOL, V83, P336, DOI 10.1111/1523-1747.ep12264144; WINTROUB BU, 1986, J CLIN INVEST, V77, P196, DOI 10.1172/JCI112276; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P811, DOI 10.1021/bi00598a010; YOSHIDA N, 1980, BIOCHEMISTRY-US, V19, P5799, DOI 10.1021/bi00566a021	59	140	144	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17173	17179						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894611				2022-12-25	WOS:A1991GF44500033
J	LISCUM, L; COLLINS, GJ				LISCUM, L; COLLINS, GJ			CHARACTERIZATION OF CHINESE-HAMSTER OVARY CELLS THAT ARE RESISTANT TO 3-BETA-[2-(DIETHYLAMINO)ETHOXY]ANDROST-5-EN-17-ONE INHIBITION OF LOW-DENSITY LIPOPROTEIN-DERIVED CHOLESTEROL-METABOLISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; NIEMANN-PICK DISEASE; INTRACELLULAR-TRANSPORT; 3-HYDROXY-3-METHYLGLUTARYL COENZYME; CULTURED FIBROBLASTS; POLYETHYLENE-GLYCOL; C FIBROBLASTS; UT-1 CELLS; AMPLIFICATION; HYBRIDIZATION	The pharmacological agent U18666A (3-beta-[2-(diethylamino)ethoxy]androst-5-en-17-one inhibits the intracellular transport of low density lipoprotein (LDL)-derived cholesterol in Chinese hamster ovary (CHO) cells. LDL-derived cholesterol accumulates in the lysosomes of U18666A-treated cells causing delayed LDL-mediated regulation of cellular cholesterol metabolism and impaired movement of LDL-derived cholesterol to other cell membranes. As a result of impaired LDL-derived cholesterol transport, LDL-dependent growth of CHO cells is also inhibited by U18666A. By selecting for cell growth in the presence of U18666A, we have identified a CHO cell line, designated U18R, that is resistant to U18666A-inhibition of LDL-derived cholesterol trafficking. When compared to parental CHO cells, U18R cells are relatively resistant to U18666A inhibition of LDL-derived cholesterol transport as well as LDL-mediated regulation of cellular cholesterol metabolism. In cell fusion experiments, the U18666A resistance observed in U18R cells displays a dominant phenotype. Identification of the U18666A-resistant factor may provide important insights toward the understanding of intracellular LDL-derived cholesterol regulation and trafficking.			LISCUM, L (corresponding author), TUFTS UNIV, SCH MED, DEPT PHYSIOL, 136 HARRISON AVE, BOSTON, MA 02111 USA.				NIDDK NIH HHS [DK 36505] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036505] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEACH LR, 1981, P NATL ACAD SCI-BIOL, V78, P2110, DOI 10.1073/pnas.78.4.2110; BRADLEY G, 1988, BIOCHIM BIOPHYS ACTA, V948, P87, DOI 10.1016/0304-419X(88)90006-6; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1973, P NATL ACAD SCI USA, V70, P2162, DOI 10.1073/pnas.70.7.2162; BROWN MS, 1980, J LIPID RES, V21, P505; BROWN MS, 1975, P NATL ACAD SCI USA, V72, P2925, DOI 10.1073/pnas.72.8.2925; CADIGAN KM, 1990, J CELL BIOL, V110, P295, DOI 10.1083/jcb.110.2.295; CHIN DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1185, DOI 10.1073/pnas.79.4.1185; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P165, DOI 10.1007/BF01542629; DAVIDSON RL, 1976, SOMAT CELL GENET, V2, P271, DOI 10.1007/BF01538965; DAWIDOWICZ EA, 1987, ANNU REV BIOCHEM, V56, P43, DOI 10.1146/annurev.bi.56.070187.000355; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; FAUST J, 1987, J BIOL CHEM, V262, P1996; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; FAUST JR, 1977, J BIOL CHEM, V252, P4861; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; Gottesman M M, 1987, Methods Enzymol, V151, P113, DOI 10.1016/S0076-6879(87)51012-6; JHA KK, 1976, SOMAT CELL GENET, V2, P215, DOI 10.1007/BF01538960; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; LISCUM L, 1989, J CELL BIOL, V108, P1625, DOI 10.1083/jcb.108.5.1625; LISCUM L, 1987, J BIOL CHEM, V262, P17002; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSKEY KL, 1983, J BIOL CHEM, V258, P8462; PENTCHEV PG, 1985, P NATL ACAD SCI USA, V82, P8247, DOI 10.1073/pnas.82.23.8247; PENTCHEV PG, 1987, FASEB J, V1, P40, DOI 10.1096/fasebj.1.1.3609608; RODRIGUEZLAFRASSE C, 1990, BIOCHIM BIOPHYS ACTA, V1043, P123, DOI 10.1016/0005-2760(90)90284-5; Schimke R T, 1987, Methods Enzymol, V151, P85, DOI 10.1016/S0076-6879(87)51010-2; SCHIMKE RT, 1977, COLD SPRING HARB SYM, V42, P649, DOI 10.1101/SQB.1978.042.01.067; SEXTON RC, 1983, BIOCHEMISTRY-US, V22, P5687, DOI 10.1021/bi00294a001; SKALNIK DG, 1985, J BIOL CHEM, V260, P1991	32	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16599	16606						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885589				2022-12-25	WOS:A1991GD63500059
J	SHIEH, SY; TSAI, MJ				SHIEH, SY; TSAI, MJ			CELL-SPECIFIC AND UBIQUITOUS FACTORS ARE RESPONSIBLE FOR THE ENHANCER ACTIVITY OF THE RAT INSULIN-II GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION CONTROL REGION; IMMUNOGLOBULIN ENHANCER; 5'-FLANKING REGION; FACTOR BINDS; BETA-CELLS; EXPRESSION; SEQUENCE; ELEMENTS; PROTEINS; DNA	Pancreatic beta-cell-specific expression of the insulin gene is mediated, at least in part, by an enhancer element termed the rat insulin promoter element 3 (RIPE3) found within the rat insulin II gene between positions -126 and -86. Here we identify three distinct factors interacting with RIPE3, namely 3a1, 3a2, and 3b1, which bind to the sequences between -100 to -90, -108 to -99, and -115 to -107, respectively. Factors 3a1 and 3b1 are beta-cell specific whereas 3a2 is ubiquitously distributed. The 3a1 site contains the consensus binding sequence (CANNTG) for a group of DNA-binding proteins called basic-helix-loop-helix proteins. We showed in this study that the 3a1 binding activity contains E12/E47, a member of the basic-helix-loop-helix protein family, or an E12/E47-like protein. Sequence comparison of the 3a2 and 3b1 binding sites suggests that they are unique and may bind to novel transcription factors. Mutation analysis of each individual binding site in transient expression experiments indicates that all of the three binding sites contribute to the enhancer activity of the RIPE3 in beta-cells. Mutation in any one of the three binding sites not only disrupts binding of the corresponding factor but decreases RIPE3 enhancer activity by 4-7-fold. The results suggest that interactions among the 3a1, 3a2, and 3b1 factors are required for maximum enhancer activity of the RIPE3 in insulin-producing cells.			SHIEH, SY (corresponding author), BAYLOR COLL MED,DEPT CELL BIOL,ONE BAYLOR PLAZA,HOUSTON,TX 77030, USA.		Shieh, Sheau-Yann/N-9512-2018	Shieh, Sheau-Yann/0000-0002-5351-4430	NICHD NIH HHS [HD17379] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD017379, R37HD017379] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALPERT S, 1988, CELL, V53, P295, DOI 10.1016/0092-8674(88)90391-1; BOAM DSW, 1989, BIOCHEM J, V264, P233, DOI 10.1042/bj2640233; BOAM DSW, 1990, J BIOL CHEM, V265, P8285; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; BUSHKIN JN, 1989, MOL CELL BIOL, V9, P2627; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FROMENTAL C, 1988, CELL, V54, P943, DOI 10.1016/0092-8674(88)90109-2; GIDDINGS SJ, 1988, J BIOL CHEM, V263, P3845; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; HWUNG YP, 1988, MOL CELL BIOL, V8, P2070, DOI 10.1128/MCB.8.5.2070; HWUNG YP, 1990, MOL CELL BIOL, V10, P1784, DOI 10.1128/MCB.10.4.1784; JONES N, 1990, CELL, V61, P9, DOI 10.1016/0092-8674(90)90207-U; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KARLSSON O, 1989, MOL CELL BIOL, V9, P823, DOI 10.1128/MCB.9.2.823; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; Maxam A M, 1980, Methods Enzymol, V65, P499; MOSS LG, 1988, MOL CELL BIOL, V8, P2620, DOI 10.1128/MCB.8.6.2620; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; OHLSSON H, 1986, CELL, V45, P35, DOI 10.1016/0092-8674(86)90535-0; OHLSSON H, 1988, P NATL ACAD SCI USA, V85, P4228, DOI 10.1073/pnas.85.12.4228; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; SANTERRE RF, 1981, P NATL ACAD SCI-BIOL, V78, P4339, DOI 10.1073/pnas.78.7.4339; SHIBASAKI Y, 1990, BIOCHEM BIOPH RES CO, V170, P314, DOI 10.1016/0006-291X(90)91276-X; SOARES MB, 1985, MOL CELL BIOL, V5, P2090, DOI 10.1128/MCB.5.8.2090; STEINER DF, 1985, ANNU REV GENET, V19, P463, DOI 10.1146/annurev.ge.19.120185.002335; WALKER MD, 1990, NUCLEIC ACIDS RES, V18, P1159, DOI 10.1093/nar/18.5.1159; WALKER MD, 1983, NATURE, V306, P557, DOI 10.1038/306557a0; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; WHELAN J, 1990, MOL CELL BIOL, V10, P1564, DOI 10.1128/MCB.10.4.1564	37	107	111	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16708	16714						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885600				2022-12-25	WOS:A1991GD63500075
J	GALJART, NJ; MORREAU, H; WILLEMSEN, R; GILLEMANS, N; BONTEN, EJ; DAZZO, A				GALJART, NJ; MORREAU, H; WILLEMSEN, R; GILLEMANS, N; BONTEN, EJ; DAZZO, A			HUMAN LYSOSOMAL PROTECTIVE PROTEIN HAS CATHEPSIN-A-LIKE ACTIVITY DISTINCT FROM ITS PROTECTIVE FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDASE DEFICIENCY; CARBOXYPEPTIDASE-II; HUMAN-FIBROBLASTS; PRECURSOR FORMS; MALTED BARLEY; CDNA CLONING; NEURAMINIDASE; EXPRESSION; DNA; YEAST	The Protective protein was first discovered because of its deficiency in the metabolic storage disorder galactosialidosis. It associates with lysosomal beta-galactosidase and neuraminidase, toward which it exerts a protective function necessary for their stability and activity. Human and mouse protective proteins are homologous to yeast and plant serine carboxypeptidases. Here, we provide evidence that this protein has enzymatic activity similar to that of lysosomal cathepsin A: 1) overexpression of human and mouse protective proteins in COS-1 cells induces a 3-4-fold increase of cathepsin A-like activity; 2) this activity is reduced to approximately 1% in three galactosialidosis patients with different clinical phenotypes; 3) monospecific antibodies raised against human protective protein precipitate virtually all cathepsin A-like activity in normal human fibroblast extracts. Mutagenesis of the serine and histidine active site residues abolishes the enzymatic activity of the respective mutant protective proteins. These mutants, however, behave as the wild-type protein with regard to intracellular routing, processing, and secretion. In contrast, modification of the very conserved Cys60 residue interferes with the correct folding of the precursor polypeptide and, hence, its intracellular transport and processing. The secreted active site mutant precursors, endocytosed by galactosialidosis fibroblasts, restore beta-galactosidase and neuraminidase activities as effectively as wild-type protective protein. These findings indicate that the catalytic activity and protective function of the protective protein are distinct.	ERASMUS UNIV,DEPT CELL BIOL & GENET,POB 1738,3000 DR ROTTERDAM,NETHERLANDS	Erasmus University Rotterdam			Galjart, Niels/D-1146-2010	Galjart, Niels/0000-0003-1964-3607				ANDRIA G, 1978, CLIN GENET, V14, P16; ANDRIA G, 1981, SIALIDASES SIALIDOSE, P379; DAZZO A, 1982, P NATL ACAD SCI-BIOL, V79, P4535, DOI 10.1073/pnas.79.15.4535; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DMOCHOWSKA A, 1987, CELL, V50, P573, DOI 10.1016/0092-8674(87)90030-4; DOI E, 1974, J BIOCHEM-TOKYO, V75, P889, DOI 10.1093/oxfordjournals.jbchem.a130462; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALJAARD H, 1980, GENETIC METABOLIC DI; GALJART NJ, 1988, CELL, V54, P755, DOI 10.1016/S0092-8674(88)90999-3; GALJART NJ, 1990, J BIOL CHEM, V265, P4678; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; HOOGEVEEN AT, 1983, J BIOL CHEM, V258, P2143; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKMAN HL, 1990, J BIOL CHEM, V265, P11265; KAWAMURA Y, 1977, J BIOCHEM-TOKYO, V81, P435, DOI 10.1093/oxfordjournals.jbchem.a131476; KAWAMURA Y, 1980, J BIOCHEM, V88, P1559, DOI 10.1093/oxfordjournals.jbchem.a133127; KLEIJER WJ, 1979, CLIN GENET, V16, P60; LIAO DI, 1990, J BIOL CHEM, V265, P6528; LOONEN MCB, 1974, LANCET, V2, P785; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MATSUDA K, 1976, J BIOCHEM, V80, P659, DOI 10.1093/oxfordjournals.jbchem.a131325; MCDONALD JK, 1986, MAMMALIAN PROTEASES, V2, P186; MURPHY G, 1988, NUCLEIC ACIDS RES, V16, P5198, DOI 10.1093/nar/16.11.5198; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PALMERI S, 1986, AM J HUM GENET, V38, P137; PROIA RL, 1984, J BIOL CHEM, V259, P3350; ROTH M, 1971, ANAL CHEM, V43, P880, DOI 10.1021/ac60302a020; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SORENSEN SB, 1989, CARLSBERG RES COMMUN, V54, P193, DOI 10.1007/BF02904473; SORENSEN SB, 1987, CARLSBERG RES COMMUN, V52, P285, DOI 10.1007/BF02907171; SUZUKI Y, 1984, DEV BRAIN ITS DISORD, P161; TAYLOR S, 1973, ANAL BIOCHEM, V56, P140, DOI 10.1016/0003-2697(73)90178-4; TRANCHEMONTAGNE J, 1990, BIOCHEM BIOPH RES CO, V168, P22, DOI 10.1016/0006-291X(90)91669-J; VALLS LA, 1987, CELL, V48, P887, DOI 10.1016/0092-8674(87)90085-7; VANDERHORST GTJ, 1989, J BIOL CHEM, V264, P1317; VANDONGEN JM, 1984, HISTOCHEM J, V16, P941, DOI 10.1007/BF01003850; VERHEIJEN F, 1982, BIOCHEM BIOPH RES CO, V108, P868, DOI 10.1016/0006-291X(82)90911-1; VERHEIJEN FW, 1985, EUR J BIOCHEM, V149, P315, DOI 10.1111/j.1432-1033.1985.tb08928.x; WENGER DA, 1978, BIOCHEM BIOPH RES CO, V82, P589, DOI 10.1016/0006-291X(78)90915-4; WILLEMSEN R, 1986, EUR J CELL BIOL, V40, P9; YAMAMOTO Y, 1982, J BIOCHEM, V92, P13, DOI 10.1093/oxfordjournals.jbchem.a133910; YAMAMOTO Y, 1987, INT J BIOCHEM, V5, P435; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194	46	141	144	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14754	14762						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907282				2022-12-25	WOS:A1991FZ35100099
J	CHA, KW; JACOBSON, KB; YIM, JJ				CHA, KW; JACOBSON, KB; YIM, JJ			ISOLATION AND CHARACTERIZATION OF GTP CYCLOHYDROLASE-I FROM MOUSE-LIVER - COMPARISON OF NORMAL AND THE HPH-1 MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANOSINE TRIPHOSPHATE CYCLOHYDROLASE; DROSOPHILA-MELANOGASTER; PARTIAL-PURIFICATION; HYPERPHENYLALANINEMIA; BIOSYNTHESIS; TETRAHYDROBIOPTERIN; SYNTHETASE; DEFICIENCY; NEOPTERIN; PROTEIN	GTP cyclohydrolase I, an enzyme that catalyzes the first reaction in the pathway for the biosynthesis of pterin compounds, was purified from of C3H mouse liver by 192-fold to apparent homogeneity, using Ultrogel AcA34, DEAE-Trisacryl, and GTP-agarose gels. Its native molecular weight was estimated at 362,000. When the enzyme was subjected to electrophoresis on a denaturing polyacrylamide gel, only one protein band was evident, and its molecular weight was estimated at 55,700. The NH2-terminal amino acid of this enzyme was serine. These results indicate the enzyme consists of six to eight subunits. No coenzyme or metal ion was required for activity. This enzyme activity was inhibited by most of divalent cations and was slightly activated by potassium ion. The K(m) value for GTP was determined to be 17.3-mu-M. The temperature and pH optima for the activity were 60-degrees-C and pH 8.0-8.5, respectively. The expected products, a dihydroneopterin compound and formic acid, were found in a molar ratio of 1.01. A polyclonal antiserum generated against the purified enzyme was used to compare GTP cyclohydrolase I from the hph-I mutant and normal mouse. The hph-1 mutant liver contained only 8% of normal specific activity, but a normal amount of GTP cyclohydrolase I antigen as compared with the C3H mouse. Subunit molecular weight and electrophoretic behavior of GTP cyclohydrolase I from hph-1 mutant were not different from those of the enzyme from C3H mouse. These results suggest that the hph-1 mutation may involve alteration of the catalytic site but does not detectably alter the whole enzyme structure.	SEOUL NATL UNIV,DEPT MICROBIOL,SEOUL 151,SOUTH KOREA; OAK RIDGE NATL LAB,DIV BIOL,OAK RIDGE,TN 37831	Seoul National University (SNU); United States Department of Energy (DOE); Oak Ridge National Laboratory								BELLAHSENE Z, 1984, BIOCHEM J, V217, P59, DOI 10.1042/bj2170059; BLAU N, 1986, BIOCHIM BIOPHYS ACTA, V880, P26, DOI 10.1016/0304-4165(86)90115-7; BODE VC, 1988, GENETICS, V118, P299; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURG AW, 1968, J BIOL CHEM, V243, P2349; CONE JE, 1974, J BIOL CHEM, V249, P5551; DUCH DS, 1984, LIFE SCI, V35, P1895, DOI 10.1016/0024-3205(84)90541-1; DUCH DS, 1986, ENDOCRINOLOGY, V118, P1897, DOI 10.1210/endo-118-5-1897; FAN CL, 1976, BIOCHEM GENET, V14, P259, DOI 10.1007/BF00484765; FUKUSHIMA K, 1977, J BIOL CHEM, V252, P5750; HAN KH, 1986, KOREAN BIOCH J, V19, P257; JACKSON RJ, 1975, BIOCHIM BIOPHYS ACTA, V403, P232, DOI 10.1016/0005-2744(75)90025-X; JACKSON RJ, 1973, BIOCHEM BIOPH RES CO, V51, P428, DOI 10.1016/0006-291X(73)91275-8; JACOBSON KB, 1989, BIOCHEM J, V260, P135, DOI 10.1042/bj2600135; KOHASHI M, 1980, AGR BIOL CHEM TOKYO, V44, P271, DOI 10.1080/00021369.1980.10863941; MAKAY WJ, 1985, GENETICS, V111, P885; MCDONALD JD, 1988, PEDIATR RES, V23, P63, DOI 10.1203/00006450-198801000-00014; MCDONALD JD, 1988, J NEUROCHEM, V50, P655, DOI 10.1111/j.1471-4159.1988.tb02961.x; NEAL MW, 1973, ANAL BIOCHEM, V55, P328, DOI 10.1016/0003-2697(73)90325-4; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NIEDERWIESER A, 1982, EUR J PEDIATR, V138, P97; PEPPERBERG DR, 1973, THESIS MIT; SHEN R, 1988, BIOCHIM BIOPHYS ACTA, V965, P9, DOI 10.1016/0304-4165(88)90144-4; SUZUKI Y, 1978, J BIOCHEM-TOKYO, V86, P1679; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VOLKER N, 1988, ELECTROPHORESIS, V9, P255; WEISBERG EP, 1986, J BIOL CHEM, V261, P1453; YIM JJ, 1976, J BIOL CHEM, V251, P5087; Ziegler I., 1969, Advances in Insect Physiology, V6, P139	29	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12294	12300						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905717				2022-12-25	WOS:A1991FV18000032
J	MEIJER, I; VANDAM, H; BOOT, AJM; BOS, JL; ZANTEMA, A; VANDEREB, AJ				MEIJER, I; VANDAM, H; BOOT, AJM; BOS, JL; ZANTEMA, A; VANDEREB, AJ			CO-REGULATED EXPRESSION OF JUNB AND MHC CLASS-I GENES IN ADENOVIRUS-TRANSFORMED CELLS	ONCOGENE			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR FAMILY; DNA-BINDING; RAT-CELLS; E1A GENE; FUNCTIONAL DOMAINS; PROTEIN; PROMOTER; AP-1; FOS	The expression of the junB gene parallels the expression of the MHC class I genes in Adenovirus (Ad) transformed cells. In Ad12E1-transformed primary BRK cells both genes are transcriptionally repressed only when the 13S product of Ad12E1A is present. This indicates that repression of MHC class I and junB genes is a function of conserved region 3 (CR3) of the Ad12E1A protein. In Ad5-transformed BRK cells expression of these genes is unchanged. In established NRK cells, however, introduction of Ad12E1A does not cause repression of the MHC class I and junB genes, but in these cells Ad5E1A increases the expression of both MHC class I and junB. Using mutant Ad5E1A genes, it is shown that this activation is mediated by CR1. Introduction of a functional junB gene under the control of a heterologous promoter in Ad12E1-transformed BRK cells causes no increase in MHC class I expression. This demonstrates that the down-regulation of junB is not directly responsible for class I repression, but rather that both genes are coregulated by the Ad12E1 region.	LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	VANDEREB, AJ (corresponding author), LEIDEN UNIV,SYLVIUS LABS,MOLEC CARCINOGENESIS LAB,POB 9503,2300 RA LEIDEN,NETHERLANDS.			van Dam, Hans/0000-0002-8307-4325				ACKRILL AM, 1988, ONCOGENE, V3, P483; ACKRILL AM, 1989, VIROLOGY, V172, P643, DOI 10.1016/0042-6822(89)90207-9; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BENBROOK DM, 1990, ONCOGENE, V5, P295; BERNARDS R, 1987, TRENDS GENET, V3, P298, DOI 10.1016/0168-9525(87)90272-1; BERNARDS R, 1983, NATURE, V305, P776, DOI 10.1038/305776a0; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CLARK L, 1988, GENE DEV, V2, P991, DOI 10.1101/gad.2.8.991; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; ISRAEL A, 1989, NUCLEIC ACIDS RES, V17, P5245, DOI 10.1093/nar/17.13.5245; JOCHEMSEN AG, 1984, EMBO J, V3, P2923, DOI 10.1002/j.1460-2075.1984.tb02233.x; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KIERAN M, 1990, CELL, V62, P1007, DOI 10.1016/0092-8674(90)90275-J; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; LILLIE JW, 1989, NATURE, V338, P39, DOI 10.1038/338039a0; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; MEIJER I, 1989, J VIROL, V63, P4039, DOI 10.1128/JVI.63.9.4039-4042.1989; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEVINS JR, 1982, CELL, V29, P913, DOI 10.1016/0092-8674(82)90453-6; OFFRINGA R, 1990, CELL, V62, P527, DOI 10.1016/0092-8674(90)90017-9; OFFRINGA R, 1988, NUCLEIC ACIDS RES, V16, P10973, DOI 10.1093/nar/16.23.10973; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; SCHNEIDER JF, 1987, EMBO J, V6, P2053, DOI 10.1002/j.1460-2075.1987.tb02470.x; SCHRIER PI, 1983, NATURE, V305, P771, DOI 10.1038/305771a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SHIRAYOSHI Y, 1987, MOL CELL BIOL, V7, P4542, DOI 10.1128/MCB.7.12.4542; STEIN B, 1989, MOL CELL BIOL, V9, P5169, DOI 10.1128/MCB.9.11.5169; STEIN R, 1984, MOL CELL BIOL, V4, P2792, DOI 10.1128/MCB.4.12.2792; TIMMERS HTM, 1989, J VIROL, V63, P1470, DOI 10.1128/JVI.63.3.1470-1473.1989; TIMMERS HTM, 1990, THESIS U LEIDEN; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDAM H, 1990, MOL CELL BIOL, V10, P5857, DOI 10.1128/MCB.10.11.5857; VANDAM H, 1989, ONCOGENE, V4, P1207; VELCICH A, 1990, MOL CELL BIOL, V10, P6273, DOI 10.1128/MCB.10.12.6273; VOGT PK, 1990, IN PRESS ADV CANCER; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	40	13	13	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					911	916						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906158				2022-12-25	WOS:A1991GU62200004
J	NICOLLI, A; REDETTI, A; BERNARDI, P				NICOLLI, A; REDETTI, A; BERNARDI, P			THE K+ CONDUCTANCE OF THE INNER MITOCHONDRIAL-MEMBRANE - A STUDY OF THE INDUCIBLE UNIPORT FOR MONOVALENT CATIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; ENERGY-DEPENDENT EXCHANGE; HEART-MITOCHONDRIA; RUTHENIUM-RED; ANION CHANNEL; ELECTROCHEMICAL GRADIENT; SARCOPLASMIC-RETICULUM; CALCIUM-TRANSPORT; DIVALENT-CATIONS; CA-2+ EFFLUX	Addition of A23187 plus EDTA to rat liver mitochondria induces a common uniport pathway for monovalent cations. In this study, we have carried out a detailed characterization of the flow/force relationship for K+ transport along this pathway under steady state conditions. In the presence of EDTA, the K+ conductance is a linear function of external K+ in the range 0-20 mM K+, with a slope of 0.15 nmol of K+ x mg of protein-1 x min-1 x mV-1. The K+ conductance is inhibited by Mg2+ in the range 10(-9)-10(-6) M, while K+ flux is stimulated by the sulfhydryl group reagent mersalyl. Uniport activity can be detected in native mitochondria. These findings are compatible with the notion that electrophoretic K+ flux across the inner membrane takes place via a regulated K+ uniport with the potential of transporting K+ at rates in excess of 600 nmol x mg of protein-1 x min-1.	UNIV PADUA,INST GEN PATHOL,VIA TRIESTE 75,I-35121 PADUA,ITALY; CNR,STUDY PHYSIOL MITOCHONDRIA UNIT,I-35100 PADUA,ITALY	University of Padua; Consiglio Nazionale delle Ricerche (CNR)			Bernardi, Paolo/C-3656-2008	Bernardi, Paolo/0000-0001-9187-3736				ANTONIU B, 1985, BIOCHIM BIOPHYS ACTA, V816, P9, DOI 10.1016/0005-2736(85)90387-6; AZZI A, 1966, BIOCHIM BIOPHYS ACTA, V120, P466, DOI 10.1016/0926-6585(66)90316-5; AZZI A, 1967, BIOCHIM BIOPHYS ACTA, V131, P468, DOI 10.1016/0005-2728(67)90006-0; AZZI A, 1967, ENZYMOL BIOL CLIN, V7, P25; BEAVIS AD, 1987, J BIOL CHEM, V262, P15085; BEAVIS AD, 1988, J BIOL CHEM, V263, P7574; BEAVIS AD, 1989, J BIOL CHEM, V264, P17148; BERNARDI P, 1990, EUR J BIOCHEM, V188, P91, DOI 10.1111/j.1432-1033.1990.tb15375.x; BERNARDI P, 1984, BIOCHEMISTRY-US, V23, P1645, DOI 10.1021/bi00303a010; BERNARDI P, 1989, J BIOL CHEM, V264, P18902; BERNARDI P, 1983, BIOCHIM BIOPHYS ACTA, V724, P212, DOI 10.1016/0005-2728(83)90140-8; BERNARDI P, 1983, EUR J BIOCHEM, V134, P377, DOI 10.1111/j.1432-1033.1983.tb07578.x; BRAGADIN M, 1979, BIOCHEMISTRY-US, V18, P5972, DOI 10.1021/bi00593a033; BRIERLEY GP, 1978, MOL BIOL MEMBRANES, P295; CHAVEZ E, 1977, ARCH BIOCHEM BIOPHYS, V183, P460, DOI 10.1016/0003-9861(77)90381-2; CROMPTON M, 1976, EUR J BIOCHEM, V69, P453, DOI 10.1111/j.1432-1033.1976.tb10930.x; CROMPTON M, 1978, EUR J BIOCHEM, V82, P25, DOI 10.1111/j.1432-1033.1978.tb11993.x; DIWAN JJ, 1973, BIOCHEM BIOPH RES CO, V50, P384; DIWAN JJ, 1975, FEBS LETT, V60, P176, DOI 10.1016/0014-5793(75)80446-7; FORBES MS, 1979, CELL TISSUE RES, V200, P367; GAMBLE JL, 1957, J BIOL CHEM, V228, P955; Garlid K.D., 1988, INTEGRATION MITOCHON, P259; GARLID KD, 1980, J BIOL CHEM, V255, P1273; GARLID KD, 1978, BIOCHEM BIOPH RES CO, V83, P1450, DOI 10.1016/0006-291X(78)91383-9; HEATON GM, 1976, BIOCHEM J, V156, P635, DOI 10.1042/bj1560635; JUNG DW, 1977, ARCH BIOCHEM BIOPHYS, V183, P452, DOI 10.1016/0003-9861(77)90380-0; KAPUS A, 1990, J BIOL CHEM, V265, P18063; LI XQ, 1990, J BIOL CHEM, V265, P15316; MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0; MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x; MITCHELL P, 1969, EUR J BIOCHEM, V9, P149, DOI 10.1111/j.1432-1033.1969.tb00588.x; MOORE CL, 1971, BIOCHEM BIOPH RES CO, V42, P298, DOI 10.1016/0006-291X(71)90102-1; NAKASHIMA RA, 1982, J BIOL CHEM, V257, P9252; POZZAN T, 1979, P NATL ACAD SCI USA, V76, P2123, DOI 10.1073/pnas.76.5.2123; RIZZUTO R, 1987, BIOCHEM J, V246, P271, DOI 10.1042/bj2460271; SCARPA A, 1970, EUR J BIOCHEM, V12, P328, DOI 10.1111/j.1432-1033.1970.tb00854.x; SELWYN MJ, 1970, FEBS LETT, V10, P1, DOI 10.1016/0014-5793(70)80402-1; SETTLEMIRE CT, 1968, BIOCHIM BIOPHYS ACTA, V162, P487, DOI 10.1016/0005-2728(68)90055-8; SHI GY, 1980, J BIOL CHEM, V255, P306; STUCKI JW, 1974, EUR J BIOCHEM, V48, P365, DOI 10.1111/j.1432-1033.1974.tb03778.x; VASINGTON FD, 1972, BIOCHIM BIOPHYS ACTA, V256, P43, DOI 10.1016/0005-2728(72)90161-2; VELOSO D, 1973, J BIOL CHEM, V248, P4811; VOLPE P, 1986, J GEN PHYSIOL, V87, P289, DOI 10.1085/jgp.87.2.289; WEHRLE JP, 1976, ARCH BIOCHEM BIOPHYS, V174, P312, DOI 10.1016/0003-9861(76)90350-7; ZORATTI M, 1986, BIOCHEMISTRY-US, V25, P760, DOI 10.1021/bi00352a004; ZORATTI M, 1982, EUR J BIOCHEM, V126, P443, DOI 10.1111/j.1432-1033.1982.tb06800.x	46	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9465	9470						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903386				2022-12-25	WOS:A1991FM45900024
J	WILBANKS, SM; DELORIMIER, R; GLAZER, AN				WILBANKS, SM; DELORIMIER, R; GLAZER, AN			PHYCOERYTHRINS OF MARINE UNICELLULAR CYANOBACTERIA .3. SEQUENCE OF A CLASS-II PHYCOERYTHRIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIN ATTACHMENT SITES; AMINO-ACID-SEQUENCE; SP STRAIN PCC-6701; ALPHA-SUBUNIT; BETA-SUBUNIT; B-PHYCOERYTHRIN; AGMENELLUM-QUADRUPLICATUM; FREMYELLA-DIPLOSIPHON; LINKER POLYPEPTIDE; N-METHYLASPARAGINE	The genes for the alpha and beta-subunits of a novel six bilin-bearing (class II) phycoerythrin were cloned from Synechococcus sp. WH8020 and sequenced. The cloned genes (mpeA and mpeB) were detected by homology with the genes for C-phycoerythrin from Pseudanabaena sp. PCC7409. The mpe locus occurs once in the genome and is arranged similarly to that of many other phycobiliproteins, with mpeA shortly 3' of mpeB. Sequence comparison suggests that this phycoerythrin (and perhaps all class II phycoerythrins) occupy a branch of the phycoerythrin family separate from five-chromophore per alpha-beta (class I) phycoerythrins, C-phycoerythrin, and B-phycoerythrin. The position of the sixth chromophore of the class II phycoerythrin of WH8020 was determined by comparison of the amino acid sequence of the chromopeptides (Ong, L. J., and Glazer, A. N. (1991) J. Biol Chem. 266, 9515-9527) with the sequence deduced from the gene. This located the chromophore at residue 75 of the alpha-subunit, very close to the alpha-83 chromophore in the primary structure and, presumably, in the three-dimensional structure.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, 229 STANLEY HALL, DONNER ASU, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley				Wilbanks, Sigurd/0000-0001-7565-8913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008295, R01GM028994] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28994, 8T2 GM 08295] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON LK, 1990, J BACTERIOL, V172, P1297, DOI 10.1128/jb.172.3.1297-1305.1990; ANDERSON LK, 1990, J BACTERIOL, V172, P1289, DOI 10.1128/jb.172.3.1289-1296.1990; Battey, 1986, BASIC METHODS MOL BI; BELKNAP WR, 1987, EMBO J, V6, P871, DOI 10.1002/j.1460-2075.1987.tb04833.x; DELORIMIER R, 1990, ARCH MICROBIOL, V153, P541, DOI 10.1007/BF00245263; DELORIMIER R, 1984, P NATL ACAD SCI-BIOL, V81, P7946; DUBBS JM, 1986, PROGR PHOTOSYNTHESIS, V4, P765; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; FEDERSPIEL NA, 1990, J BACTERIOL, V172, P4072, DOI 10.1128/jb.172.7.4072-4081.1990; FRANCHE C, 1988, METHOD ENZYMOL, V167, P803; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; HOUMARD J, 1986, MOL GEN GENET, V205, P404, DOI 10.1007/BF00338074; JOHNSON PW, 1979, LIMNOL OCEANOGR, V24, P928, DOI 10.4319/lo.1979.24.5.0928; JOHNSON TR, 1988, J BACTERIOL, V170, P1858, DOI 10.1128/jb.170.4.1858-1865.1988; KALLA SR, 1988, J BACTERIOL, V170, P2961, DOI 10.1128/jb.170.7.2961-2970.1988; KLOTZ AV, 1987, J BIOL CHEM, V262, P17350; KLOTZ AV, 1986, J BIOL CHEM, V261, P5891; KLOTZ AV, 1985, J BIOL CHEM, V260, P4856; LAGARIAS JC, 1988, J BIOL CHEM, V263, P12977; LOMAX TL, 1987, J BACTERIOL, V169, P2675, DOI 10.1128/jb.169.6.2675-2684.1987; Maniatis T., 1982, MOL CLONING; MAZEL D, 1988, MOL GEN GENET, V211, P296, DOI 10.1007/BF00330607; MAZEL D, 1986, NUCLEIC ACIDS RES, V14, P8279, DOI 10.1093/nar/14.21.8279; NAGY JO, 1985, J BIOL CHEM, V260, P4864; ONG LJ, 1991, J BIOL CHEM, V266, P9515; ONG LJ, 1987, J BIOL CHEM, V262, P6323; ONG LJ, 1988, LIGHT ENERGY TRANSDU, P102; PILOT TJ, 1984, P NATL ACAD SCI-BIOL, V81, P6983, DOI 10.1073/pnas.81.22.6983; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, J MOL BIOL, V196, P677, DOI 10.1016/0022-2836(87)90040-4; SCHOENLEBER RW, 1984, J BIOL CHEM, V259, P5481; SCHOENLEBER RW, 1984, J BIOL CHEM, V259, P5485; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; SIDLER W, 1986, BIOL CHEM H-S, V367, P627, DOI 10.1515/bchm3.1986.367.2.627; SIDLER W, 1989, BIOL CHEM H-S, V370, P115, DOI 10.1515/bchm3.1989.370.1.115; SWANSON RV, 1991, J BIOL CHEM, V266, P9528; WATERBURY JB, 1988, METHOD ENZYMOL, V167, P100; WATERBURY JB, 1979, NATURE, V277, P293, DOI 10.1038/277293a0; Waterbury JB, 1986, CAN B FISH AQUAT SCI, V214, P71	40	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9535	9539						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903390				2022-12-25	WOS:A1991FM45900033
J	FAY, PJ; HAIDARIS, PJ; SMUDZIN, TM				FAY, PJ; HAIDARIS, PJ; SMUDZIN, TM			HUMAN FACTOR-VIIIA SUBUNIT STRUCTURE - RECONSTITUTION OF FACTOR VIIIA FROM THE ISOLATED A1/A3-C1-C2 DIMER AND A2 SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE FACTOR-VIII; VONWILLEBRAND FACTOR COMPLEX; THROMBIN; ACTIVATION; PROTEIN; EXPRESSION; COAGULANT; FORMS	Heterodimeric human factor VIII was proteolytically activated by catalytic levels of thrombin to yield the (labile) active cofactor factor VIIIa possessing an initial specific activity of approximately 80 units/mu-g. Activation paralleled the generation of fragments A1 and A2 derived from the heavy chain and A3-C1-C2 derived from the light chain. Chromatography of factor VIIIa on Mono-S buffered at pH 6.0 resulted in separation of the bulk of the A2 fragment from a fraction composed predominantly of A1/A3-C1-C2 dimer plus low levels of A2 fragment. Only the latter fraction contained clotting activity (approximately 20 units/mu-g) which was stable and represented a < 10% yield when compared with the peak activity of unfractionated factor VIIIa. Further depletion of A2 fragment from Mono-S-purified factor VIIIa, achieved using an immobilized monoclonal antibody to the A2 domain, yielded a relatively inactive A1/A3-C1-C2 dimer (<0.4 unit/mu-g). Factor VIIIa (>40 units/mu-g) was reconstituted from the A1/A3-C1-C2 dimer plus the A2 fragment in a reaction that was Me2+-independent and inhibited by moderate ionic strength. Reassociation of A2 required the A1 subunit in that the A2 subunit associated weakly if at all to A3-C1-C2 in the absence of A1. These results indicated that human factor VIIIa is a trimer represented by the subunits A1/A2/A3-C1-C2 and that the A2 subunit is required for expression of factor VIIIa activity.	UNIV ROCHESTER,SCH MED & DENT,DEPT MED,HEMATOL UNIT,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT BIOCHEM,ROCHESTER,NY 14642; UNIV ROCHESTER,SCH MED & DENT,DEPT MICROBIOL & IMMUNOL,ROCHESTER,NY 14642	University of Rochester; University of Rochester; University of Rochester				, PJ/0000-0003-2778-2500	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030616, R01HL038199] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-30616, HL-38199] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BIHOREAU N, 1989, EUR J BIOCHEM, V185, P111, DOI 10.1111/j.1432-1033.1989.tb15089.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1989, J BIOL CHEM, V264, P14005; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1990, J BIOL CHEM, V265, P6197; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FAY PJ, 1987, BIOCHIM BIOPHYS ACTA, V952, P181; FENTON JW, 1977, J BIOL CHEM, V252, P3587; FOWLER WE, 1990, P NATL ACAD SCI USA, V87, P7648, DOI 10.1073/pnas.87.19.7648; HAIDARIS PJ, 1989, BLOOD, V74, P743; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOSESSON MW, 1990, J CLIN INVEST, V85, P1983, DOI 10.1172/JCI114662; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	24	224	243	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8957	8962						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1902833				2022-12-25	WOS:A1991FM03800048
J	LUKAT, GS; LEE, BH; MOTTONEN, JM; STOCK, AM; STOCK, JB				LUKAT, GS; LEE, BH; MOTTONEN, JM; STOCK, AM; STOCK, JB			ROLES OF THE HIGHLY CONSERVED ASPARTATE AND LYSINE RESIDUES IN THE RESPONSE REGULATOR OF BACTERIAL CHEMOTAXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; GENE-EXPRESSION; PROTEINS; PHOSPHORYLATION; CHEY; PHOSPHOTRANSFER; IDENTIFICATION; SITE	The chemotactic responses of bacteria such as Escherichia coli and Salmonella typhimurium are mediated by phosphorylation of the CheY protein. Phospho-CheY interacts with the flagellar motor switch to cause tumbly behavior. CheY belongs to a large family of phosphorylated response regulators that function in bacteria to control motility and regulate gene expression. Residues corresponding to Asp57, Asp13, and Lys109 in CheY are highly conserved among all of these proteins. The site of phosphorylation in CheY is Asp57, and in the three-dimensional structure of CheY the Asp57 carboxylate side chain is in close proximity to the beta-carboxylate of Asp13 and the epsilon-amino of Lys109. To further examine the roles of these residues in response regulator function, each has been mutated to a conservative substitution, Asn for Asp and Arg for Lys. All mutations abolished CheY function in vivo. Whereas the Asp to Asn mutations dramatically reduced levels of CheY phosphorylation, the Lys to Arg mutation had the opposite effect. The high level of phosphorylation in the Lys109 mutant results from a decreased autophosphatase activity as well as a lack of phosphatase stimulation by the phosphatase activating protein, CheZ. Despite its high level of phosphorylation, the Lys109 mutant protein cannot produce tumbly behavior. Thus, Lys109 is required for an event subsequent to phosphorylation. We propose that an interaction between the epsilon-amino of Lys109 and the phosphoryl group at Asp57 is essential for the conformational switch that leads to activation of CheY.	PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544	Princeton University	STOCK, JB (corresponding author), PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544, USA.			Stock, Ann/0000-0002-0446-8079	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020980] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20980] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BORKOVICH KA, 1989, P NATL ACAD SCI USA, V86, P1208, DOI 10.1073/pnas.86.4.1208; BOURRET RB, 1990, P NATL ACAD SCI USA, V87, P41, DOI 10.1073/pnas.87.1.41; BURGOYNE RD, 1989, TRENDS BIOCHEM SCI, V14, P394, DOI 10.1016/0968-0004(89)90281-8; CHARDIN P, 1988, BIOCHIMIE, V70, P865, DOI 10.1016/0300-9084(88)90226-X; CLEGG DO, 1984, P NATL ACAD SCI-BIOL, V81, P5056, DOI 10.1073/pnas.81.16.5056; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUKAT GS, 1990, BIOCHEMISTRY-US, V29, P5436, DOI 10.1021/bi00475a004; NINFA AJ, 1988, P NATL ACAD SCI USA, V85, P5492, DOI 10.1073/pnas.85.15.5492; NORBY JG, 1988, METHOD ENZYMOL, V156, P116; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PARKINSON JS, 1983, J BACTERIOL, V155, P265, DOI 10.1128/JB.155.1.265-274.1983; RAVID S, 1986, P NATL ACAD SCI USA, V83, P7157, DOI 10.1073/pnas.83.19.7157; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SANDERS DA, 1989, J BIOL CHEM, V264, P21770; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SMITH JM, 1988, J BACTERIOL, V170, P2698, DOI 10.1128/jb.170.6.2698-2704.1988; STOCK A, 1988, P NATL ACAD SCI USA, V85, P1403, DOI 10.1073/pnas.85.5.1403; STOCK AM, 1987, J BACTERIOL, V169, P3301, DOI 10.1128/jb.169.7.3301-3311.1987; STOCK AM, 1988, COLD SPRING HARB SYM, V53, P49, DOI 10.1101/SQB.1988.053.01.009; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; STOCK JB, 1990, NATURE, V344, P395, DOI 10.1038/344395a0; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; WYLIE D, 1988, BIOCHEM BIOPH RES CO, V151, P891, DOI 10.1016/S0006-291X(88)80365-6; YAMAGUCHI S, 1986, J BACTERIOL, V168, P1172, DOI 10.1128/jb.168.3.1172-1179.1986	27	200	205	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8348	8354						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1902474				2022-12-25	WOS:A1991FK44100061
J	THAYER, MM; FLAHERTY, KM; MCKAY, DB				THAYER, MM; FLAHERTY, KM; MCKAY, DB			3-DIMENSIONAL STRUCTURE OF THE ELASTASE OF PSEUDOMONAS-AERUGINOSA AT 1.5-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTRAL PROTEASE GENE; AMINO-ACID SEQUENCE; NUCLEOTIDE-SEQUENCE; ALKALINE PROTEASE; BACILLUS-SUBTILIS; THERMOLYSIN; PATHOGENESIS; INACTIVATION; INFECTIONS; PROTEINASE	Pseudomonas aeruginosa elastase (PAE) is a zinc metalloprotease with 301 amino acids. We have crystallized and solved the three-dimensional structure of PAE, using data to 1.5-angstrom resolution, and have refined the native molecular structure to R = 0.188. The overall tertiary structure of the PAE molecule is similar to that of thermolysin, with which it shares 28% amino acid sequence identity. Nearly all of the active site residues that might potentially interact with substrates are identical in the two proteins. However, the active site cleft is significantly more "open" in PAE than in thermolysin.	STANFORD UNIV,MED CTR,DEPT CELL BIOL,BECKMAN LABS STRUCT BIOL,SHERMAN FAIRCHILD BLDG,STANFORD,CA 94305; UNIV COLORADO,DEPT CHEM & BIOCHEM,BOULDER,CO 80309	Stanford University; University of Colorado System; University of Colorado Boulder					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019762] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-00631, AI-19762] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; BEVER RA, 1988, J BACTERIOL, V170, P4309, DOI 10.1128/jb.170.9.4309-4314.1988; BRANDHUBER BJ, 1987, SCIENCE, V238, P1707, DOI 10.1126/science.3500515; DRAKENBERG T, 1972, J PHYS CHEM-US, V76, P2178, DOI 10.1021/j100659a020; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; FUKUSHIMA J, 1989, J BACTERIOL, V171, P1698, DOI 10.1128/jb.171.3.1698-1704.1989; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; HANSON JC, 1979, ACTA CRYSTALLOGR A, V35, P616, DOI 10.1107/S0567739479001443; HECK LW, 1986, INFECT IMMUN, V51, P115, DOI 10.1128/IAI.51.1.115-118.1986; HECK LW, 1986, INFECT IMMUN, V54, P149, DOI 10.1128/IAI.54.1.149-153.1986; HOLDER IA, 1984, CAN J MICROBIOL, V30, P1118, DOI 10.1139/m84-175; HOLMES MA, 1982, J MOL BIOL, V160, P623, DOI 10.1016/0022-2836(82)90319-9; LESK AM, 1985, METHOD ENZYMOL, V115, P381; LESK AM, 1982, SCIENCE, V216, P539, DOI 10.1126/science.7071602; LIU PV, 1974, J INFECT DIS, V130, pS94, DOI 10.1093/infdis/130.Supplement.S94; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P539; MORIHARA K, 1975, AGR BIOL CHEM TOKYO, V39, P1123, DOI 10.1080/00021369.1975.10861729; MORIHARA K, 1984, J BIOCHEM, V95, P795, DOI 10.1093/oxfordjournals.jbchem.a134671; MORIHARA K, 1965, J BIOL CHEM, V240, P3295; MORIHARA K, 1970, EUR J BIOCHEM, V15, P374, DOI 10.1111/j.1432-1033.1970.tb01018.x; NORTH ACT, 1968, ACTA CRYSTALL A-CRYS, VA 24, P351, DOI 10.1107/S0567739468000707; PAUPTIT RA, 1988, J MOL BIOL, V199, P525, DOI 10.1016/0022-2836(88)90623-7; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; RAMACHANDRAN GN, 1976, J MOL BIOL, V107, P85, DOI 10.1016/S0022-2836(76)80019-8; REES DC, 1981, P NATL ACAD SCI-BIOL, V78, P3408, DOI 10.1073/pnas.78.6.3408; ROSSMANN MG, 1976, ACTA CRYSTALLOGR A, V32, P774, DOI 10.1107/S0567739476001587; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHULTZ DR, 1974, INFECT IMMUN, V10, P128, DOI 10.1128/IAI.10.1.128-135.1974; SIDLER W, 1986, BIOL CHEM H-S, V367, P643, DOI 10.1515/bchm3.1986.367.2.643; TAKAGI M, 1985, J BACTERIOL, V163, P824, DOI 10.1128/JB.163.3.824-831.1985; TITANI K, 1972, NATURE-NEW BIOL, V238, P35, DOI 10.1038/newbio238035a0; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VASANTHA N, 1984, J BACTERIOL, V159, P811, DOI 10.1128/JB.159.3.811-819.1984; YANG MY, 1984, J BACTERIOL, V160, P15, DOI 10.1128/JB.160.1.15-21.1984; YOUNG LS, 1980, J INFECT DIS, V142, P626, DOI 10.1093/infdis/142.4.626	37	197	200	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2864	2871						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1899664				2022-12-25	WOS:A1991EX60000033
J	LEYTE, A; VANSCHIJNDEL, HB; NIEHRS, C; HUTTNER, WB; VERBEET, MP; MERTENS, K; VANMOURIK, JA				LEYTE, A; VANSCHIJNDEL, HB; NIEHRS, C; HUTTNER, WB; VERBEET, MP; MERTENS, K; VANMOURIK, JA			SULFATION OF TYR1680 OF HUMAN BLOOD-COAGULATION FACTOR-VIII IS ESSENTIAL FOR THE INTERACTION OF FACTOR-VIII WITH VON-WILLEBRAND FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODIES; LIGHT CHAIN; PROCOAGULANT PROTEIN; TYROSINE SULFATION; FACTOR-X; RECOMBINANT; DISEASE; PLASMA; SUBENDOTHELIUM	The acidic region of the Factor VIII light chain was studied with regard to structural requirements for the formation of a functional von Willebrand factor (vWF)-binding site. Factor VIII mutants lacking the B domain, with additional deletions and an amino acid replacement within the sequence 1649-1689 were constructed using site-directed mutagenesis and expressed in Cos-1 cells. These mutants, which were recovered as single-chain molecules with similar specific activities, were compared in their binding to immobilized vWF. Deletion of amino acids 741-1648 or 741-1668 did not affect the binding of Factor VIII to vWF. However, a mutant with a deletion of residues 741-1689 was no longer capable of interacting with vWF. This indicates a role for residues within the sequence 1669-1689 in the formation of a vWF-binding site. When recombinant Factor VIII was expressed in the presence of chlorate, an inhibitor of protein sulfation, the resulting Factor VIII displayed strongly reduced binding to vWF. vWF binding was completely abolished when within the sequence 1669-1689 the tyrosine residue Tyr1680, which is part of a consensus tyrosine sulfation sequence, was replaced by phenylalanine. The Factor VIII sequence 1673-1689 was identified as a high affinity substrate for tyrosylprotein sulfotransferase (K(m) = 57-mu-M) in cell-free sulfation studies. It is concluded that sulfation of Tyr1680 is required for the interaction of Factor VIII with vWF. Two synthetic peptides that represent the sequence 1673-1689, but differ with respect to sulfation of Tyr1680 are shown to have vWF binding affinity that is considerably lower than the Factor VIII protein. Several models to accommodate our findings are discussed.	NETHERLANDS RED CROSS, DEPT BLOOD COAGULAT,BLOOD TRANSFUS SERV,CENT LAB, POB 9406, 1006 AK AMSTERDAM, NETHERLANDS; EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAMME, W-6900 HEIDELBERG, GERMANY	European Molecular Biology Laboratory (EMBL)			Huttner, Wieland B./P-4080-2018					ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; BAEUERLE PA, 1985, J BIOL CHEM, V260, P6434; BRINKHOUS KM, 1985, P NATL ACAD SCI USA, V82, P8752, DOI 10.1073/pnas.82.24.8752; BURKE RL, 1986, J BIOL CHEM, V261, P2574; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1986, BIOCHEMISTRY-US, V25, P8343, DOI 10.1021/bi00374a001; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FOSTER PA, 1990, BLOOD, V75, P1999; FOSTER PA, 1988, J BIOL CHEM, V263, P5230; HAMER RJ, 1987, EUR J BIOCHEM, V166, P37, DOI 10.1111/j.1432-1033.1987.tb13480.x; HIGUCHI M, 1989, THROMB HAEMOSTASIS, V62, P201; HILLE A, 1990, EUR J BIOCHEM, V188, P577, DOI 10.1111/j.1432-1033.1990.tb15438.x; HORTIN GL, 1989, P NATL ACAD SCI USA, V86, P1338, DOI 10.1073/pnas.86.4.1338; HOYER LW, 1980, BLOOD, V55, P1056; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Huttner WB, 1988, MODERN CELL BIOL, V6, P97; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTE A, 1989, BIOCHEM J, V257, P679, DOI 10.1042/bj2570679; LEYTE A, 1989, BIOCHEM J, V263, P187, DOI 10.1042/bj2630187; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARAGANORE JM, 1989, J BIOL CHEM, V264, P8692; MERTENS K, 1985, THROMB HAEMOSTASIS, V54, P654; MEULIEN P, 1988, PROTEIN ENG, V2, P301, DOI 10.1093/protein/2.4.301; MIKKELSEN J, 1989, THROMB HAEMOSTASIS, V62, P197; NIEHRS C, 1990, J BIOL CHEM, V265, P8525; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; OVER J, 1981, J LAB CLIN MED, V97, P332; PITTMAN DD, 1987, THROMB HAEMOSTASIS, V58, P344; PITTMAN DD, 1989, THROMB HAEMOSTASIS, V61, P161; ROTBLAT F, 1985, BIOCHEMISTRY-US, V24, P4294, DOI 10.1021/bi00337a007; RUGGERI ZM, 1980, J CLIN INVEST, V65, P1318, DOI 10.1172/JCI109795; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SADLER JE, 1987, MOL BASIS BLOOD DISE, P575; SAKARIASSEN KS, 1979, NATURE, V279, P636, DOI 10.1038/279636a0; STEL HV, 1984, BLOOD, V63, P1408; TOOLE JJ, 1986, P NATL ACAD SCI USA, V83, P5939, DOI 10.1073/pnas.83.16.5939; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TSCHOPP TB, 1974, J LAB CLIN MED, V83, P296; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; VANMOURIK JA, 1978, THROMB RES, V13, P15, DOI 10.1016/0049-3848(78)90105-6; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; WOOD WI, 1984, NATURE, V312, P330, DOI 10.1038/312330a0	47	230	255	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					740	746						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898735				2022-12-25	WOS:A1991ET17700013
J	VANDENBURGH, HH; SWASDISON, S; KARLISCH, P				VANDENBURGH, HH; SWASDISON, S; KARLISCH, P			COMPUTER-AIDED MECHANOGENESIS OF SKELETAL-MUSCLE ORGANS FROM SINGLE CELLS-INVITRO	FASEB JOURNAL			English	Article						DEVELOPMENT; MECHANICAL FORCES; ORGANOGENESIS; DYSTROPHIN; SKIN	CHICK MYOTENDINOUS ANTIGEN; POSITIONAL INFORMATION; MECHANICAL TENSION; TISSUE-CULTURE; GROWTH; MORPHOGENESIS; IMMUNOFLUORESCENCE; LOCALIZATION; HYPERTROPHY; MYOGENESIS	Complex mechanical forces generated in the growing embryo play an important role in organogenesis. Computerized mechanical application of similar forces to differentiating skeletal muscle myoblasts in vitro generate three-dimensional artificial muscle organs. These organs contain parallel networks of long unbranched myofibers organized into fascicle-like structures. Tendon development is initiated and the muscle's are capable of performing directed, functional work. Kinetically engineered organs provide a new method for studying the growth and development of normal and diseased tissue.	BROWN UNIV,DEPT PATHOL,PROVIDENCE,RI 02912; UNIV ALABAMA,DEPT CELL BIOL & ANAT,BIRMINGHAM,AL 35294	Brown University; University of Alabama System; University of Alabama Birmingham	VANDENBURGH, HH (corresponding author), MIRIAM HOSP,DEPT PATHOL,164 SUMMIT AVE,PROVIDENCE,RI 02906, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005818] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039998, R01AR036266] Funding Source: NIH RePORTER; NCRR NIH HHS [RR05818] Funding Source: Medline; NIAMS NIH HHS [AR39998, AR36266] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BISCHOFF R, 1978, MEMBRANE FUSION, P127; BRAY D, 1984, DEV BIOL, V102, P379, DOI 10.1016/0012-1606(84)90202-1; BURKE JF, 1981, ANN SURG, V194, P413, DOI 10.1097/00000658-198110000-00005; CERNY LC, 1986, J CELL BIOL, V103, P2153, DOI 10.1083/jcb.103.6.2153; CHIQUET M, 1984, J CELL BIOL, V98, P1937, DOI 10.1083/jcb.98.6.1937; CHIQUET M, 1984, J CELL BIOL, V98, P1926, DOI 10.1083/jcb.98.6.1926; CHIQUET M, 1981, DEV BIOL, V88, P220, DOI 10.1016/0012-1606(81)90166-4; CURTIS ASG, 1978, NATURE, V274, P52, DOI 10.1038/274052a0; DENNERLL TJ, 1988, J CELL BIOL, V107, P665, DOI 10.1083/jcb.107.2.665; DENT JA, 1989, DEVELOPMENT, V105, P61; DEWITT MT, 1984, CONNECT TISSUE RES, V12, P97, DOI 10.3109/03008208408992775; EDE DA, 1976, CELL SURFACE ANIMAL, P495; FOLKMAN J, 1980, NATURE, V288, P551, DOI 10.1038/288551a0; FRANCO A, 1990, NATURE, V344, P670, DOI 10.1038/344670a0; GALLICO GG, 1984, NEW ENGL J MED, V311, P448, DOI 10.1056/NEJM198408163110706; HALL BK, 1971, CLIN ORTHOP RELAT R, V74, P249; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; KAMIYA A, 1980, AM J PHYSIOL, V239, pH14, DOI 10.1152/ajpheart.1980.239.1.H14; KELLY AM, 1983, HDB PHYSL 10, P507; KIENY M, 1979, J EMBRYOL EXP MORPH, V49, P153; KLEINNULEND J, 1987, J BIOL CHEM, V262, P15490; LANDMESSER LT, 1984, J PHYSIOL-LONDON, V347, P189, DOI 10.1113/jphysiol.1984.sp015061; LEUNG DYM, 1976, SCIENCE, V191, P475; MENKE A, 1991, NATURE, V349, P69, DOI 10.1038/349069a0; MIRANDA AF, 1985, ADV CELL CULT, V4, P1; MORGAN HE, 1987, ANNU REV PHYSIOL, V49, P533; ODELL GM, 1981, DEV BIOL, V85, P446, DOI 10.1016/0012-1606(81)90276-1; PEARSON ML, 1982, MUSCLE DEV MOL CELLU; RANNELS DE, 1989, AM J PHYSIOL, V257, pL179, DOI 10.1152/ajplung.1989.257.4.L179; RYAN TJ, 1989, J AM ACAD DERMATOL, V21, P115, DOI 10.1016/S0190-9622(89)70156-0; SANDERSON RD, 1986, J CELL BIOL, V102, P740, DOI 10.1083/jcb.102.3.740; Shellswell G., 1977, VERTEBRATE LIMB SOMI, P71; SHELLSWELL GB, 1980, J EMBRYOL EXP MORPH, V60, P245; Stewart D.M, 1972, REGULATION ORGAN TIS, P77; STROHMAN RC, 1990, IN VITRO CELL DEV B, V26, P201; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; SUMMERBELL D, 1974, J EMBRYOL EXP MORPH, V32, P227; TOMANEK RJ, 1975, DEV BIOL, V42, P305, DOI 10.1016/0012-1606(75)90337-1; VANDENBURGH H, 1979, SCIENCE, V203, P265, DOI 10.1126/science.569901; VANDENBURGH HH, 1989, AM J PHYSIOL, V256, pC674, DOI 10.1152/ajpcell.1989.256.3.C674; VANDENBURGH HH, 1982, DEV BIOL, V93, P438, DOI 10.1016/0012-1606(82)90131-2; VANDENBURGH HH, 1988, IN VITRO CELL DEV B, V24, P609; VANDENBURGH HH, 1989, IN VITRO CELL DEV B, V25, P607; VANDENBURGH HH, 1987, MED SCI SPORT EXER, V19, pS142; VONDERMARK K, 1976, DEV BIOL, V53, P153, DOI 10.1016/0012-1606(76)90220-7; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; WEISS P, 1933, AM NAT, V118, P389; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	48	95	111	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	OCT	1991	5	13					2860	2867		10.1096/fasebj.5.13.1916108	http://dx.doi.org/10.1096/fasebj.5.13.1916108			8	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GJ471	1916108	Green Submitted			2022-12-25	WOS:A1991GJ47100016
J	HILDEBRAND, A; POHL, M; BHAKDI, S				HILDEBRAND, A; POHL, M; BHAKDI, S			STAPHYLOCOCCUS-AUREUS ALPHA-TOXIN - DUAL MECHANISM OF BINDING TO TARGET-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANES; GENE; OLIGOMERIZATION; HEMOLYSIN; PROTEIN	Staphylococcal alpha-toxin was radiolabeled to high specific radioactivity (1,500-3,000 Ci/mmol) under retention of its hemolytic activity. Binding studies with susceptible rabbit erythrocytes and highly resistant human erythrocytes revealed that binding of alpha-toxin to target cells can occur via two different mechanisms. Binding of alpha-toxin to rabbit erythrocytes initially involves specific binding sites and occurs at low concentrations, with half-maximal binding at 1-2 nM. In contrast, toxin binding to human erythrocytes is adsorptive and nonspecific, in this case, significant binding as well as hemolysis occur only at alpha-toxin concentrations exceeding 1-mu-M. Autoradiographic analyses of membrane-associated alpha-toxin from either cell species proved that hemolysis was inevitably associated with the formation of toxin hexamers. Our data indicate that the high susceptibility of certain target cells toward alpha-toxin is caused by the presence of specific binding sites. However, membrane damage of both susceptible and nonsusceptible target cells occurs via a common mechanism involving toxin oligomerization and pore formation.	UNIV MAINZ,INST MED MICROBIOL,W-6500 MAINZ,GERMANY	Johannes Gutenberg University of Mainz	HILDEBRAND, A (corresponding author), LA JOLLA CANC RES FDN,CANC RES CTR,10901 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							AHNERTHILGER G, 1985, J BIOL CHEM, V260, P2730; ARBUTHNOTT JP, 1973, J GEN MICROBIOL, V75, P309, DOI 10.1099/00221287-75-2-309; ARBUTHNOTT JP, 1967, J BACTERIOL, V94, P1170, DOI 10.1128/JB.94.4.1170-1177.1967; BAREI GM, 1979, CAN J MICROBIOL, V25, P12219; BELMONTE G, 1987, EUR BIOPHYS J BIOPHY, V14, P349; BHAKDI S, 1981, P NATL ACAD SCI-BIOL, V78, P5475, DOI 10.1073/pnas.78.9.5475; BHAKDI S, 1989, INFECT IMMUN, V57, P3512, DOI 10.1128/IAI.57.11.3512-3519.1989; BHAKDI S, 1988, J EXP MED, V168, P527, DOI 10.1084/jem.168.2.527; BHAKDI S, 1987, REV PHYSL BIOCH PHAR, V107, P148; BOEYNAEMS JM, 1980, OUTLINES RECEPTOR TH, P33; BUCKELEW AR, 1971, BIOCHIM BIOPHYS ACTA, V233, P7, DOI 10.1016/0005-2736(71)90352-X; CASSIDY P, 1976, BIOCHEMISTRY-US, V15, P2348, DOI 10.1021/bi00656a016; CATT KJ, 1976, METHODS RECEPTOR RES, V1, P186; DIAS JA, 1981, J BIOL CHEM, V257, P613; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Freer J.H., 1983, PHARMACOL THERAPEUT, V19, P55, DOI DOI 10.1016/0163-7258(82)90042-0; FREER JH, 1973, J GEN MICROBIOL, V75, P321, DOI 10.1099/00221287-75-2-321; FREER JH, 1968, J BACTERIOL, V95, P1153, DOI 10.1128/JB.95.3.1153-1168.1968; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; GRAY GS, 1984, INFECT IMMUN, V46, P615, DOI 10.1128/IAI.46.2.615-618.1984; HARSHMAN S, 1979, MOL CELL BIOL, V91, P83; HUGO F, 1987, INFECT IMMUN, V55, P2933, DOI 10.1128/IAI.55.12.2933-2939.1987; JONSSON P, 1985, INFECT IMMUN, V49, P765, DOI 10.1128/IAI.49.3.765-769.1985; KATO I, 1975, JPN J MED SCI BIOL, V28, P332; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LO CY, 1979, J MICROBIOL, V25, P686; MCCARTNEY C, 1978, BACTERIAL TOXINS CEL, P89; OREILLY M, 1986, MICROB PATHOGENESIS, V1, P125, DOI 10.1016/0882-4010(86)90015-X; PHIMISTER GM, 1984, J MED MICROBIOL, V18, P197, DOI 10.1099/00222615-18-2-197; REICHWEIN J, 1987, INFECT IMMUN, V55, P2940, DOI 10.1128/IAI.55.12.2940-2944.1987; SALACINSKI PRP, 1981, ANAL BIOCHEM, V117, P136, DOI 10.1016/0003-2697(81)90703-X; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; WATANABE M, 1987, BIOCHIM BIOPHYS ACTA, V898, P257, DOI 10.1016/0005-2736(87)90065-4	33	158	165	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17195	17200						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894613				2022-12-25	WOS:A1991GF44500036
J	MICHEL, H; GRIFFIN, PR; SHABANOWITZ, J; HUNT, DF; BENNETT, J				MICHEL, H; GRIFFIN, PR; SHABANOWITZ, J; HUNT, DF; BENNETT, J			TANDEM MASS-SPECTROMETRY IDENTIFIES SITES OF 3 POSTTRANSLATIONAL MODIFICATIONS OF SPINACH LIGHT-HARVESTING CHLOROPHYLL PROTEIN-II - PROTEOLYTIC CLEAVAGE, ACETYLATION, AND PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A/B BINDING-PROTEIN; SUBSTRATE-SPECIFICITY; PHOTOSYSTEM-II; SYNTHETIC PEPTIDES; BASIC RESIDUES; THYLAKOID MEMBRANES; KINASE; COMPLEX; CHLOROPLASTS; POLYPEPTIDES	The photosynthetic membranes of spinach (Spinacia oleracea L.) chloroplasts were incubated with [gamma-P-32] ATP. When the thylakoid membrane kinase was activated with light, the 25- and 27-kDa forms of the light-harvesting chlorophyll a/b protein (LHC II) were phosphorylated on their amino termini. Treatment of the membranes with proteinase K or thermolysin released phosphopeptides which were purified by ferric ion affinity chromatography and reverse phase high performance liquid chromatography. Sequencing of the phosphopeptides was performed with tandem quadrupole mass spectrometry. Three different phosphopeptides Ac-RKTAGKPKT, Ac-RKTAGKPKN, and Ac-RKSAGKPKN originating from class I LHC II were examined after release by thermolysin. One phosphopeptide, Ac-RRTVKSAPQ, originating from class II LHC II was examined after release by proteinase K. Each of the four LHC II phosphopeptides was derived from the amino terminus of a distinct protein. Peptides were acetylated at their amino-terminal arginine and were phosphorylated on either threonine or serine in the third position. We conclude that proteolytic processing of pre-LHC II occurs at a conserved methionylarginyl bond and is followed by amino-terminal acetylation of the arginine and nearby phosphorylation of the mature LHC II. Eight different peptides were synthesized in acetylated and nonacetylated forms as substrates for the thylakoid membrane kinase. From a comparison of the kinetics of phosphate incorporation into the peptides, we conclude that basic residues on both sides of the phosphorylation site are important for enzyme recognition. Acetylation of the amino terminus is not required for phosphorylation.	BROOKHAVEN NATL LAB,DEPT BIOL,UPTON,NY 11973	United States Department of Energy (DOE); Brookhaven National Laboratory	MICHEL, H (corresponding author), UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901, USA.		Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368				BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BENNETT J, 1987, FEBS LETT, V210, P22, DOI 10.1016/0014-5793(87)81290-5; BENNETT J, 1984, PHYSIOL PLANTARUM, V60, P583, DOI 10.1111/j.1399-3054.1984.tb04932.x; BHALLA P, 1987, ARCH BIOCHEM BIOPHYS, V252, P2149; BURGI R, 1987, BIOCHIM BIOPHYS ACTA, V890, P346, DOI 10.1016/0005-2728(87)90162-9; CHITNIS PR, 1988, PHOTOSYNTH RES, V16, P41, DOI 10.1007/BF00039485; CORRUZZI G, 1983, J BIOL CHEM, V258, P1399; DEMMIN DS, 1989, J MOL EVOL, V29, P266, DOI 10.1007/BF02100210; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; HIRS CHW, 1983, METHOD ENZYMOL, V91, P3, DOI 10.1016/S0076-6879(83)91003-0; HOOBER JK, 1980, ARCH BIOCHEM BIOPHYS, V202, P221, DOI 10.1016/0003-9861(80)90424-5; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUNT DF, 1986, P NATL ACAD SCI USA, V83, P6233, DOI 10.1073/pnas.83.17.6233; HUNT DF, 1987, P NATL ACAD SCI USA, V84, P620, DOI 10.1073/pnas.84.3.620; ISLAM K, 1985, BIOCHIM BIOPHYS ACTA, V810, P158, DOI 10.1016/0005-2728(85)90131-8; ISLAM K, 1987, BIOCHIM BIOPHYS ACTA, V893, P333, DOI 10.1016/0005-2728(87)90054-5; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KEMP BE, 1976, P NATL ACAD SCI USA, V73, P1083; LAMPPA GK, 1987, J CELL BIOL, V105, P2641, DOI 10.1083/jcb.105.6.2641; LUCERO HA, 1987, BIOCHIM BIOPHYS ACTA, V890, P77, DOI 10.1016/0005-2728(87)90070-3; MASON JG, 1989, NUCLEIC ACIDS RES, V17, P5387, DOI 10.1093/nar/17.13.5387; MEGGIO F, 1984, J BIOL CHEM, V259, P4576; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MICHEL H, 1989, FEBS LETT, V254, P165, DOI 10.1016/0014-5793(89)81031-2; MICHEL H P, 1981, Photosynthesis Research, V2, P203, DOI 10.1007/BF00032359; MICHEL HP, 1987, FEBS LETT, V212, P103, DOI 10.1016/0014-5793(87)81565-X; MULLET JE, 1983, J BIOL CHEM, V258, P9941; PICHERSKY E, 1985, GENE, V40, P247, DOI 10.1016/0378-1119(85)90047-2; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; SUSS KH, 1976, BIOCHIM BIOPHYS ACTA, V448, P103, DOI 10.1016/0005-2736(76)90079-1; VONHEIJNE G, 1989, EUR J BIOCHEM, V180, P535; WHITE IR, 1990, FEBS LETT, V269, P49, DOI 10.1016/0014-5793(90)81116-6; YALOVSKY S, 1990, PLANT MOL BIOL, V14, P753, DOI 10.1007/BF00016508	35	78	88	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17584	17591						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894641				2022-12-25	WOS:A1991GF44500090
J	NEMECZ, G; SCHROEDER, F				NEMECZ, G; SCHROEDER, F			SELECTIVE BINDING OF CHOLESTEROL BY RECOMBINANT FATTY-ACID BINDING-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROL CARRIER PROTEIN-2; RAT-LIVER; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; MESSENGER-RNA; BOVINE LIVER; EXPRESSION; CYTOSOL; LIGANDS; ASSAY	The sterol binding specificity of rat recombinant liver fatty acid binding protein (L-FABP) and intestinal fatty acid binding protein (I-FABP) was characterized with [H-3]cholesterol and a fluorescent sterol analog dehydroergosterol. Ligand binding analysis, fluorescence spectroscopy, and activation of microsomal acyl-CoA:cholesterol acyltransferase activity showed that L-FABP-bound sterols. 1) Lipidex-1000 assay showed a dissociation constant K(d) = 0.78 +/- 0.18-mu-M and stoichiometry of 0.47 +/- 0.16 mol/mol for [H-3] cholesterol binding to L-PABP. 2) With [H-3]cholesterol/phosphatidylcholine liposomes, the cholesterol binding parameters for L-FABP were K(d) = 1.53 +/- 0.28-mu-M and stoichiometry 0.83 +/- 0.07 mol/mol. 3) L-FABP interaction with dehydroergosterol altered the fluorescence intensity and polarization of dehydroergosterol. Dehydroergosterol bound to L-FABP with K(d) = 0.37-mu-M and a stoichiometry of 0.83 mol/mol. 4) Cholesterol and dehydroergosterol decreased L-FABP tyrosine lifetime. Dehydroergosterol binding produced sensitized emission of bound dehydroergosterol with longer lifetime. 5) L-FABP bound two cis-parinaric acid molecules/molecule of protein. Cholesterol displaced one of these bound cis-parinaric acids. 6) L-FABP enhanced acyl-CoA:cholesterol acyltransferase in a concentration-dependent manner. In contrast, these assays indicated that I-FABP did not bind sterols. Thus, L-FABP appears able to bind 1 mol of cholesterol/mol of L-FABP, the L-FABP sterol binding site is equivalent to one of the two fatty acid binding sites, and L-FABP stimulates acyl-CoA:cholesterol acyltransferase by transfer of cholesterol.	UNIV CINCINNATI, MED CTR, DEPT PHARMACOL & CELL BIOPHY, DIV PHARMACOL & MED CHEM, CINCINNATI, OH 45276 USA	University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031651] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03155-01] Funding Source: Medline; NIDDK NIH HHS [DK41402] Funding Source: Medline; NIGMS NIH HHS [GM31651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALCALA JR, 1985, ANAL INSTRUM, V14, P225; ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRECHER P, 1984, J BIOL CHEM, V259, P3395; BURNETT DA, 1979, GASTROENTEROLOGY, V77, P241; BURTON P, 1985, J BIOL CHEM, V260, P7298; BUTKO P, 1990, BIOCHEMISTRY-US, V29, P4070, DOI 10.1021/bi00469a007; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; DEMPSEY ME, 1984, CURR TOP CELL REGUL, V24, P63; FISCHER R T, 1985, Journal of Biological Physics, V13, P13, DOI 10.1007/BF01872877; FISCHER RT, 1984, CHEM PHYS LIPIDS, V36, P1, DOI 10.1016/0009-3084(84)90086-0; FISCHER RT, 1985, BIOCHEMISTRY-US, V24, P3322, DOI 10.1021/bi00334a037; GLATZ JFC, 1985, INT J BIOCHEM, V17, P13, DOI 10.1016/0020-711X(85)90080-1; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GORDON JI, 1983, J BIOL CHEM, V258, P3356; GUTFREUND H, 1972, ENZYMES PHYSICAL PRI, P68; HAUNERLAND N, 1984, H-S Z PHYSIOL CHEM, V365, P365, DOI 10.1515/bchm2.1984.365.1.365; ISHIBASHI T, 1981, J BIOL CHEM, V256, P2962; JEFFERSON JR, 1991, J BIOL CHEM, V266, P5486; JEFFERSON JR, 1990, J BIOL CHEM, V265, P11062; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KANDUTSCH AA, 1981, J BIOL CHEM, V256, P3068; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LOWE JB, 1984, J BIOL CHEM, V259, P2696; MATERESE V, 1989, PROG LIPID RES, V28, P66; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; NEMECZ G, 1991, IN PRESS J BIOL CHEM, V266; PEETERS RA, 1989, INT J BIOCHEM, V21, P407, DOI 10.1016/0020-711X(89)90365-0; RASMUSSEN JT, 1990, BIOCHEM J, V265, P849, DOI 10.1042/bj2650849; RUSTOW B, 1982, ACTA BIOL MED GER, V41, P439; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SCHROEDER F, 1990, J BIOL CHEM, V265, P151; SCHROEDER F, 1989, SER SYMP AD, V1, P29; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SCHROEDER F, 1985, J BIOL CHEM, V260, P2904; SCHULENBERGSCHELL H, 1988, EUR J BIOCHEM, V170, P565, DOI 10.1111/j.1432-1033.1988.tb13735.x; SPENER F, 1989, FEBS LETT, V44, P1; STORCH J, 1989, J BIOL CHEM, V264, P8708; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; TAKAHASHI K, 1983, EUR J BIOCHEM, V136, P589, DOI 10.1111/j.1432-1033.1983.tb07781.x; VAHOUNY GV, 1987, ADV LIPID RES, V22, P83; WARNER M, 1975, J PHYSIOL PHARMACOL, V53, P493; WINTER NS, 1990, J BIOL CHEM, V265, P10955; WOOTAN MG, 1990, BIOCHEMISTRY-US, V29, P9305, DOI 10.1021/bi00492a001	47	74	77	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17180	17186						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894612				2022-12-25	WOS:A1991GF44500034
J	RACHER, KI; KALMAR, GB; BORGFORD, TJ				RACHER, KI; KALMAR, GB; BORGFORD, TJ			EXPRESSION AND CHARACTERIZATION OF A RECOMBINANT YEAST ISOLEUCYL-TRANSFER RNA-SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING FOLD; GENE ILS1; SEQUENCE; RECOGNITION; REJECTION; PROMOTERS; VECTORS; ENZYME; VALINE	We describe the heterologous expression of a recombinant Saccharomyces cerevisiae isoleucyl-tRNA synthetase (IRS) gene in Escherchia coli, as well as the purification and characterization of the recombinant gene product. High level expression of the yeast isoleucyl-tRNA synthetase gene was facilitated by site-specific mutagenesis. The putative ribosome-binding site of the yeast IRS gene was made to be the consensus of many highly expressed genes of E. coli. Mutagenesis simultaneously created a unique BclI restriction site such that the gene coding region could be conveniently subcloned as a "cassette." The variant gene was cloned into the expression vector pKK223-3 (Brosius, J., and Holy, A. (1984) Proc. Natl. Acad. Sci. U.S.A. 81, 6929-6933) thereby creating the plasmid pKR4 in which yeast IRS expression is under the control of the isopropyl-thio-beta-galactopyranoside (IPTG)-inducible tac promoter. Recombinant yeast IRS, on the order of 10 mg/liter of cell culture, was purified from pKR4-infected and IPTG-induced E. coli strain TG2. Yeast IRS was purified to homogeneity by a combination of anion-exchange and hydroxyapatite gel chromatography. Inhibition of yeast IRS activity by the antibiotic pseudomonic acid A was tested. The yeast IRS enzyme was found to be 10(4) times less sensitive to inhibition by pseudomonic acid A (K(i) = 1.5 x 10(-5) M) than the E. coli enzyme. E. coli strain TG2 infected with pKR4, and induced with IPTG, had a plating efficiency of 100% at inhibitor concentrations in excess of 25-mu-g/ml. At the same concentrations of pseudomonic acid A, E. coli strain TG2 infected with pKK223-3 had a plating efficiency < 1%. The ability of yeast IRS to rescue E. coli from pseudomonic acid A suggests that the eukaryotic synthetase has full activity in its prokaryotic host and has specificity for E. coli tRNA(ile).	SIMON FRASER UNIV, DEPT CHEM, BURNABY V5A 1S6, BC, CANADA; SIMON FRASER UNIV, INST MOLEC BIOL & BIOCHEM, BURNABY V5A 1S6, BC, CANADA	Simon Fraser University; Simon Fraser University								BHAT TN, 1982, J MOL BIOL, V158, P699, DOI 10.1016/0022-2836(82)90255-8; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; BROSIUS J, 1988, VECTORS SURVEY MOL C, P205; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; DEBOER HA, 1983, P NATL ACAD SCI-BIOL, V80, P21; DOCTOR BP, 1963, J BIOL CHEM, V238, P3677; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; ENGLISCH U, 1987, BIOL CHEM H-S, V368, P971, DOI 10.1515/bchm3.1987.368.2.971; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P3342, DOI 10.1021/bi00660a026; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P212; FERSHT AR, 1976, BIOCHEMISTRY-US, V15, P810; HOU YM, 1991, P NATL ACAD SCI USA, V88, P976, DOI 10.1073/pnas.88.3.976; HUGHES J, 1980, BIOCHEM J, V191, P209, DOI 10.1042/bj1910209; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; KAWAKAMI M, 1985, FEBS LETT, V185, P162, DOI 10.1016/0014-5793(85)80762-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARKMEYER P, 1990, GENE, V93, P129, DOI 10.1016/0378-1119(90)90146-I; MARTINDALE DW, 1989, CURR GENET, V15, P99, DOI 10.1007/BF00435455; MEUSSDOERFFER F, 1983, J BIOL CHEM, V258, P6293; REZNIKOFF WS, 1986, MAXIMIZING GENE EXPR, P250; RISLER JL, 1981, NATURE, V292, P384, DOI 10.1038/292384a0; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; Sambrook J, 1989, MOL CLONING LABORATO; SANNI A, 1990, NUCLEIC ACIDS RES, V18, P2087, DOI 10.1093/nar/18.8.2087; SCHERER GFE, 1980, NUCLEIC ACIDS RES, V8, P3895, DOI 10.1093/nar/8.17.3895; SCHIMMEL P, 1987, ANNU REV BIOCHEM, V56, P125, DOI 10.1146/annurev.bi.56.070187.001013; SCHIMMEL PR, 1979, ANNU REV BIOCHEM, V48, P601, DOI 10.1146/annurev.bi.48.070179.003125; STARZYK RM, 1987, SCIENCE, V237, P1614, DOI 10.1126/science.3306924; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2971, DOI 10.1093/nar/10.9.2971; WEBSTER T, 1984, SCIENCE, V226, P1315, DOI 10.1126/science.6390679; WINNACKER EL, 1987, GENES CLONES, P239; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; 1989, STEP BY STEP PROTOCO, P2	35	13	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17158	17164						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910039				2022-12-25	WOS:A1991GF44500031
J	GUALERZI, CO; SEVERINI, M; SPURIO, R; LATEANA, A; PON, CL				GUALERZI, CO; SEVERINI, M; SPURIO, R; LATEANA, A; PON, CL			MOLECULAR DISSECTION OF TRANSLATION INITIATION FACTOR-IF2 - EVIDENCE FOR 2 STRUCTURAL AND FUNCTIONAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL MODIFICATION INSITU; REAGENT PYRIDOXAL-PHOSPHATE; ELONGATION FACTOR-TU; ESCHERICHIA-COLI; FACTOR-II; TRANSFER-RNA; RIBOSOMAL-PROTEINS; BINDING; GENE; SEQUENCE	By means of limited proteolysis of Bacillus stearothermophilus initiation factor IF2 and genetic manipulation of its structural gene, infB, we have been able to produce (or hyperproduce) and purify two polypeptide fragments corresponding to two structurally and functionally separate domains of the protein. The first is the G-domain (approximately 41 kDa), which makes up the central part of the molecule and contains the conserved structural elements found in all GTP/GDP-binding sites of G-proteins. This domain is resistant to proteolysis in the presence of GTP or GDP, retains the capacity to interact with the 50 S subunit, binds weakly to the 30 S subunit, and displays ribosome-dependent GTPase activity with an approximately 2-fold higher K(m) for GTP and the same V(max) as compared with intact IF2. The second is the C-domain (approximately 24 kDa), which corresponds to the COOH-terminal part of IF2 and constitutes an extraordinarily compact domain containing the fMet-tRNA binding site of IF2. In spite of its negligible affinity for the ribosomes, the C-domain weakly stimulates the ribosomal binding of fMet-tRNA, presumably by affecting the conformation of the initiator tRNA molecule.	MAX PLANCK INST MOLEC GENET,W-1000 BERLIN 33,GERMANY	Max Planck Society	GUALERZI, CO (corresponding author), UNIV CAMERINO,DEPT BIOL,GENET LAB,I-62032 CAMERINO,ITALY.			Spurio, Roberto/0000-0002-7611-4341				BROMBACH M, 1986, MOL GEN GENET, V205, P97, DOI 10.1007/BF02428037; CANONACO MA, 1989, EUR J BIOCHEM, V182, P501, DOI 10.1111/j.1432-1033.1989.tb14856.x; CENATIEMPO Y, 1987, BIOCHEMISTRY-US, V26, P5070, DOI 10.1021/bi00390a028; CROWL R, 1985, GENE, V38, P31, DOI 10.1016/0378-1119(85)90200-8; FRIEDRICH K, 1988, MOL GEN GENET, V214, P595, DOI 10.1007/BF00330501; GUALERZI CO, 1990, BIOCHEMISTRY-US, V29, P5881, DOI 10.1021/bi00477a001; GUALERZI CO, 1989, PROTEIN ENG, V3, P133, DOI 10.1093/protein/3.2.133; GUALERZI CO, 1990, STRUCTURE FUNCTION E, P281; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCH PE, 1985, P NATL ACAD SCI USA, V82, P7500, DOI 10.1073/pnas.82.22.7500; OHSAWA H, 1983, J BIOL CHEM, V258, P157; OHSAWA H, 1983, J BIOL CHEM, V258, P150; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; PAWLIK RT, 1981, BIOCHEM INT, V2, P421; PETERSEN HU, 1979, BIOCHEM BIOPH RES CO, V91, P1068, DOI 10.1016/0006-291X(79)91989-2; PON CL, 1985, J BIOL CHEM, V260, P8918; PON CL, 1988, GENE EXPRESSION REGU, P137; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; SACERDOT C, 1984, P NATL ACAD SCI-BIOL, V81, P7787, DOI 10.1073/pnas.81.24.7787; SEVERINI M, 1990, FEBS LETT, V276, P14, DOI 10.1016/0014-5793(90)80495-5; SHAZAND K, 1990, J BACTERIOL, V172, P2675, DOI 10.1128/jb.172.5.2675-2687.1990; SPURIO R, 1989, ATTI ASSOC GENET IT, V35, P349; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; TANIGUCHI T, 1979, J MOL BIOL, V128, P481, DOI 10.1016/0022-2836(79)90289-4; VACHON G, 1990, BIOCHEMISTRY-US, V29, P9728, DOI 10.1021/bi00493a031; WAKAO H, 1989, J BIOL CHEM, V264, P20363; WEIEL J, 1982, J BIOL CHEM, V257, P1215	29	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16356	16362						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885570				2022-12-25	WOS:A1991GD63500021
J	BRAMSON, HN; CASNELLIE, JE; NACHOD, H; REGAN, LM; SOMMERS, C				BRAMSON, HN; CASNELLIE, JE; NACHOD, H; REGAN, LM; SOMMERS, C			SYNTHETIC FRAGMENTS OF THE CD4 RECEPTOR CYTOPLASMIC DOMAIN AND LARGE POLYCATIONS ALTER THE ACTIVITIES OF THE PP56LCK TYROSINE PROTEIN-KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROVIRUS PROMOTER INSERTION; AMINO-TERMINAL DOMAIN; LYMPHOMA CELL-LINE; INSULIN-RECEPTOR; LYMPHOCYTES-T; LSTRA CELLS; PARTICULATE-FRACTION; RAT SPLEEN; PHOSPHORYLATION; P56LCK	In CD4+ T cells, the src-like tyrosine kinase pp56lck is associated with the CD4 receptor and cross-linking of CD4 results in the activation of this enzyme. The mechanism responsible for this activation is not known, although there is evidence that the activities of the src family of enzymes are regulated by tyrosine phosphorylation. Here we report that pp56lck-catalyzed angiotensin II phosphorylations are activated 20-fold in vitro by synthetic peptides reproducing portions of the murine CD4 cytoplasmic domain. This activation is described by a dissociation constant of about 2-mu-M. The pp56lck-catalyzed phosphorylation of other peptide substrates are effected less and in one case not at all by the peptide modulators, indicating that these CD4 sequences alter the substrate specificity of pp56lck. In contrast, peptides reproducing sequences from the CD8 receptor have a charge and size similar to the CD4 peptides, yet are vastly less effective at modulating pp56lck activities. High ionic strengths inhibit the CD4 peptide-induced modulation of pp56lck phosphotransferase activities, suggesting that charge-charge interactions are important for this process. In addition, the modulation of pp56lck activities by peptides reproducing the CD4 cytoplasmic domain are reproduced by polycations significantly larger than the CD4 cytoplasmic domain but not by those of similar size. The modulations both by CD4 peptides and the polycations do not depend on enzyme tyrosine phosphorylations.	UNIV ROCHESTER,MED CTR,DEPT PHARMACOL,ROCHESTER,NY 14642	University of Rochester	BRAMSON, HN (corresponding author), UNIV ROCHESTER,MED CTR,DEPT BIOCHEM,ROCHESTER,NY 14642, USA.				NCI NIH HHS [CA38821] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA038821] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BRAMSON HN, 1987, BIOCHEMISTRY-US, V26, P4466, DOI 10.1021/bi00388a042; BRUNATI AM, 1985, FEBS LETT, V188, P321, DOI 10.1016/0014-5793(85)80395-1; BRUNATI AM, 1988, EUR J BIOCHEM, V172, P451, DOI 10.1111/j.1432-1033.1988.tb13909.x; CASNELLIE JE, 1982, P NATL ACAD SCI-BIOL, V79, P282, DOI 10.1073/pnas.79.2.282; CASNELLIE JE, 1984, P NATL ACAD SCI-BIOL, V81, P6676, DOI 10.1073/pnas.81.21.6676; CASNELLIE JE, 1987, J BIOL CHEM, V262, P9859; CASNELLIE JE, 1983, J BIOL CHEM, V258, P738; CHEN M, 1989, J BIOL CHEM, V264, P14282; GOLDEN A, 1989, P NATL ACAD SCI USA, V86, P901, DOI 10.1073/pnas.86.3.901; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KORNBLUTH S, 1987, P NATL ACAD SCI USA, V84, P4455, DOI 10.1073/pnas.84.13.4455; LITTMAN DR, 1985, CELL, V40, P237, DOI 10.1016/0092-8674(85)90138-2; MADDON PJ, 1985, CELL, V42, P93, DOI 10.1016/S0092-8674(85)80105-7; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MORRISON BD, 1989, J BIOL CHEM, V264, P9994; NAKAUCHI H, 1985, P NATL ACAD SCI USA, V82, P5126, DOI 10.1073/pnas.82.15.5126; ROSEN OM, 1988, FEBS LETT, V231, P397, DOI 10.1016/0014-5793(88)80858-5; ROSS EM, 1977, J BIOL CHEM, V252, P5761; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; SAKAI K, 1989, BIOCHEM BIOPH RES CO, V158, P1043, DOI 10.1016/0006-291X(89)92827-1; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SUGIMOTO Y, 1985, J BIOL CHEM, V260, P3838; THOM RE, 1987, FEBS LETT, V222, P104, DOI 10.1016/0014-5793(87)80200-4; TOURVIEILLE B, 1986, SCIENCE, V234, P610, DOI 10.1126/science.3094146; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VEGA MA, 1990, EUR J IMMUNOL, V20, P453, DOI 10.1002/eji.1830200235; VEILLETTE A, 1988, MOL CELL BIOL, V8, P4353, DOI 10.1128/MCB.8.10.4353; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VEILLETTE A, 1989, MOL CELL BIOL, V9, P4441, DOI 10.1128/MCB.9.10.4441; VORONOVA AF, 1986, NATURE, V319, P682, DOI 10.1038/319682a0; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035	41	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16219	16225						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908465				2022-12-25	WOS:A1991GB97700103
J	LIU, T; LIN, Y; CISLO, T; MINETTI, CASA; BABA, JMK; LIU, TY				LIU, T; LIN, Y; CISLO, T; MINETTI, CASA; BABA, JMK; LIU, TY			LIMUNECTIN - A PHOSPHOCHOLINE-BINDING PROTEIN FROM LIMULUS AMEBOCYTES WITH ADHESION-PROMOTING PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; AMINO-ACID SEQUENCE; PLASMA FIBRONECTIN; CELL-ADHESION; VITRONECTIN; CDNA; SIMILARITY; CHROMATIN; COLLAGEN; DOMAIN	A protein that binds to and precipitates with pneumococcal C-polysaccharide and a phosphocholine (PC) derivative of bovine serum albumin has been affinity purified from Limulus amebocytes. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis reveals that the isolated protein consists of a single polypeptide chain of approximately 50 kDa. It is an intracellular protein localized in the secretory granules of amebocytes according to immunogold staining. Although it shares the PC-binding property with C-reactive protein isolated from Limulus and other animal species, it differs from C-reactive protein in that the latter binds to PC only in the presence of Ca2+, whereas the newly isolated protein binds to PC in a Ca2+-independent manner. In this respect, the newly isolated PC-binding protein resembles the antibodies to PC of mouse myelomas. The gene coding for this protein has been isolated. The gene sequence predicts a protein of 54 kDa with an unusual structural feature: it consists almost entirely of 10 contiguous segments, 45 amino acids in length, with extensive homology. Some limited sequence homologies were found between the 54-kDa protein and segments of vitronectin, gelatinase, and collagenase. It binds to bacterial cells, fixed amebocytes, and a number of extracellular matrix molecules. Due to its structural and some functional similarities to other adhesion molecules, the Limulus 54-kDa protein was named "Limunectin."	US FDA, CTR BIOL EVALUAT & RES,DIV BIOCHEM & BIOPHYS, RM 516,BLDG 29,8800 ROCKVILLE PIKE, BETHESDA, MD 20892 USA	US Food & Drug Administration (FDA)			Minetti, Conceicao/B-5077-2009; Minetti, Conceicao/AGD-6419-2022	Minetti, Conceicao/0000-0002-9682-2898; Minetti, Conceicao/0000-0002-9682-2898				ANDERSON HC, 1951, J EXP MED, V93, P25, DOI 10.1084/jem.93.1.25; ARMSTRONG PB, 1985, BIOCHIM BIOPHYS ACTA, V827, P453, DOI 10.1016/0167-4838(85)90232-8; BALDO BA, 1979, NATURWISSENSCHAFTEN, V66, P623, DOI 10.1007/BF00405134; BOYKINS RA, 1980, J BIOCHEM BIOPH METH, V2, P71, DOI 10.1016/0165-022X(80)90075-5; CLARK RAF, 1985, PLASMA FIBRONECTIN S, P197; Covey T R, 1988, Rapid Commun Mass Spectrom, V2, P249, DOI 10.1002/rcm.1290021111; CUNNINGHAM BA, 1987, SCIENCE, V236, P799, DOI 10.1126/science.3576199; DEMEY J, 1981, CELL BIOL INT REP, V5, P889, DOI 10.1016/0309-1651(81)90204-6; DUCLOS TW, 1988, J IMMUNOL, V141, P4266; FILIPPSEN LF, 1990, AM J VET RES, V51, P861; GAL K, 1955, Acta Microbiol Acad Sci Hung, V3, P41; GEBB C, 1986, J BIOL CHEM, V261, P6698; GEWURZ H, 1982, ADV INTERNAL MED, V27, P345; GROSS E, 1962, J BIOL CHEM, V237, P1856; HOKAMA Y, 1962, J BACTERIOL, V83, P1017, DOI 10.1128/JB.83.5.1017-1024.1962; HOURCADE D, 1989, ADV IMMUNOL, V45, P381, DOI 10.1016/S0065-2776(08)60697-5; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IZUMI M, 1988, CELL STRUCT FUNCT, V13, P217, DOI 10.1247/csf.13.217; JENSEN L, 1983, P NATL ACAD SCI USA, V88, P137; JOHNSTON GI, 1989, CELL, V56, P1033, DOI 10.1016/0092-8674(89)90636-3; KAPLAN MH, 1974, J IMMUNOL, V112, P2135; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEI KJ, 1985, J BIOL CHEM, V260, P3377; LIU TY, 1989, ANAL BIOCHEM, V182, P383, DOI 10.1016/0003-2697(89)90612-X; Lofstrom G, 1944, BRIT J EXP PATHOL, V25, P21; MARCUM JA, 1989, THROMB HAEMOSTASIS, V61, P294; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; NARKATES AJ, 1982, ANN NY ACAD SCI, V389, P172, DOI 10.1111/j.1749-6632.1982.tb22135.x; NEWMAN GR, 1982, J MICROSC-OXFORD, V127, pRP5, DOI 10.1111/j.1365-2818.1982.tb00418.x; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; OLIVEIRA EB, 1979, J BIOL CHEM, V254, P489; OLIVEIRA EB, 1980, J IMMUNOL, V124, P1396; Paulsson M, 1990, FEMS Microbiol Immunol, V2, P55; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PLANCHENAULT T, 1990, BIOL CHEM H-S, V371, P117, DOI 10.1515/bchm3.1990.371.1.117; ROBEY FA, 1983, J BIOL CHEM, V258, P3889; ROBEY FA, 1984, J BIOL CHEM, V259, P7311; ROBEY FA, 1981, J BIOL CHEM, V256, P969; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGAL DM, 1974, P NATL ACAD SCI USA, V71, P4298, DOI 10.1073/pnas.71.11.4298; SPACKMAN DH, 1967, METHOD ENZYMOL, V11, P3; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; SUZUKI S, 1984, J BIOL CHEM, V259, P5307; SYIN C, 1986, J BIOL CHEM, V261, P5473; TERHORST C, 1988, MOL IMMUNOL, P145; TILLETT WILLIAM S., 1930, JOUR EXP MED, V52, P561, DOI 10.1084/jem.52.4.561; VERWEIJ CL, 1986, EMBO J, V5, P1839, DOI 10.1002/j.1460-2075.1986.tb04435.x	49	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14813	14821						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907284				2022-12-25	WOS:A1991FZ35100106
J	RAUCH, U; GAO, P; JANETZKO, A; FLACCUS, A; HILGENBERG, L; TEKOTTE, H; MARGOLIS, RK; MARGOLIS, RU				RAUCH, U; GAO, P; JANETZKO, A; FLACCUS, A; HILGENBERG, L; TEKOTTE, H; MARGOLIS, RK; MARGOLIS, RU			ISOLATION AND CHARACTERIZATION OF DEVELOPMENTALLY REGULATED CHONDROITIN SULFATE AND CHONDROITIN KERATAN SULFATE PROTEOGLYCANS OF BRAIN IDENTIFIED WITH MONOCLONAL-ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARTILAGE PROTEOGLYCAN; HYALURONIC-ACID; LINK PROTEIN; IMMUNOCYTOCHEMICAL LOCALIZATION; MICROSCOPIC LOCALIZATION; RABBIT THROMBOMODULIN; ESCHERICHIA-FREUNDII; CHROMAFFIN GRANULE; BINDING PROTEIN; NERVOUS-TISSUE	A panel of monoclonal antibodies prepared to the chondroitin sulfate proteoglycans of rat brain was used for their immunocytochemical localization and isolation of individual proteoglycan species by immunoaffinity chromatography. One of these proteoglycans (designated 1D1) consists of a major component with an average molecular size of 300 kDa in 7-day brain, containing a 245-kDa core glycoprotein and an average of three 22-kDa chondroitin sulfate chains. A 1D1 proteoglycan of approximately 180 kDa with a 150-kDa core glycoprotein is also present at 7 days, and by 2-3 weeks postnatal this becomes the major species, containing a single 32-kDa chondroitin 4-sulfate chain. The concentration of 1D1 decreases during development, from 20% of the total chondroitin sulfate proteoglycan protein (0.1 mg/g brain) at 7 days postnatal to 6% in adult brain. A 45-kDa protein which is recognized by the 8A4 monoclonal antibody to rat chondrosarcoma link protein copurifies with the 1D1 proteoglycan, which aggregates to a significant extent with hyaluronic acid. A chondroitin/keratan sulfate proteoglycan (designated 3H1) with a size of approximately 500 kDa was isolated from rat brain using monoclonal antibodies to the keratan sulfate chains. The core glycoprotein obtained after treatment of the 3H1 proteoglycan with chondroitinase ABC and endo-beta-galactosidase decreases in size from approximately 360 kDa at 7 days to approximately 280 kDa in adult brain. In 7-day brain, the proteoglycan contains three to five 25-kDa chondroitin 4-sulfate chains and three to six 8.4-kDa keratan sulfate chains, whereas the adult brain proteoglycan contains two to four chondroitin 4-sulfate chains and eight to nine keratan sulfate chains, with an average size of 10 kDa. The concentration of 3H1 increases during development from 3% of the total soluble proteoglycan protein at 7 days to 11% in adult brain, and there is a developmental decrease in the branching and/or sulfation of the keratan sulfate chains. A third monoclonal antibody (3F8) was used to isolate a approximately 500-kDa chondroitin sulfate proteoglycan comprising a 400-kDa core glycoprotein and an average of four 28-kDa chondroitin sulfate chains. In the 1D1 and 3F8 proteoglycans of 7-day brain, 20 and 33%, respectively, of the chondroitin sulfate is 6-sulfated, whereas chondroitin 4-sulfate accounts for > 96% of the glycosaminoglycan chains in the adult brain proteoglycans. The 1D1, 3H1, and 3F8 proteoglycans all contain 3-sulfated HNK-1 carbohydrate epitopes as well as the novel O-glycosidic mannose-linked oligosaccharides which we have previously characterized in the chondroitin sulfate proteoglycans of brain, and these glycans show different developmental patterns in the three proteoglycans. Two other monoclonal antibodies, 5F3 and 3H7, react on immunoblots of chondroitinase-treated proteoglycans with core glycoproteins in the 350-450 and 61-105-kDa ranges, respectively. Immunocytochemical studies demonstrated that, like the total population of soluble chondroitin sulfate proteoglycans of brain whose localization we have previously examined using polyclonal antibodies, staining with all five monoclonal antibodies is generally most intense in the prospective white matter and absent from the external granule cell layer of early postnatal cerebellum, while in adult brain staining is strongest in the molecular layer and also present in the granule cell layer. However, 3F8 proteoglycan staining is most intense in the molecular layer of 7-day cerebellum, and the 5F3 and 3H7 antibodies are unusual insofar as they also stain Purkinje cells and strongly stain astrocytes in the granule cell layer. Immunoelectron microscopy using the 1D1 and 3H1 monoclonal antibodies demonstrated the extracellular location of these proteoglycans in 7-day brain, whereas predominantly intracellular (cytoplasmic) staining was seen in adult cerebellum.	SUNY HLTH SCI CTR,DEPT PHARMACOL,BROOKLYN,NY 11203	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	RAUCH, U (corresponding author), NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016, USA.			Tekotte, Hille/0000-0003-2164-7412	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS009348, R01NS013876] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-13876, NS-09348] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKESON R, 1986, EXP CELL RES, V162, P347, DOI 10.1016/0014-4827(86)90340-X; ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; AQUINO DA, 1984, J CELL BIOL, V99, P1117, DOI 10.1083/jcb.99.3.1117; AQUINO DA, 1984, J CELL BIOL, V99, P1130, DOI 10.1083/jcb.99.3.1130; ARIGA T, 1987, J BIOL CHEM, V262, P848; BAKER JR, 1991, BIOCHEM J, V273, P237, DOI 10.1042/bj2730237; BIGNAMI A, 1989, BRAIN RES BULL, V22, P67, DOI 10.1016/0361-9230(89)90129-9; BOURIN MC, 1988, J BIOL CHEM, V263, P8044; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CAMPBELL AM, 1984, MONOCLONAL ANTIBODY; CARBONETTO S, 1983, J NEUROSCI, V3, P2324; CATERSON B, 1985, FED PROC, V44, P386; CATERSON B, 1985, J BIOL CHEM, V260, P1348; CATERSON B, 1983, J BIOL CHEM, V258, P8848; Caterson B, 1987, BIOL PROTEOGLYCANS, P1; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CROSSIN KL, 1989, DEV BIOL, V136, P381, DOI 10.1016/0012-1606(89)90264-9; DOEGE K, 1987, J BIOL CHEM, V262, P17757; FLACCUS A, 1991, J NEUROCHEM, V56, P1608, DOI 10.1111/j.1471-4159.1991.tb02058.x; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; FUKUDA MN, 1976, J BIOL CHEM, V251, P6218; GOETINCK PF, 1987, J CELL BIOL, V105, P2403, DOI 10.1083/jcb.105.5.2403; GOWDA DC, 1989, BIOCHEMISTRY-US, V28, P4468, DOI 10.1021/bi00436a052; GOWDA DC, 1990, ARCH BIOCHEM BIOPHYS, V281, P219, DOI 10.1016/0003-9861(90)90435-2; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HENDRY SHC, 1988, J NEUROSCI, V8, P518; HOFFMAN S, 1988, J CELL BIOL, V106, P519, DOI 10.1083/jcb.106.2.519; JALKANEN S, 1988, J IMMUNOL, V141, P1615; KIANG WL, 1981, J BIOL CHEM, V256, P529; KLINGER MM, 1985, J BIOL CHEM, V260, P4082; KRUSIUS T, 1986, J BIOL CHEM, V261, P8237; KRUSIUS T, 1987, BIOCHEM J, V245, P229, DOI 10.1042/bj2450229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE JM, 1987, J NEUROSCI, V7, P2711; MAGNANI JL, 1987, METHOD ENZYMOL, V138, P208; MARGOLIS RK, 1991, J CELL SCI, V99, P237; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; MARGOLIS RK, 1989, NEUROBIOLOGY GLYCOCO, P85; NEAME PJ, 1987, J BIOL CHEM, V262, P17768; PERIDES G, 1989, J BIOL CHEM, V264, P5981; RATNER N, 1988, P NATL ACAD SCI USA, V85, P6992, DOI 10.1073/pnas.85.18.6992; RIPELLINO JA, 1988, J CELL BIOL, V106, P845, DOI 10.1083/jcb.106.3.845; RIPELLINO JA, 1989, J CELL BIOL, V108, P1899, DOI 10.1083/jcb.108.5.1899; Roden L., 1972, METHODS ENZYMOLOGY, V28, P73; RODRIGUEZ EM, 1984, HISTOCHEMISTRY, V81, P253, DOI 10.1007/BF00495636; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SCUDDER P, 1984, J BIOL CHEM, V259, P6586; SNOW DM, 1990, DEV BIOL, V138, P359, DOI 10.1016/0012-1606(90)90203-U; SNOW DM, 1990, EXP NEUROL, V109, P111, DOI 10.1016/S0014-4886(05)80013-5; SOMOGYI P, 1982, NEUROSCIENCE, V7, P1779, DOI 10.1016/0306-4522(82)90035-5; STALLCUP WB, 1983, COLD SPRING HARB SYM, V48, P761, DOI 10.1101/SQB.1983.048.01.078; STALLCUP WB, 1990, J CELL BIOL, V111, P3177, DOI 10.1083/jcb.111.6.3177; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; VERNA JM, 1989, INT J DEV NEUROSCI, V7, P389, DOI 10.1016/0736-5748(89)90060-9; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4; YOUNG DJ, 1982, RES DISCLOSURE, V217, P155; ZAREMBA S, 1989, NEURON, V2, P1207, DOI 10.1016/0896-6273(89)90305-X; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	60	264	269	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14785	14801						17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907283				2022-12-25	WOS:A1991FZ35100103
J	BRABET, P; PANTALONI, C; BOCKAERT, J; HOMBURGER, V				BRABET, P; PANTALONI, C; BOCKAERT, J; HOMBURGER, V			METABOLISM OF 2 G0-ALPHA ISOFORMS IN NEURONAL CELLS DURING DIFFERENTIATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BINDING PROTEIN G0; ALPHA-SUBUNIT; 3T3-L1 CELLS; GO; BRAIN; LOCALIZATION; EXPRESSION; HEART; IDENTIFICATION; PURIFICATION	We have previously shown that undifferentiated N1E-115 neuroblastoma cells express only one isoform of G(o-alpha)(pI = 5.8), whereas differentiated neuroblastoma cells expressed, in addition to this isoform, another G(o-alpha) with a more acidic pI (5.55). Moreover, primary cultures of cerebellar granule cells, which are extremely well differentiated cells yielding a high density of synapses, expressed only a single G(o-alpha) isoform with a pI of 5.55 (Brabet, P., Pantaloni, C., Rodriguez Martinez, J., Bockaert, J., and Homburger, V. (1990) J. Neurochem. 54, 1310-1320). In this report, using biosynthetic labeling with [S-35]methionine and specific quantitative immunoprecipitation with a polyclonal antibody raised against the purified G(o-alpha) protein, we have determined 1) the degradation rate of total G(o-alpha) (sum of the two isoforms) in differentiated as well as in undifferentiated neuroblastoma cells and in cerebellar granule cells, 2) the degradation rates of each isoform in differentiated neuroblastoma cells. The t1/2 for total G(o-alpha) protein degradation was very different in the three neuronal cell populations and was 28 +/- 5 h (n = 5), 58 +/- 9 h (n = 5), and 154 +/- 22 h (n = 6) in undifferentiated, differentiated neuroblastoma, and granule cells, respectively. Using two-dimensional gel analysis of immunoprecipitates, we have also determined the individual tl/2 for degradation of each G(o-alpha) isoform in differentiated neuroblastoma cells, in which the two G(o-alpha) isoforms were expressed. Results indicated that the two G(o-alpha) isoforms exhibit similar t1/2 for degradation (49 +/- 5 h, n = 3). Thus, the t1/2 for degradation of the more basic G(o-alpha) isoform is higher in differentiated neuroblastoma cells (49 +/- 5 h, n = 3) than in undifferentiated neuroblastoma cells (28 +/- 5 h, n = 5) which expressed only the more basic G(o-alpha) isoform. It can be concluded that the degradation rate of the more basic G(o-alpha) isoform is not a characteristic of the protein itself but depends on the state of the cell differentiation. The comparison between the t1/2 for degradation of the more acidic G(o-alpha) isoform in differentiated neuroblastoma cells (51 +/- 6 h, n = 3) with that of cerebellar granule cells (154 +/- 22 h, n = 6) suggests that there is also a decrease in the degradation rate of the more acidic G(o-alpha) isoform during differentiation. The decrease of both G(o-alpha) isoform degradation rates during cell differentiation was accompanied by a decrease in the synthesis of the more basic G(o-alpha) isoform and an increase in the synthesis of the more acidic G(o-alpha) isoform. This explains, as we have previously reported, why there is an accumulation of the more acidic isoform and a progressive disappearance of the more basic isoform of G(o-alpha) during differentiation.	INSERM PHARMACOL ENDOCRINOL, CNRS, RUE CARDONILLE, F-34094 MONTPELLIER 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)			Brabet, Philippe/AAO-8522-2020	Brabet, Philippe/0000-0003-2739-1622				ASANO T, 1988, J NEUROCHEM, V51, P1711, DOI 10.1111/j.1471-4159.1988.tb01149.x; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BRABET P, 1988, J NEUROSCI, V8, P701; BRABET P, 1990, J NEUROCHEM, V54, P1310, DOI 10.1111/j.1471-4159.1990.tb01964.x; BRABET P, 1988, BIOCHEM BIOPH RES CO, V152, P1185, DOI 10.1016/S0006-291X(88)80410-8; GABRION J, 1989, CELL SIGNAL, V1, P107, DOI 10.1016/0898-6568(89)90025-9; GIERSCHIK P, 1986, FEBS LETT, V199, P103, DOI 10.1016/0014-5793(86)81233-9; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; HOMBURGER V, 1987, MOL PHARMACOL, V31, P313; HSU WH, 1990, J BIOL CHEM, V265, P11220; HUFF RM, 1985, J BIOL CHEM, V260, P864; KIMHI Y, 1976, P NATL ACAD SCI USA, V73, P462, DOI 10.1073/pnas.73.2.462; KOBAYASHI I, 1989, FEBS LETT, V257, P177, DOI 10.1016/0014-5793(89)81815-0; LIANG BT, 1986, J BIOL CHEM, V261, P9011; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LUETJE CW, 1988, J NEUROCHEM, V50, P1775, DOI 10.1111/j.1471-4159.1988.tb02478.x; LUETJE CW, 1988, J BIOL CHEM, V263, P13357; MULLANEY I, 1988, BIOCHEM J, V256, P649, DOI 10.1042/bj2560649; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; PRICE SR, 1989, BIOCHEMISTRY-US, V28, P3803, DOI 10.1021/bi00435a027; SCHERER NM, 1987, ARCH BIOCHEM BIOPHYS, V259, P431, DOI 10.1016/0003-9861(87)90509-1; SILBERT S, 1990, J BIOL CHEM, V265, P3102; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; VANVLIET BJ, 1989, J NEUROCHEM, V52, P1229; WATKINS DC, 1987, J BIOL CHEM, V262, P10651	27	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					12825	12828						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1906458				2022-12-25	WOS:A1991FX13200005
J	SCHOPFER, LM; WESSIAK, A; MASSEY, V				SCHOPFER, LM; WESSIAK, A; MASSEY, V			INTERPRETATION OF THE SPECTRA OBSERVED DURING OXIDATION OF P-HYDROXYBENZOATE HYDROXYLASE RECONSTITUTED WITH MODIFIED FLAVINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTI-RIBOFLAVIN ACTIVITY; GRAM-POSITIVE BACTERIA; PSEUDOMONAS-FLUORESCENS; ANALOGS; PURIFICATION; DERIVATIVES	Oxidation of reduced p-hydroxybenzoate hydroxylase by oxygen in the presence of 2,4-dihydroxybenzoate and azide proceeds via three well established intermediates. Reconstitution of the apoprotein with either 8-thiophenyl-FAD, 8-fluoro-FAD, 8-chloro-FAD, or 8-sulfonyl-FAD does not alter this sequence of events. However, the peak positions of the intermediate spectra are somewhat shifted relative to those of native enzyme. Comparison of the spectra for intermediates II and III leads to the conclusion that the spectrum for intermediate II is a composite. One component is the spectrum of an intermediate III-like species, and the other appears to be related to the substrate. The substrate component is pH-dependent, having an absorbance maximum of 386 nm (extinction, almost-equal-to 6,000 M-1 cm-1) at pH 6.6 which shifts to almost-equal-to 430 nm (extinction, almost-equal-to 11-13,000 M-1 cm-1) at pH 9.2, with a pK of 7.9. The pH dependence for the spectrum of the substrate component combined with the pH independence of the intermediate III-like spectrum satisfactorily accounts for the pH dependence observed for intermediate II, including the fact that the high pH spectrum of native intermediate II is qualitatively quite different from that of 8-sulfonyl-FAD) intermediate II.	UNIV MICHIGAN,SCH MED,DEPT BIOL CHEM,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM011106, R01GM011106] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 11106] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON RF, 1987, J BIOL CHEM, V262, P17475; DRAPER RD, 1968, ARCH BIOCHEM BIOPHYS, V125, P802, DOI 10.1016/0003-9861(68)90517-1; ENTSCH B, 1976, J BIOL CHEM, V251, P2550; GHISLA S, 1977, EUR J BIOCHEM, V76, P139, DOI 10.1111/j.1432-1033.1977.tb11579.x; Ghisla S, 1980, Methods Enzymol, V66, P360; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; JAFFE HH, 1953, CHEM REV, V53, P191, DOI 10.1021/cr60165a003; KASAI S, 1979, J NUTR SCI VITAMINOL, V25, P289; KASAI S, 1978, J NUTR SCI VITAMINOL, V24, P339; LIGHT DR, 1980, J BIOL CHEM, V255, P4264; MACHEROUX P, 1990, BIOCHEMISTRY-US, V29, P2670, DOI 10.1021/bi00463a008; MCCORMICK DB, 1963, J BIOL CHEM, V238, P3095; MCHEROUX P, 1991, BIOCHEMISTRY-US, V30, P456; MOORE EG, 1979, J BIOL CHEM, V254, P8173; MOORE EG, 1978, J BIOL CHEM, V253, P6413; MULLER F, 1979, EUR J BIOCHEM, V101, P235, DOI 10.1111/j.1432-1033.1979.tb04236.x; MULLER F, 1982, EUR J BIOCHEM, V128, P21; RITCHIE CD, 1964, PROG PHYS ORG CHEM, V2, P323, DOI 10.1002/9780470171813.ch6; SPECTOR T, 1972, J BIOL CHEM, V247, P5632; SPENCER R, 1976, BIOCHEMISTRY-US, V15, P1043, DOI 10.1021/bi00650a015; WESSIAK A, 1984, J BIOL CHEM, V259, P2547	21	34	34	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13080	13085						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1906463				2022-12-25	WOS:A1991FX13200046
J	MIZUSHIMA, N; SPELLMEYER, D; HIRONO, S; PEARLMAN, D; KOLLMAN, P				MIZUSHIMA, N; SPELLMEYER, D; HIRONO, S; PEARLMAN, D; KOLLMAN, P			FREE-ENERGY PERTURBATION CALCULATIONS ON BINDING AND CATALYSIS AFTER MUTATING THREONINE-220 IN SUBTILISIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; TRYPSIN-INHIBITOR; NUCLEIC-ACIDS; FORCE-FIELD; COMPLEX; SIMULATIONS; RESOLUTION; REFINEMENT; DYNAMICS; PROTEINS	We present the results of free energy perturbation calculations on binding and catalysis of a tetrapeptide substrate, acetyl-Phe-Ala-Ala-Phe-NMe, by native subtilisin BPN' and a subtilisin BPN' mutant (Thr220 --> Ala220). The calculated difference in the free energy of binding was 0.70 +/- 0.72 kcal/mol. The calculated difference in the free energy of catalysis was 1.48 +/- 0.89 kcal/mol. These calculated values compare well with the experimental values in which another substrate, succinyl-Ala-Ala-Pro-Phe-p-nitroanilide, was used. These findings suggest that Thr220 is more important for catalysis than substrate binding.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Pearlman, David/0000-0002-2574-6066	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001081] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-1081] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; BRAXTON S, 1991, J BIOL CHEM, V266, P11797; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; CALDWELL JW, 1991, IN PRESS PROTEINS; CHEN ZG, 1983, J MOL BIOL, V164, P283, DOI 10.1016/0022-2836(83)90078-5; FUJINAGA M, 1982, P NATL ACAD SCI-BIOL, V79, P4868, DOI 10.1073/pnas.79.16.4868; GELLER M, 1990, J BIOMOL STRUCT DYN, V7, P1043, DOI 10.1080/07391102.1990.10508544; HIRONO S, 1984, J MOL BIOL, V178, P389, DOI 10.1016/0022-2836(84)90150-5; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; MITSUI Y, 1985, PROTEIN PROTEASE INH, pCH8; PEARLMAN DA, 1991, AMBER VERSION 4 0; RAO SN, 1987, NATURE, V328, P551, DOI 10.1038/328551a0; Singh U. C., 1986, AMBER UCSF VERSION 3; SINGH UC, 1987, J AM CHEM SOC, V109, P1607, DOI 10.1021/ja00240a001; VANGUNSTEREN WF, 1977, MOL PHYS, V34, P1311, DOI 10.1080/00268977700102571; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051	20	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11801	11809						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904871				2022-12-25	WOS:A1991FT76200060
J	RIEBLE, S; BEALE, SI				RIEBLE, S; BEALE, SI			PURIFICATION OF GLUTAMYL-TRANSFER RNA REDUCTASE FROM SYNECHOCYSTIS SP PCC 6803	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINIC-ACID; GREENING BARLEY LEAVES; ESCHERICHIA-COLI K-12; CHLOROPHYLL BIOSYNTHESIS; NUCLEOTIDE-SEQUENCE; EUGLENA-GRACILIS; SOLUBLE EXTRACTS; HEMA GENE; SALMONELLA-TYPHIMURIUM; SYNTHESIZING ENZYMES	Delta-aminolevulinic acid is the universal precursor for all tetrapyrroles including hemes, chlorophylls, and bilins. In plants, algae, cyanobacteria, and many other bacteria, delta-aminolevulinic acid is synthesized from glutamate in a reaction sequence that requires three enzymes, ATP, NADPH, and tRNA(Glu). The three enzymes have been characterized as glutamyl-tRNA synthetase, glutamyl-tRNA reductase, and glutamate-1-semialdehyde aminotransferase. All three enzymes have been separated and partially characterized from plants and algae. In prokaryotic phototrophs, only the glutamyl-tRNA synthetase and glutamate-1-semialdehyde aminotransferase have been described. We report here the purification and some properties of the glutamyl-tRNA reductase from extracts of the unicellular cyanobacterium, Synechocystis sp. PCC 6803. The glutamyl-tRNA reductase has been purified over 370-fold to apparent homogeneity. Its native molecular mass was determined to be 350 kDa by glycerol density gradient centrifugation, and its subunit size was estimated to be 39 kDa by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The N-terminal amino acid sequence was determined for 42 residues. Much higher activity occurred with NADPH than with NADH as the reduced pyridine nucleotide substrate. Half-maximal rates occurred at 5-mu-M NADPH, whereas saturation was not reached even at 10 mM NADH. Purified Synechocystis glutamyl-tRNA reductase was inhibited 50% by 5-mu-M heme. Activity was unaffected by 10-mu-M 3-amino-2,3-dihydrobenzoic acid. No flavin, pyridine nucleotide, or other light-absorbing prosthetic group was detected on the purified enzyme. The catalytic turnover number of purified Synechocystis glutamyl-tRNA reductase is comparable to those of prokaryotic and plastidic glutamyl-tRNA synthetases.	BROWN UNIV, DIV BIOL & MED, PROVIDENCE, RI 02912 USA	Brown University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007601] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-07601] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN MM, 1969, ARCH MIKROBIOL, V69, P114, DOI 10.1007/BF00409755; AVISSAR YJ, 1980, BIOCHIM BIOPHYS ACTA, V613, P220, DOI 10.1016/0005-2744(80)90208-9; AVISSAR YJ, 1989, ARCH MICROBIOL, V151, P513, DOI 10.1007/BF00454867; AVISSAR YJ, 1989, PLANT PHYSIOL, V89, P852, DOI 10.1104/pp.89.3.852; AVISSAR YJ, 1989, J BACTERIOL, V171, P2919, DOI 10.1128/jb.171.6.2919-2924.1989; AVISSAR YJ, 1990, PLANT PHYSIOL, V92, pS19; Beale S. I., 1990, BIOSYNTHESIS HEME CH, P287; BEALE SI, 1975, P NATL ACAD SCI USA, V72, P2719, DOI 10.1073/pnas.72.7.2719; BEALE SI, 1981, P NATL ACAD SCI-BIOL, V78, P1666, DOI 10.1073/pnas.78.3.1666; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUYANT P, 1987, CARLSBERG RES COMMUN, V52, P99, DOI 10.1007/BF02910432; CHANG TE, 1990, PLANT PHYSIOL, V93, P1641, DOI 10.1104/pp.93.4.1641; CHEN MW, 1990, J BIOL CHEM, V265, P4054; CHEN MW, 1990, J BIOL CHEM, V265, P4058; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DROLET M, 1989, MOL GEN GENET, V216, P347, DOI 10.1007/BF00334375; ELLIOTT T, 1989, J BACTERIOL, V171, P3948, DOI 10.1128/jb.171.7.3948-3960.1989; ELLIOTT T, 1990, J BACTERIOL, V172, P7071, DOI 10.1128/jb.172.12.7071-7084.1990; FARMERIE WG, 1982, METHODS CHLOROPLAST, P335; FRIEDMANN HC, 1986, FEBS LETT, V207, P84, DOI 10.1016/0014-5793(86)80017-5; GOUGH SP, 1977, CARLSBERG RES COMMUN, V42, P459, DOI 10.1007/BF02906281; GOUGH SP, 1989, CARLSBERG RES COMMUN, V54, P99, DOI 10.1007/BF02908302; GOUGH SP, 1979, CARLSBERG RES COMMUN, V44, P403, DOI 10.1007/BF02906189; HOUGHTON JD, 1989, CARLSBERG RES COMMUN, V54, P131, DOI 10.1007/BF02907183; HUANG DD, 1986, MOL GEN GENET, V205, P217, DOI 10.1007/BF00430430; HUANG DD, 1986, J BIOL CHEM, V261, P3451; HUANG DD, 1984, SCIENCE, V225, P1482, DOI 10.1126/science.6206568; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; JURGENSON JE, 1976, BIOCHEM BIOPH RES CO, V69, P149, DOI 10.1016/S0006-291X(76)80285-9; KIKUCHI G, 1958, J BIOL CHEM, V233, P1214; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JM, 1989, GENE, V82, P209, DOI 10.1016/0378-1119(89)90046-2; LI JM, 1989, J BACTERIOL, V171, P2547, DOI 10.1128/jb.171.5.2547-2552.1989; LITSKE JG, 1986, NUCLEIC ACIDS RES, V14, P9631, DOI 10.1093/nar/14.24.9631; MAUZERALL D, 1956, J BIOL CHEM, V219, P435; MAYER SM, 1987, J BIOL CHEM, V262, P12541; MAYER SM, 1990, PLANT PHYSIOL, V94, P1365, DOI 10.1104/pp.94.3.1365; NANDI DL, 1977, J BIOL CHEM, V252, P2278; OHHAMA T, 1988, FEBS LETT, V228, P89, DOI 10.1016/0014-5793(88)80591-X; ONEILL GP, 1990, J BACTERIOL, V172, P6363, DOI 10.1128/jb.172.11.6363-6371.1990; ONEILL GP, 1989, FEMS MICROBIOL LETT, V60, P255; PETRICEK M, 1990, J BACTERIOL, V172, P2250, DOI 10.1128/jb.172.5.2250-2258.1990; PROULX M, 1983, J BIOL CHEM, V258, P753; RATINAUD MH, 1983, EUR J BIOCHEM, V135, P471, DOI 10.1111/j.1432-1033.1983.tb07675.x; RIEBLE S, 1988, J BIOL CHEM, V263, P8864; SCHNEEGURT MA, 1988, PLANT PHYSIOL, V88, P1358, DOI 10.1104/pp.88.4.1358; SCHNEEGURT MA, 1986, PLANT PHYSIOL, V81, P965, DOI 10.1104/pp.81.4.965; SHIOI Y, 1988, ARCH BIOCHEM BIOPHYS, V266, P470, DOI 10.1016/0003-9861(88)90279-2; VERKAMP E, 1989, J BACTERIOL, V171, P4728, DOI 10.1128/jb.171.9.4728-4735.1989; WALSH CT, 1979, ENZYMATIC REACTION M; WANG WY, 1984, PLANT PHYSIOL, V74, P569, DOI 10.1104/pp.74.3.569; WEINSTEIN JD, 1983, J BIOL CHEM, V258, P6799; WEINSTEIN JD, 1985, ARCH BIOCHEM BIOPHYS, V237, P454, DOI 10.1016/0003-9861(85)90299-1; WEINSTEIN JD, 1987, PLANT PHYSIOL, V84, P244, DOI 10.1104/pp.84.2.244; WEINSTEIN JD, 1989, PLANT PHYSIOL, V89, pS74; WEK RC, 1986, J BIOL CHEM, V261, P2441	56	36	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9740	9745						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903397				2022-12-25	WOS:A1991FM45900063
J	SANFORD, J; CODINA, J; BIRNBAUMER, L				SANFORD, J; CODINA, J; BIRNBAUMER, L			GAMMA-SUBUNITS OF G-PROTEINS, BUT NOT THEIR ALPHA-SUBUNIT OR BETA-SUBUNIT, ARE POLYISOPRENYLATED - STUDIES ON POSTTRANSLATIONAL MODIFICATIONS USING INVITRO TRANSLATION WITH RABBIT RETICULOCYTE LYSATES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; ROD OUTER SEGMENTS; GTP-BINDING; GUANINE-NUCLEOTIDE; MOLECULAR-CLONING; ADENYLYL CYCLASE; RAS PROTEINS; REGULATORY COMPONENTS; POTASSIUM CHANNELS; CYSTEINE RESIDUE	Lipid modifications that may be introduced into several subunits of G proteins were explored by in vitro translation of recombinant mRNAs in reticulocyte lysates. In agreement with studies by others, myristic acid was incorporated into alpha-i's and alpha-o, but not alpha-s, beta, or gamma's. In contrast, mevalonate (Mev) was incorporated only into gamma-subunits. Both, the gamma-subunit of transducin (gamma-T) and that of other G proteins (gamma-G) were modified by the lysates but with different characteristics. Labeled gamma-T was unstable and was rapidly proteolyzed. Labeled gamma-G was stable. The Mev-derivative in gamma-G was sensitive to methyliodide and, after cleavage and chromatographic analysis, comigrated with the C20 polyisoprenol geranylgeraniol. This indicated that gamma-G had been geranylgeranylated and that this polyisoprenoid was attached to the protein through a thioether linkage. It is though that polyisoprenylation is defined by the COOH-terminal sequence Cys-A-A-X, where A is an aliphatic acid and X is any amino acid. Replacement by mutation of the Cys of the COOH-terminal -Cys-Ala-Ile-Leu sequence of gamma-G with Ser abolished Mev incorporation, suggesting this Cys as the site of attachment of the geranylgeranyl moiety. Yet, Mev incorporation was less than 10% as much into gamma-G with the Cys-A-A-X sequence -Cys-Ala-Ile-Trp. Consistent with geranylgeranylation, the C-15 farnesyl moiety of farnesyl pyrophosphate was not incorporated into gamma-G unless the incubations were fortified with Mev. In contrast, the farnesyl moiety was incorporated in an Mev-independent manner into gamma-T (COOH terminus: -Cys-Val-Ile-Ser) and c-Ha-ras (COOH terminus: -Cys-Val-Leu-Ser) which are both farnesylated rather than geranylgeranylated. Thus, 1) separate enzymes appear to be involved in transferring farnesyl and geranylgeranyl groups to proteins, 2) structural factors other than the CAAX box contribute to the activity of the polyisoprenylating enzymes, and 3) this type of lipidation may be part of a proteolytic signaling system. Polyisoprenylation, which increases hydrophobicity of the derivatized protein, may play a role in anchoring not only ras but also G proteins to membranes.	BAYLOR UNIV,DEPT CELL BIOL,HOUSTON,TX 77030; BAYLOR UNIV,DEPT MOLEC PHYSIOL & BIOPHYS,HOUSTON,TX 77030; BAYLOR UNIV,DIV NEUROSCI,HOUSTON,TX 77030	Baylor University; Baylor University; Baylor University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019318, P30DK027685, R37DK019318] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19318, DK-27685] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; AUDIGIER Y, 1988, J BIOL CHEM, V263, P16352; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; BIRNBAUMER L, 1990, ANNU REV PHARMACOL, V30, P675; BUSS JE, 1985, J VIROL, V53, P7, DOI 10.1128/JVI.53.1.7-12.1985; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CODINA J, 1983, P NATL ACAD SCI-BIOL, V80, P4276, DOI 10.1073/pnas.80.14.4276; CODINA J, 1984, J BIOL CHEM, V259, P5871; CODINA J, 1988, J BIOL CHEM, V263, P6746; CODINA J, 1984, J BIOL CHEM, V259, P1408; CODINA J, 1986, FEBS LETT, V207, P187, DOI 10.1016/0014-5793(86)81486-7; CODINA J, 1987, SCIENCE, V236, P442, DOI 10.1126/science.2436299; CODINA J, 1991, IN PRESS J RECEPT RE, V11; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FUJINO M, 1980, NATURWISSENSCHAFTEN, V67, P406, DOI 10.1007/BF00405487; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HERSON D, 1979, J BIOL CHEM, V254, P8245; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P2039; HSU WH, 1990, J BIOL CHEM, V265, P11220; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; ISHIBASHI Y, 1984, BIOCHEMISTRY-US, V23, P1399, DOI 10.1021/bi00302a010; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JOBLING SA, 1987, NATURE, V325, P622, DOI 10.1038/325622a0; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JURNOT L, 1989, FEBS LETT, V251, P230; KAMIJA Y, 1979, AGR BIOL CHEM TOKYO, V43, P1044; KAMIYA Y, 1978, BIOCHEM BIOPH RES CO, V83, P1077, DOI 10.1016/0006-291X(78)91505-X; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; Maniatis T., 1982, MOL CLONING; MATTERA R, 1989, J BIOL CHEM, V264, P465; MATTERA R, 1986, FEBS LETT, V206, P36, DOI 10.1016/0014-5793(86)81336-9; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P723; NUKADA T, 1986, FEBS LETT, V195, P220, DOI 10.1016/0014-5793(86)80164-8; OLATE J, 1988, J BIOL CHEM, V263, P10394; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; Sambrook J, 1989, MOL CLONING LABORATO; SANDHU GS, 1989, BIOTECHNIQUES, V7, P689; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHERER NM, 1987, ARCH BIOCHEM BIOPHYS, V259, P431, DOI 10.1016/0003-9861(87)90509-1; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STRUHL K, 1983, GENE, V26, P231, DOI 10.1016/0378-1119(83)90193-2; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; SUKI WN, 1987, FEBS LETT, V220, P187, DOI 10.1016/0014-5793(87)80900-6; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; TACK BF, 1980, J BIOL CHEM, V255, P8842; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; THERIAULT NY, 1988, BIOTECHNIQUES, V6, P470; VANDONGEN AMJ, 1988, SCIENCE, V242, P1433, DOI 10.1126/science.3144040; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	70	110	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9570	9579						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903391				2022-12-25	WOS:A1991FM45900038
J	HE, JS; FULCO, AJ				HE, JS; FULCO, AJ			A BARBITURATE-REGULATED PROTEIN-BINDING TO A COMMON SEQUENCE IN THE CYTOCHROME-P450 GENES OF RODENTS AND BACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOBARBITAL-INDUCIBLE CYTOCHROME-P-450; ARYL-HYDROCARBON HYDROXYLASE; BACILLUS-MEGATERIUM; RAT-LIVER; EXPRESSION; MONOOXYGENASE; INDUCTION; TRANSCRIPTION; PURIFICATION; P-450BM-3	Analyses of the 5' regulatory sequences of genes encoding barbiturate-inducible cytochromes P450BM-1 and P450BM-3 from Bacillus megaterium and of the 5' sequences of genes for barbiturate-inducible P450b and P450e of the rat revealed a string of 17 base pairs in each of the genes that shared a high degree of sequence identity. Labeled oligonucleotide probes of each of these four sequences were tested in gel retardation assays with protein obtained from B. megaterium grown either in the presence or absence of barbiturates or with protein from nuclear extracts from livers of rats left untreated or injected with phenobarbital. Each of the four 17-mers bound strongly to a single protein from bacteria grown in the absence of barbiturates, but this binding was dramatically reduced with protein from pentobarbital- or phenobarbital-grown cells. Conversely, the probes complexed weakly to one protein band from nuclear extracts from untreated rats but much more strongly with protein from phenobarbital-treated rats. Similar effects could be obtained by prolonged incubation with phenobarbital of either soluble protein from the bacteria grown in the absence of barbiturates or nuclear extract protein from untreated rats. Deletion analysis of the 5'-flanking region of the P450BM-1 gene of B. megaterium revealed a putative repressor binding site located within a 24-base pair DNA segment that included the 17-base pair sequence involved in barbiturate-regulated protein binding.	UNIV CALIF LOS ANGELES,SCH MED,BIOMED & ENVIRONM SCI LAB,900 VET AVE,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023913] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23913] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADESNIK M, 1981, J BIOL CHEM, V256, P340; ADESNIK M, 1986, CRIT REV BIOCHEM MOL, V19, P247, DOI 10.3109/10409238609084657; ANDERSEN RD, 1990, NUCLEIC ACIDS RES, V18, P6049, DOI 10.1093/nar/18.20.6049; Ausubel F.M., 1989, CURRENT PROTOCOLS MO, V2; BERNHARD HP, 1973, DEV BIOL, V35, P83, DOI 10.1016/0012-1606(73)90008-0; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; FULCO AJ, 1987, LIFE SCI, V40, P1769, DOI 10.1016/0024-3205(87)90087-7; HALTINER M, 1985, NUCLEIC ACIDS RES, V13, P1015, DOI 10.1093/nar/13.3.1015; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; HE JS, 1989, BIOCHIM BIOPHYS ACTA, V1009, P301, DOI 10.1016/0167-4781(89)90120-6; JAISWAL AK, 1987, NUCLEIC ACIDS RES, V15, P6755, DOI 10.1093/nar/15.16.6755; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; MANIATIS T, 1982, MOL CLONING LABORATO, P122; MIZUKAMI Y, 1983, P NATL ACAD SCI-BIOL, V80, P3958, DOI 10.1073/pnas.80.13.3958; NARHI LO, 1982, J BIOL CHEM, V257, P2147; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1987, J BIOL CHEM, V262, P6683; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OMIECINSKI CJ, 1985, J BIOL CHEM, V260, P3247; OWENS IS, 1975, MOL PHARMACOL, V11, P94; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; RUETTINGER RT, 1984, BIOCHIM BIOPHYS ACTA, V801, P372, DOI 10.1016/0304-4165(84)90141-7; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SCHWALB H, 1985, BIOCHIM BIOPHYS ACTA, V838, P302, DOI 10.1016/0304-4165(85)90227-2; SERFLING E, 1985, TRENDS GENET, V1, P224, DOI 10.1016/0168-9525(85)90088-5; SUWA Y, 1985, J BIOL CHEM, V260, P7980; WEN LP, 1989, J BIOL CHEM, V264, P10996; WEN LP, 1987, J BIOL CHEM, V262, P6676; WHITLOCK JP, 1986, ANNU REV PHARMACOL, V26, P333	33	121	125	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7864	7869						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902228				2022-12-25	WOS:A1991FJ34200085
J	SUAREZ, HG; DUVILLARD, JA; CAILLOU, B; SCHLUMBERGER, M; PARMENTIER, C; MONIER, R				SUAREZ, HG; DUVILLARD, JA; CAILLOU, B; SCHLUMBERGER, M; PARMENTIER, C; MONIER, R			GSP MUTATIONS IN HUMAN THYROID-TUMORS	ONCOGENE			English	Note							HUMAN PITUITARY-TUMORS; RAS GENE-MUTATIONS; ADENYLATE-CYCLASE; ONCOGENE; PROLIFERATION; STIMULATION; LEUKEMIAS; CANCER	The presence of gsp mutations at codons 201 and 227 in the gene coding for the alpha-subunit of the GTP-binding G(s) protein which stimulates adenylyl cyclase (AC) has been investigated in 31 samples of differentiated thyroid tumours, which had been previously characterized with respect to their adenylyl cyclase activity (ACA) before and after stimulation by thryoid-stimulating hormone (TSH). Polymerase chain reaction (PCR) amplification of DNA extracted from these tumours, followed by high stringency oligonucleotide probing, enabled the detection of mutations in three samples originating from tumours with high constitutive ACA, which was not significantly further stimulated by TSH. Two mutations were at codon 227 and replaced Gln227 by His or Lys, and one was at codon 201, with the substitution of Arg201 by Ser. Because thyrocytes belong to the subset of differentiated cells which are programmed to proliferate in response to elevated cAMP levels, the gsp mutations observed in some differentiated thyroid carcinomas probably contributed to their tumorigenic phenotype.	CNRS,INST RECH SCI CANC,F-94802 VILLEJUIF,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE	Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy								BILLESTRUP N, 1986, P NATL ACAD SCI USA, V83, P6854, DOI 10.1073/pnas.83.18.6854; BROWETT PJ, 1989, ONCOGENE, V4, P1029; CARAYON P, 1980, J CLIN ENDOCR METAB, V51, P915, DOI 10.1210/jcem-51-4-915; CLEMENTI E, 1990, ONCOGENE, V5, P1059; DEVRIES MV, 1986, GENE, V50, P313; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; HEDINGER C, 1989, CANCER-AM CANCER SOC, V63, P908, DOI 10.1002/1097-0142(19890301)63:5<908::AID-CNCR2820630520>3.0.CO;2-I; JANSSEN JWG, 1987, P NATL ACAD SCI USA, V84, P9228, DOI 10.1073/pnas.84.24.9228; KOSAZA T, 1988, P NATL ACAD SCI USA, V85, P2081; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEMOINE NR, 1989, ONCOGENE, V4, P159; LEMOINE NR, 1988, CANCER RES, V48, P4459; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MULDER MP, 1989, ONCOGENE, V4, P1345; SPADA A, 1984, ENDOCRINOLOGY, V115, P1203, DOI 10.1210/endo-115-3-1203; SUAREZ HG, 1990, ONCOGENE, V5, P565; THOMASMORVAN C, 1982, ACTA ENDOCRINOL-COP, V101, P25, DOI 10.1530/acta.0.1010025; VANTVEER LJ, 1989, MOL CELL BIOL, V9, P3114, DOI 10.1128/MCB.9.7.3114; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; WRIGHT PA, 1989, BRIT J CANCER, V60, P576, DOI 10.1038/bjc.1989.316; YUNIS JJ, 1989, ONCOGENE, V4, P609	21	227	230	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					677	679						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903197				2022-12-25	WOS:A1991FR93900027
J	SCHONTHAL, A; TSUKITANI, Y; FERAMISCO, JR				SCHONTHAL, A; TSUKITANI, Y; FERAMISCO, JR			TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL REGULATION OF C-FOS EXPRESSION BY THE TUMOR PROMOTER OKADAIC ACID	ONCOGENE			English	Article							PROTEIN-KINASE-C; RABBIT SKELETAL-MUSCLE; SERUM-RESPONSE ELEMENT; SWISS MOUSE 3T3-CELLS; MESSENGER-RNA; GROWTH-FACTOR; CELL-CYCLE; PHOSPHOPROTEIN PHOSPHATASE; SIGNAL TRANSDUCTION; GENE-EXPRESSION	Phosphorylation events are major regulatory mechanisms of signal transduction pathways that control cell growth and differentiation. We analyzed the potential contribution of serine/threonine specific protein phosphatases to the regulation of the c-fos gene, a proto-oncogene that is involved in the regulation of cell growth and differentiation. By use of okadaic acid, an inhibitor of protein phosphatases 1 and 2A, we present evidence that expression of the c-fos gene is regulated by serine/threonine specific protein phosphatases. This control is exerted on the transcriptional as well as the post-transcriptional level. The results suggest that dephosphorylation of regulatory phosphoproteins is an important mechanism for the down-regulation of c-fos promoter activity and the rapid degradation of c-fos mRNA. Examination of two protein kinase pathways that are known to regulate c-fos expression indicated that okadaic acid acted synergistically with protein kinase C, but not with protein kinase A. Since inhibition of serine/threonine specific phosphatases increases proto-oncogene expression, these experiments further strengthen the view that certain protein phosphatases may act as negative regulators of cell growth.	FUJISAWA PHARMACEUT CO LTD, OSAKA 532, JAPAN	Astellas Pharmaceuticals	SCHONTHAL, A (corresponding author), UNIV CALIF SAN DIEGO, CTR CANC, LA JOLLA, CA 92093 USA.		Schonthal, Axel/ABH-3846-2020	Schonthal, Axel/0000-0003-0662-5653				BADLEY JE, 1988, BIOTECHNIQUES, V6, P114; BALLOU LM, 1988, J BIOL CHEM, V263, P1188; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BECK TW, 1987, NUCLEIC ACIDS RES, V15, P595, DOI 10.1093/nar/15.2.595; BERKOWITZ LA, 1989, MOL CELL BIOL, V9, P4272, DOI 10.1128/MCB.9.10.4272; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; BRAUTIGAN DL, 1990, NATURE, V344, P74, DOI 10.1038/344074a0; BRAVO R, 1988, COLD SPRING HARB SYM, V53, P901, DOI 10.1101/SQB.1988.053.01.103; BRAWERMAN G, 1989, CELL, V57, P9, DOI 10.1016/0092-8674(89)90166-9; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN P, 1989, J BIOL CHEM, V264, P21435; Curran T, 1988, ONCOGENE HDB, P307; CYERT MS, 1989, CELL, V57, P891, DOI 10.1016/0092-8674(89)90325-5; DEPAOLIROACH AA, 1984, J BIOL CHEM, V259, P2144; FELIX MA, 1990, EMBO J, V9, P675, DOI 10.1002/j.1460-2075.1990.tb08159.x; FISCH TM, 1989, GENE DEV, V3, P198, DOI 10.1101/gad.3.2.198; FUJIKI H, 1987, P JPN ACAD B-PHYS, V63, P51, DOI 10.2183/pjab.63.51; FUKUMOTO Y, 1990, J BIOL CHEM, V265, P774; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GORIS J, 1989, FEBS LETT, V245, P91, DOI 10.1016/0014-5793(89)80198-X; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HARLOW E, 1988, ANTIBODIES; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HEMMINGS HC, 1984, NATURE, V310, P503, DOI 10.1038/310503a0; HERRLICH P, 1989, TRENDS GENET, V5, P112, DOI 10.1016/0168-9525(89)90041-3; HERSHEY JWB, 1989, J BIOL CHEM, V264, P20823; HESCHELER J, 1988, PFLUG ARCH EUR J PHY, V412, P248, DOI 10.1007/BF00582504; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HOLMES CFB, 1986, BIOCH BIOPHYS ACTA, V870; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; INGEBRITSEN TS, 1983, EUR J BIOCHEM, V132, P255, DOI 10.1111/j.1432-1033.1983.tb07357.x; ISSINGER OG, 1988, EMBO J, V7, P1621, DOI 10.1002/j.1460-2075.1988.tb02988.x; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; KIM SJ, 1990, CELL REGUL, V1, P269, DOI 10.1091/mbc.1.3.269; KLEE CB, 1988, MOL ASPECTS CELLULAR, P225; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; OLIVIER AR, 1988, P NATL ACAD SCI USA, V85, P4720, DOI 10.1073/pnas.85.13.4720; PALLAS DC, 1990, CELL, V60, P167, DOI 10.1016/0092-8674(90)90726-U; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; RAHMSDORF HJ, 1990, PHARMACOL THERAPEUT, V48, P157, DOI 10.1016/0163-7258(90)90079-H; RAHMSDORF HJ, 1987, NUCLEIC ACIDS RES, V15, P1643, DOI 10.1093/nar/15.4.1643; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; RUTHER U, 1985, EMBO J, V4, P1775, DOI 10.1002/j.1460-2075.1985.tb03850.x; SAKAI R, 1989, P NATL ACAD SCI USA, V86, P9946, DOI 10.1073/pnas.86.24.9946; SASSONECORSI P, 1988, GENE DEV, V2, P1529, DOI 10.1101/gad.2.12a.1529; SCHONTHAL A, 1990, CELL SIGNAL, V2, P215, DOI 10.1016/0898-6568(90)90049-G; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; STEWART AA, 1980, FEBS LETT, V119, P16, DOI 10.1016/0014-5793(80)80988-4; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; SUGANUMA M, 1988, P NATL ACAD SCI USA, V85, P1768, DOI 10.1073/pnas.85.6.1768; TACHIBANA K, 1981, J AM CHEM SOC, V103, P2469, DOI 10.1021/ja00399a082; TAKAI A, 1987, FEBS LETT, V217, P81, DOI 10.1016/0014-5793(87)81247-4; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VIRSHUP DM, 1989, P NATL ACAD SCI USA, V86, P3584, DOI 10.1073/pnas.86.10.3584; WAHL GM, 1983, MOL CELL BIOL, V3, P2066, DOI 10.1128/MCB.3.11.2066; WALTER G, 1990, P NATL ACAD SCI USA, V87, P2521, DOI 10.1073/pnas.87.7.2521; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0	70	81	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					423	430						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1901402				2022-12-25	WOS:A1991FT34400011
J	ZWILLER, J; SASSONECORSI, P; KAKAZU, K; BOYNTON, AL				ZWILLER, J; SASSONECORSI, P; KAKAZU, K; BOYNTON, AL			INHIBITION OF PDGF-INDUCED C-JUN AND C-FOS EXPRESSION BY A TYROSINE PROTEIN-KINASE INHIBITOR	ONCOGENE			English	Article							GROWTH-FACTORS; SIGNAL TRANSDUCTION; LEUCINE ZIPPER; 3T3 CELLS; MOUSE FIBROBLASTS; ONCOGENE; INDUCTION; FAMILY; TRANSCRIPTION; STIMULATION	The expression of the proto-oncogenes c-fos, c-jun, jun B and jun D was monitored in quiescent C3H10T1/2 fibroblasts after stimulation with PDGF. The mRNA level of c-fos, c-jun and jun B, but not of jun D, was stimulated by PDGF. The inductions were abolished when genistein, a specific tyrosine protein kinase inhibitor, was added concomitantly with PDGF, a condition in which DNA synthesis is known to be inhibited. As already shown previously, treatment with PDGF and genistein for 4 h followed by the replacement with fresh medium induces the progression of the cells through the G1 phase of their growth-division cycle, without phospholipase C activation. The removal of PDGF and genistein was accompanied by an important increase in c-fos, c-jun and jun B mRNA expression, which correlated with the entrance of cells into G1 phase. Thus, the proto-oncogene expressions induced by PDGF are also obtained in the absence of phospholipase C activation. This result also suggests that the mRNA levels of c-jun, jun B and to a lesser degree c-fos are positively regulated by tyrosine protein kinase activity, whereas jun D is negatively regulated.	CNRS,GENET MOLEC EUCARYOTES LAB,F-67085 STRASBOURG,FRANCE; UNIV HAWAII,CANC RES CTR HAWAII,HONOLULU,HI 96813	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Cancer Research Center of Hawaii; University of Hawaii System	ZWILLER, J (corresponding author), CNRS,CTR NEUROCHIM,5 RUE PASCAL,F-67084 STRASBOURG,FRANCE.		Sassone-Corsi, Paolo/H-6182-2011		NCI NIH HHS [CA42942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HABENICHT AJR, 1981, J BIOL CHEM, V256, P2329; HILL TD, 1990, SCIENCE, V248, P1660, DOI 10.1126/science.2163545; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; MCNEIL PL, 1985, J CELL BIOL, V101, P372, DOI 10.1083/jcb.101.2.372; MOOLENAAR WH, 1984, J BIOL CHEM, V259, P8066; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; OLAH Z, 1990, CANCER RES, V31, pA76; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; STILES CD, 1985, CANCER RES, V45, P5215; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922	30	56	56	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					219	221						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900355				2022-12-25	WOS:A1991FZ13400006
J	BOWEN, S; STANLEY, K; SELVA, E; DAVIS, RJ				BOWEN, S; STANLEY, K; SELVA, E; DAVIS, RJ			CONSTITUTIVE PHOSPHORYLATION OF THE EPIDERMAL GROWTH-FACTOR RECEPTOR BLOCKS MITOGENIC SIGNAL TRANSDUCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; INDEPENDENT MECHANISMS; HUMAN-FIBROBLASTS; EGF RECEPTOR; TYROSINE; CELLS; VIRUS; THREONINE-654; SERINE-24; AFFINITY	The epidermal growth factor (EGF) receptor is phosphorylated by protein kinase C at Thr654. It has been proposed that the phosphorylation of this site is an important regulatory mechanism for the control of EGF receptor function. However, the physiological significance of the phosphorylation of EGF receptor Thr654 in intact cells is not understood. To address this question, the design of an experimental strategy is required that can be used to distinguish between the pleiotropic effects of kinase C activation and the specific effects of kinase C that are mediated by the phosphorylation of the EGF receptor at Thr654. The approach that we used was to examine the function of EGF receptors that are constitutively phosphorylated at residue 654. It was observed that the constitutive phosphorylation of the EGF receptor blocked mitogenic signal transduction by the receptor. These data are consistent with the hypothesis that the phosphorylation of the EGF receptor at residue 654 in intact cells inhibits EGF-stimulated cellular proliferation.	UNIV MASSACHUSETTS,SCH MED,DEPT BIOCHEM & MOLEC BIOL,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester	BOWEN, S (corresponding author), UNIV MASSACHUSETTS,SCH MED,HOWARD HUGHES MED INST,PROGRAM MOLEC MED,WORCESTER,MA 01605, USA.				NATIONAL CANCER INSTITUTE [P01CA039240] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037845] Funding Source: NIH RePORTER; NCI NIH HHS [CA39240] Funding Source: Medline; NIGMS NIH HHS [GM37845] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEEMON K, 1978, J VIROL, V28, P551, DOI 10.1128/JVI.28.2.551-566.1978; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COCHET C, 1984, J BIOL CHEM, V259, P2553; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P13642; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DAVIS RJ, 1985, P NATL ACAD SCI USA, V82, P1974, DOI 10.1073/pnas.82.7.1974; DAVIS RJ, 1985, J BIOL CHEM, V260, P1562; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DAVIS RJ, 1988, J BIOL CHEM, V263, P9462; DAVIS RJ, 1986, J BIOL CHEM, V261, P9034; DAVIS RJ, 1987, J BIOL CHEM, V262, P6832; DECKER SJ, 1988, J VIROL, V62, P3649, DOI 10.1128/JVI.62.10.3649-3654.1988; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DOWNWARD J, 1985, J BIOL CHEM, V260, P4538; ENGLAND PJ, 1976, ANAL BIOCHEM, V75, P429, DOI 10.1016/0003-2697(76)90096-8; FRIEDMAN BA, 1984, P NATL ACAD SCI-BIOL, V81, P3034, DOI 10.1073/pnas.81.10.3034; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HONNEGER AM, 1990, MOL CELL BIOL, V10, P4035; HUNTER T, 1984, NATURE, V311, P480, DOI 10.1038/311480a0; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; IWASHITA S, 1984, J BIOL CHEM, V259, P2559; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LIVNEH E, 1988, MOL CELL BIOL, V8, P2302, DOI 10.1128/MCB.8.6.2302; MATRISIAN LM, 1982, ANAL BIOCHEM, V125, P339, DOI 10.1016/0003-2697(82)90015-X; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PESSIN JE, 1983, J BIOL CHEM, V258, P7386; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHLESSINGER J, 1988, BIOCHEMISTRY-US, V27, P3119, DOI 10.1021/bi00409a002; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479; [No title captured]	32	41	43	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1162	1169						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898731				2022-12-25	WOS:A1991ET17700076
J	SNAVELY, MD; GRAVINA, SA; CHEUNG, TT; MILLER, CG; MAGUIRE, ME				SNAVELY, MD; GRAVINA, SA; CHEUNG, TT; MILLER, CG; MAGUIRE, ME			MAGNESIUM TRANSPORT IN SALMONELLA-TYPHIMURIUM - REGULATION OF MGTA AND MGTB EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION MOTIVE ATPASES; NICKEL TRANSPORT; ESCHERICHIA-COLI; CLONING; SYSTEMS; GENE	Salmonella typhimurium contains three distinct transport systems (CorA, MgtA, and MgtB) that move Mg2+ across the cytoplasmic membrane. Mutant strains containing only one of these three systems have been constructed and used to study each system in isolation. Characterization of these systems has been hampered, however, by the need to use Mg-28(2+), a relatively unavailable, extremely expensive, and short lived radioisotope. This paper reports that Ni-63(2+) is transported into the cell by all three of the S. typhimurium Mg2+ transport systems. In a strain deficient in all three systems, uptake of Ni-63(2+) was undetectable under the conditions used. Comparison of Ni-63(2+) uptake kinetics and inhibition of Ni-63(2+) transport by other divalent cations suggest that Ni2+ can be used as an analog of Mg2+ in the study of these three transport systems. Using Ni-63(2+) to measure uptake, the effect of Mg2+ levels in the growth medium on transport by each system was tested. Transport by the CorA system was unaffected by changes in the amount of Mg2+ in the growth medium. In contrast, uptake via MgtA and MgtB was significantly increased in cells grown in 10-mu-M extracellular Mg2+ compared to cells grown in 10 mM Mg2+. The increases in uptake were the result of increases in V(max) without change in K(m). This result suggests that, in low Mg2+ medium, cells contained higher levels of the transporters. Production of beta-galactosidase from mgtA::lacZ and mgtB::lacZ but not corA::lacZ fusions was also increased when cells were grown in low extracellular concentrations of Mg2+ indicating that the regulation occurs at the level of transcription. Expression of beta-galactosidase was also inhibited by the addition of other divalent cations including Ca2+ and Mn2+. Regulation of transcription from the mgtA and mgtB promoters was similar over the range of extracellular Mg2+ concentrations from 10-mu-M to 10 mM. At 1-mu-M, however, transcription from the mgtB promoter, as measured by beta-galactosidase levels in a mgtB::lacZ transcriptional fusion strain, was increased over 800-fold, and Ca2+ could not longer inhibit transcription effectively. In contrast, growth at 1-mu-M extracellular Mg2+ increased transcription from the mgtA promoter only about 30-fold and Ca2+ could still inhibit this increase. These results suggest that at least two distinct mechanisms are responsible for regulation of the mgtA and mgtB transcription in response to extracellular cation concentration.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHARMACOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT MOLEC BIOL & MICROBIOL,CLEVELAND,OH 44106	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026340] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26340] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BETTELHEIM KA, 1989, MED J AUSTRALIA, V151, P538, DOI 10.5694/j.1326-5377.1989.tb128512.x; BRYSON MF, 1988, J BACTERIOL, V170, P234, DOI 10.1128/jb.170.1.234-238.1988; CASTILHO BA, 1984, J BACTERIOL, V158, P488, DOI 10.1128/JB.158.2.488-495.1984; GANGOLA P, 1987, J BIOL CHEM, V262, P12570; HMIEL SP, 1989, J BACTERIOL, V171, P4742, DOI 10.1128/jb.171.9.4742-4751.1989; HMIEL SP, 1986, J BACTERIOL, V168, P1444, DOI 10.1128/jb.168.3.1444-1450.1986; IANDOLO JJ, 1989, ANNU REV MICROBIOL, V43, P375, DOI 10.1146/annurev.micro.43.1.375; JARRELL KF, 1982, J BACTERIOL, V151, P1195, DOI 10.1128/JB.151.3.1195-1203.1982; KASS EH, 1989, REV INFECT DIS, V11, pS167; LOHMEYER M, 1987, ARCH MICROBIOL, V149, P130, DOI 10.1007/BF00425078; LUNDIE LL, 1988, J BACTERIOL, V170, P5705, DOI 10.1128/jb.170.12.5705-5708.1988; Lynn A.R., 1987, ION TRANSPORT PROKAR, P181; MILLER JF, 1989, SCIENCE, V243, P916, DOI 10.1126/science.2537530; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; Sambrook J, 1989, MOL CLONING LABORATO; Silver S., 1987, ION TRANSPORT PROKAR, P165; SNAVELY MD, 1991, J BIOL CHEM, V266, P815; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; SNAVELY MD, 1989, J BACTERIOL, V171, P4752, DOI 10.1128/jb.171.9.4752-4760.1989; WEBB M, 1970, BIOCHIM BIOPHYS ACTA, V222, P428, DOI 10.1016/0304-4165(70)90133-9; WILLECKE K, 1973, J BIOL CHEM, V248, P807	23	146	149	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					824	829						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898738				2022-12-25	WOS:A1991ET17700026
J	NEWTON, AC; WILLIAMS, DS				NEWTON, AC; WILLIAMS, DS			INVOLVEMENT OF PROTEIN-KINASE-C IN THE PHOSPHORYLATION OF RHODOPSIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ROD OUTER SEGMENTS; LIGHT-MEDIATED BREAKDOWN; ENDOGENOUS PHOSPHORYLATION; BETA-2-ADRENERGIC RECEPTOR; PHORBOL ESTER; CALCIUM; SITES; DESENSITIZATION; PHOTORECEPTOR; PURIFICATION	The possibility that protein kinase C is involved in phototransduction by phosphorylating rhodopsin was explored in situ and in vitro. Pretreatment of intact retinas with phorbol myristate acetate markedly increased the light-dependent phosphorylation of rhodopsin, with the greatest effects observed at lower light levels. Phorbol myristate acetate treatment did not affect rhodopsin phosphorylation in retinas not exposed to light, suggesting that protein kinase C modulates the phosphorylation state of rhodopsin in a light-dependent manner. Limited proteolysis of rhodopsin phosphorylated in situ indicates that protein kinase C modifies rhodopsin on a domain distinct from that recognized by rhodopsin kinase. In vitro, protein kinase C purified from bovine retinas phosphorylated unbleached and bleached rhodopsin. Our results are consistent with protein kinase C phosphorylating unbleached rhodopsin in response to low light, suggesting that protein kinase C plays a role in light adaptation.	INDIANA UNIV,DEPT VISUAL SCI,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington	NEWTON, AC (corresponding author), INDIANA UNIV,DEPT CHEM,BLOOMINGTON,IN 47405, USA.				NCRR NIH HHS [RR 7031-25, S07 RR 5962] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR005962] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ALUBAIDI MR, 1990, J BIOL CHEM, V265, P20563; AMES GFL, 1974, J BIOL CHEM, V249, P634; APPLEBURY ML, 1986, VISION RES, V26, P1881, DOI 10.1016/0042-6989(86)90115-X; ASHENDEL CL, 1989, RECEPTOR PHOSPHORYLA, P163; BELL RM, 1991, J BIOL CHEM, V266, P4661; BINDER BM, 1990, J BIOL CHEM, V265, P15333; BINDER BM, 1989, J BIOL CHEM, V264, P8857; DAS ND, 1987, CELL STRUCT FUNCT, V12, P471, DOI 10.1247/csf.12.471; DEGRIP WJ, 1982, METHOD ENZYMOL, V81, P197; FINDLAY JBC, 1981, NATURE, V293, P314, DOI 10.1038/293314a0; FRANKE RR, 1988, J BIOL CHEM, V263, P2119; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FUNG BKK, 1985, MOL MECHANISMS TRANS, P183; GEHM BD, 1990, BIOCHEMISTRY-US, V29, P5447, DOI 10.1021/bi00475a006; GHALAYINI A, 1984, BIOCHEM BIOPH RES CO, V124, P503, DOI 10.1016/0006-291X(84)91582-1; HARGRAVE PA, 1987, MEMBRANE PROTEINS, P81; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAYASHI F, 1985, BIOCHEM BIOPH RES CO, V128, P954, DOI 10.1016/0006-291X(85)90139-1; HAZELBAUER GL, 1989, P NATL ACAD SCI USA, V86, P1448, DOI 10.1073/pnas.86.5.1448; HOUSE C, 1987, J BIOL CHEM, V262, P772; HUANG KP, 1986, J BIOL CHEM, V261, P2134; INOUE M, 1984, JPN J OPHTHALMOL, V28, P47; KAPOOR CL, 1987, EXP EYE RES, V45, P545, DOI 10.1016/S0014-4835(87)80065-9; KAPOOR CL, 1984, BIOCHEM BIOPH RES CO, V122, P1397, DOI 10.1016/0006-291X(84)91246-4; KELLEHER DJ, 1990, J BIOL CHEM, V265, P2632; KELLEHER DJ, 1985, J CYCLIC NUCL PROT, V10, P579; KELLEHER DJ, 1986, J BIOL CHEM, V261, P4749; KISHIMOTO A, 1985, J BIOL CHEM, V260, P2492; KONIG B, 1989, FEBS LETT, V257, P163, DOI 10.1016/0014-5793(89)81811-3; LEE RH, 1982, METHOD ENZYMOL, V81, P496; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MILLER JL, 1984, VISION RES, V24, P1509, DOI 10.1016/0042-6989(84)90313-4; NEWTON AC, 1990, BIOCHEMISTRY-US, V29, P6656, DOI 10.1021/bi00480a015; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; SANDERS DA, 1988, P NATL ACAD SCI USA, V85, P8425, DOI 10.1073/pnas.85.22.8425; SCHRODER WH, 1984, NATURE, V309, P268, DOI 10.1038/309268a0; SHICHI H, 1989, RECEPTOR PHOSPHORYLA, P177; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032; WILLIAMS DS, 1989, EXP EYE RES, V49, P439, DOI 10.1016/0014-4835(89)90052-3; YAMANISHI J, 1983, BIOCHEM BIOPH RES CO, V112, P778, DOI 10.1016/0006-291X(83)91529-2	43	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17725	17728						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917916				2022-12-25	WOS:A1991GG55300002
J	BOESE, QF; SPANO, AJ; LI, JM; TIMKO, MP				BOESE, QF; SPANO, AJ; LI, JM; TIMKO, MP			AMINOLEVULINIC ACID DEHYDRATASE IN PEA (PISUM-SATIVUM L) - IDENTIFICATION OF AN UNUSUAL METAL-BINDING DOMAIN IN THE PLANT ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ACTIVE-SITE; 5-AMINOLAEVULINATE DEHYDRATASE; PORPHOBILINOGEN SYNTHASE; HUMAN-ERYTHROCYTES; RADISH COTYLEDONS; CDNA CLONE; PURIFICATION; LIVER; GENE	Aminolevulinic acid dehydratase (ALA dehydratase) catalyzes the second step of tetrapyrrole synthesis leading to the formation of heme and chlorophyll in higher plant cells. Antibodies elicited against spinach leaf ALA dehydratase were used to immunoscreen lambda-gt11 cDNA libraries constructed from etiolated pea (Pisum sativum L.) leaf poly(A)+ RNAs. A set of overlapping cDNAs was characterized that encode the pea enzyme. The predicted amino acid sequence of the pea ALA dehydratase is similar to those reported for other eukaryotic and prokaryotic ALA dehydratases. The pea enzyme has an active site domain centered on lysine that is highly conserved in comparison to other known ALA dehydratases. Consistent with the previously reported requirement of Mg2+ for catalytic activity by plant ALA dehydratases, the pea enzyme lacks the characteristic Zn2+-binding domain present in other eukaryotic ALA dehydratases, but contains a distinctive metal ligand-binding domain based upon aspartate. Northern blot analyses demonstrated that ALA dehydratase mRNA is present in leaves, stems, and to a lesser extent in roots. Steady state levels of mRNA encoding ALA dehydratase exhibit little or no change during light-induced greening.	UNIV VIRGINIA,DEPT BIOL,CHARLOTTESVILLE,VA 22901	University of Virginia			Li, Jianming/O-1772-2014	Li, Jianming/0000-0003-3231-0778				ANDERSON PM, 1979, J BIOL CHEM, V254, P6924; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BATTLE A. M. C., 1967, BIOCHEM J, V104, P244; BEALE SI, 1989, BIOSYNTHESIS HEME CH, P297; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BISHOP TR, 1986, NUCLEIC ACIDS RES, V14, P10115, DOI 10.1093/nar/14.24.10115; BISHOP TR, 1986, P NATL ACAD SCI USA, V83, P5568, DOI 10.1073/pnas.83.15.5568; BISHOP TR, 1989, NUCLEIC ACIDS RES, V17, P1775, DOI 10.1093/nar/17.4.1775; BORRALHO LM, 1990, YEAST, V6, P319, DOI 10.1002/yea.320060405; CASHMORE AR, 1982, METHODS CHLOROPLAST, P387; CHEH AM, 1976, STRUCT BOND, V29, P123; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLEMAN DL, 1966, J BIOL CHEM, V241, P5511; DENT AJ, 1990, BIOCHEMISTRY-US, V29, P7822, DOI 10.1021/bi00486a007; DOYLE D, 1971, J BIOL CHEM, V246, P4965; ECHELARD Y, 1988, MOL GEN GENET, V214, P503, DOI 10.1007/BF00330487; FREY PA, 1988, BIOCHEMISTRY-US, P347; GIBBS P, 1981, Biochemical Society Transactions, V9, P232; GIBBS PNB, 1986, BIOCHEM J, V236, P447, DOI 10.1042/bj2360447; GIBBS PNB, 1985, BIOCHEM J, V230, P25, DOI 10.1042/bj2300025; GIBSON KD, 1955, BIOCHEM J, V61, P618, DOI 10.1042/bj0610618; GRANICK S, 1978, ADV ENZYMOL, V46, P37; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HUAULT C, 1987, PLANT PHYSIOL BIOCH, V25, P723; HUAULT C, 1984, PHYSIOL PLANTARUM, V61, P469, DOI 10.1111/j.1399-3054.1984.tb06358.x; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; JAFFE EK, 1986, J BIOL CHEM, V261, P9348; JORDAN PM, 1989, BIOSYNTHESIS HEME CH, P55; KASEMIR H, 1975, PLANTA, V126, P119, DOI 10.1007/BF00380615; KRETSINGER RH, 1990, J MOL EVOL, V30, P522; LIEDGENS W, 1980, Z NATURFORSCH C, V35, P958; LIEDGENS W, 1983, EUR J BIOCHEM, V135, P75, DOI 10.1111/j.1432-1033.1983.tb07619.x; Maniatis T., 1982, MOL CLONING; MARALIHALLI GB, 1985, J BIOSCIENCE, V7, P359, DOI 10.1007/BF02716797; MARALIHALLI GB, 1985, PHYTOCHEMISTRY, V24, P2533, DOI 10.1016/S0031-9422(00)80662-7; MIERENDORF RC, 1987, METHOD ENZYMOL, V152, P458; MYERS AM, 1987, J BIOL CHEM, V262, P16822; NANDI DL, 1968, J BIOL CHEM, V243, P1224; NANDI DL, 1973, ARCH BIOCHEM BIOPHYS, V158, P305, DOI 10.1016/0003-9861(73)90626-7; NASRI F, 1988, PHYTOCHEMISTRY, V27, P1289, DOI 10.1016/0031-9422(88)80179-1; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; RAO SR, 1988, PHOTOSYNTHETICA, V22, P431; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schiff J A, 1972, Methods Enzymol, V24, P321; SCHNEIDER HA, 1970, Z PFLANZENPHYSIOL, V62, P328; SHEMIN D, 1976, PHILOS T ROY SOC B, V273, P109, DOI 10.1098/rstb.1976.0004; SHIBATA H, 1977, PLANT CELL PHYSIOL, V18, P421, DOI 10.1093/oxfordjournals.pcp.a075450; SHIOI Y, 1988, PLANT CELL PHYSIOL, V29, P843; SMITH A, 1986, REGULATION CHLOROPLA, P49; SPANO AJ, 1991, BIOCHIM BIOPHYS ACTA, V1076, P29, DOI 10.1016/0167-4838(91)90216-M; TAMAI H, 1979, PLANT CELL PHYSIOL, V20, P435, DOI 10.1093/oxfordjournals.pcp.a075828; TSUKAMOTO I, 1979, BIOCHIM BIOPHYS ACTA, V570, P167, DOI 10.1016/0005-2744(79)90211-0; VANHEYNINGEN S, 1971, BIOCHEMISTRY-US, V10, P4676, DOI 10.1021/bi00801a013; WERNEKE JM, 1988, P NATL ACAD SCI USA, V85, P787, DOI 10.1073/pnas.85.3.787; WETMUR JG, 1986, P NATL ACAD SCI USA, V83, P7703, DOI 10.1073/pnas.83.20.7703; WU WH, 1974, P NATL ACAD SCI USA, V41, P1767	57	77	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17060	17066						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894602				2022-12-25	WOS:A1991GF44500017
J	LAINE, RO; LAIPIS, PJ; SHAY, NF; KILBERG, MS				LAINE, RO; LAIPIS, PJ; SHAY, NF; KILBERG, MS			IDENTIFICATION OF AN AMINO ACID-REGULATED MESSENGER-RNA FROM RAT-LIVER AS THE MAMMALIAN EQUIVALENT OF BACTERIAL RIBOSOMAL PROTEIN-L22	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PLASMA-MEMBRANE VESICLES; SYSTEM-A; WESTERN BLOTS; TRANSPORT; CELLS; SEQUENCE; ANTIBODIES; INHIBITION; CLONING; GELS	Amino acid deprivation of rat hepatoma cells induced the levels of a 612-base pair mRNA termed ASI (Shay, N. F., Nick, H. S., and Kilberg, M. S. (1990) J. Biol. Chem. 265, 17844-17848). The ASI mRNA was present at levels equal to or greater than actin in every rat tissue tested. The corresponding full-length cDNA was cloned, and the present report demonstrates that the deduced 184-residue amino acid sequence shares greater than 30% identity to a number of bacterial and chloroplast L22 ribosomal proteins, including those from Escherichia coli and Halobacterium halobium. A monospecific anti-peptide antibody was produced that upon immunochemical analysis of subcellular fractions of rat liver recognized a band in the microsomal fraction and, more specifically, reacted with a single polypeptide in the ribosomal large subunit fraction. The antibody did not react with any proteins of the mitochondrial large subunit, but did recognize a protein in human liver homogenate at the same relative mobility (23 kDa) as that observed for rat liver.	UNIV FLORIDA,J HILLIS MILLER HLTH CTR,DEPT BIOCHEM & MOLEC BIOL,BOX J-245,GAINESVILLE,FL 32610	State University System of Florida; University of Florida					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031580] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-31580] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARORA KK, 1990, J BIOL CHEM, V265, P6481; AUER J, 1989, CAN J MICROBIOL, V35, P200, DOI 10.1139/m89-031; BARKER GA, 1990, EXP PHYSIOL, V15, P3; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRACY DS, 1986, J BIOL CHEM, V261, P1514; CARIAPPA R, 1990, J BIOL CHEM, V265, P1470; CHILES TC, 1987, ANAL BIOCHEM, V163, P136, DOI 10.1016/0003-2697(87)90103-5; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CLEGG JCS, 1970, EUR J BIOCHEM, V13, P149, DOI 10.1111/j.1432-1033.1970.tb00911.x; CLEMENS NJ, 1986, TRANSCRIPTION TRANSL, P257; DAYHOFF MO, 1983, METHOD ENZYMOL, V91, P524; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; ENGLESBERG E, 1986, J MEMBRANE BIOL, V91, P199, DOI 10.1007/BF01868814; FALIKS D, 1982, NUCLEIC ACIDS RES, V10, P789, DOI 10.1093/nar/10.3.789; Fleischer S, 1974, Methods Enzymol, V31, P6; FONG AD, 1990, BIOCHIM BIOPHYS ACTA, V1022, P325, DOI 10.1016/0005-2736(90)90281-R; GRAY MW, 1989, TRENDS GENET, V5, P294, DOI 10.1016/0168-9525(89)90111-X; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HATAKEYAMA T, 1988, FEBS LETT, V240, P21, DOI 10.1016/0014-5793(88)80333-8; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; KILBERG MS, 1986, TRENDS BIOCHEM SCI, V11, P183, DOI 10.1016/0968-0004(86)90138-6; KIMURA M, 1989, CAN J MICROBIOL, V35, P195, DOI 10.1139/m89-030; KUHSEL MG, 1990, SCIENCE, V250, P1570, DOI 10.1126/science.2125748; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAINE RO, 1989, J IMMUNOL, V143, P553; LEVINSON W, 1980, EXP CELL RES, V130, P459, DOI 10.1016/0014-4827(80)90026-9; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MANKIN AS, 1989, FEBS LETT, V246, P13, DOI 10.1016/0014-5793(89)80243-1; MEYUHAS O, 1987, MOL CELL BIOL, V7, P2691, DOI 10.1128/MCB.7.8.2691; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PRPIC V, 1984, J BIOL CHEM, V259, P1382; PUHLER G, 1989, P NATL ACAD SCI USA, V86, P4568; SAIER NH, 1988, J MEMBRANE BIOL, V104, P1; SHAY NF, 1990, J BIOL CHEM, V265, P17844; SHOTWELL MA, 1983, BIOCHIM BIOPHYS ACTA, V737, P267, DOI 10.1016/0304-4157(83)90003-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGNER M, 1985, MOL CELL BIOL, V5, P3560, DOI 10.1128/MCB.5.12.3560; WITTMANNLIEBOLD B, 1980, FEBS LETT, V121, P105; WOESE CR, 1987, MICROBIOL REV, V51, P221, DOI 10.1128/MMBR.51.2.221-271.1987	41	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					16969	16972						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894596				2022-12-25	WOS:A1991GF44500002
J	MERENMIES, J; PIHLASKARI, R; LAITINEN, J; WARTIOVAARA, J; RAUVALA, H				MERENMIES, J; PIHLASKARI, R; LAITINEN, J; WARTIOVAARA, J; RAUVALA, H			30-KDA HEPARIN-BINDING PROTEIN OF BRAIN (AMPHOTERIN) INVOLVED IN NEURITE OUTGROWTH - AMINO-ACID-SEQUENCE AND LOCALIZATION IN THE FILOPODIA OF THE ADVANCING PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLASTOMA CELLS; CHROMOSOMAL-PROTEINS; NUCLEOTIDE-SEQUENCE; GROWTH-FACTORS; HMG1; ADHESION; SURFACE; RECOGNITION; ANTIBODIES; EXPRESSION	A cDNA library constructed from mRNA of rat brain was used to clone the cDNA that encodes the 30-kDa heparin-binding protein (amphoterin) that is developmentally regulated in brain and enhances neurite outgrowth in cerebral neurons. cDNA and peptide sequencing identified a dipolar sequence that has been previously found in studies of high mobility group 1 protein: the 184-amino acid cationic region is followed by a cluster of 30 anionic residues. The mRNA encoding amphoterin is also developmentally regulated; it is strongly reduced in quantity after the rapid perinatal growth phase of the rat brain. Anti-synthetic peptide antibodies raised according to the sequence of amphoterin were shown to bind specifically to the protein isolated from brain, and were used to detect amphoterin in subcellular fractions and in immunostaining of cells. Amphoterin was found in the cytoplasm of the cell soma, in the cell processes, and the substrate-attached material. In cells that are at an active stage of spreading and extending their cytoplasmic processes amphoterin was especially associated with plasma membrane filopodia. The distinct localization to the filopodia of the advancing plasma membrane suggests that endogenous amphoterin has a role in the extension of neurite-type cytoplasmic processes in developing cells. This inference is further supported by the finding that both anti-amphoterin and the anti-synthetic peptide antibodies in the culture media strongly inhibit the outgrowth of cytoplasmic processes.	UNIV HELSINKI,NEUROBIOL RES UNIT,SF-00170 HELSINKI 17,FINLAND; UNIV HELSINKI,INST BIOTECHNOL,SF-00380 HELSINKI,FINLAND; UNIV HELSINKI,DEPT ELECTRON MICROSCOPY,SF-00300 HELSINKI,FINLAND	University of Helsinki; University of Helsinki; University of Helsinki	MERENMIES, J (corresponding author), UNIV HELSINKI,DEPT MED CHEM,SF-00170 HELSINKI 17,FINLAND.			Rauvala, Heikki/0000-0001-7809-9811				AVNUR Z, 1981, J MOL BIOL, V153, P361, DOI 10.1016/0022-2836(81)90283-7; Battey, 1986, BASIC METHODS MOL BI; BAUMANN M, 1990, ANAL BIOCHEM, V190, P198, DOI 10.1016/0003-2697(90)90181-8; BERG DK, 1984, ANNU REV NEUROSCI, V7, P149; BIANCHI ME, 1989, SCIENCE, V243, P1056, DOI 10.1126/science.2922595; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAY D, 1988, ANNU REV CELL BIOL, V4, P43, DOI 10.1146/annurev.cb.04.110188.000355; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; BUSTIN M, 1979, CELL, V16, P181, DOI 10.1016/0092-8674(79)90199-5; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CARTER WG, 1981, J CELL BIOL, V88, P138, DOI 10.1083/jcb.88.1.138; Engvall E, 1980, Methods Enzymol, V70, P419; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; Harlow E., 1988, ANTIBODIES LABORATOR, P628; Jacobson M., 2013, DEV NEUROBIOL; JOUSIMAA J, 1984, EUR J CELL BIOL, V35, P55; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KLD, 1987, NUCLEIC ACIDS RES, V15, P5051, DOI 10.1093/nar/15.13.5051; LETOURNEAU PC, 1983, TRENDS NEUROSCI, V6, P451, DOI 10.1016/0166-2236(83)90217-5; LI YS, 1990, SCIENCE, V250, P1690, DOI 10.1126/science.2270483; MERENMIES J, 1990, J BIOL CHEM, V265, P16721; MERENMIES J, 1989, 19TH M FED EUR BIOCH; MOOS M, 1988, J BIOL CHEM, V263, P6005; MOSEVITSKY MI, 1989, EUR J BIOCHEM, V185, P303, DOI 10.1111/j.1432-1033.1989.tb15116.x; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; PAONESSA G, 1987, NUCLEIC ACIDS RES, V15, P9077, DOI 10.1093/nar/15.21.9077; RAUVALA H, 1989, EMBO J, V8, P2933, DOI 10.1002/j.1460-2075.1989.tb08443.x; RAUVALA H, 1984, J CELL BIOL, V98, P1010, DOI 10.1083/jcb.98.3.1010; RAUVALA H, 1988, J CELL BIOL, V107, P2293, DOI 10.1083/jcb.107.6.2293; RAUVALA H, 1987, J BIOL CHEM, V262, P16625; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWAB M, 1983, NATURE, V303, P497, DOI 10.1038/303497a0; THOENEN H, 1985, SCIENCE, V229, P238, DOI 10.1126/science.2409599; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSUDA K, 1988, BIOCHEMISTRY-US, V27, P6159, DOI 10.1021/bi00416a050; WALKER JM, 1980, FEBS LETT, V122, P264, DOI 10.1016/0014-5793(80)80453-4; WALKER JM, 1980, COMPREHENSIVE BIOC B, V19, P507; WARTIOVAARA JJ, 1990, I PHYS C SER, V98, pCH16; YAVIN E, 1974, J CELL BIOL, V62, P540, DOI 10.1083/jcb.62.2.540	40	208	217	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16722	16729						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885601				2022-12-25	WOS:A1991GD63500077
J	PETER, GF; THORNBER, JP				PETER, GF; THORNBER, JP			BIOCHEMICAL-COMPOSITION AND ORGANIZATION OF HIGHER-PLANT PHOTOSYSTEM-II LIGHT-HARVESTING PIGMENT-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHLOROPHYLL-A/B-PROTEIN; REACTION CENTER CORE; CHLORINA F2 MUTANT; LESS BARLEY MUTANT; A-B-PROTEIN; BINDING-PROTEINS; COMPLEX-II; WILD-TYPE; POLYPEPTIDES; CHLOROPLASTS	The light-harvesting complex (LHC) of barley photosystem II (PS II) was fractionated by Deriphat-polyacrylamide gel electrophoresis into five different pigmented components: one subcomplex (LHC IIb) and four pigment-proteins (LHC IIa, -c, -d, and -e). No loss of chorophyll from the components occurred during fractionation, and violaxanthin is the only photosynthetic pigment that apparently occurs in thylakoids free of association with protein. Each LHC II component has a distinct stoichiometry of neoxanthin, violaxanthin, lutein, chlorophyll a, and chlorophyll b. LHC IIa, -d, and -e were obtained as monomeric pigment-proteins, each of which contained one apoprotein M(r) 31,000, 21,000, and 13,000, respectively. LHC IIc was also isolated as a monomer but it contained two polypeptides of M(r) 29,000 and 26,500, whereas the trimeric LHC IIb subcomplex (M(r) 72,000) contained three subunits of M(r) 28,000, 27,000, and 25,000, but not in equal stoichiometry. How the LHC II subunits are organized in PS II was examined. We isolated PS II subcomplexes which contained four of the LHC II subunits and the core complex (CC II) in unit stoichiometry; the relative strengths of association of the LHC II subunits with CC 11 are: LHC IIa > LHC IIc > LHC IIb > LHC IId. The LHC II subunits were associated with the native dimeric and not with the derived monomeric form of CC II. In addition, a multimeric LHC II subcomplex composed of the LHC IIa, LHC lIb, and LHC IId pigment-proteins was isolated. We propose that this LHC II subcomplex, which contained the M(r) 28,000 and 25,000 subunits but lacked the M(r) 27,000 subunit of LHC IIb, serves as a connector between the bulk of LHC IIb and CC II. An LHC IIb pigmented fraction of M(r) 250,000 was isolated which contained only the M(r) 28,000 and 27,000 subunits. The LHC IIb subunits in this complex were the most highly phosphorylated on a protein basis. These data together with analyses of the chlorophyll b-less barley chlorina f2 mutant were used to construct a model for the LHC II pigment-protein arrangement in higher plant PS II.			PETER, GF (corresponding author), UNIV CALIF LOS ANGELES,DEPT BIOL,LOS ANGELES,CA 90024, USA.				NIGMS NIH HHS [GM-07185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON JM, 1988, TRENDS BIOCHEM SCI, V13, P351, DOI 10.1016/0968-0004(88)90106-5; ANDERSON JM, 1986, ENCY PLANT PHYSL, V19, P269; BARBER J, 1982, ANNU REV PLANT PHYS, V33, P261, DOI 10.1146/annurev.pp.33.060182.001401; BASSI R, 1987, J BIOL CHEM, V262, P13333; BELLEMARE G, 1982, J BIOL CHEM, V257, P7762; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNETT J, 1981, FEBS LETT, V131, P325, DOI 10.1016/0014-5793(81)80396-1; BRANDT P, 1982, BIOCHIM BIOPHYS ACTA, V679, P404, DOI 10.1016/0005-2728(82)90161-X; BRYANT DA, 1986, CAN B FISH AQUAT SCI, V214, P423; BUTLER PJG, 1988, P NATL ACAD SCI USA, V85, P3797, DOI 10.1073/pnas.85.11.3797; CAMM EL, 1989, BIOCHIM BIOPHYS ACTA, V974, P180, DOI 10.1016/S0005-2728(89)80370-6; CAMM EL, 1980, PLANT PHYSIOL, V66, P428, DOI 10.1104/pp.66.3.428; DAINESE P, 1990, PHOTOCHEM PHOTOBIOL, V51, P693, DOI 10.1111/php.1990.51.6.693; DARR SC, 1986, J CELL BIOL, V103, P733, DOI 10.1083/jcb.103.3.733; Davies B.H., 1965, CHEM BIOCH PLANT PIG, Vpp, P489; DUNAHAY TG, 1986, PLANT PHYSIOL, V80, P429, DOI 10.1104/pp.80.2.429; DUNAHAY TG, 1987, FEBS LETT, V215, P25, DOI 10.1016/0014-5793(87)80107-2; DUNSMUIR P, 1985, NUCLEIC ACIDS RES, V13, P2503, DOI 10.1093/nar/13.7.2503; DURANTON J, 1987, PHOTOSYNTH RES, V11, P141, DOI 10.1007/BF00018272; GHANOTAKIS DF, 1987, BIOCHIM BIOPHYS ACTA, V891, P15, DOI 10.1016/0005-2728(87)90078-8; GHANOTAKIS DF, 1983, FEBS LETT, V153, P231, DOI 10.1016/0014-5793(83)80154-9; GHIRARDI ML, 1986, BIOCHIM BIOPHYS ACTA, V851, P331, DOI 10.1016/0005-2728(86)90069-1; GLAZER AN, 1983, ANNU REV BIOCHEM, V52, P125, DOI 10.1146/annurev.bi.52.070183.001013; GLICK RE, 1988, BIOCHIM BIOPHYS ACTA, V934, P151, DOI 10.1016/0005-2728(88)90130-2; GREEN BR, 1982, BIOCHIM BIOPHYS ACTA, V681, P256, DOI 10.1016/0005-2728(82)90030-5; GREEN BR, 1988, PHOTOSYNTH RES, V15, P3, DOI 10.1007/BF00054985; HOYERHANSEN G, 1988, PLANTA, V173, P12, DOI 10.1007/BF00394481; IKEUCHI M, 1985, FEBS LETT, V185, P316, DOI 10.1016/0014-5793(85)80930-3; KUEHLBRANDT W, 1984, NATURE, V307, P478; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON UK, 1985, BIOCHIM BIOPHYS ACTA, V809, P396, DOI 10.1016/0005-2728(85)90190-2; MACHOLD O, 1979, BIOCHIM BIOPHYS ACTA, V546, P472, DOI 10.1016/0005-2728(79)90082-3; MACHOLD O, 1984, ADV PHOTOSYNTHESIS R, V2, P107; MARKWELL JP, 1979, P NATL ACAD SCI USA, V76, P1233, DOI 10.1073/pnas.76.3.1233; MARKWELL JP, 1982, FEBS LETT, V142, P171, DOI 10.1016/0014-5793(82)80245-7; MELIS A, 1983, BIOCHIM BIOPHYS ACTA, V724, P473, DOI 10.1016/0005-2728(83)90108-1; MORISHIGE DT, 1990, FEBS LETT, V264, P239, DOI 10.1016/0014-5793(90)80257-J; MORISHIGE DT, 1990, CURRENT RES PHOTOSYN, V2, P261; MORRISSEY PJ, 1989, PLANT CELL PHYSIOL, V30, P335; NECHUSHTAI R, 1987, EUR J BIOCHEM, V164, P345, DOI 10.1111/j.1432-1033.1987.tb11064.x; OWENS GC, 1982, J CELL BIOL, V93, P712, DOI 10.1083/jcb.93.3.712; PETER GF, 1987, PROGR PHOTOSYNTHESIS, V2, P101; PETER GF, 1988, PLANT MEMBRANES STRU, P17; PETER GF, 1988, PHOTOSYNTHETIC LIGHT, P175; PICHERSKY E, 1989, PLANT MOL BIOL, V12, P257, DOI 10.1007/BF00043203; SCHWARTZ E, 1990, PLANT MOL BIOL, V15, P157, DOI 10.1007/BF00017734; THORNBER JP, 1987, PHYSIOL PLANTARUM, V71, P236, DOI 10.1111/j.1399-3054.1987.tb02874.x; THORNBER JP, 1974, EUR J BIOCHEM, V41, P109, DOI 10.1111/j.1432-1033.1974.tb03250.x; THORNBER JP, 1966, BIOCHEM J, V100, pP14; THORNBER JP, 1986, REGULATION CHLOROPLA, P249; THORNBER JP, 1986, ENCY PLANT PHYSL, V19, P98; TOKUHISA JG, 1985, PLANTA, V164, P321, DOI 10.1007/BF00402943; WHITE MJ, 1987, EUR J BIOCHEM, V165, P531, DOI 10.1111/j.1432-1033.1987.tb11471.x; Zieger R., 1965, BEITR BIOL PFLANZ, V41, P11; ZUBER H, 1985, PHOTOCHEM PHOTOBIOL, V42, P821, DOI 10.1111/j.1751-1097.1985.tb01655.x	55	451	458	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16745	16754						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885603				2022-12-25	WOS:A1991GD63500080
J	PRICE, DJ; MUKHOPADHYAY, NK; AVRUCH, J				PRICE, DJ; MUKHOPADHYAY, NK; AVRUCH, J			INSULIN-ACTIVATED PROTEIN-KINASES PHOSPHORYLATE A PSEUDOSUBSTRATE SYNTHETIC PEPTIDE INHIBITOR OF THE P70 S6 KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							RIBOSOMAL PROTEIN-S6; IDENTIFICATION; ENZYME; CYCLOHEXIMIDE; PURIFICATION; EPINEPHRINE; DOMAINS; CELLS	p70 S6 kinase, a major insulin-mitogen-activated ribosomal S6 protein kinase in mammalian cells, is activated by phosphorylation of multiple Ser/Thr residues on the enzyme polypeptide. A synthetic peptide, corresponding to a 37-residue segment from the carboxyl-terminal tail of the kinase which resembles the sequence phosphorylated in S6, acts as a competitive inhibitor of p70 S6 kinase without itself being phosphorylated by the enzyme. This synthetic peptide is phosphorylated by an array of protein kinases which are rapidly activated by insulin. Thus, these sequences of p70 S6 kinase constitute a potential autoinhibitory pseudosubstrate site, whose phosphorylation is catalyzed by candidate upstream-activating protein kinases.	MASSACHUSETTS GEN HOSP,DIABET UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,MED SERV,BOSTON,MA 02114; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017776, R01DK017776, R01DK041762] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41762, DK17776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AVRUCH J, 1976, J BIOL CHEM, V251, P1511; AVRUCH J, 1990, HDB EXPT PHARM, V92, P313; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BENJAMIN WB, 1975, BIOCHEMISTRY-US, V14, P3301, DOI 10.1021/bi00686a003; BLENIS J, 1987, J BIOL CHEM, V262, P14373; BROWNSEY RW, 1979, BIOCHEM J, V184, P23, DOI 10.1042/bj1840023; CHAN YL, 1988, J BIOL CHEM, V263, P2891; ENDEMANN G, 1990, J BIOL CHEM, V265, P396; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; GROVE JR, 1987, SCIENCE, V238, P530; JENO P, 1988, P NATL ACAD SCI USA, V85, P406, DOI 10.1073/pnas.85.2.406; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KEMP BE, 1987, J BIOL CHEM, V262, P2542; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KRIEG J, 1988, J BIOL CHEM, V263, P11473; KYRIAKIS JM, 1990, BIOCHIM BIOPHYS ACTA, V1054, P73, DOI 10.1016/0167-4889(90)90207-T; PRICE DJ, 1989, J BIOL CHEM, V264, P13825; PRICE DJ, 1990, P NATL ACAD SCI USA, V87, P7944, DOI 10.1073/pnas.87.20.7944; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SMITH CJ, 1979, P NATL ACAD SCI USA, V76, P2725, DOI 10.1073/pnas.76.6.2725; SMITH MK, 1990, J BIOL CHEM, V265, P1837; SODERLING TR, 1990, J BIOL CHEM, V265, P1823; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TABATABAI LB, 1978, J BIOL CHEM, V253, P2196	27	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16281	16284						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1909327				2022-12-25	WOS:A1991GD63500007
J	STURLEY, SL; CULBERTSON, MR; ATTIE, AD				STURLEY, SL; CULBERTSON, MR; ATTIE, AD			SECRETION AND LIPID ASSOCIATION OF HUMAN APOLIPOPROTEIN-E IN SACCHAROMYCES-CEREVISIAE REQUIRES A HOST MUTATION IN STEROL ESTERIFICATION AND UPTAKE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							OVARIAN GRANULOSA-CELLS; LOW-DENSITY LIPOPROTEIN; CHOLESTEROL TRANSPORT; ACID-PHOSPHATASE; YEAST-CELLS; PROTEIN; LIVER; MACROPHAGES; BIOSYNTHESIS; NERVE	We have expressed a cDNA to human apolipoprotein E (apoE) in Saccharomyces cerevisiae. Secretion of apoE was achieved only by the use of a mutant (upc2) strain of yeast with the phenotype of enhanced uptake and intracellular esterification of exogenous cholesterol. Approximately 40 ng/ml apoE was secreted by upc2 mutants in the absence of media cholesterol. ApoE secretion was increased 2-3-fold upon the inclusion of cholesterol in the growth media. This response to exogenous cholesterol was not mediated at the transcriptional level, since apoE mRNA levels were constant under all culture conditions. Concomitant with the increase in secretion following cholesterol uptake by upc2 strains, approximately 5% of secreted apoE was associated with lipid; polar and non-polar lipids were detected in this lipoprotein fraction. Intracellular degradation of apoE in non-secreting strains of yeast was minimized by the presence of null mutations in both vacuolar proteases with non-specific activity (pep4) and a Golgi endopeptidase with specificity for paired basic residues (kex2). The approach of expressing human apolipoproteins in yeast may identify factors that mediate lipoprotein biosynthesis in higher cells. One such factor could be the mammalian equivalent of the gene product of UPC2.	UNIV WISCONSIN,DEPT BIOCHEM,420 HENRY MALL,MADISON,WI 53706; UNIV WISCONSIN,DEPT COMPARAT BIOSCI,MADISON,WI 53706; UNIV WISCONSIN,DEPT GENET,MADISON,WI 53706; UNIV WISCONSIN,MOLEC BIOL LAB,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL037251] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040310] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL37251] Funding Source: Medline; NIGMS NIH HHS [GM40310] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BASU SK, 1981, P NATL ACAD SCI-BIOL, V78, P7545, DOI 10.1073/pnas.78.12.7545; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLUE ML, 1983, P NATL ACAD SCI-BIOL, V80, P283, DOI 10.1073/pnas.80.1.283; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOSTIAN KA, 1983, CELL, V32, P169, DOI 10.1016/0092-8674(83)90507-X; BOSTIAN KA, 1980, P NATL ACAD SCI-BIOL, V77, P4504, DOI 10.1073/pnas.77.8.4504; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARR TP, 1990, ARTERIOSCLEROSIS, V10, pA823; DRISCOLL DM, 1985, J BIOL CHEM, V260, P9031; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P203, DOI 10.1073/pnas.82.1.203; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1991, J BIOL CHEM, V266, P7963; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KAYDEN HJ, 1985, ARCH BIOCHEM BIOPHYS, V239, P388, DOI 10.1016/0003-9861(85)90704-0; KEESLER GA, 1991, BIOCHEM BIOPH RES CO, V174, P631, DOI 10.1016/0006-291X(91)91464-N; KHAN B, 1989, BIOCHEM J, V258, P807, DOI 10.1042/bj2580807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS TA, 1985, J BACTERIOL, V163, P199, DOI 10.1128/JB.163.1.199-207.1985; LEWIS TL, 1988, YEAST, V4, P93, DOI 10.1002/yea.320040203; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MAZZONE T, 1989, J LIPID RES, V30, P1055; NEVALAINEN LT, 1988, EUR J BIOCHEM, V178, P39, DOI 10.1111/j.1432-1033.1988.tb14426.x; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; RALL CJN, 1988, ARTERIOSCLEROSIS, V8, P804, DOI 10.1161/01.ATV.8.6.804; ROGERS DT, 1982, P NATL ACAD SCI USA, V79, P1929; SNIPES JG, 1986, P NATL ACAD SCI USA, V83, P1130; STURLEY SL, 1986, EMBO J, V5, P3381, DOI 10.1002/j.1460-2075.1986.tb04654.x; TAKAGI Y, 1988, J LIPID RES, V29, P859; THILL GP, 1983, MOL CELL BIOL, V3, P570, DOI 10.1128/MCB.3.4.570; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; WERNETTEHAMMOND ME, 1989, J BIOL CHEM, V264, P9094; WYNE KL, 1989, J BIOL CHEM, V264, P16530; WYNE KL, 1989, J BIOL CHEM, V264, P981; ZINSER E, 1991, J BACTERIOL, V173, P2026, DOI 10.1128/jb.173.6.2026-2034.1991	37	10	11	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16273	16276						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885560				2022-12-25	WOS:A1991GD63500005
J	DEAN, RA; CHRISTIAN, CD; SAMPLE, RHB; BOSRON, WF				DEAN, RA; CHRISTIAN, CD; SAMPLE, RHB; BOSRON, WF			HUMAN LIVER COCAINE ESTERASES - ETHANOL-MEDIATED FORMATION OF ETHYLCOCAINE	FASEB JOURNAL			English	Article						COCAINE; ESTERASE; ALCOHOL; HUMAN; LIVER	ECGONINE METHYL-ESTER; METABOLITES; HYDROLYSIS; ALCOHOL; INVITRO; SERUM	A new, pharmacologically active metabolite of cocaine, ethylcocaine, has been reported in individuals after concurrent use of cocaine and ethanol. Formation of ethylcocaine may contribute to the common coabuse of these two drugs and the apparent danger of this practice. We have identified a nonspecific carboxyl-esterase that catalyzes the ethyl transesterification of cocaine to ethylcocaine in the presence of ethanol. In the absence of ethanol, this human liver esterase catalyzes the hydrolysis of cocaine to benzoylecgonine, a metabolite that is inactive as a psychomotor stimulant. A second human liver esterase is also described. This enzyme catalyzes hydrolysis of cocaine to ecgonine methyl ester, also inactive as a stimulant. These two liver esterases may play important roles in regulating the metabolic inactivation of cocaine.	INDIANA UNIV,SCH MED,DEPT BIOCHEM & MICROBIOL,MED SCI BLDG 405,635 BARNHILL DR,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT PATHOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED,INDIANAPOLIS,IN 46202	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis					NIAAA NIH HHS [P50-AA07611] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA007611] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Adams E H, 1985, NIDA Res Monogr, V61, P1; AMBRE J, 1988, J ANAL TOXICOL, V12, P301, DOI 10.1093/jat/12.6.301; DEAN RA, 1991, 3RD INT S PHARM BIOM; ELSWORTH JD, 1990, NEUR ABSTR, V16; FOLTIN RW, 1989, PHARM BIOCH BEHAV, V31, P877; HEARN WL, 1991, J NEUROCHEM, V56, P698, DOI 10.1111/j.1471-4159.1991.tb08205.x; ISENSCHMID DS, 1989, J ANAL TOXICOL, V13, P250, DOI 10.1093/jat/13.5.250; ISNER JM, 1986, NEW ENGL J MED, V315, P1438, DOI 10.1056/NEJM198612043152302; Jain N C, 1977, J Forensic Sci, V22, P7; JATLOW P, 1979, ANESTH ANALG, V58, P235; JOHNSON CE, 1989, PHARMACOL REV, V41, P3; JONES RT, 1987, COCAINE CLIN HDB, P55; LEIGHTY EG, 1974, RES COMMUN CHEM PATH, V8, P65; LIN MF, 1989, PHARMACOLOGIST, V31, P159; MADDEN JA, 1990, LIFE SCI, V47, P1109, DOI 10.1016/0024-3205(90)90169-R; MASH DC, 1990, NEUR ABSTR, V16; MASUR J, 1989, ALCOHOL, V6, P181, DOI 10.1016/0741-8329(89)90015-3; MATSUBARA K, 1984, FORENSIC SCI INT, V26, P169, DOI 10.1016/0379-0738(84)90215-9; MISERA AL, 1975, J PHARM PHARMACOL, V27, P784; RAFLA FK, 1979, J ANAL TOXICOL, V3, P59, DOI 10.1093/jat/3.2.59; ROSE S, 1990, NEUR ABSTR, V16; SAMPLE RHB, 1991, 3RD INT S PHARM BIOM; SHARKEY J, 1988, J PHARMACOL EXP THER, V246, P1048; SMITH RM, 1984, J ANAL TOXICOL, V8, P38, DOI 10.1093/jat/8.1.38; SPEALMAN RD, 1989, J PHARMACOL EXP THER, V251, P142; STEWART DJ, 1977, LIFE SCI, V20, P1557, DOI 10.1016/0024-3205(77)90448-9; STEWART DJ, 1979, CLIN PHARMACOL THER, V25, P464; TAYLOR D, 1976, RES COMMUN CHEM PATH, V14, P249; WEISS RD, 1988, J NERV MENT DIS, V176, P719, DOI 10.1097/00005053-198812000-00004; 1988, INSTRUCTION MANUAL	30	207	222	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	SEP	1991	5	12					2735	2739		10.1096/fasebj.5.12.1916095	http://dx.doi.org/10.1096/fasebj.5.12.1916095			5	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	GE811	1916095				2022-12-25	WOS:A1991GE81100016
J	FURSTENBERGER, G; HAGEDORN, H; JACOBI, T; BESEMFELDER, E; STEPHAN, M; LEHMANN, WD; MARKS, F				FURSTENBERGER, G; HAGEDORN, H; JACOBI, T; BESEMFELDER, E; STEPHAN, M; LEHMANN, WD; MARKS, F			CHARACTERIZATION OF AN 8-LIPOXYGENASE ACTIVITY INDUCED BY THE PHORBOL ESTER TUMOR PROMOTER 12-O-TETRADECANOYLPHORBOL-13-ACETATE IN MOUSE SKIN INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; HYDROXY FATTY-ACIDS; 12L-HYDROXY-5,8,10,14-EICOSATETRAENOIC ACID; EPITHELIAL-CELLS; EPIDERMAL-CELLS; PSORIATIC SKIN; GUINEA-PIG; LIPOXYGENASE; GENERATION; INDUCTION	An enzymatic activity has been found in cytosolic preparations from mouse epidermis which catalyzes the formation of 8-hydroperoxyeicosatetraenoic acid/8-hydroxyeicosatetraenoic acid (8-HPETE/8-HETE) from arachidonate. In contrast to 12-lipoxygenase this enzyme activity was not detectable in normal (untreated) mouse skin but only after in vivo treatment with the phorbol ester tumor promoter TPA (12-O-tetradecanoylphorbol-13-acetate). The induction showed a maximum at 24 h after TPA treatment strictly depended on the age of the mice and the TPA dose and was prevented by cycloheximide. The primary product formed from arachidonic acid was 8-HPETE, and the enzyme seems not to possess a significant peroxidase activity. This result as well as studies with specific inhibitors and its cytosolic localization indicates this enzyme to be a member of the lipoxygenase family. Most of the 8-lipoxygenase activity is located in cells of the suprabasal compartment of the epidermis. In spite of being a cytosolic enzyme 8-lipoxygenase appeared to be lipophilic to some extent and was activated by lecithin. The enzyme did not require calcium ions or ATP and showed a pH optimum at 7.5-8.0. 8-HPETE/8-HETE levels in mouse epidermis in vivo were determined by gas chromatography-mass spectrometry and found to be strongly increased after phorbol ester treatment, in agreement with the induction of 8-lipoxygenase observed.	GERMAN CANC RES CTR,DEPT CENT SPECT,W-6900 HEIDELBERG,GERMANY	Helmholtz Association; German Cancer Research Center (DKFZ)	FURSTENBERGER, G (corresponding author), GERMAN CANC RES CTR,DEPT BIOCHEM,W-6900 HEIDELBERG,GERMANY.							BABA A, 1989, J BIOL CHEM, V264, P15790; BRASH AR, 1987, J BIOL CHEM, V262, P15829; BUNDY GL, 1986, J BIOL CHEM, V261, P747; BURRALL BA, 1988, J INVEST DERMATOL, V91, P294, DOI 10.1111/1523-1747.ep12475450; CAMERON GS, 1990, J INVEST DERMATOL, V94, P292, DOI 10.1111/1523-1747.ep12874434; CAMP RDR, 1983, PROSTAGLANDINS, V26, P431, DOI 10.1016/0090-6980(83)90178-8; CAPDEVILA J, 1986, BIOCHEM BIOPH RES CO, V141, P1007, DOI 10.1016/S0006-291X(86)80144-9; CHAN CC, 1985, J INVEST DERMATOL, V85, P333, DOI 10.1111/1523-1747.ep12276933; CUNNINGHAM F, 1990, J LIPID MEDIATOR, V2, P61; ELATTAR TMA, 1985, CANCER LETT, V27, P255, DOI 10.1016/0304-3835(85)90182-X; FISCHER SM, 1988, CANCER RES, V48, P658; FITZPATRICK FA, 1989, PHARMACOL REV, V40, P229; FLOWER RJ, 1974, PHARMACOL RES COMMUN, V26, P33; FORDHUTCHINSON AW, 1990, ADV PROSTAG THROMB L, V20, P161; FUNK CD, 1990, JP NATL ACAD SCI US, V487, P5638; Fursin G. I., 1990, Engineering Information in Data Bases and Knowledge Based Systems. Techno-Data '90. Proceedings of the International Conference Techno-Data '90, P107; FURSTENBERGER G, 1986, CARCINOGENESIS, V7, P1745, DOI 10.1093/carcin/7.10.1745; FURSTENBERGER G, 1985, CARCINOGENESIS, V6, P289, DOI 10.1093/carcin/6.2.289; FURSTENBERGER G, 1980, BIOCHEM BIOPH RES CO, V92, P749, DOI 10.1016/0006-291X(80)90767-6; FURSTENBERGER G, 1989, CARCINOGENESIS, V10, P749, DOI 10.1093/carcin/10.4.749; FURSTENBERGER G, 1987, PROSTAGLANDINS CANCE, P48; GOETZL EJ, 1979, J EXP MED, V150, P406, DOI 10.1084/jem.150.2.406; GSCHWENDT M, 1986, CARCINOGENESIS, V7, P449, DOI 10.1093/carcin/7.3.449; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HAMBERG M, 1976, BIOCHIM BIOPHYS ACTA, V431, P651, DOI 10.1016/0005-2760(76)90232-0; HAMMARSTROM S, 1979, J INVEST DERMATOL, V73, P180, DOI 10.1111/1523-1747.ep12581645; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HENKE D, 1986, BIOCHIM BIOPHYS ACTA, V876, P271, DOI 10.1016/0005-2760(86)90284-5; HOGABOOM GK, 1986, MOL PHARMACOL, V30, P510; HOLTZMAN MJ, 1989, J CLIN INVEST, V84, P1446, DOI 10.1172/JCI114319; HUGHES MA, 1991, BIOCHIM BIOPHYS ACTA, V1081, P347, DOI 10.1016/0005-2760(91)90292-P; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; JIM K, 1982, J BIOL CHEM, V257, P294; KATO R, 1983, CARCINOGENESIS, V4, P1301, DOI 10.1093/carcin/4.10.1301; KRAGBALLE K, 1990, EICOSANOIDS SKIN, P67; KUHN H, 1990, J BIOL CHEM, V265, P18351; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKS F, 1990, CARCINOGENESIS, V11, P2085, DOI 10.1093/carcin/11.12.2085; MEIJER L, 1986, J BIOL CHEM, V261, P7040; NAKADATE T, 1985, PROSTAGLANDINS, V30, P357, DOI 10.1016/0090-6980(85)90112-1; NAKADATE T, 1990, EICOSANOIDS SKIN, P203; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NUGTEREN DH, 1987, BIOCHIM BIOPHYS ACTA, V921, P135, DOI 10.1016/0005-2760(87)90179-2; OGLETREE ML, 1982, METHOD ENZYMOL, V86, P607; PACEASCIAK CR, 1989, FREE RADICAL BIO MED, V7, P409, DOI 10.1016/0891-5849(89)90125-1; PAPATHEOFANIS FJ, 1985, BIOCH ARACHIDONIC AC, P9; POWELL WS, 1982, METHOD ENZYMOL, V86, P467; RABINOVITCH H, 1981, AGENTS ACTIONS, V11, P580, DOI 10.1007/BF01978750; ROSENBACH T, 1985, BRIT J DERMATOL, V113, P157, DOI 10.1111/j.1365-2133.1985.tb15647.x; ROUZER CA, 1988, J BIOL CHEM, V263, P10980; RUZICKA T, 1983, BIOCHIM BIOPHYS ACTA, V751, P369, DOI 10.1016/0005-2760(83)90295-3; Ruzicka T, 1990, EICOSANOIDS SKIN; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; WESTCOTT JY, 1985, BIOMED ENVIRON MASS, V12, P714, DOI 10.1002/bms.1200121208; WOOLLARD PM, 1986, BIOCHEM BIOPH RES CO, V136, P169, DOI 10.1016/0006-291X(86)90891-0; WOOLLARD PM, 1987, BRIT J DERMATOL, V116, pA437; ZIBOH VA, 1984, J INVEST DERMATOL, V83, P248, DOI 10.1111/1523-1747.ep12340250	57	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15738	15745						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874732				2022-12-25	WOS:A1991GB97700036
J	RUF, W; KALNIK, MW; LUNDHANSEN, T; EDGINGTON, TS				RUF, W; KALNIK, MW; LUNDHANSEN, T; EDGINGTON, TS			CHARACTERIZATION OF FACTOR-VII ASSOCIATION WITH TISSUE FACTOR IN SOLUTION - HIGH AND LOW AFFINITY CALCIUM-BINDING SITES IN FACTOR-VII CONTRIBUTE TO FUNCTIONALLY DISTINCT INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE BETA-TRYPSIN; HUMAN FACTOR-IX; CELL-SURFACE; FACTOR-X; PHOSPHOLIPID-VESICLES; CATALYZED ACTIVATION; BLOOD-COAGULATION; LIGAND-BINDING; RESOLUTION; MONOCYTES	Protein-phospholipid as well as protein-protein interactions may be critical for tight binding of the serine protease factor VIIa (VIIa) to its receptor cofactor tissue factor (TF). To elucidate the role of protein-protein interactions, we analyzed the interaction of VII/VIIa with TF in the absence of phospholipid. Binding of VII occurred with similar affinity to solubilized and phospholipid-reconstituted TF. Lack of the gamma-carboxyglutamic acid (Gla)-domain (des-(1-38)-VIIa) resulted in a 10- to 30-fold increase of the K(d) for the interaction, as did blocking the Gla-domain by Fab fragments of a specific monoclonal antibody. These results suggest that the VII Gla-domain can participate in protein-protein interaction with the TF molecule per se rather than only in interactions with the charged phospholipid surface. Gla-domain-independent, low affinity binding of VII to TF required micromolar Ca2+, indicating involvement of high affinity calcium ion binding sites suggested to be localized in VII rather than TF. Interference with Gla-domain-dependent interactions with TF did not alter the TF.VIIa-dependent cleavage of a small peptidyl substrate, whereas the proteolytic activation of the protein substrate factor X was markedly decreased, suggesting that the VIIa Gla-domain not only participates in the formation of a more stable TF.VIIa complex but contributes to extended substrate recognition.	Scripps Res Inst, RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; NOVO NORDISK AB, BIOPHARMACEUT DIV, DK-2820 GENTOFTE, DENMARK	Scripps Research Institute; Novo Nordisk	RUF, W (corresponding author), Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA.				NATIONAL CANCER INSTITUTE [P01CA041085] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL016411] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA-41085] Funding Source: Medline; NHLBI NIH HHS [P01 HL-16411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BODE W, 1975, J MOL BIOL, V98, P693, DOI 10.1016/S0022-2836(75)80005-2; BODE W, 1975, FEBS LETT, V56, P139, DOI 10.1016/0014-5793(75)80128-1; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; BOM VJJ, 1990, BIOCHEM J, V265, P327, DOI 10.1042/bj2650327; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; CARSON SD, 1980, SCIENCE, V208, P307, DOI 10.1126/science.7367861; COULTER A, 1983, J IMMUNOL METHODS, V59, P199, DOI 10.1016/0022-1759(83)90031-5; DERIAN CK, 1989, J BIOL CHEM, V264, P6615; DRAKE TA, 1989, J CELL BIOL, V109, P389, DOI 10.1083/jcb.109.1.389; FAIR DS, 1987, J BIOL CHEM, V262, P11692; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GODING JW, 1978, J IMMUNOL METHODS, V20, P241, DOI 10.1016/0022-1759(78)90259-4; GUHA A, 1986, P NATL ACAD SCI USA, V83, P299, DOI 10.1073/pnas.83.2.299; HANDFORD PA, 1990, EMBO J, V9, P475, DOI 10.1002/j.1460-2075.1990.tb08133.x; KUMAR A, 1991, J BIOL CHEM, V266, P915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYNARD JR, 1975, J CLIN INVEST, V55, P814, DOI 10.1172/JCI107992; MORRISSEY JH, 1988, THROMB RES, V50, P481, DOI 10.1016/0049-3848(88)90197-1; MORRISSEY JH, 1988, THROMB RES, V52, P247, DOI 10.1016/0049-3848(88)90084-9; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NELSESTUEN GL, 1978, BIOCHEMISTRY-US, V17, P2134, DOI 10.1021/bi00604a017; PLOPLIS VA, 1987, J BIOL CHEM, V262, P9503; RANCE M, 1983, J MAGN RESON, V52, P221, DOI 10.1016/0022-2364(83)90190-7; RAO LVM, 1988, P NATL ACAD SCI USA, V85, P6687, DOI 10.1073/pnas.85.18.6687; RAO LVM, 1990, BLOOD, V75, P1069; RAO VM, 1990, CIRCULATION, V82, P132; RUF W, 1991, J BIOL CHEM, V266, P2158; RYAN J, 1989, J BIOL CHEM, V264, P20283; SAKAI T, 1990, J BIOL CHEM, V265, P1890; SEAMON KB, 1980, BIOCHEMISTRY-US, V19, P207, DOI 10.1021/bi00542a031; SKELTON NJ, 1990, BIOCHEMISTRY-US, V29, P5752, DOI 10.1021/bi00476a016; THIM L, 1988, BIOCHEMISTRY-US, V27, P7785, DOI 10.1021/bi00420a030; VANDIEIJEN G, 1981, BIOCHEMISTRY-US, V20, P7096, DOI 10.1021/bi00528a007; WILDGOOSE P, 1990, P NATL ACAD SCI USA, V87, P7290, DOI 10.1073/pnas.87.18.7290	36	131	141	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15719	15725						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874730				2022-12-25	WOS:A1991GB97700034
J	TAKAO, M; YASUI, A; OIKAWA, A				TAKAO, M; YASUI, A; OIKAWA, A			UNIQUE CHARACTERISTICS OF SUPEROXIDE-DISMUTASE OF A STRICTLY ANAEROBIC ARCHAEBACTERIUM METHANOBACTERIUM-THERMOAUTOTROPHICUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HALOBACTERIUM-HALOBIUM; NUCLEOTIDE-SEQUENCE; IRON; MANGANESE; GENE; CUTIRUBRUM; PROTEIN	The superoxide dismutase (SOD) gene of Methanobacterium thermoautotrophicum (Takao, M., Oikawa, A., and Yasui, A. (1990) Arch. Biochem. Biophys. 283, 210-216), a strictly anaerobic archaebacterium, was expressed in Escherichia coli. The gene product accounted for more than 30% of the host's soluble protein. The purified protein was an active iron-containing tetrameric SOD with specific activity similar to known manganese-containing SODs (MnSODs) of aerobic archaebacteria. Although M. thermoautotrophicum SOD is an iron-containing SOD (FeSOD), it resembles MnSODs in amino acid sequence as judged by criteria distinguishing FeSODs from MnSODs. Moreover, M. thermoautotrophicum SOD is resistant to azide and hydrogen peroxide as MnSODs are, suggesting that its evolution is distinct from known eubacterial FeSODs.	TOHOKU UNIV, TB & CANC RES INST, 4-1 SEIRYOMACHI, AOBA KU, SENDAI, MIYAGI 980, JAPAN; KITASATO UNIV, SCH HYG SCI, DEPT BIOSCI, SAGAMIHARA, KANAGAWA 228, JAPAN	Tohoku University; Kitasato University								ASADA K, 1975, J BIOL CHEM, V250, P2801; Asada K, 1980, CHEM BIOCH ASPECTS S, P136; BEAUCHAM.C, 1971, ANAL BIOCHEM, V44, P276, DOI 10.1016/0003-2697(71)90370-8; BEYER WF, 1987, BIOCHEMISTRY-US, V26, P1251, DOI 10.1021/bi00379a008; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIOZ A, 1988, J BIOL CHEM, V263, P1555; CLARE DA, 1984, J BIOL CHEM, V259, P5932; HASSAN HM, 1988, FREE RADICAL BIO MED, V5, P377, DOI 10.1016/0891-5849(88)90111-6; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; KIRBY TW, 1981, ARCH BIOCHEM BIOPHYS, V210, P140, DOI 10.1016/0003-9861(81)90174-0; KONDO S, 1987, CHIRYOGAKU, V19, P659; MARTIN ME, 1986, J BIOL CHEM, V261, P9361; MAY BP, 1987, J BACTERIOL, V169, P1417, DOI 10.1128/jb.169.4.1417-1422.1987; MAY BP, 1989, J BIOL CHEM, V264, P12253; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; MISRA HP, 1978, ARCH BIOCHEM BIOPHYS, V189, P317, DOI 10.1016/0003-9861(78)90218-7; PARKER MW, 1988, FEBS LETT, V229, P377, DOI 10.1016/0014-5793(88)81160-8; PENNINGTON CD, 1986, J BACTERIOL, V166, P528, DOI 10.1128/jb.166.2.528-532.1986; ROTILIO G, 1972, BIOCHIM BIOPHYS ACTA, V268, P605, DOI 10.1016/0005-2744(72)90359-2; SALIN ML, 1988, ARCH BIOCHEM BIOPHYS, V260, P806, DOI 10.1016/0003-9861(88)90511-5; SALIN ML, 1988, GENE, V70, P153, DOI 10.1016/0378-1119(88)90113-8; SEARCY KB, 1981, BIOCHIM BIOPHYS ACTA, V670, P39, DOI 10.1016/0005-2795(81)90046-5; Steinman H., 1982, SUPEROXIDE DISMUTASE, P11; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAKAO M, 1990, ARCH BIOCHEM BIOPHYS, V283, P210, DOI 10.1016/0003-9861(90)90633-A; TAKAO M, 1989, J BACTERIOL, V171, P6323, DOI 10.1128/jb.171.11.6323-6329.1989; TOUATI D, 1988, FREE RADICAL BIO MED, V5, P393, DOI 10.1016/0891-5849(88)90113-X; TYLER DD, 1975, BIOCHEM J, V147, P493, DOI 10.1042/bj1470493	28	59	61	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14151	14154						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907270				2022-12-25	WOS:A1991FZ35100004
J	BISCHOFF, DS; ORDAL, GW				BISCHOFF, DS; ORDAL, GW			SEQUENCE AND CHARACTERIZATION OF BACILLUS-SUBTILIS CHEB, A HOMOLOG OF ESCHERICHIA-COLI CHEY, AND ITS ROLE IN A DIFFERENT MECHANISM OF CHEMOTAXIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSORY TRANSDUCTION; BACTERIAL CHEMOTAXIS; PROTEIN-PHOSPHORYLATION; SALMONELLA-TYPHIMURIUM; METHYLATION; GENES; COMPLEMENTATION; EXPRESSION; MUTANTS; SYSTEM	The Bacillus subtilis gene encoding CheB, which is homologous to Escherichia coli CheY, the regulator of flagellar rotation, has been cloned and sequenced. It has been verified, using a phage T7 expression system, by showing that a small protein, the same size as E. coli CheY, is actually made from this DNA. Despite the fact that the two proteins are 36% identical, with many highly conserved residues, they appear to play different roles. Unlike CheY null mutants, which swim smoothly, CheB null mutants tumble incessantly. However, a CheB point mutant swims smoothly, even in the presence of a plasmid bearing cheB, which restores the null mutants to wild type. Expression of CheB in wild type B. subtilis makes the cells exhibit more tumbling. Since both absence of CheB and presence of high levels of CheB cause tumbling, CheB appears to be required, in certain circumstances, for both smooth swimming and tumbling. Expression in wild type E. coli makes the cells smooth swimmers and strongly inhibits chemotaxis.	UNIV ILLINOIS,COLL MED,CHAMPAIGN,IL 61820; UNIV ILLINOIS,COLL LIBERAL ARTS & SCI,CHAMPAIGN,IL 61820	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	BISCHOFF, DS (corresponding author), UNIV ILLINOIS,DEPT BIOCHEM,CHAMPAIGN,IL 61820, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020336] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20336] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BEDALE WA, 1988, J BACTERIOL, V170, P223, DOI 10.1128/jb.170.1.223-227.1988; BOURRET RB, 1989, J BIOL CHEM, V264, P7085; CHELSKY D, 1980, BIOCHEMISTRY-US, V19, P4633, DOI 10.1021/bi00561a015; CORARRUBLAS L, 1982, GENE, V17, P79; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; Hanahan D., 1985, DNA CLONING, V1; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; KIHARA M, 1989, J BACTERIOL, V171, P3247, DOI 10.1128/jb.171.6.3247-3257.1989; KOMEDA Y, 1980, GENETICS, V94, P277; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONHARDT H, 1988, J GEN MICROBIOL, V134, P605; LIU JD, 1989, P NATL ACAD SCI USA, V86, P8703, DOI 10.1073/pnas.86.22.8703; Mamur J, 1961, J MOL BIOL, V3, P208; MCCLEARY WR, 1990, J BACTERIOL, V172, P4877, DOI 10.1128/jb.172.9.4877-4887.1990; MUTOH N, 1986, J BACTERIOL, V165, P161, DOI 10.1128/jb.165.1.161-166.1986; ORDAL GW, 1983, J BACTERIOL, V154, P1088, DOI 10.1128/JB.154.3.1088-1097.1983; ORDAL GW, 1975, SCIENCE, V189, P802, DOI 10.1126/science.808854; ORDAL GW, 1985, J BACTERIOL, V164, P802, DOI 10.1128/JB.164.2.802-810.1985; PARKINSON JS, 1978, J BACTERIOL, V135, P45, DOI 10.1128/JB.135.1.45-53.1978; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON MI, 1989, BIOCHIMIE, V79, P1010; SPRINGER MS, 1977, P NATL ACAD SCI USA, V74, P3312, DOI 10.1073/pnas.74.8.3312; STOCK A, 1985, P NATL ACAD SCI USA, V82, P7989, DOI 10.1073/pnas.82.23.7989; STOCK AM, 1989, NATURE, V337, P745, DOI 10.1038/337745a0; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THOELKE MS, 1990, J BIOL CHEM, V265, P1928; THOELKE MS, 1988, BIOCHEMISTRY-US, V27, P8453, DOI 10.1021/bi00422a024; THOELKE MS, 1987, J BIOL CHEM, V262, P2811; THOELKE MS, 1989, BIOCHEMISTRY-US, V28, P5585, DOI 10.1021/bi00439a037; TINOCO I, 1973, NATURE-NEW BIOL, V246, P40, DOI 10.1038/newbio246040a0; ULLAH AHJ, 1981, J BACTERIOL, V145, P958, DOI 10.1128/JB.145.2.958-965.1981; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WOLFE AJ, 1987, J BACTERIOL, V169, P1878, DOI 10.1128/jb.169.5.1878-1885.1987; YANSURA DG, 1983, BIOL BIOTECHNOLOGY B, V1; ZUBERI AR, 1991, J BACTERIOL, V173, P710, DOI 10.1128/jb.173.2.710-719.1991; ZUBERI AR, 1990, J BACTERIOL, V172, P1870, DOI 10.1128/jb.172.4.1870-1876.1990	38	60	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12301	12305						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905718				2022-12-25	WOS:A1991FV18000033
J	KATAYAMA, M; KAWATA, M; YOSHIDA, Y; HORIUCHI, H; YAMAMOTO, T; MATSUURA, Y; TAKAI, Y				KATAYAMA, M; KAWATA, M; YOSHIDA, Y; HORIUCHI, H; YAMAMOTO, T; MATSUURA, Y; TAKAI, Y			THE POSTTRANSLATIONALLY MODIFIED C-TERMINAL STRUCTURE OF BOVINE AORTIC SMOOTH-MUSCLE RHOA P21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; BOTULINUM ADP-RIBOSYLTRANSFERASE; GAMMA SUBUNITS CONTAIN; GENE-PRODUCT; SACCHAROMYCES-CEREVISIAE; BRAIN MEMBRANES; RAS PROTEINS; CLOSTRIDIUM-BOTULINUM; CARBOXYL-METHYLATION; TREMELLA-MESENTERICA	rhoA p21, a ras p21-like small GTP-binding protein, has the same C-terminal consensus motif of Cys-A-A-X (A is an aliphatic amino acid and X is any amino acid) as ras p21s, which is posttranslationally processed. We here determine the posttranslationally processed C-terminal structure of the rhoA p21 purified from bovine aortic smooth muscle. Incubation of rhoA p21-expressing insect cells with exogenous [H-3]mevalonolactone caused the labeling of rhoA p21, suggesting that rhoA p21 is prenylated. Consistently, Raney nickel treatment of rhoA p21 released a geranylgeranyl moiety as estimated by gas chromatography/mass spectrometry. No lipid moiety was released by KOH or NH2OH treatment. Extensive digestion of rhoA p21 with Achromobacter protease I yielded a C-terminal peptide, Ser-Gly-Cys190, that lacked the three C-terminal amino acids predicted from the cDNA but was geranylgeranylated and carboxyl methylated at the cysteine residue. Bovine brain cytosol geranylgeranylated the bacterial rhoA p21 having the three C-terminal amino acids predicted from the cDNA but not the protein lacking the three C-terminal amino acids. Bovine brain membranes methylated the synthetic C-terminal peptide with 10 amino acids of rhoA p21 which was geranylgeranylated at its C-terminal cysteine residue but not the peptide which was not geranylgeranylated. These results suggest that rhoA p21 is first geranylgeranylated followed by removal of the three C-terminal amino acids and the subsequent carboxyl methylation of the exposed cysteine residue.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN; NATL INST HLTH,DEPT BACTERIOL & IMMUNOL,TOKYO 141,JAPAN	Kobe University; National Institute of Health Sciences - Japan								ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FINEGOLD AA, 1990, SCIENCE, V249, P165, DOI 10.1126/science.1695391; FUJINO M, 1980, NATURWISSENSCHAFTEN, V67, P406, DOI 10.1007/BF00405487; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HORI Y, 1991, IN PRESS ONCOGENE; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; HRYCYNA CA, 1990, MOL CELL BIOL, V10, P5071, DOI 10.1128/MCB.10.10.5071; ISHIBASHI Y, 1984, BIOCHEMISTRY-US, V23, P1399, DOI 10.1021/bi00302a010; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; ISOMURA M, 1991, ONCOGENE, V6, P119; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P363, DOI 10.1080/00021369.1979.10863433; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KIM S, 1989, MOL BRAIN RES, V6, P167, DOI 10.1016/0169-328X(89)90051-X; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LOWE PN, 1990, ONCOGENE, V5, P1045; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MATSUURA Y, 1987, J GEN VIROL, V68, P1233, DOI 10.1099/0022-1317-68-5-1233; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHGA N, 1989, BIOCHEM BIOPH RES CO, V163, P1523, DOI 10.1016/0006-291X(89)91153-4; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAKAGAMI Y, 1981, SCIENCE, V212, P1525, DOI 10.1126/science.212.4502.1525; Sambrook J, 1989, MOL CLONING LABORATO; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SUMMERS MD, 1988, TEX AGR EXP STN B, V1555; TACHIBANA S, 1988, PEPTIDE CHEM, P481; TAKAI Y, 1991, IN PRESS FASEB J; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YAMANE HK, 1989, J BIOL CHEM, V264, P20100; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	64	64	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12639	12645						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905729				2022-12-25	WOS:A1991FV18000084
J	BANNISTER, AJ; COOK, A; KOUZARIDES, T				BANNISTER, AJ; COOK, A; KOUZARIDES, T			INVITRO DNA-BINDING ACTIVITY OF FOS/JUN AND BZLF1 BUT NOT C/EBP IS AFFECTED BY REDOX CHANGES	ONCOGENE			English	Article								The leucine zipper family of proteins have a DNA binding domain composed of a leucine zipper dimerisation interface and a basic DNA binding structure. We show here that redox changes affect the in vitro DNA binding ability of a select subset of leucine zipper proteins. The bacterially expressed DNA binding domains of Fos/Jun and BZLF1 are unable to bind DNA under non-reducing conditions whereas binding of the C/EBP DNA binding domain is unaffected. Sensitivity to redox state is due to the presence of a conserved cysteine residue in the basic DNA binding motif of Fos, Jun and BZLF1 but not C/EBP. Under non-reducing conditions an intermolecular disulphide bridge is formed between the cysteine residues of each basic motif within a dimer, which prevents DNA binding. We show that oxidation of these C residues can be achieved enzymatically, using glutathione peroxidase, and that DNA binding protects them from oxidation. These data raise the possibility that intracellular changes in the redox state may differentially regulate the activity of leucine zipper family members. In addition the loss of DNA binding activity under non-reducing conditions has implications for the purification methods used to isolate proteins of the leucine zipper family for structural analysis.	UNIV CAMBRIDGE, ADDENBROOKES HOSP, DEPT PATHOL, DIV VIROL, CAMBRIDGE CB2 2QQ, ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	KOUZARIDES, T (corresponding author), UNIV CAMBRIDGE, WELLCOME INST, CTR CANC RES, TENNIS COURT RD, CAMBRIDGE CB2 1QR, ENGLAND.			Bannister, Andrew/0000-0002-6312-4436; Kouzarides, Tony/0000-0002-8918-4162	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ABATE C, 1990, MOL CELL BIOL, V10, P5532, DOI 10.1128/MCB.10.10.5532; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ANGEL P, 1989, New Biologist, V1, P35; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V57, P209; BUSCH SJ, 1990, ONCOGENE, V5, P1549; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHRISTY RJ, 1989, GENE DEV, V3, P1323, DOI 10.1101/gad.3.9.1323; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FRIEDMAN AD, 1989, GENE DEV, V3, P1314, DOI 10.1101/gad.3.9.1314; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HERRERA R, 1989, MOL CELL BIOL, V9, P5331, DOI 10.1128/MCB.9.12.5331; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KOUZARIDES T, 1989, CANCER CELL-MON REV, V1, P71; KOUZARIDES T, 1991, ONCOGENE, V6, P195; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MATSUI M, 1990, ONCOGENE, V5, P249; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PATEL L, 1990, NATURE, V347, P572, DOI 10.1038/347572a0; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WALTERS DW, 1986, J BIOL CHEM, V261, P5372; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; ZIEGLER DM, 1985, ANNU REV BIOCHEM, V54, P305, DOI 10.1146/annurev.bi.54.070185.001513	47	160	163	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	1991	6	7					1243	1250						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GV260	1907361				2022-12-25	WOS:A1991GV26000021
J	AMANO, J; STRAEHL, P; BERGER, EG; KOCHIBE, N; KOBATA, A				AMANO, J; STRAEHL, P; BERGER, EG; KOCHIBE, N; KOBATA, A			STRUCTURES OF MUCIN-TYPE SUGAR CHAINS OF THE GALACTOSYLTRANSFERASE PURIFIED FROM HUMAN-MILK - OCCURRENCE OF THE ABO AND LEWIS BLOOD-GROUP DETERMINANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDO-BETA-GALACTOSIDASE; COMPLEX-TYPE; OLIGOSACCHARIDES; LECTIN; PURIFICATION; POLYLACTOSAMINOGLYCANS; IDENTIFICATION; GLYCOPROTEINS; HETEROGENEITY; ANTIGENS	The mucin-type sugar chains of human milk galactosyltransferase samples purified from two donors with different blood types were released by alkaline borohydride treatment and quantitatively labeled by N-[H-3]acetylation. The radioactive oligosaccharides thus obtained were fractionated by high performance liquid chromatography and immobilized lectin chromatography, and their structures were studied by sequential digestion with endo- or exoglycosidases, methylation analysis, and periodate oxidation. It was revealed that the structures of the mucin-type sugar chains of galactosyltransferase are extremely various, and many blood group determinants are expressed on more than 13 different backbone sugar chains. The characteristic features of the sugar chains could be summarized as follows. 1) The sugar chains of both samples are composed of core 1, Gal-beta-1 --> 3GalNAc, and core 2, GlcNAc-beta-1 --> 6(Gal-beta-1 --> 3)GalNAc. 2) One or two N-acetyllactosamine repeating units extend from the core through GlcNAc-beta-1 --> 6Gal and GlcNAc-beta-1 --> 3Gal linkages. 3) Blood group determinants are expressed in accord with the blood types of the donors: sample 1 from a donor of blood type O, Le(a+b-) contains oligosaccharides with Le(a) and X determinants, and sample 2 from a donor of B, Le(a-b-) contains those with H, X, Y, and B determinants.	UNIV ZURICH, INST PHYSIOL, CH-8006 ZURICH, SWITZERLAND; GUNMA UNIV, FAC EDUC, DEPT BIOL, MAEBASHI, GUNMA 371, JAPAN	University of Zurich; Gunma University	AMANO, J (corresponding author), UNIV TOKYO, INST MED SCI, DEPT BIOCHEM, TOKYO 108, JAPAN.							AMANO J, 1988, J BIOL CHEM, V263, P1157; Amano J., 1985, Glycoconjugate Journal, V2, P121, DOI 10.1007/BF01050469; AMANO J, 1989, METHOD ENZYMOL, V179, P261; ENDO T, 1986, CARBOHYD RES, V150, P241, DOI 10.1016/0008-6215(86)80020-9; GERBER AC, 1979, EUR J BIOCHEM, V93, P453, DOI 10.1111/j.1432-1033.1979.tb12843.x; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; GREEN ED, 1987, J BIOL CHEM, V262, P12030; HANISCH FG, 1989, J BIOL CHEM, V264, P872; HINDSGAUL O, 1982, CARBOHYD RES, V109, P109, DOI 10.1016/0008-6215(82)84034-2; HOUNSELL EF, 1988, BIOCHEM J, V256, P397, DOI 10.1042/bj2560397; IMBER MJ, 1982, J BIOL CHEM, V257, P8205; KOCHIBE N, 1989, J BIOL CHEM, V264, P173; KOENDERMAN AHL, 1987, EUR J BIOCHEM, V166, P199, DOI 10.1111/j.1432-1033.1987.tb13502.x; Li Y.-T., 1972, METHOD ENZYMOL, V28, P702; MATSUNAGA A, 1987, CANCER RES, V47, P56; PAULSON JC, 1979, J BIOL CHEM, V254, P2120; PIERCECRETEL A, 1989, EUR J BIOCHEM, V182, P457, DOI 10.1111/j.1432-1033.1989.tb14853.x; RENKONEN O, 1989, GLYCOCONJUGATE J, V6, P129, DOI 10.1007/BF01047895; TAKASAKI S, 1986, GLYCOCONJUGATE J, V3, P321, DOI 10.1007/BF01049501; TAKASAKI S, 1976, J BIOL CHEM, V251, P3603; TANG PW, 1987, CARBOHYD RES, V161, P133, DOI 10.1016/0008-6215(87)84012-0; YAMASHITA K, 1985, J BIOL CHEM, V260, P4688; YAMASHITA K, 1989, J BIOL CHEM, V264, P17873; YAMASHITA K, 1982, METHOD ENZYMOL, V83, P105	24	37	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11461	11477						17	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904864				2022-12-25	WOS:A1991FT76200013
J	BRAXTON, S; WELLS, JA				BRAXTON, S; WELLS, JA			THE IMPORTANCE OF A DISTAL HYDROGEN-BONDING GROUP IN STABILIZING THE TRANSITION-STATE IN SUBTILISIN BPN'	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; BACILLUS-SUBTILIS; CATALYSIS; ENERGETICS; PROTEASE; PROTEINS; MUTATION; CLONING; NOVO	Stabilization of an oxyanion transition state is important to catalysis of peptide bond hydrolysis in all proteases. For subtilisin BPN', a bacterial serine protease, structural data suggest that two hydrogen bonds stabilize the tetrahedral-like oxyanion intermediate: one from the main chain NH of Ser221 and another from the side chain NH2 of Asn155. Molecular dynamic studies (Rao, S., N., Singh, U., C. Bush, P. A., and Kollman, P. A. (1987) Nature 328, 551-554) have indicated the gamma-hydroxyl of Thr220 may be a third hydrogen bond donor even though it is 4A away in the static x-ray structure. We have probed the role of Thr220 by replacing it with serine, cysteine, valine, or alanine by site-directed mutagenesis. These substitutions were intended to alter the size and hydrogen bonding ability of residue 220. Removal of the gamma-hydroxyl group reduced the transition state stabilization energy (DELTA-DELTA-G(T)) by 1.8-2.1 kcal/mol depending upon the substitution. By comparison, removal of the gamma-methyl group in the Thr220 to serine mutation only decreased DELTA-G(T) by 0.5 kcal/mol. The gamma-hydroxyl of Thr220 is most important for catalysis, not substrate binding, because virtually all of the effects were on k(cat) and not K(M). The role of the Thr220 hydroxyl is functionally independent from the amide NH2 of Asn155 because the free energy effects of double alanine mutants at these two positions are additive. These data indicate that a distal hydrogen bond donor, namely the hydroxyl of Thr220, plays a functionally important role in stabilizing the oxyanion transition state in subtilisin which is independent of Asn155.	GENENTECH INC,DEPT PROT ENGN,460 POINT SAN BRUNO BLVD,S SAN FRANCISCO,CA 94080; UNIV CALIF SAN FRANCISCO,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	Roche Holding; Genentech; University of California System; University of California San Francisco			Wells, Jim A/O-9854-2016					ADAMSON AW, 1979, TXB PHYSICAL CHEM, P286; BRYAN P, 1986, P NATL ACAD SCI USA, V83, P3743, DOI 10.1073/pnas.83.11.3743; CARTER P, 1987, SCIENCE, V237, P394, DOI 10.1126/science.3299704; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CARTER P, 1988, NATURE, V332, P564, DOI 10.1038/332564a0; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; Crampton MR., 1974, CHEM THIOL GROUP, P379; HWANG JK, 1988, NATURE, V334, P270, DOI 10.1038/334270a0; KRAUT J, 1988, SCIENCE, V242, P533, DOI 10.1126/science.3051385; MATSUBAR.H, 1965, J BIOL CHEM, V240, P1125; MATTHEWS DA, 1975, J BIOL CHEM, V250, P7120; MCPHALEN CA, 1988, BIOCHEMISTRY-US, V27, P6582, DOI 10.1021/bi00417a058; PAUL IC, 1974, CHEM SH GROUP, P111; RAO SN, 1987, NATURE, V328, P551, DOI 10.1038/328551a0; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P4293, DOI 10.1021/bi00773a016; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5464; WARSHEL A, 1987, NATURE, V330, P15, DOI 10.1038/330015a0; WARSHEL A, 1986, J AM CHEM SOC, V108, P6569, DOI 10.1021/ja00281a021; WARSHEL A, 1988, J MOL BIOL, V201, P139, DOI 10.1016/0022-2836(88)90445-7; WARSHEL A, 1978, P NATL ACAD SCI USA, V75, P5250, DOI 10.1073/pnas.75.11.5250; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WETZEL R, 1988, PROTEIN ENG, V2, P1, DOI 10.1093/protein/2.1.1; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; YANG MY, 1984, J BACTERIOL, V160, P15, DOI 10.1128/JB.160.1.15-21.1984	26	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11797	11800						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904870				2022-12-25	WOS:A1991FT76200059
J	TESCHKE, CM; KIM, J; SONG, T; PARK, S; PARK, C; RANDALL, LL				TESCHKE, CM; KIM, J; SONG, T; PARK, S; PARK, C; RANDALL, LL			MUTATIONS THAT AFFECT THE FOLDING OF RIBOSE-BINDING PROTEIN SELECTED AS SUPPRESSORS OF A DEFECT IN EXPORT IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIOPHAGE-T4 LYSOZYME; SEQUENCE; ACID; STABILITY; TRANSPORT; MUTANTS; LAMBDA; GENES; K-12	It has been proposed (Randall, L. L., and Hardy, S. J. S. (1986) Cell 46, 921-928) that export of protein involves a kinetic partitioning between the pathway that leads to productive export and the pathway that leads to the folding of polypeptides into a stable conformation that is incompatible with export. As predicted from this model, a decrease in the rate of export of maltose-binding protein to the periplasmic space in Escherichia coli resulting from a defect in the leader sequence was able to be partially overcome by a mutation that slowed the folding of the precursor, thereby increasing the time in which the polypeptide was competent for export. (Liu, G., Topping, T. B., Cover, W. H., and Randall, L. L. (1988) J. Biol. Chem. 263, 14790-14793). Here we describe mutations of the gene encoding ribose-binding protein that were selected as suppressors of a defect in export of that protein and that alter the folding pathway. We propose that selection of such suppressors may provide a general method to obtain mutations that affect the folding properties of any protein that can be expressed and exported in E. coli.	WASHINGTON STATE UNIV,DEPT BIOCHEM & BIOPHYS,PULLMAN,WA 99164; KOREA ADV INST SCI & TECHNOL,DEPT BIOL SCI & ENGN,SEOUL 131,SOUTH KOREA; KOREA ADV INST SCI & TECHNOL,CTR GENET ENGN,CELL BIOL LAB,SEOUL,SOUTH KOREA	Washington State University; Korea Advanced Institute of Science & Technology (KAIST); Korea Advanced Institute of Science & Technology (KAIST)			Park, Chankyu/C-1936-2011		NIGMS NIH HHS [GM29798] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM029798, R01GM029798] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADLER J, 1973, J GEN MICROBIOL, V74, P77, DOI 10.1099/00221287-74-1-77; ALBER T, 1987, BIOCHEMISTRY-US, V26, P3754, DOI 10.1021/bi00387a002; BEASTY AM, 1986, BIOCHEMISTRY-US, V25, P2965, DOI 10.1021/bi00358a035; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; COVER WH, 1987, J BACTERIOL, V169, P1794, DOI 10.1128/jb.169.5.1794-1800.1987; CREIGHTON TE, 1987, PROTEIN ENG, P83; GOLDENBERG DP, 1989, NATURE, V338, P127, DOI 10.1038/338127a0; GROARKE JM, 1983, J BIOL CHEM, V258, P2952; HAWKES R, 1984, J MOL BIOL, V175, P195, DOI 10.1016/0022-2836(84)90474-1; IIDA A, 1985, EMBO J, V4, P1875, DOI 10.1002/j.1460-2075.1985.tb03863.x; IIDA A, 1984, J BACTERIOL, V158, P674, DOI 10.1128/JB.158.2.674-682.1984; King J., 1987, PROTEIN ENG, P109; Lakowicz J.R., 1983, PRINC FLUORESC SPECT, P341, DOI [10.1007/978-1-4615-7658-7_11, DOI 10.1007/978-1-4615-7658-7_11]; LIU G, 1988, J BIOL CHEM, V263, P14790; LOPILATO JE, 1984, J BACTERIOL, V158, P665, DOI 10.1128/JB.158.2.665-673.1984; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T, 1989, DECONTAMINATION DILU; Miller J.H., 1972, EXPT MOL GENETICS; ORDAL GW, 1974, J BACTERIOL, V117, P509, DOI 10.1128/JB.117.2.509-516.1974; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; PAKULA AA, 1990, NATURE, V344, P363, DOI 10.1038/344363a0; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PARK SH, 1988, SCIENCE, V239, P1033, DOI 10.1126/science.3278378; PERRY KM, 1987, BIOCHEMISTRY-US, V26, P2674, DOI 10.1021/bi00384a004; RANDALL LL, 1989, SCIENCE, V243, P1156, DOI 10.1126/science.2646712; RANDALL LL, 1986, CELL, V46, P921, DOI 10.1016/0092-8674(86)90074-7; SCHELLMAN JA, 1978, BIOPOLYMERS, V17, P1305, DOI 10.1002/bip.1978.360170515; SHIBA K, 1984, EMBO J, V3, P631, DOI 10.1002/j.1460-2075.1984.tb01859.x; SHORTLE D, 1986, Proteins Structure Function and Genetics, V1, P81, DOI 10.1002/prot.340010113; SPURLINO JC, 1988, THESIS IM RICE U HOU; STURTEVANT JM, 1989, J BIOL CHEM, V264, P10693; TESCHKE CM, 1990, THESIS WASHINGTON ST	32	42	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11789	11796						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904869				2022-12-25	WOS:A1991FT76200058
J	TAN, EW; PEREZSALA, D; CANADA, FJ; RANDO, RR				TAN, EW; PEREZSALA, D; CANADA, FJ; RANDO, RR			IDENTIFYING THE RECOGNITION UNIT FOR G-PROTEIN METHYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-SUBUNIT; POSTTRANSLATIONAL MODIFICATION; CARBOXYL METHYLTRANSFERASES; FARNESYL CYSTEINE; GTP-BINDING; IDENTIFICATION; TRANSDUCIN; P21RAS	Signal transducing G proteins, such as transducin, are prenylated and methylated at carboxyl-terminal cysteine residues. The methylation of transducin occurs by means of a membrane bound S-adenosyl methionine-dependent methyltransferase. This methyltransferase accepts the simple modified amino acid N-acetyl-S-farnesyl-L-cysteine (AFC) as a substrate. This means that the enzyme does not require peptide sequences of transducin in a putative substrate. Moreover, small structural changes in the AFC structural unit all lead to molecules incapable of being substrates. For example, neither N-acetyl-S-farnesylhomocysteine (AFHC) nor the saturated form of AFC are substrates. Interestingly, substitution of the N-acetyl moiety of AFC with a hydrogen atom leads to S-farnesylthiopropionic acid (FTP), which is an excellent substrate for the methyltransferase. The methyltransferase shows great specificity for the FTP pharmacophore. So far, alterations in this structure have not led to active substrates. For example, removal of a methylene group of FTP, producing S-farnesylthioacetic acid (FTA), abolished substrate activity. FTA is a potent competitive inhibitor of the enzyme. FTP is thus the ultimately simplified substrate for the methyltransferase and does not contain any remnants of the peptide structure of transducin.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard Medical School			Cañada, Francisco J./D-5837-2014; Perez-Sala, Dolores/L-5969-2014	Cañada, Francisco J./0000-0003-4462-1469; Perez-Sala, Dolores/0000-0003-0600-665X	NEI NIH HHS [EY-03624] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY003624] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AASETH J, 1975, ACTA PHARMACOL TOX, V36, P193; ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BACKLUND PS, 1990, J BIOL CHEM, V265, P15572; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; FUNG BKK, 1990, FEBS LETT, V260, P313, DOI 10.1016/0014-5793(90)80132-3; Furniss B.S., 1978, VOGELS TXB PRACTICAL; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P363, DOI 10.1080/00021369.1979.10863433; KORT EN, 1975, P NATL ACAD SCI USA, V72, P3939, DOI 10.1073/pnas.72.10.3939; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MART RS, 1990, J BIOL CHEM, V265, P20057; Means G.E., 1971, CHEM MODIFICATION PR; PEREZSALA D, 1991, P NATL ACAD SCI USA, V88, P3043, DOI 10.1073/pnas.88.8.3043; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SHAFER WR, 1989, SCIENCE, V245, P379; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1989, J BIOL CHEM, V264, P20100	24	114	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10719	10722						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1904056				2022-12-25	WOS:A1991FQ77400003
J	ONG, LJ; GLAZER, AN				ONG, LJ; GLAZER, AN			PHYCOERYTHRINS OF MARINE UNICELLULAR CYANOBACTERIA .1. BILIN TYPES AND LOCATIONS AND ENERGY-TRANSFER PATHWAYS IN SYNECHOCOCCUS-SPP PHYCOERYTHRINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; BLUE-GREEN-ALGAE; ATTACHMENT SITES; C-PHYCOCYANIN; MASTIGOCLADUS-LAMINOSUS; B-PHYCOERYTHRIN; FLOW-CYTOMETRY; ALPHA-SUBUNIT; BETA-SUBUNIT; EPIFLUORESCENCE MICROSCOPY	Marine Synechococcus strains WH8103, WH8020, and WH7803 each possess two different phycoerythrins, PE(II) and PE(I), in a weight ratio of 2-4:1. PE(II) and PE(I) differ in amino acid sequence and in bilin composition and content. Studies with strain WH7803 indicated that both PE(II) and PE(I) were present in the same phycobilisome rod substructures and that energy absorbed by PE(II) was transferred to PE(I). Strain WH8103 and WH8020 PE(I)s carried five bilin chromophores thioether-linked to cysteine residues in sequences homologous to those previously characterized in C-, B-, and R-PEs. In contrast, six bilins were attached to strain WH8103 and WH8020 PE(II)s. Five of these were at positions homologous to bilin attachment sites in other phycoerythrins. The additional bilin attachment site was on the alpha-subunit. The locations and bilin types in these PE(s) and in the marine Synechocystis strain WH8501 PE(I) (Swanson, R. V., Ong, L. J., Wilbanks, S. M., and Glazer, A. N. (1991) J. Biol. Chem. 266, 9528-9534) are: [GRAPHICS] Since phycourobilin (PUB) (lambda-max approximately 495 nm) transfers energy to phycoerythrobilin (PEB) (lambda-max approximately 550 nm), inspection of these data shows that the invariant PEB group at beta-82 is the terminal energy acceptor in phycoerythrins. The adaptations to blue-green light, high PUB content and the presence of an additional bilin on the alpha-subunit, increase the efficiency of light absorption by PE(II)s at approximately 500 nm.	UNIV CALIF BERKELEY, DIV BIOCHEM & MOLEC BIOL, 229 STANLEY HALL, DONNER ASU, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley					NIGMS NIH HHS [5 T 32 GM 07232, GM28994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028994, T32GM007232] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTE RS, 1984, PLANT PHYSIOL, V75, P732, DOI 10.1104/pp.75.3.732; ANDERSON LK, 1990, J BACTERIOL, V172, P1297, DOI 10.1128/jb.172.3.1297-1305.1990; [Anonymous], [No title captured]; BERKELMAN TR, 1986, ANAL BIOCHEM, V156, P194, DOI 10.1016/0003-2697(86)90173-9; BRYANT DA, 1979, ARCH MICROBIOL, V123, P113, DOI 10.1007/BF00446810; CHANG JY, 1978, FEBS LETT, V93, P205, DOI 10.1016/0014-5793(78)81105-3; CLAYTON RK, 1980, PHOTOSYNTHESIS PHYSI; DUBBS JM, 1987, PROG PHOTOSYNTH RES, V4, P765; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; GANTT E, 1972, J CELL BIOL, V54, P313, DOI 10.1083/jcb.54.2.313; Gantt E., 1980, INT REV CYTOL, V66, P45, DOI 10.1016/S0074-7696(08)61971-3; Glazer A. N., 1981, The biochemistry of plants. A comprehensive treatise. Volume 8. Photosynthesis., P51; Glazer A.N., 1987, CYANOBACTERIA, P69; GLAZER AN, 1984, BIOCHIM BIOPHYS ACTA, V768, P29, DOI 10.1016/0304-4173(84)90006-5; GLAZER AN, 1989, J BIOL CHEM, V264, P1; GLAZER AN, 1982, BIOCHEM SYST ECOL, V10, P203, DOI 10.1016/0305-1978(82)90031-X; GLAZER AN, 1983, ANNU REV BIOCHEM, V52, P125, DOI 10.1146/annurev.bi.52.070183.001013; GLAZER AN, 1973, J BIOL CHEM, V248, P663; GLAZER AN, 1979, P NATL ACAD SCI USA, V76, P6162, DOI 10.1073/pnas.76.12.6162; GLAZER AN, 1975, J BIOL CHEM, V250, P5487; GLAZER AN, 1979, ANAL BIOCHEM, V92, P489, DOI 10.1016/0003-2697(79)90689-4; GLAZER AN, 1988, METHOD ENZYMOL, V167, P304; Glover HE., 1985, ADV AQUATIC MICROB, V3, P49; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HONSELL E, 1984, BOT MAR, V27, P1, DOI 10.1515/botm.1984.27.1.1; JOHNSON PW, 1979, LIMNOL OCEANOGR, V24, P928, DOI 10.4319/lo.1979.24.5.0928; KANA TM, 1987, DEEP-SEA RES, V34, P497, DOI 10.1016/0198-0149(87)90002-1; KLOTZ AV, 1985, J BIOL CHEM, V260, P4856; Krieg NR, 1989, BERGEYS MANUAL SYSTE, V3, P1728; KURSAR TA, 1981, P NATL ACAD SCI USA, V78, P1; LARKUM AWD, 1983, ADV BOT RES, V10, P1, DOI 10.1016/S0065-2296(08)60260-8; LI WKW, 1988, DEEP-SEA RES, V35, P1615, DOI 10.1016/0198-0149(88)90106-9; LUNDELL DJ, 1984, J BIOL CHEM, V259, P5472; MacColl R., 1987, P1; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; MAZEL D, 1986, NUCLEIC ACIDS RES, V14, P8279, DOI 10.1093/nar/14.21.8279; MORSCHEL E, 1977, CYTOBIOLOGIE, V16, P118; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OLSON RJ, 1990, LIMNOL OCEANOGR, V35, P45, DOI 10.4319/lo.1990.35.1.0045; OLSON RJ, 1988, DEEP-SEA RES, V35, P425, DOI 10.1016/0198-0149(88)90019-2; ONG LJ, 1987, J BIOL CHEM, V262, P6323; ONG LJ, 1984, SCIENCE, V224, P80, DOI 10.1126/science.224.4644.80; ONG LJ, 1988, THESIS U CALIFORNIA; ONG LJ, 1988, LIGHT ENERGY TRANSDU, P102; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, BIOCHIM BIOPHYS ACTA, V893, P379, DOI 10.1016/0005-2728(87)90090-9; SIDLER W, 1986, BIOL CHEM H-S, V367, P627, DOI 10.1515/bchm3.1986.367.2.627; SIDLER W, 1989, BIOL CHEM H-S, V370, P115, DOI 10.1515/bchm3.1989.370.1.115; SIEBZEHNRUBL S, 1987, Z NATURFORSCH C, V42, P258; SIEGELMAN HW, 1965, ANAL BIOCHEM, V13, P402, DOI 10.1016/0003-2697(65)90332-5; SWANSON RV, 1991, J BIOL CHEM, V266, P9528; WATERBURY JB, 1988, METHOD ENZYMOL, V167, P100; WATERBURY JB, 1979, NATURE, V277, P293, DOI 10.1038/277293a0; Waterbury JB, 1986, CAN B FISH AQUAT SCI, V214, P71; WILBANKS SM, 1991, J BIOL CHEM, V266, P9535; WOOD AM, 1985, NATURE, V316, P253, DOI 10.1038/316253a0; WOOD AM, 1985, LIMNOL OCEANOGR, V30, P1303, DOI 10.4319/lo.1985.30.6.1303; YAMANAKA G, 1978, J BIOL CHEM, V253, P8303; YENTSCH CS, 1980, PHYSL ECOLOGY PHYTOP, P95; Zuber H., 1987, PHOTOSYNTHESIS, P233	62	116	125	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9515	9527						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903388				2022-12-25	WOS:A1991FM45900031
J	ZIELINSKI, NA; CHAKRABARTY, AM; BERRY, A				ZIELINSKI, NA; CHAKRABARTY, AM; BERRY, A			CHARACTERIZATION AND REGULATION OF THE PSEUDOMONAS-AERUGINOSA ALGC GENE ENCODING PHOSPHOMANNOMUTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; HOST-RANGE; KLEBSIELLA-PNEUMONIAE; CYSTIC-FIBROSIS; ALGINATE; EXPRESSION; CLONING; PLASMID; PROMOTER; BIOSYNTHESIS	The nucleotide sequence of the Pseudomonas aeruginosa algC gene encoding phosphomannomutase (PMM; EC 5.4.2.8) was determined. The codon usage in algC in the wobble base position was 90.4% G + C, typical of Pseudomonas genes. The predicted amino acid sequence of phosphomannomutase (PMM) showed homology over a stretch of 112 amino acids in the carboxyl terminus with rabbit muscle phosphoglucomutase (PGM), an enzyme that catalyzes a reaction analogous to that catalyzed by PMM. In addition, a specific amino acid sequence within PMM showed homology with the catalytic site of PGM. DNA sequence analysis of a defective algC gene (algC') cloned from a mutant of P. aeruginosa that lacked PMM activity revealed one point mutation (a C to T transition) in the carboxyl terminus of PMM which resulted in an amino acid change from arginine 420 to cysteine 420. The mutation identified in the algC' gene was not within the regions of homology with PGM. The algC promoter showed significant homology with the promoters of two other P. aeruginosa genes involved in alginate synthesis, algD and algR1. Both the algD and algR1 promoters are activated by the product of the algR1 gene in P. aeruginosa. The upstream region of the algC gene contained a sequence identical to the algD upstream sequence that is known to be the binding site for the AlgR1 protein. Expression of algC was reduced 5.7-fold in an algR1 mutant of P. aeruginosa compared to its isogenic parent strain (lacking the algR1 mutation), suggesting that the algR1 gene product activates the transcription of the algC gene.	UNIV ILLINOIS,COLL MED CHICAGO,DEPT MICROBIOL & IMMUNOL,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital					NIAID NIH HHS [AI-07890, AI-16790-12] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016790, R37AI016790] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALDRICH TL, 1989, MOL GEN GENET, V218, P266, DOI 10.1007/BF00331277; BAGDASARIAN MM, 1983, GENE, V26, P273, DOI 10.1016/0378-1119(83)90197-X; BENYON J, 1983, CELL, V34, P665; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAKRABARTY AM, 1978, P NATL ACAD SCI USA, V75, P3109, DOI 10.1073/pnas.75.7.3109; DARZINS A, 1985, J BACTERIOL, V164, P516, DOI 10.1128/JB.164.2.516-524.1985; DARZINS A, 1984, J BACTERIOL, V159, P9, DOI 10.1128/JB.159.1.9-18.1984; DAVISON J, 1987, GENE, V51, P275, DOI 10.1016/0378-1119(87)90316-7; DERETIC V, 1987, J BACTERIOL, V169, P351, DOI 10.1128/jb.169.1.351-358.1987; DERETIC V, 1987, NUCLEIC ACIDS RES, V15, P4567, DOI 10.1093/nar/15.11.4567; DIXON R, 1984, NUCLEIC ACIDS RES, V12, P7811, DOI 10.1093/nar/12.20.7811; FIALHO AM, 1990, APPL ENVIRON MICROB, V56, P436, DOI 10.1128/AEM.56.2.436-443.1990; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; FRANTZ B, 1987, P NATL ACAD SCI USA, V84, P4460, DOI 10.1073/pnas.84.13.4460; FURSTE JP, 1986, GENE, V48, P119, DOI 10.1016/0378-1119(86)90358-6; GILL JF, 1986, J BACTERIOL, V167, P611, DOI 10.1128/jb.167.2.611-615.1986; GLASER L, 1959, BIOCHIM BIOPHYS ACTA, V33, P522, DOI 10.1016/0006-3002(59)90143-X; KATO J, 1991, P NATL ACAD SCI USA, V88, P1760, DOI 10.1073/pnas.88.5.1760; KEPES F, 1988, J BIOL CHEM, V263, P9155; KIMBARA K, 1989, BIOCHEM BIOPH RES CO, V164, P601, DOI 10.1016/0006-291X(89)91502-7; KNUTSON CA, 1968, ANAL BIOCHEM, V24, P470, DOI 10.1016/0003-2697(68)90154-1; MAY TB, 1991, CLIN MICROBIOL REV, V4, P191, DOI 10.1128/CMR.4.2.191-206.1991; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; Miller JH., 1972, EXPT MOL GENETICS; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MORETT E, 1989, J MOL BIOL, V210, P65, DOI 10.1016/0022-2836(89)90291-X; NAKAI C, 1983, J BIOL CHEM, V258, P2923; NIES A, 1989, J BACTERIOL, V171, P5065, DOI 10.1128/jb.171.9.5065-5070.1989; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; PADGETT PJ, 1986, CURR MICROBIOL, V14, P187, DOI 10.1007/BF01568516; RAY WJ, 1983, J BIOL CHEM, V258, P9166; ROSE ZB, 1986, TRENDS BIOCHEM SCI, V11, P253, DOI 10.1016/0968-0004(86)90188-X; ROYCHOUDHURY S, 1989, J BIOL CHEM, V264, P9380; SACORREIA I, 1987, J BACTERIOL, V169, P3224, DOI 10.1128/jb.169.7.3224-3231.1987; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINABARGER D, 1991, J BIOL CHEM, V266, P2080; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SMALL DM, 1979, PHYTOCHEMISTRY, V18, P1147, DOI 10.1016/0031-9422(79)80123-5; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WANG SK, 1987, J GEN MICROBIOL, V133, P2303; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZIELINSKI NA, 1990, PSEUDOMONAS : BIOTRANSFORMATIONS, PATHOGENESIS, AND EVOLVING BIOTECHNOLOGY, P15; 1984, DIFCO MANUAL, P711	46	122	129	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9754	9763						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903398				2022-12-25	WOS:A1991FM45900065
J	SCHRODER, S; UNGEWICKELL, E				SCHRODER, S; UNGEWICKELL, E			SUBUNIT INTERACTION AND FUNCTION OF CLATHRIN-COATED VESICLE ADAPTERS FROM THE GOLGI AND THE PLASMA-MEMBRANE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-II; PROTEIN-KINASE; AFFINITY PURIFICATION; ASSEMBLY POLYPEPTIDES; BINDING; IDENTIFICATION; SPECIFICITY; COMPLEX; PHOSPHORYLATION; ANTIBODIES	Clathrin in coated vesicles is linked to transmembrane receptors by adaptor protein complexes. The Golgi-associated adaptor complex HA1 is a tetramer, made up of beta', gamma, 47-kDa, and 20-kDa subunits, whereas the tetrameric plasma membrane adaptor, HA2, contains alpha, beta, 50-kDa, and 16-kDa subunits (Ahle, S., Mann, A., Eichelsbacher, U., and Ungewickell, E. (1988) EMBO J. 7, 919-929). Here we report on the structural organization of adaptor subunits as revealed by proteolytic dissection. We show that the beta' and gamma-subunits of HA1 are cleaved into 60-67-kDa "trunk" and 32-44-kDa "head" fragments. Interactions between adaptor subunits involve the trunk domains only. In overall organization of their domains, the Golgi and plasma membrane adaptors are very similar. The similarity encompasses also the location of phosphorylated serine residues in the alpha-a, beta, beta', and gamma-subunits, which are found in the head domains in all cases. In the alpha-a and beta-subunits they probably occur in the proline- and glycine-rich hinge region, which connects the head to the trunk. Identical adaptor fragments were obtained by controlled digestion of clathrin-coated vesicles. Under conditions that did not affect the integrity of the clathrin heavy chain, the adaptor head fragments were always quantitatively released from coated vesicles. The release of the bulk of the adaptors occurred concomitantly with the cleavage of their beta-type subunits (beta and beta') and under buffer conditions that prevent aggregation of adaptors. These observations taken together with the results of reconstitution experiments confirm and extend previous data (Ahle, S., and Ungewickell, E. (1989) J. Biol. Chem. 264, 20089-20093) which suggested that adaptors attach to clathrin through their beta-type (beta and beta') subunits. Moreover, high affinity interaction between adaptors and clathrin requires the participation of regions from both the head and trunk domains of the beta-type subunits.			SCHRODER, S (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.		Schröder-Köhne, Stephan/J-5652-2017	Schröder-Köhne, Stephan/0000-0002-2472-077X				AHLE S, 1990, J CELL BIOL, V111, P19, DOI 10.1083/jcb.111.1.19; AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BARZVI D, 1988, J BIOL CHEM, V263, P4408; BARZVI D, 1986, J BIOL CHEM, V261, P9614; BRETSCHER A, 1978, FEBS LETT, V85, P145, DOI 10.1016/0014-5793(78)81267-8; CAMPBELL C, 1984, BIOCHEMISTRY-US, V23, P4420, DOI 10.1021/bi00314a028; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1987, J BIOL CHEM, V262, P3864; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; Morris SA, 1989, CURR OPIN CELL BIOL, V1, P684, DOI 10.1016/0955-0674(89)90034-3; MORRIS SA, 1990, J BIOL CHEM, V265, P3354; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PAULOIN A, 1982, NATURE, V298, P574, DOI 10.1038/298574a0; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PONNAMBALAM S, 1990, J BIOL CHEM, V265, P4814; ROBINSON MS, 1986, J CELL BIOL, V102, P48, DOI 10.1083/jcb.102.1.48; ROBINSON MS, 1989, J CELL BIOL, V108, P833, DOI 10.1083/jcb.108.3.833; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SPENCER M, 1978, J CHROMATOGR, V166, P435, DOI 10.1016/S0021-9673(00)95626-7; UNANUE ER, 1981, CELL, V26, P439, DOI 10.1016/0092-8674(81)90213-0; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	35	65	65	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7910	7918						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902231				2022-12-25	WOS:A1991FJ34200092
J	SIMS, PJ; GINSBERG, MH; PLOW, EF; SHATTIL, SJ				SIMS, PJ; GINSBERG, MH; PLOW, EF; SHATTIL, SJ			EFFECT OF PLATELET ACTIVATION ON THE CONFORMATION OF THE PLASMA-MEMBRANE GLYCOPROTEIN-IIB-IIIA COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENCE ENERGY-TRANSFER; FIBRINOGEN RECEPTOR; CELL-SURFACE; MONOCLONAL-ANTIBODY; CALCIUM REGULATION; WHOLE-BLOOD; GPIIB-IIIA; BINDING; EPINEPHRINE; EXPRESSION	Platelet activation converts the membrane GP IIb-IIIa complex into a functional receptor for fibrinogen, but the mechanism is poorly understood. We asked whether induction of receptor competency coincides with a conformational change affecting the spatial arrangement of exoplasmic domains of the IIb and IIIa subunits. Epitopes on these subunits were labeled with monoclonal antibodies conjugated to either a donor fluorescein (FITC) or an acceptor tetramethylrhodamine (TR) chromophore. Then, fluorescence resonance energy transfer (RET) between platelet-bound FITC and TR was measured by flow cytometry. In unstimulated platelets, 6-8% RET efficiency was detected between antibody B1B5, bound to GP IIb, and antibody SSA6, bound to GP IIIa, regardless of which antibody served as RET donor. RET was also observed between these antibodies and A2A9, an antibody specific for the GP IIb-IIIa complex. Cell stimulation by thrombin, ADP plus epinephrine or phorbol-ester caused up to a 2-fold increase in RET between chromophore-labeled, platelet-bound B1B5, SSA6, and A2A9 (p less-than-or-equal-to 0.05), suggesting a change in the separation or orientation of these epitopes within the GP IIb-IIIa complex. The activation-related conformational change detected by the increase in RET between antibody B1B5 and SSA6 was independent of receptor occupancy since it was unaffected by the addition of fibrinogen or by the inhibition of fibrinogen binding by the antibody, A2A9, or the peptide, RGDS. In contrast to these results with antibodies bound to different epitopes within GP IIb-IIIa, no RET was observed between FITC-A2A9 and TR-A2A9 bound to different GP IIb-IIIa complexes or between a TR-labeled GP Ib antibody and FITC-labeled GP IIb-IIIa antibodies. These studies demonstrate that platelet activation causes a change in the spatial separation or orientation of exoplasmic domains within GP IIb and IIIa, which may serve to convert this integrin into a functional adhesion receptor.	SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA; OKLAHOMA MED RES FDN, CARDIOVASC BIOL RES PROGRAM, OKLAHOMA CITY, OK 73104 USA; UNIV PENN, SCH MED, DEPT MED, HEMATOL ONCOL SECT, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL & LAB MED, PHILADELPHIA, PA 19104 USA	Scripps Research Institute; Oklahoma Medical Research Foundation; University of Pennsylvania; University of Pennsylvania					NHLBI NIH HHS [HL 28235, HL 40387, HL 36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036946, R01HL028235, P01HL040387] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAMS CS, 1990, BLOOD, V75, P128; ANDO B, 1988, J BIOL CHEM, V263, P11907; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1988, J BIOL CHEM, V263, P12948; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; Brass L F, 1991, Prog Hemost Thromb, V10, P127; BRASS LF, 1985, J BIOL CHEM, V260, P7875; BRASS LF, 1984, J CLIN INVEST, V73, P626, DOI 10.1172/JCI111252; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; COLLER BS, 1989, PLATELET IMMUNOBIOLO, P166; DRAKE JDW, 1986, AM J PATHOL, V124, P324; FISHER GJ, 1985, BIOCHEM BIOPH RES CO, V129, P958, DOI 10.1016/0006-291X(85)91984-9; FITZGERALD LA, 1985, J BIOL CHEM, V260, P1366; FITZGERALD LA, 1987, J BIOL CHEM, V262, P3936; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FUJIMURA K, 1983, J BIOL CHEM, V258, P247; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MONTGOMERY RR, 1983, J CLIN INVEST, V71, P385, DOI 10.1172/JCI110780; OLIVER JA, 1987, SCANNING MICROSCOPY, V1, P745; OTOOLE TE, 1989, BLOOD, V74, P14; PARISE LV, 1990, BLOOD, V75, P2363; PARISE LV, 1985, J BIOL CHEM, V260, P1750; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1983, ANN NY ACAD SCI, V416, P166, DOI 10.1111/j.1749-6632.1983.tb35187.x; PHILLIPS DR, 1988, BLOOD, V71, P831; PIDARD D, 1986, BLOOD, V67, P604; PLOW EF, 1989, PROG HEMOST THROMB, V9, P117; PONCZ M, 1987, J BIOL CHEM, V262, P8476; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, BLOOD, V66, P92; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHATTIL SJ, 1987, BLOOD, V70, P307; SHATTIL SJ, 1986, BLOOD, V68, P1224; SHATTIL SJ, 1988, PLATELET MEMBRANE RE, P345; SHIBA E, 1988, CIRCULATION, V78, P309; SILVER SM, 1987, BLOOD, V69, P1031; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; SZOLLOSI J, 1984, CYTOMETRY, V5, P210, DOI 10.1002/cyto.990050216; SZOLLOSI J, 1989, J IMMUNOL, V143, P208; SZOLLOSI J, 1987, CYTOMETRY, V8, P120, DOI 10.1002/cyto.990080204; TAUB R, 1989, J BIOL CHEM, V264, P259; TRON L, 1987, IMMUNOL LETT, V16, P1, DOI 10.1016/0165-2478(87)90052-6; TRON L, 1984, BIOPHYS J, V45, P939, DOI 10.1016/S0006-3495(84)84240-X; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WOODS VL, 1986, J BIOL CHEM, V261, P5242	52	240	242	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7345	7352						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902217				2022-12-25	WOS:A1991FJ34200008
J	HATA, Y; KAIBUCHI, K; KAWAMURA, S; HIROYOSHI, M; SHIRATAKI, H; TAKAI, Y				HATA, Y; KAIBUCHI, K; KAWAMURA, S; HIROYOSHI, M; SHIRATAKI, H; TAKAI, Y			ENHANCEMENT OF THE ACTIONS OF SMG P21 GDP/GTP EXCHANGE PROTEIN BY THE PROTEIN KINASE-A-CATALYZED PHOSPHORYLATION OF SMG P21	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; PUTATIVE EFFECTOR DOMAIN; RAS GENE-PRODUCTS; BOVINE BRAIN MEMBRANES; MOLECULAR-WEIGHT; HUMAN-PLATELETS; ACTIVATING PROTEINS; SIGNAL TRANSDUCTION; PURIFICATION; IDENTIFICATION	We have previously shown that cyclic AMP-dependent protein kinase (protein kinase A) phosphorylates smg p21A and -B, ras p21-like small GTP-binding proteins. In the present study, we investigated the function(s) of this phosphorylation by use of the smg p21B purified from human platelets. smg p21B bound to plasma membranes and the protein kinase A-catalyzed phosphorylation of smg p21B reduced this binding. Moreover, the phosphorylation of smg p21B enhanced the two actions of its specific GDP/GTP exchange protein, named GDP dissociation stimulator, when tested in a cell-free system: one is the action to stimulate the GDP/GTP exchange reaction of smg p21B, and the other is the action to inhibit the binding of smg p21B to membranes. Consistently, smg p21B was translocated from the membranes to the cytoplasm when it was phosphorylated by protein kinase A in intact platelets in response to prostaglandin E1 or dibutyryl cyclic AMP. The protein kinase A-catalyzed phosphorylation of smg p21B affected neither its basal GDP/GTP exchange reaction, basal GTPase activity, nor the GTPase activity stimulated by its specific GTPase activating protein. On the other hand, we have recently clarified that the structure of the C-terminal region of the post-translationally processed human platelet smg p21B is Lys-Lys-Ser-Ser-all-trans-geranylgeranyl Cys181 methyl ester, and that this modification of the C-terminal region is essential for smg p21B to bind to membranes. We furthermore determined here that protein kinase A phosphorylated Ser179 in this C-terminal region of smg p21B. These results indicate that protein kinase A-catalyzed phosphorylation of smg p21B makes smg p21B sensitive to the actions of smg p21 GDP dissociation stimulator.	KOBE UNIV, SCH MED, DEPT BIOCHEM, KOBE 650, JAPAN	Kobe University								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; Baenziger N L, 1974, Methods Enzymol, V31, P149; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECHTEL PJ, 1977, J BIOL CHEM, V252, P2691; Berridge M J, 1975, Adv Cyclic Nucleotide Res, V6, P1; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FEINSTEIN MB, 1981, PLATELETS BIOL PATHO, V2, P437; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HASLAM RJ, 1977, BIOCHEM BIOPH RES CO, V77, P714, DOI 10.1016/S0006-291X(77)80037-5; HATA Y, 1990, J BIOL CHEM, V265, P7104; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KAWATA M, 1990, IN PRESS ONCOGENE; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MIZOGUCHI A, 1989, MOL BRAIN RES, V5, P31, DOI 10.1016/0169-328X(89)90015-6; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; NAGATA K, 1989, J BIOL CHEM, V264, P17000; OHMORI T, 1988, BIOCHEM BIOPH RES CO, V157, P670, DOI 10.1016/S0006-291X(88)80302-4; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SATOH T, 1990, P NATL ACAD SCI USA, V87, P7926, DOI 10.1073/pnas.87.20.7926; TAKAI Y, 1984, ADV CYCLIC NUCL PROT, V18, P119; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; Tarr G E, 1977, Methods Enzymol, V47, P335; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WISE BC, 1982, J BIOL CHEM, V257, P8481; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	52	92	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6571	6577						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1901063				2022-12-25	WOS:A1991FE37300084
J	BROWN, DE; MCGUIRL, MA; DOOLEY, DM; JANES, SM; MU, D; KLINMAN, JP				BROWN, DE; MCGUIRL, MA; DOOLEY, DM; JANES, SM; MU, D; KLINMAN, JP			THE ORGANIC FUNCTIONAL-GROUP IN COPPER-CONTAINING AMINE OXIDASES - RESONANCE RAMAN-SPECTRA ARE CONSISTENT WITH THE PRESENCE OF TOPA QUINONE (6-HYDROXYDOPA QUINONE) IN THE ACTIVE-SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIAMINE OXIDASE; COFACTOR; PYRROLOQUINOLINEQUINONE; SPECTROSCOPY	Resonance Raman spectroscopy has been used to probe the structure of the organic cofactor in copper-containing amine oxidases from bovine plasma, porcine kidney, pea seedlings, and the bacterium Arthrobacter P1. The enzymes were first derivatized with phenylhydrazine or p-nitrophenylhydrazine; resonance Raman spectra were obtained on the intact derivatized enzymes and on a derivatized active-site peptide isolated from bovine plasma amine oxidase. Spectra of the intact amine oxidase phenylhydrazones are practically identical, consistent with the enzymes examined containing a similar cofactor. Only minor frequency shifts and some intensity variations are detected between the resonance Raman spectra of intact bovine plasma amine oxidase and the isolated peptide. These spectral perturbations are attributable to differences in the micro-environment between the intact, folded protein and the isolated small peptide in aqueous solution. This rules out the possibility that a new structure is formed during the isolation of the derivatized active-site peptide. Importantly, the resonance Raman spectra of the phenylhydrazine and p-nitrophenylhydrazine derivatives of the bovine plasma amine oxidase peptide are identical to the spectra of the corresponding derivatives of topa quinone (6-hydroxydopa quinone). Hence these data provide strong, independent support for the recent identification of topa as the organic functional group in bovine plasma amine oxidase (Janes, S. M., Mu, D., Wemmer, D., Smith, A. J., Kaur, S., Maltby, D., Burlingame, A. L., and Klinman, J. P. (1990) Science 248, 981-987).	AMHERST COLL,DEPT CHEM,AMHERST,MA 01002; UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	Amherst College; University of California System; University of California Berkeley			McGuirl, Michele/N-2311-2014; Mu, David/E-8933-2011	Mu, David/0000-0002-7762-0182	NIGMS NIH HHS [GM 39296, GM 27659] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039296, R01GM027659] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMEYAMA M, 1984, AGR BIOL CHEM TOKYO, V48, P561, DOI 10.1080/00021369.1984.10866184; BUFFONI F, 1990, ANAL BIOCHEM, V187, P44, DOI 10.1016/0003-2697(90)90414-5; CAREY PR, 1982, BIOCH APPLICATIONS R, P154; DOOLEY DM, 1986, INORG CHIM A-BIOINOR, V123, P231, DOI 10.1016/S0020-1693(00)85680-7; DOOLEY DM, 1990, J AM CHEM SOC, V112, P2782, DOI 10.1021/ja00163a047; DOOLEY DM, 1987, FEBS LETT, V214, P274, DOI 10.1016/0014-5793(87)80069-8; DUINE JA, 1989, ANNU REV BIOCHEM, V58, P403; DUINE JA, 1987, ADV ENZYMOL, V59, P170; HARTMANN C, 1988, Biofactors, V1, P41; HARTMANN C, 1990, FEBS LETT, V261, P441, DOI 10.1016/0014-5793(90)80611-L; HARTMANN C, 1987, J BIOL CHEM, V262, P962; JANES SM, 1990, SCIENCE, V248, P981, DOI 10.1126/science.2111581; KLUETZ MD, 1980, PREP BIOCHEM, V10, P615, DOI 10.1080/00327488008061757; KNOWLES PF, 1987, BIOCHEM J, V241, P603, DOI 10.1042/bj2410603; KNOWLES PF, 1984, COPPER PROTEINS COPP, V2, P103; LEVENE C I, 1988, Pharmacological Research Communications, V20, P157, DOI 10.1016/S0031-6989(88)80587-3; LOBENSTEINVERBEEK CL, 1984, FEBS LETT, V170, P305, DOI 10.1016/0014-5793(84)81333-2; MCINTIRE WS, 1991, BIOCHEMISTRY-US, V30, P125, DOI 10.1021/bi00215a019; MCINTIRE WS, 1990, METHOD ENZYMOL, V188, P227; Mondovi B, 1985, STRUCTURE FUNCTIONS; MOOG RS, 1986, P NATL ACAD SCI USA, V83, P8435, DOI 10.1073/pnas.83.22.8435; NISHIMURA Y, 1978, ADV INFRARED RAMAN S, V5, P217; WILLIAMSON PR, 1986, J BIOL CHEM, V261, P6302	23	113	113	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4049	4051						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900285				2022-12-25	WOS:A1991FA69400007
J	HADVARY, P; SIDLER, W; MEISTER, W; VETTER, W; WOLFER, H				HADVARY, P; SIDLER, W; MEISTER, W; VETTER, W; WOLFER, H			THE LIPASE INHIBITOR TETRAHYDROLIPSTATIN BINDS COVALENTLY TO THE PUTATIVE ACTIVE-SITE SERINE OF PANCREATIC LIPASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-TOXYTRICINI; LIPSTATIN; PEPTIDE; MECHANISM; IONS	Tetrahydrolipstatin (THL) is a selective inhibitor of fat absorption. In animal models, it has anti-obesity and anti-hypercholesterolemic activity and is presently in clinical trials for these indications. THL binds covalently to pancreatic lipase. Complete inhibition of lipolytic activity is obtained concomitant with the incorporation of 1 mol of THL/mol of enzyme. Pancreatic lipase is the best studied lipase, but published results concerning its catalytic mechanism are still controversial. In order to learn more about the inhibitory mechanism of THL, a selective lipase inhibitor interacting at or near the catalytic site, and therefore, to obtain more information on the catalytic mechanism of lipase, we have determined the amino acid residue to which THL is bound. After proteolytic degradation of porcine pancreatic lipase inhibited with radioactively labeled THL, the labeled peptides were isolated and analyzed by quantitative amino acid analysis, N-terminal sequencing, and by mass spectrometry with fast atom bombardment ionization. The data clearly show that THL is bound as an ester to the serine 152 of the lipase.	F HOFFMANN LA ROCHE & CO LTD, CENT RES DEPT, CH-4002 BASEL, SWITZERLAND; SWISS FED INST TECHNOL, INST MOLEC BIOL & BIOPHYS, CH-8093 ZURICH, SWITZERLAND	Roche Holding; Swiss Federal Institutes of Technology Domain; ETH Zurich	HADVARY, P (corresponding author), F HOFFMANN LA ROCHE & CO LTD, PHARMACEUT RES DEPT, PF CVD 68-309, GRENZACHERSTR 124, CH-4002 BASEL, SWITZERLAND.							ADAMS J, 1989, J AM CHEM SOC, V111, P435, DOI 10.1021/ja00184a004; Atherton E., 1987, PEPTIDES ANAL SYNTHE, V9, P1; BARBIER P, 1987, HELV CHIM ACTA, V70, P196, DOI 10.1002/hlca.19870700124; BIEMANN K, 1988, BIOMED ENVIRON MASS, V16, P99, DOI 10.1002/bms.1200160119; BORGSTROM B, 1988, BIOCHIM BIOPHYS ACTA, V962, P308, DOI 10.1016/0005-2760(88)90260-3; BRUDERER H, 1970, ORG MASS SPECTROM, V3, P777; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4988, DOI 10.1021/bi00668a007; CHAPUS C, 1988, BIOCHIMIE, V70, P1223, DOI 10.1016/0300-9084(88)90188-5; DECARO J, 1981, BIOCHIM BIOPHYS ACTA, V671, P129, DOI 10.1016/0005-2795(81)90126-4; DECARO JD, 1986, EUR J BIOCHEM, V158, P601; FRANK G, 1976, H-S Z PHYSIOL CHEM, V357, P585, DOI 10.1515/bchm2.1976.357.1.585; FRANK G, 1989, METHODS PROTEIN SEQU, P52; GUIDONI A, 1981, BIOCHIM BIOPHYS ACTA, V660, P148, DOI 10.1016/0005-2744(81)90120-0; HADVARY P, 1988, BIOCHEM J, V256, P357, DOI 10.1042/bj2560357; HADVARY P, 1987, INT J OBESITY, V11, P21; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; HIRS CHW, 1956, J BIOL CHEM, V219, P611; HOCHULI E, 1987, J ANTIBIOT, V40, P1086, DOI 10.7164/antibiotics.40.1086; HOGAN S, 1987, INT J OBESITY, V11, P35; LENGSFELD H, 1988, 8TH INT S ATH ROM, P533; LOTTSPEICH F, 1985, J CHROMATOGR, V326, P321, DOI 10.1016/S0021-9673(01)87457-4; MARAGANORE JM, 1986, TRENDS BIOCHEM SCI, V11, P497, DOI 10.1016/0968-0004(86)90076-9; MEIER MK, 1989, INT J OBESITY S1, V13; ROEPSTORFF P, 1984, BIOMED MASS SPECTROM, V11, P601, DOI 10.1002/bms.1200111109; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; STALDER H, 1990, HELV CHIM ACTA, V73, P1022, DOI 10.1002/hlca.19900730427; Verger R., 1984, P83; WEIBEL EK, 1987, J ANTIBIOT, V40, P1081, DOI 10.7164/antibiotics.40.1081; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0	29	238	244	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2021	2027						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899234				2022-12-25	WOS:A1991EV51500005
J	ZHANG, J; CORDEN, JL				ZHANG, J; CORDEN, JL			IDENTIFICATION OF PHOSPHORYLATION SITES IN THE REPETITIVE CARBOXYL-TERMINAL DOMAIN OF THE MOUSE RNA POLYMERASE-II LARGEST SUBUNIT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; ESCHERICHIA-COLI; PROTEIN-KINASE; REPEAT DOMAIN; WHEAT-GERM; TRANSCRIPTION; INVIVO; INITIATION; SEQUENCE; INVITRO	The largest subunit of eukaryotic RNA polymerase II contains a carboxyl-terminal domain (CTD) which is comprised of repetitive heptapeptides with a consensus sequence Tyr1-Ser2-Pro3-Thr4-Ser5-Pro6-Ser7. We demonstrate here that the mouse CTD expressed in and purified from Escherichia coli can be phosphorylated in vitro by a p34cdc2/CDC28-containing CTD kinase from mouse ascites tumor cells. The product of this reaction, a phosphorylated form of the CTD, contains phosphoserine and phosphothreonine, but not phosphotyrosine. The same phosphoamino acid content is observed in the in vivo phosphorylated CTD from a mouse cell line. Synthetic peptides with naturally occurring non-consensus heptapeptide sequences can also be phosphorylated by CTD kinase in vitro. Phosphoamino acid analysis of these non-consensus heptapeptides together with direct sequencing of a phosphorylated heptapeptide reveals that serine (or threonines) at positions two and five are the sites phosphorylated by mouse CTD kinase. Thus, the -Ser(Thr)-Pro- motif common to p34cdc2/CDC28-containing protein kinases is the recognition site for mouse CTD kinase.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University								AHEARN JM, 1987, J BIOL CHEM, V262, P10695; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; BAKER TA, 1984, P NATL ACAD SCI-BIOL, V81, P6779, DOI 10.1073/pnas.81.21.6779; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BYLUND DB, 1976, ANAL BIOCHEM, V73, P477, DOI 10.1016/0003-2697(76)90197-4; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, IN PRESS METHODS ENZ; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; CORDEN JL, 1985, P NATL ACAD SCI USA, V82, P7924; DAHMUS ME, 1981, J BIOL CHEM, V256, P3319; DREYFUSS G, 1984, MOL CELL BIOL, V4, P415, DOI 10.1128/MCB.4.3.415; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; GUILFOYLE TJ, 1989, PLANT CELL, V1, P827, DOI 10.1105/tpc.1.8.827; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; JAY DG, 1984, J BIOL CHEM, V259, P5572; KIM WY, 1986, J BIOL CHEM, V261, P14219; KIM WY, 1989, J BIOL CHEM, V264, P3169; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LEE JM, 1989, P NATL ACAD SCI USA, V86, P3624, DOI 10.1073/pnas.86.10.3624; Maniatis T., 1984, MOL CLONING; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; PAYNE JM, 1989, J BIOL CHEM, V264, P19621; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; SAWADOGO M, 1990, ANNU REV BIOCHEM, V59, P711, DOI 10.1146/annurev.bi.59.070190.003431; SNOW CM, 1987, J CELL BIOL, V104, P143; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WANG YH, 1988, ANAL BIOCHEM, V174, P537, DOI 10.1016/0003-2697(88)90053-X; WOYCHIK NA, 1990, TRENDS BIOCHEM SCI, V15, P347, DOI 10.1016/0968-0004(90)90074-L; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698	36	111	113	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2290	2296						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899239				2022-12-25	WOS:A1991EV51500044
J	RITTER, JK; CRAWFORD, JM; OWENS, IS				RITTER, JK; CRAWFORD, JM; OWENS, IS			CLONING OF 2 HUMAN LIVER BILIRUBIN UDP-GLUCURONOSYL-TRANSFERASE CDNAS WITH EXPRESSION IN COS-1 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUNN-RAT; GLUCURONYLTRANSFERASE; SEQUENCE; SPECIFICITY; JAUNDICE; FORM; ACID	We report the isolation and characterization of two human liver cDNA clones, HUG-Br1 and HUG-Br2; each encodes a UDP-glucuronosyltransferase enzyme which glucuronidates bilirubin IX-alpha to form both the IX-alpha-C8 and IX-alpha-C12 monoconjugates and a diconjugate. HUG-Br1 cDNA (2351 base pairs) and HUG-Br2 cDNA (2368 base pairs) encode proteins with 533 and 534 amino acid residues, respectively, with a typical membrane-insertion signal peptide, membrane-spanning domain, and 3 or 5 potential asparagine-linked glycosylation sites. At the nucleic acid and deduced amino acid sequence levels the two clones are 82% similar overall, 66% similar in the amino termini, and identical after codon 287, thus encoding proteins with the same carboxyl terminus. The mRNA encoding HUG-Br1 is of high abundance, and the one encoding HUG-Br2 is of low abundance; both are 2.6 kilobases in length. Both messages (2.6 kilobases) were present in the explanted liver of a Type I Crigler-Najjar patient, although the level for that of HUG-Br1 was reduced 4.5-fold. Northern blot analysis of poly(A)+ RNA isolated from the liver of an untreated and a phenobarbital-treated Erythrocebus patas monkey with 5'-specific probes for each clone indicated that the HUG-Br2-encoded message is induced two fold, but that for HUG-Br1 is not. These data indicate that bilirubin is glucuronidated by at least two different proteins, most likely present in very different amounts. These cDNAs which encode functional bilirubin UDP-glucuronosyltransferases will allow the isolation of an appropriate gene to develop a gene therapy model for patients which have the totally deficient trait.	NICHHD, HUMAN GENET BRANCH,GENET DISORDERS DRUG METAB SECT, BLDG 10,RM 9S-242, BETHESDA, MD 20892 USA; BRIGHAM & WOMENS HOSP, DEPT PATHOL, BOSTON, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Brigham & Women's Hospital								ARIAS IM, 1957, SCIENCE, V126, P563, DOI 10.1126/science.126.3273.563; BLACK M, 1970, LANCET, V1, P1359; BLANCKAERT N, 1980, BIOCHEM J, V185, P115, DOI 10.1042/bj1850115; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOWDHURY NR, 1987, J CLIN INVEST, V79, P327, DOI 10.1172/JCI112816; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Dutton G., 1980, GLUCURONIDATION DRUG, P3; EISEN HJ, 1983, BIOCHEM ACTION HORM, V10, P227; ELAWADY M, 1990, J BIOL CHEM, V265, P10752; FROHLING KW, 1973, BIOCHIM BIOPHYS ACTA, V327, P46, DOI 10.1016/0005-2744(73)90102-2; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; Gunn CH, 1938, J HERED, V29, P137, DOI 10.1093/oxfordjournals.jhered.a104478; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; HAUSER SC, 1984, J BIOL CHEM, V259, P4527; IYANAGI T, 1989, J BIOL CHEM, V264, P21302; IYANAGI T, 1986, J BIOL CHEM, V261, P5607; JAYE M, 1983, NUCLEIC ACIDS RES, V11, P2325, DOI 10.1093/nar/11.8.2325; KAUFMAN SS, 1986, HEPATOLOGY, V6, P1259, DOI 10.1002/hep.1840060606; MACKENZIE PI, 1986, J BIOL CHEM, V261, P6119; MACKENZIE PI, 1990, J BIOL CHEM, V265, P3432; MACKENZIE PI, 1986, J BIOL CHEM, V261, P14112; MACKENZIE PI, 1983, BIOCHEM PHARMACOL, V32, P3777, DOI 10.1016/0006-2952(83)90149-1; MALIK N, 1981, J BIOL CHEM, V256, P9599; MCKINNON RD, 1987, MOL CELL BIOL, V7, P2148, DOI 10.1128/MCB.7.6.2148; NEBERT DW, 1984, BIOCHEM PHARMACOL, V33, P917, DOI 10.1016/0006-2952(84)90446-5; RITTER JK, 1990, J BIOL CHEM, V265, P7900; Roy Chowdhury J, 1987, METABOLIC BASIS INHE, P1367; SATO H, 1990, BIOCHEM BIOPH RES CO, V169, P260, DOI 10.1016/0006-291X(90)91462-2; SCRAGG I, 1985, FEBS LETT, V183, P37, DOI 10.1016/0014-5793(85)80949-2; WEATHERILL PJ, 1980, BIOCHEM J, V191, P155, DOI 10.1042/bj1910155; YOUNG RA, 1981, CELL, V23, P451, DOI 10.1016/0092-8674(81)90140-9	31	253	266	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1043	1047						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898728				2022-12-25	WOS:A1991ET17700059
J	LAREW, JSA; PETERSON, JE; GRAVES, DJ				LAREW, JSA; PETERSON, JE; GRAVES, DJ			DETERMINATION OF THE KINETIC MECHANISM OF ARGININE-SPECIFIC ADP-RIBOSYLTRANSFERASES USING A HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TURKEY ERYTHROCYTES; ADENYLATE-CYCLASE; CHOLERAGEN; RIBOSYLATION; TRANSFERASE; MEMBRANE; NAD; ACTIVATION; PROTEINS; LIVER	A high performance liquid chromatographic method has been developed for the assay of arginine-specific ADP-ribosyl transferases. The assay utilizes L-arginine methyl ester (LAME) as the acceptor substrate. ADP-ribosylated-LAME is separated from the reaction mixture using a C-8 reversed-phase column. Before injection, the assay mixture is derivatized with an orthophthaldialdehyde/2-mercaptoethanol reagent. Fluorescence detection of the orthophthaldialdehyde-derivatized product provides excellent sensitivity and a limit of detection of less than 100 fmol. The kinetic mechanism of two arginine-specific ADP-ribosyltransferases, cholera toxin A subunit and an endogenous transferase from rabbit skeletal muscle, were both determined to be random sequential. The kinetic studies utilized 3-aminobenzamide and N(G)- monomethylarginine as competitive inhibitors for NAD and LAME, respectively. Cholera toxin was reported to have K(m) values of 5.6 and 39 mM for NAD and LAME, respectively. K(m) values of 0.56 and 1.2 mM were determined for NAD and LAME, respectively, using the transferase from rabbit skeletal muscle.	IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,AMES,IA 50011	Iowa State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034262] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 34262-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRIGHTWELL MD, 1975, BIOCHEM J, V147, P119, DOI 10.1042/bj1470119; DEWOLF MJS, 1981, J BIOL CHEM, V256, P2287; FROMM HJ, 1975, MOL BIOL BIOCH BIOPH, V22, P121; GODEAU F, 1984, ANAL BIOCHEM, V137, P287, DOI 10.1016/0003-2697(84)90087-3; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; HAMMERMAN MR, 1982, J BIOL CHEM, V257, P2380; HARA N, 1987, BIOCHEM BIOPH RES CO, V148, P989, DOI 10.1016/S0006-291X(87)80229-2; MEKALANOS JJ, 1979, J BIOL CHEM, V254, P5849; MOSS J, 1981, P NATL ACAD SCI-BIOL, V78, P4809, DOI 10.1073/pnas.78.8.4809; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; MOSS J, 1977, J BIOL CHEM, V252, P2455; MOSS J, 1981, J BIOL CHEM, V256, P7830; MOSS J, 1980, J BIOL CHEM, V255, P5838; MOSS J, 1978, J CLIN INVEST, V62, P281, DOI 10.1172/JCI109127; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5235, DOI 10.1021/bi00340a042; SOMAN G, 1986, BIOCHEMISTRY-US, V25, P4113, DOI 10.1021/bi00362a019; SOMAN G, 1984, BIOCHEM BIOPH RES CO, V120, P973, DOI 10.1016/S0006-291X(84)80202-8; SOMAN G, 1983, ANAL BIOCHEM, V134, P101, DOI 10.1016/0003-2697(83)90269-5; TABATABAI LB, 1976, THESIS ANN ARBOR; TANIGAWA Y, 1984, J BIOL CHEM, V259, P2022; WATKINS PA, 1980, J BIOL CHEM, V255, P3959; WATKINS PA, 1987, BIOCHEM J, V248, P749, DOI 10.1042/bj2480749	22	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					52	57						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1898725				2022-12-25	WOS:A1991EQ33900010
J	VANCE, JE				VANCE, JE			NEWLY MADE PHOSPHATIDYLSERINE AND PHOSPHATIDYLETHANOLAMINE ARE PREFERENTIALLY TRANSLOCATED BETWEEN RAT-LIVER MITOCHONDRIA AND ENDOPLASMIC-RETICULUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID TRANSFER PROTEINS; PLASMA-MEMBRANE; LIPOPROTEIN SECRETION; ANIMAL-CELLS; BIOSYNTHESIS; PHOSPHATIDYLCHOLINE; GOLGI; COMPARTMENTALIZATION; PURIFICATION; HEPATOCYTES	The translocation of: (i) phosphatidylserine (PtdSer) from its site of synthesis on microsomal membranes to its site of decarboxylation in mitochondrial membranes and (ii) phosphatidylethanolamine (PtdEtn) from the mitochondria to its site of methylation to phosphatidylcholine on microsomal membranes has been reconstituted in cell-free systems consisting of rat liver mitochondria and microsomes. Two types of systems have been reconstituted. In one, the translocation of newly made PtdSer or PtdEtn was examined by incubation of microsomes and mitochondria with [3-H-3]serine. In the other, membranes were prelabeled with radioactive PtdSer or PtdEtn, and the transfer of these two lipids between mitochondria and microsomes was monitored. For the transfer of both PtdSer from microsomes to mitochondria and PtdEtn from mitochondria to microsomes, newly made phospholipids were translocated much more readily than pre-existing phospholipids. The data suggest that with respect to their translocation between these two organelles, the pools of newly synthesized PtdSer and PtdEtn were distinct from the pools of "older" phospholipids pre-existing in the membranes. Transfer of neither phospholipid in vitro depended on the presence of cytosolic proteins (i.e. soluble phospholipid transfer proteins) or on the hydrolysis of ATP, although there was some stimulation of PtdSer transfer by ATP and several other nucleoside mono-, di-, and triphosphates. The data are consistent with a collision-based mechanism in which the endoplasmic reticulum and mitochondria come into contact with one another, thereby effecting the transfer of phospholipids. The proposal that there is contact between the endoplasmic reticulum and mitochondria is supported by the recent isolation of a membrane fraction having many, but not all, of the properties of the endoplasmic reticulum, but which was isolated in association with mitochondria (Vance, J. E. (1990) J. Biol. 265, 7248-7256).	UNIV ALBERTA, DEPT MED, EDMONTON T6G 2S2, ALBERTA, CANADA	University of Alberta	VANCE, JE (corresponding author), UNIV ALBERTA, LIPID & LIPOPROT GRP, EDMONTON T6G 2S2, ALBERTA, CANADA.							ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BELL RM, 1981, J LIPID RES, V22, P391; BJERVE KS, 1985, BIOCHIM BIOPHYS ACTA, V833, P396, DOI 10.1016/0005-2760(85)90096-7; BLOK MC, 1971, BIOCHIM BIOPHYS ACTA, V233, P61, DOI 10.1016/0005-2736(71)90358-0; CROZE EM, 1984, J CELL PHYSIOL, V119, P46, DOI 10.1002/jcp.1041190109; DAUM G, 1986, BIOCHIM BIOPHYS ACTA, V878, P93, DOI 10.1016/0005-2760(86)90347-4; DENNIS EA, 1972, J LIPID RES, V13, P263; ERNSTER L, 1962, J CELL BIOL, V15, P541, DOI 10.1083/jcb.15.3.541; GIEROW P, 1989, BIOCHEM J, V262, P55, DOI 10.1042/bj2620055; GLAUMANN H, 1970, J CELL BIOL, V47, P34, DOI 10.1083/jcb.47.1.34; HELMKAMP GM, 1986, J BIOENERG BIOMEMBR, V18, P71, DOI 10.1007/BF00743477; INFANTE JP, 1977, BIOCHEM J, V167, P847, DOI 10.1042/bj1670847; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KATZ J, 1983, BIOCHEM J, V214, P795, DOI 10.1042/bj2140795; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KUGE O, 1986, J BIOL CHEM, V261, P5795; LEWIS JA, 1973, J CELL SCI, V13, P447; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCMURRAY WC, 1969, BIOCHEM J, V112, P91, DOI 10.1042/bj1120091; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; NORDLIE RC, 1966, METHOD ENZYMOL, V9, P619; PELECH SL, 1984, BIOCHIM BIOPHYS ACTA, V779, P217, DOI 10.1016/0304-4157(84)90010-8; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; POORTHUIS BJHM, 1981, BIOCHIM BIOPHYS ACTA, V665, P256, DOI 10.1016/0005-2760(81)90010-2; RIDGWAY ND, 1987, J BIOL CHEM, V262, P17231; SAMBORSKI RW, 1990, J BIOL CHEM, V265, P18322; SIMBENI R, 1990, J BIOL CHEM, V265, P281; SLEIGHT RG, 1983, J BIOL CHEM, V258, P9050; SUNDLER R, 1975, BIOCHEM J, V146, P309, DOI 10.1042/bj1460309; VALTERSSON C, 1982, J LIPID RES, V23, P868; VANCE DE, 1977, NATURE, V270, P268, DOI 10.1038/270268a0; VANCE JE, 1989, BIOCHIM BIOPHYS ACTA, V1006, P59, DOI 10.1016/0005-2760(89)90323-8; VANCE JE, 1986, J BIOL CHEM, V261, P4486; VANCE JE, 1988, J BIOL CHEM, V263, P5898; VANCE JE, 1988, BIOCHIM BIOPHYS ACTA, V963, P10, DOI 10.1016/0005-2760(88)90332-3; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; VOELKER DR, 1989, P NATL ACAD SCI USA, V86, P9921, DOI 10.1073/pnas.86.24.9921; VOELKER DR, 1985, BIOCH LIPIDS MEMBRAN, P475; Wharton DC., 1967, METHOD ENZYMOL, P245; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9; YAFFE MP, 1983, BIOCHEMISTRY-US, V22, P1497, DOI 10.1021/bi00275a026; YAO ZM, 1988, J BIOL CHEM, V263, P2998; ZBOROWSKI J, 1983, FEBS LETT, V157, P179, DOI 10.1016/0014-5793(83)81141-7	47	177	177	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					89	97						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1898727				2022-12-25	WOS:A1991EQ33900016
J	NAIR, SK; CALDERONE, TL; CHRISTIANSON, DW; FIERKE, CA				NAIR, SK; CALDERONE, TL; CHRISTIANSON, DW; FIERKE, CA			ALTERING THE MOUTH OF A HYDROPHOBIC POCKET - STRUCTURE AND KINETICS OF HUMAN CARBONIC ANHYDRASE-II MUTANTS AT RESIDUE VAL-121	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERACTIVE COMPUTER-GRAPHICS; DIOXIDE HYDRATION ACTIVITY; ACID SIDE-CHAINS; CATALYTIC MECHANISM; MACROMOLECULAR STRUCTURES; GLOBULAR-PROTEINS; RNA-POLYMERASE; CO2; HISTIDINE-64; EXPRESSION	Eleven amino acid substitutions at Val-121 of human carbonic anhydrase II including Gly, Ala, Ser, Leu, Ile, Lys, and Arg, were constructed by site-directed mutagenesis. This residue is at the mouth of the hydrophobic pocket in the enzyme active site. The CO2 hydrase activity and the p-nitrophenyl esterase activity of these CAII variants correlate with the hydrophobicity of the residue is important for catalysis. The effects of these mutations on the steady-state kinetics for CO2 hydration occur mainly in k(cat)/K(m) and K(m), consistent with involvement of this residue in CO2 association. The Val-121 --> Ala mutant, which exhibits about one-third normal CO2 hydrase activity, has been studied by x-ray crystallographic methods. No significant changes in the mutant enzyme conformation are evident relative to the wild-type enzyme. Since Val-121 is at the mouth of the hydrophobic pocket, its substitution by the methyl side chain of alanine makes the pocket mouth significantly wider than that of the wild-type enzyme. Hence, although a moderately wide (and deep) pocket is important for substrate association, a wider mouth to this pocket does not seriously compromise the catalytic approach of CO2 toward nucleophilic zinc-bound hydroxide.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA	Duke University	NAIR, SK (corresponding author), UNIV PENN, DEPT CHEM, PHILADELPHIA, PA 19104 USA.		Nair, Satish/AAY-2510-2021		NIGMS NIH HHS [GM40602, GM07229, GM45614] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045614, R29GM045614, T32GM007229, R01GM040602, R29GM040602] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARMSTRONG JM, 1966, J BIOL CHEM, V241, P5137; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BERTINI I, 1983, J INORG BIOCHEM, V18, P221, DOI 10.1016/0162-0134(83)85004-1; BERTINI I, 1987, J AM CHEM SOC, V109, P7855, DOI 10.1021/ja00259a038; BERTINI I, 1979, J AM CHEM SOC, V101, P7069, DOI 10.1021/ja00517a051; BRION LP, 1988, ANAL BIOCHEM, V175, P289, DOI 10.1016/0003-2697(88)90391-0; CHEN RF, 1967, J BIOL CHEM, V242, P5813; CHOTHIA C, 1976, J MOL BIOL, V105, P1, DOI 10.1016/0022-2836(76)90191-1; CHRISTIANSON DW, 1991, ADV PROTEIN CHEM, V42, P281; COLEMAN JE, 1967, J BIOL CHEM, V242, P5212; Coleman JE., 1986, ZINC ENZYMES, P49; CULL M, 1990, METHOD ENZYMOL, V182, P147; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; EIGENBROT C, 1990, PROTEIN ENG, V3, P591, DOI 10.1093/protein/3.7.591; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; ERIKSSON AE, 1988, PROTEINS, V4, P283, DOI 10.1002/prot.340040407; Eriksson E. A., 1986, ZINC ENZYMES, P317; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; FIERKE CA, 1991, INT WORKSH CARB ANH, P22; FORSMAN C, 1988, FEBS LETT, V229, P360, DOI 10.1016/0014-5793(88)81156-6; HENDERSON LE, 1976, J BIOL CHEM, V251, P5457; Hendrickson W. A., 1981, BIOMOLECULAR STRUCTU, V1, P43; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HEWETTEMMETT D, 1991, IN PRESS CARBONIC AN; JANIN J, 1979, NATURE, V277, P491, DOI 10.1038/277491a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; JONSSON BH, 1976, FEBS LETT, V64, P310, DOI 10.1016/0014-5793(76)80317-1; KARPUSAS M, 1989, P NATL ACAD SCI USA, V86, P8237, DOI 10.1073/pnas.86.21.8237; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; KREBS J, 1991, IN PRESS BIOCHEMISTR; LED JJ, 1982, FEBS LETT, V147, P74, DOI 10.1016/0014-5793(82)81014-4; LIANG JY, 1988, BIOCHEMISTRY-US, V27, P8676, DOI 10.1021/bi00423a025; LIANG JY, 1990, P NATL ACAD SCI USA, V87, P3675, DOI 10.1073/pnas.87.10.3675; LILJAS A, 1972, NATURE-NEW BIOL, V235, P131, DOI 10.1038/newbio235131a0; LINDSKOG S, 1973, P NATL ACAD SCI USA, V70, P2505, DOI 10.1073/pnas.70.9.2505; LINDSKOG S, 1984, J MOL CATAL, V23, P357, DOI 10.1016/0304-5102(84)80021-8; LINDSKOG S, 1966, BIOCHEMISTRY-US, V5, P2641, DOI 10.1021/bi00872a023; LINDSKOG S, 1986, ZINC ENZYMES, P307; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Maniatis T., 1982, MOL CLONING; MCPHERSON A, 1986, J BIOL CHEM, V261, P1969; MCREE DE, 1990, J BIOL CHEM, V265, P14234; MERZ KM, 1990, J MOL BIOL, V214, P799, DOI 10.1016/0022-2836(90)90333-H; MERZ KM, 1991, J AM CHEM SOC, V113, P406, DOI 10.1021/ja00002a004; MURAKAMI H, 1987, Genomics, V1, P159, DOI 10.1016/0888-7543(87)90008-5; NOZAKI Y, 1971, J BIOL CHEM, V246, P2211; OSBORNE WRA, 1975, ANAL BIOCHEM, V64, P297, DOI 10.1016/0003-2697(75)90434-0; PERRY KM, 1990, PROTEINS, V8, P315, DOI 10.1002/prot.340080406; POCKER Y, 1972, BIOCHEMISTRY-US, V11, P698, DOI 10.1021/bi00755a005; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; RIEPE ME, 1968, J BIOL CHEM, V243, P2779; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; ROWLETT RS, 1984, J PROTEIN CHEM, V3, P369, DOI 10.1007/BF01025173; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SILVERMAN DN, 1975, J AM CHEM SOC, V97, P2263, DOI 10.1021/ja00841a045; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; STEIGEMANN W, 1974, THESIS MAXPLANCK I B; STEIN PJ, 1977, J AM CHEM SOC, V99, P3194, DOI 10.1021/ja00451a070; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TENEYCK LF, 1973, ACTA CRYSTALLOGR A, VA 29, P183, DOI 10.1107/S0567739473000458; TENEYCK LF, 1977, ACTA CRYSTALLOGR A, V33, P486, DOI 10.1107/S0567739477001211; TILANDER B, 1965, J MOL BIOL, V12, P740, DOI 10.1016/S0022-2836(65)80324-2; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; VEDANI A, 1984, J PHARM SCI, V73, P352, DOI 10.1002/jps.2600730316; VIDGREN J, 1990, INT J BIOL MACROMOL, V12, P342, DOI 10.1016/0141-8130(90)90040-H; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; WILLIAMS TJ, 1985, BIOCHEMISTRY-US, V24, P2459, DOI 10.1021/bi00331a010; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030	73	153	154	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17320	17325						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910042				2022-12-25	WOS:A1991GF44500054
J	NAPOLITANO, M; MODI, WS; CEVARIO, SJ; GNARRA, JR; SEUANEZ, HN; LEONARD, WJ				NAPOLITANO, M; MODI, WS; CEVARIO, SJ; GNARRA, JR; SEUANEZ, HN; LEONARD, WJ			THE GENE ENCODING THE ACT-2 CYTOKINE - GENOMIC STRUCTURE, HTLV-I TAX RESPONSIVENESS OF 5' UPSTREAM SEQUENCES, AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; TRANSACTIVATOR GENE; ACTIVATION; IDENTIFICATION; PROTEIN; SUPERFAMILY; MEMBERS; CULTURE; ELEMENT	Act-2 is a cytokine that belongs to a superfamily of structurally related proteins. Act-2 expression is rapidly induced in T cells, B cells, and monocytes upon mitogenic stimulation. The Act-2 genomic locus is on chromosome 17q. The exons and exon/intron splice junctions have been sequenced, as have the sequences upstream of exon 1. A classical TATA box is located immediately upstream of the transcription initiation site. The upstream sequences possess promoter activity and can be functionally activated after treatment of Jurkat T cells with phythohemagglutinin plus phorbol myristrate acetate. In addition, Act-2 promoter chloramphenicol acetyltransferase constructs are expressed in human T cell lymphotropic virus type I (HTLV-I)-infected MT-2 cells and in Jurkat cells which can be induced to express the transactivator gene (tax) product of HTLV-I.	PROGRAM RESOURCES INC,FREDERICK CANC RES FACIL,BIOL CARCINOGENESIS & DEV PROGRAM,FREDERICK,MD 21701; NCI,FREDERICK CANC RES FACIL,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	NAPOLITANO, M (corresponding author), NICHHD,CELL BIOL & METAB BRANCH,BETHESDA,MD 20892, USA.		Napolitano, Monica/AAB-3982-2021; Leonard, Warren/AAA-1397-2022	Gnarra, James/0000-0002-6369-3110	NCI NIH HHS [N01-CO-74102] Funding Source: Medline; OFFICE OF THE DIRECTOR, NCI [N01CO074102] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BAKHSHI A, 1986, P NATL ACAD SCI USA, V83, P2689, DOI 10.1073/pnas.83.8.2689; BROWN KD, 1989, J IMMUNOL, V142, P679; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONLON TA, 1990, GENOMICS, V6, P548, DOI 10.1016/0888-7543(90)90485-D; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IRVING SG, 1990, NUCLEIC ACIDS RES, V18, P3261, DOI 10.1093/nar/18.11.3261; JEANG KT, 1988, J VIROL, V62, P4499, DOI 10.1128/JVI.62.12.4499-4509.1988; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KRUH J, 1982, MOL CELL BIOCHEM, V42, P65; LEONGK, 1988, NATURE, V333, P776; LIPES MA, 1988, P NATL ACAD SCI USA, V85, P9704, DOI 10.1073/pnas.85.24.9704; MODI WS, 1987, GENE ANAL TECH, V4, P75; MONTMINY MR, 1987, NATURE, V328, P175, DOI 10.1038/328175a0; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAPOLITANO M, 1990, J EXP MED, V172, P285, DOI 10.1084/jem.172.1.285; OBRIEN SJ, 1982, TECHNIQUES SOMATIC C, P513; OHTANI K, 1989, NUCLEIC ACIDS RES, V17, P1589, DOI 10.1093/nar/17.4.1589; SHAPIRO M, 1990, BINARY, V2, P187; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; TOLEDANO MB, 1990, P NATL ACAD SCI USA, V87, P1830, DOI 10.1073/pnas.87.5.1830; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068; ZIPFEL PF, 1989, J IMMUNOL, V142, P1582	28	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17531	17536						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894635				2022-12-25	WOS:A1991GF44500082
J	SCHMITT, D; PAKUSCH, AE; MATERN, U				SCHMITT, D; PAKUSCH, AE; MATERN, U			MOLECULAR-CLONING, INDUCTION, AND TAXONOMIC DISTRIBUTION OF CAFFEOYL-COA 3-O-METHYLTRANSFERASE, AN ENZYME INVOLVED IN DISEASE RESISTANCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENYLALANINE AMMONIA-LYASE; CELL-SUSPENSION CULTURES; LIGASE MESSENGER-RNAS; NUCLEOTIDE-SEQUENCE; PHENOLIC-COMPOUNDS; ESCHERICHIA-COLI; PLANT-CELLS; DNA; ELICITOR; GENE	Trans-Caffeoyl-CoA 3-O-methyltransferase is involved in reinforcement of the plant cell wall under conditions that trigger the disease resistance response (Pakusch, A.-E., Kneusel, R. E., and Matern, U. (1989) Arch. Biochem. Biophys. 271, 488-494). Partial amino acid sequences of the enzyme from cultured parsley cells that had been treated with a crude elicitor were identified (Pakusch, A.-E., Matern, U., and Schiltz, E. (1991) Plant Physiol. 95, 137-143), and corresponding degenerated oligonucleotides of 29- and 30-nucleotide length were synthesized. Northern hybridizations with these probes revealed one specific RNA band, and the amount of this RNA appeared to be transiently induced upon elicitation of the cells. De novo enzyme synthesis was confirmed by Western blotting experiments using a specific antiserum. The time course of induction closely followed the pattern observed for phenylalanine ammonia-lyase and suggested the operational coordination of the methyltransferase with the general phenylpropanoid pathway in vivo. Full size cDNA of 1.258 kilobases was isolated in lambda-gt11, sequenced and found to contain a remarkably long 5'-untranslated leader sequence followed by an open reading frame that codes for a 241-residue polypeptide representing the 27-kDa subunit of the native, dimeric parsley enzyme. Almost no homology was found to protein sequences filed in data banks. Southern hybridization with genomic DNA suggested that only one or two copies of the respective gene(s) are present in the parsley genome. Caffeoyl-CoA-specific methyltransferase activity was demonstrated in taxonomically widely diverse plants such as Dianthus caryophyllus (Caryophyllaceae), Carthamus tinctorius (Asteraceae) or Daucus carota, and Ammi majus (Apiaceae) where it is commonly induced by elicitor treatment. In Northern blots with RNA from Ammi or Daucus, parsley cDNA hybridized specifically to one band comparable in size to the parsley RNA, whereas Dianthus and Carthamus appear to code for slightly larger RNAs (roughly 1.45 and 1.3 kilobases, respectively). Slot-blot hybridizations revealed in all instances the rapid and transient increase of mRNA levels in response to elicitation. This emphasizes the integral role of the enzyme in disease resistance expression in plants far beyond parsley and also illustrates a new physiological context for the induction of 4-coumarate:CoA ligase.	UNIV FREIBURG, INST BIOL 2, LEHRSTUHL BIOCHEM PFLANZEN, SCHANZLESTR 1, W-7800 FREIBURG, GERMANY	University of Freiburg								AIST JR, 1988, PHYSIOL MOL PLANT P, V33, P17, DOI 10.1016/0885-5765(88)90040-9; ANGENON G, 1990, FEBS LETT, V271, P144, DOI 10.1016/0014-5793(90)80392-V; BARKER WC, 1990, METHOD ENZYMOL, V183, P31; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIGGIN MD, 1983, P NATL ACAD SCI-BIOL, V80, P3963, DOI 10.1073/pnas.80.13.3963; BOLWELL GP, 1985, EUR J BIOCHEM, V148, P571, DOI 10.1111/j.1432-1033.1985.tb08878.x; BRAVO A, 1987, MOL GEN GENET, V210, P101, DOI 10.1007/BF00337764; BRENNER V, 1990, NUCLEIC ACIDS RES, V18, P355, DOI 10.1093/nar/18.2.355; BRUCE RJ, 1989, PLANT PHYSIOL, V91, P889, DOI 10.1104/pp.91.3.889; BUGOS RC, 1990, JUL ANN M AM SOC PLA; CARUTHERS MH, 1982, GENETIC ENG, V14, P1; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOGGETT DL, 1989, J VIROL, V63, P2108, DOI 10.1128/JVI.63.5.2108-2117.1989; DRETZEN G, 1981, ANAL BIOCHEM, V112, P295, DOI 10.1016/0003-2697(81)90296-7; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRITZEMEIER KH, 1987, PLANT PHYSIOL, V85, P34, DOI 10.1104/pp.85.1.34; HAHLBROCK K, 1989, ANNU REV PLANT PHYS, V40, P347, DOI 10.1146/annurev.pp.40.060189.002023; HAHLBROCK K, 1979, ANNU REV PLANT PHYS, V30, P105, DOI 10.1146/annurev.pp.30.060179.000541; HAMERSKI D, 1990, PHYTOCHEMISTRY, V29, P1137, DOI 10.1016/0031-9422(90)85418-F; HEIDECKER G, 1986, ANNU REV PLANT PHYS, V37, P439, DOI 10.1146/annurev.arplant.37.1.439; HELLER W, 1988, FLAVONOIDS ADV RES 1, P399; HYODO H, 1971, PLANT PHYSIOL, V47, P765, DOI 10.1104/pp.47.6.765; JACOBSON A, 1987, METHOD ENZYMOL, V152, P254; KAHN P, 1990, METHOD ENZYMOL, V183, P23; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; KNEUSEL RE, 1989, ARCH BIOCHEM BIOPHYS, V269, P455, DOI 10.1016/0003-9861(89)90129-X; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUHN DN, 1984, P NATL ACAD SCI-BIOL, V81, P1102, DOI 10.1073/pnas.81.4.1102; LAUSTER R, 1987, FEBS LETT, V220, P167, DOI 10.1016/0014-5793(87)80897-9; LEGRAND M, 1976, PHYTOCHEMISTRY, V15, P1353, DOI 10.1016/S0031-9422(00)97117-6; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; LIANG XW, 1989, J BIOL CHEM, V264, P14486; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LOZOYA E, 1988, EUR J BIOCHEM, V176, P661, DOI 10.1111/j.1432-1033.1988.tb14328.x; LUTCKE HA, 1987, EMBO J, V6, P43, DOI 10.1002/j.1460-2075.1987.tb04716.x; MATERN U, 1988, PHYTOPARASITICA, V16, P153, DOI 10.1007/BF02980469; MIYADA CG, 1987, METHOD ENZYMOL, V154, P94; MOOI FR, 1986, NUCLEIC ACIDS RES, V14, P2443, DOI 10.1093/nar/14.6.2443; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; MULLINGS R, 1988, GENE, V74, P245, DOI 10.1016/0378-1119(88)90297-1; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; OGAWA H, 1987, EUR J BIOCHEM, V168, P141, DOI 10.1111/j.1432-1033.1987.tb13398.x; PAKUSCH AE, 1989, ARCH BIOCHEM BIOPHYS, V271, P488, DOI 10.1016/0003-9861(89)90299-3; PAKUSCH AE, 1991, PLANT PHYSIOL, V96, P327, DOI 10.1104/pp.96.1.327; PAKUSCH AE, 1991, PLANT PHYSIOL, V95, P137, DOI 10.1104/pp.95.1.137; PALMITER RD, 1974, BIOCHEMISTRY-US, V13, P3606, DOI 10.1021/bi00714a032; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETERS NK, 1990, MOL PLANT MICROBE IN, V3, P4, DOI 10.1094/MPMI-3-004; REINHARD K, 1989, ARCH BIOCHEM BIOPHYS, V275, P295, DOI 10.1016/0003-9861(89)90376-7; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1989, BIOCHEM BIOPH RES CO, V161, P342, DOI 10.1016/0006-291X(89)91602-1; SCHEEL D, 1987, NATO ASI SER, P315; SCHNITZLER JP, 1989, Z NATURFORSCH C, V44, P1020; SCHRODER G, 1982, MOL GEN GENET, V185, P51, DOI 10.1007/BF00333789; SCHRODER G, 1988, EUR J BIOCHEM, V172, P161, DOI 10.1111/j.1432-1033.1988.tb13868.x; SHAH DM, 1982, P NATL ACAD SCI-BIOL, V79, P1022, DOI 10.1073/pnas.79.4.1022; SPENCER GF, 1990, PHYTOCHEMISTRY, V29, P2495, DOI 10.1016/0031-9422(90)85173-D; STEFAN C, 1991, NUCLEIC ACIDS RES, V19, P307, DOI 10.1093/nar/19.2.307; STRACK D, 1977, Z PFLANZENPHYSIOL, V84, P139, DOI 10.1016/S0044-328X(77)80186-4; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; TIETJEN KG, 1983, EUR J BIOCHEM, V131, P401, DOI 10.1111/j.1432-1033.1983.tb07277.x; TIETJEN KG, 1984, ARCH BIOCHEM BIOPHYS, V229, P136, DOI 10.1016/0003-9861(84)90138-3; VANCE CP, 1980, ANNU REV PHYTOPATHOL, V18, P259, DOI 10.1146/annurev.py.18.090180.001355; WALLACE RB, 1987, METHOD ENZYMOL, V152, P432; WALTER MH, 1990, PLANT MOL BIOL, V15, P525, DOI 10.1007/BF00019173; WELLE R, 1989, ARCH BIOCHEM BIOPHYS, V272, P97, DOI 10.1016/0003-9861(89)90199-9	70	92	104	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17416	17423						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894629				2022-12-25	WOS:A1991GF44500067
J	WILLIAMS, AM; ENNS, CA				WILLIAMS, AM; ENNS, CA			A MUTATED TRANSFERRIN RECEPTOR LACKING ASPARAGINE-LINKED GLYCOSYLATION SITES SHOWS REDUCED FUNCTIONALITY AND AN ASSOCIATION WITH BINDING IMMUNOGLOBULIN PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C; ENDOPLASMIC-RETICULUM; PHORBOL ESTER; PHOSPHORYLATION; CELLS; SERINE-24; IDENTIFICATION; GLYCOPROTEINS; BIOSYNTHESIS; ENDOCYTOSIS	The function of the transferrin receptor is to transport iron-bound transferrin into the cell. In order to function properly, this dimeric glycoprotein must be expressed on the cell surface and be able to bind transferrin. Site-directed mutagenesis was performed to abolish the three asparagine-linked glycosylation consensus sequences of the human transferrin receptor. The DNA encoding the mutated transferrin receptor was stably transfected into mouse fibroblasts. This form of the human transferrin receptor shows reduced transferrin binding, reduced intersubunit bond formation, and reduced cell surface expression, indicating that the transferrin receptor which lacks asparagine-linked glycosylation is not fully functional. In addition, the mutated form of the receptor is not processed as quickly. It shows an association with an endoplasmic reticular chaperone protein, binding immunoglobulin protein, leading to the hypothesis that the mutated transferrin receptor experiences increased retention in the endoplasmic reticulum.	OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT L215,PORTLAND,OR 97201	Oregon Health & Science University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040608] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-40608] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BUYS SS, 1984, CELL, V38, P569, DOI 10.1016/0092-8674(84)90511-7; DAVIS RJ, 1987, J BIOL CHEM, V262, P16041; DAVIS RJ, 1986, J BIOL CHEM, V261, P9034; DO SI, 1990, J BIOL CHEM, V265, P114; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ENNS CA, 1991, J BIOL CHEM, V266, P13272; ENNS CA, 1982, P NATL ACAD SCI-BIOL, V79, P3241, DOI 10.1073/pnas.79.10.3241; ENNS CA, 1981, P NATL ACAD SCI-BIOL, V78, P4222, DOI 10.1073/pnas.78.7.4222; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JING S, 1987, EMBO J, V6, P327, DOI 10.1002/j.1460-2075.1987.tb04758.x; KLAUSNER RD, 1984, P NATL ACAD SCI-BIOL, V81, P3005, DOI 10.1073/pnas.81.10.3005; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCLELLAND A, 1984, CELL, V39, P267, DOI 10.1016/0092-8674(84)90004-7; MCGRAW TE, 1988, J CELL BIOL, V106, P1061, DOI 10.1083/jcb.106.4.1061; NEEFJES JJ, 1988, J CELL BIOL, V107, P79, DOI 10.1083/jcb.107.1.79; OLDEN K, 1982, BIOCHIM BIOPHYS ACTA, V650, P209, DOI 10.1016/0304-4157(82)90017-X; OMARY MB, 1981, J BIOL CHEM, V256, P2888; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RECKHOW CL, 1988, J BIOL CHEM, V263, P7297; ROOT BJ, 1988, J BIOL CHEM, V263, P19071; ROTHENBERGER S, 1987, CELL, V49, P423, DOI 10.1016/0092-8674(87)90295-9; SCHNEIDER C, 1984, NATURE, V311, P675, DOI 10.1038/311675b0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; ZERIAL M, 1987, EMBO J, V6, P2661, DOI 10.1002/j.1460-2075.1987.tb02557.x	25	57	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17648	17654						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894645				2022-12-25	WOS:A1991GF44500098
J	ISOSAKI, M; NAKASHIMA, T; KUROGOCHI, Y				ISOSAKI, M; NAKASHIMA, T; KUROGOCHI, Y			ROLE OF PROTEIN-KINASE-C IN CATECHOLAMINE SECRETION FROM DIGITONIN-PERMEABILIZED BOVINE ADRENAL-MEDULLARY CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER TPA; CHROMAFFIN CELLS; MICROMOLAR CA-2+; PHOSPHORYLATION; EXOCYTOSIS; PURIFICATION; INHIBITOR; RECEPTOR; CALCIUM; RELEASE	The effects of staurosporine and K-252a, potent inhibitors of protein kinases, and 12-O-tetradecanoylphorbol-13-acetate (TPA) on catecholamine secretion and protein phosphorylation in digitonin-permeabilized bovine adrenal medullary cells were investigated. Staurosporine and K-252a (0.01-10-mu-M) did not cause large changes in catecholamine secretion evoked by Ca2+ in digitonin-permeabilized cells whereas these compounds strongly prevented TPA-induced enhancement of catecholamine secretion in a concentration-dependent manner. Incubation of digitonin-permeabilized cells with [gamma-P-32]ATP resulted in P-32(i) incorporation into a large number of proteins, detected as several major bands and darkened background in autoradiograms. Ca2+ and TPA increased phosphorylation of these proteins. Staurosporine and K-252a markedly inhibited Ca2+-induced and TPA-induced increases in protein phosphorylation as well as basal (0 Ca2+) protein phosphorylation in digitonin-permeabilized cells. Long term treatment (24 h) of adrenal medullary cells with 1-mu-M TPA markedly decreased total cellular protein kinase C activity to about 5.3% of control. Pretreatment of the cells with 1-mu-M TPA strongly inhibited the TPA-induced enhancement of catecholamine secretion whereas it did not cause large changes in total cellular catecholamine amounts, Ca2+-induced catecholamine secretion, and cAMP-induced enhancement of catecholamine secretion from digitonin-permeabilized cells. From these results we conclude that protein kinase C plays a modulatory role in catecholamine secretion rather than being essential for initiating catecholamine secretion.			ISOSAKI, M (corresponding author), NARA MED UNIV,DEPT PHARMACOL,KASHIHARA,NARA 634,JAPAN.							AMY CM, 1981, J NEUROCHEM, V36, P847, DOI 10.1111/j.1471-4159.1981.tb01671.x; BADER MF, 1989, J BIOL CHEM, V264, P16426; BAKER PF, 1986, PROG ZOOL, V33, P265; BALLESTER R, 1985, J BIOL CHEM, V260, P5194; BERS DM, 1982, AM J PHYSIOL, V242, pC404, DOI 10.1152/ajpcell.1982.242.5.C404; BROCKLEHURST KW, 1985, FEBS LETT, V183, P107, DOI 10.1016/0014-5793(85)80964-9; BROCKLEHURST KW, 1986, BIOSCIENCE REP, V6, P749, DOI 10.1007/BF01116543; BURGOYNE RD, 1988, FEBS LETT, V238, P151, DOI 10.1016/0014-5793(88)80246-1; DOUGLAS WW, 1961, NATURE, V192, P1299, DOI 10.1038/1921299a0; HOLZ RW, 1988, CELL MOL NEUROBIOL, V8, P115, DOI 10.1007/BF00712917; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KNIGHT DE, 1988, J MEMBRANE BIOL, V104, P21, DOI 10.1007/BF01871899; KNIGHT DE, 1983, FEBS LETT, V160, P98, DOI 10.1016/0014-5793(83)80944-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SA, 1986, J BIOL CHEM, V261, P7089; NIEDEL JE, 1983, P NATL ACAD SCI-BIOL, V80, P36, DOI 10.1073/pnas.80.1.36; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OKA M, 1979, CATECHOLAMINES BASIC, V1, P70; POCOTTE SL, 1985, P NATL ACAD SCI USA, V82, P930, DOI 10.1073/pnas.82.3.930; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TERBUSH DR, 1986, J BIOL CHEM, V261, P7099; WAYMIRE JC, 1983, J NEUROSCI METH, V7, P329, DOI 10.1016/0165-0270(83)90026-2; WEILMALHERBE H, 1952, BIOCHEM J, V51, P311, DOI 10.1042/bj0510311; WILSON SP, 1977, J NEUROCHEM, V28, P687, DOI 10.1111/j.1471-4159.1977.tb10615.x; WILSON SP, 1990, J BIOL CHEM, V265, P648; YAMADA K, 1988, BIOCHEM PHARMACOL, V37, P1161	27	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16703	16707						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885599				2022-12-25	WOS:A1991GD63500074
J	SKALNIK, DG; STRAUSS, EC; ORKIN, SH				SKALNIK, DG; STRAUSS, EC; ORKIN, SH			CCAAT DISPLACEMENT PROTEIN AS A REPRESSOR OF THE MYELOMONOCYTIC-SPECIFIC GP91-PHOX GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC GRANULOMATOUS-DISEASE; BOX-BINDING-PROTEINS; GAMMA-GLOBIN GENE; TRANSGENIC MICE; EXPRESSION; DNA; TRANSCRIPTION; SEQUENCE; REGION; CELLS	The cytochrome b heavy chain (gp91-phox) is expressed exclusively in terminally differentiating myelomonocytic cells. The human gp91-phox gene spans approximately 30 kilobases, and is divided into 13 exons. A ubiquitous factor that is indistinguishable from the CCAAT-binding factor CP1 interacts in vitro with the distal gp91-phox promoter CCAAT box motif. CP1 binding is prevented, however, by a CCAAT displacement protein (CDP) that binds to the region surrounding the CCAAT box. CDP DNA-binding activity is found in nuclear extracts prepared from cells in which the endogenous gp91-phox gene is transcriptionally inactive, but is absent or reduced in expressing cells, consistent with CDP functioning as a repressor of gp91-phox transcription. Introduction of gp91-phox promoter/reporter constructs into nonexpressing cells yields significantly less expression than that produced by the parental reporter vector alone. The reduction in expression is relieved when the CDP/CP1-binding site is removed from the gp91-phox promoter, confirming that it is a target for repression. No derepression is observed if the CP1-binding site is selectively mutated. Derepression of expression exhibited upon deletion of the CDP/CP1-binding site suggests that, in addition to blocking the interaction of the CCAAT-binding factor with the gp91-phox promoter, CDP may also repress transcription mediated through a distinct cis-element(s). We propose that down-regulation of CDP DNA-binding activity is a necessary step in the induction of myelomonocytic-specific expression of the gp91-phox gene.	HARVARD UNIV, CHILDRENS HOSP,SCH MED,DANA FARBER CANC INST, DEPT PEDIAT,DIV HEMATOL & ONCOL, BOSTON, MA 02115 USA; HARVARD MIT DIV HLTH SCI & TECHNOL, BOSTON, MA 02115 USA; HOWARD HUGHES MED INST, BOSTON, MA 02115 USA	Harvard University; Boston Children's Hospital; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Howard Hughes Medical Institute					NICHD NIH HHS [HD 18661] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD018661, R01HD018661] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Ausubel FA, 1990, CURRENT PROTOCOLS MO; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; DENDUNNEN JT, 1989, GENE, V78, P201, DOI 10.1016/0378-1119(89)90223-0; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; GARGIABLANCO MA, 1989, GENE DEV, V3, P739, DOI 10.1101/gad.3.6.739; GREER P, 1990, MOL CELL BIOL, V10, P2521, DOI 10.1128/MCB.10.6.2521; HAYASHI S, 1990, CELL, V63, P883, DOI 10.1016/0092-8674(90)90492-W; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; HOHN PA, 1989, J BIOL CHEM, V264, P13412; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KATO H, 1991, SCIENCE, V251, P1476, DOI 10.1126/science.2006421; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; LUBBERT M, 1991, BLOOD, V77, P909; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MORISHITA K, 1987, J BIOL CHEM, V262, P15208; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; OHKUMA Y, 1990, P NATL ACAD SCI USA, V87, P2289, DOI 10.1073/pnas.87.6.2289; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; ORKIN SH, 1989, ANNU REV IMMUNOL, V7, P277; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Sambrook J, 1989, MOL CLONING LABORATO; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SKALNIK DG, 1991, IN PRESS MOL CELL BI; SMITH RM, 1991, BLOOD, V77, P673; SUPERTIFURGA G, 1989, BIOCHIM BIOPHYS ACTA, V1007, P237, DOI 10.1016/0167-4781(89)90046-8; SUPERTIFURGA G, 1988, EMBO J, V7, P3099, DOI 10.1002/j.1460-2075.1988.tb03176.x; TAKAHASHI H, 1988, J BIOL CHEM, V263, P14739; TAUBER AI, 1983, MEDICINE, V62, P286, DOI 10.1097/00005792-198309000-00003; TREISMAN R, 1987, EMBO J, V6, P2711, DOI 10.1002/j.1460-2075.1987.tb02564.x; TUCKER KA, 1987, BLOOD, V70, P372	39	240	243	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16736	16744						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885602				2022-12-25	WOS:A1991GD63500079
J	DEUTSCH, D; PALMON, A; FISHER, LW; KOLODNY, N; TERMINE, JD; YOUNG, MF				DEUTSCH, D; PALMON, A; FISHER, LW; KOLODNY, N; TERMINE, JD; YOUNG, MF			SEQUENCING OF BOVINE ENAMELIN (TUFTELIN) A NOVEL ACIDIC ENAMEL PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT INCISOR ENAMEL; MATRIX PROTEINS; IMMUNOHISTOCHEMICAL LOCALIZATION; FETAL ENAMEL; TOOTH; BIOSYNTHESIS; AMELOGENINS; HYDROLYSIS; PEPTIDES; ALBUMIN	Enamelins are a major group of 28-70-kDa acidic proteins rich in aspartic acid, glutamic acid, serine, and glycine found in developing and mature extracellular enamel; a unique and highly mineralized ectodermal tissue covering vertebrate teeth. They have been associated with the mineralization and structural organization of this tissue. In an attempt to elucidate the primary structure of enamelin, a 2674-base pair cDNA isolated from a bovine ameloblast-enriched, lambda Zap 2 expression library, was sequenced. The identity and localization of the deduced protein was confirmed by amino acid composition, enzyme-linked immunosorbent assay, Western blotting, indirect immunohistochemistry, and high resolution protein-A gold immunocytochemistry. The immunological techniques were employed using antibodies directed against synthetic peptides corresponding to the protein sequence deduced from the cloned cDNA sequence. The results reveal the deduced protein to be a novel acidic enamel protein. It contains 389 amino acids and has a calculated molecular weight of 43,814. Its amino acid composition is similar to that of "tuft" proteins (enamel matrix protein fragments remaining in the mature tissue). It contains one potential N-glycosylation site and 5 cysteine residues. Southern hybridization of the cloned cDNA with genomic bovine DNA indicated the existence of a single gene with one or more introns.	NIDR,BONE RES BRANCH,BETHESDA,MD 20892; NIDR,CELLULAR DEV & ONCOL LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	DEUTSCH, D (corresponding author), HEBREW UNIV JERUSALEM,HADASSAH FAC DENT MED,DENT RES UNIT,POB 1172,JERUSALEM,ISRAEL.			Young, Marian F/0000-0003-0929-8854	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE005780] Funding Source: NIH RePORTER; NIDCR NIH HHS [R0I-DEO-5780] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMIZUKA N, 1989, TOOTH ENAMEL, V5, P410; ARSENAULT AL, 1989, CALCIFIED TISSUE INT, V45, P111, DOI 10.1007/BF02561410; BENDAYAN M, 1984, J ELECTRON MICR TECH, V1, P243, DOI 10.1002/jemt.1060010304; DACLUUSI G, 1984, TOOTH ENAMEL, V4, P14; Deutsch D, 1987, Adv Dent Res, V1, P282; DEUTSCH D, 1989, ANAT RECORD, V224, P189, DOI 10.1002/ar.1092240209; Deutsch D., 1991, P73; DEUTSCH D, 1986, CURRENT ADV SKELETOG, P165; DEUTSCH D, 1984, TOOTH ENAMEL, V4, P234; DEUTSCH D, 1989, TOOTH ENAMEL, V5, P308; DOI Y, 1984, TOOTH ENAMEL, V4, P19; EASTOE JE, 1979, J DENT RES B, V58, P735; FARGE P, 1987, ARCH ORAL BIOL, V32, P655, DOI 10.1016/0003-9969(87)90040-9; FINCHAM AG, 1982, CARIES RES, V16, P64, DOI 10.1159/000260578; Fincham AG, 1985, CHEM BIOL MINERALIZE, P240; GLIMCHER MJ, 1977, CALC TISS RES, V24, P259, DOI 10.1007/BF02223326; GLIMCHER MJ, 1979, J DENT RES, V58, P790, DOI 10.1177/00220345790580023101; HAYASHI Y, 1986, BASIC APPL HISTOCHEM, V30, P291; HEROLD R, 1989, CALCIFIED TISSUE INT, V45, P88, DOI 10.1007/BF02561407; HILLER CR, 1975, CALC TISS RES, V18, P1, DOI 10.1007/BF02546222; KOLODNY N, 1990, ANAL BIOCHEM, V187, P136, DOI 10.1016/0003-2697(90)90431-8; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBLOND CP, 1979, J DENT RES, V58, P950, DOI 10.1177/00220345790580024901; LIMEBACK H, 1989, J BONE MINER RES, V4, P235; Maniatis T., 1982, MOL CLONING; MENANTEAU J, 1988, CALCIFIED TISSUE INT, V42, P196, DOI 10.1007/BF02556334; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MESSING J, 1981, NUCLEIC ACIDS RES, V9, P309, DOI 10.1093/nar/9.2.309; NANCI A, 1989, ANAT REC, V224, P277, DOI 10.1002/ar.1092240218; OGATA Y, 1988, CALCIFIED TISSUE INT, V43, P389, DOI 10.1007/BF02553284; ROBINSON C, 1975, ARCH ORAL BIOL, V20, P29, DOI 10.1016/0003-9969(75)90149-1; ROBINSON C, 1989, CALCIFIED TISSUE INT, V44, P393, DOI 10.1007/BF02555967; ROBINSON C, 1977, CALC TISS RES, V23, P19, DOI 10.1007/BF02012762; ROBINSON C, 1985, CHEM BIOL MINERALIZE, P249; Robinson C, 1989, TOOTH ENAMEL, P59; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Shimokawa H, 1987, Adv Dent Res, V1, P293; Shimokawa H, 1984, TOOTH ENAMEL, P161; SLAVKIN HC, 1988, DIFFERENTIATION, V37, P26, DOI 10.1111/j.1432-0436.1988.tb00793.x; SLAVKIN HC, 1984, TOOTH ENAMEL, V4, P167; SNEAD ML, 1985, BIOCHEM BIOPH RES CO, V129, P812, DOI 10.1016/0006-291X(85)91964-3; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STACK MV, 1967, STRUCTURE CHEMICAL O, V2, P317; STRAWICH E, 1990, EUR J BIOCHEM, V191, P47, DOI 10.1111/j.1432-1033.1990.tb19092.x; TERMINE JD, 1980, J BIOL CHEM, V255, P9760; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRAUB W, 1985, CHEM BIOL MINERALISE, P221; WALLACE RB, 1981, GENE, V16, P21, DOI 10.1016/0378-1119(81)90057-3; WARSHAWSKY H, 1984, TOOTH ENAMEL, V4, P177; YANAGISAWA T, 1982, JPN J ORAL BIOL, V24, P777; ZEICHNERDAVID M, 1987, J DENT RES, V66, P142; ZEICHNERDAVID M, 1985, CHEM BIOL MINERALIZE, P264	53	134	141	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16021	16028						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874744				2022-12-25	WOS:A1991GB97700075
J	VANIWAARDEN, PR; DRIESSEN, AJM; MENICK, DR; KABACK, HR; KONINGS, WN				VANIWAARDEN, PR; DRIESSEN, AJM; MENICK, DR; KABACK, HR; KONINGS, WN			CHARACTERIZATION OF PURIFIED, RECONSTITUTED SITE-DIRECTED CYSTEINE MUTANTS OF THE LACTOSE PERMEASE OF ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAC CARRIER PROTEIN; MEMBRANE-VESICLES; MONOCLONAL-ANTIBODIES; ACTIVE-TRANSPORT; CYTOPLASMIC SIDE; COOH TERMINUS; MUTAGENESIS; MECHANISM; BINDING; PROTON	lac Permease mutated at each of the 8 cysteinyl residues in the molecule was solubilized from the membrane, purified, and reconstituted into proteoliposomes. The transport activity of proteoliposomes reconstituted with each mutant permease relative to the wild-type is virtually identical with that reported for intact cells and/or right-side-out membrane vesicles. Moreover, a double mutant containing Ser in place of both Cys148 and Cys154 exhibits significant ability to catalyze active lactose transport. The results provide strong confirmation for the contention that cysteinyl residues in lac permease do not play an important role in the transport mechanism. The effect of sulfhydryl oxidant 5-hydroxy-2-methyl-1,4-naphthoquinone on lactose transport in proteoliposomes reconstituted with wild-type or mutant permeases was also investigated, and the results indicate that inactivation is probably due to formation of a covalent adduct with Cys148 and/or Cys154 rather than disulfide formation. Thus, it seems unlikely that sulfhydryl-disulfide interconversion functions to regulate permease activity.	STATE UNIV GRONINGEN, DEPT MICROBIOL, KERKLAAN 30, 9751 NN HAREN, NETHERLANDS; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, DEPT PHYSIOL, LOS ANGELES, CA 90024 USA	University of Groningen; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Driessen, Arnold J.M./D-1876-2012; Konings, Wilhelmus N./C-7063-2013	Driessen, Arnold J.M./0000-0001-9258-9104				BEYREUTHER K, 1981, METHODS PROTEIN SEQU, P139; BROOKER RJ, 1986, J BIOL CHEM, V261, P1765; BUCHEL DE, 1980, NATURE, V283, P541, DOI 10.1038/283541a0; CALAMIA J, 1990, P NATL ACAD SCI USA, V87, P4937, DOI 10.1073/pnas.87.13.4937; CARRASCO N, 1984, BIOCHEMISTRY-US, V23, P3681, DOI 10.1021/bi00311a017; CARRASCO N, 1982, P NATL ACAD SCI-BIOL, V79, P6894, DOI 10.1073/pnas.79.22.6894; CARRASCO N, 1984, P NATL ACAD SCI-BIOL, V81, P4672, DOI 10.1073/pnas.81.15.4672; FOSTER DL, 1983, J BIOL CHEM, V258, P31; FOSTER DL, 1982, BIOCHEMISTRY-US, V21, P5634, DOI 10.1021/bi00265a038; FOX CF, 1965, P NATL ACAD SCI USA, V54, P891, DOI 10.1073/pnas.54.3.891; GOLDKORN T, 1983, P NATL ACAD SCI-BIOL, V80, P3322, DOI 10.1073/pnas.80.11.3322; HERZLINGER D, 1984, BIOCHEMISTRY-US, V23, P3688, DOI 10.1021/bi00311a018; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; KABACK HR, 1989, HARVEY LECT, V83, P77; KABACK HR, 1971, J BIOL CHEM, V246, P5523; KABACK HR, 1978, BIOCHEMISTRY-US, V17, P1640, DOI 10.1021/bi00602a010; KABACK HR, 1990, PHILOS T R SOC B, V326, P425, DOI 10.1098/rstb.1990.0022; KABACK HR, 1983, J MEMBRANE BIOL, V76, P95; KENNEDY EP, 1974, J BIOL CHEM, V249, P33; KONINGS WN, 1982, P NATL ACAD SCI-BIOL, V79, P5480, DOI 10.1073/pnas.79.18.5480; MENICK DR, 1985, BIOCHEM BIOPH RES CO, V132, P162, DOI 10.1016/0006-291X(85)91002-2; MENICK DR, 1987, BIOCHEMISTRY-US, V26, P1132, DOI 10.1021/bi00378a022; NEUHAUS JM, 1985, FEBS LETT, V185, P83, DOI 10.1016/0014-5793(85)80745-6; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NICKERSON WJ, 1963, BIOCHEMISTRY-US, V2, P537, DOI 10.1021/bi00903a025; PAGE MGP, 1988, J BIOL CHEM, V263, P15906; PAGE MGP, 1988, J BIOL CHEM, V263, P15897; PAGE MGP, 1986, BIOCHIM BIOPHYS ACTA, V858, P67, DOI 10.1016/0005-2736(86)90292-0; ROBILLARD GT, 1982, EUR J BIOCHEM, V127, P597; SARKAR HK, 1986, METHOD ENZYMOL, V125, P214; SARKAR HK, 1986, J BIOL CHEM, V261, P8914; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SECKLER R, 1986, BIOCHEMISTRY-US, V25, P2403, DOI 10.1021/bi00357a016; SECKLER R, 1984, EUR J BIOCHEM, V142, P269, DOI 10.1111/j.1432-1033.1984.tb08281.x; SECKLER R, 1983, J BIOL CHEM, V258, P817; STOCHAJ U, 1986, EUR J BIOCHEM, V158, P423, DOI 10.1111/j.1432-1033.1986.tb09770.x; TEATHER RM, 1980, EUR J BIOCHEM, V108, P223, DOI 10.1111/j.1432-1033.1980.tb04715.x; TRUMBLE WR, 1984, BIOCHEM BIOPH RES CO, V119, P860, DOI 10.1016/0006-291X(84)90853-2; VIITANEN P, 1983, BIOCHEMISTRY-US, V22, P2531, DOI 10.1021/bi00279a034; VIITANEN P, 1984, P NATL ACAD SCI-BIOL, V81, P1629, DOI 10.1073/pnas.81.6.1629; VIITANEN P, 1986, METHOD ENZYMOL, V125, P429; VIITANEN PV, 1985, BIOCHEMISTRY-US, V24, P7628, DOI 10.1021/bi00347a020; VOGEL H, 1985, EMBO J, V4, P3625, DOI 10.1002/j.1460-2075.1985.tb04126.x; WRIGHT JK, 1986, ANNU REV BIOCHEM, V55, P225	44	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15688	15692						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874727				2022-12-25	WOS:A1991GB97700028
J	HAMAGUCHI, N; CHARIFSON, PS; PEDERSEN, LG; BRAYER, GD; SMITH, KJ; STAFFORD, DW				HAMAGUCHI, N; CHARIFSON, PS; PEDERSEN, LG; BRAYER, GD; SMITH, KJ; STAFFORD, DW			EXPRESSION AND CHARACTERIZATION OF HUMAN FACTOR-IX - FACTOR-IXTHR-397 AND FACTOR-IXVAL-397	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; HUMAN ALPHA-THROMBIN; SERINE PROTEASES; FACTOR-X; HEMOPHILIA-B; ACTIVATION; PROTEINS; DOMAIN; GENE; DNA	Factor IX(Long Beach) has a single amino acid substitution at 397 (Ile to Thr) in the catalytic domain which results in severe hemophilia B. Recent investigations have shown that the substitution of threonine for isoleucine at 397 may affect a part of the macromolecular substrate binding site. Because threonine has a hydroxyl group in its side chain, it is possible that this hydroxyl group makes new hydrogen bonds and disturbs the substrate binding site. We used three techniques: molecular biology, which includes site-directed mutagenesis and recombinant protein expression in tissue culture; computer-aided kinetic data analysis; and molecular modeling to study this mutation site. We have produced two mutant factor IX molecules that have isoleucine 397 replaced by valine or threonine. Factor IX(wild type) and the two mutants (factor IX(Val) and factor IX(Thr) were expressed in human kidney cells and purified using a conformation-specific monoclonal antibody column. After the activation by factor XIa, these three molecules were able to bind p-aminobenzamidine and increase its fluorescence intensity in a similar manner. Factor IX(Val) and factor IX(wild type) had indistinguishable activities in an activated partial thromboplastin time (aPTT) assay and similar kinetic parameters with factor X as a substrate. Factor IX(Thr) had only 5% clotting activity compared with normal factor IX, a slightly lower K(m) and significantly reduced k(cat), using factor X as a substrate. We developed energy-refined (AMBER v.3.1) computer models of the three factor IX molecules based on previous work. Three factor IXa models (Ile, Val, or Thr at 397) with a fragment of the factor X activation site were used to predict the effect of the mutation at 397 and evaluate the significance of the new hydrogen bond thought to form between the side chain hydroxyl group of threonine 397 and the carbonyl oxygen of tryptophan 385. This new hydrogen bond would affect the position of an amide proton of adjacent glycine 386 which has been proposed to make a hydrogen bond with a backbone carbonyl oxygen of the P3 residue of factor X. In addition to the new hydrogen bond, there is significant movement in the side chain of tryptophan 385 between the factor IXa(wild type)-factor X model and the factor IXa(Thr)-factor X model that could interfere with substrate binding. This movement could be caused by the change in the molecular volume, the orientation of the side chain at 397, and the new hydrogen bond.	UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27514; UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27514; UNIV N CAROLINA,CTR THROMBOSIS & HEMOSTASIS,CHAPEL HILL,NC 27514; UNIV NEW MEXICO,SCH MED,DEPT MED,ALBUQUERQUE,NM 87131; UNIV NEW MEXICO,SCH MED,DEPT PATHOL,ALBUQUERQUE,NM 87131; UNITED BLOOD SERV,ALBUQUERQUE,NM 87131; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1W5,BC,CANADA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of New Mexico; University of New Mexico; University of British Columbia			Pedersen, Lee G/E-3405-2013	Pedersen, Lee G/0000-0003-1262-9861	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038973] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL38973-03] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERK AJ, 1978, P NATL ACAD SCI USA, V75, P1274, DOI 10.1073/pnas.75.3.1274; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BOTTEMA CDK, 1990, BRIT J HAEMATOL, V75, P2212; BRAUNSTEIN KM, 1981, J CLIN INVEST, V68, P1420, DOI 10.1172/JCI110393; CHIRLIAN LE, 1987, J COMPUT CHEM, V8, P894, DOI 10.1002/jcc.540080616; CRAIK CS, 1985, SCIENCE, V228, P291, DOI 10.1126/science.3838593; DEMPSEY S, 1986, MOL MODELLING SYSTEM; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; Fersht A., 1984, ENZYME STRUCTURE MEC; FRANCO R, 1984, INT J BIOMED COMPUT, V15, P419, DOI 10.1016/0020-7101(84)90013-8; FRAZIER D, 1989, BLOOD, V74, P971; FURIE B, 1982, J BIOL CHEM, V257, P3875; GEDDES VA, 1989, J BIOL CHEM, V264, P4689; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAY CW, 1986, BLOOD, V67, P1508; KARPLUS M, 1990, NATURE, V347, P631, DOI 10.1038/347631a0; KOERBER SC, 1987, ANAL BIOCHEM, V165, P75, DOI 10.1016/0003-2697(87)90203-X; KRAMER W, 1987, METHOD ENZYMOL, V154, P350; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LUNDBLAD RL, 1987, THROMB RES, V48, P395, DOI 10.1016/0049-3848(87)90397-5; MANN KG, 1990, BLOOD, V76, P1; MCCORD DM, 1990, J BIOL CHEM, V265, P10250; MERTENS K, 1984, BIOCHEM J, V223, P607, DOI 10.1042/bj2230607; MONROE DM, 1988, ANAL BIOCHEM, V172, P427, DOI 10.1016/0003-2697(88)90465-4; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PIMENTEL GC, 1960, HYDROGEN BOND, P242; PRESS WH, 1988, NUMERICAL RECIPES, P549; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SARKAR G, 1990, GENOMICS, V6, P133, DOI 10.1016/0888-7543(90)90458-7; Schulz G. E., 1979, PRINCIPLES PROTEIN S; SMITH KJ, 1987, AM J CLIN PATHOL, V87, P370, DOI 10.1093/ajcp/87.3.370; SPITZER SG, 1990, BIOCHEM J, V265, P219, DOI 10.1042/bj2650219; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; THOMPSON AR, 1986, BLOOD, V67, P565; THOMSEN DR, 1984, P NATL AAD SCI US, V84, P4767; TONGE PJ, 1990, BIOCHEMISTRY-US, V29, P10723, DOI 10.1021/bi00500a002; WARE J, 1988, P NATL ACAD SCI USA, V85, P3165, DOI 10.1073/pnas.85.9.3165; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051	41	22	22	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15213	15220						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1907972				2022-12-25	WOS:A1991GB09700061
J	OTTER, M; BARRETTBERGSHOEFF, MM; RIJKEN, DC				OTTER, M; BARRETTBERGSHOEFF, MM; RIJKEN, DC			BINDING OF TISSUE-TYPE PLASMINOGEN-ACTIVATOR BY THE MANNOSE RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA CELLS; MEDIATED ENDOCYTOSIS; LINE HEP-G2; RAT-LIVER; CLEARANCE; PURIFICATION; MACROPHAGES; DEGRADATION; IDENTIFICATION; GLYCOPROTEINS	Previous studies have shown that tissue-type plasminogen activator (t-PA) in blood is cleared by the liver partially through a mannose-specific uptake system. The present study was undertaken to investigate, in a purified system, whether t-PA is recognized by the mannose receptor which is expressed on macrophages and liver sinusoidal cells. The mannose receptor was isolated and purified from bovine alveolar macrophages and migrated as a single protein band at M(r) 175,000 on polyacrylamide gel electrophoresis in t he presence of sodium dodecyl sulfate. Ligand blotting revealed that this protein specifically bound t-PA. The t-PA-receptor interaction was further characterized in a binding assay, which showed saturable binding with an apparent dissociation constant of 1 nm. t-PA binding required calcium ions and was negligible in the presence of EDTA or at acid pH. Mannose-albumin was an effective inhibitor, whereas galactose-albumin did not have a significant effect. From a series of monosaccharides tested, D-mannose and L-fucose were the most potent inhibitors, N-acetyl-D-glucosamine was a moderate inhibitor, whereas D-galactose and N-acetyl-D-galactosamine were ineffective. t-PA, deglycosylated by endoglycosidase H, did not interact with the receptor. It is concluded that the mannose receptor specifically binds t-PA, probably through its high mannose-type oligosaccharide.	TNO, GAUBIUS INST, IVVO, GAUBIUS LAB, POB 430, 2300 AK LEIDEN, NETHERLANDS	Netherlands Organization Applied Science Research								ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BACHMANN F, 1987, THROMB DIATH HAEMO, P227; BAKHIT C, 1987, J BIOL CHEM, V262, P8716; BAYNES JW, 1976, J BIOL CHEM, V251, P6016; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROWNE MJ, 1985, THROMB HAEMOSTASIS, V54, P422; COLLEN D, 1989, DRUGS, V38, P346, DOI 10.2165/00003495-198938030-00003; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; EINARSSON M, 1988, THROMB HAEMOSTASIS, V59, P474; EINARSSON M, 1989, THROMB HAEMOSTASIS, V62, P1088; EZEKOWITZ RAB, 1988, J CELL SCI, P121; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; GOLDSTEIN JL, 1979, NATURE, V279, P679, DOI 10.1038/279679a0; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P5696; HOTCHKISS A, 1988, THROMB HAEMOSTASIS, V60, P255; KUIPER J, 1988, J BIOL CHEM, V263, P18220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHRMAN MA, 1986, J BIOL CHEM, V261, P7419; LENNARTZ MR, 1987, J BIOL CHEM, V262, P9942; LUCORE CL, 1988, CIRCULATION, V77, P906, DOI 10.1161/01.CIR.77.4.906; MAYNARD Y, 1981, J BIOL CHEM, V256, P8063; ORD JM, 1990, FIBRINOLYSIS, V4, P203, DOI 10.1016/0268-9499(90)90015-C; OTTER M, 1989, THROMB HAEMOSTASIS, V62, P667; OWENSBY DA, 1988, J BIOL CHEM, V263, P10587; PAREKH RB, 1989, BIOCHEMISTRY-US, V28, P7644, DOI 10.1021/bi00445a021; Patthy L, 1990, Blood Coagul Fibrinolysis, V1, P153; POHL G, 1987, EUR J BIOCHEM, V170, P69, DOI 10.1111/j.1432-1033.1987.tb13668.x; RADCLIFFE R, 1981, ARCH BIOCHEM BIOPHYS, V211, P750, DOI 10.1016/0003-9861(81)90512-9; RIJKEN DC, 1990, THROMB RES, P63; RIJKEN DC, 1979, BIOCHIM BIOPHYS ACTA, V580, P140, DOI 10.1016/0005-2795(79)90205-8; RIJKEN DC, 1985, THROMB HAEMOSTASIS, V54, P788; RIJKEN DC, 1981, J BIOL CHEM, V256, P7035; RIJKEN DC, 1986, BIOCHEM J, V238, P643, DOI 10.1042/bj2380643; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHEPHERD VL, 1990, BIOCHEM J, V270, P771, DOI 10.1042/bj2700771; SHEPHERD VL, 1981, P NATL ACAD SCI-BIOL, V78, P1019, DOI 10.1073/pnas.78.2.1019; SMEDSROD B, 1990, BIOCHEM J, V271, P345, DOI 10.1042/bj2710345; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; STAHL P, 1986, J CLIN INVEST, V77, P657, DOI 10.1172/JCI112359; STAHL PD, 1980, TRENDS BIOCHEM SCI, V5, P194, DOI 10.1016/0968-0004(80)90238-8; SUNG SSJ, 1983, J CELL BIOL, V96, P160, DOI 10.1083/jcb.96.1.160; TANSWELL P, 1989, FIBRINOLYSIS, V3, P79, DOI 10.1016/0268-9499(89)90035-0; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; WARR GA, 1980, BIOCHEM BIOPH RES CO, V93, P737, DOI 10.1016/0006-291X(80)91139-0; WILEMAN TE, 1986, P NATL ACAD SCI USA, V83, P2501, DOI 10.1073/pnas.83.8.2501	46	94	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13931	13935						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906888				2022-12-25	WOS:A1991FY02700075
J	KALLIO, PT; FAGELSON, JE; HOCH, JA; STRAUCH, MA				KALLIO, PT; FAGELSON, JE; HOCH, JA; STRAUCH, MA			THE TRANSITION-STATE REGULATOR HPR OF BACILLUS-SUBTILIS IS A DNA-BINDING PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONTROL SCO MUTATIONS; SPORULATION; GENE; ABRB; TRANSCRIPTION; EXPRESSION; PROMOTER; OPERON; MUTANTS; REGIONS	The synthesis of a variety of proteins, including the well characterized degradative enzymes, which occurs during the transition state between vegetative growth and the onset of sporulation in Bacillus subtilis is controlled by a class of molecules known as transition state regulators. One of these regulators is the product of the hpr gene, first identified by mutations affecting the synthesis of extracellular proteases. We have purified the Hpr protein and found that it binds specifically to DNA fragments carrying the promoters and the upstream regions of the alkaline (aprE) and neutral (nprE) protease genes of B. subtilis. DNase I protection experiments revealed that the Hpr protein is able to bind at four and two regions of the aprE and nprE promoters, respectively. We have also located two Hpr binding sites in the promoter region of a gene of unknown function which is nevertheless known to be developmentally regulated during the transition state and which occurs in the same operon as the gene encoding another transition state regulator, Sin. The location of one of the Hpr binding sites on the aprE gene occurs adjacent to a region to which the Sin protein binds. However, in mixing competition experiments we have shown that Hpr and Sin binding occurred independently, and no visible alterations of protected regions were detected.	Scripps Res Inst, RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	Scripps Research Institute					NIGMS NIH HHS [GM19416, GM39442] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM019416, R01GM039442, R37GM019416] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BURBULYS D, 1991, CELL, V64, P545, DOI 10.1016/0092-8674(91)90238-T; DOD B, 1978, MOL GEN GENET, V163, P57, DOI 10.1007/BF00268964; FERRARI E, 1988, J BACTERIOL, V170, P289, DOI 10.1128/JB.170.1.289-295.1988; GAUR NK, 1991, J BACTERIOL, V173, P678, DOI 10.1128/jb.173.2.678-686.1991; GAUR NK, 1986, J BACTERIOL, V168, P860, DOI 10.1128/jb.168.2.860-869.1986; GAUR NK, 1988, J BACTERIOL, V170, P1046, DOI 10.1128/jb.170.3.1046-1053.1988; HENNER DJ, 1988, J BACTERIOL, V170, P296, DOI 10.1128/jb.170.1.296-300.1988; HIGERD TB, 1972, J BACTERIOL, V112, P1026, DOI 10.1128/JB.112.2.1026-1028.1972; HOCH JA, 1976, ADV GENET, V18, P69, DOI 10.1016/S0065-2660(08)60437-X; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; HONJO M, 1990, J BACTERIOL, V172, P1783, DOI 10.1128/jb.172.4.1783-1790.1990; HUO L, 1988, P NATL ACAD SCI USA, V85, P5444, DOI 10.1073/pnas.85.15.5444; ITO J, 1973, C INT CEN NATL RES S, V227, P81; JEANNODA V, 1978, MOL GEN GENET, V163, P65, DOI 10.1007/BF00268965; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAYNE E, 1957, METHOD ENZYMOL, V3, P447, DOI 10.1016/S0076-6879(57)03413-8; LOSICK R, 1986, ANNU REV GENET, V20, P625, DOI 10.1146/annurev.ge.20.120186.003205; Lovett P S, 1979, Methods Enzymol, V68, P342; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MARAHIEL MA, 1987, J BACTERIOL, V169, P2215, DOI 10.1128/jb.169.5.2215-2222.1987; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; PEREGO M, 1988, J BACTERIOL, V170, P2560, DOI 10.1128/jb.170.6.2560-2567.1988; PEREGO M, 1989, J BACTERIOL, V171, P6187, DOI 10.1128/jb.171.11.6187-6196.1989; PEREGO M, 1988, MOL MICROBIOL, V2, P689, DOI 10.1111/j.1365-2958.1988.tb00079.x; PEREGO M, 1991, J BACTERIOL, V173, P2514, DOI 10.1128/jb.173.8.2514-2520.1991; Sambrook J, 1989, MOL CLONING LABORATO; STRAUCH M, 1990, P NATL ACAD SCI USA, V87, P1801, DOI 10.1073/pnas.87.5.1801; STRAUCH MA, 1989, MOL MICROBIOL, V3, P1203, DOI 10.1111/j.1365-2958.1989.tb00270.x; STRAUCH MA, 1989, EMBO J, V8, P1615, DOI 10.1002/j.1460-2075.1989.tb03546.x; STRAUCH MA, 1991, IN PRESS BIOL BACILL; TOMA S, 1986, J BACTERIOL, V167, P740, DOI 10.1128/jb.167.2.740-743.1986; VALLE F, 1989, REGULATION OF PROCARYOTIC DEVELOPMENT, P131; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZUBER P, 1987, J BACTERIOL, V169, P2223, DOI 10.1128/jb.169.5.2223-2230.1987	36	59	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13411	13417						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1906467				2022-12-25	WOS:A1991FX13200095
J	HOJ, PB; RODRIGUEZ, EB; ISER, JR; STICK, RV; STONE, BA				HOJ, PB; RODRIGUEZ, EB; ISER, JR; STICK, RV; STONE, BA			ACTIVE SITE-DIRECTED INHIBITION BY OPTICALLY PURE EPOXYALKYL CELLOBIOSIDES REVEALS DIFFERENCES IN ACTIVE-SITE GEOMETRY OF 2 1,3-1,4-BETA-D-GLUCAN 4-GLUCANOHYDROLASES - THE IMPORTANCE OF EPOXIDE STEREOCHEMISTRY FOR ENZYME INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONDURITOL-B-EPOXIDE; ALPHA-D-GLUCOPYRANOSIDE; BETA-GLUCAN HYDROLASES; GERMINATING BARLEY; GLUCOSIDASE; IDENTIFICATION; SUBSTRATE; AMYLASE; (1->4)-BETA-D-GLUCAN; FRUCTOSIDASE	1,3-1,4-beta-D-Glucan 4-glucanohydrolases (EC 3.2.-1.73) from Bacillus subtilis and barley (Hordeum vulgare) with identical substrate specificities but unrelated primary structures have been probed with (R,S)-epoxyalkyl (-propyl, -butyl, -pentyl) beta-cellobiosides and with optically pure (3S)- and (3R)-3,4-cellobiosides as active site-directed inhibitors. The optimal aglycon length for inactivation differs for the two enzymes, and they are differentially inhibited by the pure epoxybutyl beta-cellobioside diastereoisomers. The (3S)-epoxybutyl beta-cellobioside inactivates the B. subtilis enzyme much more efficiently than does the (3R)-isomer, whereas the reverse is true for the barley enzyme. Both enzymes are inactivated by a mixture of the stereoisomers at a rate intermediate of that observed with the individual isomers. The two beta-glucan endohydrolases may therefore employ sterically different mechanisms to achieve glycoside bond hydrolysis in their common substrate. The efficiency and specificity of epoxide-based "suicide" inhibitors may be enhanced significantly by the use of inhibitors bearing only one stereoisomeric form of the epoxide group.	LA TROBE UNIV, COMMONWEALTH SPECIAL RES CTR PROT & ENZYME TECHNOL, BUNDOORA, VIC 3083, AUSTRALIA; UNIV WESTERN AUSTRALIA, DEPT ORGAN CHEM, NEDLANDS, WA 6009, AUSTRALIA	La Trobe University; University of Western Australia	HOJ, PB (corresponding author), LA TROBE UNIV, DEPT BIOCHEM, BUNDOORA, VIC 3083, AUSTRALIA.		Hoj, Peter B/E-8526-2011					ANDERSON MA, 1975, FEBS LETT, V52, P202, DOI 10.1016/0014-5793(75)80806-4; BAUSE E, 1980, BIOCHIM BIOPHYS ACTA, V626, P459, DOI 10.1016/0005-2795(80)90142-7; BESSELL EM, 1973, CHEM-BIOL INTERACT, V7, P343, DOI 10.1016/0009-2797(73)90008-2; BRAUN H, 1977, BIOCHIM BIOPHYS ACTA, V485, P141, DOI 10.1016/0005-2744(77)90201-7; BRAUN H, 1976, BIOCHIM BIOPHYS ACTA, V452, P452, DOI 10.1016/0005-2744(76)90195-9; BRAUN H, 1977, BIOCHIM BIOPHYS ACTA, V483, P135, DOI 10.1016/0005-2744(77)90015-8; CLARKE AJ, 1988, BIOCHEM CELL BIOL, V66, P871, DOI 10.1139/o88-099; DATEMA R, 1982, P NATL ACAD SCI-BIOL, V79, P6787, DOI 10.1073/pnas.79.22.6787; ESHDAT Y, 1973, J BIOL CHEM, V248, P5892; FINCHER GB, 1986, P NATL ACAD SCI USA, V83, P2081, DOI 10.1073/pnas.83.7.2081; GRABOWSKI GA, 1986, J BIOL CHEM, V261, P8263; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HOJ PB, 1990, J CEREAL SCI, V11, P261, DOI 10.1016/S0733-5210(09)80170-7; HOJ PB, 1989, J BIOL CHEM, V264, P4939; ISODA Y, 1987, AGR BIOL CHEM TOKYO, V51, P3223; ISODA Y, 1988, AGR BIOL CHEM TOKYO, V52, P271; ISODA Y, 1986, J BIOCHEM-TOKYO, V99, P1631, DOI 10.1093/oxfordjournals.jbchem.a135637; KITZ R, 1962, J BIOL CHEM, V237, P3245; LEGLER G, 1973, CARBOHYD RES, V28, P45, DOI 10.1016/S0008-6215(00)82855-4; LEGLER G, 1968, Z. Physiol. Chem., V349, P767; MARLETTA MA, 1979, J BIOL CHEM, V254, P1879; MCCLEAR BV, 1985, J I BREWING, V91, P285, DOI 10.1002/j.2050-0416.1985.tb04345.x; MURPHY N, 1984, NUCLEIC ACIDS RES, V12, P5355, DOI 10.1093/nar/12.13.5355; NEWBURG DS, 1986, BIOCHIM BIOPHYS ACTA, V877, P121, DOI 10.1016/0005-2760(86)90126-8; NITTA Y, 1989, J BIOCHEM-TOKYO, V105, P573, DOI 10.1093/oxfordjournals.jbchem.a122706; PLAPP BV, 1982, METHOD ENZYMOL, V87, P469; POST CB, 1986, J AM CHEM SOC, V108, P1317, DOI 10.1021/ja00266a044; RODRIGUEZ EB, 1990, AUST J CHEM, V43, P665, DOI 10.1071/CH9900665; RODRIGUEZ EB, 1990, AUST J CHEM, V43, P1391, DOI 10.1071/CH9901391; SHULMAN ML, 1976, BIOCHIM BIOPHYS ACTA, V445, P169, DOI 10.1016/0005-2744(76)90170-4; TANG J, 1971, J BIOL CHEM, V246, P4510; THOMAS EW, 1969, NATURE, V222, P485, DOI 10.1038/222485a0; TSURU D, 1986, J BIOCHEM-TOKYO, V99, P1537, DOI 10.1093/oxfordjournals.jbchem.a135624; WHITE WJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P198, DOI 10.1016/0167-4838(86)90046-4; WOODWARD JR, 1982, EUR J BIOCHEM, V121, P663, DOI 10.1111/j.1432-1033.1982.tb05837.x; WOODWARD JR, 1982, CARBOHYD RES, V106, P111, DOI 10.1016/S0008-6215(00)80737-5	36	49	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11628	11631						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904865				2022-12-25	WOS:A1991FT76200035
J	PAPAZAFIRI, P; OGAMI, K; RAMJI, DP; NICOSIA, A; MONACI, P; CLADARAS, C; ZANNIS, VI				PAPAZAFIRI, P; OGAMI, K; RAMJI, DP; NICOSIA, A; MONACI, P; CLADARAS, C; ZANNIS, VI			PROMOTER ELEMENTS AND FACTORS INVOLVED IN HEPATIC TRANSCRIPTION OF THE HUMAN APOA-I GENE POSITIVE AND NEGATIVE REGULATORS BIND TO OVERLAPPING SITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY LIPOPROTEINS; HUMAN PLASMA APOLIPOPROTEINS; CELL-SPECIFIC EXPRESSION; FAMILIAL HYPERALPHALIPOPROTEINEMIA; CHOLESTEROL ACYLTRANSFERASE; PROTEIN-BINDING; RAT-LIVER; DNA; IDENTIFICATION	DNase I footprinting analysis of the proximal apoA-I promoter sequences with rat liver nuclear extracts identified four protected regions: A, -22 to +17; B, -128 to -77; C, -175 to -148; and D, -220 to -190. Region D (-220 to -190) binds at least two distinct activities, designated AID1 and AID2, respectively, which can be separated by ion exchange chromatography. Region C (-175 to -148) forms five DNA protein complexes. Three of the complexes (2, 4, and 5) originate from the binding of more than one heat-stable nuclear factor, and two (1 and 3), from the binding of two heat-labile factors. The heat-stable factors bind in the -175 to -148 region and can be distinguished from C/EBP, which recognizes the same region, with DNA binding gel electrophoretic assays. Both factors 1 and 3 bind in the -168 to -148 apoA-I region. Despite the lack of a CCAAT motif in this region, the binding of factor 1 is competed out by oligonucleotides containing the binding sites of NFY and NFY*. Mutagenesis of the promoter region showed that mutations in the -171 to -166 and -158 to -153 regions diminished the binding of the heat-stable factors and reduced hepatic transcription to 14 and 8% of control, respectively. In contrast, a mutation in the -164 to -159 region abolished the binding of factor 1 and was associated with a 4.6-fold increase in hepatic transcription. These findings suggest that the heat-stable factors act as positive regulators, whereas factor 1 acts as a negative regulator in apoA-I gene transcription.	BOSTON UNIV, MED CTR,INST CARDIOVASC,HOUSMAN MED RES CTR, DEPT MED, BOSTON, MA 02118 USA; BOSTON UNIV, MED CTR, HOUSMAN MED RES CTR, DEPT BIOCHEM, BOSTON, MA 02118 USA; EUROPEAN MOLEC BIOL LAB, W-6900 HEIDELBERG, GERMANY; UNIV CRETE, SCH MED, Iraklion, GREECE; INST MOLEC BIOL & BIOTECHNOL, Iraklion, GREECE	Boston University; Boston University; European Molecular Biology Laboratory (EMBL); University of Crete			Ramji, Dipak/A-7092-2010	Ramji, Dipak/0000-0002-6419-5578	NHLBI NIH HHS [HL33952, HL43909] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043909, R01HL033952] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIESBROECK R, 1983, J CLIN INVEST, V71, P525, DOI 10.1172/JCI110797; BOHMANN D, 1987, NATURE, V325, P268, DOI 10.1038/325268a0; BREWER HB, 1978, BIOCHEM BIOPH RES CO, V80, P623, DOI 10.1016/0006-291X(78)91614-5; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CASTELLI WP, 1977, CIRCULATION, V55, P767, DOI 10.1161/01.CIR.55.5.767; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; FIDGE NH, 1985, J BIOL CHEM, V260, P3570; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; Glomset J A, 1980, Adv Intern Med, V25, P91; GLUECK CJ, 1975, ARCH INTERN MED, V135, P1025, DOI 10.1001/archinte.135.8.1025; GLUECK CJ, 1976, J LAB CLIN MED, V88, P941; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM DL, 1987, J BIOL CHEM, V262, P7439; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRAVES BJ, 1986, CELL, V44, P565, DOI 10.1016/0092-8674(86)90266-7; HADDAD IA, 1986, J BIOL CHEM, V261, P3268; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HEISS G, 1982, NIH831266 PUBL, P7; HIGUCHI K, 1988, J BIOL CHEM, V263, P18530; HWANG JL, 1985, J BIOL CHEM, V260, P5660; JACKSON RL, 1975, J BIOL CHEM, V250, P7204; JOHNSON PF, 1987, GENE DEV, V1, P133, DOI 10.1101/gad.1.2.133; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KARDASSIS D, 1990, J BIOL CHEM, V265, P21733; KARDASSIS D, 1990, MOL CELL BIOL, V10, P2653, DOI 10.1128/MCB.10.6.2653; KNOWLES BB, 1980, SCIENCE, V209, P497, DOI 10.1126/science.6248960; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LENICH C, 1988, J LIPID RES, V29, P755; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAKRIDES SC, 1988, EUR J BIOCHEM, V173, P465, DOI 10.1111/j.1432-1033.1988.tb14022.x; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OGAMI K, 1990, J BIOL CHEM, V265, P9808; ORAM JF, 1981, J BIOL CHEM, V256, P8348; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PATSCH W, 1981, ARTERIOSCLEROSIS, V1, P156, DOI 10.1161/01.ATV.1.2.156; PROTTER AA, 1984, DNA-J MOLEC CELL BIO, V3, P449, DOI 10.1089/dna.1.1984.3.449; RANGAN VS, 1990, J BIOL CHEM, V265, P8874; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; ROGHANI A, 1988, BIOCHEMISTRY-US, V27, P7428, DOI 10.1021/bi00419a038; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SCHONFELD G, 1982, J CLIN INVEST, V69, P1072, DOI 10.1172/JCI110542; SLOTTE JP, 1987, J BIOL CHEM, V262, P12904; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAM SP, 1986, P NATL ACAD SCI USA, V83, P3111, DOI 10.1073/pnas.83.10.3111; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; VANHUIJSDUIJNEN RH, 1990, EMBO J, V9, P3119, DOI 10.1002/j.1460-2075.1990.tb07509.x; WALSH A, 1989, J BIOL CHEM, V264, P6488; WU AL, 1979, J BIOL CHEM, V254, P7316; ZANNIS VI, 1984, J BIOL CHEM, V259, P5495	60	106	111	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5790	5797						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1900840				2022-12-25	WOS:A1991FD37000068
J	WINEGAR, DA; OHMSTEDE, CA; CHU, L; REEP, B; LAPETINA, EG				WINEGAR, DA; OHMSTEDE, CA; CHU, L; REEP, B; LAPETINA, EG			ANTISERA SPECIFIC FOR RAP1 PROTEINS DISTINGUISH BETWEEN PROCESSED AND NON-PROCESSED RAP1B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; PUTATIVE EFFECTOR DOMAIN; RAS-RELATED PROTEIN; HUMAN-PLATELETS; GENE-PRODUCTS; SMG P21; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; MEMBRANES	Polyclonal antisera were generated against synthetic peptides corresponding to distinct regions of the rap1 protein sequences. A "rap1-common" antiserum, prepared against an 18-amino acid segment of the rap1a protein near the proposed GTP-binding region, reacted with both rap1a and rap1b recombinant proteins expressed in Escherichia coli and with two low molecular weight GTP-binding proteins of 22 and 24 kDa in unstimulated human platelets. An antiserum raised against a carboxyl-terminal peptide of rap1b containing the putative site of post-translational processing reacted strongly with bacterial-expressed recombinant rap1b and with a 24-kDa GTP-binding protein in platelets, but not with recombinant rap1a or a 22-kDa GTP-binding protein. The mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis of this rap1b immunoreactive protein coincided with that of bacterial-expressed rap1b and not with the faster migrating form of rap1b that incorporates radioactivity from [H-3]mevalonic acid in the insect/baculovirus system. This suggests that our rap1b-specific antiserum recognizes only one form of rap1b, that which has not undergone carboxyl-terminal post-translational processing.			WINEGAR, DA (corresponding author), BURROUGHS WELLCOME CO,DIV CELL BIOL,RES TRIANGLE PK,NC 27709, USA.							BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; CHARDIN P, 1988, BIOCHIMIE, V70, P865, DOI 10.1016/0300-9084(88)90226-X; DERKSEN A, 1973, J BIOL CHEM, V248, P7396; ECKLES NE, 1955, J LAB CLIN MED, V46, P359; FARRELL FX, 1990, NUCLEIC ACIDS RES, V18, P4281, DOI 10.1093/nar/18.14.4281; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1989, BIOCHEM BIOPH RES CO, V163, P1418, DOI 10.1016/0006-291X(89)91137-6; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAPETINA EG, 1989, FEBS LETT, V17, P451; LAZAROWSKI ER, 1989, BIOCHEM BIOPH RES CO, V161, P972, DOI 10.1016/0006-291X(89)91338-7; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; Maniatis T., 1982, MOL CLONING; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; OHMORI T, 1988, BIOCHEM BIOPH RES CO, V157, P670, DOI 10.1016/S0006-291X(88)80302-4; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; SINGER SC, 1989, J BACTERIOL, V171, P1372, DOI 10.1128/jb.171.3.1372-1378.1989; Summers MD, 1987, TEXAS AGR EXPT STATI; VEDIA LMY, 1990, BIOCHEM BIOPH RES CO, V171, P319; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	38	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4375	4380						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900291				2022-12-25	WOS:A1991FA69400056
J	COHEN-ARMON, M; SOKOLOVSKY, M				COHEN-ARMON, M; SOKOLOVSKY, M			DEPOLARIZATION-INDUCED CHANGES IN THE MUSCARINIC RECEPTOR IN RAT-BRAIN AND HEART ARE MEDIATED BY PERTUSSIS-TOXIN-SENSITIVE G-PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; HIGH-AFFINITY BINDING; GTP-BINDING; ACETYLCHOLINE-RECEPTORS; SODIUM-CHANNELS; ION CHANNELS; PHOSPHOLIPID-VESICLES; TRANSFORMED-CELLS; ADENYLATE-CYCLASE; ALPHA-SUBUNIT	Muscarinic receptor properties in rat cortical and brain stem synaptoneurosomes and in heart myocytes were examined at resting potential and at depolarization. Depolarization induced the conversion of agonist-binding sites of the receptor from a high to a low affinity state, which could be reversed by a return to resting potential. No effect was observed on the affinity of the receptor for antagonists. Pertussis-toxin (PTX)-catalyzed ADP-ribosylation of all substrates in both synaptoneurosomal and myocyte membranes, when conducted at resting potential, prevented depolarization-induced conversion of the receptor affinity in these preparations. The target substrates were identified by [P-32]ADP-ribosylation of membranes prepared from brain stem synaptoneurosomes. Autoradiography revealed labeling of a 39-kDa protein band, which reacted mainly with antibodies to the alpha-subunit of G(o)-proteins. The possible involvement of G-proteins in depolarization-induced changes in the receptor activity was further investigated by examining the effect of membrane potential on the PTX-sensitive binding of di- and triphosphated guanine nucleotides to synaptoneurosomal membranes. Brain stem synaptoneurosomes were made permeable to guanine nucleotides ([H-3]GTP, [H-3] GDP, [H-3]5'-guanylyl imidodiphosphate) by treatment with ATP. After the synaptoneurosomes had been loaded with labeled GTP/GDP, resealed, and then subjected to either resting potential of short depolarization, binding of [H-3]GDP to the membranes of depolarized synaptoneurosomes was 4.0 +/- 0.3 (n = 20) times higher than to the membranes of synaptoneurosomes at resting potential. Repolarization reversed this effect. Enhancement of [H-3]GDP binding to the synaptoneurosomal membranes was induced also by muscarinic activation, although the increase obtained was only 30-40% (n = 5) relative to [H-3]GDP binding at resting potential. Both the depolarization-induced and the muscarinically-induced enhancement of [H-3]GDP binding were prevented following PTX-catalyzed ADP-ribosylation of G-proteins in the synaptoneurosomal membrane. Our results suggest that the depolarization-induced enhancement in the binding of [H-3]GTP/[H-3]GDP may be attributable to activation of PTX-sensitive G-proteins, which mediate the depolarization-induced alteration of the affinity of the muscarinic receptor for agonists.	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT BIOCHEM, NEUROBIOCHEM LAB, IL-69978 TEL AVIV, ISRAEL	Tel Aviv University								AGNARSSON U, 1988, J PHARMACOL EXP THER, V247, P150; AVISSAR S, 1988, NATURE, V331, P440, DOI 10.1038/331440a0; BOCHNER BR, 1982, J BIOL CHEM, V257, P9759; BRANDT DR, 1986, J BIOL CHEM, V261, P1656; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; CASSEL D, 1978, P NATL ACAD SCI USA, V75, P4155, DOI 10.1073/pnas.75.9.4155; CATTERALL WA, 1975, J BIOL CHEM, V250, P4053; CERIONE RA, 1986, J BIOL CHEM, V261, P3901; CHABRE M, 1985, ANNU REV BIOPHYS BIO, V14, P331, DOI 10.1146/annurev.biophys.14.1.331; CHENG K, 1980, J MEMBRANE BIOL, V56, P191, DOI 10.1007/BF01869476; COCKCROFT S, 1985, NATURE, V314, P534, DOI 10.1038/314534a0; COHEN-ARMON M, 1986, J BIOL CHEM, V261, P2498; COHEN-ARMON M, 1985, P NATL ACAD SCI USA, V82, P3524, DOI 10.1073/pnas.82.10.3524; COHEN-ARMON M, 1988, BIOCHEMISTRY-US, V27, P368, DOI 10.1021/bi00401a055; DALY JW, 1982, J TOXICOL-TOXIN REV, V1, P33, DOI 10.3109/15569548209016467; DRAPEAU P, 1983, J NEUROSCI, V3, P703; EGLEN RM, 1988, J PHARMACOL EXP THER, V247, P911; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; GIERSCHIK P, 1986, P NATL ACAD SCI USA, V83, P2258, DOI 10.1073/pnas.83.7.2258; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; GURWITZ D, 1985, MOL PHARMACOL, V28, P297; GUSOVSKY F, 1988, CELL MOL NEUROBIOL, V8, P157, DOI 10.1007/BF00711242; HAGA K, 1989, MOL PHARMACOL, V35, P286; HAGA K, 1986, J BIOL CHEM, V261, P133; HEPPEL LA, 1985, J MEMBRANE BIOL, V86, P189, DOI 10.1007/BF01870597; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOFTMAN JE, 1974, J PHYSIOL-LONDON, V239, P519; HOLLINGSWORTH EB, 1985, J NEUROSCI, V5, P2240; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; KASTEN FH, 1973, TISSUE CULTURE METHO, P72; KATADA T, 1984, J BIOL CHEM, V259, P3578; KHODOROV BI, 1985, PROG BIOPHYS MOL BIO, V45, P57, DOI 10.1016/0079-6107(85)90005-7; KLOOG Y, 1979, MOL PHARMACOL, V15, P545; KORTH M, 1987, BRIT J PHARMACOL, V90, P81, DOI 10.1111/j.1476-5381.1987.tb16827.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELIOR LF, 1957, METHOD ENZYMOL, V3, P840; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNING DR, 1984, J BIOL CHEM, V259, P749; MILLIGAN G, 1988, BIOCHEM J, V254, P391, DOI 10.1042/bj2540391; MOSCONAAMIR E, 1988, BIOCHEMISTRY-US, V27, P4985, DOI 10.1021/bi00414a006; MURAYAMA T, 1984, J BIOL CHEM, V259, P761; Nernst W., 1888, Z F PHYS CHEM, V2U, P613, DOI 10.1515/zpch- 1888-0274.; NICOLL RA, 1988, SCIENCE, V241, P545, DOI 10.1126/science.2456612; PAUWELS PJ, 1986, EUR J PHARMACOL, V132, P289, DOI 10.1016/0014-2999(86)90618-7; PERRY MC, 1969, BIOCHEM J, V115, P865, DOI 10.1042/bj1150865; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; RODBELL M, 1985, TRENDS BIOCHEM SCI, V10, P461, DOI 10.1016/0968-0004(85)90032-5; SASAKI K, 1987, NATURE, V325, P259, DOI 10.1038/325259a0; SOKOLOVSKY M, 1984, INT REV NEUROBIOL, V25, P138; SOKOLOVSKY M, 1989, ADV DRUG RES, V18, P432; TOTA MR, 1987, BIOCHEMISTRY-US, V26, P8175, DOI 10.1021/bi00399a023; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGGONER A, 1976, J MEMBRANE BIOL, V27, P317, DOI 10.1007/BF01869143; WEISMAN GA, 1984, J CELL PHYSIOL, V119, P211, DOI 10.1002/jcp.1041190211; YATANI A, 1988, SCIENCE, V241, P828, DOI 10.1126/science.2457252	58	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2595	2605						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899242				2022-12-25	WOS:A1991EV51500089
J	FRAME, MC; WILKIE, NM; DARLING, AJ; CHUDLEIGH, A; PINTZAS, A; LANG, JC; GILLESPIE, DAF				FRAME, MC; WILKIE, NM; DARLING, AJ; CHUDLEIGH, A; PINTZAS, A; LANG, JC; GILLESPIE, DAF			REGULATION OF AP-1/DNA COMPLEX-FORMATION INVITRO	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; JUN PROTO-ONCOGENE; DNA-BINDING; RAT FIBROBLASTS; GENE; EXPRESSION; PROMOTER; FOS; TPA; IDENTIFICATION	The level of AP-1 DNA-binding activity exhibited in vitro by unfractionated extracts of Hela nuclei can be stimulated by a low molecular weight fraction from rabbit reticulocyte lysate. Stimulation also requires a heat labile component of the nuclear extract, probably a protein. Stimulated and unstimulated extracts with high and low AP-1 DNA-binding activities contain the same levels of proteins reactive with antisera against Jun and Fos, proteins which are shown to be involved in the AP-1/DNA complexes detected in vitro. The low molecular weight fraction from reticulocyte lysate can be substituted by the reducing agent dithiothreitol (DTT) in the stimulation reaction and conversely oxidised glutathione greatly reduces formation of AP-1/DNA complexes. The binding activities of transcription factors SP-1, NF-1 and CBP are unaffected by DTT or oxidised glutathione. These observations, taken together, suggest that the efficiency with which pre-existing Fos and Jun proteins can bind an AP-1 target sequence in vitro can be controlled by a nuclear activity which is sensitive to oxidation/reduction and that this control mechanism is specific for AP-1.			FRAME, MC (corresponding author), BEATSON INST CANC RES,BEATSON LABS,CANC RES CAMPAIGN,GARSCUBE ESTATE,SWITCHBACK RD,GLASGOW G61 1BD,SCOTLAND.		Gillespie, David/R-4771-2019	Gillespie, David/0000-0002-6338-0544				Abate C, 1990, Semin Cancer Biol, V1, P19; ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARNHART KM, 1988, MOL CELL BIOL, V8, P3215, DOI 10.1128/MCB.8.8.3215; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; FULTON R, 1990, J VIROL, V64, P1675, DOI 10.1128/JVI.64.4.1675-1682.1990; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JONES KA, 1985, NATURE, V317, P179, DOI 10.1038/317179a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; Maniatis T., 1982, MOL CLONING; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; MULLER R, 1987, ONCOGENE RES, V2, P19; NISHIMURA T, 1988, ONCOGENE, V3, P659; PLUMB M, 1989, NUCLEIC ACIDS RES, V17, P63; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WELHAM MJ, 1990, ONCOGENE, V5, P161	25	53	53	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					205	209						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900354				2022-12-25	WOS:A1991FZ13400004
J	BALTZ, JM; BIGGERS, JD; LECHENE, C				BALTZ, JM; BIGGERS, JD; LECHENE, C			RELIEF FROM ALKALINE LOAD IN 2-CELL STAGE MOUSE EMBRYOS BY BICARBONATE CHLORIDE EXCHANGE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH TRANSIENTS; CELLS; ANTIPORT; FIBROBLASTS; TRANSPORT	Mouse embryos at the two-cell stage are able to recover from an alkaline load. We found that this recovery is mediated by sodium-independent bicarbonate/chloride exchange: intracellular pH (pHi) recovery from alkaline load is inhibited by the anion exchange inhibitor 4,4'-diisothiocyanostilbene disulfonic acid, lack of bicarbonate, or lack of chloride. The dependence of the pHi recovery on extracellular chloride concentration exhibits Michaelis-Menten kinetics. Furthermore, uptake of chloride is inhibited in a dose-dependent manner by extracellular bicarbonate. The Km for external chloride was found to be about 3 mM, with a Ki for external bicarbonate of about 2 mM. The exchanger is active above approximately pH 7.15. These results demonstrate that mouse embryos at the two-cell stage possess a sodium-independent bicarbonate/chloride exchange mechanism that is similar to that found in other mammalian cells. This bicarbonate/chloride exchanger appears to be the sole pHi-regulatory mechanism in the two-cell stage mouse embryo, since our previous results have shown that there are apparently no specific mechanisms active in these cells for relieving acid loads.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, CELLULAR PHYSIOL LAB, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	BALTZ, JM (corresponding author), HARVARD UNIV, SCH MED, HUMAN REPROD & REPROD BIOL LAB, 45 SHATTUCK ST, BOSTON, MA 02115 USA.			Baltz, Jay/0000-0002-9749-2480				ABRAHAM EH, 1985, AM J PHYSIOL, V248, pC154, DOI 10.1152/ajpcell.1985.248.1.C154; BALTZ JM, 1990, DEV BIOL, V138, P421, DOI 10.1016/0012-1606(90)90208-Z; BALTZ JM, 1991, J BIOL CHEM, V266, P6052; BORLAND RM, 1977, BIOL REPROD, V16, P147, DOI 10.1095/biolreprod16.2.147; BORON WF, 1976, J GEN PHYSIOL, V67, P91, DOI 10.1085/jgp.67.1.91; BORON WF, 1977, AM J PHYSIOL, V233, pC61, DOI 10.1152/ajpcell.1977.233.3.C61; CASSEL D, 1988, J BIOL CHEM, V263, P6122; CHATTERJEE S, 1977, REGESSION ANAL EXAMP, P49; COHEN BJ, 1990, AM J PHYSIOL, V258, pC24, DOI 10.1152/ajpcell.1990.258.1.C24; FINEMAN I, 1990, AM J PHYSIOL, V258, pF883, DOI 10.1152/ajprenal.1990.258.4.F883; FULTON BP, 1978, NATURE, V273, P149, DOI 10.1038/273149a0; HOGAN B, 1986, MANIPULATING MOUSE E; KURTZ I, 1987, J BIOL CHEM, V262, P4516; LARSSON L, 1986, ACTA PHYSIOL SCAND, V126, P321, DOI 10.1111/j.1748-1716.1986.tb07823.x; LECHENE C, 1986, ANN NY ACAD SCI, V483, P270, DOI 10.1111/j.1749-6632.1986.tb34532.x; MUALLEM S, 1985, J BIOL CHEM, V260, P6641; NORD EP, 1988, J BIOL CHEM, V263, P5599; OLSNES S, 1986, J CELL BIOL, V102, P967, DOI 10.1083/jcb.102.3.967; REINERTSEN KV, 1988, J BIOL CHEM, V263, P11117; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Whittingham D G, 1971, J Reprod Fertil Suppl, V14, P7	22	43	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17212	17217						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894615				2022-12-25	WOS:A1991GF44500038
J	BEYER, P; KRONCKE, U; NIEVELSTEIN, V				BEYER, P; KRONCKE, U; NIEVELSTEIN, V			ON THE MECHANISM OF THE LYCOPENE ISOMERASE CYCLASE REACTION IN NARCISSUS-PSEUDONARCISSUS L CHROMOPLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAROTENOGENIC ENZYMES; DAFFODIL CHROMOPLASTS; ISOMERIZING ACTIVITY; MOLECULAR-OXYGEN; DEHYDROGENASE; DESATURATION; CYCLIZATION; MEMBRANES; CHEMISTRY	The lycopene cyclase reaction was investigated in Narcissus pseudonarcissus L. membranes using the terminal desaturation product of the system, 7,9,9',7'-tetra-cis-lycopene (prolycopene) as substrate. The enzymatically formed bicyclic carotenes were trans configured, so the overall reaction consists of two individual processes, isomerization and cyclization. The two reactions were experimentally distinguished by use of the inhibitor [2-(p-chlorophenylthio)triethylammonium chloride. NADPH, the essential cofactor for the overall reaction, originates from the plastid glycolytic pathway. It is shown that NADPH exhibits its function at the stage of isomerization and is also able to promote reduction of the prolycopene substrate in vitro.			BEYER, P (corresponding author), UNIV FREIBURG,INST BIOL 2,SCHANZLESTR 1,W-7800 FREIBURG,GERMANY.							BEYER P, 1989, EUR J BIOCHEM, V184, P141, DOI 10.1111/j.1432-1033.1989.tb15000.x; BEYER P, 1985, EUR J BIOCHEM, V153, P341, DOI 10.1111/j.1432-1033.1985.tb09308.x; BRAMLEY PM, 1987, PHYTOCHEMISTRY, V26, P1935, DOI 10.1016/S0031-9422(00)81733-1; BRITTON G, 1977, J CHEM SOC CHEM COMM, P655, DOI 10.1039/c39770000655; BRITTON G, 1979, J CHEM SOC CHEM COMM, P27, DOI 10.1039/c39790000027; BRITTON G, 1976, CHEM BIOCH PLANT PIG; CAMARA B, 1985, BIOCHIM BIOPHYS ACTA, V836, P262, DOI 10.1016/0005-2760(85)90074-8; CAMARA B, 1982, EUR J BIOCHEM, V127, P255, DOI 10.1111/j.1432-1033.1982.tb06863.x; EUGSTER CH, 1979, PURE APPL CHEM, V51, P463, DOI 10.1351/pac197951030463; HILL HM, 1971, PHYTOCHEMISTRY, V10, P2051, DOI 10.1016/S0031-9422(00)97196-6; HUMBECK K, 1990, PLANTA, V182, P204, DOI 10.1007/BF00197112; KLEINIG H, 1980, PLANTA, V150, P166, DOI 10.1007/BF00582361; KREUZ K, 1982, PLANTA, V154, P66, DOI 10.1007/BF00385498; KUSHWAHA SC, 1969, J BIOL CHEM, V244, P3635; LAM E, 1982, FEBS LETT, V141, P98, DOI 10.1016/0014-5793(82)80024-0; LIEDVOGEL B, 1976, CYTOBIOLOGIE, V12, P155; LUTKEBRINKHAUS F, 1982, PLANTA, V156, P176, DOI 10.1007/BF00395433; MAYER MP, 1990, EUR J BIOCHEM, V191, P359, DOI 10.1111/j.1432-1033.1990.tb19130.x; PORTER JW, 1950, ARCH BIOCHEM, V27, P390; SCHUETZ RD, 1958, J AM CHEM SOC, V80, P162, DOI 10.1021/ja01534a043; SELTZER S, 1972, ENZYMES, V6, P381; Spurgeon S.L, 1983, BIOSYNTHESIS ISOPREN, V2; TATSUMI K, 1979, BIOCHIM BIOPHYS ACTA, V567, P75, DOI 10.1016/0005-2744(79)90174-8; TOMOEDA M, 1977, BIOCHIM BIOPHYS ACTA, V480, P315, DOI 10.1016/0005-2744(77)90344-8; WALSH C, 1979, ENZYMATIC REACTION M, P617; WILLIAMS RJ, 1967, BIOCHEM J, V105, P99, DOI 10.1042/bj1050099	26	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17072	17078						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894603				2022-12-25	WOS:A1991GF44500019
J	HEWLETT, EL; GRAY, L; ALLIETTA, M; EHRMANN, I; GORDON, VM; GRAY, MC				HEWLETT, EL; GRAY, L; ALLIETTA, M; EHRMANN, I; GORDON, VM; GRAY, MC			ADENYLATE-CYCLASE TOXIN FROM BORDETELLA-PERTUSSIS - CONFORMATIONAL CHANGE ASSOCIATED WITH TOXIN ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI HEMOLYSIN HLYA; ESCHERICHIA-COLI; CALMODULIN; PURIFICATION; BINDING; IDENTIFICATION; CALCIUM; CELLS; FLUORESCENCE; PROGRAMS	Adenylate cyclase (AC) toxin from Bordetella pertussis interacts with and enters eukaryotic cells to catalyze the production of supraphysiologic levels of cyclic AMP. Although the calmodulin-activated enzymatic activity (ability to convert ATP to cyclic AMP in a cell-free assay) of this molecule is calcium independent, its toxin activity (ability to increase cyclic AMP levels in intact target cells) requires extracellular calcium. Toxin activity as a function of calcium concentration is biphasic, with no intoxication occurring in the absence of calcium, low level intoxication (200-300 pmol of cyclic AMP/mg of Jurkat cell protein) occurring with free calcium concentrations between 100 nM and 100-mu-M and a 10-fold increase in AC toxin activity at free calcium concentrations above 300-mu-M. The molecule exhibits a conformational change when free calcium concentrations exceed 100-mu-M as demonstrated by shift in intrinsic tryptophan fluorescence, an alteration in binding of one anti-AC monoclonal antibody, protection of a fragment from trypsin-mediated proteolysis, and a structural modification as illustrated by electron microscopy. Thus, it appears that an increase in the ambient calcium concentration to a critical point and the ensuing interaction of the toxin with calcium induces a conformational change which is necessary for its insertion into the target cell and for delivery of its catalytic domain to the cell interior.	UNIV VIRGINIA,SCH MED,DEPT PHARMACOL,CHARLOTTESVILLE,VA 22908; UNIV VIRGINIA,SCH MED,DEPT PATHOL,CHARLOTTESVILLE,VA 22908	University of Virginia; University of Virginia	HEWLETT, EL (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,SCH MED,DEPT MED,BOX 419,CHARLOTTESVILLE,VA 22908, USA.			gray, mary/0000-0003-4441-5905	NCI NIH HHS [R29 CA47401] Funding Source: Medline; NIAID NIH HHS [R01 AI18000] Funding Source: Medline; NIDDK NIH HHS [DK38942] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA047401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018000] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038942] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELLALOU J, 1990, INFECT IMMUN, V58, P1195, DOI 10.1128/IAI.58.5.1195-1200.1990; BLEWITT MG, 1984, BIOCHEM BIOPH RES CO, V120, P286, DOI 10.1016/0006-291X(84)91446-3; BOEHM DF, 1990, INFECT IMMUN, V58, P1951, DOI 10.1128/IAI.58.6.1951-1958.1990; BROOKER G, 1976, SCIENCE, V194, P270, DOI 10.1126/science.184530; CONFER DL, 1984, ADV CYCLIC NUCL PROT, V17, P183; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EHRMANN IE, 1991, FEBS LETT, V278, P79, DOI 10.1016/0014-5793(91)80088-K; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; GENTILE F, 1990, J BIOL CHEM, V265, P10686; GILLES AM, 1990, BIOCHEMISTRY-US, V29, P8126, DOI 10.1021/bi00487a020; GLASER P, 1989, EMBO J, V8, P967, DOI 10.1002/j.1460-2075.1989.tb03459.x; GLASER P, 1988, MOL MICROBIOL, V2, P19, DOI 10.1111/j.1365-2958.1988.tb00003.x; GOLDHAMMER R, 1981, EUR J BIOCHEM, V115, P605; GORDON VM, 1989, J BIOL CHEM, V264, P14792; GREENLEE DV, 1982, BIOCHEMISTRY-US, V21, P2759, DOI 10.1021/bi00540a028; HANSKI E, 1985, J BIOL CHEM, V260, P5526; HEWLETT EL, 1976, P NATL ACAD SCI USA, V73, P1926, DOI 10.1073/pnas.73.6.1926; HEWLETT EL, 1989, J BIOL CHEM, V264, P19379; HEWLETT EL, 1990, DHHS901164 US PHS DE, P13; KESSIN RH, 1986, J BACTERIOL, V166, P290, DOI 10.1128/jb.166.1.290-296.1986; KILHOFFER MC, 1983, EUR J BIOCHEM, V133, P11, DOI 10.1111/j.1432-1033.1983.tb07423.x; Kretsinger R.H., 1991, NOVEL CALCIUM BINDIN, P17; LADANT D, 1988, J BIOL CHEM, V263, P2612; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P345; LEUSCH MS, 1990, INFECT IMMUN, V58, P3621, DOI 10.1128/IAI.58.11.3621-3626.1990; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUDWIG A, 1988, MOL GEN GENET, V214, P553, DOI 10.1007/BF00330494; MASURE HR, 1989, BIOCHEMISTRY-US, V28, P438, DOI 10.1021/bi00428a005; MASURE HR, 1988, J BIOL CHEM, V263, P6933; RAPTIS A, 1989, INFECT IMMUN, V57, P1725, DOI 10.1128/IAI.57.6.1725-1730.1989; ROGEL A, 1989, EMBO J, V8, P2755, DOI 10.1002/j.1460-2075.1989.tb08417.x; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; STOCKBRIDGE N, 1987, COMPUT BIOL MED, V17, P299, DOI 10.1016/0010-4825(87)90019-9; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEISS AA, 1986, ANNU REV MICROBIOL, V40, P661, DOI 10.1146/annurev.micro.40.1.661; WEISS AA, 1986, MICROBIOLOGY 1986, P70; WELCH RA, 1986, PROTEIN CARBOHYDRATE, P433; WOLFF J, 1984, ADV CYCLIC NUCL PROT, V17, P161; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841	41	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17503	17508						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894634				2022-12-25	WOS:A1991GF44500078
J	KOUNNAS, MZ; WOLZ, RL; GORBEA, CM; BOND, JS				KOUNNAS, MZ; WOLZ, RL; GORBEA, CM; BOND, JS			MEPRIN-A AND MEPRIN-B - CELL-SURFACE ENDOPEPTIDASES OF THE MOUSE KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE; PROTEINS; PURIFICATION; METALLOENDOPEPTIDASE; PROTEASE	The proteinase meprin-A is a disulfide-linked tetramer of 90-kDa glycoprotein subunits. It is expressed at high levels in kidney brush border membranes of random bred and certain inbred strains of mice. Some mouse strains (e.g. C3H/He) do not express meprin-A subunits, but do produce a similar but less well characterized metalloendopeptidase, meprin-B. In the present study, meprin-B was purified from C3H/He mouse kidneys to electrophoretic homogeneity, and the relationship between it and meprin-A was investigated. The papain-solubilized form of meprin-B was similar to meprin-A in amino acid composition, molecular mass, secondary, and quaternary structure. However, immunoblots indicated that the enzymes have some common and some distinct epitopes. Lectin blots indicated both enzymes have high mannose and/or complex biantennary oligosaccharides, but there are differences in the complex-type glycosylation. Peptide maps and sequencing of cyanogen-bromide fragments of the enzymes revealed some different amino aicd sequences. Thermal inactivation studies indicated that meprin-B was much less stable than meprin-A; the half-life for inactivation at 58-degrees-C for meprin-A was 50 min, whereas for meprin-B it was < 3 min. Both enzymes hydrolyzed azocasein and insulin B chain, but limited proteolysis of the enzymes with trypsin activated meprin-B 5-20-fold, whereas meprin-A was activated 2-fold at most. Analysis of hydrolysis products of the oxidized insulin B chain revealed some common and some distinct sites of cleavage. Bradykinin was a good substrate for meprin-A, while it was not hydrolyzed by meprin-B. A synthetic peptide, YLVC(SO3-)GERG, derived from insulin B chain was hydrolyzed faster by meprin-B than meprin-A, and neither enzyme was activated by trypsin treatment against this substrate. Taken together, the data indicate that the two metalloendopeptidases have many similarities but are distinct enzymes.	VIRGINIA POLYTECH INST & STATE UNIV, DEPT BIOCHEM, BLACKSBURG, VA 24061 USA	Virginia Polytechnic Institute & State University			Gorbea, Carlos/L-4406-2019		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK019691, R37DK019691, R01DK019691] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK19691] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEYNON RJ, 1981, BIOCHEM J, V199, P591, DOI 10.1042/bj1990591; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BJARNASON JB, 1988, J TOXICOL-TOXIN REV, V7, P121, DOI 10.3109/15569548809059729; BOND JS, 1986, CURR TOP CELL REGUL, V28, P263; BOND JS, 1984, P NATL ACAD SCI-BIOL, V81, P5542, DOI 10.1073/pnas.81.17.5542; BOND JS, 1987, MOL ASPECTS MED, V9, P173, DOI 10.1016/0098-2997(87)90021-5; BUTLER PE, 1988, J BIOL CHEM, V263, P13419; BUTLER PE, 1987, BIOCHEM J, V241, P229, DOI 10.1042/bj2410229; BUTLER PE, 1989, PROTEOLYTIC ENZYMES, P193; DEDDISH PA, 1990, J BIOL CHEM, V265, P15083; HIRS CHW, 1956, J BIOL CHEM, V219, P611; HOOPER NM, 1990, BIOCHEM J, V267, P509, DOI 10.1042/bj2670509; KENNY AJ, 1987, BIOCHEM J, V245, P515, DOI 10.1042/bj2450515; KRAMER MD, 1986, J IMMUNOL, V136, P4644; LABOMBARDI VJ, 1983, BIOCHEM J, V211, P695, DOI 10.1042/bj2110695; MACADAM GC, 1990, INT J BIOCHEM, V22, P989, DOI 10.1016/0020-711X(90)90205-H; MASSAGUE J, 1990, J BIOL CHEM, V265, P21393; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORIHARA K, 1968, ARCH BIOCHEM BIOPHYS, V123, P572, DOI 10.1016/0003-9861(68)90179-3; OI VT, 1980, SELECTED METHODS CEL, P4; Pfleiderer G, 1970, METHOD ENZYMOL, V19, P514; RECKELHOFF JF, 1985, IMMUNOGENETICS, V22, P617, DOI 10.1007/BF00430310; SCARSDALE JN, 1990, J PROTEIN CHEM, V9, P647, DOI 10.1007/BF01025019; SEGER R, 1988, J BIOL CHEM, V263, P3496; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; STERCHI EE, 1988, ARCH BIOCHEM BIOPHYS, V265, P105, DOI 10.1016/0003-9861(88)90376-1; STROUPE ST, 1991, AM J PHYSIOL, V261, pE354, DOI 10.1152/ajpendo.1991.261.3.E354; STUDIER FW, 1973, J MOL BIOL, V79, P237, DOI 10.1016/0022-2836(73)90003-X; TANAKA K, 1986, J BIOL CHEM, V261, P2610; Tarr G E, 1977, Methods Enzymol, V47, P335; WOLZ RL, 1990, ANAL BIOCHEM, V191, P314; WOLZ RL, 1991, IN PRESS BIOCHEMISTR; ZINGDE SM, 1986, ANAL BIOCHEM, V155, P10, DOI 10.1016/0003-2697(86)90216-2	34	59	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17350	17357						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894622				2022-12-25	WOS:A1991GF44500058
J	SKELTON, TP; HOOPER, LV; SRIVASTAVA, V; HINDSGAUL, O; BAENZIGER, JU				SKELTON, TP; HOOPER, LV; SRIVASTAVA, V; HINDSGAUL, O; BAENZIGER, JU			CHARACTERIZATION OF A SULFOTRANSFERASE RESPONSIBLE FOR THE 4-0-SULFATION OF TERMINAL BETA-N-ACETYL-D-GALACTOSAMINE ON ASPARAGINE-LINKED OLIGOSACCHARIDES OF GLYCOPROTEIN HORMONES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-A GLYCOPROTEIN; COMPLEX CARBOHYDRATE UNITS; VASCULAR ENDOTHELIAL-CELLS; MAMMARY GOLGI MEMBRANES; CHICK-EMBRYO CARTILAGE; DICTYOSTELIUM-DISCOIDEUM; SULFATED GLYCOPROTEINS; LYSOSOMAL-ENZYMES; MAMMALIAN-CELLS; GLYCOSIDASE-F	The Asn-linked oligosaccharides on the glycoprotein hormones lutropin (LH) and thyrotropin terminate with the sequence SO4-4GalNAc-beta-1-4GlcNAc-beta-1-2 Man-alpha-. Using a chemically synthesized trisaccharide GalNAc-beta-1-4GlcNAc-beta-1-2Man-alpha-1-O(CH2)8COOCH3 (GGnM-MCO), we have developed a sensitive assay for the sulfotransferase responsible for the 4-O-sulfation of the terminal beta-D-GalNAc. GGnM-MCO is incubated with a bovine pituitary membrane extract and [S-35]3'-phosphoadenosine 5'-phosphosulfate ([S-35]PAPS). The sulfated product [S-35]SGGnM-MCO is separated from [S-35]PAPS, PAPS degradation products, and endogenous sulfated products by a two-step procedure utilizing an Ecteola cellulose column and a Sep-Pak (C18) cartridge. Characterization of the [S-35]SGGnM-MCO produced in the assay indicates that sulfate is incorporated exclusively on the 4-position of GalNAc. Linear incorporation of sulfate into GGnM-MCO can be maintained for greater than 10 h. GGnM-4-sulfotransferase has a pH optimum of 7.2, requires the presence of a reducing agent, and is stimulated by, but does not require, divalent cations. Initial velocity studies indicate an apparent K(m) (Henri-Michaelis-Menten equilibrium constant) for PAPS of 4-mu-M and for GGnM-MCO of 9-mu-M. Incorporation of sulfate into the trisaccharide is stimulated 3-fold by the presence of basic proteins including deglycosylated LH. The stimulation by deglycosylated LH suggests that the protein component of glycoproteins that bear oligosaccharides terminating with GalNAc-GlcNAc-Man- may modulate GGnM-4-sulfotransferase.	WASHINGTON UNIV,SCH MED,DEPT PATHOL,ST LOUIS,MO 63110; UNIV ALBERTA,DEPT CHEM,EDMONTON T6G 2G2,ALBERTA,CANADA	Washington University (WUSTL); University of Alberta			Baenziger, Jacques U/E-9430-2012		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041738] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01-DK41738] Funding Source: Medline; NIGMS NIH HHS [GM07200] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMINOFF D, 1952, BIOCHEM J, V51, P379, DOI 10.1042/bj0510379; BAENZIGER JU, 1988, BIOCHIM BIOPHYS ACTA, V947, P287, DOI 10.1016/0304-4157(88)90012-3; BAENZIGER JU, 1979, J BIOL CHEM, V235, P267; BERTHOLDT G, 1985, CELL DIFFER DEV, V16, P187, DOI 10.1016/0045-6039(85)90516-0; BOIME I, 1972, ARCH BIOCHEM BIOPHYS, V153, P703; BOURBONNAIS Y, 1985, J BIOL CHEM, V260, P5832; BRAULKE T, 1987, BIOCHEM BIOPH RES CO, V143, P178, DOI 10.1016/0006-291X(87)90647-4; CAPASSO JM, 1984, J BIOL CHEM, V259, P4263; CHENG PW, 1982, J BIOL CHEM, V257, P6251; COLBURN P, 1987, BIOCHEM BIOPH RES CO, V147, P920, DOI 10.1016/S0006-291X(87)80158-4; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DAHMS NM, 1985, J IMMUNOL, V134, P3978; DELFERT DM, 1985, J BIOL CHEM, V260, P4446; DENNIS MV, 1984, J CELL SCI, V67, P121; FAROOQUI AA, 1970, BIOCHIM BIOPHYS ACTA, V198, P56, DOI 10.1016/0005-2744(70)90032-X; FAROOQUI AA, 1980, INT J BIOCHEM, V12, P529, DOI 10.1016/0020-711X(80)90003-8; FREEZE HH, 1986, BIOCHEM BIOPH RES CO, V140, P967, DOI 10.1016/0006-291X(86)90730-8; FREEZE HH, 1989, J BIOL CHEM, V264, P5653; FREEZE HH, 1986, J BIOL CHEM, V261, P127; GREEN ED, 1985, J BIOL CHEM, V260, P5631; GREEN ED, 1985, P NATL ACAD SCI USA, V82, P7850, DOI 10.1073/pnas.82.23.7850; GREEN ED, 1984, P NATL ACAD SCI-BIOL, V81, P5320, DOI 10.1073/pnas.81.17.5320; GREEN ED, 1986, MOL CELL BIOCHEM, V72, P81; GRISWOLD MD, 1986, BIOCHEMISTRY-US, V25, P7265, DOI 10.1021/bi00371a003; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; HABUCHI O, 1982, BIOCHIM BIOPHYS ACTA, V717, P414, DOI 10.1016/0304-4165(82)90282-3; HABUCHI O, 1985, J BIOL CHEM, V260, P3102; HART GW, 1978, J BIOL CHEM, V253, P5795; HEIFETZ A, 1982, BIOCHEMISTRY-US, V21, P171, DOI 10.1021/bi00530a029; HEIFETZ A, 1982, J BIOL CHEM, V257, P13581; HEIFETZ A, 1980, J BIOL CHEM, V255, P4528; HEIFETZ A, 1979, J BIOL CHEM, V254, P6119; HOHMANN HP, 1985, J BIOL CHEM, V260, P3869; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P1048; HORTIN G, 1986, BIOCHEM J, V235, P407, DOI 10.1042/bj2350407; KAMERLING JP, 1988, FEBS LETT, V241, P246, DOI 10.1016/0014-5793(88)81070-6; KATO Y, 1989, J BIOL CHEM, V264, P3364; KORNFELD S, 1987, FASEB J, V1, P462, DOI 10.1096/fasebj.1.6.3315809; LACOSTE CH, 1989, ARCH BIOCHEM BIOPHYS, V273, P505, DOI 10.1016/0003-9861(89)90510-9; LECHNER J, 1985, J BIOL CHEM, V260, P860; LEONG WS, 1987, BIOCHEM SOC T, V15, P1079, DOI 10.1042/bst0151079; MERKLE RK, 1985, J BIOL CHEM, V260, P1083; MERKLE RK, 1984, ARCH BIOCHEM BIOPHYS, V234, P460, DOI 10.1016/0003-9861(84)90293-5; NAKAMURA K, 1978, VIROLOGY, V84, P303, DOI 10.1016/0042-6822(78)90250-7; NAKAZAWA K, 1983, J BIOL CHEM, V258, P6051; NAVARATNAM N, 1986, BIOCHEM J, V239, P423, DOI 10.1042/bj2390423; NAVARATNAM N, 1988, EUR J BIOCHEM, V171, P623, DOI 10.1111/j.1432-1033.1988.tb13833.x; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OKEEFFE ET, 1980, BIOCHEMISTRY-US, V19, P4954, DOI 10.1021/bi00563a003; PALCIC MM, 1988, GLYCOCONJUGATE J, V5, P49, DOI 10.1007/BF01048331; PARTRIDGE SM, 1948, BIOCHEM J, V42, P238, DOI 10.1042/bj0420238; PARTRIDGE SM, 1949, NATURE, V164, P443, DOI 10.1038/164443a0; PERCIVAL E, 1963, J CHEM SOC, P5459, DOI 10.1039/jr9630005459; PERCIVAL E, 1978, ACS SYM SER, V77, P213; PERCIVAL EGV, 1949, Q REV CHEM SOC, V3, P369, DOI 10.1039/qr9490300369; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; PODUSLO JF, 1990, J BIOL CHEM, V265, P3719; POWELL JT, 1976, J BIOL CHEM, V251, P3645; PREHM P, 1979, J BIOL CHEM, V254, P9669; REES DA, 1961, J CHEM SOC, P5168, DOI 10.1039/jr9610005168; ROBBINS PW, 1958, J BIOL CHEM, V233, P686; ROUX L, 1988, J BIOL CHEM, V263, P8879; SCHWARZ JK, 1984, J BIOL CHEM, V259, P3554; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SORKIN BC, 1984, SCIENCE, V225, P1476, DOI 10.1126/science.6474186; SPIRO MJ, 1988, ENDOCRINOLOGY, V123, P56; SPIRO RG, 1988, J BIOL CHEM, V263, P14351; SRIVASTAVA V, 1989, CARBOHYD RES, V185, P163, DOI 10.1016/0008-6215(89)84031-5; SRIVASTAVA V, 1987, CAN J CHEM, V65, P1645; STADLER J, 1983, EMBO J, V2, P1137, DOI 10.1002/j.1460-2075.1983.tb01558.x; STROMINGER JL, 1959, J BIOL CHEM, V234, P3263; SUNDBLAD G, 1988, J BIOL CHEM, V263, P8897; SUNDBLAD G, 1988, J BIOL CHEM, V263, P8890; SUZUKI S, 1960, J BIOL CHEM, V235, P257; SUZUKI S, 1960, J BIOL CHEM, V235, P2768; SUZUKI S, 1960, J BIOL CHEM, V235, P267; TARENTINO AL, 1985, BIOCHEMISTRY-US, V24, P4665, DOI 10.1021/bi00338a028; VONWURTEMBERG MM, 1989, BIOCHEMISTRY-US, V28, P4088; WEAVER TE, 1987, BIOCHIM BIOPHYS ACTA, V914, P205, DOI 10.1016/0167-4838(87)90065-3; WHITTEMORE RM, 1985, BIOCHEM PHARMACOL, V34, P1647, DOI 10.1016/0006-2952(85)90629-X; WIELAND F, 1983, P NATL ACAD SCI-BIOL, V80, P5470, DOI 10.1073/pnas.80.18.5470; WITSELL DL, 1990, J BIOL CHEM, V265, P15731; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YAMASHITA K, 1983, J BIOL CHEM, V258, P4144	84	54	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17142	17150						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894609				2022-12-25	WOS:A1991GF44500029
J	HOOGEWERF, AJ; CISAR, LA; EVANS, DC; BENSADOUN, A				HOOGEWERF, AJ; CISAR, LA; EVANS, DC; BENSADOUN, A			EFFECT OF CHLORATE ON THE SULFATION OF LIPOPROTEIN-LIPASE AND HEPARAN-SULFATE PROTEOGLYCANS - SULFATION OF HEPARAN-SULFATE PROTEOGLYCANS AFFECTS LIPOPROTEIN-LIPASE DEGRADATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP DECREASES; CULTURED ADIPOCYTES; 3T3-L1 ADIPOCYTES; CDNA SEQUENCE; BIOSYNTHESIS; CELLS; SECRETION; TURNOVER; PROTEINS; KINETICS	In avian-cultured adipocytes 76% of the newly synthesized lipoprotein lipase is degraded before release into the medium (Cupp, M., Bensadoun, A., and Melford, K. (1987) J. Biol. Chem. 262, 6383-6388). The same group (Cisar, L. A., Hoogewerf, A. J., Cupp, M., Rapport, C. A., and Bensadoun, A. (1989) J. Biol. Chem. 264, 1767-1774) has proposed that the interaction of lipoprotein lipase with a class of cell surface heparan sulfate proteoglycans is necessary for degradation to occur. To test further this hypothesis, the binding capacity of the plasma membrane for the lipase was decreased by inhibiting the sulfation of glycosaminoglycans with sodium chlorate, an inhibitor of sulfate adenyltransferase. Chlorate decreased sulfate incorporation into trypsin-releasable heparan sulfate proteoglycans to 20% of control levels. The amount of uronic acid in the trypsin-releasable heparan sulfate proteoglycans remained constant. Therefore, chlorate decreased sulfation density on heparan sulfate chains by approximately 5-fold. In the same fractions, chlorate increased the median heparan sulfate M(r) measured on Sephacryl S-300. Chlorate decreased the maximum binding of I-125-lipoprotein lipase to adipocytes by 4-fold, but no significant effects on the affinity constants were observed. Chlorate increased lipoprotein lipase secretion in a dose-dependent relationship up to 30 mm. Utilizing a pulse-chase protocol, it was shown that lipase synthesis in control and chlorate-treated cells was not significantly different and that the increased secretion could be accounted for by a decreased lipoprotein lipase degradation rate. In control cells 77 +/- 11% of the synthesized enzyme was degraded whereas in chlorate-treated cells degradation was reduced to 42 +/- 9% of the synthesized amount. The present study shows that decreased sulfation of heparan sulfate proteoglycans decreases the maximum binding of the lipase for the adipocyte cell surface. Consistent with the model that binding of lipoprotein lipase to cell surface heparan sulfate is required for lipase degradation, degradation is reduced in chlorate-treated cultures. In this report it is also shown that chlorate inhibits lipoprotein lipase sulfation and that desulfation of the enzyme has no effect on its catalytic efficiency or on its binding to cultured adipocytes.	CORNELL UNIV,DIV NUTR SCI,321 SAVAGE HALL,ITHACA,NY 14853; CORNELL UNIV,DIV BIOL SCI,ITHACA,NY 14853	Cornell University; Cornell University				Berryman, Darlene/0000-0003-4240-9229	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024873, R01HL014990] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-24873, HL-14990] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870; BENGTSSON G, 1980, BIOCHEM J, V189, P625, DOI 10.1042/bj1890625; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BENSADOUN A, 1986, BIOCHIM BIOPHYS ACTA, V879, P253, DOI 10.1016/0005-2760(86)90214-6; BIENKOWSKI MJ, 1984, J BIOL CHEM, V259, P2989; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; CHEUNG AH, 1979, ANAL BIOCHEM, V94, P346, DOI 10.1016/0003-2697(79)90371-3; CISAR LA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P196, DOI 10.1016/0005-2760(89)90268-3; CISAR LA, 1989, J BIOL CHEM, V264, P1767; COOPER DA, 1989, BIOCHIM BIOPHYS ACTA, V1008, P92, DOI 10.1016/0167-4781(89)90174-7; CUPP M, 1987, J BIOL CHEM, V262, P6383; DELL RB, 1973, CIRC RES, V32, P71, DOI 10.1161/01.RES.32.1.71; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P4570; Fischer C. F., 1970, Computer Physics Communications, V1, P151, DOI 10.1016/0010-4655(70)90002-0; GREVE H, 1988, J BIOL CHEM, V263, P12886; HOOGEWERF AJ, 1991, J BIOL CHEM, V266, P1048; HUMPHRIES DE, 1988, BIOCHEM BIOPH RES CO, V154, P365, DOI 10.1016/0006-291X(88)90694-8; IOZZO RV, 1987, J BIOL CHEM, V262, P1888; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KIM JJ, 1974, J BIOL CHEM, V249, P3091; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MARTIN GA, 1988, J BIOL CHEM, V263, P10907; MILLER RE, 1980, J BIOL CHEM, V255, P5490; SAITO H, 1968, J BIOL CHEM, V243, P1536; SEMB H, 1987, BIOCHIM BIOPHYS ACTA, V921, P104, DOI 10.1016/0005-2760(87)90176-7; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SHISHIBA Y, 1988, J BIOL CHEM, V263, P1745; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; VANNIER C, 1989, J BIOL CHEM, V264, P13206	33	47	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16564	16571						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885587				2022-12-25	WOS:A1991GD63500054
J	MISUMI, Y; ODA, K; FUJIWARA, T; TAKAMI, N; TASHIRO, K; IKEHARA, Y				MISUMI, Y; ODA, K; FUJIWARA, T; TAKAMI, N; TASHIRO, K; IKEHARA, Y			FUNCTIONAL EXPRESSION OF FURIN DEMONSTRATING ITS INTRACELLULAR-LOCALIZATION AND ENDOPROTEASE ACTIVITY FOR PROCESSING OF PROALBUMIN AND COMPLEMENT PRO-C3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-1-PROTEASE INHIBITOR; YEAST KEX2 PROTEASE; SERUM-ALBUMIN; SECRETORY VESICLES; GENE-PRODUCT; COS-1 CELLS; CDNA; BIOSYNTHESIS; SUBTILISIN; IDENTIFICATION	We have cloned a rat cDNA encoding furin which is structurally related to yeast Kex2 protease. Products of 88 and 94 kDa were obtained by in vitro transcription/translation of the cDNA in the absence and presence of microsomes. When the cDNA was transfected into COS-1 cells, furin was expressed as a major glycosylated form of 94 kDa, accompanied by a minor proteolytic form of 86 kDa, and found to be localized in the Golgi complex. Proalbumin and complement pro-C3 are intracellularly processed into their mature forms by cleavage at the dibasic residues Arg-Arg, a common cleavage signal found in many pro-type precursors. In cells transfected with the cDNA of C3 or albumin alone, only about half of each proform expressed was processed by an endogenous activity of the cells. When furin was co-expressed, the proforms of both C3 and albumin were completely processed into their mature forms. In addition, co-expression of rat alpha-1-protease inhibitor mutant (Met352 --> Arg) resulted in inhibition of the endogenous and exogenous processing activities, as observed for the naturally occurring mutant Pittsburgh which has been identified as a specific inhibitor for the processing enzyme. Taken together, these results indicate that furin is an endoprotease localized to the Golgi complex and capable of processing proalbumin and pro-C3 into the mature forms.	FUKUOKA UNIV,SCH MED,DEPT BIOCHEM,JONAN KU,FUKUOKA 81401,JAPAN; FUKUOKA UNIV,SCH MED,RADIOISOTOPE LAB,JONAN KU,FUKUOKA 81401,JAPAN; UNIV TOKYO,FAC SCI,DEPT ZOOL,BUNKYO KU,TOKYO 113,JAPAN	Fukuoka University; Fukuoka University; University of Tokyo								ANDREWS PC, 1987, EXPERIENTIA, V43, P784, DOI 10.1007/BF01945356; BATHURST IC, 1987, SCIENCE, V235, P348, DOI 10.1126/science.3541206; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRENNAN SO, 1990, J BIOL CHEM, V265, P21494; BRENNAN SO, 1988, FEBS LETT, V229, P167, DOI 10.1016/0014-5793(88)80819-6; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; DOCHERTY K, 1983, P NATL ACAD SCI-BIOL, V80, P3245, DOI 10.1073/pnas.80.11.3245; FISCHER JM, 1988, J BIOL CHEM, V263, P16515; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; FULLER RS, 1990, J CELL BIOCH SC, V14, P69; GODSON GN, 1973, BIOCHIM BIOPHYS ACTA, V299, P516, DOI 10.1016/0005-2787(73)90223-2; GRAHAM RC, 1966, J HISTOCHEM CYTOCHEM, V14, P291, DOI 10.1177/14.4.291; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HANLEY JM, 1983, J BIOL CHEM, V258, P7858; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; IKEHARA Y, 1977, J BIOCHEM-TOKYO, V81, P1293; IKEHARA Y, 1976, BIOCHEM BIOPH RES CO, V72, P319, DOI 10.1016/0006-291X(76)90996-7; JUDAH JD, 1976, TRENDS BIOCHEM SCI, V1, P107, DOI 10.1016/0968-0004(76)90017-7; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; LAPPS W, 1988, J BIOL CHEM, V263, P13456; LAUB O, 1983, J BIOL CHEM, V258, P6043; MARKLAND FS, 1967, J BIOL CHEM, V242, P5198; MISUMI Y, 1984, FEBS LETT, V175, P63, DOI 10.1016/0014-5793(84)80570-0; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P6719, DOI 10.1093/nar/18.22.6719; MISUMI Y, 1983, BIOCHEM BIOPH RES CO, V114, P729, DOI 10.1016/0006-291X(83)90841-0; MISUMI Y, 1990, BIOCHEM BIOPH RES CO, V171, P236, DOI 10.1016/0006-291X(90)91382-3; MISUMI Y, 1990, J BIOCHEM-TOKYO, V108, P230, DOI 10.1093/oxfordjournals.jbchem.a123185; MISUMI Y, 1990, NUCLEIC ACIDS RES, V18, P2178, DOI 10.1093/nar/18.8.2178; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; NOEL G, 1987, J BIOL CHEM, V262, P1876; ODA K, 1988, J BIOCHEM-TOKYO, V104, P159, DOI 10.1093/oxfordjournals.jbchem.a122432; ODA K, 1983, EUR J BIOCHEM, V135, P209, DOI 10.1111/j.1432-1033.1983.tb07639.x; ODA K, 1989, BIOCHEM BIOPH RES CO, V163, P194, DOI 10.1016/0006-291X(89)92120-7; OGATA S, 1989, J BIOL CHEM, V264, P3596; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PARISH DC, 1986, J BIOL CHEM, V261, P4392; POWER SD, 1986, P NATL ACAD SCI USA, V83, P3096, DOI 10.1073/pnas.83.10.3096; RHODES CJ, 1989, J BIOL CHEM, V264, P14240; ROEBROEK AJM, 1986, EMBO J, V5, P2197, DOI 10.1002/j.1460-2075.1986.tb04484.x; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; TARTAKOFF AM, 1983, J CELL BIOL, V97, P1243, DOI 10.1083/jcb.97.4.1243; THIM L, 1986, P NATL ACAD SCI USA, V83, P6766, DOI 10.1073/pnas.83.18.6766; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; VIRTANEN I, 1980, J CELL BIOL, V85, P429, DOI 10.1083/jcb.85.2.429; WARREN TG, 1984, CELL, V39, P547, DOI 10.1016/0092-8674(84)90461-6; WELLS JA, 1983, NUCLEIC ACIDS RES, V11, P7911, DOI 10.1093/nar/11.22.7911; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	55	161	167	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16954	16959						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885622				2022-12-25	WOS:A1991GD63500112
J	PETRONILLI, V; AMES, GF				PETRONILLI, V; AMES, GF			BINDING PROTEIN-INDEPENDENT HISTIDINE PERMEASE MUTANTS - UNCOUPLING OF ATP HYDROLYSIS FROM TRANSMEMBRANE SIGNALING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BACTERIAL PERIPLASMIC PERMEASES; MALTOSE TRANSPORT-SYSTEM; SALMONELLA-TYPHIMURIUM; MEMBRANE-VESICLES; ESCHERICHIA-COLI; MULTIDRUG RESISTANCE; RECONSTITUTION; COMPONENTS; ATPASES	Periplasmic permeases consist of a substrate-binding receptor, located in the periplasm, and a membrane-bound complex composed of two integral membrane proteins and two nucleotide-binding proteins. The receptor interacts with the membrane-bound complex, which, upon receiving this signal, is postulated to hydrolyze ATP and translocate the substrate. We show that a class of mutations in the membrane-bound complex of the histidine permease, which allow transport in the absence of the substrate-binding protein, hydrolyze ATP independently from any signal. The data are compatible with the notion that cross-membrane signaling between the liganded periplasmic receptor and the cytoplasmic ATP-binding site initiates conformational changes leading to ATP hydrolysis and substrate translocation.	CNR, IST PATOL GEN, DIPARTIMENTO BIOL, I-35131 PADUA, ITALY	Consiglio Nazionale delle Ricerche (CNR)	PETRONILLI, V (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.		Petronilli, Valeria/C-3558-2015	Petronilli, Valeria/0000-0003-4026-6404	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK012121, R01DK012121] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK12121] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES GF, 1986, CELL, V47, P323, DOI 10.1016/0092-8674(86)90585-4; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1989, J BIOL CHEM, V264, P3998; AMES GFL, 1990, J BACTERIOL, V172, P4133, DOI 10.1128/jb.172.8.4133-4137.1990; AMES GFL, 1991, IN PRESS ADV ENZYMOL; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; DAVIDSON AL, 1990, J BIOL CHEM, V265, P4254; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JENKINS WT, 1984, ANAL BIOCHEM, V141, P155; KABACK HR, 1974, SCIENCE, V186, P882, DOI 10.1126/science.186.4167.882; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; KUSTU SG, 1979, J BACTERIOL, V138, P218, DOI 10.1128/JB.138.1.218-234.1979; KUSTU SG, 1973, J BACTERIOL, V116, P107, DOI 10.1128/JB.116.1.107-113.1973; MIMMACK ML, 1989, P NATL ACAD SCI USA, V86, P8257, DOI 10.1073/pnas.86.21.8257; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; Rosen B P, 1979, Methods Enzymol, V56, P233; SHYAMALA V, 1989, J BACTERIOL, V171, P1602, DOI 10.1128/jb.171.3.1602-1608.1989; SHYAMALA V, 1991, IN PRESS J BIOL CHEM; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; TREPTOW NA, 1985, J BACTERIOL, V163, P654, DOI 10.1128/JB.163.2.654-660.1985	24	74	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16293	16296						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885562				2022-12-25	WOS:A1991GD63500010
J	ZAPATA, JM; MAROTO, FG; SIERRA, JM				ZAPATA, JM; MAROTO, FG; SIERRA, JM			INACTIVATION OF MESSENGER-RNA CAP-BINDING PROTEIN COMPLEX IN DROSOPHILA-MELANOGASTER EMBRYOS UNDER HEAT-SHOCK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION FACTOR-II; POLYPEPTIDE-CHAIN-INITIATION; TRANSLATIONAL CONTROL; HELA-CELLS; UNTRANSLATED LEADER; PHOSPHORYLATION; INHIBITION; SEQUENCE; RECOVERY; GENES	We have studied the role of Drosophila 35-kDa cap-binding protein (CBP) and CBP complex in the mechanism of messenger RNA discrimination established in heat-shocked Drosophila embryos. Drosophila 35-kDa CBP is functionally equivalent to the mammalian eucaryotic initiation factor (eIF)-4E and CBP complex, which includes eIF-4E, might be the counterpart of mammalian eIF-4F. By using anti-eIF-4E antibodies, we found that although translation of the bulk of normal messengers in Drosophila lysates was very dependent on eIF-4E, the mRNAs for the heat shock proteins (hsps) (particularly hsp70 mRNA and with the exception of hsp83 mRNA) were translated almost independently of this factor, suggesting that they may have unstructured leaders. Accordingly, hsp70 mRNA and, to a lesser extent, the mRNAs for the small hsps were found to be more resistant to inhibition by K+ than normal and hsp83 mRNAs. Moreover, Drosophila CBP complex was able to rescue partial but specifically the synthesis of normal proteins when added to a lysate from heat-shocked embryos. However, no significant effect was obtained by Drosophila eIF-4E or eIF-2. Consistent with these results, we found a great decrease in the amount of the CBP complex purified from heat-shocked embryos as compared with normal ones, whereas the amounts of free eIF-4E purified from either source were similar. Together, the above results suggest that some modification leading to the disruption of Drosophila CBP complex may account, at least to some extent, for the mRNA discrimination established in heat-shocked Drosophila embryos.	CSIC, CTR BIOL MOLEC, CANTOBLANCO, E-28049 MADRID, SPAIN; UNIV AUTONOMA MADRID, E-28049 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); Autonomous University of Madrid			Maroto, Federico Garcia/G-8616-2013; Zapata, Juan M/J-6304-2014	Maroto, Federico Garcia/0000-0002-0565-6995; Zapata, Juan M/0000-0002-0110-0009				BALLINGER DG, 1983, CELL, V33, P103, DOI 10.1016/0092-8674(83)90339-2; BONNEAU AM, 1987, J BIOL CHEM, V262, P11134; BURDON RH, 1986, BIOCHEM J, V240, P313, DOI 10.1042/bj2400313; DEBENEDETTI A, 1986, J BIOL CHEM, V261, P338; DENISENKO ON, 1989, FEBS LETT, V247, P251, DOI 10.1016/0014-5793(89)81346-8; DRUMMOND IAS, 1986, MOL CELL BIOL, V6, P1767, DOI 10.1128/MCB.6.5.1767; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1989, J CELL BIOL, V109, P1467, DOI 10.1083/jcb.109.4.1467; EDERY I, 1984, BIOCHEMISTRY-US, V23, P2456, DOI 10.1021/bi00306a021; GLOVER CVC, 1982, P NATL ACAD SCI-BIOL, V79, P1781, DOI 10.1073/pnas.79.6.1781; GORDON ED, 1987, J BIOL CHEM, V262, P16590; HICKEY ED, 1982, BIOCHEMISTRY-US, V21, P1513, DOI 10.1021/bi00536a008; HOLMGREN R, 1981, P NATL ACAD SCI-BIOL, V78, P3775, DOI 10.1073/pnas.78.6.3775; HULTMARK D, 1986, CELL, V44, P429, DOI 10.1016/0092-8674(86)90464-2; INGOLIA TD, 1981, NUCLEIC ACIDS RES, V9, P1627, DOI 10.1093/nar/9.7.1627; JACKSON RJ, 1986, EUR J BIOCHEM, V158, P623, DOI 10.1111/j.1432-1033.1986.tb09800.x; KLEMENZ R, 1985, EMBO J, V4, P2053, DOI 10.1002/j.1460-2075.1985.tb03891.x; KRUGER C, 1981, CELL, V23, P595, DOI 10.1016/0092-8674(81)90155-0; LAMPHEAR BJ, 1990, J BIOL CHEM, V265, P5333; LAWSON TG, 1988, J BIOL CHEM, V263, P7266; LEE KAW, 1983, J BIOL CHEM, V258, P707; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LINDQUIST S, 1975, P NATL ACAD SCI USA, V72, P1117, DOI 10.1073/pnas.72.3.1117; LINDQUIST S, 1981, NATURE, V293, P311, DOI 10.1038/293311a0; LINDQUIST S, 1980, J MOL BIOL, V137, P151, DOI 10.1016/0022-2836(80)90322-8; LODISH HF, 1976, ANNU REV BIOCHEM, V45, P39, DOI 10.1146/annurev.bi.45.070176.000351; MARIANO TM, 1986, BIOCHEM BIOPH RES CO, V138, P519, DOI 10.1016/S0006-291X(86)80527-7; MAROTO FG, 1989, MOL CELL BIOL, V9, P2181, DOI 10.1128/MCB.9.5.2181; MAROTO FG, 1988, J BIOL CHEM, V263, P15720; MATEU MG, 1987, EUR J BIOCHEM, V162, P221, DOI 10.1111/j.1432-1033.1987.tb10564.x; MATEU MG, 1987, EUR J BIOCHEM, V165, P507, DOI 10.1111/j.1432-1033.1987.tb11468.x; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; MIRAULT ME, 1977, COLD SPRING HARB SYM, V42, P819, DOI 10.1101/SQB.1978.042.01.082; MUNOZ A, 1984, VIROLOGY, V137, P150, DOI 10.1016/0042-6822(84)90018-7; OLSEN AS, 1983, MOL CELL BIOL, V3, P2017, DOI 10.1128/MCB.3.11.2017; PANNIERS R, 1985, J BIOL CHEM, V260, P9648; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; PETERSEN NS, 1981, P NATL ACAD SCI-BIOL, V78, P1708, DOI 10.1073/pnas.78.3.1708; ROSE DW, 1989, J BIOL CHEM, V264, P6239; Sambrook J, 1989, MOL CLONING LABORATO; SANDERS MM, 1981, J CELL BIOL, V91, P579, DOI 10.1083/jcb.91.2.579; SANDERS MM, 1986, J BIOL CHEM, V261, P2189; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SCOTT MP, 1980, CELL, V22, P929, DOI 10.1016/0092-8674(80)90570-X; SCOTT MP, 1981, P NATL ACAD SCI-BIOL, V78, P3353, DOI 10.1073/pnas.78.6.3353; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; SPRADLING A, 1977, J MOL BIOL, V109, P559, DOI 10.1016/S0022-2836(77)80091-0; STORTI RV, 1980, CELL, V22, P825, DOI 10.1016/0092-8674(80)90559-0; TANGUAY RM, 1983, CAN J BIOCHEM CELL B, V61, P414, DOI 10.1139/o83-056	50	48	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16007	16014						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908463				2022-12-25	WOS:A1991GB97700073
J	MUKUND, S; ADAMS, MWW				MUKUND, S; ADAMS, MWW			THE NOVEL TUNGSTEN-IRON-SULFUR PROTEIN OF THE HYPERTHERMOPHILIC ARCHAEBACTERIUM, PYROCOCCUS-FURIOSUS, IS AN ALDEHYDE FERREDOXIN OXIDOREDUCTASE - EVIDENCE FOR ITS PARTICIPATION IN A UNIQUE GLYCOLYTIC PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP-NOV REPRESENTS; THERMOPLASMA-ACIDOPHILUM; SULFOLOBUS-SOLFATARICUS; GLUCOSE-DEHYDROGENASE; MOLYBDENUM COFACTOR; ESCHERICHIA-COLI; GEN-NOV; PURIFICATION; METABOLISM; ENZYME	The anaerobic archaebacterium, Pyrococcus furiosus, grows optimally at 100-degrees-C by a fermentative-type metabolism in which H-2, CO2, and organic acids are end products. The growth of this organism is stimulated by tungsten, and, from it, a novel, red-colored, tungsten-iron-sulfur protein, abbreviated RTP, has been purified (Mukund, S., and Adams, M. W. W. (1 990) J. Biol. Chem. 265, 11508-11516). RTP (M(r) approximately 85,000) contained approximately 1W, 7Fe, and 5 acid-labile sulfide atoms/molecule and exhibited unique EPR properties. The physiological function of the protein, however, was unknown. We show here that RTP is an inactive form of an aldehyde ferredoxin oxidoreductase (AOR). The active enzyme was obtained by rapid purification under anaerobic conditions using buffers containing dithiothreitol and glycerol. AOR catalyzed the oxidation of a range of aliphatic aldehydes with an optimum temperature for activity above 90-degrees-C, but it did not oxidize glucose or glyceraldehyde 3-phosphate, nor reduce NAD(P), and its activity was independent of CoA. The active (AOR) and inactive (RTP) forms of the enzyme were indistinguishable in their contents of metals and acid-labile sulfide and in their EPR properties. The latter are thought to originate from two nonidentical and spin-coupled iron-sulfur clusters, whereas the tungsten in this enzyme, which was not detectable by EPR, appears to be present as a novel pterin cofactor. Inhibition and activation studies indicated that AOR contains a catalytically essential W-SH group that is not present in RTP, the inactive form. AOR is a new type of aldehyde-oxidizing enzyme and is the first aldehyde oxidoreductase to be purified from an archaebacterium or a nonacetogenic anaerobic bacterium. Its physiological role in P. furiosus is proposed as the oxidation of glyceraldehyde to glycerate in a unique, partially nonphosphorylated, glycolytic pathway that generates acetyl-CoA from glucose without the participation of nicotinamide nucleotides.	UNIV GEORGIA, CTR METALLOENZYME STUDIES, ATHENS, GA 30602 USA	University System of Georgia; University of Georgia	MUKUND, S (corresponding author), UNIV GEORGIA, DEPT BIOCHEM, ATHENS, GA 30602 USA.			Adams, Michael/0000-0002-9796-5014				ADAMS MWW, 1982, J BIOL CHEM, V257, P1791; ADAMS MWW, 1990, FEMS MICROBIOL LETT, V75, P219, DOI 10.1016/0378-1097(90)90533-V; ADAMS MWW, 1984, BIOCHIM BIOPHYS ACTA, V766, P51, DOI 10.1016/0005-2728(84)90216-0; Anthony C., 1982, BIOCH METHYLOTROPHS; AONO S, 1989, J BACTERIOL, V171, P3433, DOI 10.1128/jb.171.6.3433-3439.1989; BLUMENTALS II, 1990, APPL ENVIRON MICROB, V56, P1992, DOI 10.1128/AEM.56.7.1992-1998.1990; BRYANT FO, 1989, J BIOL CHEM, V264, P5070; BUDGEN N, 1986, FEBS LETT, V196, P207, DOI 10.1016/0014-5793(86)80247-2; CHEN JS, 1977, ANAL BIOCHEM, V79, P157, DOI 10.1016/0003-2697(77)90390-6; COSTANTINO HR, 1990, J BACTERIOL, V172, P3654, DOI 10.1128/jb.172.7.3654-3660.1990; Coughlan M. P., 1980, Molybdenum and molybdenum-containing enzymes, P119; Danson M J, 1988, Adv Microb Physiol, V29, P165, DOI 10.1016/S0065-2911(08)60348-3; Dawson R. M. C., 1986, DATA BIOCH RES, V3rd; DEROSA M, 1984, BIOCHEM J, V224, P407, DOI 10.1042/bj2240407; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EGGEN R, 1990, FEMS MICROBIOL LETT, V71, P17; EVCES S, 1989, ARCH BIOCHEM BIOPHYS, V274, P518, DOI 10.1016/0003-9861(89)90465-7; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; GIARDINA P, 1986, BIOCHEM J, V239, P517, DOI 10.1042/bj2390517; HALES BJ, 1987, J BIOL CHEM, V262, P16205; HEMPEL J, 1984, EUR J BIOCHEM, V141, P21, DOI 10.1111/j.1432-1033.1984.tb08150.x; Hille R., 1985, Metal Ions in Biology, V7, P443; HUBER R, 1987, ARCH MICROBIOL, V149, P95, DOI 10.1007/BF00425072; HUBER R, 1986, ARCH MICROBIOL, V144, P324, DOI 10.1007/BF00409880; JOHANSSON J, 1988, EUR J BIOCHEM, V172, P527, DOI 10.1111/j.1432-1033.1988.tb13920.x; Johnson J. L., 1980, MOLYBDENUM MOLYBDENU, P345; JOHNSON JL, 1982, P NATL ACAD SCI-BIOL, V79, P6856, DOI 10.1073/pnas.79.22.6856; KELLY RM, 1988, BIOTECHNOL PROGR, V4, P47, DOI 10.1002/btpr.5420040202; KESSELER FP, 1987, BIOL CHEM H-S, V368, P566; Loach P. A., 1976, HDB BIOCH MOL BIOL, V1, P122; LOOMES KM, 1990, BIOCHEMISTRY-US, V29, P2070, DOI 10.1021/bi00460a015; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAEYAMA M, 1982, METHOD ENZYMOL, V89, P491; MORTENSON LE, 1964, BIOCHIM BIOPHYS ACTA, V81, P71, DOI 10.1016/0926-6569(64)90336-0; MUKUND S, 1990, J BIOL CHEM, V265, P11508; Ng TK, 1986, THERMOPHILES GENERAL, P197; PAGE MD, 1986, J GEN MICROBIOL, V132, P1553; PATEL RN, 1980, ARCH BIOCHEM BIOPHYS, V203, P654, DOI 10.1016/0003-9861(80)90223-4; PLEDGER RJ, 1991, J GEN MICROBIOL, V137, P203, DOI 10.1099/00221287-137-1-203; POELS PA, 1989, ARCH BIOCHEM BIOPHYS, V271, P240, DOI 10.1016/0003-9861(89)90274-9; POELS PA, 1987, EUR J BIOCHEM, V166, P575, DOI 10.1111/j.1432-1033.1987.tb13552.x; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; SMITH LD, 1989, BIOCHEM J, V261, P973, DOI 10.1042/bj2610973; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STETTER KO, 1983, SYST APPL MICROBIOL, V4, P535, DOI 10.1016/S0723-2020(83)80011-3; STETTER KO, 1986, THERMOPHILES GENERAL, P39; TAYLOR EC, 1989, J AM CHEM SOC, V111, P7664, DOI 10.1021/ja00201a084; THAUER RK, 1977, BACTERIOL REV, V41, P100, DOI 10.1128/MMBR.41.1.100-180.1977; TIPTON KF, 1985, ENZYMOLOGY CARBONYL, V2, P3; WEBER K, 1972, METHOD ENZYMOL, V26, P2; WHITE H, 1989, EUR J BIOCHEM, V184, P89, DOI 10.1111/j.1432-1033.1989.tb14993.x; WHITE RH, 1991, J BACTERIOL, V173, P1987, DOI 10.1128/jb.173.6.1987-1991.1991; WHITE RH, 1990, BIOCHEMISTRY-US, V29, P5397, DOI 10.1021/bi00474a027; YAMAMOTO I, 1983, J BIOL CHEM, V258, P1826; YAN RT, 1990, APPL ENVIRON MICROB, V56, P2591, DOI 10.1128/AEM.56.9.2591-2599.1990; ZILLIG W, 1983, SYST APPL MICROBIOL, V4, P79, DOI 10.1016/S0723-2020(83)80035-6; ZILLIG W, 1990, J BACTERIOL, V172, P3959, DOI 10.1128/jb.172.7.3959-3965.1990; ZWICKL P, 1990, J BACTERIOL, V172, P4329, DOI 10.1128/jb.172.8.4329-4338.1990	59	225	229	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14208	14216						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907273				2022-12-25	WOS:A1991FZ35100017
J	DOZIER, C; ANSIEAU, S; FERREIRA, E; COLL, J; STEHELIN, D				DOZIER, C; ANSIEAU, S; FERREIRA, E; COLL, J; STEHELIN, D			AN ALTERNATIVELY SPLICED C-MIL/RAF MESSENGER-RNA IS PREDOMINANTLY EXPRESSED IN CHICKEN MUSCULAR TISSUES AND CONSERVED AMONG VERTEBRATE SPECIES	ONCOGENE			English	Note							ONCOGENE V-MIL; KINASE-ACTIVITY; RAF ONCOGENE; PROTEIN; PHOSPHORYLATION; ACTIVATION; GENE; SEQUENCE; RECEPTOR; IDENTIFICATION	The chicken c-mil gene produces two mRNA species generated by an alternative splicing mechanism. These two transcripts differ at least by the presence or absence of a 60 nucleotide exon (E7a) localized at the splice junction of c-mil exons 7 and 8. By using RNAase protection assays, we have analysed the pattern of expression of these two mRNA species in several chicken tissues. Here we report that the two c-mil mRNAs are differentially expressed in chicken tissues: the mRNA lacking E7a is detected in all tissues tested, while the mRNA containing E7a is detected only in the skeletal muscle, heart and brain. Sequences homologous to E7a have also been detected in DNAs from quail, mouse and human cells and their sequencing revealed that the alternative E7a is structurally preserved in these species. By PCR analyses performed on RNAs extracted from muscular tissues of these species, we also show that the alternative splicing mechanism described in chicken also occurs in these species.			DOZIER, C (corresponding author), INST PASTEUR,CNRS,UA 1160,INSERM,U186,1 RUE CALMETTE,F-59019 LILLE,FRANCE.		Ansieau, Stephane/I-6195-2016; DOZIER, Christine/P-1539-2014	ANSIEAU, Stephane/0000-0003-0989-2108				BACCARINI M, 1990, EMBO J, V9, P3649, DOI 10.1002/j.1460-2075.1990.tb07576.x; BONNER TI, 1986, NUCLEIC ACIDS RES, V14, P1009, DOI 10.1093/nar/14.2.1009; BREITBART RE, 1987, ANNU REV BIOCHEM, V56, P467, DOI 10.1146/annurev.bi.56.070187.002343; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLL J, 1983, EMBO J, V2, P2189, DOI 10.1002/j.1460-2075.1983.tb01722.x; DENHEZ F, 1988, EMBO J, V7, P541, DOI 10.1002/j.1460-2075.1988.tb02843.x; DOZIER C, 1988, MOL CELL BIOL, V8, P1835, DOI 10.1128/MCB.8.4.1835; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; JAMAL S, 1990, NATURE, V344, P463, DOI 10.1038/344463a0; JANSEN HW, 1985, VIROLOGY, V143, P359, DOI 10.1016/0042-6822(85)90376-9; JANSEN HW, 1984, VIROLOGY, V137, P217, DOI 10.1016/0042-6822(84)90028-X; KOENEN M, 1988, ONCOGENE, V2, P179; LEVY JB, 1989, MOL CELL BIOL, V9, P3332, DOI 10.1128/MCB.9.8.3332; MARTINEZ R, 1987, SCIENCE, V237, P411, DOI 10.1126/science.2440106; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; PATCHINSKY T, 1986, MOL CELL BIOL, V6, P739; PYPER JM, 1990, MOL CELL BIOL, V10, P2035, DOI 10.1128/MCB.10.5.2035; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIEGEL JN, 1990, J BIOL CHEM, V265, P18472; STORM SM, 1990, ONCOGENE, V5, P345; TAHIRA T, 1987, NUCLEIC ACIDS RES, V15, P4809, DOI 10.1093/nar/15.12.4809	25	14	17	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1307	1311						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886707				2022-12-25	WOS:A1991GX27200002
J	CHAMBAZ, J; CARDOT, P; PASTIER, D; ZANNIS, VI; CLADARAS, C				CHAMBAZ, J; CARDOT, P; PASTIER, D; ZANNIS, VI; CLADARAS, C			PROMOTER ELEMENTS AND FACTORS REQUIRED FOR HEPATIC TRANSCRIPTION OF THE HUMAN APOA-II GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-II; TISSUE-SPECIFIC EXPRESSION; HIGH-DENSITY LIPOPROTEIN; CELL-SPECIFIC EXPRESSION; DNA-BINDING; NUCLEAR FACTOR; CHOLESTEROL ACYLTRANSFERASE; INTESTINAL TRANSCRIPTION; ACID SEQUENCE; B GENE	The apolipoprotein A-II (apoA-II) gene regulatory region -911 to +29 strongly promotes the transcription of the promotorless chloramphenicol acetyltransferase (CAT) gene in cells of hepatic (HepG2) and intestinal (CaCo2) origin but not in HeLa cells. Deletion of nucleotides -91 1 to -860 decreased the hepatic and intestinal transcription to 7% and 18% of control, respectively. Further progressive deletions extending to nucleotides -614, -440, -230, and -80 abolished both hepatic and intestinal transcription, indicating that the distal promoter region -911 to -614 contains regulatory elements that are essential for intestinal and hepatic transcription. An internal deletion of the -614 to -230 region decreased hepatic transcription 60% while it increased intestinal transcription 140% of control indicating that the elements which control hepatic and intestinal transcription of the apoA-II gene may be different within this regulatory region. DNase I footprinting analysis with rat liver nuclear extracts identified 14 protected regions: A, -40 to -33; B, -65 to -42; C, -126 to -110; D, -276 to -255; E, -377 to -364; F, -404 to -384; G, -468 to -455; H, -573 to -554; 1, -706 to -680; J, -734 to -716; K, -760 to -743; L, -803 to -773; M, -853 to -829, and N, -903 to -879, as the DNA binding sites for nuclear factors. Five of the regions (B, C, G, H, and K) bind to heat-stable factors. DNA binding gel electrophoretic assays indicated that region N (-903 to -879), which is essential for efficient transcription, binds predominantly a nuclear activity designated AIIN3. This activity is present in cells of hepatic and intestinal origin but absent in HeLa cells. Similar analysis showed that region H (-573 to -554) binds to the liver-specific factor HNF1/LFB1. Deletion of this region decreased hepatic and intestinal transcription 80 and 64% of control, respectively, suggesting that HNF1/LFB 1 or a related activity contributes to optimal transcription but is not essential for the tissue-specific expression of the human apoA-II gene.	BOSTON UNIV,MED CTR,HOUSMAN MED RES CTR,DEPT MED,INST CARDIOVASC,MOLEC GENET SECT,BOSTON,MA 02118; BOSTON UNIV,MED CTR,HOUSMAN MED RES CTR,DEPT BIOCHEM,BOSTON,MA 02118	Boston University; Boston University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL043909, R01HL033952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL43909, HL33952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BACH I, 1990, GENOMICS, V8, P155, DOI 10.1016/0888-7543(90)90238-P; BAUMHUETER S, 1988, EMBO J, V7, P2485, DOI 10.1002/j.1460-2075.1988.tb03095.x; BAUMHUETER S, 1990, GENE DEV, V4, P372, DOI 10.1101/gad.4.3.372; BREWER HB, 1972, P NATL ACAD SCI USA, V69, P1304, DOI 10.1073/pnas.69.5.1304; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; CEREGHINI S, 1990, EMBO J, V9, P2257, DOI 10.1002/j.1460-2075.1990.tb07396.x; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DESIMONE V, 1987, EMBO J, V6, P2759, DOI 10.1002/j.1460-2075.1987.tb02570.x; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; EDLUND T, 1985, SCIENCE, V230, P912, DOI 10.1126/science.3904002; FIDGE NH, 1985, J BIOL CHEM, V260, P3570; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GODBOUT R, 1986, MOL CELL BIOL, V6, P477, DOI 10.1128/MCB.6.2.477; GORDON JI, 1985, J BIOL CHEM, V260, P4824; GORDON JI, 1984, J BIOL CHEM, V259, P5556; GORDON JI, 1983, J BIOL CHEM, V258, P4054; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARDON EM, 1988, EMBO J, V7, P1711, DOI 10.1002/j.1460-2075.1988.tb03000.x; HUSSAIN MM, 1990, BIOCHEMISTRY-US, V29, P209, DOI 10.1021/bi00453a029; JAHN CE, 1983, EUR J BIOCHEM, V131, P25, DOI 10.1111/j.1432-1033.1983.tb07227.x; JOHNSON PF, 1989, ANNU REV BIOCHEM, V58, P799, DOI 10.1146/annurev.biochem.58.1.799; KARDASSIS D, 1990, J BIOL CHEM, V265, P21733; KARDASSIS D, 1990, MOL CELL BIOL, V10, P2653, DOI 10.1128/MCB.10.6.2653; KNOTT TJ, 1984, BIOCHEM BIOPH RES CO, V120, P734, DOI 10.1016/S0006-291X(84)80168-0; LACKNER KJ, 1984, FEBS LETT, V175, P159, DOI 10.1016/0014-5793(84)80590-6; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; LUCERO MA, 1989, NUCLEIC ACIDS RES, V17, P2283, DOI 10.1093/nar/17.6.2283; LUSIS AJ, 1988, J LIPID RES, V29, P397; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; OCHOA A, 1989, NUCLEIC ACIDS RES, V17, P119, DOI 10.1093/nar/17.1.119; OGAMI K, 1990, J BIOL CHEM, V265, P9808; OGAMI K, 1991, J BIOL CHEM, V266, P9640; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; PAPAZAFIRI P, 1991, J BIOL CHEM, V266, P5790; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SCHONFELD G, 1982, J CLIN INVEST, V69, P1072, DOI 10.1172/JCI110542; SHARPE CR, 1984, NUCLEIC ACIDS RES, V12, P3917, DOI 10.1093/nar/12.9.3917; SHELLEY CS, 1987, NUCLEIC ACIDS RES, V15, P3801, DOI 10.1093/nar/15.9.3801; SHINOMIYA M, 1982, BIOCHIM BIOPHYS ACTA, V713, P292; SORCITHOMAS M, 1989, J LIPID RES, V30, P1397; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; STRAUSS F, 1984, CELL, V37, P889, DOI 10.1016/0092-8674(84)90424-0; TSAO YK, 1985, J BIOL CHEM, V260, P5222	55	47	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11676	11685						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904868				2022-12-25	WOS:A1991FT76200042
J	PATWARDHAN, S; GASHLER, A; SIEGEL, MG; CHANG, LC; JOSEPH, LJ; SHOWS, TB; LEBEAU, MM				PATWARDHAN, S; GASHLER, A; SIEGEL, MG; CHANG, LC; JOSEPH, LJ; SHOWS, TB; LEBEAU, MM			EGR3, A NOVEL MEMBER OF THE EGR FAMILY OF GENES ENCODING IMMEDIATE-EARLY TRANSCRIPTION FACTORS	ONCOGENE			English	Article							GROWTH-FACTORS ENCODES; ZINC-FINGER GENE; C-FOS; G0/G1 TRANSITION; MOLECULAR-CLONING; CULTURED-CELLS; BINDING-SITES; MESSENGER-RNA; HUMAN GENOME; EXPRESSION	We have previously described two cellular immediate-early genes, Egr-1 (mouse) and EGR2 (human) that encode zinc finger proteins. Here we report the characterization of a new member of the Egr family referred to as EGR3 (human). This cDNA clone was isolated using low stringency hybridization with the zinc finger domain of Egr-1. The EGR3 cDNA sequence predicts a 387 amino acid (a.a.) protein containing three Cys2-His2 zinc fingers nearly identical to those of Egr-1 and EGR2. This similarity has a functional consequence: EGR3 can activate transcription of a CAT gene linked to the sequence CGCCCCCGC, a cis element which is a target for Egr-1 and EGR2. We show that EGR3 is an immediate-early growth response gene induced by mitogenic stimulation of rodent and human fibroblasts and a monkey kidney epithelial cell line. The EGR3 gene has a single intron and maps to chromosome 8 at bands p21-23.	UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA; UNIV CHICAGO, DEPT MED, HEMATOL ONCOL SECT, CHICAGO, IL 60637 USA; NEW YORK STATE DEPT HLTH, ROSWELL PK MEM INST, DEPT HUMAN GENET, BUFFALO, NY 14263 USA	Howard Hughes Medical Institute; University of Chicago; University of Chicago; Roswell Park Cancer Institute	LEBEAU, MM (corresponding author), UNIV CHICAGO, HOWARD HUGHES MED INST, DEPT MED MOLEC GENET & CELL BIOL, CHICAGO, IL 60637 USA.			Groh, Margaret/0000-0002-7473-597X	NCI NIH HHS [CA40046] Funding Source: Medline; NICHD NIH HHS [HD05196] Funding Source: Medline; NIGMS NIH HHS [GM20454] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD005196] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA040046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020454] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; Curran T, 1988, ONCOGENE HDB, P307; DOOLITTLE RF, 1986, URFS ORFS; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; GESSLER M, 1990, NATURE, V343, P774, DOI 10.1038/343774a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAZEL TG, 1988, P NATL ACAD SCI USA, V85, P8444, DOI 10.1073/pnas.85.22.8444; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KARTHA S, 1987, AM J PHYSIOL, V252, pF1175, DOI 10.1152/ajprenal.1987.252.6.F1175; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEBEAU MM, 1984, NATURE, V312, P70, DOI 10.1038/312070a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LIM RW, 1987, ONCOGENE, V1, P263; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MILBRANDT J, 1988, NEURON, V1, P183, DOI 10.1016/0896-6273(88)90138-9; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MORGAN JI, 1989, TRENDS NEUROSCI, V12, P459, DOI 10.1016/0166-2236(89)90096-9; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAYLOR SL, 1983, J EXP MED, V157, P1020, DOI 10.1084/jem.157.3.1020; OUELLETTE AJ, 1990, J CLIN INVEST, V85, P766, DOI 10.1172/JCI114502; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; RYSECK RP, 1989, EMBO J, V8, P3327, DOI 10.1002/j.1460-2075.1989.tb08494.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHOWS T, 1984, SOMAT CELL MOLEC GEN, V10, P315, DOI 10.1007/BF01535253; SHOWS TB, 1983, ISOZYMES-CURR T BIOL, V10, P323; SHOWS TB, 1978, CYTOGENET CELL GENET, V21, P99, DOI 10.1159/000130882; SHOWS TB, 1982, ADV HUM GENET, V12, P341; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TSUI LC, 1989, CYTOGENET CELL GENET, V51, P166, DOI 10.1159/000132791; WAHL GM, 1987, METHOD ENZYMOL, V152, P572; WILKINSON DG, 1989, NATURE, V337, P461, DOI 10.1038/337461a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	56	218	225	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					917	928						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906159				2022-12-25	WOS:A1991GU62200005
J	LENZ, A; CORDES, F; HEINEMANN, U; SAENGER, W				LENZ, A; CORDES, F; HEINEMANN, U; SAENGER, W			EVIDENCE FOR A SUBSTRATE-BINDING SUBSITE IN RIBONUCLEASE-T1 - CRYSTAL-STRUCTURE OF THE COMPLEX WITH 2 GUANOSINES, AND MODEL-BUILDING OF THE COMPLEX WITH THE SUBSTRATE GUANYLYL-3',5'-GUANOSINE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEAST-SQUARES REFINEMENT; MACROMOLECULAR STRUCTURES; 3-DIMENSIONAL STRUCTURE; MOLECULAR-DYNAMICS; 1.9-A RESOLUTION; ACID COMPLEX; X-RAY; RNA; MECHANISM	The enzyme ribonuclease T1 cleaves single-stranded RNA at the 3'-side of guanosine. The structure of the complex with two guanosines has been analyzed at 1.8-angstrom resolution and refined to a crystallographic R value of 14.0%. One guanosine occupies the guanosine recognition site as observed in previously analyzed complexes of ribonuclease T1 with guanosine phosphates. The other is bound to a base-unspecific subsite marking the binding locus of the nucleoside 3'-proximal to guanosine in a cleavable RNA chain. The positions of the guanosine bound to the recognition site and of the guanine base at the subsite were used to guide model building of the substrate guanylyl-3',5'-guanosine bound to the active site of ribonuclease T1. After energy minimization and a 7-ps stochastic dynamics simulation, a plausible model of the enzyme-substrate complex was obtained which may serve as a reference point in consideration of the mechanism of RNA hydrolysis by ribonuclease T1.			LENZ, A (corresponding author), FREE UNIV BERLIN, INST KRISTALLOG, W-1000 BERLIN 33, GERMANY.		Heinemann, Udo/S-3379-2016; Heinemann, Udo/AAH-4766-2019	Heinemann, Udo/0000-0002-8191-3850; Heinemann, Udo/0000-0002-8191-3850				ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; ARNI R, 1988, J BIOL CHEM, V263, P15358; BERENDSEN HJC, 1988, GROMOS USERS MANUAL; DONISKELLER H, 1977, NUCLEIC ACIDS RES, V4, P2527, DOI 10.1093/nar/4.8.2527; ECKSTEIN F, 1972, BIOCHEMISTRY-US, V11, P3507, DOI 10.1021/bi00769a002; Egami F, 1980, Mol Biol Biochem Biophys, V32, P250; FINZEL BC, 1987, J APPL CRYSTALLOGR, V20, P53, DOI 10.1107/S0021889887087144; HEINEMANN U, 1983, J BIOMOL STRUCT DYN, V1, P523, DOI 10.1080/07391102.1983.10507459; HEINEMANN U, 1982, NATURE, V299, P27, DOI 10.1038/299027a0; Heinemann U., 1989, PROTEIN NUCLEIC ACID, P111; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HENDRICKSON WA, 1980, COMPUTING CRYSTALLOG; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KIMURA S, 1979, J BIOCHEM-TOKYO, V86, P301, DOI 10.1093/oxfordjournals.jbchem.a132527; KOEPKE J, 1989, J MOL BIOL, V206, P475, DOI 10.1016/0022-2836(89)90495-6; KOSTREWA D, 1989, BIOCHEMISTRY-US, V28, P7592, DOI 10.1021/bi00445a014; MACKERELL AD, 1989, PROTEINS, V6, P20, DOI 10.1002/prot.340060103; NISHIKAWA S, 1987, BIOCHEMISTRY-US, V26, P8620, DOI 10.1021/bi00400a019; NORTH ACT, 1968, ACTA CRYSTALL A-CRYS, VA 24, P351, DOI 10.1107/S0567739468000707; OSTERMAN HL, 1978, BIOCHEMISTRY-US, V17, P4124, DOI 10.1021/bi00613a003; POSTMA JPM, 1985, THESIS U GRONINGEN N; QUAAS R, 1988, EUR J BIOCHEM, V173, P617, DOI 10.1111/j.1432-1033.1988.tb14043.x; RYCKAERT JP, 1977, J COMPUT PHYS, V23, P327, DOI 10.1016/0021-9991(77)90098-5; SAENGER W, 1984, PRINCIPLES NUCL ACID, P167; SHERIFF S, 1987, J APPL CRYSTALLOGR, V20, P55, DOI 10.1107/S0021889887087132; Silberklang M, 1979, Methods Enzymol, V59, P58; SIMONCSITS A, 1977, NATURE, V269, P833, DOI 10.1038/269833a0; SUGIO S, 1988, J BIOCHEM-TOKYO, V103, P354, DOI 10.1093/oxfordjournals.jbchem.a122274; SUSSMAN JL, 1977, ACTA CRYSTALLOGR A, V33, P800, DOI 10.1107/S0567739477001958; Takahashi K., 1982, ENZYMES, V15, p435 468; WALZ FG, 1976, BIOCHEMISTRY-US, V15, P2837, DOI 10.1021/bi00658a021; WARSHEL A, 1984, Q REV BIOPHYS, V17, P283, DOI 10.1017/S0033583500005333; [No title captured]	33	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7661	7667						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902225				2022-12-25	WOS:A1991FJ34200055
J	BROSTROM, MA; PROSTKO, CR; GMITTERYELLEN, D; GRANDISON, LJ; KUZNETSOV, G; WONG, WL; BROSTROM, CO				BROSTROM, MA; PROSTKO, CR; GMITTERYELLEN, D; GRANDISON, LJ; KUZNETSOV, G; WONG, WL; BROSTROM, CO			INHIBITION OF TRANSLATIONAL INITIATION BY METALLOENDOPROTEASE ANTAGONISTS - EVIDENCE FOR INVOLVEMENT OF SEQUESTERED CA2+ STORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN-BINDING-PROTEIN; GLUCOSE-REGULATED PROTEINS; FREE CA-2+ CONCENTRATIONS; ADRENAL CHROMAFFIN CELLS; HORMONE-INDUCED SPIKE; INTRACELLULAR-TRANSPORT; ENDOPLASMIC-RETICULUM; EUKARYOTIC CELLS; SECRETION; HAMSTER	Synthetic oligopeptide inhibitors of metalloendoprotease activity have been shown to block membrane fusion events, to slow transport of secretory proteins from the endoplasmic reticulum (ER) to the Golgi, and to perturb Ca2+ homeostasis. Effects of such agents on translational activity, which requires Ca2+ sequestered putatively within the ER, were examined in this study. Cbz-Gly-Phe-NH2 (where Cbz is benzyloxycarbonyl) provoked rapid inhibition of amino acid incorporation into a broad spectrum of proteins in GH3 pituitary, C6 glial, and Neuro-2a cells but not in reticulocytes, which lack ER. Polysome accumulation and incorporation were reduced concurrently, indicating that the dipeptide acted to slow translational initiation. Inhibitions were largest at low extracellular Ca2+, were reversed by increasing extracellular Ca2+, were comparable to those achieved in the presence of EGTA or Ca2+ ionophores, and were observed with assorted metalloendoprotease antagonists but not with leupeptin. At concentrations inhibitory to protein synthesis Cbz-Gly-Phe-NH2 mobilized cell-associated Ca-45, lowered cytosolic free Ca2+, and did not generate inositol phosphates. Cells treated for 3-4 h with Cbz-Gly-Phe-NH2 reacquired the ability to synthesize proteins at nearly normal rates; a phorbol ester or cAMP-elevating agent was necessary for such recovery in GH3, but not C6 or Neuro-2a, cells. GRP78, which may function in the folding and assembly of secretory proteins and in translational accommodation to agents that deplete sequestered Ca2+ stores, was induced during such treatments. Accumulation of GRP78 mRNA in treated preparations was reduced as extracellular Ca2+ was increased. Extended exposure to dipeptide followed by brief recovery in its absence rendered protein synthesis resistant to inhibition by Ca2+ ionophore. It is concluded that metalloendoprotease antagonists suppress translational initiation as a consequence of their capacity to mobilize sequestered Ca2+ stores.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHYSIOL & BIOPHYS,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center	BROSTROM, MA (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT PHARMACOL,PISCATAWAY,NJ 08854, USA.				NIDDK NIH HHS [DK 35393] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035393] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABDELLATIF AA, 1986, PHARMACOL REV, V38, P227; AIELLO LP, 1986, BIOCHEMISTRY-US, V25, P3944, DOI 10.1021/bi00361a031; ALBERT PR, 1984, J BIOL CHEM, V259, P5350; ALBERT PR, 1986, AM J PHYSIOL, V251, pC887, DOI 10.1152/ajpcell.1986.251.6.C887; ALBERT PR, 1984, J BIOL CHEM, V259, P5827; BAXTER DA, 1983, P NATL ACAD SCI-BIOL, V80, P4174, DOI 10.1073/pnas.80.13.4174; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BROSTROM CO, 1989, J BIOL CHEM, V264, P1644; BROSTROM CO, 1983, J BIOL CHEM, V258, P4390; BROSTROM CO, 1990, ANNU REV PHYSIOL, V52, P577; BROSTROM MA, 1990, J BIOL CHEM, V265, P20539; BROSTROM MA, 1984, CALCIUM CELL FUNCT, V5, P165; CHIN KV, 1987, J BIOL CHEM, V262, P16509; CHIN KV, 1988, INT J BIOCHEM, V20, P1313, DOI 10.1016/0020-711X(88)90236-4; CHLEBOWSKI JF, 1976, MET IONS BIOL SYST, V6, P1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COUCH CB, 1983, CELL, V32, P257, DOI 10.1016/0092-8674(83)90516-0; DEAN NM, 1987, BIOCHEM J, V242, P361, DOI 10.1042/bj2420361; DORNER AJ, 1988, MOL CELL BIOL, V8, P4063, DOI 10.1128/MCB.8.10.4063; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; DRUMMOND IAS, 1987, J BIOL CHEM, V262, P12801; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GRANDISON L, 1990, ENDOCRINOLOGY, V127, P1786, DOI 10.1210/endo-127-4-1786; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMMERSCHLAG R, 1989, J NEUROCHEM, V52, P268, DOI 10.1111/j.1471-4159.1989.tb10927.x; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250, DOI 10.1128/MCB.8.10.4250; HOLLANDER MC, 1990, BIOTECHNIQUES, V9, P174; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KELLY RB, 1990, NATURE, V345, P480, DOI 10.1038/345480a0; KIMBALL SR, 1990, J BIOL CHEM, V265, P16794; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LELKES PI, 1987, J BIOL CHEM, V262, P15496; LODISH HF, 1990, J BIOL CHEM, V265, P10893; MARTIN TFJ, 1986, J BIOL CHEM, V261, P141; MORIHARA K, 1974, ADV ENZYMOL RAMB, V41, P179; MUNDY DI, 1985, CELL, V40, P645, DOI 10.1016/0092-8674(85)90213-2; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; PELHAM HRB, 1989, EMBO J, V8, P3171, DOI 10.1002/j.1460-2075.1989.tb08475.x; RANDRIAMAMPITA C, 1990, J BIOL CHEM, V265, P18059; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; Safer B, 1979, Methods Enzymol, V60, P61; Sambrook J, 1989, MOL CLONING LABORATO; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHARMA S, 1985, EMBO J, V4, P1479, DOI 10.1002/j.1460-2075.1985.tb03806.x; STROUS GJ, 1988, J BIOL CHEM, V263, P18197; TING J, 1987, GENE, V55, P147, DOI 10.1016/0378-1119(87)90258-7	47	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7037	7043						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1901861				2022-12-25	WOS:A1991FG72700062
J	FRANCOIS, J; HIGGINS, DL; CHANG, F; TATCHELL, K				FRANCOIS, J; HIGGINS, DL; CHANG, F; TATCHELL, K			INHIBITION OF GLYCOGEN-SYNTHESIS IN SACCHAROMYCES-CEREVISIAE BY THE MATING PHEROMONE ALPHA-FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-CEREVISIAE; FACTOR RECEPTOR; A-FACTOR; RAS PROTEINS; GENE ENCODES; CELL-FUSION; 2 FORMS; YEAST; PHOSPHORYLASE; METABOLISM	Treatment of the yeast Saccharomyces cerevisiae with the pheromone alpha-factor caused an inhibition of glycogen synthesis in MATa haploid cells but not in MAT-alpha cells or MATa/MAT-alpha diploid cells. The concentration of alpha-factor required for a half-maximal inhibition was comparable to that required for the induction of the FUS1 gene. Strains containing a disruption in ste2 or ste12 or temperature-sensitive mutations in ste4, ste7, or ste11 continued to divide and to accumulate glycogen in the presence of alpha-factor. In contrast, inhibition of glycogen occurred upon exposure to mating pheromone of far1 mutants which, under this condition, fail to arrest in G1 and continue to divide while simultaneously undergoing the transcriptional induction and morphological changes typical of mating cells. The inhibition of glycogen accumulation by alpha-factor persisted in a strain lacking glycogen phosphorylase (EC 2.4.1.1), which ruled out the participation of this enzyme in the pheromone response. Glycogen synthase (EC 2.4.1.11) from a cells treated with alpha-factor was found primarily in the glucose 6-phosphate-dependent (inactive) form whereas the total activity was unaltered. This indicates that the action of mating pheromone is mainly to inhibit the interconversion of the inactive glucose 6-phosphate-dependent form to the active glucose 6-phosphate-independent form of glycogen synthase without affecting the concentration of the enzyme.	N CAROLINA STATE UNIV,DEPT MICROBIOL,BOX 7615,RALEIGH,NC 27695; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of North Carolina; North Carolina State University; University of California System; University of California San Francisco			Tatchell, Kelly/A-9643-2009	Francois, Jean marie/0000-0001-9884-5535	NATIONAL CANCER INSTITUTE [R01CA037702] Funding Source: NIH RePORTER; NCI NIH HHS [CA37702] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECKER JU, 1979, ARCH MICROBIOL, V123, P143, DOI 10.1007/BF00446813; BECKER JU, 1982, J GEN MICROBIOL, V128, P447; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1986, GENETICS, V113, P247; CHAN RK, 1982, MOL CELL BIOL, V2, P11, DOI 10.1128/MCB.2.1.11; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CIEJEK E, 1979, CELL, V18, P623, DOI 10.1016/0092-8674(79)90117-X; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CROSS F, 1988, ANNU REV CELL BIOL, V4, P429, DOI 10.1146/annurev.cb.04.110188.002241; DIETZEL C, 1987, CELL, V50, P1001, DOI 10.1016/0092-8674(87)90166-8; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FIELD J, 1987, MOL CELL BIOL, V7, P2128, DOI 10.1128/MCB.7.6.2128; FIELDS S, 1987, MOL CELL BIOL, V7, P3818, DOI 10.1128/MCB.7.10.3818; FOSSET M, 1971, BIOCHEMISTRY-US, V10, P4105, DOI 10.1021/bi00798a015; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P561, DOI 10.1111/j.1432-1033.1988.tb14135.x; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P551, DOI 10.1111/j.1432-1033.1988.tb14134.x; FRANCOIS J, 1987, EUR J BIOCHEM, V164, P369, DOI 10.1111/j.1432-1033.1987.tb11067.x; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HAGEN DC, 1986, P NATL ACAD SCI USA, V83, P1418, DOI 10.1073/pnas.83.5.1418; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; HUANG KP, 1974, J BIOL CHEM, V249, P3851; HWANG PK, 1989, MOL CELL BIOL, V9, P1659, DOI 10.1128/MCB.9.4.1659; JENNESS DD, 1983, CELL, V35, P521, DOI 10.1016/0092-8674(83)90186-1; JULIUS D, 1983, CELL, V32, P839, DOI 10.1016/0092-8674(83)90070-3; LILLIE SH, 1980, J BACTERIOL, V143, P1384, DOI 10.1128/JB.143.3.1384-1394.1980; LIPKE PN, 1976, J BACTERIOL, V127, P610, DOI 10.1128/JB.127.1.610-618.1976; MACKAY VL, 1988, P NATL ACAD SCI USA, V85, P55, DOI 10.1073/pnas.85.1.55; MCCAFFREY G, 1987, MOL CELL BIOL, V7, P2680, DOI 10.1128/MCB.7.8.2680; MIYAJIMA I, 1987, CELL, V50, P1011, DOI 10.1016/0092-8674(87)90167-X; NAKAYAMA N, 1988, MOL CELL BIOL, V8, P3777, DOI 10.1128/MCB.8.9.3777; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; PENG ZY, 1990, J BIOL CHEM, V265, P13871; REED SI, 1980, GENETICS, V95, P561; RENEKE JE, 1988, CELL, V55, P221, DOI 10.1016/0092-8674(88)90045-1; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SCHEKMAN R, 1979, P NATL ACAD SCI USA, V76, P645, DOI 10.1073/pnas.76.2.645; STRAZDIS JR, 1982, J BACTERIOL, V151, P1153, DOI 10.1128/JB.151.3.1153-1161.1982; TATCHELL K, 1984, NATURE, V309, P523, DOI 10.1038/309523a0; TATCHELL K, 1985, P NATL ACAD SCI USA, V82, P3785, DOI 10.1073/pnas.82.11.3785; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WATZELE G, 1989, J BIOL CHEM, V264, P8753; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3	52	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6174	6180						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1901058				2022-12-25	WOS:A1991FE37300029
J	SCHUERMANN, M; JOOSS, K; MULLER, R				SCHUERMANN, M; JOOSS, K; MULLER, R			FOSB IS A TRANSFORMING GENE ENCODING A TRANSCRIPTIONAL ACTIVATOR	ONCOGENE			English	Article							DNA-BINDING PROTEINS; JUN PROTO-ONCOGENE; C-FOS; LEUCINE ZIPPER; CYCLIC-AMP; V-FOS; NEGATIVE REGULATOR; MOUSE FIBROBLASTS; MAMMALIAN-CELLS; GROWTH-FACTORS	The fosB gene encodes a nuclear protein that shows a high degree of homology with c-Fos in several of the known functionally crucial domains, e.g., the leucine zipper and the DNA-binding site, but shows considerable divergence in other regions. Here, we report that FosB, when placed under the control of a constitutive promoter, exhibits clear transforming properties in focus assays using mouse NIH3T3 or rat 208F fibroblasts. The transforming potential of FosB is considerably stronger than that of a corresponding c-fos construct and resembles that of viral fos genes. Using chimeric fos/fosB constructs we show that the C-terminal half of FosB is responsible for these stronger transforming properties, apparently by giving rise to significantly higher levels of protein as compared with the corresponding c-fos sequence. Surprisingly, substitution of the N-terminus of Fos with that of FosB decreases its transforming potential. These differences in the transforming potential are not related to DNA or protein expression, but rather seem to reflect differences in the molecular function(s) encoded in the N-terminal halves of Fos and FosB protein. Both, fosB- and v-fos transformed cells show increased expression of a number of endogenous genes, including c-jun, transin, alpha-1(III) collagen and tissue plasminogen activator. Transactivation by FosB and v-fos of the c-jun and alpha-1(III) collagen gene promoters and of a 3 x TRE-tk chimeric promoter could be shown in transient CAT assays. v-Fos, but not FosB-transformed cells, also show elevated levels of urokinase and plasminogen activator inhibitor mRNAs, pointing to potential differences in the gene regulatory properties of the two Fos family members.			SCHUERMANN, M (corresponding author), UNIV MARBURG, INST MOLEK BIOL & TUMORFORSCH, EMIL MANNKOPFF STR 2, W-3550 MARBURG, GERMANY.		Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; CURRAN T, 1982, VIROLOGY, V116, P221, DOI 10.1016/0042-6822(82)90415-9; DONY C, 1987, NATURE, V328, P711, DOI 10.1038/328711a0; FRANZA BR, 1988, SCIENCE, V239, P1150, DOI 10.1126/science.2964084; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HE CS, 1989, P NATL ACAD SCI USA, V86, P2632, DOI 10.1073/pnas.86.8.2632; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JENUWEIN T, 1985, CELL, V41, P629, DOI 10.1016/S0092-8674(85)80035-0; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KERR LD, 1988, SCIENCE, V242, P1424, DOI 10.1126/science.2462278; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE WMF, 1988, MOL CELL BIOL, V8, P5521, DOI 10.1128/MCB.8.12.5521; LIAU G, 1985, J BIOL CHEM, V260, P531; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATRISIAN LM, 1985, EMBO J, V4, P1435, DOI 10.1002/j.1460-2075.1985.tb03799.x; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATSUI M, 1990, ONCOGENE, V5, P249; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NEUBERG M, 1989, NATURE, V341, P243, DOI 10.1038/341243a0; PRENDERGAST GC, 1989, MOL CELL BIOL, V9, P124, DOI 10.1128/MCB.9.1.124; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; REDEMANNFIBI B, 1991, IN PRESS DIFFERENTIA; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; SCHUERMANN M, 1989, CELL, V56, P507, DOI 10.1016/0092-8674(89)90253-5; SCHUERMANN M, 1990, NUCLEIC ACIDS RES, V18, P4945, DOI 10.1093/nar/18.16.4945; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SETOYAMA C, 1986, P NATL ACAD SCI USA, V83, P3213, DOI 10.1073/pnas.83.10.3213; SETOYAMA C, 1986, BIOCHEM BIOPH RES CO, V136, P1042, DOI 10.1016/0006-291X(86)90438-9; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VERRIER B, 1986, EMBO J, V5, P913, DOI 10.1002/j.1460-2075.1986.tb04303.x; WASYLYK C, 1988, EMBO J, V7, P2475, DOI 10.1002/j.1460-2075.1988.tb03094.x; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	73	31	31	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR	1991	6	4					567	576						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903195				2022-12-25	WOS:A1991FR93900010
J	MARTINEZBILBAO, M; HOLDSWORTH, RE; EDWARDS, LA; HUBER, RE				MARTINEZBILBAO, M; HOLDSWORTH, RE; EDWARDS, LA; HUBER, RE			A HIGHLY REACTIVE BETA-GALACTOSIDASE (ESCHERICHIA-COLI) RESULTING FROM A SUBSTITUTION OF AN ASPARTIC-ACID FOR GLY-794	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; HYDROLYSIS; SEQUENCE; REGIONS; BINDING; ENZYME; DNA; PH	The beta-galactosidases of several mutagenized strains of Escherichia coli K12 which grew on lactobionate were found to be heat labile. Sequence analysis of the lacZ gene (ligated into Bluescript(TM)) of one of these strains (E. coli REH4) showed that the only change in the amino acid sequence was a substitution of an Asp for Gly-794. This change caused a dramatic increase of the activity when lactose was the substrate. The k(cat) of the purified enzyme from E. coli REH4 (G794D-beta-galactosidase) with lactose as the substrate was five to six times as large as the k(cat) of the normal enzyme with lactose. Purified G794D-beta-galactosidase was, however, less stable to heat and also to chymotrypsin (which cleaves next to Trp-585) than was normal beta-galactosidase. G794D-beta-Galactosidase bound substrates and substrate analog inhibitors less well than did normal beta-galactosidase while planar transition state analog inhibitors were more strongly bound. The ability to bind 2-amino-D-galactose (a positively charged transition state analog inhibitor) was either unaltered or was decreased somewhat. The data showed that the alteration in structure caused an increase in the value of k2 (the rate constant for the step in which the glycosidic bond is cleaved) with each substrate tested (the increase was at least 25-fold when lactose was the substrate) while k3 was decreased about 4-fold (k3 is the rate constant for the common hydrolysis step with each substrate). Since k2 is rate determining when lactose is the substrate of the normal enzyme, the increase in k2 resulted in a large increase in rate despite the fact that the value of k3 decreased. Large rate increases were not found with the other two substrates because the k2 values were not increased by large factors and because the decrease in the value of k3 negated the effects of the increased k2 values. The destabilization of the substrate binding coupled with a stabilization of the binding of a planar transition state is a possible cause of the significant increase in the value of k2 and of the enhanced activity with lactose.	UNIV CALGARY, FAC SCI, DIV BIOCHEM, CALGARY T2N 1N4, ALBERTA, CANADA	University of Calgary								BADER DE, 1988, BIOCHEM BIOPH RES CO, V153, P301, DOI 10.1016/S0006-291X(88)81222-1; BECKWITH JR, 1966, J MOL BIOL, V19, P254, DOI 10.1016/S0022-2836(66)80003-7; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P211, DOI 10.1021/bi00699a001; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; CORNISHBOWDEN A, 1976, PRINCIPLES ENZYME KI, P168; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; CUPPLES CG, 1988, GENETICS, V120, P637; DESCHAVANNE PJ, 1978, J BIOL CHEM, V253, P833; EDWARDS LA, 1988, J BIOL CHEM, V263, P1848; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; Gibson T.J., 1984, THESIS U CAMBRIDGE; HERRCHEN M, 1984, EUR J BIOCHEM, V138, P527, DOI 10.1111/j.1432-1033.1984.tb07947.x; HOFSTEE BHJ, 1959, NATURE, V184, P1296, DOI 10.1038/1841296b0; HUBER RE, 1984, ARCH BIOCHEM BIOPHYS, V234, P151, DOI 10.1016/0003-9861(84)90336-9; HUBER RE, 1976, BIOCHEMISTRY-US, V15, P1994, DOI 10.1021/bi00654a029; HUBER RE, 1987, BIOCHEMISTRY-US, V26, P1526, DOI 10.1021/bi00380a005; HUBER RE, 1983, CAN J BIOCHEM CELL B, V61, P198, DOI 10.1139/o83-028; HUBER RE, 1982, CAN J BIOCHEM CELL B, V60, P608, DOI 10.1139/o82-075; HUBER RE, 1986, ARCH BIOCHEM BIOPHYS, V246, P411, DOI 10.1016/0003-9861(86)90487-X; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; LANDGRID.J, 1968, MOL GEN GENET, V103, P116, DOI 10.1007/BF00427139; LANGRIDGE J, 1968, P NATL ACAD SCI USA, V60, P1260, DOI 10.1073/pnas.60.4.1260; LANGRIDGE J, 1969, MOL GEN GENET, V105, P74, DOI 10.1007/BF00750315; LANGRIDGE J, 1969, MOL GEN GENET, V103, P339, DOI 10.1007/BF00383484; LANGRIDGE J, 1968, Journal of Bacteriology, V96, P1711; LEE YC, 1969, BIOCHEM BIOPH RES CO, V35, P161, DOI 10.1016/0006-291X(69)90499-9; LEGLER G, 1983, CARBOHYD RES, V116, P95, DOI 10.1016/S0008-6215(00)90957-1; LEHMANN J, 1972, CARBOHYD RES, V23, P359, DOI 10.1016/S0008-6215(00)82706-8; MANIATIS T, 1982, MOL CLONING LABORATO, P75; MULLERHILL B, 1964, J MOL BIOL, V10, P303, DOI 10.1016/S0022-2836(64)80049-8; RING M, 1985, BIOCHEM BIOPH RES CO, V131, P675, DOI 10.1016/0006-291X(85)91290-2; RING M, 1990, ARCH BIOCHEM BIOPHYS, V283, P342, DOI 10.1016/0003-9861(90)90652-F; RING M, 1988, BIOCHEM BIOPH RES CO, V152, P1050, DOI 10.1016/S0006-291X(88)80390-5; ROSENBERG S, 1981, BIOCHEMISTRY-US, V20, P3189, DOI 10.1021/bi00514a031; SINNOTT ML, 1973, BIOCHEM J, V133, P89, DOI 10.1042/bj1330089; SINNOTT ML, 1974, BIOCHEM J, V143, P751, DOI 10.1042/bj1430751; TENU JP, 1971, EUR J BIOCHEM, V20, P363, DOI 10.1111/j.1432-1033.1971.tb01402.x; THOMAS CA, 1966, PROCEDURES NUCLEIC A, P535; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; Wallenfels K., 1972, ENZYMES, V7, P617; WENTWORTH DF, 1974, BIOCHEMISTRY-US, V13, P4715, DOI 10.1021/bi00720a006	43	35	36	4	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4979	4986						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1900512				2022-12-25	WOS:A1991FC21700048
J	HANSEN, JC; VANHOLDE, KE; LOHR, D				HANSEN, JC; VANHOLDE, KE; LOHR, D			THE MECHANISM OF NUCLEOSOME ASSEMBLY ONTO OLIGOMERS OF THE SEA-URCHIN 5-S DNA POSITIONING SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE PARTICLE; CHROMATIN; HISTONES; COMPLEXES; CLEAVAGE; INVITRO; OCTAMER; INVIVO	We have used a model system composed of tandem repeats of Lytechinus variegatus 5 S rDNA (Simpson, R. T., Thoma, F., and Brubaker, J. M. (1985) Cell 42, 799-808) reconstituted into chromatin with chicken erythrocyte core histones to investigate the mechanism of chromatin assembly. Nucleosomes are assembled onto the DNA template by mixing histone octamers and DNA in 2 M NaCl followed by stepwise dialysis into very low ionic strength buffer over a 24-h period. By 1.0 M NaCl, a defined intermediate composed of arrays of H3.H4 tetramers has formed, as shown by analytical and preparative ultracentrifugation. Digestion with methidium propyl EDTA.Fe(II) indicates that these tetramers are spaced at 207 base pair intervals, i.e. one/repeat length of the DNA positioning sequence. In 0.8 M NaCl, some H2A.H2B has become associated with the H3.H4 tetramers and DNA. Surprisingly, under these conditions DNA is protected from methidium propyl EDTA.Fe(II) digestion almost as well as in the complete nucleosome, even though these structures are quite deficient in H2A.H2B. By 0.6 M NaCl, nucleosome assembly is complete, and the MPE digestion pattern is indistinguishable from that observed for oligonucleosomes at very low ionic strength. Below 0.6 M NaCl, the oligonucleosomes are involved in various salt-dependent conformational equilibria: at approximately 0.6 M, a 15% reduction in s20,w that mimics a conformational change observed previously with nucleosome core particles; at and above 0.1 M, folding into a more compact structure(s); at and above 0.1 M NaCl, a reaction involving varying amounts of dissociation of histone octamers from a small fraction of the DNA templates. In low ionic strength buffer (< 1 mM NaCl), oligonucleosomes are present as fully loaded templates in the extended beads-on-a-string structure.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; ARIZONA STATE UNIV,DEPT CHEM,TEMPE,AZ 85287	Oregon State University; Arizona State University; Arizona State University-Tempe					NIGMS NIH HHS [GM11719, GM22916, GM37788] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM011719, R01GM037788, R01GM022916] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNUNZIATO AT, 1982, J BIOL CHEM, V257, P8507; AUSIO J, 1984, J MOL BIOL, V176, P77, DOI 10.1016/0022-2836(84)90383-8; BAER BW, 1983, NATURE, V301, P482, DOI 10.1038/301482a0; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; FOTEDAR R, 1989, P NATL ACAD SCI USA, V86, P6459, DOI 10.1073/pnas.86.17.6459; HANSEN JC, 1989, BIOCHEMISTRY-US, V28, P9129, DOI 10.1021/bi00449a026; HANSEN JC, 1989, ANAL BIOCHEM, V179, P167, DOI 10.1016/0003-2697(89)90219-4; HENDZEL MJ, 1990, BIOCHEM J, V271, P67, DOI 10.1042/bj2710067; HERTZBERG RP, 1984, BIOCHEMISTRY-US, V23, P3934, DOI 10.1021/bi00312a022; JACKSON V, 1981, CELL, V23, P121, DOI 10.1016/0092-8674(81)90277-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1980, NATURE, V286, P763, DOI 10.1038/286763a0; LOUTERS L, 1985, BIOCHEMISTRY-US, V24, P3080, DOI 10.1021/bi00334a002; READ CM, 1985, BIOCHEMISTRY-US, V24, P4435, DOI 10.1021/bi00337a027; SIMON RH, 1978, NUCLEIC ACIDS RES, V5, P4805, DOI 10.1093/nar/5.12.4805; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; SIMPSON RT, 1986, BIOESSAYS, V4, P172, DOI 10.1002/bies.950040408; SIMPSON RT, 1985, CELL, V42, P779; STEIN A, 1979, J MOL BIOL, V130, P103, DOI 10.1016/0022-2836(79)90421-2; STOCKLEY PG, 1979, FEBS LETT, V99, P129, DOI 10.1016/0014-5793(79)80264-1; SUN YL, 1986, EMBO J, V5, P295; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; THOMAS JO, 1979, NUCLEIC ACIDS RES, V7, P611, DOI 10.1093/nar/7.3.611; TREMETHICK D, 1990, J BIOL CHEM, V265, P5014; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; VANHOLDE KE, 1988, CHROMATIN, P307; WORCEL A, 1978, CELL, V15, P969, DOI 10.1016/0092-8674(78)90280-5; YAGER TD, 1984, J BIOL CHEM, V259, P4212	30	78	78	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4276	4282						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900288				2022-12-25	WOS:A1991FA69400042
J	WEIDNER, KM; VOSS, EW				WEIDNER, KM; VOSS, EW			IMMUNOLOGICAL CHARACTERIZATION OF XENOGENIC ANTI-METATYPE ANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCYL ANTIBODIES; IDIOTYPIC DETERMINANTS; MONOCLONAL-ANTIBODIES; BINDING-SPECIFICITY; IMMUNE-RESPONSE; CHAIN; LOCALIZATION; REPERTOIRE; IDIOTOPES; LIGAND	High affinity murine anti-fluorescein monoclonal antibody (Mab) 4-4-20 (K(a) = 1.3 x 10(10) M-1; IgG2a;k), affinity labeled with fluorescein isothiocyanate (I), served as the immunogen to elicit a xenogenic (rabbit) polyclonal "anti-metatype" reagent in a rabbit specific for the liganded state. The reagent did not bind Mab 4-4-20 in its nonliganded (idiotypic) conformation and demonstrated no reactivity with fluorescein ligand. Interaction of the anti-metatype reagent with liganded 4-4-20 caused a significant decrease in the dissociation rate o fluorescyl ligand bound to Mab 4-4-20 and a single-chain antibody derivative of 4-4-20. Additionally, most members of the 4-4-20 idiotype family displayed the same kinetic effect in the presence of anti-metatype. Members most closely related to Mab 4-4-20 (based on concentration in Mab required to inhibit the 4-4-20 idiotype/4-4-20 anti-idiotype interaction 50%) showed relatively greater decreases in the dissociation rate, establishing a quantitative correlation between idiotype and metatype. The immunologically distinct metatypic state is discussed in terms of conformational changes in or near the active site upon binding ligand, possibly involving two amino acid residues which "close-off" the mouth of the antibody-active site upon binding fluorescein.	UNIV ILLINOIS,DEPT MICROBIOL,131 BURRILL HALL,407 S GOODWIN AVE,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign								BALLARD DW, 1983, P NATL ACAD SCI-BIOL, V80, P5071, DOI 10.1073/pnas.80.16.5071; BATES RM, 1985, MOL IMMUNOL, V22, P871, DOI 10.1016/0161-5890(85)90072-0; BEDZYK WD, 1986, MOL IMMUNOL, V23, P1319, DOI 10.1016/0161-5890(86)90017-9; BEDZYK WD, 1990, J BIOL CHEM, V265, P133; BEDZYK WD, 1990, J BIOL CHEM, V265, P18615; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BRUGGEMANN M, 1986, EMBO J, V5, P1561, DOI 10.1002/j.1460-2075.1986.tb04397.x; CLAFLIN JL, 1975, J IMMUNOL, V114, P70; DAVIES DR, 1983, ANNU REV IMMUNOL, V4, P147; EISEN HN, 1964, BIOCHEMISTRY-US, V3, P996, DOI 10.1021/bi00895a027; HERRON JN, 1989, PROTEINS, V5, P271, DOI 10.1002/prot.340050404; HERRON JN, 1984, FLUORESCEIN HAPTEN I, P49; Jerne N.K., 1984, HARVEY LECT, V79, P5; JERNE NK, 1974, ANN INST PASTEUR IMM, VC125, P373; JESKE D, 1986, J IMMUNOL, V136, P2568; KRANZ DM, 1983, MOL IMMUNOL, V20, P1301, DOI 10.1016/0161-5890(83)90161-X; KRANZ DM, 1982, J BIOL CHEM, V257, P6987; KRANZ DM, 1981, MOL IMMUNOL, V18, P889, DOI 10.1016/0161-5890(81)90012-2; KUNKEL HG, 1963, SCIENCE, V140, P1218, DOI 10.1126/science.140.3572.1218; LENERT P, 1990, SCIENCE, V248, P1639, DOI 10.1126/science.2363051; NEMAZEE DA, 1982, P NATL ACAD SCI-BIOL, V79, P3828, DOI 10.1073/pnas.79.12.3828; OI VT, 1979, MOL IMMUNOL, V16, P1005, DOI 10.1016/0161-5890(79)90034-8; OUDIN J, 1963, CR HEBD ACAD SCI, V257, P805; RADBRUCH A, 1985, NATURE, V315, P506, DOI 10.1038/315506a0; REINITZ DM, 1985, J IMMUNOL, V135, P3365; RETH M, 1979, EUR J IMMUNOL, V9, P1004, DOI 10.1002/eji.1830091216; SAWUTZ DG, 1987, BIOCHEMISTRY-US, V26, P5275, DOI 10.1021/bi00391a010; SCHIFF C, 1979, EUR J IMMUNOL, V9, P831, DOI 10.1002/eji.1830091102; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; VOSS EW, 1990, IMMUNOL TODAY, V11, P355, DOI 10.1016/0167-5699(90)90140-5; VOSS EW, 1988, MOL IMMUNOL, V25, P751, DOI 10.1016/0161-5890(88)90111-3; VOSS EW, 1989, MOL IMMUNOL, V26, P971, DOI 10.1016/0161-5890(89)90115-6; VOSS EW, 1984, FLUORESCEIN HAPTEN I, P3; VOSS EW, 1989, FLUORESCENT BIOMOLEC, P247; WATT RM, 1979, J BIOL CHEM, V254, P1684; WATT RM, 1978, IMMUNOCHEMISTRY, V15, P875, DOI 10.1016/0161-5890(78)90121-9	36	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2513	2519						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899241				2022-12-25	WOS:A1991EV51500076
J	DALLASTA, V; BUSSOLATI, O; GUIDOTTI, GG; GAZZOLA, GC				DALLASTA, V; BUSSOLATI, O; GUIDOTTI, GG; GAZZOLA, GC			ENERGIZATION OF AMINO-ACID-UPTAKE BY SYSTEM-A IN CULTURED HUMAN FIBROBLASTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES-TUMOR-CELLS; ELECTROCHEMICAL GRADIENT; EHRLICH CELLS; ANIMAL-CELLS; TRANSPORT; MEMBRANE; SODIUM; STIMULATION; NA+; ACCUMULATION	The energization of System A in cultured human fibroblasts has been studied by measuring the energy transfer from the electrochemical gradient of Na+ to the chemical gradient of the site A-specific substrate amino acid 2-methylaminoisobutyric acid. The co-transport Na+/amino acid, studied by kinetic analysis and radiochemical measurements, showed a coupling ratio of 1:1. The assessment of the Na+ electrochemical gradient in cultured adherent cells relied on the development of noninvasive procedures as follows: the membrane electrical potential was estimated from the accumulation of L-arginine at equilibrium (Bussolati, O., Laris, P. C., Nucci, F. A., Dall'Asta, V., Longo, N., Guidotti, G. G., and Gazzola, G. C. (1987) Am. J. Physiol. 253, C391-C397); the chemical gradient of Na+ was determined from spectrometric measurements of Na+. The accumulation of 2-methylaminoisobutyric acid was strongly sensitive to changes of Na+ gradient and of membrane electrical potential, indicating that the electrochemical gradient of Na+ contributed energy for the uphill transport of the amino acid through System A. Changes in the Na+ electrochemical gradient were obtained by: (i) alterations of extracellular concentration of Na+; (ii) changes of membrane electrical potential obtained by variation of extracellular [K+]; and (iii) changes of [Na+]in and membrane electrical potential upon incubation of the cells in serum-free saline solutions (Dall'Asta, V., Gazzola, G. C., Longo, N., Bussolati, O., Franchi-Gazzola, R., and Guidotti, G. G. (1986) Biochim. Biophys. Acta 860, 1-8). The correlation between the chemical gradient of 2-methylaminoisobutyric acid and the Na+ electrochemical potential followed a straight line with a yield close to the thermodynamic equilibrium, thus suggesting that the energy stored in the gradient of Na+ electrochemical potential is fully adequate to energize the intracellular accumulation of site A-reactive amino acids in human fibroblasts.			DALLASTA, V (corresponding author), UNIV PARMA,IST PATOL GEN,VIA GRAMSCI 14,I-43100 PARMA,ITALY.		Bussolati, Ovidio/B-7589-2013; Dall'Asta, Valeria/M-6698-2015	Bussolati, Ovidio/0000-0002-4301-2939; Dall'Asta, Valeria/0000-0001-8540-0916				BANNAI S, 1980, J BIOL CHEM, V255, P2372; BUSSOLATI O, 1986, BIOCHIM BIOPHYS ACTA, V854, P240, DOI 10.1016/0005-2736(86)90116-1; BUSSOLATI O, 1987, AM J PHYSIOL, V253, pC391, DOI 10.1152/ajpcell.1987.253.3.C391; CHAIKEN RL, 1986, J CLIN ENDOCR METAB, V63, P1181, DOI 10.1210/jcem-63-5-1181; COLLARINI EJ, 1987, ANNU REV NUTR, V7, P75, DOI 10.1146/annurev.nu.07.070187.000451; CRANE RK, 1962, FED PROC, V21, P891; DALLASTA V, 1986, BIOCHIM BIOPHYS ACTA, V860, P1, DOI 10.1016/0005-2736(86)90491-8; DALLASTA V, 1983, J BIOL CHEM, V258, P6371; DAWSON WD, 1987, BIOCHIM BIOPHYS ACTA, V897, P5, DOI 10.1016/0005-2736(87)90309-9; EDDY AA, 1985, ANN NY ACAD SCI, V456, P51, DOI 10.1111/j.1749-6632.1985.tb14844.x; FRANCHIGAZZOLA R, 1982, J BIOL CHEM, V257, P9582; GARCIASANCHO J, 1977, P NATL ACAD SCI USA, V74, P1488, DOI 10.1073/pnas.74.4.1488; GAZZOLA GC, 1981, J BIOL CHEM, V256, P6054; GAZZOLA GC, 1980, J BIOL CHEM, V255, P929; GAZZOLA GC, 1981, J BIOL CHEM, V256, P3191; GAZZOLA GC, 1981, ANAL BIOCHEM, V115, P368, DOI 10.1016/0003-2697(81)90019-1; GUIDOTTI GG, 1978, BIOCHIM BIOPHYS ACTA, V515, P329, DOI 10.1016/0304-4157(78)90009-6; HACKING C, 1981, BIOCHEM J, V194, P415, DOI 10.1042/bj1940415; HEINZ A, 1981, J MEMBRANE BIOL, V62, P149, DOI 10.1007/BF01870207; HEINZ E, 1980, J MEMBRANE BIOL, V57, P91, DOI 10.1007/BF01868995; KAPLOWITZ PB, 1987, J CLIN ENDOCR METAB, V64, P563, DOI 10.1210/jcem-64-3-563; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; KRISTENSEN LO, 1986, AM J PHYSIOL, V251, pG575, DOI 10.1152/ajpgi.1986.251.5.G575; LONGO N, 1985, BIOCHIM BIOPHYS ACTA, V844, P216, DOI 10.1016/0167-4889(85)90093-X; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; PHILO RD, 1978, BIOCHEM J, V174, P811, DOI 10.1042/bj1740811; SCHULTZ SG, 1970, PHYSIOL REV, V50, P637, DOI 10.1152/physrev.1970.50.4.637; Segel I. H., 1975, ENZYME KINETICS, P360; WANG CS, 1975, ANAL BIOCHEM, V63, P414, DOI 10.1016/0003-2697(75)90363-2; WHITE MF, 1982, J BIOL CHEM, V257, P4443	30	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1591	1596						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1899091				2022-12-25	WOS:A1991EU49700038
J	LOW, SH; WONG, SH; TANG, BL; TAN, P; SUBRAMANIAM, VN; HONG, WJ				LOW, SH; WONG, SH; TANG, BL; TAN, P; SUBRAMANIAM, VN; HONG, WJ			INHIBITION BY BREFELDIN-A OF PROTEIN SECRETION FROM THE APICAL CELL-SURFACE OF MADIN-DARBY CANINE KIDNEY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TRANS-GOLGI CISTERNAE; COMPLEX; EPITHELIA; RETICULUM; APPARATUS; MEMBRANE; NETWORK; MDCK	The effect of brefeldin A (BFA) on total and polarized protein secretion was examined in MDCK cells. Increasing concentrations of BFA have increasingly inhibitory effects on total protein secretion. The total protein secretion was essentially unaffected by BFA at 0.5-mu-g/ml. When the BFA concentration was increased to 10 and 30-mu-g/ml, the total protein secretion was reduced to about 70 and 25%, respectively, of the control level. Consistent with this effect on total protein secretion, the Golgi structure as revealed by C6-NBD-ceramide (a fluorescent ceramide analog) staining was essentially unaltered by 0.5-mu-g/ml BFA, while 10 and 30-mu-g/ml BFA significantly dispersed the Golgi apparatus. When the polarity of protein secretion was examined, it was found that the ratio of proteins secreted from the apical to those from the basolateral surface was reduced from 1.5-2.0 to 0.4-0.7 by all three BFA concentrations. Furthermore, several proteins which are preferentially released from the apical surface were found to be released without apparent surface polarity, while several other proteins which were preferentially released from the basolateral surface were unaffected. This study suggests that BFA, at 0.5-mu-g/ml, can selectively inhibit protein secretion from the apical surface without affecting total protein secretion. The inhibition of apical secretion results in enhanced protein secretion from the basolateral surface.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, MEMBRANE BIOL LAB, 10 KENT RIDGE CRESCENT, SINGAPORE 0511, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			HONG, Wanjin/E-9927-2010; Subramaniam, V. Nathan/A-1901-2010; Tang, Bor Luen/E-4548-2012	Subramaniam, V. Nathan/0000-0002-4583-7790; Tang, Bor Luen/0000-0002-1925-636X				ADORINI L, 1990, NATURE, V346, P63, DOI 10.1038/346063a0; CAPLAN MJ, 1987, NATURE, V329, P632, DOI 10.1038/329632a0; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; COOPER MS, 1990, CELL, V61, P135, DOI 10.1016/0092-8674(90)90221-Y; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GOTTLIEB TA, 1986, P NATL ACAD SCI USA, V83, P2100, DOI 10.1073/pnas.83.7.2100; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; KONDORKOCH C, 1985, CELL, V43, P297, DOI 10.1016/0092-8674(85)90035-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1991, J CELL BIOL, V112, P567, DOI 10.1083/jcb.112.4.567; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; MATLIN KS, 1986, J CELL BIOL, V103, P2565, DOI 10.1083/jcb.103.6.2565; ORCI L, 1991, CELL, V64, P1183; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PETELL JK, 1987, J BIOL CHEM, V262, P14753; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SERAFINI T, 1991, NATURE, V349, P214, DOI 10.1038/349215a0; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; WESSELS HP, 1989, J BIOL CHEM, V264, P17	29	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17729	17732						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917917				2022-12-25	WOS:A1991GG55300003
J	LENFANT, F; LABIA, R; MASSON, JM				LENFANT, F; LABIA, R; MASSON, JM			REPLACEMENT OF LYSINE-234 AFFECTS TRANSITION-STATE STABILIZATION IN THE ACTIVE-SITE OF BETA-LACTAMASE TEM1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENES; AMINO-ACID REPLACEMENTS; ESCHERICHIA-COLI; DIRECTED MUTAGENESIS; CRYSTAL-STRUCTURE; CLAVULANIC ACID; ANTIBIOTICS; CONSTRUCTION; RESOLUTION; INTERMEDIATE	Lysine 234 is a residue highly conserved in all beta-lactamases, except in the carbenicillin-hydrolyzing enzymes, in which it is replaced by an arginine. Informational suppression has been used to create amino acid substitutions at this position in the broad spectrum Escherichia coli beta-lactamase TEM-1, in order to elucidate the role of this residue which lies on the wall at the closed end of the active site cavity. The mutants K234R and K234T were constructed and their kinetic constants measured. Replacement of lysine 234 by arginine yields an enzyme with similar activity toward cephalosporins and most penicillins, except toward the carboxypenicillins for which the presence of the guanidine group enhances the transition state binding. The removal of the basic group in the mutant K234T yields a protein variant which retains a low activity toward penicillins, but losts drastically its ability to hydrolyze cephalosporins. Moreover, these two mutations largely decreased the affinity of the enzyme for penicillins (10-fold for K234R and 50-fold for K234T). This can be correlated with the disruption of the predicted electrostatic binding between the C3 carboxylic group of penicillins and the amine function of the lysine. Therefore, lysine 234 in the E. coli beta-lactamase TEM-1 is involved both in the initial recognition of the substrate and in transition state stabilization.	CNRS, URA 544, INST NATL SCI APPL, GENIE BIOCHIM & ALIMENTAIRE LAB, F-31077 TOULOUSE, FRANCE; MUSEUM NATL HIST NAT, CNRS, URA 401, F-75231 PARIS 05, FRANCE	Centre National de la Recherche Scientifique (CNRS); Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite de Toulouse; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); Museum National d'Histoire Naturelle (MNHN)				LENFANT, Francoise/0000-0003-0024-7241				AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; ANDERSON EG, 1983, J BIOL CHEM, V258, P3120; BARTHELEMY M, 1978, ANTIMICROB AGENTS CH, V13, P695, DOI 10.1128/AAC.13.4.695; BLANCHINROLAND S, 1989, PROTEIN ENG, V2, P473, DOI 10.1093/protein/2.6.473; BOISSINOT M, 1990, J BIOL CHEM, V265, P1225; CAMPBELL JIA, 1989, BIOCHEM J, V260, P803, DOI 10.1042/bj2600803; CHEN ST, 1984, NUCLEIC ACIDS RES, V12, P3219, DOI 10.1093/nar/12.7.3219; COHEN NC, 1983, J MED CHEM, V26, P259, DOI 10.1021/jm00356a027; COLLATZ E, 1990, MOL MICROBIOL, V4, P1615, DOI 10.1111/j.1365-2958.1990.tb00537.x; DECLERCK N, 1990, J BIOL CHEM, V265, P15481; DIDEBERG O, 1987, BIOCHEM J, V245, P911, DOI 10.1042/bj2450911; ELLERBY LM, 1990, BIOCHEMISTRY-US, V29, P5797, DOI 10.1021/bi00476a022; FERSHT AR, 1985, NATURE, V314, P235, DOI 10.1038/314235a0; FISHER J, 1978, BIOCHEMISTRY-US, V17, P2180, DOI 10.1021/bi00604a024; FISHER J, 1980, BIOCHEMISTRY-US, V19, P2895, DOI 10.1021/bi00554a012; GIBSON RM, 1990, BIOCHEM J, V272, P613, DOI 10.1042/bj2720613; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HEALEY WJ, 1989, PROTEINS, V6, P275, DOI 10.1002/prot.340060310; HERZBERG O, 1987, SCIENCE, V236, P694, DOI 10.1126/science.3107125; HUTLETSKY A, 1990, ANTIMICROB AGENTS CH, V34, P1725; JACOB F, 1990, BIOCHEM J, V271, P399, DOI 10.1042/bj2710399; JORIS B, 1988, BIOCHEM J, V250, P313, DOI 10.1042/bj2500313; KLEINA LG, 1990, J MOL BIOL, V213, P705, DOI 10.1016/S0022-2836(05)80257-8; KLEINA LG, 1990, J MOL BIOL, V212, P295, DOI 10.1016/0022-2836(90)90126-7; LABIA R, 1978, BIOCHIM BIOPHYS ACTA, V526, P572, DOI 10.1016/0005-2744(78)90147-X; LABIA R, 1973, FEBS LETT, V33, P42, DOI 10.1016/0014-5793(73)80154-1; LABIA R, 1981, J ANTIMICROB CHEMOTH, V7, P49, DOI 10.1093/jac/7.1.49; LAWS AP, 1989, J CHEM SOC PERK T 2, P1577, DOI 10.1039/p29890001577; LENFANT F, 1990, BIOCHIMIE, V72, P495, DOI 10.1016/0300-9084(90)90073-P; LENFANT F, 1988, 28TH INT C ANT CHEM; MADGWICK PJ, 1987, BIOCHEM J, V248, P657, DOI 10.1042/bj2480657; Maniatis T., 1982, MOL CLONING; MASSON JM, 1986, GENE, V47, P179, DOI 10.1016/0378-1119(86)90061-2; MCCLAIN WH, 1988, SCIENCE, V241, P1804, DOI 10.1126/science.2459773; MOEWS PC, 1990, PROTEINS, V7, P156, DOI 10.1002/prot.340070205; NORMANLY J, 1990, J MOL BIOL, V213, P719, DOI 10.1016/S0022-2836(05)80258-X; NORMANLY J, 1986, P NATL ACAD SCI USA, V83, P6548, DOI 10.1073/pnas.83.17.6548; OCALLAGHAN CH, 1972, ANTIMICROB AGENTS CH, V1, P283, DOI 10.1128/AAC.1.4.283; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; WARSHEL A, 1989, BIOCHEMISTRY-US, V28, P3629, DOI 10.1021/bi00435a001	40	42	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17187	17194						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910040				2022-12-25	WOS:A1991GF44500035
J	INOUE, S; BARNUN, S; ROITELMAN, J; SIMONI, RD				INOUE, S; BARNUN, S; ROITELMAN, J; SIMONI, RD			INHIBITION OF DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL-COENZYME-A REDUCTASE INVIVO BY CYSTEINE PROTEASE INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HMG-COA REDUCTASE; ACTIVATED NEUTRAL PROTEASE; COENZYME-A REDUCTASE; ENDOPLASMIC-RETICULUM; REGULATED DEGRADATION; NUCLEOTIDE-SEQUENCE; DOMAIN-STRUCTURE; MEMBRANE; PROTEINS; PHOSPHORYLATION	3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is a key regulatory enzyme of cholesterol biosynthesis and is located in the endoplasmic reticulum (ER). A fusion protein, HMGal, consisting of the membrane domain of HMG-CoA reductase fused to Escherichia coli beta-galactosidase and expressed in Chinese hamster ovary (CHO) cells from the SV40 promoter, was previously constructed and was found to respond to regulatory signals for degradation in a similar fashion to the intact HMG-CoA reductase. Degradation of both HMG-CoA reductase and HMGal in CHO cells was enhanced by addition of mevalonate or low density lipoprotein (LDL). In this report we show that 2 cysteine protease inhibitors, N-acetyl-leucyl-leucyl-norleucinal (ALLN) and N-acetyl-leucyl-leucyl-methioninal (ALLM), completely inhibit the mevalonate- or LDL-accelerated degradation of HMG-CoA reductase and HMGal and also block the basal degradation of these enzymes. It has been shown that in vitro these protease inhibitors inhibit the activities of Ca2+-dependent neutral proteases as well as lysosomal proteases, including cathepsin L, cathepsin B, and cathepsin D. However, the mevalonate-accelerated degradation of HMG-CoA reductase and HMGal is not affected by lysosomotropic agents, suggesting that the site of action of these inhibitor peptides in preventing the degradation is not the cathepsins. In brefeldin A-treated cells, where protein export from the ER is blocked, ALLN is still effective in inhibiting the degradation of HMG-CoA reductase and HMGal. These results indicate the involvement of non-lysosomal Ca2+-dependent proteases in the basal and the accelerated degradation of HMG-CoA reductase and HMGal. Enzymatic assays in vitro and immunoblot analyses have revealed calpain- and calpastatin-like proteins in CHO cells. The activities and the amount of these proteins do not change under conditions of enhanced degradation, indicating that the levels of these proteins are not subject to mevalonate regulation.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL26502] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT AJ, 1981, METHOD ENZYMOL, V80, P771; BEG ZH, 1981, CURR TOP CELL REGUL, V20, P139; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MS, 1979, P NATL ACAD SCI USA, V76, P3330, DOI 10.1073/pnas.76.7.3330; BROWN MS, 1980, J LIPID RES, V21, P505; CHIN DJ, 1984, NATURE, V308, P613, DOI 10.1038/308613a0; CHUN KT, 1990, J BIOL CHEM, V265, P22004; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; FAUST JR, 1982, P NATL ACAD SCI-BIOL, V79, P5205, DOI 10.1073/pnas.79.17.5205; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HIWASA T, 1990, CARCINOGENESIS, V11, P75, DOI 10.1093/carcin/11.1.75; IMAJOH S, 1988, BIOCHEMISTRY-US, V27, P8122, DOI 10.1021/bi00421a022; INOMATA M, 1989, J BIOL CHEM, V264, P18838; KAJIWARA Y, 1987, BIOCHEM INT, V15, P935; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LISCUM L, 1985, J BIOL CHEM, V260, P522; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; OSHIMA M, 1989, J BIOL CHEM, V264, P20811; PARKER RA, 1989, J BIOL CHEM, V264, P4877; PARKER RA, 1984, BIOCHEM BIOPH RES CO, V125, P629, DOI 10.1016/0006-291X(84)90585-0; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SATO R, 1990, J BIOL CHEM, V265, P11880; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SKALNIK DG, 1985, DNA-J MOLEC CELL BIO, V4, P439, DOI 10.1089/dna.1985.4.439; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; TAKANO E, 1982, J BIOCHEM-TOKYO, V92, P2021, DOI 10.1093/oxfordjournals.jbchem.a134134; TAMAI M, 1986, J PHARMACOBIO-DYNAM, V9, P672, DOI 10.1248/bpb1978.9.672; TANAKA RD, 1986, J LIPID RES, V27, P261; TWINING SS, 1984, ANAL BIOCHEM, V143, P30, DOI 10.1016/0003-2697(84)90553-0; URBANI L, 1990, J BIOL CHEM, V265, P1919	40	109	114	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13311	13317						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1906466				2022-12-25	WOS:A1991FX13200080
J	NAKAMURA, F; OGATA, K; SHIOZAKI, K; KAMEYAMA, K; OHARA, K; HAGA, T; NUKADA, T				NAKAMURA, F; OGATA, K; SHIOZAKI, K; KAMEYAMA, K; OHARA, K; HAGA, T; NUKADA, T			IDENTIFICATION OF 2 NOVEL GTP-BINDING PROTEIN ALPHA-SUBUNITS THAT LACK APPARENT ADP-RIBOSYLATION SITES FOR PERTUSSIS TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATING G-PROTEIN; AMINO-ACID-SEQUENCE; ADENYLATE-CYCLASE; MOLECULAR-CLONING; REGULATORY PROTEINS; CDNA SEQUENCE; RAS PROTEINS; BETA-SUBUNIT; SIGNAL TRANSDUCTION; GUANINE-NUCLEOTIDES	Molecular cloning of cDNAs encoding alpha-subunits of guanine nucleotide-binding regulatory proteins (G-proteins) has revealed the existence of nine species of alpha-subunits. We have identified two additional G-protein alpha-subunits, which we refer to as G(L)1-alpha and G(L)2-alpha, by isolating bovine liver cDNA clones that cross-hybridized at reduced stringency with bovine G(i)1 alpha-subunit cDNA. The deduced amino acid sequences of G(L)1-alpha and G(L)2-alpha share 83% identity with each other and show 45-55% identity with those of other known G-protein alpha-subunits. Both G(L)1-alpha and G(L)2-alpha lack a consensus site for ADP-ribosylation by pertussis toxin. Messenger RNA corresponding to G(L)2-alpha was detected in all tissues examined, but G(L)1-alpha mRNA was detected only in liver, lung, and kidney. Antiserum prepared against a synthetic pentadecapeptide corresponding to the deduced carboxyl terminus of G(L)2-alpha specifically reacted with a 40-kDa protein in mouse liver, brain, lung, heart, kidney, and spleen. The amount of the 40-kDa protein was highest in brain and lung. We suggest that G(L)1-alpha and G(L)2-alpha are new members of a subfamily of pertussis toxin-insensitive G-proteins.	HAMAMATSU UNIV SCH MED, DEPT PSYCHIAT & NEUROL, HAMAMATSU, SHIZUOKA 431-31, JAPAN	Hamamatsu University School of Medicine	NAKAMURA, F (corresponding author), UNIV TOKYO, FAC MED, INST BRAIN RES, DEPT BIOCHEM, TOKYO 113, JAPAN.							AMBROSINI A, 1989, J NEUROCHEM, V53, P825; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU AS, 1988, BIOCHEM J, V256, P995, DOI 10.1042/bj2560995; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEVOS AM, 1988, SCIENCE, V239, P888, DOI 10.1126/science.2448879; DIDSBURY JR, 1987, FEBS LETT, V219, P259, DOI 10.1016/0014-5793(87)81228-0; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSMITH P, 1987, J BIOL CHEM, V262, P14683; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOCHRIE MA, 1985, SCIENCE, V228, P96, DOI 10.1126/science.3856323; MATSUOKA M, 1988, P NATL ACAD SCI USA, V85, P5384, DOI 10.1073/pnas.85.15.5384; MCCORMICK F, 1985, SCIENCE, V230, P78, DOI 10.1126/science.3898366; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAKAJIMA Y, 1988, P NATL ACAD SCI USA, V85, P3643, DOI 10.1073/pnas.85.10.3643; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NUKADA T, 1986, FEBS LETT, V197, P305, DOI 10.1016/0014-5793(86)80347-7; NUKADA T, 1986, FEBS LETT, V195, P220, DOI 10.1016/0014-5793(86)80164-8; NUKADA T, 1987, FEBS LETT, V211, P5, DOI 10.1016/0014-5793(87)81263-2; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PANG IH, 1990, J BIOL CHEM, V265, P18707; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; ROSS EM, 1989, NEURON, V3, P141, DOI 10.1016/0896-6273(89)90027-5; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TANABE T, 1985, NATURE, V315, P242, DOI 10.1038/315242a0; TAYLOR SJ, 1990, J BIOL CHEM, V265, P17150; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; UHING RJ, 1986, J BIOL CHEM, V261, P2140; VANDOP C, 1984, J BIOL CHEM, V259, P696; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WEST RE, 1985, J BIOL CHEM, V260, P4428	57	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12676	12681						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905731				2022-12-25	WOS:A1991FV18000089
J	NIEDZWIECKI, A; KONGPACHITH, AM; FLEMING, JE				NIEDZWIECKI, A; KONGPACHITH, AM; FLEMING, JE			AGING AFFECTS EXPRESSION OF 70-KDA HEAT-SHOCK PROTEINS IN DROSOPHILA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD MONONUCLEAR-CELLS; ABNORMAL PROTEINS; MESSENGER-RNA; DIPLOID FIBROBLASTS; GENE-EXPRESSION; MUTANT TS85; THERMOTOLERANCE; MELANOGASTER; INDUCTION; ELECTROPHORESIS	We examined the effect of cellular aging on adult mortality and hsp70 gene expression in Drosophila melanogaster under thermal stress. The results showed that flies exposed to 37-degrees-C for various time intervals had reduced survival rate with age. The level of hsp70 mRNA increases in flies up to 23-28 days of age, but then declines as they get older. When flies are shifted to 25-degrees-C after 30 min of heat stress, the time-dependent decrease in hsp70 mRNA levels occurs more rapidly in young flies than in old ones. The hsp70 mRNA present during this recovery period is translated into protein, and senescent flies continue to synthesize this protein for up to 5 h after heat shock. The prolonged expression of hsp70 RNA during recovery from heat shock was also observed in young flies fed canavanine, an arginine analogue. These data suggest that in old insects, the accumulation of conformationally altered proteins plays a role in the regulation of hsp70 RNA expression. These results are discussed in relation to the finding that old flies are more sensitive to thermal stress than young ones.			NIEDZWIECKI, A (corresponding author), LINUS PAULING INST SCI & MED, RYOICHI SASAKAWA CTR AGING RES, PALO ALTO, CA 94306 USA.							ALTSCHULER M, 1982, Plant Molecular Biology, V1, P103, DOI 10.1007/BF00024974; ANANTHAN J, 1986, SCIENCE, V232, P522, DOI 10.1126/science.3083508; ANDERSON NG, 1978, ANAL BIOCHEM, V85, P331, DOI 10.1016/0003-2697(78)90229-4; BLAKE MJ, 1990, J BIOL CHEM, V265, P15275; BUTTYAN R, 1988, MOL ENDOCRINOL, V2, P650, DOI 10.1210/mend-2-7-650; CARPER SW, 1987, CANCER RES, V47, P5249; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DEGUCHI Y, 1990, ANN RHEUM DIS, V49, P893, DOI 10.1136/ard.49.11.893; DEGUCHI Y, 1988, BIOCHEM BIOPH RES CO, V157, P580, DOI 10.1016/S0006-291X(88)80289-4; DIDOMENICO BJ, 1982, CELL, V31, P593, DOI 10.1016/0092-8674(82)90315-4; FARGNOLI J, 1990, P NATL ACAD SCI USA, V87, P846, DOI 10.1073/pnas.87.2.846; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FERRIS DK, 1988, P NATL ACAD SCI USA, V85, P3850, DOI 10.1073/pnas.85.11.3850; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; FLEMING JE, 1988, P NATL ACAD SCI USA, V85, P4099, DOI 10.1073/pnas.85.11.4099; FLEMING JE, 1986, SCIENCE, V231, P1157, DOI 10.1126/science.3080809; FYRBERG EA, 1981, CELL, V24, P107, DOI 10.1016/0092-8674(81)90506-7; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; HAHN GM, 1982, RADIAT RES, V92, P452, DOI 10.2307/3575917; HENLE KJ, 1979, CANCER RES, V39, P2665; HIGHTOWER LE, 1978, NEGATIVE STRAND VIRU, P395; KACZMAREK L, 1987, J CELL BIOL, V104, P183, DOI 10.1083/jcb.104.2.183; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KUBO T, 1985, ARTHRITIS RHEUM, V28, P1140, DOI 10.1002/art.1780281010; LASZLO A, 1988, EXP CELL RES, V178, P401, DOI 10.1016/0014-4827(88)90409-0; LATTER GI, 1983, ELECTROPHORESIS, V4, P122, DOI 10.1002/elps.1150040204; LI GC, 1982, P NATL ACAD SCI-BIOL, V79, P3218, DOI 10.1073/pnas.79.10.3218; LINDQUIST S, 1980, DEV BIOL, V77, P463, DOI 10.1016/0012-1606(80)90488-1; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1980, J MOL BIOL, V137, P151, DOI 10.1016/0022-2836(80)90322-8; LINDQUIST S, 1982, HEAT SHOCK BACTERIA, P167; LIU AYC, 1989, J BIOL CHEM, V264, P12037; LOOMIS WF, 1980, DEV BIOL, V79, P399, DOI 10.1016/0012-1606(80)90125-6; Maniatis T., 1982, MOL CLONING; MCALISTER L, 1980, BIOCHEM BIOPH RES CO, V93, P819, DOI 10.1016/0006-291X(80)91150-X; MITCHELL HK, 1979, DEV GENET, V1, P181, DOI 10.1002/dvg.1020010206; MIZUNO S, 1989, INT J HYPERTHER, V5, P105, DOI 10.3109/02656738909140437; MORAN L, 1979, CELL, V17, P1, DOI 10.1016/0092-8674(79)90289-7; NEIDHARDT FC, 1984, ANNU REV GENET, V18, P295, DOI 10.1146/annurev.ge.18.120184.001455; NIEDZWIECKI A, 1990, MECH AGEING DEV, V52, P295, DOI 10.1016/0047-6374(90)90133-Z; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PALTER KB, 1986, MOL CELL BIOL, V6, P1187, DOI 10.1128/MCB.6.4.1187; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PERIMUTTER DH, 1989, J CLIN INVEST, V84, P1555; PINE MJ, 1967, J BACTERIOL, V93, P1527, DOI 10.1128/JB.93.5.1527-1533.1967; RIABOWOL KT, 1988, SCIENCE, V242, P433, DOI 10.1126/science.3175665; Richardson A, 1983, REV BIOL RES AGING, V1, P255; ROBERTS DB, 1986, DROSOPHILA PRACTICAL, P15; SANDERS MM, 1986, J BIOL CHEM, V261, P2189; SCHAMHART DHJ, 1984, RADIAT RES, V98, P82, DOI 10.2307/3576053; Sokal R. R, 1981, BIOMETRY; TSUJI Y, 1986, MECH AGEING DEV, V36, P155, DOI 10.1016/0047-6374(86)90016-3; WESTRA A, 1971, INT J RADIAT BIOL RE, V19, P467, DOI 10.1080/09553007114550601; WHITE CN, 1984, MOL CELL BIOL, V4, P1534, DOI 10.1128/MCB.4.8.1534; WIDELITZ RB, 1986, MOL CELL BIOL, V6, P1088, DOI 10.1128/MCB.6.4.1088; XIAO H, 1989, MOL CELL BIOL, V9, P1746, DOI 10.1128/MCB.9.4.1746; YOST HJ, 1986, CELL, V45, P185, DOI 10.1016/0092-8674(86)90382-X	60	46	47	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9332	9338						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1902836				2022-12-25	WOS:A1991FM03800101
J	RIVIERE, M; PUZO, G				RIVIERE, M; PUZO, G			A NEW TYPE OF SERINE-CONTAINING GLYCOPEPTIDOLIPID FROM MYCOBACTERIUM-XENOPI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MASS-SPECTROMETRY; GLYCOLIPID ANTIGEN; STRUCTURAL ELUCIDATION; PHENOLIC GLYCOLIPIDS; ELECTRON-IMPACT; KANSASII; IDENTIFICATION; CHROMATOGRAPHY; CONFIGURATION; DESORPTION	An unknown immunogenic glycopeptidolipid, named GPL X-1, was isolated from Mycobacterium xenopi, which is a nontuberculous mycobacterium responsible for pulmonary and disseminated infectious diseases mainly occurring in immunocompromised patients. The glycopeptidolipid was purified until homogeneity, in the native form, by direct phase high performance liquid chromatography. A new route is proposed for the structural elucidation of its unusual lipopeptidic core. The presence of allothreonine (aThr), phenylalanine, and serine in the molecular ratio 1:1:2, respectively, was established by reverse phase high performance liquid chromatography analysis of the phenylthiocarbamyl amino acid derivatives. From the molecular mass (1828 Da) of the native glycopeptidolipid, determined by cesium ion liquid secondary ion mass spectrometry using the amphipathic triethylene glycol monobutyl ether matrix, it was deduced that the tetrapeptide was amidified by a dodecanoic acid. The complete structure, C-12-Ser-Ser-Phe-aThr-OCH3, of the lipopeptidic core was established by pyrolysis electron impact-mass spectrometry of the native glycopeptidolipid. To date, this is the first example of a mycobacterial glycopeptidolipid with a C-12-tetrapeptidic core containing serine. A novel approach, based on two dimensional H-1,H-1 correlated spectroscopy analysis of the native and peracetylated GPL X-1, was developed, allowing the structural determination of the monosaccharidic residues with their alkali-labile groups "in situ" on the whole complex molecule. 2-O-Acyl-alpha-L-Rhap, alpha-L-Rhap,2,4-di-O-acyl-6-deoxy-alpha-L-Glcp,2,3,4-tri-O-Me-alpha-L-Rhap, and 3-O-Me-6-deoxy-alpha-L-Talp were identified, where Me, Rhap, and Talp are methyl, rhamnopyranosyl, and talopyranosyl, respectively. The latter two were localized at the carbohydrate nonreducing ends, and the C-3's of the remaining monosaccharide residues were found involved in the interglycosidic linkage. The alpha-anomeric configurations were inferred from the J(C-1,H-1) heteronuclear coupling constants, and the L absolute configurations for all the monosaccharide residues were established by gas chromatography analysis of the trimethylsilyl (+/-)-2-butyl glycosides. Finally, by pyrolysis electron impact mass spectrometry of peracetylated GPL X-1, the following tetrasaccharide appendage structure was proposed: 2,3,4-tri-O-Me-L-Rhap(alpha-1 --> 3)-2-O-lauryl-L-Rhap-(alpha-1 --> 3)-L-Rhap-(alpha-1 --> 3)-2,4-di-O-(acetyl,lauryl)-6-deoxy-alpha-L-Glcp. Compared to the oligosaccharidic glycopeptidolipid structures, the particular features of the GPL X-1 tetrasaccharide structure arise from the presence of monosaccharide residues esterified by C-12 fatty acids and from the absence of the basal disaccharide core, L-Rhap-(alpha-1 --> 2)-6-deoxy-alpha-L-Talp. Finally, the tetrasaccharide appendage was found to be attached to the hydroxy function of the allothreonine methyl ester, whereas the remaining 3-O-Me-6-deoxy-alpha-L-Talp is glycosidically linked to the distal serine resine. The M. xenopi glycopeptidolipid structure described below represents a new type of mycobacterial glycopeptidolipid antigen that is characterized by the absence of a C-mycoside core structure. Thus, the GPL X-1 structure is unique in the mycobacterium genus and can be used as a type-specific probe for M. xenopi identification.	CNRS,CTR RECH BIOCHIM & GENET CELLULAIRES,118 ROUTE NARBONNE,F-31062 TOULOUSE,FRANCE	Centre National de la Recherche Scientifique (CNRS)								ALTONA C, 1980, ORG MAGN RESONANCE, V13, P417, DOI 10.1002/mrc.1270130606; AUSINA V, 1988, ANN INTERN MED, V109, P929; BARBER M., 1965, TETRAHEDRON LETT, V18, P1331; BARBER M, 1965, BIOCHEM BIOPH RES CO, V18, P469, DOI 10.1016/0006-291X(65)90775-8; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BIEMANN K, 1987, MASS SPECTROM REV, V6, P1, DOI 10.1002/mas.1280060102; BJORKMAN S, 1982, BIOMED MASS SPECTROM, V9, P315, DOI 10.1002/bms.1200090802; BRENNAN PJ, 1978, J CLIN MICROBIOL, V8, P374; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; BRENNAN PJ, 1984, MYCOBACTERIA SOURCEB, P467; BRENNAN PJ, 1984, MICROBIOLOGY 1984, P366; CAMPHAUSEN RT, 1985, P NATL ACAD SCI USA, V82, P3068, DOI 10.1073/pnas.82.10.3068; CHATTERJEE D, 1987, J BIOL CHEM, V262, P3528; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; CONTRERAS MA, 1988, AM REV RESPIR DIS, V137, P149, DOI 10.1164/ajrccm/137.1.149; COSTRINI AM, 1981, AM REV RESPIR DIS, V123, P104; DAFFE M, 1983, BIOCHIM BIOPHYS ACTA, V751, P439, DOI 10.1016/0005-2760(83)90304-1; DAMSKER B, 1982, HUM PATHOL, V13, P866, DOI 10.1016/S0046-8177(82)80084-1; DEPAUW E, 1986, MASS SPECTROM REV, V5, P191, DOI 10.1002/mas.1280050204; DHARIWAL KR, 1986, J BACTERIOL, V168, P283, DOI 10.1128/jb.168.1.283-293.1986; FOURNIE JJ, 1987, EUR J BIOCHEM, V168, P181, DOI 10.1111/j.1432-1033.1987.tb13402.x; FOURNIE JJ, 1987, J BIOL CHEM, V262, P3174; GERWIG GJ, 1978, CARBOHYD RES, V62, P349, DOI 10.1016/S0008-6215(00)80881-2; Goren M. B., 1979, TUBERCULOSIS, P63; HAVERKAMP J, 1975, CARBOHYD RES, V39, P201, DOI 10.1016/S0008-6215(00)86130-3; HOOPER LC, 1986, INFECT IMMUN, V54, P133, DOI 10.1128/IAI.54.1.133-141.1986; JARDINE I, 1989, ANAL CHEM, V61, P416, DOI 10.1021/ac00180a008; LANEELLE G, 1968, EUR J BIOCHEM, V5, P487, DOI 10.1111/j.1432-1033.1968.tb00396.x; LEMERCIER JP, 1979, REV FR MAL RESPIR, V7, P510; PUZO G, 1990, CRIT REV MICROBIOL, V17, P305, DOI 10.3109/10408419009105730; RIVIERE M, 1988, J CHROMATOGR, V445, P87, DOI 10.1016/S0021-9673(01)84510-6; RIVIERE M, 1988, BIOMED ENVIRON MASS, V16, P275, DOI 10.1002/bms.1200160153; RIVIERE M, 1987, J BIOL CHEM, V262, P14879; SIMOR AE, 1984, AM REV RESPIR DIS, V129, P435; TECSONTUMANG FT, 1984, ANN INTERN MED, V86, P145; TSANG AY, 1984, INT J SYST BACTERIOL, V34, P35, DOI 10.1099/00207713-34-1-35; VERCELLONE A, 1989, J BIOL CHEM, V264, P7447; VERCELLONE A, 1989, ADV MASS SPECTROM B, V11, P1350; WESTMORE JB, 1986, MASS SPECTROM REV, V5, P381, DOI 10.1002/mas.1280050403; WOLINSKY E, 1979, AM REV RESPIR DIS, V119, P107; WOODBURY JL, 1989, J GEN MICROBIOL, V135, P1875	41	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9057	9063						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1902834				2022-12-25	WOS:A1991FM03800063
J	NASHEUER, HP; MOORE, A; WAHL, AF; WANG, TSF				NASHEUER, HP; MOORE, A; WAHL, AF; WANG, TSF			CELL CYCLE-DEPENDENT PHOSPHORYLATION OF HUMAN DNA POLYMERASE-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P34CDC2 PROTEIN-KINASE; XENOPUS CDC2 PROTEIN; FISSION YEAST; KB-CELLS; ENZYMOLOGICAL CHARACTERIZATION; SACCHAROMYCES-CEREVISIAE; REPLICATION INVITRO; PRIMASE COMPLEX; GENE-EXPRESSION; MITOSIS	The expression of DNA polymerase-alpha, a principal chromosome replication enzyme, is constitutive during the cell cycle. We show in this report that DNA polymerase-alpha catalytic polypeptide p180 is phosphorylated throughout the cell cycle and is hyperphosphorylated in G2/M phase. The p70 subunit is phosphorylated only in G2/M phase. This cell cycle-dependent phosphorylation is due to cell cycle-dependent kinase(s) and not to phosphatase(s). In vitro evidence indicates the involvement of p34cdc2 kinase in the mitotic phosphorylation of DNA polymerase-alpha. Tryptic phosphopeptide maps demonstrate that peptides phosphorylated in vitro are identical to those phosphorylated in vivo. DNA polymerase-alpha from mitotic cells is found to have lower affinity for single-stranded DNA than does polymerase-alpha from G1/S phase cells. These results imply that the mitotic phosphorylation of polymerase-alpha may affect its physical interaction with other replicative proteins and/or with DNA at the replication fork.	STANFORD UNIV,MED CTR,SCH MED,DEPT PATHOL,EXPTL ONCOL LAB,STANFORD,CA 94305	Stanford University			Nasheuer, Heinz P./B-9025-2008	Nasheuer, Heinz Peter/0000-0002-9218-9079	NATIONAL CANCER INSTITUTE [T32CA009151, R01CA014835] Funding Source: NIH RePORTER; NCI NIH HHS [CA09151, CA09302, CA14835] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; BLOW JJ, 1990, CELL, V62, P855, DOI 10.1016/0092-8674(90)90261-C; BOOHER R, 1987, EMBO J, V6, P3441, DOI 10.1002/j.1460-2075.1987.tb02667.x; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUNPHY WG, 1988, CELL, V55, P925, DOI 10.1016/0092-8674(88)90234-6; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; DUNPHY WG, 1989, CELL, V58, P181, DOI 10.1016/0092-8674(89)90414-5; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; FISHER PA, 1979, J BIOL CHEM, V254, P6128; HEALD R, 1990, CELL, V61, P579, DOI 10.1016/0092-8674(90)90470-Y; IKEGAMI S, 1978, NATURE, V275, P458, DOI 10.1038/275458a0; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEHMAN IR, 1989, J BIOL CHEM, V264, P4265; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; LUCCHINI G, 1988, MOL GEN GENET, V212, P459, DOI 10.1007/BF00330850; MALLER JL, 1990, BIOCHEMISTRY-US, V29, P3157, DOI 10.1021/bi00465a001; MEIJER L, 1989, EMBO J, V8, P2275, DOI 10.1002/j.1460-2075.1989.tb08353.x; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; MORGAN DO, 1989, CELL, V57, P775, DOI 10.1016/0092-8674(89)90792-7; MURRAY AW, 1989, SCIENCE, V246, P614, DOI 10.1126/science.2683077; NORBURY CJ, 1989, BIOCHIM BIOPHYS ACTA, V989, P85, DOI 10.1016/0304-419X(89)90036-X; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; NURSE P, 1990, CELL, V61, P549; PLEVANI P, 1985, J BIOL CHEM, V260, P7102; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; SO AG, 1988, BIOCHEMISTRY-US, V27, P4591, DOI 10.1021/bi00413a001; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; TANAKA S, 1982, J BIOL CHEM, V257, P8386; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; WAHL AF, 1986, BIOCHEMISTRY-US, V25, P7821, DOI 10.1021/bi00372a006; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016; WANG TSF, 1989, FASEB J, V3, P14, DOI 10.1096/fasebj.3.1.2642867; WANG TSF, 1984, J BIOL CHEM, V259, P1854; WARD GE, 1990, CELL, V61, P561, DOI 10.1016/0092-8674(90)90469-U; WITTENBERG C, 1989, MOL CELL BIOL, V9, P4064, DOI 10.1128/MCB.9.9.4064; WONG SW, 1986, J BIOL CHEM, V261, P7958; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x	43	132	133	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7893	7903						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902230				2022-12-25	WOS:A1991FJ34200090
J	ABBOTT, WM; FEIZI, T				ABBOTT, WM; FEIZI, T			SOLUBLE 14-KDA BETA-GALACTOSIDE-SPECIFIC BOVINE LECTIN - EVIDENCE FROM MUTAGENESIS AND PROTEOLYSIS THAT ALMOST THE COMPLETE POLYPEPTIDE-CHAIN IS NECESSARY FOR INTEGRITY OF THE CARBOHYDRATE RECOGNITION DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; IGE-BINDING PROTEIN; ENDOGENOUS LECTINS; CULTURED-CELLS; POLYACRYLAMIDE GELS; 3T3 FIBROBLASTS; CALF HEART; LUNG; LOCALIZATION; HOMOLOGY	The soluble beta-galactoside-specific bovine lectin of subunit 14 kDa has been expressed in vitro by transcription and then translation in a rabbit reticulocyte lysate. The protein thus expressed shows the predicted binding to lactose coupled to Sepharose. Several mutants of the 134 amino acid protein have been expressed and insight gained into (a) the polypeptide length required to form the carbohydrate recognition domain and (b) the functional importance of some of the highly conserved amino acids. The following amino acids have been deleted: 1-9, 1-23, 88-122, 88-134, 107-134, or 124-134. In addition, a frame-shift mutant has been made in which the 23 amino acids at the C-terminal end were completely changed. Among these seven mutants only mutant 1-9 shows carbohydrate binding but with congruent-to 30% of the activity of the wild-type protein (as assessed by the percentage of the protein bound to lactose-Sepharose). On the other hand, carbohydrate binding is relatively well preserved (75-90%) in mutant proteins where the C-terminal octapeptide sequence of the bovine lectin has been changed to sequences that resemble those in the chick 14-kDa lectin. When the single tryptophan at position 68 is changed by point mutagenesis to phenylalanine or to a leucine residue, a weak binding activity (congruent-to 20%) is retained only with the former. When either of the cysteines 2 or 60 is changed to serine, binding activity is reduced to congruent-to 60%, and when both are changed, to congruent-to 20% of that for the wild-type protein. The susceptibility of the lectin to oxidative inactivation is unaffected when these 2 cysteines and cysteine 130 are changed to serine individually or in tandem (cysteines 2 and 60). In a second approach we show that the natural protein isolated from bovine heart is protected from proteolysis by trypsin and V8-protease in the presence of saccharide ligand. Although further work is required to identify residues which come into contact with the carbohydrate ligand, these results indicate that almost the complete polypeptide chain is necessary for the integrity of the carbohydrate recognition domain.	CLIN RES CTR, MRC, GLYCOCONJUGATES SECT, WATFORD RD, HARROW HA1 3UJ, MIDDX, ENGLAND	Medical Research Council Clinical Trials Unit				Feizi, Ten/0000-0001-6495-0329				ABBOTT WM, 1989, BIOCHEM J, V259, P283, DOI 10.1042/bj2590283; ABBOTT WM, 1989, BIOCHEM J, V259, P291, DOI 10.1042/bj2590291; ABBOTT WM, 1988, BIOCHEM J, V252, P283, DOI 10.1042/bj2520283; ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; BARONDES SH, 1984, SCIENCE, V223, P1259, DOI 10.1126/science.6367039; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRILES EB, 1979, J CELL BIOL, V81, P528, DOI 10.1083/jcb.81.3.528; CHILDS RA, 1979, FEBS LETT, V99, P175, DOI 10.1016/0014-5793(79)80273-2; CLERCH LB, 1988, BIOCHEMISTRY-US, V27, P692, DOI 10.1021/bi00402a030; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; DEWAARD A, 1976, J BIOL CHEM, V251, P7581; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; FEIZI T, 1987, BIOCHEM J, V245, P1; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; HIRABAYASHI J, 1988, J BIOCHEM-TOKYO, V104, P1; JIA SH, 1988, J BIOL CHEM, V263, P6009; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEFFLER H, 1986, J BIOL CHEM, V261, P119; LEVI G, 1981, J BIOL CHEM, V256, P5735; LEWIS ED, 1983, P NATL ACAD SCI-BIOL, V80, P7065, DOI 10.1073/pnas.80.23.7065; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MOUTSATSOS IK, 1986, J CELL BIOL, V102, P477, DOI 10.1083/jcb.102.2.477; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; OHYAMA Y, 1986, BIOCHEM BIOPH RES CO, V134, P51, DOI 10.1016/0006-291X(86)90525-5; RAZ A, 1989, CANCER RES, V49, P3489; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROFF CF, 1983, J BIOL CHEM, V258, P657; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; WHITNEY PL, 1986, BIOCHEM J, V238, P683, DOI 10.1042/bj2380683	32	90	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5552	5557						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1900835				2022-12-25	WOS:A1991FD37000032
J	ADUNYAH, SE; UNLAP, TM; WAGNER, F; KRAFT, AS				ADUNYAH, SE; UNLAP, TM; WAGNER, F; KRAFT, AS			REGULATION OF C-JUN EXPRESSION AND AP-1 ENHANCER ACTIVITY BY GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MYC GENE-EXPRESSION; PHORBOL ESTERS; SIGNAL-TRANSDUCTION; FOS PROTEIN; TRANSCRIPTION; ONCOGENE; BRYOSTATIN; RECEPTOR	Granulocyte-macrophage colony stimulating factor (GM-CSF) stimulates the growth and differentiation of human hematopoietic progenitor cells by activating transcription of specific genes. The mechanism by which binding of GM-CSF to its receptor stimulates gene expression remains unknown. To examine this process in more detail, we have transfected human monocytic leukemia cells U937 with a plasmid containing an AP-1 enhancer element and a chloramphenicol acetyltransferase recorder gene and treated them with GM-CSF. We find that GM-CSF stimulates a 2-3-fold increase in chloramphenicol acetyltransferase activity over a concentration range 1-1,000 units/ml. Northern and Western blot analysis demonstrates that the mechanism by which GM-CSF stimulates AP-1 enhancer activity involves increases in c-jun and c-fos mRNA levels, and increases in Jun protein. In a similar fashion the treatment of normal human monocytes with GM-CSF also induced increases in total cellular c-jun. Because protein kinase C plays a crucial role in activating c-jun transcription we examined the role of this enzyme in mediating the effects of GM-CSF. Treatment of U937 cells with inhibitors of protein kinase C including staurosporine 10 nM and H-7 50-mu-M, or down-regulation of protein kinase C by phorbol ester pretreatment blocks the induction of c-jun by GM-CSF. However, HA which does not block protein kinase C had no effect on GM-CSF stimulation of c-jun RNA levels. In addition, GM-CSF treatment causes the rapid translocation of protein kinase C to the particulate fraction which was maximal by 5 min and returned to base line by 80 min. These data suggest that the binding of GM-CSF to its receptor stimulates increases in c-jun mRNA and protein and activates AP-1 enhancer activity. These effects may be at least in part mediated by activation of protein kinase C.	UNIV ALABAMA,DIV HEMATOL ONCOL,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham					NATIONAL CANCER INSTITUTE [R01CA042533] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA42533-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BERKOW RL, 1985, BIOCHEM BIOPH RES CO, V131, P1109, DOI 10.1016/0006-291X(85)90205-0; BOS TJ, 1988, CELL, V52, P705, DOI 10.1016/0092-8674(88)90408-4; CHIU R, 1987, NATURE, V329, P648, DOI 10.1038/329648a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; DOWNING JR, 1988, MOL CELL BIOL, V8, P1795, DOI 10.1128/MCB.8.4.1795; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; GOUGH NM, 1984, NATURE, V309, P763, DOI 10.1038/309763a0; HARRIS P, 1985, J LEUKOCYTE BIOL, V37, P407, DOI 10.1002/jlb.37.4.407; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; IMAMURA K, 1990, EMBO J, V9, P2423, DOI 10.1002/j.1460-2075.1990.tb07418.x; KANAKURA Y, 1990, BLOOD, V76, P706; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; KRAFT AS, 1988, J BIOL CHEM, V263, P8437; KRAFT AS, 1987, ONCOGENE, V1, P111; KRAFT AS, 1989, CANCER RES, V49, P1287; KRAFT AS, 1983, NATURE, V301, P621, DOI 10.1038/301621a0; LINDEMANN A, 1989, J CLIN INVEST, V83, P1308, DOI 10.1172/JCI114016; LINDEMANN A, 1988, J IMMUNOL, V140, P837; LUSCHER B, 1989, GENE DEV, V3, P1507, DOI 10.1101/gad.3.10.1507; MERCURIO F, 1989, EMBO J, V8, P1455, DOI 10.1002/j.1460-2075.1989.tb03528.x; METCALF D, 1985, CELL, V43, P5, DOI 10.1016/0092-8674(85)90004-2; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; METCALF D, 1986, BLOOD, V67, P257; MILLER AD, 1984, CELL, V36, P51; MILLER LJ, 1986, J IMMUNOL, V137, P2891; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; NISHIMURA J, 1982, P NATL ACAD SCI-BIOL, V79, P4303, DOI 10.1073/pnas.79.14.4303; PARK LS, 1986, J EXP MED, V164, P251, DOI 10.1084/jem.164.1.251; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; RANSONE LJ, 1989, GENE DEV, V3, P770, DOI 10.1101/gad.3.6.770; REIS LFL, 1989, J BIOL CHEM, V264, P16351; SHERMAN ML, 1990, J BIOL CHEM, V265, P3320; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WARD CJ, 1990, BIOCHEM BIOPH RES CO, V167, P659, DOI 10.1016/0006-291X(90)92076-C; WASYLYK C, 1989, MOL CELL BIOL, V9, P2247, DOI 10.1128/MCB.9.5.2247; WILLIAM F, 1990, J BIOL CHEM, V265, P18166	48	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5670	5675						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1900839				2022-12-25	WOS:A1991FD37000049
J	LINDER, ME; PANG, IH; DURONIO, RJ; GORDON, JI; STERNWEIS, PC; GILMAN, AG				LINDER, ME; PANG, IH; DURONIO, RJ; GORDON, JI; STERNWEIS, PC; GILMAN, AG			LIPID MODIFICATIONS OF G-PROTEIN SUBUNITS - MYRISTOYLATION OF G-ALPHA INCREASES ITS AFFINITY FOR BETA-GAMMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; BOVINE BRAIN; REGULATORY PROTEINS; ADENYLATE-CYCLASE; ESCHERICHIA-COLI; 2 FORMS; PURIFICATION; EXPRESSION; ENZYMOLOGY; ACYLATION	Myristoylated recombinant proteins can be synthesized in Escherichia coli by concurrent expression of the enzyme myristoyl-CoA:protein N-myristoyl-transferase with its protein substrates (Duronio, R. J., Jackson-Machelski, E., Heuckeroth, R. O., Olins, P. O., Devine, C. S., Yonemoto, W., Slice, L. W., Taylor, S. S., and Gordon, J. I. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 1506-1510). Expression of the G protein subunit G(o-alpha) in this system results in the synthesis of two forms of the protein; these were separated on a column of heptylamine-Sepharose. Purification of the more abundant form of G(o-alpha) yielded a product that has a blocked amino terminus. Chemical analysis of the fatty acids released by acid hydrolysis of the protein revealed myristic acid. The second form of the protein was not myristoylated. Myristoylated and nonmyristoylated recombinant G(o-alpha) were compared with brain G(o-alpha) (which is myristoylated) for their ability to interact with G protein beta-gamma-subunits. The nonmyristoylated recombinant protein clearly had a reduced affinity for beta-gamma, while the myristoylated recombinant protein was indistinguishable from native G(o-alpha) in its subunit interactions. Thus, myristoylation increases the affinity of alpha-subunits for beta-gamma. We propose that the function of myristoylation of G protein alpha-subunits is, at least in part, to facilitate formation of the heterotrimer and the localization of alpha to the plasma membrane.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235; WASHINGTON UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOPHYS,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Washington University (WUSTL); Washington University (WUSTL)			Linder, Maurine/AAU-9999-2021	Linder, Maurine/0000-0003-2202-9712; Duronio, Robert/0000-0001-6469-6965	NIAID NIH HHS [AI27179] Funding Source: Medline; NIGMS NIH HHS [GM31954, GM34497] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034497, R01GM034497, R01GM031954] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLUMER KJ, 1990, P NATL ACAD SCI USA, V87, P4363, DOI 10.1073/pnas.87.11.4363; BOKOCH GM, 1984, J BIOL CHEM, V259, P3560; BUSS JE, 1987, P NATL ACAD SCI USA, V84, P7493, DOI 10.1073/pnas.84.21.7493; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CASEY PJ, 1988, POST TRANSLATIONAL M, P64; CHOW M, 1987, NATURE, V327, P482, DOI 10.1038/327482a0; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GODDARD C, 1989, J BIOL CHEM, V264, P15173; GRAZIANO MP, 1987, J BIOL CHEM, V262, P11375; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MUMBY S, 1988, J BIOL CHEM, V263, P2020; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; NEER EJ, 1984, J BIOL CHEM, V259, P4222; PANG IH, 1989, P NATL ACAD SCI USA, V86, P7814, DOI 10.1073/pnas.86.20.7814; RASH MD, 1989, CELL, V58, P281; RESH MD, 1990, NATURE, V346, P84, DOI 10.1038/346084a0; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHULTZ AM, 1987, BIOCHEM BIOPH RES CO, V146, P1234, DOI 10.1016/0006-291X(87)90780-7; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868	36	250	255	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4654	4659						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900297				2022-12-25	WOS:A1991FA69400096
J	ARIELI, B; PADAN, E; SHAHAK, Y				ARIELI, B; PADAN, E; SHAHAK, Y			SULFIDE-INDUCED SULFIDE-QUINONE REDUCTASE-ACTIVITY IN THYLAKOIDS OF OSCILLATORIA-LIMNETICA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHETIC ELECTRON-TRANSPORT; DEPENDENT HYDROGEN EVOLUTION; CYTOCHROME B/F COMPLEX; ANOXYGENIC PHOTOSYNTHESIS; PROTON TRANSLOCATION; N-OXIDE; CHLOROPLASTS; INHIBITION; CYANOBACTERIA; STIGMATELLIN	Sulfide-dependent partial electron-transport reactions were studied in thylakoids isolated from cells of the cyanobacterium oscillatoria limnetica, which had been induced to perform sulfide-driven anoxygenic photosynthesis. It was found that these thylakoids have the capacity to catalyze electron transfer, from sulfide to externally added quinones, in the dark. Assay conditions were developed to measure the reaction either as quinone-dependent sulfide oxidation (colorimetrically) or as sulfide-dependent quinone reduction (by UV dual-wavelength spectrophotometry). The main features of this reaction are as follows. (i) It is exclusively catalyzed by thylakoids of sulfide-induced cells. Noninduced thylakoids lack this reaction. (ii) Plastoquinone-1 or -2 are equally good substrates. ubiquinone-1 and duroquinone yield somewhat slower rates. (iii) The apparent K(m) for plastoquinone-1 was 32-mu-M and for sulfide about 4-mu-M. Maximal rates (at 25-degrees-C) were about 75-mu-mol of quinone reduced per mg of chlorophyll.h. (iv) The reaction was not affected by extensive washes of the membranes. (v) Unlike sulfide-dependent NADP photoreduction activity of these thylakoids, which is sensitive to all the specific inhibitors of the cytochrome b6f complex, the new dark reaction exhibited differential sensitivity to these inhibitors. 2-n-nonyl-4-hydroxyquinoline-N-oxide was the most potent inhibitor of both light and dark reactions, working at submicromolar concentrations. 5-n-Undecyl-6-hydroxy-4,7-dioxobenzothiazole also inhibited the two reactions to a similar extent, but at 10 times higher concentrations than 2-n-nonyl-4-hydroxyquinoline-N-oxide. 2,5-Dibromo-3-methyl-6-isopropyl-p-benzo-quinone, 2-iodo-6-isopropyl-3-methyl-2',4,4'-trinitrodiphenyl ether, and stigmatellin had no effect on the dark reaction at concentrations sufficient to fully inhibit the light reaction from sulfide. We propose that the sulfide-induced factor which enables the use of sulfide as the electron donor for anoxygenic photosynthesis in Oscillatria limnetica is a membrane-bound sulfide-quinone reductase. its site of interaction is suggested to be either the cytochrome b6 (at the Qc quinone binding site or the b(H) site) or the plastoquinone pool. The analogy to other anoxygenic photosynthetic systems is discussed.	WEIZMANN INST SCI,DEPT BIOCHEM,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	ARIELI, B (corresponding author), HEBREW UNIV JERUSALEM,INST LIFE SCI,DIV MICROBIAL & MOLEC ECOL,IL-91904 JERUSALEM,ISRAEL.							BELKIN S, 1983, J GEN MICROBIOL, V129, P3091; BELKIN S, 1984, BIOCHIM BIOPHYS ACTA, V766, P563, DOI 10.1016/0005-2728(84)90115-4; BELKIN S, 1983, PLANT PHYSIOL, V72, P825, DOI 10.1104/pp.72.3.825; BELKIN S, 1982, ISRAEL J BOT, V31, P199; BELKIN S, 1978, FEBS LETT, V94, P291, DOI 10.1016/0014-5793(78)80959-4; BELKIN S, 1987, METHOD ENZYMOL, V167, P380; BRUNE DC, 1986, ARCH MICROBIOL, V145, P295, DOI 10.1007/BF00443662; BRUNE DC, 1989, BIOCHIM BIOPHYS ACTA, V975, P189, DOI 10.1016/S0005-2728(89)80251-8; CLARK RD, 1983, P NATL ACAD SCI-BIOL, V80, P6249, DOI 10.1073/pnas.80.20.6249; CLINE JD, 1969, LIMNOL OCEANOGR, V14, P454, DOI 10.4319/lo.1969.14.3.0454; COHEN Y, 1975, NATURE, V257, P489, DOI 10.1038/257489a0; COHEN Y, 1975, J BACTERIOL, V123, P858; Cramer W, 1987, TOPICS PHOTOSYNTHESI, V8, P447; Davies E.C., 1987, PROGR PHOTOSYNTHESIS, V2, P485; GODDE D, 1980, ARCH MICROBIOL, V127, P245, DOI 10.1007/BF00427200; HANGARTER RP, 1987, BIOCHIM BIOPHYS ACTA, V890, P106, DOI 10.1016/0005-2728(87)90074-0; HAUSKA G, 1983, BIOCHIM BIOPHYS ACTA, V726, P97, DOI 10.1016/0304-4173(83)90002-2; HAUSKA G, 1986, ENCY PLANT PHYSL, V10, P496; HOUCHINS JP, 1982, BIOCHIM BIOPHYS ACTA, V682, P86, DOI 10.1016/0005-2728(82)90122-0; HOUCHINS JP, 1984, PLANT PHYSIOL, V76, P456, DOI 10.1104/pp.76.2.456; JOLIOT P, 1988, BIOCHIM BIOPHYS ACTA, V933, P319, DOI 10.1016/0005-2728(88)90039-4; JONES RW, 1988, BIOCHIM BIOPHYS ACTA, V933, P258, DOI 10.1016/0005-2728(88)90033-3; KNAFF DB, 1975, BIOCHIM BIOPHYS ACTA, V376, P549, DOI 10.1016/0005-2728(75)90174-7; LEEGOOD RC, 1983, BIOCHIM BIOPHYS ACTA, V722, P116, DOI 10.1016/0005-2728(83)90164-0; MALKIN R, 1982, BIOCHEMISTRY-US, V21, P2945, DOI 10.1021/bi00541a022; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; MORTON RA, 1965, BIOCH QUINONES, P23; NITSCHKE W, 1989, BIOCHIM BIOPHYS ACTA, V974, P223, DOI 10.1016/S0005-2728(89)80376-7; OETTMEIER W, 1985, BIOCHIM BIOPHYS ACTA, V807, P216, DOI 10.1016/0005-2728(85)90125-2; OKEEFE DP, 1988, PHOTOSYNTH RES, V17, P189, DOI 10.1007/BF00035448; OREN A, 1978, J BACTERIOL, V133, P558, DOI 10.1128/JB.133.2.558-563.1978; OREN A, 1979, BIOCHIM BIOPHYS ACTA, V546, P270, DOI 10.1016/0005-2728(79)90045-8; OREN A, 1977, P NATL ACAD SCI USA, V74, P2152, DOI 10.1073/pnas.74.5.2152; PADAN E, 1979, ANNU REV PLANT PHYS, V30, P27, DOI 10.1146/annurev.pp.30.060179.000331; PADAN E, 1979, ADV MICROB ECOL, V3, P1; RICH P, 1987, CYTOCHROME SYSTEMS M, P495; RICH PR, 1986, J BIOENERG BIOMEMBR, V18, P145, DOI 10.1007/BF00743461; SCHERER S, 1988, ARCH BIOCHEM BIOPHYS, V267, P228, DOI 10.1016/0003-9861(88)90027-6; SCHUBERT K, 1990, CURRENT RES PHOTOSYN, V3, P279; SHAHAK Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P605, DOI 10.1016/0003-9861(87)90527-3; SHAHAK Y, 1981, BIOCHIM BIOPHYS ACTA, V636, P234, DOI 10.1016/0005-2728(81)90097-9; SHILL DA, 1985, ARCH MICROBIOL, V146, P82; SLOOTEN L, 1989, BIOCHIM BIOPHYS ACTA, V973, P272, DOI 10.1016/S0005-2728(89)80432-3; SYBESMA C, 1987, PROG PHOTOSYN RES, V2, P633; TRUMPOWER BL, 1981, BIOCHIM BIOPHYS ACTA, V639, P129, DOI 10.1016/0304-4173(81)90008-2; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; [No title captured]	47	33	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					104	111						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1898723				2022-12-25	WOS:A1991EQ33900018
J	YUBISUI, T; SHIRABE, K; TAKESHITA, M; KOBAYASHI, Y; FUKUMAKI, Y; SAKAKI, Y; TAKANO, T				YUBISUI, T; SHIRABE, K; TAKESHITA, M; KOBAYASHI, Y; FUKUMAKI, Y; SAKAKI, Y; TAKANO, T			STRUCTURAL ROLE OF SERINE-127 IN THE NADH-BINDING SITE OF HUMAN NADH-CYTOCHROME-B5 REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; CYTOCHROME-B5 REDUCTASE; HUMAN-ERYTHROCYTES; METHEMOGLOBINEMIA; DEFICIENCY; PROTEINS; RESIDUE; DNA	Serine 127 of human NADH-cytochrome b5 reductase was replaced by proline and alanine by site-directed mutagenesis. The former mutation has been found in the genes of patients with hereditary deficiency of the enzyme. Both the mutant enzymes (Ser-127 --> Pro mutant and Ser-127 --> Ala mutant) were overproduced in Escherichia coli and purified to homogeneity. The two purified mutant enzymes showed indistinguishable spectral properties which differed from those of the wild-type enzyme. The mutant enzymes showed higher molecular extinction coefficients at 462 nm than that of the wild-type enzyme. Quenching of FAD fluorescence in these mutant enzymes was significantly less than that in the wild-type enzyme. Furthermore, circular dichroism spectra of the mutant enzymes were different, in both the visible and ultraviolet regions, from that of the wild-type enzyme. The spectra of the mutant enzymes in the visible region were restored to almost the same spectrum as the wild type upon reduction with NADH. Ser-127 --> Pro mutant and Ser-127 --> Ala mutant showed very low K(cat)/K(m) (NADH) values (5 X 10(7) and 3.5 X 10(7) S-1 M-1, respectively) with cytochrome b5 as an electron acceptor, than that of the wild-type enzyme (K(cat)/K(m) (NADH) = 179 X 10(7) S-1 M-1), while the k(cat)/K(m) (cytochrome b5 value for each enzyme was similar. The mutant enzymes were less thermostable than the wild-type enzyme. These results indicate that serine 127 plays an important role to maintain the structure of the NADH-binding site in the enzyme.	SETSUNAN UNIV,FAC PHARMACEUT SCI,OSAKA 57301,JAPAN; KYUSHU UNIV,GENET INFORMAT LAB,FUKUOKA 812,JAPAN	Setsunan University; Kyushu University	YUBISUI, T (corresponding author), MED COLL OITA,DEPT BIOCHEM,HAZAMA CHO,OITA 87956,JAPAN.							HACKETT CS, 1986, J BIOL CHEM, V261, P9854; HACKETT CS, 1988, J BIOL CHEM, V263, P7539; HULTQUIST DE, 1971, NATURE-NEW BIOL, V229, P252, DOI 10.1038/newbio229252a0; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P399; IYANAGI T, 1977, BIOCHEMISTRY-US, V16, P2725, DOI 10.1021/bi00631a021; KOBAYASHI Y, 1990, BLOOD, V75, P1408; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEROUX A, 1975, NATURE, V258, P619, DOI 10.1038/258619a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOTT EM, 1959, BIOCHIM BIOPHYS ACTA, V134, P584; SHIRABE K, 1989, BIOCHIM BIOPHYS ACTA, V1008, P189, DOI 10.1016/0167-4781(80)90007-X; STRITTMATTER P, 1959, J BIOL CHEM, V234, P2661; TANISHIMA K, 1985, BLOOD, V66, P1288; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; TOMATSU S, 1989, GENE, V80, P353; YUBISUI T, 1984, J BIOCHEM-TOKYO, V96, P579, DOI 10.1093/oxfordjournals.jbchem.a134871; YUBISUI T, 1988, BIOCHIM BIOPHYS ACTA, V936, P447, DOI 10.1016/0005-2728(88)90022-9; YUBISUI T, 1980, J BIOL CHEM, V255, P2454; YUBISUI T, 1984, BIOCHEM INT, V8, P319; YUBISUI T, 1987, P NATL ACAD SCI USA, V84, P3609, DOI 10.1073/pnas.84.11.3609; YUBISUI T, 1986, J BIOCHEM-TOKYO, V99, P407, DOI 10.1093/oxfordjournals.jbchem.a135495; YUTANI K, 1987, P NATL ACAD SCI USA, V84, P4441, DOI 10.1073/pnas.84.13.4441; ZEREZ CR, 1987, ANAL BIOCHEM, V164, P367, DOI 10.1016/0003-2697(87)90506-9	23	29	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					66	70						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1898726				2022-12-25	WOS:A1991EQ33900012
J	BIZZOZERO, OA; GOOD, LK				BIZZOZERO, OA; GOOD, LK			RAPID METABOLISM OF FATTY-ACIDS COVALENTLY BOUND TO MYELIN PROTEOLIPID PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN MYELIN; ACYL-COENZYME-A; PALMITIC ACID; BOVINE RHODOPSIN; ACYLATION; MEMBRANE; INVIVO; INVITRO; STIMULATION; ATTACHMENT	Proteolipid protein (PLP), the major protein of central nervous system myelin, contains approximately 2 mol of covalently bound fatty acids. In this study, the in vivo turnover rate of the acyl chains bound to PLP was determined in 40-day-old rats after a single intracranial injection of [H-3]palmitic acid. The apparent half-life of total fatty acids bound to PLP was approximately 7 days. After correction for acyl chain interconversion, the half-life of palmitate bound to PLP was only 3 days. This turnover rate is much more rapid than that of the protein moiety calculated under the same experimental conditions (t1/2 = 1 month). Additional evidence for the dynamic metabolism of acyl groups was provided by experiments in brain tissue slices which showed that acylation of PLP occurs in adult animals as well as during active myelination. Acylation of endogenous PLP in purified myelin and its subfractions was also studied during rat brain development using either [H-3]palmitoyl-CoA or [H-3]palmitic acid plus ATP and CoA. Labeling of endogenous PLP with [H-3]palmitoyl-CoA was observed as early as 10 days postnatal and continued at the same rate throughout development. When [H-3]palmitic acid was used as precursor in the presence of both ATP and CoA, esterification of myelin PLP occurred rapidly in adult animals, indicating that both nonacylated PLP and acyl-CoA ligase are present in myelin. Finally, pulse-chase experiments in a cell-free system showed that PLP-bound fatty acids turn over with a half-life shorter than 10 min. These observations are consistent with the concept that acylation of myelin PLP is a dynamic process involved mainly in myelin maintenance and function.	EK SHRIVER CTR, DEPT BIOCHEM, WALTHAM, MA 02254 USA		BIZZOZERO, OA (corresponding author), UNIV NEW MEXICO, SCH MED, DEPT BIOCHEM, BASIC MED SCI BLDG, 914 CAMINO SALUD, ALBUQUERQUE, NM 87131 USA.				NICHD NIH HHS [HD-05515] Funding Source: Medline; NINDS NIH HHS [NS-28129, NS-13469] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD005515] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS028129] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AGRAWAL HC, 1982, J BIOL CHEM, V257, P4588; AUTILIO LA, 1964, J NEUROCHEM, V11, P17, DOI 10.1111/j.1471-4159.1964.tb06719.x; BIZZOZERO OA, 1984, NEUROCHEM INT, V6, P659, DOI 10.1016/0197-0186(84)90047-0; BIZZOZERO OA, 1986, J NEUROCHEM, V47, P772; BIZZOZERO OA, 1986, BIOCHEMISTRY-US, V25, P6762, DOI 10.1021/bi00370a006; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P13550; BIZZOZERO OA, 1990, J NEUROCHEM, V55, P1986, DOI 10.1111/j.1471-4159.1990.tb05786.x; BIZZOZERO OA, 1990, BIOCHEM BIOPH RES CO, V170, P375, DOI 10.1016/0006-291X(90)91284-Y; BIZZOZERO OA, 1987, J BIOL CHEM, V262, P2138; BIZZOZERO OA, 1985, J NEUROSCI RES, V14, P197, DOI 10.1002/jnr.490140205; BIZZOZERO OA, 1983, NEUROCHEM INT, V5, P729, DOI 10.1016/0197-0186(83)90098-0; BIZZOZERO OA, 1986, J NEUROCHEM, V46, P630, DOI 10.1111/j.1471-4159.1986.tb13013.x; BIZZOZERO OA, 1991, T AM SOC NEUROCHEM, V22, P265; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BURGISSER P, 1989, NEUROCHEM RES, V14, P91, DOI 10.1007/BF00969764; DESJARDINS KC, 1983, J CELL BIOL, V97, P438, DOI 10.1083/jcb.97.2.438; FISCHER CA, 1974, BRAIN RES, V74, P51, DOI 10.1016/0006-8993(74)90111-5; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; KAHN DW, 1988, J NEUROCHEM, V50, P1542, DOI 10.1111/j.1471-4159.1988.tb03042.x; KISHIMOTO Y, 1972, METHODS NEUROCHEMIST, V3, P75; KONAT G, 1987, J NEUROCHEM S, V48, P139; LAROCCA JN, 1987, BRAIN RES, V436, P357, DOI 10.1016/0006-8993(87)91679-9; Lees M., 1984, MYELIN, P197; LEES M B, 1988, Society for Neuroscience Abstracts, V14, P786; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGEE AI, 1987, EMBO J, V6, P3353, DOI 10.1002/j.1460-2075.1987.tb02656.x; MCILHINNEY RAJ, 1985, EMBO J, V4, P1145, DOI 10.1002/j.1460-2075.1985.tb03752.x; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Norton WT., 1984, MYELIN, P147, DOI DOI 10.1007/978-1-4757-1830-0_5; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PASQUINI JM, 1987, NEUROCHEM INT, V11, P17, DOI 10.1016/0197-0186(87)90143-4; SCHMIDT MFG, 1980, J BIOL CHEM, V255, P3334; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; STAUFENBIEL M, 1987, MOL CELL BIOL, V7, P2981, DOI 10.1128/MCB.7.8.2981; STJULES RS, 1986, EXP EYE RES, V43, P929, DOI 10.1016/0014-4835(86)90071-0; STOFFYN P, 1971, BIOCHEM BIOPH RES CO, V44, P157, DOI 10.1016/S0006-291X(71)80172-9; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TOWNSEND LE, 1982, J BIOL CHEM, V257, P9745; TOWNSEND LE, 1983, J NEUROCHEM, V40, P1333, DOI 10.1111/j.1471-4159.1983.tb13575.x; TOWNSEND LE, 1983, T AM SOC NEUROCHEM, V14, P213; VANCE DE, 1967, J LIPID RES, V8, P621; VASWANI KK, 1987, J NEUROSCI RES, V17, P65, DOI 10.1002/jnr.490170110; WEBER K, 1969, J BIOL CHEM, V244, P4406; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	47	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17092	17098						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894605				2022-12-25	WOS:A1991GF44500022
J	SCHONHERR, E; JARVELAINEN, HT; SANDELL, LJ; WIGHT, TN				SCHONHERR, E; JARVELAINEN, HT; SANDELL, LJ; WIGHT, TN			EFFECTS OF PLATELET-DERIVED GROWTH-FACTOR AND TRANSFORMING GROWTH FACTOR-BETA-1 ON THE SYNTHESIS OF A LARGE VERSICAN-LIKE CHONDROITIN SULFATE PROTEOGLYCAN BY ARTERIAL SMOOTH-MUSCLE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BETA; EXTRACELLULAR-MATRIX; INTERSTITIAL PROTEOGLYCANS; PROTEIN-SYNTHESIS; MESSENGER-RNA; BOVINE AORTA; EXPRESSION; INVITRO; GLYCOSAMINOGLYCANS; ATHEROGENESIS	Platelet-derived growth factor (PDGF) and transforming growth factor-beta-1 (TGF-beta-1) increase [S-35]sulfate incorporation into proteoglycan (PG) by monkey arterial smooth muscle cells but have opposite effects on cell proliferation. The combination of these two growth regulatory peptides has an additive effect on PG synthesis but no effects on cell proliferation. The time course of sulfate incorporation after stimulation indicates that both growth factors cause maximal incorporation of sulfate into glycosaminoglycan chains by 12-18 h. The PG that is most affected is a large CSPG (M(r) approximately 1.2 x 10(6)) which can be immunoprecipitated by an antibody against versican, a large CSPG synthesized by human skin fibroblasts. The hydrodynamic size of this molecule increases after PDGF and TGF-beta-1 stimulation, but the size of the core glycoprotein (M(r) approximately 450,000) remains the same. Treatment with either growth factor leads to an increase in the amount of core glycoprotein for this PG. This increase correlates with an increase in the steady state level of mRNA identified by hybridization to a cDNA encoding versican. The two growth factors also increase the glycosaminoglycan chain length of this PG accounting for the greater hydrodynamic size of the molecule after stimulation. In contrast, PDGF and not TGF-beta-1 changes the composition of the glycosaminoglycan chains attached to this PG by doubling the ratio of chondroitin 6-sulfate to chondroitin 4-sulfate. These results indicate that although both of these growth factors increase the net synthesis of a large versican like CSPG, they differ in their effects on the structure of the glycosaminoglycan chains. These post-translational modifications may relate to the growth state of the cells.	UNIV WASHINGTON, SCH MED, DEPT PATHOL, SM-30, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT ORTHOPAED, SEATTLE, WA 98108 USA; UNIV WASHINGTON, DEPT BIOCHEM, SEATTLE, WA 98108 USA; VET ADM MED CTR, SEATTLE, WA 98108 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NHLBI NIH HHS [HL 18645] Funding Source: Medline; NIAMS NIH HHS [AR36994] Funding Source: Medline; NIDCR NIH HHS [DE-08229] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036994] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE008229] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ASUNDI V, 1990, EUR J CELL BIOL, V52, P98; BASSOLS A, 1988, J BIOL CHEM, V263, P3039; BAUER EA, 1985, P NATL ACAD SCI USA, V82, P4132, DOI 10.1073/pnas.82.12.4132; BERENSON GS, 1984, EXP MOL PATHOL, V41, P267, DOI 10.1016/0014-4800(84)90043-1; BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; CAMEJO G, 1982, ADV LIPID RES, V19, P1; CANALIS E, 1981, METABOLISM, V30, P970, DOI 10.1016/0026-0495(81)90094-9; CARLSON DM, 1968, J BIOL CHEM, V243, P616; CATERSON B, 1990, BIOCHEM SOC T, V18, P820, DOI 10.1042/bst0180820; CHANG Y, 1983, J BIOL CHEM, V258, P5679; CHEN JK, 1987, P NATL ACAD SCI USA, V84, P5287, DOI 10.1073/pnas.84.15.5287; CHEN JK, 1991, IN VITRO CELL DEV B, V27, P6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTNER JE, 1990, ANAL BIOCHEM, V184, P388, DOI 10.1016/0003-2697(90)90698-9; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; DEUEL TF, 1987, ANNU REV CELL BIOL, V3, P443, DOI 10.1146/annurev.cb.03.110187.002303; DOEGE K, 1987, J BIOL CHEM, V262, P17757; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; EDWARDS IJ, 1988, J BIOL CHEM, V263, P9612; GELMAN RA, 1973, BIOCHIM BIOPHYS ACTA, V297, P452, DOI 10.1016/0304-4165(73)90092-5; GLIMELIUS B, 1981, CELL DIFFER DEV, V10, P173, DOI 10.1016/0045-6039(81)90038-5; Hascall V.C., 1981, CELL BIOL EXTRACELLU, P39; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; HOLDERBAUM D, 1984, EXP CELL RES, V153, P16, DOI 10.1016/0014-4827(84)90443-9; HOLLMANN J, 1986, EXP CELL RES, V167, P484, DOI 10.1016/0014-4827(86)90188-6; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; KAPOOR R, 1986, BIOCHEM J, V240, P575, DOI 10.1042/bj2400575; KINDY MS, 1988, J BIOL CHEM, V263, P11426; KOBAYASHI S, 1985, BIOCHIM BIOPHYS ACTA, V841, P71, DOI 10.1016/0304-4165(85)90275-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIAU G, 1989, J BIOL CHEM, V264, P10315; LINDAHL U, 1973, J BIOL CHEM, V248, P7234; MAJACK RA, 1985, J CELL BIOL, V101, P1059, DOI 10.1083/jcb.101.3.1059; MANIATIS T, 1982, MOL CLONING LABORATO, V1, P433; MCQUILLAN DJ, 1989, J BIOL CHEM, V264, P13245; MORGELIN M, 1989, J BIOL CHEM, V264, P12080; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; NARAYANAN AS, 1983, J BIOL CHEM, V258, P1694; OEGEMA TR, 1975, J BIOL CHEM, V250, P6151; OWEN AJ, 1982, P NATL ACAD SCI-BIOL, V79, P3203, DOI 10.1073/pnas.79.10.3203; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PRINS APA, 1982, ARTHRITIS RHEUM, V25, P1228, DOI 10.1002/art.1780251012; RADHAKRISHNAMURTHY B, 1986, BIOCHIM BIOPHYS ACTA, V882, P85, DOI 10.1016/0304-4165(86)90059-0; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1989, LANCET, V1, P1179; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; RUOSLAHTI E, 1989, J BIOL CHEM, V264, P13369; SRINIVASAN SR, 1979, ATHEROSCLEROSIS, V34, P105, DOI 10.1016/0021-9150(79)90134-5; SUBBAIAH PV, 1982, ATHEROSCLEROSIS, V44, P49, DOI 10.1016/0021-9150(82)90052-1; SUGAHARA K, 1989, J BIOCHEM-TOKYO, V106, P910, DOI 10.1093/oxfordjournals.jbchem.a122951; TAN EML, 1991, LAB INVEST, V64, P474; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; THYBERG J, 1987, EXP CELL RES, V170, P160, DOI 10.1016/0014-4827(87)90125-X; UETSUKI T, 1989, J BIOL CHEM, V264, P5791; WASTESON A, 1971, J CHROMATOGR, V59, P87, DOI 10.1016/S0021-9673(01)80009-1; WASTESON A, 1973, BIOCHEM J, V136, P1069, DOI 10.1042/bj1361069; Wight T N, 1980, Prog Hemost Thromb, V5, P1; WIGHT TN, 1983, J CELL BIOL, V96, P167, DOI 10.1083/jcb.96.1.167; WIGHT TN, 1989, ARTERIOSCLEROSIS, V9, P1, DOI 10.1161/01.ATV.9.1.1; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	66	306	314	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17640	17647						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894644				2022-12-25	WOS:A1991GF44500097
J	VANDEGRIFF, KD; LETELLIER, YC; WINSLOW, RM; ROHLFS, RJ; OLSON, JS				VANDEGRIFF, KD; LETELLIER, YC; WINSLOW, RM; ROHLFS, RJ; OLSON, JS			DETERMINATION OF THE RATE AND EQUILIBRIUM-CONSTANTS FOR OXYGEN AND CARBON-MONOXIDE BINDING TO R-STATE HUMAN HEMOGLOBIN CROSS-LINKED BETWEEN THE ALPHA SUBUNITS AT LYSINE-99	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUATERNARY CONFORMATIONAL-CHANGES; HUMAN OXYHEMOGLOBIN; LASER PHOTOLYSIS; LIGAND-BINDING; 2-STATE MODEL; TETRAMERS; CURVES; CHAINS; BLOOD	The kinetics of O2 and CO binding to R-state human hemoglobin A0 and human hemoglobin cross-linked between the alpha-chains at Lys99 residues were examined using ligand displacement and partial photolysis techniques. Oxygen equilibrium curves were measured by Imai's continuous recording method (Imai, K. (1981) Methods Enzymol. 76, 438-449). The rate of the R to T transition was determined after full laser photolysis of the carbon monoxide derivative by measuring the resultant absorbance changes at an isosbestic point for ligand binding. Chemical cross-linking caused the R-state O2 affinity of alpha-subunits to decrease 6-fold compared with unmodified hemoglobin. This inhibition of O2 binding was the result of both a decrease in the rate constant for ligand association and an increase in the rate constant for dissociation. The O2 affinity of R-state beta-subunits was reduced 2-fold because of an increase in the O2 dissociation rate constant. These changes were attributed to proximal effects on the R-state hemes as the result of the covalent cross-link between alpha-chain G helices. This proximal strain in cross-linked hemoglobin was also expressed as a 5-fold higher rate for the unliganded R to T allosteric transition. The fourth O2 equilibrium binding constant, K4, measured by kinetic techniques, could be used to analyze equilibrium curves for either native or cross-linked hemoglobin. The resultant fitted values of the Adair constants, a1, a2, and a3, were similar to those obtained when K4 was allowed to vary, and the fits were of equal quality. When K4 was fixed to the kinetically determined value, the remaining Adair constants, particularly a3, became better defined.	RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251	Rice University	VANDEGRIFF, KD (corresponding author), LETTERMAN ARMY INST RES,DIV BLOOD RES,SAN FRANCISCO,CA 94129, USA.			Olson, John/0000-0002-0760-5403	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035649] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-07933, GM-35649] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adair GS, 1925, J BIOL CHEM, V63, P529; BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; BRUNORI M, 1968, J MOL BIOL, V34, P357, DOI 10.1016/0022-2836(68)90259-3; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; CHRISTENSEN SM, 1988, J BIOCHEM BIOPH METH, V17, P143, DOI 10.1016/0165-022X(88)90045-0; CHU AH, 1981, J BIOL CHEM, V256, P1199; DICERA E, 1987, BIOCHEMISTRY-US, V26, P4003, DOI 10.1021/bi00387a039; GIBSON QH, 1987, J BIOL CHEM, V262, P516; GIBSON QH, 1959, BIOCHEM J, V71, P293, DOI 10.1042/bj0710293; GILL SJ, 1987, BIOCHEMISTRY-US, V26, P3995, DOI 10.1021/bi00387a038; HAYASHI A, 1973, BIOCHIM BIOPHYS ACTA, V310, P309, DOI 10.1016/0005-2795(73)90110-4; HOFRICHTER J, 1983, P NATL ACAD SCI-BIOL, V80, P2235, DOI 10.1073/pnas.80.8.2235; Imai K, 1981, Methods Enzymol, V76, P438; JOHNSON ML, 1977, BIOPHYS CHEM, V7, P77, DOI 10.1016/0301-4622(77)87017-8; LARSEN RW, 1990, J BIOL CHEM, V265, P4449; MARDEN MC, 1986, BIOCHEMISTRY-US, V25, P7591, DOI 10.1021/bi00371a049; MARDEN MC, 1989, J MOL BIOL, V208, P341, DOI 10.1016/0022-2836(89)90393-8; MATHEWS AJ, 1989, J BIOL CHEM, V264, P16573; MILLS FC, 1976, BIOCHEMISTRY-US, V15, P5350, DOI 10.1021/bi00669a023; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MORRIS RJ, 1984, J BIOL CHEM, V259, P6701; Olson J S, 1981, Methods Enzymol, V76, P652; Olson J S, 1981, Methods Enzymol, V76, P631; OLSON JS, 1971, J BIOL CHEM, V246, P5919; OLSON JS, 1971, J BIOL CHEM, V246, P5241; PHILO JS, 1990, J BIOL CHEM, V265, P139; SAWICKI CA, 1977, J BIOL CHEM, V252, P7538; SAWICKI CA, 1976, J BIOL CHEM, V251, P1533; SAWICKI CA, 1977, J BIOL CHEM, V252, P5783; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; VANDEGRIFF KD, 1989, J BIOL CHEM, V264, P17824; VANDEGRIFF KD, 1991, J BIOL CHEM, V266, P2697; WINSLOW RM, 1977, J BIOL CHEM, V252, P2331	33	45	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17049	17059						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910038				2022-12-25	WOS:A1991GF44500016
J	CARRAWAY, CAC; FANG, H; YE, XH; JUANG, SH; LIU, YC; CARVAJAL, ME; CARRAWAY, KL				CARRAWAY, CAC; FANG, H; YE, XH; JUANG, SH; LIU, YC; CARVAJAL, ME; CARRAWAY, KL			MEMBRANE-MICROFILAMENT INTERACTIONS IN ASCITES TUMOR-CELL MICROVILLI - IDENTIFICATION AND ISOLATION OF A LARGE MICROFILAMENT-ASSOCIATED MEMBRANE GLYCOPROTEIN COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY ADENOCARCINOMA CELLS; SURFACE SIALOMUCIN COMPLEX; PLASMA-MEMBRANES; PHALLOIDIN SHIFT; BINDING PROTEIN; ALPHA-ACTININ; ANIMAL-CELLS; CYTOSKELETON; RECEPTORS; COMPONENTS	[C-14]Glucosamine metabolic labeling and concanavalin A blots were used to identify four major glycoprotein species associated with ascites tumor cell microvillar microfilament cores and with a transmembrane complex containing actin. Phalloidin shift analysis of glucosamine-labeled microvilli showed that glycoproteins of 110-120, 80, 65, and 55 kDa are stably associated with the microfilament cores. Analysis of large (> 10(6) kDa) transmembrane complexes from microvillar membranes made under microfilament-depolymerizing conditions (Carraway, C. A. C., Jung, G., and Carraway, K. L. (1983) Proc. Natl. Acad. Sci. U. S. A. 80, 430-434) revealed glycoproteins of the same M, values, showing the same relative staining or labeling patterns as those observed with the microfilament cores. Gel filtration of high salt, high pH extracts of intact microvilli, microfilament cores, or transmembrane complexes showed that in all of these fractions the glycoproteins are associated in a very large, stable complex. The glycoprotein multimer was isolated essentially free of actin and other components by Sephacryl S-1000 chromatography of microvilli, microvillar membranes prepared at pH 11, microfilament cores, or transmembrane complex fractions in Triton X-100, 1 M KCl, glycine, pH 9.5. Purified glycoprotein complex bound actin when incubated under polymerizing conditions. The presence of the glycoprotein heteromultimer in both microfilament cores and transmembrane complex from isolated membranes and the association of the purified glycoprotein complex with actin are consistent with our hypothesis that the glycoprotein-containing transmembrane complex is an association site for microfilaments at the plasma membrane.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,MIAMI,FL 33101	University of Miami	CARRAWAY, CAC (corresponding author), UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL R-629,MIAMI,FL 33101, USA.				NCI NIH HHS [CA 14395] Funding Source: Medline; NIGMS NIH HHS [GM 33795] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA014395] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033795] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENNETT V, 1985, ANNU REV BIOCHEM, V54, P273, DOI 10.1146/annurev.biochem.54.1.273; BOURGUIGNON LYW, 1978, P NATL ACAD SCI USA, V75, P2406, DOI 10.1073/pnas.75.5.2406; BRANDTS JF, 1983, SURV SYN PATHOL RES, V2, P107; BROWN SS, 1983, P NATL ACAD SCI-BIOL, V80, P5927, DOI 10.1073/pnas.80.19.5927; BURRIDGE K, 1983, CELL MOTIL CYTOSKEL, V3, P405, DOI 10.1002/cm.970030509; CAMPBELL KP, 1989, NATURE, V338, P259, DOI 10.1038/338259a0; CARRAWAY CAC, 1983, P NATL ACAD SCI-BIOL, V80, P430, DOI 10.1073/pnas.80.2.430; CARRAWAY CAC, 1986, BIOCHIM BIOPHYS ACTA, V885, P68, DOI 10.1016/0167-4889(86)90039-X; CARRAWAY CAC, 1985, EXP CELL RES, V161, P150, DOI 10.1016/0014-4827(85)90499-9; CARRAWAY CAC, 1982, BIOCHIM BIOPHYS ACTA, V719, P126; CARRAWAY CAC, 1985, EXP CELL RES, V157, P71, DOI 10.1016/0014-4827(85)90153-3; CARRAWAY CAC, 1983, CELL MOTIL CYTOSKEL, V3, P491, DOI 10.1002/cm.970030516; CARRAWAY CAC, 1991, IN PRESS CYTOSKELETO; CARRAWAY CAC, 1983, EXP CELL RES, V143, P301; CARRAWAY KL, 1980, NATURE, V285, P508, DOI 10.1038/285508a0; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; CARRAWAY KL, 1979, J CELL BIOL, V83, P529, DOI 10.1083/jcb.83.3.529; CARRAWAY KL, 1984, BIOESSAYS, V1, P55, DOI 10.1002/bies.950010204; CARRAWAY KL, 1988, EUKARYOTIC CELL RECO, P20; CUATRECASAS P, 1986, HARVEY LECT, V80, P89; DAVISON MD, 1988, CELL, V52, P159, DOI 10.1016/0092-8674(88)90503-X; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FROEHNER SC, 1986, TRENDS NEUROSCI, V9, P37, DOI 10.1016/0166-2236(86)90013-5; GEIGER B, 1985, TRENDS BIOCHEM SCI, V10, P456, DOI 10.1016/0968-0004(85)90031-3; GEIGER B, 1979, CELL, V18, P193, DOI 10.1016/0092-8674(79)90368-4; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOULD RJ, 1981, BIOCHEMISTRY-US, V20, P6776, DOI 10.1021/bi00527a006; HAMMONDS RG, 1987, CELL, V51, P1, DOI 10.1016/0092-8674(87)90002-X; HELM RM, 1981, EXP CELL RES, V135, P418, DOI 10.1016/0014-4827(81)90181-6; HUGGINS JW, 1980, EXP CELL RES, V127, P27; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; JUNG G, 1985, J CELL BIOCHEM, V28, P243, DOI 10.1002/jcb.240280402; JUNG G, 1984, J CELL BIOL, V98, P179, DOI 10.1083/jcb.98.1.179; KING J, 1971, J MOL BIOL, V62, P465, DOI 10.1016/0022-2836(71)90148-3; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; LEVINE BA, 1990, FEBS LETT, V263, P159, DOI 10.1016/0014-5793(90)80728-2; LEVINE J, 1983, P NATL ACAD SCI-BIOL, V80, P191, DOI 10.1073/pnas.80.1.191; LIU Y, 1986, J BIOL CHEM, V261, P4568; LIU YC, 1989, J BIOL CHEM, V264, P1208; LIU YC, 1987, J CELL BIOCHEM, V35, P185, DOI 10.1002/jcb.240350303; MATSUDAIRA PT, 1979, J CELL BIOL, V83, P667, DOI 10.1083/jcb.83.3.667; MCCLOSKEY M, 1984, INT REV CYTOL, V87, P19, DOI 10.1016/S0074-7696(08)62439-0; MENON AK, 1986, J CELL BIOL, V102, P534, DOI 10.1083/jcb.102.2.534; MOOSEKER MS, 1975, J CELL BIOL, V67, P725, DOI 10.1083/jcb.67.3.725; NICOLSON GL, 1976, BIOCHIM BIOPHYS ACTA, V457, P57, DOI 10.1016/0304-4157(76)90014-9; PAINTER RG, 1985, J CELL BIOCHEM, V27, P277, DOI 10.1002/jcb.240270309; RINDLER MJ, 1982, CIBA F SYMP, V92, P184; ROSEVEAR P, 1980, BIOCHEMISTRY-US, V19, P4108, DOI 10.1021/bi00558a032; ROTUNDO RL, 1982, MEMBRANES GROWTH DEV, P259; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SCHRAMM M, 1984, SCIENCE, V225, P1350, DOI 10.1126/science.6147897; SHENG Z, 1989, J CELL BIOCHEM, V40, P453, DOI 10.1002/jcb.240400406; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; STEINBACH JH, 1986, RECEPTORS CELLULAR R, P183; VANDERPUYE OA, 1988, EXP CELL RES, V178, P211, DOI 10.1016/0014-4827(88)90392-8; WUESTEHUBE LJ, 1987, J CELL BIOL, V105, P1741, DOI 10.1083/jcb.105.4.1741; YE XH, 1989, EXP CELL RES, V182, P160, DOI 10.1016/0014-4827(89)90288-7	58	19	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16238	16246						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874753				2022-12-25	WOS:A1991GB97700106
J	TOULLEC, D; PIANETTI, P; COSTE, H; BELLEVERGUE, P; GRANDPERRET, T; AJAKANE, M; BAUDET, V; BOISSIN, P; BOURSIER, E; LORIOLLE, F; DUHAMEL, L; CHARON, D; KIRILOVSKY, J				TOULLEC, D; PIANETTI, P; COSTE, H; BELLEVERGUE, P; GRANDPERRET, T; AJAKANE, M; BAUDET, V; BOISSIN, P; BOURSIER, E; LORIOLLE, F; DUHAMEL, L; CHARON, D; KIRILOVSKY, J			THE BISINDOLYLMALEIMIDE GF-109203X IS A POTENT AND SELECTIVE INHIBITOR OF PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SWISS 3T3 CELLS; CGP-41-251 SHOWS SELECTIVITY; INSULIN-RECEPTOR KINASE; ANTI-TUMOR ACTIVITY; HUMAN-PLATELETS; PHORBOL ESTERS; INOSITOL TRISPHOSPHATE; SIGNAL TRANSDUCTION; CELLULAR-REGULATION	Staurosporine is the most potent inhibitor of protein kinase C (PKC) described in the literature with a half-maximal inhibitory concentration (IC50) of 10 nM. Nevertheless, this natural product is poorly selective when assayed against other protein kinases. In order to obtain specific PKC inhibitors, a series of bisindolylmaleimides has been synthesized. Structure-activity relationship studies allowed the determination of the substructure responsible for conferring high potency and lack of selectivity in the staurosporine molecule. Several aminoalkyl bisindolylmaleimides were found to be potent and selective PKC inhibitors (IC50 values from 5 to 70 nm). Among these compounds GF 109203X has been chosen for further studies aiming at the characterization of this chemical family. GF 109203X was a competitive inhibitor with respect to ATP (K(i) = 14 +/- 3 nm) and displayed high selectivity for PKC as compared to five different protein kinases. We further determined the potency and specificity of GF 109203X in two cellular models: human platelets and Swiss 3T3 fibroblasts. GF 109203X efficiently prevented PKC-mediated phosphorylations of an M(r) = 47,000 protein in platelets and of an M(r) = 80,000 protein in Swiss 3T3 cells. In contrast, in the same models, the PKC inhibitor failed to prevent PKC-independent phosphorylations. GF 109203X inhibited collagen- and alpha-thrombin-induced platelet aggregation as well as collagen-triggered ATP secretion. However, ADP-dependent reversible aggregation was not modified. In Swiss 3T3 fibroblasts, GF 109203X reversed the inhibition of epidermal growth factor binding induced by phorbol 12,13-dibutyrate and prevented [H-3] thymidine incorporation into DNA, only when this was elicited by growth promoting agents which activate PKC. Our results illustrate the potential of GF 109203X as a tool for studying the involvement of PKC in signal transduction pathways.	LABS GLAXO,CTR RECH,BIOL LAB,25 AVE QUEBEC,F-91951 LES ULIS,FRANCE; LABS GLAXO,CTR RECH,CHIM LAB,F-91951 LES ULIS,FRANCE; UNIV ROUEN HAUTE NORMANDIE,CHIM ORGAN LAB,F-76134 MT ST AIGNAN,FRANCE	GlaxoSmithKline; GlaxoSmithKline; Universite de Rouen Normandie								BELL RL, 1980, J BIOL CHEM, V255, P1790; BERGMAN J, 1989, J ORG CHEM, V54, P824, DOI 10.1021/jo00265a020; Bergman J., 1988, STUDIES NATURAL PR A, V1, P3; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BRENNER M, 1988, TETRAHEDRON, V44, P2887, DOI 10.1016/S0040-4020(88)90025-7; BREWSTER JH, 1954, J AM CHEM SOC, V76, P6364, DOI 10.1021/ja01653a035; BROWN KD, 1984, BIOCHEM BIOPH RES CO, V123, P377, DOI 10.1016/0006-291X(84)90424-8; BROWN KD, 1976, BIOCHEM BIOPH RES CO, V86, P1037; BURNS DJ, 1990, J BIOL CHEM, V265, P12044; COHEN P, 1983, METHOD ENZYMOL, V99, P243; CORBIN JD, 1973, J BIOL CHEM, V248, P1813; DANIEL JL, 1986, FEBS LETT, V206, P299, DOI 10.1016/0014-5793(86)81000-6; DAVIS PD, 1989, FEBS LETT, V259, P61, DOI 10.1016/0014-5793(89)81494-2; DAVIS RJ, 1984, J BIOL CHEM, V259, P8545; DICKER P, 1980, NATURE, V287, P607, DOI 10.1038/287607a0; DIXON M, 1953, BIOCHEM J, V55, P161, DOI 10.1042/bj0550161; DRAY A, 1988, NEUROSCI LETT, V91, P301, DOI 10.1016/0304-3940(88)90697-0; EK B, 1982, J BIOL CHEM, V257, P486; ERNEUX C, 1983, J BIOL CHEM, V258, P4137; ERUSALIMSKY JD, 1989, J CELL PHYSIOL, V141, P253, DOI 10.1002/jcp.1041410204; ESCRIBANO J, 1988, J CELL PHYSIOL, V137, P223, DOI 10.1002/jcp.1041370204; FISHER GJ, 1985, BIOCHEM BIOPH RES CO, V129, P958, DOI 10.1016/0006-291X(85)91984-9; FREIDENBERG GR, 1985, J BIOL CHEM, V260, P2444; GAMBLE JR, 1988, J IMMUNOL METHODS, V109, P175, DOI 10.1016/0022-1759(88)90240-2; GERRARD JM, 1989, BLOOD, V74, P2405; HANNUN YA, 1988, J BIOL CHEM, V263, P5124; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1984, METHOD ENZYMOL, V141, P287; HASLAM RJ, 1977, BIOCHEM BIOPH RES CO, V77, P714, DOI 10.1016/S0006-291X(77)80037-5; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; HUANG KP, 1988, J BIOL CHEM, V263, P14839; HUBERT JC, 1975, TETRAHEDRON, V31, P1437, DOI 10.1016/0040-4020(75)87076-1; IMAOKA T, 1983, J BIOL CHEM, V258, P1404; JAKEN S, 1987, METHOD ENZYMOL, V141, P275; JOHNSON JA, 1990, BIOCHEM J, V268, P507, DOI 10.1042/bj2680507; KAIBUCHI K, 1983, J BIOL CHEM, V258, P6701; KARNIGUIAN A, 1990, BIOCHEM J, V268, P325, DOI 10.1042/bj2680325; KASE H, 1986, J ANTIBIOT, V39, P1059, DOI 10.7164/antibiotics.39.1059; KASE H, 1987, BIOCHEM BIOPH RES CO, V142, P436, DOI 10.1016/0006-291X(87)90293-2; KAWAHARA Y, 1980, BIOCHEM BIOPH RES CO, V97, P309, DOI 10.1016/S0006-291X(80)80169-0; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1985, J BIOL CHEM, V260, P1358; LEE LS, 1978, SCIENCE, V202, P313, DOI 10.1126/science.308698; LOOMIS CR, 1988, J BIOL CHEM, V263, P1682; LOVE JT, 1989, BIOCHEM BIOPH RES CO, V162, P138, DOI 10.1016/0006-291X(89)91973-6; MAGUN BE, 1980, J BIOL CHEM, V255, P6373; MEKSURIYEN D, 1988, J NAT PROD, V51, P884, DOI 10.1021/np50059a012; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; NAKA M, 1983, NATURE, V306, P490, DOI 10.1038/306490a0; NAKA M, 1988, ARCH BIOCHEM BIOPHYS, V261, P235, DOI 10.1016/0003-9861(88)90337-2; NAKANISHI S, 1986, J ANTIBIOT, V39, P1066; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1989, JAMA-J AM MED ASSOC, V262, P1826, DOI 10.1001/jama.262.13.1826; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OSADA H, 1990, J ANTIBIOT, V43, P163, DOI 10.7164/antibiotics.43.163; PATEL G, 1989, CELL SIGNAL, V1, P227, DOI 10.1016/0898-6568(89)90040-5; ROZENGURT E, 1983, P NATL ACAD SCI-BIOL, V80, P7244, DOI 10.1073/pnas.80.23.7244; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; ROZENGURT E, 1975, P NATL ACAD SCI USA, V72, P4492, DOI 10.1073/pnas.72.11.4492; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; SAKO T, 1988, CANCER RES, V48, P4646; SARSTEDT B, 1983, HETEROCYCLES, V20, P469; SEKIGUCHI K, 1988, J BIOCHEM-TOKYO, V103, P759, DOI 10.1093/oxfordjournals.jbchem.a122343; SHOYAB M, 1979, NATURE, V279, P387, DOI 10.1038/279387a0; SIESS W, 1988, BIOCHEM J, V255, P309; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SMITH CD, 1988, BIOCHEM BIOPH RES CO, V156, P1250, DOI 10.1016/S0006-291X(88)80767-8; STADTMAUER L, 1986, J BIOL CHEM, V261; STUMPO DJ, 1989, P NATL ACAD SCI USA, V86, P4012, DOI 10.1073/pnas.86.11.4012; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; TYERS M, 1989, J CELL BIOCHEM, V40, P133, DOI 10.1002/jcb.240400202; Vedejs E., 1975, ORG REACTIONS, V22, P401; WALTON GM, 1987, ANAL BIOCHEM, V161, P425, DOI 10.1016/0003-2697(87)90471-4; WATSON SP, 1988, BIOCHEM J, V249, P345, DOI 10.1042/bj2490345; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YASUZAWA T, 1986, J ANTIBIOT, V39, P1072, DOI 10.7164/antibiotics.39.1072; ZACHARY I, 1986, J CELL BIOL, V102, P2211, DOI 10.1083/jcb.102.6.2211	82	2464	2511	0	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15771	15781						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874734				2022-12-25	WOS:A1991GB97700041
J	FUNDERBURGH, JL; FUNDERBURGH, ML; MANN, MM; CONRAD, GW				FUNDERBURGH, JL; FUNDERBURGH, ML; MANN, MM; CONRAD, GW			UNIQUE GLYCOSYLATION OF 3 KERATAN SULFATE PROTEOGLYCAN ISOFORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNEAL PROTEOKERATAN SULFATE; ENDO-BETA-GALACTOSIDASE; LINKAGE-REGION; CORE PROTEIN; NITROCELLULOSE; GLYCOPROTEINS; HETEROGENEITY; BINDING; CHAINS; ACID	Recent work demonstrates isoforms of bovine corneal keratan sulfate proteoglycan containing structurally unique core proteins of 25 and 37 kDa (Funderburgh, J., and Conrad, G. (1990) J. Biol. Chem. 265, 8297-8303). In the current study, two forms (37A and 37B) of the 37-kDa protein were separated by ion-exchange chromatography after removal of keratan sulfate with endo-beta-galactosidase. Keratan sulfate linkage sites in core proteins were labeled with UDP-[H-3] galactose using galactosyltransferase. Labeled proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and analyzed by tryptic digestion and reversed-phase chromatography. The 37A protein has three keratan sulfate-linkage sites, and the 37B and 25-kDa proteins each contain one linkage site. Reversed-phase tryptic maps of the three proteins differed in total peptide profile and in glycosylated peptides labeled with periodate-[H-3]-NaBH4. Tryptic mapping of the two 37-kDa isoforms after deglycosylation showed differences in total tryptic peptides, in peptides labeled with [C-14]iodoacetic acid, and in peptides recognized by antibodies to a mixture of the 37-kDa cores. Antibody to a synthetic peptide with N-terminal sequence obtained from mixed 37-kDa cores reacted exclusively with the 37B isoform. These results show that bovine corneal keratan sulfate proteoglycan has three different core proteins each with distinct glycosylation and unique primary structure.			FUNDERBURGH, JL (corresponding author), KANSAS STATE UNIV AGR & APPL SCI, DIV BIOL, ACKERT HALL, MANHATTAN, KS 66506 USA.				NATIONAL EYE INSTITUTE [R01EY000952] Funding Source: NIH RePORTER; NEI NIH HHS [EY00952] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; AXELSSON I, 1975, BIOCHEM J, V145, P491, DOI 10.1042/bj1450491; BLOCHBERGER TC, 1991, INVEST OPHTH VIS SCI, V32, P966; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CONRAD GW, 1982, J BIOL CHEM, V257, P464; EDGE ASB, 1981, ANAL BIOCHEM, V118, P131, DOI 10.1016/0003-2697(81)90168-8; EDMONDSON JM, 1988, BIOTECHNIQUES, V6, P868; FUKUDA MN, 1981, J BIOL CHEM, V256, P3900; FUNDERBURGH JL, 1986, DEV BIOL, V116, P267, DOI 10.1016/0012-1606(86)90130-2; FUNDERBURGH JL, 1987, J BIOL CHEM, V262, P11634; FUNDERBURGH JL, 1990, J BIOL CHEM, V265, P8297; KLEIN DJ, 1988, J CELL BIOL, V106, P963, DOI 10.1083/jcb.106.3.963; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; NAKAZAWA K, 1983, ARCH BIOCHEM BIOPHYS, V222, P105, DOI 10.1016/0003-9861(83)90507-6; NILSSON B, 1983, J BIOL CHEM, V258, P6056; OBEN M, 1987, BIOCHEM J, V248, P85; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; SAITOH F, 1987, J BIOCHEM-TOKYO, V101, P453, DOI 10.1093/oxfordjournals.jbchem.a121931; SPILLMANN D, 1987, J NEUROCHEM, V49, P874, DOI 10.1111/j.1471-4159.1987.tb00975.x; STEIN T, 1982, H-S Z PHYSIOL CHEM, V363, P825, DOI 10.1515/bchm2.1982.363.2.825; Stewart JM, 1984, SOLID PHASE PEPTIDE; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANLENTEN L, 1971, METHOD ENZYMOL, V28, P209; VIITALA J, 1984, EUR J BIOCHEM, V138, P393, DOI 10.1111/j.1432-1033.1984.tb07928.x; WHITEHEART SW, 1989, METHOD ENZYMOL, V179, P82	25	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14226	14231						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907274				2022-12-25	WOS:A1991FZ35100019
J	NADER, HB				NADER, HB			CHARACTERIZATION OF A HEPARAN-SULFATE AND A PECULIAR CHONDROITIN 4-SULFATE PROTEOGLYCAN FROM PLATELETS - INHIBITION OF THE AGGREGATION PROCESS BY PLATELET CHONDROITIN SULFATE PROTEOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVOBACTERIUM-HEPARINUM; CORE PROTEIN; GLYCOSAMINOGLYCANS; PURIFICATION; CELL; RAT; RELEASE; CARRIER; TISSUE; ACID	A high molecular weight chondroitin sulfate proteoglycan (M(r) 240,000) is released from platelet surface during aggregation induced by several pharmacological agents. Some details on the structure of this compound are reported. Beta-elimination with alkali and borohydride produces chondroitin sulfate chains with a molecular weight of 40,000. The combined results indicate a proteoglycan molecule containing 5-6 chondroitin sulfate chains and a protein core rich in serine and glycine residues. Degradation with chondroitinase AC shows that a 4-sulfated disaccharide is the only disaccharide released from this chondroitin sulfate, characterizing it as a chondroitin 4-sulfate homopolymer. It is shown that this proteoglycan inhibits the aggregation of platelets induced by ADP. Analysis of the sulfated glycosaminoglycans not released during aggregation revealed the presence of a heparan sulfate in the platelets. Degradation by heparitinases I and II yielded the four disaccharide units of heparan sulfates: N,O-disulfated disaccharide, N-sulfated disaccharide, N-acetylated 6-sulfated disaccharide, and N-acetylated disaccharide. The possible role of the sulfated glycosaminoglycans on cell-cell interaction is discussed in view of the present findings.			NADER, HB (corresponding author), ESCOLA PAULISTA MED SCH,DEPT BIOQUIM,CAIXA POSTAL 20372,BR-04023 SAO PAULO,BRAZIL.		Nader, Helena Bonciani/D-9253-2012	NADER, HELENA/0000-0002-7569-2166				ANDERSON B, 1958, P SOC EXP BIOL MED, V99, P765; BARBER AJ, 1972, BIOCHIM BIOPHYS ACTA, V286, P312, DOI 10.1016/0304-4165(72)90267-X; CHOI HU, 1975, BIOCHEM J, V151, P543, DOI 10.1042/bj1510543; CIFONELLI JA, 1960, J BIOL CHEM, V235, P3283; DIETRICH CP, 1984, BRAZ J MED BIOL RES, V17, P5; DIETRICH CP, 1983, BIOCHEM BIOPH RES CO, V111, P865, DOI 10.1016/0006-291X(83)91379-7; DIETRICH CP, 1974, BIOCHIM BIOPHYS ACTA, V343, P34, DOI 10.1016/0304-4165(74)90237-2; DISCHE Z, 1947, J BIOL CHEM, V167, P189; GALLAGHER JT, 1986, BIOCHEM J, V236, P313, DOI 10.1042/bj2360313; HAGEN I, 1972, BIOCHIM BIOPHYS ACTA, V273, P141, DOI 10.1016/0304-4165(72)90201-2; HARDINGHAM TE, 1974, BIOCHEM J, V139, P565, DOI 10.1042/bj1390565; HASSELL JR, 1986, ANNU REV BIOCHEM, V55, P539, DOI 10.1146/annurev.bi.55.070186.002543; HORNER AA, 1971, J BIOL CHEM, V246, P231; HUANG SS, 1982, J BIOL CHEM, V257, P1546; KOLSET SO, 1987, EXP CELL RES, V168, P318, DOI 10.1016/0014-4827(87)90004-8; MACPHERSON GG, 1972, J CELL SCI, V10, P705; MICHELACCI YM, 1976, J BIOL CHEM, V251, P1154; MICHELACCI YM, 1976, BIOCHIM BIOPHYS ACTA, V451, P436, DOI 10.1016/0304-4165(76)90138-0; NADER HB, 1987, P NATL ACAD SCI USA, V84, P3565, DOI 10.1073/pnas.84.11.3565; NADER HB, 1984, J BIOL CHEM, V259, P1431; NADER HB, 1990, J BIOL CHEM, V265, P16807; NADER HB, 1977, ANAL BIOCHEM, V78, P112, DOI 10.1016/0003-2697(77)90014-8; NADER HB, 1981, GLYCOCONJUGATES, P339; RONDLE CJM, 1955, BIOCHEM J, V61, P586, DOI 10.1042/bj0610586; SAITO H, 1968, J BIOL CHEM, V243, P1536; SAMPAIO LO, 1981, J BIOL CHEM, V256, P9205; SELDIN DC, 1985, J BIOL CHEM, V260, P1131; STEVENS RL, 1985, J BIOL CHEM, V260, P4194; VARGAFTIG BB, 1974, PROSTAG OTH LIPID M, V8, P133, DOI 10.1016/0090-6980(74)90076-8; WARD JV, 1979, BIOCHIM BIOPHYS ACTA, V583, P196, DOI 10.1016/0304-4165(79)90427-6	30	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10518	10523						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1903792				2022-12-25	WOS:A1991FP08600079
J	KALTHOFF, H; ROEDER, C; HUMBURG, I; THIELE, HG; GRETEN, H; SCHMIEGEL, W				KALTHOFF, H; ROEDER, C; HUMBURG, I; THIELE, HG; GRETEN, H; SCHMIEGEL, W			MODULATION OF PLATELET-DERIVED GROWTH FACTOR-A-CHAIN AND FACTOR-B-CHAIN C-SIS MESSENGER-RNA BY TUMOR-NECROSIS-FACTOR AND OTHER AGENTS IN ADENOCARCINOMA CELLS	ONCOGENE			English	Article							SMOOTH-MUSCLE CELLS; PROTEIN KINASE-C; ENDOTHELIAL-CELLS; HUMAN-FIBROBLASTS; PANCREATIC ADENOCARCINOMA; MOLECULAR-CLONING; GENE-EXPRESSION; FACTOR RECEPTOR; PDGF; LINES	Human Platelet Derived Growth Factors (PDGF) are potent mitogens for mesenchymal cells and encoded by two related genes, the A- (or 1-) and B- (or 2-) chain. The latter is known as the human homolog (c-sis) of the v-sis oncogene. We investigated the expression and cytokine-mediated regulation of PDGF A- and B-chain mRNA in endoderm-derived cells, i.e. cultured human pancreatic adenocarcinoma cells. Northern blot analysis revealed that out of 14 cell lines 11 were positive for the A-chain and 10 for the B-chain. Tumor Necrosis Factor (TNF) -alpha and -beta, but not Interferon (IFN) -gamma, drastically upregulate the mRNA levels for PDGF B-chain and for the A-chain in a dose-dependent manner in nearly every pancreatic tumor cell line investigated (n = 6). With respect to the signal pathway stimulated by TNF, no evidence emerged for an activation of protein kinase A. The inhibition of protein kinase C by staurosporine (in the absence or presence of TNF) as well as its stimulation by PMA resulted in an increased mRNA level for the B-chain, indicating a functional role of PKC in this system. Furthermore, time course experiments and Cycloheximide treatment showed that the A- and B-chain mRNA are regulated by different mechanisms in transformed epithelial cells. Irrespective of these differences, the sum of their biological functions may contribute to the phenomenon of desmoplasia in pancreatic tumors by epithelial/mesenchymal interactions.			KALTHOFF, H (corresponding author), UNIV HAMBURG,MED KLIN 1,IMMUNOL ABT,MARTINSTR 52,W-2000 HAMBURG 20,GERMANY.		Kalthoff, Holger/B-1618-2010					AGGARWAL BB, 1984, THYMIC HORMONES LYMP, P235; ALITALO R, 1987, EMBO J, V6, P1213, DOI 10.1002/j.1460-2075.1987.tb02356.x; BETSHOLTZ C, 1984, CELL, V39, P447, DOI 10.1016/0092-8674(84)90452-5; BIRD TA, 1989, J IMMUNOL, V142, P126; BRONZERT DA, 1987, P NATL ACAD SCI USA, V84, P5763, DOI 10.1073/pnas.84.16.5763; CAMPS JL, 1990, P NATL ACAD SCI USA, V87, P75, DOI 10.1073/pnas.87.1.75; CHEN WH, 1982, IN VITRO CELL DEV B, V18, P24; COLAMONICI OR, 1986, MOL CELL BIOL, V6, P1847, DOI 10.1128/MCB.6.5.1847; DANIEL TO, 1986, J BIOL CHEM, V261, P9579; FAHRER C, 1989, INT J CANCER, V44, P652, DOI 10.1002/ijc.2910440416; FOGH J, 1977, JNCI-J NATL CANCER I, V59, P221, DOI 10.1093/jnci/59.1.221; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FRIEDMAN BA, 1990, CANCER RES, V50, P533; GIARD DJ, 1973, J NATL CANCER I, V51, P1417, DOI 10.1093/jnci/51.5.1417; GIESE NA, 1987, SCIENCE, V236, P1315, DOI 10.1126/science.3035718; GULLBERG D, 1990, EXP CELL RES, V186, P264, DOI 10.1016/0014-4827(90)90305-T; HAJJAR KA, 1987, J EXP MED, V166, P235, DOI 10.1084/jem.166.1.235; HELDIN CH, 1989, TRENDS GENET, V5, P108, DOI 10.1016/0168-9525(89)90040-1; HELDIN NE, 1988, P NATL ACAD SCI USA, V85, P9302, DOI 10.1073/pnas.85.23.9302; KAKU M, 1980, GANN, V71, P596; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MAJESKY MW, 1988, P NATL ACAD SCI USA, V85, P1524, DOI 10.1073/pnas.85.5.1524; MELLSTROM K, 1988, EXP CELL RES, V177, P347, DOI 10.1016/0014-4827(88)90468-5; METZGAR RS, 1982, CANCER RES, V42, P601; MORGAN RT, 1980, INT J CANCER, V25, P591, DOI 10.1002/ijc.2910250507; MOTOYAMA T, 1983, JPN J CANCER RES, V74, P679; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NISTER M, 1988, CANCER RES, V48, P3910; NISTER M, 1988, CELL, V52, P791, DOI 10.1016/0092-8674(88)90421-7; NOGUCHI P, 1979, IN VITRO CELL DEV B, V15, P401; OKABE T, 1983, CANCER, V51, P662, DOI 10.1002/1097-0142(19830215)51:4<662::AID-CNCR2820510419>3.0.CO;2-X; PALOMBELLA VJ, 1988, J CELL PHYSIOL, V135, P23, DOI 10.1002/jcp.1041350104; PAULSSON Y, 1989, EXP CELL RES, V180, P490, DOI 10.1016/0014-4827(89)90075-X; PAULSSON Y, 1987, NATURE, V328, P715, DOI 10.1038/328715a0; PIMENTEL E, 1987, HORMONES GROWTH FACT, P195; RAINES EW, 1989, SCIENCE, V243, P393, DOI 10.1126/science.2783498; RATNER L, 1989, NUCLEIC ACIDS RES, V17, P4101, DOI 10.1093/nar/17.11.4101; REILLY CF, 1989, BIOCHEM BIOPH RES CO, V160, P1047, DOI 10.1016/S0006-291X(89)80108-1; RO J, 1989, ONCOGENE, V4, P351; ROSS R, 1989, LANCET, V1, P1179; ROZENGURT E, 1985, INT J CANCER, V36, P247, DOI 10.1002/ijc.2910360218; SARIBAN E, 1988, J CLIN INVEST, V82, P1157, DOI 10.1172/JCI113712; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHEURICH P, 1989, J EXP MED, V170, P947, DOI 10.1084/jem.170.3.947; SCHMIEGEL WH, 1988, PANCREAS, V3, P180, DOI 10.1097/00006676-198804000-00012; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; SUZUKI H, 1989, AM J PATHOL, V134, P35; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; THORENS B, 1987, CELL, V48, P671, DOI 10.1016/0092-8674(87)90245-5; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; WEIMA SM, 1990, EXP CELL RES, V186, P324, DOI 10.1016/0014-4827(90)90312-X; WILLIAMS LT, 1988, MECH CONTROL GENE EX, P351; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; ZHANG YH, 1988, P NATL ACAD SCI USA, V85, P6802, DOI 10.1073/pnas.85.18.6802	58	40	42	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JUN	1991	6	6					1015	1021						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906154				2022-12-25	WOS:A1991GU62200017
J	AMAR, S; SIRES, B; SABSAY, B; CLOHISY, J; VEIS, A				AMAR, S; SIRES, B; SABSAY, B; CLOHISY, J; VEIS, A			THE ISOLATION AND PARTIAL CHARACTERIZATION OF A RAT INCISOR DENTIN MATRIX POLYPEPTIDE WITH INVITRO CHONDROGENIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN; IMMOBILIZED PH GRADIENTS; GROWTH FACTOR-BETA; 2-DIMENSIONAL ANALYSIS; TISSUE PROTEINS; CELL FRACTIONS; PURIFICATION; MUSCLE; DIFFERENTIATION; METHODOLOGY	In vivo implants of demineralized dentin matrix into muscle induce the formation of bone within the muscle. As with bone matrix implants, the bone induction appears to follow a chondrogenic pathway. Outgrowth cells from explants of neonatal rat muscle respond to bone matrix, in vitro, by expressing a heightened synthesis of sulfated proteoglycans and type II collagen, phenotypic of cartilage. The in vitro cell culture system has been used as an assay to monitor the isolation of the factor responsible for expression of this phenotypic transformation. Soluble proteins extracted from rat incisor dentin matrix during demineralization with EDTA, and not precipitable with 1.0 M CaCl2, were active in the in vitro system. The active extract was fractionated by Sephacryl S-100 chromatography in 6 M guanidine HCl, isoelectric focusing in Immobilines, and by reverse phase high performance liquid chromatography. All fractions were assayed for activity at every stage. The final active fraction from the reverse phase chromatography on a Zorbax Poly-F column was purified to homogeneity, and yielded a single spot on two-dimensional gel electrophoresis. The component, RP-4, had pI 5.4-5.5, and an apparent M(r) 6,000-10,000, based on globular protein standards. Maximal activity with respect to both sulfate incorporation into proteoglycan and production of type II collagen was in the 1.0-10 ng/ml range. The RP-4 had a unique amino-terminal amino sequence and was rich in Gly, Pro, Glx, and Ala residues. It was different from transforming growth factor-beta and the bone morphogenetic protein family of proteins in these essential features.	NORTHWESTERN UNIV,DIV ORAL BIOL,CONNECT TISSUE RES LAB,CHICAGO,IL 60611	Northwestern University				Amar, Salomon/0000-0002-0017-5930	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE001374] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008525, R37DE001374] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 01374, DE 08525] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AMAR S, 1989, DIFFERENTIATION, V41, P56, DOI 10.1111/j.1432-0436.1989.tb00732.x; ANDERSON NG, 1978, ANAL BIOCHEM, V85, P331, DOI 10.1016/0003-2697(78)90229-4; ANDERSON NL, 1978, ANAL BIOCHEM, V85, P341, DOI 10.1016/0003-2697(78)90230-0; ASSOIAN RK, 1983, J BIOL CHEM, V258, P7155; BENYA PD, 1979, ARCH BIOCHEM BIOPHYS, V192, P327, DOI 10.1016/0003-9861(79)90100-0; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BJELLQVIST B, 1982, J BIOCHEM BIOPH METH, V6, P317, DOI 10.1016/0165-022X(82)90013-6; BROWNELL AG, 1988, CONNECT TISSUE RES, V17, P261, DOI 10.3109/03008208809017477; BROWNELL AG, 1990, CONNECT TISSUE RES, V24, P13, DOI 10.3109/03008209009152418; BUTLER WT, 1981, COLLAGEN REL RES, V1, P187; EK K, 1983, J BIOCHEM BIOPH METH, V8, P135, DOI 10.1016/0165-022X(83)90040-4; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; HUGGINS C, 1970, J EXP MED, V132, P1250, DOI 10.1084/jem.132.6.1250; INOUE T, 1986, J DENT RES, V65, P12, DOI 10.1177/00220345860650010101; KAWAI T, 1989, J DENT RES, V68, P1069, DOI 10.1177/00220345890680060301; KOSKINEN KP, 1985, CONNECT TISSUE RES, V14, P141, DOI 10.3109/03008208509015020; KUBOKI Y, 1979, J DENT RES, V58, P1926, DOI 10.1177/00220345790580092001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYNE R, 1976, P NATL ACAD SCI USA, V73, P1674, DOI 10.1073/pnas.73.5.1674; NATHANSON MA, 1985, CLIN ORTHOP RELAT R, V200, P142; PRICE PA, 1985, CHEM BIOL MINERALIZE, P159; RUCH JV, 1982, DIFFERENTIATION, V21, P7, DOI 10.1111/j.1432-0436.1982.tb01187.x; SAARNI H, 1977, ANAL BIOCHEM, V81, P40, DOI 10.1016/0003-2697(77)90596-6; SAMPATH TK, 1990, J BIOL CHEM, V265, P13198; SEYEDIN SM, 1987, J BIOL CHEM, V262, P1946; SOMERMAN MJ, 1987, J DENT RES, V66, P1551, DOI 10.1177/00220345870660100801; TSAY TG, 1985, BIOCHEMISTRY-US, V24, P6363, DOI 10.1021/bi00344a007; URIST MR, 1984, P NATL ACAD SCI-BIOL, V81, P371, DOI 10.1073/pnas.81.2.371; URIST MR, 1971, J DENT RES, V50, P1392, DOI 10.1177/00220345710500060601; URIST MR, 1983, SCIENCE, V220, P680, DOI 10.1126/science.6403986; URIST MR, 1965, SCIENCE, V150, P893, DOI 10.1126/science.150.3698.893; URIST MR, 1973, P NATL ACAD SCI USA, V70, P3511, DOI 10.1073/pnas.70.12.3511; URIST MR, 1985, CHEM BIOL MINERALIZE, P62; VEIS A, 1989, CONNECT TISSUE RES, V23, P137, DOI 10.3109/03008208909002413; VEIS A, 1990, BIOMATERIALS, V11, P35; WANG EA, 1988, P NATL ACAD SCI USA, V85, P9484, DOI 10.1073/pnas.85.24.9484; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; ZLABINGER GJ, 1988, AGENTS ACTIONS, V23, P45, DOI 10.1007/BF01967183	39	28	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8609	8618						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1902476				2022-12-25	WOS:A1991FK44100097
J	IZUMI, T; TAMEMOTO, H; NAGAO, M; KADOWAKI, T; TAKAKU, F; KASUGA, M				IZUMI, T; TAMEMOTO, H; NAGAO, M; KADOWAKI, T; TAKAKU, F; KASUGA, M			INSULIN AND PLATELET-DERIVED GROWTH-FACTOR STIMULATE PHOSPHORYLATION OF THE C-RAF PRODUCT AT SERINE AND THREONINE RESIDUES IN INTACT-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; 3T3 CELLS; S6 KINASE; RECEPTOR; ONCOGENE; REQUIREMENT; ACTIVATION; PP60C-SRC; MEMBRANE	We have examined the phosphorylation of the serine/threonine kinase, the product of c-raf proto-oncogene in response to insulin or platelet-derived growth factor in intact cells. Both insulin and platelet-derived growth factor stimulated phosphorylation of the c-raf protein about 2- to 3-fold. The phosphorylation occurred exclusively on serine and threonine residues; phosphotyrosine was not detected. In immune-complex kinase assays, treatment with insulin, and platelet-derived growth factor increased autophosphorylation of the c-raf kinase, suggesting activation of its kinase activity. To investigate whether the phosphorylation of the c-raf protein in intact cells results from an autophosphorylation event or from the phosphorylation by other cellular kinase(s), we replaced lysine 375 in the putative ATP-binding domain of the c-raf protein with alanine using oligonucleotide site-directed mutagenesis and expressed the mutated protein in NIH3T3 cells. The substitution resulted in the inactivation of the serine/threonine-specific autophosphorylation in immune-complex kinase assays. In intact cells, however, although phosphorylation of the mutant protein in response to insulin and platelet-derived growth factor occurred to a lesser extent than that of the wild-type protein, the phosphopeptide maps were indistinguishable. These results suggest that serine/threonine phosphorylation might be responsible for the activation of c-raf kinase upon treatment of cells with insulin and platelet-derived growth factor, and most of the phosphate associated with the c-raf protein results from its phosphorylation by as yet uncharacterized cellular serine/threonine kinase(s).	NATL CANC CTR,RES INST,DIV CARCINOGENESIS,CHUO KU,TOKYO 104,JAPAN	National Cancer Center - Japan	IZUMI, T (corresponding author), UNIV TOKYO,FAC MED,DEPT INTERNAL MED 3,7-3-1 HONGO,BUNKYO KU,TOKYO 113,JAPAN.							AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BALLOU LM, 1988, P NATL ACAD SCI USA, V85, P7154, DOI 10.1073/pnas.85.19.7154; BLACKSHEAR PJ, 1990, J BIOL CHEM, V265, P12131; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; GOULD KL, 1988, MOL CELL BIOL, V8, P3345, DOI 10.1128/MCB.8.8.3345; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HOFMANN C, 1989, ENDOCRINOLOGY, V124, P257, DOI 10.1210/endo-124-1-257; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; ISHIKAWA F, 1987, MOL CELL BIOL, V7, P1226, DOI 10.1128/MCB.7.3.1226; ISHIKAWA F, 1988, ONCOGENE, V3, P653; IZUMI T, 1987, J BIOL CHEM, V262, P1282; IZUMI T, 1988, J BIOL CHEM, V263, P10386; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MASSAGUE J, 1982, J BIOL CHEM, V257, P3958; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; MORRISON DK, 1989, CELL, V58, P649, DOI 10.1016/0092-8674(89)90100-1; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; PAVLAKIS GN, 1983, P NATL ACAD SCI-BIOL, V80, P397, DOI 10.1073/pnas.80.2.397; PIWNICAWORMS H, 1986, MOL CELL BIOL, V6, P2033, DOI 10.1128/MCB.6.6.2033; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHLUTZ AM, 1985, VIROLOGY, V146, P78; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	31	51	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7933	7939						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902232				2022-12-25	WOS:A1991FJ34200095
J	GRAHAM, A; BROWN, L; HEDGE, PJ; GAMMACK, AJ; MARKHAM, AF				GRAHAM, A; BROWN, L; HEDGE, PJ; GAMMACK, AJ; MARKHAM, AF			STRUCTURE OF THE HUMAN ALDOSE REDUCTASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE CONDUCTION-VELOCITY; POLYMERASE CHAIN-REACTION; ENZYMATIC AMPLIFICATION; DIABETES-MELLITUS; MESSENGER-RNA; INHIBITOR; SEQUENCE; DNA; PURIFICATION; SUPERFAMILY	The structure and sequence of the human gene for aldose reductase (AR) was determined by analysis of cDNA and genomic clones. The AR gene was independently isolated from two different cosmid libraries and the clones were characterized by restriction mapping, Southern blotting, and DNA sequencing. The gene extends over approximately 18 kilobases and consists of 10 exons giving rise to a 1,384 nucleotide mRNA (excluding the poly(A) tail). The human aldose reductase gene codes for a 316-amino acid protein with a molecular mass of 35,858 daltons. The size range for the exons is 82-168 base pairs (bp), whereas that for the introns is 325 to about 7,160 bp. A major site of transcription initiation in liver was mapped to an A residue 31 nucleotides upstream from the A of the ATG initiation codon. The promotor region of the gene contains a TATA (TATTTA) box and a CCAAT box which are located 37 and 104 nucleotides upstream, respectively, from the transcription initiation site. We have found four Alu elements in the AR gene; two are found in intron 1 and one each in intron 4 and intron 9.			GRAHAM, A (corresponding author), ICI PLC,PHARMACEUT,DEPT BIOTECHNOL,ALDERLEY PK,MACCLESFIELD SK10 4TG,CHESHIRE,ENGLAND.							AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEYERMEARS A, 1986, PHARMACOLOGY, V32, P52, DOI 10.1159/000138152; BLAKE C, 1983, NATURE, V306, P535, DOI 10.1038/306535a0; BOHREN KM, 1989, J BIOL CHEM, V264, P9547; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CARPER D, 1987, FEBS LETT, V220, P209, DOI 10.1016/0014-5793(87)80905-5; CHEN EY, 1985, DNA NY, V4, P1650; CHUNG S, 1989, J BIOL CHEM, V264, P14775; CROSS SH, 1986, GENE, V49, P9, DOI 10.1016/0378-1119(86)90381-1; EHRICH E, 1987, GENE, V57, P229, DOI 10.1016/0378-1119(87)90126-0; ENGERMAN RL, 1984, DIABETES, V33, P97, DOI 10.2337/diabetes.33.1.97; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; GRAHAM A, 1989, NUCLEIC ACIDS RES, V17, P8368, DOI 10.1093/nar/17.20.8368; GRAHAM A, IN PRESS HUMAN GENT; GRUNDMANN U, 1990, DNA CELL BIOL, V9, P149, DOI 10.1089/dna.1990.9.149; JANSEN R, 1989, GENOMICS, V4, P198, DOI 10.1016/0888-7543(89)90300-5; KARIYA Y, 1987, GENE, V53, P1, DOI 10.1016/0378-1119(87)90087-4; KINOSHIT.JH, 1974, INVEST OPHTH VISUAL, V13, P713; NEWTON CR, 1988, NUCLEIC ACIDS RES, V16, P8233, DOI 10.1093/nar/16.17.8233; NISHIMURA C, 1990, J BIOL CHEM, V265, P9788; NISHIMURA C, 1987, J NEUROCHEM, V49, P290, DOI 10.1111/j.1471-4159.1987.tb03428.x; NISHIMURA C, 1988, POLYOL PATHWAY ITS R, P182; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; ROBISON WG, 1983, SCIENCE, V221, P1177, DOI 10.1126/science.6612330; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOMLINSON DR, 1982, NEUROSCI LETT, V31, P189, DOI 10.1016/0304-3940(82)90115-X; YUE DK, 1982, DIABETES, V31, P789, DOI 10.2337/diabetes.31.9.789	31	77	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6872	6877						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1901857				2022-12-25	WOS:A1991FG72700038
J	HURST, JS; BALAZY, M; BAZAN, HEP; BAZAN, NG				HURST, JS; BALAZY, M; BAZAN, HEP; BAZAN, NG			THE EPITHELIUM, ENDOTHELIUM, AND STROMA OF THE RABBIT CORNEA GENERATE (12S)-HYDROXYEICOSATETRAENOIC ACID AS THE MAIN LIPOXYGENASE METABOLITE IN RESPONSE TO INJURY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING FACTOR; TUMOR-CELL ADHESION; ARACHIDONIC-ACID; LEUKOCYTE; PRODUCTS; ALTERS	Previous work has shown that, shortly after rabbit corneas are injured, arachidonic acid metabolism is activated, and 12-hydroxyeicosatetraenoic acid (12-HETE) is one of the main products formed (Bazan, H. E. P., Birkle, D. L., Beuerman, R., and Bazan, N. G. (1985) Invest. Ophthalmol. & Visual Sci. 26, 474-480; Bazan, H. E. P. (1987) Invest. Ophthalmol. Visual Sci. 28, 314-319). In order to determine whether this metabolite is a lipoxygenase product, anesthetized rabbit corneas injured in vivo, either cryogenically or by 1 M NaOH, were subsequently incubated in vitro with [C-14] arachidonic acid in the presence of indomethacin. 12-HETE was the main metabolite produced, as established by gas chromatography-mass spectrometry. The (R)- and (S)-enantiomers of novel naphthoyl-penta-fluorobenzoyl derivatives of 12-HETE were resolved by chiral-phase high performance liquid chromatography. The radiolabeled 12-HETE from whole cornea and from isolated epithelium, endothelium, or stroma eluted as a single peak co-chromatographing with the (S)-enantiomer and was detected both by UV absorbance at 234 nm and by radioactivity. In noninjured corneas a smaller peak of radiolabeled (12S)-HETE was also eluted from the chiral column. The stereo-chemistry was additionally confirmed by liquid chromatography-mass spectrometry. These studies suggest that (12S)-lipoxygenase is activated in the injured rabbit cornea.	LOUISIANA STATE UNIV,MED CTR,SCH MED,CTR EYE,DEPT OPHTHALMOL,2020 GRAVIER ST,SUITE B,NEW ORLEANS,LA 70112	Louisiana State University System			Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444; Balazy, Ph.D., Michael/0000-0003-0218-8820	NATIONAL EYE INSTITUTE [P30EY002377, R01EY004928] Funding Source: NIH RePORTER; NEI NIH HHS [EY04928, EY02377] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BARROW SE, 1987, PROSTAGLANDINS RELAT; BAZAN HEP, 1987, INVEST OPHTH VIS SCI, V28, P314; BAZAN HEP, 1985, INVEST OPHTH VIS SCI, V26, P474; BAZAN HEP, 1987, BIOCHEM BIOPH RES CO, V149, P915, DOI 10.1016/0006-291X(87)90495-5; BAZAN HEP, 1991, IN PRESS EXP EYE RES, V52; BAZAN HEP, 1989, OCULAR EFFECTS PROST, P73; BAZAN NG, 1990, LIPID MEDIATORS EYE, V5, P168; BRAQUET P, 1987, PHARMACOL REV, V39, P97; DEBOER TJ, 1963, ORG SYNTH, V4, P250; FALGUEYRET JP, 1988, BIOCHEM BIOPH RES CO, V156, P1083, DOI 10.1016/S0006-291X(88)80743-5; FALGUEYRET JP, 1990, FEBS LETT, V262, P197, DOI 10.1016/0014-5793(90)80188-O; GOETZL EJ, 1977, J CLIN INVEST, V59, P179, DOI 10.1172/JCI108617; GROSSI IM, 1989, CANCER RES, V49, P1029; HADGIAGAPIOU C, 1986, PROSTAGLANDINS, V31, P1135; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; HAWKINS DJ, 1988, ANAL BIOCHEM, V173, P456, DOI 10.1016/0003-2697(88)90214-X; HONN KV, 1989, FASEB J, V3, P2285, DOI 10.1096/fasebj.3.11.2673900; HURST J S, 1990, Investigative Ophthalmology and Visual Science, V31, P580; KRAGBALLE K, 1986, ARCH DERMATOL RES, V278, P449, DOI 10.1007/BF00455162; MAAS RL, 1981, P NATL ACAD SCI-BIOL, V78, P5523, DOI 10.1073/pnas.78.9.5523; MASFERRER JL, 1990, INVEST OPHTH VIS SCI, V31, P535; MURPHY RC, 1988, J BIOL CHEM, V263, P17197; NISHIZUKA Y, 1989, CANCER, V63, P1892, DOI 10.1002/1097-0142(19890515)63:10<1892::AID-CNCR2820631005>3.0.CO;2-Z; NUGTEREN DH, 1975, BIOCHIM BIOPHYS ACTA, V380, P299, DOI 10.1016/0005-2760(75)90016-8; PATERSON CA, 1984, EXP EYE RES, V39, P701, DOI 10.1016/0014-4835(84)90069-1; SCHWARTZMAN ML, 1987, P NATL ACAD SCI USA, V84, P8125, DOI 10.1073/pnas.84.22.8125; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; TSUDA T, 1985, FEBS LETT, V191, P205, DOI 10.1016/0014-5793(85)80009-0; TURK J, 1983, BIOCHIM BIOPHYS ACTA, V750, P78, DOI 10.1016/0005-2760(83)90206-0; WIGGINS RE, 1990, PROSTAGLANDINS, V40, P131, DOI 10.1016/0090-6980(90)90079-B; YOSHIMOTO T, 1982, BIOCHIM BIOPHYS ACTA, V713, P638	31	62	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6726	6730						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1901855				2022-12-25	WOS:A1991FG72700015
J	FAVREAU, LV; PICKETT, CB				FAVREAU, LV; PICKETT, CB			TRANSCRIPTIONAL REGULATION OF THE RAT NAD(P)H-QUINONE REDUCTASE GENE - IDENTIFICATION OF REGULATORY ELEMENTS CONTROLLING BASAL LEVEL EXPRESSION AND INDUCIBLE EXPRESSION BY PLANAR AROMATIC-COMPOUNDS AND PHENOLIC ANTIOXIDANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; AH RECEPTOR COMPLEX; QUINONE REDUCTASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; STRUCTURAL GENE; DT-DIAPHORASE; MESSENGER-RNA; CDNA CLONE; LIVER	We have identified two regions in the 5'-flanking sequence of the rat quinone reductase gene that contain xenobiotic responsive elements. The DNA sequence of the first region spans nucleotides -393 to -352 of the 5'-flanking region and shares sequence identity with the xenobiotic responsive element (XRE) described for the cytochrome P-450 CYPIA1 gene. The DNA sequence of the second region spans nucleotides -434 to -404 of the 5'-flanking region of the quinone reductase structural gene. When a synthetic oligonucleotide corresponding to nucleotides -434 to -404 was inserted in front of a heterologous promoter linked to the chloramphenicol acetyltransferase structural gene, an increase in basal level expression as well as responsiveness to beta-naphthoflavone and t-butylhydroquinone, but not 2,3,7,8-tetrachlorodibenzo-p-dioxin, was observed. The sequence, -434 to -404, did not have any sequence identity with the XRE but shared a large degree of identity with the antioxidant responsive element recently described for the rat glutathione S-transferase Ya subunit gene (Rushmore, T. H., King, R. G., Paulson, K. E., and Pickett, C. B. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3826-3830; Rushmore, T. H., and Pickett, C. B. (1990) J. Biol. Chem. 265, 14648-14653). These results indicate that the antioxidant responsive element can be distinguished functionally from the classical XRE and is also involved in the regulation of the quinone reductase gene by planar aromatic compounds and phenolic antioxidants.			FAVREAU, LV (corresponding author), MERCK FROSST CTR THERAPEUT RES,POB 1005,POINTE CLAIRE H9R 4P8,QUEBEC,CANADA.							BAYNEY RM, 1988, ARCH BIOCHEM BIOPHYS, V260, P847, DOI 10.1016/0003-9861(88)90516-4; BAYNEY RM, 1987, J BIOL CHEM, V262, P572; BAYNEY RM, 1989, J BIOL CHEM, V264, P21793; CHESIS PL, 1984, P NATL ACAD SCI-BIOL, V81, P1696, DOI 10.1073/pnas.81.6.1696; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHRISTMAN MF, 1989, P NATL ACAD SCI USA, V86, P3484, DOI 10.1073/pnas.86.10.3484; CLEWELL DB, 1972, J BACTERIOL, V110, P667, DOI 10.1128/JB.110.2.667-676.1972; COURTOIS G, 1988, P NATL ACAD SCI USA, V85, P7937, DOI 10.1073/pnas.85.21.7937; DELONG MJ, 1986, P NATL ACAD SCI USA, V83, P787; DENISON MS, 1989, J BIOL CHEM, V264, P16478; DENISON MS, 1988, J BIOL CHEM, V263, P17221; ERNSTER L, 1960, BIOCHEM BIOPH RES CO, V2, P88, DOI 10.1016/0006-291X(60)90193-5; ERNSTER L, 1967, METHOD ENZYMOL, V10, P309, DOI DOI 10.1016/0076-6879(67)10059-1; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HUANG MT, 1979, J BIOL CHEM, V254, P1223; KUMAKI K, 1977, J BIOL CHEM, V252, P157; LIND C, 1985, ARCH BIOCHEM BIOPHYS, V240, P226, DOI 10.1016/0003-9861(85)90027-X; LIND C, 1982, ARCH BIOCHEM BIOPHYS, V216, P178, DOI 10.1016/0003-9861(82)90202-8; Maniatis T., 1982, MOL CLONING; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NEUHOLD LA, 1989, MOL CELL BIOL, V9, P2378, DOI 10.1128/MCB.9.6.2378; PAULSON KE, 1990, MOL CELL BIOL, V10, P1841, DOI 10.1128/MCB.10.5.1841; PROCHASKA HJ, 1988, CANCER RES, V48, P4776; PROCHASKA HJ, 1985, P NATL ACAD SCI USA, V82, P8232, DOI 10.1073/pnas.82.23.8232; ROBERTSON JA, 1986, J BIOL CHEM, V261, P5794; RUSHMORE TH, 1990, J BIOL CHEM, V265, P14648; RUSHMORE TH, 1990, P NATL ACAD SCI USA, V87, P3826, DOI 10.1073/pnas.87.10.3826; STORZ G, 1990, SCIENCE, V248, P189, DOI 10.1126/science.2183352; TALALAY P, 1988, P NATL ACAD SCI USA, V85, P8261, DOI 10.1073/pnas.85.21.8261; TARTAGLIA LA, 1989, J MOL BIOL, V210, P709, DOI 10.1016/0022-2836(89)90104-6; TELAKOWSKIHOPKINS CA, 1988, P NATL ACAD SCI USA, V85, P1000, DOI 10.1073/pnas.85.4.1000; THOR H, 1982, J BIOL CHEM, V257, P2419; WHITLOCK JP, 1987, PHARMACOL REV, V39, P147; WILLIAMS JB, 1986, J BIOL CHEM, V261, P5524; WILLIAMS JB, 1984, ARCH BIOCHEM BIOPHYS, V232, P408, DOI 10.1016/0003-9861(84)90556-3	36	462	474	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4556	4561						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900296				2022-12-25	WOS:A1991FA69400082
J	LIJNEN, HR; VANHOEF, B; COLLEN, D				LIJNEN, HR; VANHOEF, B; COLLEN, D			ON THE REVERSIBLE INTERACTION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND WITH UROKINASE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							SINGLE-CHAIN UROKINASE; MURINE MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; PRO-UROKINASE; PURIFICATION; MUTAGENESIS; EXPRESSION; KINETICS; CLONING; MUTANTS	The reaction between plasminogen activators and plasminogen activator inhibitor-1 is characterized by an initial rapid formation of an inactive reversible complex. The second-order association rate constant (k1) of complex formation of recombinant two-chain tissue-type plasminogen activator (rt-PA) or recombinant two-chain urokinase-type plasminogen activator (rtcu-PA) by recombinant plasminogen activator inhibitor-1 (rPAI-1) is 2.9 +/- 0.4 x 10(7) M-1 s-1 (mean +/- S.D., n = 30) and 2.0 +/- 0.6 x 10(7) M-1 s-1 (n = 12), respectively. Different molecular forms of tissue- or urokinase-type plasminogen activator which do not form covalent complexes with rPAI-1, including rt-PA-Ala478 (rt-PA with the active-site Ser478 mutagenized to Ala) and anhydro-urokinase (rtcu-PA with the active-site Ser356 converted to dehydroalanine) reduced k1 in a concentration-dependent manner, compatible with 1:1 stoichiometric complex formation between rPAI-1 and these ligands. The apparent dissociation constant (K(D)) of the complex between rPAI-1 and rt-PA-Ala478, determined as the concentration of rt-PA-Ala478 which reduced k1 to 50% of its control value, was 3-5 nM. Corresponding concentrations of active-site-blocked two-chain rt-PA were 150-250-fold higher. The concentration of anhydro-urokinase which reduced k1 to 50% was 4-6 nM, whereas that of active-site-blocked rtcu-PA was 100-250-fold higher. Recombinant single-chain urokinase-type plasminogen activator had an apparent K(D) of about 2-mu-M. These results suggest that inhibition of rt-PA or rtcu-PA by rPAI-1 proceeds via a reversible high affinity interaction which does not require a functional active site but which is markedly reduced following inactivation of the enzymes with active-site titrants.			LIJNEN, HR (corresponding author), CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,CAMPUS GASTHUISBERG,O&N HEREST 49,B-3000 LOUVAIN,BELGIUM.		Lijnen, Roger/AAA-4085-2020					ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; DARRAS V, 1986, THROMB HAEMOSTASIS, V56, P411; GUENZLER W A, 1982, Hoppe-Seyler's Zeitschrift fuer Physiologische Chemie, V363, P133; HOLMES WE, 1985, BIO-TECHNOL, V3, P923, DOI 10.1038/nbt1085-923; HOLVOET P, 1985, THROMB HAEMOSTASIS, V54, P684; KRUITHOF EKO, 1984, BLOOD, V64, P907; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1984, THROMB RES, V34, P431, DOI 10.1016/0049-3848(84)90247-0; LIJNEN HR, 1986, BIOCHIM BIOPHYS ACTA, V884, P402, DOI 10.1016/0304-4165(86)90190-X; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; NELLES L, 1987, J BIOL CHEM, V262, P5682; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; PANNELL R, 1987, BLOOD, V69, P22; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; RUSSELL ME, 1990, J BIOL CHEM, V265, P2569; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; WALLEN P, 1982, BIOCHIM BIOPHYS ACTA, V719, P318, DOI 10.1016/0304-4165(82)90105-2; WHITE WF, 1966, BIOCHEMISTRY-US, V5, P2160, DOI 10.1021/bi00871a003; WIMAN B, 1978, EUR J BIOCHEM, V84, P573, DOI 10.1111/j.1432-1033.1978.tb12200.x; WUN TC, 1982, J BIOL CHEM, V257, P7262; WUN TC, 1989, J BIOL CHEM, V264, P7862; 1985, THROMB HAEMOSTASIS, V54, P893	26	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4041	4044						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900284				2022-12-25	WOS:A1991FA69400005
J	SENECA, S; PUNYAMMALEE, B; BAILLY, M; GHYSDAEL, J; CRABEEL, M				SENECA, S; PUNYAMMALEE, B; BAILLY, M; GHYSDAEL, J; CRABEEL, M			ETS1, WHEN FUSED TO THE GAL4 DNA-BINDING DOMAIN, EFFICIENTLY ENHANCES GALACTOSE PROMOTOR DEPENDENT GENE-EXPRESSION IN YEAST	ONCOGENE			English	Article							UPSTREAM ACTIVATING SEQUENCES; ONCOGENE C-ETS; SACCHAROMYCES-CEREVISIAE; PROTO-ONCOGENE; TRANSCRIPTIONAL ACTIVATOR; V-ETS; REGULATORY PROTEIN; TRANSFORMING GENE; LEUKEMIA VIRUSES; E26 RETROVIRUS	Ets1, the translation product of the c-ets1 proto-oncogene and the related Ets2 protein, act as sequence-specific transcriptional factors in transient transfection experiments in animal cells. We report here that in S. cerevisiae, expression of a lacZ test gene placed under the control of the GAL1 promoter is stimulated efficiently by a fusion protein in which the chicken Ets1 sequence starting from amino acid 37, is linked to the DNA binding domain of the yeast GAL4 transcriptional activator. This suggests that Ets1 contains one or more intrinsic transcription activation domain(s). However, the GAL4 integral Ets1 fusion protein was unable to restore growth of a gal4 deletion mutant on galactose, implying that the fusion product cannot substitute for GAL4 enhancement on all GAL genes.	VRIJE UNIV BRUSSELS, CERIA COOVI, EMILE GRYSONLAAN 1, B-1070 BRUSSELS, BELGIUM; INST PASTEUR, CNRS, UA 041160, INSERM, U186, F-59019 LILLE, FRANCE	Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille			GHYSDAEL, Jacques/F-3377-2013	Seneca, Sara/0000-0002-0853-9890				BEUG H, 1984, CELL, V39, P579, DOI 10.1016/0092-8674(84)90465-3; BOSSELUT R, 1990, IN PRESS EMBO J; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; BOULUKOS KE, 1990, GENE DEV, V4, P401, DOI 10.1101/gad.4.3.401; BOULUKOS KE, 1988, EMBO J, V7, P697, DOI 10.1002/j.1460-2075.1988.tb02865.x; BRAM RJ, 1986, EMBO J, V5, P603, DOI 10.1002/j.1460-2075.1986.tb04253.x; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHEN JH, 1985, MOL CELL BIOL, V5, P2993, DOI 10.1128/MCB.5.11.2993; CHEN JH, 1988, ONCOGENE RES, V2, P371; CHEVALLIER MR, 1980, GENE, V11, P11, DOI 10.1016/0378-1119(80)90082-7; CRABEEL M, 1983, EMBO J, V2, P205, DOI 10.1002/j.1460-2075.1983.tb01406.x; DUTERQUECOQUILLAUD M, 1988, ONCOGENE RES, V2, P335; FINLEY RL, 1989, MOL CELL BIOL, V9, P4282, DOI 10.1128/MCB.9.10.4282; FLICK JS, 1990, MOL CELL BIOL, V10, P4757, DOI 10.1128/MCB.10.9.4757; GEGONNE A, 1987, MOL CELL BIOL, V7, P806, DOI 10.1128/MCB.7.2.806; GHYSDAEL J, 1986, EMBO J, V5, P2251, DOI 10.1002/j.1460-2075.1986.tb04492.x; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; GOLAY J, 1988, CELL, V55, P1147, DOI 10.1016/0092-8674(88)90259-0; GRAF T, 1979, VIROLOGY, V99, P431, DOI 10.1016/0042-6822(79)90024-2; GUNTHER CV, 1990, GENE DEV, V4, P667, DOI 10.1101/gad.4.4.667; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; JOHNSTON M, 1987, MICROBIOL REV, V51, P458, DOI 10.1128/MMBR.51.4.458-476.1987; JOHNSTON M, 1990, Yeast, V6, pS16; JOHNSTON SA, 1982, P NATL ACAD SCI-BIOL, V79, P6971, DOI 10.1073/pnas.79.22.6971; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KALKBRENNER F, 1990, ONCOGENE, V5, P657; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LEPRINCE D, 1983, NATURE, V306, P395, DOI 10.1038/306395a0; LEPRINCE D, 1988, J VIROL, V62, P3233, DOI 10.1128/JVI.62.9.3233-3241.1988; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MOSCOVICI C, 1981, VIROLOGY, V113, P765, DOI 10.1016/0042-6822(81)90205-1; MYLIN LM, 1989, GENE DEV, V3, P1157, DOI 10.1101/gad.3.8.1157; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NUNN MF, 1983, NATURE, V306, P391, DOI 10.1038/306391a0; NUNN MF, 1989, J VIROL, V63, P398, DOI 10.1128/JVI.63.1.398-402.1989; POGNONEC P, 1989, ONCOGENE, V4, P691; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; RADKE K, 1982, CELL, V31, P643, DOI 10.1016/0092-8674(82)90320-8; RAO VN, 1989, SCIENCE, V244, P66, DOI 10.1126/science.2539641; REDDY ESP, 1987, P NATL ACAD SCI USA, V84, P6131, DOI 10.1073/pnas.84.17.6131; ROUSSEL M, 1979, NATURE, V281, P452, DOI 10.1038/281452a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; TAJIMA M, 1986, MOL CELL BIOL, V6, P246, DOI 10.1128/MCB.6.1.246; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WATSON DK, 1985, P NATL ACAD SCI USA, V82, P7294, DOI 10.1073/pnas.82.21.7294; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1	51	12	12	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR	1991	6	3					357	360						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FT344	1901401				2022-12-25	WOS:A1991FT34400002
J	SELLMAYER, A; UEDELHOVEN, WM; WEBER, PC; BONVENTRE, JV				SELLMAYER, A; UEDELHOVEN, WM; WEBER, PC; BONVENTRE, JV			ENDOGENOUS NONCYCLOOXYGENASE METABOLITES OF ARACHIDONIC-ACID MODULATE GROWTH AND MESSENGER-RNA LEVELS OF IMMEDIATE-EARLY RESPONSE GENES IN RAT MESANGIAL CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS EXPRESSION; NA+/H+ EXCHANGE; DNA-SYNTHESIS; LIPOXYGENASE; LEUKOTRIENES; STIMULATION; INHIBITION; PROLIFERATION; ACTIVATION	The role of endogenous arachidonic acid and its metabolites as mediators of cell growth was studied in rat mesangial cells. Inhibitors of the cytochrome P450 monooxygenase and lipoxygenase systems (nordihydroguaiaretic acid (NDGA), SK&F 525A, and ketoconazole) significantly reduced serum-stimulated cell growth as determined by cell counts and incorporation of [H-3] thymidine. Inhibition of cyclooxygenase or lipoxygenases alone had no effect on cell growth. Stimulation with arginine vasopressin, epidermal growth factor, or phorbol myristate acetate increased [H-3]thymidine incorporation and mRNA levels of the immediate-early response genes c-fas and Egr-1. These increases in [H-3]thymidine incorporation and mRNA levels were reduced by NDGA and ketoconazole. NDGA, SK&F 525A, and ketoconazole had no effect on cellular ATP levels. Indomethacin had no effect upon cell growth. 14,15-Epoxyeicosatrienoic acid potentiated the effect of arginine vasopressin to enhance [H-3]thymidine incorporation. Reverse-phase high pressure liquid chromatography analysis of lipid extracts from cells prelabeled with [H-3]arachidonic acid resulted in the detection of a radioactive peak which eluted with lipoxygenase and monooxygenase products, with the same retention time as vicinal dihydroxyeicosatrienoic acids. This peak increased after stimulation with arginine vasopressin or epidermal growth factor and was reduced by preincubation with NDGA. Furthermore, analysis of unlabeled cell extracts by gas chromatography-mass spectrometry revealed the presence of a compound with epoxyeicosatrienoic acid-like characteristics. These results indicate that mesangial cells in culture likely produce products of the cytochrome P450 monooxygenase system that are important endogenous mediators of the growth response to mitogenic agents.	MASSACHUSETTS GEN HOSP, MED SERV,ARTHRITIS UNIT, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED,DEPT MED, BOSTON, MA 02115 USA; UNIV MUNICH, KREISLAUFKRANKHEITEN,INST PROPHYLAXE & EPIDEMIOL, W-8000 MUNICH, GERMANY	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of Munich					NIDDK NIH HHS [DK 38452, DK 39773, DK 38165] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038165, R01DK039773, R37DK039773, P01DK038452] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEETENS JR, 1986, BIOCHEM PHARMACOL, V35, P883, DOI 10.1016/0006-2952(86)90072-9; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BONVENTRE JV, 1988, J CLIN INVEST, V82, P168, DOI 10.1172/JCI113566; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BONVENTRE JV, 1986, AM J PHYSIOL, V251, pF94, DOI 10.1152/ajprenal.1986.251.1.F94; BONVENTRE JV, 1988, AM J PHYSIOL, V254, pF87, DOI 10.1152/ajprenal.1988.254.1.F87; BRADSHAW RA, 1987, ONCOGENES GROWTH FAC; BUTTNER N, 1989, NATURE, V342, P553, DOI 10.1038/342553a0; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DONADIO JV, 1988, DISEASES KIDNEY, P2035; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FORCE T, 1991, IN PRESS J BIOL CHEM, V266; FORCE T, 1990, IN PRESS J BIOL CHEM; GANZ MB, 1988, AM J PHYSIOL, V255, pF898, DOI 10.1152/ajprenal.1988.255.5.F898; GARRICK R, 1990, KIDNEY INT, V37, P368; GOODWIN JS, 1986, IMMUNOL RES, V5, P233, DOI 10.1007/BF02919204; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GRINSTEIN S, 1989, BIOCHIM BIOPHYS ACTA, V988, P73, DOI 10.1016/0304-4157(89)90004-X; HORIGUCHI J, 1989, MOL CELL BIOL, V9, P252, DOI 10.1128/MCB.9.1.252; JAFFER F, 1988, KIDNEY INT, V33, P318; KACICH RL, 1988, MOL ENDOCRINOL, V2, P73, DOI 10.1210/mend-2-1-73; KOSHIHARA Y, 1984, BIOCHIM BIOPHYS ACTA, V792, P92; KREISBERG JI, 1982, KIDNEY INT, V22, P355, DOI 10.1038/ki.1982.181; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUI M, 1990, ONCOGENE, V5, P249; MENE P, 1988, KIDNEY INT, V33, P276; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MILLER AM, 1989, J LAB CLIN MED, V113, P355; MITCHELL RH, 1989, LANCET, V1, P765; MONCADA S, 1976, PROSTAGLANDINS, V12, P323, DOI 10.1016/0090-6980(76)90014-9; OLIW EH, 1981, J BIOL CHEM, V256, P9924; ONDREY F, 1989, CANCER RES, V49, P1138; PETERS SP, 1983, J IMMUNOL METHODS, V64, P335, DOI 10.1016/0022-1759(83)90441-6; PIOMELLI D, 1987, NATURE, V328, P38, DOI 10.1038/328038a0; PRETUS HA, 1985, PROSTAGLANDINS, V30, P591, DOI 10.1016/0090-6980(85)90023-1; ROUZER CA, 1981, P NATL ACAD SCI-BIOL, V78, P2532, DOI 10.1073/pnas.78.4.2532; SAMUELSSON B, 1983, SCIENCE, V220, P568, DOI 10.1126/science.6301011; SCHLONDORFF D, 1987, FASEB J, V1, P272, DOI 10.1096/fasebj.1.4.3308611; SCHWARTZMAN M, 1985, HYPERTENSION, V7, pI136, DOI 10.1161/01.HYP.7.3_Pt_2.I136; SETTY BNY, 1987, J BIOL CHEM, V262, P17613; SETTY BNY, 1987, BIOCHEM BIOPH RES CO, V144, P345; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; Strehler B. L., 1974, METHOD ENZYMAT AN, P2112, DOI [10.1016/b978-0-12-091304-6.50065-3, DOI 10.1016/B978-0-12-091304-6.50065-3]; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; THEODOR L, 1985, BIOCHIM BIOPHYS ACTA, V826, P137, DOI 10.1016/0167-4781(85)90119-8; UEDELHOVEN WM, 1989, J CHROMATOGR-BIOMED, V497, P1; VERMA IM, 1987, ONCOGENES GROWTH FAC, P67	51	145	146	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3800	3807						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1899867				2022-12-25	WOS:A1991EY68200069
J	HOLTZMAN, EJ; SOPER, BW; STOW, JL; AUSIELLO, DA; ERCOLANI, L				HOLTZMAN, EJ; SOPER, BW; STOW, JL; AUSIELLO, DA; ERCOLANI, L			REGULATION OF THE G-PROTEIN ALPHA-I-2-SUBUNIT GENE IN LLC-PK1 RENAL-CELLS AND ISOLATION OF PORCINE GENOMIC CLONES ENCODING THE GENE PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; ALPHA-SUBUNIT; ADENYLATE-CYCLASE; BINDING-PROTEINS; MAMMALIAN-CELLS; MESSENGER-RNA; CEREBRAL-CORTEX; PERTUSSIS TOXIN; DNA; EXPRESSION	Heterotrimeric G-proteins function as signal transducers for a variety of hormone-coupled enzyme and ion transport systems in eukaryotic cells. We have studied G-protein-coupled processes that appear to be developmentally regulated in polarized pig kidney cells (LLC-PK1). Following trypsinization, LLC-PK1 cells differentiate from a rounded cell type to a fully polarized epithelium by 7 days of culture. During this differentiation, the expression of G-protein alpha-i-2 subunit mRNA was not detected until day 4 of culture, it peaked at day 6, and declined thereafter. In contrast, G-protein alpha-(s) subunit mRNA which peaked on day 4 was easily detected on all culture days. The presence of the alpha-i-2 protein on epithelial cell basolateral membranes followed the same pattern of mRNA expression during culture. To understand the developmental expression of the alpha-i-2 subunit in non-polarized cells and its potential regulation by hormones and second messengers in polarized cells at the transcriptional level, genomic DNA segments encoding the alpha-i-2 gene promoter were isolated from an EMBL-3 porcine genomic library. S1 nuclease analysis of LLC-PK1 mRNA with cRNA probes derived from these DNA segments revealed major and a minor transcriptional start sites 131 and 171 base pairs upstream of the translation initiation site. The porcine and human alpha-i-2 subunit genes shared a 78% sequence identity in their 5' flanks which suggested an evolutionary conversation of cis elements required to influence their transcription. The porcine alpha-i-2 gene promoter was identified by fusing DNA segments encoding putative 5'-flanking areas of the gene to a plasmid that contained a firefly luciferase reporter gene but lacked a promoter. The minimal promoter was found between -130 and -60 base pairs from the major transcription start site. No typical "TATA-like" sequences were found. However, a "GC" box and a "TGTGG" sequence were two potential cis elements required for basal transcription of the porcine gene promoter which shared a 76% sequence identity to the promoter of another GTP-binding protein, the human c-Ha-ras proto-oncogene. Transcription of the gene was inhibited following treatment of renal cells with 10(-8) M dexamethasone. These studies suggest that alpha-i-2 gene expression is regulated in LLC-PK1 cells. Identification of the gene's promoter and 5'-flanking sequences provide a basis for elucidating "cis-acting" DNA sequences and "trans-acting" protein factors that act in concert to control the transcriptional regulation of the alpha-i-2 gene which may modulate G-protein coupled effector responses in vasopressin-sensitive renal epithelia.	MASSACHUSETTS GEN HOSP,RENAL UNIT,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT MED,BOSTON,MA 02114; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114; HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Stow, Jennifer/I-4723-2013	Stow, Jennifer/0000-0002-5409-9101	NIDDK NIH HHS [DK 19406] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK019406, R01DK019406] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BOCKAERT J, 1972, J BIOL CHEM, V247, P7073; BRASIER AR, 1989, MOL ENDOCRINOL, V3, P1022, DOI 10.1210/mend-3-6-1022; CANTIELLO HF, 1989, J BIOL CHEM, V264, P20867; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CHAPMAN AB, 1984, J BIOL CHEM, V259, P5548; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; COOPER DMF, 1979, J BIOL CHEM, V254, P8927; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ERCOLANI L, 1988, J BIOL CHEM, V263, P15335; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FIRTEL RA, 1989, CELL, V58, P235, DOI 10.1016/0092-8674(89)90837-4; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GOLDSMITH P, 1988, BIOCHEMISTRY-US, V27, P7085, DOI 10.1021/bi00418a062; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HEN R, 1983, NUCLEIC ACIDS RES, V11, P8747, DOI 10.1093/nar/11.24.8747; HENTHORN P, 1988, P NATL ACAD SCI USA, V85, P6342, DOI 10.1073/pnas.85.17.6342; HOLMER SR, 1989, CIRC RES, V65, P1136, DOI 10.1161/01.RES.65.4.1136; HUFF RM, 1985, J BIOL CHEM, V260, P864; IGUCHIARIGA SMM, 1989, GENE DEV, V3, P612, DOI 10.1101/gad.3.5.612; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; ISHII S, 1985, SCIENCE, V230, P1378, DOI 10.1126/science.2999983; ITOH H, 1988, J BIOL CHEM, V263, P6656; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LEE RT, 1989, FEBS LETT, V249, P139, DOI 10.1016/0014-5793(89)80610-6; LEUTJE CW, 1988, J BIOL CHEM, V263, P13357; LEVINE MA, 1990, J BIOL CHEM, V265, P3553; LIANG BT, 1986, J BIOL CHEM, V261, P9011; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MOHRMANN M, 1987, AM J PHYSIOL, V253, pF372, DOI 10.1152/ajprenal.1987.253.2.F372; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; OWENS JR, 1985, J BIOL CHEM, V260, P5946; QUARLESS SA, 1986, BIOTECHNIQUES, V4, P434; RAPORT CJ, 1989, J BIOL CHEM, V264, P7122; ROS M, 1988, J BIOL CHEM, V263, P4362; SAGER R, 1982, P NATL ACAD SCI-BIOL, V79, P480, DOI 10.1073/pnas.79.2.480; SAITO N, 1989, P NATL ACAD SCI USA, V86, P3906, DOI 10.1073/pnas.86.10.3906; SALTZMAN AG, 1989, FASEB J, V3, P1723, DOI 10.1096/fasebj.3.6.2649403; SHINAR D, 1989, DIFFERENTIATION, V41, P16; SILBERT S, 1990, J BIOL CHEM, V265, P3102; SINHA ND, 1984, NUCLEIC ACIDS RES, V12, P4539, DOI 10.1093/nar/12.11.4539; SKORECKI KL, 1987, BIOCHEMISTRY-US, V26, P639, DOI 10.1021/bi00376a040; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; WATKINS DC, 1989, BIOCHEM BIOPH RES CO, V165, P929, DOI 10.1016/0006-291X(89)92692-2; WATKINS DC, 1987, J BIOL CHEM, V262, P10651; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WIGENDER E, 1988, NUCLEIC ACIDS RES, V16, P1879	58	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1763	1771						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1899094				2022-12-25	WOS:A1991EU49700064
J	JIMENEZ, M; TSUKAMOTO, K; HEARING, VJ				JIMENEZ, M; TSUKAMOTO, K; HEARING, VJ			TYROSINASES FROM 2 DIFFERENT LOCI ARE EXPRESSED BY NORMAL AND BY TRANSFORMED MELANOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENCODING MOUSE TYROSINASE; MELANOMA CELL-CULTURES; MAMMALIAN TYROSINASE; STIMULATING HORMONE; DOPACHROME OXIDOREDUCTASE; MONOCLONAL-ANTIBODIES; MURINE MELANOCYTES; ALBINO LOCUS; METAL-IONS; CDNA	Two pigmentation related genes have recently been cloned which map to the brown (b) and albino (c) loci of mice; these loci influence the quality and quantity, respectively, of melanin produced by melanocytes. Both these gene products are biochemically similar and have extensive amino acid sequence similarity to each other and to lower forms of tyrosinase (EC 1.14.18.1), a copper binding enzyme responsible for melanin production. In order to characterize the catalytic activities of these molecules, we have synthesized peptides and prepared antibodies to them which specifically recognize the gene products in question. By use of immune affinity purification protocols, we have isolated the proteins encoded by the brown and albino loci and have determined that both have the catalytic functions ascribed to tyrosinase, i.e. hydroxylation of tyrosine to 3,4-dihydroxyphenylalanine (DOPA) and the oxidation of DOPA to DOPAquinone. These are the critical reactions to melanogenesis since melanin pigment can be spontaneously produced from those products. The specific activity of the albino locus encoded product is considerably higher than that of the protein encoded by the brown locus, although the latter protein is present in higher quantity in melanocytes than is the protein encoded by the albino locus. These results are surprising since it was anticipated that tyrosinase was the product of single gene locus, and suggest that regulation of melanogenesis in mammals is controlled at the enzymatic level by several different gene products.	NIH, CELL BIOL LAB, BLDG 37, RM 1B22, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA								ABDELMALEK ZA, 1988, J CELL PHYSIOL, V136, P273, DOI 10.1002/jcp.1041360209; AROCA P, 1990, BIOCHIM BIOPHYS ACTA, V1035, P266, DOI 10.1016/0304-4165(90)90088-E; BARBER JI, 1984, J INVEST DERMATOL, V83, P145, DOI 10.1111/1523-1747.ep12263381; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BENNETT DC, 1987, INT J CANCER, V39, P414, DOI 10.1002/ijc.2910390324; BOUCHARD B, 1989, J EXP MED, V169, P2029, DOI 10.1084/jem.169.6.2029; COHEN T, 1990, NUCLEIC ACIDS RES, V18, P2807, DOI 10.1093/nar/18.9.2807; COLEMAN DL, 1962, ARCH BIOCHEM BIOPHYS, V96, P562, DOI 10.1016/0003-9861(62)90337-5; DISCHIA M, 1990, IN PRESS BIOCH BIOPH; ELLER M, 1990, J INVEST DERMATOL, V94, P521; FULLER BB, 1988, J CELL PHYSIOL, V134, P149, DOI 10.1002/jcp.1041340119; FULLER BB, 1987, J BIOL CHEM, V262, P4024; GLUECKSOHNWAELSCH S, 1979, CELL, V16, P225, DOI 10.1016/0092-8674(79)90001-1; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; HALABAN R, 1988, P NATL ACAD SCI USA, V85, P7241, DOI 10.1073/pnas.85.19.7241; HEARING VJ, 1987, METHOD ENZYMOL, V142, P154; HEARING VJ, 1981, INT J BIOCHEM, V13, P99, DOI 10.1016/0020-711X(81)90141-5; HEARING VJ, 1989, PIGM CELL RES, V2, P75, DOI 10.1111/j.1600-0749.1989.tb00166.x; HEARING VJ, 1986, J IMMUNOL, V137, P379; HEARING VJ, 1973, NATURE-NEW BIOL, V245, P81, DOI 10.1038/newbio245081a0; HEARING VJ, 1987, INT J BIOCHEM, V19, P1141, DOI 10.1016/0020-711X(87)90095-4; HEARING VJ, 1976, BIOCHEM J, V157, P549, DOI 10.1042/bj1570549; HEARING VJ, 1978, BIOCHIM BIOPHYS ACTA, V522, P327, DOI 10.1016/0005-2744(78)90067-0; HOGANSON GE, 1989, SOMAT CELL MOLEC GEN, V15, P255, DOI 10.1007/BF01534876; JACKSON IJ, 1985, TRENDS GENET, V1, P321, DOI 10.1016/0168-9525(85)90126-X; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JIMENEZ M, 1988, P NATL ACAD SCI USA, V85, P3830, DOI 10.1073/pnas.85.11.3830; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KAMEYAMA K, 1989, DIFFERENTIATION, V42, P28, DOI 10.1111/j.1432-0436.1989.tb00604.x; KAMEYAMA K, 1988, J CELL PHYSIOL, V137, P35, DOI 10.1002/jcp.1041370105; KING RA, 1976, NATURE, V263, P69, DOI 10.1038/263069a0; KWON BS, 1988, BIOCHEM BIOPH RES CO, V153, P1301, DOI 10.1016/S0006-291X(88)81370-6; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; KWON BS, 1987, MOL BIOL MED, V4, P339; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKIN JD, 1986, J BIOL CHEM, V261, P6626; LEONARD LJ, 1988, BIOCHEMISTRY-US, V27, P6156, DOI 10.1021/bi00416a049; MARTINEZ JH, 1988, CANCER LETT, V38, P339, DOI 10.1016/0304-3835(88)90026-2; MOJAMDAR M, 1983, J INVEST DERMATOL, V81, P119, DOI 10.1111/1523-1747.ep12542966; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; NISHIOKA K, 1977, FEBS LETT, V80, P225, DOI 10.1016/0014-5793(77)80445-6; OHKURA T, 1984, ARCH BIOCHEM BIOPHYS, V235, P63, DOI 10.1016/0003-9861(84)90255-8; PALUMBO A, 1990, BIOCHIM BIOPHYS ACTA, V1033, P256, DOI 10.1016/0304-4165(90)90129-K; PALUMBO A, 1988, BIOCHIM BIOPHYS ACTA, V964, P193, DOI 10.1016/0304-4165(88)90166-3; PAWELEK J, 1980, NATURE, V286, P617, DOI 10.1038/286617a0; PAWELEK JM, 1990, BIOCHEM BIOPH RES CO, V166, P1328, DOI 10.1016/0006-291X(90)91011-G; PAWELEK JM, 1985, YALE J BIOL MED, V58, P571; POMERANTZ SH, 1974, NATURE, V252, P241, DOI 10.1038/252241a0; PROTA G, 1988, COENZYMES COFACTORS, P538; RUPPERT S, 1988, EMBO J, V7, P2715, DOI 10.1002/j.1460-2075.1988.tb03125.x; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBAHARA S, 1988, TOHOKU J EXP MED, V156, P403, DOI 10.1620/tjem.156.403; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; SHIBARA S, 1988, ADV PIGMENT CELL RES, P263; Silvers W.K., 1979, COAT COLORS MICE, P1; TAKEUCHI S, 1988, BIOCHEM BIOPH RES CO, V155, P470, DOI 10.1016/S0006-291X(88)81110-0; TAMURA A, 1987, IN VITRO CELL DEV B, V23, P519; TERAO M, 1989, BIOCHEM BIOPH RES CO, V159, P848, DOI 10.1016/0006-291X(89)90072-7; TOMITA Y, 1986, DIAGN CLIN IMMUNOL, V4, P149; TOMITA Y, 1985, J INVEST DERMATOL, V85, P426, DOI 10.1111/1523-1747.ep12277121; TOWNSEND D, 1981, J EXP ZOOL, V216, P113, DOI 10.1002/jez.1402160112; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; WOLFE HG, 1966, BIOL LABORATORY MOUS, P405; WONG G, 1975, NATURE, V255, P644, DOI 10.1038/255644a0; YAMAMOTO H, 1989, JPN J GENET, V64, P121, DOI 10.1266/jjg.64.121; YAMAMOTO H, 1987, JPN J GENET, V62, P271, DOI 10.1266/jjg.62.271; ZDARSKY E, 1990, GENETICS, V126, P443	67	237	240	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1147	1156						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898730				2022-12-25	WOS:A1991ET17700074
J	MADSHUS, IH; STENMARK, H; SANDVIG, K; OLSNES, S				MADSHUS, IH; STENMARK, H; SANDVIG, K; OLSNES, S			ENTRY OF DIPHTHERIA TOXIN-PROTEIN-A CHIMERAS INTO CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; LOW PH; VERO CELLS; MEMBRANE TRANSLOCATION; ANION TRANSPORT; RAPID ENTRY; FRAGMENT; RICIN; REQUIREMENT; FUSION	Fusion proteins consisting of diphtheria toxin and a duplicated Fc-binding domain of protein A were made in vitro after amplification of the DNA template by the polymerase chain reaction. The fusion proteins bound avidly to Vero cells coated with antibodies. A fusion protein containing full-length diphtheria toxin was toxic at lower concentrations than diphtheria toxin alone, apparently due to more efficient binding. The enzymatic part of the fusion protein was translocated across the surface membrane upon exposure to low pH. Like authentic diphtheria toxin, the fusion protein formed cation selective channels at low pH. Excess amounts of unlabeled diphtheria toxin inhibited formation of pronase-protected fragments derived from radiolabeled fusion protein. Furthermore, conditions that down-regulate the diphtheria toxin receptors reduced the sensitivity of the cells to the fusion protein, supporting the notion that authentic diphtheria toxin receptors are required. At temperatures below 18-degrees-C the toxicity of the fusion protein was strongly reduced, whereas there was no temperature block for authentic diphtheria toxin. Brefeldin A protected Vero cells against the fusion protein but not against diphtheria toxin. The results indicate that the diphtheria toxin receptor is required for efficient toxin translocation even under conditions where the toxin is bound by an alternate binding moiety, and they suggest that the intracellular routing of the fusion protein is different from that of diphtheria toxin.			MADSHUS, IH (corresponding author), NORWEGIAN RADIUM HOSP,INST CANC RES,N-0310 OSLO 3,NORWAY.		Stenmark, Harald/B-8868-2008					BACHA P, 1983, J BIOL CHEM, V258, P1565; BACHA P, 1988, J EXP MED, V167, P612, DOI 10.1084/jem.167.2.612; BARBIERI JT, 1987, INFECT IMMUN, V55, P1647, DOI 10.1128/IAI.55.7.1647-1651.1987; BLEWITT MG, 1985, BIOCHEMISTRY-US, V24, P5458, DOI 10.1021/bi00341a027; CHANG TM, 1982, J BIOL CHEM, V257, P2563; COLOMBATTI M, 1986, J BIOL CHEM, V261, P3030; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DRAPER RK, 1980, J CELL BIOL, V87, P849, DOI 10.1083/jcb.87.3.849; DUNN WA, 1980, J BIOL CHEM, V255, P5971; GILLILAND DG, 1980, P NATL ACAD SCI USA, V78, P4950; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; GREENFIELD L, 1987, SCIENCE, V238, P536, DOI 10.1126/science.3498987; JOHNSON VG, 1989, J BIOL CHEM, V264, P17739; JOHNSON VG, 1988, J BIOL CHEM, V263, P1259; KAGAN BL, 1981, P NATL ACAD SCI-BIOL, V78, P4950, DOI 10.1073/pnas.78.8.4950; KIM K, 1965, J BACTERIOL, V90, P1552, DOI 10.1128/JB.90.6.1552-1556.1965; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOWENADLER B, 1987, GENE, V58, P87, DOI 10.1016/0378-1119(87)90032-1; MARSH JW, 1988, J BIOL CHEM, V263, P15993; MCGILL S, 1989, EMBO J, V8, P2843, DOI 10.1002/j.1460-2075.1989.tb08431.x; MONTECUCCO C, 1985, BIOCHEM J, V231, P123, DOI 10.1042/bj2310123; MOOLTEN FL, 1970, SCIENCE, V169, P68, DOI 10.1126/science.169.3940.68; MORRIS RE, 1985, INFECT IMMUN, V50, P721, DOI 10.1128/IAI.50.3.721-727.1985; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; MOSKAUG JO, 1988, J BIOL CHEM, V263, P2518; MURPHY JR, 1988, AM J KIDNEY DIS, V11, P159, DOI 10.1016/S0272-6386(88)80204-X; OELTMANF T, 1985, BIOCHEM BIOPH RES CO, V132, P430; OKEEFE DO, 1985, J BIOL CHEM, V260, P932; OLSNES S, 1989, J BIOL CHEM, V264, P12749; OLSNES S, 1986, J BIOL CHEM, V261, P1562; OLSNES S, 1989, IMMUNOL TODAY, V10, P291; PAPINI E, 1988, EMBO J, V7, P3353, DOI 10.1002/j.1460-2075.1988.tb03207.x; PAPINI E, 1987, EUR J BIOCHEM, V169, P637, DOI 10.1111/j.1432-1033.1987.tb13655.x; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; ROEDERER M, 1987, J CELL PHYSIOL, V131, P200, DOI 10.1002/jcp.1041310209; SANDVIG K, 1982, J BIOL CHEM, V257, P7495; SANDVIG K, 1986, J BIOL CHEM, V261, P1570; SANDVIG K, 1988, J BIOL CHEM, V263, P12352; SANDVIG K, 1986, CANCER RES, V46, P6418; SANDVIG K, 1986, J BIOL CHEM, V261, P1639; SANDVIG K, 1984, J CELL BIOL, V98, P963, DOI 10.1083/jcb.98.3.963; SANDVIG K, 1981, J BIOL CHEM, V256, P9068; SANDVIG K, 1980, J CELL BIOL, V87, P828, DOI 10.1083/jcb.87.3.828; SANDVIG K, 1991, IN PRESS 2ND EUR WOR; SCHAUDIES RP, 1987, BIOCHEM BIOPH RES CO, V143, P710, DOI 10.1016/0006-291X(87)91412-4; STENMARK H, 1988, J BIOL CHEM, V263, P13449; THORPE PE, 1977, NATURE, V271, P752; VANDEURS B, 1986, J CELL BIOL, V102, P37, DOI 10.1083/jcb.102.1.37; WILEY HS, 1985, J BIOL CHEM, V260, P5290; YOSHIDA T, 1990, EXP CELL RES, V190, P11, DOI 10.1016/0014-4827(90)90137-Y	51	27	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17446	17453						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894632				2022-12-25	WOS:A1991GF44500071
J	REINSTEIN, J; SCHLICHTING, I; FRECH, M; GOODY, RS; WITTINGHOFER, A				REINSTEIN, J; SCHLICHTING, I; FRECH, M; GOODY, RS; WITTINGHOFER, A			P21 WITH A PHENYLALANINE 28-] LEUCINE MUTATION REACTS NORMALLY WITH THE GTPASE ACTIVATING PROTEIN GAP BUT NEVERTHELESS HAS TRANSFORMING PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; H-RAS P21; GENE-PRODUCT; TRIPHOSPHATE CONFORMATION; PC12 CELLS; METAL-ION; GDP; HYDROLYSIS; MECHANISM; DOMAIN	The H-ras gene product p21H has been mutated at Phe-28, which makes a hydrophobic interaction with the guanine base of bound GDP/GTP. The mutation Phe-28 --> Leu drastically increases nucleotide dissociation rates without affecting association rates. This is due to a perturbed binding of base, alpha- and beta-phosphate, and Mg2+, as evidenced from P-31 NMR and fluorescence measurements. The region around the gamma-phosphate appears normal. The affinity of Mg2+ for both the di- and the triphosphate conformation of the mutant was also measured by fluorescence. The association constant is 3.5 x 10(7) M-1 for the Gpp(NH)p complex, 500 times higher than for the GDP form. The mutation does not change appreciably the intrinsic or the GTPase activating protein (GAP)-stimulated GTPase. The mutated protein induces neurite differentiation however when pressure-loaded into PC12 cells, which is equivalent to transformation of NIH 3T3 cells. This shows that p21 (F28L) is converted to the GDP bound form by GAP but is transforming because the high dissociation rate for nucleotides leads to a protein predominantly in the active GTP bound form.	MAX PLANCK INST MED RES, BIOPHYS ABT, JAHNSTR 29, W-6900 HEIDELBERG 1, GERMANY	Max Planck Society			Schlichting, Ilme/I-1339-2013; Goody, Roger S/J-8845-2014	Goody, Roger S/0000-0002-0772-0444				ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BORASIO GD, 1989, NEURON, V2, P1087; BOS JL, 1989, CANCER RES, V49, P4682; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CLANTON DJ, 1986, P NATL ACAD SCI USA, V83, P5076, DOI 10.1073/pnas.83.14.5076; CRECHET JB, 1990, SCIENCE, V248, P866, DOI 10.1126/science.2188363; DER CJ, 1988, ONCOGENE, V3, P105; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; FASANO O, 1978, EUR J BIOCHEM, V89, P557, DOI 10.1111/j.1432-1033.1978.tb12560.x; FEIG LA, 1988, MOL CELL BIOL, V8, P2472, DOI 10.1128/MCB.8.6.2472; FEIG LA, 1986, P NATL ACAD SCI USA, V83, P4607, DOI 10.1073/pnas.83.13.4607; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FEUERSTEIN J, 1987, J BIOL CHEM, V262, P8455; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; FEUERSTEIN J, 1987, EUR J BIOCHEM, V162, P49, DOI 10.1111/j.1432-1033.1987.tb10540.x; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; HALENBECK R, 1990, J BIOL CHEM, V265, P21922; HALL A, 1990, CELL, V61, P921, DOI 10.1016/0092-8674(90)90054-I; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; JOHN J, 1989, NATO ADV SCI I A-LIF, V165, P209; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; JOHN J, 1988, J BIOL CHEM, V263, P11792; JOHN J, 1990, THESIS UHEIDELBERG; KLAUS W, 1986, BIOL CHEM H-S, V367, P781, DOI 10.1515/bchm3.1986.367.2.781; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCCORMICK F, 1988, COLD SPRING HARB SYM, V53, P849, DOI 10.1101/SQB.1988.053.01.097; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCCORMICK F, 1989, ONCOGENES MOL ORIGIN, P125; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NEAL SE, 1988, J BIOL CHEM, V263, P9178; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; SASSONECORSI P, 1989, MOL CELL BIOL, V9, P3174, DOI 10.1128/MCB.9.8.3174; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHLICHTING I, 1988, BIOCHEM BIOPH RES CO, V150, P444, DOI 10.1016/0006-291X(88)90540-2; SCHLICHTING I, 1990, BIOCHEMISTRY-US, V29, P504, DOI 10.1021/bi00454a026; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SIGAL IS, 1988, COLD SPRING HARB SYM, V53, P863, DOI 10.1101/SQB.1988.053.01.099; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P952, DOI 10.1073/pnas.83.4.952; SMITHERS GW, 1990, ARCH BIOCHEM BIOPHYS, V280, P416, DOI 10.1016/0003-9861(90)90351-X; TONG L, 1989, SCIENCE, V245, P244, DOI 10.1126/science.2665078; TONG L, 1991, J MOL BIOL, V217, P503, DOI 10.1016/0022-2836(91)90753-S; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VOGEL U, 1988, NASTURE, V5, P90; WALTER M, 1986, SCIENCE, V233, P649, DOI 10.1126/science.3487832; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667	54	91	92	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17700	17706						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894650				2022-12-25	WOS:A1991GF44500106
J	SCHROCK, RD; LLOYD, RS				SCHROCK, RD; LLOYD, RS			REDUCTIVE METHYLATION OF THE AMINO TERMINUS OF ENDONUCLEASE-V ERADICATES CATALYTIC ACTIVITIES - EVIDENCE FOR AN ESSENTIAL ROLE OF THE AMINO TERMINUS IN THE CHEMICAL MECHANISMS OF CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIMER-DNA GLYCOSYLASE; DEOXYRIBONUCLEIC-ACID; ESCHERICHIA-COLI; APURINIC SITES; DENV-GENE; SODIUM CYANOBOROHYDRIDE; PYRIMIDINE DIMERS; RIBONUCLEASE-A; REPAIR ENZYME; BACTERIOPHAGE-T4	Endonuclease V, a pyrimidine dimer-specific DNA repair enzyme, was chemically modified by reductive methylation, a technique that specifically methylates primary amino groups. Upon reaction of endonuclease V with [C-14]formaldehyde ((CH2O)-C-14) in the presence of the reducing agent sodium cyanoborohydride (Na-CNBH3), it was discovered that 0.8 methylation/endonuclease V molecule was required to reduce both the glycosylase and the phosphodiester lyase activities by 70-80%. Pyrimidine dimer-specific binding was not eradicated at a level of methylation equivalent to 0.8 CH3/endonuclease V molecule but was eradicated at higher levels of methylation. Endonuclease V that had been modified with an average of 1.6 CH3/molecule was digested with Staphylococcus aureus strain V8 protease and the peptides subsequently separated by reverse-phase high performance liquid chromatography. Radiolabel was found exclusively on the peptide including the amino terminus, as determined by the percent amino acid composition. Neither intact CH3-endonuclease V nor radiolabeled peptides were able to be sequenced by Edman degradation indicating blockage of the amino terminus by methylation. This study shows strong evidence for the unusual involvement of the alpha-NH2 moiety in the chemical mechanisms of endonuclease V. A reaction mechanism that incorporates these findings is presented.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,CTR MOLEC TOXICOL,SCH MED,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University				Lloyd, R. Stephen/0000-0001-7273-372X	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004091, T32ES007028, P30ES000267] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES 00267, ES 04091, ES 07028] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BEHMOARAS T, 1981, NATURE, V292, P858, DOI 10.1038/292858a0; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; CHANG JY, 1981, BIOCHEM J, V199, P547, DOI 10.1042/bj1990547; DODSON ML, 1989, MUTAT RES, V218, P49, DOI 10.1016/0921-8777(89)90011-6; DOETSCH PW, 1990, MUTAT RES, V236, P173, DOI 10.1016/0921-8777(90)90004-O; DOTTAVIOMARTIN D, 1978, ANAL BIOCHEM, V87, P562, DOI 10.1016/0003-2697(78)90706-6; DOWD DR, 1989, BIOCHEMISTRY-US, V28, P8699, DOI 10.1021/bi00448a005; DOWD DR, 1989, J MOL BIOL, V208, P701, DOI 10.1016/0022-2836(89)90160-5; GERLT JA, 1991, BIOCHEMISTRY-US, V30, P1119; GROSSMAN L, 1988, FASEB J, V2, P2696, DOI 10.1096/fasebj.2.11.3294078; GRUSKIN EA, 1988, J BIOL CHEM, V263, P12728; GRUSKIN EA, 1986, J BIOL CHEM, V261, P9607; HELENE C, 1982, BIOCHIMIE, V64, P697, DOI 10.1016/S0300-9084(82)80113-2; HIGGINS KM, 1987, MUTAT RES, V183, P117, DOI 10.1016/0167-8817(87)90053-8; JENTOFT JE, 1981, J BIOL CHEM, V256, P231; JENTOFT JE, 1979, J BIOL CHEM, V254, P4366; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KIM J, 1988, NUCLEIC ACIDS RES, V16, P1135, DOI 10.1093/nar/16.3.1135; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3610, DOI 10.1021/bi00769a018; LINDAHL T, 1972, BIOCHEMISTRY-US, V11, P3618, DOI 10.1021/bi00769a019; LIUZZI M, 1987, BIOCHEMISTRY-US, V26, P3315, DOI 10.1021/bi00386a011; LLOYD RS, 1978, CANCER RES, V38, P3191; LLOYD RS, 1986, MUTAT RES, V165, P86; MANOHARAN M, 1988, J AM CHEM SOC, V110, P2690, DOI 10.1021/ja00216a074; MEANS GE, 1968, BIOCHEMISTRY-US, V7, P2192, DOI 10.1021/bi00846a023; MYLES GM, 1989, CHEM RES TOXICOL, V2, P197, DOI 10.1021/tx00010a001; NAKABEPPU Y, 1982, J BIOL CHEM, V257, P2556; NAKABEPPU Y, 1981, P NATL ACAD SCI-BIOL, V78, P2742, DOI 10.1073/pnas.78.5.2742; PIERRE J, 1981, J BIOL CHEM, V256, P217; PRINCE MA, 1991, J BIOL CHEM, V266, P10686; RADANY EH, 1980, NATURE, V286, P182, DOI 10.1038/286182a0; RADANY EH, 1984, J VIROL, V52, P846, DOI 10.1128/JVI.52.3.846-856.1984; RECINOS A, 1988, BIOCHEMISTRY-US, V27, P1832, DOI 10.1021/bi00406a006; RECINOS A, 1986, J BACTERIOL, V168, P1014, DOI 10.1128/jb.168.2.1014-1018.1986; SEAWELL PC, 1980, BIOCHEMISTRY-US, V19, P1685, DOI 10.1021/bi00549a026; SEAWELL PC, 1980, J VIROL, V35, P790, DOI 10.1128/JVI.35.3.790-796.1980; Stark GR., 1967, METHOD ENZYMOL, V25, P590; STUMP DG, 1988, BIOCHEMISTRY-US, V27, P1839, DOI 10.1021/bi00406a007; TANFORD C, 1956, J AM CHEM SOC, V78, P5287, DOI 10.1021/ja01601a036; VALERIE K, 1984, NUCLEIC ACIDS RES, V12, P8085, DOI 10.1093/nar/12.21.8085; VANMINDERHOUT L, 1974, MUTAT RES, V29, P333; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1	42	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17631	17639						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894643				2022-12-25	WOS:A1991GF44500096
J	BRADSHAW, MS; TSAI, SY; LENG, XH; DOBSON, ADW; CONNEELY, OM; OMALLEY, BW; TSAI, MJ				BRADSHAW, MS; TSAI, SY; LENG, XH; DOBSON, ADW; CONNEELY, OM; OMALLEY, BW; TSAI, MJ			STUDIES ON THE MECHANISM OF FUNCTIONAL COOPERATIVITY BETWEEN PROGESTERONE AND ESTROGEN-RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE TRANSCRIPTION; GLUCOCORTICOID RECEPTOR; RESPONSIVE ELEMENTS; SYNERGISTIC ACTION; HORMONE RECEPTOR; GENE; ACTIVATION; ENHANCER; BINDING; PROMOTER	Steroid response elements (SREs) cooperate with many different cis-acting elements including NF-1 sites, CACCC boxes, and other SREs to induce target gene expression (Schule, R., Muller, M., Otsuka-Murakami, H., and Renkawitz, R. (1988) Nature 332, 87-90; Strahle, U., Schmid, W., and Schutz, G. (1988) EMBO J. 7, 3389-3395). Induction of gene expression can be additive or synergistic with respect to the level of activation by either transactivators. Two mechanisms have been proposed for how synergism occurs: 1) cooperative binding of transcriptional activators to DNA or 2) simultaneous interaction of individually bound activators with a common target protein. We have shown previously that cooperative binding of receptors is important for synergism between two progesterone response elements (PREs). Here we showed that an estrogen response element (ERE) and a PRE can also functionally cooperate and this synergism between an ERE and a PRE is not contributed by cooperative DNA binding. Furthermore, we have demonstrated that the activation domains of the progesterone receptor (PR) (C1Act) are required for synergism between two PREs and sufficient for confirming cooperative binding. However these two activation domains of PR are not sufficient for synergism between an ERE and a PRE. Additional regions within the NH2-terminal and COOH-terminal domains are also required for synergistic interaction between two heterologous SREs.	BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine			Dobson, Alan D W/M-7844-2017	Dobson, Alan D W/0000-0002-7713-5574				ANKENBAUER W, 1988, P NATL ACAD SCI USA, V85, P7526, DOI 10.1073/pnas.85.20.7526; BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BRADSHAW MS, 1988, J BIOL CHEM, V263, P8485; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CARSON MA, 1987, MOL ENDOCRINOL, V1, P791, DOI 10.1210/mend-1-11-791; CATO ACB, 1989, MOL CELL BIOL, V9, P5324, DOI 10.1128/MCB.9.12.5324; CONNEELY OM, 1987, MOL ENDOCRINOL, V1, P517, DOI 10.1210/mend-1-8-517; Conneely OM, 1989, GENE REGULATION STER, V4, P220; DANESCH U, 1987, EMBO J, V6, P625, DOI 10.1002/j.1460-2075.1987.tb04800.x; DOBSON ADW, 1989, J BIOL CHEM, V264, P4207; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREENE GL, 1984, BIOCH ACTIONS HORMON, V11; KLEINHITPASS L, 1988, J MOL BIOL, V201, P537; KLEINHITPASS L, 1989, MOL CELL BIOL, V9, P43, DOI 10.1128/MCB.9.1.43; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; MIKSICEK R, 1986, CELL, V46, P283, DOI 10.1016/0092-8674(86)90745-2; PHAM TA, 1991, IN PRESS P NATL ACAD; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; RENKAWITZ R, 1984, CELL, V37, P503, DOI 10.1016/0092-8674(84)90380-5; SCHMID W, 1989, EMBO J, V8, P2257, DOI 10.1002/j.1460-2075.1989.tb08350.x; SCHULE R, 1988, NATURE, V332, P87, DOI 10.1038/332087a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STEINER C, 1987, NUCLEIC ACIDS RES, V15, P4163, DOI 10.1093/nar/15.10.4163; STRAHLE U, 1988, EMBO J, V7, P3389, DOI 10.1002/j.1460-2075.1988.tb03212.x; SULLIVAN WP, 1986, ENDOCRINOLOGY, V119, P1549, DOI 10.1210/endo-119-4-1549; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; WONG GG, 1985, SCIENCE, V228, P811; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	38	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16684	16690						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885597				2022-12-25	WOS:A1991GD63500071
J	GUSEV, NB; GRABAREK, Z; GERGELY, J				GUSEV, NB; GRABAREK, Z; GERGELY, J			STABILIZATION BY A DISULFIDE BOND OF THE N-TERMINAL DOMAIN OF A MUTANT TROPONIN-C (TNC48/82)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE; BINDING-SITES; CONFORMATIONAL-CHANGES; PROTEOLYTIC FRAGMENTS; CALCIUM-BINDING; CONTRACTION; PROTEIN; LOCALIZATION; CALMODULIN; RESOLUTION	The regulatory activity of troponin C is reversibly inhibited by a disulfide bridge between cysteine residues introduced by site-directed mutagenesis in positions 48 and 82 (TnC48/82) in the N-terminal domain of rabbit skeletal troponin C (sTnC; Grabarek, Z., Tan, R.-Y., Tao, T., and Gergely, J. (1990) Nature 345, 132-135). In the present work we have investigated the effects of the disulfide on structural properties of TnC48/82 monitored by CD spectroscopy and limited trypsinolysis. The CD spectra of the mutant protein in the oxidized form (oxTnC48/82) with and without Ca2+ are similar to the corresponding ones of the reduced and carboxamidomethylated form (CAMTnC48/82), indicating that the disulfide has essentially no effect on the overall secondary structure. The N-terminal domain of oxTnC48/82 is resistant to thermal unfolding, but that of CAMTnC48/82 is only slightly more stable than the corresponding domain of sTnC. In the presence of Ca2+ oxTnC48/82 is more resistant to trypsinolysis than sTnC whereas the rate of tryptic digestion of CAMTnC48/82 is the same as that of sTnC, indicating that peptide bonds adjacent to lysine residues at position 84 and 88, the sites of tryptic attack, are protected by the disulfide. The disulfide cross-linked N-terminal peptide of TnC48/82 does not bind TnI, unlike its reduced or carboxamidomethylated forms. Our data indicate that the disulfide between Cys48 and Cys82 Stabilizes the structure of the N-terminal domain of TnC and blocks its ability to interact with TnI. The effects of the disulfide appear to be restricted to the N-terminal domain of TnC.	BOSTON BIOMED RES INST, DEPT MUSCLE RES, 20 STANIFORD ST, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, DEPT BIOL CHEM & MOLEC PHARMACOL, BOSTON, MA 02115 USA; MASSACHUSETTS GEN HOSP, DEPT NEUROL, BOSTON, MA 02114 USA	Boston Biomedical Research Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital			B.Gusev, Nikolai/D-7533-2012	Grabarek, Zenon/0000-0002-3636-5701	NHLBI NIH HHS [R37-HL-05949] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL005949] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRZESKA H, 1983, FEBS LETT, V153, P169, DOI 10.1016/0014-5793(83)80141-0; DRABIKOWSKI W, 1977, BIOCHIM BIOPHYS ACTA, V490, P216, DOI 10.1016/0005-2795(77)90122-2; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GRABAREK Z, 1981, J BIOL CHEM, V256, P3121; GRABAREK Z, 1990, NATURE, V345, P132, DOI 10.1038/345132a0; GRABAREK Z, 1981, BIOCHIM BIOPHYS ACTA, V671, P227, DOI 10.1016/0005-2795(81)90138-0; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; INGRAHAM RH, 1983, EUR J BIOCHEM, V132, P85, DOI 10.1111/j.1432-1033.1983.tb07328.x; KOBAYASHI T, 1991, J BIOL CHEM, V266, P13746; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LEAVIS PC, 1978, J BIOL CHEM, V253, P5452; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1990, BIOCHEMISTRY-US, V29, P299, DOI 10.1021/bi00453a041; MATSUMURA M, 1989, P NATL ACAD SCI USA, V86, P6562, DOI 10.1073/pnas.86.17.6562; NAGY B, 1979, J BIOL CHEM, V254, P2732; NAGY B, 1978, J BIOL CHEM, V253, P5971; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; POTTER JD, 1975, J BIOL CHEM, V250, P4628; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; SILLEN LG, 1964, SPECIAL PUBLICATION, V17; TSALKOVA TN, 1985, J MOL BIOL, V181, P533, DOI 10.1016/0022-2836(85)90425-5; TSALKOVA TN, 1980, BIOCHIM BIOPHYS ACTA, V624, P196, DOI 10.1016/0005-2795(80)90238-X; WANG ZY, 1990, J BIOL CHEM, V265, P4953; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535	27	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16622	16626						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885591				2022-12-25	WOS:A1991GD63500062
J	PEI, ZH; ELLISON, RT; BLASER, MJ				PEI, ZH; ELLISON, RT; BLASER, MJ			IDENTIFICATION, PURIFICATION, AND CHARACTERIZATION OF MAJOR ANTIGENIC PROTEINS OF CAMPYLOBACTER-JEJUNI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEINS; VACCINIA VIRUS ENCODES; GEL-ELECTROPHORESIS; POLYACRYLAMIDE GELS; SILVER STAIN; ENTERITIS; INFECTION; FLAGELLA; SEQUENCE; GENE	Evidence from developing countries and volunteer studies indicates that immunity to Campylobacter jejuni and Campylobacter coli may be acquired, but the antigenic basis for this protection is poorly defined. We have purified to homogeneity four proteins with molecular weights of 28,000 (PEB1), 29,000 (PEB2), 30,000 (PEB3), and 31,000 (PEB4) from epidemic C. jejuni strain 81-176 using acid extraction and sequential ion-exchange, hydrophobic interaction, and gel filtration chromatography. The relative amino acid compositions of these four proteins are similar. NH2-terminal sequence analysis indicates that all four proteins are different, although the first 35 amino acids of PEB2 and PEB3 are 51.4% homologous. Isoelectric focusing showed that all four are basic proteins with pI of 8.5 for PEBI protein and > 9.3 for the others. Use of the purified proteins as antigens in an IgG enzyme-linked immunosorbent assay (ELISA) found that seroconversion to the PEB1 or PEB3 proteins occurred in 15 of 19 patients with sporadic C. jejuni or C. coli infection. In comparison, only two, six, and 14 of these patients seroconverted to PEB2, PEB4, or the acid extract antigen. In an ELISA with whole bacterial cells as antigens, antiserum to the acid-extracted antigens showed broad recognition of C. jejuni, C. coli, C. fetus, C. lari, and Helicobacter pylori. Antiserum to PEB1 recognized all 35 C. jejuni and all 15 C. coli strains but none of the isolates of the other three bacterial species. The PEB1 and PEB3 proteins appear to be candidate antigens for both a Campylobacter vaccine and for serological assays for the pathogen.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV INFECT DIS,A-3310 MED CTR N,NASHVILLE,TN 37232; VANDERBILT UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232; DEPT VET AFFAIRS MED CTR,NASHVILLE,TN 37212; DEPT VET AFFAIRS MED CTR,MED SERV,DENVER,CO 80220; DEPT VET AFFAIRS MED CTR,RES SERV,DENVER,CO 80220; UNIV COLORADO,SCH MED,DEPT MED,DIV INFECT DIS,DENVER,CO 80220	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Pei, Zhiheng/0000-0001-8570-6747				AMES GFL, 1974, J BIOL CHEM, V249, P634; BARBAS JA, 1988, EMBO J, V7, P625, DOI 10.1002/j.1460-2075.1988.tb02856.x; BLACK RE, 1988, J INFECT DIS, V157, P472, DOI 10.1093/infdis/157.3.472; BLASER MJ, 1984, INFECT IMMUN, V44, P292, DOI 10.1128/IAI.44.2.292-298.1984; BLASER MJ, 1987, JAMA-J AM MED ASSOC, V257, P43, DOI 10.1001/jama.257.1.43; BLASER MJ, 1984, INFECT IMMUN, V43, P986, DOI 10.1128/IAI.43.3.986-993.1984; BLASER MJ, 1981, NEW ENGL J MED, V305, P1444, DOI 10.1056/NEJM198112103052404; BLASER MJ, 1985, J CLIN MICROBIOL, V21, P164, DOI 10.1128/JCM.21.2.164-167.1985; BLASER MJ, 1979, AM J MED, V67, P715, DOI 10.1016/0002-9343(79)90272-9; BLASER MJ, 1986, J INFECT DIS, V153, P249, DOI 10.1093/infdis/153.2.249; BLASER MJ, 1983, INFECT IMMUN, V42, P276, DOI 10.1128/IAI.42.1.276-284.1983; CALDWELL MB, 1985, INFECT IMMUN, V50, P941, DOI 10.1128/IAI.50.3.941-943.1985; CHOWDHURY MNH, 1984, TROP GEOGR MED, V36, P215; CIANCIOTTO NP, 1990, J INFECT DIS, V162, P121, DOI 10.1093/infdis/162.1.121; DEMING MS, 1987, AM J EPIDEMIOL, V126, P525; DUBREUIL JD, 1990, J CLIN MICROBIOL, V28, P1321, DOI 10.1128/JCM.28.6.1321-1328.1990; DUNN BE, 1987, INFECT IMMUN, V55, P1564, DOI 10.1128/IAI.55.7.1564-1572.1987; ENGLEBERG NC, 1989, INFECT IMMUN, V57, P1263, DOI 10.1128/IAI.57.4.1263-1270.1989; GUSTAFSSON K, 1987, J BIOL CHEM, V262, P8776; HARLEY MG, 1987, P NATL ADCAD SCI US, V84, P5153; HARRIS LA, 1987, J BACTERIOL, V169, P5066, DOI 10.1128/jb.169.11.5066-5071.1987; HARRIS NV, 1986, AM J PUBLIC HEALTH, V76, P401, DOI 10.2105/AJPH.76.4.401; HARRIS NV, 1986, AM J PUBLIC HEALTH, V76, P407, DOI 10.2105/AJPH.76.4.407; JONES BN, 1981, J LIQ CHROMATOGR, V4, P565, DOI 10.1080/01483918108059956; KOTWAL GJ, 1989, J VIROL, V63, P600, DOI 10.1128/JVI.63.2.600-606.1989; LOGAN SM, 1983, INFECT IMMUN, V42, P675, DOI 10.1128/IAI.42.2.675-682.1983; MCCOY EC, 1975, INFECT IMMUN, V11, P517, DOI 10.1128/IAI.11.3.517-525.1975; MEINERSMANN RJ, 1990, CURR MICROBIOL, V21, P17, DOI 10.1007/BF02090094; MELO MA, 1990, INFECT IMMUN, V58, P1749; MIOTTI PG, 1987, EUR J EPIDEMIOL, V3, P356, DOI 10.1007/BF00145645; NEWELL DG, 1984, J GEN MICROBIOL, V130, P1201; OAKLEY BR, 1980, ANAL BIOCHEM, V105, P361, DOI 10.1016/0003-2697(80)90470-4; PATTON CM, 1985, J CLIN MICROBIOL, V22, P558, DOI 10.1128/JCM.22.4.558-565.1985; PEI ZH, 1988, J BIOL CHEM, V263, P6416; PEREZPEREZ GI, 1989, J INFECT DIS, V160, P460, DOI 10.1093/infdis/160.3.460; POTTS WJ, 1988, MOL MICROBIOL, V2, P647, DOI 10.1111/j.1365-2958.1988.tb00073.x; RUSSELL RG, 1989, INFECT IMMUN, V57, P1438, DOI 10.1128/IAI.57.5.1438-1444.1989; SMITH GL, 1989, J GEN VIROL, V70, P2333, DOI 10.1099/0022-1317-70-9-2333; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALKER RI, 1986, MICROBIOL REV, V50, P81, DOI 10.1128/MMBR.50.1.81-94.1986; WILLOUGHBY EW, 1983, ANAL BIOCHEM, V130, P353, DOI 10.1016/0003-2697(83)90599-7; YAMAMOTO T, 1987, J BACTERIOL, V169, P1352, DOI 10.1128/jb.169.3.1352-1357.1987	42	96	112	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16363	16369						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885571				2022-12-25	WOS:A1991GD63500022
J	PAUL, S; MEI, S; MODY, B; EKLUND, SH; BEACH, CM; MASSEY, RJ; HAMEL, F				PAUL, S; MEI, S; MODY, B; EKLUND, SH; BEACH, CM; MASSEY, RJ; HAMEL, F			CLEAVAGE OF VASOACTIVE-INTESTINAL-PEPTIDE AT MULTIPLE SITES BY AUTOANTIBODIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC ANTIBODIES; 3-DIMENSIONAL STRUCTURE; DEGRADATION; COMPLEX	Vasoactive intestinal peptide (VIP) fragments generated by autoantibodies purified from the blood of two human beings were separated and sequenced. Based on the identity of these fragments, seven peptide bonds cleaved by the antibodies were identified. Six of the seven scissile bonds are clustered in the region of VIP spanning residues 14-22 and were cleaved by antibodies from both human subjects. The seventh scissile bond is located at residues 7-8 and was cleaved by antibodies from one of the subjects. The scissile bonds link amino acid residues with different size, charge, and hydrophobicity. The hydrolytic activity of the antibodies was selective in that they failed to hydrolyze polypeptides unrelated in sequence to VIP (insulin and atrial natriuretic peptide). These observations demonstrate substrate specific hydrolysis by naturally occurring antibodies and expand the range of peptide bonds hydrolyzed by these antibodies.	UNIV NEBRASKA, MED CTR, DEPT BIOCHEM, OMAHA, NE 68198 USA; UNIV NEBRASKA, MED CTR, DEPT INTERNAL MED, OMAHA, NE 68198 USA; IGEN INC, ROCKVILLE, MD 20852 USA; UNIV KENTUCKY, MACROMOLEC ANAL FACIL, LEXINGTON, KY 40536 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Kentucky	PAUL, S (corresponding author), UNIV NEBRASKA, MED CTR, DEPT PHARMACOL, OMAHA, NE 68198 USA.				PHS HHS [44126, 40348] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AMIT AG, 1985, NATURE, V313, P156, DOI 10.1038/313156a0; BARRETT AJ, 1986, RES MONOG CELL TISSU, V12, P515; BLACKBURN GM, 1989, BIOCHEM J, V262, P381, DOI 10.1042/bj2620381; BLOOM SR, 1979, LANCET, V1, P14; BRENNEMAN DE, 1990, J NEUROSCI RES, V25, P386, DOI 10.1002/jnr.490250316; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FINK AL, 1987, ENZYME MECHANISMS, P159; GEIGER T, 1987, J BIOL CHEM, V262, P785; HAMEL FG, 1986, ENDOCRINOLOGY, V118, P328, DOI 10.1210/endo-118-1-328; HEGERSTRAND A, 1989, P NATL ACAD SCI USA, V86, P5993; MEI S, 1991, IN PRESS J BIOL CHEM, V266; PAUL S, 1989, COLD SPRING HARB SYM, V54, P283; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1990, J IMMUNOL, V145, P1196; PAUL S, 1988, LIFE SCI, V43, P1079, DOI 10.1016/0024-3205(88)90203-2; PAUL S, 1989, J NEUROIMMUNOL, V23, P133, DOI 10.1016/0165-5728(89)90032-5; PAUL S, 1990, J BIOL CHEM, V265, P11910; PRYSORJONES RA, 1989, J ENDOCRINOL, V120, P171, DOI 10.1677/joe.0.1200171; ROSSELIN G, 1986, PEPTIDES, V7, P89, DOI 10.1016/0196-9781(86)90170-1; SAID S, 1982, VASOACTIVE INTESTINA; SAID SI, 1984, PEPTIDES, V5, P144; SHOKAT KM, 1990, ANNU REV IMMUNOL, V8, P335; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; 1986, AFFINITY CHROMATOGR, P12	26	70	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16128	16134						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874750				2022-12-25	WOS:A1991GB97700090
J	SEYAMA, K; NUKIWA, T; TAKABE, K; TAKAHASHI, H; MIYAKE, K; KIRA, S				SEYAMA, K; NUKIWA, T; TAKABE, K; TAKAHASHI, H; MIYAKE, K; KIRA, S			SIIYAMA (SERINE-53 (TCC) TO PHENYLALANINE-53 (TTC)) - A NEW ALPHA-1-ANTITRYPSIN-DEFICIENT VARIANT WITH MUTATION ON A PREDICTED CONSERVED RESIDUE OF THE SERPIN BACKBONE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFICIENCY VARIANT; MOLECULAR-BASIS; CODING SEQUENCE; ANTI-THROMBIN; GENE; INHIBITOR; PROTEIN; ALLELE; EMPHYSEMA; CDNA	Alpha-1-antitrypsin (alpha-1AT), a plasma serine protease inhibitor, increases the risk of precocious pulmonary emphysema in individuals when deficient. Although more than 25 years have passed since a deficiency in the serum level of alpha-1AT was reported, it is only recently that the consequence of the amino acid replacement which leads to the deficient state has been discussed in terms of the crystallographic structure of alpha-1AT and the amino acid residues conserved in the superfamily to which it belongs. Our case involved a 38-year-old Japanese male with alpha-1AT deficiency which was analyzed and identified as a new deficient variant. The serum alpha-1AT of the proband migrated to the S position of the reference serum which is more cathodal than M1, the predominant normal variant, when isoelectric focusing (pH 4.2-4.9) is performed by a combination of Western blotting and crossed immunoelectrophoresis. The new deficient variant is designated as S(iiyama) after his birthplace. Although liver biopsy specimen showed no apparent pathological findings, PAS-positive with diastase-resistant inclusion bodies and immunoreactive aggregates were detected ir, several hepatocytes. In addition, similar alpha-1AT mRNA transcript levels were observed in peripheral blood leukocytes from the proband and healthy subjects by Northern analysis. All the coding exons (exon Ic, II, III, IV, and V) of the alpha-1AT gene of the proband and his family were amplified by polymerase chain reaction and followed by direct sequencing. A single missense mutation, Ser53 (TCC) to Phe53 (TTC) was identified in exon II of the proband's alpha-1AT gene. All his family examined were heterozygous at this base. Ser53 is one of the most conserved residues as predicted by Huber and Carrell (Huber, R., and Carrell, R. W. (1989) Biochemistry 28, 8951-8966) and is thought to contribute to the organization of the internal core element of the alpha-1AT molecule. The mutational matrix number of Ser to Phe substitution is -3, indicating that this change is evolutionally rare. In this regard, a possible explanation for the deficient state in alpha-1AT S(iiyama) is that the change from an uncharged polar to a nonpolar amino acid imposed on the conserved serpin backbone exerts severe effects on the integrity of the molecule, and hence alters the intracellular processing of alpha-1AT.	HOKUSHIN GEN HOSP, DEPT INTERNAL MED, NAGANO, JAPAN; TEIKYO UNIV, SCH MED, DEPT INTERNAL MED 1, TOKYO 173, JAPAN	Teikyo University	SEYAMA, K (corresponding author), JUNTENDO UNIV, SCH MED, DEPT RESP MED, 2-1-1 HONGO, BUNKYO KU, TOKYO 113, JAPAN.							ARNAUD P, 1988, METHOD ENZYMOL, V163, P400; BOCK SC, 1988, BIOCHEMISTRY-US, V27, P6171, DOI 10.1021/bi00416a052; BRANTLY M, 1988, AM J MED, V84, P13; BRANTLY ML, 1988, AM REV RESPIR DIS, V138, P327, DOI 10.1164/ajrccm/138.2.327; BRENNAN SO, 1986, BIOCHIM BIOPHYS ACTA, V873, P13, DOI 10.1016/0167-4838(86)90183-4; CARRELL R, 1985, TRENDS BIOCHEM SCI, V10, P20, DOI 10.1016/0968-0004(85)90011-8; Carrell R.W, 1986, PROTEINASE INHIBITOR, P403; Cox DW, 1989, METABOLIC BASIS INHE, P2409; CRYSTAL RG, 1990, J CLIN INVEST, V85, P1343, DOI 10.1172/JCI114578; CURIEL D, 1989, AM J RESP CELL MOL, V1, P471, DOI 10.1165/ajrcmb/1.6.471; CURIEL DT, 1990, MOL CELL BIOL, V10, P47, DOI 10.1128/MCB.10.1.47; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; FABER JP, 1989, AM J HUM GENET, V45, P161; FRAIZER GC, 1990, J CLIN INVEST, V86, P1878; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GRAHAM A, 1989, HUM GENET, V84, P55, DOI 10.1007/BF00210671; HOFKER MH, 1989, HUM GENET, V81, P264, DOI 10.1007/BF00279001; HOLMES MD, 1990, AM J HUM GENET, V46, P810; HOLMES MD, 1990, BIOCHEM BIOPH RES CO, V170, P1013, DOI 10.1016/0006-291X(90)90493-7; HOLMES MD, 1990, AM REV RESPIR DIS, V142, P1185, DOI 10.1164/ajrccm/142.5.1185; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; JEFFREYS AJ, 1977, CELL, V12, P429, DOI 10.1016/0092-8674(77)90119-2; KURACHI K, 1981, P NATL ACAD SCI-BIOL, V78, P6826, DOI 10.1073/pnas.78.11.6826; LOEBERMANN H, 1984, J MOL BIOL, V177, P531, DOI 10.1016/0022-2836(84)90298-5; LONG GL, 1984, BIOCHEMISTRY-US, V23, P4828, DOI 10.1021/bi00316a003; MATSUNAGA E, 1990, AM J HUM GENET, V46, P602; METCALF JA, 1968, LABORATORY MANUAL NE, P2; NUKIWA T, 1988, AM J HUM GENET, V43, P322; NUKIWA T, 1986, J BIOL CHEM, V261, P5989; NUKIWA T, 1987, BIOCHEMISTRY-US, V26, P5259, DOI 10.1021/bi00391a008; OKAYAMA H, 1989, BIOCHEM BIOPH RES CO, V162, P1560, DOI 10.1016/0006-291X(89)90853-X; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; PERLINO E, 1987, EMBO J, V6, P2767, DOI 10.1002/j.1460-2075.1987.tb02571.x; PERLMUTTER DH, 1985, P NATL ACAD SCI USA, V82, P795, DOI 10.1073/pnas.82.3.795; RABIN M, 1986, SOMAT CELL MOLEC GEN, V12, P209, DOI 10.1007/BF01560668; TAKAHASHI H, 1988, J BIOL CHEM, V263, P15528; YE RD, 1987, J BIOL CHEM, V262, P3718; YOSHIDA A, 1976, P NATL ACAD SCI USA, V73, P1324, DOI 10.1073/pnas.73.4.1324	40	87	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12627	12632						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905728				2022-12-25	WOS:A1991FV18000082
J	JENNE, DE; LOWIN, B; PEITSCH, MC; BOTTCHER, A; SCHMITZ, G; TSCHOPP, J				JENNE, DE; LOWIN, B; PEITSCH, MC; BOTTCHER, A; SCHMITZ, G; TSCHOPP, J			CLUSTERIN (COMPLEMENT LYSIS INHIBITOR) FORMS A HIGH-DENSITY-LIPOPROTEIN COMPLEX WITH APOLIPOPROTEIN-A-I IN HUMAN PLASMA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUANTITATIVE DENSITOMETRIC METHOD; FREE-FLOW ISOTACHOPHORESIS; THIN-LAYER CHROMATOGRAPHY; MEMBRANE ATTACK COMPLEX; RAT VENTRAL PROSTATE; RETE TESTIS FLUID; SULFATED GLYCOPROTEIN-2; MONOCLONAL-ANTIBODIES; CHOLESTEROL TRANSPORT; GENE-EXPRESSION	Clusterin/human complement lysis inhibitor (CLI) is incorporated stoichiometrically into the soluble terminal complement complex and inhibits the cytolytic reaction of purified complement components C5b-9 in vitro. Using an anti-clusterin affinity column, we found that an additional protein component with a molecular mass of 28-kDa co-purifies with clusterin from human plasma. We show by immunoblotting and amino acid sequencing that this component is apolipoprotein A-I (apoA-I). By using physiological salt buffers containing 0.5% Triton X-100, apoA-I is completely dissociated from clusterin bound to the antibody column. Free clusterin immobilized on the antibody-Sepharose selectively retains apoA-I from total human plasma. Delipidated apoA-I and to a lesser extent ultracentrifugation-purified high density lipoproteins (HDL) adsorbed to nitrocellulose also have a binding affinity for purified clusterin devoid of apoA-I. The isolated apoA-I-clusterin complex contains approximately 22% (w/w) lipids which are composed of 54% (mole/mol) total cholesterol (molar ratio of unesterified/ esterified cholesterol, 0.58), 42% phospholipids, and 4% triglycerides. In agreement with the low lipid content, apoA-I-clusterin complexes are detected only in trace amounts in HDL fractions prepared by density ultracentrifugation. In free flow isotachophoresis, the purified apoA-I-clusterin complex has the same mobility as the native clusterin complex in human plasma and is found in the slow-migrating HDL fraction of fasting plasma. Our data indicate that clusterin circulates in plasma as a HDL complex, which may serve not only as an inhibitor of the lytic terminal complement cascade, but also as a regulator of lipid transport and local lipid redistribution.	UNIV LAUSANNE,INST BIOCHEM,CH-1066 EPALINGES,SWITZERLAND; UNIV MUNSTER,INST CLIN CHEM,W-4400 MUNSTER,GERMANY; UNIV MUNSTER,MED LAB,W-4400 MUNSTER,GERMANY; UNIV MUNSTER,INST ARTERIOSCLEROSIS RES,W-4400 MUNSTER,GERMANY	University of Lausanne; University of Munster; University of Munster; University of Munster			Jenne, Dieter Erich/AAP-1414-2020; Peitsch, Manuel/J-7416-2017	Peitsch, Manuel/0000-0001-5324-359X				ANDERSON DW, 1977, BIOCHIM BIOPHYS ACTA, V493, P55, DOI 10.1016/0005-2795(77)90259-8; BANDYK MG, 1990, J UROLOGY, V143, P407, DOI 10.1016/S0022-5347(17)39975-5; BETTUZZI S, 1989, BIOCHEM J, V257, P293, DOI 10.1042/bj2570293; BHAKDI S, 1985, J IMMUNOL METHODS, V80, P25, DOI 10.1016/0022-1759(85)90160-7; BLASCHUK O, 1983, J BIOL CHEM, V258, P7714; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOYLES JK, 1989, J CLIN INVEST, V83, P1015, DOI 10.1172/JCI113943; BRESLOW JL, 1985, ANNU REV BIOCHEM, V54, P699, DOI 10.1146/annurev.biochem.54.1.699; BUTTYAN R, 1989, MOL CELL BIOL, V9, P3473, DOI 10.1128/MCB.9.8.3473; CHENG CY, 1988, BIOCHEM BIOPH RES CO, V155, P398; CHENG CY, 1988, BIOCHEMISTRY-US, V27, P4079, DOI 10.1021/bi00411a026; CHOI NH, 1990, INT IMMUNOL, V2, P413, DOI 10.1093/intimm/2.5.413; COLLARD MW, 1987, BIOCHEMISTRY-US, V26, P3297, DOI 10.1021/bi00386a008; DESILVA HV, 1990, J BIOL CHEM, V265, P14292; DESILVA HV, 1990, J BIOL CHEM, V265, P13240; DESILVA HV, 1990, BIOCHEMISTRY-US, V29, P5380, DOI 10.1021/bi00474a025; DUGUID JR, 1989, P NATL ACAD SCI USA, V86, P7260, DOI 10.1073/pnas.86.18.7260; EISENBERG S, 1984, J LIPID RES, V25, P1017; FRITZ IB, 1989, J CELL PHYSIOL, V140, P18, DOI 10.1002/jcp.1041400104; GRISWOLD MD, 1986, BIOCHEMISTRY-US, V25, P7265, DOI 10.1021/bi00371a003; HAEFLIGER JA, 1989, J BIOL CHEM, V264, P18041; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JAMES RW, 1988, J LIPID RES, V29, P1557; JAMES RW, 1989, 8TH INT S ATH ATH, V8, P259; JENNE D, 1985, BIOSCIENCE REP, V5, P343, DOI 10.1007/BF01116907; JENNE DE, 1989, P NATL ACAD SCI USA, V86, P7123, DOI 10.1073/pnas.86.18.7123; KIRSZBAUM L, 1989, EMBO J, V8, P711, DOI 10.1002/j.1460-2075.1989.tb03430.x; LEGER JG, 1987, BIOCHEM BIOPH RES CO, V147, P196, DOI 10.1016/S0006-291X(87)80106-7; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHEL D, 1989, ONCOGENE RES, V4, P127; Murphy B F, 1989, Int Immunol, V1, P551, DOI 10.1093/intimm/1.5.551; MURPHY BF, 1989, PATHOLOGY, V21, P275, DOI 10.3109/00313028909061073; MURPHY BF, 1988, PATHOLOGY, V20, P130, DOI 10.3109/00313028809066623; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; NOWICKA G, 1990, J LIPID RES, V31, P1947; NOWICKA G, 1990, J LIPID RES, V31, P1173; OBRYAN MK, 1990, J CLIN INVEST, V85, P1477, DOI 10.1172/JCI114594; PEITSCH MC, 1989, ANAL BIOCHEM, V178, P301, DOI 10.1016/0003-2697(89)90642-8; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RENNIE PS, 1988, CANCER RES, V48, P6309; SAWCZUK IS, 1989, KIDNEY INT, V35, P1315, DOI 10.1038/ki.1989.128; SCHMITZ G, 1985, P NATL ACAD SCI USA, V82, P6305, DOI 10.1073/pnas.82.18.6305; SCHMITZ G, 1984, J CHROMATOGR, V307, P81, DOI 10.1016/S0378-4347(00)84074-8; SCHMITZ G, 1990, EUR HEART J, V11, P197, DOI 10.1093/eurheartj/11.suppl_E.197; SCHMITZ G, 1985, J CHROMATOGR, V320, P253, DOI 10.1016/S0021-9673(01)90503-5; SCHMITZ G, 1984, J CHROMATOGR, V307, P65, DOI 10.1016/S0378-4347(00)84073-6; STEINBERG D, 1989, CIRCULATION, V80, P719, DOI 10.1161/01.CIR.80.3.719; TSCHOPP J, 1984, J BIOL CHEM, V259, P7857; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	50	228	234	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11030	11036						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1904058				2022-12-25	WOS:A1991FQ77400052
J	MILES, EW				MILES, EW			THE TRYPTOPHAN SYNTHASE ALPHA-2-BETA-2 COMPLEX - CLEAVAGE OF A FLEXIBLE LOOP IN THE ALPHA-SUBUNIT ALTERS ALLOSTERIC PROPERTIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							YEAST TRIOSEPHOSPHATE ISOMERASE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; 1.9-A RESOLUTION; HINGE REGION; BETA-SUBUNIT; L-SERINE; IDENTIFICATION; SITE; FRAGMENTS	This study explores the catalytic and allosteric roles of a flexible loop in tryptophan synthase. Trypsin is known to cleave the tryptophan synthase alpha-2-beta-2 complex in an alpha-subunit loop at Arg-188. Cleavage yields an active "nicked" alpha-2-beta-2 derivative. The new results provide evidence that the alpha-subunit loop serves two important roles: substrate binding and communicating the effects of substrate binding to the beta-subunit. A role for the loop in substrate binding is supported by our finding that addition of a substrate analogue of the alpha-subunit, alpha-glycerol 3-phosphate, decreases the rate of cleavage by trypsin. An allosteric role for the loop is supported by the finding although the native alpha-2-beta-2 complex is strongly inhibited by alpha-glycerol 3-phosphate, the nicked alpha-2-beta-2 Complex is desensitized to this inhibition. The time course of proteolysis in the presence and absence of alpha-glycerol 3-phosphate is followed by sodium dodecyl sulfate-gel electrophoresis and by assays of activity in the presence and absence of alpha-glycerol 3-phosphate. We use spectroscopic measurements of the pyridoxal phosphate-L-tryptophan intermediates at the active site of the beta-subunit to determine the affinity of the native and nicked enzymes for L-tryptophan and alpha-glycerol 3-phosphate. Although cleavage alters the equilibrium distribution of intermediates and reduces the affinity for alpha-glycerol 3-phosphate, it has little effect on the affinity for amino acids bound to the beta-subunit. We conclude that the loop in the alpha-subunit is important for ligand binding and for communicating the effects of ligand binding from the alpha-subunit to the beta-subunit in the alpha-2-beta-2 complex.			MILES, EW (corresponding author), NIDDKD, BIOCHEM PHARMACOL LAB, BLDG 8, RM 225, BETHESDA, MD 20892 USA.							AHMED SA, 1986, BIOCHEMISTRY-US, V25, P3118, DOI 10.1021/bi00359a008; BEASTY AM, 1985, BIOCHEMISTRY-US, V24, P3547, DOI 10.1021/bi00335a024; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; FARBER GK, 1990, TRENDS BIOCHEM SCI, V15, P228, DOI 10.1016/0968-0004(90)90035-A; GALAKATOS NG, 1989, BIOCHEMISTRY-US, V28, P8167, DOI 10.1021/bi00446a031; HIGGINS W, 1979, BIOCHEMISTRY-US, V18, P4827, DOI 10.1021/bi00589a010; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KIRSCHNER K, 1991, BIOCHEMISTRY-US, V30, P472, DOI 10.1021/bi00216a024; LANE AN, 1991, BIOCHEMISTRY-US, V30, P479, DOI 10.1021/bi00216a025; LANE AN, 1983, EUR J BIOCHEM, V129, P571; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6619, DOI 10.1021/bi00480a010; LOLIS E, 1990, BIOCHEMISTRY-US, V29, P6609, DOI 10.1021/bi00480a009; MARCEAU M, 1990, J BIOL CHEM, V265, P20421; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; Miles E.W., 1986, PYRIDOXAL PHOSPHAT B, V1, P253; MILES EW, 1982, BIOCHEMISTRY-US, V21, P2586, DOI 10.1021/bi00540a002; MILES EW, 1991, ADV ENZYMOL RAMB, V64, P93; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILES EW, 1978, J BIOL CHEM, V253, P6266; MILES EW, 1989, J BIOL CHEM, V264, P6280; Yanofsky C., 1972, ENZYMES, P1, DOI [10.1016/s1874-6047(08)60445-x, DOI 10.1016/S1874-6047(08)60445-X]	24	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10715	10718						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1904055				2022-12-25	WOS:A1991FQ77400002
J	KANG, HS; WELCH, WJ				KANG, HS; WELCH, WJ			CHARACTERIZATION AND PURIFICATION OF THE 94-KDA GLUCOSE-REGULATED PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN BINDING-PROTEIN; HEAT-SHOCK PROTEINS; ENDOPLASMIC-RETICULUM PROTEINS; MAMMALIAN STRESS PROTEINS; CHICK-EMBRYO FIBROBLASTS; LUMINAL ER PROTEINS; AMINO-ACID-ANALOGS; INDUCTION; IDENTIFICATION; GLYCOPROTEIN	Increased synthesis of so-called glucose-regulated proteins (grp) of 78 and 94 kDa occurs in mammalian cells exposed to a variety of agents, including 2-mercaptoethanol, tunicamycin, agents which perturb calcium homeostasis, and amino acid analogs. Herein we describe a number of properties of 94-kDa grp (grp 94) and present a method for its purification to homogeneity. The protein, within the endoplasmic reticulum (ER), is modified by the addition of high mannose-containing oligosaccharides. The predicted amino acid sequence of grp 94, as determined by others, has revealed the protein to contain a putative transmembrane domain near its amino terminus, but in addition, a potential endoplasmic reticulum retention sequence (KDEL) at its COOH terminus. Consequently, the question of whether grp 94 exists as a transmembrane or luminal protein of the ER remains controversial. Results using isolated microsomes subjected to either limited proteolysis or lactoperoxidase-mediated iodination were consistent with the idea that the grp is a transmembrane protein. On the other hand, using the method of sodium carbonate extraction, grp 94 exhibited properties of both a luminal and integral membrane protein. These results raise the question of whether there exist two different forms of grp 94 within the ER.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco	KANG, HS (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033551] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 33551] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; EDWARDS DP, 1984, BIOCHEMISTRY-US, V23, P4427, DOI 10.1021/bi00314a029; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HICKEY E, 1989, MOL CELL BIOL, V9, P2615, DOI 10.1128/MCB.9.6.2615; HIGHTOWER LE, 1980, J CELL PHYSIOL, V102, P407, DOI 10.1002/jcp.1041020315; KASSENBROCK CK, 1988, NATURE, V333, P90, DOI 10.1038/333090a0; KELLEY PM, 1978, CELL, V15, P1277, DOI 10.1016/0092-8674(78)90053-3; KOCH G, 1986, J CELL SCI, V86, P217; KOCH GLE, 1987, J CELL SCI, V87, P491; KOCH GLE, 1988, J CELL SCI, V90, P485; KOYASU S, 1989, J BIOL CHEM, V264, P15083; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKS KW, 1979, BIOCHIM BIOPHYS ACTA, V578, P1, DOI 10.1016/0005-2795(79)90106-5; LEWIS MJ, 1985, J BIOL CHEM, V260, P6926; LEWIS MJ, 1985, J BIOL CHEM, V260, P3050; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MACER DRJ, 1988, J CELL SCI, V91, P61; MARUJAMA K, 1984, J BIOCHEM-TOKYO, V104, P335; MAZZARELLA RA, 1987, J BIOL CHEM, V262, P8875; MIZZEN LA, 1989, J BIOL CHEM, V264, P20664; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; OLDEN K, 1979, P NATL ACAD SCI USA, V76, P791, DOI 10.1073/pnas.76.2.791; POUYSSEGUR J, 1978, CELL, V13, P149; REBBE NF, 1987, GENE, V53, P235, DOI 10.1016/0378-1119(87)90012-6; ROSE JK, 1980, P NATL ACAD SCI-BIOL, V77, P3884, DOI 10.1073/pnas.77.7.3884; SARGAN DR, 1986, BIOCHEMISTRY-US, V25, P6252, DOI 10.1021/bi00368a062; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; SHIU RPC, 1979, BIOCHIM BIOPHYS ACTA, V576, P141, DOI 10.1016/0005-2795(79)90493-8; SHIU RPC, 1977, P NATL ACAD SCI USA, V74, P3840, DOI 10.1073/pnas.74.9.3840; Thomas G P, 1982, Cold Spring Harb Symp Quant Biol, V46 Pt 2, P985; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WELCH WJ, 1985, MOL CELL BIOL, V5, P1229, DOI 10.1128/MCB.5.6.1229; WELCH WJ, 1983, J BIOL CHEM, V258, P7102; WELCH WJ, 1982, J BIOL CHEM, V257, P4949; Welch WJ, 1990, STRESS PROTEINS BIOL, P223; WHELAN SA, 1985, J CELL PHYSIOL, V125, P251, DOI 10.1002/jcp.1041250212; WU FS, 1981, J BIOL CHEM, V256, P5309; ZALA CA, 1980, CAN J BIOCHEM, V58, P1175	47	62	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5643	5649						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1900837				2022-12-25	WOS:A1991FD37000045
J	BENNETT, WF; PAONI, NF; KEYT, BA; BOTSTEIN, D; JONES, AJS; PRESTA, L; WURM, FM; ZOLLER, MJ				BENNETT, WF; PAONI, NF; KEYT, BA; BOTSTEIN, D; JONES, AJS; PRESTA, L; WURM, FM; ZOLLER, MJ			HIGH-RESOLUTION ANALYSIS OF FUNCTIONAL DETERMINANTS ON HUMAN TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ONE-CHAIN; KRINGLE-2 DOMAIN; CORONARY THROMBOLYSIS; MYOCARDIAL-INFARCTION; DIRECTED MUTAGENESIS; PROLONGED CLEARANCE; STRUCTURAL DOMAINS; ESCHERICHIA-COLI; CONTROLLED TRIAL; RAT HEPATOCYTES	Sixty-four variants of human tissue-type plasminogen activator (tPA) were produced using recombinant DNA techniques. Charged residues were converted to alanine in clusters of from one to four changes per variant; these clusters spanned all the domains of the molecule. The variants were expressed by mammalian cells and were analyzed for a variety of properties. Variants of tPA were found that had reduced activity with respect to each tested property; in a few cases increased activity was observed. Analysis of these effects prompted the following conclusions: 1) charged residues in the nonprotease domains are less involved in fibrin stimulation of tPA activity than those in the protease domain, and it is possible to increase the fibrin specificity (i.e. the stimulation of tPA activity by fibrin compared to fibrinogen) by mutations at several sites in the protease domain; 2) the difference in enzymatic activity between the one- and two-chain forms of tPA can be increased by mutations at several sites on the protease domain; 3) binding of tPA to lysine-Sepharose was affected only by mutations to kringle-2, whereas binding to fibrin was affected most by mutations in the other domains; 4) clot lysis was influenced by mutations in all domains except kringle-2; 5) sensitivity to plasminogen activator inhibitor-1 seems to reside exclusively in the region surrounding residue 300. A model of the tPA protease domain has been used to map some of the critical residues and regions.	GENENTECH INC,DEPT PHARMACEUT RES & DEV,SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT ENGN,SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT CELL CULTURE RES & DEV,SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	BENNETT, WF (corresponding author), GENENTECH INC,DEPT CARDIOVASC RES,460 POINT SAN BRUNO BLVD,SAN FRANCISCO,CA 94080, USA.		Wurm, Florian M./D-7224-2013					BAKHIT C, 1987, J BIOL CHEM, V262, P8716; BIRNBOIM HC, 1983, METHOD ENZYMOL, V100, P243; BOOSE JA, 1989, BIOCHEMISTRY-US, V28, P635, DOI 10.1021/bi00428a033; BROWNE MJ, 1988, J BIOL CHEM, V263, P1599; BUGELSKI PJ, 1989, THROMB RES, V53, P287, DOI 10.1016/0049-3848(89)90104-7; CARLSON RH, 1988, ANAL BIOCHEM, V168, P428, DOI 10.1016/0003-2697(88)90340-5; CHMIELEWSKA J, 1988, BIOCHEM J, V251, P327, DOI 10.1042/bj2510327; CLEARY S, 1989, BIOCHEMISTRY-US, V28, P1884, DOI 10.1021/bi00430a068; COLLEN D, 1984, CIRCULATION, V70, P1012, DOI 10.1161/01.CIR.70.6.1012; COLLEN D, 1988, BLOOD, V71, P216; CUNNINGHAM BC, 1989, SCIENCE, V244, P1801; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; FRIBERGER P, 1978, HAEMOSTASIS, V7, P138; FROEHLER BC, 1986, NUCLEIC ACIDS RES, V14, P5399, DOI 10.1093/nar/14.13.5399; FU KP, 1988, THROMB RES, V50, P33, DOI 10.1016/0049-3848(88)90172-7; GARDELL SJ, 1989, J BIOL CHEM, V264, P17947; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; GOLDHABER SZ, 1988, LANCET, V2, P293; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HAIGWOOD NL, 1989, PROTEIN ENG, V2, P611, DOI 10.1093/protein/2.8.611; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; HUSAIN SS, 1989, BLOOD, V74, P999; KALYAN NK, 1988, J BIOL CHEM, V263, P3971; KRUITHOF EKO, 1988, ENZYME, V40, P113, DOI 10.1159/000469153; LARSEN GR, 1989, BLOOD, V73, P1842, DOI 10.1182/blood.V73.7.1842.1842; LAU D, 1988, BIO-TECHNOL, V6, P734, DOI 10.1038/nbt0688-734c; LAU D, 1987, BIO-TECHNOL, V5, P953, DOI 10.1038/nbt0987-953; LOSCALZO J, 1988, J CLIN INVEST, V82, P1391, DOI 10.1172/JCI113743; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; MADISON EL, 1989, NATURE, V339, P721, DOI 10.1038/339721a0; MARKLAND W, 1989, PROTEIN ENG, V3, P117, DOI 10.1093/protein/3.2.117; MORTON PA, 1989, J BIOL CHEM, V264, P7228; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NILSSON S, 1985, THROMB RES, V39, P511, DOI 10.1016/0049-3848(85)90174-4; PARKER JA, 1988, RADIOLOGY, V166, P441, DOI 10.1148/radiology.166.2.3122266; PATTHY L, 1985, CELL, V41, P657, DOI 10.1016/S0092-8674(85)80046-5; PENNICA D, 1983, NATURE, V301, P214, DOI 10.1038/301214a0; PETERSEN LC, 1990, BIOCHEMISTRY-US, V29, P3451, DOI 10.1021/bi00466a005; PETERSEN LC, 1988, BIOCHIM BIOPHYS ACTA, V952, P245, DOI 10.1016/0167-4838(88)90123-9; RAUBER P, 1988, ANAL BIOCHEM, V168, P259, DOI 10.1016/0003-2697(88)90316-8; REFINO CJ, 1988, FIBRINOLYSIS, V2, P30; RIJKEN DC, 1982, J BIOL CHEM, V257, P2920; SOBEL BE, 1984, CIRCULATION, V69, P983, DOI 10.1161/01.CIR.69.5.983; SPELLMAN MW, 1989, J BIOL CHEM, V264, P14100; STERN A, 1989, GENE, V79, P333, DOI 10.1016/0378-1119(89)90215-1; STUMP DC, 1989, CIRCULATION, V80, P1222, DOI 10.1161/01.CIR.80.5.1222; TATE KM, 1987, BIOCHEMISTRY-US, V26, P338, DOI 10.1021/bi00376a002; TOPOL EJ, 1988, J AM COLL CARDIOL, V12, pA24, DOI 10.1016/0735-1097(88)92638-1; TULINSKY A, 1988, PROTEINS, V3, P85, DOI 10.1002/prot.340030203; URANO S, 1989, P NATL ACAD SCI USA, V86, P2568, DOI 10.1073/pnas.86.8.2568; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VANZONNEVELD AJ, 1986, J CELL BIOCHEM, V32, P169, DOI 10.1002/jcb.240320302; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VAUGHAN DE, 1989, J CLIN INVEST, V84, P586, DOI 10.1172/JCI114202; VEHAR GA, 1986, COLD SPRING HARB SYM, V51, P551, DOI 10.1101/SQB.1986.051.01.067; VERHEIJEN JH, 1982, THROMB HAEMOSTASIS, V48, P266; VERHEIJEN JH, 1986, EMBO J, V5, P3525, DOI 10.1002/j.1460-2075.1986.tb04678.x; VIEIRA J, 1987, METHOD ENZYMOL, V155, P3; WIMAN B, 1984, J BIOL CHEM, V259, P3644; 1989, NEW ENGL J MED, V320, P618	62	184	216	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5191	5201						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1900516				2022-12-25	WOS:A1991FC21700076
J	GUTIERREZ, C; MARTIN, G; SOGO, JM; SALAS, M				GUTIERREZ, C; MARTIN, G; SOGO, JM; SALAS, M			MECHANISM OF STIMULATION OF DNA-REPLICATION BY BACTERIOPHAGE-PHI-29 SINGLE-STRANDED DNA-BINDING PROTEIN-P5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBTILIS PHAGE PHI-29; NUCLEAR MAGNETIC-RESONANCE; TERMINAL PROTEIN; ADENOVIRUS TYPE-5; ELECTRON-MICROSCOPY; NUCLEOTIDE-SEQUENCE; GENE-5 PROTEIN; 5' TERMINI; POLYMERASE; VIRUS	Protein p5 is a Bacillus subtilis phage phi-29-encoded protein required for phi-29 DNA replication in vivo. Protein p5 has single-stranded DNA binding (SSB) capacity and stimulates in vitro DNA replication severalfold when phi-29 DNA polymerase is used to replicate either the natural phi-29 DNA template or primed M13 single-stranded DNA (ssDNA). Furthermore, other SSB proteins, including Escherichia coli SSB, T4 gp32, adenovirus DNA-binding protein, and human replication factor A, can functionally substitute for protein p5. The stimulatory effect of phi-29 protein p5 is not due to an increase of the DNA replication rate. When both phi-29 DNA template and M13 competitor ssDNA are added simultaneously to the replication reaction, phi-29 DNA replication is strongly inhibited. This inhibition is fully overcome by adding protein p5, suggesting that protein p5-coated M13 ssDNA is no longer able to compete for replication factors, probably phi-29 DNA polymerase, which has a strong affinity for ssDNA. Electron microscopy demonstrates that protein p5 binds to M13 ssDNA forming saturated complexes with a smoothly contoured appearance and producing a 2-fold reduction of the DNA length. Protein p5 also binds to ssDNA in the phi-29 replicative intermediates produced in vitro, which are similar in structure to those observed in vivo. Our results strongly suggest that phi-29 protein p5 is the phi-29 SSB protein active during phi-29 DNA replication.	UNIV AUTONOMA MADRID, CSIC, CTR BIOL MOLEC, CANTO BLANCO, E-28049 MADRID, SPAIN; SWISS FED INST TECHNOL, INST ZELLBIOL, CH-8093 ZURICH, SWITZERLAND	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); Swiss Federal Institutes of Technology Domain; ETH Zurich			Salas, Margarita/J-9873-2014; Gutierrez, Crisanto/ABH-8782-2020	Salas, Margarita/0000-0001-5939-3441; Martin Estrada, Gil/0000-0002-5217-3849; Gutierrez, Crisanto/0000-0001-8905-8222	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM027242] Funding Source: NIH RePORTER; NIGMS NIH HHS [5 R01 GM27242-11] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAER R, 1984, NATURE, V310, P207, DOI 10.1038/310207a0; BLANCO L, 1985, P NATL ACAD SCI USA, V82, P6404, DOI 10.1073/pnas.82.19.6404; BLANCO L, 1989, J BIOL CHEM, V264, P8935; BLANCO L, 1984, P NATL ACAD SCI-BIOL, V81, P5325, DOI 10.1073/pnas.81.17.5325; BROWN WC, 1990, P NATL ACAD SCI USA, V87, P677, DOI 10.1073/pnas.87.2.677; CASASFINET JR, 1987, FEBS LETT, V220, P347, DOI 10.1016/0014-5793(87)80844-X; CHASE JW, 1986, ANNU REV BIOCHEM, V55, P103, DOI 10.1146/annurev.biochem.55.1.103; CUYPERS T, 1974, BIOCHEM BIOPH RES CO, V59, P557, DOI 10.1016/S0006-291X(74)80016-1; DAVISON AJ, 1986, J GEN VIROL, V67, P1759, DOI 10.1099/0022-1317-67-9-1759; DEJONG EAM, 1989, J MOL BIOL, V206, P119, DOI 10.1016/0022-2836(89)90528-7; DEJONG EAM, 1989, J MOL BIOL, V206, P133, DOI 10.1016/0022-2836(89)90529-9; DELIUS H, 1972, J MOL BIOL, V67, P341, DOI 10.1016/0022-2836(72)90454-8; ESCARMIS C, 1989, VIROLOGY, V169, P152, DOI 10.1016/0042-6822(89)90051-2; GALLO ML, 1989, J VIROL, V63, P5023, DOI 10.1128/JVI.63.12.5023-5029.1989; GRIFFITH JD, 1984, COLD SPRING HARB SYM, V49, P553, DOI 10.1101/SQB.1984.049.01.062; INCIARTE MR, 1980, J VIROL, V34, P187, DOI 10.1128/JVI.34.1.187-199.1980; KEDINGER C, 1978, J VIROL, V26, P364, DOI 10.1128/JVI.26.2.364-379.1978; Kelly T J, 1988, Adv Virus Res, V34, P1, DOI 10.1016/S0065-3527(08)60514-X; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KHAMIS MI, 1987, J BIOL CHEM, V262, P10938; KHAMIS MI, 1987, FEBS LETT, V211, P155, DOI 10.1016/0014-5793(87)81427-8; KING GC, 1987, BIOCHEMISTRY-US, V26, P2929, DOI 10.1021/bi00384a039; KING GC, 1988, BIOCHEMISTRY-US, V27, P6947, DOI 10.1021/bi00418a041; KORNBERG A, 1980, DNA REPLICATION, P489; KRUIJER W, 1981, NUCLEIC ACIDS RES, V9, P4439, DOI 10.1093/nar/9.18.4439; LINDBERG G, 1989, J BIOL CHEM, V264, P12700; LINDENBAUM JO, 1986, J BIOL CHEM, V261, P218; LOHMAN TM, 1988, TRENDS BIOCHEM SCI, V13, P250; LUCCHINI R, 1987, J MOL BIOL, V196, P829, DOI 10.1016/0022-2836(87)90408-6; MARTIN G, 1989, NUCLEIC ACIDS RES, V17, P3663, DOI 10.1093/nar/17.10.3663; MARTIN G, 1988, GENE, V67, P193, DOI 10.1016/0378-1119(88)90396-4; MCGEOCH DJ, 1988, J GEN VIROL, V69, P1531, DOI 10.1099/0022-1317-69-7-1531; MELLADO RP, 1980, VIROLOGY, V104, P84, DOI 10.1016/0042-6822(80)90367-0; MYERS TW, 1988, J BIOL CHEM, V263, P17006; NAKASHIM.Y, 1974, FEBS LETT, V43, P125; NEALE GAM, 1990, J VIROL, V64, P630, DOI 10.1128/JVI.64.2.630-638.1990; PEETERS BPH, 1983, J MOL BIOL, V169, P197, DOI 10.1016/S0022-2836(83)80180-6; PENALVA MA, 1982, P NATL ACAD SCI-BIOL, V79, P5522, DOI 10.1073/pnas.79.18.5522; PRASAD BVV, 1987, J MOL BIOL, V193, P579; PRIETO I, 1984, P NATL ACAD SCI-BIOL, V81, P1639, DOI 10.1073/pnas.81.6.1639; PRIGODICH RV, 1986, BIOCHEMISTRY-US, V25, P3666, DOI 10.1021/bi00360a029; QUINN CO, 1986, J VIROL, V60, P653, DOI 10.1128/JVI.60.2.653-661.1986; SALAS M, 1988, CURR TOP MICROBIOL, V136, P71; SALAS M, 1978, J MOL BIOL, V119, P269, DOI 10.1016/0022-2836(78)90438-2; SANCAR A, 1981, P NATL ACAD SCI-BIOL, V78, P4274, DOI 10.1073/pnas.78.7.4274; SHAMOO Y, 1989, BIOCHEMISTRY-US, V28, P7409, DOI 10.1021/bi00444a039; SOGO JM, 1989, METHOD ENZYMOL, V170, P142; SOGO JM, 1982, VIROLOGY, V116, P1, DOI 10.1016/0042-6822(82)90398-1; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; SOGO JM, 1986, J MOL BIOL, V189, P189, DOI 10.1016/0022-2836(86)90390-6; SOGO JM, 1987, ELECTRON MICROS, P61; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; VANDERVLIET PC, 1978, EUR J BIOCHEM, V86, P389; VLCEK C, 1986, GENE, V46, P215, DOI 10.1016/0378-1119(86)90406-3; WANG YS, 1990, J VIROL, V64, P2082, DOI 10.1128/JVI.64.5.2082-2089.1990; WATABE K, 1984, P NATL ACAD SCI-BIOL, V81, P5374, DOI 10.1073/pnas.81.17.5374; WILLIAMS KR, 1981, J BIOL CHEM, V256, P1754; WOLLENZIEN PL, 1988, PSORALEN DNA PHOTOBI, V2, P51	58	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2104	2111						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899235				2022-12-25	WOS:A1991EV51500017
J	ROWLETT, RS; GARGIULO, NJ; SANTOLI, FA; JACKSON, JM; CORBETT, AH				ROWLETT, RS; GARGIULO, NJ; SANTOLI, FA; JACKSON, JM; CORBETT, AH			ACTIVATION AND INHIBITION OF BOVINE CARBONIC ANHYDRASE-III BY DIANIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC MECHANISM; SKELETAL-MUSCLE; HYDRATION; CO2; KINETICS; RESOLUTION; ISOENZYME; BUFFER; FLOW; CAT	We have found that many dianionic species, at millimolar concentrations, significantly activate or inhibit the bovine carbonic anhydrase III-catalyzed hydration of CO2. Dianionic species such as HPO4(2-) and SO3(2-), with pK(b) values near 7, are activators, whereas weakly basic species such as SO4(2-) act as inhibitors. Both activation and inhibition are partial hyperbolic in nature and do not appear to compete with monoanionic linear inhibitors like N3-. Our kinetic data are consistent with a formal mechanism of action for carbonic anhydrase III that is directly analogous to that of carbonic anhydrase II, in which Lys-64 of carbonic anhydrase III can act as an intramolecular H+ transfer group during CO2 hydration. Our data suggest that dianionic inhibitors depress the rate of H+ transfer during turnover by stabilizing the protonated form of Lys-64. We postulate that dianionic activators enhance the rate of a rate-limiting H+ transfer step in the mechanism, probably by acting directly as H+ acceptors.			ROWLETT, RS (corresponding author), COLGATE UNIV,DEPT CHEM,HAMILTON,NY 13346, USA.		Corbett, Anita/AAH-6106-2021	Corbett, Anita/0000-0002-0461-6895; Rowlett, Roger/0000-0002-9859-8164				CLELAND WW, 1967, ADV ENZYMOL RAMB, V29, P1; ENGBERG P, 1985, ARCH BIOCHEM BIOPHYS, V241, P628, DOI 10.1016/0003-9861(85)90589-2; ERIKSSON AE, 1988, PROTEINS, V4, P274, DOI 10.1002/prot.340040406; ERIKSSON AE, 1988, THESIS U SWEDEN UPPS; HAWK PB, 1954, PRACTICAL PHYSL CHEM, P269; HURST RO, 1967, CAN J BIOCHEM CELL B, V45, P2015, DOI 10.1139/o67-235; JONSSON BH, 1976, FEBS LETT, V64, P310, DOI 10.1016/0014-5793(76)80317-1; KANNAN KK, 1975, P NATL ACAD SCI USA, V72, P51, DOI 10.1073/pnas.72.1.51; KARARLI T, 1984, ANN NY ACAD SCI, V429, P129, DOI 10.1111/j.1749-6632.1984.tb12323.x; KARARLI T, 1985, J BIOL CHEM, V260, P3484; KHALIFAH RG, 1971, J BIOL CHEM, V246, P2561; LINDSKOG S, 1968, EUR J BIOCHEM, V3, P453, DOI 10.1111/j.1432-1033.1967.tb19552.x; LINDSKOG S, 1984, J MOL CATAL, V23, P357, DOI 10.1016/0304-5102(84)80021-8; POCKER Y, 1982, J AM CHEM SOC, V104, P2424, DOI 10.1021/ja00373a016; POCKER Y, 1977, BIOCHEMISTRY-US, V16, P5698, DOI 10.1021/bi00645a008; RAY WJ, 1983, BIOCHEMISTRY-US, V22, P4625, DOI 10.1021/bi00289a003; REN X, 1988, EUR J BIOCHEM, V173, P73, DOI 10.1111/j.1432-1033.1988.tb13968.x; REN XL, 1988, BIOCHIM BIOPHYS ACTA, V953, P79, DOI 10.1016/0167-4838(88)90011-8; RICKLI EE, 1964, J BIOL CHEM, V239, P1065; ROWLETT RS, 1982, J AM CHEM SOC, V104, P6737, DOI 10.1021/ja00388a043; ROWLETT RS, 1984, J PROTEIN CHEM, V3, P369, DOI 10.1007/BF01025173; SANYAL G, 1984, ANN NY ACAD SCI, V429, P165, DOI 10.1111/j.1749-6632.1984.tb12330.x; SHELTON JB, 1988, BIOCHEM SOC T, V16, P853, DOI 10.1042/bst0160853; SILVERMAN DN, 1988, ACCOUNTS CHEM RES, V21, P30, DOI 10.1021/ar00145a005; SILVERMAN DN, 1986, BIOCHEMISTRY-US, V25, P8402, DOI 10.1021/bi00374a012; SIMONSSON I, 1982, EUR J BIOCHEM, V123, P29, DOI 10.1111/j.1432-1033.1982.tb06494.x; SIMONSSON I, 1979, EUR J BIOCHEM, V93, P409, DOI 10.1111/j.1432-1033.1979.tb12837.x; SIMONSSON I, 1982, EUR J BIOCHEM, V129, P163; STEINER H, 1975, EUR J BIOCHEM, V59, P253, DOI 10.1111/j.1432-1033.1975.tb02449.x; TIBELL L, 1984, BIOCHIM BIOPHYS ACTA, V789, P302, DOI 10.1016/0167-4838(84)90186-9; TU CK, 1986, J BIOL CHEM, V261, P100; TU CK, 1990, BIOCHEMISTRY-US, V29, P6400, DOI 10.1021/bi00479a009; TU CK, 1989, BIOCHEMISTRY-US, V28, P7913, DOI 10.1021/bi00445a054; TU CK, 1986, J AM CHEM SOC, V108, P6065, DOI 10.1021/ja00279a079; WEAST RC, 1988, CRC HDB CHEM PHYSICS, pD163	35	40	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					933	941						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898739				2022-12-25	WOS:A1991ET17700042
J	HORIUCHI, H; KAWATA, M; KATAYAMA, M; YOSHIDA, Y; MUSHA, T; ANDO, S; TAKAI, Y				HORIUCHI, H; KAWATA, M; KATAYAMA, M; YOSHIDA, Y; MUSHA, T; ANDO, S; TAKAI, Y			A NOVEL PRENYLTRANSFERASE FOR A SMALL GTP-BINDING PROTEIN HAVING A C-TERMINAL CYS-ALA-CYS STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE BRAIN CYTOSOL; RAS PROTEINS; SUBSEQUENT BINDING; REGULATORY PROTEIN; PURIFICATION; DISSOCIATION; FARNESYL; P21RAS; GDP; TRANSFERASE	smg p25A/rab3A p25 is a member of the small GTP-binding protein superfamily which is implicated in intracellular vesicle transport. smg p25A has a cDNA-predicted C-terminal structure of Cys-Ala-Cys. The protein purified from bovine brain membranes is geranylgeranylated at both the two cysteine residues and carboxyl-methylated at the C-terminal cysteine residue. Two types of prenyltransferase for small GTP-binding proteins have thus far been reported: ras p21 farnesyltransferase (ras p21 FT) and rhoA p21 geranylgeranyltransferase (rhoA p21 GGT). Neither of them geranylgeranylated smg p25A having a C-terminal Cys-Ala-Cys structure. In this paper, a smg p25A GGT was partially purified from bovine brain cytosol and separated from the ras p21 FT and rhoA p21 GGT by column chromatographies. smg p25A GGT transferred the geranylgeranyl moiety from geranylgeranyl pyrophosphate to both the two cysteine residues in the C-terminal Cys-Ala-Cys structure of smg p25A. smg p25A GGT did not use farnesyl pyrosphosphate as a substrate and was also inactive on C-Ha-ras p21 and rhoA p21 with either farnesyl pyrophosphate or geranylgeranyl pyrophosphate as a substrate. These results indicate that there are at least three types of prenyltransferase for small GTP-binding proteins in mammalian tissues.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ARAKI S, 1991, MOL CELL BIOL, V11, P1438, DOI 10.1128/MCB.11.3.1438; ARAKI S, 1990, J BIOL CHEM, V265, P13007; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; GOODMAN LE, 1990, P NATL ACAD SCI USA, V87, P9665, DOI 10.1073/pnas.87.24.9665; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HIROYOSHI M, 1991, J BIOL CHEM, V266, P2962; HORI Y, 1991, ONCOGENE, V6, P515; ISOMURA M, 1991, ONCOGENE, V6, P119; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KATAYAMA M, 1991, J BIOL CHEM, V266, P12639; KAWAMURA S, 1991, BIOCHEM BIOPH RES CO, V174, P1095, DOI 10.1016/0006-291X(91)91533-I; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SATOH T, 1988, BIOCHIM BIOPHYS ACTA, V949, P97, DOI 10.1016/0167-4781(88)90059-0; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; TACHIBANA S, 1988, PEPTIDE CHEM, P481; TAKAI Y, 1991, IN PRESS INT REV CYT; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M	33	75	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					16981	16984						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910036				2022-12-25	WOS:A1991GF44500005
J	SHUPNIK, MA; ROSENZWEIG, BA				SHUPNIK, MA; ROSENZWEIG, BA			IDENTIFICATION OF AN ESTROGEN-RESPONSIVE ELEMENT IN THE RAT LH-BETA GENE - DNA-ESTROGEN RECEPTOR INTERACTIONS AND FUNCTIONAL-ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GONADOTROPIN-RELEASING-HORMONE; MESSENGER RIBONUCLEIC-ACIDS; THYROID-HORMONE; COOPERATIVE BINDING; PROLACTIN GENE; RNA LEVELS; PITUITARY; ESTRADIOL; EXPRESSION; TRANSCRIPTION	Previous work from this laboratory demonstrated that 17-beta estradiol (E2) can directly stimulate the transcription rate of the rat luteinizing hormone-beta (LH-beta) gene and that an upstream portion of the LH-beta-gene between -2.0 and -0.6 kilobases could confer an E2-stimulated response to a reporter gene in transient expression assays. To localize the LH-beta estrogen response element (ERE) by biological function, portions of the 5'-flanking region of the LH-beta-gene or synthetic oligonucleotides were inserted in expression vectors next to the herpes simplex virus thymidine kinase promoter fused to the chloramphenicol acetyltransferase gene. Constructs were transfected into GH3 cells, and transfected cells were treated for 48 h with E2. E2 stimulation of activity (2-4-fold) occurred with constructs containing the 15-base pair palindromic sequence (GGACACCATCTGTCC), found at bases -1173 to -1159 relative to the transcriptional start site in the LH-beta-gene. A construct containing a synthetic oligonucleotide of this putative LH-beta ERE was stimulated 1.7-3-fold by E2, while a construct containing two copies of the sequence was stimulated to a slightly higher level (2.5-4.0-fold). An oligonucleotide in which the palindrome was mutated failed to confer E2 stimulation, and mutation of the palindromic region within the upstream region of the LH-beta-gene also eliminated the E2 response. The anti-estrogen tamoxifen could not elicit a response, nor could dehydrotestosterone or dexamethasone; however, thyroid hormone treatment resulted in a 2-2.5-fold stimulation. The 15-base pair LH-beta-gene palindrome was found to bind estrogen receptor (ER) complex directly by gel retardation experiments. Labeled LH-beta ERE DNA formed three complexes with proteins from immature rat uterine extract. Two of these were associated with ER complexes, as determined by the comigration of [H-3] estradiol bound to ER with these complexes, and by the ability of anti-ER antibody to associate with these complexes. The affinity of the LH-beta ERE for ER was calculated by Scatchard analysis to be 2.2-5.0 nM, an approximately 5-10-fold lower affinity than for the ERE in the vitellogenin A2 gene region. The mutated ERE, which had no biological activity, could not compete effectively for binding to ER. ER which was heat-transformed at 30-degrees-C had a similar affinity (2-5 nM) for the ERE as ER occupied with E2 (2-4 nM), while ER occupied by estrone had a lower affinity (9 nM). There was no observed alteration in the pattern of migration of LH-beta ERE.ER complexes formed with heat-transformed ER, or ER occupied by various estrogens. These data indicate that E2 can act directly through the ER at a specific regulatory element in the upstream region of the rat LH-beta-gene. This interaction results in E2-stimulated transcription of the gene and has important implications for the physiological regulation of the gene by sex steroids.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MED, DIV ENDOCRINOL & METAB, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, DEPT PHYSIOL, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD025719] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK038942] Funding Source: NIH RePORTER; NICHD NIH HHS [R01 HD25719] Funding Source: Medline; NIDDK NIH HHS [DK38942] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BELCHETZ PE, 1978, SCIENCE, V202, P631, DOI 10.1126/science.100883; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; CATT KJ, 1978, REPRODUCTIVE ENDOCRI, P37; COUNIS R, 1983, BIOCHEM BIOPH RES CO, V114, P65, DOI 10.1016/0006-291X(83)91594-2; Crowley W F Jr, 1985, Recent Prog Horm Res, V41, P473; CURTIS SW, 1990, MOL ENDOCRINOL, V4, P276, DOI 10.1210/mend-4-2-276; DAY RN, 1989, MOL ENDOCRINOL, V3, P931, DOI 10.1210/mend-3-6-931; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V17, P6545; FEAVERS IM, 1987, P NATL ACAD SCI USA, V84, P7453, DOI 10.1073/pnas.84.21.7453; FURLOW JD, 1990, ENDOCRINOLOGY, V127, P1028, DOI 10.1210/endo-127-3-1028; GHARIB SD, 1986, J CLIN INVEST, V77, P582, DOI 10.1172/JCI112340; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; GLASS CK, 1988, CELL, V54, P313, DOI 10.1016/0092-8674(88)90194-8; HAISENLEDER DJ, 1991, ENDOCRINOLOGY, V128, P509, DOI 10.1210/endo-128-1-509; HAISENLEDER DJ, 1988, MOL ENDOCRINOL, V2, P338, DOI 10.1210/mend-2-4-338; HODIN RA, 1989, SCIENCE, V244, P76, DOI 10.1126/science.2539642; KLOCK G, 1987, NATURE, V329, P734, DOI 10.1038/329734a0; KUMAR V, 1988, CELL, V55, P145, DOI 10.1016/0092-8674(88)90017-7; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LALLOZ MRA, 1988, ENDOCRINOLOGY, V122, P1681, DOI 10.1210/endo-122-4-1681; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; LEVINE JE, 1982, ENDOCRINOLOGY, V111, P1439, DOI 10.1210/endo-111-5-1439; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MERCER JE, 1988, NEUROENDOCRINOLOGY, V47, P563, DOI 10.1159/000124969; MIDGLEY AR, 1971, J CLIN ENDOCR METAB, V33, P962, DOI 10.1210/jcem-33-6-962; MURDOCH FE, 1990, BIOCHEMISTRY-US, V29, P8377, DOI 10.1021/bi00488a026; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; PAUL SJ, 1990, MOL ENDOCRINOL, V4, P1943, DOI 10.1210/mend-4-12-1943; PERHEENTUPA A, 1990, ENDOCRINOLOGY, V126, P3204, DOI 10.1210/endo-126-6-3204; RAMEY JW, 1987, ENDOCRINOLOGY, V120, P1503, DOI 10.1210/endo-120-4-1503; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASSON S, 1988, MOL ENDOCRINOL, V2, P307, DOI 10.1210/mend-2-4-307; SASSON S, 1983, J BIOL CHEM, V258, P8118; SAVOYMOORE RT, 1980, SCIENCE, V209, P942, DOI 10.1126/science.6250218; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHUPNIK MA, 1988, ENDOCRINOLOGY, V122, P1842, DOI 10.1210/endo-122-5-1842; SHUPNIK MA, 1989, MOL ENDOCRINOL, V3, P474, DOI 10.1210/mend-3-3-474; SHUPNIK MA, 1990, MOL ENDOCRINOL, V4, P1444, DOI 10.1210/mend-4-10-1444; SHUPNIK MA, 1989, J BIOL CHEM, V264, P80; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; STEINER RA, 1982, ENDOCRINOLOGY, V111, P2055, DOI 10.1210/endo-111-6-2055; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; WIERMAN ME, 1990, BIOL REPROD, V42, P563, DOI 10.1095/biolreprod42.3.563; WIERMAN ME, 1989, ENDOCRINOLOGY, V124, P272, DOI 10.1210/endo-124-1-272; WINDLE JJ, 1990, MOL ENDOCRINOL, V4, P597, DOI 10.1210/mend-4-4-597; ZMEILI SM, 1986, ENDOCRINOLOGY, V119, P1867, DOI 10.1210/endo-119-4-1867	48	75	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17084	17091						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894604				2022-12-25	WOS:A1991GF44500021
J	JI, JP; SARGENT, RG; MATHEWS, CK				JI, JP; SARGENT, RG; MATHEWS, CK			T4-PHAGE RIBONUCLEOTIDE REDUCTASE - ALLOSTERIC REGULATION INVIVO BY THYMIDINE TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							DIPHOSPHATE REDUCTASE; BACTERIOPHAGE-T4; MUTAGENESIS; PHAGE-T4; SEQUENCE; COMPLEX; ENZYMES; POOLS; NRDA; GENE	Based upon analyses of purified enzyme preparations, T4 bacteriophage-coded ribonucleotide reductase is considered to be relatively insensitive to control by allosteric inhibition. However, two factors suggest that CDP reduction to dCDP is feedback-controlled by dTTP in infected cells. First, the pool of 5-hydroxymethyldeoxycytidine triphosphate, which expands manyfold upon infection by a dCMP deaminase-deficient T4 mutant, shrinks to near-normal levels as a consequence of dTTP accumulation, and ribonucleotide reductase is the only apparent control point. Second, analysis of mutagenesis by 5-bromodeoxyuridine suggests that most induced mutations result from localized pool depletion of 5-hydroxymethyl-dCTP at replication sites, as if 5-bromo-dUTP were behaving like dTTP in inhibiting the CDP reductase activity of the phage enzyme. We found that CDP reductase activity in crude extracts of T4 phage-infected bacteria is sensitive to inhibition by either dTTP or 5-bromo-dUTP, at concentrations as low as 0.01 mM. However, in partially purified enzyme preparations that sensitivity is lost. Although we don't know the basis for this loss of feedback sensitivity, the results suggest that kinetic properties of enzymes in intact cells are determined by the cellular milieu in ways not apparent from analysis of purified enzymes.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331	Oregon State University								ALLEN JR, 1983, J BIOL CHEM, V258, P5746; BERGLUND O, 1975, J BIOL CHEM, V250, P7450; BERGLUND O, 1972, J BIOL CHEM, V247, P7270; COOK KS, 1983, J BIOL CHEM, V258, P6064; FLANEGAN JB, 1977, J BIOL CHEM, V252, P3019; HOPKINS RL, 1980, P NATL ACAD SCI-BIOL, V77, P1801, DOI 10.1073/pnas.77.4.1801; JI JP, 1991, MOL GEN GENET, V226, P257, DOI 10.1007/BF00273611; MATHEWS CK, 1988, TRENDS BIOCHEM SCI, V13, P394, DOI 10.1016/0968-0004(88)90182-X; Moen L K, 1988, J Mol Recognit, V1, P48, DOI 10.1002/jmr.300010109; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; SARGENT RG, 1989, MOL GEN GENET, V217, P13; SARGENT RG, 1987, J BIOL CHEM, V262, P5546; SJOBERG BM, 1986, EMBO J, V5, P2031, DOI 10.1002/j.1460-2075.1986.tb04460.x; SLABAUGH MB, 1984, J VIROL, V52, P507, DOI 10.1128/JVI.52.2.507-514.1984; SRERE PA, 1990, STRUCTURAL ORG ASPEC; THELANDER L, 1979, ANNU REV BIOCHEM, V48, P133, DOI 10.1146/annurev.bi.48.070179.001025; TOMICH PK, 1974, J BIOL CHEM, V249, P7613; TSENG MJ, 1988, J BIOL CHEM, V263, P16242	18	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16289	16292						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885561				2022-12-25	WOS:A1991GD63500009
J	SUZUKI, T; MATSUNO, K; TAKIYA, S; OHNO, K; UENO, K; SUZUKI, Y				SUZUKI, T; MATSUNO, K; TAKIYA, S; OHNO, K; UENO, K; SUZUKI, Y			PURIFICATION AND CHARACTERIZATION OF AN ENHANCER-BINDING PROTEIN OF THE FIBROIN GENE .1. COMPLETE PURIFICATION OF FIBROIN FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION; SEQUENCE; EXTRACTS; PROMOTER; SITES	An enhancer-binding protein of the fibroin gene, fibroin factor 1 (FF1), has been purified to homogeneity from crude nuclear extracts of posterior silk gland cells where this gene is transcribed specifically. There is a multiplicity of FF1; the FF1 activity was eluted as at least three major fractions on column chromatographies. FF1 is able to form a stable complex with the enhancer DNA sequence in the presence of another proteinous factor named FF2, which lacks ability to bind DNA molecules by itself. One of FF1 forms, FF1a, was purified with a combination of classical purification techniques without using a sequence-specific affinity column, and identified as a protein with molecular mass 125 kDa using sodium dodecyl sulfatepolyacrylamide gel electrophoresis. To obtain homogeneous protein of FF1a, purification of more than 26,000-fold from the starting nuclear extract was necessary.	NATL INST BASIC BIOL,DEPT DEV BIOL,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)			Takiya, Shigeharu/A-6439-2012; Suzuki, Toshiharu/B-5342-2013					HUI CC, 1990, J MOL BIOL, V213, P651, DOI 10.1016/S0022-2836(05)80253-0; HUI CC, 1989, GENE AMST, V85, P4033; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; MATSUNO K, 1989, J BIOL CHEM, V264, P18707; MATSUNO K, 1989, J BIOL CHEM, V264, P4599; SUZUKI T, 1988, J BIOL CHEM, V263, P5979; SUZUKI T, 1991, J BIOL CHEM, V266, P16942; SUZUKI Y, 1990, DEV GROWTH DIFFER, V32, P179; SUZUKI Y, 1986, P NATL ACAD SCI USA, V83, P9522, DOI 10.1073/pnas.83.24.9522; TAKIYA S, 1990, EMBO J, V9, P489, DOI 10.1002/j.1460-2075.1990.tb08135.x; TSUDA M, 1981, CELL, V27, P175, DOI 10.1016/0092-8674(81)90371-8	13	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16935	16941						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885619				2022-12-25	WOS:A1991GD63500109
J	JOHNSON, DL; FAN, RS; TREINIES, ML				JOHNSON, DL; FAN, RS; TREINIES, ML			ANALYSIS OF THE MOLECULAR MECHANISMS FOR THE SPECIES-SPECIFIC TRANSCRIPTION OF DROSOPHILA AND HUMAN TRANSFER-RNA GENE-TRANSCRIPTION COMPONENTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-III; INVITRO TRANSCRIPTION; RIBOSOMAL-RNA; PARTIAL-PURIFICATION; COMPLEX-FORMATION; SEQUENCE; BINDING; 5'-FLANKING; SEPARATION; INITIATION	The transcription of eucaryotic tRNA genes requires two factors IIIB and IIIC, in addition to RNA polymerase III, to reconstitute this process in vitro. We have examined the functional exchangeability of these components from Drosophila and human systems. The reconstitution of heterologous IIIB and IIIC components demonstrated that neither factor will functionally substitute for the homologous components to activate tRNA gene transcription. The addition of the heterologous Drosophila factors to HeLa transcription assays causes an inhibition of RNA synthesis that is dependent upon the order of addition of these proteins to the DNA template. Thus, it appears that tRNA gene transcription in these systems is species-specific. We have further analyzed the reason for the apparent incompatibilities of these components by the use of stable complex formation assays. We find that human HeLa IIIB and Drosophila IIIC are unable to form stably associated complexes with a tRNA gene template, whereas the Drosophila IIIB and HeLa IIIC do form stable but nonproductive complexes. These results demonstrate that specific IIIC-IIIB interactions are critical in the formation of productive transcription complexes and are responsible for the observed species specificity of Drosophila and human tRNA gene transcription.	UNIV SO CALIF,SCH MED,DEPT BIOCHEM,LOS ANGELES,CA 90033	University of Southern California	JOHNSON, DL (corresponding author), UNIV SO CALIF,SCH PHARM,DEPT MOLEC PHARMACOL & TOXICOL,LOS ANGELES,CA 90033, USA.				NIGMS NIH HHS [GM-40623] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM040623] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RE, 1984, EMBO J, V3, P2793, DOI 10.1002/j.1460-2075.1984.tb02211.x; BELL SP, 1989, CELL, V59, P489, DOI 10.1016/0092-8674(89)90032-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURKE DJ, 1985, J BIOL CHEM, V260, P816; BURKE DJ, 1983, J BIOL CHEM, V258, P5224; DEAN N, 1987, NUCLEIC ACIDS RES, V15, P9895, DOI 10.1093/nar/15.23.9895; DEAN N, 1988, MOL CELL BIOL, V8, P3017, DOI 10.1128/MCB.8.8.3017; DINGERMANN T, 1983, J BIOL CHEM, V258, P395; DINGERMANN T, 1982, J BIOL CHEM, V257, P4738; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; FUHRMAN SA, 1984, J BIOL CHEM, V259, P1934; GASKINS CJ, 1989, NUCLEIC ACIDS RES, V17, P781, DOI 10.1093/nar/17.2.781; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GRUMMT I, 1982, NATURE, V296, P173, DOI 10.1038/296173a0; KASSAVETIS GA, 1989, MOL CELL BIOL, V9, P2551, DOI 10.1128/MCB.9.6.2551; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KLEKAMP MS, 1986, J BIOL CHEM, V261, P2819; KOVELMAN R, 1990, GENE DEV, V4, P646, DOI 10.1101/gad.4.4.646; LASSAR AB, 1983, SCIENCE, V222, P740, DOI 10.1126/science.6356356; LOFQUIST A, 1986, J BIOL CHEM, V261, P4600; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; OTTONELLO S, 1987, EMBO J, V6, P1921, DOI 10.1002/j.1460-2075.1987.tb02452.x; PALMER JM, 1990, TRENDS BIOCHEM SCI, V15, P300, DOI 10.1016/0968-0004(90)90018-7; SCHAACK J, 1984, J BIOL CHEM, V259, P1461; SCHAACK J, 1983, J BIOL CHEM, V258, P2447; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHARP SJ, 1985, CRC CR REV BIOCH MOL, V19, P107, DOI 10.3109/10409238509082541; SILVERMAN S, 1979, J BIOL CHEM, V254, P290; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; SPRAGUE KU, 1980, CELL, V22, P171, DOI 10.1016/0092-8674(80)90165-8; WAMPLER SL, 1990, J BIOL CHEM, V265, P21223	31	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16037	16043						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874746				2022-12-25	WOS:A1991GB97700077
J	CECCARELLI, EA; VIALE, AM; KRAPP, AR; CARRILLO, N				CECCARELLI, EA; VIALE, AM; KRAPP, AR; CARRILLO, N			EXPRESSION, ASSEMBLY, AND PROCESSING OF AN ACTIVE-PLANT FERREDOXIN-NADP+ OXIDOREDUCTASE AND ITS PRECURSOR PROTEIN IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; SPINACH FERREDOXIN; BINDING-SITE; REDUCTASE; CDNA; CHLOROPLASTS; RESIDUES; PROBES	The flavoprotein ferredoxin-NADP+ reductase (FNR) catalyzes the final step of the photosynthetic electron transport chain, i.e. the reduction of NADP+ by ferredoxin. A cloned FNR cDNA from a pea library (Newman, B., and Gray, J. (1988) Plant Mol. Biol. 10, 511-520) was used to construct plasmids which express the apoenzyme in Escherichia coli. Two recombinant vectors were prepared, one containing the sequence corresponding to the mature enzyme and another including, in addition, the sequence of the transit peptide that directs FNR to the chloroplast. These proteins were expressed as fusion products to the NH2-terminal portion of beta-galactosidase. In both cases, a 35-kDa immunoreactive polypeptide was the major product, suggesting that the proteins were processed in vivo. NH2-terminal sequence determination of the purified recombinant proteins indicate cleavage at positions -1/-2 with respect to the normal processing site in chloroplasts. The processed enzymes showed enzymatic activities and spectral properties that were similar or identical to those of native plant FNR. When a La protease-deficient E. coli strain was used as a host, the expressed FNR precursor was found to be poorly processed, associated to bacterial pellets, and showed no detectable FNR activity. The overall results indicate that acquisition of the native enzyme conformation and assembly of the prosthetic group takes place in the bacterial host, generating an enzyme that is, as far as studied, indistinguishable from plant FNR.	UNIV NACL ROSARIO,FAC CIENCIAS BIOQUIM & FARMACEUT,DEPT CIENCIAS BIOL,SUIPACHA 531,RA-2000 ROSARIO,ARGENTINA; UNIV NACL ROSARIO,FAC CIENCIAS BIOQUIM & FARMACEUT,DEPT MICROBIOL,RA-2000 ROSARIO,ARGENTINA	National University of Rosario; National University of Rosario			Ceccarelli, Eduardo A./M-8699-2014	Ceccarelli, Eduardo A./0000-0001-5776-3306				ALIVERTI A, 1990, EUR J BIOCHEM, V191, P551, DOI 10.1111/j.1432-1033.1990.tb19156.x; Carlton BC, 1981, MANUAL METHODS GENER, P222; CARRILLO N, 1981, J BIOL CHEM, V256, P6823; CARRILLO N, 1983, BIOCHEMISTRY-US, V22, P5889, DOI 10.1021/bi00294a031; CARRILLO N, 1985, EUR J BIOCHEM, V150, P469, DOI 10.1111/j.1432-1033.1985.tb09045.x; Carrillo N, 1987, TOPICS PHOTOSYNTHESI, V8, P527; CECCARELLI EA, 1985, FEBS LETT, V190, P165, DOI 10.1016/0014-5793(85)80450-6; CHAN RL, 1984, ARCH BIOCHEM BIOPHYS, V229, P340, DOI 10.1016/0003-9861(84)90160-7; CHAN RL, 1987, ARCH BIOCHEM BIOPHYS, V253, P56, DOI 10.1016/0003-9861(87)90636-9; CIDARIA D, 1985, EUR J BIOCHEM, V146, P295, DOI 10.1111/j.1432-1033.1985.tb08652.x; FORTI G, 1970, ARCH BIOCHEM BIOPHYS, V140, P107, DOI 10.1016/0003-9861(70)90014-7; GADDA G, 1990, J BIOL CHEM, V265, P11955; GROSSMAN AR, 1982, J BIOL CHEM, V257, P1558; JANSEN T, 1988, CURR GENET, V13, P517, DOI 10.1007/BF02427758; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHALOWSKI CB, 1989, PLANT PHYSIOL, V89, P817, DOI 10.1104/pp.89.3.817; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6; SHERIFF S, 1981, J MOL BIOL, V145, P441, DOI 10.1016/0022-2836(81)90214-X; Shin M, 1971, METHOD ENZYMOL, V23, P440; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALLEJOS RH, 1984, J BIOL CHEM, V259, P8048; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YAO Y, 1984, J BIOCHEM-TOKYO, V95, P1513, DOI 10.1093/oxfordjournals.jbchem.a134759; YOUNG RA, 1983, P NATL ACAD SCI-BIOL, V80, P1194, DOI 10.1073/pnas.80.5.1194; ZANETTI G, 1983, EUR J BIOCHEM, V132, P201, DOI 10.1111/j.1432-1033.1983.tb07348.x; ZANETTI G, 1976, BIOCHIM BIOPHYS ACTA, V445, P14, DOI 10.1016/0005-2744(76)90157-1; ZANETTI G, 1979, BIOCHIM BIOPHYS ACTA, V569, P127	32	33	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14283	14287						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907276				2022-12-25	WOS:A1991FZ35100028
J	GRIMMINGER, F; SCHOLZ, C; BHAKDI, S; SEEGER, W				GRIMMINGER, F; SCHOLZ, C; BHAKDI, S; SEEGER, W			SUBHEMOLYTIC DOSES OF ESCHERICHIA-COLI HEMOLYSIN EVOKE LARGE QUANTITIES OF LIPOXYGENASE PRODUCTS IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PLATELET-ACTIVATING FACTOR; ARACHIDONIC-ACID METABOLISM; HUMAN-ENDOTHELIAL CELLS; EICOSAPENTAENOIC ACID; FATTY-ACIDS; ALPHA-HEMOLYSIN; BOVINE NEUTROPHILS; LEUKOTRIENE-B4; RELEASE	Polymorphonuclear leukocytes (PMN) have been identified as preferred target cells for Escherichia coli hemolysin in human blood (Bhakdi, S., Greulich, S., Muhly, M., Eberspacher, B., Becker, H., Thiele, A., and Hugo, F. (1989) J. Exp. Med. 169, 737-754). Leukotriene and 5-hydroxyeicosatetraenoic acid generation was investigated in human PMN challenged with E. coli hemolysin in the absence or presence of free arachidonic acid or eicosapentaenoic acid (EPA). In the absence of exogenous free fatty acids, E. coli hemolysin (0.01-10 hemolytic units/ml) induced moderate generation of leukotriene B4 (LTB4) and its omega-oxidation products. The presence of free arachidonic acid (10-mu-M) during E. coli hemolysin (0.1 hemolytic unit/ml) challenge evoked the generation of large quantities of these products (> 100 pmol/1.5 x 10(7) PMN). In parallel, large amounts of 5-hydroxyeicosatetraenoic acid and nonenzymatic LTA4 hydrolysis products appeared. Product release peaked or plateaued 5-10 min after E. coli hemolysin challenge. The presence of exogenous EPA upon E. coli hemolysin challenge resulted in the exclusive generation of LTB5 and metabolites, LTA5 decay products and 5-hydroxyeicosapentaenoic acid. Dose and time dependences corresponded to those with arachidonic acid provision, and the total of EPA-derived products surpassed that of arachidonic acid metabolites in corresponding experiments approximately 2-fold. Increasing the time between free fatty acid provision and E. coli hemolysin challenge resulted in a rapid decline in the generation of arachidonic acid or EPA metabolites. Thus, subhemolytic doses of E. coli hemolysin evoke marked PMN eicosanoid generation that is dependent on exogenous free fatty acid supply, with total amounts approximating those found in calcium ionophore-stimulated neutrophils.	UNIV GIESSEN,DEPT MED MICROBIOL,W-6300 GIESSEN,GERMANY	Justus Liebig University Giessen	GRIMMINGER, F (corresponding author), UNIV GIESSEN,DEPT INTERNAL MED,W-6300 GIESSEN,GERMANY.			Grimminger, Friedrich/0000-0001-8725-6276; Seeger, Werner/0000-0003-1946-0894				BHAKDI S, 1989, J EXP MED, V169, P737, DOI 10.1084/jem.169.3.737; BHAKDI S, 1986, INFECT IMMUN, V52, P63, DOI 10.1128/IAI.52.1.63-69.1986; BHAKDI S, 1988, PROG ALLERGY, V40, P1; BHAKDI S, 1987, REV PHYSL BIOCH PHAR, V107, P148; CAVALIERI SJ, 1984, MICROBIOL REV, V48, P326, DOI 10.1128/MMBR.48.4.326-343.1984; CERRA FB, 1990, CRIT CARE MED, V18, pS154; CHABOT MC, 1987, BIOCHIM BIOPHYS ACTA, V922, P214, DOI 10.1016/0005-2760(87)90157-3; CHILTON FH, 1989, BIOCHEM J, V258, P327, DOI 10.1042/bj2580327; CHILTON FH, 1988, J BIOL CHEM, V263, P5260; CLAESSON HE, 1988, EUR J BIOCHEM, V173, P93, DOI 10.1111/j.1432-1033.1988.tb13971.x; CLANCY RM, 1983, P NATL ACAD SCI-BIOL, V80, P7200, DOI 10.1073/pnas.80.23.7200; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FIGARD PH, 1986, J LIPID RES, V27, P771; Friberger P, 1982, Prog Clin Biol Res, V93, P195; FUNFSTUCK R, 1986, INFECTION, V14, P145, DOI 10.1007/BF01643482; GODFREY RW, 1987, J CELL BIOL, V104, P925, DOI 10.1083/jcb.104.4.925; GOLDMAN DW, 1983, BIOCHEM BIOPH RES CO, V117, P282, DOI 10.1016/0006-291X(83)91572-3; GRIMMINGER F, 1990, J IMMUNOL, V144, P1866; GRIMMINGER F, 1988, BLOOD, V72, P1687; GRIMMINGER F, 1988, J IMMUNOL, V141, P2431; HACKER J, 1983, INFECT IMMUN, V42, P57, DOI 10.1128/IAI.42.1.57-63.1983; HAINES KA, 1987, BIOCHEM J, V241, P55, DOI 10.1042/bj2410055; HAM EA, 1983, P NATL ACAD SCI-BIOL, V80, P4349, DOI 10.1073/pnas.80.14.4349; HAMMARSTROM S, 1975, P NATL ACAD SCI USA, V72, P5130, DOI 10.1073/pnas.72.12.5130; HEIDEL JR, 1989, AM J PATHOL, V134, P671; HJORTH R, 1981, J IMMUNOL METHODS, V43, P95, DOI 10.1016/0022-1759(81)90040-5; IBE BO, 1988, BIOCHIM BIOPHYS ACTA, V960, P309, DOI 10.1016/0005-2760(88)90039-2; KORONAKIS V, 1987, J BACTERIOL, V169, P1509, DOI 10.1128/jb.169.4.1509-1515.1987; KRAGBALLE K, 1987, J INVEST DERMATOL, V88, P555, DOI 10.1111/1523-1747.ep12470151; LEAF A, 1988, NEW ENGL J MED, V318, P549, DOI 10.1056/NEJM198803033180905; LEE TH, 1988, CLIN SCI, V74, P467, DOI 10.1042/cs0740467; LEE TH, 1984, J BIOL CHEM, V259, P2383; LO RYC, 1987, INFECT IMMUN, V55, P1987, DOI 10.1128/IAI.55.9.1987-1996.1987; MACKMAN N, 1984, MOL GEN GENET, V193, P312, DOI 10.1007/BF00330686; MACLOUF J, 1989, BLOOD, V74, P703; MAHADEVAPPA VG, 1989, J CELL BIOCHEM, V40, P341, DOI 10.1002/jcb.240400310; MENESTRINA G, 1988, FEBS LETT, V232, P217, DOI 10.1016/0014-5793(88)80420-4; MENESTRINA G, 1987, BIOCHIM BIOPHYS ACTA, V905, P109, DOI 10.1016/0005-2736(87)90014-9; NADEAU M, 1984, CAN J BIOCHEM CELL B, V62, P1321, DOI 10.1139/o84-168; NATHANIEL DJ, 1985, BIOCHEM BIOPH RES CO, V131, P827, DOI 10.1016/0006-291X(85)91314-2; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OCHI K, 1983, J BIOL CHEM, V258, P5754; POWELL WS, 1984, J BIOL CHEM, V259, P3082; POWELL WS, 1989, J BIOL CHEM, V264, P5364; PRESCOTT SM, 1984, J BIOL CHEM, V259, P7615; REINHOLD SL, 1989, J BIOL CHEM, V264, P21652; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; SAYA A, 1988, PROSTAGLANDINS LEUKO, V34, P47; SEEGER W, 1986, J IMMUNOL, V137, P1286; SEEGER W, 1989, J CLIN INVEST, V84, P220, DOI 10.1172/JCI114144; SELLMAYER A, 1987, BIOCHIM BIOPHYS ACTA, V927, P417, DOI 10.1016/0167-4889(87)90107-8; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; STOLL LL, 1987, J CELL PHYSIOL, V133, P103, DOI 10.1002/jcp.1041330113; STRATHDEE CA, 1987, INFECT IMMUN, V55, P3233, DOI 10.1128/IAI.55.12.3233-3236.1987; SWENDSEN CL, 1987, BIOCHIM BIOPHYS ACTA, V919, P79, DOI 10.1016/0005-2760(87)90220-7; TAKAYAMA H, 1989, BIOCHEM J, V258, P427, DOI 10.1042/bj2580427; TANIZAWA H, 1989, BIOCHEM PHARMACOL, V38, P2559; TAYLOR SM, 1987, J LEUKOCYTE BIOL, V42, P253, DOI 10.1002/jlb.42.3.253; TERANO T, 1984, PROSTAGLANDINS, V27, P217, DOI 10.1016/0090-6980(84)90075-3; TERANO T, 1986, PROG LIPID RES, V25, P129, DOI 10.1016/0163-7827(86)90026-3; TOCHER DR, 1986, BIOCHIM BIOPHYS ACTA, V876, P592, DOI 10.1016/0005-2760(86)90048-2; TOU JS, 1984, LIPIDS, V19, P573, DOI 10.1007/BF02534713; UNTERBERG A, 1987, ACTA NEUROPATHOL, V73, P209, DOI 10.1007/BF00686613; WEBER PC, 1986, PROG LIPID RES, V25, P273, DOI 10.1016/0163-7827(86)90056-1; WELCH RA, 1981, NATURE, V294, P665, DOI 10.1038/294665a0; WELCH RA, 1984, INFECT IMMUN, V43, P156, DOI 10.1128/IAI.43.1.156-160.1984	68	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14262	14269						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907275				2022-12-25	WOS:A1991FZ35100025
J	MCNEIL, M; DAFFE, M; BRENNAN, PJ				MCNEIL, M; DAFFE, M; BRENNAN, PJ			LOCATION OF THE MYCOLYL ESTER SUBSTITUENTS IN THE CELL-WALLS OF MYCOBACTERIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAS-CHROMATOGRAPHY; MASS-SPECTROMETRY; TUBERCULOSIS; ARABINOGALACTAN; PEPTIDOGLYCAN; LEPRAE	The question of the precise location of mycolic acids, the single most distinctive cell wall entity of members of the Mycobacterium genus, has now been addressed. The free hydroxyl functions of the arabinogalactan component of the mycobacterial cell wall were O-methylated under conditions in which the mycolyl esters were not cleaved. Subsequent replacement of the mycolyl functions with O-ethyl groups resulted in an acid- and base-stable differentially O-alkylated surrogate polysaccharide, more amenable to analysis. Complete hydrolysis, reduction, acetylation, and gas chromatography/mass spectrometry revealed the unexpected finding that the mycolyl substituents were selectively and equally distributed on the 5-hydroxyl functions of terminal- and 2-linked arabinofuranosyl (Araf) residues. Further analysis of the O-alkylated cell wall through partial acid hydrolysis, NaB[H-2]4 reduction, pentadeuterioethylation, and gas chromatography/mass spectrometry demonstrated that the mycolyl units are clustered in groups of four on the previously recognized nonreducing terminal pentaarabinosyl unit [beta-Araf-(1 --> 2)-alpha-Araf)2-3,5-alpha-Araf. However, only about two-thirds of the available pentasaccharide units are so substituted. Thus, the antigenicity of the arabinan component of mycobacterial cell walls may be explained by the fact that about one-third of the pentaarabinosyl units are not mycolyated and are available for interaction with the immune system. On the other hand, the extreme hydrophobicity and impenetrability of the mycobacterial cell may be explained by the same motif also acting as the fulcrum for massive esterified paraffin residues. New fundamental information on the structure of mycobacterial cell walls will aid in our comprehension of its impenetrability to antibiotics and role in immunopathogenesis and persistence of disease.	COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523	Colorado State University					NIAID NIH HHS [N01 AI-05074, AI-18357] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI005074, R01AI018357, R22AI018357, R37AI018357] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMARNACASCH C, 1970, B SOC CHIM BIOL, V52, P145; AZUMA I, 1968, J BACTERIOL, V96, P1885, DOI 10.1128/JB.96.5.1885-1887.1968; AZUMA I, 1974, JNCI-J NATL CANCER I, V52, P95, DOI 10.1093/jnci/52.1.95; AZUMA I, 1969, J BACTERIOL, V98, P331, DOI 10.1128/JB.98.1.331-333.1969; BJORVATN B, 1976, CLIN EXP IMMUNOL, V26, P388; BRENNAN PJ, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P55; CAMPHAUSEN RT, 1987, J BACTERIOL, V169, P5473, DOI 10.1128/jb.169.12.5473-5480.1987; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DANNENBERG AJ, 1989, REV INFECT DIS, V11, P5369; DRAPER P, 1982, BIOL MYCOBACTERIA, V1, P9; Goren M.B., 1979, TUBERCULOSIS, P69; GOREN MB, 1978, AM REV RESPIR DIS, V118, P151; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HIRSCHFIELD GR, 1990, J BACTERIOL, V172, P1005, DOI 10.1128/jb.172.2.1005-1013.1990; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1989, J IMMUNOL, V142, P2864; JARLIER V, 1990, J BACTERIOL, V172, P1418, DOI 10.1128/jb.172.3.1418-1423.1990; KANETSUN.F, 1969, BIOCHIM BIOPHYS ACTA, V173, P341, DOI 10.1016/0005-2736(69)90117-5; KAUFMANN SHE, 1989, CURR OPIN IMMUNOL, V1, P431, DOI 10.1016/0952-7915(88)90023-4; KOTANI S, 1971, BIKEN J, V14, P379; LEDERER E, 1975, MOL CELL BIOCHEM, V7, P87, DOI 10.1007/BF01792076; MCNEIL M, 1982, METHOD ENZYMOL, V83, P3; MCNEIL M, 1990, J BIOL CHEM, V265, P18200; MCNEIL M, 1987, CARBOHYD RES, V169, P299; MELANCONKAPLAN J, 1988, P NATL ACAD SCI USA, V85, P1917, DOI 10.1073/pnas.85.6.1917; MINNIKIN DE, 1982, BIOL MYCOBACTERIA, V1, P95; MISAKI A, 1974, J BIOCHEM-TOKYO, V76, P15, DOI 10.1093/oxfordjournals.jbchem.a130540; PETIT JF, 1984, MYCOBACTERIA SOURC A, P301; PREHM P, 1980, CARBOHYD RES, V78, P372, DOI 10.1016/0008-6215(80)90018-X; VALENT BS, 1980, CARBOHYD RES, V79, P165, DOI 10.1016/S0008-6215(00)83830-6; WIETZERB.J, 1970, BIOCHEM BIOPH RES CO, V40, P57, DOI 10.1016/0006-291X(70)91045-4; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353	32	166	174	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13217	13223						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1906464				2022-12-25	WOS:A1991FX13200066
J	GRIMM, B; SMITH, AJ; KANNANGARA, CG; SMITH, M				GRIMM, B; SMITH, AJ; KANNANGARA, CG; SMITH, M			GABACULINE-RESISTANT GLUTAMATE 1-SEMIALDEHYDE AMINOTRANSFERASE OF SYNECHOCOCCUS - DELETION OF A TRIPEPTIDE CLOSE TO THE NH2 TERMINUS AND INTERNAL AMINO-ACID SUBSTITUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREENING BARLEY LEAVES; DELTA-AMINOLEVULINATE; ASPARTATE-AMINOTRANSFERASE; BIOSYNTHESIS; PHOSPHATE; MECHANISM; MUTANTS; ENZYMES; PROTEIN; DNA	Glutamate 1-semialdehyde aminotransferase (GSA-AT) is the last enzyme in the C5 pathway converting glutamate into the tetrapyrrole precursor delta-aminolevulinate in plants, algae, and several bacteria. Sequence analysis of the genes encoding GSA-AT in barley, Synechococcus, and Escherichia coli revealed 50-70% similarity in the primary structures of the proteins. The enzyme is inhibited rapidly by gabaculine when added in approximately stoichiometric amounts with the enzyme. A gabaculine-tolerant Synechococcus strain, GR6, was found to produce a GSA-AT less sensitive to the inhibitor. Accordingly, the mutant gene was isolated and sequenced. In comparison with the wild-type gene it contains a deletion of nine nucleotides (position 12-20) and a guanine to adenine substitution (position 743). This resulted in the loss of the amino acids serine, proline, and phenylalanine (position 5-7) close to the NH2 terminus of the enzyme and an exchange of Met-248 for isoleucine in the middle of the polypeptide chain. Wild-type and mutant GSA-AT were expressed in E. coli and purified close to homogeneity. Although the specific activity of the mutant GSA-AT was only one-fifth of the wild type, it displayed a 100-fold increased resistance to gabaculine. Peaks in the absorption spectrum of the purified recombinant GSA-ATs at 335 and 417 nm are typical of a transaminase containing a B-6 cofactor. Incubation with substrate and with inhibitor induced spectral changes characteristic of other gabaculine-sensitive, B-6-requiring enzymes.	UNIV COLL ABERYSTWYTH, DEPT BIOCHEM, ABERYSTWYTH SY23 3DD, DYFED, WALES; BRIGHAM YOUNG UNIV, DEPT CHEM, PROVO, UT 84602 USA	Aberystwyth University; Brigham Young University	GRIMM, B (corresponding author), CARLSBERG LAB, DEPT PHYSIOL, GAMLE CARLSBERG VEJ 10, DK-2500 COPENHAGEN, DENMARK.							AVISSAR YJ, 1989, PLANT PHYSIOL, V89, P852, DOI 10.1104/pp.89.3.852; BEALE SI, 1990, CHLOROPHYLLS; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braunstein AE., 1973, ENZYMES, V3d, P379, DOI [10.1016/S1874-6047%2808%2960122-5, DOI 10.1016/S1874-6047%2808%2960122-5]; BUJARD H, 1981, METHOD ENZYMOL, V155, P410; BULL AD, 1989, BIOCHEM SOC T, V17, P911, DOI 10.1042/bst0170911; BULL AD, 1990, ARCH MICROBIOL, V154, P56; ELLIOTT T, 1990, J BACTERIOL, V172, P7071, DOI 10.1128/jb.172.12.7071-7084.1990; GOTTESMAN S, 1981, J BACTERIOL, V148, P265, DOI 10.1128/JB.148.1.265-273.1981; GOUGH SP, 1989, CARLSBERG RES COMMUN, V54, P99, DOI 10.1007/BF02908302; GRIMM B, 1989, CARLSBERG RES COMMUN, V54, P67, DOI 10.1007/BF02907586; GRIMM B, 1990, P NATL ACAD SCI USA, V87, P4169, DOI 10.1073/pnas.87.11.4169; GRIMM B, 1991, MOL GEN GENET, V225, P1; HOOBER JK, 1988, CARLSBERG RES COMMUN, V53, P11, DOI 10.1007/BF02908411; HOUGHTON JD, 1989, CARLSBERG RES COMMUN, V54, P131, DOI 10.1007/BF02907183; JAHN D, 1991, J BIOL CHEM, V266, P161; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; KAHN A, 1987, CARLSBERG RES COMMUN, V52, P73, DOI 10.1007/BF02910429; KANNANGARA CG, 1985, CARLSBERG RES COMMUN, V50, P179, DOI 10.1007/BF02907144; KANNANGARA CG, 1984, CARLSBERG RES COMMUN, V49, P417, DOI 10.1007/BF02907783; KANNANGARA CG, 1978, CARLSBERG RES COMMUN, V43, P185, DOI 10.1007/BF02914241; KANNANGARA CG, 1988, TRENDS BIOCHEM SCI, V13, P139; KIRSCH JF, 1984, J MOL BIOL, V174, P497, DOI 10.1016/0022-2836(84)90333-4; MAUZERALL D, 1956, J BIOL CHEM, V219, P435; MEHTA PK, 1989, EUR J BIOCHEM, V186, P249, DOI 10.1111/j.1432-1033.1989.tb15202.x; MORINO Y, 1984, METHOD ENZYMOL, V106, P116; MORINO Y, 1990, ANN NY ACAD SCI, V585, P32, DOI 10.1111/j.1749-6632.1990.tb28039.x; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; ONEILL GP, 1990, IN PRESS BIOFACTORS; RANDO RR, 1977, BIOCHEMISTRY-US, V16, P4604, DOI 10.1021/bi00640a012; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARDI V, 1963, BIOCHEM J, V88, P172, DOI 10.1042/bj0880172; SHEMIN D, 1953, J AM CHEM SOC, V75, P4873, DOI 10.1021/ja01115a546; SMITH AJ, 1967, J BACTERIOL, V94, P972, DOI 10.1128/JB.94.4.972-983.1967; SOPER TS, 1982, J BIOL CHEM, V257, P3930; TORCHINSKY YM, 1986, VITAMIN B6 PYRIDOXAL, V2, P179; WANG WY, 1981, CARLSBERG RES COMMUN, V46, P243, DOI 10.1007/BF02906501	39	39	42	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12495	12501						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905724				2022-12-25	WOS:A1991FV18000063
J	DYER, DG; BLACKLEDGE, JA; THORPE, SR; BAYNES, JW				DYER, DG; BLACKLEDGE, JA; THORPE, SR; BAYNES, JW			FORMATION OF PENTOSIDINE DURING NONENZYMATIC BROWNING OF PROTEINS BY GLUCOSE - IDENTIFICATION OF GLUCOSE AND OTHER CARBOHYDRATES AS POSSIBLE PRECURSORS OF PENTOSIDINE INVIVO	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIABETES-MELLITUS; GLYCATED PROTEINS; MAILLARD REACTION; HUMAN COLLAGEN; CROSS-LINKING; AGING PROCESS; GLYCOSYLATION; AGE; N-EPSILON-(CARBOXYMETHYL)LYSINE; SPECIFICITY	A fluorescent compound has been detected in proteins browned during Maillard reactions with glucose in vitro and shown to be identical to pentosidine, a pentose-derived fluorescent cross-link formed between arginine and lysine residues in collagen (Sell, D. R., and Monnier, V. M. (1989) J. Biol. Chem. 264, 21597-21602). Pentosidine was the major fluorophore formed during nonenzymatic browning of ribonuclease and lysozyme by glucose, but accounted for < 1% of nondisulfide cross-links in protein dimers formed during the reaction. Pentosidine was formed in greatest yields in reactions of pentoses with lysine and arginine in model systems but was also formed from glucose, fructose, ascorbate, Amadori compounds, 3-deoxyglucosone, and other sugars. Pentosidine was not formed from peroxidized polyunsaturated fatty acids or malondialdehyde. Its formation from carbohydrates was inhibited under nitrogen or anaerobic conditions and by aminoguanidine, an inhibitor of advanced glycation and browning reactions. Pentosidine was detected in human lens proteins, where its concentration increased gradually with age, but it did not exceed trace concentrations (less-than-or-equal-to 5-mu-mol/mol lysine), even in the 80-year-old lens. Although its precise carbohydrate source in vivo is uncertain and it is present in only trace concentrations in tissue proteins, pentosidine appears to be a useful biomarker for assessing cumulative damage to proteins by nonenzymatic browning reactions with carbohydrates.	UNIV S CAROLINA,DEPT CHEM,COLUMBIA,SC 29208; UNIV S CAROLINA,SCH CHEM,COLUMBIA,SC 29208	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; University of South Carolina; University of South Carolina System; University of South Carolina Columbia					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019971, R37DK019971] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19971] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHMED MU, 1988, J BIOL CHEM, V263, P8816; AHMED MU, 1986, J BIOL CHEM, V261, P4889; BAYNE SJW, 1990, GLYCATED PROTEINS DI, P221; Baynes JW, 1989, MAILLARD REACTION AG; BROWNLEE M, 1986, SCIENCE, V232, P1629, DOI 10.1126/science.3487117; CERAMI A, 1985, J AM GERIATR SOC, V33, P626, DOI 10.1111/j.1532-5415.1985.tb06319.x; COHEN MP, 1986, DIABETES PROTEIN GLY; DEROME AE, 1987, MODERN NMR TECHNIQUE, P133; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1991, BIOCHEMISTRY-US, V30, P1205, DOI 10.1021/bi00219a007; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; DUNN JA, 1990, MAILLARD REACTION FO, P379; DYER DG, 1991, IN PRESS J NUTR SCI; EBLE AS, 1983, J BIOL CHEM, V258, P9406; Harding JJ, 1984, EYE B, V1b, P207; HAYASHI T, 1985, AGR BIOL CHEM TOKYO, V49, P3131, DOI 10.1080/00021369.1985.10867244; HEATH H, 1962, EXP EYE RES, V1, P362, DOI 10.1016/S0014-4835(62)80025-6; ISBELL HS, 1952, J RES NAT BUR STAND, V48, P163, DOI 10.6028/jres.048.023; KIM JH, 1967, ANAL BIOCHEM, V20, P258, DOI 10.1016/0003-2697(67)90031-0; LAYNE E, 1957, METHOD ENZYMOL, V3, P450; LEDL F, 1990, ANGEW CHEM INT EDIT, V29, P565, DOI 10.1002/anie.199005653; LYONS TJ, 1985, DIABETOLOGIA, V28, P2, DOI 10.1007/BF00276991; LYONS TJ, 1990, GLYCATED PROTEINS DI, P265; MEANS GE, 1971, CHEM MODIFICATION PR, P194; MONNIER VM, 1984, P NATL ACAD SCI-BIOL, V81, P583, DOI 10.1073/pnas.81.2.583; MONNIER VM, 1986, NEW ENGL J MED, V314, P403, DOI 10.1056/NEJM198602133140702; MONNIER VM, 1981, SCIENCE, V211, P491, DOI 10.1126/science.6779377; MONNIER VM, 1990, J GERONTOL, V45, pB105, DOI 10.1093/geronj/45.4.B105; PATRICK JS, 1990, J GERONTOL, V45, pB18, DOI 10.1093/geronj/45.1.B18; RICHMOND ML, 1982, J DAIRY SCI, V65, P1394, DOI 10.3168/jds.S0022-0302(82)82360-6; SCHUCHMANN MN, 1977, J CHEM SOC PERK T 2, P1958, DOI 10.1039/p29770001958; SELA M, 1959, BIOCHIM BIOPHYS ACTA, V31, P417, DOI 10.1016/0006-3002(59)90016-2; SELL DR, 1989, J BIOL CHEM, V264, P21597; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; WATKINS NG, 1985, J BIOL CHEM, V260, P629; WATKINS NG, 1987, J BIOL CHEM, V262, P7207	36	517	531	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11654	11660						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904867				2022-12-25	WOS:A1991FT76200039
J	SHEN, H; SCHMUCK, M; PILZ, I; GILKES, NR; KILBURN, DG; MILLER, RC; WARREN, RAJ				SHEN, H; SCHMUCK, M; PILZ, I; GILKES, NR; KILBURN, DG; MILLER, RC; WARREN, RAJ			DELETION OF THE LINKER CONNECTING THE CATALYTIC AND CELLULOSE-BINDING DOMAINS OF ENDOGLUCANASE-A (CENA) OF CELLULOMONAS-FIMI ALTERS ITS CONFORMATION AND CATALYTIC ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUORESCENS SUBSPECIES CELLULOSA; ESCHERICHIA-COLI; LIMITED PROTEOLYSIS; BACTERIAL CELLULASE; TRICHODERMA-REESEI; FUNCTIONAL DOMAINS; SUBSTRATE-BINDING; PROTEIN; GENE; SEQUENCE	The Pro-Thr box is a linker of 23 amino acids ((PT)4T(PT)7) connecting the catalytic domain and the cellulose-binding domain (CBD) of endoglucanase A (CenA) from the bacterium Cellulomonas fimi. Deletion of the Pro-Thr box alters the conformation of CenA by changing the relative orientation of the catalytic domain and the CBD. The tertiary structures of the catalytic domain and the CBD appear to be unchanged. The change in conformation reduces the catalytic efficiency of the enzyme and masks one of two protease-sensitive sites between the domains. The deletion does not affect the adsorption of the enzyme to microcrystalline cellulose, but it does affect its desorption from cellulose. The results suggest that the Pro-Thr box in CenA has an extended, kinked, and rigid conformation.	UNIV BRITISH COLUMBIA, DEPT MICROBIOL, 300-6174 UNIV BLVD, VANCOUVER V6T 1W5, BC, CANADA; GRAZ UNIV, INST PHYS CHEM, A-8010 GRAZ, AUSTRIA	University of British Columbia; University of Graz								ARGOS P, 1990, J MOL BIOL, V211, P943, DOI 10.1016/0022-2836(90)90085-Z; Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BEGUIN P, 1983, ANAL BIOCHEM, V131, P333, DOI 10.1016/0003-2697(83)90178-1; BELDMAN G, 1987, BIOTECHNOL BIOENG, V30, P251, DOI 10.1002/bit.260300215; BHANDARI DG, 1986, EUR J BIOCHEM, V160, P349, DOI 10.1111/j.1432-1033.1986.tb09978.x; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURTON J, 1989, BIOPHYS CHEM, V33, P39, DOI 10.1016/0301-4622(89)80005-5; BUSHUEV VN, 1989, J BIOL CHEM, V264, P4498; CHEN R, 1980, P NATL ACAD SCI-BIOL, V77, P4592, DOI 10.1073/pnas.77.8.4592; EVANS JS, 1986, FEBS LETT, V208, P211, DOI 10.1016/0014-5793(86)81020-1; FERREIRA LMA, 1990, BIOCHEM J, V269, P261, DOI 10.1042/bj2690261; GHANGAS GS, 1988, APPL ENVIRON MICROB, V54, P2521, DOI 10.1128/AEM.54.10.2521-2526.1988; GILBERT HJ, 1990, MOL MICROBIOL, V4, P759, DOI 10.1111/j.1365-2958.1990.tb00646.x; GILKES NR, 1989, J BIOL CHEM, V264, P17802; GILKES NR, 1988, J BIOL CHEM, V263, P10401; GOUGH CL, 1990, GENE, V89, P53, DOI 10.1016/0378-1119(90)90205-6; GUO Z, 1988, FEMS MICROBIOL LETT, V49, P279; HALL J, 1989, MOL MICROBIOL, V3, P1211, DOI 10.1111/j.1365-2958.1989.tb00271.x; HALLIWELL G, 1978, BIOCHEM J, V169, P713, DOI 10.1042/bj1690713; KOENIG M, 1990, J BIOL CHEM, V265, P4560; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGSFORD ML, 1984, J GEN MICROBIOL, V130, P1367; Maniatis T., 1982, MOL CLONING; MCGAVIN M, 1989, J BACTERIOL, V171, P3310, DOI 10.1128/jb.171.6.3310-3315.1989; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; ONEILL G, 1986, GENE, V44, P325, DOI 10.1016/0378-1119(86)90197-6; PERHAM RN, 1989, ANN NY ACAD SCI, V573, P1, DOI 10.1111/j.1749-6632.1989.tb14983.x; PILZ I, 1990, BIOCHEM J, V271, P277, DOI 10.1042/bj2710277; PLAUT AG, 1975, SCIENCE, V190, P1103, DOI 10.1126/science.810892; RADFORD SE, 1989, J BIOL CHEM, V264, P767; REESE ET, 1982, PROCESS BIOCHEM, V17, P2; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; SEE PY, 1989, PROTEIN STRUCTURE PR, P1; TEATHER RM, 1982, APPL ENVIRON MICROB, V43, P777, DOI 10.1128/AEM.43.4.777-780.1982; TOMME P, 1988, EUR J BIOCHEM, V170, P575, DOI 10.1111/j.1432-1033.1988.tb13736.x; VANTILBEURGH H, 1986, FEBS LETT, V204, P223, DOI 10.1016/0014-5793(86)80816-X; WONG WKR, 1986, GENE, V44, P315; Yablonsky M. D., 1988, Biochemistry and genetics of cellulose degradation, P249; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	43	104	111	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11335	11340						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1904063				2022-12-25	WOS:A1991FQ77400096
J	ALTAMURA, S; CAPRINI, E; LONDEI, P				ALTAMURA, S; CAPRINI, E; LONDEI, P			EARLY ASSEMBLY PROTEINS OF THE LARGE RIBOSOMAL-SUBUNIT OF THE THERMOPHILIC ARCHAEBACTERIUM SULFOLOBUS - IDENTIFICATION AND BINDING TO HETEROLOGOUS RIBOSOMAL-RNA SPECIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; CALDARIELLA-ACIDOPHILA; RNA; SOLFATARICUS; FEATURES; 50S	Studies of ribosome structure in thermophilic archaebacteria may provide valuable information on (i) the mechanisms involved in the stabilization of nucleic acid-protein complexes at high temperatures and (ii) the degree of evolutionary conservation of the ribosomal components in the primary kingdoms of cell descent. In this work we investigate certain aspects of RNA/protein interaction within the large ribosomal subunits of the extremely thermophilic archaebacterium Sulfolobus solfataricus. Ther ribosomal proteins involved in the early reactions leading to in vitro particle assembly have been identified; it is shown that they can interact with the RNA in a temperature-independent fashion, forming a thermally stable "core" particle that can subsequently be converted into complete 50 S ribosomes. Among the protein components of the core particle, those capable of independently binding to 23 and 5 S RNA species have also been identified. Finally, we show that the early assembly proteins of Sulfolobus large ribosomal subunits are able to interact cooperatively with 23 S RNAs from other archaebacteria or from eubacteria, thereby suggesting that RNA/protein recognition sites are largely conserved within prokaryotic ribosomes. By contrast, no specific binding of the archaebacterial proteins to eukaryotic RNA could be demonstrated.	UNIV ROMA LA SAPIENZA POLICLIN,DEPT BIOPATHOL UMANA,SEZ BIOL CELLULARE,VIALE REGINA ELENA 324,I-00161 ROME,ITALY	Sapienza University Rome								BATTANER E, 1974, METHOD ENZYMOL, V20, P446; CAMMARANO P, 1983, BIOCHIM BIOPHYS ACTA, V740, P300, DOI 10.1016/0167-4781(83)90139-2; CLARK CG, 1984, NUCLEIC ACIDS RES, V12, P6197, DOI 10.1093/nar/12.15.6197; GEYL D, 1981, MOL GEN GENET, V181, P309, DOI 10.1007/BF00425603; Held W.A., 1974, RIBOSOMES, P193; LONDEI P, 1986, EUR J BIOCHEM, V157, P455, DOI 10.1111/j.1432-1033.1986.tb09689.x; LONDEI P, 1986, NUCLEIC ACIDS RES, V14, P2269, DOI 10.1093/nar/14.5.2269; LONDEI P, 1983, BIOCHEM J, V209, P461, DOI 10.1042/bj2090461; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; NIERHAUS KH, 1973, P NATL ACAD SCI USA, V70, P1931, DOI 10.1073/pnas.70.7.1931; NIERHAUS KH, 1980, RIBOSOMES STRUCTURE, P267; ROHL R, 1982, P NATL ACAD SCI-BIOL, V79, P729, DOI 10.1073/pnas.79.3.729; SPIERER P, 1978, BIOCHEMISTRY-US, V17, P2474, DOI 10.1021/bi00606a002; TEIXIDO J, 1989, NUCLEIC ACIDS RES, V17, P845, DOI 10.1093/nar/17.3.845; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	15	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6195	6200						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1901059				2022-12-25	WOS:A1991FE37300032
J	TAKAHASHI, S; NEGISHI, M; ICHIKAWA, A				TAKAHASHI, S; NEGISHI, M; ICHIKAWA, A			CYTOSOL PROMOTES THE GUANINE NUCLEOTIDE-INDUCED RELEASE OF THE ALPHA-SUBUNIT OF GI2 FROM THE MEMBRANE OF MOUSE MASTOCYTOMA P-815 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ISLET-ACTIVATING PROTEIN; GTP-BINDING-PROTEIN; PLASMA-MEMBRANE; ADP-RIBOSYLATION; PERTUSSIS-TOXIN; BOVINE BRAIN; TRANSDUCERS; ANTIBODY; SYSTEM; GO	Translocation of the alpha-subunit of G(i2) from the membrane to the cytosol was studied in mouse mastocytoma P-815 cells. To monitor G(i2)-alpha the membrane (300,000 x g pellet) was [P-32]ADP-ribosylated with pertussis toxin. Incubation of the [P-32]ADP-ribosylated membrane with guanosine 5'-O-(3-thiotriphosphate) (GTP-gamma-S) caused a small release (10%) of [P-32]ADP-ribosylated G(i2)-alpha from the membrane. Whereas cytosol (300,000 x g supernatant) alone had no ability to release the [P-32]ADP-ribosylated G(i2)-alpha from the membrane, it markedly augmented the release induced by GTP-gamma-S, about 50% of the total [P-32]ADP-ribosylated G(i2)-alpha being released by 30 min. The GTP-gamma-S-induced release and its enhancement by the cytosol were specific for GTP and GTP-gamma-S. When the cytosol was boiled this promoting activity was lost. The [P-32]ADP-ribosylated G(i2)-alpha released by the cytosol plus GTP-gamma-S from the membrane was eluted as a single peak corresponding to a molecular weight of about 100,000 from an Ultrogel AcA 44 column. In contrast, the [P-32]ADP-ribosylated G(i2)-alpha released by GTP-gamma-S alone was eluted at the position of M(r) = 40,000, but it was eluted at the position of M(r) = about 100,000 when it was incubated with the cytosol. Furthermore, G(i2)-alpha purified from bovine lung also behaved in a similar way on gel filtration. The addition of thrombin, a stimulant of histamine secretion from mast cells, to mastocytoma cells drastically induced the translocation of G(i2)-alpha from the membrane to the cytosol in a pertussis toxin-sensitive manner. These results taken together demonstrate that the cytosol contains some factor(s) that promotes the release of GTP-activated G(i2)-alpha from the membrane and that the released G(i2)-alpha exists in the cytosol as a soluble complex with unidentified component(s) in mastocytoma cells.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,KYOTO 606,JAPAN	Kyoto University								BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DUNN TB, 1957, J NATL CANCER I, V18, P587; EIDE B, 1987, BIOCHEM BIOPH RES CO, V148, P1398, DOI 10.1016/S0006-291X(87)80287-5; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; KATADA T, 1982, J BIOL CHEM, V257, P7210; KATADA T, 1982, P NATL ACAD SCI-BIOL, V79, P3129, DOI 10.1073/pnas.79.10.3129; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCARDLE H, 1988, BIOCHEM BIOPH RES CO, V152, P243, DOI 10.1016/S0006-291X(88)80706-X; MILLIGAN G, 1988, BIOCHEM J, V254, P391, DOI 10.1042/bj2540391; MILLIGAN G, 1989, BIOCHEM J, V260, P837, DOI 10.1042/bj2600837; MORISHITA R, 1988, EUR J BIOCHEM, V174, P87, DOI 10.1111/j.1432-1033.1988.tb14066.x; NAKAMURA T, 1985, J BIOL CHEM, V260, P3584; RANSNAS LA, 1989, P NATL ACAD SCI USA, V86, P7900, DOI 10.1073/pnas.86.20.7900; RAZIN E, 1985, EXP CELL RES, V160, P380, DOI 10.1016/0014-4827(85)90184-3; RODBELL M, 1985, TRENDS BIOCHEM SCI, V10, P461, DOI 10.1016/0968-0004(85)90032-5; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TAKAHASHI S, 1989, SPR INT WASH S, V9, P355; YAMAZAKI A, 1983, J BIOL CHEM, V258, P8188; YATSUNAMI K, 1981, BIOCHEM PHARMACOL, V30, P1325, DOI 10.1016/0006-2952(81)90316-6	22	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5367	5370						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1900833				2022-12-25	WOS:A1991FD37000004
J	MEINKE, MH; EDSTROM, RD				MEINKE, MH; EDSTROM, RD			MUSCLE GLYCOGENOLYSIS - REGULATION OF THE CYCLIC INTERCONVERSION OF PHOSPHORYLASE-A AND PHOSPHORYLASE-B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; DEPENDENT PROTEIN-KINASE; COVALENT MODIFICATION; CELLULAR-REGULATION; CATALYTIC SUBUNIT; CLYCOGEN PARTICLE; ACTIVATION; PHOSPHATASE; PURIFICATION; SYSTEMS	Regulation of glycogenolysis in skeletal muscle is dependent on a network of interacting enzymes and effectors that determine the relative activity of the enzyme phosphorylase. That enzyme is activated by phosphorylase kinase and inactivated by protein phosphatase-1 in a cyclic process of covalent modification. We present evidence that the cyclic interconversion is subject to zero-order ultrasensitivity, and the effect is responsible for the "flash" activation of phosphorylase by Ca2+ in the presence of glycogen. The zero-order effect is observable either by varying the amounts of kinase and phosphatase or by modifying the ratio of their activities by a physiological effector, protein phosphatase inhibitor-2. The sensitivity of the system is enhanced in the presence of the phosphorylase limit dextrin of glycogen which lowers the K(m) of phosphorylase kinase for phosphorylase. The in vitro experimental results are examined in terms of physiological conditions in muscle, and it is shown that zero-order ultrasensitivity would be more pronounced under the highly compartmentalized condition found in that tissue. The sensitivity of this system of effector changes is much greater than that found for allosteric enzymes. Furthermore, the sensitivity enhancement increases more rapidly than energy consumption (ATP) as the phosphorylase concentration increases. Energy effectiveness is shown to be a possible evolutionary factor in favor of the development of zero-order ultrasensitivity in compartmentalized systems.	UNIV MINNESOTA,DEPT BIOCHEM,4-225 MILLARD HALL,MINNEAPOLIS,MN 55455	University of Minnesota System; University of Minnesota Twin Cities								AXELSON JT, 1981, ANAL BIOCHEM, V116, P357, DOI 10.1016/0003-2697(81)90371-7; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; BALLOU LM, 1986, ENZYMES, V17, P311; BRAUTIGAN DL, 1985, J BIOL CHEM, V260, P4295; CARDENAS ML, 1989, BIOCHEM J, V257, P339, DOI 10.1042/bj2570339; Carlson G M, 1979, Adv Enzymol Relat Areas Mol Biol, V50, P41; CHASIOTIS D, 1983, ACTA PHYSL SCAND S, V68, P1; CHENG A, 1985, J BIOL CHEM, V260, P2535; COHEN P, 1980, EUR J BIOCHEM, V111, P563, DOI 10.1111/j.1432-1033.1980.tb04972.x; COHEN P, 1972, EUR J BIOCHEM, V34, P1; COX DE, 1982, J BIOL CHEM, V257, P2728; DOMBRADI V, 1981, INT J BIOCHEM, V13, P125, DOI 10.1016/0020-711X(81)90147-6; EDSTROM RD, 1990, BIOPHYS J, V58, P1437, DOI 10.1016/S0006-3495(90)82489-9; ELINGS VB, 1990, J VAC SCI TECHNOL A, V8, P652, DOI 10.1116/1.576365; ENTMAN ML, 1980, J BIOL CHEM, V255, P6245; Fischer E. H., 1971, CURR TOP CELL REGUL, V4, P211; FISCHER EH, 1962, METHOD ENZYMOL, V5, P369, DOI 10.1016/S0076-6879(62)05243-X; GOLDBETER A, 1981, P NATL ACAD SCI-BIOL, V78, P6840, DOI 10.1073/pnas.78.11.6840; GOLDBETER A, 1987, J BIOL CHEM, V262, P4460; GOLDBETER A, 1983, Q REV BIOPHYS, V3, P555; HAGBERG H, 1985, PFLUG ARCH EUR J PHY, V404, P342, DOI 10.1007/BF00585346; HALLENBECK PC, 1986, J BIOL CHEM, V261, P5442; HEILMEYER LM, 1970, J BIOL CHEM, V245, P6649; HELMREICH E, 1964, P NATL ACAD SCI USA, V51, P131, DOI 10.1073/pnas.51.1.131; HUANG FL, 1976, EUR J BIOCHEM, V70, P419, DOI 10.1111/j.1432-1033.1976.tb11032.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P711, DOI 10.1111/j.1432-1033.1989.tb15264.x; INGEBRITSEN TS, 1983, SCIENCE, V221, P331, DOI 10.1126/science.6306765; KACSER H, 1987, TRENDS BIOCHEM SCI, V12, P5, DOI 10.1016/0968-0004(87)90005-3; KOSHLAND DE, 1982, SCIENCE, V217, P220, DOI 10.1126/science.7089556; KREBS EG, 1964, BIOCHEMISTRY-US, V3, P1022, DOI 10.1021/bi00896a003; KREBS EG, 1959, METHOD ENZYMOL, V5, P373; LAPORTE DC, 1983, NATURE, V305, P286, DOI 10.1038/305286a0; LEE EYC, 1970, BIOCHEMISTRY-US, V9, P2347, DOI 10.1021/bi00813a019; MARTENSEN TM, 1973, J BIOL CHEM, V248, P8329; MEINKE MH, 1986, P NATL ACAD SCI USA, V83, P2865, DOI 10.1073/pnas.83.9.2865; MEYER F, 1970, J BIOL CHEM, V245, P6642; NELSON NC, 1981, J BIOL CHEM, V256, P3743; NIMMO GA, 1978, EUR J BIOCHEM, V87, P341, DOI 10.1111/j.1432-1033.1978.tb12383.x; NIMMO HG, 1976, EUR J BIOCHEM, V68, P21, DOI 10.1111/j.1432-1033.1976.tb10761.x; Pickett-Gies CA., 1986, ENZYMES, V17, P395; PICKETTGIES CA, 1985, J BIOL CHEM, V260, P2046; SHACTER E, 1984, J BIOL CHEM, V259, P2252; SHACTER E, 1984, J BIOL CHEM, V259, P2260; SHENOLIKAR S, 1979, EUR J BIOCHEM, V100, P329, DOI 10.1111/j.1432-1033.1979.tb04175.x; SILBERMAN SR, 1984, J BIOL CHEM, V259, P2913; Stadtman E R, 1978, Curr Top Cell Regul, V13, P53; STEINER RF, 1982, BIOCHIM BIOPHYS ACTA, V707, P38, DOI 10.1016/0167-4838(82)90393-4; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; WALKER GJ, 1960, BIOCHEM J, V76, P264, DOI 10.1042/bj0760264; WALSETH TF, 1979, BIOCHIM BIOPHYS ACTA, V562, P11, DOI 10.1016/0005-2787(79)90122-9	50	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2259	2266						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899238				2022-12-25	WOS:A1991EV51500039
J	THOMPSON, MR; FORRISTAL, J; KAUFFMANN, P; MADDEN, T; KOZAK, K; MORRIS, RE; SAELINGER, CB				THOMPSON, MR; FORRISTAL, J; KAUFFMANN, P; MADDEN, T; KOZAK, K; MORRIS, RE; SAELINGER, CB			ISOLATION AND CHARACTERIZATION OF PSEUDOMONAS-AERUGINOSA EXOTOXIN-A BINDING GLYCOPROTEIN FROM MOUSE LM CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; DOMAIN-II; RECEPTOR; TOXIN; PROTEINS; FIBROBLASTS; INFECTIONS; TRANSFERRIN; TOXICITY; PROTEASE	A Pseudomonas aeruginosa exotoxin A (PE) binding glycoprotein was affinity purified from toxin sensitive mouse LM cells. The binding protein was solubilized with Triton X-100 or Nonidet P-40 and purified on a PE-Sepharose affinity column. Polyacrylamide gel electrophoresis yielded a single band with an estimated molecular mass of greater than 300,000 Da. N-Linked carbohydrate was present, accounting for approximately 10% of the total mass of the molecule. The purified protein specifically bound PE. Incubation of purified PE binding protein with toxin reduced toxicity to LM cells. We speculate on the role of this toxin binding glycoprotein in the intoxication process.	UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET BIOCHEM & MICROBIOL,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DIV DIGEST DIS,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT ANAT & CELL BIOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017529] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024028] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 17529] Funding Source: Medline; NIGMS NIH HHS [GM 24028] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; CARPENTER G, 1986, EXP CELL RES, V164, P1, DOI 10.1016/0014-4827(86)90449-0; CHAUDHARY VK, 1988, P NATL ACAD SCI USA, V85, P2939, DOI 10.1073/pnas.85.9.2939; CHAUDRY GJ, 1989, J BIOL CHEM, V265, P15151; CIECHANOVER A, 1983, J CELL BIOCHEM, V23, P107, DOI 10.1002/jcb.240230111; FITZGERALD D, 1980, CELL, V21, P867, DOI 10.1016/0092-8674(80)90450-X; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GRAY GL, 1984, P NATL ACAD SCI-BIOL, V81, P2645, DOI 10.1073/pnas.81.9.2645; GUIDIRONTANI C, 1987, MOL MICROBIOL, V1, P67, DOI 10.1111/j.1365-2958.1987.tb00528.x; HAMOOD AN, 1989, J BACTERIOL, V171, P1817, DOI 10.1128/jb.171.4.1817-1824.1989; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HOLDER IA, 1989, J BURN CARE REHABIL, V9, P285; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HWANG J, 1987, CELL, V48, P129, DOI 10.1016/0092-8674(87)90363-1; IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284; JINNO Y, 1988, J BIOL CHEM, V263, P13203; Johnson D. A., 1984, Gene Analysis Techniques, V1, P3, DOI 10.1016/0735-0651(84)90049-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEPPLA SH, 1978, BIOCHEM BIOPH RES CO, V81, P532, DOI 10.1016/0006-291X(78)91567-X; MANHART MD, 1984, INFECT IMMUN, V45, P596, DOI 10.1128/IAI.45.3.596-603.1984; MICHAEL M, 1979, CURR MICROBIOL, V2, P103, DOI 10.1007/BF02603065; MIDDLEBROOK JL, 1977, CAN J MICROBIOL, V23, P183, DOI 10.1139/m77-026; MORRIS RE, 1984, J HISTOCHEM CYTOCHEM, V32, P124, DOI 10.1177/32.1.6690597; MORRIS RE, 1990, TRAFFICKING BACTERIA, P49; PAVLOVSKIS OR, 1978, INFECT IMMUN, V19, P29, DOI 10.1128/IAI.19.1.29-33.1978; SAELINGER CB, 1977, J INFECT DIS, V136, P555, DOI 10.1093/infdis/136.4.555; SAELINGER CB, 1990, TRAFFICKING BACTERIA, P1; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SCHNEIDER WJ, 1982, J BIOL CHEM, V257, P2664; SIEGALL CB, 1989, J BIOL CHEM, V264, P14256; SNELL K, 1978, INFECT IMMUN, V19, P839, DOI 10.1128/IAI.19.3.839-845.1978; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	33	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2390	2396						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899240				2022-12-25	WOS:A1991EV51500058
J	BARTHA, K; DECLERCK, PJ; MOREAU, H; NELLES, L; COLLEN, D				BARTHA, K; DECLERCK, PJ; MOREAU, H; NELLES, L; COLLEN, D			SYNTHESIS AND SECRETION OF PLASMINOGEN-ACTIVATOR INHIBITOR-1 BY HUMAN ENDOTHELIAL-CELLS INVITRO - EFFECT OF ACTIVE-SITE MUTAGENIZED TISSUE-TYPE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED IMMUNOSORBENT-ASSAY; FIBRO-SARCOMA CELLS; MONOCLONAL-ANTIBODIES; PLASMA-LEVELS; T-PA; PURIFICATION; CLONING; RNA; IDENTIFICATION; ASSOCIATION	The effects of recombinant tissue-type plasminogen activator (rt-PA) and of an inactive mutant of rt-PA, obtained by mutagenesis of the active site Ser478 to Ala (rt-PA-Ala478), on the synthesis and secretion of plasminogen activator inhibitor-1 (PAI-1) by human umbilical vein endothelial cells (HUVEC) in culture were studied. Under base-line conditions, PAI-1 antigen secretion was 4.3 +/- 1.0-mu-g (mean +/- S.D., n = 8) per 10(6) cells in 24 h. This PAI-1 had a low specific activity (6,000 +/- 1,600 units/mg) and M(r) of 50,000, which was not altered by addition of rt-PA. In HUVEC cultured with 2-mu-g/ml rt-PA-Ala478, PAI-1 antigen secretion was 2.1 +/- 0.8-mu-g (n = 5) per 10(6) cells in 24 h with a specific activity of 120,000 +/- 42,000 units/mg and M(r) of 50,000. Addition of rt-PA to this conditioned medium resulted in generation of three main components: 16% migrated as an M(r) 106,000 rt-PA.PAI-1 complex, 16% as an M(r) 81,000 degraded rt-PA.PAI-1 complex and the remainder as an M(r) 45,000 degradation product of PAI-1. HUVEC cultured with 2-mu-g/ml rt-PA secreted 3.9 +/- 0.6-mu-g (n = 8) PAI-1 antigen per 10(6) cells within 24 h, of which 20-50% occurred as intact or degraded complexes with t-PA (M(r) 106,000 and 81,000) and the rest as an inactive M(r) 45,000 degradation product of PAI-1. PAI-1 mRNA levels, determined by Northern blot analysis and expressed relative to beta-actin mRNA levels, were very similar for HUVEC cultured in the absence or the presence of rt-PA or rt-PA-Ala478. It is concluded that PAI-1 is secreted by HUVEC in culture in fully active form which spontaneously inactivates. PAI-1 can be stabilized by addition of rt-PA-Ala478 to the culture medium, resulting in a 20-fold increase in specific activity. Interaction of rt-PA with active PAI-1 produces both t-PA.PAI-1 complex and an inactive degradation product of PAI-1.			BARTHA, K (corresponding author), CATHOLIC UNIV LEUVEN, CTR THROMBOSIS & VASC RES, B-3000 LOUVAIN, BELGIUM.		Declerck, Paul J/A-2330-2017	Declerck, Paul J/0000-0003-1259-9105				AHO H, 1974, BIOCHEMISTRY-US, V13, P132; ALESSI MC, 1988, EUR J BIOCHEM, V175, P531, DOI 10.1111/j.1432-1033.1988.tb14225.x; BOOTH NA, 1985, J CLIN PATHOL, V38, P825, DOI 10.1136/jcp.38.7.825; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLEN D, 1986, THROMB HAEMOSTASIS, V56, P415; DAVANLOO P, 1984, P NATL ACAD SCI-BIOL, V81, P2035, DOI 10.1073/pnas.81.7.2035; DECLERCK P J, 1988, Fibrinolysis, V2, P77; DECLERCK PJ, 1988, BLOOD, V71, P220; DECLERCK PJ, 1988, J BIOL CHEM, V263, P15454; ERICKSON LA, 1984, J CLIN INVEST, V74, P1465, DOI 10.1172/JCI111559; GINSBURG D, 1986, J CLIN INVEST, V78, P1673, DOI 10.1172/JCI112761; HAMSTEN A, 1985, NEW ENGL J MED, V313, P1557, DOI 10.1056/NEJM198512193132501; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; HOLVOET P, 1985, THROMB HAEMOSTASIS, V54, P684; ISHII SI, 1983, METHOD ENZYMOL, V91, P378; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JUHANVAGUE I, 1984, THROMB RES, V33, P523, DOI 10.1016/0049-3848(84)90018-5; JUHANVAGUE I, 1987, THROMB HAEMOSTASIS, V57, P67; KNUDSEN BS, 1988, J BIOL CHEM, V263, P9476; KRUITHOF EKO, 1984, BLOOD, V64, P907; KRUITHOF EKO, 1985, PROGR FIBRINOLYSIS, V7, P130; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1987, J BIOL CHEM, V262, P17467; LEVIN EG, 1987, J CELL BIOL, V105, P2543, DOI 10.1083/jcb.105.6.2543; LOSKUTOFF DJ, 1987, BIOCHEMISTRY-US, V26, P3763, DOI 10.1021/bi00387a004; LOSKUTOFF DJ, 1977, P NATL ACAD SCI USA, V74, P3903, DOI 10.1073/pnas.74.9.3903; MEDCALF RL, 1988, J CELL BIOL, V106, P971, DOI 10.1083/jcb.106.3.971; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIMURO J, 1987, BLOOD, V70, P721; NIELSEN LS, 1986, FEBS LETT, V196, P269, DOI 10.1016/0014-5793(86)80261-7; NIELSEN LS, 1986, THROMB HAEMOSTASIS, V55, P206; NILSSON IM, 1985, BRIT MED J, V290, P1453, DOI 10.1136/bmj.290.6480.1453; NY T, 1986, P NATL ACAD SCI USA, V83, P6776, DOI 10.1073/pnas.83.18.6776; PANNEKOEK H, 1986, EMBO J, V5, P2539, DOI 10.1002/j.1460-2075.1986.tb04532.x; PARAMO JA, 1985, BRIT MED J, V291, P573, DOI 10.1136/bmj.291.6495.573; RAMAKRISHNAN V, 1990, J BIOL CHEM, V265, P2755; RUSSELL ME, 1990, J BIOL CHEM, V265, P2569; SAKATA Y, 1988, J BIOL CHEM, V263, P1960; SCHLEEF RR, 1990, J CELL BIOL, V110, P155, DOI 10.1083/jcb.110.1.155; SPRENGERS ED, 1985, J LAB CLIN MED, V105, P751; SPRENGERS ED, 1987, BLOOD, V69, P381; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; VAGUE P, 1986, METABOLISM, V35, P250, DOI 10.1016/0026-0495(86)90209-X; VANMOURIK JA, 1984, J BIOL CHEM, V259, P14914; VINCENT JP, 1974, BIOCHEMISTRY-US, V13, P4205, DOI 10.1021/bi00717a023; WAGNER OF, 1986, J BIOL CHEM, V261, P4474	46	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					792	797						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898737				2022-12-25	WOS:A1991ET17700021
J	LAFORET, GA; KENDALL, DA				LAFORET, GA; KENDALL, DA			FUNCTIONAL LIMITS OF CONFORMATION, HYDROPHOBICITY, AND STERIC CONSTRAINTS IN PROKARYOTIC SIGNAL PEPTIDE CLEAVAGE REGIONS - WILD-TYPE TRANSPORT BY A SIMPLE POLYMERIC SIGNAL SEQUENCE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; ALKALINE-PHOSPHATASE; PROTEIN SECRETION; BETA-LACTAMASE; LEADER PEPTIDE; MEMBRANES; EXPORT; LOCALIZATION; MECHANISM	These experiments examine the role of conformation, hydrophobicity, and steric constraints in the function of the prokaryotic signal peptide cleavage region. The experimental strategy involves replacement of the wild type Escherichia coli alkaline phosphatase signal peptide cleavage region with a series of idealized model sequences designed to epitomize the particular structural and physical variables under study. By analyzing model sequences whose conformations have been determined by physical studies, we have demonstrated that efficient transport does not depend on the structural preference of the cleavage region. Although previous studies based on Chou-Fasman analysis have suggested that the cleavage region forms a beta-turn which is required for transport, our results demonstrate that either a beta-turn- or alpha-helix-fostering sequence in the cleavage region functions indistinguishably from wild type. Furthermore, the presence of a proline residue between the core and cleavage region, although common in natural sequences, is not essential for export. Cleavage regions of varying hydrophobicities can support translocation across the inner membrane, but the placement of bulky residues at positions -1 and -3 upstream of the cleavage site abolishes processing and transport to the periplasm. By reducing the signal peptide to simplified, idealized segments, this study has identified a largely polymeric sequence, MKQST(L10)-(A6), that functions equivalently to the wild type alkaline phosphatase signal peptide. This work starts to provide a basis for the design of a universal prokaryotic signal peptide that incorporates all the critical physical and structural characteristics required for transport function.	UNIV CONNECTICUT,DEPT MOLEC & CELL BIOL,BOX U-44,STORRS,CT 06269; ROCKEFELLER UNIV,BIOORGAN CHEM & BIOCHEM LAB,NEW YORK,NY 10021	University of Connecticut; Rockefeller University					NIGMS NIH HHS [GM37639] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037639] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUER HE, 1966, BIOCHEMISTRY-US, V5, P1716, DOI 10.1021/bi00869a038; AUER HE, 1966, BIOCHEMISTRY-US, V5, P1708, DOI 10.1021/bi00869a037; Boyd D, 1987, PHOSPHATE METABOLISM, P89; BRIGGS MS, 1986, ADV PROTEIN CHEM, V38, P109, DOI 10.1016/S0065-3233(08)60527-6; BUTLERRANSOHOFF JE, 1988, P NATL ACAD SCI USA, V85, P4276, DOI 10.1073/pnas.85.12.4276; CHOU MM, 1990, J BIOL CHEM, V265, P2873; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DAVIS NG, 1985, CELL, V41, P607, DOI 10.1016/S0092-8674(85)80033-7; DUFFAUD G, 1988, J BIOL CHEM, V263, P10224; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FERRETTI JA, 1969, BIOPOLYMERS, V7, P155, DOI 10.1002/bip.1969.360070203; FIKES JD, 1990, J BIOL CHEM, V265, P3417; GHOSH SS, 1986, SCIENCE, V231, P145, DOI 10.1126/science.3510454; INOUYE H, 1981, J BACTERIOL, V146, P668, DOI 10.1128/JB.146.2.668-675.1981; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; KABSCH W, 1984, P NATL ACAD SCI-BIOL, V81, P1075, DOI 10.1073/pnas.81.4.1075; KADONAGA JT, 1985, J BIOL CHEM, V260, P6192; KAISER CA, 1987, SCIENCE, V235, P312, DOI 10.1126/science.3541205; KAISER ET, 1983, P NATL ACAD SCI USA, V80, P1137, DOI 10.1073/pnas.80.4.1137; KENDALL DA, 1990, BIOPOLYMERS, V29, P139, DOI 10.1002/bip.360290119; KENDALL DA, 1988, J BIOL CHEM, V263, P7261; KENDALL DA, 1986, NATURE, V321, P706, DOI 10.1038/321706a0; KOSHLAND D, 1982, CELL, V30, P903, DOI 10.1016/0092-8674(82)90295-1; KRULL LH, 1965, BIOCHEMISTRY-US, V4, P626, DOI 10.1021/bi00880a003; KUHN A, 1985, J BIOL CHEM, V260, P5914; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFORET GA, 1989, J BIOL CHEM, V264, P14478; LI P, 1988, P NATL ACAD SCI USA, V85, P7685, DOI 10.1073/pnas.85.20.7685; Maniatis T., 1982, MOL CLONING; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NOTHWEHR SF, 1989, J BIOL CHEM, V264, P3979; PERLMAN D, 1983, J MOL BIOL, V167, P391, DOI 10.1016/S0022-2836(83)80341-6; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; ROSENBLATT M, 1980, P NATL ACAD SCI-BIOL, V77, P3983, DOI 10.1073/pnas.77.7.3983; RUSSEL M, 1982, CELL, V28, P177, DOI 10.1016/0092-8674(82)90387-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUMMERS RG, 1989, J BIOL CHEM, V264, P20074; SUMMERS RG, 1989, J BIOL CHEM, V264, P20082; THOM JR, 1988, J BACTERIOL, V170, P5654, DOI 10.1128/jb.170.12.5654-5661.1988; VLASUK GP, 1984, J BIOL CHEM, V259, P6195; VONHEIJNE G, 1985, CURR TOP MEMBR TRANS, V24, P151; VONHEIJNE G, 1979, EUR J BIOCHEM, V97, P175; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1984, J MOL BIOL, V173, P243, DOI 10.1016/0022-2836(84)90192-X; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WICKNER W, 1980, SCIENCE, V210, P861, DOI 10.1126/science.7001628; YAMAMOTO Y, 1989, BIOCHEMISTRY-US, V28, P2728, DOI 10.1021/bi00432a054; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529; ZWIZINSKI C, 1980, J BIOL CHEM, V255, P7973	58	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1326	1334						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898733				2022-12-25	WOS:A1991ET17700098
J	ALIVERTI, A; LUBBERSTEDT, T; ZANETTI, G; HERRMANN, RG; CURTI, B				ALIVERTI, A; LUBBERSTEDT, T; ZANETTI, G; HERRMANN, RG; CURTI, B			PROBING THE ROLE OF LYSINE-116 AND LYSINE-244 IN THE SPINACH FERREDOXIN-NADP+ REDUCTASE BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; ESCHERICHIA-COLI; BINDING-SITE; OXIDOREDUCTASE; EXPRESSION; PEPTIDE; RESIDUE; CDNA	Two mutants of the spinach ferredoxin-NADP+ reductase (FNR) were constructed, expressed by using a heterologous expression system previously described (Aliverti, A., Jansen, T., Zanetti, G., Ronchi, S., Herrmann, R. G., and Curti, B. (1990) Eur. J. Biochem. 191, 551-555), and purified to homogeneity. The mutant enzymes FNR-Lys116Gln and FNR-Lys244Gln were similar to the wild-type enzyme in the physicochemical properties measured; however, both enzymes showed a lower activity. Steady-state kinetic analyses and NADP+ binding measurements of the mutant proteins have revealed that the Lys116Gln enzyme had a catalytic efficiency (k(cat)/K(m)NADPH) 500-fold lower than that of the wild-type enzyme, and its interaction with NADP+ was greatly impaired. The Lys244Gln enzyme instead had almost the same k(cat) in the ferricyanide reductase reaction as the wild-type enzyme, while higher values of K(m)NADPH and K(d) for NADP+ were observed. Thus, protein engineering has enabled us to define the role of Lys-116 and Lys-244 in ferredoxin-NADP+ reductase; whereas Lys-244 contributes to the stabilization of the Michaelis complex, the Lys-116 side chain plays an important role also in the further steps of the catalytic cycle, because both K(m) and k(cat) are highly affected by the mutation.	UNIV MILAN,DIPARTIMENTO FISIOL & BIOCHIM GEN,VIA CELORIA 26,I-20133 MILAN,ITALY; UNIV MUNICH,INST BOT,W-8000 MUNICH 19,GERMANY	University of Milan; University of Munich			Aliverti, Alessandro/B-7875-2017	Aliverti, Alessandro/0000-0002-1226-3655; Lubberstedt, Thomas/0000-0002-0526-0798				ALIVERTI A, 1990, EUR J BIOCHEM, V191, P551, DOI 10.1111/j.1432-1033.1990.tb19156.x; ALIVERTI A, 1991, EUR J BIOCHEM, V198, P21, DOI 10.1111/j.1432-1033.1991.tb15981.x; BRNS CM, 1991, FLAVINS FLAVOPROTEIN, P487; CHAN RL, 1985, ARCH BIOCHEM BIOPHYS, V240, P172, DOI 10.1016/0003-9861(85)90020-7; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; CIDARIA D, 1985, EUR J BIOCHEM, V146, P295, DOI 10.1111/j.1432-1033.1985.tb08652.x; DEONARAIN MP, 1989, BIOCHEMISTRY-US, V28, P9602, DOI 10.1021/bi00451a008; FILLAT MF, 1990, NUCLEIC ACIDS RES, V18, P7161, DOI 10.1093/nar/18.23.7161; FOUST GP, 1969, J BIOL CHEM, V244, P964; GEREN LM, 1981, J BIOL CHEM, V256, P485; GOZZER C, 1977, BIOCHIM BIOPHYS ACTA, V485, P278, DOI 10.1016/0005-2744(77)90164-4; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KRAMER W, 1984, NUCLEIC ACIDS RES, V10, P5765; LEATHERBARROW RJ, 1987, ENZYME MECHANISMS, P78; LEVITT M, 1978, BIOCHEMISTRY-US, V17, P4277, DOI 10.1021/bi00613a026; MATTHEWS RG, 1991, FLAVINS AND FLAVOPROTEINS 1990, P593; MICHALOWSKI CB, 1989, PLANT PHYSIOL, V89, P817, DOI 10.1104/pp.89.3.817; NEWMAN BJ, 1988, PLANT MOL BIOL, V10, P511, DOI 10.1007/BF00033606; SANCHO J, 1990, EUR J BIOCHEM, V187, P39, DOI 10.1111/j.1432-1033.1990.tb15275.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; YAO Y, 1984, J BIOCHEM-TOKYO, V95, P1513, DOI 10.1093/oxfordjournals.jbchem.a134759; ZANETTI G, 1981, PLANT SCI LETT, V23, P55, DOI 10.1016/0304-4211(81)90025-0; ZANETTI G, 1976, BIOCHIM BIOPHYS ACTA, V445, P14, DOI 10.1016/0005-2744(76)90157-1; ZANETTI G, 1984, FLAVINS FLAVOPROTEIN, P179	25	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17760	17763						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917920				2022-12-25	WOS:A1991GG55300010
J	OLSON, SC; BOWMAN, EP; LAMBETH, JD				OLSON, SC; BOWMAN, EP; LAMBETH, JD			PHOSPHOLIPASE-D ACTIVATION IN A CELL-FREE SYSTEM FROM HUMAN NEUTROPHILS BY PHORBOL 12-MYRISTATE 13-ACETATE AND GUANOSINE 5'-O-(3-THIOTRIPHOSPHATE) - ACTIVATION IS CALCIUM DEPENDENT AND REQUIRES PROTEIN FACTORS IN BOTH THE PLASMA-MEMBRANE AND CYTOSOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FMET-LEU-PHE; KINASE-C; HL-60 GRANULOCYTES; RAT-BRAIN; PHOSPHATIDYLCHOLINE HYDROLYSIS; DIACYLGLYCEROL FORMATION; STIMULATED NEUTROPHILS; RESPIRATORY BURST; 2ND MESSENGERS; DIGLYCERIDE	Receptor-linked activation of phospholipase D has been demonstrated recently in a variety of intact cell types including granulocytes, but little is known about the enzyme, its cofactor requirements, and regulation. Using [H-3]alkyllysophosphatidylcholine to prelable an endogenous phosphatidylcholine substrate pool in conjunction with transphosphatidylation using ethanol to generate labeled phosphatidylethanol, we demonstrated a novel phospholipase D activity in neutrophil subcellular fractions. Guanosine 5'-O-3-(thiotriphosphate) (GTP-gamma-S) and phorbol 12-myristate 13-acetate (PMA) activated both phosphatidic acid generation and transphosphatidylation. Activity using both activators required the presence of not only plasma membrane but also cytosol, and proteolytic and thermal inactivation demonstrated the requirement for protein factors in both fractions. Using both stimuli, activity increased with increasing cytosol concentration. Product formation was approximately linear for about 10 min with PMA and 30 min with GTP-gamma-S, and both activators resulted in the total hydrolysis of up to 10% of the labeled phosphatidylcholine. The activity using both activators showed similar broad neutral pH optima, and both required the presence of micromolar levels of calcium, which by itself failed to activate at concentrations up to 1 mM. At low micromolar concentrations of nucleotides, activation was specific for guanine nucleotides and showed a specificity of GTP-gamma-S > guanyl-5'-yl imidodiphosphate > GTP, with no effect of GDP and GMP or adenine nucleotides, consistent with the participation of a guanine nucleotide regulatory protein. PMA activation was dependent on the presence of ATP, in particular when dialyzed cytosol was used, and was inhibited by about 50% by staurosporine, supporting a role for protein kinase C. However, purified protein kinase C failed to substitute for cytosol, implicating an additional cytosolic factor(s) in this response. These results indicate that the granulocytic phospholipase D pathway is a complex system that is regulated by at least two activation pathways, each comprised of components in two subcellular compartments.	EMORY UNIV,SCH MED,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University					NCI NIH HHS [CA46508] Funding Source: Medline; NIAID NIH HHS [AI22809] Funding Source: Medline; NIGMS NIH HHS [T32 GM08367] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008367] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGWU DE, 1989, J BIOL CHEM, V264, P1405; ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; AUGERT G, 1989, J BIOL CHEM, V264, P21689; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; BERRIDGE MJ, 1984, BIOCHEM J, V220, P345, DOI 10.1042/bj2200345; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CABOT MC, 1988, FEBS LETT, V233, P153, DOI 10.1016/0014-5793(88)81374-7; CAO YZ, 1990, BIOCHEM BIOPH RES CO, V171, P955, DOI 10.1016/0006-291X(90)90777-K; CHALIFA V, 1990, J BIOL CHEM, V265, P17512; CHALIFOUR RJ, 1980, BIOCHEM BIOPH RES CO, V96, P742, DOI 10.1016/0006-291X(80)91417-5; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; COCKCROFT S, 1985, FEBS LETT, V181, P259, DOI 10.1016/0014-5793(85)80271-4; COCKCROFT S, 1984, BIOCHIM BIOPHYS ACTA, V795, P37, DOI 10.1016/0005-2760(84)90102-4; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DOUGHERTY RW, 1989, J BIOL CHEM, V264, P11263; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; HANNAHAN DJ, 1991, J BIOL CHEM, V168, P233; Heller M, 1978, Adv Lipid Res, V16, P267; HOKINNEAVERSON M, 1975, BIOCHEM BIOPH RES CO, V67, P1537, DOI 10.1016/0006-291X(75)90201-6; HUANG R, 1991, J BIOL CHEM, V266, P1652; KATER LA, 1976, J CLIN INVEST, V57, P1173, DOI 10.1172/JCI108385; LAMBETH JD, 1988, J BIOENERG BIOMEMBR, V20, P709, DOI 10.1007/BF00762549; MUELLER HW, 1984, J LIPID RES, V25, P383; MULLMANN TJ, 1990, BIOCHEM BIOPH RES CO, V170, P1197, DOI 10.1016/0006-291X(90)90520-W; OLSON SC, 1990, FEBS LETT, V272, P19, DOI 10.1016/0014-5793(90)80439-P; ONO Y, 1970, J BACTERIOL, V103, P111, DOI 10.1128/JB.103.1.111-115.1970; PAI JK, 1991, P NATL ACAD SCI USA, V88, P598, DOI 10.1073/pnas.88.2.598; PAI JK, 1988, J BIOL CHEM, V263, P12472; PEMBER SO, 1983, ARCH BIOCHEM BIOPHYS, V221, P391, DOI 10.1016/0003-9861(83)90158-3; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QIAN Z, 1989, J BIOL CHEM, V264, P21720; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RIDER LG, 1988, J IMMUNOL, V140, P200; SHUKLA SD, 1991, LIFE SCI, V48, P851, DOI 10.1016/0024-3205(91)90031-6; TAKI T, 1979, J BIOL CHEM, V254, P9761; TENCE M, 1985, THROMB RES, V38, P207, DOI 10.1016/0049-3848(85)90148-3; TETTENBORN CS, 1988, BIOCHEM BIOPH RES CO, V155, P249, DOI 10.1016/S0006-291X(88)81076-3; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; TYAGI SR, 1989, J BIOL CHEM, V264, P12977; VANDERMEULEN J, 1990, BIOCHEM J, V271, P693, DOI 10.1042/bj2710693	47	145	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17236	17242						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894616				2022-12-25	WOS:A1991GF44500042
J	INOUE, M; WATANABE, N; MATSUNO, K; SASAKI, J; TANAKA, Y; HATANAKA, H; AMACHI, T				INOUE, M; WATANABE, N; MATSUNO, K; SASAKI, J; TANAKA, Y; HATANAKA, H; AMACHI, T			EXPRESSION OF A HYBRID CU/ZN-TYPE SUPEROXIDE-DISMUTASE WHICH HAS HIGH-AFFINITY FOR HEPARIN-LIKE PROTEOGLYCANS ON VASCULAR ENDOTHELIAL-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; EFFICIENT; MUTATIONS; RADICALS; SEQUENCE; SURFACE; PLASMA; DNA; RAT	Since plasma levels of enzymes, such as superoxide dismutase (SOD), that scavenge reactive oxygen species are low, surface membranes of endothelial and parenchymal cells of various tissues are often exposed to oxidative stress. To dismutate superoxide radicals efficiently in and around vascular endothelial cells, we constructed a fusion gene encoding a hybrid SOD (HBSOD) consisting of human Cu/Zn-SOD and a C-terminal basic peptide that binds to heparin-like proteoglycans. The fusion gene was expressed in yeast, and the resulting HB-SOD was highly purified. Upon sodium dodecyl sulfate-polyacrylamide gel electrophoresis, HB-SOD revealed a protein band with an apparent molecular weight of 20,000. HB-SOD bound to endothelial cells of aortic segments by a mechanism which was inhibited by heparin but not by antithrombin III. When injected intravenously to rats, I-125-labeled HBSOD rapidly disappeared from the circulation; the rate of disappearance was decreased by heparin. Less than 1% of the injected HB-SOD was found in the urine 20 min after administration at which time more than 70% of SOD was excreted in its intact form. Immunohistochemical studies revealed that HB-SOD predominantly bound to heparin-like proteoglycans on endothelial cells of the artery and other tissues. HB-SOD might permit studies on pathophysiological roles of superoxide radicals in and around vascular endothelial cells in vivo.	KUMAMOTO UNIV,SCH MED,DEPT ANAT,KUMAMOTO 860,JAPAN; SUNTORY LTD,INST FUNDAMENTAL RES CTR,SHIMAMOTO,OSAKA 618,JAPAN; OKAYAMA COLL SCI,SCH MED,DEPT ANAT,OKAYAMA 700,JAPAN	Kumamoto University; Suntory Holdings Ltd; Okayama University of Science	INOUE, M (corresponding author), KUMAMOTO UNIV,SCH MED,DEPT BIOCHEM,2-2-1 HONJO,KUMAMOTO 860,JAPAN.							ANDERSON L, 1974, THROMB RES, V5, P439; ASHIKARI T, 1989, APPL MICROBIOL BIOT, V30, P515; Balentine J.D., 1982, PATHOLOGY OXYGEN TOX; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; Burkholder PR, 1943, AM J BOT, V30, P206, DOI 10.2307/2437241; COHEN JJ, 1981, KIDNEY, P144; EMERIT I, 1990, ANTIOXIDANTS THERAPY; FEE JA, 1972, BIOCHEM BIOPH RES CO, V49, P150, DOI 10.1016/0006-291X(72)90022-8; FORMAN HJ, 1973, J BIOL CHEM, V248, P2645; GRANGER DN, 1981, GASTROENTEROLOGY, V81, P22; HARTZ JW, 1972, J BIOL CHEM, V247, P7043; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; HUBER W, 1977, SUPEROXIDE SUPEROXID; IKEHARA M, 1984, P NATL ACAD SCI-BIOL, V81, P5956, DOI 10.1073/pnas.81.19.5956; INOUE M, 1977, EUR J BIOCHEM, V73, P335, DOI 10.1111/j.1432-1033.1977.tb11323.x; INOUE M, 1989, BIOCHEMISTRY-US, V28, P6619, DOI 10.1021/bi00442a013; INOUE M, 1990, FEBS LETT, V269, P89, DOI 10.1016/0014-5793(90)81126-9; INOUE M, 1990, Free Radical Biology and Medicine, V9, P103, DOI 10.1016/0891-5849(90)90539-U; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jaques LB, 1980, PHARMACOL REV, V31, P99; KARLSSON K, 1987, BIOCHEM J, V242, P55, DOI 10.1042/bj2420055; KURAMITSU S, 1985, J BIOCHEM, V97, P1337, DOI 10.1093/oxfordjournals.jbchem.a135186; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKLUND SL, 1982, CLIN CHIM ACTA, V126, P41, DOI 10.1016/0009-8981(82)90360-6; MATSUNO K, 1989, CELL TISSUE RES, V257, P459, DOI 10.1007/BF00221456; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Sambrook J, 1989, MOL CLONING LABORATO; SHERMAN L, 1983, P NATL ACAD SCI-BIOL, V80, P5465, DOI 10.1073/pnas.80.18.5465; SHIMADA K, 1985, J CLIN INVEST, V75, P1308, DOI 10.1172/JCI111831; Sies H., 1985, OXIDATIVE STRESS; SUEMATSU M, 1987, J CLIN LAB IMMUNOL, V24, P125; SUGI K, 1989, BIOCHIM BIOPHYS ACTA, V991, P405, DOI 10.1016/0304-4165(89)90065-2; TANAKA Y, 1988, J BIOCHEM-TOKYO, V103, P954, DOI 10.1093/oxfordjournals.jbchem.a122393; TEMPST P, 1989, ANAL BIOCHEM, V183, P290, DOI 10.1016/0003-2697(89)90482-X; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487	37	45	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16409	16414						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885572				2022-12-25	WOS:A1991GD63500029
J	SUZUKI, T; TAKIYA, S; MATSUNO, K; OHNO, K; UENO, K; SUZUKI, Y				SUZUKI, T; TAKIYA, S; MATSUNO, K; OHNO, K; UENO, K; SUZUKI, Y			PURIFICATION AND CHARACTERIZATION OF AN ENHANCER-BINDING PROTEIN OF THE FIBROIN GENE .2. FUNCTIONAL ANALYSES OF FIBROIN FACTOR-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILK GLAND EXTRACTS; TRANSCRIPTION FACTOR; PROMOTER; INVITRO; SEQUENCE; UPSTREAM; COMPLEX; ACTIVATION; REGION; IDENTIFICATION	Fibroin factor 1 (FF1) when coupled with fibroin factor 2 (FF2) is an enhancer binding protein of the fibroin gene. FF1a, one type of FF1, has been purified to homogeneity from crude nuclear extracts of posterior silk gland cells and identified as a protein with molecular mass 125 kDa (Suzuki, T., Matsuno, K., Takiya, S., Ohno, K., Ueno, K., and Suzuki, Y. (1991) J. Biol. Chem. 266, 16935-16941). FF1 is able to recognize and bind a sequence of -205 to -185 in the enhancer I of the fibroin gene in the presence of FF2. The binding sequence of FF1 with FF2 contains two repeats of the derivative of consensus sequence which is recognized by homeobox-containing proteins. Though FF1 activity to construct the major band complex I is specific to posterior silk gland cells, use of a specific antibody raised against FF1a showed that FF1 protein is ubiquitous in Bombyx cells. These results suggest the possibility that FF1 molecules present as multiple proteins might be specifically modified and activated for the binding to enhancer DNA in posterior silk gland cells. Since the FF1 a antibody also inhibited a transcriptional enhancement activity governed by the enhancer sequence, we conclude that FF1 is one of the transcriptional factors of the fibroin gene. The functions of FF1 on fibroin gene transcription are discussed.	NATL INST BASIC BIOL,DEPT DEV BIOL,OKAZAKI,AICHI 444,JAPAN	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB)			Takiya, Shigeharu/A-6439-2012; Suzuki, Toshiharu/B-5342-2013					BIGGIN MD, 1989, CELL, V58, P433, DOI 10.1016/0092-8674(89)90424-8; DESPLAN C, 1988, CELL, V54, P1081, DOI 10.1016/0092-8674(88)90123-7; FLETCHER C, 1987, CELL, V51, P773, DOI 10.1016/0092-8674(87)90100-0; HAN KH, 1989, CELL, V56, P573, DOI 10.1016/0092-8674(89)90580-1; HIROSE S, 1982, P NATL ACAD SCI-BIOL, V79, P7258, DOI 10.1073/pnas.79.23.7258; HUI CC, 1990, DEV GROWTH DIFFER, V32, P263; HUI CC, 1989, GENE, V85, P403, DOI 10.1016/0378-1119(89)90433-2; HUI CC, 1990, J MOL BIOL, V213, P651, DOI 10.1016/S0022-2836(05)80253-0; JAYNES JB, 1988, NATURE, V336, P744, DOI 10.1038/336744a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATSUNO K, 1989, J BIOL CHEM, V264, P4599; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; SAWADOGO M, 1988, J BIOL CHEM, V263, P11985; SCHEIDEREIT C, 1987, CELL, V51, P783, DOI 10.1016/0092-8674(87)90101-2; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; STERN S, 1989, NATURE, V341, P624, DOI 10.1038/341624a0; SUZUKI T, 1988, J BIOL CHEM, V263, P5979; SUZUKI T, 1991, J BIOL CHEM, V266, P16935; SUZUKI T, 1986, INSECT BIOCHEM, V16, P589, DOI 10.1016/0020-1790(86)90001-6; SUZUKI Y, 1990, DEV GROWTH DIFFER, V32, P179; SUZUKI Y, 1986, P NATL ACAD SCI USA, V83, P9522, DOI 10.1073/pnas.83.24.9522; TAKIYA S, 1990, EMBO J, V9, P489, DOI 10.1002/j.1460-2075.1990.tb08135.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI SY, 1987, CELL, V50, P701, DOI 10.1016/0092-8674(87)90328-X; TSUDA M, 1986, MOL CELL BIOL, V6, P3928, DOI 10.1128/MCB.6.11.3928; TSUDA M, 1981, CELL, V27, P175, DOI 10.1016/0092-8674(81)90371-8; TSUDA M, 1983, P NATL ACAD SCI-BIOL, V80, P7442, DOI 10.1073/pnas.80.24.7442; TSUJIMOTO Y, 1984, P NATL ACAD SCI-BIOL, V81, P1644, DOI 10.1073/pnas.81.6.1644; TSUJIMOTO Y, 1981, P NATL ACAD SCI-BIOL, V78, P4838, DOI 10.1073/pnas.78.8.4838	30	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16942	16947						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885620				2022-12-25	WOS:A1991GD63500110
J	MEI, S; MODY, B; EKLUND, SH; PAUL, S				MEI, S; MODY, B; EKLUND, SH; PAUL, S			VASOACTIVE-INTESTINAL-PEPTIDE HYDROLYSIS BY ANTIBODY LIGHT-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							3-DIMENSIONAL STRUCTURE; CATALYTIC ANTIBODIES; RECOMBINATION; AUTOANTIBODY; COMPLEX	This paper describes evidence for hydrolysis of a neuropeptide, vasoactive intestinal peptide (VIP), by light chains purified from the IgG of a human subject positive for VIP binding antibodies. Purified IgG was digested with papain, resultant fragment antigen binding (Fab) fragments were reduced with 2-mercaptoethanol and alkylated with iodoacetamide, and light chains were purified by chromatography on immobilized antibodies to light chains and immobilized antibodies to heavy chains. Non-immunoglobulin components were undetectable in the light chain preparation, judged by sodium dodecyl sulfate-electrophoresis and Western blotting with anti-heavy and anti-light chain antibodies. The light chains hydrolyzed VIP with specific activity 32-fold greater than that of Fab, the pH optimum for light chain-mediated VIP hydrolysis was 7.0-7.5, and the hydrolytic activity was saturable (V(max), 0.19 pmol/min/mu-g light chains; substrate concentration at V(max)/2,380 nM).	UNIV NEBRASKA,MED CTR,DEPT PHARMACOL,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT BIOCHEM,OMAHA,NE 68198; UNIV NEBRASKA,MED CTR,DEPT INTERNAL MED,OMAHA,NE 68198	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center					NHLBI NIH HHS [HL44126, HL02217, HL40348] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL044126, R01HL040348, K04HL002217] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMIT AG, 1985, NATURE, V313, P156, DOI 10.1038/313156a0; BJORK I, 1971, BIOCHEMISTRY-US, V10, P1280; COLMAN PM, 1987, NATURE, V326, P358, DOI 10.1038/326358a0; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.bi.59.070190.002255; EDELMAN GM, 1963, P NATL ACAD SCI USA, V50, P753, DOI 10.1073/pnas.50.4.753; EDMONDSON AB, 1984, MOL IMMUNOL, V21, P561; ELLIS KJ, 1982, METHOD ENZYMOL, V87, P405; FLEISCHMAN JB, 1963, BIOCHEM J, V88, P220, DOI 10.1042/bj0880220; FRANEK F, 1963, BIOCHEMISTRY-MOSCOW+, V28, P193; JACOBS J, 1987, J AM CHEM SOC, V109, P2174, DOI 10.1021/ja00241a042; KOHEN F, 1980, BIOCHIM BIOPHYS ACTA, V629, P328, DOI 10.1016/0304-4165(80)90105-1; KOHEN F, 1980, FEBS LETT, V111, P427, DOI 10.1016/0014-5793(80)80842-8; OLINS DE, 1964, J EXP MED, V119, P789, DOI 10.1084/jem.119.5.789; PARHAM P, 1987, HDB EXPT IMMUNOLOGY, V1; PAUL S, 1989, COLD SPRING HARB SYM, V54, P283; PAUL S, 1991, J BIOL CHEM, V266, P16128; PAUL S, 1989, SCIENCE, V244, P1158, DOI 10.1126/science.2727702; PAUL S, 1990, J IMMUNOL, V145, P1196; PAUL S, 1989, J NEUROIMMUNOL, V23, P133, DOI 10.1016/0165-5728(89)90032-5; PAUL S, 1990, J BIOL CHEM, V365, P11910; ROHOLT O, 1963, P NATL ACAD SCI USA, V51, P173; STEVENSON GT, 1970, BIOCHEM J, V118, P703, DOI 10.1042/bj1180703; TRAMONTANO A, 1986, SCIENCE, V234, P1566, DOI 10.1126/science.3787261; UTSUMI S, 1964, BIOCHEMISTRY-US, V3, P1329, DOI 10.1021/bi00897a024; WARD ES, 1989, NATURE, V341, P544, DOI 10.1038/341544a0; WATT RM, 1979, J BIOL CHEM, V254, P7105; 1986, AFFINITY CHROMATOGR, P12	27	57	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15571	15574						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908455				2022-12-25	WOS:A1991GB97700005
J	TAKADATAKAYAMA, R; HANAOKA, F; YAMADA, M; UI, M				TAKADATAKAYAMA, R; HANAOKA, F; YAMADA, M; UI, M			IMMUNOAFFINITY-PURIFIED DNA POLYMERASE-ALPHA FROM A MOUSE TEMPERATURE-SENSITIVE MUTANT, TSFT20 STRAIN, IS HEAT-LABILE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMASE COMPLEX; FM3A CELLS; PURIFICATION; REPLICATION	We have purified DNA polymerase-alpha from a temperature-sensitive mutant cell line of mouse FM3A cells, tsFT20, that shows temperature-sensitive activity of DNA polymerase-alpha (Murakami, Y., Yasuda, H., Miyazawa, H., Hanaoka, F., and Yamada, M. (1985) Proc. Natl. Acad. Sci. U. S. A. 82, 1761-1765). The purified enzyme was composed of two polypeptides with the same apparent molecular weights as those of purified DNA polymerase-alpha from the parental strain, FM3A (M(r) 180,000 and 68,000). Heat inactivation experiments revealed that this purified DNA polymerase-alpha from tsFT20 celts was more heat-labile than the wild-type enzyme. We have also purified primase from both tsFT20 cells and wild-type cells. Both primase fractions consist of two polypeptides with molecular weights of 54,000 and 46,000. No difference was observed between the heat labilities of the primases from tsFT20 cells and wild-type cells. Comparisons of wild-type and mutant polymerase indicated that the temperature-sensitive mutation in DNA polymerase-alpha from tsFT20 cells affect the dCTP-binding site of the enzyme. The mutation also changed the optimum pH and the optimum KCl concentration of the enzyme.	RIKEN INST PHYS & CHEM RES,CELLULAR PHYS LAB,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,TOKYO 113,JAPAN	RIKEN; University of Tokyo				Takada, Ritsuko/0000-0002-1615-056X				Alberts B.M., 1971, METHODS ENZYMOL, V21, P198; APOSHIAN HV, 1962, J BIOL CHEM, V237, P519; BROOKE RG, 1991, J BIOL CHEM, V266, P3005; COTTERILL SM, 1987, P NATL ACAD SCI USA, V84, P5635, DOI 10.1073/pnas.84.16.5635; EKI T, 1988, ARCH BIOCHEM BIOPHYS, V260, P552, DOI 10.1016/0003-9861(88)90481-X; EKI T, 1987, EXP CELL RES, V171, P24, DOI 10.1016/0014-4827(87)90248-5; EKI T, 1986, J BIOL CHEM, V261, P8888; FRY M, 1986, ANIMAL CELL DNA POLY, P13; KAGUNI LS, 1988, BIOCHIM BIOPHYS ACTA, V950, P87, DOI 10.1016/0167-4781(88)90001-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDELL TJ, 1970, SCIENCE, V170, P47; MURAKAMI Y, 1986, EXP CELL RES, V163, P135, DOI 10.1016/0014-4827(86)90565-3; MURAKAMI Y, 1985, P NATL ACAD SCI USA, V82, P1761, DOI 10.1073/pnas.82.6.1761; NAKANO N, 1966, TOHOKU J EXP MED, V88, P69, DOI 10.1620/tjem.88.69; OGURO M, 1979, EUR J BIOCHEM, V97, P603, DOI 10.1111/j.1432-1033.1979.tb13149.x; SUZUKI M, 1989, J BIOL CHEM, V264, P10065; TAKADATAKAYAMA R, 1990, BIOCHEM BIOPH RES CO, V170, P589, DOI 10.1016/0006-291X(90)92132-J; TAKADATAKAYAMA R, 1990, FEBS LETT, V273, P27, DOI 10.1016/0014-5793(90)81043-N; TANAKA S, 1982, J BIOL CHEM, V257, P8386; WONG SW, 1986, J BIOL CHEM, V261, P7958; WONG SW, 1988, EMBO J, V7, P37, DOI 10.1002/j.1460-2075.1988.tb02781.x; YOSHIDA S, 1977, BIOCHIM BIOPHYS ACTA, V477, P144, DOI 10.1016/0005-2787(77)90230-1	22	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15716	15718						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874729				2022-12-25	WOS:A1991GB97700033
J	ANDRIEUX, A; RABIET, MJ; CHAPEL, A; CONCORD, E; MARGUERIE, G				ANDRIEUX, A; RABIET, MJ; CHAPEL, A; CONCORD, E; MARGUERIE, G			A HIGHLY CONSERVED SEQUENCE OF THE ARG-GLY-ASP-BINDING DOMAIN OF THE INTEGRIN BETA-3 SUBUNIT IS SENSITIVE TO STIMULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IIB-IIIA COMPLEX; PLATELET RECEPTOR; RECOGNITION SITE; VONWILLEBRAND-FACTOR; GLYCOPROTEIN FAMILY; FIBRINOGEN RECEPTOR; MONOCLONAL-ANTIBODY; ACTIVATED PLATELETS; PLASMA FIBRONECTIN; ADHESION RECEPTOR	The Arg-Gly-Asp (RGD)-binding domain of GPIIb-IIIa has been localized in a fragment of the GPIIIa subunit that includes the sequence between amino acids 109 and 171. To examine, in a platelet membrane environment, the activated versus nonactivated status of this domain, we have produced a monoclonal antibody against a synthetic peptide (residues 109-128) located within the RGD-binding region on GPIIIa. This kappa-IgM, named AC7, was specific for GPIIIa peptide 109-128 and interacted only with activated platelets. Fibrinogen, RGDF peptide, and the fibrinogen tau-chain decapeptide LGGAKQAGDV inhibited the binding of AC7 to ADP-stimulated platelets. AC7 IgM and "small fragments" inhibited fibrinogen binding and platelet aggregation in a dose-dependent fashion. Induction of AC7 binding by D33C, a monoclonal antibody recognizing the GPIIb 426-437 sequence and stimulating fibrinogen binding, indicated that the GPIIb 426-437 and the GPIIIa 109-128 sequences were both involved in a stimulation-dependent conformational modification of the receptor. AC7 was able to recognize beta-subunits other than GPIIIa on leucocyte surfaces but only after cell fixation with glutaraldehyde. The results are consistent with the implication of the RGD-binding domain in receptor ligand interaction on the platelet surface and its conformational modification and exposure upon receptor induction.			ANDRIEUX, A (corresponding author), CEN,DEPT BIOL MOLEC & STRUCT,INSERM,U217,HEMATOL LAB,85X,F-38041 GRENOBLE,FRANCE.		ANDRIEUX, ANNIE/B-2134-2017	ANDRIEUX, ANNIE/0000-0002-4022-6405				ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; BENET JS, 1979, J CLIN INVEST, V64, P1393; COLLER BS, 1986, J CELL BIOL, V103, P451, DOI 10.1083/jcb.103.2.451; COOK JJ, 1990, BLOOD, V79, pA452; DANA N, 1986, PATHOL IMMUNOPATH R, V5, P371, DOI 10.1159/000157027; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; DSOUZA SE, 1990, J BIOL CHEM, V265, P3440; FITZGERALD LA, 1985, ANAL BIOCHEM, V151, P169, DOI 10.1016/0003-2697(85)90067-3; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; GARCIAGONZALEZ A, 1988, J IMMUNOL METHODS, V111, P17; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GULINO D, 1990, J BIOL CHEM, V265, P9575; HAVERSTICK DM, 1985, BLOOD, V66, P946; HAWIGER J, 1982, P NATL ACAD SCI-BIOL, V79, P2068, DOI 10.1073/pnas.79.6.2068; HEMLER ME, 1987, J BIOL CHEM, V262, P3300; HEMLER ME, 1990, EMBO J, V9, P1561; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KAJIJI S, 1989, EMBO J, V8, P673, DOI 10.1002/j.1460-2075.1989.tb03425.x; KLOCZEWIAK M, 1984, BIOCHEMISTRY-US, V23, P1767, DOI 10.1021/bi00303a028; LANGUINO LR, 1989, BLOOD, V73, P734; LOFTUS JC, 1990, SCIENCE, V249, P915, DOI 10.1126/science.2392682; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; OBARA M, 1987, FEBS LETT, V213, P261, DOI 10.1016/0014-5793(87)81502-8; PARISE LV, 1988, J BIOL CHEM, V263, P12597; PIOTROWICZ RS, 1990, J CELL BIOL, V5, pA403; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1984, J BIOL CHEM, V259, P5388; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1981, J BIOL CHEM, V256, P9477; RUGGERI ZM, 1982, P NATL ACAD SCI-BIOL, V79, P6038, DOI 10.1073/pnas.79.19.6038; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHATTIL SJ, 1987, J BIOL CHEM, V262, P992; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SMITH JW, 1988, J BIOL CHEM, V263, P18726; SPRINGER TA, 1985, FED PROC, V44, P2660; SPRINGER TA, 1986, CIBA F SYMP, V118, P102, DOI 10.1002/9780470720998.ch8; SPRINGER TA, 1985, HYBRIDOMA TECHNOLOGY, P191; SUZUKI S, 1990, EMBO J, V9, P757, DOI 10.1002/j.1460-2075.1990.tb08170.x; TAKADA Y, 1987, P NATL ACAD SCI USA, V84, P3239, DOI 10.1073/pnas.84.10.3239; TAUB R, 1989, J BIOL CHEM, V264, P259; THIAGARAJAN P, 1988, J BIOL CHEM, V263, P3035; TRANQUI L, 1989, J CELL BIOL, V108, P2519, DOI 10.1083/jcb.108.6.2519	48	75	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14202	14207						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907272				2022-12-25	WOS:A1991FZ35100016
J	TOYAMA, H; TANIZAWA, K; YOSHIMURA, T; ASANO, S; LIM, YH; ESAKI, N; SODA, K				TOYAMA, H; TANIZAWA, K; YOSHIMURA, T; ASANO, S; LIM, YH; ESAKI, N; SODA, K			THERMOSTABLE ALANINE RACEMASE OF BACILLUS-STEAROTHERMOPHILUS - CONSTRUCTION AND EXPRESSION OF ACTIVE FRAGMENTARY ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SEQUENCE DETERMINATION; MUSCLE LACTATE-DEHYDROGENASE; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; LIMITED PROTEOLYSIS; (1-AMINOETHYL)PHOSPHONIC ACID; PURIFICATION; DNA; GALACTOSIDASE; INTERDOMAIN	Limited proteolysis studies on alanine racemase suggested that the enzyme subunit is composed of two domains (Galakatos, N. G., and Walsh, C. T. (1987) Biochemistry 26, 8475-8480). We have constructed a mutant gene that tandemly encodes the two polypeptides of the Bacillus stearothermophilus enzyme subunit cleaved at the position corresponding to the predicted hinge region. The mutant gene product purified was shown to be composed of two sets of the two polypeptide fragments and was immunologically identical to the wild-type enzyme. The mutant enzyme, i.e. the fragmentary alanine racemase, was active in both directions of the racemization of alanine. The maximum velocity (V(max)) was about half that of the wild-type enzyme, and the K(m) value was about double. Absorption and circular dichroism spectra of the fragmentary enzyme were similar to those of the wild-type enzyme. An attempt was made to separately express in Escherichia coli a single polypeptide corresponding to each domain, but no protein reactive with the antibody against the wild-type alanine racemase was produced. Therefore, it is suggested that the two polypeptide fragments can fold into an active structure only when they are co-translated and that they correspond to structural folding units in the parental polypeptide chain.	KYOTO UNIV,INST CHEM RES,MICROBIAL BIOCHEM LAB,UJI,KYOTO 611,JAPAN; OSAKA UNIV,INST SCI & IND RES,FOOD CHEM LAB,IBARAKI,OSAKA 567,JAPAN	Kyoto University; Osaka University								ATHERTON FR, 1986, J MED CHEM, V29, P29, DOI 10.1021/jm00151a005; BADET B, 1985, BIOCHEMISTRY-US, V24, P1333, DOI 10.1021/bi00327a010; BONAVITA V, 1960, ARCH BIOCHEM BIOPHYS, V88, P366, DOI 10.1016/0003-9861(60)90252-6; EDWARDS LA, 1988, J BIOL CHEM, V263, P1848; FERRARI E, 1985, BIO-TECHNOL, V3, P1003, DOI 10.1038/nbt1185-1003; GALAKATOS NG, 1989, BIOCHEMISTRY-US, V28, P8167, DOI 10.1021/bi00446a031; GALAKATOS NG, 1987, BIOCHEMISTRY-US, V26, P8475, DOI 10.1021/bi00399a066; GALAKATOS NG, 1986, BIOCHEMISTRY-US, V25, P3255, DOI 10.1021/bi00359a026; GIRG R, 1983, BIOCHEM INT, V7, P433; GOLDBERG ME, 1969, J MOL BIOL, V46, P441, DOI 10.1016/0022-2836(69)90187-9; INAGAKI K, 1986, BIOCHEMISTRY-US, V25, P3268, DOI 10.1021/bi00359a028; KIRSCHNER K, 1980, J MOL BIOL, V143, P395, DOI 10.1016/0022-2836(80)90219-3; LEVITT M, 1976, NATURE, V261, P552, DOI 10.1038/261552a0; MANNING JM, 1974, P NATL ACAD SCI USA, V71, P417, DOI 10.1073/pnas.71.2.417; NEIDHART DJ, 1987, J BIOL CHEM, V262, P15323; OPITZ U, 1987, BIOCHEMISTRY-US, V26, P1399, DOI 10.1021/bi00379a028; SODA K, 1986, COENZYMES COFACTOR B, V1, P223; STROMINGER J, 1990, J AM CHEM SOC, V82, P998; TANIZAWA K, 1988, BIOCHEMISTRY-US, V27, P1311, DOI 10.1021/bi00404a033; WALSH CT, 1989, J BIOL CHEM, V264, P2393; WANG E, 1978, BIOCHEMISTRY-US, V17, P1313, DOI 10.1021/bi00600a028; WASSERMAN SA, 1984, BIOCHEMISTRY-US, V23, P5182, DOI 10.1021/bi00317a015	22	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13634	13639						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906880				2022-12-25	WOS:A1991FY02700031
J	AZUMA, H; DENT, JA; SUGIMOTO, M; RUGGERI, ZM; WARE, J				AZUMA, H; DENT, JA; SUGIMOTO, M; RUGGERI, ZM; WARE, J			INDEPENDENT ASSEMBLY AND SECRETION OF A DIMERIC ADHESIVE DOMAIN OF VONWILLEBRAND-FACTOR CONTAINING THE GLYCOPROTEIN-IB-BINDING SITE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON WILLEBRAND FACTOR; FACTOR VWF; COLLAGEN; SEQUENCE; PROTEIN; CDNA; PLATELETS; FRAGMENT; MULTIMERIZATION; SUBENDOTHELIUM	von Willebrand factor (vWF) is a multimeric glycoprotein that supports platelet adhesion on thrombogenic surfaces as part of the normal hemostatic response to vascular injury. We have employed a domain-specific expression strategy to analyze the biosynthetic processing steps and minimum structural requirements for assembly of the platelet receptor glycoprotein Ib-binding domain of vWF. A chimeric cDNA that codes for the vWF signal peptide and a segment of vWF internal primary sequence, residues 441-730, directs the secretion of a functional vWF fragment from mammalian cells. The recombinant molecule intrinsically assembles through intermolecular disulfide bond formation into a dimeric adhesive domain without contributions from other regions of vWF, including propeptide, previously indicated as essential for vWF multimer assembly. Prevention of N-linked glycosylation on the recombinant domain does not impair dimer formation or the ability to support platelet aggregation. These results identify a minimum structural element for vWF subunit assembly and provide new insights into the processing steps to produce vWF multimers and adhesive domains.	SCRIPPS RES INST, COMM VASC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	AZUMA, H (corresponding author), SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, DIV EXPTL HEMOSTASIS & THROMBOSIS, LA JOLLA, CA 92037 USA.							ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; BONTHRON D, 1986, NUCLEIC ACIDS RES, V14, P7125, DOI 10.1093/nar/14.17.7125; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUJIMURA Y, 1991, BLOOD, V77, P113; FUJIMURA Y, 1986, J BIOL CHEM, V261, P381; FUJIMURA Y, 1987, J BIOL CHEM, V262, P1734; HANDA M, 1986, J BIOL CHEM, V261, P2579; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MACFARLANE DE, 1975, THROMB DIATH HAEMOST, V34, P306, DOI 10.1055/s-0038-1651343; MANCUSO DJ, 1989, J BIOL CHEM, V264, P19514; MARTI T, 1987, BIOCHEMISTRY-US, V26, P8099, DOI 10.1021/bi00399a013; MOHRI H, 1989, J BIOL CHEM, V264, P17361; MOHRI H, 1988, J BIOL CHEM, V263, P17901; NIIYA K, 1987, BLOOD, V70, P475; PARETI FI, 1987, J BIOL CHEM, V262, P13835; PARETI FI, 1986, J BIOL CHEM, V261, P15310; ROTH GJ, 1986, BIOCHEMISTRY-US, V25, P8357, DOI 10.1021/bi00374a004; RUGGERI ZM, 1987, BLOOD, V70, P895; RUGGERI ZM, 1983, J CLIN INVEST, V72, P1, DOI 10.1172/JCI110946; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SEED B, 1987, NATURE, V329, P840, DOI 10.1038/329840a0; SHELTONINLOES BB, 1986, BIOCHEMISTRY-US, V25, P3164, DOI 10.1021/bi00359a014; SODETZ JM, 1979, J BIOL CHEM, V254, P754; SPORN LA, 1987, BLOOD, V69, P1531; SPORN LA, 1986, CELL, V46, P185, DOI 10.1016/0092-8674(86)90735-X; STEL HV, 1985, BLOOD, V65, P85; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TURITTO VT, 1985, BLOOD, V65, P823; VERWEIJ CL, 1987, EMBO J, V6, P2885, DOI 10.1002/j.1460-2075.1987.tb02591.x; VOORBERG J, 1990, EMBO J, V9, P797, DOI 10.1002/j.1460-2075.1990.tb08176.x; WAGNER DD, 1986, J CELL BIOL, V102, P1320, DOI 10.1083/jcb.102.4.1320; WAGNER DD, 1987, BLOOD, V69, P27; WAGNER DD, 1984, P NATL ACAD SCI-BIOL, V81, P471, DOI 10.1073/pnas.81.2.471; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WARE J, 1991, P NATL ACAD SCI USA, V88, P2946, DOI 10.1073/pnas.88.7.2946; WEISS HJ, 1978, J LAB CLIN MED, V92, P750; WISE RJ, 1988, CELL, V52, P229, DOI 10.1016/0092-8674(88)90511-9	39	36	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12342	12347						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905720				2022-12-25	WOS:A1991FV18000039
J	CARVER, MA; TURCO, SJ				CARVER, MA; TURCO, SJ			CELL-FREE BIOSYNTHESIS OF LIPOPHOSPHOGLYCAN FROM LEISHMANIA-DONOVANI - CHARACTERIZATION OF MICROSOMAL GALACTOSYLTRANSFERASE AND MANNOSYLTRANSFERASE ACTIVITIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR PROMASTIGOTES; PHOSPHATIDYLINOSITOL; MEMBRANE; ANCHOR; EXPRESSION; DEFICIENT; FAMILY; THY-1; GLYCOCONJUGATE; GLYCOSYLATION	Incubation of microsomal preparations from Leishmania donovani parasites with UDP-[H-3]galactose or GDP-[C-14]mannose resulted in incorporation of radio-label into an endogenous product that exhibited the chemical and chromatographic characteristics of the parasite's major surface glycoconjugate, lipophosphoglycan. The [H-3]galactose- or [C-14]mannose-labeled product was (i) cleaved by phosphatidylinositol-specific phospholipase C; (ii) deaminated by nitrous acid; and (iii) degraded into radioactive, low molecular weight fragments upon hydrolysis with mild acid. Analysis of the products of mild acid hydrolysis revealed the presence of phosphorylated Gal-beta-Man as the major fragment with lesser amounts of mono-, tri-, and tetrasaccharides. The incorporation of the two isotopic precursors was neither stimulated by the addition of dolichylphosphate nor inhibited by amphomycin, indicating that dolichol-saccharide intermediates are not involved in assembly of the repeating units of lipophosphoglycan. Development of this cell-free glycosylating system will facilitate further studies on the pathway and enzymes involved in lipophosphoglycan biosynthesis.	UNIV KENTUCKY,MED CTR,DEPT BIOCHEM,LEXINGTON,KY 40536	University of Kentucky					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI020941, R01AI020941] Funding Source: NIH RePORTER; NIAID NIH HHS [AI20941] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANET EFLJ, 1954, NATURE, V174, P930, DOI 10.1038/174930a0; BANERJEE DK, 1981, BIOCHEMISTRY-US, V20, P1561, DOI 10.1021/bi00509a024; BRAELL WA, 1976, ANAL BIOCHEM, V74, P484, DOI 10.1016/0003-2697(76)90229-3; BRETTHAUER RK, 1969, BIOCHEM BIOPH RES CO, V37, P820, DOI 10.1016/0006-291X(69)90965-6; CONZELMANN A, 1986, EMBO J, V5, P3291, DOI 10.1002/j.1460-2075.1986.tb04642.x; DAVIES CR, 1990, PARASITOLOGY, V101, P337, DOI 10.1017/S0031182000060522; DOERING TL, 1990, J BIOL CHEM, V265, P611; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; FATEMI SH, 1987, J BIOL CHEM, V262, P4728; FATEMI SH, 1986, CELL, V46, P653, DOI 10.1016/0092-8674(86)90340-5; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; HANDMAN E, 1986, J IMMUNOL, V137, P3608; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; HUBBARD SC, 1979, J BIOL CHEM, V254, P4568; KHORANA HG, 1957, J AM CHEM SOC, V79, P430, DOI 10.1021/ja01559a054; KING DL, 1988, MOL BIOCHEM PARASIT, V28, P285, DOI 10.1016/0166-6851(88)90013-8; MacDonald D L., 1972, CARBOHYDRATES CHEM A, V1A, P253; MCCONVILLE MJ, 1987, P NATL ACAD SCI USA, V84, P8941, DOI 10.1073/pnas.84.24.8941; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P7385; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1989, J BIOL CHEM, V264, P757; MCCONVILLE MJ, 1990, MOL BIOCHEM PARASIT, V38, P57, DOI 10.1016/0166-6851(90)90205-Z; MCNEELY TB, 1990, J IMMUNOL, V144, P2745; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; MOLNAR J, 1971, BIOCHIM BIOPHYS ACTA, V239, P401, DOI 10.1016/0005-2760(71)90033-6; ORLANDI PA, 1987, J BIOL CHEM, V262, P10384; ORLEAN P, 1990, MOL CELL BIOL, V10, P5796, DOI 10.1128/MCB.10.11.5796; PALADINI AC, 1952, BIOCHEM J, V51, P426, DOI 10.1042/bj0510426; PIRAS R, 1963, ARCH BIOCHEM BIOPHYS, V103, P291, DOI 10.1016/0003-9861(63)90409-0; PREVIATO JO, 1986, MOL BIOCHEM PARASIT, V18, P343, DOI 10.1016/0166-6851(86)90091-5; PUENTES SM, 1988, J EXP MED, V167, P887, DOI 10.1084/jem.167.3.887; ROSEN G, 1989, J BIOL CHEM, V264, P10457; ROSEN G, 1988, MOL BIOCHEM PARASIT, V27, P93, DOI 10.1016/0166-6851(88)90028-X; SACKS DL, 1990, MOL BIOCHEM PARASIT, V42, P225, DOI 10.1016/0166-6851(90)90165-I; SCHWARZ RT, 1989, BIOCHEM SOC T, V17, P746, DOI 10.1042/bst0170746; TALAMASROHANA P, 1990, J IMMUNOL, V144, P4817; TURCO SJ, 1990, EXP PARASITOL, V70, P241, DOI 10.1016/0014-4894(90)90105-L; TURCO SJ, 1984, J BIOL CHEM, V259, P3883; TURCO SJ, 1987, BIOCHEMISTRY-US, V26, P6233, DOI 10.1021/bi00393a042; TURCO SJ, 1989, J BIOL CHEM, V264, P6711; VOLWERK JJ, 1989, J CELL BIOCHEM, V39, P315, DOI 10.1002/jcb.240390311	41	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					10974	10981						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1904057				2022-12-25	WOS:A1991FQ77400044
J	ANDREWS, TJ; KANE, HJ				ANDREWS, TJ; KANE, HJ			PYRUVATE IS A BY-PRODUCT OF CATALYSIS BY RIBULOSEBISPHOSPHATE CARBOXYLASE OXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; SLOW INACTIVATION; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; REACTION-INTERMEDIATE; SMALL SUBUNITS; ACTIVE-SITE; SUBSTRATE; CHLOROPLASTS; INHIBITOR	Pyruvate is a minor product of the reaction catalyzed by ribulosebisphosphate carboxylase/oxygenase from spinach leaves. Labeled pyruvate was detected, in addition to the major labeled product, 3-phosphoglycerate, when (CO2)-C-14 was the substrate. Pyruvate production was also measured spectrophotometrically in the presence of lactate dehydrogenase and NADH. The K(m) for CO2 of the pyruvate-producing activity was 12.5-mu-M, similar to the CO2 affinity of the 3-phosphoglycerate-producing activity. No pyruvate was detected by the coupled assay when ribulose 1,5-bisphosphate was replaced by 3-phosphoglycerate or when the carboxylase was inhibited by the reaction-intermediate analog, 2'-carboxyarabinitol 1,5-bisphosphate. Therefore, pyruvate was not being produced from 3-phosphoglycerate by contaminant enzymes. The ratio of pyruvate produced to ribulose bisphosphate consumed at 25-degrees-C was 0.7%, and this ratio was not altered by varying pH or CO2 concentration or by substituting Mn2+ for Mg2+ as the catalytically essential metal. The ratio increased with increasing temperature. Ribulosebisphosphate carboxylases from the cyanobacterium Synechococcus PCC 6301 and the bacterium Rhodospirillum rubrum also catalyzed pyruvate formation and to the same extent as the spinach enzyme. When the reaction was carried out in (H2O)-H-2, the spinach carboxylase increased the proportion of its product partitioned to pyruvate to 2.2%. These observations provide evidence that the C-2 carbanion form of 3-phosphoglycerate is an intermediate in the catalytic sequence of ribulose-bisphosphate carboxylase. Pyruvate is formed by beta-elimination of a phosphate ion from a small portion of this intermediate.			ANDREWS, TJ (corresponding author), AUSTRALIAN NATL UNIV, RES SCH BIOL SCI, PLANT ENVIRONM BIOL GRP, POB 475, CANBERRA, ACT 2601, AUSTRALIA.							ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; ANDREWS TJ, 1983, J BIOL CHEM, V258, P7514; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; BRANDEN R, 1980, BIOCHEM BIOPH RES CO, V92, P1297, DOI 10.1016/0006-291X(80)90427-1; CALVIN M, 1956, J CHEM SOC, P1895, DOI 10.1039/jr9560001895; CAMPBELL ID, 1979, BIOCHEM J, V179, P607, DOI 10.1042/bj1790607; Collatz GJ, 1979, CARNEGIE I WASH YR B, V78, P171; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1383, DOI 10.1104/pp.93.4.1383; EDMONDSON DL, 1990, FEBS LETT, V260, P62, DOI 10.1016/0014-5793(90)80066-R; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1376, DOI 10.1104/pp.93.4.1376; EDMONDSON DL, 1990, PLANT PHYSIOL, V93, P1390, DOI 10.1104/pp.93.4.1390; FIEDLER F, 1967, EUR J BIOCHEM, V1, P395, DOI 10.1111/j.1432-1033.1967.tb00087.x; HARTMAN FC, 1985, J BIOL CHEM, V260, P3968; HURWITZ J, 1956, BIOCHIM BIOPHYS ACTA, V22, P194, DOI 10.1016/0006-3002(56)90243-8; JAWOROWSKI A, 1984, J BIOL CHEM, V259, P6783; KENNEDY RA, 1974, PLANT PHYSIOL, V54, P608, DOI 10.1104/pp.54.4.608; LORIMER GH, 1986, PHILOS T ROY SOC B, V313, P397, DOI 10.1098/rstb.1986.0046; MORELL MK, 1990, FEBS LETT, V265, P41, DOI 10.1016/0014-5793(90)80879-N; PAULSEN JM, 1966, BIOCHEMISTRY-US, V5, P2350, DOI 10.1021/bi00871a025; PIERCE J, 1986, J BIOL CHEM, V261, P248; ROSE IA, 1981, PHILOS T ROY SOC B, V293, P131, DOI 10.1098/rstb.1981.0067; SAVER BG, 1982, BIOCHEMISTRY-US, V21, P5398, DOI 10.1021/bi00265a003; SCHLOSS JV, 1982, J BIOL CHEM, V257, P4691; SCHULZESIEBERT D, 1984, PLANT PHYSIOL, V76, P465, DOI 10.1104/pp.76.2.465; SIMON H, 1964, Z NATURFORSCH PT B, VB 19, P734; STITT M, 1979, PHYTOCHEMISTRY, V18, P1905, DOI 10.1016/S0031-9422(00)82700-4	27	74	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9447	9452						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903385				2022-12-25	WOS:A1991FM45900021
J	PEI, G; BAKER, K; EMFINGER, SM; FOWLKES, DM; LENTZ, BR				PEI, G; BAKER, K; EMFINGER, SM; FOWLKES, DM; LENTZ, BR			EXPRESSION, ISOLATION, AND CHARACTERIZATION OF AN ACTIVE-SITE (SERINE 528-]ALANINE) MUTANT OF RECOMBINANT BOVINE PROTHROMBIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALPHA-THROMBIN; CRYSTAL-STRUCTURE; ENZYME COMPLEXES; VITAMIN-K; MEIZOTHROMBIN; ACTIVATION; PROTEIN; BINDING; IDENTIFICATION; INTERMEDIATE	An active site mutant bovine prothrombin cDNA (Ser528 --> Ala) has been constructed, subcloned, and expressed in Chinese hamster ovary cells. The recombinant mutant prothrombin, expressed at the level of 1.5-2.0-mu-g/ml of cell medium, was fully carboxylated (9.9 +/- 0.4 mol of gamma-carboxyglutamic acid/mol of prothrombin). The mutant prothrombin could be activated to thrombin by Taipan snake venom and activated to meizothrombin by ecarin in a manner comparable to native bovine prothrombin or recombinant wild-type bovine prothrombin. The mutant meizothrombin thus formed was stable and did not autolyze. The initial rate of cleavage of mutant prothrombin catalyzed by the full prothrombinase was only 28% of the rate of cleavage of native prothrombin, while recombinant wild-type prothrombin was cleaved at the same rate as the native molecule. The mutant thrombin, obtained from the mutant prothrombin in situ by prothrombinase or Taipan snake venom activation, showed no enzymatic activity toward either fibrinogen or a synthetic chromogenic substrate, D-phenylalanyl-L-pipecolyl-L-arginine-p-nitroanilide dihydrochloride (S2238). The mutant thrombin also bound dansylarginine-N-(3-ethyl-1,5-pentanediyl)amide, a specific fluorescent inhibitor of the thrombin active site, with a weaker binding affinity (k(d) = 5.4 x 10(-8) M) than did native thrombin (k(d) = 1.7 x 10(-8) M). These results indicate that the mutant recombinant prothrombin described here is a useful tool for the study of meizothrombin or thrombin without the complications arising from the proteolytic activities of these molecules. Study of the activation of this mutant has already revealed a functional link between the site of initial cleavage by the prothrombinase and the conformation at the nascent active site of prothrombin.	UNIV N CAROLINA,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT PATHOL,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill					NHLBI NIH HHS [HL36197, HL26309, HL31012] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL026309, R23HL031012, F32HL136197, R01HL036197, R01HL031012] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARMSTRONG SA, 1990, J BIOL CHEM, V265, P6210; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CUTSFORTH GA, 1989, BIOCHEMISTRY-US, V28, P7453, DOI 10.1021/bi00444a045; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GRUTTER MG, 1990, EMBO J, V9, P2361, DOI 10.1002/j.1460-2075.1990.tb07410.x; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; HUBER P, 1990, J BIOL CHEM, V265, P12467; Jesty J, 1976, Methods Enzymol, V45, P95; JORGENSEN MJ, 1987, J BIOL CHEM, V262, P6729; KISIEL W, 1981, METHOD ENZYMOL, V80, P275; KRISHNASWAMY S, 1986, J BIOL CHEM, V261, P8977; KRISHNASWAMY S, 1990, J BIOL CHEM, V265, P3708; MACGILLIVRAY RTA, 1980, P NATL ACAD SCI-BIOL, V77, P5153, DOI 10.1073/pnas.77.9.5153; Mann K G, 1976, Methods Enzymol, V45, P123; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; NELSESTUEN GL, 1974, J BIOL CHEM, V249, P6347; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NESHEIM ME, 1983, J BIOL CHEM, V258, P5386; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; PEI G, 1991, IN PRESS BLOOD COAG; ROSING J, 1988, THROMB HAEMOSTASIS, V60, P355; ROSING J, 1986, J BIOL CHEM, V261, P4224; RYDEL TJ, 1990, SCIENCE, V249, P277, DOI 10.1126/science.2374926; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SKRZYPCZAKJANKUN E, 1989, J MOL BIOL, V206, P755, DOI 10.1016/0022-2836(89)90582-2; TENDIAN SW, 1990, BIOCHEMISTRY-US, V29, P6720, DOI 10.1021/bi00480a023; TULINSKY A, 1988, J MOL BIOL, V202, P885, DOI 10.1016/0022-2836(88)90565-7; WRIGHT SF, 1986, J BIOL CHEM, V261, P598	32	19	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9598	9604						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903392				2022-12-25	WOS:A1991FM45900042
J	TOKISHITA, S; KOJIMA, A; AIBA, H; MIZUNO, T				TOKISHITA, S; KOJIMA, A; AIBA, H; MIZUNO, T			TRANSMEMBRANE SIGNAL TRANSDUCTION AND OSMOREGULATION IN ESCHERICHIA-COLI - FUNCTIONAL IMPORTANCE OF THE PERIPLASMIC DOMAIN OF THE MEMBRANE-LOCATED PROTEIN-KINASE, ENVZ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 REGULATORY PROTEINS; OMPC GENES; ENVIRONMENTAL SENSOR; ANESTHETIC PROCAINE; ACTIVATOR PROTEIN; PORIN PROTEINS; EXPRESSION; PHOSPHORYLATION; K-12	The EnvZ protein is presumably a membrane-located osmotic sensor which is involved in expression of the ompF and ompC genes in Escherichia coli. Previously, we developed an in vitro method for analyzing the intact form of the EnvZ protein located in isolated cytoplasmic membranes, and demonstrated that this particular form of the EnvZ protein exhibits the ability not only as to OmpR phosphorylation but also OmpR dephosphorylation. In this study, to gain an insight into the structural and functional importance of the putative periplasmic domain of the EnvZ protein, a set of mutant EnvZ proteins,which lack various portions of the periplasmic domain, were characterized in terms of not only their in vivo osmoregulatory phenotypes but also in vitro EnvZ-OmpR phosphotransfer reactions. It was revealed that these deletion mutant EnvZ proteins are normally incorporated into the cytoplasmic membrane. Cells harboring these mutant EnvZ proteins showed a pleiotropic phenotype, namely, OmpF- Mal- LamB- PhoA-, and produced the OmpC protein constitutively irrespective of the medium osmolarity. It was also suggested that all of these mutant EnvZ proteins were defective in their in vitro OmpR dephosphorylation ability, while their OmpR phosphorylation ability remained unaffected. These results imply the functional importance of the periplasmic domain of the EnvZ protein for modulation of the kinase/phosphatase activity exhibited by the cytoplasmic domain in response to an environmental osmotic stimulus.	NAGOYA UNIV,SCH AGR,MICROBIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN	Nagoya University								AIBA H, 1989, J BIOL CHEM, V264, P14090; AIBA H, 1989, J BIOL CHEM, V264, P8563; AIBA H, 1989, J BIOCHEM-TOKYO, V106, P5, DOI 10.1093/oxfordjournals.jbchem.a122817; AIBA H, 1990, FEBS LETT, V261, P19, DOI 10.1016/0014-5793(90)80626-T; AMES P, 1988, CELL, V55, P817, DOI 10.1016/0092-8674(88)90137-7; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; FORST S, 1987, J BIOL CHEM, V262, P16433; FORST S, 1989, P NATL ACAD SCI USA, V86, P6052, DOI 10.1073/pnas.86.16.6052; GRANETT S, 1981, J BACTERIOL, V147, P289, DOI 10.1128/JB.147.2.289-296.1981; HALL MN, 1981, ANNU REV GENET, V15, P91, DOI 10.1146/annurev.ge.15.120181.000515; HALL MN, 1981, J MOL BIOL, V146, P23, DOI 10.1016/0022-2836(81)90364-8; IGO MM, 1989, GENE DEV, V3, P598, DOI 10.1101/gad.3.5.598; IGO MM, 1988, J BACTERIOL, V170, P5971, DOI 10.1128/jb.170.12.5971-5973.1988; IGO MM, 1989, GENE DEV, V3, P1725, DOI 10.1101/gad.3.11.1725; JO YL, 1986, J BIOL CHEM, V261, P5252; KANAMARU K, 1989, J BIOL CHEM, V264, P21633; KAWAJI H, 1979, J BACTERIOL, V140, P843, DOI 10.1128/JB.140.3.843-847.1979; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING; MATSUYAMA SI, 1986, J BACTERIOL, V168, P1309, DOI 10.1128/jb.168.3.1309-1314.1986; Miller JH, 1972, EXPT MOL GENETICS, P201; MIZUNO T, 1982, J BIOL CHEM, V257, P13692; MIZUNO T, 1987, J BIOCHEM-TOKYO, V101, P387, DOI 10.1093/oxfordjournals.jbchem.a121923; MIZUNO T, 1990, MOL MICROBIOL, V4, P1077, DOI 10.1111/j.1365-2958.1990.tb00681.x; RONSON CW, 1987, CELL, V49, P579, DOI 10.1016/0092-8674(87)90530-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SLAUCH JM, 1988, J BACTERIOL, V170, P439, DOI 10.1128/jb.170.1.439-441.1988; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TAYLOR RK, 1983, J MOL BIOL, V166, P273, DOI 10.1016/S0022-2836(83)80085-0; TOKISHITA S, 1990, J BIOCHEM-TOKYO, V108, P488, DOI 10.1093/oxfordjournals.jbchem.a123226; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K	32	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					6780	6785						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1901856				2022-12-25	WOS:A1991FG72700024
J	BECK, KA; KEEN, JH				BECK, KA; KEEN, JH			SELF-ASSOCIATION OF THE PLASMA MEMBRANE-ASSOCIATED CLATHRIN ASSEMBLY PROTEIN AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLE PROTEINS; MONOCLONAL-ANTIBODIES; PURIFICATION; RECEPTOR; BINDING; PHOSPHORYLATION; HETEROGENEITY; DISSOCIATION; POLYPEPTIDES; ADAPTORS	A self-association reaction involving the plasma membrane-associated clathrin assembly protein AP-2 has been detected by incubating AP-2 alone under solution conditions that would favor the assembly of complete coat structures if clathrin were present. Self-association was rapid, unaffected by nonionic detergents, readily reversible, and gave rise to sedimentable aggregates. Only the AP subtype AP-2 exhibited self-association: the structurally or functionally related assembly proteins AP-1 and AP-3 and unrelated proteins neither self-associated nor were incorporated into the AP-2 aggregate. AP-2 interactions responsible for self-association were of high affinity, with an apparent K(d) of approximately 10(-8) M. By proteolytic dissection, the self-association domain was localized to the core of the molecule containing the intact 50- and 16-kDa polypeptides in association with the truncated 60-66-kDa moieties of the parent alpha/beta-polypeptides. Self-association of the intact AP-2 molecule was pH-dependent, exhibiting an apparent pK(a) almost-equal-to 7.4. While it is unlikely that the large AP-2 aggregates formed in solution are themselves biologically relevant structures, the AP-2 interactions involved in their formation have properties consistent with their occurrence in intact cells and thus may be important in cellular functions of the plasma membrane-localized assembly protein.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,3420 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028526] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28526] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1986, EMBO J, V5, P3143, DOI 10.1002/j.1460-2075.1986.tb04621.x; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ANDERSON RA, 1984, NATURE, V307, P655, DOI 10.1038/307655a0; BARZVI D, 1988, J BIOL CHEM, V263, P4408; BECK KA, 1991, J BIOL CHEM, V266, P4442; CARLIER MF, 1984, P NATL ACAD SCI-BIOL, V81, P771, DOI 10.1073/pnas.81.3.771; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; GEUZE HJ, 1987, J CELL BIOL, V104, P1715, DOI 10.1083/jcb.104.6.1715; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GOUD B, 1985, J CELL BIOL, V100, P521, DOI 10.1083/jcb.100.2.521; GRASBERGER B, 1986, P NATL ACAD SCI USA, V83, P6258, DOI 10.1073/pnas.83.17.6258; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; KEEN JH, 1986, J CELL BIOL, V102, P1325, DOI 10.1083/jcb.102.4.1325; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KEEN JH, 1985, ENDOCYTOSIS, P85; KIRCHHAUSEN T, 1981, CELL, V23, P755, DOI 10.1016/0092-8674(81)90439-6; KOHTZ DS, 1988, J BIOL CHEM, V263, P7418; MADSHUS IH, 1988, BIOCHEM J, V250, P1, DOI 10.1042/bj2500001; Pastan I., 1985, ENDOCYTOSIS, V1-44; PEARSE BMF, 1987, ANNU REV BIOPHYS BIO, V16, P49, DOI 10.1146/annurev.bb.16.060187.000405; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PRASAD K, 1988, BIOCHEMISTRY-US, V27, P6098, DOI 10.1021/bi00416a040; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; STOSSEL TP, 1985, ANNU REV CELL BIOL, V1, P353, DOI 10.1146/annurev.cb.01.110185.002033; UNGEWICKELL E, 1981, NATURE, V289, P420, DOI 10.1038/289420a0; WEGNER A, 1983, P NATL ACAD SCI-BIOL, V80, P4922, DOI 10.1073/pnas.80.16.4922; WEISENBERG RC, 1986, ANN NY ACAD SCI, V466, P543, DOI 10.1111/j.1749-6632.1986.tb38431.x; WIEDENMANN B, 1985, J CELL BIOL, V101, P12, DOI 10.1083/jcb.101.1.12; WOODWARD MP, 1978, P NATL ACAD SCI USA, V75, P4394, DOI 10.1073/pnas.75.9.4394; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	36	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4437	4441						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900294				2022-12-25	WOS:A1991FA69400065
J	CARTER, R; COSENZA, SC; PENA, A; LIPSON, K; SOPRANO, DR; SOPRANO, KJ				CARTER, R; COSENZA, SC; PENA, A; LIPSON, K; SOPRANO, DR; SOPRANO, KJ			A POTENTIAL ROLE FOR C-JUN IN CELL-CYCLE PROGRESSION THROUGH LATE G1 AND S	ONCOGENE			English	Article							TRANSCRIPTION FACTOR AP-1; HUMAN-DIPLOID FIBROBLASTS; TUMOR NECROSIS FACTOR; PROTO-ONCOGENE; GROWTH-FACTOR; G0/G1 TRANSITION; FOS; BINDING; GENE; EXPRESSION	When the level of c-jun mRNA was analyzed in WI-38 human fibroblasts exciting short- and long-term quiescence, two peaks of c-jun mRNA accumulation were found. The first occurred one hour after stimulation and lasted three to five hours, whereas the second occurred at the G1/S border and was coupled to the time of entry to S phase rather than to the time of stimulation. The early peak is well documented and in agreement with the proposed role of c-Jun/AP-1 in mediating cellular responses to receptor-generated signals. The later peak, however, has not been previously reported. Additional follow-up studies showed that late G1/S expression was not solely a phenomenon of cells exiting a quiescent state, nor was it restricted only to human cells. Gel retardation studies confirmed that there is AP-1 specific DNA binding activity in nuclear extracts isolated in late G1 and S phase, and that this AP-1 binding activity is due to the presence of Jun protein. An anti-Fos antibody was able to significantly decrease AB-1 binding activity in early G1 extracts, but had no effect on extracts isolated in late G1 and S phase, indicating that the complexes observed in late G1 and S phase are clearly different from those seen in early G1. These studies are among the first to suggest a functional dissociation of c-Jun from c-Fos. Our results identify a new, previously unreported role for c-Jun/AP-1 in regulation of cell cycle progression and mammalian cell growth.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,3400 N BROAD ST,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT PATHOL,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University				Borghaei, Ruth/0000-0003-4206-0231; Lipson, Kenneth/0000-0001-8847-6051				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; AUGENLICHT LH, 1974, EXP CELL RES, V89, P255, DOI 10.1016/0014-4827(74)90789-7; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; COSENZA SC, 1988, J BIOL CHEM, V263, P12751; CRESS AE, 1977, EXP CELL RES, V110, P347, DOI 10.1016/0014-4827(77)90301-9; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DIXIT VM, 1989, J BIOL CHEM, V264, P16905; FLOROS J, 1978, CELL BIOL INT REP, V2, P259, DOI 10.1016/0309-1651(78)90006-1; GLENN GM, 1990, J VIROL, V64, P2193, DOI 10.1128/JVI.64.5.2193-2201.1990; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HATTORI K, 1988, P NATL ACAD SCI USA, V85, P9148, DOI 10.1073/pnas.85.23.9148; IVASHKIV LB, 1990, MOL CELL BIOL, V10, P1609, DOI 10.1128/MCB.10.4.1609; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; OWEN TA, 1987, J BIOL CHEM, V262, P15111; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAO PN, 1984, J CELL PHYSIOL, V119, P77, DOI 10.1002/jcp.1041190113; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SAUVE G, IN PRESS; SCHUTTE J, 1989, CELL, V59, P989; SHARMA A, 1989, P NATL ACAD SCI USA, V86, P491, DOI 10.1073/pnas.86.2.491; SOPRANO KJ, 1987, MOL CELL BIOCHEM, V75, P61, DOI 10.1007/BF00231609; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; THOMAS P, 1980, P NATL ACAD SCI USA, V77, P54201; TOBEY RA, 1988, EXP CELL RES, V179, P400, DOI 10.1016/0014-4827(88)90279-0; TOLMACH LJ, 1988, CELL TISSUE KINET, V23, P125; TOSCANI A, 1987, ANAL BIOCHEM, V165, P309, DOI 10.1016/0003-2697(87)90274-0; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; TUSCHINSKI R, 1977, P NATL ACAD SCI USA, V74, P2357; WASYLYK C, 1990, ONCOGENE, V5, P1055; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	43	65	65	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					229	235						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900357				2022-12-25	WOS:A1991FZ13400008
J	LOWE, PN; PAGE, MJ; BRADLEY, S; RHODES, S; SYDENHAM, M; PATERSON, H; SKINNER, RH				LOWE, PN; PAGE, MJ; BRADLEY, S; RHODES, S; SYDENHAM, M; PATERSON, H; SKINNER, RH			CHARACTERIZATION OF RECOMBINANT HUMAN KIRSTEN-RAS(4B) P21 PRODUCED AT HIGH-LEVELS IN ESCHERICHIA-COLI AND INSECT BACULOVIRUS EXPRESSION SYSTEMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KI-RAS P21; PROTEINS; PURIFICATION; GENE; MECHANISM; PROTEASE; OMPT; SITE	Kirsten-ras is the oncogene most frequently activated in human tumors. Studies of its bilogical function have been limited by the nonavailability of significant amounts of the major protein product, Kirstenras (4B) p21. When expressed in Escherichia coli K12, the recombinant protein was rapidly cleaved upon cell lysis in the lysine-rich C terminus region, probably by the ompT protease. However, soluble full-length protein was obtained when the Kirsten-ras gene was expressed in an E. coli strain lacking the ompt gene, and also in a baculovirus/insect cell expression system. Additionally, the baculovirus/insect cell system produced about half of the Kirsten-ras protein in a membrane-associated form, which was post-translationally modified by polyisoprenylation and carboxyl-methylation. A C-terminally truncated form (residues 1-166) was also expressed at high levels in E. coli for x-ray crystallographic studies. The kinetics of GDP release and of GTP hydrolysis of the purified proteins are similar to those of the corresponding Harvey-ras proteins, though there are small differences in the relative affinities for GDP and GTP. Biological activity of full-length Kirsten Val-12 p21 was demonstrated by microinjection into Swiss 3T3 cells, resulting in morphological transformation, with a lower potency than that of Harvey Val-12 protein.	WELLCOME BIOTECH LTD,DEPT MOLEC BIOL,BECKENHAM,KENT,ENGLAND; INST CANC RES,CHESTER BEATTY LABS,LONDON SW3 6JB,ENGLAND	GlaxoSmithKline; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	LOWE, PN (corresponding author), WELLCOME RES LABS,DEPT MOLEC SCI,LANGLEY COURT,BECKENHAM BR3 3BS,KENT,ENGLAND.							ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; FERAMISCO JR, 1984, CELL, V38, P109, DOI 10.1016/0092-8674(84)90531-2; FEUERSTEIN J, 1987, EUR J BIOCHEM, V162, P49, DOI 10.1111/j.1432-1033.1987.tb10540.x; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JOHN J, 1989, J BIOL CHEM, V264, P13086; JOHN J, 1988, J BIOL CHEM, V263, P11792; KAHN S, 1987, ANTICANCER RES, V7, P639; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lacal J. C., 1988, ONCOGENE HDB, P257; LOWE PN, 1988, BIOCHEM J, V250, P789, DOI 10.1042/bj2500789; LOWE PN, 1990, ONCOGENE, V5, P1045; Maniatis T., 1982, MOL CLONING; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MIURA K, 1987, CHEM PHARM BULL, V35, P4878; NAKANO ET, 1987, J VIROL, V61, P302, DOI 10.1128/JVI.61.2.302-307.1987; NEAL SE, 1988, J BIOL CHEM, V263, P19718; PAGE MJ, 1989, NUCLEIC ACIDS RES, V17, P454, DOI 10.1093/nar/17.1.454; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PINGOUD A, 1988, BIOCHEMISTRY-US, V27, P4735, DOI 10.1021/bi00413a023; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; STACEY D, 1984, NATURE, V310, P109; SUGIMURA K, 1988, J BACTERIOL, V170, P5625, DOI 10.1128/jb.170.12.5625-5632.1988; TAMAOKI T, 1985, BIOCHEM BIOPH RES CO, V132, P126, DOI 10.1016/0006-291X(85)90997-0; TRAHEY M, 1987, MOL CELL BIOL, V7, P541, DOI 10.1128/MCB.7.1.541; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; YAMASHITA T, 1988, J BIOL CHEM, V263, P17181	35	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1672	1678						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1899093				2022-12-25	WOS:A1991EU49700050
J	ISOMURA, M; KIKUCHI, A; OHGA, N; TAKAI, Y				ISOMURA, M; KIKUCHI, A; OHGA, N; TAKAI, Y			REGULATION OF BINDING OF RHOB P20 TO MEMBRANES BY ITS SPECIFIC REGULATORY PROTEIN, GDP DISSOCIATION INHIBITOR	ONCOGENE			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; BOVINE BRAIN; GUANINE-NUCLEOTIDE; GENE-PRODUCT; SUBCELLULAR-DISTRIBUTION; CLOSTRIDIUM-BOTULINUM; KINETIC-ANALYSIS; RAS; RIBOSYLATION; SEQUENCE	We have previously purified from bovine brain cytosol a novel regulatory protein for the GTP-binding proteins of the rho gene family. This regulatory protein, designated as rho GDP dissociation inhibitor (GDI), makes a complex stoichiometrically with the GDP-bound form of the rho gene products and thereby regulates the GDP/GTP exchange reaction by inhibiting the dissociation of GDP from and the subsequent binding of GTP to them. We show here that rho GDI also regulates the binding of rhoB p20, a member of the rho gene products, to various membranes including rat brain synaptic plasma membranes and human erythrocyte ghosts. Both the GDP- and GTP-bound forms of rhoB p20 bound to the membranes. This binding was not inhibited by prior treatment of the membranes with boiling or tryptic digestion, suggesting that a protein molecule of the membranes is not essential for the binding of rhoB p20 to the membranes. rho GDI inhibited the binding of the GDP-bound form of rhoB p20, but not that of the GTP-bound form, to the membranes. Moreover, rho GDI induced the dissociation of the GDP-bound form, but not that of the GTP-bound form, of rhoB p20 exogenously bound to the membranes from them. These results suggest that the rho gene products bind to the membranes, presumably in a reversible manner and that this binding is regulated by their specific GDI.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ADAMVIZI V, 1988, FEBS LETT, V238, P277, DOI 10.1016/0014-5793(88)80496-4; AKTORIES K, 1987, BIOCHEM J, V247, P363, DOI 10.1042/bj2470363; ARAKI S, 1990, J BIOL CHEM, V265, P13007; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAUNU, 1989, FEBS LETT, V243, P70; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FUKUMOTO Y, 1990, IN PRESS ONCOGENE; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; HOSHINO M, 1987, J BIOCHEM-TOKYO, V102, P503, DOI 10.1093/oxfordjournals.jbchem.a122082; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KIM S, 1989, MOL BRAIN RES, V6, P167, DOI 10.1016/0169-328X(89)90051-X; KURODA S, 1989, BIOCHEM BIOPH RES CO, V163, P674, DOI 10.1016/0006-291X(89)92276-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUOKA I, 1989, J BIOL CHEM, V264, P706; MIZOGUCHI A, 1989, MOL BRAIN RES, V5, P31, DOI 10.1016/0169-328X(89)90015-6; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OHASHI Y, 1987, J BIOL CHEM, V262, P1430; OHGAN, 1989, BIOCHEM BIOPH RES CO, V163, P1523; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SHOJI I, 1989, BIOCHEM BIOPH RES CO, V162, P273, DOI 10.1016/0006-291X(89)91992-X; Steck T L, 1974, Methods Enzymol, V31, P172; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; UEDA T, 1979, J CELL BIOL, V83, P308, DOI 10.1083/jcb.83.2.308; UEDA T, 1990, J BIOL CHEM, V265, P9373; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	38	107	108	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					119	124						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899476				2022-12-25	WOS:A1991EY03900016
J	PETTINGILL, TM; STRANGE, RW; BLACKBURN, NJ				PETTINGILL, TM; STRANGE, RW; BLACKBURN, NJ			CARBONMONOXY DOPAMINE BETA-HYDROXYLASE - STRUCTURAL CHARACTERIZATION BY FOURIER-TRANSFORM INFRARED, FLUORESCENCE, AND X-RAY ABSORPTION-SPECTROSCOPY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; CURVED-WAVE THEORY; COPPER SITES; CRYSTAL-STRUCTURE; COORDINATION GEOMETRY; HEXAMERIC HEMOCYANIN; EXAFS CALCULATIONS; EDGE SPECTROSCOPY; 3.2-A RESOLUTION; MONO-OXYGENASE	The carbon monoxide complex of ascorbate-reduced dopamine beta-hydroxylase has been prepared and characterized by Fourier transform infrared, fluorescence, and x-ray absorption spectroscopies. CO has previously been shown to be a competitive inhibitor with respect to O2, and binds to only one of the two copper atoms/active site (Blackburn, N. J., Pettingill, T. M., Seagraves, K. S., and Shigeta, R. T. (1990) J. Biol. Chem. 265, 15383-15386). Thus, it acts as an excellent probe of the O2-binding site. A single C-O infrared absorption band is observed at 2089 cm-1, shifting by 46 cm-1 to lower energy on substitution with either (CO)-C-13-O-16 or (CO)-C-12-O-18. The C-13 isotope shift is reversed to the position expected for (CO)-C-12 upon vacuum flushing with (CO)-C-12 gas, indicating that formation of the CO adduct is a fully reversible process. Binding of the substrate tyramine does not eliminate the infrared peak but causes a 3-cm-1 shift to lower energy. On the other hand, binding of a bifunctional inhibitor which cross-links the substrate and O2-binding site does eliminate the CO peak. These data, in conjunction with the competitive nature of CO binding with respect to O2, identify the CO-binding site as the O2-binding site, and place it in close proximity to the substrate-binding site. CO-dopamine beta-hydroxylase exhibits no luminescence in the visible region, suggesting a structure different from carbonmonoxy hemocyanin, and in all probability mononuclear. Analysis of extended x-ray absorption spectroscopy data is most consistent with an average coordination per Cu of 2-3 histidines, 0.5 CO, and 0.5 S atoms as ligands, and absorption edge comparisons indicates pseudo-4 coordination as the most likely geometry at each Cu(I) center. The results can be interpreted by a model involving inequivalent 4-coordination at each Cu(I) center in the CO adduct with CuAHis3S ... CuBHis2CO-X as the coordination most consistent with all of the data.	OREGON GRAD INST SCI & TECHNOL, DEPT CHEM & BIOL SCI, BEAVERTON, OR 97006 USA						NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027583] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS-27583] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADMAN ET, 1991, IN PRESS ADV PROTEIN; ALBEN JO, 1968, BIOCHEMISTRY-US, V7, P175, DOI 10.1021/bi00841a022; ASH DE, 1984, J BIOL CHEM, V259, P3395; BINSTED N, 1988, SERC EXCURV88 DAR LA; BLACKBURN NJ, 1989, INORG CHEM, V28, P1349, DOI 10.1021/ic00306a027; BLACKBURN NJ, 1988, BIOCHEMISTRY-US, V27, P6001, DOI 10.1021/bi00416a026; BLACKBURN NJ, 1984, BIOCHEM J, V220, P447, DOI 10.1042/bj2200447; BLACKBURN NJ, 1990, J BIOL CHEM, V265, P15383; BLACKBURN NJ, 1989, SYNCHROTRON RAD BIOP, P63; BLUMBERG WE, 1989, J BIOL CHEM, V264, P6029; BRENNER MC, 1989, BIOCHEMISTRY-US, V28, P4664, DOI 10.1021/bi00437a023; BROWN JM, 1980, J AM CHEM SOC, V102, P4210, DOI 10.1021/ja00532a037; CO MS, 1981, J AM CHEM SOC, V103, P3200, DOI 10.1021/ja00401a044; COLOMBO G, 1987, ARCH BIOCHEM BIOPHYS, V252, P71, DOI 10.1016/0003-9861(87)90009-9; EINARSDOTTIR O, 1988, J BIOL CHEM, V263, P13641; FAGER LY, 1972, BIOCHEMISTRY-US, V11, P4786, DOI 10.1021/bi00775a023; FIAMINGO FG, 1982, J BIOL CHEM, V257, P1639; FINAZZIAGRO A, 1982, BIOCHEMISTRY-US, V21, P415, DOI 10.1021/bi00531a032; GURMAN SJ, 1984, J PHYS C SOLID STATE, V17, P143, DOI 10.1088/0022-3719/17/1/019; GURMAN SJ, 1986, J PHYS C SOLID STATE, V19, P1845, DOI 10.1088/0022-3719/19/11/021; GURMAN SJ, 1989, SYNCHROTON RAD BIOPH, P9; HASNAIN SS, 1984, BIOCHEM J, V221, P545, DOI 10.1042/bj2210545; KARLIN KD, 1987, PROG INORG CHEM, V35, P219, DOI 10.1002/9780470166369.ch3; KAU LS, 1987, J AM CHEM SOC, V109, P6433, DOI 10.1021/ja00255a032; KITAJIMA N, 1989, J AM CHEM SOC, V111, P8975, DOI 10.1021/ja00206a062; KLINMAN JP, 1984, J BIOL CHEM, V259, P3399; KRUSE LI, 1986, BIOCHEMISTRY-US, V25, P7271, DOI 10.1021/bi00371a004; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; MCCRACKEN J, 1988, BIOCHEMISTRY-US, V27, P4133, DOI 10.1021/bi00411a034; MESSERSCHMIDT A, 1989, J MOL BIOL, V206, P513, DOI 10.1016/0022-2836(89)90498-1; OBATA A, 1987, BIOCHEMISTRY-US, V26, P4962, DOI 10.1021/bi00390a012; Pasquali M, 1984, COPPER COORDINATION, P311; PATCH MG, 1990, INORG CHEM, V29, P110, DOI 10.1021/ic00326a023; ROBB DA, 1984, COPPER PROTEINS COPP, V2, P207; SAYERS DE, 1988, XRAY ABSORPTION PRIN, P211; SCOTT RA, 1988, BIOCHEMISTRY-US, V27, P5411, DOI 10.1021/bi00415a005; SHEPARD WEB, 1990, J AM CHEM SOC, V112, P7817, DOI 10.1021/ja00177a065; SMITH TA, 1985, J AM CHEM SOC, V107, P5945, DOI 10.1021/ja00307a020; SOLOMON EI, 1981, METAL IONS BIOL, P40; SORRELL TN, 1986, J AM CHEM SOC, V108, P2479, DOI 10.1021/ja00269a075; SORRELL TN, 1987, J AM CHEM SOC, V109, P4255, DOI 10.1021/ja00248a020; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; STEWART LC, 1987, BIOCHEMISTRY-US, V26, P5302, DOI 10.1021/bi00391a013; STEWART LC, 1988, ANNU REV BIOCHEM, V57, P551; STRANGE RW, 1987, J AM CHEM SOC, V109, P7157, DOI 10.1021/ja00257a042; STRANGE RW, 1989, SYNCHROTRON RAD BIOP, P105; Teo BK., 1986, EXAFS BASIC PRINCIPL, P114, DOI DOI 10.1007/978-3-642-50031-2; THOMPSON JS, 1984, INORG CHEM, V23, P2813, DOI 10.1021/ic00186a020; TYEKLAR Z, 1989, ACCOUNTS CHEM RES, V22, P241, DOI 10.1021/ar00163a003; VILLACORTA GM, 1987, INORG CHEM, V26, P3672, DOI 10.1021/ic00269a012; VILLAFRANCA JJ, 1981, METAL IONS BIOL, V3, P263; VOLBEDA A, 1989, J MOL BIOL, V209, P249, DOI 10.1016/0022-2836(89)90276-3; ZOLLA L, 1984, BIOCHIM BIOPHYS ACTA, V788, P206, DOI 10.1016/0167-4838(84)90263-2	53	56	56	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					16996	17003						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894598				2022-12-25	WOS:A1991GF44500009
J	XU, XX; TABAS, I				XU, XX; TABAS, I			LIPOPROTEINS ACTIVATE ACYL-COENZYME-A - CHOLESTEROL ACYLTRANSFERASE IN MACROPHAGES ONLY AFTER CELLULAR CHOLESTEROL POOLS ARE EXPANDED TO A CRITICAL THRESHOLD LEVEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; CULTURED FIBROBLASTS; TRANSFERASE-ACTIVITY; ESTER ACCUMULATION; J774 MACROPHAGES; PLASMA-MEMBRANE; FOAM CELLS; RECEPTOR; LDL	Activation of acyl-CoA:cholesterol actyltransferase (ACAT) in macrophages by lipoproteins is a key event in atheroma foam cell formation. To help elucidate the mechanisms whereby lipoproteins stimulate ACAT, the early cellular events of lipoprotein-induced ACAT stimulation were studied in mouse peritoneal macrophages. As a function of increasing lipoprotein-cholesterol influx to the cell during the first few hours of incubation, ACAT activity was markedly stimulated by beta-very low density lipoprotein (beta-VLDL) and acetyl-low density lipoprotein (acetyl-LDL) only after lipoprotein-cholesterol influx reached a threshold level of approximately 25% above the basal cell cholesterol content. In contrast, LDL stimulated ACAT only minimally at this level of lipoprotein-cholesterol influx. In further experiments, the source of ACAT cholesterol substrate during the initial stimulation of ACAT was shown to be a mixture of cellular (approximately 75%) and lipoprotein-cholesterol (approximately 25%) in proportions that approximated the proportions of originally cellular and lipoprotein-cholesterol in the cell. Thus, lipoprotein-cholesterol rapidly mixed with most or all of cellular cholesterol before ACAT esterification. Additional studies showed that LDL caused significant efflux of cellular cholesterol, thus providing at least a partial explanation for the relatively weak ACAT stimulatory potential of LDL. To support this idea, LDL that was modified to decrease its ability to induce net cellular cholesterol efflux stimulated ACAT 2-fold greater than control LDL when matched for lysosomal LDL-cholesterol influx. Moreover, when the effective efflux potentials of beta-VLDL and acetyl-LDL were increased, ACAT stimulation was markedly decreased despite unchanged lipoprotein-cholesterol influx. Thus, macrophage ACAT is stimulated not directly by the influx of newly hydrolyzed lipoprotein-cholesterol but rather by net expansion of cellular cholesterol pools to a particular threshold level. This scheme has potentially important implications regarding the cellular and molecular mechanisms of foam cell formation.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University; Columbia University					NHLBI NIH HHS [HL-39703, HL-21006] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL021006, R01HL039703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARBOGAST LY, 1976, P NATL ACAD SCI USA, V73, P3680, DOI 10.1073/pnas.73.10.3680; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; BROWN MS, 1975, P NATL ACAD SCI USA, V72, P2925, DOI 10.1073/pnas.72.8.2925; DOOLITTLE GM, 1982, BIOCHIM BIOPHYS ACTA, V713, P529, DOI 10.1016/0005-2760(82)90313-7; FIELDING CJ, 1984, J LIPID RES, V25, P1624; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HO YK, 1980, J LIPID RES, V21, P391; JOHNSON WJ, 1990, J BIOL CHEM, V265, P5546; KHOO JC, 1989, BIOCHIM BIOPHYS ACTA, V1012, P215, DOI 10.1016/0167-4889(89)90099-2; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNDBERG B, 1982, CHEM PHYS LIPIDS, V31, P275, DOI 10.1016/0009-3084(82)90062-7; REINHART MP, 1987, J BIOL CHEM, V262, P9649; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBLAT GH, 1978, J LIPID RES, V19, P350; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SCHECHTER I, 1981, J LIPID RES, V22, P63; SLOTTE JP, 1989, BIOCHIM BIOPHYS ACTA, V985, P90, DOI 10.1016/0005-2736(89)90108-9; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SPECTOR A A, 1979, Progress in Lipid Research, V18, P31, DOI 10.1016/0163-7827(79)90003-1; STEIN O, 1981, BIOCHIM BIOPHYS ACTA, V665, P477, DOI 10.1016/0005-2760(81)90261-7; SUCKLING KE, 1985, J LIPID RES, V26, P647; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1987, J CLIN INVEST, V79, P418, DOI 10.1172/JCI112828; TABAS I, 1986, J BIOL CHEM, V261, P3147; TABAS I, 1988, CIRCULATION, V78, P49; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053	35	110	110	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17040	17048						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894601				2022-12-25	WOS:A1991GF44500015
J	YU, B; PEREIRA, ME; WILK, S				YU, B; PEREIRA, ME; WILK, S			CHEMICAL MODIFICATION OF THE BOVINE PITUITARY MULTICATALYTIC PROTEINASE COMPLEX BY N-ACETYLIMIDAZOLE - REVERSIBLE ACTIVATION OF CASEIN HYDROLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NEUTRAL ENDOPEPTIDASE; RAT SKELETAL-MUSCLE; PROTEASE COMPLEX; MAMMALIAN-CELLS; PURIFICATION; SPECIFICITY; ENZYME; LATENT; FORMS; LIVER	The effect of N-acetylimidazole, a mild acetylating reagent, on the catalytic activities and subunit structure of the bovine pituitary multicatalytic proteinase complex (MPC) was studied. The trypsin-like activity (cleavage of Cbz-D-Ala-Leu-Arg-2-naphthylamide) and the peptidylglutamyl-peptide bond hydrolyzing (PGP) activity (cleavage of Cbz-Leu-Leu-Glu-2-naphthylamide) of MPC were rapidly inactivated by N-acetylimidazole, whereas the chymotrypsin-like activity (cleavage of Cbz-Gly-Gly-Leu-p-nitroanilide) was inactivated slowly. However, the hydrolysis of casein was markedly stimulated. Hydrolysis of casein by the acetylated enzyme generated a stable intermediate (21 kDa) which could be further degraded by native MPC. Treatment of acetylated MPC with hydroxylamine reversed the changes in trypsin-like and caseinolytic activities but did not restore the PGP activity. N-Acetylimidazole did not dissociate MPC but altered its migration on nondissociating gels presumably by acetylation of epsilon-amino groups of lysine residues. Hydroxylamine did not alter the gel electrophoretic appearance of the acetylated enzyme. These results indicate that acetylation of thiol or tyrosyl groups changes the trypsin-like and caseinolytic activities, and that amino group acetylation inhibits the PGP activity. Degradation of casein by MPC appears to be a sequential process with initial cleavage catalyzed by a component distinct from the chymotrypsin-like, trypsin-like, and PGP activities. The latter three components likely participate in the secondary proteolysis of the generated intermediates.	CUNY MT SINAI SCH MED,DEPT PHARMACOL,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai			Pereira, Maria/GZA-9681-2022		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS017392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [T32DA007135] Funding Source: NIH RePORTER; NIDA NIH HHS [2T32-DA07135-11] Funding Source: Medline; NIMH NIH HHS [MH-00350] Funding Source: Medline; NINDS NIH HHS [NS-17392] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; DAHLMANN B, 1985, BIOCHEM J, V228, P161, DOI 10.1042/bj2280161; DICK LR, 1991, BIOCHEMISTRY-US, V30, P2725, DOI 10.1021/bi00224a022; DUMAS BR, 1972, EUR J BIOCHEM, V25, P505, DOI 10.1111/j.1432-1033.1972.tb01722.x; FALKENBURG PE, 1988, NATURE, V331, P190, DOI 10.1038/331190a0; FENNER C, 1975, ANAL BIOCHEM, V63, P595, DOI 10.1016/0003-2697(75)90386-3; KOPP F, 1986, BIOCHIM BIOPHYS ACTA, V872, P253, DOI 10.1016/0167-4838(86)90278-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MELLGREN RL, 1990, BIOCHIM BIOPHYS ACTA, V1040, P28, DOI 10.1016/0167-4838(90)90142-3; MYKLES DL, 1989, ARCH BIOCHEM BIOPHYS, V274, P216, DOI 10.1016/0003-9861(89)90433-5; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; ORLOWSKI M, 1981, BIOCHEM BIOPH RES CO, V101, P814; PEREIRA ME, 1990, ARCH BIOCHEM BIOPHYS, V283, P68, DOI 10.1016/0003-9861(90)90613-4; RAY K, 1986, FEBS LETT, V194, P91, DOI 10.1016/0014-5793(86)80057-6; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; RIORDAN JF, 1965, BIOCHEMISTRY-US, V4, P1785; RIVETT AJ, 1985, J BIOL CHEM, V260, P2600; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; SACCHETTA P, 1990, BIOCHIM BIOPHYS ACTA, V1037, P337, DOI 10.1016/0167-4838(90)90035-E; TANAKA K, 1990, CELL STRUCT FUNCT, V15, P127, DOI 10.1247/csf.15.127; TANAKA K, 1986, J BIOL CHEM, V261, P5197; WAGNER BJ, 1982, EXP EYE RES, V35, P293, DOI 10.1016/S0014-4835(82)80054-7; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1970, BIOCHEMISTRY-US, V9, P2039, DOI 10.1021/bi00812a002; WILK S, 1979, LIFE SCI, V24, P457, DOI 10.1016/0024-3205(79)90218-2; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x	29	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17396	17400						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894626				2022-12-25	WOS:A1991GF44500064
J	CONCA, W; AURON, PE; AOUNWATHNE, M; BENNETT, N; SECKINGER, P; WELGUS, HG; GOLDRING, SR; EISENBERG, SP; DAYER, JM; KRANE, SM; GEHRKE, L				CONCA, W; AURON, PE; AOUNWATHNE, M; BENNETT, N; SECKINGER, P; WELGUS, HG; GOLDRING, SR; EISENBERG, SP; DAYER, JM; KRANE, SM; GEHRKE, L			AN INTERLEUKIN-1-BETA POINT MUTANT DEMONSTRATES THAT JUN FOS EXPRESSION IS NOT SUFFICIENT FOR FIBROBLAST METALLOPROTEINASE EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA; C-JUN; COLLAGENASE GENE; RHEUMATOID-ARTHRITIS; RECEPTOR ANTAGONIST; INDUCTION; AP-1; TRANSCRIPTION; INHIBITOR; BINDING	Substitution of glycine for arginine at position 127 of the mature human interleukin 1-beta protein generates a mutant IL-1-beta protein (IL-1-beta-R --> G) which binds cellular IL-1 receptors with high affinity but fails to elicit significant proliferation of T-helper cells (Gehrke, L., Jobling, S. A., Paik, L. S. K., McDonald, B., Rosenwasser, L. J., and Auron, P. E. (1990) J. Biol. Chem. 265, 5922-5925). Although both IL-1-beta and the IL-1-beta-R --> G mutein stimulate transcription of fibroblast immediate early (fos and jun) and early (IL-1-beta and IL-6) genes, the IL-1-beta-R --> G mutein, in contrast to the wild-type IL-1-beta protein, induces minimal or no transcription of late genes such as procollagenase and prostromelysin. The effect of the naturally occurring IL-1 receptor antagonist protein (IL-1 ra) on fibroblast transcription is distinct from that of the IL-1-beta-R --> G mutein, for the IL-1 ra fails to stimulate not only late (procollagenase and prostromelysin) but also immediate early (fos and jun) gene expression. These data suggest that the IL-I-beta-R --> G mutein triggers an incomplete or defective signal transduction cascade and demonstrate that fibroblast fos and jun expression is not necessarily accompanied by increased transcription of genes containing the AP-1 binding site. These data also suggest that at least two events are required for IL-1-mediated late gene induction in fibroblasts.	HARVARD UNIV,MASSACHUSETTS GEN HOSP,SCH MED,DEPT MED,BOSTON,MA 02114; CTR BLOOD RES,BOSTON,MA 02115; WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV DERMATOL,ST LOUIS,MO 63110; SYNERGEN INC,BOULDER,CO 80301; UNIV GENEVA,HOP CANTONAL,DEPT MED,DIV IMMUNOL & ALLERGY,CH-1211 GENEVA 4,SWITZERLAND; MIT,HARVARD MIT DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Barnes-Jewish Hospital; Washington University (WUSTL); University of Geneva; Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School				Conca, Walter/0000-0003-3427-2664				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1986, MOL CELL BIOL, V6, P1760, DOI 10.1128/MCB.6.5.1760; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BRINCKERHOFF CE, 1990, ANN NY ACAD SCI, V580, P355, DOI 10.1111/j.1749-6632.1990.tb17944.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; CONCA W, 1989, J CLIN INVEST, V83, P1753, DOI 10.1172/JCI114077; COOPER TW, 1983, COLLAGEN REL RES, V3, P205; DAYER JM, 1989, INTERLEUKIN 1 INFLAM, P283; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; GEHRKE L, 1990, J BIOL CHEM, V265, P5922; GUTMAN A, 1990, EMBO J, V9, P2241, DOI 10.1002/j.1460-2075.1990.tb07394.x; HANNUM CH, 1990, NATURE, V343, P336, DOI 10.1038/343336a0; HENDERSON B, 1987, BRIT MED BULL, V43, P415, DOI 10.1093/oxfordjournals.bmb.a072191; KRANE SM, 1985, COLLAGEN REL RES, V5, P99; KRANE SM, 1990, ANN NY ACAD SCI, V580, P340, DOI 10.1111/j.1749-6632.1990.tb17943.x; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; MCCACHREN SS, 1989, ARTHRITIS RHEUM, V32, P1539, DOI 10.1002/anr.1780321207; MCDONNELL SE, 1990, MOL CELL BIOL, V10, P4284, DOI 10.1128/MCB.10.8.4284; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; RIFAS L, 1989, J CLIN INVEST, V84, P686, DOI 10.1172/JCI114216; SECKINGER P, 1987, J IMMUNOL, V139, P1541; WASYLYK B, 1990, NATURE, V346, P191, DOI 10.1038/346191a0; WHITHAM SE, 1986, BIOCHEM J, V240, P913, DOI 10.1042/bj2400913; WINGFIELD P, 1986, EUR J BIOCHEM, V160, P491, DOI 10.1111/j.1432-1033.1986.tb10066.x	28	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16265	16268						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1909326				2022-12-25	WOS:A1991GD63500003
J	CUMMINGS, HS; SANDS, JF; FOREMAN, PC; FRASER, J; HERSHEY, JWB				CUMMINGS, HS; SANDS, JF; FOREMAN, PC; FRASER, J; HERSHEY, JWB			STRUCTURE AND EXPRESSION OF THE INFA OPERON ENCODING TRANSLATIONAL INITIATION FACTOR-IF1 - TRANSCRIPTIONAL CONTROL BY GROWTH-RATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; RNA-POLYMERASE; GENE; CLONING; PROTEIN; PROMOTERS	The cellular levels of the three translational initiation factors, IF1, IF2, and IF3, increase as a function of growth rate in parallel with those of ribosomes. Therefore both ribosomal and initiation factor gene expression is under metabolic control. To address how expression of the Escherichia coli gene for IF1, infA, is regulated, a 3-kilobase region of the genome surrounding infA was sequenced. The 5' and 3' termini of in vivo infA transcripts were defined by S1 nuclease mapping, and mRNA size was measured by Northern blot hybridization. The infA gene is transcribed by two promoters, P1 and P2, which generate transcripts of 525 and 330 nucleotides, apparently ending at the same rho-independent terminator. Analyses of operon and protein fusions to lacZ demonstrate that neither infA transcription nor translation is affected by high cellular levels of IF1. However, P2, but not P1, increases in activity as a function of the growth rate of the cell and is the dominant promoter in rich medium. Therefore, metabolic control of infA expression occurs exclusively at the level of transcription by the P2 promoter			CUMMINGS, HS (corresponding author), UNIV CALIF DAVIS,SCH MED,DEPT BIOL CHEM,DAVIS,CA 95616, USA.				NIGMS NIH HHS [GM07467, NP70, GM40082, GM10914] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040082, T32GM007467, F32GM010914] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BURTON ZF, 1983, CELL, V32, P335, DOI 10.1016/0092-8674(83)90453-1; BUTLER JS, 1986, J MOL BIOL, V192, P767, DOI 10.1016/0022-2836(86)90027-6; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GRUNBERGMANAGO M, 1987, ESCHERICHIA COLI SAL, P1380; HOWE JG, 1983, J BIOL CHEM, V258, P1954; ISHII S, 1984, P NATL ACAD SCI-BIOL, V81, P409, DOI 10.1073/pnas.81.2.409; JINKSROBERTSON S, 1987, ESCHERICHIA COLI SAL, P1358; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; LINDAHL L, 1986, ANNU REV GENET, V20, P297; MILLER JH, 1972, ADV BACTERIAL GENETI; MULLIGAN ME, 1984, NUCLEIC ACIDS RES, V12, P789, DOI 10.1093/nar/12.1Part2.789; NEIDHARDT FC, 1977, J BACTERIOL, V129, P378, DOI 10.1128/JB.129.1.378-387.1977; PLUMBRIDGE JA, 1985, EMBO J, V4, P223, DOI 10.1002/j.1460-2075.1985.tb02339.x; PLUMBRIDGE JA, 1982, P NATL ACAD SCI-BIOL, V79, P5033, DOI 10.1073/pnas.79.16.5033; REGNIER P, 1986, J MOL BIOL, V187, P23, DOI 10.1016/0022-2836(86)90403-1; RODRIQUEZ RC, 1983, RECOMBINANT DNA TECH, P192; SANCAR A, 1979, J BACTERIOL, V137, P692, DOI 10.1128/JB.137.1.692-693.1979; SANDS JF, 1988, NUCLEIC ACIDS RES, V16, P10803, DOI 10.1093/nar/16.22.10803; SANDS JF, 1987, NUCLEIC ACIDS RES, V15, P5157, DOI 10.1093/nar/15.13.5157; SANDS JF, 1986, THESIS U CALIF, P109; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMONS RW, 1987, GENE, V53, P85, DOI 10.1016/0378-1119(87)90095-3; SPRINGER M, 1979, MOL GEN GENET, V169, P337, DOI 10.1007/BF00382279; TRAVERS AA, 1984, NUCLEIC ACIDS RES, V12, P2605, DOI 10.1093/nar/12.6.2605; VALENTINHANSEN P, 1986, EMBO J, V5, P2015, DOI 10.1002/j.1460-2075.1986.tb04458.x; WEIVISTOCK GM, 1983, GENE AMPLIFICATORS A, V3, P27	28	21	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16491	16498						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1909328				2022-12-25	WOS:A1991GD63500043
J	METSARANTA, M; TOMAN, D; DECROMBRUGGHE, B; VUORIO, E				METSARANTA, M; TOMAN, D; DECROMBRUGGHE, B; VUORIO, E			MOUSE TYPE-II COLLAGEN GENE - COMPLETE NUCLEOTIDE-SEQUENCE, EXON STRUCTURE, AND ALTERNATIVE SPLICING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; AMINO-TERMINAL PROPEPTIDE; SINGLE BASE MUTATION; PROCOLLAGEN GENE; MILD CHONDRODYSPLASIA; MESSENGER-RNA; 1ST INTRON; IDENTIFICATION; CARTILAGE; DOMAIN	Several overlapping clones covering the entire mouse type II collagen gene including 10 kilobases (kb) of 5'- and 15 kb of 3'-flanking sequences were isolated from a cosmid library. The overall gene structure was determined by restriction mapping and sequencing. The gene spans 28.9 kb from the start of transcription to the polyadenylation site and contains 54 exons. It codes for a major mRNA species of 4910 bases which translates into a polypeptide of 1419 amino acids. A less abundant RNA species of 5110 bases contains additional sequences corresponding to an alternatively spliced exon 2. Except for the amino-terminal propeptide (N-propeptide) domain the exon-intron organization of the mouse pro-alpha-1(II) collagen gene is remarkably similar to genes for other fibrillar collagen types. The overall identity of the coding sequences of the mouse and human type II collagen genes is 89% at the nucleotide level, but only 37 amino acid changes occur within the mature alpha-1(II) collagen chains between mouse and man. Intron sizes are also conserved between the mouse and human genes but not with the chick alpha-1(II) gene. The promoter of the mouse type II collagen gene is similar to those of the rat and human genes containing a TATA box and several G + C-rich elements but no CCAAT box. The 3'-untranslated sequence contains two regions of high homology between chick, mouse, bovine, and human genes preceding the major polyadenylation site. Additional size variation in the mRNA arises from the use of a minor polyadenylation signal. Information on conserved noncoding sequences will help in studies on the regulation of the pro-alpha-1(II) collagen gene. Detailed knowledge of the gene is also necessary for site-directed mutagenesis and work with transgenic mice.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA; UNIV TURKU, DEPT MED BIOCHEM, SF-20520 TURKU 52, FINLAND	University of Texas System; UTMD Anderson Cancer Center; University of Turku				Vuorio, Eero/0000-0003-3404-2439	NIAMS NIH HHS [AR 40335] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040335] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; ALAKOKKO L, 1990, GENOMICS, V8, P454, DOI 10.1016/0888-7543(90)90031-O; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BORNSTEIN P, 1989, PROG NUCLEIC ACID RE, V37, P67; CHEAH KSE, 1985, P NATL ACAD SCI USA, V82, P2555, DOI 10.1073/pnas.82.9.2555; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELIMA K, 1987, NUCLEIC ACIDS RES, V15, P9499, DOI 10.1093/nar/15.22.9499; Eyre D, 1987, STRUCTURE FUNCTION C, P261; EYRE DR, 1987, FEBS LETT, V220, P337, DOI 10.1016/0014-5793(87)80842-6; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; FRANCOMANO C A, 1987, Genomics, V1, P293, DOI 10.1016/0888-7543(87)90027-9; HAMERMAN D, 1989, NEW ENGL J MED, V320, P1322; HORTON W, 1987, P NATL ACAD SCI USA, V84, P8864, DOI 10.1073/pnas.84.24.8864; KNOWLTON RG, 1990, NEW ENGL J MED, V322, P526, DOI 10.1056/NEJM199002223220807; KOHNO K, 1985, J BIOL CHEM, V260, P4441; KOHNO K, 1984, J BIOL CHEM, V259, P3668; KOSHER RA, 1989, DEV BIOL, V131, P558, DOI 10.1016/S0012-1606(89)80026-0; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; LOVELLBADGE RH, 1987, P NATL ACAD SCI USA, V84, P2803, DOI 10.1073/pnas.84.9.2803; Mayne R., 1987, STRUCTURE FUNCTION C; NAH HD, 1988, COLLAGEN REL RES, V8, P277; NUNEZ AM, 1986, GENE, V44, P11, DOI 10.1016/0378-1119(86)90037-5; PALOTIE A, 1989, LANCET, V1, P924; RYAN MC, 1990, J BIOL CHEM, V265, P10334; RYAN MC, 1990, GENOMICS, V8, P41, DOI 10.1016/0888-7543(90)90224-I; Sambrook J, 1989, MOL CLONING LABORATO; SANDELL LJ, 1984, J BIOL CHEM, V259, P7826; SANGIORGI FO, 1985, NUCLEIC ACIDS RES, V13, P2815, DOI 10.1093/nar/13.8.2815; SANGIORGI FO, 1985, NUCLEIC ACIDS RES, V13, P2207, DOI 10.1093/nar/13.7.2207; SAVAGNER P, 1990, J BIOL CHEM, V265, P6669; SEYER JM, 1989, EUR J BIOCHEM, V181, P159, DOI 10.1111/j.1432-1033.1989.tb14707.x; STOCKWELL RA, 1979, BIOL CARTILAGE CELLS; STROM CM, 1984, NUCLEIC ACIDS RES, V12, P1025, DOI 10.1093/nar/12.2.1025; SU MW, 1989, GENOMICS, V4, P438, DOI 10.1016/0888-7543(89)90353-4; THOROGOOD P, 1986, DEV BIOL, V116, P497, DOI 10.1016/0012-1606(86)90150-8; TROMP G, 1988, P NATL ACAD SCI USA, V85, P5254, DOI 10.1073/pnas.85.14.5254; UPHOLT WB, 1986, P NATL ACAD SCI USA, V83, P2325, DOI 10.1073/pnas.83.8.2325; UPHOLT WB, 1989, COLLAGEN, V4, P31; VANDERREST M, 1988, J BIOL CHEM, V263, P1615; VIKKULA M, 1989, FEBS LETT, V250, P171, DOI 10.1016/0014-5793(89)80713-6; VISSING H, 1989, J BIOL CHEM, V264, P18265; von der Mark K, 1977, Dev Biol, V59, P75, DOI 10.1016/0012-1606(77)90241-X; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WEIL D, 1988, J BIOL CHEM, V263, P8561; WOODBURY D, 1989, J BIOL CHEM, V264, P2735	46	136	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16862	16869						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885613				2022-12-25	WOS:A1991GD63500098
J	MOREMEN, KW; TOUSTER, O; ROBBINS, PW				MOREMEN, KW; TOUSTER, O; ROBBINS, PW			NOVEL PURIFICATION OF THE CATALYTIC DOMAIN OF GOLGI ALPHA-MANNOSIDASE-II - CHARACTERIZATION AND COMPARISON WITH THE INTACT ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; NH2-TERMINAL SIGNAL ANCHOR; RAT-LIVER; ENDOPLASMIC-RETICULUM; GLYCOPROTEIN-BIOSYNTHESIS; TRANSMEMBRANE PROTEINS; N-ACETYLGLUCOSAMINE; MONOCLONAL-ANTIBODY; BREFELDIN-A; MEMBRANES	Rat liver alpha-mannosidase II, a hydrolase involved in the processing of asparagine-linked oligosaccharides, is an integral membrane glycoprotein facing the lumen of Golgi membranes. We have previously shown (Moremen, K. W., and Touster, O. (I 986) J. Biol. Chem. 261, 10945-10951) that mild chymotrypsin digestion of permeabilized or solubilized Golgi membranes will result in the cleavage of the intact 124,000-dalton alpha-mannosidase II subunit, releasing a 110,000-dalton hydrophilic polypeptide which contains the catalytic site. Consistent with the removal of a membrane binding domain, the chymotrypsin-generated 110,000-dalton peptide was found exclusively in the aqueous phase in Triton X-1 14 phase separation studies, whereas the intact enzyme was found in the the detergent phase. Taking advantage of this conversion in phase partitioning behavior, a purification procedure was developed to isolate the 110,000-dalton proteolytic digestion product as a homogeneous polypeptide for further characterization and protein sequencing at a yield of > 65% from a rat liver Golgi-enriched membrane fraction. An improved purification procedure for the intact enzyme was also developed. The two forms of the enzyme were compared yielding the following results. (a) The catalytic activity of the intact and cleaved forms of alpha-mannosidase II were indistinguishable in K(m), V(max), inhibition by the alkaloid, swainsonine, and in their activity toward the natural substrate GlcNAcMan5GlcNAc. (b) Both the intact and cleaved forms of the enzyme appear to be disulfide-linked dimers. (c) The two forms of the enzyme contain different NH2-terminal sequences suggesting that the cleaved NH2 terminus contains the membrane-spanning domain. (d) Additional peptide sequences were obtained from proteolytic fragments and cyanogen bromide digestion products in order to create a partial protein sequence map of the enzyme. These results are consistent with a model common among Golgi processing enzymes of a hydrophilic catalytic domain anchored to the lumenal face of Golgi membranes through an NH2-terminal hydrophobic membrane-anchoring domain.	MIT,CTR CANC RES,CAMBRIDGE,MA 02139; VANDERBILT UNIV,DEPT MOLEC BIOL,NASHVILLE,TN 37235	Massachusetts Institute of Technology (MIT); Vanderbilt University			Moremen, Kelley/AAD-4661-2019	Robbins, Phillips/0000-0002-5121-1524	NCI NIH HHS [CA14051, CA26712] Funding Source: Medline; NIGMS NIH HHS [GM26430] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA026712, P30CA014051] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026430] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER R, 1972, J BIOL CHEM, V247, P7135; BARON MD, 1990, J BIOL CHEM, V265, P19928; BENDIAK B, 1987, J BIOL CHEM, V262, P5775; Beyer T A, 1981, Adv Enzymol Relat Areas Mol Biol, V52, P23; BLANKEN WM, 1985, J BIOL CHEM, V260, P2927; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURKE B, 1982, EMBO J, V1, P1621, DOI 10.1002/j.1460-2075.1982.tb01364.x; CLAUSEN H, 1990, J BIOL CHEM, V265, P1139; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; DAHLLOF B, 1991, J BIOL CHEM, V266, P1804; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; FARQUHAR MG, 1985, ANNU REV CELL BIOL, V1, P447, DOI 10.1146/annurev.cb.01.110185.002311; FORSEE WT, 1989, J BIOL CHEM, V264, P3869; HIGGINS RC, 1979, ANAL BIOCHEM, V93, P257, DOI 10.1016/S0003-2697(79)80077-9; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; JELINEKKELLY S, 1988, J BIOL CHEM, V263, P14757; JOZIASSE DH, 1985, J BIOL CHEM, V260, P4941; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LEELAVATHI DE, 1970, BIOCHIM BIOPHYS ACTA, V211, P124, DOI 10.1016/0005-2736(70)90087-8; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIYAGI T, 1982, EUR J BIOCHEM, V126, P253; MOREMEN K, 1988, PROTEIN TRANSFER ORG, P209; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; MOREMEN KW, 1989, P NATL ACAD SCI USA, V86, P5276, DOI 10.1073/pnas.86.14.5276; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; MOREMEN KW, 1986, FASEB J, V45, P1680; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; NISHIKAWA Y, 1988, J BIOL CHEM, V263, P8270; NOVIKOFF PM, 1983, P NATL ACAD SCI-BIOL, V80, P4364, DOI 10.1073/pnas.80.14.4364; PAABO S, 1987, CELL, V50, P311, DOI 10.1016/0092-8674(87)90226-1; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; SCHWEDEN J, 1989, BIOCHEM J, V264, P347, DOI 10.1042/bj2640347; SHIN J, 1991, P NATL ACAD SCI USA, V88, P1918, DOI 10.1073/pnas.88.5.1918; TEMPST P, 1984, ANAL BIOCHEM, V137, P188, DOI 10.1016/0003-2697(84)90369-5; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; TULSIANI DRP, 1982, J BIOL CHEM, V257, P3660; TULSIANI DRP, 1977, J BIOL CHEM, V252, P3227; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEINSTEIN J, 1982, J BIOL CHEM, V257, P13835; YAMAMOTO F, 1990, J BIOL CHEM, V265, P1146	43	150	151	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16876	16885						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885615				2022-12-25	WOS:A1991GD63500100
J	AOTA, S; NAGAI, T; YAMADA, KM				AOTA, S; NAGAI, T; YAMADA, KM			CHARACTERIZATION OF REGIONS OF FIBRONECTIN BESIDES THE ARGININE-GLYCINE-ASPARTIC ACID SEQUENCE REQUIRED FOR ADHESIVE FUNCTION OF THE CELL-BINDING DOMAIN USING SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PLASMA FIBRONECTIN; CYTOSKELETAL ORGANIZATION; MONOCLONAL-ANTIBODIES; FRAGMENTS; ATTACHMENT; IDENTIFICATION; FIBROBLASTS; MOLECULE	Previous studies of adhesion mediated by the central cell-binding domain of fibronectin suggest that additional polypeptide information besides the Arg-Gly-Asp sequence is required for full activity. We analyzed this putative second, synergistic region of fibronectin more extensively by deletion analysis and oligonucleotide-based site-directed mutagenesis. Resulting mutated fusion proteins expressed using lambda-gt11 were assayed for baby hamster kidney fibroblast cell spreading activity. Deletion mutants truncating from the amino terminus showed a decrease of activity in two apparently discrete steps. Complementary studies using a series of overlapped internal deletions designed to retain the repetitive fibronectin structure also indicated that two distinct peptide regions besides the RGD sequence were necessary for full activity. Removal of the carboxyl-terminal region resulted in the greatest loss of activity (greater-than-or-equal-to 20- versus 3-5-fold). Very similar results were obtained with HT-1080 cells dependent on the alpha-5-beta-1 integrin receptor for adhesion to fibronectin. An anti-fibronectin monoclonal antibody that inhibits cell adhesion was found to bind to the carboxyl-terminal functional region, and a point mutation caused specific loss of its epitope. These studies reveal unexpected complexity in the organization of these functional regions, which contrasts with adhesion models based only on simple, short peptide recognition sequences.	NIDR,DEV BIOL LAB,BLDG 30,RM 414,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)				Yamada, Kenneth/0000-0003-1512-6805				AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; AKIYAMA SK, 1985, J BIOL CHEM, V260, P402; Carsons SE, 1989, FIBRONECTIN HLTH DIS; Clark R. A. F., 1988, MOL CELLULAR BIOL WO; DUFOUR S, 1988, EMBO J, V7, P2661, DOI 10.1002/j.1460-2075.1988.tb03119.x; HUMPHRIES MJ, 1986, J CELL BIOL, V103, P2637, DOI 10.1083/jcb.103.6.2637; HUMPHRIES MJ, 1987, J BIOL CHEM, V262, P6886; Hynes RO, 1990, FIBRONECTINS; IZZARD CS, 1986, EXP CELL RES, V165, P320, DOI 10.1016/0014-4827(86)90586-0; KIMIZUKA F, 1991, J BIOL CHEM, V266, P3045; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEWANDOWSKA K, 1990, J CELL SCI, V95, P75; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; Mosher DF, 1989, FIBRONECTIN; MUGNAI G, 1988, J CELL BIOL, V106, P931, DOI 10.1083/jcb.106.3.931; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIERSCHBACHER MD, 1981, CELL, V26, P259, DOI 10.1016/0092-8674(81)90308-1; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; RUOSLAHTI E, 1988, SCIENCE, V238, P291; STREETER HB, 1987, J CELL BIOL, V105, P507, DOI 10.1083/jcb.105.1.507; WOODS A, 1986, EMBO J, V5, P665, DOI 10.1002/j.1460-2075.1986.tb04265.x; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3; YAMADA KM, 1984, J CELL BIOL, V99, P29, DOI 10.1083/jcb.99.1.29	25	170	177	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15938	15943						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874740				2022-12-25	WOS:A1991GB97700063
J	TANIGUCHI, T; KOBAYASHI, T; KONDO, J; TAKAHASHI, K; NAKAMURA, H; SUZUKI, J; NAGAI, K; YAMADA, T; NAKAMURA, S; YAMAMURA, H				TANIGUCHI, T; KOBAYASHI, T; KONDO, J; TAKAHASHI, K; NAKAMURA, H; SUZUKI, J; NAGAI, K; YAMADA, T; NAKAMURA, S; YAMAMURA, H			MOLECULAR-CLONING OF A PORCINE GENE SYK THAT ENCODES A 72-KDA PROTEIN-TYROSINE KINASE SHOWING HIGH SUSCEPTIBILITY TO PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-YES GENE; RAT SPLEEN; MONOCLONAL-ANTIBODIES; SRC GENE; ABL GENE; PURIFICATION; ACTIVATION; TISSUES; PRODUCT; PHOSPHOTYROSINE	By using antibodies raised against a portion of N terminus of 40-kDa kinase (Kobayashi, T., Nakamura, S., Taniguchi, T., and Yamamura, H. (1990) Eur. J. Biochem. 188, 535-540), not only 40-kDa protein but also 72-kDa protein were detected on immunoblot analysis of porcine spleen homogenate. In splenocytes preparation, the antibodies could immunoprecipitate protein-tyrosine kinase activity of the 72-kDa protein but not detect the 40-kDa protein even on immunoblot. After incubation of crude spleen homogenate at 37-degrees-C with or without various protease inhibitors, immunoblot analysis revealed proteolytic breakdown of the 72-kDa protein to 40-kDa fragment. Next, using oligonucleotides designed according to partially sequenced information of the 40-kDa kinase as a probe, we have isolated a clone containing entire coding sequence for the 40-kDa kinase from a porcine spleen cDNA library. This clone had a 1884-base-pair-long open reading frame encoding 628-amino-acid polypeptide with a calculated molecular weight of 71,618. The deduced amino acid sequence did not contain a ligand binding or membrane spanning region but did a well-conserved protein-tyrosine kinase domain and two src homology region 2 domains. The sequences of these domains showed 30-40% identity to those of other protein-tyrosine kinases, but those of remaining parts were quite unique. From these results, we concluded that the 40-kDa kinase was generated by proteolysis from the 72-kDa holoprotein which was a new member of nonreceptor protein-tyrosine kinase so far reported. We therefore designated this gene as syk after spleen tyrosine kinase.	FUKUI MED SCH,DEPT BIOCHEM,23 SHIMOAIZUKI,FUKUI 91011,JAPAN; MITSUBISHI KASEI CORP,RES CTR,YOKOHAMA 227,JAPAN	University of Fukui								BATZER AG, 1990, EUR J BIOCHEM, V194, P251, DOI 10.1111/j.1432-1033.1990.tb19450.x; BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BRUNATI AM, 1988, EUR J BIOCHEM, V172, P451, DOI 10.1111/j.1432-1033.1988.tb13909.x; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CLARI G, 1988, EUR J BIOCHEM, V175, P673, DOI 10.1111/j.1432-1033.1988.tb14243.x; COTTON PC, 1983, MOL CELL BIOL, V3, P1157, DOI 10.1128/MCB.3.6.1157; EK B, 1984, J BIOL CHEM, V259, P1145; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GONZATTIHACESMI, 1986, J BIOL CHEM, V261, P15266; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HASHIMOTO E, 1991, INT J BIOCHEM, V23, P507; HASUMA T, 1990, ARCH BIOCHEM BIOPHYS, V280, P206, DOI 10.1016/0003-9861(90)90537-9; HUNTER T, 1985, ANNU REV BIOCHEM, V54, P897, DOI 10.1146/annurev.biochem.54.1.897; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; KOBAYASHI T, 1990, EUR J BIOCHEM, V188, P535, DOI 10.1111/j.1432-1033.1990.tb15433.x; KOBAYASHI T, 1989, ANN CLIN BIOCHEM, V26, P164, DOI 10.1177/000456328902600213; KONOPKA JB, 1985, BIOCHIM BIOPHYS ACTA, V823, P1, DOI 10.1016/0304-419X(85)90012-5; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LIPSICH LA, 1983, J VIROL, V48, P352, DOI 10.1128/JVI.48.2.352-360.1983; LITWIN CME, 1991, J BIOL CHEM, V266, P2557; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1991, P NATL ACAD SCI USA, V88, P627, DOI 10.1073/pnas.88.2.627; NAKAMURA S, 1989, J BIOL CHEM, V264, P7089; NAKAMURA S, 1988, EUR J BIOCHEM, V174, P471, DOI 10.1111/j.1432-1033.1988.tb14122.x; OKADA H, 1989, BIOCHEM BIOPH RES CO, V162, P1553, DOI 10.1016/0006-291X(89)90852-8; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PHANDINHTUY F, 1983, NATURE, V305, P435; ROEBROEK AJM, 1985, EMBO J, V4, P2897, DOI 10.1002/j.1460-2075.1985.tb04020.x; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHTIVELMAN E, 1986, CELL, V47, P277, DOI 10.1016/0092-8674(86)90450-2; SUKEGAWA J, 1987, MOL CELL BIOL, V7, P41, DOI 10.1128/MCB.7.1.41; SUKEGAWA J, 1990, ONCOGENE, V5, P611; SWARUP G, 1983, J BIOL CHEM, V258, P341; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; TOKUDA M, 1986, BIOCHEM BIOPH RES CO, V139, P910, DOI 10.1016/S0006-291X(86)80264-9; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WONG TW, 1984, J BIOL CHEM, V259, P8505; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637; [No title captured]	42	418	443	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15790	15796						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874735				2022-12-25	WOS:A1991GB97700043
J	WANG, A; COHEN, DS; PALMER, E; SHEPPARD, D				WANG, A; COHEN, DS; PALMER, E; SHEPPARD, D			POLARIZED REGULATION OF FIBRONECTIN SECRETION AND ALTERNATIVE SPLICING BY TRANSFORMING GROWTH-FACTOR-BETA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MESSENGER-RNA; TGF-BETA; POLYACRYLAMIDE GELS; RAT FIBRONECTIN; HUMAN-CELLS; PROTEINS; RECEPTOR; BINDING; GENE; IDENTIFICATION	Fibronectin is a multifunctional protein that is synthesized in several different forms that result from alternative splicing of mRNA. Although expression of splicing variants appears to be both developmentally regulated and tissue-specific, the functional significance of these isoforms is largely unknown. We found that cultured airway epithelial cells vectorially secrete two distinct species of fibronectin, one which contains the alternatively spliced EIIIA region (EIIIA+) and one in which the EIIIA segment is spliced out (EIIIA-). Fibronectin containing the EIIIA region is preferentially secreted apically. Although both apical and basal stimulation with transforming growth factor beta-1 increased fibronectin synthesis, the secretory response differed depending on which surface was being stimulated. Apical secretion of fibronectin and expression of EIIIA+ fibronectin mRNA increased only after apical stimulation. These data demonstrate a novel mechanism for the polarized regulation of targeted secretion and alternative splicing of fibronectin and suggest that the EIIIA segment may act as a targeting signal for the vectorial secretion of fibronectin.	UNIV CALIF SAN FRANCISCO, CTR LUNG BIOL, BOX 0854, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO GEN HOSP, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CTR OCCUPAT & ENVIRONM HLTH, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES CTR, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, MED SERV, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [HL/A1 33259, 1-F32-HL08289-01] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033259, F32HL008289] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADLER KB, 1987, BIOTECHNIQUES, V5, P462; BALZA E, 1988, FEBS LETT, V228, P42, DOI 10.1016/0014-5793(88)80580-5; BLATTLER DP, 1972, J CHROMATOGR, V64, P147, DOI 10.1016/S0021-9673(00)92958-3; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BORSI L, 1990, FEBS LETT, V261, P175, DOI 10.1016/0014-5793(90)80664-5; BORSI L, 1987, J CELL BIOL, V104, P595, DOI 10.1083/jcb.104.3.595; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CARNEMOLLA B, 1987, FEBS LETT, V215, P269, DOI 10.1016/0014-5793(87)80160-6; CHEIFETZ S, 1988, J BIOL CHEM, V263, P16984; COHEN DS, 1991, IN PRESS AM J RESPIR; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FFRENCHCONSTANT C, 1989, J CELL BIOL, V109, P903, DOI 10.1083/jcb.109.2.903; FFRENCHCONSTANT C, 1988, DEVELOPMENT, V104, P369; GUAN JL, 1990, J CELL BIOL, V110, P833, DOI 10.1083/jcb.110.3.833; GUTMAN A, 1987, P NATL ACAD SCI USA, V84, P7179, DOI 10.1073/pnas.84.20.7179; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KUUSELA P, 1984, INFECT IMMUN, V45, P433, DOI 10.1128/IAI.45.2.433-436.1984; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LIAO NS, 1989, EXP CELL RES, V181, P348, DOI 10.1016/0014-4827(89)90093-1; MASSAGUE J, 1982, P NATL ACAD SCI-BIOL, V79, P6822, DOI 10.1073/pnas.79.22.6822; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MASSAGUE J, 1987, METHOD ENZYMOL, V146, P174; MASSAGUE J, 1985, J BIOL CHEM, V260, P2636; MOSHER DF, 1980, SCIENCE, V209, P927, DOI 10.1126/science.7403857; NORTON PA, 1987, MOL CELL BIOL, V7, P4297, DOI 10.1128/MCB.7.12.4297; PAUL JI, 1984, J BIOL CHEM, V259, P3477; POTTRATZ ST, 1990, J CLIN INVEST, V85, P351, DOI 10.1172/JCI114445; RENNARD SI, 1982, J CLIN INVEST, V69, P113, DOI 10.1172/JCI110421; ROBINSON C B, 1989, American Review of Respiratory Disease, V139, pA367; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; Sambrook J, 1989, MOL CLONING LABORATO; SCHWARZBAUER JE, 1987, EMBO J, V6, P2573, DOI 10.1002/j.1460-2075.1987.tb02547.x; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; SPORN MB, 1990, CELL REGUL, V1, P875, DOI 10.1091/mbc.1.12.875; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; YAMAUCHI K, 1988, AM REV RESPIR DIS, V137, P1360, DOI 10.1164/ajrccm/137.6.1360; ZARDI L, 1987, EMBO J, V6, P2337, DOI 10.1002/j.1460-2075.1987.tb02509.x	38	65	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15598	15601						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874718				2022-12-25	WOS:A1991GB97700012
J	ENNS, CA; CLINTON, EM; RECKHOW, CL; ROOT, BJ; DO, SI; COOK, C				ENNS, CA; CLINTON, EM; RECKHOW, CL; ROOT, BJ; DO, SI; COOK, C			ACQUISITION OF THE FUNCTIONAL-PROPERTIES OF THE TRANSFERRIN RECEPTOR DURING ITS BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEIN; OLIGOSACCHARIDES; PROLIFERATION; EXPRESSION; ANTIBODY	The properties of the newly synthesized and partially glycosylated forms of the transferrin receptor were examined to determine which co- and post-translational modifications are necessary for the acquisition of transferrin binding activity and transport of the receptor to the cell surface. The nascent transferrin receptor containing core-glycosylated asparagine-linked oligosaccharides does not possess complete intersubunit disulfide bonds, sediments predominantly as a monomer in sucrose density gradients, and shows reduced binding to transferrin-agarose. Within 20-30 min after synthesis, the transferrin receptor acquires the ability to bind to a transferrin-linked affinity column. Intersubunit disulfide bond formation occurs slowly throughout the transit of the receptor to the cell surface. These results indicate that core glycosylation of the receptor may be necessary but is not sufficient for the acquisition of the ability of the receptor to bind transferrin and that intersubunit disulfide bond formation is a post-translational event. Inhibition of complex carbohydrate synthesis by either swainsonine (1-mu-g/ml) or deoxynojirimycin (4 mM) does not inhibit the ability of this receptor to form intersubunit disulfide bonds or to be transported to the cell surface. The partially glycosylated receptor, however, does show an approximately 3-fold reduced affinity for transferrin.	SYRACUSE UNIV,DEPT BIOL,SYRACUSE,NY 13244; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602	Syracuse University; University System of Georgia; University of Georgia	ENNS, CA (corresponding author), OREGON HLTH SCI UNIV,DEPT CELL BIOL & ANAT,PORTLAND,OR 97201, USA.				NIDDK NIH HHS [DK-40608] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040608] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DO SI, 1990, J BIOL CHEM, V265, P114; DOMINGO DL, 1988, J BIOL CHEM, V263, P13386; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ENNS CA, 1982, P NATL ACAD SCI-BIOL, V79, P3241, DOI 10.1073/pnas.79.10.3241; ENNS CA, 1981, P NATL ACAD SCI-BIOL, V78, P4222, DOI 10.1073/pnas.78.7.4222; ENNS CA, 1981, J BIOL CHEM, V256, P9820; GODING JW, 1981, J IMMUNOL, V127, P1256; HUNT RC, 1989, J BIOL CHEM, V264, P9643; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; OMARY MB, 1981, J BIOL CHEM, V256, P2888; RECKHOW CL, 1988, J BIOL CHEM, V263, P7297; ROOT BJ, 1988, J BIOL CHEM, V263, P19071; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHNEIDER C, 1982, J BIOL CHEM, V257, P8516; SUTHERLAND R, 1981, P NATL ACAD SCI-BIOL, V78, P4515, DOI 10.1073/pnas.78.7.4515; TRIMBLE RB, 1984, ANAL BIOCHEM, V141, P515, DOI 10.1016/0003-2697(84)90080-0; TROWBRIDGE IS, 1981, P NATL ACAD SCI-BIOL, V78, P3039, DOI 10.1073/pnas.78.5.3039	18	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					13272	13277						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1906465				2022-12-25	WOS:A1991FX13200074
J	NAEGELI, H; ALTHAUS, FR				NAEGELI, H; ALTHAUS, FR			REGULATION OF POLY(ADP-RIBOSE) POLYMERASE - HISTONE-SPECIFIC ADAPTATIONS OF REACTION-PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION; MG-2+-DEPENDENT REACTION; EUKARYOTE CHROMATIN; H-1; SYNTHETASE; INVITRO; MODE; OPERATION; PROTEINS; REGIONS	The post-translational poly ADP-ribosylation of proteins by the nuclear enzyme poly(ADP-ribose) polymerase (EC 2.4.2.30) involves a complex pattern of ADP-ribose polymers. We have determined how this enzyme produces the various polymer size patterns responsible for altered protein function. The results show that histone H1 and core histones are potent regulators of both the numbers and sizes of ADP-ribose polymers. Each histone induced the polymerase to synthesize a specific polymer size pattern. Various other basic and/or DNA binding proteins as well as other known stimulators of poly(ADP-ribose) polymerase (spermine, MgCl2, nicked DNA) were ineffective as polymer size modulators. Testing specific proteolytic fragments of histone H1, the polymer number and polymer size modulating activity could be mapped to specific polypeptide domains. The results suggest that histones specifically regulate the polymer termination reaction of poly(ADP-ribose) polymerase.	UNIV ZURICH,INST PHARMACOL & BIOCHEM,WINTERTHURERSTR 260,CH-8057 ZURICH,SWITZERLAND	University of Zurich								ALLAN J, 1980, NATURE, V288, P675, DOI 10.1038/288675a0; ALTHAUS FR, 1987, ADP RIBOSYLATION PRO; ALTHAUS FR, 1985, ADP RIBOSYLATION PRO; ALVAREZGONZALEZ R, 1987, BIOCHEMISTRY-US, V26, P3218, DOI 10.1021/bi00385a042; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BOULIKAS T, 1980, P NATL ACAD SCI-BIOL, V77, P127, DOI 10.1073/pnas.77.1.127; BRADBURY EM, 1975, EUR J BIOCHEM, V57, P521, DOI 10.1111/j.1432-1033.1975.tb02327.x; FERRO AM, 1982, J BIOL CHEM, V257, P7808; GURLEY LR, 1983, ANAL BIOCHEM, V129, P132, DOI 10.1016/0003-2697(83)90061-1; HARTMAN PG, 1977, EUR J BIOCHEM, V77, P45, DOI 10.1111/j.1432-1033.1977.tb11639.x; HAYAISHI O, 1982, ADP RIBOSYLATION REA; HOLTLUND J, 1983, EUR J BIOCHEM, V130, P309, DOI 10.1111/j.1432-1033.1983.tb07153.x; JACOBSON MK, 1984, METHOD ENZYMOL, V106, P483; JACOBSON MK, 1989, ADP RIBOSE TRANSFER; KAWAICHI M, 1980, J BIOL CHEM, V255, P816; KAWAICHI M, 1981, J BIOL CHEM, V256, P9483; KAWAMURA M, 1981, BIOCHIM BIOPHYS ACTA, V652, P121, DOI 10.1016/0005-2787(81)90215-X; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; NAEGELI H, 1989, J BIOL CHEM, V264, P14382; NAEGELI H, 1989, THESIS U ZURICH SWIT; NOLL M, 1975, SCIENCE, V187, P1203, DOI 10.1126/science.187.4182.1203; OGATA N, 1980, J BIOL CHEM, V255, P7616; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; RIQUELME PT, 1979, J BIOL CHEM, V254, P3018; SANDERS C, 1974, T BIOCHEM SOC, V2, P547; SHEROD D, 1974, J BIOL CHEM, V249, P3923; SINGER DS, 1976, NUCLEIC ACIDS RES, V3, P2531, DOI 10.1093/nar/3.10.2531; TANAKA Y, 1979, J BIOL CHEM, V254, P2433; THOMA F, 1983, J MOL BIOL, V167, P619, DOI 10.1016/S0022-2836(83)80102-8; UEDA K, 1985, ANNU REV BIOCHEM, V54, P73, DOI 10.1146/annurev.biochem.54.1.73; UEDA K, 1986, PYRIDINE NUCLEOTIDE, P549; USHIRO H, 1987, J BIOL CHEM, V262, P2352	34	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10596	10601						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1903793				2022-12-25	WOS:A1991FP08600089
J	LIMPER, AH; QUADE, BJ; LACHANCE, RM; BIRKENMEIER, TM; RANGWALA, TS; MCDONALD, JA				LIMPER, AH; QUADE, BJ; LACHANCE, RM; BIRKENMEIER, TM; RANGWALA, TS; MCDONALD, JA			CELL-SURFACE MOLECULES THAT BIND FIBRONECTINS MATRIX ASSEMBLY DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; ADHESIVE FUNCTION; MELANOMA-CELLS; RECEPTOR; PROTEINS; SITE; LOCALIZATION; FIBROBLASTS	The assembly of fibronectin into disulfide cross-linked extracellular matrices requires the interaction of mesenchymal cells with two distinct sites on fibronectin, the Arg-Gly-Asp cell adhesive site and an amino-terminal site contained within the first five type I homologous repeats (Quade, B. J., and McDonald, J. A. (1988) J. Biol. Chem. 263, 19602-19609). Proteolytically derived 29-kDa fragments of fibronectin (29kDa) containing these repeats bind to monolayers of cultured fibroblasts and inhibit fibronectin matrix assembly. The cell surface molecules interacting with fibronectin's 29-kDa matrix assembly domain have resisted purification using conventional methods such as affinity chromatography. Accordingly, in order to identify molecules which bind this fragment, I-125-labeled 29kDa was allowed to bind to fibroblast monolayers and chemically cross-linked to the cell surface with bis(sulfosuccinimidyl)suberate. Extraction of the cross-linked cell layer yielded radiolabeled complexes of 56, 150, and 280 kDa. Formation of these cross-linked complexes was specifically inhibited by the addition of excess unlabeled 29kDa but was unaffected by the presence of fibronectin fragments containing other type I repeats outside of the 29kDa matrix assembly domain. The cross-linked complexes were insoluble in nondenaturing detergents but soluble when denatured and reduced, suggesting that 29kDa may be cross-linked to components of the pericellular matrix. Immunoprecipitation of cross-linked cell extracts with a polyclonal antibody to fibronectin that does not recognize the amino terminus demonstrate that the 280-kDa band contains 29kDa cross-linked to fibronectin present on the cell surface. Formation of the 150-kDa complex was inhibited by EDTA, suggesting that divalent cations are required for its formation. Although the molecular mass and divalent cation requirement suggest that the 150-kDa complex may be related to an integrin, this complex was not immunoprecipitated by polyclonal antibodies generated to the alpha-5-beta-1 integrin fibronectin receptor.	WASHINGTON UNIV,SCH MED,DEPT INTERNAL MED,DIV RESP & CRIT CARE,BOX 8052,660 S EUCLID,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT CELL BIOL & PHYSIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007317] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038276] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32 HL 07317] Funding Source: Medline; NIGMS NIH HHS [2 R01 GM 38276] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKIYAMA SK, 1985, J BIOL CHEM, V260, P3256; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; BIRKENMEIER TM, 1989, J CELL BIOL, V109, P236; BOUCAUT JC, 1984, NATURE, V307, P364, DOI 10.1038/307364a0; BURNS GF, 1988, J CELL BIOL, V107, P1225, DOI 10.1083/jcb.107.3.1225; CARTER WG, 1984, J CELL BIOL, V99, P105, DOI 10.1083/jcb.99.1.105; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CHOI MG, 1979, J BIOL CHEM, V254, P2050; ELICES MJ, 1991, J CELL BIOL, V112, P169, DOI 10.1083/jcb.112.1.169; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; GRINNELL F, 1984, J CELL BIOCHEM, V26, P107, DOI 10.1002/jcb.240260206; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCDONALD JA, 1987, J BIOL CHEM, V262, P2957; MCDONALD JA, 1988, ANNU REV CELL BIOL, V4, P183, DOI 10.1146/annurev.cb.04.110188.001151; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MCKEOWNLONGO PJ, 1985, J CELL BIOL, V100, P364, DOI 10.1083/jcb.100.2.364; MCKEOWNLONGO PJ, 1987, J CELL BIOL, V104, P601, DOI 10.1083/jcb.104.3.601; OBARA M, 1987, FEBS LETT, V213, P261, DOI 10.1016/0014-5793(87)81502-8; OBARA M, 1988, CELL, V53, P649, DOI 10.1016/0092-8674(88)90580-6; PAUL JI, 1986, J BIOL CHEM, V261, P2258; PETERSEN TE, 1985, PLASMA FIBRONECTIN S, P7; QUADE BJ, 1988, J BIOL CHEM, V263, P19602; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROMAN J, 1989, J CELL BIOL, V108, P2529, DOI 10.1083/jcb.108.6.2529; ROVASIO RA, 1983, J CELL BIOL, V96, P462, DOI 10.1083/jcb.96.2.462; SPIEGEL S, 1986, J CELL BIOL, V102, P1; STAROS JV, 1987, METHOD ENZYMOL, V150, P503; THOMPSON LK, 1986, J BIOL CHEM, V261, P5209; VAUDAUX P, 1984, J INFECT DIS, V150, P546, DOI 10.1093/infdis/150.4.546; VILLIGER B, 1981, J CELL BIOL, V90, P711, DOI 10.1083/jcb.90.3.711	31	40	41	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9697	9702						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903394				2022-12-25	WOS:A1991FM45900056
J	SWANSON, RV; ONG, LJ; WILBANKS, SM; GLAZER, AN				SWANSON, RV; ONG, LJ; WILBANKS, SM; GLAZER, AN			PHYCOERYTHRINS OF MARINE UNICELLULAR CYANOBACTERIA .2. CHARACTERIZATION OF PHYCOBILIPROTEINS WITH UNUSUALLY HIGH PHYCOUROBILIN CONTENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILIN-CONTAINING PEPTIDES; AMINO-ACID-SEQUENCE; C-PHYCOCYANIN; MASTIGOCLADUS-LAMINOSUS; BETA-SUBUNITS; AGMENELLUM-QUADRUPLICATUM; ATTACHMENT SITES; R-PHYCOERYTHRIN; ALPHA-SUBUNITS; ABSORPTION	A survey of marine unicellular cyanobacterial strains for phycobiliproteins with high phycourobilin (PUB) content led to a detailed investigation of Synechocystis sp. WH8501. The phycobiliproteins of this strain were purified and characterized with respect to their bilin composition and attachment sites. Amino-terminal sequences were determined for the alpha and beta-subunits of the phycocyanin and the major and minor phycoerythrins. The amino acid sequences around the attachment sites of all bilin prosthetic groups of the phycocyanin and of the minor phycoerythrin were also determined. The phycocyanin from this strain carries a single PUB on the alpha-subunit and two phycocyanobilins on the beta-subunit. It is the only phycocyanin known to carry a PUB chromophore. The native protein, isolated in the (alpha-beta)2 aggregation state, displays absorption maxima at 490 and 592 nm. Excitation at 470 nm, absorbed almost exclusively by PUB, leads to emission at 644 nm from phycocyanobilin. The major and minor phycoerythrins from strain WH8501 each carry five bilins per alpha-beta unit, four PUBs and one phycoerythrobilin. Spectroscopic properties determine that the PUB groups function as energy donors to the sole phycoerythrobilin. Analysis of the bilin peptides unambiguously identifies the phycoerythrobilin at position beta-82 (residue numbering assigned by homology with B-phycoerythrin; Sidler, W., Kumpf, B., Suter, F., Klotz, A. V., Glazer, A. N., and Zuber, H. (1989) Biol. Chem. Hoppe-Seyler 370, 115-124) as the terminal energy acceptor in phycoerythrins.	UNIV CALIF BERKELEY,DIV BIOCHEM & MOLEC BIOL,229 STANLEY HALL,DONNER ASU,BERKELEY,CA 94720	University of California System; University of California Berkeley				Swanson, Ronald/0000-0002-6486-2676; Wilbanks, Sigurd/0000-0001-7565-8913	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007232, R01GM028994, T32GM008352] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 08352, GM 28994, GM 07232] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRYANT DA, 1978, J BIOL CHEM, V253, P220; DELORIMIER R, 1984, P NATL ACAD SCI-BIOL, V81, P7946; DUERRING M, 1990, J MOL BIOL, V211, P633, DOI 10.1016/0022-2836(90)90270-V; FUGLISTALLER P, 1983, H-S Z PHYSIOL CHEM, V364, P691, DOI 10.1515/bchm2.1983.364.1.691; GLAZER AN, 1982, BIOCHEM SYST ECOL, V10, P203, DOI 10.1016/0305-1978(82)90031-X; GLAZER AN, 1973, J BIOL CHEM, V248, P659; Gros E., 1967, METHOD ENZYMOL, V11, P238; HONSELL E, 1984, BOT MAR, V27, P1, DOI 10.1515/botm.1984.27.1.1; KLOTZ AV, 1985, J BIOL CHEM, V260, P4856; MARTIN RG, 1961, J BIOL CHEM, V236, P1372; NAGY JO, 1985, J BIOL CHEM, V260, P4864; OCARRA P, 1961, J AM CHEM SOC, V83, P1091; ONG LJ, 1991, J BIOL CHEM, V266, P9515; ONG LJ, 1987, J BIOL CHEM, V262, P6323; ONG LJ, 1984, SCIENCE, V224, P80, DOI 10.1126/science.224.4644.80; PECCI J, 1969, BIOCHIM BIOPHYS ACTA, V188, P230, DOI 10.1016/0005-2795(69)90070-1; PILOT TJ, 1984, P NATL ACAD SCI-BIOL, V81, P6983, DOI 10.1073/pnas.81.22.6983; SCHIRMER T, 1985, J MOL BIOL, V184, P257, DOI 10.1016/0022-2836(85)90379-1; SCHIRMER T, 1986, J MOL BIOL, V188, P651, DOI 10.1016/S0022-2836(86)80013-4; SCHIRMER T, 1987, BIOCHIM BIOPHYS ACTA, V893, P379, DOI 10.1016/0005-2728(87)90090-9; SIDLER W, 1989, BIOL CHEM H-S, V370, P115, DOI 10.1515/bchm3.1989.370.1.115; SIEBZEHNRUBL S, 1987, Z NATURFORSCH C, V42, P258; SIEGELMAN HW, 1965, ANAL BIOCHEM, V13, P402, DOI 10.1016/0003-2697(65)90332-5; Smith R.C., 1976, PHOTOCHEMICAL PHOTOB, P117; SWANSON RV, 1990, ANAL BIOCHEM, V188, P295, DOI 10.1016/0003-2697(90)90609-D; VAUGHAN MH, 1964, THESIS MIT BOSTON; WATERBURY JB, 1988, BERGEYS MANUAL SYSTE, V3, P1728; Waterbury JB, 1986, CAN B FISH AQUAT SCI, V214, P71; WILBANKS SM, 1991, J BIOL CHEM, V266, P9535; WILLIAMS VP, 1978, J BIOL CHEM, V253, P202	30	49	52	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9528	9534						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903389				2022-12-25	WOS:A1991FM45900032
J	NISHITANI, K; NEVINS, DJ				NISHITANI, K; NEVINS, DJ			GLUCURONOXYLAN XYLANOHYDROLASE - A UNIQUE XYLANASE WITH THE REQUIREMENT FOR APPENDANT GLUCURONOSYL UNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL POLYSACCHARIDES; BACILLUS-SUBTILIS; POLYPORUS-TULIPIFERAE; ENZYMIC DISSOCIATION; PURIFICATION; ACID; GLUCURONOARABINOXYLAN; STREPTOMYCES; STRAIN; MODE	A new category of beta-(1 --> 4)-xylan xylanohydrolases that exhibit a specific capacity to hydrolyze glucuronoxylans was characterized using heteroxylans prepared from Vigna (Vigna angularis Ohwi et Ohashi cv. Takara) and maize (Zea mays L.) cell walls together with appropriate derivatives as substrates. Glucuronopyranosyl moieties, as side chains, were prerequisite for enzyme-mediated hydrolysis of the beta-(1 --> 4)-xylosyl linkages. The enzyme degraded glucuronoxylans derived from Vigna cell walls to yield a major oligomeric species [GRAPHICS] where Xyl represents xylose and GlcA represents glucuronic acid. The enzyme also degraded glucuronoarabinoxylans derived from maize cell walls to yield a major oligomeric species containing a single glucuronosyl side chain and a single unsubstituted beta-1 --> 4Xyl pendant terminal. These results indicate that this xylanohydrolase recognizes glucuronosyl moieties inserted as monomeric side chains along the xylan backbone and mediates the hydrolysis of the beta-(1 --> 4)-xylosyl linkage of the adjacent unsubstituted xylosyl residue in heteroxylans. This enzyme is the first xylanohydrolase identified that recognizes distinctly different sugars constituting side chains. We propose to designate this new enzyme as a glucuronoxylan xylanohydrolase to be abbreviated as glucuronoxylanase. Use of this unique enzyme demonstrated the presence of repeating units in heteroxylans in cell walls of higher plants.	UNIV CALIF DAVIS, DEPT VEGETABLE CROPS, DAVIS, CA 95616 USA	University of California System; University of California Davis	NISHITANI, K (corresponding author), KAGOSHIMA UNIV, COLL LIBERAL ARTS, DEPT BIOL, KAGOSHIMA 890, JAPAN.			Nishitani, Kazuhiko/0000-0002-0073-9564				ALBERSHEIM PETER, 1967, CARBOHYD RES, V5, P340, DOI 10.1016/S0008-6215(00)80510-8; ANDERSON MA, 1985, CARBOHYD POLYM, V5, P115, DOI 10.1016/0144-8617(85)90029-3; BLUMENKR.N, 1973, ANAL BIOCHEM, V54, P484, DOI 10.1016/0003-2697(73)90377-1; BRILLOUET JM, 1987, CARBOHYD RES, V159, P165, DOI 10.1016/S0008-6215(00)90015-6; COMTAT J, 1981, CARBOHYD RES, V95, P101, DOI 10.1016/S0008-6215(00)85299-4; DARVILL JE, 1980, PLANT PHYSIOL, V66, P1135, DOI 10.1104/pp.66.6.1135; DESHPANDE V, 1985, BIOTECHNOL BIOENG, V28, P1827; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FREDERICK MM, 1985, BIOTECHNOL BIOENG, V27, P524, DOI 10.1002/bit.260270420; FRY SC, 1986, ANNU REV PLANT PHYS, V37, P165, DOI 10.1146/annurev.arplant.37.1.165; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HONDA H, 1985, AGR BIOL CHEM TOKYO, V49, P3165, DOI 10.1080/00021369.1985.10867251; HOWARD BH, 1960, BIOCHEM J, V74, P173, DOI 10.1042/bj0740173; INAOKA M, 1956, NATURE, V178, P202, DOI 10.1038/178202a0; KANDA T, 1985, J BIOCHEM-TOKYO, V98, P1545, DOI 10.1093/oxfordjournals.jbchem.a135423; KATO Y, 1984, PLANT PHYSIOL, V75, P753, DOI 10.1104/pp.75.3.753; KATO Y, 1984, PLANT PHYSIOL, V75, P759, DOI 10.1104/pp.75.3.759; KATO Y, 1985, CARBOHYD RES, V137, P139, DOI 10.1016/0008-6215(85)85155-7; KUSAKABE I, 1983, AGR BIOL CHEM TOKYO, V47, P2713, DOI 10.1080/00021369.1983.10866038; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPPALAINEN A, 1986, Biotechnology and Applied Biochemistry, V8, P437; MARUI M, 1985, AGR BIOL CHEM TOKYO, V49, P3399, DOI 10.1080/00021369.1985.10867283; MITSUISHI Y, 1987, AGR BIOL CHEM TOKYO, V51, P3207; Nelson N, 1944, J BIOL CHEM, V153, P375; NISHITANI K, 1979, PLANT CELL PHYSIOL, V20, P63; NISHITANI K, 1990, PLANT PHYSIOL, V93, P396, DOI 10.1104/pp.93.2.396; NISHITANI K, 1982, PHYSIOL PLANTARUM, V56, P38, DOI 10.1111/j.1399-3054.1982.tb04897.x; NISHITANI K, 1988, PLANT PHYSIOL, V87, P883, DOI 10.1104/pp.87.4.883; NISHITANI K, 1989, PLANT PHYSIOL, V91, P242, DOI 10.1104/pp.91.1.242; SMITH MM, 1983, CARBOHYD RES, V118, P65, DOI 10.1016/0008-6215(83)88036-7; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; SWEET DP, 1975, CARBOHYD RES, V40, P217, DOI 10.1016/S0008-6215(00)82604-X; TAKENISHI S, 1975, AGR BIOL CHEM TOKYO, V39, P2315, DOI 10.1080/00021369.1975.10861963; WAEGHE TJ, 1983, CARBOHYD RES, V123, P281, DOI 10.1016/0008-6215(83)88484-5; Wilkie K. C. B., 1979, Advances in Carbohydrate Chemistry and Biochemistry, V36, P215	35	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6539	6543						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1901062				2022-12-25	WOS:A1991FE37300080
J	BERTHIAUME, L; LOISEL, TP; SYGUSCH, J				BERTHIAUME, L; LOISEL, TP; SYGUSCH, J			CARBOXYL TERMINUS REGION MODULATES CATALYTIC ACTIVITY OF RECOMBINANT MAIZE ALDOLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; MUSCLE ALDOLASE; CATHEPSIN-B; INHIBITION; CLONING; VECTORS; LIVER	Site-directed mutagenesis was utilized to study the functional role of the COOH-terminal region in recombinant maize aldolase. A single mutation was created in each of the last nine amino acids of the COOH terminus and characterized kinetically. Point mutations in the COOH-terminal region were found to influence both the rate of fructose 1,6-bisphosphate and fructose 1-phosphate cleavage. Catalytic efficiency, k(cat)/K(m), was not affected by the mutations within experimental error consistent with this region of the COOH terminus modulating product release. Concentrations of the carbanion-enamine enzyme intermediate complex produced upon substrate cleavage increased with the severity of the point mutation. A condensation assay was developed to directly measure fructose 1,6-bisphosphate synthesized by aldolases in the presence of high triose phosphate concentrations. The maximal rate of aldol condensation of triose phosphates, D-glyceralehyde-3-P and dihydroxyacetone-P, was affected by the point mutations to the same extent as the maximal rate of substrate cleavage. Interpretation of the data is consistent with point mutations in the COOH terminus predominantly affecting the proton exchange with the dihydroxyacetone-P enzymatic complex at the carbanion-enamine step and that this step is probably rate-limiting in the catalytic mechanism of recombinant maize aldolase. The role of the COOH-terminal region in aldolases is thus consistent with a sequence dependent modulation of catalytic activity.	UNIV SHERBROOKE,FAC MED,DEPT BIOCHEM,SHERBROOKE J1H 5N4,QUEBEC,CANADA	University of Sherbrooke				Berthiaume, Luc/0000-0003-0926-059X				BERTHIAUME L, 1989, ARCH BIOCHEM BIOPHYS, V272, P281, DOI 10.1016/0003-9861(89)90221-X; BERTHIAUME L, 1991, THESIS U SHERBROOKE; BIRKENHAGER JC, 1960, BIOCHIM BIOPHYS ACTA, V40, P182, DOI 10.1016/0006-3002(60)91336-6; BOND JS, 1980, BIOCHEM J, V189, P17, DOI 10.1042/bj1890017; DISCHE Z, 1960, BIOCHIM BIOPHYS ACTA, V39, P140, DOI 10.1016/0006-3002(60)90129-3; DOBELI H, 1990, MOL BIOCHEM PARASIT, V41, P259, DOI 10.1016/0166-6851(90)90189-S; GRAZI E, 1962, BIOCHEM BIOPH RES CO, V7, P250, DOI 10.1016/0006-291X(62)90184-5; HANNAPPEL E, 1982, ARCH BIOCHEM BIOPHYS, V214, P293, DOI 10.1016/0003-9861(82)90033-9; HEALY MJ, 1973, BIOCHEMISTRY-US, V12, P35, DOI 10.1021/bi00725a006; HUMPHREYS L, 1986, INT J BIOCHEM, V18, P7, DOI 10.1016/0020-711X(86)90003-0; KELLY PM, 1987, PLANT PHYSIOL, V87, P1076; LEWIS DJ, 1977, EUR J BIOCHEM, V80, P119, DOI 10.1111/j.1432-1033.1977.tb11864.x; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MIDELFORT CF, 1972, J BIOL CHEM, V247, P3618; MODEL P, 1968, BIOCHEMISTRY-US, V7, P1339, DOI 10.1021/bi00844a014; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NEIDHARDT FC, 1985, 2 DIMENSIONAL GEL EL, P417; OFFERMANN MK, 1984, J BIOL CHEM, V259, P8886; RACKER E, 1947, J BIOL CHEM, V167, P843; ROSE IA, 1969, J BIOL CHEM, V244, P126; ROSE IA, 1987, J BIOL CHEM, V262, P692; RUTTER WJ, 1961, J BIOL CHEM, V236, P3193; RUTTER WJ, 1964, FED PROC, V23, P1248; Sambrook J, 1989, MOL CLONING LABORATO; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; TAKAHASHI I, 1989, J BIOCHEM, V105, P281, DOI 10.1093/oxfordjournals.jbchem.a122654; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8479; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; 1969, TRENTHAM DR, V114, P19	31	33	33	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17099	17105						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894606				2022-12-25	WOS:A1991GF44500023
J	CHAN, AC; TRAN, K; RAYNOR, T; GANZ, PR; CHOW, CK				CHAN, AC; TRAN, K; RAYNOR, T; GANZ, PR; CHOW, CK			REGENERATION OF VITAMIN-E IN HUMAN PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BLOOD PLASMA; ALPHA-TOCOPHEROL; ASCORBIC-ACID; ARACHIDONATE METABOLISM; ERYTHROCYTE-MEMBRANES; LIPID-PEROXIDATION; FREE-RADICALS; ANTIOXIDANT; OXIDATION; INHIBITION	Human platelets possess active lipoxygenase and cyclooxygenase which convert arachidonic acid to (12S)-12-hydroperoxy-5,8,10,14-eicosatetraenoic acid (12-HPETE) plus (12S)-12-hydroxy-5,8,10,14-eicosatetraenoic acid (12-HETE) and thromboxane B2 plus 12-hydroxy-5,8,10-heptadecatrienoic acid (HHT), respectively. When platelet homogenates were incubated with arachidonate, there was a rapid consumption of platelet tocopherol. Time course analysis revealed that within 0.5 min, over half of arachidonate and tocopherol were metabolized. Mass formation of 12-HPETE and 12-HETE or thromboxane B2 and HHT exceeded that of the mass of tocopherol oxidized. Preincubation with the lipoxygenase inhibitor 5,8,11,14-eicosatetraynoic acid (ETYA) completely abolished this arachidonate-induced tocopherol oxidation whereas cyclooxygenase inhibitors (indomethacin and aspirin) further potentiated tocopherol oxidation, indicating that this oxidation is closely linked with platelet 12-lipoxygenase activity. Incubation with lipoxygenase metabolites of arachidonic acid showed that only 12-HPETE caused a rapid tocopherol oxidation which was followed by a gradual tocopherol regeneration. By using nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor which is also a strong reductant, over 60% of the arachidonate-induced oxidized tocopherol was regenerated. Tocopherol regeneration declined with increasing oxidation time induced by arachidonate, and after 30-60 min virtually no regeneration could be observed, suggesting that the precursor molecule was unstable. We postulate that the precursor molecule is the tocopheroxyl radical. In the presence of ETYA, a lipoxygenase inhibitor without antioxidant properties, either ascorbate or GSH provided significant tocopherol regeneration. Kinetic studies showed that tocopherol regeneration after the addition of ascorbate was essentially completed by 1 min. By contrast, GSH addition caused a steady increase in tocopherol which peaked after 10 min of its addition. To determine whether this rapid regeneration is chemical or enzymic, regeneration was studied in the presence of chloroform and methanol. Comparison of various reductants in this denaturing condition for enzymes showed that ascorbate and NDGA afforded significant regeneration whereas GSH was ineffective, indicating that there are distinct enzymic and non-enzymic mechanisms for tocopherol regeneration. This study provides direct evidence from mass analysis that tocopherol can be regenerated in human cell homogenates. This finding implies that maintenance of membrane tocopherol status may be an essential function of ascorbate and GSH which operate in concert to ensure maximum membrane protection against oxidative damage.	UNIV KENTUCKY, DEPT NUTR & FOOD SCI, LEXINGTON, KY 40506 USA	University of Kentucky	CHAN, AC (corresponding author), UNIV OTTAWA, FAC MED, DEPT BIOCHEM, OTTAWA K1H 8M5, ONTARIO, CANADA.							BARCLAY LRC, 1983, CAN J CHEM, V61, P1288, DOI 10.1139/v83-225; BARCLAY LRC, 1985, CAN J CHEM, V63, P366, DOI 10.1139/v85-062; BASCETTA E, 1983, CHEM PHYS LIPIDS, V33, P207, DOI 10.1016/0009-3084(83)90022-1; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BURTON GW, 1983, ARCH BIOCHEM BIOPHYS, V221, P281, DOI 10.1016/0003-9861(83)90145-5; BURTON GW, 1981, J AM CHEM SOC, V103, P6472, DOI 10.1021/ja00411a035; CHAN AC, 1989, BIOCHIM BIOPHYS ACTA, V1005, P265, DOI 10.1016/0005-2760(89)90047-7; CHAN AC, 1986, AM J CLIN NUTR, V44, P278, DOI 10.1093/ajcn/44.2.278; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; FRIDOVICH I, 1986, ARCH BIOCHEM BIOPHYS, V247, P1, DOI 10.1016/0003-9861(86)90526-6; Golumbic C., 1941, J AM CHEM SOC, V63, P1279, DOI [10.1021/ja01850a037, DOI 10.1021/JA01850A037]; HALLIWELL B, 1990, FREE RADICAL BIO MED, P416; HAMBERG M, 1980, BIOCHEM BIOPH RES CO, V95, P1090, DOI 10.1016/0006-291X(80)91584-3; KAGAN VE, 1990, FREE RADICAL BIO MED, V9, P117, DOI 10.1016/0891-5849(90)90114-X; LEUNG HW, 1981, BIOCHIM BIOPHYS ACTA, V664, P266; LIEBLER DC, 1986, J BIOL CHEM, V261, P2114; LIEBLER DC, 1989, BIOCHEMISTRY-US, V28, P9772, DOI 10.1021/bi00451a034; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAGUIRE JJ, 1989, J BIOL CHEM, V264, P21462; MCCAY PB, 1989, ANN NY ACAD SCI, V570, P32; MCCAY PB, 1985, ANNU REV NUTR, V5, P323, DOI 10.1146/annurev.nu.05.070185.001543; MEHLHORN RJ, 1989, J BIOL CHEM, V264, P13448; NIKI E, 1983, CHEM LETT, P631, DOI 10.1246/cl.1983.631; NIKI E, 1984, J BIOL CHEM, V259, P4177; NIKI E, 1982, CHEM LETT, P789, DOI 10.1246/cl.1982.789; NIKI E, 1986, B CHEM SOC JPN, V59, P497, DOI 10.1246/bcsj.59.497; NIKI E, 1987, ANN NY ACAD SCI, V498, P186, DOI 10.1111/j.1749-6632.1987.tb23761.x; PACKER JE, 1979, NATURE, V278, P737, DOI 10.1038/278737a0; PACKER L, 1989, BIOCHEM BIOPH RES CO, V159, P229, DOI 10.1016/0006-291X(89)92427-3; SATO K, 1990, ARCH BIOCHEM BIOPHYS, V279, P402, DOI 10.1016/0003-9861(90)90508-V; SCARPA M, 1984, BIOCHIM BIOPHYS ACTA, V801, P215, DOI 10.1016/0304-4165(84)90070-9; SIEGEL MI, 1979, BIOCHEM BIOPH RES CO, V89, P1273, DOI 10.1016/0006-291X(79)92146-6; SIEGEL MI, 1979, P NATL ACAD SCI USA, V76, P3774, DOI 10.1073/pnas.76.8.3774; Sies H., 1985, OXIDATIVE STRESS, V501, P1, DOI DOI 10.1016/B978-0-12-642760-8.50005-3; TAPPEL AL, 1961, J AM OIL CHEM SOC, V38, P5, DOI 10.1007/BF02633109; TRAN K, 1990, BIOCHIM BIOPHYS ACTA, V1043, P189, DOI 10.1016/0005-2760(90)90295-9; VANDENBERG JJM, 1990, CHEM PHYS LIPIDS, V53, P309, DOI 10.1016/0009-3084(90)90028-P; VATASSERY GT, 1989, LIPIDS, V24, P1043, DOI 10.1007/BF02544077	38	95	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17290	17295						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910041				2022-12-25	WOS:A1991GF44500050
J	GINTY, DD; GLOWACKA, D; BADER, DS; HIDAKA, H; WAGNER, JA				GINTY, DD; GLOWACKA, D; BADER, DS; HIDAKA, H; WAGNER, JA			INDUCTION OF IMMEDIATE EARLY GENES BY CA2+ INFLUX REQUIRES CAMP-DEPENDENT PROTEIN-KINASE IN PC12 CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; C-FOS; PHEOCHROMOCYTOMA CELLS; MEMBRANE DEPOLARIZATION; PHOSPHORYLATION; TRANSCRIPTION; CALMODULIN; EXPRESSION; INHIBITION; CALCIUM	Agents that activate cAMP-dependent protein kinase (PKA) as well as agents that increase intracellular calcium induce the expression of certain immediate early genes (IEGs). Recently, it has been demonstrated that the same cis-acting element in the 5' region of the c-fos gene has the ability to mediate both cAMP- and calcium-induced c-fos expression in PC12 cells (Sheng, M., McFadden, G., and Greenberg, M. (1990) Neuron 4, 571-582). Here we demonstrate that both cAMP- and calcium-mediated induction of c-fos and egr1 are dependent on PKA activity. Addition of either depolarizing concentrations of KCl or the calcium ionophore, ionomycin, to PC12 cells increased the expression of both c-fos and egr1, but these inductions were dramatically reduced in three PKA-deficient cell lines, 123.7, AB.11, and A126-1B2. Furthermore, pretreatment of PC12 cells with 20-mu-M H89, a specific inhibitor of PKA, inhibited forskolin, dibutyryl cAMP, and KCl-induced c-fos and egr1 induction, while having no effect on NGF induction. Likewise, in the PKA-deficient cells, NGF or an activator of protein kinase C induced c-fos and egr1 normally. To determine if PKA deficiency modifies the ability of Ca2+ to activate calcium-dependent kinases, autophosphorylation of multifunctional Ca2+/calmodulin-dependent protein kinase (CaM kinase) in response to Ca2+ influx was determined. In parental PC12 cells, PC12 cells pretreated with H89, and PKA-deficient cell lines, CaM kinase was activated equivalently in response to KCl depolarization. These results suggest that PKA is not required for Ca2+-induced increase in CaM kinase activity and that the induction of IEGs in response to Ca2+ influx is PKA-dependent. Thus, the requirement for PKA resides at a point distal to the activation of calmodulin-dependent processes.	HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; NAGOYA UNIV,SCH MED,DEPT PHARMACOL,NAGOYA,AICHI 466,JAPAN	Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Nagoya University					NATIONAL CANCER INSTITUTE [P01CA022427, R01CA040929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS008764] Funding Source: NIH RePORTER; NCI NIH HHS [CA22427, CA40929] Funding Source: Medline; NINDS NIH HHS [NS08764] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY MJ, 1990, J NEUROCHEM, V54, P1034, DOI 10.1111/j.1471-4159.1990.tb02354.x; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; CURRAN T, 1982, J VIROL, V44, P674, DOI 10.1128/JVI.44.2.674-682.1982; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; GINTY DD, 1991, J BIOL CHEM, V266, P15325; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GRIFFITH LC, 1988, J BIOL CHEM, V263, P9542; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; MACNICOL M, 1990, J BIOL CHEM, V265, P18055; MOBLEY WC, 1976, BIOCHEMISTRY-US, V15, P5543, DOI 10.1021/bi00670a019; MORGAN JI, 1986, NATURE, V322, P552, DOI 10.1038/322552a0; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SUIDAN HS, 1991, CELL REGUL, V2, P13, DOI 10.1091/mbc.2.1.13; VANBUSKIRK R, 1985, MOL CELL BIOL, V5, P1984, DOI 10.1128/MCB.5.8.1984; WALDMANN R, 1990, BIOCHEMISTRY-US, V29, P1679, DOI 10.1021/bi00459a002; ZIEGLER A, 1990, J BIOL CHEM, V265, P21194	27	145	145	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17454	17458						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910045				2022-12-25	WOS:A1991GF44500072
J	HUSTEN, EJ; EIPPER, BA				HUSTEN, EJ; EIPPER, BA			THE MEMBRANE-BOUND BIFUNCTIONAL PEPTIDYLGLYCINE ALPHA-AMIDATING MONOOXYGENASE PROTEIN - EXPLORATION OF ITS DOMAIN-STRUCTURE THROUGH LIMITED PROTEOLYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID SYNTHASE; BOVINE NEUROINTERMEDIATE PITUITARY; MESSENGER-RNA; PEPTIDE AMIDATION; STABLE INTERMEDIATE; NUCLEOTIDE-SEQUENCE; MULTIPLE FORMS; ENZYME; RAT; PURIFICATION	The biosynthesis of alpha-amidated peptides from their glycine-extended precursors is catalyzed by the sequential action of peptidylglycine alpha-hydroxylating monooxygenase (PHM) and peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL). The two enzymes are part of a bifunctional, integral membrane protein precursor, peptidylglycine alpha-amidating monooxygenase (PAM). The major forms of PAM mRNA in the adult rat atrium differ by the presence or absence of optional exon A, a 315-nucleotide segment separating the PHM and PAL domains. Using antipeptide antibodies specific to the PHM, exon A, PAL, and cytoplasmic domains of rat PAM, carbonate-washed atrial membranes were found to contain proteins corresponding to rPAM-1 and rPAM-2. Digestion of atrial membranes with a variety of endoproteinases released PHM and PAL catalytic activities. Dose-response curves indicated that both catalytic activities were extremely resistant to inactivation by trypsin. Endoproteolytic digestion of atrial membranes with trypsin, chymotrypsin, elastase, thermolysin, or endoproteinase Lys-C generated a 35-kDa PHM fragment. Digestion with trypsin, elastase, thermolysin, or endoproteinase Lys-C generated a 42-kDa PAL fragment. In contrast to the stability exhibited by the PHM and PAL domains, the cytoplasmic domain of PAM was destroyed by most of the enzymes; only digestion with endoproteinase Lys-C generated a stable fragment. Digestion with endoproteinase Arg-C removed the carboxyl-terminal tail from PAM but failed to release the PHM or PAL domains from the membranes. The PHM fragments generated by some of the endoproteinases showed a tendency to adhere to the membranes. Thus the bifunctional PAM protein consists of independent catalytic domains separated from each other and from the putative transmembrane domain by flexible regions accessible to attack by a wide variety of endoproteinases.	JOHNS HOPKINS UNIV,SCH MED,DEPT NEUROSCI,WOOD BASIC SCI BLDG,RM 907,725 N WOLFE ST,BALTIMORE,MD 21205	Johns Hopkins University					NIDA NIH HHS [DA-00098] Funding Source: Medline; NIDDK NIH HHS [DK-32949, DK-08504] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032949, R37DK032949, R56DK032949, F32DK008504] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEAUDRY GA, 1990, J BIOL CHEM, V265, P17694; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; BRADBURY AF, 1987, EUR J BIOCHEM, V169, P579, DOI 10.1111/j.1432-1033.1987.tb13648.x; COGGINS JR, 1986, MULTIDOMAIN PROTEINS, P1; DUNCAN K, 1988, FEBS LETT, V241, P83, DOI 10.1016/0014-5793(88)81036-6; EIPPER BA, 1988, ANNU REV PHYSIOL, V50, P333, DOI 10.1146/annurev.ph.50.030188.002001; EIPPER BA, 1991, J BIOL CHEM, V266, P7827; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; EIPPER BA, 1988, J BIOL CHEM, V263, P8371; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GILLIGAN JP, 1989, ENDOCRINOLOGY, V124, P2729, DOI 10.1210/endo-124-6-2729; KAMEDA K, 1991, J BIOL CHEM, V266, P419; KATO I, 1990, BIOCHEM BIOPH RES CO, V172, P197, DOI 10.1016/S0006-291X(05)80193-7; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; MEHTA NM, 1988, ARCH BIOCHEM BIOPHYS, V261, P44, DOI 10.1016/0003-9861(88)90102-6; MINAMIISHII N, 1989, EUR J BIOCHEM, V185, P73, DOI 10.1111/j.1432-1033.1989.tb15083.x; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; MURTHY ASN, 1986, J BIOL CHEM, V261, P1815; NEEDLEMAN P, 1989, ANNU REV PHARMACOL, V29, P23, DOI 10.1146/annurev.pa.29.040189.000323; OUAFIK L, 1989, J BIOL CHEM, V264, P5839; OUAFIK L, 1991, 73RD ANN M END SOC; PAZIRANDEH M, 1989, J BIOL CHEM, V264, P18195; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; PERKINS SN, 1990, ENDOCRINOLOGY, V127, P2771, DOI 10.1210/endo-127-6-2771; RECHSTEINER M, 1987, TRENDS BIOCHEM SCI, V12, P390; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; SAKATA J, 1986, BIOCHEM BIOPH RES CO, V140, P230, DOI 10.1016/0006-291X(86)91080-6; SCHWEIZER M, 1986, MOL GEN GENET, V203, P479, DOI 10.1007/BF00422073; SCHWEIZER M, 1989, NUCLEIC ACIDS RES, V17, P567, DOI 10.1093/nar/17.2.567; SILVERMAN GJ, 1990, 241 MILL TECHN SERV; SIMMER JP, 1990, P NATL ACAD SCI USA, V87, P174, DOI 10.1073/pnas.87.1.174; SOUTHAN C, 1989, FEBS LETT, V255, P116, DOI 10.1016/0014-5793(89)81072-5; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; SUZUKI K, 1990, EMBO J, V9, P4259, DOI 10.1002/j.1460-2075.1990.tb07874.x; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088	37	66	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17004	17010						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894599				2022-12-25	WOS:A1991GF44500010
J	ROZAKISADCOCK, M; KELLY, PA				ROZAKISADCOCK, M; KELLY, PA			MUTATIONAL ANALYSIS OF THE LIGAND-BINDING DOMAIN OF THE PROLACTIN RECEPTOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; EPIDERMAL GROWTH-FACTOR; HUMAN THYROTROPIN RECEPTOR; SITE-DIRECTED MUTAGENESIS; HORMONE-BINDING; LINKED OLIGOSACCHARIDES; MONOCLONAL-ANTIBODIES; LUTROPIN RECEPTOR; SEQUENCE-ANALYSIS; MAMMARY-GLAND	The recent isolation and sequencing of the rat liver prolactin (PRL) receptor cDNA (clone F3) revealed that the receptor is a small molecular weight protein (nonglycosylated form, M(r) 33,000; glycosylated form, M(r) 42,000) comprised of 291 amino acids. A second form of the PRL receptor exists (591 amino acids) that contains a much longer cytoplasmic domain. In the present study, site-directed point mutations of the 5 conserved cysteine (Cys) residues and of the three potential N-linked glycosylation sites in the extracellular domain of the rat PRL receptor were constructed to assess their involvement in hormone binding. In addition, a truncation mutant (T-DELTA-237) lacking 55 of 57 intracellular amino acids was constructed to determine the influence of the cytoplasmic domain on ligand-receptor interactions. Binding studies of transiently transfected COS-7 cells demonstrated that serine substitution of the first 4 Cys residues (Cys12, Cys22, Cys51, and Cys62) completely eliminated binding of I-125-ovine PRL and I-125-U5 and -U6, two monoclonal antibodies that bind the receptor molecule outside the PRL-binding domain. RNA blot analysis of the transfected cells showed that both the wild-type and mutant clones had similar levels of expression of receptor mRNA. Immunoblot analysis demonstrated that lack of PRL binding in these mutants was not due to incomplete processing of the protein, since the fully glycosylated M(r) 42,000 form of the receptor was seen. Mutation of Cys184 had no effect on affinity or dimerization capacity of the receptor, suggesting the 5th cysteine is not directly involved in the binding domain. Carbohydrate groups of some receptors have been shown to be involved in ligand-receptor interactions as well as intracellular trafficking. This does not appear to be the case for the PRL receptor, since there was no corresponding decrease in affinity for PRL or cell surface receptor expression, following mutation of each of the 3 asparagine residues to aspartate. Interestingly, T-DELTA-237 showed a 4-5-fold increase in affinity for PRL as well as a marked increase in the number of receptor sites. Whole cell binding assays also demonstrated that loss of the cytoplasmic domain lead to inefficient recycling of the receptor. These studies suggest that the first 4 conserved Cys residues are crucial for ligand binding. The putative pattern of disulfide bridging between the 1st and 2nd and between the 3rd and 4th cysteines (Fuh, G., Mulkerrin, M. G., Bass, S., McFarland, N., Brochier, M., Bourell, J. H., Light, D. R., and Wells, J. A. (1990) J. Biol. Chem. 265, 3111-3115) provides strong spatial constraints for tertiary folding of the receptor. Disruption of these bonds leads to the formation of abnormally folded receptors and thus to the loss of the hormone-binding site. The studies also suggest that the cytoplasmic domain not only influences binding but also regulates the cellular distribution of the PRL receptor.	MCGILL UNIV, ROYAL VICTORIA HOSP, MOLEC ENDOCRINOL LAB, MONTREAL H3A 1A1, QUEBEC, CANADA	McGill University; Royal Victoria Hospital			Kelly, Paul/A-7951-2008					BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BERGERON JJM, 1978, J BIOL CHEM, V253, P4058; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; CHAZENBALK GD, 1990, J BIOL CHEM, V265, P20970; CULLEN BR, 1988, J BIOL CHEM, V263, P4900; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; CZECH MP, 1989, CELL, V59, P235, DOI 10.1016/0092-8674(89)90281-X; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; DIXON RAF, 1987, NATURE, V326, P73, DOI 10.1038/326073a0; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FEIGE JJ, 1988, J BIOL CHEM, V263, P14023; FISCHER T, 1990, J BIOL CHEM, V265, P1710; FOSTER R, 1988, J BIOL CHEM, V263, P11528; FUH G, 1990, J BIOL CHEM, V265, P3111; GETHING MJ, 1986, CELL, V46, P939, DOI 10.1016/0092-8674(86)90076-0; GIRI JG, 1990, J BIOL CHEM, V265, P17416; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; HEMPSTEAD BL, 1990, J BIOL CHEM, V265, P9595; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; JI IH, 1990, ENDOCRINOLOGY, V127, P494, DOI 10.1210/endo-127-1-494; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KEINANEN KP, 1988, BIOCHEM J, V256, P719, DOI 10.1042/bj2560719; KELLY PA, 1991, IN PRESS TRENDS ENDO; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASCOLS O, 1989, MOL CELL ENDOCRINOL, V65, P145, DOI 10.1016/0303-7207(89)90175-5; LAX I, 1988, MOL CELL BIOL, V8, P1831, DOI 10.1128/MCB.8.4.1831; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; Maniatis T., 1982, MOL CLONING; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; MEITES J, 1988, INT CONGR SER, V819, P123; MISRAHI M, 1990, BIOCHEM BIOPH RES CO, V166, P394, DOI 10.1016/0006-291X(90)91958-U; Nicoll C.S., 1972, LACTOGENIC HORMONES, P299; NISBET IT, 1985, GENE ANAL TECH, V2, P23, DOI 10.1016/0735-0651(85)90001-9; OKAMURA H, 1989, J BIOL CHEM, V264, P5904; OKAMURA H, 1989, ENDOCRINOLOGY, V124, P2499, DOI 10.1210/endo-124-5-2499; POSTELVINAY MC, 1991, IN PRESS P NATL ACAD; PRYWES R, 1986, EMBO J, V5, P2179, DOI 10.1002/j.1460-2075.1986.tb04482.x; RAFAELOFF R, 1989, J BIOL CHEM, V264, P15900; RAGUET S, 1988, 8TH INT C PROL KYOT, P68; RANDS E, 1990, J BIOL CHEM, V265, P10759; RONNETT GV, 1981, J BIOL CHEM, V256, P4704; RUSSO D, 1991, MOL ENDOCRINOL, V5, P29, DOI 10.1210/mend-5-1-29; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHLESSINGER J, 1986, J CELL BIOL, V103, P2067, DOI 10.1083/jcb.103.6.2067; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHIU RPC, 1980, ANNU REV PHYSIOL, V42, P83, DOI 10.1146/annurev.ph.42.030180.000503; SODERQUIST AM, 1984, J BIOL CHEM, V259, P2586; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STRADER CD, 1987, J BIOL CHEM, V262, P16439; SZECOWKA J, 1990, ENDOCRINOLOGY, V126, P1834, DOI 10.1210/endo-126-4-1834; TAKAKI S, 1990, EMBO J, V9, P4367, DOI 10.1002/j.1460-2075.1990.tb07886.x; VANKOPPEN CJ, 1990, J BIOL CHEM, V265, P20887; WADSWORTH HL, 1990, SCIENCE, V249, P1423, DOI 10.1126/science.2169649; WU DG, 1989, J BIOL CHEM, V264, P17469; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466	59	65	67	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16472	16477						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885580				2022-12-25	WOS:A1991GD63500040
J	JEDLICKA, P; PANNIERS, R				JEDLICKA, P; PANNIERS, R			MECHANISM OF ACTIVATION OF PROTEIN-SYNTHESIS INITIATION IN MITOGEN-STIMULATED LYMPHOCYTES-T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-EXCHANGE FACTOR; FACTOR-II; PHYSIOLOGICAL STRESSES; CELLS; INHIBITION; PHYTOHEMAGGLUTININ; PHOSPHORYLATION; TRANSLATION	The pronounced stimulation of protein synthesis in T lymphocytes in response to mitogens is partly due to increased cell size and hence ribosome number. There is also a large increase in translation rate per ribosome as a result of an increased rate of initiation. In response to mitogen, levels of both eukaryotic initiation factor (eIF)-2 and guanine nucleotide exchange factor, GEF, increase in parallel with ribosomes which is consistent with a general increase in the translational machinery but cannot explain the increase in activity per ribosome. However, as total eIF-2 accumulates, the ratio of phosphorylated eIF-2-alpha (eIF-2(alpha-P)) to eIF-2-alpha decreases. Further, the levels of eIF-2(alpha-P) and GEF in resting T lymphocytes are similar. As eIF-2(alpha-P) inhibits GEF by effectively sequestering the exchange factor in an inactive 1:1 complex, the level of GEF available for protein synthesis initiation must be very low in resting cells. Hence, as GEF is synthesized and rises above the level of eIF-2(alpha-P), there will be a disproportionate increase in GEF available for initiation compared with the increase in total GEF. This increase in available GEF is probably great enough to support the increase in translation rate per ribosome as well as the increase in ribosome number.	UNIV ROCHESTER,CTR CANC,ROCHESTER,NY 14642; UNIV ROCHESTER,DEPT BIOCHEM,ROCHESTER,NY 14642	University of Rochester; University of Rochester					NCRR NIH HHS [S7RR05403-28] Funding Source: Medline	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AHERN T, 1973, BIOCHIM BIOPHYS ACTA, V331, P91, DOI 10.1016/0005-2787(73)90422-X; AHERN T, 1974, NATURE, V248, P519, DOI 10.1038/248519a0; BOAL TR, 1990, FASEB J, V4, pA1999; COOPER HL, 1977, J CELL PHYSIOL, V93, P213, DOI 10.1002/jcp.1040930207; COOPER HL, 1976, J BIOL CHEM, V251, P4891; COOPER HL, 1981, J BIOL CHEM, V256, P7461; COOPER HL, 1969, J BIOL CHEM, V244, P5590; DUNCAN R, 1984, J BIOL CHEM, V259, P1882; HALLINAN T, 1963, BIOCHIM BIOPHYS ACTA, V68, P131; HENSHAW EC, 1971, J BIOL CHEM, V246, P436; JULIUS MH, 1973, EUR J IMMUNOL, V3, P645, DOI 10.1002/eji.1830031011; KAY JE, 1978, FEBS LETT, V91, P40, DOI 10.1016/0014-5793(78)80012-X; KAY JE, 1975, BIOCHIM BIOPHYS ACTA, V378, P241, DOI 10.1016/0005-2787(75)90112-4; KAY JE, 1971, BIOCHIM BIOPHYS ACTA, V247, P322, DOI 10.1016/0005-2787(71)90680-0; KAY JE, 1969, BIOCHIM BIOPHYS ACTA, V186, P62, DOI 10.1016/0005-2787(69)90490-0; KRUGER C, 1980, Biochemical Society Transactions, V8, P355; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MISHELL BB, 1980, SELECTED METHODS CEL, P182; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; OCHOA S, 1983, ARCH BIOCHEM BIOPHYS, V223, P325, DOI 10.1016/0003-9861(83)90598-2; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PANNIERS R, 1983, J BIOL CHEM, V258, P7928; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; ROWLANDS AG, 1988, EUR J BIOCHEM, V175, P93, DOI 10.1111/j.1432-1033.1988.tb14170.x; SCORSONE KA, 1987, J BIOL CHEM, V262, P14538; SIEKIERKA J, 1984, P NATL ACAD SCI USA, V76, P4350; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	27	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15663	15669						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874724				2022-12-25	WOS:A1991GB97700023
J	LOWNDES, JM; GUPTA, SK; OSAWA, S; JOHNSON, GL				LOWNDES, JM; GUPTA, SK; OSAWA, S; JOHNSON, GL			GTPASE-DEFICIENT G-ALPHA-I2 ONCOGENE GIP2 INHIBITS ADENYLYLCYCLASE AND ATTENUATES RECEPTOR-STIMULATED PHOSPHOLIPASE-A2 ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY COMPONENT; PROTEIN KINASE-C; GUANINE-NUCLEOTIDE; ADENYLATE-CYCLASE; GS-ALPHA; BETA-GAMMA; HUMAN-PLATELETS; PHORBOL ESTER; ACTIVATION; SUBUNIT	The GTPase activity of a G protein alpha-subunit functions as a timer to control the lifetime of the activated conformation of the protein. Expression of the GTPase-deficient G(i2) alpha-subunit oncogene, gip2 (alpha-i2Q205L), in Chinese hamster ovary cells inhibited the stimulation of adenylylcyclase and altered the calcium regulation of the G(i2)-phospholipase A2 (PLA2) effector complex. The phenotypic consequence of the activated alpha-i2 mutant on hormonal stimulation of PLA2 varied depending on the cytoplasmic calcium transient elicited by different G(i2)-linked receptors. The stimulation of PLA2 by thrombin, which mobilized calcium only from internal stores, was markedly attenuated in gip2-expressing cells. In contrast, the attenuation of the PLA2 response to ATP, a purinergic agonist which mobilizes calcium from both extracellular space and internal stores, was significantly less than that observed for thrombin. Ionomycin, a calcium ionophore, stimulated PLA2 activity in clones which expressed gip2 to a level similar to that observed in wild-type Chinese hamster ovary cells. Thus, the dominant GTPase-deficient gip2 polypeptide will constitutively inhibit adenylylcyclase but differentially modulate enzymes regulated by calcium and coupled to G(i2).	NATL JEWISH CTR IMMUNOL & RESP MED, DIV BASIC SCI, DENVER, CO 80206 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80226 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NICHD NIH HHS [HD 07437] Funding Source: Medline; NIDDK NIH HHS [DK 37071] Funding Source: Medline; NIGMS NIH HHS [GM 30324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030324, R37GM030324] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROCK TA, 1985, J BIOL CHEM, V260, P4158; CHEE WW, 1989, J BIOL CHEM, V264, P5687; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; DANIELISSAKANI S, 1989, J BIOL CHEM, V264, P20240; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GUPTA SK, 1990, SCIENCE, V249, P662, DOI 10.1126/science.2166341; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P3178; HILDEBRANDT JD, 1990, J BIOL CHEM, V265, P9825; HUDSON TH, 1981, J BIOL CHEM, V256, P1459; JAKOBS KH, 1985, EUR J BIOCHEM, V151, P425, DOI 10.1111/j.1432-1033.1985.tb09119.x; JOHNSON GL, 1989, ENDOCR REV, V10, P317, DOI 10.1210/edrv-10-3-317; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KIKUCHI A, 1986, CANCER RES, V46, P3401; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; NARASIMHAN V, 1990, J BIOL CHEM, V265, P1459; NEER EJ, 1988, J BIOL CHEM, V263, P8996; OHTA H, 1985, J BIOL CHEM, V260, P5771; OSAWA S, 1990, CELL, V63, P697, DOI 10.1016/0092-8674(90)90136-3; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; RYU SH, 1990, J BIOL CHEM, V265, P17941; TAYLOR SJ, 1987, BIOCHEM J, V248, P791, DOI 10.1042/bj2480791; WEISS ER, 1990, J MOL ENDOCRINOL, V4, P71, DOI 10.1677/jme.0.0040071; WESSLINGRESNICK M, 1989, BIOCHEM BIOPH RES CO, V159, P651, DOI 10.1016/0006-291X(89)90044-2; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; ZACHARY I, 1990, BIOCHEM BIOPH RES CO, V168, P1184, DOI 10.1016/0006-291X(90)91154-K; ZICK Y, 1986, P NATL ACAD SCI USA, V83, P9294, DOI 10.1073/pnas.83.24.9294	34	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14193	14197						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907271				2022-12-25	WOS:A1991FZ35100014
J	JOLY, A; POPJAK, G; EDWARDS, PA				JOLY, A; POPJAK, G; EDWARDS, PA			INVITRO IDENTIFICATION OF A SOLUBLE PROTEIN-GERANYLGERANYL TRANSFERASE FROM RAT-TISSUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MEVALONIC ACID; POSTTRANSLATIONAL MODIFICATION; SACCHAROMYCES-CEREVISIAE; CARBOXYL-METHYLATION; FARNESYL CYSTEINE; CELL-PROTEINS; GAMMA-SUBUNIT; GTP-BINDING; P21RAS; LIVER	The gamma-subunit of mammalian trimeric G proteins has been shown previously to be modified in vivo on a cysteine residue situated at the carboxyl-terminal sequence-Cys-Ala-Ile-Leu-COOH by a 20-carbon prenyl moiety geranylgeranyl (Mumby, S. M., Casey, P. J., Gilman, A. G., Gutowski, S., and Sternweis, P. C. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 5873-5877; Yamane, H. K., Farnsworth, C. C., Xie, H., Howald, W., Fung, B. K-K., Clarke, S., Gelb, M. H., and Glomset, J.A. (1990) Proc. Natl. Acad. Sci. U.S.A. 87,8 5866-5872). A biotinylated peptide acceptor comprising the eight carboxyl-terminal amino acids of the gamma-subunit and tritiated geranylgeranyl diphosphate were utilized to monitor a protein:prenyl transferase activity in rat organs of varying age. The transferase activity was dependent upon the presence of divalent metal ions and maximal activity was achieved with either 1 mM ZnCl2 or 20 mm MgCl2. Activity was shown to be linear with respect to time, protein concentration, substrate concentration, and the pH optimum was 7.5. Protein:geranylgeranyl transferase activity was detected in all rat organs studied with the highest specific activity in brain S100. No activity was detected in the membrane fraction. The specific activity in brain, liver, kidney, and heart increased with age. Radioactivity incorporated into the peptide acceptor from both [1-H-3]geranylgeranyl diphosphate and [5-H-3]mevalonate by 21-day-old rat brain S100 was released by treatment with methyl iodide, and in both cases, analysis of the cleavage products by reversed phase high performance liquid chromatography showed a peak of radioactivity co-eluting with a geranylgeraniol standard which was well resolved from a farnesol standard. This indicated that the rat brain S100 contained not only the protein:geranylgeranyl transferase but also geranylgeranyl synthetase activity and that the peptide acceptor was specific for geranylgeranyl under the conditions tested.	UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	JOLY, A (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90024, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; ASHBY MN, 1989, J BIOL CHEM, V264, P635; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; Benjamins JA, 1984, MYELIN, P225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHELSKY D, 1989, J BIOL CHEM, V264, P7637; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DAVISSON VJ, 1985, METHOD ENZYMOL, V110, P130; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FIESER LF, 1967, REAGENTS ORGANIC SYN, P1049; FRIESSMUTH M, 1989, FASEB J, V3, P2125; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOODMAN DS, 1960, J LIPID RES, V1, P286; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KAMIYA Y, 1979, AGR BIOL CHEM TOKYO, V43, P1049, DOI 10.1080/00021369.1979.10863559; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LI AC, 1988, J LIPID RES, V29, P781; LONDON M, 1953, ARCH BIOCHEM BIOPHYS, V46, P141, DOI 10.1016/0003-9861(53)90177-5; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; RINE J, 1990, New Biologist, V2, P219; SAGAMI H, 1985, METHOD ENZYMOL, V110, P184; SAGAMI H, 1981, BIOCHEM INT, V3, P669; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5866; 1985, METHOD ENZYMOL, V110, P1	45	41	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13495	13498						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906876				2022-12-25	WOS:A1991FY02700008
J	HOSAKA, M; NAGAHAMA, M; KIM, WS; WATANABE, T; HATSUZAWA, K; IKEMIZU, J; MURAKAMI, K; NAKAYAMA, K				HOSAKA, M; NAGAHAMA, M; KIM, WS; WATANABE, T; HATSUZAWA, K; IKEMIZU, J; MURAKAMI, K; NAKAYAMA, K			ARG-X-LYS/ARG-ARG MOTIF AS A SIGNAL FOR PRECURSOR CLEAVAGE CATALYZED BY FURIN WITHIN THE CONSTITUTIVE SECRETORY PATHWAY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MOUSE SUBMANDIBULAR-GLAND; SITE-DIRECTED MUTAGENESIS; PITUITARY ATT-20 CELLS; PROCESSING ENZYME; MAMMALIAN-CELLS; PROTEOLYTIC CLEAVAGE; GENE-PRODUCT; SUBSTRATE-SPECIFICITY; CONVERTING ENZYME; SERINE PROTEASE	Many peptide hormones are produced from larger precursors by endoproteolysis at pairs of basic amino acids (e.g. Lys-Arg and Arg-Arg) within the regulated secretory pathway in endocrine cells. However, many other secretory and membrane proteins appear to be produced from precursors through cleavage at multiple, rather than paired, basic residues within the constitutive secretory pathway in non-endocrine cells. By surveying various precursors processed constitutively, we noticed that most of them have the consensus sequence, Arg-X-Lys/Arg-Arg (RXK/RR), at the cleavage site. When expressed in endocrine and non-endocrine cells, a precursor with the RXKR sequence was cleaved in both types of cells, whereas that with the Lys-Arg pair was cleaved only in the endocrine cells. When the RXKR precursor was coexpressed with furin and PC3, both of which are mammalian homologues of the yeast precursor-processing endoprotease Kex2, in non-endocrine cells, enhancement of the precursor cleavage by furin but not by PC3 was observed. By contrast, when the Lys-Arg precursor was coexpressed with the two mammalian proteases in endocrine cells with no endogenous processing activity at dibasic sites, it was cleaved only by PC3. These results indicate that the basic pair and the RXK/RR sequence are the signals for precursor cleavages catalyzed by PC3 within the regulated secretory pathway and by furin within the constitutive pathway, respectively.	UNIV TSUKUBA, INST BIOL SCI, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, CTR GENE EXPT, TSUKUBA, IBARAKI 305, JAPAN; UNIV TSUKUBA, INST APPL BIOCHEM, TSUKUBA, IBARAKI 305, JAPAN	University of Tsukuba; University of Tsukuba; University of Tsukuba			Nakayama, Kazuhisa/ABF-2924-2020	Nakayama, Kazuhisa/0000-0001-7701-7183; Hosaka, Masahiro/0000-0002-1422-1774				BENTLEY AK, 1986, CELL, V45, P343, DOI 10.1016/0092-8674(86)90319-3; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; BRESNAHAN PA, 1990, J CELL BIOL, V111, P2851, DOI 10.1083/jcb.111.6.2851; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CROMLISH JA, 1986, J BIOL CHEM, V261, P850; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; EDWARDS RH, 1988, MOL CELL BIOL, V8, P2456, DOI 10.1128/MCB.8.6.2456; FOSTER DC, 1990, BIOCHEMISTRY-US, V29, P347, DOI 10.1021/bi00454a007; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRITZ LC, 1987, J BIOL CHEM, V262, P12409; FRITZ LC, 1986, P NATL ACAD SCI USA, V83, P4114, DOI 10.1073/pnas.83.12.4114; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GLUSCHANKOF P, 1987, J BIOL CHEM, V262, P9615; HATSUZAWA K, 1990, J BIOCHEM-TOKYO, V107, P854, DOI 10.1093/oxfordjournals.jbchem.a123137; HATSUZAWA K, 1990, J BIOL CHEM, V265, P22075; HUYLEBROECK D, 1990, MOL ENDOCRINOL, V4, P1153, DOI 10.1210/mend-4-8-1153; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; KIM WS, 1990, J BIOL CHEM, V265, P5930; Klenk H D, 1988, Adv Virus Res, V34, P247, DOI 10.1016/S0065-3527(08)60520-5; LOH YP, 1985, J BIOL CHEM, V260, P7194; MAINS RE, 1987, ANN NY ACAD SCI, V493, P278, DOI 10.1111/j.1749-6632.1987.tb27213.x; MIZUNO K, 1989, BIOCHEM BIOPH RES CO, V159, P305, DOI 10.1016/0006-291X(89)92438-8; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOORE HPH, 1983, CELL, V35, P531, DOI 10.1016/0092-8674(83)90187-3; NAGAHAMA M, 1991, EUR J BIOCHEM, V197, P135, DOI 10.1111/j.1432-1033.1991.tb15891.x; NAGAI Y, 1976, VIROLOGY, V72, P494, DOI 10.1016/0042-6822(76)90178-1; NAKAYAMA K, 1990, J BIOL CHEM, V265, P21027; NAKAYAMA K, 1989, FEBS LETT, V257, P89, DOI 10.1016/0014-5793(89)81793-4; PATERSON RG, 1989, J VIROL, V63, P1293, DOI 10.1128/JVI.63.3.1293-1301.1989; RODRIGUEZ C, 1989, J BIOL CHEM, V264, P5988; SEIDAH NG, 1991, MOL ENDOCRINOL, V5, P111, DOI 10.1210/mend-5-1-111; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SHEN FS, 1989, J BIOL CHEM, V264, P15600; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SOSSIN WS, 1990, J CELL BIOL, V110, P1, DOI 10.1083/jcb.110.1.1; SPAETE RR, 1990, J VIROL, V64, P2922, DOI 10.1128/JVI.64.6.2922-2931.1990; STOLLER TJ, 1989, J BIOL CHEM, V264, P6922; THOMAS G, 1988, ANNU REV PHYSIOL, V50, P323; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; VANDENOUWELAND AMW, 1990, NUCLEIC ACIDS RES, V18, P664, DOI 10.1093/nar/18.3.664; VANDEVEN WJM, 1990, MOL BIOL REP, V14, P265, DOI 10.1007/BF00429896; WHITE JM, 1989, CELL, V56, P725, DOI 10.1016/0092-8674(89)90674-0; WISE RJ, 1990, P NATL ACAD SCI USA, V87, P9378, DOI 10.1073/pnas.87.23.9378	45	550	591	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12127	12130						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905715				2022-12-25	WOS:A1991FV18000004
J	POLONIS, VR; ANDERSON, GR; VAHEY, MT; MORROW, PJ; STOLER, D; REDFIELD, RR				POLONIS, VR; ANDERSON, GR; VAHEY, MT; MORROW, PJ; STOLER, D; REDFIELD, RR			ANOXIA INDUCES HUMAN-IMMUNODEFICIENCY-VIRUS EXPRESSION IN INFECTED T-CELL LINES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							TUMOR NECROSIS FACTOR; LONG TERMINAL REPEAT; FACTOR-ALPHA; TYPE-1; INDUCTION; PROTEINS; HIV-1; CLONE; TRANSCRIPTION; REOXYGENATION	The effects of oxygen deprivation, or anoxia, on human immunodeficiency virus (HIV-1) expression in chronically (ACH.2) and acutely (H9/HIV-1-IIIB) infected cell lines was investigated. Temporary cellular anoxia has previously been shown to activate transcription of endogenous type C leukemia virus sequences, resulting in a significant increase in retroviral RNA within the cell (1). Here we report a 15-fold increase in HIV-1-specific RNA in unstimulated ACH.2 T cells within 24 h of anoxia. This induction of RNA is accompanied by an accumulation of intracellular p24 gag protein as well as an increase in envelope protein. Anoxia induces a further increase in total HIV-1 RNA in ACH.2 cells prestimulated to produce virus by phorbol 12-myristate 13-acetate and in H9 T cells acutely infected with HIV-1-IIIB. The induction of RNA in ACH.2 cells appears to be reversible. Anoxic culture for 24 h followed by a 24-h re-oxygenation period results in a return to "resting state" levels of HIV-1 RNA. These data indicate that oxygen tension within the cellular environment modulates HIV-1 expression, providing a model system in which to study the reversible regulation of HIV-1 RNA and viral gene products within the cell.	NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT CELL & MOLEC BIOL,BUFFALO,NY 14263	Roswell Park Cancer Institute	POLONIS, VR (corresponding author), WALTER REED ARMY MED CTR,DEPT RETROVIRAL RES,13 TAFT CT,SUITE 201,ROCKVILLE,MD 20850, USA.				NATIONAL CANCER INSTITUTE [R01CA048828] Funding Source: NIH RePORTER; NCI NIH HHS [CA48828] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDERSON GR, 1989, J BIOL CHEM, V264, P14885; ANDERSON GR, 1977, SCIENCE, V197, P1371, DOI 10.1126/science.197602; ANDERSON GR, 1989, J MOL BIOL, V205, P765, DOI 10.1016/0022-2836(89)90320-3; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLOUSE KA, 1989, J IMMUNOL, V142, P431; COOMBS RW, 1989, NEW ENGL J MED, V321, P1626, DOI 10.1056/NEJM198912143212402; DUH EJ, 1989, P NATL ACAD SCI USA, V86, P5974, DOI 10.1073/pnas.86.15.5974; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOLKS TM, 1987, SCIENCE, V238, P800, DOI 10.1126/science.3313729; FOLKS TM, 1988, J IMMUNOL, V140, P1117; FOLKS TM, 1989, P NATL ACAD SCI USA, V86, P2365, DOI 10.1073/pnas.86.7.2365; GEELEN JLMC, 1988, J GEN VIROL, V69, P2913, DOI 10.1099/0022-1317-69-11-2913; HAHN BH, 1984, NATURE, V312, P166, DOI 10.1038/312166a0; HO DD, 1989, NEW ENGL J MED, V321, P1621, DOI 10.1056/NEJM198912143212401; HO DD, 1987, NEW ENGL J MED, V317, P278; KLIEWER S, 1989, J VIROL, V63, P4616, DOI 10.1128/JVI.63.11.4616-4625.1989; KNIGHTON DR, 1983, SCIENCE, V221, P1283, DOI 10.1126/science.6612342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEGRANDPOELS S, 1990, AIDS RES HUM RETROV, V6, P1389, DOI 10.1089/aid.1990.6.1389; LEIBOVICH SJ, 1987, NATURE, V329, P630, DOI 10.1038/329630a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOSCA JD, 1987, NATURE, V325, P67, DOI 10.1038/325067a0; NABEL GJ, 1988, SCIENCE, V239, P1299, DOI 10.1126/science.2830675; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; POLI G, 1990, J EXP MED, V172, P151, DOI 10.1084/jem.172.1.151; POLI G, 1990, P NATL ACAD SCI USA, V87, P782, DOI 10.1073/pnas.87.2.782; POMERANTZ RJ, 1990, CELL, V61, P1271, DOI 10.1016/0092-8674(90)90691-7; POMERANTZ RJ, 1990, J EXP MED, V172, P253, DOI 10.1084/jem.172.1.253; REDFIELD RR, 1988, SCI AM, V259, P90, DOI 10.1038/scientificamerican1088-90; SCIANDRA JJ, 1984, P NATL ACAD SCI-BIOL, V81, P4843, DOI 10.1073/pnas.81.15.4843; SHATOS MA, 1990, J BIOL CHEM, V265, P20443; STANLEY SK, 1989, AIDS RES HUM RETROV, V5, P375, DOI 10.1089/aid.1989.5.375; STEIN B, 1989, J VIROL, V63, P4540, DOI 10.1128/JVI.63.11.4540-4544.1989; SUTHERLAND RM, 1988, SCIENCE, V240, P177, DOI 10.1126/science.2451290; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITAKERDOWLING PA, 1979, J VIROL, V32, P234, DOI 10.1128/JVI.32.1.234-239.1979; YASUDA Y, 1990, J ACQ IMMUN DEF SYND, V3, P1046	37	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11421	11424						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904863				2022-12-25	WOS:A1991FT76200005
J	FAUSTINELLA, F; SMITH, LC; SEMENKOVICH, CF; CHAN, L				FAUSTINELLA, F; SMITH, LC; SEMENKOVICH, CF; CHAN, L			STRUCTURAL AND FUNCTIONAL ROLES OF HIGHLY CONSERVED SERINES IN HUMAN LIPOPROTEIN-LIPASE - EVIDENCE THAT SERINE 132 IS ESSENTIAL FOR ENZYME CATALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PANCREATIC LIPASE; DEVELOPMENTAL REGULATION; HEPATIC LIPASE; BOVINE-MILK; GENE; EXPRESSION; SITE; MECHANISM; EVOLUTION; SEQUENCE	The structure of human lipoprotein lipase was recently deduced from its cDNA sequence. It contains 8 serine residues (residues 45, 132, 143, 172, 193, 244, 251, and 363) that are absolutely conserved in both lipoprotein lipase and hepatic lipase across all species studied. The high homology between lipoprotein lipase, hepatic lipase, and pancreatic lipase suggests that the catalytic functions of these enzymes share a common mechanism and that one of the 8 conserved serines in human lipoprotein lipase must play a catalytic role as does serine 152 in the case of pancreatic lipase (Winkler, F. K., D'Arcy, A., and Hunziker, W. Nature 343, 771-774). We expressed wild-type and site-specific mutants of human lipoprotein lipase in COS cells in vitro. We produced two to four substitution mutants involving each of the 8 serines and assayed a total of 22 mutants for both enzyme activity and the amount of immunoreactive enzyme mass produced. Immunoreactive lipase was detected in all cases. With the exception of Ser132, for each of the 8 serine mutants we studied, at least one of several mutants at each position showed detectable enzyme activity. All three substitution mutants at Ser132, Ser --> Thr, Ser --> Ala, and Ser --> Asp, were totally inactive. Ser132 occurs in the consensus sequence Gly-Xaa-Ser-Xaa-Gly present in all serine proteinases and in human pancreatic lipase. The x-ray crystallography structure of human pancreatic lipase suggests that the analogous serine residue in human pancreatic lipase, Ser152, is the nucleophilic residue essential for catalysis. Our biochemical data strongly support the conclusion that Ser132 in human lipoprotein lipase is the crucial residue required for enzyme catalysis. The observed specific activities of the variants involving the other seven highly conserved serines in human lipoprotein lipase are consistent with the interpretation that this enzyme has a three-dimensional structure very similar to that of human pancreatic lipase.	BAYLOR UNIV, DEPT CELL BIOL, ONE BAYLOR PL, HOUSTON, TX 77030 USA; BAYLOR UNIV, DEPT MED, HOUSTON, TX 77030 USA; METHODIST HOSP, HOUSTON, TX 77030 USA	Baylor University; Baylor University; The Methodist Hospital System; The Methodist Hospital - Houston				Semenkovich, Clay/0000-0003-1163-1871	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016512, R01HL016512, R01HL015648] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001762] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 15648, HL 16512] Funding Source: Medline; NIDDK NIH HHS [DK 01762] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLOW D, 1990, NATURE, V343, P694, DOI 10.1038/343694a0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; CAI SJ, 1989, BIOCHEMISTRY-US, V28, P8966, DOI 10.1021/bi00449a002; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4980, DOI 10.1021/bi00668a006; CHAPUS C, 1976, BIOCHEMISTRY-US, V15, P4988, DOI 10.1021/bi00668a007; DATTA S, 1988, J BIOL CHEM, V263, P1107; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; GUIDONI A, 1981, BIOCHIM BIOPHYS ACTA, V660, P148, DOI 10.1016/0005-2744(81)90120-0; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; KIRCHGESSNER TG, 1989, J BIOL CHEM, V264, P1473; MAYLIE MF, 1972, BIOCHIM BIOPHYS ACTA, V276, P162, DOI 10.1016/0005-2744(72)90017-4; MICKEL FS, 1989, J BIOL CHEM, V264, P12895; Olivecrona T., 1987, LIPOPROTEIN LIPASE, P15; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; REDDY MN, 1986, J BIOL CHEM, V261, P9678; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VOYTA JC, 1985, J BIOL CHEM, V260, P893; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623	23	78	82	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9481	9485						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903387				2022-12-25	WOS:A1991FM45900026
J	TREJO, J; BROWN, JH				TREJO, J; BROWN, JH			C-FOS AND C-JUN ARE INDUCED BY MUSCARINIC RECEPTOR ACTIVATION OF PROTEIN-KINASE-C BUT ARE DIFFERENTIALLY REGULATED BY INTRACELLULAR CALCIUM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1321N1 ASTROCYTOMA-CELLS; STIMULATES DNA-SYNTHESIS; EPIDERMAL GROWTH-FACTOR; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; ANGIOTENSIN RECEPTOR; CA-2+ MOBILIZATION; MOUSE FIBROBLASTS; G0/G1 TRANSITION; SWISS 3T3-CELLS	It has become increasingly clear that agents classically thought to act as neurotransmitters can also alter gene expression. To understand the early events by which neurotransmitters could effect genetic responses, we have studied the induction of two immediate early genes, c-fos and c-jun. These genes encode proteins that form a dimeric complex (AP-1) active as a transcriptional factor. Using the stable acetylcholine analog carbachol to activate muscarinic receptors (mAChR) in a glial cell line (1321N1), we show that c-fos and c-jun mRNA levels are transiently increased, reaching a maximum at 30 min after agonist addition. Experiments in which the actions of carbachol are blocked by adding atropine at various times demonstrate that only 1.5 min of agonist stimulation is needed to give maximal increases in c-fos or c-jun mRNA at 30 min. These results suggest that events previously shown to occur in the first minute of mAChR occupation (the mobilization of intracellular Ca2+, activation of protein kinase C) are sufficient for induction of these immediate early genes. In cells in which protein kinase C has been down-regulated, carbachol no longer stimulates c-fos or c-jun expression, indicating a critical role for protein kinase C in these responses. In cells loaded with bis-(omicron-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid (BAPTA) to buffer increases in cytosolic [Ca2+], mAChR-mediated induction of c-fos is markedly reduced; in contrast there is enhanced c-jun expression. The strong enhancement of c-jun induction by carbachol in BAPTA-treated cells is due at least in part to mRNA stabilization. Experiments using phorbol ester (phorbol 12-myristate 13-acetate) in combination with the Ca2+ ionophore ionomycin confirm that activation of protein kinase C induces c-fos and c-jun expression and that a concomitant increase in cytosolic [Ca2+] potentiates the induction of c-fos while repressing that of c-jun. The data suggest that the ability of neurotransmitters or growth factors to mobilize Ca2+ would modulate the effect of concomitant protein kinase C activation on AP-1 generation and consequent target gene expression.	UNIV CALIF SAN DIEGO,DEPT PHARMACOL,0636,LA JOLLA,CA 92093	University of California System; University of California San Diego				TREJO, JOANN/0000-0003-4405-6228	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036927] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 36927] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBRECHT G, 1984, J MOL BIOL, V178, P881, DOI 10.1016/0022-2836(84)90317-6; ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; AMBLER SK, 1987, MOL PHARMACOL, V32, P376; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ARENANDER AT, 1989, J NEUROSCI RES, V24, P107, DOI 10.1002/jnr.490240115; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, SCIENCE, V234, P80, DOI 10.1126/science.3749894; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HEPLER JR, 1987, BIOCHEM J, V247, P793, DOI 10.1042/bj2470793; JACKSON TR, 1989, FEBS LETT, V251, P27, DOI 10.1016/0014-5793(89)81422-X; JACKSON TR, 1988, NATURE, V335, P437, DOI 10.1038/335437a0; JULIUS D, 1990, P NATL ACAD SCI USA, V87, P928, DOI 10.1073/pnas.87.3.928; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; KUJUBU DA, 1987, ONCOGENE, V1, P257; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; MAKI Y, 1987, P NATL ACAD SCI USA, V84, P2848, DOI 10.1073/pnas.84.9.2848; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MARTINSON EA, 1989, J BIOL CHEM, V264, P14748; MCCAFFREY P, 1987, J BIOL CHEM, V262, P1442; MCDONOUGH PM, 1988, BIOCHEM J, V249, P135, DOI 10.1042/bj2490135; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, CELL, V52, P471, DOI 10.1016/S0092-8674(88)80039-4; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; ROZENGURT E, 1987, J CELL PHYSIOL, V131, P218, DOI 10.1002/jcp.1041310211; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SUBRAMANIAM M, 1989, NATURE, V340, P64, DOI 10.1038/340064a0; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; TRILIVAS I, 1989, J BIOL CHEM, V264, P3102; TRILIVAS I, 1991, IN PRESS J BIOL CHEM, V266; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANDENPLAS ML, 1990, BIOCHEM J, V267, P349, DOI 10.1042/bj2670349; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183	58	108	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7876	7882						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902229				2022-12-25	WOS:A1991FJ34200087
J	ROSENBERG, L; CHOI, HU; TANG, LH; PAL, S; JOHNSON, T; LYONS, DA; LAUE, TM				ROSENBERG, L; CHOI, HU; TANG, LH; PAL, S; JOHNSON, T; LYONS, DA; LAUE, TM			PROTEOGLYCANS OF BOVINE ARTICULAR-CARTILAGE - THE EFFECTS OF DIVALENT-CATIONS ON THE BIOCHEMICAL-PROPERTIES OF LINK PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FETAL EPIPHYSEAL CARTILAGE; HYALURONIC-ACID; BINDING REGION; AGGREGATION	In cartilage proteoglycan aggregates, link protein stabilizes the binding of proteoglycan monomers to hyaluronate by binding simultaneously to hyaluronate and to the G1 globular domain of proteoglycan monomer core protein. Studies reported here involving metal chelate affinity chromatography demonstrate that link protein is a metalloprotein that binds Zn2+, Ni2+, and Co2+. Zn2+ and Ni2+ decrease the solubility of link protein and result in its precipitation. However, link protein is readily soluble and functional in low ionic strength solvents from which divalent cations have been removed with Chelex 100. These observations make it possible to study the biochemical properties of link protein in low ionic strength, physiologic solvents. Studies were carried out to define the oligomeric state of link protein alone in physiologic solvents, and the transformation in oligomeric state that occurs when link protein binds hyaluronate. Sedimentation equilibrium studies demonstrate that in 0.15 M NaCl, 5 mM EDTA, 50 mM Tris, pH 7, link protein exists as a monomer-hexamer equilibrium controlled by a formation constant of 2 x 10(27) M-5, yielding a DELTA-G' of -36 kcal/mol for the formation of the hexamer from six monomers. On binding hyaluronate oligosaccharides (HA10 or HA12), link protein dissociates to dimer. Link protein hexamer is rendered insoluble by Zn2+. Greater than 90% of the protein is precipitated by 2 mol of Zn2+/mol of link protein monomer. The binding of hyaluronate oligosaccharide by link protein strongly inhibits the precipitation of link protein by Zn2+. The link protein/hyaluronate oligosaccharide complex is completely soluble in the presence of 2 mol of Zn2+/mol of link protein. At higher molar ratios of Zn2+/link protein, the inhibitory effect of hyaluronate oligosaccharide on the precipitation of link protein is gradually overcome. Hyaluronate oligosaccharide is not dissociated from link protein by Zn2+. Hyaluronate remains bound to the link protein which is precipitated by Zn2+, or to the link protein which binds to Zn2+-charged iminodiacetate-Sepharose columns. Hyaluronate oligosaccharides and Zn2+ bind to different sites on link protein.	UNIV NEW HAMPSHIRE,DEPT BIOCHEM,DURHAM,NH 03824	University System Of New Hampshire; University of New Hampshire	ROSENBERG, L (corresponding author), MONTEFIORE MED CTR,BRONX,NY 10467, USA.		Laue, Tom/AAI-5136-2020	Laue, Tom/0000-0003-3571-9368	NIAMS NIH HHS [AR 21498, AR 34614] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR034614, R37AR021498] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARAKAWA T, 1987, J BIOL CHEM, V262, P7484; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BONNET F, 1985, BIOCHEM J, V228, P77, DOI 10.1042/bj2280077; BUCKWALTER JA, 1983, COLLAGEN REL RES, V3, P489; BUCKWALTER JA, 1982, J BIOL CHEM, V257, P9830; CROUCH TH, 1980, BIOCHEMISTRY-US, V19, P3692, DOI 10.1021/bi00557a009; HARDINGHAM TE, 1974, BIOCHEM J, V139, P565, DOI 10.1042/bj1390565; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HASCALL VC, 1982, METHOD ENZYMOL, V82, P769; HEINEGARD D, 1972, BIOCHIM BIOPHYS ACTA, V285, P181, DOI 10.1016/0005-2795(72)90190-0; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HOILAND H, 1986, THERMODYNAMIC DATA B, P129; JOHNSON ML, 1981, BIOPHYS J, V36, P575, DOI 10.1016/S0006-3495(81)84753-4; JOHNSON ML, 1985, METHOD ENZYMOL, V117, P302; KIMURA JH, 1980, J BIOL CHEM, V255, P7134; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Laue T. M, 1981, THESIS U CONNECTICUT; LAUE TM, 1984, BIOCHEMISTRY-US, V23, P1339, DOI 10.1021/bi00302a001; LYON M, 1983, BIOCHEM J, V213, P445, DOI 10.1042/bj2130445; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PERIN JP, 1987, J BIOL CHEM, V262, P13269; ROSENBERG L, 1988, J BIOL CHEM, V263, P18071; ROSENBERG L, 1975, J BIOL CHEM, V250, P1877; TANG LH, 1979, J BIOL CHEM, V254, P523; TANG LH, 1989, CONNECT TISSUE RES, V19, P177, DOI 10.3109/03008208909043896; TENGBLAD A, 1981, BIOCHEM J, V199, P297, DOI 10.1042/bj1990297; WEAST RC, 1986, HDB CHEM PHYSICS; WILLIAMS RC, 1972, ANAL BIOCHEM, V48, P164, DOI 10.1016/0003-2697(72)90180-7; YPHANTIS DA, 1960, ANN NY ACAD SCI, V88, P586, DOI 10.1111/j.1749-6632.1960.tb20055.x	31	27	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7016	7024						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1901860				2022-12-25	WOS:A1991FG72700059
J	HO, MF; BAHLER, M; CZERNIK, AJ; SCHIEBLER, W; KEZDY, FJ; KAISER, ET; GREENGARD, P				HO, MF; BAHLER, M; CZERNIK, AJ; SCHIEBLER, W; KEZDY, FJ; KAISER, ET; GREENGARD, P			SYNAPSIN-I IS A HIGHLY SURFACE-ACTIVE MOLECULE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; TERMINAL-SPECIFIC PHOSPHOPROTEIN; SMALL SYNAPTIC VESICLES; LENGTH-FUNCTION CORRELATION; AIR-WATER-INTERFACE; PROTEIN KINASE-II; TETRATETRACONTAPEPTIDE SEGMENT; AMPHIPHILIC PEPTIDES; CIRCULAR-DICHROISM; F-ACTIN	Synapsin I is a neuron-specific phosphoprotein localized on the surface of small synaptic vesicles to which it binds with high affinity (K(d) = 10 nM). Synapsin I exhibits a tendency to self-associate, suggesting that it might have amphiphilic properties. We have now found that synapsin I forms a stable monolayer at an air-water interface which can be compressed under a lateral force of up to 60 dynes/cm, indicating the presence of amphiphilic characteristics in its structure. This interpretation was also supported by circular dichroism spectra of synapsin I, which showed induction of secondary structure in the presence of trifluoroethanol. The various phosphorylated forms of synapsin I did not show any noticeable differences in the force-area isotherms. The monolayer properties of synapsin I fragments derived by cysteine-specific cleavage indicated the presence of amphiphilic characteristics throughout the entire sequence, although the C-terminal region showed less of such surfactant properties. Compositional studies of these fragments revealed that there is little interaction between the N-terminal and middle fragment regions, but that there may be some interaction between the C-terminal and middle fragment regions which affects the surface area occupied by these fragments. Based on this information, we propose a molecular topology for synapsin I consisting of amphiphilic regions and a hydrophilic region.	ROCKEFELLER UNIV,1230 YORK AVE,NEW YORK,NY 10021; SUNY BUFFALO,DEPT MED CHEM,BUFFALO,NY 14260; UNIV CHICAGO,DEPT BIOCHEM,CHICAGO,IL 60639	Rockefeller University; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; University of Chicago			Ho, Mengfei/Q-6844-2019	Ho, Mengfei/0000-0002-8315-8158				ADAMSON AW, 1982, PHYSICAL CHEM SURFAC, pCH3; BAHLER M, 1987, NATURE, V326, P704, DOI 10.1038/326704a0; BAHLER M, 1989, J CELL BIOL, V108, P1841, DOI 10.1083/jcb.108.5.1841; BENFENATI F, 1989, J CELL BIOL, V108, P1863, DOI 10.1083/jcb.108.5.1863; BENFENATI F, 1989, J CELL BIOL, V108, P1851, DOI 10.1083/jcb.108.5.1851; CZERNIK AJ, 1987, P NATL ACAD SCI USA, V84, P7518, DOI 10.1073/pnas.84.21.7518; DECAMILLI P, 1983, J CELL BIOL, V96, P1337, DOI 10.1083/jcb.96.5.1337; DECAMILLI P, 1990, ANNU REV CELL BIOL, V6, P433, DOI 10.1146/annurev.cellbio.6.1.433; DECAMILLI P, 1983, J CELL BIOL, V96, P1355, DOI 10.1083/jcb.96.5.1355; DECAMILLI P, 1986, BIOCHEM PHARMACOL, V35, P4349, DOI 10.1016/0006-2952(86)90747-1; DEGRADO WF, 1985, J AM CHEM SOC, V107, P7684, DOI 10.1021/ja00311a076; EISENBERG D, 1984, ANNU REV BIOCHEM, V53, P595, DOI 10.1146/annurev.bi.53.070184.003115; FUKUSHIMA D, 1980, J BIOL CHEM, V255, P651; HENNESSEY JP, 1981, BIOCHEMISTRY-US, V20, P1085, DOI 10.1021/bi00508a007; HUTTNER WB, 1981, J BIOL CHEM, V256, P1482; HUTTNER WB, 1983, J CELL BIOL, V96, P1374, DOI 10.1083/jcb.96.5.1374; KACZMAREK LK, 1980, P NATL ACAD SCI-BIOL, V77, P7487, DOI 10.1073/pnas.77.12.7487; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LLINAS R, 1985, P NATL ACAD SCI USA, V82, P3035, DOI 10.1073/pnas.82.9.3035; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MATSUDAIRA P, 1985, P NATL ACAD SCI USA, V82, P6788, DOI 10.1073/pnas.82.20.6788; MCGUINNESS TL, 1985, J BIOL CHEM, V260, P1696; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NAKAGAWA SH, 1985, J AM CHEM SOC, V107, P7087, DOI 10.1021/ja00310a055; NAKAGAWA Y, 1983, J BIOL CHEM, V258, P2594; NAVONE F, 1984, SCIENCE, V226, P1209, DOI 10.1126/science.6438799; OSTERMAN D, 1984, J AM CHEM SOC, V106, P6845, DOI 10.1021/ja00334a065; OSTERMAN D, 1985, THESIS U CHICAGO; OTVOS L, 1988, J PROTEIN CHEM, V7, P365, DOI 10.1007/BF01024886; SCHIEBLER W, 1986, J BIOL CHEM, V261, P8383; SHEN BW, 1980, BIOCHEMISTRY-US, V19, P3643, DOI 10.1021/bi00557a001; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; SUDHOF TC, 1989, SCIENCE, V245, P1474, DOI 10.1126/science.2506642; TAYLOR JW, 1990, BIOCHEMISTRY-US, V29, P5364, DOI 10.1021/bi00474a023; UEDA T, 1977, J BIOL CHEM, V252, P5155; WALLACE BA, 1984, P NATL ACAD SCI-BIOL, V81, P1406, DOI 10.1073/pnas.81.5.1406; WATTERSON DM, 1976, J BIOL CHEM, V251, P4501; YAMASHIRO D, 1978, J AM CHEM SOC, V100, P5174, DOI 10.1021/ja00484a045; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	44	24	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5600	5607						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1900836				2022-12-25	WOS:A1991FD37000039
J	CHEN, JM; HELLER, D; POON, B; KANG, L; WANG, LH				CHEN, JM; HELLER, D; POON, B; KANG, L; WANG, LH			THE PROTOONCOGENE C-ROS CODES FOR A TRANSMEMBRANE TYROSINE PROTEIN-KINASE SHARING SEQUENCE AND STRUCTURAL HOMOLOGY WITH SEVENLESS PROTEIN OF DROSOPHILA-MELANOGASTER	ONCOGENE			English	Article							AVIAN-SARCOMA VIRUS-UR2; HUMAN INSULIN-RECEPTOR; NUCLEOTIDE-SEQUENCE; TRANSFORMING SEQUENCE; GENETIC-STRUCTURE; C-ROS-1 GENE; SRC GENE; EXPRESSION; CDNA; PRODUCT	Our earlier study predicted that proto-oncogene c-ros codes for a receptor-like tyrosine protein kinase (TPK). To further understand its protein structure and physiological function, we have analysed its expression in various tissues of chicken and have isolated and sequenced cDNA clones containing the entire coding region of the gene. Confirming our earlier study, we found that kidney is the organ that expresses the highest level of c-ros mRNA, in addition, we found a lower level of expression in gonad, thymus, bursa and brain. A distinctive 8.3 kb c-ros mRNA is present in kidney. No detectable amount of c-ros mRNA was found in the rest of tissues examined. Nucleotide sequence of the c-ros cDNA predicts that it codes for a transmembrane (TM) TPK molecule of 2311 amino acids (aa). The extracellular domain consists of 1873 amino acids which share 20 to 43% homology with that of the Drosophila sevenless protein and TPK domains of the two genes have 58 to 74% homology. The extracellular domain containing 37 potential N-linked glycosylation sites is preceded by a 5' hydrophobic sequence resembling a typical signal peptide. An internal hydrophobic domain of 26 amino acids, the presumed transmembrane domain, is followed by a spacer sequence of 58 amino acids, a TPK domain of 270 amino acids and a carboxyl tail of 84 amino acids. Overall, our result indicates that c-ros codes for a glycosylated transmembrane TPK molecule which shares a remarkable sequence and structural homology with that of Drosophila sevenless protein.	CUNY MT SINAI SCH MED,DEPT MICROBIOL,ONE GUSTAVE L LEVY PL,NEW YORK,NY 10029	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai					NCI NIH HHS [CA29339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BASLER K, 1988, CELL, V54, P299; BESMER P, 1986, NATURE, V320, P415, DOI 10.1038/320415a0; BIRCHMEIER C, 1990, P NATL ACAD SCI USA, V87, P4799, DOI 10.1073/pnas.87.12.4799; BIRCHMEIER C, 1987, P NATL ACAD SCI USA, V84, P9270, DOI 10.1073/pnas.84.24.9270; BIRCHMEIER C, 1986, MOL CELL BIOL, V6, P1122; BOWTELL DDL, 1988, GENE DEV, V2, P620, DOI 10.1101/gad.2.6.620; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; DORAI T, 1990, MOL CELL BIOL, V10, P4068, DOI 10.1128/MCB.10.8.4068; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FELDMAN RA, 1982, J VIROL, V42, P228, DOI 10.1128/JVI.42.1.228-236.1982; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; HAMPE A, 1984, P NATL ACAD SCI-BIOL, V81, P85, DOI 10.1073/pnas.81.1.85; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JONG SMJ, 1987, ONCOGENE RES, V1, P7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; MATSUSHIME H, 1990, J VIROL, V64, P2117, DOI 10.1128/JVI.64.5.2117-2125.1990; MATSUSHIME H, 1986, MOL CELL BIOL, V6, P3000, DOI 10.1128/MCB.6.8.3000; NAGARAJAN L, 1986, P NATL ACAD SCI USA, V83, P6568, DOI 10.1073/pnas.83.17.6568; NECKAMEYER WS, 1985, J VIROL, V53, P879, DOI 10.1128/JVI.53.3.879-884.1985; NECKAMEYER WS, 1986, MOL CELL BIOL, V6, P1478, DOI 10.1128/MCB.6.5.1478; PODELL SB, 1987, ONCOGENE, V2, P9; REINKE R, 1988, CELL, V55, P321, DOI 10.1016/0092-8674(88)90055-4; RUBIN GM, 1989, CELL, V57, P519, DOI 10.1016/0092-8674(89)90120-7; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHARMA S, 1989, ONCOGENE RES, V5, P91; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIBUYA M, 1982, J VIROL, V42, P143, DOI 10.1128/JVI.42.1.143-152.1982; SIMON MA, 1989, P NATL ACAD SCI USA, V86, P8333, DOI 10.1073/pnas.86.21.8333; TAKEYA T, 1983, CELL, V32, P881, DOI 10.1016/0092-8674(83)90073-9; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1977, SCIENCE, V196, P1313, DOI 10.1126/science.325648; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LH, 1981, J VIROL, V40, P258, DOI 10.1128/JVI.40.1.258-267.1981; WANG LH, 1982, J VIROL, V41, P833, DOI 10.1128/JVI.41.3.833-841.1982; WATSON CJ, 1985, DNA CLONING PRACTICA, V1, P79; WOOLFORD J, 1988, CELL, V55, P965, DOI 10.1016/0092-8674(88)90242-5	40	37	43	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					257	264						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900358				2022-12-25	WOS:A1991FZ13400011
J	FUJITA, H; YAMAMOTO, M; YAMAGAMI, T; HAYASHI, N; SASSA, S				FUJITA, H; YAMAMOTO, M; YAMAGAMI, T; HAYASHI, N; SASSA, S			ERYTHROLEUKEMIA DIFFERENTIATION - DISTINCTIVE RESPONSES OF THE ERYTHROID-SPECIFIC AND THE NONSPECIFIC DELTA-AMINOLEVULINATE SYNTHASE MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICALLY DEFINED MEDIUM; EMBRYO LIVER-CELLS; 5-AMINOLEVULINATE SYNTHASE; HEME-BIOSYNTHESIS; RAT-LIVER; ACID SYNTHETASE; GENE-EXPRESSION; X-CHROMOSOME; INDUCTION; DEHYDRATASE	We have examined the levels of delta-aminolevulinate synthase (ALAS) mRNAs encoding the erythroid-specific (ALAS-E) and the nonspecific (ALAS-N) ALAS isozymes in murine Friend virus-transformed erythroleukemia (MEL) cells. Both ALAS-E and ALAS-N mRNAs were detected in a clone of dimethyl sulfoxide (Me2SO)-sensitive MEL cells, termed DS-19, without cross-hybridization. Untreated DS-19 cells contained almost-equal-to 10-fold more ALAS-E mRNA than ALAS-N mRNA. When DS-19 cells were treated with Me2SO or hemin, ALAS-N mRNA declined rapidly, which was followed by a marked increase in ALAS-E mRNA. Similarly, the immunoquantifiable ALAS-N protein decreased, while the ALAS-E protein increased upon Me2SO treatment. A clone of Me2SO-resistant cells, termed DR-1, which fails to undergo erythroid differentiation, was found to lack ALAS-E mRNA, whereas it showed significant induction responses of mRNAs for other heme pathway enzymes by Me2SO treatment. DR-1 cells contained a similar level of an erythroid-specific transcription factor, GATA-1, as did DS-19 cells, and had neither major deletion nor rearrangement of the ALAS-E gene. These findings indicate that the genes encoding the two ALAS isozymes are under separate controls and suggest that ALAS-E mRNA accumulation is responsible for increased heme synthesis in MEL cells undergoing erythroid differentiation.	ROCKEFELLER UNIV HOSP,NEW YORK,NY 10021; TOHOKU UNIV,SCH MED,DEPT BIOCHEM,SENDAI,MIYAGI 980,JAPAN	Rockefeller University; Tohoku University			Yamamoto, Masayuki/A-4873-2010	Yamamoto, Masayuki/0000-0002-9073-9436	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032890] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-32890] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BISHOP DF, 1981, ARCH BIOCHEM BIOPHYS, V206, P380, DOI 10.1016/0003-9861(81)90105-3; BISHOP DF, 1990, GENOMICS, V7, P207, DOI 10.1016/0888-7543(90)90542-3; BISHOP TR, 1986, P NATL ACAD SCI USA, V83, P5568, DOI 10.1073/pnas.83.15.5568; COX TC, 1990, AM J HUM GENET, V46, P107; DAVIS LG, 1986, BASIS METHODS MOL BI; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DEVERNEUIL H, 1986, J CLIN INVEST, V77, P431, DOI 10.1172/JCI112321; ELFERINK CJ, 1987, J BIOL CHEM, V262, P3988; ELFERINK CJ, 1988, J BIOL CHEM, V263, P13012; FRASER PJ, 1987, GENE DEV, V1, P855, DOI 10.1101/gad.1.8.855; FRIEND C, 1971, P NATL ACAD SCI USA, V68, P378; FUJITA H, 1984, BIOCHIM BIOPHYS ACTA, V800, P1, DOI 10.1016/0304-4165(84)90087-4; FUJITA H, 1983, BRIT J HAEMATOL, V73, P557; GRANDCHAMP B, 1986, C INSERM, V134, P35; GRANICK JL, 1978, J BIOL CHEM, V253, P5402; GRANICK S, 1975, J BIOL CHEM, V250, P9215; GUSELLA J, 1976, CELL, V9, P221, DOI 10.1016/0092-8674(76)90113-6; HENSOLD JO, 1988, MOL CELL BIOL, V8, P2219, DOI 10.1128/MCB.8.5.2219; HOFFMAN R, 1980, BLOOD, V56, P567; ISHIDA N, 1990, BIOCHEM BIOPH RES CO, V172, P237, DOI 10.1016/S0006-291X(05)80199-8; KAPPAS A, 1989, METABOLIC BASIS INHE, P1305; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Maniatis T., 1982, MOL CLONING; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MIGNOTTE V, 1989, P NATL ACAD SCI USA, V86, P6548, DOI 10.1073/pnas.86.17.6548; OHTA Y, 1976, P NATL ACAD SCI USA, V73, P1232, DOI 10.1073/pnas.73.4.1232; RIDDLE RD, 1989, P NATL ACAD SCI USA, V86, P792, DOI 10.1073/pnas.86.3.792; ROSS J, 1976, CELL, V8, P513, DOI 10.1016/0092-8674(76)90219-1; ROSS J, 1972, P NATL ACAD SCI USA, V69, P3620, DOI 10.1073/pnas.69.12.3620; ROUGEON F, 1977, GENE, V1, P229, DOI 10.1016/0378-1119(77)90047-6; RUTHERFORD T, 1979, P NATL ACAD SCI USA, V76, P833, DOI 10.1073/pnas.76.2.833; SASSA S, 1983, J CLIN INVEST, V71, P625, DOI 10.1172/JCI110809; SASSA S, 1970, P NATL ACAD SCI USA, V67, P517, DOI 10.1073/pnas.67.2.517; SASSA S, 1976, J EXP MED, V143, P305, DOI 10.1084/jem.143.2.305; SASSA S, 1977, J BIOL CHEM, V252, P2428; SASSA S, 1983, REGULATION HEMOGLOBI, P359; SASSA S, 1990, MOL BIOL HEMATOPOIES, P413; SCHOENHAUT DS, 1989, NUCLEIC ACIDS RES, V17, P7013, DOI 10.1093/nar/17.17.7013; SCHOENHAUT DS, 1986, GENE, V48, P55, DOI 10.1016/0378-1119(86)90351-3; SHIBAHARA S, 1988, SEMIN HEMATOL, V25, P370; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SRIVASTAVA G, 1988, J BIOL CHEM, V263, P5202; SUTHERLAND GR, 1988, AM J HUM GENET, V43, P331; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; TSCHUDY DP, 1981, J BIOL CHEM, V256, P9915; WADA D, 1967, BIOCHIM BIOPHYS ACTA, V148, P585; WATANABE N, 1983, BIOCHEM BIOPH RES CO, V113, P377, DOI 10.1016/0006-291X(83)91737-0; WHITING MJ, 1976, J BIOL CHEM, V251, P1347; WOODS JS, 1975, MOL PHARMACOL, V11, P70; YAMAGAMI T, 1989, SEIKAGAKU, V61, P817; YAMAMOTO M, 1986, ARCH BIOCHEM BIOPHYS, V245, P76, DOI 10.1016/0003-9861(86)90191-8; YAMAMOTO M, 1985, P NATL ACAD SCI USA, V82, P3702, DOI 10.1073/pnas.82.11.3702; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YAMAMOTO M, 1988, J BIOL CHEM, V263, P15973; 1990, ECL W BLOTTING DETEC	57	84	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17494	17502						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894633				2022-12-25	WOS:A1991GF44500077
J	MOLDRUP, A; ALLEVATO, G; DYRBERG, T; NIELSEN, JH; BILLESTRUP, N				MOLDRUP, A; ALLEVATO, G; DYRBERG, T; NIELSEN, JH; BILLESTRUP, N			GROWTH-HORMONE ACTION IN RAT INSULINOMA CELLS EXPRESSING TRUNCATED GROWTH-HORMONE RECEPTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLACTIN RECEPTOR; BINDING-PROTEIN; CLONING; PURIFICATION; ADIPOCYTES; SEQUENCE; LIVER; INTERNALIZATION; IDENTIFICATION; MODEL	Transfection of the insulin-producing rat islet tumor cell line RIN-5AH with a full length cDNA of the rat hepatic growth hormone (GH) receptor (GH-R1-638) augments the GH-responsive insulin synthesis in these cells. Using this functional system we analyzed the effect of COOH-terminal truncation of the GH receptor. Two mutated cDNAs encoding truncated GH receptors, GH-R1-294 and GH-R1-454, respectively, were generated by site-directed mutagenesis and transfected into the RIN cells. Both receptor mutants were expressed on the cell surface and displayed normal GH binding affinity. Whereas GH-R1-638 had a molecular mass of about 110 kDa, GH-R1-294 and GH-R1-454 showed molecular masses of 49 and 80 kDa, respectively. Cells expressing GH-R1-454 internalized GH to a similar extent as cells transfected with the full length receptor and the parent cell line, but GH-R1-294-expressing cells showed a markedly reduced capability of GH internalization. In contrast to cells transfected with GH-R1-638, none of the cell lines expressing truncated GH receptors exhibited any increase of the GH-stimulated insulin production. We conclude that domains within the COOH-terminal half of the cytoplasmic part of the GH receptor are required for transduction of the signal for GH-stimulated insulin synthesis, whereas cytoplasmic domains proximal to the transmembrane region are involved in receptor-mediated GH internalization.			MOLDRUP, A (corresponding author), HAGEDORN RES LAB, NIELS STEENSSENS VEJ 6, DK-2820 GENTOFTE, DENMARK.			Nielsen, Jens Hoiriis/0000-0001-8252-3048; Billestrup, Nils/0000-0002-4968-8067				BACKER JM, 1990, J BIOL CHEM, V265, P16450; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; BILLESTRUP N, 1985, ENDOCRINOLOGY, V116, P1175, DOI 10.1210/endo-116-3-1175; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; BOUTIN JM, 1989, MOL ENDOCRINOL, V3, P1455, DOI 10.1210/mend-3-9-1455; CATALIOTO RM, 1990, BIOCHEM BIOPH RES CO, V173, P840, DOI 10.1016/S0006-291X(05)80863-0; COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DONNER DB, 1983, J BIOL CHEM, V258, P2736; EDERY M, 1989, P NATL ACAD SCI USA, V86, P2112, DOI 10.1073/pnas.86.6.2112; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; GORIN E, 1984, ENDOCRINOLOGY, V114, P1279, DOI 10.1210/endo-114-4-1279; HAUSER SD, 1990, MOL CELL ENDOCRINOL, V72, P187, DOI 10.1016/0303-7207(90)90143-V; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HOCQUETTE JF, 1990, ENDOCRINOLOGY, V127, P1665, DOI 10.1210/endo-127-4-1665; HUGHES JP, 1983, ENDOCRINOLOGY, V112, P1980, DOI 10.1210/endo-112-6-1980; HUSMAN B, 1989, J BIOL CHEM, V264, P690; KARLSEN A, 1990, J IMMUNOL METHODS, V128, P151, DOI 10.1016/0022-1759(90)90205-A; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; MATHEWS LS, 1989, J BIOL CHEM, V264, P9905; MOLDRUP A, 1990, J BIOL CHEM, V265, P8686; MOLDRUP A, 1989, MOL ENDOCRINOL, V3, P1173, DOI 10.1210/mend-3-8-1173; NIELSEN JH, 1989, MOL ENDOCRINOL, V3, P165, DOI 10.1210/mend-3-1-165; NIELSEN JH, 1982, ENDOCRINOLOGY, V110, P600, DOI 10.1210/endo-110-2-600; ROUPAS P, 1986, MOL CELL ENDOCRINOL, V47, P81, DOI 10.1016/0303-7207(86)90018-3; SERUP P, 1989, DIABETOLOGIA, V32, P409, DOI 10.1007/BF00271259; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SMAL J, 1989, P NATL ACAD SCI USA, V86, P4705, DOI 10.1073/pnas.86.12.4705; SMITH WC, 1988, MOL ENDOCRINOL, V2, P108, DOI 10.1210/mend-2-2-108; SMITH WC, 1989, MOL ENDOCRINOL, V3, P984, DOI 10.1210/mend-3-6-984; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; THIES RS, 1989, J BIOL CHEM, V264, P12820; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0	36	60	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17441	17445						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894631				2022-12-25	WOS:A1991GF44500070
J	STADTMAN, ER; BERLETT, BS				STADTMAN, ER; BERLETT, BS			FENTON CHEMISTRY - AMINO-ACID OXIDATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MIXED-FUNCTION OXIDATION; COLI GLUTAMINE-SYNTHETASE; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; ESCHERICHIA-COLI; OXYGEN RADICALS; XANTHINE-OXIDASE; PROTEIN DAMAGE; CATALYZED OXIDATION; HYDROXYL RADICALS	The oxidation of amino acids by Fenton reagent (H2O2 + Fe(II)) leads mainly to the formation of NH4+, alpha-ketoacids, CO2, oximes, and aldehydes or carboxylic acids containing one less carbon atom. Oxidation is almost completely dependent on the presence of bicarbonate ion and is stimulated by iron chelators at levels which are substoichiometric with respect to the iron concentration but is inhibited at higher concentrations. The stimulatory effect of chelators is not due merely to solubilization of catalytically inactive polymeric forms of Fe(OH)3 nor to the conversion of Fe(II) to complexes incapable of scavenging hydroxyl radicals. The results suggest that an iron chelate and another as yet unidentified form of iron are both required for maximal rates of amino acid oxidation. The metal ion-catalyzed oxidation of amino acids is likely a "caged" process, since the oxidation is not inhibited by hydroxyl radical scavengers, and the relative rates of oxidation of various amino acids by the Fenton system as well as the distribution of products formed (especially products of aromatic amino acids) are significantly different from those reported for amino acid oxidation by ionizing radiation. Several iron-binding proteins, peptides, and hemoglobin degradation products can replace Fe(II) or Fe(III) in the bicarbonate-dependent oxidation of amino acids. In view of their ability to sequester metal ions and their susceptibility to oxidation by H2O2 in the presence of physiological concentrations of bicarbonate, amino acids may serve an important role in antioxidant defense against tissue damage.			STADTMAN, ER (corresponding author), NHLBI,BIOCHEM LAB,BLDG 3,RM 222,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							ALEXANDER P, 1961, RADIAT RES, V15, P475, DOI 10.2307/3571291; AMICI A, 1989, J BIOL CHEM, V264, P3341; ANBAR M, 1967, INT J APPL RADIAT IS, V18, P493, DOI 10.1016/0020-708X(67)90115-9; BEHAR D, 1970, J PHYS CHEM-US, V74, P2206, DOI 10.1021/j100909a029; BERLETT BS, 1990, P NATL ACAD SCI USA, V87, P389, DOI 10.1073/pnas.87.1.389; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BRAUGHLER JM, 1988, BIOCHEM BIOPH RES CO, V153, P933, DOI 10.1016/S0006-291X(88)81317-2; BUCHER JR, 1983, FUND APPL TOXICOL, V3, P222, DOI 10.1016/S0272-0590(83)80130-4; Dakin HD, 1908, J BIOL CHEM, V4, P63; DAKIN HD, 1905, J BIOL CHEM, V1, P271; DAKIN HD, 1905, J BIOL CHEM, V1, P171; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1988, FREE RADICAL BIO MED, V5, P215, DOI 10.1016/0891-5849(88)90015-9; DAVIES KJA, 1987, J BIOL CHEM, V262, P9902; DAVIES KJA, 1987, J BIOL CHEM, V262, P8227; FARBER JM, 1986, J BIOL CHEM, V261, P4574; FLETCHER GL, 1961, RADIAT RES, V15, P349, DOI 10.2307/3571239; FLITTER W, 1983, FEBS LETT, V158, P310, DOI 10.1016/0014-5793(83)80602-4; FUCCI L, 1983, P NATL ACAD SCI-BIOL, V80, P1521, DOI 10.1073/pnas.80.6.1521; GARRISON WARREN M., 1968, CURR TOP RADIAT RES, VVol. 4-4, P43; GARRISON WM, 1962, RADIAT RES, V16, P483, DOI 10.2307/3571084; GARRISON WM, 1964, RADIATION RES      S, V4, P158; GUTTERIDGE JMC, 1979, BIOCHEM J, V184, P469, DOI 10.1042/bj1840469; HALLIWELL B, 1986, ARCH BIOCHEM BIOPHYS, V246, P501, DOI 10.1016/0003-9861(86)90305-X; HODGSON EK, 1976, ARCH BIOCHEM BIOPHYS, V172, P202, DOI 10.1016/0003-9861(76)90067-9; Keene J. P., 1965, PULSE RADIOLYSIS, P99; LEVINE RL, 1981, P NATL ACAD SCI-BIOL, V78, P2120, DOI 10.1073/pnas.78.4.2120; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LIEBSTER J, 1966, RADIAT RES, V27, P162, DOI 10.2307/3571908; MAXWELL CR, 1955, RADIAT RES, V2, P431, DOI 10.2307/3570188; MAXWELL CR, 1954, RADIAT RES, V1, P530, DOI 10.2307/3570220; MINOTTI G, 1987, J BIOL CHEM, V262, P1098; OLIVER CN, 1987, ARCH BIOCHEM BIOPHYS, V253, P62, DOI 10.1016/0003-9861(87)90637-0; OLIVER CN, 1987, J BIOL CHEM, V262, P5488; OLIVER CN, 1990, P NATL ACAD SCI USA, V87, P5144, DOI 10.1073/pnas.87.13.5144; OLIVER CN, 1981, METABOLIC INTERCONVE, P259; OLIVER CN, 1985, CELLULAR REGULATION, P320; RIVETT AJ, 1985, J BIOL CHEM, V260, P300; ROSEMAN JE, 1987, J BIOL CHEM, V262, P2101; ROSEN H, 1981, ARCH BIOCHEM BIOPHYS, V208, P512, DOI 10.1016/0003-9861(81)90539-7; Scholes G., 1965, PULSE RADIOLYSIS, V68, P151; SCHUESSLER H, 1980, INT J RADIAT BIOL, V37, P71, DOI 10.1080/09553008014550071; SCHUESSLER H, 1984, INT J RADIAT BIOL, V45, P267, DOI 10.1080/09553008414550381; STADTMAN ER, 1986, TRENDS BIOCHEM SCI, V11, P11, DOI 10.1016/0968-0004(86)90221-5; STADTMAN ER, 1985, ARCH BIOCHEM BIOPHYS, V239, P379, DOI 10.1016/0003-9861(85)90703-9; STADTMAN ER, 1990, P NATL ACAD SCI USA, V87, P384, DOI 10.1073/pnas.87.1.384; STADTMAN ER, 1979, ANAL BIOCHEM, V95, P275, DOI 10.1016/0003-2697(79)90217-3; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; STADTMAN ER, 1988, J GERONTOL, V43, pB112, DOI 10.1093/geronj/43.5.B112; STADTMAN ER, 1989, OXYGEN RADICALS BIOL, P131; STARKEREED PE, 1989, ARCH BIOCHEM BIOPHYS, V275, P559, DOI 10.1016/0003-9861(89)90402-5; SUTTON HC, 1984, ARCH BIOCHEM BIOPHYS, V235, P106, DOI 10.1016/0003-9861(84)90259-5; SWALLOW AJ, 1960, RAD CHEM ORGANIC COM, P211; SYCHEV AY, 1978, ZH FIZ KHIM+, V52, P55; TIEN M, 1982, ARCH BIOCHEM BIOPHYS, V218, P450, DOI 10.1016/0003-9861(82)90367-8; UMBREIT WW, 1957, MANOMETRIC TECHNIQUE, P18; WINTERBOURN CC, 1986, ARCH BIOCHEM BIOPHYS, V244, P27, DOI 10.1016/0003-9861(86)90090-1; YIM MB, 1990, P NATL ACAD SCI USA, V87, P5006, DOI 10.1073/pnas.87.13.5006; YIM MB, 1990, P NATL ACAD SCI USA, V87, P394, DOI 10.1073/pnas.87.1.394; ZSNAGY I, 1984, BIOCHIM BIOPHYS ACTA, V790, P238, DOI 10.1016/0167-4838(84)90028-1	61	256	265	1	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17201	17211						11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894614				2022-12-25	WOS:A1991GF44500037
J	TAKASAKI, I; CHOBANIAN, AV; BRECHER, P				TAKASAKI, I; CHOBANIAN, AV; BRECHER, P			BIOSYNTHESIS OF FIBRONECTIN BY RABBIT AORTA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ENDOTHELIAL-CELL; EXTRACELLULAR-MATRIX; PLASMA FIBRONECTIN; HYPERTENSIVE RATS; MESSENGER-RNA; EXPRESSION; GROWTH; ARTERIES; INTIMA	The in vitro interactions between vascular cells and fibronectin have been shown to influence phenotypic expression of both cultured endothelial and smooth muscle cells. To more effectively assess the potential functional role of fibronectin in vivo in modulating vascular phenotypes, we have established methodology for studying fibronectin biosynthesis in the rabbit aorta using aortic rings that are morphologically and functionally intact and metabolically active. Aortic rings were incubated with S-35-labeled methionine in a supplemented physiological salt solution. The tissue was fractionated, and quantitative immunoprecipitation was performed using a polyclonal antibody directed against human plasma fibronectin. Newly synthesized fibronectin was most abundant in the fraction solubilized using 4% sodium dodecyl sulfate and in the incubation medium. In all fractions studied, fibronectin was present predominantly as a dimer with no detectable aggregates of fibronectin. Pulse-chase experiments showed that a substantial amount of newly synthesized fibronectin was found in the 4% sodium dodecyl sulfate extract after only 1 h, suggesting that fibronectin was rapidly incorporated into the extracellular matrix. The more soluble forms of newly synthesized fibronectin appeared to be the precursors for secreted fibronectin, and no precursor-product relationship between soluble and insoluble fibronectin was found. Dissection of aortic rings following incubation with labeled methionine showed that newly synthesized fibronectin was uniformally distributed in both intima-media and media-adventitia segments. Endothelial cell denudation caused only a 20% decrease of fibronectin biosynthesis concomitant with similar changes in total protein biosynthesis, consistent with the medial smooth muscle cell as the major source of newly synthesized fibronectin. Biosynthesis of fibronectin was increased following a 24-h preincubation of the aortic rings, and concomitant increases in steady state mRNA for fibronectin were found. These in vitro studies documented the utility of aortic rings for the general purpose of studying protein synthesis in vascular cells and provide new information on the characteristics of fibronectin biosynthesis by aortic tissue.	BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118	Boston University	TAKASAKI, I (corresponding author), BOSTON UNIV,SCH MED,DEPT MED,BOSTON,MA 02118, USA.			Brecher, Peter/0000-0002-9347-6643	NHLBI NIH HHS [HL31195, HL18318] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031195, P50HL018318, P60HL018318] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLATTI SP, 1988, P NATL ACAD SCI USA, V85, P1119, DOI 10.1073/pnas.85.4.1119; BOND JF, 1983, MOL CELL BIOL, V3, P1333, DOI 10.1128/MCB.3.8.1333; BOWERSOX JC, 1987, IN VITRO CELL DEV B, V23, P759, DOI 10.1007/BF02623677; BRAY BA, 1985, BIOCHEM J, V226, P811, DOI 10.1042/bj2260811; BRECHER P, 1978, CIRC RES, V43, P561, DOI 10.1161/01.RES.43.4.561; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI MG, 1979, J BIOL CHEM, V254, P2050; CLARK RAF, 1988, J BIOL CHEM, V263, P12115; CLARK RAF, 1982, J EXP MED, V156, P646, DOI 10.1084/jem.156.2.646; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; GLUKHOVA MA, 1990, DEV BIOL, V141, P193, DOI 10.1016/0012-1606(90)90114-X; GLUKHOVA MA, 1989, J CELL BIOL, V109, P357, DOI 10.1083/jcb.109.1.357; GRYGLEWSKI RJ, 1988, HYPERTENSION, V12, P530, DOI 10.1161/01.HYP.12.6.530; GUPTE A, 1990, IN VITRO CELL DEV B, V26, P57; HAGIWARA T, 1990, AM J PATHOL, V136, P39; HEDIN U, 1990, DIFFERENTIATION, V44, P222, DOI 10.1111/j.1432-0436.1990.tb00621.x; HERMAN IM, 1987, ARTERIOSCLEROSIS, V7, P463, DOI 10.1161/01.ATV.7.5.463; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; HYNES RO, 1977, P NATL ACAD SCI USA, V74, P2855, DOI 10.1073/pnas.74.7.2855; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; INGBER DE, 1990, P NATL ACAD SCI USA, V87, P3579, DOI 10.1073/pnas.87.9.3579; JAFFE EA, 1978, J EXP MED, V147, P1779, DOI 10.1084/jem.147.6.1779; JENSEN BA, 1983, HISTOCHEMISTRY, V77, P395, DOI 10.1007/BF00490900; KOHANE DS, 1990, AM J PHYSIOL, V258, pH1699, DOI 10.1152/ajpheart.1990.258.6.H1699; MADRI JA, 1988, J CELL BIOL, V106, P1375, DOI 10.1083/jcb.106.4.1375; MCKEOWNLONGO PJ, 1983, J CELL BIOL, V97, P466, DOI 10.1083/jcb.97.2.466; MCKEOWNLONGO PJ, 1984, J BIOL CHEM, V259, P2210; MECHAM RP, 1987, SCIENCE, V237, P423, DOI 10.1126/science.3603030; MERRILEES MJ, 1982, IN VITRO CELL DEV B, V18, P900, DOI 10.1007/BF02796346; OREKHOV AN, 1984, ATHEROSCLEROSIS, V53, P213, DOI 10.1016/0021-9150(84)90197-7; RASMUSSEN LH, 1989, VIRCHOWS ARCH A, V415, P579, DOI 10.1007/BF00718654; RASMUSSEN LM, 1989, LAB INVEST, V61, P440; RISAU W, 1988, DEV BIOL, V125, P441, DOI 10.1016/0012-1606(88)90225-4; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375, DOI 10.1146/annurev.bi.57.070188.002111; SARZANI R, 1989, J CLIN INVEST, V83, P1404, DOI 10.1172/JCI114029; SCHWARTZ SM, 1990, PHYSIOL REV, V70, P1177, DOI 10.1152/physrev.1990.70.4.1177; SCHWARZBAUER JE, 1989, J CELL BIOL, V109, P3445, DOI 10.1083/jcb.109.6.3445; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; SHEKHONIN BV, 1987, ATHEROSCLEROSIS, V67, P9, DOI 10.1016/0021-9150(87)90259-0; SMITH EB, 1986, BIOCHIM BIOPHYS ACTA, V880, P10, DOI 10.1016/0304-4165(86)90113-3; TAKASAKI I, 1990, AM J PHYSIOL, V259, pH442, DOI 10.1152/ajpheart.1990.259.2.H442; TAKASAKI I, 1990, J BIOL CHEM, V265, P21935; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TOZZI CA, 1989, J CLIN INVEST, V84, P1005, DOI 10.1172/JCI114221; VINCENT PA, 1989, AM J PHYSIOL, V257, pR1406; WOLINSKY H, 1970, P SOC EXP BIOL MED, V135, P364	47	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17686	17694						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894648				2022-12-25	WOS:A1991GF44500104
J	LAROCHE, Y; DEMAEYER, M; STASSEN, JM; GANSEMANS, Y; DEMARSIN, E; MATTHYSSENS, G; COLLEN, D; HOLVOET, P				LAROCHE, Y; DEMAEYER, M; STASSEN, JM; GANSEMANS, Y; DEMARSIN, E; MATTHYSSENS, G; COLLEN, D; HOLVOET, P			CHARACTERIZATION OF A RECOMBINANT SINGLE-CHAIN MOLECULE COMPRISING THE VARIABLE DOMAINS OF A MONOCLONAL-ANTIBODY SPECIFIC FOR HUMAN FIBRIN FRAGMENT D-DIMER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE PLASMINOGEN-ACTIVATOR; CROSS-LINKED FIBRIN; ESCHERICHIA-COLI; CROSSLINKED FIBRIN; EXPRESSION VECTORS; VENOUS THROMBI; INSECT CELLS; UROKINASE; BINDING; PROTEINS	A recombinant single-chain molecule, scFv-K12G0, containing the variable domains of the monoclonal antibody MA-15C5, specific for fragment D-dimer of human cross-linked fibrin, was constructed and expressed in Spodoptera frugiperda, Sf9, insect cells. The Arg108 carboxyl-terminal amino acid of the variable domain of the light-chain of the antibody was connected through a synthetic Ala-Gly-Gln-Gly-Ser-Ser-Val peptide linker with the Gln 1 amino-terminal amino acid of the variable domain of its heavy chain. scFv-K12G0 was secreted by the infected Sf9 cells at a rate of 10-mu-g/10(6) cells within 48 h, resulting in conditioned medium with a maximal concentration of 15 mg of scFv-K12G0/liter. The molecule, purified to homogeneity by ion exchange chromatography and gel filtration, migrated as a single M(r) band on reduced sodium dodecyl sulfate-gel electrophoresis. It bound to immobilized fragment D-dimer with an affinity constant of 4.0 x 10(9) m-1 (2.0 X 10(10) M-1 for intact MA15C5). Clearing of scFv-K12G0 from the circulation in rabbits occurred with an initial half-life (t1/2-alpha) of 10 min and a clearance of 5.1 ml min-1, as compared to 90 min and 210 ml min-1 for intact MA-15C5. Nephrectomy resulted in a prolongation of t1/2-alpha to 110 min, suggesting that the rapid clearance of scFv-K12G0 occurs primarily via the kidney, presumably by glomerular filtration. The results indicate that the single-chain recombinant molecule scFv-K12G0 is secreted in functionally intact form and suggest that it may be useful for targeting of radioisotopes or plasminogen activators to blood clots in vivo.	CATHOLIC UNIV LEUVEN,CTR THROMBOSIS & VASC RES,B-3000 LOUVAIN,BELGIUM; CORVAS INT NV,GHENT,BELGIUM	KU Leuven			HOLVOET, PAUL/T-8434-2017	HOLVOET, PAUL/0000-0001-9201-0772; Gansemans, Yannick/0000-0001-5018-044X				Atkinson T., 1984, OLIGONUCLEOTIDE SYNT, P35; BATRA JK, 1990, J BIOL CHEM, V265, P15198; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BETZEL C, 1988, ACTA CRYSTALLOGR B, V44, P163, DOI 10.1107/S010876818700939X; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; BODE C, 1989, J BIOL CHEM, V264, P944; BODE C, 1985, SCIENCE, V229, P765, DOI 10.1126/science.4023710; BODE C, 1987, J BIOL CHEM, V262, P10819; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BULENS F, 1991, EUR J BIOCHEM, V195, P235, DOI 10.1111/j.1432-1033.1991.tb15699.x; CHAUDHARY VK, 1990, P NATL ACAD SCI USA, V87, P1066, DOI 10.1073/pnas.87.3.1066; CHAUDHARY VK, 1989, NATURE, V339, P394, DOI 10.1038/339394a0; CLAESSENS M, 1989, PROTEIN ENG, V2, P335, DOI 10.1093/protein/2.5.335; COLLEN D, 1989, FIBRINOLYSIS, V3, P197, DOI 10.1016/0268-9499(89)90046-5; DECLERCK PJ, 1987, THROMB HAEMOSTASIS, V58, P1024; DEWERCHIN M, 1990, FIBRINOLYSIS, V4, P19, DOI 10.1016/S0268-9499(05)80036-0; DEWERCHIN M, 1990, FIBRINOLYSIS, V4, P11, DOI 10.1016/S0268-9499(05)80035-9; DEWERCHIN M, 1989, EUR J BIOCHEM, V185, P141, DOI 10.1111/j.1432-1033.1989.tb15095.x; EDMAN P, 1967, EUR J BIOCHEM, V1, P80, DOI 10.1111/j.1432-1033.1967.tb00047.x; GIBALDI M, 1983, PHARMACOKINETICS, P45; GORMAN C, 1983, SCIENCE, V221, P551, DOI 10.1126/science.6306768; HABER E, 1986, HOSP PRACT, V21, P147; HASEMANN CA, 1990, P NATL ACAD SCI USA, V87, P3942, DOI 10.1073/pnas.87.10.3942; HASHIMOTO Y, 1989, RADIOLOGY, V171, P223, DOI 10.1148/radiology.171.1.2928528; HOCHMAN J, 1973, BIOCHEMISTRY-US, V12, P1130, DOI 10.1021/bi00730a018; HOGG PJ, 1987, MOL IMMUNOL, V24, P797, DOI 10.1016/0161-5890(87)90064-2; HOLVOET P, 1989, THROMB HAEMOSTASIS, V61, P307; HONKAPILLER MV, 1983, METHOD ENZYMOL, V91, P399; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; KAFATOS FC, 1979, NUCLEIC ACIDS RES, V7, P1541, DOI 10.1093/nar/7.6.1541; KNIGHT LC, 1989, RADIOLOGY, V173, P163, DOI 10.1148/radiology.173.1.2781002; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KUDRYK B, 1984, MOL IMMUNOL, V21, P89, DOI 10.1016/0161-5890(84)90093-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MANIATIS T, 1982, MOL CLONING LABORATO, P200; MORRISON SL, 1984, P NATL ACAD SCI-BIOL, V81, P6851, DOI 10.1073/pnas.81.21.6851; PENNOCK GD, 1984, MOL CELL BIOL, V4, P399, DOI 10.1128/MCB.4.3.399; PUTLITZ JZ, 1990, BIO-TECHNOL, V8, P651, DOI 10.1038/nbt0790-651; RODWELL JD, 1989, NATURE, V342, P99, DOI 10.1038/342099a0; ROSEBROUGH SF, 1987, RADIOLOGY, V162, P575, DOI 10.1148/radiology.162.2.3797675; RUNGE MS, 1988, BIOCHEMISTRY-US, V27, P1153, DOI 10.1021/bi00404a012; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEE JM, 1987, P NATL ACAD SCI USA, V84, P6904, DOI 10.1073/pnas.84.19.6904; SHERIFF S, 1987, P NATL ACAD SCI USA, V84, P8075, DOI 10.1073/pnas.84.22.8075; STANSSENS P, 1989, NUCLEIC ACIDS RES, V17, P4441, DOI 10.1093/nar/17.12.4441; SUMMERS MD, 1987, TEXAS AGR EXPT STATI, V1555, P1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TYMKEWYCZ PM, 1989, THROMB RES, V54, P411, DOI 10.1016/0049-3848(89)90211-9; VANDAMME AM, 1990, EUR J BIOCHEM, V192, P767, DOI 10.1111/j.1432-1033.1990.tb19288.x; WASSER MNJM, 1989, BLOOD, V74, P708; Wu R., 1984, OLIGONUCLEOTIDE SYNT, P135	53	50	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16343	16349						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885569				2022-12-25	WOS:A1991GD63500019
J	REID, T; RAMESHA, CS; RINGOLD, GM				REID, T; RAMESHA, CS; RINGOLD, GM			RESISTANCE TO KILLING BY TUMOR-NECROSIS-FACTOR IN AN ADIPOCYTE CELL-LINE CAUSED BY A DEFECT IN ARACHIDONIC-ACID BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTOXIN-INDUCED MEDIATOR; PLATELET-ACTIVATING FACTOR; PHOSPHOLIPASE-A2 ACTIVITY; GROWTH-FACTORS; EXUDATE CELLS; FACTOR-ALPHA; INVITRO; BINDING; DIFFERENTIATION; INHIBITION	We have found that TA1-R6, which are resistant to the cytotoxic effects of tumor necrosis factor (TNF) in the presence of cycloheximide (Reid, T. R., Torti, F., and Ringold, G. M. (1989) J. Biol. Chem. 264, 45834589), have reduced ability to release arachidonic acid (20:4) from membrane phospholipids in response to either TNF or the calcium ionophore A23187 treatment. However, no defect in the activity of phospholipase A2, the principal enzyme responsible for the release of 20:4 from phospholipids, was observed in these cells. Detailed biochemical characterization of these TNF-resistant cells has revealed that these cells are unable to synthesize 20:4 endogenously because of a defect in DELTA-6-desaturase, the rate-limiting enzyme of 20:4 biosynthesis. This deficiency leads to a marked decrease in the steady-state levels of 20:4 present in choline-containing phospholipid (PC) and ethanolamine-containing phospholipid (PE). The TA1-R6 cells, however, are capable of incorporating exogenous 20:4 into PC and PE, and when loaded in such manner they become significantly more sensitive to the cytotoxic effects of TNF in the presence of cycloheximide. Therefore, the release of arachidonic acid from phospholipids appears to be a critical element in the signaling pathway utilized by TNF and is essential to the rapid Cytotoxic response elicited by TNF in the absence of protein synthesis in wild-type TA1 cells.	SYNTEX INC, INST CANC & DEV BIOL, 3401 HILLVIEW AVE, PALO ALTO, CA 94304 USA; SYNTEX INC, INST IMMUNOL & BIOL SCI, PALO ALTO, CA 94304 USA	Syntex Corporation; Syntex Corporation								BEUTLER B, 1985, J EXP MED, V161, P984, DOI 10.1084/jem.161.5.984; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CHAPKIN RS, 1984, BIOCHEM BIOPH RES CO, V124, P784, DOI 10.1016/0006-291X(84)91026-X; CLARK MA, 1988, BIOCHEM J, V250, P125, DOI 10.1042/bj2500125; DAYER JM, 1985, J EXP MED, V162, P2163, DOI 10.1084/jem.162.6.2163; FRANSON RC, 1980, BIOCHEM J, V186, P633, DOI 10.1042/bj1860633; HELSON L, 1975, NATURE, V258, P731, DOI 10.1038/258731a0; HUBER M, 1988, EUR J IMMUNOL, V18, P2085, DOI 10.1002/eji.1830181233; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KAWAKAMI M, 1982, P NATL ACAD SCI-BIOL, V79, P912, DOI 10.1073/pnas.79.3.912; KNIGHT DM, 1987, MOL ENDOCRINOL, V1, P36, DOI 10.1210/mend-1-1-36; KRAMER RM, 1983, J BIOL CHEM, V258, P3806; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; NEALE ML, 1988, IMMUNOLOGY, V64, P81; OLD LJ, 1988, SCI AM, V258, P59, DOI 10.1038/scientificamerican0588-59; OLD LJ, 1985, SCIENCE, V230, P630, DOI 10.1126/science.2413547; PEKALA PH, 1983, P NATL ACAD SCI-BIOL, V80, P2743, DOI 10.1073/pnas.80.9.2743; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; RAMESHA CS, 1991, ANAL BIOCHEM, V192, P173, DOI 10.1016/0003-2697(91)90203-6; REID TR, 1989, J BIOL CHEM, V264, P4583; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; ROUSER G, 1966, LIPIDS, V1, P85, DOI 10.1007/BF02668129; SCHLEIMER RP, 1985, ANNU REV PHARMACOL, V25, P381, DOI 10.1146/annurev.pharmtox.25.1.381; SHALABY MR, 1985, J IMMUNOL, V135, P2069; SUGA K, 1990, J BIOL CHEM, V265, P12363; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; SUGARMAN BJ, 1987, CANCER RES, V47, P780; SUGIURA T, 1987, J BIOL CHEM, V262, P1199; TAKEDA K, 1986, NATURE, V323, P338, DOI 10.1038/323338a0; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TSUJIMOTO M, 1985, P NATL ACAD SCI USA, V82, P7626, DOI 10.1073/pnas.82.22.7626; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; WRIGHT RS, 1971, J CHROMATOGR, V59, P220, DOI 10.1016/S0021-9673(01)80033-9	37	53	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16580	16586						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1909330				2022-12-25	WOS:A1991GD63500056
J	ABRIL, MA; BUCK, M; RAMOS, JL				ABRIL, MA; BUCK, M; RAMOS, JL			ACTIVATION OF THE PSEUDOMONAS TOL PLASMID UPPER PATHWAY OPERON - IDENTIFICATION OF BINDING-SITES FOR THE POSITIVE REGULATOR-XYLR AND FOR INTEGRATION HOST FACTOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN-FIXATION GENES; ESCHERICHIA-COLI; RNA-POLYMERASE; PROMOTER; EXPRESSION; TRANSCRIPTION; INITIATION; CLONING; PUTIDA; NIFA	Expression of the Pseudomonas putida TOL plasmid upper pathway operon requires a promoter that belongs to the -12/-24 class. Stimulation of transcription from this promoter is positively controlled by the effector-activated XylR protein and requires a form of RNA-polymerase holoenzyme containing the RpoN-encoded sigma-factor, sigma-54. XylR-dependent stimulation of transcription from the Pseudomonas TOL upper pathway promoter was examined using deletions, insertions, and in vivo dimethyl sulfate footprinting. Two upstream activator sequences were identified in the -160 (UAS1) and -130 (UAS2) regions. Deletion of these two regions abolished transcription activation, although conservation of the UAS2 element alone allowed limited transcription stimulation. Separation of UAS1 from UAS2 by half a turn or a full turn significantly reduced XylR stimulation of transcription from the upper pathway operon promoter. An inverted repeated ATTTGN2CAAAT (where N is any nucleoside), which most likely represented the XylR recognition sequence, was identified. Binding of XylR was observed in vivo in the absence of effector, but changes in the binding pattern were induced in the presence of m-methylbenzyl alcohol, a XylR effector. In vivo footprinting analysis revealed that changes in the methylation pattern of G and T also occurred in the -50 to -90 region, which is probably occupied by integration host factor (IHF) protein. IHF was required for maximal expression from the TOL upper pathway operon promoter in Escherichia coli. Separation of the IHF site from UAS2 by a full helix turn did not significantly affect stimulation of transcription, which is consistent with this region playing a conformational role, rather than a regulatory one, in promoter function.	CSIC,ESTAC EXPTL ZAIDIN,DEPT PLANT BIOCHEM,APTO 419,E-18080 GRANADA,SPAIN; UNIV SUSSEX,NITROGEN FIXAT LAB,BRIGHTON BN1 9RQ,E SUSSEX,ENGLAND	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental del Zaidin (EEZ); University of Sussex				Ramos, Juan L./0000-0002-8731-7435				ABRIL MA, 1989, J BACTERIOL, V171, P6782, DOI 10.1128/jb.171.12.6782-6790.1989; AUSUBEL FM, 1984, CELL, V37, P5, DOI 10.1016/0092-8674(84)90294-0; BETTER M, 1985, EMBO J, V4, P2419, DOI 10.1002/j.1460-2075.1985.tb03950.x; BIEK DP, 1986, J BACTERIOL, V167, P594, DOI 10.1128/jb.167.2.594-603.1986; BIRKMANN A, 1989, MOL MICROBIOL, V3, P187, DOI 10.1111/j.1365-2958.1989.tb01807.x; BUCK M, 1986, NATURE, V320, P374, DOI 10.1038/320374a0; CANNON WV, 1990, NUCLEIC ACIDS RES, V18, P1693, DOI 10.1093/nar/18.7.1693; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; DELORENZO V, 1991, EMBO J, V10, P1159, DOI 10.1002/j.1460-2075.1991.tb08056.x; DIXON R, 1986, MOL GEN GENET, V203, P129, DOI 10.1007/BF00330393; DIXON RA, 1984, J GEN MICROBIOL, V130, P2745; FELLAY R, 1987, GENE, V52, P147, DOI 10.1016/0378-1119(87)90041-2; FRANKLIN FCH, 1981, P NATL ACAD SCI-BIOL, V78, P7458, DOI 10.1073/pnas.78.12.7458; GOODRICH JA, 1990, NUCLEIC ACIDS RES, V18, P4993, DOI 10.1093/nar/18.17.4993; GUBLER M, 1989, MOL MICROBIOL, V63, P149; HOLTEL A, 1990, MOL MICROBIOL, V4, P1551, DOI 10.1111/j.1365-2958.1990.tb02066.x; HOOVER TR, 1990, CELL, V63, P11, DOI 10.1016/0092-8674(90)90284-L; INOUYE S, 1981, J BACTERIOL, V148, P413, DOI 10.1128/JB.148.2.413-418.1981; INOUYE S, 1987, P NATL ACAD SCI USA, V84, P5182, DOI 10.1073/pnas.84.15.5182; INOUYE S, 1984, P NATL ACAD SCI-BIOL, V81, P1688, DOI 10.1073/pnas.81.6.1688; KOHLER T, 1989, J BACTERIOL, V171, P4326; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUSTU S, 1989, MICROBIOL REV, V53, P367, DOI 10.1128/MMBR.53.3.367-376.1989; Maniatis T., 1982, MOL CLONING; MICHIN SD, 1990, EMBO J, V8, P3491; Miller J.H., 1972, EXPT MOL GENETICS; NINFA AJ, 1987, CELL, V50, P1039, DOI 10.1016/0092-8674(87)90170-X; POPHAM DL, 1989, SCIENCE, V243, P629, DOI 10.1126/science.2563595; RAMOS JL, 1986, P NATL ACAD SCI USA, V83, P8467, DOI 10.1073/pnas.83.22.8467; RAMOS JL, 1987, MOL MICROBIOL, V1, P297; REITZER LJ, 1986, CELL, V45, P785, DOI 10.1016/0092-8674(86)90553-2; RONSON CW, 1987, NUCLEIC ACIDS RES, V15, P7921, DOI 10.1093/nar/15.19.7921; SANTERO E, 1989, P NATL ACAD SCI USA, V86, P7346, DOI 10.1073/pnas.86.19.7346; SASSEDWIGHT S, 1988, P NATL ACAD SCI USA, V85, P8934, DOI 10.1073/pnas.85.23.8934; SCHMITZ G, 1988, MOL GEN GENET, V215, P107, DOI 10.1007/BF00331311; SERRANO M, 1990, SCIENCE, V248, P1012, DOI 10.1126/science.2111580; SU W, 1990, P NATL ACAD SCI USA, V87, P5504, DOI 10.1073/pnas.87.14.5504; THONY B, 1989, FEMS MICROBIOL LETT, V63, P341; TSO POP, 1974, BASIC PRINCIPLES NUC, V2, P58; WINKELMAN JW, 1990, J BIOL CHEM, V265, P10055; WORSEY MJ, 1975, J BACTERIOL, V124, P7, DOI 10.1128/JB.124.1.7-13.1975	41	69	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15832	15838						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874736				2022-12-25	WOS:A1991GB97700048
J	TOMASSELLI, AG; HUI, JO; ADAMS, L; CHOSAY, J; LOWERY, D; GREENBERG, B; YEM, A; DEIBEL, MR; ZURCHERNEELY, H; HEINRIKSON, RL				TOMASSELLI, AG; HUI, JO; ADAMS, L; CHOSAY, J; LOWERY, D; GREENBERG, B; YEM, A; DEIBEL, MR; ZURCHERNEELY, H; HEINRIKSON, RL			ACTIN, TROPONIN-C, ALZHEIMER AMYLOID PRECURSOR PROTEIN AND PRO-INTERLEUKIN-1-BETA AS SUBSTRATES OF THE PROTEASE FROM HUMAN-IMMUNODEFICIENCY-VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; RECOMBINANT HUMAN INTERLEUKIN-1-BETA; SYNTHETIC HIV-1 PROTEASE; RABBIT SKELETAL-MUSCLE; RETROVIRAL PROTEASES; CRYSTAL-STRUCTURE; BOVINE BRAIN; INHIBITION; CLEAVAGE; SPECIFICITY	We show here for the first time that actin, troponin C, Alzheimer amyloid precursor protein (AAP), and pro-interleukin 1-beta (pro-IL-1-beta), are substrates of the protease encoded by the human immunodeficiency virus (HIV) type-1. As has been seen in other non-viral protein substrates of the HIV protease, the presence of Glu residues in the P2' position appears to play an important role in substrate recognition. Three of the four bonds cleaved in actin, two of the three in troponin C, and all of the bonds hydrolyzed in AAP and pro-IL-1-beta have a P2' Glu residue. In fact, Glu residues are accommodated in all positions from P4 to P4' surrounding the scissile bond in substrates of the HIV proteases, and as many as 4 adjacent Glu residues were seen in one of the bonds cleaved in AAP. This study of nonviral protein substrates has also revealed unexpected amino acids such as Gly, Arg, and Glu in the scissile bond itself rather than the more conventional hydrophobic amino acids. The HIV-2 protease hydrolyzed actin in a manner similar to that of the HIV-1 enzyme, but its cleavage of troponin C was distinct in that it split a bond adjacent to a triplet of Glu residues in P2, P3, and P4 that was refractory to the HIV-1 enzyme. Documentation of cleavage sites in the several important cellular proteins noted above has extended our understanding of the features in a substrate that are recognized by these multi sub-site proteases of retroviral maturation. Moreover, the present work adds to an accumulating body of evidence which demonstrates that these enzymes can damage crucial structural and regulatory cellular proteins if ever their activity is expressed outside the viral particle itself.	UPJOHN CO,UPJOHN LABS,DISCOVERY RES,KALAMAZOO,MI 49001	Pfizer				Lowery, David/0000-0001-5111-4719				ADAMS LD, 1987, CURRENT PROTOCOLS MO; ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; ASHORN P, 1990, P NATL ACAD SCI USA, V87, P7472, DOI 10.1073/pnas.87.19.7472; CARTER DB, 1988, PROTEINS, V3, P121, DOI 10.1002/prot.340030207; COLLINS JH, 1975, J BIOL CHEM, V250, P5915; DARKE PL, 1988, BIOCHEM BIOPH RES CO, V156, P297, DOI 10.1016/S0006-291X(88)80839-8; HANAUER A, 1983, NUCLEIC ACIDS RES, V11, P3503, DOI 10.1093/nar/11.11.3503; HAZUDA D, 1989, J BIOL CHEM, V264, P1689; HENDERSON LE, 1988, J VIROL, V62, P2587, DOI 10.1128/JVI.62.8.2587-2595.1988; HUI JO, 1990, J BIOL CHEM, V265, P21386; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KAPLAN AH, 1991, P NATL ACAD SCI USA, V88, P4528, DOI 10.1073/pnas.88.10.4528; KIAGUCHI N, 1988, NATURE, V331, P530; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWERY DE, 1991, IN PRESS J BIOL CHEM; LU RC, 1977, BIOCHEMISTRY-US, V16, P5801, DOI 10.1021/bi00645a025; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; MILLER M, 1989, NATURE, V337, P576, DOI 10.1038/337576a0; PARTIN K, 1990, J VIROL, V64, P3938, DOI 10.1128/JVI.64.8.3938-3947.1990; Pearl L., 1990, RETROVIRAL PROTEASES, P131; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PICHUANTES S, 1990, J BIOL CHEM, V265, P13890; POORMAN RA, 1991, J BIOL CHEM, V265, P14554; POORMAN RA, 1991, NATURE, V350, P625; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; ROBERTS NA, 1990, SCIENCE, V248, P358, DOI 10.1126/science.2183354; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P408; TOMASSELLI AG, 1991, IN PRESS PROTEINS ST; TOZSER J, 1991, FEBS LETT, V281, P77, DOI 10.1016/0014-5793(91)80362-7; VANDEKERCKHOVE J, 1978, EUR J BIOCHEM, V90, P451, DOI 10.1111/j.1432-1033.1978.tb12624.x; WALLIN M, 1990, J GEN VIROL, V71, P1985, DOI 10.1099/0022-1317-71-9-1985; WATTERSON DM, 1980, J BIOL CHEM, V255, P962; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YEM AW, 1988, LYMPHOKINE RES, V7, P85	40	81	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14548	14553						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907279				2022-12-25	WOS:A1991FZ35100069
J	KAUFFMAN, MG; ROSE, PA; KELLY, TJ				KAUFFMAN, MG; ROSE, PA; KELLY, TJ			MUTATIONS IN THE THYMIDINE KINASE GENE THAT ALLOW EXPRESSION OF THE ENZYME IN QUIESCENT (G0) CELLS	ONCOGENE			English	Article							SERUM-STIMULATED CELLS; MESSENGER-RNA; MOLECULAR-CLONING; NUCLEAR ANTIGEN; S-PHASE; CYCLE; PROMOTER; PROGRESSION; SEQUENCE; LEVEL	Thymidine kinase (TK) is a nucleotide salvage pathway enzyme whose activity is highly dependent on the growth state and cell cycle phase of a cell. Cells in the resting or quiescent (G0) phase express very low levels of TK mRNA and protein. When quiescent cells are stimulated to enter the cell cycle by the addition of serum, TK mRNA, activity and polypeptide increase coordinately after about 10-15 h, at the beginning of S phase. When growth-independent heterologous promoters are substituted for the natural TK promoter, TK mRNA can be expressed in quiescent cells. Despite the presence of TK mRNA in such G0 cells, there is little expression of TK polypeptide; the normal increase in enzyme at S phase is observed following serum stimulation. Deletion of the introns and 3' untranslated sequences does not affect the expression of the TK gene in serum stimulation experiments. In contrast, deletion of the C-terminal 40 amino acids or fusion of a small segment of a beta-galactosidase to the C-terminus overcomes the block to expression of the TK polypeptide in G0 cells. These C-terminal alterations are the same as those which lead to constitutive expression of TK during the cell cycle of proliferating cells, suggesting that mechanisms which control the levels of TK in cycling cells may also operate in quiescent cells.	JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007309, R01GM042780] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM42780-02, 5-T32-GM-07309-16] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELLO LJ, 1974, EXP CELL RES, V89, P263, DOI 10.1016/0014-4827(74)90790-3; BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316; BRADSHAW HD, 1983, P NATL ACAD SCI-BIOL, V80, P5588, DOI 10.1073/pnas.80.18.5588; CHEETHAM BF, 1982, J CELL PHYSIOL, V110, P114, DOI 10.1002/jcp.1041100203; CHEETHAM BF, 1982, MOL CELL BIOL, V2, P1295, DOI 10.1128/MCB.2.10.1295; COPPOCK DL, 1987, MOL CELL BIOL, V7, P2925, DOI 10.1128/MCB.7.8.2925; FEDER JN, 1989, J BIOL CHEM, V264, P20583; GROSS MK, 1987, DEV BIOL, V122, P439, DOI 10.1016/0012-1606(87)90308-3; GROSS MK, 1989, P NATL ACAD SCI USA, V86, P4987, DOI 10.1073/pnas.86.13.4987; GROUDINE M, 1984, NUCLEIC ACIDS RES, V12, P1427, DOI 10.1093/nar/12.3.1427; GUDAS JM, 1988, P NATL ACAD SCI USA, V85, P4705, DOI 10.1073/pnas.85.13.4705; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; HOFBAUER R, 1987, NUCLEIC ACIDS RES, V15, P741, DOI 10.1093/nar/15.2.741; ITO M, 1990, J BIOL CHEM, V265, P6954; JASKULSKI D, 1988, J BIOL CHEM, V263, P10175; JOHNSON LF, 1982, EXP CELL RES, V138, P79, DOI 10.1016/0014-4827(82)90093-3; KAUFFMAN MG, 1990, ANAL BIOCHEM, V191, P41, DOI 10.1016/0003-2697(90)90384-L; KAUFFMAN MG, 1991, IN PRESS MOL CELL BI, V11; KIT S, 1965, J BIOL CHEM, V240, P2565; KREIDBERG JA, 1986, MOL CELL BIOL, V6, P2903, DOI 10.1128/MCB.6.8.2903; KWOH TJ, 1984, NUCLEIC ACIDS RES, V23, P39595; LEWIS JA, 1986, MOL CELL BIOL, V6, P2262, DOI 10.1128/MCB.6.6.2262; LIEBERMAN HB, 1988, MOL CELL BIOL, V8, P5280, DOI 10.1128/MCB.8.12.5280; MERRILL GF, 1984, MOL CELL BIOL, V4, P1769, DOI 10.1128/MCB.4.9.1769; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; PEDEN KWC, 1989, EXP CELL RES, V185, P60, DOI 10.1016/0014-4827(89)90037-2; ROEHL HH, 1990, MOL CELL BIOL, V10, P3834, DOI 10.1128/MCB.10.7.3834; SCHLOSSER CA, 1981, P NATL ACAD SCI USA, V74, P5463; SHERLEY JL, 1988, J BIOL CHEM, V263, P375; SHERLEY JL, 1988, J BIOL CHEM, V263, P8350; STEWART CJ, 1987, MOL CELL BIOL, V7, P1156, DOI 10.1128/MCB.7.3.1156; STUART P, 1985, MOL CELL BIOL, V5, P1490, DOI 10.1128/MCB.5.6.1490; TRAVALI S, 1988, MOL CELL BIOL, V8, P1551, DOI 10.1128/MCB.8.4.1551; WAHL AF, 1988, MOL CELL BIOL, V8, P5016, DOI 10.1128/MCB.8.11.5016	34	26	27	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1427	1435						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1909430				2022-12-25	WOS:A1991GX27200020
J	AXLEY, MJ; GRAHAME, DA				AXLEY, MJ; GRAHAME, DA			KINETICS FOR FORMATE DEHYDROGENASE OF ESCHERICHIA-COLI FORMATE-HYDROGENLYASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYASE; SELENOCYSTEINE; METABOLISM; ENZYMES	Kinetic parameters of the selenium-containing, formate dehydrogenase component of the Escherichia coli formate-hydrogenlyase complex have been determined with purified enzyme. A ping-pong Bi Bi kinetic mechanism was observed. The K(m) for formate is 26 mM, and the K(m) for the electron-accepting dye, benzyl viologen, is in the range 1-5 mm. The maximal turnover rate for the formate-dependent catalysis of benzyl viologen reduction was calculated to be 1.7 x 10(5) min-1. Isotope exchange analysis showed that the enzyme catalyzes carbon exchange between carbon dioxide and formate in the absence of other electron acceptors, confirming the ping-pong reaction mechanism. Dissociation constants for formate (12.2 mM) and CO2 (8.3 mM) were derived from analysis of the isotope exchange data. The enzyme catalyzes oxidation of the alternative substrate deuterioformate with little change in the V(max), but the K(m) for deuterioformate is approximately three times that of protioformate. This implies formate oxidation is not rate-limiting in the overall coupled reaction of formate oxidation and benzyl viologen reduction. The deuterium isotope effect on V(max)/K(m) was observed to be approximately 4.2-4.5. Sodium nitrate was found to inhibit enzyme activity in a competitive manner with respect to formate, with a K(i) of 7.1 mM. Sodium azide is a noncompetitive inhibitor with a K(i) of about 80-mu-M.			AXLEY, MJ (corresponding author), NHLBI,BIOCHEM LAB,BLD 3,RM 103,9000 ROCKVILLE PIKE,BETHESDA,MD 20892, USA.							AXLEY MJ, 1989, ANNU REV NUTR, V9, P127, DOI 10.1146/annurev.nu.09.070189.001015; AXLEY MJ, 1990, J BIOL CHEM, V265, P18213; BIRKMANN A, 1987, MOL GEN GENET, V210, P535, DOI 10.1007/BF00327209; BIRKMANN A, 1987, ARCH MICROBIOL, V148, P44, DOI 10.1007/BF00429646; BLANCHARD JS, 1980, BIOCHEMISTRY-US, V19, P3543, DOI 10.1021/bi00556a020; Bock A, 1988, Biofactors, V1, P245; COX JC, 1981, J BACTERIOL, V145, P1317, DOI 10.1128/JB.145.3.1317-1324.1981; FROMM HJ, 1975, INITIAL RATE ENZYME, P161; LEVINE RL, 1983, J BIOL CHEM, V258, P1823; LIN ECC, 1987, ESCHERICHIA COLI SAL, V1, P201; NORTHROP DB, 1982, METHOD ENZYMOL, V87, P607; PECHER A, 1983, ARCH MICROBIOL, V136, P131, DOI 10.1007/BF00404787; PECK HD, 1957, J BACTERIOL, V73, P706, DOI 10.1128/JB.73.6.706-721.1957; RUIZHERRERA J, 1972, BIOCHIM BIOPHYS ACTA, V289, P254, DOI 10.1016/0005-2744(72)90075-7; STADTMAN TC, 1990, ANNU REV BIOCHEM, V59, P111, DOI 10.1146/annurev.bi.59.070190.000551; ZINONI F, 1987, P NATL ACAD SCI USA, V84, P3156, DOI 10.1073/pnas.84.10.3156; ZINONI F, 1986, P NATL ACAD SCI USA, V83, P4650, DOI 10.1073/pnas.83.13.4650	17	48	48	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13731	13736						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906883				2022-12-25	WOS:A1991FY02700044
J	DELBOCCIO, G; PENNELLI, A; WHITEHEAD, EP; LOBELLO, M; PETRUZZELLI, R; FEDERICI, G; RICCI, G				DELBOCCIO, G; PENNELLI, A; WHITEHEAD, EP; LOBELLO, M; PETRUZZELLI, R; FEDERICI, G; RICCI, G			INTERACTION OF GLUTATHIONE TRANSFERASE FROM HORSE ERYTHROCYTES WITH 7-CHLORO-4-NITROBENZO-2-OXA-1,3-DIAZOLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL ATPASE; IDENTIFICATION; REAGENT; RESIDUE; SITE	7-Chloro-4-nitrobenzo-2-oxa-1,3-diazole reacts with two thiol groups of the dimeric horse erythrocyte glutathione transferase at pH 5.0, with strong inactivation reversible on dithiothreitol treatment. The inactivation kinetic follows a biphasic pattern, similar to that caused by other thiol reagents as recently reported. Both S-methylglutathione and 1-chloro-2,4-dinitrobenzene protect the enzyme from inactivation. Analysis of the reactive SH group-containing peptide gives the sequence Ala-Ser-Cys-Leu-Tyr, identical with that of the peptide that contains the reactive cysteine 47 of the human placental transferase. In the presence of glutathione, the enzyme is not inactivated by this reagent, but it catalyzes its conjugation to glutathione. At higher pH values, 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole reacts with 2 tyrosines/dimer and lysines, as well as with cysteines. Reaction with lysine seems essentially without effect on activity; whether the reactive tyrosines are important for activity could not be determined using this reagent only. However, 2 tyrosines among the 4 that are nitrated by tetranitromethane are important for activity.	EUROPEAN COMMISS,DIV RADIOPROTECT,ROME,ITALY; UNIV TOR VERGATA,DEPT BIOL,I-00173 ROME,ITALY	European Commission Joint Research Centre; University of Rome Tor Vergata	DELBOCCIO, G (corresponding author), UNIV CHIETI G DANNUNZIO,INST BIOCHEM SCI,VIA VESTINI 6,I-66100 CHIETI,ITALY.			Ricci, Giorgio/0000-0002-7108-2846				ABODERIN AA, 1973, BIOCHIM BIOPHYS ACTA, V328, P20, DOI 10.1016/0005-2795(73)90325-5; AWASTHI YC, 1987, BIOCHEM BIOPH RES CO, V143, P965, DOI 10.1016/0006-291X(87)90345-7; BIRKETT DJ, 1970, FEBS LETT, V6, P346, DOI 10.1016/0014-5793(70)80095-3; CARNE T, 1979, BIOCHEM J, V177, P433, DOI 10.1042/bj1770433; Chasseaud L F, 1979, Adv Cancer Res, V29, P175, DOI 10.1016/S0065-230X(08)60848-9; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DELBOCCIO G, 1986, BIOCHEM MED METAB B, V36, P306, DOI 10.1016/0885-4505(86)90140-4; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P127, DOI 10.1111/j.1432-1033.1975.tb04121.x; FERGUSON SJ, 1975, EUR J BIOCHEM, V54, P117, DOI 10.1111/j.1432-1033.1975.tb04120.x; FROST A, 1961, KINETICS MECHANISM, P263; GHOSH PB, 1968, BIOCHEM J, V108, P155, DOI 10.1042/bj1080155; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; LOBELLO M, 1990, FEBS LETT, V263, P389, DOI 10.1016/0014-5793(90)81421-J; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; Mannervik B, 1985, Adv Enzymol Relat Areas Mol Biol, V57, P357; MANNERVIK B, 1988, CRC CRIT REV BIOCH, V23, P281; Mannervik B., 1978, CONJUGATION REACTION, P101; PERSSON B, 1988, BIOCHIM BIOPHYS ACTA, V953, P241, DOI 10.1016/0167-4838(88)90031-3; RICCI G, 1989, J BIOL CHEM, V264, P5462; SHASTEEN CS, 1983, FED PROC, V42, P2036; Simons P C, 1981, Methods Enzymol, V77, P235; SOKOLOVS.M, 1966, BIOCHEMISTRY-US, V5, P3582, DOI 10.1021/bi00875a029; TURANO C, 1971, EUR J BIOCHEM, V23, P349	25	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13777	13782						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906885				2022-12-25	WOS:A1991FY02700052
J	KOUNS, WC; FOX, CF; LAMOREAUX, WJ; COONS, LB; JENNINGS, LK				KOUNS, WC; FOX, CF; LAMOREAUX, WJ; COONS, LB; JENNINGS, LK			THE EFFECT OF GLYCOPROTEIN-IIB-IIIA RECEPTOR OCCUPANCY ON THE CYTOSKELETON OF RESTING AND ACTIVATED PLATELETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN-PLATELETS; ACTIN-BINDING PROTEIN; FIBRINOGEN-BINDING; MONOCLONAL-ANTIBODY; SHAPE-CHANGE; CONTRACTILE CYTOSKELETONS; FIBRONECTIN RECEPTOR; VONWILLEBRAND-FACTOR; SYNTHETIC PEPTIDES; MEMBRANE SKELETON	The platelet integrin, glycoprotein IIb-IIIa (GPIIb-IIIa), serves as the receptor for fibrinogen. This study examined what effect GPIIb-IIIa receptor occupancy had on the cytoskeleton of resting and activated platelets. Triton X-100-insoluble residues (cytoskeletons) were isolated from resting washed platelets incubated with either 500-mu-M RGDS or 500-mu-M RGES and examined for protein content. RGDS did not increase the amount of GPIIb-IIIa associated with the cytoskeletal residues which sedimented at either 15,800 x g or 100,000 x g. To determine the effect of receptor occupancy on the formation of the activated platelet cytoskeleton, stirred and nonstirred RGDS-treated platelets in plasma were activated with ADP. Triton X-100-insoluble residues were isolated and examined for both protein content and retention of GPIIb-IIIa. Further, morphological studies were performed on the RGDS-ADP-stimulated platelets. The results of this study suggest that 1) RGDS peptide receptor occupancy does not lead to GPIIb-IIIa linkage to the cytoskeleton, 2) ADP-stimulated platelet shape change, polymerization of actin, and association of myosin with the cytoskeleton are unaffected by RGDS peptide receptor occupancy, 3) RGDS inhibits an aggregation-dependent incorporation of ABP, alpha-actinin, talin, and GPIIb-IIIa into the Triton-insoluble residue.	UNIV TENNESSEE,CTR HLTH SCI,DEPT BIOCHEM,DIV HEMATOL ONCOL,956 COURT AVE,RM A303,MEMPHIS,TN 38163; UNIV TENNESSEE,CTR HLTH SCI,DEPT MED,MEMPHIS,TN 38163; MEMPHIS STATE UNIV,CTR ELECTRON MICROSCOPY,MEMPHIS,TN 38152	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Memphis				L'Amoreaux, William/0000-0002-1254-9370	NHLBI NIH HHS [HL 38171] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038171] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDRIEUX A, 1989, J BIOL CHEM, V264, P9258; AYSEE GM, 1987, EXP CELL RES, V168, P358; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; BENNETT JS, 1982, J BIOL CHEM, V257, P8049; BENNETT JS, 1983, P NATL ACAD SCI-BIOL, V80, P2417, DOI 10.1073/pnas.80.9.2417; BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; BRASS LF, 1985, J BIOL CHEM, V260, P2231; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CARLSSON L, 1979, P NATL ACAD SCI USA, V76, P6376, DOI 10.1073/pnas.76.12.6376; CARROLL RC, 1982, CELL, V30, P385, DOI 10.1016/0092-8674(82)90236-7; CHARO IF, 1986, P NATL ACAD SCI USA, V83, P8351, DOI 10.1073/pnas.83.21.8351; COOPER JA, 1987, J CELL BIOL, V105, P1473, DOI 10.1083/jcb.105.4.1473; DSOUZA SE, 1988, J BIOL CHEM, V263, P3943; FERLINGER AL, 1990, J BIOL CHEM, V265, P6346; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FUJIMOTO T, 1982, J CLIN INVEST, V69, P1212, DOI 10.1172/JCI110560; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GEAR ARL, 1981, BLOOD, V58, P477; GEORGE JN, 1984, NEW ENGL J MED, V311, P1084, DOI 10.1056/NEJM198410253111705; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1988, THROMB HAEMOSTASIS, V59, P1; GOGSTAD GO, 1982, BLOOD, V60, P663; HARTWIG JH, 1979, J MOL BIOL, V134, P539, DOI 10.1016/0022-2836(79)90366-8; HEMLER ME, 1988, J BIOL CHEM, V263, P7660; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; ISENBERG W M, 1987, Journal of Cell Biology, V105, p130A; ISENBERG WM, 1987, J CELL BIOL, V104, P1655, DOI 10.1083/jcb.104.6.1655; ISENBERG WM, 1987, FED PROC, V46, P1314; ISENBERG WM, 1988, J CELL BIOL, V6, P256; JENNINGS LK, 1981, J BIOL CHEM, V256, P6927; JENNINGS LK, 1988, CIRCULATION, V78, P517; KIRCHHOFER D, 1990, J BIOL CHEM, V265, P18525; KOMETANI M, 1986, THROMB RES, V41, P801, DOI 10.1016/0049-3848(86)90378-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER BG, 1984, BLOOD, V63, P606; LOMBARDO VT, 1985, J CLIN INVEST, V76, P1950, DOI 10.1172/JCI112193; MARGUERIE GA, 1980, J BIOL CHEM, V255, P154; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; NACHMAN RL, 1982, J CLIN INVEST, V69, P263, DOI 10.1172/JCI110448; NAKATA T, 1987, J CELL BIOL, V105, P1771, DOI 10.1083/jcb.105.4.1771; NEWMAN PJ, 1987, BLOOD, V69, P668; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; PAINTER RG, 1982, J CELL BIOL, V92, P565, DOI 10.1083/jcb.92.2.565; PAINTER RG, 1985, J CELL BIOL, V100, P652, DOI 10.1083/jcb.100.2.652; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PHILLIPS DR, 1980, J CELL BIOL, V86, P77, DOI 10.1083/jcb.86.1.77; PHILLIPS DR, 1988, BLOOD, V71, P831; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PISCHEL KD, 1987, J IMMUNOL, V138, P226; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1981, J BIOL CHEM, V256, P9477; PRIBLUDA V, 1982, BIOCHEMISTRY-US, V21, P2825, DOI 10.1021/bi00541a003; PYETELA R, 1986, SCIENCE, V231, P1559; RINK TJ, 1982, FEBS LETT, V148, P21, DOI 10.1016/0014-5793(82)81234-9; RUGGERI ZM, 1982, P NATL ACAD SCI-BIOL, V79, P6038, DOI 10.1073/pnas.79.19.6038; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RYBAK ME, 1988, BLOOD, V72, P714; RYBAK MEM, 1989, J BIOL CHEM, V264, P14617; SCHICK PK, 1983, BLOOD, V61, P163; SINIGAGLIA F, 1988, BIOCHEM BIOPH RES CO, V154, P258, DOI 10.1016/0006-291X(88)90678-X; WHEELER ME, 1985, J CELL BIOL, V101, P993, DOI 10.1083/jcb.101.3.993; WHEELER ME, 1984, J CLIN INVEST, V74, P1080, DOI 10.1172/JCI111475; WHITE JG, 1990, EUR J CELL BIOL, V52, P341; WHITE JG, 1971, PLATELET AGGREGATION, P15; YAMAGUCHI A, 1987, FEBS LETT, V225, P228, DOI 10.1016/0014-5793(87)81163-8; ZUCKER MB, 1983, BLOOD, V61, P676	73	67	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13891	13900						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906886				2022-12-25	WOS:A1991FY02700069
J	KNOPS, J; JOHNSONWOOD, K; SCHENK, DB; SINHA, S; LIEBERBURG, I; MCCONLOGUE, L				KNOPS, J; JOHNSONWOOD, K; SCHENK, DB; SINHA, S; LIEBERBURG, I; MCCONLOGUE, L			ISOLATION OF BACULOVIRUS-DERIVED SECRETED AND FULL-LENGTH BETA-AMYLOID PRECURSOR PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; ALZHEIMERS-DISEASE; EXPRESSION VECTORS; INSECT CELLS; DOMAIN; IDENTIFICATION; BIOGENESIS; FORM	We have expressed two forms of the Alzheimer's beta-amyloid precursor protein (beta-APP), the 695-amino acid form (695-beta-APP), and the 751-amino acid form (751-beta-APP) in a baculovirus system. Both forms were expressed as full-length precursor, and were subsequently processed in vivo to release extracellular secreted proteins. The secreted forms were cleaved from the full-length beta-APP in a manner analogous to the cleavage of beta-APP during constitutive secretions in mammalian cells (Weidemann, A., Konig, G., Bunke, D., Fischer, P., Salbaum, J. M., Masters, C. L., Beyreuther, K. (1989) Cell 57, 115-126; Oltersdorf, T., Ward, P. J., Henriksson, T., Beattie, E. C., Neve, R., Lieberburg, I., and Fritz, L. J. (1990) J. Biol. Chem. 265, 4492-4497). High levels of expression of 20-50 mg/liter were achieved. Both full-length and secreted forms of the beta-amyloid precursor proteins were purified using a combination of ion-exchange and immunoaffinity chromatography using a monoclonal antibody directed against beta-APP. The 751-beta-APP-derived full-length and secreted forms, which contain the Kunitz protease inhibitor domain, were shown to be as active in the inhibition of trypsin as is mammalian-derived secreted beta-APP. The availability of purified full-length beta-APP from the baculovirus system will be valuable for biochemical and cell biological analyses tha may elucidate the mechanism of the inappropriate processing that leads to beta-amyloid formation in Alzheimer's disease.	ATHENA NEUROSCI INC, 800F GATEWAY BLVD, San Francisco, CA 94080 USA									ABRAHAM CR, 1990, NEUROBIOL AGING, V11; BIETH JG, 1980, CLIN RES PROC, V16, P183; BRINGMAN TS, 1987, CELL, V48, P429, DOI 10.1016/0092-8674(87)90194-2; BUSH AI, 1990, J BIOL CHEM, V265, P15977; DEFEUDIS FV, 1989, TRENDS PHARMACOL SCI, V10, P479, DOI 10.1016/0165-6147(89)90042-4; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GREENFIELD C, 1988, EMBO J, V7, P139, DOI 10.1002/j.1460-2075.1988.tb02793.x; HENRIKSSON T, 1991, J NEUROCHEM, V56, P1037, DOI 10.1111/j.1471-4159.1991.tb02026.x; JARVIS DL, 1989, MOL CELL BIOL, V9, P214, DOI 10.1128/MCB.9.1.214; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; LUCKOW VA, 1988, BIO-TECHNOL, V6, P47, DOI 10.1038/nbt0188-47; MANOS MM, 1988, MOL CELL BIOL, V8, P5035, DOI 10.1128/MCB.8.11.5035; MASTERS CL, 1985, P NATL ACAD SCI USA, V82, P4245, DOI 10.1073/pnas.82.12.4245; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; NELSON RB, 1990, J BIOL CHEM, V265, P3836; OLTERSDORF T, 1990, J BIOL CHEM, V265, P4492; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; RETTENMIER CW, 1988, MOL CELL BIOL, V8, P5026, DOI 10.1128/MCB.8.11.5026; SCHUBERT D, 1989, BIOCHEM BIOPH RES CO, V162, P83, DOI 10.1016/0006-291X(89)91965-7; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SELKOE DJ, 1989, ANNU REV NEUROSCI, V12, P463, DOI 10.1146/annurev.ne.12.030189.002335; SELKOE DJ, 1990, SCIENCE, V248, P1058, DOI 10.1126/science.2111582; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SIMAN R, 1990, J NEUROSCI, V10, P2400; SINHA S, 1990, J BIOL CHEM, V265, P8983; SMITH RP, 1990, SCIENCE, V248, P1126, DOI 10.1126/science.2111585; SUMMERS MD, 1987, TEX AGR EXP STN B, V1555; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1990, SCIENCE, V248, P745, DOI 10.1126/science.2110384; VISSAVAJJHALA P, 1990, J BIOL CHEM, V265, P4746; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WHITSON JS, 1989, SCIENCE, V243, P1488, DOI 10.1126/science.2928783; YANKNER BA, 1990, SCIENCE, V250, P279, DOI 10.1126/science.2218531	41	37	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7285	7290						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1901866				2022-12-25	WOS:A1991FG72700099
J	BARR, CL; SAUNDERS, GF				BARR, CL; SAUNDERS, GF			INTERFERON-GAMMA-INDUCIBLE REGULATION OF THE HUMAN INVARIANT CHAIN GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLASS-I GENE; INDUCED NUCLEAR FACTORS; LONG TERMINAL REPEAT; INDUCED TRANSCRIPTION; SYNTHETASE GENE; RESPONSIVE SEQUENCES; GEL-ELECTROPHORESIS; CONSENSUS SEQUENCE; ALPHA-INTERFERON; PROMOTER ELEMENT	Interferon-gamma (IFN-gamma) regulates a variety of immunoregulatory functions through the induction of a specific set of IFN-gamma response genes. This includes the invariant chain associated with the major histocompatibility complex class II molecules. To investigate the mechanism involved in the invariant chain (In) response to IFN-gamma we constructed chloramphenicol acetyltransferase (CAT) hybrid genes in which the CAT gene is under the control of the In promoter. The glioblastoma cell line, U-373 MG, transfected with a CAT construct having the In promoter sequence -790 to +1 bp showed over 3-fold increased CAT activity when treated with IFN-gamma indicating that this region confers IFN-gamma responsiveness to the CAT gene. The IFN-gamma response element in the promoter was further sublocalized to the region -120 to -61 base pairs (bp). This region contains homology to the interferon-stimulated response elements identified in other IFN responsive genes. By gel shift analyses, an IFN-gamma-induced sequence-specific DNA-binding factor was identified. This induced complex binds to an oligonucleotide corresponding to -107 to -79 bp of the In promoter. Mutations of this binding site at -94 and -92 bp drastically decreased binding of the constitutive and IFN-gamma-induced complexes. This IFN-gamma induced factor also binds to an oligonucleotide corresponding to -91 to -62 bp of the interferon-beta (IFN-beta) gene promoter, a region necessary for the induction of the IFN-beta gene by virus and double-stranded RNA. This binding specificity is characteristic of a family of DNA binding factors that bind both the interferon-stimulated response elements and the IFN-beta gene promoter.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOCHEM & MOLEC BIOL,HOUSTON,TX 77030	University of Texas System; UTMD Anderson Cancer Center				Barr, Cathy/0000-0003-0361-0106	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672] Funding Source: Medline; NICHD NIH HHS [HD 07325] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BASTA PV, 1988, P NATL ACAD SCI USA, V85, P8618, DOI 10.1073/pnas.85.22.8618; BENECH P, 1987, MOL CELL BIOL, V7, P4498, DOI 10.1128/MCB.7.12.4498; BLANAR MA, 1989, EMBO J, V8, P1139, DOI 10.1002/j.1460-2075.1989.tb03484.x; BOSS JM, 1986, P NATL ACAD SCI USA, V83, P9139, DOI 10.1073/pnas.83.23.9139; COHEN B, 1988, EMBO J, V7, P1411, DOI 10.1002/j.1460-2075.1988.tb02958.x; COHEN B, 1989, NUCLEIC ACIDS RES, V17, P1679, DOI 10.1093/nar/17.4.1679; DALE TC, 1989, P NATL ACAD SCI USA, V86, P1203, DOI 10.1073/pnas.86.4.1203; DAY CE, 1983, NATURE, V302, P157, DOI 10.1038/302157a0; DECKER T, 1989, EMBO J, V8, P2009, DOI 10.1002/j.1460-2075.1989.tb03608.x; DEFRANCO D, 1986, MOL CELL BIOL, V6, P993, DOI 10.1128/MCB.6.4.993; DEMAEYER E, 1988, INTERFERONS OTHER RE, P174; DEMAEYER E, 1988, INTERFERONS OTHER RE, P91; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; EADES AM, 1990, J IMMUNOL, V144, P4399; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; FRIEDMAN RL, 1985, NATURE, V314, P637, DOI 10.1038/314637a0; FUJITA T, 1988, EMBO J, V7, P3397, DOI 10.1002/j.1460-2075.1988.tb03213.x; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GOODBOURN S, 1988, P NATL ACAD SCI USA, V85, P1447, DOI 10.1073/pnas.85.5.1447; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HARADA H, 1989, CELL, V58, P729, DOI 10.1016/0092-8674(89)90107-4; HUG H, 1988, MOL CELL BIOL, V8, P3065, DOI 10.1128/MCB.8.8.3065; ISRAEL A, 1986, NATURE, V322, P743, DOI 10.1038/322743a0; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KELLER AD, 1988, P NATL ACAD SCI USA, V85, P3309, DOI 10.1073/pnas.85.10.3309; KESSLER DS, 1988, EMBO J, V7, P3779, DOI 10.1002/j.1460-2075.1988.tb03262.x; KOCH N, 1989, TRENDS BIOCHEM SCI, V14, P383, DOI 10.1016/0968-0004(89)90013-3; KORBER B, 1988, SCIENCE, V239, P1302, DOI 10.1126/science.3125612; KORBER B, 1987, P NATL ACAD SCI USA, V84, P3380, DOI 10.1073/pnas.84.10.3380; KORMAN AJ, 1985, IMMUNOL REV, V85, P45, DOI 10.1111/j.1600-065X.1985.tb01130.x; LAIMINS LA, 1984, J VIROL, V49, P183, DOI 10.1128/JVI.49.1.183-189.1984; LEVY DE, 1988, GENE DEV, V2, P383, DOI 10.1101/gad.2.4.383; LONG EO, 1985, SURV IMMUNOL RES, V4, P27; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; PAULNOCKKING D, 1985, J IMMUNOL, V135, P632; PINE R, 1989, MOL CELL BIOL, V9, P3533, DOI 10.1128/MCB.9.8.3533; PINE R, 1990, MOL CELL BIOL, V10, P2448, DOI 10.1128/MCB.10.6.2448; PORTER ACG, 1988, EMBO J, V7, P85, DOI 10.1002/j.1460-2075.1988.tb02786.x; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; REICH NC, 1989, NUCLEIC ACIDS RES, V17, P3415, DOI 10.1093/nar/17.9.3415; REID LE, 1989, P NATL ACAD SCI USA, V86, P810; RUTHERFORD MN, 1988, EMBO J, V7, P751, DOI 10.1002/j.1460-2075.1988.tb02872.x; SHIRAYOSHI Y, 1988, P NATL ACAD SCI USA, V85, P5884, DOI 10.1073/pnas.85.16.5884; SUGITA K, 1987, MOL CELL BIOL, V7, P2625, DOI 10.1128/MCB.7.7.2625; TAKIGUCHI M, 1985, EUR J IMMUNOL, V15, P809, DOI 10.1002/eji.1830150813; TANIGUCHI T, 1989, J INTERFERON RES, V9, P633, DOI 10.1089/jir.1989.9.633; THANOS D, 1988, P NATL ACAD SCI USA, V85, P3075, DOI 10.1073/pnas.85.9.3075; TSANG SY, 1988, P NATL ACAD SCI USA, V85, P8598, DOI 10.1073/pnas.85.22.8598; WATHELET MG, 1988, EUR J BIOCHEM, V174, P323, DOI 10.1111/j.1432-1033.1988.tb14101.x	53	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3475	3481						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1899864				2022-12-25	WOS:A1991EY68200024
J	ABDOLLAHI, A; LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA				ABDOLLAHI, A; LORD, KA; HOFFMANLIEBERMANN, B; LIEBERMANN, DA			SEQUENCE AND EXPRESSION OF A CDNA-ENCODING MYD118 - A NOVEL MYELOID DIFFERENTIATION PRIMARY RESPONSE GENE INDUCED BY MULTIPLE CYTOKINES	ONCOGENE			English	Note							LEUKEMIA-INHIBITORY FACTOR; HEPATOCYTE-STIMULATING FACTOR; NEURONAL DIFFERENTIATION; CELLS; DISSECTION; IDENTITY; CLONING; PROTEIN	We report here the full length cDNA sequence and the deduced amino acid sequence of MyD118, a novel myeloid differentiation primary response gene transiently expressed in M1D + myeloid precursors following induction of terminal differentiation and growth arrest by IL6. MyD118 expression was observed to be induced also in the absence of protein synthesis, following stimulation of M1D + cells by IL1, LPS and Leukemia Inhibitory Factor (LIF). Detectable levels of MyD118 RNA were observed in myeloid precursor enriched murine bone marrow, but not in several other nonmyeloid murine tissues.	UNIV PENN,SCH MED,DEPT BIOCHEM & BIOPHYS,PHILADELPHIA,PA 19104	University of Pennsylvania					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007152] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1RO1CA43618-01] Funding Source: Medline; NICHD NIH HHS [5T32HD07152] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAUMANN H, 1989, J IMMUNOL, V143, P1163; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; LIEBERMANN D, 1980, DEV BIOL, V79, P46, DOI 10.1016/0012-1606(80)90072-X; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LOMEDICO PT, 1984, NATURE, V312, P458, DOI 10.1038/312458a0; LORD KA, 1990, ONCOGENE, V5, P387; LORD KA, 1990, ONCOGENE, V5, P1095; LORD KA, 1990, NUCLEIC ACIDS RES, V18, P2823, DOI 10.1093/nar/18.9.2823; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATOH T, 1988, MOL CELL BIOL, V8, P3546, DOI 10.1128/MCB.8.8.3546; SHABO Y, 1988, BLOOD, V72, P1543; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641	15	131	143	0	2	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					165	167						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899477				2022-12-25	WOS:A1991EY03900024
J	SHIBUYA, N; AMANO, K; AZUMA, J; NISHIHARA, T; KITAMURA, Y; NOGUCHI, T; KOGA, T				SHIBUYA, N; AMANO, K; AZUMA, J; NISHIHARA, T; KITAMURA, Y; NOGUCHI, T; KOGA, T			6-DEOXY-D-TALAN AND 6-DEOXY-L-TALAN - NOVEL SEROTYPE-SPECIFIC POLYSACCHARIDE ANTIGENS FROM ACTINOBACILLUS-ACTINOMYCETEMCOMITANS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PERIODONTAL-DISEASE; LOCALIZED JUVENILE PERIODONTITIS; SERUM ANTIBODY-RESPONSES; GRAM-NEGATIVE BACTERIA; HUMAN IMMUNE-RESPONSES; ORAL MICROORGANISMS; LIPOPOLYSACCHARIDE; ENDOCARDITIS; ASSOCIATION; SEROLOGY	Serotype-specific polysaccharide antigens from Actinobacillus actinomycetemcomitans ATCC 29523 (serotype a) and NCTC 9710 (serotype c) were extracted from whole cells by autoclaving and purified by ion-exchange chromatography and gel filtration. Analysis of component sugars by gas-liquid chromatography-mass spectrometry, high performance liquid chromatography, and NMR together with optical rotation data showed that the serotype a antigen was composed solely of 6-deoxy-D-talose, whereas the serotype c antigen consisted of 6-deoxy-L-talose. Structural analysis indicated that both of these antigens were composed of closely related repeating units, -3)-6-deoxy-alpha-D-Tal(p)-(1-2)-6-deoxy-alpha-D-Tal(p)-(1- (serotype a) and -3)-6-deoxy-alpha-L-Tal(p)-(1-2)-6-deoxy-alpha-L-Tal(p)-(1- (serotype c). H-1 and C-13 NMR analysis showed that both of these serotype antigens contained one acetyl group/2 sugar residues. These acetyl groups localized at the O-2 position of 3-linked 6-deoxy-D-talose (serotype a) or 0-4 position of 3-linked 6-deoxy-L-talose residues (serotype c), respectively. These results coupled with our previous findings on the serotype b antigen (Amano, K., Nishihara, T., Shibuya, N., Noguchi, T., and Koga, T. (1989) Infect. Immun. 57, 2942-2946) showed that the serotype antigens from A. actinomycetemcomitans are a group of novel polysaccharides with structural features closely related biosynthetically.	MINIST AGR FORESTRY & FISHERIES, NATL FOOD RES INST, TSUKUBA 305, JAPAN; AICHI GAKUIN UNIV, SCH DENT, DEPT PERIODONTOL, CHIKUSA KU, NAGOYA 464, JAPAN; KYOTO UNIV, FAC AGR, KYOTO 606, JAPAN; NATL INST HLTH, DEPT DENT RES, TOKYO 141, JAPAN	Ministry of Agriculture Forestry & Fisheries - Japan; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; Aichi Gakuin University; Kyoto University; National Institute of Health Sciences - Japan								AMANO K, 1989, INFECT IMMUN, V57, P2942, DOI 10.1128/IAI.57.10.2942-2946.1989; BAX A, 1981, J MAGN RESON, V44, P542, DOI 10.1016/0022-2364(81)90287-0; Bax A., 1982, 2 DIMENSIONAL NMR LI; BURGHER LW, 1973, AM J CLIN PATHOL, V60, P412; CHRISTIAN R, 1986, CARBOHYD RES, V150, P265, DOI 10.1016/0008-6215(86)80021-0; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; EBERSOLE JL, 1982, CLIN EXP IMMUNOL, V47, P43; EBERSOLE JL, 1983, J CLIN IMMUNOL, V3, P321, DOI 10.1007/BF00915793; ELLNER JJ, 1979, MEDICINE, V58, P145, DOI 10.1097/00005792-197903000-00003; GORSHKOVA RP, 1985, EUR J BIOCHEM, V150, P527, DOI 10.1111/j.1432-1033.1985.tb09053.x; GOTSCHLICH EC, 1981, J BIOL CHEM, V256, P8915; GRACE CJ, 1988, REV INFECT DIS, V10, P922; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HARDY MR, 1988, ANAL BIOCHEM, V170, P54, DOI 10.1016/0003-2697(88)90089-9; HOFFMAN J, 1980, CARBOHYD RES, V78, P212, DOI 10.1016/S0008-6215(00)83675-7; HONDA S, 1980, ANAL CHEM, V52, P1079, DOI 10.1021/ac50057a019; HOROWITZ EA, 1987, J INFECT DIS, V155, P152, DOI 10.1093/infdis/155.1.152; JOSELEAU JP, 1982, CARBOHYD RES, V101, P175, DOI 10.1016/S0008-6215(00)80998-2; KELETI J, 1971, EUR J BIOCHEM, V20, P237, DOI 10.1111/j.1432-1033.1971.tb01386.x; KOGA T, 1990, ZBL BAKT-INT J MED M, V274, P91; LEONTEIN K, 1978, CARBOHYD RES, V62, P359, DOI 10.1016/S0008-6215(00)80882-4; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDELL RL, 1987, J CLIN PERIODONTOL, V14, P534, DOI 10.1111/j.1600-051X.1987.tb00996.x; MARKOVITZ A, 1962, J BIOL CHEM, V237, P1767; MUHLE I, 1979, JAMA-J AM MED ASSOC, V241, P1824, DOI 10.1001/jama.241.17.1824; NAGAOKA M, 1988, J BIOCHEM-TOKYO, V103, P618, DOI 10.1093/oxfordjournals.jbchem.a122316; NISHIHARA T, 1988, INFECT IMMUN, V56, P619, DOI 10.1128/IAI.56.3.619-625.1988; OUCHTERLONY O, 1958, PROG ALLERGY, V5, P1, DOI 10.1159/000273347; PAZUR JH, 1972, ARCH BIOCHEM BIOPHYS, V150, P382, DOI 10.1016/0003-9861(72)90053-7; RANTZ LOWELL A., 1955, STANFORD MED BULL, V13, P290; SANDHOLM L, 1987, J CLIN PERIODONTOL, V14, P289, DOI 10.1111/j.1600-051X.1987.tb01535.x; SAWARDEKER JS, 1965, ANAL CHEM, V37, P1602, DOI 10.1021/ac60231a048; SCHAFFER R, 1972, CARBOHYDRATES      A, V1, P69; SHIBAEV VN, 1986, ADV CARBOHYD CHEM BI, V44, P277; SLOTS J, 1982, J PERIODONTAL RES, V17, P447, DOI 10.1111/j.1600-0765.1982.tb02022.x; SLOTS J, 1984, J DENT RES, V63, P412, DOI 10.1177/00220345840630031101; SLOTS J, 1988, J CLIN PERIODONTOL, V15, P85, DOI 10.1111/j.1600-051X.1988.tb00999.x; SMITH ARW, 1985, EUR J BIOCHEM, V149, P73, DOI 10.1111/j.1432-1033.1985.tb08895.x; TAKAHASHI T, 1991, INFECT IMMUN, V59, P18, DOI 10.1128/IAI.59.1.18-23.1991; TAKEUCHI S, 1977, TETRAHEDRON LETT, P2943; TEKEUCHI M, 1984, NIPPON NOGEIKAGAKU K, V58, P385; YOKOTA S, 1987, EUR J BIOCHEM, V167, P203, DOI 10.1111/j.1432-1033.1987.tb13324.x; Zambon J J, 1988, Adv Dent Res, V2, P269; ZAMBON JJ, 1985, J CLIN PERIODONTOL, V12, P1, DOI 10.1111/j.1600-051X.1985.tb01348.x; ZAMBON JJ, 1984, INFECT IMMUN, V44, P22, DOI 10.1128/IAI.44.1.22-27.1984; ZAMBON JJ, 1983, INFECT IMMUN, V41, P19, DOI 10.1128/IAI.41.1.19-27.1983	46	51	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16318	16323						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885566				2022-12-25	WOS:A1991GD63500015
J	GOLOSINSKA, K; PEARLSTONE, JR; BORGFORD, T; OIKAWA, K; KAY, CM; CARPENTER, MR; SMILLIE, LB				GOLOSINSKA, K; PEARLSTONE, JR; BORGFORD, T; OIKAWA, K; KAY, CM; CARPENTER, MR; SMILLIE, LB			DETERMINATION OF AND CORRECTIONS TO SEQUENCES OF TURKEY AND CHICKEN TROPONINS-C - EFFECTS OF THR-130 TO ILE MUTATION ON CA2+ AFFINITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; SITE-DIRECTED MUTAGENESIS; ALKALI LIGHT-CHAINS; SKELETAL-MUSCLE; CONFORMATIONAL TRANSITION; BINDING-PROTEINS; MULTIPLE METALS; RESOLUTION; DNA; CONTRACTION	Reported differences in the primary structures of chicken muscle troponin C (Wilkinson, J. M. (1976) FEBS Lett. 70, 254-256) and recombinant protein deduced from a chick muscle cDNA (Reinach, F. C. and Karlsson, R. (1988) J. Biol. Chem. 263, 2371-2376) have been reinvestigated. The complete amino acid sequence of turkey muscle troponin C has also been elucidated. Residue 100, originally reported as Asp in the chicken muscle protein, is shown to be Asn in all three structures. The three amino acid sequences are identical except as follows: 1) the blocked NH2-terminal Ala at residue 1 of the chicken protein is replaced by nonblocked Met-Ala in the recombinant protein and by nonblocked Pro in turkey troponin-C; 2) residue 130 is Thr in both avian muscle proteins but Ile in the recombinant protein; 3) Asp-133 in the chicken muscle and recombinant troponins-C is replaced by Glu in the turkey protein; 4) residue 99, originally identified as Glu in the x-ray structure of the turkey protein, is shown to be Ala in all three proteins. Calcium titration of the metal-induced conformational transition of the protein as monitored by far UV CD measurements indicated a significant decrease in Ca2+ affinity of the high-affinity sites in the case of the recombinant protein as compared with the chicken muscle protein. Both pairs of sites showed high cooperativity. That this decreased Ca2+ affinity could be attributed to different amino acid residues at position 130 and not to the differences at the NH2 termini was confirmed by site-specific mutation of Ile-130 to Thr in the recombinant protein. The mutated recombinant protein now titrated identically to the chicken muscle protein. Thr-130, whereas over 21 angstrom from the metal of sites III and IV, is involved in a hydrogen bonding network with structured water and the NH2-terminal region of helix G.			SMILLIE, LB (corresponding author), UNIV ALBERTA, DEPT BIOCHEM, MRC, PROT STRUCT & FUNCT GRP, EDMONTON T6G 2H7, ALBERTA, CANADA.							ARLEY N, 1950, INTRO THEORY PROBABI, P181; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; COLLINS JH, 1976, NATURE, V259, P699, DOI 10.1038/259699a0; EBASHI S, 1971, J BIOCHEM, V69, P441, DOI 10.1093/oxfordjournals.jbchem.a129486; ESNOUF MP, 1962, BIOCHEM J, V84, P62, DOI 10.1042/bj0840062; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FRANK G, 1974, EUR J BIOCHEM, V44, P317; FUJIMORI K, 1990, NATURE, V345, P182, DOI 10.1038/345182a0; GRAND RJA, 1977, BIOCHEM J, V167, P183, DOI 10.1042/bj1670183; GRAND RJA, 1985, TOP MOL STRUCT BIOL, V7, P65; GREASER ML, 1971, J BIOL CHEM, V246, P4226; HANAHAN D, 1986, DNA CLONING, V1, P115; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HERZBERG O, 1986, J BIOL CHEM, V261, P2638; HERZBERG O, 1985, BIOCHEMISTRY-US, V24, P5298, DOI 10.1021/bi00341a004; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HULL WE, 1975, THESIS HARVARD U; KOBAYASHI T, 1989, J BIOL CHEM, V264, P18247; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LEBHERZ HG, 1984, J BIOL CHEM, V259, P1132; MANI RS, 1983, BIOCHEMISTRY-US, V22, P3902, DOI 10.1021/bi00285a027; NGAI K, 1987, METHOD ENZYMOL, V153, P461; NIKRAD PV, 1990, BIOCHEM J, V272, P343, DOI 10.1042/bj2720343; OFFORD RE, 1966, NATURE, V211, P591, DOI 10.1038/211591a0; PEARLSTONE JR, 1987, J BIOL CHEM, V262, P5985; PEARLSTONEJR, 1986, J BIOL CHEM, V262, P16795; PERRIN DD, 1967, TALANTA, V14, P833, DOI 10.1016/0039-9140(67)80105-X; REINACH FC, 1988, J BIOL CHEM, V263, P2371; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATYSHUR KA, 1988, J BIOL CHEM, V263, P1628; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; SUNDARALINGAM M, 1985, SCIENCE, V227, P945, DOI 10.1126/science.3969570; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WILKINSON JM, 1978, NATURE, V271, P31, DOI 10.1038/271031a0; WILKINSON JM, 1976, FEBS LETT, V70, P254, DOI 10.1016/0014-5793(76)80769-7; XU GQ, 1988, J BIOL CHEM, V263, P13962; ZOLLER MJ, 1982, NUCLEIC ACIDS RES, V10, P6487, DOI 10.1093/nar/10.20.6487; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; 1987, STEP BY STEP PROTOCO	41	52	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15797	15809						13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908459				2022-12-25	WOS:A1991GB97700044
J	LEE, H; BROEKAERT, WF; RAIKHEL, NV				LEE, H; BROEKAERT, WF; RAIKHEL, NV			CO-TRANSLATIONAL AND POSTTRANSLATIONAL PROCESSING OF THE HEVEIN PREPROPROTEIN OF LATEX OF THE RUBBER TREE (HEVEA-BRASILIENSIS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT-GERM-AGGLUTININ; LEAF-SPECIFIC THIONINS; MESSENGER-RNAS; PROTEINS; CHITINASE; BARLEY; GENES; ACCUMULATION; EXPRESSION; SEQUENCE	Hevein is a chitin-binding protein of 43 amino acids found in the lutoid body-enriched fraction of rubber tree latex. A hevein cDNA clone (HEV1) (Broekaert, W., Lee, H.-i., Kush, A., Nam, C.-H., and Raikhel, N. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 7633-7637) encodes a putative signal sequence of 17 amino acids followed by a polypeptide of 187 amino acids. Interestingly, this polypeptide has two distinct domains: an amino-terminal domain of 43 amino acids, corresponding to mature hevein, and a carboxyl-terminal domain of 144 amino acids. To investigate the mechanisms involved in processing of the protein encoded by HEV1, three domain-specific antisera were raised against fusion proteins harboring the amino-terminal domain (N domain), carboxyl-terminal domain (C domain), and both domains (NC domain). Translocation experiments using an in vitro translation system show that the first 17-amino acid sequence encoded by the cDNA functions as a signal peptide. Immunoblot analysis of proteins extracted from lutoid bodies demonstrates that a 5-kDa protein comigrated with purified mature hevein and cross-reacted with N domain- and NC domain-specific antibodies. A 14-kDa protein was recognized by C domain- and NC domain-specific antibodies. A 20-kDa protein was cross-reactive with all three antibodies. Microsequencing data further suggest that the 5-kDa (amino-terminal domain) and 14-kDa (carboxyl-terminal domain) proteins are post-translational cleavage products of the 20-kDa polypeptide (both domains) which corresponds to the proprotein encoded by HEV1. In addition, it was found that the amino-terminal domain could provide chitin-binding properties to a fusion protein bearing it either amino terminally or carboxyl terminally.	MICHIGAN STATE UNIV,DEPT ENERGY,PLANT RES LAB,E LANSING,MI 48824; CATHOLIC UNIV LEUVEN,FA JANSSENS LAB,B-3001 HEVERLEE,BELGIUM	Michigan State University; KU Leuven								ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; ARCHER BL, 1960, BIOCHEM J, V75, P236, DOI 10.1042/bj0750236; BLACK MS, 1984, ANAL BIOCHEM, V136, P175; BOHLMANN H, 1988, EMBO J, V7, P1559, DOI 10.1002/j.1460-2075.1988.tb02980.x; BOHLMANN H, 1987, MOL GEN GENET, V207, P446, DOI 10.1007/BF00331614; BROEKAERT W, 1990, P NATL ACAD SCI USA, V87, P7633, DOI 10.1073/pnas.87.19.7633; BROGLIE KE, 1986, P NATL ACAD SCI USA, V83, P6820, DOI 10.1073/pnas.83.18.6820; CHRISPEELS MJ, 1991, PLANT CELL, V3, P1, DOI 10.1105/tpc.3.1.1; D'Auzac J., 1989, PHYSL RUBBER TREE LA; GAUSING K, 1987, PLANTA, V171, P241, DOI 10.1007/BF00391100; GUAN C, 1987, GENE AMST, V67, P459; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFLAMME D, 1989, PLANT MOL BIOL, V13, P249, DOI 10.1007/BF00016142; LERNER DR, 1989, PLANT PHYSIOL, V91, P124, DOI 10.1104/pp.91.1.124; LUCAS J, 1985, FEBS LETT, V193, P208, DOI 10.1016/0014-5793(85)80152-6; MANSFIELD MA, 1988, PLANTA, V173, P482, DOI 10.1007/BF00958961; MARTIN MN, 1991, PLANT PHYSIOL, V95, P469, DOI 10.1104/pp.95.2.469; MOIR GFJ, 1959, NATURE, V184, P1626, DOI 10.1038/1841626a0; MOLANO J, 1977, ANAL BIOCHEM, V83, P648, DOI 10.1016/0003-2697(77)90069-0; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARSONS TJ, 1989, P NATL ACAD SCI USA, V86, P7895, DOI 10.1073/pnas.86.20.7895; RAIKHEL NV, 1987, P NATL ACAD SCI USA, V84, P6745, DOI 10.1073/pnas.84.19.6745; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHINSHI H, 1987, P NATL ACAD SCI USA, V84, P89, DOI 10.1073/pnas.84.1.89; STANFORD A, 1989, MOL GEN GENET, V215, P200, DOI 10.1007/BF00339718; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VANPARIJS J, 1991, PLANTA, V183, P258, DOI 10.1007/BF00197797; Walujono K., 1976, P INT RUBBER C KUALA, V2, P518; WILKINS TA, 1989, PLANT CELL, V1, P541, DOI 10.1105/tpc.1.5.541	30	83	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15944	15948						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874741				2022-12-25	WOS:A1991GB97700064
J	YOUNG, SL; SEARLES, RP; KAYNARD, AH; MELNER, MH				YOUNG, SL; SEARLES, RP; KAYNARD, AH; MELNER, MH			SPECIFIC-INHIBITION OF PROTEIN KINASE-A IN GRANULOSA-CELLS ABOLISHES GONADOTROPIN REGULATION OF THE PROOPIOMELANOCORTIN PROMOTER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER RIBONUCLEIC-ACID; CYCLIC-AMP; HORMONAL-REGULATION; CHLORAMPHENICOL ACETYLTRANSFERASE; ADRENOCORTICAL 21-HYDROXYLASE; GENE-TRANSCRIPTION; MOLECULAR-CLONING; ENHANCER ELEMENT; LEYDIG-CELLS; FREE CA-2+	Gonadotropins (follicle-stimulating hormone (FSH), luteinizing hormone, and human chorionic gonadotropin) and beta-adrenergic agonists have been shown to stimulate expression of the proopiomelanocortin (POMC) gene in ovarian granulosa cells. The current studies investigate the intracellular mechanisms by which gonadotropins regulate gene expression. Primary cultures of rat granulosa cells were transfected with the plasmid POMC-CAT-150, which expresses the chloramphenicol acetyltransferase (CAT) reporter gene under the regulation of the rat POMC 5'-flanking region. CAT activity was stimulated by treatment of the cells with either 20 ng/ml FSH or 1-mu-M isoproterenol. To assess the role of protein kinase A (ATP:protein phosphotransferase; EC 2.7.1.37) in the gonadotropin and adrenergic response, an expression vector, MtR-AB, encoding a mutant RI regulatory subunit was cotransfected with POMC-CAT-150. The mutant protein kinase A regulatory subunit encoded by MtR-AB lacks functional cAMP-binding sites but effectively binds and specifically inhibits the catalytic activity of protein kinase A. The results of this analysis demonstrated that gonadotropin and adrenergic agonist stimulation of the POMC-CAT reporter construct in primary cultures of rat granulosa cells were abolished by cotransfection with MtR-AB; whereas a control SV40-promoter construct was unaffected by either gonadotropin treatment or cotransfection with MtR-AB. Basal expression directed by the POMC promoter was also decreased by cotransfection with the MtR-AB, implying that basal expression from the POMC promoter may also depend on protein kinase A. Deletion analysis of the POMC sequence indicated regions (-40 to -33 and +4 to +63) important for basal and FSH-stimulated expression. These studies suggest that both gonadotropin and adrenergic stimulation of the POMC promoter are mediated by protein kinase A and that regions proximal to the promoter are essential for gonadotropin-regulated expression from the promoter.	OREGON REG PRIMATE RES CTR, DIV REPROD BIOL, 505 NW 185TH AVE, BEAVERTON, OR 97006 USA; OREGON REG PRIMATE RES CTR, DIV NEUROSCI, BEAVERTON, OR 97006 USA; OREGON HLTH SCI UNIV, DEPT CELL BIOL & ANAT, PORTLAND, OR 97201 USA	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University					NATIONAL CENTER FOR RESEARCH RESOURCES [P51RR000163] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041035] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00163] Funding Source: Medline; NIDDK NIH HHS [DK-41035] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADASHI EY, 1981, ENDOCRINOLOGY, V108, P2170, DOI 10.1210/endo-108-6-2170; BUCHLER W, 1988, FEBS LETT, V228, P27, DOI 10.1016/0014-5793(88)80577-5; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CAMPBELL KL, 1979, BIOL REPROD, V21, P773, DOI 10.1095/biolreprod21.4.773; CLARK MR, 1976, BIOCHEM J, V158, P175, DOI 10.1042/bj1580175; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; DAVIS JS, 1987, J BIOL CHEM, V262, P8515; DAY RN, 1989, J BIOL CHEM, V264, P431; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GROVE JR, 1987, SCIENCE, V238, P530; HABENER JF, 1990, MOL ENDOCRINOL, V4, P1087, DOI 10.1210/mend-4-8-1087; HALES DB, 1990, ENDOCRINOLOGY, V126, P2800, DOI 10.1210/endo-126-6-2800; HANDLER JD, 1988, J BIOL CHEM, V263, P13068; HARDY KG, 1987, PLASMIDS PRACTICAL A, P1; HEDIN L, 1987, ENDOCRINOLOGY, V120, P1928, DOI 10.1210/endo-120-5-1928; HSUEH AJW, 1984, ENDOCR REV, V5, P76, DOI 10.1210/edrv-5-1-76; HUNZICKERDUNN M, 1982, BIOCHIM BIOPHYS ACTA, V714, P395, DOI 10.1016/0304-4165(82)90146-5; HYMAN SE, 1989, MOL CELL BIOL, V9, P321, DOI 10.1128/MCB.9.1.321; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; JEANNOTTE L, 1987, MOL ENDOCRINOL, V1, P749, DOI 10.1210/mend-1-10-749; KNECHT M, 1981, J BIOL CHEM, V256, P628; KNEPEL W, 1990, ENDOCRINOLOGY S, V126, P533; LEFKOWITZ RJ, 1988, J BIOL CHEM, V263, P4993; LEVY FO, 1988, MOL ENDOCRINOL, V2, P1364, DOI 10.1210/mend-2-12-1364; Marsh J M, 1975, Adv Cyclic Nucleotide Res, V6, P137; MARSH JM, 1966, J BIOL CHEM, V241, P5436; MASMONTEIL TL, 1985, P NATL ACAD SCI USA, V84, P7261; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MELNER MH, 1986, ENDOCRINOLOGY, V119, P2082, DOI 10.1210/endo-119-5-2082; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NIMROD A, 1976, MOL CELL ENDOCRINOL, V5, P315, DOI 10.1016/0303-7207(76)90093-9; RIABOWOL KT, 1988, NATURE, V336, P83, DOI 10.1038/336083a0; RIEGEL AT, 1990, NUCLEIC ACIDS RES, V18, P4513, DOI 10.1093/nar/18.15.4513; ROBERTS JL, 1987, ANN NY ACAD SCI, V512, P275, DOI 10.1111/j.1749-6632.1987.tb24966.x; SANDERS SL, 1990, MOL ENDOCRINOL, V4, P1311, DOI 10.1210/mend-4-9-1311; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAW WV, 1983, CRC CR REV BIOCH MOL, V14, P1, DOI 10.3109/10409238309102789; SULLIVAN MHF, 1986, BIOCHEM J, V236, P45, DOI 10.1042/bj2360045; USUI T, 1989, MOL CELL ENDOCRINOL, V62, P141, DOI 10.1016/0303-7207(89)90123-8; WANG HY, 1990, MOL ENDOCRINOL, V4, P80, DOI 10.1210/mend-4-1-80; YOUNG SL, 1989, STEROIDS, V54, P583, DOI 10.1016/0039-128X(89)90082-2; YOUNG SL, 1989, MOL ENDOCRINOL, V3, P15, DOI 10.1210/mend-3-1-15; YOUNG SL, 1985, DNA-J MOLEC CELL BIO, V4, P469, DOI 10.1089/dna.1985.4.469	45	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15839	15844						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908460				2022-12-25	WOS:A1991GB97700049
J	GIBSON, JL; FALCONE, DL; TABITA, FR				GIBSON, JL; FALCONE, DL; TABITA, FR			NUCLEOTIDE-SEQUENCE, TRANSCRIPTIONAL ANALYSIS, AND EXPRESSION OF GENES ENCODED WITHIN THE FORM-I CO2 FIXATION OPERON OF RHODOBACTER-SPHAEROIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE 1,5-BISPHOSPHATE CARBOXYLASE; SMALL SUBUNIT GENES; ESCHERICHIA-COLI; RHODOPSEUDOMONAS-SPHAEROIDES; FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; PHOSPHORIBULOKINASE ACTIVITY; TRANSPOSON MUTAGENESIS; ALCALIGENES-EUTROPHUS; OXYGENASE GENES; MESSENGER-RNA	In Rhodobacter sphaeroides, many of the structural genes encoding enzymes of the Calvin cycle are duplicated and grouped within two separate clusters. In this study, the nucleotide sequence of a 5627-base pair region of DNA that contains the form I Calvin cycle gene cluster has been determined. The five open reading frames are arranged in the order, fbpA prkA cfxA rbcL rbcS and are tightly linked and oriented in the same direction. The results of insertional mutagenesis studies suggest the genes are organized within an operon. Consistent with this proposal, the cfxA gene has been tentatively identified as a gene encoding the Calvin cycle enzyme, aldolase. Measurement of the activities of various Calvin cycle enzymes in the insertion mutants showed that inactivation of genes within one CO2 fixation cluster affected expression of genes within the second cluster, revealing a complex regulatory network.	OHIO STATE UNIV,DEPT MICROBIOL,484 W 12TH AVE,COLUMBUS,OH 43210; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210	Ohio State University; Ohio State University					NIGMS NIH HHS [GM 24497] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024497] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALEFOUNDER PR, 1989, BIOCHEM J, V257, P529, DOI 10.1042/bj2570529; ALEFOUNDER PR, 1989, MOL MICROBIOL, V3, P723, DOI 10.1111/j.1365-2958.1989.tb00221.x; ANDERSEN K, 1987, J BACTERIOL, V169, P4547, DOI 10.1128/jb.169.10.4547-4558.1987; BAGA M, 1988, CELL, V52, P197, DOI 10.1016/0092-8674(88)90508-9; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; FALCONE DL, 1991, J BACTERIOL, V173, P2099, DOI 10.1128/jb.173.6.2099-2108.1991; FALCONE DL, 1988, J BACTERIOL, V170, P5, DOI 10.1128/jb.170.1.5-11.1988; GIBSON JL, 1986, GENE, V44, P271, DOI 10.1016/0378-1119(86)90191-5; GIBSON JL, 1987, J BACTERIOL, V169, P3685, DOI 10.1128/jb.169.8.3685-3690.1987; GIBSON JL, 1988, J BACTERIOL, V170, P2153, DOI 10.1128/jb.170.5.2153-2158.1988; GIBSON JL, 1990, BIOCHEMISTRY-US, V29, P8085, DOI 10.1021/bi00487a014; GIBSON JL, 1985, J BACTERIOL, V164, P1188, DOI 10.1128/JB.164.3.1188-1193.1985; GIBSON JL, 1977, J BIOL CHEM, V252, P943; HALLENBECK PL, 1990, J BACTERIOL, V172, P1749, DOI 10.1128/jb.172.4.1749-1761.1990; HALLENBECK PL, 1990, J BACTERIOL, V172, P1736, DOI 10.1128/jb.172.4.1736-1748.1990; HALLENBECK PL, 1987, J BACTERIOL, V169, P3669, DOI 10.1128/jb.169.8.3669-3678.1987; HWANG SR, 1991, J BIOL CHEM, V266, P6271; JOUANNEAU Y, 1986, J BACTERIOL, V165, P620, DOI 10.1128/jb.165.2.620-624.1986; KAY R, 1987, NUCLEIC ACIDS RES, V15, P2778, DOI 10.1093/nar/15.6.2778; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEIJER WG, 1991, MOL GEN GENET, V225, P320, DOI 10.1007/BF00269865; MEIJER WG, 1990, J GEN MICROBIOL, V136, P2225, DOI 10.1099/00221287-136-11-2225; NARGANG F, 1984, MOL GEN GENET, V193, P220, DOI 10.1007/BF00330671; QUIVEY RG, 1984, GENE, V31, P91, DOI 10.1016/0378-1119(84)90198-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; TABITA FR, 1980, J BACTERIOL, V143, P1275, DOI 10.1128/JB.143.3.1275-1280.1980; TABITA FR, 1986, BIO-TECHNOL, V4, P138, DOI 10.1038/nbt0286-138; TRUPER HG, 1979, PHOTOSYNTHETIC BACTE, P19; VIALE AM, 1989, J BACTERIOL, V171, P2391, DOI 10.1128/jb.171.5.2391-2400.1989; WAGNER SJ, 1988, FEMS MICROBIOL LETT, V55, P217, DOI 10.1111/j.1574-6968.1988.tb13937.x; WEAVER KE, 1983, J BACTERIOL, V165, P507; WINDHOVEL U, 1990, ARCH MICROBIOL, V154, P85; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHU Y S, 1985, Journal of Bacteriology, V162, P925	36	101	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14646	14653						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907281				2022-12-25	WOS:A1991FZ35100082
J	YE, RW; TOROSUAREZ, I; TIEDJE, JM; AVERILL, BA				YE, RW; TOROSUAREZ, I; TIEDJE, JM; AVERILL, BA			(H2O)-O-18 ISOTOPE EXCHANGE STUDIES ON THE MECHANISM OF REDUCTION OF NITRIC-OXIDE AND NITRITE TO NITROUS-OXIDE BY DENITRIFYING BACTERIA - EVIDENCE FOR AN ELECTROPHILIC NITROSYL DURING REDUCTION OF NITRIC-OXIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							N-N-BOND; PSEUDOMONAS-STUTZERI; MICROBIAL DENITRIFICATION; PARACOCCUS-DENITRIFICANS; INTERMEDIATE; PORPHYRINS; CATALYSIS	Reduction of NO and NO2- by whole cells of eight strains of denitrifying bacteria known to contain either heme cd1 or copper-containing nitrite reductases (NiRs) has been examined in the presence of (H2O)-O-18. All organisms containing heme cd1 NiRs exhibited relatively large extents of exchange between NO2- and (H2O)-O-18 (39-100%), as monitored by the O-18 content of product N2O. Organisms containing copper NiRs gave highly variable results, with Achromobacter cycloclastes and Pseudomonas aureofaciens exhibiting no O-18 incorporation and Rhodopseudomonas sphaeroides and Alcaligenes entrophus exhibiting complete exchange between NO2- and (H2O)-O-18. Organisms containing heme cd1 NiRs exhibited significant but lower levels of exchange between NO and (H2O)-O-18 than between NO2- and (H2O)-O-18, while organisms containing copper NiRs gave significantly higher amounts of O-18 incorporation than observed for the heme cd1 organisms. These results demonstrate the existence of an NO-derived species capable of undergoing 0-atom exchange with (H2O)-O-18 during the reduction of NO. Trapping experiments with (NO)-N-15, N-14(3)-, and crude extracts of R. sphaeroides support the electrophilic nature of this intermediate and suggest its formulation as an enzyme nitrosyl, E-NO+, analogous to that observed during reduction of NO2-. The observation of lower levels of O-18 incorporation with NO2- than with NO as substrate for A. cycloclastes and P. aureofaciens indicates that, for these organisms at least, a sequential pathway involving free NO as an intermediate is significantly less important than a direct pathway in which N2O is formed via reaction of two NO2- ions on a single enzyme.	MICHIGAN STATE UNIV,DEPT MICROBIOL & PUBL HLTH,E LANSING,MI 48824; MICHIGAN STATE UNIV,DEPT CROP & SOIL SCI,E LANSING,MI 48824; UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901	Michigan State University; Michigan State University; University of Virginia								AERSSENS E, 1986, J BIOL CHEM, V261, P9652; AVERILL BA, 1982, FEBS LETT, V138, P8, DOI 10.1016/0014-5793(82)80383-9; BARLEY MH, 1986, J AM CHEM SOC, V108, P5876, DOI 10.1021/ja00279a036; BESSIERES P, 1984, BIOCHIMIE, V66, P313, DOI 10.1016/0300-9084(84)90008-7; BETLACH MR, 1981, APPL ENVIRON MICROB, V42, P1074, DOI 10.1128/AEM.42.6.1074-1084.1981; BRYAN BA, 1983, J BIOL CHEM, V258, P8613; CARR GJ, 1989, EUR J BIOCHEM, V179, P683, DOI 10.1111/j.1432-1033.1989.tb14601.x; CARR GJ, 1990, BIOCHEM J, V269, P423, DOI 10.1042/bj2690423; COYNE MS, 1989, APPL ENVIRON MICROB, V55, P2924, DOI 10.1128/AEM.55.11.2924-2931.1989; FERGUSON SJ, 1987, TRENDS BIOCHEM SCI, V12, P354, DOI 10.1016/0968-0004(87)90164-2; FUJITA E, 1983, J AM CHEM SOC, V105, P6743, DOI 10.1021/ja00360a049; GARBER EAE, 1982, J BIOL CHEM, V257, P8091; GORETSKI J, 1990, J BIOL CHEM, V265, P889; GORETSKI J, 1990, J BIOL CHEM, V265, P11535; HEISS B, 1989, J BACTERIOL, V171, P3288, DOI 10.1128/jb.171.6.3288-3297.1989; HOCHSTEIN LI, 1988, ANNU REV MICROBIOL, V42, P231, DOI 10.1146/annurev.mi.42.100188.001311; HOGLEN J, 1989, J BIOL CHEM, V264, P7556; HULSE CL, 1989, J AM CHEM SOC, V111, P2322, DOI 10.1021/ja00188a067; KIM CH, 1984, J BIOL CHEM, V259, P2092; OLSON LW, 1982, J AM CHEM SOC, V104, P2042, DOI 10.1021/ja00371a051; PAYNE WJ, 1981, DENITRIFICATION, P79; SHEARER G, 1988, J BIOL CHEM, V263, P13231; Tiedje JM, 1988, MICROORGANISMS, V717, P179; WEEGAERSSENS E, 1988, J AM CHEM SOC, V110, P6851, DOI 10.1021/ja00228a039; WEEGAERSSENS E, 1987, J AM CHEM SOC, V109, P7214, DOI 10.1021/ja00257a065; WHARTON DC, 1980, BIOCHEM BIOPH RES CO, V97, P236, DOI 10.1016/S0006-291X(80)80159-8; ZAFIRIOU OC, 1989, J BIOL CHEM, V264, P5694; Zumft W. G., 1988, The Nitrogen and Sulphur Cycles. Proceedings of the 42nd Symposium of the Society for General Microbiology. Southampton, UK, January 1988., P245; ZUMFT WG, 1988, ARCH MICROBIOL, V149, P492, DOI 10.1007/BF00446750	29	89	91	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					12848	12851						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1906460				2022-12-25	WOS:A1991FX13200011
J	FOSTER, R; GEDAMU, L				FOSTER, R; GEDAMU, L			FUNCTIONAL ANALYSES OF PROMOTER ELEMENTS RESPONSIBLE FOR THE DIFFERENTIAL EXPRESSION OF THE HUMAN METALLOTHIONEIN (MT)-IG AND MT-IF GENES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METAL REGULATORY ELEMENTS; HEAVY-METALS; TRANSCRIPTIONAL REGULATION; SEQUENCES; ENHANCER; GLUCOCORTICOIDS; INDUCTION; INTERACTS; PROTEIN; INVITRO	The sequences responsible for heavy metal-inducible expression are situated within the proximal 437 and 160 base pairs (bp) of MT-IF and MT-IG 5'-flanking sequence, respectively. Only 105 bp of proximal MT-IG 5'-flanking sequence containing a TATA box, two metal responsive elements (MREs), and three GC motifs and 147 bp of proximal MT-IF 5'-flanking sequence containing a TATCA box, four MREs, and two GC motifs were required for heavy metal-inducible expression. However, the proximal 111 bp of MT-IF 5'-flanking sequences (a TATCA box, two MREs, and two GC motifs) was not responsive to heavy metals and competes less efficiently than the 105-bp MT-IG fragment in a competition transfection analysis. The MT-IF promoter fragment containing MREc and MREd is substantially stronger and a more efficient competitor than the MT-IG promoter fragment containing MREc and MREd. Furthermore, the proximal 160 bp of MT-IG 5'-flanking sequence functions as a strong metal-inducible promoter but not as a metal-inducible enhancer. Mobility shift analysis of MT-IF and MT-IG promoter subregions suggests a correlation between protein binding to MRE sequences and MT gene expression. These data illstrate that the overall structural and functional organization of the MT-IF and MT-IG promoters are very different and that the molecular mechanisms governing differential expression levels of human MT genes are quite complex.	UNIV CALGARY,DEPT BIOL SCI,CALGARY T2N 1N4,ALBERTA,CANADA	University of Calgary								BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARTER AD, 1984, P NATL ACAD SCI-BIOL, V81, P7392, DOI 10.1073/pnas.81.23.7392; CHUI R, 1987, NATURE, V329, P648; CULOTTA VC, 1989, MOL CELL BIOL, V9, P1376, DOI 10.1128/MCB.9.3.1376; DURNAM DM, 1981, J BIOL CHEM, V256, P5712; EHRICH R, 1988, MOL CELL BIOL, V8, P695; FOSTER R, 1988, J BIOL CHEM, V263, P11528; HAGER LJ, 1981, NATURE, V291, P340, DOI 10.1038/291340a0; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HAMER DH, 1986, ANNU REV BIOCHEM, V55, P913, DOI 10.1146/annurev.biochem.55.1.913; HEGUY A, 1986, MOL CELL BIOL, V6, P2149, DOI 10.1128/MCB.6.6.2149; IMBERT J, 1989, MOL CELL BIOL, V9, P5315, DOI 10.1128/MCB.9.12.5315; JAHROUDI N, 1990, J BIOL CHEM, V265, P6506; Kagi J.H.R., 1979, METALLOTHIONEIN; KAGI JHR, 1984, ENVIRON HEALTH PERSP, V54, P93, DOI 10.2307/3429795; KARIN M, 1980, NATURE, V286, P295, DOI 10.1038/286295a0; KARIN M, 1982, NATURE, V299, P797, DOI 10.1038/299797a0; KARIN M, 1984, NATURE, V308, P513, DOI 10.1038/308513a0; KNOWLES BB, 1984, ADV HEPATITIS RES; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LIVANT DL, 1988, P NATL ACAD SCI USA, V85, P7607, DOI 10.1073/pnas.85.20.7607; MARTINEZ E, 1987, EMBO J, V6, P3719, DOI 10.1002/j.1460-2075.1987.tb02706.x; MUELLER PR, 1988, GENE DEV, V2, P412, DOI 10.1101/gad.2.4.412; RICHARDS RI, 1984, CELL, V37, P263, DOI 10.1016/0092-8674(84)90322-2; SADHU C, 1988, J BIOL CHEM, V263, P2679; SCHMIDT CJ, 1986, P NATL ACAD SCI USA, V83, P3346, DOI 10.1073/pnas.83.10.3346; SCHMIDT CJ, 1985, J BIOL CHEM, V260, P7731; SCHOLER HR, 1984, CELL, V36, P403, DOI 10.1016/0092-8674(84)90233-2; SEGUIN C, 1984, NATURE, V312, P781, DOI 10.1038/312781a0; SEGUIN C, 1987, SCIENCE, V235, P1383, DOI 10.1126/science.3103216; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; STUART GW, 1984, P NATL ACAD SCI-BIOL, V81, P7318, DOI 10.1073/pnas.81.23.7318; STUART GW, 1985, NATURE, V317, P828, DOI 10.1038/317828a0; VARSHNEY U, 1986, MOL CELL BIOL, V6, P26, DOI 10.1128/MCB.6.1.26; WESTIN G, 1988, EMBO J, V7, P3763, DOI 10.1002/j.1460-2075.1988.tb03260.x; ZAFARULLAH M, 1988, MOL CELL BIOL, V8, P4469, DOI 10.1128/MCB.8.10.4469	36	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9866	9875						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903400				2022-12-25	WOS:A1991FM45900079
J	MOLL, J; SANSIG, G; FATTORI, E; VANDERPUTTEN, H				MOLL, J; SANSIG, G; FATTORI, E; VANDERPUTTEN, H			THE MURINE RAC1 GENE - CDNA CLONING, TISSUE DISTRIBUTION AND REGULATED EXPRESSION OF RAC1 MESSENGER-RNA BY DISASSEMBLY OF ACTIN MICROFILAMENTS	ONCOGENE			English	Note							5' NONCODING REGION; RNA SECONDARY STRUCTURE; MESSENGER-RNA; TRANSLATIONAL EFFICIENCY; EUKARYOTIC RIBOSOMES; CPG ISLANDS; RAS; PROTEIN; FAMILY; SECRETION	A 886 bp cDNA encoding the murine rac1 protein has been isolated. The abundance of rac1 mRNA was determined in fourteen tissues from both mouse and pig. The mRNA 5' non-coding sequence is very rich in G + C, and has the potential to form several stable secondary structures. In addition, this region contains a putative open reading frame of 57 amino acids. Disruption of the actin microfilament network by cytochalasin B in LLC-PK1 cells results in down regulation of rac1 mRNA. In agreement with the proposed role of rac1 in exocytosis, these results could explain the inhibitory effect of cytochalasin B on secretory processes.	CIBA GEIGY AG,DEPT BIOTECHNOL,DIV PHARMA,K 681447,CH-4002 BASEL,SWITZERLAND	Novartis	VANDERPUTTEN, H (corresponding author), CIBA GEIGY AG,DEPT BIOTECHNOL,DIV PHARMA,K 681447,CH-4002 BASEL,SWITZERLAND.							AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1986, SCIENCE, V233, P1061, DOI 10.1126/science.3090687; BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BOTTERI FM, 1990, J BIOL CHEM, V265, P13327; BOTTERI FM, 1990, SERINE PROTEASES THE, P105; BUCCI C, 1988, NUCLEIC ACIDS RES, V16, P9979, DOI 10.1093/nar/16.21.9979; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGOYNE RD, 1982, PROC R SOC SER B-BIO, V216, P111, DOI 10.1098/rspb.1982.0064; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHEEK TR, 1986, FEBS LETT, V207, P110, DOI 10.1016/0014-5793(86)80022-9; COCKROFT S, 1987, J CELL BIOL, V5105, P2745; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P814; DRENCKHAHN D, 1983, EUR J CELL BIOL, V30, P167; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; GALLWITZ D, 1983, NATURE, V306, P704, DOI 10.1038/306704a0; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GOLDSTEIN AL, 1977, P NATL ACAD SCI USA, V74, P725, DOI 10.1073/pnas.74.2.725; KITIYAMA H, 1989, CELL, V56, P77; KNIGHT DE, 1985, NATURE, V317, P719, DOI 10.1038/317719a0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1988, MOL CELL BIOL, V8, P2737, DOI 10.1128/MCB.8.7.2737; KOZAK M, 1990, P NATL ACAD SCI USA, V87, P8301, DOI 10.1073/pnas.87.21.8301; KOZAK M, 1989, MOL CELL BIOL, V9, P5073, DOI 10.1128/MCB.9.11.5073; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; ORCI L, 1972, SCIENCE, V175, P1128, DOI 10.1126/science.175.4026.1128; PARKIN N, 1988, MOL CELL BIOL, V8, P2875, DOI 10.1128/MCB.8.7.2875; PELLETIER J, 1987, BIOCHEM CELL BIOL, V65, P576, DOI 10.1139/o87-074; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PELLETIER J, 1988, J VIROL, V62, P2219, DOI 10.1128/JVI.62.7.2219-2227.1988; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; RAO CD, 1988, MOL CELL BIOL, V8, P284, DOI 10.1128/MCB.8.1.284; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SIMPSON LL, 1981, PHARMACOL REV, V33, P158; SNYDERMAN R, 1986, J LEUKOCYTE BIOL, V40, P785, DOI 10.1002/jlb.40.6.785; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	51	78	84	0	4	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	MAY	1991	6	5					863	866						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GT825	1905006				2022-12-25	WOS:A1991GT82500024
J	ROPP, PA; TRAUT, TW				ROPP, PA; TRAUT, TW			PURINE NUCLEOSIDE PHOSPHORYLASE - ALLOSTERIC REGULATION OF A DISSOCIATING ENZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; CHICKEN LIVER; CATALYTIC MECHANISM; INORGANIC-PHOSPHATE; PHYSICAL-PROPERTIES; PURIFICATION; ERYTHROCYTES; PROTEIN	Purine nucleoside phosphorylase (EC 2.4.2.1) from bovine spleen is a trimeric enzyme that readily dissociates to the monomer. Dilution of enzyme from 20 to 0.02-mu-g of protein/ml is accompanied by a greater than 50-fold increase in the specific activity (nu-trimer = 0.23 nmol/min/mu-g; nu-monomer = 12.5 nmol/min/mu-g). Gel permeation chromatography in the presence of the substrate phosphate shows the enzyme to be predominantly trimeric at 50 mM P(i) and predominantly monomeric at 100 mM P(i), when experiments are done at 24-degrees-C. No significant dissociation was observed at 4-degrees-C with P(i) or at either temperature with the substrate inosine. As measured by dissociation, the L0.5 for P(i) is 88 mM and thus significantly higher than the K(m) of 3.1 mM for P(i). Enzyme activity as a function of phosphate concentration showed negative cooperativity, but the conformational response measured by the change in native M(r) during dissociation showed positive cooperativity toward P(i). These data support a model for two separate phosphate binding sites on the enzyme. The activity and stability of purine nucleoside phosphorylase are quite sensitive to the concentration of the enzyme as well as appropriate substrates. Although the monomer is interpreted as being a fully active form of the enzyme, the data in general are most consistent with the enzyme functioning in vivo as a regulated trimer.	UNIV N CAROLINA,SCH MED,DEPT BIOCHEM & BIOPHYS,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine								AGARWAL RP, 1969, J BIOL CHEM, V244, P644; AKERBOOM TPM, 1978, EUR J BIOCHEM, V84, P413, DOI 10.1111/j.1432-1033.1978.tb12182.x; ANANEV AV, 1988, BIOCHEMISTRY-US, V52, P1749; BEZIRDZHYAN KO, 1988, BIOCHEMISTRY-US, V52, P1526; BOWEN JW, 1982, J CELL PHYSIOL, V110, P149, DOI 10.1002/jcp.1041100207; CHOI HS, 1986, J BIOL CHEM, V261, P599; COOK PF, 1978, J BIOL CHEM, V253, P7874; EALICK SE, 1990, J BIOL CHEM, V265, P1812; EDWARDS YH, 1973, FEBS LETT, V32, P235, DOI 10.1016/0014-5793(73)80840-3; GHANGAS G, 1979, J BIOL CHEM, V254, P4233; IKEZAWA Z, 1978, COMP BIOCHEM PHYS B, V60, P111, DOI 10.1016/0305-0491(78)90113-X; KALCKAR HM, 1947, J BIOL CHEM, V167, P429; KRENITSKY TA, 1967, MOL PHARMACOL, V3, P526; KURGANOV BI, 1982, ALLOSTERIC ENZYMES; LEJOHN HB, 1969, J BIOL CHEM, V244, P2484; LEWIS AS, 1976, J BIOL CHEM, V251, P407; LEWIS AS, 1976, BIOCHEMISTRY-US, V15, P4451, DOI 10.1021/bi00665a018; LEWIS AS, 1979, J BIOL CHEM, V254, P9927; LEWIS AS, 1978, ARCH BIOCHEM BIOPHYS, V190, P662, DOI 10.1016/0003-9861(78)90324-7; MANKOVITZ R, 1969, BIOCHEMISTRY-US, V8, P3757, DOI 10.1021/bi00837a040; MILMAN G, 1976, BIOCHEMISTRY-US, V15, P4967, DOI 10.1021/bi00668a004; MORA M, 1985, COMP BIOCHEM PHYS B, V82, P805, DOI 10.1016/0305-0491(85)90528-0; MOYER TP, 1976, ARCH BIOCHEM BIOPHYS, V174, P622, DOI 10.1016/0003-9861(76)90391-X; MURAKAMI K, 1975, BIOCHIM BIOPHYS ACTA, V384, P390, DOI 10.1016/0005-2744(75)90040-6; OSBORNE WRA, 1980, J BIOL CHEM, V255, P7089; PARKS RE, 1972, ENZYMES, V7, P483; PILZ RB, 1984, J BIOL CHEM, V259, P2927; READ SM, 1981, ANAL BIOCHEM, V116, P53, DOI 10.1016/0003-2697(81)90321-3; REIMANN EM, 1971, J BIOL CHEM, V246, P1986; SAVAGE B, 1977, BIOCHEM J, V167, P703, DOI 10.1042/bj1670703; SIMONSEN LO, 1978, BIOCHIM BIOPHYS ACTA, V511, P213, DOI 10.1016/0005-2736(78)90315-2; STOECKLER JD, 1978, BIOCHEMISTRY-US, V17, P278, DOI 10.1021/bi00595a014; STOECKLER JD, 1986, FASEB J, V45, P2773; TRAUT TW, 1988, CRC CR REV BIOCH MOL, V23, P121, DOI 10.3109/10409238809088318; TUTTLE JV, 1984, J BIOL CHEM, V259, P4065; UMEMURA S, 1982, J BIOL CHEM, V257, P13374; ZANNIS V, 1978, J BIOL CHEM, V253, P504	37	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7682	7687						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902226				2022-12-25	WOS:A1991FJ34200058
J	HUZOORAKBAR; WINEGAR, DA; LAPETINA, EG				HUZOORAKBAR; WINEGAR, DA; LAPETINA, EG			CARBOXYL METHYLATION OF PLATELET RAP1 PROTEINS IS STIMULATED BY GUANOSINE 5'-(3-O-THIO)TRIPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-RELATED PROTEIN; GTP-BINDING PROTEIN; METHYLTRANSFERASES; PHOSPHORYLATION; PURIFICATION; THROMBIN; GI	Carboxyl methylation of platelet ras-related proteins, known as rap proteins, was investigated in this study. Platelet membrane proteins of M(r) 23,000 incorporated radioactivity in the presence of S-[methyl-H-3] adenosylmethionine and platelet cytosol. About 97% of the radioactivity present in the M(r) 23,000 proteins was liberated as volatile methanol under basic (1 M sodium hydroxide) conditions. Cycloheximide, an inhibitor of protein synthesis, inhibited incorporation of S-[methyl-H-3]adenosylmethionine by 25%. These results suggest that at least 75% of the radioactivity present in the M(r) 23,000 proteins is due to carboxyl methylation and not due to the incorporation of S-[methyl-H-3]adenosylmethionine into proteins or due to the incorporation of base-stable methyl groups into side chains of arginine, histidine, or lysine residues. Protein methylation did not occur if membranes or cytosol alone was incubated with S-[methyl-H-3]adenosylmethionine. Guanosine 5'(3-O-thio)triphosphate increased methylation of the M(r) 23,000 proteins in a time- and concentration-dependent manner. Acetylfarnesylcysteine, a synthetic substrate for carboxyl methyltransferases, completely blocked methylation of the M(r) 23,000 membrane proteins. On the basis of one- and two-dimensional Western blots using rap-specific antisera, the M(r) 23,000 methylated proteins were identified as rap1 proteins. The existence of the carboxyl-terminal CAAX motif in rap1 proteins, similar to the CAAX motif present in p21ras as well as in the yeast mating factors, leads us to suggest that methylation of rap1 proteins possibly occurs at the alpha-carboxyl-terminal cysteine.	BURROUGHS WELLCOME CO, DIV CELL BIOL, RES TRIANGLE PK, NC 27709 USA	Burroughs Wellcome Fund								BACKLUND PS, 1988, J BIOL CHEM, V263, P15864; BINSTOCK J, 1984, METHOD ENZYMOL, V106, P310; CARLSON KE, 1989, J BIOL CHEM, V264, P13298; CHEN ZQ, 1985, J VIROL, V56, P607, DOI 10.1128/JVI.56.2.607-612.1985; CLARKE S, 1985, ANNU REV BIOCHEM, V54, P479, DOI 10.1146/annurev.bi.54.070185.002403; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; CROUCH MF, 1989, P NATL ACAD SCI USA, V86, P1776, DOI 10.1073/pnas.86.6.1776; CROUCH MF, 1988, J BIOL CHEM, V263, P3363; DESCHENES RJ, 1989, J BIOL CHEM, V264, P11865; FARRELL FX, 1990, NUCLEIC ACIDS RES, V18, P4281, DOI 10.1093/nar/18.14.4281; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KIEFFER N, 1987, EUR J BIOCHEM, V164, P189, DOI 10.1111/j.1432-1033.1987.tb11010.x; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAZAROWSKI ER, 1989, BIOCHEM BIOPH RES CO, V161, P972, DOI 10.1016/0006-291X(89)91338-7; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NEWMAN PJ, 1988, J CLIN INVEST, V82, P739, DOI 10.1172/JCI113656; ODEA RF, 1978, BIOCHEM PHARMACOL, V27, P679, DOI 10.1016/0006-2952(78)90504-X; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; STOCK J, 1990, IN PRESS ANN REV BIO, V20; VEDIA LMY, 1990, BIOCHEM BIOPH RES CO, V171, P319; WINEGAR DA, 1991, J BIOL CHEM, V266, P4375; YAMANE HK, 1989, J BIOL CHEM, V264, P20100	33	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4387	4391						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900293				2022-12-25	WOS:A1991FA69400058
J	FIELD, CJ; CHAYOTH, R; MONTAMBAULT, M; MARLISS, EB				FIELD, CJ; CHAYOTH, R; MONTAMBAULT, M; MARLISS, EB			ENHANCED 2-DEOXY-D-GLUCOSE UPTAKE AND METABOLISM IN SPLENOCYTES FROM DIABETIC AND DIABETES-PRONE BB RATS - FURTHER EVIDENCE TO SUPPORT PRIOR INVIVO ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET CELL-SURFACE; GLUCOSE-TRANSPORT; GLUTAMINE-METABOLISM; LYMPHOCYTE-TRANSFORMATION; AEROBIC GLYCOLYSIS; STIMULATION; THYMOCYTES; INSULIN; PHYTOHEMAGGLUTININ; PROLIFERATION	Glucose metabolism in splenocytes from the BB rat was studied for the presence of abnormalities in [C-14] 2-deoxy-D-glucose (2-dGlc) uptake, [U-C-14]glucose conversion to (CO2)-C-14, and the production of lactate and pyruvate. Cells were studied freshly isolated ("resting"), and following culture both unstimulated (control) and stimulated with concanavalin A (ConA) or phorbol myristate acetate (PMA) + ionomycin. Both resting and control cells from diabetic (BBd) and diabetes-prone (BBdp) rats transported more (p < 0.05) 2-dGlc than did cells from nondiabetes-prone (BBn) rats. Consistent with prior in vivo activation, sustained in vitro, lactate production was higher (p < 0.05) under control conditions in BBd and BBdp than in BBn cells. Lactate production increased less with ConA and PMA + ionomycin in both BBd and BBdp than in BBn cells. PMA + ionomycin increased 2-dGlc uptake as much in BBd and BBdp cells as in BBn cells. Elevated rates of pyruvate production were observed in BBd cells under resting, control, and (especially) ConA conditions, suggesting an abnormality in pyruvate conversion to lactate. Few changes were observed in (CO2)-C-14 production. The presence of similar abnormalities in BBdp cells to those of the BBd cells suggests that the diabetic state is not causal, and the absence of an in vitro effect of 15 mmol/liter glucose in BBn cells further tends to exclude hyperglycemia as a cause of these alterations.	ROYAL VICTORIA HOSP,MCGILL NUTR & FOOD SCI CTR,687 PINE AVE W,MONTREAL H3A 1A1,QUEBEC,CANADA	McGill University; Royal Victoria Hospital				Field, Catherine/0000-0001-7285-4767				ARDAWI MSM, 1985, ESSAYS BIOCHEM, V21, P1; ARDAWI MSM, 1983, BIOCHEM J, V212, P835, DOI 10.1042/bj2120835; BRAND K, 1984, BIOCHEM J, V221, P471, DOI 10.1042/bj2210471; BRAND K, 1986, IMMUNOBIOLOGY, V173, P23, DOI 10.1016/S0171-2985(86)80086-9; DAVIS L, 1985, J IMMUNOL, V135, P2946; DEAN BM, 1987, CLIN EXP IMMUNOL, V69, P308; DYRBERG T, 1984, DIABETOLOGIA, V26, P159; FIELD CJ, 1990, BIOCHEM J, V272, P445, DOI 10.1042/bj2720445; FRANCFORT JW, 1985, SURGERY, V98, P251; HELDERMAN JH, 1981, J CLIN INVEST, V67, P1636, DOI 10.1172/JCI110199; HUME DA, 1978, BIOCHEM J, V174, P703, DOI 10.1042/bj1740703; JACKSON R, 1983, METABOLISM, V32, P83, DOI 10.1016/S0026-0495(83)80017-1; JACOBS DB, 1989, J CLIN INVEST, V83, P437, DOI 10.1172/JCI113902; LLOYD B, 1978, CLIN CHEM, V24, P1724; METROZDAYER MD, 1990, DIABETES, V39, P928, DOI 10.2337/diabetes.39.8.928; MOOKERJEE BK, 1982, J IMMUNOL, V128, P2153; MORDES JP, 1987, DIABETES METAB REV, V3, P725, DOI 10.1002/dmr.5610030307; NAFTALIN RJ, 1989, BIOCHEM J, V260, P143, DOI 10.1042/bj2600143; NAFTALIN RJ, 1990, BIOCHEM J, V265, P251, DOI 10.1042/bj2650251; NEWSHOLME P, 1986, BIOCHEM J, V239, P121, DOI 10.1042/bj2390121; PETERS JH, 1971, EUR J BIOCHEM, V19, P509, DOI 10.1111/j.1432-1033.1971.tb01342.x; POUSSIER P, 1982, ENDOCRINOLOGY, V110, P1825, DOI 10.1210/endo-110-5-1825; POUSSIER P, 1983, METABOLISM, V32, P73, DOI 10.1016/S0026-0495(83)80015-8; PRUDHOMME GJ, 1985, IMMUNOL TODAY, V6, P160, DOI 10.1016/0167-5699(85)90145-8; PRUDHOMME GJ, 1984, J EXP MED, V159, P463, DOI 10.1084/jem.159.2.463; REEVES JP, 1975, J BIOL CHEM, V250, P9413; RESCH K, 1976, J IMMUNOL, V117, P1705; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROOS D, 1973, EXP CELL RES, V77, P127, DOI 10.1016/0014-4827(73)90561-2; SZONDY Z, 1989, BIOCHEM J, V261, P979, DOI 10.1042/bj2610979; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0; WEISS A, 1987, ADV IMMUNOL, V41, P1, DOI 10.1016/S0065-2776(08)60029-2; WHITESELL RR, 1985, J BIOL CHEM, V260, P2894; WHITESELL RR, 1977, J BIOL CHEM, V252, P3533; WHITESELL RR, 1977, J CELL BIOL, V72, P456, DOI 10.1083/jcb.72.2.456; WODA BA, 1986, J IMMUNOL, V137, P1860; WU G, 1990, LESSONS ANIMAL DIABE, V3; WU G, 1991, IN PRESS BIOCH J; YALE JF, 1984, CLIN EXP IMMUNOL, V57, P1; YALE JF, 1985, DIABETES, V34, P955, DOI 10.2337/diabetes.34.10.955	40	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3675	3681						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1899865				2022-12-25	WOS:A1991EY68200051
J	SCHREIBER, G; METZGER, S; AIZENMAN, E; ROZA, S; CASHEL, M; GLASER, G				SCHREIBER, G; METZGER, S; AIZENMAN, E; ROZA, S; CASHEL, M; GLASER, G			OVEREXPRESSION OF THE RELA GENE IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-RNA PROMOTERS; RATE-DEPENDENT REGULATION; ELONGATION-FACTOR-TU; GUANOSINE TETRAPHOSPHATE; INDIVIDUAL PROTEINS; STRINGENT RESPONSE; PPGPP; STRAINS; INVIVO; STARVATION	Intracellular levels of guanosine 3', 5'-bispyrophosphate (ppGpp) governed by the relA gene are normally regulated by aminoacyl-tRNA availability for protein synthesis. An experimental system is described in which cellular levels of ppGpp are controlled instead by induction of plasmid pKK223-3 derivatives with the relA structural gene, or portions thereof, under control of the P(tac) promoter. In amino acid-rich media, isopropyl-l-thio-beta-D-galactopyranoside induction of transcription of the wild type relA gene in pSM10 yields about a 100-fold overexpression of a metabolically stable, full length (743 amino acid) RelA protein to levels approximating the number of cellular ribosomes. This overexpression is accompanied by a roughly parallel and relC-dependent elevation of ppGpp levels. Induction of a relA gene deletion mutant in pSM11 containing 455 amino-terminal amino acids results in much lower levels of expression of a metabolically unstable 55-kDa protein and elevated ppGpp levels that are almost equivalent to induced pSM10 and are relC-independent. Induction of a larger deletion in pSM12 containing 331 amino-terminal amino acids does not provoke ppGpp accumulation. We are able to elicit high levels of ppGpp without changing nutritional abundance and without massive overexpression of the RelA protein by inducing the metabolically unstable, truncated RelA protein. We find the effects of elevated ppGpp levels to include a slowing of growth, an inhibition of stable RNA accumulation, an inhibition of cellular rrn P1 promoter activities as measured by primer extension, and changes in the pattern of gene expression viewed by two-dimensional electrophoresis of cellular proteins.	NICHHD, MOLEC GENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	SCHREIBER, G (corresponding author), HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT CELLULAR BIOCHEM, IL-91010 JERUSALEM, ISRAEL.		Schreiber, Gideon/C-7332-2008		NIGMS NIH HHS [GM25282] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARACCHINI E, 1988, J BIOL CHEM, V263, P2597; Bremer H., 1987, ESCHERICHIA COLI SAL, V2, P1527, DOI [10.1046/j.1365-2486.2000.06017.x, DOI 10.1046/J.1365-2486.2000.06017.X]; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CASHEL M, 1987, ESCHERICHIA COLI SAL, V2, P1410; DALE RMK, 1985, PLASMID, V13, P31, DOI 10.1016/0147-619X(85)90053-8; Davis R., 1980, ADV BACTERIAL GENETI; FEHR S, 1981, J BACTERIOL, V145, P68, DOI 10.1128/JB.145.1.68-73.1981; FRIESEN JD, 1974, P NATL ACAD SCI USA, V71, P3465, DOI 10.1073/pnas.71.9.3465; FURANO AV, 1976, CELL, V8, P115, DOI 10.1016/0092-8674(76)90192-6; GALLANT J, 1969, J BIOL CHEM, V244, P3125; GOURSE RL, 1986, CELL, V44, P197, DOI 10.1016/0092-8674(86)90498-8; GOURSE RL, 1983, CELL, V32, P1347, DOI 10.1016/0092-8674(83)90315-X; HERNANDEZ VJ, 1990, J BIOL CHEM, V265, P11605; HWANG YW, 1987, J BIOL CHEM, V262, P13081; Jinks-Robertson S., 1987, ESCHERICHIA COLI SAL, P1358; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; JUSTESEN J, 1986, BIOCHIMIE, V68, P715, DOI 10.1016/S0300-9084(86)80165-1; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LAZZARINI RA, 1971, J BIOL CHEM, V246, P4381; LINDAHL L, 1986, ANNU REV GENET, V20, P297; MaalOe O, 1966, CONTROL MACROMOLECUL; METZGER S, 1989, J BIOL CHEM, V264, P21146; METZGER S, 1989, J BIOL CHEM, V264, P9122; METZGER S, 1988, J BIOL CHEM, V263, P15699; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, V1, P3; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OFARRELL PH, 1978, CELL, V14, P545, DOI 10.1016/0092-8674(78)90241-6; PARKER J, 1976, MOL GEN GENET, V144, P111, DOI 10.1007/BF00277313; PHILLIPS TA, 1987, ESCHERICHIA COLI SAL, V2, P919; RAMAGOPAL S, 1974, P NATL ACAD SCI USA, V71, P820, DOI 10.1073/pnas.71.3.820; REEH S, 1976, MOL GEN GENET, V149, P279, DOI 10.1007/BF00268529; ROJIANI MV, 1989, J BACTERIOL, V171, P6493, DOI 10.1128/jb.171.12.6493-6502.1989; RYALS J, 1982, J BACTERIOL, V151, P1261, DOI 10.1128/JB.151.3.1261-1268.1982; SARMIENTOS P, 1983, P NATL ACAD SCI-BIOL, V80, P7010, DOI 10.1073/pnas.80.22.7010; SARMIENTOS P, 1983, CELL, V32, P1337, DOI 10.1016/0092-8674(83)90314-8; SARUBBI E, 1988, MOL GEN GENET, V213, P214, DOI 10.1007/BF00339584; SCHAECHTER M, 1958, J GEN MICROBIOL, V19, P592, DOI 10.1099/00221287-19-3-592; SHAND RF, 1989, J BACTERIOL, V171, P737, DOI 10.1128/jb.171.2.737-743.1989; STEPHENS JC, 1975, P NATL ACAD SCI USA, V72, P4389, DOI 10.1073/pnas.72.11.4389; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; TOSA T, 1971, J BACTERIOL, V106, P972, DOI 10.1128/JB.106.3.972-982.1971; XIAO H, 1991, IN PRESS J BIOL CHEM; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; 1989, NUCLEIC ACIDS RES, V17, P9811	45	171	174	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3760	3767						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1899866				2022-12-25	WOS:A1991EY68200064
J	NGSEE, JK; ELFERINK, LA; SCHELLER, RH				NGSEE, JK; ELFERINK, LA; SCHELLER, RH			A FAMILY OF RAS-LIKE GTP-BINDING PROTEINS EXPRESSED IN ELECTROMOTOR NEURONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MUTATIONAL ANALYSIS; ADENYLATE-CYCLASE; HUMAN-PLATELETS; BOVINE BRAIN; CDNA CLONES; YEAST; GENE; SECRETION; MEMBRANE	The cDNAs encoding seven low molecular weight (LMW) GTP-binding proteins were isolated from an electric lobe library of the marine ray Discopyge ommata. Four were assigned as the ray homologues of previously identified LMW GTP-binding proteins rab1, ral, Krev, and rho. Three other showed unique sequences, including two exhibiting significant similarity to the yeast SEC4 protein. Northern analysis indicated that several of the transcripts are enriched in neural tissues with a moderate level of expression in cardiac muscle. This tissue distribution was corroborated with affinity purified antibodies against the LMW GTP-binding proteins. Subcellular fractionation revealed that the proteins co-purify with cholinergic synaptic vesicles. Immunohistochemical analysis confirms this localization. At least two of the proteins, o-ral and o-rho, are localized to the pre-synaptic terminals.	STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305	Stanford University								BACON RA, 1989, J CELL BIOL, V109, P1015, DOI 10.1083/jcb.109.3.1015; BALLESTER R, 1989, CELL, V59, P681, DOI 10.1016/0092-8674(89)90014-7; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BROEK D, 1985, CELL, V41, P763, DOI 10.1016/S0092-8674(85)80057-X; CARLSON SS, 1978, BIOCHEMISTRY-US, V17, P1188, DOI 10.1021/bi00600a009; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; DIECKMANN CL, 1985, J BIOL CHEM, V260, P1513; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FUJIYAMA A, 1990, J BIOL CHEM, V265, P3362; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NGSEE JK, 1990, J NEUROSCI, V10, P317; NGSEE JK, 1989, DNA-J MOLEC CELL BIO, V8, P555, DOI 10.1089/dna.1989.8.555; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; ROBINSON LC, 1987, SCIENCE, V235, P1218, DOI 10.1126/science.3547648; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT HD, 1986, CELL, V47, P401, DOI 10.1016/0092-8674(86)90597-0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WAGNER P, 1987, EMBO J, V6, P2373, DOI 10.1002/j.1460-2075.1987.tb02514.x; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	49	61	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2675	2680						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899244				2022-12-25	WOS:A1991EV51500099
J	FRANGAKIS, MV; CHATILA, T; WOOD, ER; SAHYOUN, N				FRANGAKIS, MV; CHATILA, T; WOOD, ER; SAHYOUN, N			EXPRESSION OF A NEURONAL CA2+ CALMODULIN-DEPENDENT PROTEIN-KINASE, CAM KINASE-GR, IN RAT THYMUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR COMPLEX; CALCIUM; ACTIVATION; BRAIN; LOCALIZATION; LYMPHOCYTES; BINDING; CELLS; CA-2+	The regional and tissue-specific expression of the Ca2+/calmodulin-dependent protein kinase, CaM kinase-Gr, were examined. The M(r) 65,000 alpha-polypeptide of CaM kinase-Gr is expressed ubiquitously in different anatomical regions of rat brain, whereas an additional M(r) 67,000 beta-polypeptide is observed solely in the cerebellum. The alpha-polypeptide appears in the neonatal rat forebrain and cerebellum, whereas the beta-polypeptide appears by the second postnatal week and may reflect cerebellar granule cell differentiation. Most peripheral tissues do not express either CaM kinase-Gr polypeptide. However, rat thymus and thymocytes derived therefrom express CaM kinase-Gr at levels comparable to those of the central nervous system. The identity of the enzyme in rat thymus was corroborated by immunoblot assays, Northern blots, and direct enzyme purification. Rat spleen and testis also produce CaM kinase-Gr, but at lower levels than either thymus or brain. These observations demonstrate selective regional and developmental expression of CaM kinase-Gr polypeptide in brain, and suggest that it may participate in Ca2+ signalling in cells derived both from the immune system as well as the central nervous system.	WELLCOME RES LABS, RES TRIANGLE PK, NC 27709 USA; CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA	Wellcome Research Laboratories; Harvard University; Boston Children's Hospital				Chatila, Talal/0000-0001-7439-2762				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAMBIER JC, 1987, ANNU REV IMMUNOL, V5, P175, DOI 10.1146/annurev.immunol.5.1.175; COLBRAN RJ, 1989, BIOCHEM J, V258, P313, DOI 10.1042/bj2580313; FISHER CL, 1991, J IMMUNOL, V146, P1743; FRANGAKIS MV, 1991, J BIOL CHEM, V266, P11309; FUKUNAGA K, 1988, J NEUROCHEM, V51, P1070, DOI 10.1111/j.1471-4159.1988.tb03070.x; GARDNER P, 1989, CELL, V59, P15, DOI 10.1016/0092-8674(89)90865-9; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P4050, DOI 10.1073/pnas.88.9.4050; JENSEN KF, 1991, P NATL ACAD SCI USA, V88, P2850, DOI 10.1073/pnas.88.7.2850; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEWIS RS, 1990, ANNU REV PHYSIOL, V52, P415; MAY WS, 1985, NATURE, V317, P549, DOI 10.1038/317549a0; NAIRN AC, 1987, J BIOL CHEM, V262, P7273; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; OHMSTEDE CA, 1991, P NATL ACAD SCI USA, V88, P5784, DOI 10.1073/pnas.88.13.5784; OHMSTEDE CA, 1989, J BIOL CHEM, V264, P5866; OHMSTEDE CA, 1990, FASEB J, V4; ONO T, 1989, J BIOL CHEM, V264, P2081; POGNONEC P, 1988, EMBO J, V7, P977, DOI 10.1002/j.1460-2075.1988.tb02904.x; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAHYOUN N, 1991, P NATL ACAD SCI USA, V88, P2643, DOI 10.1073/pnas.88.7.2643; SCHULMAN H, 1988, ADV SEC MESS PHOSPH, V22, P39; SCHWARTZ RH, 1989, CELL, V57, P1073, DOI 10.1016/0092-8674(89)90044-5; SIKELA JM, 1989, GENOMICS, V4, P21, DOI 10.1016/0888-7543(89)90309-1; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; WEISS A, 1986, ANNU REV IMMUNOL, V4, P593, DOI 10.1146/annurev.iy.04.040186.003113; WOLF M, 1985, NATURE, V317, P546, DOI 10.1038/317546a0	29	74	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17592	17596						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894642				2022-12-25	WOS:A1991GF44500091
J	HENDRICKS, LC; GABEL, CA; SUH, K; FARQUHAR, MG				HENDRICKS, LC; GABEL, CA; SUH, K; FARQUHAR, MG			A 58-KDA RESIDENT PROTEIN OF THE CIS GOLGI CISTERNA IS NOT TERMINALLY GLYCOSYLATED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; HUMAN CHORIONIC-GONADOTROPIN; POLYACRYLAMIDE GELS; CYTOCHEMICAL-LOCALIZATION; ELECTROPHORETIC TRANSFER; N-ACETYLGLUCOSAMINE; RICINUS-COMMUNIS; E1 GLYCOPROTEIN; O-GLYCOSYLATION; GOBLET CELLS	A 58-kDa Golgi protein (gp58) was previously identified and found to be concentrated in cis Golgi cisternae in several cell types (Saraste, J., Palade, G. E., and Farquhar, M.G. (1987) J. Cell Biol. 105, 2021-2029). In this study the protein was partially purified from rat pancreas and mouse myeloma cells in order to characterize its oligosaccharides. It migrated on sodium dodecyl sulfate-polyacrylamide gels as a 57-58-kDa doublet under reducing conditions or as a single approximately 116-kDa band under nonreducing conditions. Pancreatic gp58 was susceptible to alpha-N-acetylgalactosaminidase digestion and it bound concanavalin A, Helix pomatia, Dolichos biflorus, soybean agglutinin, and Bauhinia purpurea lectins, but not Ricinus communis agglutinin or lectins from Griffonia simplicifolia-1, Arachis hypogaea, and Limulus polyphemus. It bound Ricinus communis agglutinin after galactosylation with GlcNAc galactosyltransferase. These data demonstrate that pancreatic p58 contains immature N-linked moieties with nonreducing terminal GlcNAc residues as well as the initiating GalNAc of O-linked glycoproteins. Myeloma gp58 was sensitive to endo-beta-N-acetylglucosaminidase H, and oligosaccharide analysis of its [H-3]glucosamine-labeled glycopeptides indicated that it also contained immature N-linked glycans. Some of the latter consist of high mannose chains (high affinity for concanavalin A, endo-beta-N-acetylglucosaminidase H-sensitive), but the predominant (95%) species are neutral tri- or tetraantennary N-linked chains containing GlcNAc (no binding to concanavalin A). Glycopeptides from biosynthetically labeled myeloma cells did not contain detectable base labile oligosaccharides, indicating that unlike pancreatic p58, myeloma gp58 may not be an O-linked glycoprotein. Neither pancreatic nor myeloma gp58 contained terminally processed oligosaccharides, indicating that gp58 has not been modified by trans-Golgi glycosyltransferases. Thus, the oligosaccharide content of gp58 is consistent with the assumption that this protein is retained in the cis Golgi cisternae during biosynthesis instead of being transported across the Golgi stacks and targeted back to the cis Golgi from the trans side.	COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University	HENDRICKS, LC (corresponding author), UNIV CALIF SAN DIEGO,DIV CELLULAR & MOLEC MED,LA JOLLA,CA 92093, USA.				NATIONAL CANCER INSTITUTE [P01CA046128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033342] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA46128] Funding Source: Medline; NIDDK NIH HHS [R01-DK17780] Funding Source: Medline; NIGMS NIH HHS [GM 33342] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1987, J BIOL CHEM, V262, P4153; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; BAENZIGER JU, 1979, J BIOL CHEM, V254, P2400; BROWN WJ, 1984, CELL, V36, P295, DOI 10.1016/0092-8674(84)90223-X; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CUMMINGS RD, 1983, J BIOL CHEM, V258, P5261; DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8; ELHAMMER A, 1984, J CELL BIOL, V98, P327; FARQUHAR MG, 1985, ANN REV CELL BIOL, V1, P448; FUKUDA M, 1985, Biochimica et Biophysica Acta, V780, P119; FUKUDA M, 1988, J BIOL CHEM, V263, P5314; GABEL CA, 1985, J CELL BIOL, V101, P460, DOI 10.1083/jcb.101.2.460; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; GONATAS JO, 1989, J BIOL CHEM, V264, P646; HAMMARSTROM S, 1977, BIOCHEMISTRY-US, V16, P2750, DOI 10.1021/bi00631a025; HAMMARSTROM S, 1971, Biochemistry, V10, P1684; HANOVER JA, 1982, J BIOL CHEM, V257, P172; KOBATA A, 1979, ANAL BIOCHEM, V100, P1, DOI 10.1016/0003-2697(79)90102-7; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kornfeld R., 1980, BIOCH GLYCOPROTEINS, P1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTAN R, 1975, J BIOL CHEM, V250, P8518; MACHAMER CE, 1990, P NATL ACAD SCI USA, V87, P6944, DOI 10.1073/pnas.87.18.6944; MOREMEN K, 1988, PROTEIN TRANSFER ORG, P209; MOREMEN KW, 1985, J BIOL CHEM, V260, P6654; Murphy L A, 1978, Methods Enzymol, V50, P345; NICOLSON GL, 1972, BIOCHIM BIOPHYS ACTA, V266, P543, DOI 10.1016/0005-2736(72)90109-5; NICOLSON GL, 1974, BIOCHEMISTRY-US, V13, P196, DOI 10.1021/bi00698a029; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; Osawa T, 1978, Methods Enzymol, V50, P367; PAABO S, 1987, CELL, V50, P331; PARCHMENT RE, 1986, ANAL BIOCHEM, V154, P460, DOI 10.1016/0003-2697(86)90015-1; PATHAK RK, 1988, J CELL BIOL, V106, P1831, DOI 10.1083/jcb.106.6.1831; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; PERSONEN M, 1982, J VIROL, V41, P390; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTH J, 1984, J CELL BIOL, V98, P399, DOI 10.1083/jcb.98.2.399; ROTH J, 1982, J CELL BIOL, V93, P223, DOI 10.1083/jcb.93.1.223; ROTH J, 1985, CELL, V43, P287, DOI 10.1016/0092-8674(85)90034-0; SCHACHTER H, 1980, BIOCH GLYCOPROTEINS, P85; SMITH PL, 1988, SCIENCE, V242, P930, DOI 10.1126/science.2460923; SWITZER RC, 1979, ANAL BIOCHEM, V98, P231, DOI 10.1016/0003-2697(79)90732-2; TARENTINO AL, 1974, J BIOL CHEM, V249, P811; TOOZE SA, 1988, J CELL BIOL, V106, P1475, DOI 10.1083/jcb.106.5.1475; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TULSIANI DRP, 1988, J BIOL CHEM, V263, P5408; ULMER JB, 1989, P NATL ACAD SCI USA, V86, P6992, DOI 10.1073/pnas.86.18.6992; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; WILLIAMS MA, 1988, MOL CELL BIOL, V8, P1186, DOI 10.1128/MCB.8.3.1186; YUAN L, 1987, J CELL BIOL, V105, P215, DOI 10.1083/jcb.105.1.215	50	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17559	17565						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894639				2022-12-25	WOS:A1991GF44500086
J	MOULD, RM; SHACKLETON, JB; ROBINSON, C				MOULD, RM; SHACKLETON, JB; ROBINSON, C			TRANSPORT OF PROTEINS INTO CHLOROPLASTS - REQUIREMENTS FOR THE EFFICIENT IMPORT OF 2 LUMENAL OXYGEN-EVOLVING COMPLEX PROTEINS INTO ISOLATED THYLAKOIDS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIT PEPTIDE; PRECURSOR; TRANSLOCATION; POLYPEPTIDES; MATURATION; MEMBRANE; PROTEASE; ATP	The 33- and 23-kDa proteins of the photosynthetic oxygen-evolving complex are synthesized in the cytosol and targeted into the thylakoid lumen by bipartite presequences. In this report, we describe conditions for the efficient import of each of these proteins by isolated pea thylakoids. Import of the 33-kDa protein requires both light and stromal extract. The probable function of the stromal extract is to provide stromal processing peptidase to remove the first "envelope transit" signal of the presequence. Import of the 23-kDa protein is also driven by light, but stromal extract is not required for import; furthermore, efficient import is still observed if the precursor is modified to completely block cleavage by residual stromal processing peptidase activity. The intermediate form of the 23-kDa protein, which is generated by incubation of the precursor protein with stromal processing peptidase, is also efficiently imported. The results indicate that the thylakoidal protein transport system can import both the precursor and intermediate forms of the 23-kDa protein, but probably only the intermediate form of the 33-kDa protein.	UNIV WARWICK,DEPT BIOL SCI,COVENTRY CV4 7AL,W MIDLANDS,ENGLAND	University of Warwick								ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; BAUERLE C, 1991, J BIOL CHEM, V266, P5876; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHITNIS PR, 1987, PLANT MOL BIOL, V10, P3, DOI 10.1007/BF00014181; CLINE K, 1985, J BIOL CHEM, V260, P3691; CLINE K, 1986, J BIOL CHEM, V261, P4804; FLUGGE UI, 1986, EUR J BIOCHEM, V160, P563, DOI 10.1111/j.1432-1033.1986.tb10075.x; GROSSMAN A, 1980, NATURE, V285, P625, DOI 10.1038/285625a0; HAGEMAN J, 1986, NATURE, V324, P567, DOI 10.1038/324567a0; JAMES HE, 1989, J BIOL CHEM, V264, P19573; KIRWIN PM, 1989, EMBO J, V8, P2251, DOI 10.1002/j.1460-2075.1989.tb08349.x; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; MOULD RM, 1991, J BIOL CHEM, V266, P12189; MUSGROVE JE, 1989, PLANT PHYSIOL, V90, P1616, DOI 10.1104/pp.90.4.1616; PAIN D, 1987, P NATL ACAD SCI USA, V84, P3288, DOI 10.1073/pnas.84.10.3288; ROBINSON C, 1984, EUR J BIOCHEM, V142, P337, DOI 10.1111/j.1432-1033.1984.tb08291.x; ROBINSON C, 1984, EUR J BIOCHEM, V142, P343, DOI 10.1111/j.1432-1033.1984.tb08292.x; ROBINSON C, 1988, PLANT MOL BIOL PRACT, P67; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; THEG SM, 1989, J BIOL CHEM, V264, P6730	20	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17286	17289						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894619				2022-12-25	WOS:A1991GF44500049
J	LEE, DK; EVANS, RK; BLANCO, J; GOTTESFELD, J; JOHNSON, JD				LEE, DK; EVANS, RK; BLANCO, J; GOTTESFELD, J; JOHNSON, JD			CONTACTS BETWEEN 5S DNA AND XENOPUS TFIIIA IDENTIFIED USING 5-AZIDO-2'-DEOXYURIDINE-SUBSTITUTED DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; DIRECTS SPECIFIC INITIATION; INTERNAL CONTROL REGION; ZINC-BINDING DOMAINS; RNA POLYMERASE-III; GLUCOCORTICOID RECEPTOR; REGULATORY PROTEIN; FUNCTIONAL DOMAINS; CRYSTAL-STRUCTURE; LEUCINE ZIPPER	A highly photosensitive analogue of thymidine, 5-azidodeoxyuridine 5'-triphosphate, has been incorporated into 61-base pair (bp) DNA fragments corresponding to the central region of Xenopus somatic-type 5 S RNA genes such that 5-azidodeoxyuridine replaces some or all T residues in either the coding or noncoding strand of the TFIIIA binding site. Photolysis of TFIIIA.DNA complexes formed with these probes results in efficient, sequence-specific cross-linking to the Zn-finger protein providing direct evidence that this class of proteins have contacts in the major groove of their target sequence. Of the 20 T residues present in the 61-bp probes, > 90% of the cross-linking occurs from two sites in the 5 S RNA gene corresponding to T residues at positions 84 and 88 in the noncoding and coding strands, respectively. Digestion by V8 protease of the complex formed with the noncoding strand probe releases peptides not bound to the DNA. Amino acid sequence analysis of the remaining, cross-linked peptides indicates the region including zinc-finger 2 plus the finger 2-3 linker is in contact with position 84. The linker region between fingers 5 and 6 is also in close proximity to the major groove somewhere upstream from position 84.	UNIV WYOMING,DEPT MOLEC BIOL,LARAMIE,WY 82071; MED BIOL INST,LA JOLLA,CA 92037; WILLIAMS COLL,DEPT CHEM,WILLIAMSTOWN,MA 01267	University of Wyoming; Williams College			Blanco, Jeronimo/H-2764-2015	Blanco, Jeronimo/0000-0003-3765-0640; Gottesfeld, Joel/0000-0002-4643-5777	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026453] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-26453] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER RE, 1986, J BIOL CHEM, V261, P5275; BARTHOLOMEW B, 1990, EMBO J, V9, P2197, DOI 10.1002/j.1460-2075.1990.tb07389.x; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BLANCO J, 1989, GENE DEV, V3, P1602, DOI 10.1101/gad.3.10.1602; BLANCO J, 1988, NUCLEIC ACIDS RES, V16, P11267, DOI 10.1093/nar/16.23.11267; BOGENHAGEN DF, 1980, CELL, V19, P27, DOI 10.1016/0092-8674(80)90385-2; BOULANGER PA, 1987, J BIOL CHEM, V262, P15098; CHURCHILL MEA, 1990, P NATL ACAD SCI USA, V87, P5528, DOI 10.1073/pnas.87.14.5528; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; CROTHERS DM, 1987, NATURE, V325, P464, DOI 10.1038/325464a0; Czarnecki J, 1979, Methods Enzymol, V56, P642; ENGELKE DR, 1980, CELL, V19, P717, DOI 10.1016/S0092-8674(80)80048-1; EVANS RK, 1987, BIOCHEMISTRY-US, V26, P269, DOI 10.1021/bi00375a037; EVANS RK, 1986, P NATL ACAD SCI USA, V83, P5382, DOI 10.1073/pnas.83.15.5382; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; FISERLITTELL RM, 1988, J BIOL CHEM, V263, P1607; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GIBSON TJ, 1988, PROTEIN ENG, V2, P209, DOI 10.1093/protein/2.3.209; GINSBERG AM, 1984, CELL, V39, P479, DOI 10.1016/0092-8674(84)90455-0; HANAS JS, 1983, P NATL ACAD SCI-BIOL, V80, P2142, DOI 10.1073/pnas.80.8.2142; HOLLENBERG SM, 1987, CELL, V49, P39, DOI 10.1016/0092-8674(87)90753-7; JOHNSTON M, 1987, P NATL ACAD SCI USA, V84, P2401, DOI 10.1073/pnas.84.8.2401; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; MADER S, 1989, NATURE, V338, P271, DOI 10.1038/338271a0; MAJOWSKI K, 1987, EMBO J, V6, P3057, DOI 10.1002/j.1460-2075.1987.tb02612.x; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MILLSTEIN L, 1987, J BIOL CHEM, V262, P17100; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1984, ANNU REV BIOCHEM, V53, P293, DOI 10.1146/annurev.bi.53.070184.001453; PIELER T, 1985, EMBO J, V4, P3751, DOI 10.1002/j.1460-2075.1985.tb04144.x; PIELER T, 1987, CELL, V48, P91, DOI 10.1016/0092-8674(87)90359-X; POTTER RL, 1983, METHOD ENZYMOL, V91, P613; RHODES D, 1986, CELL, V46, P123, DOI 10.1016/0092-8674(86)90866-4; ROUX E, 1989, GENE DEV, V3, P1613, DOI 10.1101/gad.3.10.1613; SAKONJU S, 1982, CELL, V31, P395, DOI 10.1016/0092-8674(82)90133-7; SAKONJU S, 1980, CELL, V19, P13, DOI 10.1016/0092-8674(80)90384-0; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VRANA KE, 1988, MOL CELL BIOL, V8, P1684, DOI 10.1128/MCB.8.4.1684; WITTE MM, 1988, MOL CELL BIOL, V8, P3726, DOI 10.1128/MCB.8.9.3726; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; XING YY, 1989, MOL CELL BIOL, V9, P499, DOI 10.1128/MCB.9.2.499	48	18	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16478	16484						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885581				2022-12-25	WOS:A1991GD63500041
J	LUNARDI, J; ATTARDI, G				LUNARDI, J; ATTARDI, G			DIFFERENTIAL REGULATION OF EXPRESSION OF THE MULTIPLE ADP/ATP TRANSLOCASE GENES IN HUMAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCATOR; ADP ATP TRANSLOCASE; RAT-LIVER MITOCHONDRIA; HELA-CELLS; SACCHAROMYCES-CEREVISIAE; UNCOUPLING PROTEIN; MOLECULAR-CLONING; MESSENGER-RNAS; LEUKEMIA-CELLS; NUCLEAR GENES	The expression of the genes encoding the three isoforms of the human ADP/ATP translocase (T1, T2, and T3) has been investigated in cultured cell systems under different experimental conditions, using isoform-specific probes. In several human cell lines tested, i.e. HeLa, Hep3B, 143B, HL60, the T3 gene is expressed as a single 1300-nucleotide mRNA, whereas the T2 gene produces two species of mRNA, 1450 and 1600 nucleotides in size. These two species, which are present in HeLa cells in approximately equivalent amounts, were shown to derive from the use of two different polyadenylation signals. The gene for the muscle-specific isoform of ADP/ATP translocase, T1, was not found to be expressed in any of the cell lines investigated. The levels of T2 and T3 mRNAs in HeLa cells are differentially affected by the growth conditions. In fact, the T2 mRNA level remains relatively constant throughout the exponential and stationary phases, whereas the T3 mRNA level decreases progressively in the second half of the exponential phase and in the stationary phase down to less than 50%. This difference in quantitative behavior of the two mRNAs must reflect changes in their rates of synthesis, since their half-lives are very similar (t1/2 = 5-6 h), with no significant growth-related differences. Treatment of HL60 cells with 12-O-tetradecanoylphorbol-13-acetate or retinoic acid, two agents which induce cessation of cell proliferation and cell differentiation, resulted in a marked decrease in both T2 and T3 mRNA levels. Exposure of HeLa cells to chloramphenicol produced a pronounced decrease in the levels of both T2 and T3 mRNAs after 48 to 72 h of treatment. Half-life time measurements strongly suggested that this decrease reflected a reduction in the rate of synthesis of the two transcripts. Treatment of HeLa cells with dinitrophenol also produced a dramatic decrease in the steady state levels of both T2 and T3 mRNA, which, however, in contrast to the just mentioned situation, could be accounted for by a decrease in their metabolic stability. Control experiments indicated that the chloramphenicol- and dinitrophenol-induced changes were not a nonspecific consequence of mitochondrial dysfunction. The observations reported here clearly demonstrate that the expression of the multiple ADP/ATP translocase genes in human cells is sensitive to the cell physiological conditions, responding to the varying cellular demands by changes in the rate of synthesis or stability of their mRNAs.	CALTECH,DIV BIOL,PASADENA,CA 91125	California Institute of Technology					NIGMS NIH HHS [GM-11726] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMALDI F, 1968, J MOL BIOL, V33, P737, DOI 10.1016/0022-2836(68)90317-3; AMALRIC F, 1978, J MOL BIOL, V118, P1, DOI 10.1016/0022-2836(78)90241-3; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; BATHGATE B, 1989, EUR J BIOCHEM, V183, P303, DOI 10.1111/j.1432-1033.1989.tb14929.x; BATTINI R, 1987, J BIOL CHEM, V262, P4355; BISACCIA F, 1988, BIOCHIM BIOPHYS ACTA, V933, P229, DOI 10.1016/0005-2728(88)90030-8; CHEN LB, 1988, ANNU REV CELL BIOL, V4, P155, DOI 10.1146/annurev.cellbio.4.1.155; CHEN ST, 1990, SOMAT CELL MOLEC GEN, V16, P143, DOI 10.1007/BF01233044; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLEVELAND DW, 1988, TRENDS BIOCHEM SCI, V13, P339, DOI 10.1016/0968-0004(88)90103-X; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4; DANI C, 1984, EUR J BIOCHEM, V145, P299, DOI 10.1111/j.1432-1033.1984.tb08552.x; DAVIS LG, 1986, BASIC METHODS MOL BI, P143; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; GAINES G, 1984, MOL CELL BIOL, V4, P1605, DOI 10.1128/MCB.4.8.1605; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KLINGENBERG M, 1990, TRENDS BIOCHEM SCI, V15, P108, DOI 10.1016/0968-0004(90)90194-G; KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5; KOEFFLER HP, 1983, BLOOD, V62, P709; KOLAROV J, 1990, J BIOL CHEM, V265, P12711; KU DH, 1990, J BIOL CHEM, V265, P16060; KUIPER MTR, 1988, J BIOL CHEM, V263, P2840; LARIS PC, 1977, BIOCHIM BIOPHYS ACTA, V459, P110, DOI 10.1016/0005-2728(77)90013-5; LAWSON JE, 1988, J BIOL CHEM, V263, P14812; LI K, 1989, J BIOL CHEM, V264, P13998; NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; POWELL SJ, 1989, BIOCHEMISTRY-US, V28, P866, DOI 10.1021/bi00428a069; RIGAUD G, 1987, NUCLEIC ACIDS RES, V15, P857, DOI 10.1093/nar/15.2.857; ROVERA G, 1979, P NATL ACAD SCI USA, V76, P2779, DOI 10.1073/pnas.76.6.2779; RUNSWICK MJ, 1987, EMBO J, V6, P1367, DOI 10.1002/j.1460-2075.1987.tb02377.x; SCHULTHEISS HP, 1984, EUR J BIOCHEM, V143, P599, DOI 10.1111/j.1432-1033.1984.tb08412.x; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STORRIE B, 1972, J MOL BIOL, V71, P177, DOI 10.1016/0022-2836(72)90345-2; SWIMMER C, 1985, NUCLEIC ACIDS RES, V13, P8053, DOI 10.1093/nar/13.22.8053; SZEKELY E, 1984, MOL CELL BIOL, V4, P939, DOI 10.1128/MCB.4.5.939; Vignais P. V., 1985, STRUCTURE PROPERTIES, V2, P139; WEST DW, 1984, BIOCHEM J, V219, P181, DOI 10.1042/bj2190181; [No title captured]	44	58	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16534	16540						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885585				2022-12-25	WOS:A1991GD63500050
J	SOMERS, CE; SHAPIRO, BM				SOMERS, CE; SHAPIRO, BM			FUNCTIONAL DOMAINS OF PROTEOLIAISIN, THE ADHESIVE PROTEIN THAT ORCHESTRATES FERTILIZATION ENVELOPE ASSEMBLY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARG-GLY-ASP; SEA-URCHIN; OVOPEROXIDASE; MEMBRANE; PURIFICATION; CROSSLINKING; RECEPTORS; INVITRO; CALCIUM; EGG	Ovoperoxidase, the enzyme that hardens the sea urchin fertilization envelope, is inserted into the assembling extracellular matrix through the action of an intermediary protein, proteoliaisin (PLN). The domain structure of PLN, a large, rod-shaped protein that binds to ovoperoxidase and the vitelline layer, was examined by limited proteolytic cleavage. Purified proteolytic fragments of PLN were tested for their ability to bind ovoperoxidase, inhibit the binding of I-125-PLN to the vitelline layer, or act as substrates for the hardening reaction. Based on these results, the vitelline layer-binding domain can be placed near the amino terminus, followed by the binding site for ovoperoxidase; the distal two-thirds of the protein contain sites for ovoperoxidase-catalyzed dityrosine formation. The pentapeptide GRGDS (but not RGD) inhibited PLN-vitelline layer binding half-maximally at 0.2 mM. Moreover, PLN promoted adhesion of bovine aortic endothelial cells to plastic dishes, a process inhibited by GRGDS. Thus PLN is a new member of the adhesive protein family, the function of which is to coordinate the morphogenesis of a specific, rapidly assembled extracellular matrix.	UNIV WASHINGTON,DEPT BIOCHEM SJ70,SEATTLE,WA 98195	University of Washington; University of Washington Seattle					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023910, T32GM007270] Funding Source: NIH RePORTER; NIGMS NIH HHS [NRSA 5 T32 GM07270, GM23910] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; DEITS T, 1984, J BIOL CHEM, V259, P3525; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KAY E, 1982, CELL, V29, P867, DOI 10.1016/0092-8674(82)90448-2; KAY ES, 1987, DEV BIOL, V121, P325, DOI 10.1016/0012-1606(87)90168-0; KAY ES, 1985, BIOL FERTILIZATION, V3, P45; KONIGSBERG WH, 1977, PROTEINS, P2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWLER J, 1988, J CELL BIOL, V107, P2351, DOI 10.1083/jcb.107.6.2351; LONGO F, 1989, CELL BIOL FERTILIZAT, P108; PIERSCHBACHER MD, 1984, NATURE, V309, P3; PRINCE RC, 1988, TRENDS BIOCHEM SCI, V13, P286, DOI 10.1016/0968-0004(88)90119-3; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; SHAPIRO B, 1988, CELL BIOL FERTILIZAT, V1, P251; SOMERS CE, 1989, DEV GROWTH DIFFER, V31, P1; SOMERS CE, 1989, DEV BIOL, V131, P226, DOI 10.1016/S0012-1606(89)80054-5; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEIDMAN PJ, 1987, J BIOL CHEM, V262, P15076; WEIDMAN PJ, 1985, J CELL BIOL, V100, P938, DOI 10.1083/jcb.100.3.938; WEIDMAN PJ, 1987, J CELL BIOL, V105, P561, DOI 10.1083/jcb.105.1.561; WEIDMAN PJ, 1986, METHOD CELL BIOL, V27, P111, DOI 10.1016/S0091-679X(08)60345-3	22	15	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16870	16875						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885614				2022-12-25	WOS:A1991GD63500099
J	VANHOEK, AN; HOM, ML; LUTHJENS, LH; DEJONG, MD; DEMPSTER, JA; VANOS, CH				VANHOEK, AN; HOM, ML; LUTHJENS, LH; DEJONG, MD; DEMPSTER, JA; VANOS, CH			FUNCTIONAL UNIT OF 30-KDA FOR PROXIMAL TUBULE WATER CHANNELS AS REVEALED BY RADIATION INACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL WATER; GLUCOSE TRANSPORTER; TARGET ANALYSIS; UREA TRANSPORT; BRUSH-BORDER; MEMBRANE; KIDNEY; PERMEABILITY; PATHWAYS	The high water permeability of kidney proximal tubules is of paramount importance for isotonic reabsorption of 70% of the glomerular filtrate, and water channels have been postulated to account for the high water permeability. Target analysis following radiation inactivation was used to probe the molecular size of the water channel. Samples of brush border membranes from rat renal cortex were subjected to 3-MeV electron pulses from the Van de Graaff accelerator at a temperature of - 130-degrees-C. The inactivation of the renal brush border enzymes, alkaline phosphatase, and maltase was used for internal standardization of accumulated dose measurements in target analysis of the water channel. Osmotic water permeability was measured by following the change in scattered light intensity upon rapid mixing of vesicles with a hypertonic solution using stopped-flow spectrophotometry. The vesicle shrinkage response was biphasic and the rate of the fast phase decreased dose dependently by irradiation corresponding to a target size of 30 +/- 3.5 kDa. The total change in scattered light intensity was unaltered, indicating that irradiation did not destroy the lipid barrier. Our results provide strong support for the hypothesis that the high osmotic water permeability of renal proximal tubules results from a water channel-specific protein with a functional unit of 30 kDa.	TECH UNIV DELFT, INTERFAC REACTOR INST, 2629 JB DELFT, NETHERLANDS	Delft University of Technology	VANHOEK, AN (corresponding author), CATHOLIC UNIV NIJMEGEN, DEPT PHYSIOL, POB 9101, 6500 HB NIJMEGEN, NETHERLANDS.			Van Hoek, Alfred/0000-0003-2724-6855				CARPIMEDINA P, 1988, J MEMBRANE BIOL, V104, P35, DOI 10.1007/BF01871900; DAHLQVIST A, 1964, ANAL BIOCHEM, V7, P18, DOI 10.1016/0003-2697(64)90115-0; DIX JA, 1985, BIOCHIM BIOPHYS ACTA, V821, P243, DOI 10.1016/0005-2736(85)90093-8; FISCHBARG J, 1989, P NATL ACAD SCI USA, V86, P8397, DOI 10.1073/pnas.86.21.8397; FISCHBARG J, 1987, BIOCHIM BIOPHYS ACTA, V898, P266, DOI 10.1016/0005-2736(87)90066-6; HARMON JT, 1985, METHOD ENZYMOL, V117, P65; Holm N. W., 1970, MANUAL RAD DOSIMETRY; KEMPNER ES, 1989, METHOD ENZYMOL, V172, P410; MEYER MM, 1987, J MEMBRANE BIOL, V96, P107, DOI 10.1007/BF01869237; MIRCHEFF AK, 1976, J MEMBRANE BIOL, V28, P309, DOI 10.1007/BF01869703; PRATZ J, 1986, BIOCHIM BIOPHYS ACTA, V856, P259, DOI 10.1016/0005-2736(86)90035-0; STEVENS BR, 1990, P NATL ACAD SCI USA, V86, P8397; VANHEESWIJK MPE, 1986, J MEMBRANE BIOL, V92, P183, DOI 10.1007/BF01870707; VANHOEK AN, 1990, BIOCHIM BIOPHYS ACTA, V1030, P203, DOI 10.1016/0005-2736(90)90296-Z; VERKMAN AS, 1989, AM J PHYSIOL, V257, pC837, DOI 10.1152/ajpcell.1989.257.5.C837; VERKMAN AS, 1985, AM J PHYSIOL, V249, pF806, DOI 10.1152/ajprenal.1985.249.6.F806; ZHANG R, 1990, J BIOL CHEM, V265, P15375; [No title captured]	18	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16633	16635						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885592				2022-12-25	WOS:A1991GD63500064
J	NIKKOLA, M; GLEASON, FK; SAARINEN, M; JOELSON, T; BJORNBERG, O; EKLUND, H				NIKKOLA, M; GLEASON, FK; SAARINEN, M; JOELSON, T; BJORNBERG, O; EKLUND, H			A PUTATIVE GLUTATHIONE-BINDING SITE IN T4 GLUTAREDOXIN INVESTIGATED BY SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; PIG-LIVER THIOLTRANSFERASE; CALF THYMUS GLUTAREDOXIN; AMINO-ACID SEQUENCE; PROTEIN; REDUCTASE; RESOLUTION; SPECTROSCOPY; PURIFICATION; PEROXIDASE	A glutathione monomer has been docked into the active site cleft of T4 glutaredoxin (previously called T4 thioredoxin) using molecular graphics. The central part of the cleft is formed by the side chain of Tyr-16 on one side and the residues Thr-64, Met-65, and Pro-66 on the other. The entire glutathione molecule fits well into the cleft. A cis-peptide bond between the residues Met-65 and Pro-66 allows glutathione to bind in an anti-parallel fashion to residues 64-66. Hydrogen bonds can be formed between Met-65 and the glutathione cysteine. This binding positions the glutathione sulfur atom ideally for reaction with the glutaredoxin disulfide. In the model, glutathione can form a hydrogen bond to the hydroxyl group of Tyr-16. Charged interactions at opposite ends of the the binding cleft are provided by His-12 and Asp-80. The negatively charged alpha-carboxyl group of glutathione may interact with a positive helix dipole of the protein. Fifteen mutant T4 glutaredoxins have been produced and assayed for glutathione binding by determining thioltransferase activity. Mutant proteins with substitutions in the sides of the cleft (Tyr-16, Pro-66) exhibited the most marked decreases in thioltransferase activity. Mutation of His-12 to a serine decreases the catalytic efficiency whereas substitution of Asp-80 by serine increases the catalytic efficiency. A double mutant, D80S;H12S, has much less affinity for glutathione than either single mutant. Substitution of Cys-14 produces an inactive protein, whereas C17S retains some thioltransferase activity.	SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT MOLEC BIOL,BOX 590,S-75124 UPPSALA,SWEDEN; UNIV MINNESOTA,DEPT PLANT BIOL,ST PAUL,MN 55108	Swedish University of Agricultural Sciences; University of Minnesota System; University of Minnesota Twin Cities								BERGLUND O, 1969, J BIOL CHEM, V244, P6306; CAMBILLAU C, 1984, J MOL GRAPHICS, V2, P53, DOI 10.1016/0263-7855(84)80036-3; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; DYSON HJ, 1988, FEBS LETT, V228, P254, DOI 10.1016/0014-5793(88)80010-3; DYSON HJ, 1990, BIOCHEMISTRY-US, V29, P4129, DOI 10.1021/bi00469a016; EKLUND H, 1984, EMBO J, V3, P1443, DOI 10.1002/j.1460-2075.1984.tb01994.x; EKLUND H, 1987, PYRIDINE NUCLEOTIDE, V2, P51; EKLUND H, 1991, IN PRESS PROTEINS; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; FUCHS A, 1989, GLUTAREDOXIN GLUTATH, P551; GAN ZR, 1987, J BIOL CHEM, V262, P6699; GAN ZR, 1990, ARCH BIOCHEM BIOPHYS, V282, P110, DOI 10.1016/0003-9861(90)90093-E; GAN ZR, 1986, J BIOL CHEM, V261, P996; HIRAOKI T, 1988, BIOCHEMISTRY-US, V27, P5000, DOI 10.1021/bi00414a008; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1978, J BIOL CHEM, V253, P7424; HOLMGREN A, 1985, METHOD ENZYMOL, V113, P525; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1982, BIOCHEM BIOPH RES CO, V107, P1475, DOI 10.1016/S0006-291X(82)80165-4; HOPPER S, 1989, J BIOL CHEM, V264, P20438; JOELSON T, 1990, J BIOL CHEM, V265, P3183; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KARPLUS PA, 1989, EUR J BIOCHEM, V178, P693, DOI 10.1111/j.1432-1033.1989.tb14500.x; KLINTROT IM, 1984, EUR J BIOCHEM, V144, P417, DOI 10.1111/j.1432-1033.1984.tb08481.x; KURIYAN J, 1989, J BIOL CHEM, V264, P12752; LADENSTEIN R, 1979, J MOL BIOL, V134, P199, DOI 10.1016/0022-2836(79)90032-9; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NICHOLSON H, 1988, NATURE, V336, P651, DOI 10.1038/336651a0; PAI EF, 1983, J BIOL CHEM, V258, P1752; PAPAYANNOPOULOS IA, 1989, BIOCHEM BIOPH RES CO, V159, P1448, DOI 10.1016/0006-291X(89)92272-9; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SJOBERG BM, 1972, J BIOL CHEM, V247, P8063; SODERBERG BO, 1978, P NATL ACAD SCI USA, V75, P5827, DOI 10.1073/pnas.75.12.5827; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; WRIGHT WB, 1958, ACTA CRYSTALLOGR, V11, P632, DOI 10.1107/S0365110X58001699; YANG Y, 1990, J BIOL CHEM, V265, P589	39	57	57	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16105	16112						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874748				2022-12-25	WOS:A1991GB97700087
J	MANCHANDA, N; SCHWARTZ, BS				MANCHANDA, N; SCHWARTZ, BS			SINGLE CHAIN UROKINASE - AUGMENTATION OF ENZYMATIC-ACTIVITY UPON BINDING TO MONOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR; RECEPTOR-BOUND UROKINASE; HUMAN SARCOMA-CELLS; PRO-UROKINASE; SURFACE; PLASMA; PROUROKINASE; LOCALIZATION; INACTIVATION; PROENZYME	Cellular migration typically requires cell surface-associated urokinase-type plasminogen activator (u-PA) and plasminogen, both of which are present as proenzymes. Because each active enzyme can activate the other zymogen, the mechanism by which the initial proteolytic event of this two-zymogen system occurs is unclear. A mutant of single chain u-PA that could not be cleaved to the more active two-chain u-PA was used to demonstrate that (i) u-PA in its single-chain form exhibits a reactive active site serine, (ii) the enzymatic activity of this molecule is augmented 100-fold upon binding to the u-PA receptor on monocytes as compared with the enzymatic activity of the same number of molecules in the fluid phase, and (iii) the molecule thus bound and active remains in the single-chain form. This is likely an important mechanism for the initiation and control of cell surface-associated fibrinolysis.	UNIV WISCONSIN,DEPT MED,HEMATOL ONCOL SECT,1300 UNIV AVE,MADISON,WI 53706	University of Wisconsin System; University of Wisconsin Madison					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043506, K04HL001870] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-01870, HL-43506] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; BEEBE DP, 1989, BLOOD, V74, P2034; BLASI F, 1990, FIBRINOLYSIS S3, V4, P184; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; ELLIS V, 1990, J BIOL CHEM, V265, P9904; GUREWICH V, 1984, J CLIN INVEST, V73, P1731, DOI 10.1172/JCI111381; HEBERT CA, 1988, J CELL BIOL, V106, P1241, DOI 10.1083/jcb.106.4.1241; KIRCHHEIMER JC, 1989, BLOOD, V74, P1396; KIRCHHEIMER JC, 1989, J IMMUNOL, V143, P2634; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIJNEN HR, 1989, BLOOD, V73, P1864; MANCHANDA N, 1990, J IMMUNOL, V145, P4174; MIGNATTI P, 1986, CELL, V47, P487, DOI 10.1016/0092-8674(86)90613-6; MURANO G, 1980, BLOOD, V55, P430; NELLES L, 1987, J BIOL CHEM, V262, P5682; OSWALD RE, 1989, NATURE, V337, P579, DOI 10.1038/337579a0; PANNELL R, 1987, BLOOD, V69, P22; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1988, J CELL BIOL, V106, P87, DOI 10.1083/jcb.106.1.87; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; SAKSELA O, 1988, ANNU REV CELL BIOL, V4, P93, DOI 10.1146/annurev.cb.04.110188.000521; SCHWARTZ BS, 1988, BLOOD, V71, P734; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1986, CELL, V45, P675, DOI 10.1016/0092-8674(86)90782-8; VASSALLI JD, 1984, J EXP MED, V159, P1653, DOI 10.1084/jem.159.6.1653; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86	27	92	92	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14580	14584						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907280				2022-12-25	WOS:A1991FZ35100073
J	DHUT, S; CHAPLIN, T; YOUNG, BD				DHUT, S; CHAPLIN, T; YOUNG, BD			NORMAL C-ABL GENE PROTEIN - A NUCLEAR-COMPONENT	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE KINASES; BCR; LOCALIZATION; ONCOGENE; PRODUCT; VIRUS; CELLS; PHOSPHORYLATION; ACTIVATION	The subcellular distribution of the c-abl and bcr-abl gene products from KG1A and K562 cells has been studied by two different techniques. Firstly, physical disruption followed by subcellular fractionation was used to demonstrate that normal c-abl (p145) was recovered from the cytosol and the nuclear fractions of KG1A cells. In contrast, bcr-abl products were recovered exclusively from the cytosol fraction of K562 cells. Secondly, indirect immunofluorescence was used to localize c-abl protein to the cytoplasm, nuclear membrane and infrequently to the nucleus of KG1A cells and bcr-abl protein to only the cytoplasm of K562 cells. Thus both the approaches indicate that there is a component of normal c-abl products which appears to be nuclear and this is not reflected in the distribution of the bcr-abl 210 kDa protein, which remains cytosolic.			DHUT, S (corresponding author), ST BARTHOLOMEWS HOSP, MED ONCOL LAB, IMPERIAL CANC RES FUND, LONDON EC1 7BA, ENGLAND.							BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNARDS A, 1987, MOL CELL BIOL, V7, P3231, DOI 10.1128/MCB.7.9.3231; BROTT BK, 1991, P NATL ACAD SCI USA, V88, P755, DOI 10.1073/pnas.88.3.755; DHUT S, 1988, ONCOGENE, V3, P561; DHUT S, 1991, LEUKEMIA, V5, P49; DHUT S, 1990, LEUKEMIA, V4, P745; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FAINSTEIN E, 1989, ONCOGENE, V4, P1477; FOULKES JG, 1985, J BIOL CHEM, V260, P8070; FRANZ WM, 1989, EMBO J, V8, P137, DOI 10.1002/j.1460-2075.1989.tb03358.x; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HEISTERKAMP N, 1983, NATURE, V306, P239, DOI 10.1038/306239a0; HUNTER T, 1986, ENZYMES, V17, P191; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KIPREOS ET, 1990, SCIENCE, V248, P217, DOI 10.1126/science.2183353; KITAZAWA S, 1990, MED ONCOL TUMOR PHAR, V7, P35; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; PAWSON T, 1988, ONCOGENE, V3, P491; Potts W M, 1988, Oncogene Res, V3, P343; REDDY EP, 1988, ONCOGENE HDB, P3; ROHRSCHNEIDER LR, 1979, CELL, V16, P11, DOI 10.1016/0092-8674(79)90183-1; ROHRSCHNEIDER LR, 1984, J VIROL, V51, P547, DOI 10.1128/JVI.51.2.547-552.1984; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; SHORE SK, 1990, P NATL ACAD SCI USA, V87, P6502, DOI 10.1073/pnas.87.17.6502; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WATANABE SM, 1984, J VIROL, V51, P620, DOI 10.1128/JVI.51.3.620-627.1984; WESTIN EH, 1982, P NATL ACAD SCI-BIOL, V79, P2490, DOI 10.1073/pnas.79.8.2490	31	20	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1459	1464						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886716				2022-12-25	WOS:A1991GX27200024
J	CHAN, D; COLE, WG				CHAN, D; COLE, WG			LOW BASAL TRANSCRIPTION OF GENES FOR TISSUE-SPECIFIC COLLAGENS BY FIBROBLASTS AND LYMPHOBLASTOID-CELLS - APPLICATION TO THE CHARACTERIZATION OF A GLYCINE-997 TO SERINE SUBSTITUTION IN ALPHA-1(II) COLLAGEN CHAINS OF A PATIENT WITH SPONDYLOEPIPHYSEAL DYSPLASIA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; PERINATAL OSTEOGENESIS IMPERFECTA; TRIPLE HELICAL DOMAIN; II PROCOLLAGEN; MESSENGER-RNA; MILD CHONDRODYSPLASIA; DNA-POLYMERASE; AMPLIFIED DNA; CDNA; COL2A1	Cultured dermal fibroblasts were shown, using amplification of cDNA by the polymerase chain reaction, to produce very low levels of spliced transcripts from the COL2A1 gene that encodes the cartilage-specific alpha-1 (II) chains of type II collagen. Cultured lymphoblastoid cells were also shown to produce very low levels of spliced transcripts from the COL1A1 and COL1A2 genes that encode the alpha-1(I) and alpha-2(I) chains of type I collagen, the COL2A1 gene that encodes type II collagen, and the COL3A1 gene that encodes the alpha-1(III) chains of type III collagen. Amplified cDNAs prepared from lymphoblastoid cells were used to identify previously characterized heterozygous mutations in the COL1A1 and COL1A2 genes from two patients with osteogenesis imperfecta and in the COL3A1 gene from a patient with the Ehlers-Danlos syndrome type IV. Amplified alpha-1(II) cDNA from fibroblasts and lymphoblastoid cells of a child with spondyloepiphyseal dysplasia congenita was also used to localize sequence mismatches using chemical modification of cDNA:cDNA heteroduplexes by hydroxylamine and cleavage with piperidine. The amplification products containing the mismatched region were sequenced and the mutation was shown to change the codon GGC for glycine 997 to AGC for serine in the triple helical domain of the alpha-1(II) chains. The corresponding region of the genomic DNA was sequenced and the heterozygous point mutation was shown to be in exon 48 of the COL2A1 gene. Allelic restriction mapping showed that neither parent carried the mutation in their leucocytes. This mutation emphasizes the importance of COL2A1 mutations in producing the spondyloepiphyseal dysplasia phenotype. The low basal rate of transcription ("illegitimate transcription"), splicing, and polyadenylation of tissue-specific mRNAs by cultured dermal fibroblasts and lymphoblastoid cells provides the opportunity to localize and sequence mutations in amplified cDNA in patients from whom affected tissue is unavailable.	UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne			Chan, Danny/C-4203-2009	Chan, Danny/0000-0003-3824-5778				ALAKOKKO L, 1990, P NATL ACAD SCI USA, V87, P6565, DOI 10.1073/pnas.87.17.6565; ALAKOKKO L, 1989, BIOCHEM J, V260, P509, DOI 10.1042/bj2600509; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; Bateman J F, 1988, Ann N Y Acad Sci, V543, P95, DOI 10.1111/j.1749-6632.1988.tb55321.x; BATEMAN JF, 1988, ANAL BIOCHEM, V168, P171, DOI 10.1016/0003-2697(88)90025-5; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; CHEAH KSE, 1985, P NATL ACAD SCI USA, V82, P2555, DOI 10.1073/pnas.82.9.2555; CHELLY J, 1990, EUR J BIOCHEM, V187, P691, DOI 10.1111/j.1432-1033.1990.tb15355.x; CHELLY J, 1988, NATURE, V333, P858, DOI 10.1038/333858a0; CHELLY J, 1989, P NATL ACAD SCI USA, V86, P2617, DOI 10.1073/pnas.86.8.2617; CHENEVIXTRENCH G, 1990, AM J HUM GENET, V46, P635; CHENKIANG S, 1978, P NATL ACAD SCI USA, V75, P1379, DOI 10.1073/pnas.75.3.1379; CHU ML, 1982, NUCLEIC ACIDS RES, V10, P5925, DOI 10.1093/nar/10.19.5925; COLE WG, 1986, J BIOL CHEM, V261, P5496; COLE WG, 1981, BIOCHEM J, V197, P377, DOI 10.1042/bj1970377; COLE WG, 1990, J BIOL CHEM, V265, P17070; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; DAHL HHM, 1989, ANAL BIOCHEM, V183, P263, DOI 10.1016/0003-2697(89)90477-6; DEWET W, 1987, J BIOL CHEM, V262, P16032; ENNIS PD, 1990, P NATL ACAD SCI USA, V87, P2833, DOI 10.1073/pnas.87.7.2833; FRANCOMANO C A, 1987, Genomics, V1, P293, DOI 10.1016/0888-7543(87)90027-9; GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919; GOLDBERG B, 1968, P NATL ACAD SCI USA, V59, P1110, DOI 10.1073/pnas.59.4.1110; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; KNOWLTON RG, 1990, NEW ENGL J MED, V322, P526, DOI 10.1056/NEJM199002223220807; KOGAN SC, 1987, NEW ENGL J MED, V317, P985, DOI 10.1056/NEJM198710153171603; LAMANDE SR, 1989, J BIOL CHEM, V264, P15809; LEE B, 1989, SCIENCE, V244, P978, DOI 10.1126/science.2543071; Maniatis T., 1982, MOL CLONING; MEINKOTH J, 1984, ANAL BIOCHEM, V138, P267, DOI 10.1016/0003-2697(84)90808-X; MILLER EJ, 1973, BIOCHEMISTRY-US, V12, P3153, DOI 10.1021/bi00741a003; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; REISS J, 1990, NUCLEIC ACIDS RES, V18, P973, DOI 10.1093/nar/18.4.973; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SARKAR G, 1989, SCIENCE, V244, P331, DOI 10.1126/science.2565599; SPRANGER JW, 1970, RADIOLOGY, V94, P313, DOI 10.1148/94.2.313; STARMAN BJ, 1989, J CLIN INVEST, V84, P1206, DOI 10.1172/JCI114286; SU MW, 1989, NUCLEIC ACIDS RES, V17, P9473, DOI 10.1093/nar/17.22.9473; TILLER GE, 1990, P NATL ACAD SCI USA, V87, P3889, DOI 10.1073/pnas.87.10.3889; TINDALL KR, 1988, BIOCHEMISTRY-US, V27, P6008, DOI 10.1021/bi00416a027; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; VISSING H, 1989, J BIOL CHEM, V264, P18265	44	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12487	12494						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905723				2022-12-25	WOS:A1991FV18000062
J	EIPPER, BA; PERKINS, SN; HUSTEN, EJ; JOHNSON, RC; KEUTMANN, HT; MAINS, RE				EIPPER, BA; PERKINS, SN; HUSTEN, EJ; JOHNSON, RC; KEUTMANN, HT; MAINS, RE			PEPTIDYL-ALPHA-HYDROXYGLYCINE ALPHA-AMIDATING LYASE - PURIFICATION, CHARACTERIZATION, AND EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE NEUROINTERMEDIATE PITUITARY; MESSENGER-RNA; MONOOXYGENASE ACTIVITY; URATE DEGRADATION; XENOPUS-LAEVIS; RAT PITUITARY; ENZYME; ATRIUM; FORMS; INTERMEDIATE	The production of alpha-amidated peptides from their glycine-extended precursors is a two-step process involving the sequential action of two catalytic domains encoded by the bifunctional peptidylglycine alpha-amidating monooxygenase (PAM) precursor. The NH2-terminal third of the PAM precursor contains the first enzyme, peptidylglycine alpha-hydroxylating monooxygenase (PHM), a copper, molecular oxygen, and ascorbate-dependent enzyme. The middle third of the PAM precursor contains the second enzyme, peptidyl-alpha-hydroxyglycine alpha-amidating lyase (PAL). The COOH-terminal third of the PAM precursor encodes a transmembrane domain and a hydrophilic domain that may form a cytoplasmic tail. Antisera to a peptide within the PAL domain were used to identify a 50-kDa protein as the major form of PAL in bovine neurointermediate pituitary granules. This 50-kDa PAL protein was purified and found to begin at Asp434 of bPAM, indicating that it could arise through endoproteolytic cleavage of the bPAM precursor at Lys432-Lys433. With alpha-N-acetyl-Tyr-Val-alpha-hydroxyglycine as the substrate, PAL exhibits a pH optimum of 5.0; enzymatic activity is inhibited by high concentrations of salt but is relatively resistant to thiol reagents and urea. PAL activity is inhibited by EDTA and restored by a number of divalent metals, including Cd2+, Cu2+, Zn2+, and Ca2+. Kinetic studies using alpha-N-acetyl-Tyr-Val-alpha-hydroxyglycine indicate that PAL has a K(m) of 38-mu-M and a turnover number of 220/s. Expression vectors encoding only the soluble PHM domain or the PAM precursor from which the PHM domain had been deleted were constructed. hEK293 cells transfected with the PHM vector exhibited a 10-fold increase in secretion of PHM activity with no PHM activity detectable in control or transfected cells. hEK293 cells transfected with the PAL vector exhibited a 2-fold increase in secretion of PAL activity and a 15-fold increase in cellular PAL activity. Most of the PAL activity produced by the transfected cells remained membrane-associated.			EIPPER, BA (corresponding author), JOHNS HOPKINS UNIV, SCH MED,DEPT NEUROSCI,WOOD BASIC SCI BLDG,RM 207, 725 N WOLFE ST, BALTIMORE, MD 21205 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK032948, R01DK032948, R37DK032948, R37DK032949, R56DK032949, R01DK032949] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00097] Funding Source: Medline; NIDDK NIH HHS [DK-32949, DK-32948] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BEAUDRY GA, 1990, J BIOL CHEM, V265, P17694; BERTELSEN AH, 1990, ARCH BIOCHEM BIOPHYS, V279, P87, DOI 10.1016/0003-9861(90)90466-C; BRAAS KM, 1989, MOL ENDOCRINOL, V3, P1387, DOI 10.1210/mend-3-9-1387; BRADBURY AF, 1987, EUR J BIOCHEM, V169, P579, DOI 10.1111/j.1432-1033.1987.tb13648.x; BRADBURY AF, 1985, BIOGENETICS NEUROHOR, P171; CASTLE JD, 1987, ANN NY ACAD SCI, V493, P448, DOI 10.1111/j.1749-6632.1987.tb27230.x; CHANG ACY, 1988, FOCUS, V10, P66; Cleland W W, 1979, Methods Enzymol, V63, P103; DAWSON RMC, 1988, DATA BIOCH RES, P31; DICKERSON IM, 1990, J BIOL CHEM, V265, P2462; EIPPER BA, 1987, MOL ENDOCRINOL, V1, P777, DOI 10.1210/mend-1-11-777; EIPPER BA, 1988, J BIOL CHEM, V263, P8371; EIPPER BA, 1985, ENDOCRINOLOGY, V116, P2497, DOI 10.1210/endo-116-6-2497; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GLAUDER J, 1990, BIOCHEM BIOPH RES CO, V169, P551, DOI 10.1016/0006-291X(90)90366-U; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; HUANG MTF, 1990, MOL CELL BIOL, V10, P1805, DOI 10.1128/MCB.10.4.1805; JOHNSON RG, 1987, ANN NY ACAD SCI, V493, P162, DOI 10.1111/j.1749-6632.1987.tb27198.x; KATOPODIS AG, 1990, BIOCHEMISTRY-US, V29, P6115, DOI 10.1021/bi00478a001; KOJIMA M, 1989, J BIOCHEM-TOKYO, V105, P440, DOI 10.1093/oxfordjournals.jbchem.a122683; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; MAINS RE, 1991, IN PRESS MOL ENDOCRI, V5; MAY V, 1988, J BIOL CHEM, V263, P7550; MAY V, 1986, ENDOCRINOLOGY, V118, P1284, DOI 10.1210/endo-118-4-1284; MEHTA NM, 1988, ARCH BIOCHEM BIOPHYS, V261, P44, DOI 10.1016/0003-9861(88)90102-6; MIZUNO K, 1987, BIOCHEM BIOPH RES CO, V148, P546, DOI 10.1016/0006-291X(87)90911-9; MIZUNO K, 1985, PEPTIDE CHEM 1985, P351; MURTHY ASN, 1986, J BIOL CHEM, V261, P1815; MURTHY ASN, 1987, MOL ENDOCRINOL, V1, P290, DOI 10.1210/mend-1-4-290; OHSUYE K, 1988, BIOCHEM BIOPH RES CO, V150, P1275, DOI 10.1016/0006-291X(88)90767-X; OUAFIK L, 1989, J BIOL CHEM, V264, P5839; PARKINSON D, 1990, J BIOL CHEM, V265, P17101; PERKINS SN, 1990, BIOCHEM BIOPH RES CO, V171, P926, DOI 10.1016/0006-291X(90)90772-F; PERKINS SN, 1990, ENDOCRINOLOGY, V127, P2771, DOI 10.1210/endo-127-6-2771; PERKINS SN, 1990, MOL ENDOCRINOL, V4, P132, DOI 10.1210/mend-4-1-132; RENSDOMIANO S, 1989, J BIOL CHEM, V264, P899; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STOFFERS DA, 1991, J BIOL CHEM, V266, P1701; STOFFERS DA, 1989, P NATL ACAD SCI USA, V86, P735, DOI 10.1073/pnas.86.2.735; STOFFERS DA, 1989, ICSU SHORT REPORTS, V9, P120; TAJIMA M, 1990, J BIOL CHEM, V265, P9602; TAKADA Y, 1986, BIOCHEM J, V235, P391, DOI 10.1042/bj2350391; TAKADA Y, 1987, J BACTERIOL, V169, P2284, DOI 10.1128/jb.169.5.2284-2286.1987; TAKAHASHI K, 1990, BIOCHEM BIOPH RES CO, V169, P524, DOI 10.1016/0006-291X(90)90362-Q; YOUNG SD, 1989, J AM CHEM SOC, V111, P1933, DOI 10.1021/ja00187a088	48	125	130	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7827	7833						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902227				2022-12-25	WOS:A1991FJ34200080
J	SHEEHAN, JE; PITOT, HC; KASPER, CB				SHEEHAN, JE; PITOT, HC; KASPER, CB			TRANSCRIPTIONAL REGULATION AND LOCALIZATION OF THE TISSUE-SPECIFIC INDUCTION OF EPOXIDE HYDROLASE BY LEAD ACETATE IN RAT-KIDNEY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-STILBENE OXIDE; NUCLEAR-ENVELOPE; ARENE OXIDES; DNA COMPLEMENTARY; HEME OXYGENASE; OXIDOREDUCTASE; CADMIUM; CYTOCHROME-P-450; HYDRATION; GLUCOCORTICOIDS	Intraperitoneal administration of lead acetate to male Sprague-Dawley rats resulted in the tissue-specific transcriptional activation of the microsomal epoxide hydrolase gene in kidney. This response was followed by a 15-fold increase in the level of kidney epoxide hydrolase mRNA, while no change in mRNA level was noted in liver. Treated animals also showed no increase in mRNA levels for NADPH-cytochrome P-450 oxidoreductase, cytochrome P-450b/e, cytochrome P-450PCN (where PCN is pregnenolone 16-alpha-carbonitrile), or serum albumin in either kidney or liver. Immunoquantitation of the enzyme revealed a 16-fold increase in kidney upon treatment with lead acetate, but significant changes in epoxide hydrolase levels were not noted in liver, heart, spleen, lung, small intestine, or testis. The enzymatic activity for liver and kidney paralleled the immunochemical results; however, the activity increase in kidney was only one-third of the increase noted for total enzyme protein. Immunohistochemical analysis of epoxide hydrolase protein in sections of rat kidney demonstrated that in lead acetate-treated animals there was a marked increase in staining of the cytoplasm of the proximal tubular cells in the outer cortex as compared with kidneys from control animals. In contrast, considerable protein was also localized to collecting ducts, but no change was evident in the content of the epoxide hydrolase gene product in these structures in control and lead acetate-treated animals. Immunohistochemical differences were not noted between livers from control and lead-treated animals. Furthermore, the staining patterns for NADPH-cytochrome P-450 oxidoreductase were the same for control and treated animals in both kidney and liver. Quantitative measurements of lead uptake by various rat tissues showed liver, spleen, and small intestine reaching a maximum of approximately 12,000 ng of lead/g of dry tissue at 8, 8, and 16 h, respectively, while kidney, lung, and testis peaked (approximately 3,000 ng of lead/g of dry tissue) at 16, 16, and 12 h, respectively.			SHEEHAN, JE (corresponding author), UNIV WISCONSIN,MCARDLE LAB CANC RES,MADISON,WI 53706, USA.				NATIONAL CANCER INSTITUTE [P01CA022484] Funding Source: NIH RePORTER; NCI NIH HHS [CA22484] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL PA, 1990, ARCH BIOCHEM BIOPHYS, V279, P363, DOI 10.1016/0003-9861(90)90503-Q; CLAVEL JP, 1985, PATHOL BIOL, V33, P61; DALY JW, 1972, EXPERIENTIA, V28, P1129, DOI 10.1007/BF01946135; DING VDH, 1990, CANCER RES, V50, P256; EVENSON MA, 1975, CLIN CHEM, V21, P537; FAHL WE, 1978, J BIOL CHEM, V253, P3106; FALANY CN, 1987, J BIOL CHEM, V262, P5924; GILL SS, 1989, BIOCHEM BIOPH RES CO, V89, P965; GONZALEZ FJ, 1982, J BIOL CHEM, V257, P5962; GONZALEZ FJ, 1982, J BIOL CHEM, V257, P1032; GONZALEZ FJ, 1982, MOL PHARMACOL, V21, P511; GONZALEZ FJ, 1976, BIOCHEM BIOPH RES CO, V436, P387; GOYER RA, 1975, LAB INVEST, V32, P149; GOYER RA, 1989, TOXICOL LETT, V46, P153, DOI 10.1016/0378-4274(89)90124-0; GRAICHEN ME, 1986, P AM ASSOC CANC RES, V27, P72; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HAMMOCK BD, 1983, TOXICOL APPL PHARM, V71, P254, DOI 10.1016/0041-008X(83)90342-3; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; HARDWICK JP, 1983, J BIOL CHEM, V258, P182; HENDRICH S, 1987, CARCINOGENESIS, V8, P1245, DOI 10.1093/carcin/8.9.1245; Kasper C B, 1974, Methods Enzymol, V31, P279; KASPER CB, 1971, J BIOL CHEM, V246, P577; LEVANDER OA, 1977, J NUTR, V107, P363, DOI 10.1093/jn/107.3.363; LEVIN W, 1983, ARCH BIOCHEM BIOPHYS, V220, P485, DOI 10.1016/0003-9861(83)90439-3; LU AYH, 1977, J BIOL CHEM, V252, P3715; MAINES MD, 1974, P NATL ACAD SCI USA, V71, P4293, DOI 10.1073/pnas.71.11.4293; OESCH F, 1984, CARCINOGENESIS, V5, P7, DOI 10.1093/carcin/5.1.7; PALMITER RD, 1985, CURRENT COMMUNICATIO, P144; PARKKI MG, 1980, BIOCHIM BIOPHYS ACTA, V614, P625, DOI 10.1016/0005-2744(80)90252-1; PORTER TD, 1986, ARCH BIOCHEM BIOPHYS, V248, P121, DOI 10.1016/0003-9861(86)90408-X; SCHMASSMANN H, 1982, BIOCHEM PHARMACOL, V27, P2237; SEARLE PF, 1985, MOL CELL BIOL, V5, P1480, DOI 10.1128/MCB.5.6.1480; SEIDEGARD J, 1979, BIOCHIM BIOPHYS ACTA, V586, P10, DOI 10.1016/0304-4165(79)90400-8; SHELTON KR, 1986, J BIOL CHEM, V261, P1935; SIMMONS DL, 1987, J BIOL CHEM, V262, P326; TAKETANI S, 1989, FEBS LETT, V245, P173, DOI 10.1016/0014-5793(89)80215-7; YAGLE MK, 1985, MOL CELL BIOL, V5, P291, DOI 10.1128/MCB.5.2.291; ZIMMERMAN JJ, 1978, ARCH BIOCHEM BIOPHYS, V190, P726, DOI 10.1016/0003-9861(78)90333-8	38	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5122	5127						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1900514				2022-12-25	WOS:A1991FC21700066
J	ENTSCH, B; PALFEY, BA; BALLOU, DP; MASSEY, V				ENTSCH, B; PALFEY, BA; BALLOU, DP; MASSEY, V			CATALYTIC FUNCTION OF TYROSINE RESIDUES IN PARA-HYDROXYBENZOATE HYDROXYLASE AS DETERMINED BY THE STUDY OF SITE-DIRECTED MUTANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE HALF-REACTION; CONTAINING MONO-OXYGENASE; PSEUDOMONAS-FLUORESCENS; ANTHRANILATE HYDROXYLASE; CRYSTAL-STRUCTURE; ENZYME-SUBSTRATE; PH-DEPENDENCE; STEADY-STATE; ACTIVE-SITE; COMPLEX	The role of protein residues in activating the substrate in the reaction catalyzed by the flavoprotein p-hydroxybenzoate hydroxylase was studied. X-ray crystallography (Schreuder, H. A., Prick, P. A. J., Wieringa, R. K., Vriend, G., Wilson, K. S., Hol, W. G. J., and Drenth, J. (1989) J. Mol. Biol. 208, 679-696) indicates that Tyr-201 and Tyr-385 form a hydrogen bond network with the 4-OH of p-hydroxybenzoate. Therefore, site directed mutants were constructed, converting each of these tyrosines into phenylalanines. Spectral (visible and fluorescence) properties, reduction potentials, and binding constants are very similar to those of wild type, indicating that there are no major structural changes in the mutants. In the absence of substrate, the mutants and wild type exhibit similar pH-dependent changes in the FAD spectrum. However, the enyme-substrate complex of Tyr-201 --> Phe lacks an ionization observed in both wild type and Tyr-385 --> Phe, which preferentially bind the phenolate form of substrates. Tyr-201 --> Phe shows no preference, indicating that Tyr-201 is required to ionize the substrate. The mutants have less than 6% the activity of the wild type enzyme. The effects on catalysis were studied by stopped flow techniques. Reduction of FAD by NADPH is slower by 10-fold in Tyr-201 --> Phe and 100-fold in Tyr-385 --> Phe. When the reduced Tyr-201 --> Phe-p-hydroxybenzoate complex reacts with oxygen, a long-lived flavin-C(4a)-hydroperoxide is observed, which slowly eliminates H2O2 with very little hydroxylation. Thus, the role of Tyr-201 is to activate the substrate by stabilizing the phenolate. Tyr-385 --> Phe reacts with oxygen to form 25% oxidized enzyme, and 75% flavin hydroperoxide, which successfully hydroxylates the substrate. This mutant also hydroxylates the product (3,4-dihydroxybenzoate) to form gallic acid.	UNIV MICHIGAN,DEPT BIOL CHEM,MED SCI BLDG I,BOX 0606,ANN ARBOR,MI 48109; UNIV NEW ENGLAND,DEPT BIOCHEM MICROBIOL & NUTR,ARMIDALE,NSW 2351,AUSTRALIA	University of Michigan System; University of Michigan; University of New England				Palfey, Bruce/0000-0001-5098-259X	NIGMS NIH HHS [GM 20877, GM 11106, GM 08270] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008270, R01GM011106, R01GM020877, R37GM011106, R37GM020877] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ballou D. P., 1984, FLAVINS FLAVOPROTEIN, P605; Ballou D. P., 1982, FLAVINS FLAVOPROTEIN, P301; BEATY NB, 1981, J BIOL CHEM, V256, P4619; BEATY NB, 1981, J BIOL CHEM, V256, P4611; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; DETMER K, 1985, J BIOL CHEM, V260, P5998; ENTSCH B, 1976, J BIOL CHEM, V251, P7367; ENTSCH B, 1987, J BIOL CHEM, V262, P6060; ENTSCH B, 1990, METHOD ENZYMOL, V188, P138; ENTSCH B, 1989, BIOCHIM BIOPHYS ACTA, V999, P313, DOI 10.1016/0167-4838(89)90014-9; ENTSCH B, 1988, GENE, V71, P279, DOI 10.1016/0378-1119(88)90044-3; ENTSCH B, 1990, FLAVINS FLAVOPROTEIN, P219; ENTSCH B, 1975, 5TH INT S FLAV FLAV, P111; ENTSCH B, 1976, J BIOL CHEM, V251, P2555; GHISLA S, 1977, EUR J BIOCHEM, V76, P139, DOI 10.1111/j.1432-1033.1977.tb11579.x; GIBSON QH, 1964, J BIOL CHEM, V239, P3927; HOWELL LG, 1972, J BIOL CHEM, V247, P4340; HUSAIN M, 1979, J BIOL CHEM, V254, P6657; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Maniatis T, 1982, MOL CLONING LABORATO, P68; MANSTEIN DJ, 1986, BIOCHEMISTRY-US, V25, P6807, DOI 10.1021/bi00370a012; MARCH J, 1985, ADV ORG CHEM, P237; Massey V, 1988, Prog Clin Biol Res, V274, P147; MASSEY V, 1982, BIOL OXIDATIONS, P114; Massey V, 1990, FLAVINS FLAVOPROTEIN, P59; MULLER F, 1985, BIOCHEM SOC T, V13, P443; POWLOWSKI J, 1989, J BIOL CHEM, V264, P5606; POWLOWSKI J, 1990, J BIOL CHEM, V265, P4969; POWLOWSKI JB, 1987, J BIOL CHEM, V262, P69; RYERSON CC, 1982, BIOCHEMISTRY-US, V21, P2644, DOI 10.1021/bi00540a011; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHOPFER LM, 1980, J BIOL CHEM, V255, P5355; SCHREUDER HA, 1989, J MOL BIOL, V208, P679, DOI 10.1016/0022-2836(89)90158-7; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; SCHREUDER HA, 1990, BIOCHEMISTRY-US, V29, P3101, DOI 10.1021/bi00464a029; SCHREUDER HA, 1988, THESIS U GRONINGEN N; SHOUN H, 1979, J BIOL CHEM, V254, P944; SPECTOR T, 1972, J BIOL CHEM, V247, P7123; SPECTOR T, 1972, J BIOL CHEM, V247, P4679; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048; TABOR S, 1987, P NATL ACAD SCI USA, V84, P4767, DOI 10.1073/pnas.84.14.4767; VANBERKEL WJH, 1989, EUR J BIOCHEM, V179, P307; VANDERLAAN JM, 1989, EUR J BIOCHEM, V179, P715, DOI 10.1111/j.1432-1033.1989.tb14605.x; VANDERLAAN JM, 1989, BIOCHEMISTRY-US, V28, P7199, DOI 10.1021/bi00444a011; WEIJER WJ, 1982, BIOCHIM BIOPHYS ACTA, V704, P385, DOI 10.1016/0167-4838(82)90170-4; WESSIAK A, 1984, J BIOL CHEM, V259, P2547; WESTPHAL AH, 1990, FLAVINS FLAVOPROTEIN, P231; WIJNANDS RA, 1986, BIOCHEMISTRY-US, V25, P4211, DOI 10.1021/bi00363a007; WILLIAMSON G, 1988, BIOCHIM BIOPHYS ACTA, V953, P258, DOI 10.1016/0167-4838(88)90033-7; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	50	124	127	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17341	17349						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910043				2022-12-25	WOS:A1991GF44500057
J	WOUTERSTYROU, D; CHARTIERHARLIN, MC; MARTINPONTHIEU, A; BOUTILLON, C; VANDORSSELAER, A; SAUTIERE, P				WOUTERSTYROU, D; CHARTIERHARLIN, MC; MARTINPONTHIEU, A; BOUTILLON, C; VANDORSSELAER, A; SAUTIERE, P			CUTTLEFISH SPERMATID-SPECIFIC PROTEIN-T - MOLECULAR CHARACTERIZATION OF 2 VARIANT-T1 AND VARIANT-T2, PUTATIVE PRECURSORS OF SPERM PROTAMINE VARIANT-SP1 AND VARIANT-SP2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FISH SCYLLIORHINUS-CANICULUS; NUCLEAR BASIC-PROTEINS; AMINO-ACID SEQUENCES; TRANSITION PROTEIN-1; NUCLEOTIDE-SEQUENCE; SECONDARY STRUCTURE; CDNA; MOUSE; SPERMATOGENESIS; DIFFERENTIATION	In cuttlefish, as in selachians and mammals, spermiogenesis is characterized by the double nuclear protein transition histones --> intermediate protein (protein T) --> protamine (protein Sp). The cuttlefish protein T, which consists of two structural variants phosphorylated at different degrees, is the first invertebrate spermatid-specific protein to be fully characterized and sequenced. The primary structures of these two variants were established from sequence analysis and mass spectrometric data of the proteins and their fragments. T1 and T2 are two highly related proteins of 78 and 77 residues, respectively, which differ only by four conservative substitutions, two inversions Ser <--> Arg, and the deletion of 1 residue of arginine in variant T2. The asymmetrical distribution of the hydrophobic and basic residues determines two well defined domains: an amino-terminal domain (residues 1-21) devoid of arginine and aromatic residues and containing all the aliphatic hydrophobic residues and a highly basic carboxyl-terminal domain (residues 22-77 or 78) that contains 77% of arginine, all the tyrosine residues, and most of the phosphorylated serine residues present in the protein. The complete structural identity of the basic carboxyl-terminal domain of spermatidal proteins T1 and T2 with the protamine variants Sp1 and Sp2 isolated from cuttlefish spermatozoa strongly suggests that T1 and T2 could be precursors of Sp1 and Sp2, respectively.	CTR NEUROCHIM, CHIM ORGAN SUBST NAT LAB, CNRS, URA 31, F-67084 STRASBOURG, FRANCE	Centre National de la Recherche Scientifique (CNRS)	WOUTERSTYROU, D (corresponding author), UNIV LILLE 2, INST RECH CANC, CNRS, URA 409, PL DE VERDUN, F-59045 LILLE, FRANCE.		Chartier-Harlin, Marie-Christine/L-4527-2018	Chartier-Harlin, Marie-Christine/0000-0001-6416-6526				BALHORN R, 1984, EXP CELL RES, V150, P298, DOI 10.1016/0014-4827(84)90572-X; CHAUVIERE M, 1987, EUR J BIOCHEM, V169, P105, DOI 10.1111/j.1432-1033.1987.tb13586.x; CHAUVIERE M, 1983, FEBS LETT, V152, P231, DOI 10.1016/0014-5793(83)80386-X; CHAUVIERE M, 1989, EUR J BIOCHEM, V180, P329, DOI 10.1111/j.1432-1033.1989.tb14652.x; CHIRAT F, 1991, EUR J BIOCHEM, V198, P13, DOI 10.1111/j.1432-1033.1991.tb15980.x; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DUPRESSOIR T, 1985, EXP CELL RES, V161, P63, DOI 10.1016/0014-4827(85)90490-2; ECKHART W, 1979, CELL, V18, P925, DOI 10.1016/0092-8674(79)90205-8; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIBRAT JF, 1987, J MOL BIOL, V198, P425, DOI 10.1016/0022-2836(87)90292-0; GRIMES SR, 1977, PEXP CELL RES, V110, P31; GUSSE M, 1986, BIOCHIM BIOPHYS ACTA, V884, P124, DOI 10.1016/0304-4165(86)90235-7; KADURA SN, 1988, EUR J BIOCHEM, V175, P603, DOI 10.1111/j.1432-1033.1988.tb14234.x; KISTLER WS, 1975, J BIOL CHEM, V250, P1847; KLEENE KC, 1988, BIOCHIM BIOPHYS ACTA, V950, P215, DOI 10.1016/0167-4781(88)90013-9; KLEENE KC, 1987, J BIOL CHEM, V262, P17272; KREMLING H, 1989, DIFFERENTIATION, V40, P184, DOI 10.1111/j.1432-0436.1989.tb00597.x; LEVIN JM, 1986, FEBS LETT, V205, P303, DOI 10.1016/0014-5793(86)80917-6; LUERSSEN H, 1988, NUCLEIC ACIDS RES, V16, P7723, DOI 10.1093/nar/16.15.7723; LUERSSEN H, 1989, NUCLEIC ACIDS RES, V17, P3585, DOI 10.1093/nar/17.9.3585; MARTINAGE A, 1990, EUR J BIOCHEM, V191, P449, DOI 10.1111/j.1432-1033.1990.tb19142.x; MARTINAGE A, 1980, FEBS LETT, V118, P323, DOI 10.1016/0014-5793(80)80249-3; MARTINAGE A, 1989, 2ND FORUM PEPTIDES, V174, P57; MARTINPONTHIEU A, 1991, EUR J BIOCHEM, V195, P611, DOI 10.1111/j.1432-1033.1991.tb15744.x; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; OHE Y, 1979, J BIOCHEM-TOKYO, V85, P615, DOI 10.1093/oxfordjournals.jbchem.a132371; PANYIM S, 1969, ARCH BIOCHEM BIOPHYS, V130, P337, DOI 10.1016/0003-9861(69)90042-3; RHOLAM M, 1986, FEBS LETT, V207, P1, DOI 10.1016/0014-5793(86)80002-3; ROBSON B, 1971, J MOL BIOL, V58, P237, DOI 10.1016/0022-2836(71)90243-9; ROUSSEAUXPREVOST R, 1988, GAMETE RES, V19, P277, DOI 10.1002/mrd.1120190307; SAUTIERE P, 1988, J BIOL CHEM, V263, P11059; SCHINDLER P, 1991, EUR J BIOCHEM, V195, P621, DOI 10.1111/j.1432-1033.1991.tb15746.x; SHLYAPNIKOV SV, 1975, FEBS LETT, V53, P316, DOI 10.1016/0014-5793(75)80045-7; SUBIRANA JA, 1973, BIOCHIM BIOPHYS ACTA, V317, P364, DOI 10.1016/0005-2795(73)90231-6; SWIDEREK K, 1988, EUR J BIOCHEM, V176, P335, DOI 10.1111/j.1432-1033.1988.tb14286.x; WEBSTER A, 1989, J GEN VIROL, V70, P3225, DOI 10.1099/0022-1317-70-12-3225; WOUTERSTYROU D, 1988, BIOCHIM BIOPHYS ACTA, V953, P86, DOI 10.1016/0167-4838(88)90012-X; YELICK PC, 1987, MOL CELL BIOL, V7, P2173, DOI 10.1128/MCB.7.6.2173	39	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17388	17395						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894625				2022-12-25	WOS:A1991GF44500063
J	RANDOLPH, RK; ROSS, AC				RANDOLPH, RK; ROSS, AC			VITAMIN-A STATUS REGULATES HEPATIC LECITHIN - RETINOL ACYLTRANSFERASE ACTIVITY IN RATS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; SMALL-INTESTINE; ACYL-COA; LIVER MICROSOMES; ESTERIFICATION; METABOLISM; CELLS; ACID; POLYSACCHARIDE; TISSUES	The activity of lecithin:retinol acyltransferase (LRAT) was determined in microsomes from the liver and small intestine of rats with differing vitamin A status. In animals depleted of retinol, as judged by undetectable liver vitamin A stores and low plasma retinol concentrations, hepatic LRAT activity was almost undetectable, whether assayed with retinol bound to cellular retinol-binding protein or solvent-dispersed retinol. In contrast, neither the activity of intestinal LRAT nor that of acyl-CoA:retinol acyltransferase in either liver or intestine differed from that of vitamin A-adequate rats. During the course of vitamin A depletion, liver LRAT activity fell progressively, nearly in parallel to the decrease in plasma retinol concentration. Oral repletion of vitamin A-depleted rats with 0.8 mg of retinol resulted in a very rapid restoration of plasma retinol concentration and full recovery of hepatic LRAT activity within 24 h, together with deposition of retinyl ester in the liver. These data strongly implicate LRAT activity in liver as responsible for the storage of hepatic retinyl esters. Retention of the intestine's capacity to esterify retinol during vitamin A deficiency provides a mechanism for capture of dietary vitamin A, while reduced hepatic LRAT activity may function to redirect retinol in liver from storage to other metabolic pathways.	MED COLL PENN,DEPT PHYSIOL & BIOCHEM,DIV NUTR,3300 HENRY AVE,PHILADELPHIA,PA 19129	Drexel University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD016484] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL022633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041479] Funding Source: NIH RePORTER; NHLBI NIH HHS [P0-1 HL-22633] Funding Source: Medline; NICHD NIH HHS [R-01 HD-16484] Funding Source: Medline; NIDDK NIH HHS [R-01 DK-41479] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLANER WS, 1986, J LIPID RES, V27, P1084; BLANER WS, 1990, FEBS LETT, V274, P89, DOI 10.1016/0014-5793(90)81336-M; BLOMHOFF R, 1982, P NATL ACAD SCI-BIOL, V79, P7326, DOI 10.1073/pnas.79.23.7326; BLOMHOFF R, 1985, J BIOL CHEM, V260, P3571; CHYTIL F, 1987, ANNU REV NUTR, V7, P321, DOI 10.1146/annurev.nu.07.070187.001541; GOODMAN DS, 1965, J LIPID RES, V6, P390; GOODMAN DWS, 1966, J CLIN INVEST, V45, P1615, DOI 10.1172/JCI105468; GREEN MH, 1987, J NUTR, V117, P694, DOI 10.1093/jn/117.4.694; HARRISON EH, 1987, J LIPID RES, V28, P973; HELGERUD P, 1982, J LIPID RES, V23, P609; KANAI M, 1968, J CLIN INVEST, V47, P2025, DOI 10.1172/JCI105889; KEILSON B, 1979, J NUTR, V109, P787, DOI 10.1093/jn/109.5.787; LEWIS KC, 1990, J LIPID RES, V31, P1535; MACDONALD PN, 1988, BIOCHEM BIOPH RES CO, V156, P157, DOI 10.1016/S0006-291X(88)80818-0; MACDONALD PN, 1988, J BIOL CHEM, V263, P12478; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MUTO Y, 1972, J BIOL CHEM, V247, P2542; NAPOLI JL, 1987, ARCH BIOCHEM BIOPHYS, V255, P95, DOI 10.1016/0003-9861(87)90298-0; ONG DE, 1987, J BIOL CHEM, V262, P2729; ONG DE, 1988, J BIOL CHEM, V263, P5789; PASATIEMPO AMG, 1989, AM J CLIN NUTR, V49, P501, DOI 10.1093/ajcn/49.3.501; PASATIEMPO AMG, 1990, FASEB J, V4, P2518, DOI 10.1096/fasebj.4.8.2110538; QUICK TC, 1990, BIOCHEMISTRY-US, V29, P11116, DOI 10.1021/bi00502a015; RAJAN N, 1990, J LIPID RES, V31, P821; ROSS AC, 1982, J BIOL CHEM, V257, P2453; ROSS AC, 1977, J LIPID RES, V18, P169; ROSS AC, 1986, METHOD ENZYMOL, V123, P68, DOI 10.1016/S0076-6879(86)23010-4; ROSS AC, 1990, METHOD ENZYMOL, V189, P442; Underwood BA, 1984, RETINOIDS, P281; YOST RW, 1988, J BIOL CHEM, V263, P18693	30	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16453	16457						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885578				2022-12-25	WOS:A1991GD63500037
J	BAI, R; PAULL, KD; HERALD, CL; MALSPEIS, L; PETTIT, GR; HAMEL, E				BAI, R; PAULL, KD; HERALD, CL; MALSPEIS, L; PETTIT, GR; HAMEL, E			HALICHONDRIN-B AND HOMOHALICHONDRIN-B, MARINE NATURAL-PRODUCTS BINDING IN THE VINCA DOMAIN OF TUBULIN - DISCOVERY OF TUBULIN-BASED MECHANISM OF ACTION BY ANALYSIS OF DIFFERENTIAL CYTOTOXICITY DATA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTINEOPLASTIC AGENTS; PROTEIN PHOSPHATASE-1; PHOMOPSIN-A; SITE; POLYMERIZATION; NUCLEOTIDE; DOLASTATIN-10; DISTINCT; CYCLE	Data generated in the new National Cancer Institute drug evaluation program, which is based on inhibition of cell growth in 60 human tumor cell lines, were used to compare new compounds with agents of known mechanism of action in terms of their differential cytotoxicity. Two marine natural products, halichondrin B and homohalichondrin B, appeared repeatedly when the data base was probed with known antimitotic agents. We confirmed that both compounds were highly cytotoxic (IC50 values for L1210 murine leukemia cells of 0.3 and 1 nM, respectively), with accumulation of cells arrested in mitosis at toxic concentrations, that both inhibited the polymerization of purified tubulin, and that both inhibited microtubule assembly dependent on microtubule-associated proteins. Limited amounts of homohalichondrin B, the less active agent, were available, so only halichondrin B was studied in detail. Halichondrin B did not interfere with colchicine binding to tubulin, but it was a noncompetitive inhibitor of the binding of vinblastine to tubulin (apparent K(i), 5.0-mu-M). Halichondrin B was therefore compared with other agents which interfere with the binding of vinca alkaloids to tubulin (vinblastine, maytansine, dolastatin 10, phomopsin A, rhizoxin) in terms of its effects on tubulin polymerization, inhibition of GTP hydrolysis, inhibition of nucleotide exchange, and stabilization of tubulin, as well as the quantitative assessment of its effects on vinca alkaloid binding and inhibition of cell growth. Since halichondrin B was originally isolated from the same organism as the phosphatase inhibitor okadaic acid, and since it is about 50-fold more effective than okadaic acid as an inhibitor of L1210 cell growth, perturbations of cellular microtubules observed following treatment with okadaic acid should be interpreted cautiously.	NCI, DIV CANC TREATMENT,DEV THERAPEUT PROGRAM, MOLEC PHARMACOL LAB,BLDG 37, RM 5C25, BETHESDA, MD 20892 USA; NCI, DIV CANC TREATMENT, DEV THERAPEUT PROGRAM, INFORMAT TECHNOL BRANCH, ROCKVILLE, MD 20892 USA; ARIZONA STATE UNIV, CANC RES INST, TEMPE, AZ 85287 USA; ARIZONA STATE UNIV, DEPT CHEM, TEMPE, AZ 85287 USA; NCI, FREDERICK CANC RES & DEV CTR, DIV CANC TREATMENT, FREDERICK, MD 21701 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Arizona State University; Arizona State University-Tempe; Arizona State University; Arizona State University-Tempe; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NATIONAL CANCER INSTITUTE [R35CA044344] Funding Source: NIH RePORTER; NCI NIH HHS [CA-44344-01A1-02] Funding Source: Medline; PHS HHS [16049-10-12] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AXTON JM, 1990, CELL, V63, P33, DOI 10.1016/0092-8674(90)90286-N; BAI R, 1990, J BIOL CHEM, V265, P17141; BAI R, 1990, BIOCHEM PHARMACOL, V39, P1941, DOI 10.1016/0006-2952(90)90613-P; BORISY GG, 1972, ANAL BIOCHEM, V50, P373, DOI 10.1016/0003-2697(72)90046-2; Boyd M. R., 1989, CANCER PRINCIPLES PR, V3, P1; BOYD MR, 1986, ACCOMPLISHMENTS ONCO, V1, P68; CULVENOR CCJ, 1983, J CHEM SOC CHEM COMM, P1259, DOI 10.1039/c39830001259; DIXON M, 1979, ENZYMES, P332; DUANMU C, 1986, BIOCHIM BIOPHYS ACTA, V881, P113, DOI 10.1016/0304-4165(86)90104-2; HAMEL E, 1984, J BIOL CHEM, V259, P1060; HAMEL E, 1982, BIOCHEMISTRY-US, V21, P503, DOI 10.1021/bi00532a014; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; Hamel E., 2018, MICROTUBULE PROTEINS, P89, DOI [10.1201/9781351074643-4, DOI 10.1201/9781351074643-4]; HIRATA Y, 1986, PURE APPL CHEM, V58, P701, DOI 10.1351/pac198658050701; HUANG AB, 1985, BIOCHEM BIOPH RES CO, V128, P1239, DOI 10.1016/0006-291X(85)91073-3; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LUDUENA RF, 1989, ARCH BIOCHEM BIOPHYS, V272, P32, DOI 10.1016/0003-9861(89)90191-4; MANDELBAUMSHAVIT F, 1976, BIOCHEM BIOPH RES CO, V72, P47, DOI 10.1016/0006-291X(76)90958-X; MONKS A, 1991, J NATL CANCER I, V83, P757, DOI 10.1093/jnci/83.11.757; PAULL KD, 1989, J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PETTIT GR, 1989, J AM CHEM SOC, V111, P5463, DOI 10.1021/ja00196a061; PETTIT GR, 1987, J AM CHEM SOC, V109, P6883, DOI 10.1021/ja00256a070; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; TAKAHASHI M, 1987, BIOCHIM BIOPHYS ACTA, V926, P215, DOI 10.1016/0304-4165(87)90206-6; VANDRE D D, 1990, Journal of Cell Biology, V111, p280A; YAMASHITA K, 1990, EMBO J, V9, P4331, DOI 10.1002/j.1460-2075.1990.tb07882.x	27	337	366	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15882	15889						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874739				2022-12-25	WOS:A1991GB97700056
J	KAHN, RA				KAHN, RA			FLUORIDE IS NOT AN ACTIVATOR OF THE SMALLER (20-25 KDA) GTP-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STIMULATORY REGULATORY COMPONENT; GUANINE-NUCLEOTIDE-BINDING; ADP-RIBOSYLATION FACTOR; ADENYLATE-CYCLASE; BOVINE BRAIN; ESCHERICHIA-COLI; GAMMA-PHOSPHATE; ALPHA-SUBUNIT; CHOLERA-TOXIN; BETA-SUBUNIT	Effects of aluminum, magnesium, and fluoride (AMF) on members of both the trimeric G protein and smaller (20-25 kDa) monomeric GTP-binding protein families were examined. The dissociation of GDP from G proteins was blocked by AMF but was unchanged with the addition of AMF to any of six of the monomeric GTP-binding proteins. Biochemical activities and properties of one of the smaller GTP-binding proteins, ADP-ribosylation factor, were also found to be unaffected by AMF. It is concluded that the ability of AMF to activate the trimeric G proteins is not shared by the smaller GTP-binding proteins and thus should prove to be a useful discriminator between cellular activities regulated by these two families of regulatory proteins.			KAHN, RA (corresponding author), NCI, DIV CANC TREATMENT, BIOL CHEM LAB, BETHESDA, MD 20892 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601				BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAMEL E, 1984, J BIOL CHEM, V259, P1060; HIGASHIJIMA T, 1991, J BIOL CHEM, V266, P3396; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1984, J BIOL CHEM, V259, P6235; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1989, G PROTEINS, P201; KAHN RA, 1988, DEV CANCER CHEMOTHER, P57; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KHOSRAVIFAR R, 1991, IN PRESS P NATL ACAD; MANNE V, 1984, P NATL ACAD SCI-BIOL, V81, P6953, DOI 10.1073/pnas.81.22.6953; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RALL TW, 1958, J BIOL CHEM, V232, P1065; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; WEISS O, 1989, J BIOL CHEM, V264, P21066	29	261	264	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15595	15597						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908456				2022-12-25	WOS:A1991GB97700011
J	GISHIZKY, ML; MCLAUGHLIN, J; PENDERGAST, AM; WITTE, ON				GISHIZKY, ML; MCLAUGHLIN, J; PENDERGAST, AM; WITTE, ON			THE 5' NONCODING REGION OF THE BCR/ABL ONCOGENE AUGMENTS ITS ABILITY TO STIMULATE THE GROWTH OF IMMATURE LYMPHOID-CELLS	ONCOGENE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE LYMPHOCYTIC-LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; BCR-ABL ONCOGENE; PHILADELPHIA-CHROMOSOME; BONE-MARROW; V-ABL; FUSED TRANSCRIPT; TRANSGENIC MICE	The Philadelphia chromosome (Ph1, t9: 22; 34:q11) is a reciprocal translocation between chromosome 22 and chromosome 9 which results in the formation of the chimeric BCR/ABL oncogene. Alternative forms of BCR/ABL are produced by splicing different sets of exons of the BCR gene to a common set of c-ABL sequences. This results in the formation of an 8.7 kilobase mRNA that encodes the P210 BCR/ABL gene product or a 7.0 kilobase mRNA that encodes the P185 BCR/ABL gene product. Both BCR/ABL transcripts derive their 5' non-coding sequences from the BCR gene locus. This 5' region is over 500 nucleotides in length, has a GC content > 75% and has a short open reading frame. To determine if this unusual 5' non-coding region plays a role in BCR/ABL transformation, we prepared retroviral vectors containing identical BCR/ABL coding regions but differing in the length of the BCR 5' non-coding region. Matched viral stocks were evaluated for their ability to transform bone marrow in vitro and for their ability to cause tumors when inoculated into 3- to 4-week-old mice. In this report we present the unexpected finding that the BCR/ABL 5' non-coding region augments the transforming activity of both P210 and P185 BCR/ABL in vitro. In vivo, BCR/ABL is a weak tumorigenic agent and its potency is enhanced by the presence of the 5' non-coding region.	UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, 405 HILGARD AVE, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Howard Hughes Medical Institute; University of California System; University of California Los Angeles				Pendergast, Ann Marie/0000-0002-1250-6880				ABELSON HT, 1970, CANCER RES, V30, P2208; BORZILLO GV, 1990, MOL CELL BIOL, V10, P2703, DOI 10.1128/MCB.10.6.2703; CHAMPLIN RE, 1985, BLOOD, V65, P1039; CHAN LC, 1987, NATURE, V325, P635, DOI 10.1038/325635a0; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; CLARK SS, 1989, ANNU REV MED, V40, P113; COFFMAN RL, 1983, IMMUNOL REV, V69, P5, DOI 10.1111/j.1600-065X.1983.tb00446.x; COLLINS LS, 1987, J IMMUNOL, V138, P1082; COOK WD, 1985, CELL, V41, P677, DOI 10.1016/S0092-8674(85)80048-9; COOK WD, 1982, P NATL ACAD SCI-BIOL, V79, P2917, DOI 10.1073/pnas.79.9.2917; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DAVIDSON WF, 1988, J EXP MED, V168, P389, DOI 10.1084/jem.168.1.389; EARLY P, 1980, CELL, V19, P981, DOI 10.1016/0092-8674(80)90089-6; ELEFANTY AG, 1990, EMBO J, V9, P1069, DOI 10.1002/j.1460-2075.1990.tb08212.x; FAINSTEIN E, 1987, NATURE, V330, P386, DOI 10.1038/330386a0; GODEAU F, 1986, EMBO J, V5, P3571, DOI 10.1002/j.1460-2075.1986.tb04684.x; GOLD DP, 1987, P NATL ACAD SCI USA, V84, P7649, DOI 10.1073/pnas.84.21.7649; Hariharan I K, 1988, Oncogene Res, V3, P387; HARIHARAN IK, 1987, EMBO J, V6, P115, DOI 10.1002/j.1460-2075.1987.tb04727.x; HARIHARAN IK, 1989, MOL CELL BIOL, V9, P2798, DOI 10.1128/MCB.9.7.2798; HEARD JM, 1987, CELL, V51, P663, DOI 10.1016/0092-8674(87)90135-8; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; HERMANS A, 1987, CELL, V51, P33, DOI 10.1016/0092-8674(87)90007-9; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; KELLIHER MA, 1990, P NATL ACAD SCI USA, V87, P6649, DOI 10.1073/pnas.87.17.6649; KLINKEN SP, 1988, CELL, V53, P857, DOI 10.1016/S0092-8674(88)90309-1; KONOPKA JB, 1984, J VIROL, V51, P223, DOI 10.1128/JVI.51.1.223-232.1984; KONOPKA JB, 1984, CELL, V37, P1035, DOI 10.1016/0092-8674(84)90438-0; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P3873, DOI 10.1093/nar/12.9.3873; KOZAK M, 1986, CELL, V47, P481, DOI 10.1016/0092-8674(86)90609-4; KURZROCK R, 1987, NATURE, V325, P631, DOI 10.1038/325631a0; LANDAU NR, 1984, P NATL ACAD SCI-BIOL, V81, P5836, DOI 10.1073/pnas.81.18.5836; MARTH JD, 1988, NATURE, V332, P171, DOI 10.1038/332171a0; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCLAUGHLIN J, 1989, MOL CELL BIOL, V9, P1866, DOI 10.1128/MCB.9.5.1866; MELTON DA, 1989, CIBA F SYMP, V144, P16; MESMASSON AM, 1986, P NATL ACAD SCI USA, V83, P9768, DOI 10.1073/pnas.83.24.9768; MULLER AJ, 1989, MOL CELL BIOL, V9, P5234, DOI 10.1128/MCB.9.11.5234; PIERCE JH, 1985, CELL, V41, P685, DOI 10.1016/S0092-8674(85)80049-0; ROGERS J, 1980, CELL, V20, P303, DOI 10.1016/0092-8674(80)90616-9; ROSENBERG N, 1988, ADV VIRUS RES, V35, P39; ROSENBERG N, 1978, J EXP MED, V147, P1126, DOI 10.1084/jem.147.4.1126; SCHATZ DG, 1989, CELL, V59, P1035, DOI 10.1016/0092-8674(89)90760-5; SCHERLE PA, 1990, P NATL ACAD SCI USA, V87, P1908, DOI 10.1073/pnas.87.5.1908; SHEN FW, 1985, P NATL ACAD SCI USA, V82, P7360, DOI 10.1073/pnas.82.21.7360; SHTIVELMAN E, 1985, NATURE, V315, P550, DOI 10.1038/315550a0; TAYLOR MV, 1986, EMBO J, V5, P3563, DOI 10.1002/j.1460-2075.1986.tb04683.x; WALKER LC, 1987, NATURE, V329, P851, DOI 10.1038/329851a0; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608	50	6	6	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1299	1306						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886706				2022-12-25	WOS:A1991GX27200001
J	SOMOGYI, R; STUCKI, JW				SOMOGYI, R; STUCKI, JW			HORMONE-INDUCED CALCIUM OSCILLATIONS IN LIVER-CELLS CAN BE EXPLAINED BY A SIMPLE ONE POOL MODEL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; FURA-2-LOADED HEPATOCYTES; ENDOPLASMIC-RETICULUM; CA-2+ OSCILLATIONS; SINGLE HEPATOCYTES; CALMODULIN; TRANSIENT; INHIBITOR; RELEASE; BINDING	Hormone-induced oscillations of the free intracellular calcium concentration are thought to be relevant for frequency encoding of hormone signals. In liver cells, such Ca2+ oscillations occur in response to stimulation by hormones acting via phosphoinositide breakdown. This observation may be explained by co-operative, positive feedback of Ca2+ on its own release from one inositol 1,4,5-trisphosphate-sensitive pool, obviating oscillations of inositol 1,4,5-trisphosphate. The kinetic rate laws of the associated model have a mathematical structure reminiscent of the Brusselator, a hypothetical chemical model involving a rather improbable trimolecular reaction step, thus giving a realistic biological interpretation to this hallmark of dissipative structures. We propose that calmodulin is involved in mediating this cooperativity and positive feedback, as suggested by the presented experiments. For one, hormone-induced calcium oscillations can be inhibited by the (nonphenothiazine) calmodulin antagonists calmidazolium or CGS 9343 B. Alternatively, in cells overstimulated by hormone, as characterized by a non-oscillatory elevated Ca2+ concentration, these antagonists could again restore sustained calcium oscillations. The experimental observations, including modulation of the oscillations by extracellular calcium, were in qualitative agreement with the predictions of our mathematical model.	UNIV BERN,INST PHARMAKOL,FRIEDBUHLSTR 49,CH-3010 BERN,SWITZERLAND	University of Bern								BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BLACKMORE PF, 1981, FEBS LETT, V123, P245, DOI 10.1016/0014-5793(81)80298-0; CHAN KM, 1987, ARCH BIOCHEM BIOPHYS, V256, P472, DOI 10.1016/0003-9861(87)90604-7; Chandrasekhar S., 1981, HYDRODYNAMIC HYDROMA; EXTON JH, 1988, HEPATOLOGY, V8, P152, DOI 10.1002/hep.1840080129; FABIATO A, 1975, J PHYSIOL-LONDON, V249, P469, DOI 10.1113/jphysiol.1975.sp011026; Glansdorff P., 1971, THERMODYNAMICS STRUC; GOLDBETER A, 1990, P NATL ACAD SCI USA, V87, P1461, DOI 10.1073/pnas.87.4.1461; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HILL TD, 1988, J BIOL CHEM, V263, P16479; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; MANALAN AS, 1984, ADV CYCLIC NUCL PROT, V18, P227; MEYER T, 1988, P NATL ACAD SCI USA, V85, P5051, DOI 10.1073/pnas.85.14.5051; Moldeus P, 1978, Methods Enzymol, V52, P60; Nicolis G., 1989, EXPLORING COMPLEXITY; NORMAN JA, 1987, MOL PHARMACOL, V31, P535; Press W., 1986, NUMERICAL RECIPES; PRIGOGIN.I, 1968, J CHEM PHYS, V48, P1695, DOI 10.1063/1.1668896; REBER BFX, 1990, BIOCHIM BIOPHYS ACTA, V1018, P190, DOI 10.1016/0005-2728(90)90246-Z; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SANCHEZBUENO A, 1990, BIOCHEM J, V268, P627, DOI 10.1042/bj2680627; SCHUTZE S, 1987, BIOCHEM J, V243, P729, DOI 10.1042/bj2430729; SHOSHANBARMATZ V, 1990, BIOCHEM J, V268, P699, DOI 10.1042/bj2680699; SHOSHANBARMATZ V, 1990, FEBS LETT, V263, P317, DOI 10.1016/0014-5793(90)81403-B; STOCLET JC, 1987, PROG NEUROBIOL, V29, P321, DOI 10.1016/0301-0082(87)90018-9; STUCKI JW, 1978, PROG BIOPHYS MOL BIO, V33, P99; VANBELLE H, 1981, CELL CALCIUM, V2, P483, DOI 10.1016/0143-4160(81)90007-5; WAKUI M, 1989, NATURE, V339, P317, DOI 10.1038/339317a0; WILLIAMSON JR, 1989, ANNU REV PHYSIOL, V51, P107, DOI 10.1146/annurev.ph.51.030189.000543; Wolfram S., 1988, MATH SYSTEM DOING MA; WOODS NM, 1986, NATURE, V319, P600, DOI 10.1038/319600a0; WOODS NM, 1987, BIOCHEM J, V246, P619, DOI 10.1042/bj2460619; WOODS NM, 1990, CELL CALCIUM, V11, P353, DOI 10.1016/0143-4160(90)90038-V	35	134	136	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 15	1991	266	17					11068	11077						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FQ774	1904060				2022-12-25	WOS:A1991FQ77400058
J	SADDIK, M; LOPASCHUK, GD				SADDIK, M; LOPASCHUK, GD			MYOCARDIAL TRIGLYCERIDE TURNOVER AND CONTRIBUTION TO ENERGY SUBSTRATE UTILIZATION IN ISOLATED WORKING RAT HEARTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOGENOUS LIPID-METABOLISM; FATTY-ACIDS; TRIACYLGLYCEROL METABOLISM; CARBOHYDRATE METABOLISM; FASTING MEN; ACCUMULATION; INFUSION; MUSCLE; TISSUE	The objective of this study was to determine the contribution of myocardial triglycerides to overall ATP production in isolated working rat hearts. Endogenous lipid pools were initially prelabeled (pulsed) by perfusing hearts for 60 min with Krebs-Henseleit buffer containing 1.2 mM [1-C-14]palmitate. During a subsequent 60-min period (chase), hearts were perfused with either no fat, low fat (0.4 mM [9,10-H-3]palmitate), or high fat (1.2 mM [9,10-H-3]palmitate). All buffers contained 11 mM glucose. During the "chase," (CO2)-C-14 production (a measure of endogenous fatty acid oxidation) and (H2O)-H-3 production (a measure of exogenous fatty acid oxidation) were determined. Oxidative rates of endogenous fatty acids during the chase were 279 +/- 50, 88 +/- 14, and 88 +/- 8 nmol of [C-14]palmitate oxidized per g dry weight.min in the no fat, low fat, and high fat groups, respectively, compared to exogenous palmitate oxidation rates of 0, 361 +/- 68, and 633 +/- 60 nmol of [H-3]palmitate/g dry weight.min, in the no fat, low fat, and high fat groups, respectively. Endogenous [C-14]palmitate oxidation rates were matched by loss of [C-14]palmitate from endogenous myocardial triglycerides. Overall triglyceride content decreased during the no fat and low fat chase perfusion but did not change during the high fat chase. Loss of triglyceride [C-14]palmitate during the high fat chase was matched by incorporation of exogenous [H-3]palmitate in triglycerides. In a second series of perfusions, three groups of hearts were perfused under similar conditions, except that unlabeled palmitate was used during the "pulse" and that 11 mM [2-H-3/U-C-14] glucose and unlabeled palmitate was present during the chase. During the chase, both glycolysis ((H2O)-H-3 production) and glucose oxidation ((CO2)-C-14 production) rates were measured. Rates of glucose oxidation were inversely related to the fatty acid concentration in the perfusate (1257 +/- 158, 366 +/- 40, and 124 +/- 26 nmol of glucose oxidized per min.g dry weight in the no fat, low fat, and high fat groups, respectively), while rates of glycolysis were not significantly different between these groups. Calculation of overall ATP production from both oxidative and glycolytic sources determined that even in the presence of high concentrations of fatty acids, myocardial triglyceride turnover can provide over 11% of steady state ATP production in the aerobically perfused heart. In the absence of fatty acids, myocardial triglyceride fatty acids can become the major energy substrate of the heart. Using this experimental model in which triglyceride turnover can be directly measured, we conclude that endogenous triglycerides are an important source of fatty acids for oxidative metabolism in the heart and their contribution is inversely related to the concentration of fatty acids in the perfusate.	UNIV ALBERTA, DEPT PEDIAT, CARDIOVASC DIS RES GRP, 423 HERITAGE MED RES BLDG, EDMONTON T6G 2S2, ALBERTA, CANADA; UNIV ALBERTA, DEPT PEDIAT, CARDIOVASC DIS RES GRP, EDMONTON T6G 2S2, ALBERTA, CANADA; UNIV ALBERTA, DEPT PHARMACOL, EDMONTON T6G 2S2, ALBERTA, CANADA	University of Alberta; University of Alberta; University of Alberta								BING RJ, 1953, AM J MED, V15, P284, DOI 10.1016/0002-9343(53)90082-5; BING RJ, 1955, HARVEY LECT, P27; BOWYER DE, 1977, J CHROMATOGR, V143, P473, DOI 10.1016/S0378-4347(00)81794-6; CORR PB, 1984, CIRC RES, V55, P135, DOI 10.1161/01.RES.55.2.135; CRASS MF, 1972, BIOCHIM BIOPHYS ACTA, V280, P71, DOI 10.1016/0005-2760(72)90213-5; CRASS MF, 1977, FED PROC, V36, P1995; CRASS MF, 1966, BIOCHIM BIOPHYS ACTA, V125, P106, DOI 10.1016/0005-2760(66)90148-2; CUNNANE SC, 1988, LIPIDS, V23, P62, DOI 10.1007/BF02535306; DELCHER HK, 1965, BIOCHIM BIOPHYS ACTA, V106, P10, DOI 10.1016/0005-2760(65)90090-1; ENSER MB, 1967, BIOCHEM J, V104, P306, DOI 10.1042/bj1040306; GOODALE WT, 1953, CIRC RES, V1, P509, DOI 10.1161/01.RES.1.6.509; GOODALE WT, 1959, AM J MED, V27, P212, DOI 10.1016/0002-9343(59)90341-9; Kaijser L, 1980, Adv Myocardiol, V2, P51; KAIJSER L, 1972, J APPL PHYSIOL, V32, P847, DOI 10.1152/jappl.1972.32.6.847; KERBEY AL, 1976, BIOCHEM J, V154, P327, DOI 10.1042/bj1540327; KOBAYASHI K, 1979, CIRC RES, V44, P166, DOI 10.1161/01.RES.44.2.166; KRYSKI A, 1985, AM J PHYSIOL, V248, pH208, DOI 10.1152/ajpheart.1985.248.2.H208; LASSERS BW, 1972, EUR J CLIN INVEST, V2, P348, DOI 10.1111/j.1365-2362.1972.tb00661.x; LIEDTKE AJ, 1981, PROG CARDIOVASC DIS, V23, P321, DOI 10.1016/0033-0620(81)90019-0; LOPASCHUK GD, 1988, CIRC RES, V63, P1036, DOI 10.1161/01.RES.63.6.1036; LOPASCHUK GD, 1986, AM J PHYSIOL, V250, pH351, DOI 10.1152/ajpheart.1986.250.3.H351; LOPASCHUK GD, 1990, CIRC RES, V66, P546, DOI 10.1161/01.RES.66.2.546; LOPASCHUK GD, 1987, CIRC RES, V61, P853, DOI 10.1161/01.RES.61.6.853; MURTHY VK, 1983, DIABETES, V32, P718, DOI 10.2337/diab.32.8.718; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; NEWSHOLME EA, 1962, NATURE, V193, P270, DOI 10.1038/193270a0; OPIE LH, 1969, AM HEART J, V77, P100, DOI 10.1016/0002-8703(69)90135-5; PAULSON DJ, 1986, BASIC RES CARDIOL, V81, P180, DOI 10.1007/BF01907382; PAULSON DJ, 1982, AM J PHYSIOL, V242, P1084, DOI 10.1152/ajpheart.1982.242.6.H1084; PRINZEN FW, 1984, AM J PHYSIOL, V247, pH264, DOI 10.1152/ajpheart.1984.247.2.H264; ROGERS WJ, 1977, AM J CARDIOL, V40, P421, DOI 10.1016/0002-9149(77)90166-7; SCHOONDERWOERD K, 1989, MOL CELL BIOCHEM, V88, P129, DOI 10.1007/BF00223434; SEVERSON DL, 1979, CAN J PHYSIOL PHARM, V57, P923, DOI 10.1139/y79-142; VANBILSEN M, 1989, CIRC RES, V64, P304, DOI 10.1161/01.RES.64.2.304; VANDERVUSSE GJ, 1989, MOL CELL BIOCHEM, V88, P83, DOI 10.1007/BF00223428; WISNESKI JA, 1990, J CLIN INVEST, V85, P1648, DOI 10.1172/JCI114616	36	335	342	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8162	8170						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1902472				2022-12-25	WOS:A1991FK44100035
J	WHINNA, HC; BLINDER, MA; SZEWCZYK, M; TOLLEFSEN, DM; CHURCH, FC				WHINNA, HC; BLINDER, MA; SZEWCZYK, M; TOLLEFSEN, DM; CHURCH, FC			ROLE OF LYSINE 173 IN HEPARIN BINDING TO HEPARIN COFACTOR-II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANTITHROMBIN-III; HEREDITARY ABNORMAL ANTITHROMBIN; SELECTIVE CHEMICAL MODIFICATION; AMINO-ACID-SEQUENCE; ANTI-THROMBIN-III; DERMATAN SULFATE; CRITICAL TRYPTOPHAN; ESCHERICHIA-COLI; EFFICIENT METHOD; HUMAN-PLASMA	Heparin cofactor II (HC) is a plasma serine proteinase inhibitor (serpin) that inhibits alpha-thrombin in a reaction that is dramatically enhanced by heparin and other glycosaminoglycans/polyanions. We investigated the glycosaminoglycan binding site in HC by: (i) chemical modification with pyridoxal 5'-phosphate (PLP) in the absence and presence of heparin and dermatan sulfate; (ii) molecular modeling; and (iii) site-directed oligonucleotide mutagenesis. Four lysyl residues (173, 252, 343, and 348) were protected from modification by heparin and to a lesser extent by dermatan sulfate. Heparin-protected PLPHC retained both heparin cofactor and dermatan sulfate cofactor activity while dermatan sulfate-protected PLPHC retained some dermatan sulfate cofactor activity and little heparin cofactor activity. Molecular modeling studies revealed that Lys173 and Lys252 are within a region previously shown to contain residues involved in glycosaminoglycan binding. Lys343 and Lys348 are distant from this region, but protection by heparin and dermatan sulfate might result from a conformational change following glycosaminoglycan binding to the inhibitor. Site-directed mutagenesis of Lys173 and Lys343 was performed to further dissect the role of these two regions during HC-heparin and HC-dermatan sulfate interactions. The Lys343 --> Asn or Thr mutants had normal or only slightly reduced heparin or dermatan sulfate cofactor activity and eluted from heparin-Sepharose at the same ionic strength as native recombinant HC. However, the Lys173 --> Gln or Leu mutants had greatly reduced heparin cofactor activity and eluted from heparin-Sepharose at a significantly lower ionic strength than native recombinant HC but retained normal dermatan sulfate cofactor activity. Our results demonstrate that Lys173 is involved in the interaction of HC with heparin but not with dermatan sulfate, whereas Lys343 is not critical for HC binding to either glycosaminoglycan. These data provide further evidence for the determinants required for glycosaminoglycan binding to HC.	UNIV N CAROLINA, DEPT PATHOL, DIV HEMATOL, 416 BURNETT WOMACK, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, DEPT MED, CHAPEL HILL, NC 27599 USA; UNIV N CAROLINA, CTR THROMBOSIS & HEMOSTASIS, CHAPEL HILL, NC 27599 USA; WASHINGTON UNIV, SCH MED, DEPT MED & BIOCHEM, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOPHYS, ST LOUIS, MO 63110 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Washington University (WUSTL); Washington University (WUSTL)					NHLBI NIH HHS [HL-32656, HL-14147] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014147, R01HL032656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; Blackburn M N, 1981, Ann N Y Acad Sci, V370, P700, DOI 10.1111/j.1749-6632.1981.tb29777.x; BLACKBURN MN, 1980, J BIOL CHEM, V255, P824; BLACKBURN MN, 1984, J BIOL CHEM, V259, P939; BLINDER MA, 1989, J BIOL CHEM, V264, P5128; BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BLINDER MA, 1990, J BIOL CHEM, V265, P286; BORG JY, 1988, J CLIN INVEST, V81, P1292, DOI 10.1172/JCI113447; BRENNAN SO, 1987, FEBS LETT, V219, P431, DOI 10.1016/0014-5793(87)80266-1; BRUNEL F, 1987, AM J HEMATOL, V25, P223, DOI 10.1002/ajh.2830250214; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CASU B, 1985, ADV CARBOHYD CHEM BI, V43, P51, DOI 10.1016/S0065-2318(08)60067-0; CASU B, 1989, ANN NY ACAD SCI, V556, P1; CHANG JY, 1986, J BIOL CHEM, V261, P1174; CHANG JY, 1989, J BIOL CHEM, V264, P3111; CHURCH FC, 1984, BIOCHEM BIOPH RES CO, V124, P745, DOI 10.1016/0006-291X(84)91021-0; CHURCH FC, 1986, ARCH BIOCHEM BIOPHYS, V246, P175, DOI 10.1016/0003-9861(86)90461-3; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1989, J BIOL CHEM, V264, P3618; CHURCH FC, 1987, BIOCHEM BIOPH RES CO, V148, P362, DOI 10.1016/0006-291X(87)91119-3; CHURCH FC, 1988, FEBS LETT, V237, P26, DOI 10.1016/0014-5793(88)80164-9; DANIELSSON A, 1986, J BIOL CHEM, V261, P5467; DERECHIN VM, 1990, J BIOL CHEM, V265, P5623; GANDRILLE S, 1990, J BIOL CHEM, V265, P18997; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; GRIFFITH MJ, 1983, P NATL ACAD SCI-BIOL, V80, P5460, DOI 10.1073/pnas.80.18.5460; KOIDE T, 1984, P NATL ACAD SCI-BIOL, V81, P289, DOI 10.1073/pnas.81.2.289; LI E, 1987, J BIOL CHEM, V262, P13773; LIEBERMANN H, 1984, J MOL BIOL, V107, P531; Liszewski M K, 1989, Biotechniques, V7, P1079; LIU CS, 1987, J BIOL CHEM, V262, P17356; LIU CS, 1987, EUR J BIOCHEM, V167, P247, DOI 10.1111/j.1432-1033.1987.tb13330.x; NAKAMAYE KL, 1986, NUCLEIC ACIDS RES, V14, P9679, DOI 10.1093/nar/14.24.9679; NESHEIM M, 1986, J BIOL CHEM, V261, P3214; OWEN MC, 1987, BLOOD, V69, P1275; PARKER KA, 1985, J BIOL CHEM, V260, P3501; PECON JM, 1984, J BIOL CHEM, V259, P935; PETERSON CB, 1987, J BIOL CHEM, V262, P7559; PETERSON CB, 1987, J BIOL CHEM, V262, P8061; PRATT CW, 1989, ANN NY ACAD SCI, V556, P104; RAGG H, 1990, J BIOL CHEM, V265, P5211; ROSENBERG RD, 1973, J BIOL CHEM, V248, P6490; ROSENFELD L, 1986, BIOCHEM J, V237, P639, DOI 10.1042/bj2370639; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMITH JW, 1987, J BIOL CHEM, V262, P11964; SUN XJ, 1990, BIOCHEMISTRY-US, V29, P8957, DOI 10.1021/bi00490a011; SUN XJ, 1989, J BIOL CHEM, V264, P11288; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1981, J CLIN INVEST, V68, P589, DOI 10.1172/JCI110292; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4	53	67	68	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8129	8135						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1902471				2022-12-25	WOS:A1991FK44100030
J	KARARA, A; DISHMAN, E; FALCK, JR; CAPDEVILA, JH				KARARA, A; DISHMAN, E; FALCK, JR; CAPDEVILA, JH			ENDOGENOUS EPOXYEICOSATRIENOYL-PHOSPHOLIPIDS - A NOVEL CLASS OF CELLULAR GLYCEROLIPIDS CONTAINING EPOXIDIZED ARACHIDONATE MOIETIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL GLOMERULOSA CELLS; LIPID-PEROXIDATION; HYDROXYEICOSATETRAENOIC ACIDS; ALDOSTERONE RELEASE; MITOCHONDRIA; LIVER; ESTERIFICATION; IDENTIFICATION; CHROMATOGRAPHY; RETICULOCYTES	By chromatographic and mass spectral techniques we document in rat liver the presence of new classes of glycerophospholipids which contain an epoxyeicosatrienoate moiety, esterified to the glycerol-sn-2 position. These novel lipids are formed in vivo from endogenous precursors and under physiological conditions. Chromatographic resolution followed by hydrolysis and regioisomeric analysis showed that they consist of the 8,9-, 11,12-, and 14,15-epoxyeicosatrienoyl derivatives of phosphatidylcholine, phosphatidylethanolamine, andphosphatidylinositol. Their relative concentrations (micromoles of oxidized lipid/mol of phospholipid) were 70, 85, and 106 for phosphatidylcholine, phosphatidylethanolamine, and phosphatidylinositol, respectively. Chiral analysis of the fatty acids at sn-2 revealed an enantioselective preference for 8(S), 9(R)-, 11(S), 12(R)-, and 14(R), 15(S)-epoxyeicosatrienoates in all three lipid classes. The data suggest a multienzyme process initiated by cytochrome P-450 epoxidation of arachidonic acid followed by ATP-dependent activation to epoxyeicosatrienoyl-CoA derivatives and stereoselective lysolipid acylation. These results provide a molecular basis for a potential physiological role of cytochrome P-450 in the biosynthesis of unique cellular glycerolipids and, consequently, in the control of cell membrane strucute and function.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, DIV NEPHROL, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas				Falck, John/0000-0002-9219-7845	NIGMS NIH HHS [GM31278, GM37922] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031278] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ C, 1988, J CHEM SOC CHEM COMM, P1002, DOI 10.1039/c39880001002; BAER AN, 1990, J LIPID RES, V31, P125; Baker F C, 1981, Methods Enzymol, V72, P41; BALLOU LR, 1987, P NATL ACAD SCI USA, V84, P6990, DOI 10.1073/pnas.84.20.6990; BONSER RW, 1981, BIOCHEMISTRY-US, V20, P5297, DOI 10.1021/bi00521a032; BOWSER PA, 1985, BIOCHIM BIOPHYS ACTA, V834, P419, DOI 10.1016/0005-2760(85)90016-5; BRASH AR, 1987, BIOCHEMISTRY-US, V26, P5465, DOI 10.1021/bi00391a038; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; CAPDEVILA JH, 1990, METHOD ENZYMOL, V187, P385; CAPDEVILA JH, 1990, J BIOL CHEM, V265, P10865; CAPDEVILA JH, 1987, BIOCHEM BIOPH RES CO, V146, P638, DOI 10.1016/0006-291X(87)90576-6; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; CHILTON FH, 1987, BIOCHIM BIOPHYS ACTA, V917, P48, DOI 10.1016/0005-2760(87)90282-7; COREY EJ, 1983, TETRAHEDRON LETT, V24, P37, DOI 10.1016/S0040-4039(00)81320-9; FALCK JR, 1987, J LIPID RES, V28, P840; FALCK JR, 1990, J BIOL CHEM, V265, P10244; FITZPATRICK FA, 1988, PHARMACOL REV, V40, P229; FREI B, 1985, EUR J BIOCHEM, V149, P633, DOI 10.1111/j.1432-1033.1985.tb08971.x; GAMACHE DA, 1988, BIOCHIM BIOPHYS ACTA, V958, P116, DOI 10.1016/0005-2760(88)90252-4; GAST K, 1982, BIOCHIM BIOPHYS ACTA, V686, P99, DOI 10.1016/0005-2736(82)90155-9; HAMMONDS TD, 1989, ANAL BIOCHEM, V182, P300, DOI 10.1016/0003-2697(89)90598-8; HARRIS RC, 1990, J CELL PHYSIOL, V144, P429, DOI 10.1002/jcp.1041440310; HOSAKA K, 1981, METHOD ENZYMOL, V71, P325; JACOBSON HR, 1984, PROSTAGLANDINS MEMBR, P311; JUNIER MP, 1990, ENDOCRINOLOGY, V126, P1534, DOI 10.1210/endo-126-3-1534; KARARA A, 1989, J BIOL CHEM, V264, P19822; KARARA A, 1990, FEBS LETT, V268, P227, DOI 10.1016/0014-5793(90)81014-F; KUHN H, 1990, J BIOL CHEM, V265, P18351; KUHN H, 1990, J BIOL CHEM, V265, P1454; KUHN H, 1990, ARCH BIOCHEM BIOPHYS, V279, P218, DOI 10.1016/0003-9861(90)90484-G; LAPOSATA M, 1985, J BIOL CHEM, V260, P1016; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; PATTON GM, 1982, J LIPID RES, V23, P190; POYER JL, 1971, J BIOL CHEM, V246, P263; RAPOPORT SM, 1986, BIOCHIM BIOPHYS ACTA, V864, P471, DOI 10.1016/0304-4157(86)90006-7; RICHARDS CF, 1989, PROSTAGLANDINS, V38, P565, DOI 10.1016/0090-6980(89)90150-0; ROBINSON M, 1985, J BIOL CHEM, V260, P7889; SCHEWE T, 1975, FEBS LETT, V60, P149, DOI 10.1016/0014-5793(75)80439-X; SEVANIAN A, 1988, BIOCHIM BIOPHYS ACTA, V961, P316, DOI 10.1016/0005-2760(88)90079-3; SEVANIAN A, 1985, ANNU REV NUTR, V5, P365, DOI 10.1146/annurev.nu.05.070185.002053; SNYDER G, 1986, BIOCHEM BIOPH RES CO, V139, P1188, DOI 10.1016/S0006-291X(86)80303-5; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; STERK H, 1989, J MOL LIQ, V40, P101, DOI 10.1016/0167-7322(89)80039-X; SUGIURA T, 1985, BIOCHEM BIOPH RES CO, V127, P384, DOI 10.1016/S0006-291X(85)80171-6; TAKAHASHI K, 1990, AM J PHYSIOL, V258, pF781, DOI 10.1152/ajprenal.1990.258.4.F781; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; VANKUIJK FJGM, 1987, TRENDS BIOCHEM SCI, V12, P31, DOI 10.1016/0968-0004(87)90014-4	48	134	135	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7561	7569						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902222				2022-12-25	WOS:A1991FJ34200040
J	KUSCHE, M; OSCARSSON, LG; REYNERTSON, R; RODEN, L; LINDAHL, U				KUSCHE, M; OSCARSSON, LG; REYNERTSON, R; RODEN, L; LINDAHL, U			BIOSYNTHESIS OF HEPARIN - ENZYMATIC SULFATION OF PENTASACCHARIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITHROMBIN-BINDING SEQUENCE; DEPOLYMERIZATION; OLIGOSACCHARIDES; IDENTIFICATION; PROTEOGLYCANS; AFFINITY; CHAINS	Heparin-derived pentasaccharides with the general structures GlcN-GlcA/IdoA-GlcN-GlcA/IdoA-GlcN (where GlcA represents D-glucuronic acid and IdoA represents L-iduronic acid) and GlcNSO3-GlcA/IdoA-GlcNSO3-GlcA/IdoA-GlcNSO3 (where -NSO3 represetns an N-sulfate group) were tested as exogenous sulfate acceptors in incubations with adenosine 3'-phosphate 5'-[S-35]phosphosulfate and microsomal enzymes from a heparin-producing mouse mastocytoma. No transfer occurred to the N-unsubstituted pentasaccharide containing only L-iduronic acid, but the other three isomers incorporated various amounts of S-35, which was totally present in N-sulfate groups. After complete chemical N-sulfation, all four pentasaccharides served as acceptors in O-sulfotransferase reactions and incorporated from 20 to > 200 times as much radioactivity as did the nonsulfated parent compounds. The C-6 position of the internal glucosamine unit was labeled preferentially, irrespective of the structures of the adjacent hexuronic acid units. Significant 2-O-S-35-sulfation of IdoA units occurred in both -IdoA-Glc-NSO3-GlcA- and -GlcA-GlcNSO3-IdoA- sequences, whereas no significant sulfation of GlcA residues was detected. The pentasaccharide GlcNSO3-GlcA-Glc-NSO3-GlcA-GlcNSO3 thus can be used as a selective substrate in assays for glucosaminyl-6-O-sulfotransferase activity. The antithrombin-binding region, essential for the blood anticoagulant activity of heparin, has been identified as a pentasaccharide sequence with the predominant structure GlcNR(6-OSO3)-GlcA-GlcNSO3(3,6-di-OSO3)-IdoA(2-OSO3)-GlcNSO3(6-OSO3) (where R represents either a sulfate or an acetyl group and -OSO3 represents an O-sulfate/ester sulfate group, with locations of O-sulfate groups indicated in parentheses) (Lindahl U., Thunberg, L., Backstrom, G., Riesenfeld, J., Nordling, K., and Bjork, I. (1984) J. Biol. Chem. 259, 12368-12376). The products of [S-35]sulfate transfer to the pentasaccharide GlcNSO3-GlcA-GlcNSO3-IdoA-GlcNSO3 contained molecules with high affinity for antithrombin, corresponding to 0.3-0.5% of the total label. Structural analysis suggested the occurrence of O-[S-35]sulfate groups at both C-6 of the nonreducing terminal glucosamine unit and C-3 of the internal glucosamine unit. No products with high affinity for antithrombin were formed from the pentasaccharides that had a different monosaccharide sequence than the binding region; and moreover, these oligosaccharides appeared unable to incorporate glucosaminyl 3-O-sulfate groups. These findings point to the importanace of the uronic acid sequence in the generation of the antithrombin-binding region of heparin.	UNIV ALABAMA, DEPT MED, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, METAB DIS RES LAB, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	KUSCHE, M (corresponding author), SWEDISH UNIV AGR SCI, CTR BIOMED, DEPT VET MED CHEM, S-75123 UPPSALA, SWEDEN.				NIDCR NIH HHS [DE 08252] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE008252] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; BIENKOWSKI MJ, 1985, J BIOL CHEM, V260, P356; BITTER T, 1962, ANAL BIOCHEM, V4, P330, DOI 10.1016/0003-2697(62)90095-7; BJORK I, 1982, MOL CELL BIOCHEM, V48, P161, DOI 10.1007/BF00421226; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; EDGE ASB, 1990, J BIOL CHEM, V265, P15874; FURTH J, 1957, P SOC EXP BIOL MED, V95, P824; HOOK M, 1976, FEBS LETT, V66, P90, DOI 10.1016/0014-5793(76)80592-3; HORNER AA, 1988, BIOCHEM J, V251, P141, DOI 10.1042/bj2510141; JACOBSSON I, 1984, J BIOL CHEM, V259, P1056; JACOBSSON I, 1980, J BIOL CHEM, V255, P5094; JACOBSSON I, 1979, J BIOL CHEM, V254, P2975; JACOBSSON I, 1979, BIOCHEM J, V179, P77, DOI 10.1042/bj1790077; JACOBSSON KG, 1986, BIOCHEM J, V240, P625, DOI 10.1042/bj2400625; KUSCHE M, 1988, J BIOL CHEM, V263, P15474; KUSCHE M, 1991, BIOCHEM J, V275, P151, DOI 10.1042/bj2750151; KUSCHE M, 1990, J BIOL CHEM, V265, P7292; KUSCHE M, 1990, J BIOL CHEM, V275, P151; LEVY L, 1962, P SOC EXP BIOL MED, V109, P901; LINDAHL U, 1986, TRENDS BIOCHEM SCI, V11, P221, DOI 10.1016/0968-0004(86)90011-3; LINDAHL U, 1984, J BIOL CHEM, V259, P2368; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; LINDAHL U, 1989, ANN NY ACAD SCI, V556, P36; Lindahl U., 1989, HEPARIN, P159; LINDAHL U, 1987, BIOL PROTEOGLYCANS, P59; Lindberg B., 1975, ADV CARBOHYD CHEM BI, V31, P185; PEJLER G, 1987, J BIOL CHEM, V262, P11413; PEJLER G, 1987, J BIOL CHEM, V262, P5036; PETITOU M, 1989, HEPARIN CHEM BIOL PR, P65; REYNERTSON R, 1983, J BIOL CHEM, V258, P7449; RIESENFELD J, 1990, ANAL BIOCHEM, V188, P383, DOI 10.1016/0003-2697(90)90624-I; SHAKLEE PN, 1984, BIOCHEM J, V217, P187, DOI 10.1042/bj2170187; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3943, DOI 10.1021/bi00663a006; SHIVELY JE, 1976, BIOCHEMISTRY-US, V15, P3932, DOI 10.1021/bi00663a005; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2	35	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7400	7409						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902219				2022-12-25	WOS:A1991FJ34200017
J	MORII, N; KAWANO, K; SEKINE, A; YAMADA, T; NARUMIYA, S				MORII, N; KAWANO, K; SEKINE, A; YAMADA, T; NARUMIYA, S			PURIFICATION OF GTPASE-ACTIVATING PROTEIN-SPECIFIC FOR THE RHO-GENE PRODUCTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOTULINUM ADP-RIBOSYLTRANSFERASE; CLOSTRIDIUM-BOTULINUM; BOVINE BRAIN; RAS; SUBSTRATE; IDENTIFICATION; BINDING; P21	A GTPase-activating protein specific for the rho gene products (rho-GAP) was purified from the cytosol of bovine adrenal gland. Purification procedures consisted of ammonium sulfate fractionation,chromatographies on columns of phenyl-Sepharose and CM-Sepharose, gel filtration on a TSK-gel G3000SW, and Mono S fast protein liquid chromatography. By these procedures the activity was purified about 36,000-fold with a recovery of 0.6%. The final preparation showed a major protein band at M(r) 28,000 on sodium dodecyl sulfate-polyacrylamide gel electrophoresis and stimulated GTP hydrolysis by the purified rho A protein in a time- and dose-dependent manner. No stimulation was found for ras p21. The ADP-ribosylation on the rho protein by botulinum C3 exoenzyme did not affect its interaction with the purified rho-GAP.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University								AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERRIL CR, 1979, P NATL ACAD SCI USA, V76, P4335, DOI 10.1073/pnas.76.9.4335; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORII N, 1990, J BIOCHEM-TOKYO, V107, P769, DOI 10.1093/oxfordjournals.jbchem.a123123; MORII N, 1988, J BIOL CHEM, V263, P12420; NARUMIYA S, 1988, BIOCHEM BIOPH RES CO, V150, P1122, DOI 10.1016/0006-291X(88)90745-0; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NARUMIYA S, 1990, J PHYSIOL-PARIS, V84, P267; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OGOROCHI T, 1989, BIOCHEM BIOPH RES CO, V163, P1175, DOI 10.1016/0006-291X(89)92344-9; POLAKIS PG, 1991, P NATL ACAD SCI USA, V88, P239, DOI 10.1073/pnas.88.1.239; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEKINE A, 1989, J BIOL CHEM, V264, P8602; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UEDA T, 1990, J BIOL CHEM, V265, P9373; WOLFMAN A, 1990, SCIENCE, V248, P67, DOI 10.1126/science.2181667; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H	31	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7646	7650						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902224				2022-12-25	WOS:A1991FJ34200052
J	PREISER, PR; LEVINGER, LF				PREISER, PR; LEVINGER, LF			INVITRO PROCESSING OF DROSOPHILA-MELANOGASTER 5-S RIBOSOMAL-RNA - 3' END EFFECTS AND REQUIREMENT FOR INTERNAL DOMAINS OF MATURE 5-S RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIIA; 5S RNA; BINDING-SITE; PROTEIN-BINDING; XENOPUS-LAEVIS; POLYMERASE-II; GENE-CLUSTER; 5' END; PRECURSOR; DNA	5 S RNA processing in Drosophila melanogaster, the removal of 15 nucleotides from the 3' end of the 135-nucleotide (nt) primary transcript, may play an important role in the regulation of 5 S RNA transport and ribosome assembly. We have uncoupled processing from transcription using gel purified primary transcripts processed in vitro by a cellular S100 extract. The RNA was generated by a homologous transcription system or by a T7 RNA polymerase reaction using a constructed 5 S RNA gene linked to a T7 promoter. In vitro D. melanogaster 5 S RNA processing is heat- and EDTA-sensitive, suggesting a requirement for protein, and produces a 3' end characteristic of mature 5 S RNA. Processing of substrate RNAs with altered 3' ends shows that the 3'-U5 tail (nt 131-135) inhibits the reaction. 30 nt, including all of domain IV and most of domain V, are dispensible for processing, whereas deletions including the base of stem V and all or part of stem III severely inhibit it. Several possible mechanisms are discussed.	UNIV DELAWARE,SCH LIFE & HLTH SCI,NEWARK,DE 19716	University of Delaware			Preiser, Peter R/A-2201-2011		NIGMS NIH HHS [GM08153] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSEN J, 1984, BIOCHEMISTRY-US, V23, P5759, DOI 10.1021/bi00319a014; ARTAVANISTSAKONAS S, 1977, CELL, V12, P1057, DOI 10.1016/0092-8674(77)90169-6; BOGENHAGEN DF, 1981, CELL, V24, P261, DOI 10.1016/0092-8674(81)90522-5; BOROS I, 1984, GENE, V30, P257, DOI 10.1016/0378-1119(84)90130-6; BROW DA, 1987, J BIOL CHEM, V262, P13959; Capellos C., 1972, KINETIC SYSTEMS; COZZARELLI NR, 1983, CELL, V34, P829, DOI 10.1016/0092-8674(83)90540-8; DEB S, 1986, MOL CELL BIOL, V6, P4578, DOI 10.1128/MCB.6.12.4578; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWACHTER R, 1972, ANAL BIOCHEM, V49, P184, DOI 10.1016/0003-2697(72)90257-6; DINGERMANN T, 1981, NUCLEIC ACIDS RES, V9, P3907, DOI 10.1093/nar/9.16.3907; ESCHALIER G, 1970, IN VITRO, V6, P162; FRENDEWEY D, 1985, J BIOL CHEM, V260, P449; GARRETT RA, 1981, TRENDS BIOCHEM SCI, V6, P137, DOI 10.1016/0968-0004(81)90051-7; GRODBERG J, 1988, J BACTERIOL, V170, P1245, DOI 10.1128/jb.170.3.1245-1253.1988; GRUNDSTROM T, 1985, NUCLEIC ACIDS RES, V13, P3305, DOI 10.1093/nar/13.9.3305; HAMADA H, 1979, CELL, V17, P163, DOI 10.1016/0092-8674(79)90304-0; Hardesty B., 1986, STRUCTURE FUNCTION G; HUBER PW, 1986, J BIOL CHEM, V261, P3002; HUBER PW, 1986, P NATL ACAD SCI USA, V83, P1593, DOI 10.1073/pnas.83.6.1593; IYER RK, 1988, GENE ANAL TECH, V5, P125, DOI 10.1016/0735-0651(88)90012-X; JACQ B, 1977, J MOL BIOL, V117, P785, DOI 10.1016/0022-2836(77)90069-9; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LIM HM, 1988, GENE ANAL TECH, V5, P32, DOI 10.1016/0735-0651(88)90024-6; Maniatis T., 1982, MOL CLONING; NAZAR RN, 1983, NUCLEIC ACIDS RES, V11, P3155, DOI 10.1093/nar/11.10.3155; PACE NR, 1980, TRANSFER RNA BIOL AS, P155; PIELER T, 1986, NUCLEIC ACIDS RES, V14, P6313, DOI 10.1093/nar/14.15.6313; PIKIELNY CW, 1989, GENE DEV, V3, P479, DOI 10.1101/gad.3.4.479; PIPER PW, 1983, EMBO J, V2, P353, DOI 10.1002/j.1460-2075.1983.tb01430.x; PRICE DH, 1987, J BIOL CHEM, V262, P3244; PROCUNIER JD, 1976, NATURE, V263, P255, DOI 10.1038/263255a0; RANDERATH K, 1967, METHODS ENZYMOLOGY A, V12, P323; RINKE J, 1982, CELL, V29, P149, DOI 10.1016/0092-8674(82)90099-X; Roeder R.G., 1976, RNA POLYMERASE, P285; ROMANIUK PJ, 1987, NUCLEIC ACIDS RES, V15, P2737, DOI 10.1093/nar/15.6.2737; ROUGVIE AE, 1988, CELL, V54, P795, DOI 10.1016/S0092-8674(88)91087-2; RUBIN GM, 1975, CELL, V6, P207, DOI 10.1016/0092-8674(75)90011-2; SANDS MS, 1987, MOL CELL BIOL, V7, P3985, DOI 10.1128/MCB.7.11.3985; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Segel I.H., 1975, ENZYME KINETICS; SHARP S, 1984, NUCLEIC ACIDS RES, V12, P7617, DOI 10.1093/nar/12.20.7617; SHARP SJ, 1988, MOL CELL BIOL, V8, P1266, DOI 10.1128/MCB.8.3.1266; SIMMONS DT, 1990, J VIROL, V64, P1973, DOI 10.1128/JVI.64.5.1973-1983.1990; STEFANO JE, 1984, CELL, V36, P145, DOI 10.1016/0092-8674(84)90083-7; STEITZ JA, 1988, J CELL BIOL, V106, P545, DOI 10.1083/jcb.106.3.545; TEKAMP PA, 1980, J BIOL CHEM, V255, P9501; TSCHUDI C, 1980, NUCLEIC ACIDS RES, V8, P441, DOI 10.1093/nar/8.3.441; XING YY, 1989, GENE DEV, V3, P1008, DOI 10.1101/gad.3.7.1008; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	51	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7509	7516						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902221				2022-12-25	WOS:A1991FJ34200032
J	SHIMOKAWA, T; SMITH, WL				SHIMOKAWA, T; SMITH, WL			ESSENTIAL HISTIDINES OF PROSTAGLANDIN ENDOPEROXIDE SYNTHASE - HIS-309 IS INVOLVED IN HEME BINDING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR GLAND MICROSOMES; HIGHER OXIDATION-STATES; ELECTRON-PARAMAGNETIC-RES; H-SYNTHASE; PEROXIDASE-ACTIVITIES; COMPLEMENTARY-DNA; CYCLOOXYGENASE; SYNTHETASE; PURIFICATION; ENZYME	Prostaglandin endoperoxide (PGH) synthase has a single iron protoporphyrin IX which is required for both the cyclooxygenase and peroxidase activities of the enzyme. At room temperature, the heme iron is coordinated at the axial position by an imidazole, and about 20% of the heme iron is coordinated at the distal position by an imidazole. We have used site-directed mutagenesis to investigate which histidine residues are involved in PGH synthase catalysis and heme binding. Individual mutant cDNAs for ovine PGH synthases were prepared with amino acid substitutions at each of 13 conserved histidines. cos-1 cells were transfected with each of these cDNAs, and the cyclooxygenase and peroxidase activities of the resulting microsomal PGH synthases were measured. Mutant PGH synthases in which His-207, His-309, or His-388 was replaced with either glutamine or alanine lacked both activities. Gln-386 and Ala-386 PGH synthase mutants exhibited cyclooxygenase but not peroxidase activities. Other mutants exhibited both activities at varying levels. Because binding of heme renders native PGH synthase resistant to cleavage by trypsin, we examined the effects of heme on the relative sensitivities of native, Ala-204, Ala-207, Ala-309, Ala-386, and Ala-388 mutant PGH synthases to trypsin as a measure of the heme-protein interaction. The Ala-309 PGH synthase mutant was notably hypersensitive to tryptic cleavage, even in the presence of exogenous heme; in contrast, the native enzyme and the other alanine mutants exhibited similar, lower sensitivities toward trypsin and, except for the Ala-386 mutant, were partially protected from trypsin cleavage by heme. Preincubation of the native and each of the alanine mutant PGH synthases, including the Ala-309 mutant, with indomethacin protected the proteins from trypsin cleavage. Thus, all the mutant proteins retain sufficient three-dimensional structure to bind cyclooxygenase inhibitors. Our results suggest that His-309 is one of the heme ligands, probably the axial ligand, of PGH synthase. Two other histidines, His-207 and His-388, are essential for both PGH synthase activities suggesting that either His-207 or His-388 can serve as the distal heme ligand; however, the trypsin cleavage measurements imply that neither His-207 nor His-388 is required for heme binding. This is consistent with the fact that only 20% of the distal coordination position of the heme iron of PGH synthase is occupied by an imidazole side chain.	MICHIGAN STATE UNIV, DEPT BIOCHEM, RM 510, BIOCHEM BLDG, E LANSING, MI 48824 USA	Michigan State University			SHIMOKAWA, Teruhiko/GZA-4834-2022		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK022042, R37DK022042] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YNP, 1987, J BIOL CHEM, V262, P16892; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DIETZ R, 1988, EUR J BIOCHEM, V171, P321, DOI 10.1111/j.1432-1033.1988.tb13793.x; DREZEN G, 1981, ANAL BIOCHEM, V112, P295; HEMLER M, 1976, J BIOL CHEM, V251, P5575; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; KULMACZ RJ, 1990, BIOCHEMISTRY-US, V29, P8760, DOI 10.1021/bi00489a037; KULMACZ RJ, 1987, J BIOL CHEM, V262, P10524; KULMACZ RJ, 1983, PROSTAGLANDINS, V25, P531, DOI 10.1016/0090-6980(83)90025-4; KULMACZ RJ, 1984, J BIOL CHEM, V259, P6358; KULMACZ RJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P502, DOI 10.1016/0003-9861(89)90317-2; KULMACZ RJ, 1989, J BIOL CHEM, V264, P14136; KULMACZ RJ, 1982, BIOCHEM BIOPH RES CO, V104, P758, DOI 10.1016/0006-291X(82)90702-1; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAMBEIR AM, 1985, J BIOL CHEM, V260, P4894; Maniatis T., 1989, MOL CLONING LABORATO, P21; MARNETT LJ, 1988, J BIOL CHEM, V263, P16532; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; MIZUNO K, 1982, PROSTAGLANDINS, V23, P743; OGINO N, 1978, J BIOL CHEM, V253, P5061; OHKI S, 1979, J BIOL CHEM, V254, P829; PAGELS WR, 1983, J BIOL CHEM, V258, P6517; PICOT D, 1989, CYTOCHROME P-450 : BIOCHEMISTRY AND BIOPHYSICS /, P29; Putter J., 1974, METHODS ENZYMATIC AN, P685, DOI [DOI 10.1016/B978-0-12-091302-2.50033-5, 10.1016/B978-0-12-091302-2.50033-5]; RUF HH, 1984, FEBS LETT, V165, P293, DOI 10.1016/0014-5793(84)80189-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHIMOKAWA T, 1990, J BIOL CHEM, V265, P20073; SMITH WL, 1990, ADV PROSTAG THROMB L, V20, P14; SMITH WL, 1982, METHOD ENZYMOL, V86, P213; SMITH WL, 1990, STROKE, V21, P24; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; VANDEROUDERAA FJ, 1979, BIOCHIM BIOPHYS ACTA, V572, P29, DOI 10.1016/0005-2760(79)90197-8; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	39	120	120	0	2	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6168	6173						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1901057				2022-12-25	WOS:A1991FE37300028
J	HIROYOSHI, M; KAIBUCHI, K; KAWAMURA, S; HATA, Y; TAKAI, Y				HIROYOSHI, M; KAIBUCHI, K; KAWAMURA, S; HATA, Y; TAKAI, Y			ROLE OF THE C-TERMINAL REGION OF SMG P21, A RAS P21-LIKE SMALL GTP-BINDING PROTEIN, IN MEMBRANE AND SMG P21 GDP GTP EXCHANGE PROTEIN INTERACTIONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PUTATIVE EFFECTOR DOMAIN; BOVINE BRAIN; GENE-PRODUCTS; ACTIVATING PROTEINS; GUANINE-NUCLEOTIDE; MOLECULAR-WEIGHT; KINETIC-ANALYSIS; HUMAN-PLATELETS; PURIFICATION; PHOSPHORYLATION	Limited proteolysis with trypsin of smg p21B, a ras p21-like small GTP-binding protein having the same putative effector domain as ras p21s, produced the N-terminal fragment and the C-terminal tail of Lys-Lys-Ser-Ser-geranylgeranyl-Cys methyl ester. The M(r) values of the intact smg p21B, the N-terminal fragment, and the C-terminal tail were estimated to be about 22,000, 20,500, and less than 1,000, respectively, by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Both the GDP- and GTP-bound forms of the intact smg p21B bound to various membranes and phosphatidylserine-linked Affi-Gel. However, both the GDP- and GTP-bound forms of the N-terminal fragment failed to bind to membranes and phosphatidylserine-linked Affi-Gel. In contrast, the C-terminal tail bound to membranes and phosphatidylserine-linked Affi-Gel. The N-terminal fragment contained a GDP/GTP-binding and GTPase domain and exhibited these two activities, but the C-terminal tail did not show any such activity. A GTPase-activating protein for smg p21 stimulated the GTPase activity of both the intact smg p21B and the N-terminal fragment. In contrast, a GDP/GTP exchange protein for smg p21, named GDP dissociation stimulator, stimulated the GDP/GTP exchange reaction of the intact smg p21B but not that of the N-terminal fragment. These results indicate 1) that smg p21B is composed of at least two functionally different domains, the N-terminal GDP/GTP-binding and GTPase domain and the C-terminal membrane-binding domain, 2) that smg p21B binds to membranes through its C-terminal hydrophobic and basic domain, and 3) that this C-terminal domain is also essential for the smg p21 GDP dissociation stimulator action but not for the smg p21 GTPase-activating protein action.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ARAKI S, 1990, J BIOL CHEM, V265, P18007; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; GUITERREZ L, 1989, EMBO J, V8, P1093; HALL A, 1986, J BIOL CHEM, V261, P963; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HOSHIJIMA M, 1988, BIOCHEM BIOPH RES CO, V157, P851, DOI 10.1016/S0006-291X(88)80953-7; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; ISOMURA M, 1991, IN PRESS ONCOGENE; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, 1989, BIOCHEM BIOPH RES CO, V163, P1418, DOI 10.1016/0006-291X(89)91137-6; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KAWATA M, 1989, J BIOL CHEM, V264, P15688; KAWATA M, 1991, IN PRESS ONCOGENE; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KURODA S, 1989, BIOCHEM BIOPH RES CO, V163, P674, DOI 10.1016/0006-291X(89)92276-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; MIZOGUCHI A, 1989, MOL BRAIN RES, V5, P31, DOI 10.1016/0169-328X(89)90015-6; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; OHGA N, 1989, BIOCHEM BIOPH RES CO, V163, P1523, DOI 10.1016/0006-291X(89)91153-4; OHMORI T, 1988, BIOCHEM BIOPH RES CO, V157, P670, DOI 10.1016/S0006-291X(88)80302-4; OHMORI T, 1989, J BIOL CHEM, V264, P1877; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SHOJI I, 1989, BIOCHEM BIOPH RES CO, V162, P273, DOI 10.1016/0006-291X(89)91992-X; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; UEDA T, 1989, BIOCHEM BIOPH RES CO, V159, P1411, DOI 10.1016/0006-291X(89)92267-5; UEDA T, 1990, J BIOL CHEM, V265, P9373; WISE BC, 1982, J BIOL CHEM, V257, P8481; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626	49	56	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2962	2969						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1899665				2022-12-25	WOS:A1991EX60000047
J	XU, ZL; BYERS, DM; PALMER, FBS; SPENCE, MW; COOK, HW				XU, ZL; BYERS, DM; PALMER, FBS; SPENCE, MW; COOK, HW			SERINE UTILIZATION AS A PRECURSOR OF PHOSPHATIDYLSERINE AND ALKENYL-(PLASMENYL)AMINE, ALKYLAMINE, AND ACYLETHANOLAMINE PHOSPHOGLYCERIDES IN CULTURED GLIOMA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE-EXCHANGE ENZYME; NEURO-BLASTOMA CELLS; HAMSTER OVARY CELLS; RAT-LIVER; PHOSPHATIDYLETHANOLAMINE BIOSYNTHESIS; PHOSPHOLIPID-METABOLISM; SUBCELLULAR-FRACTIONS; ETHANOLAMINE; MITOCHONDRIA; PHOSPHATIDYLCHOLINE	In several tissues and cell lines, serine utilized for phosphatidylserine (PS) synthesis is an eventual precursor of the base moiety of ethanolamine phosphoglycerides (PE). We investigated the biosynthesis and decarboxylation of PS in cultured C6 glioma cells, with particular attention to 1-O-alk-1'-enyl-2-acyl-sn-glycero-3-phosphoethanolamine (plasmenylethanolamine) biosynthesis. Incorporation of [H-3]serine into PS reached a maximum within 4-8 h, and label in nonplasmenylethanolamine phosphoglyceride (NP-PE) and plasmenylethanolamine was maximal by 12-24 h and 48 h, respectively. After 8 h, label in PS decreased even though 40-60% of initial label remained in the culture medium. Serial additions of fresh [H-3]serine restored PS synthesis to higher levels of labeled PS accumulation followed by a subsequent decrease in 4-8 h. High performance liquid chromatographic analyses confirmed that medium serim was depleted by 8 h, and thereafter metabolites, including acetate and formate, accounted for radioactivity in the medium. The rapid but transient appearance of labeled glycine and ATP inside the cells indicated conversion of serine by hydroxymethyltransferase. 78-85% of label from serine was in headgroup of PS or of PE formed by decarboxylation. A precursor-product relationship was suggested for label from [H-3]serine appearing in the headgroup of diacyl, alkylacyl, and alkenylacyl subclasses of PE. By 48 h, a constant specific activity ratio of approximately 1:1 was reached between plasmenylethanolamine and NP-PE, similar to the molar distribution of these lipids. In contrast, equilibrium was not achieved in cells incubated with [1,2-C-14]ethanolamine; plasmenylethanolamine had 2-fold greater specific activity than labeled NP-PE by 72-96 h. These observations indicate that in cultured glioma cells 1) serine serves as a precursor of the head group of PS and of both plasmenyl and non-plasmenyl species of PE; 2) exchange of headgroup between NP-PE and plasmenylethanolamine may involve different donor pools of PE depending on whether the headgroup originates with exogenous serine or ethanolamine; 3) serine is rapidly converted to other metabolites, which limits exogenous serine as a direct phospholipid precursor.	DALHOUSIE UNIV,CLIN RES CTR,ATLANTIC RES CTR MENTAL RETARDAT,RM C-204,5849 UNIV AVE,HALIFAX B3H 4H7,NS,CANADA; DALHOUSIE UNIV,DEPT PEDIAT,HALIFAX B3H 4H7,NS,CANADA; DALHOUSIE UNIV,DEPT BIOCHEM,HALIFAX B3H 4H7,NS,CANADA	Dalhousie University; Dalhousie University; Dalhousie University								ANSELL GB, 1982, PHOSPHOLIPIDS, P1; BARANSKA J, 1982, ADV LIPID RES, V19, P163; BARANSKA J, 1980, BIOCHIM BIOPHYS ACTA, V619, P258, DOI 10.1016/0005-2760(80)90074-0; BARANSKA J, 1989, FEBS LETT, V256, P33, DOI 10.1016/0014-5793(89)81712-0; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; BJERVE KS, 1984, BIOCHEM J, V219, P781, DOI 10.1042/bj2190781; BJERVE KS, 1973, BIOCHIM BIOPHYS ACTA, V306, P396, DOI 10.1016/0005-2760(73)90178-1; BJERVE KS, 1973, BIOCHIM BIOPHYS ACTA, V296, P549, DOI 10.1016/0005-2760(73)90115-X; BJERVE KS, 1985, BIOCHIM BIOPHYS ACTA, V833, P396, DOI 10.1016/0005-2760(85)90096-7; BORKENHAGEN L, 1961, J BIOL CHEM, V236, pPC28; BRADBURY K, 1984, J NEUROCHEM, V43, P382, DOI 10.1111/j.1471-4159.1984.tb00912.x; BUTLER M, 1983, J NEUROCHEM, V41, P1445, DOI 10.1111/j.1471-4159.1983.tb00844.x; CHABNER BA, 1986, METHOTREXATE CANCER, P1; COOK HW, 1988, ANAL BIOCHEM, V174, P552, DOI 10.1016/0003-2697(88)90055-3; COOK HW, 1983, J BIOL CHEM, V258, P7586; DAWSON RMC, 1967, LIPID CHROMATOGRAPHI, V4, P163; DENNIS EA, 1972, J LIPID RES, V13, P263; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; GEDDES JW, 1984, J NEUROCHEM, V42, P16, DOI 10.1111/j.1471-4159.1984.tb09691.x; GLANVILLE NT, 1989, BIOCHIM BIOPHYS ACTA, V1004, P169, DOI 10.1016/0005-2760(89)90265-8; GLANVILLE NT, 1987, BIOCHIM BIOPHYS ACTA, V904, P392, DOI 10.1016/0005-2736(87)90389-0; HASEGAWA K, 1989, J BIOL CHEM, V264, P19887; HUBSCHER G, 1962, BIOCHIM BIOPHYS ACTA, V57, P555, DOI 10.1016/0006-3002(62)91163-0; HUBSCHER G, 1959, BIOCHIM BIOPHYS ACTA, V36, P518, DOI 10.1016/0006-3002(59)90194-5; JELSEMA CL, 1978, J BIOL CHEM, V253, P7960; KANFER JN, 1972, J LIPID RES, V13, P468; KANFER JN, 1980, CAN J BIOCHEM CELL B, V58, P1370, DOI 10.1139/o80-186; KANOSUEOKA T, 1987, J BIOL CHEM, V262, P6074; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KUGE O, 1986, J BIOL CHEM, V261, P5790; KUGE O, 1986, J BIOL CHEM, V261, P5795; KUGE O, 1985, P NATL ACAD SCI USA, V82, P1926, DOI 10.1073/pnas.82.7.1926; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER MA, 1986, J BIOL CHEM, V261, P9753; MORASH SC, 1988, BIOCHIM BIOPHYS ACTA, V961, P194, DOI 10.1016/0005-2760(88)90114-2; MOSER HW, 1988, NEUROLOGY, V38, P1617, DOI 10.1212/WNL.38.10.1617; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; POLOKOFF MA, 1981, J BIOL CHEM, V256, P7687; PULLARKAT RK, 1981, BIOCHIM BIOPHYS ACTA, V663, P117; SCHIRCH LVG, 1963, J BIOL CHEM, V238, P1032; SHUTGENS RB, 1986, EUR J PEDIATR, V44, P430; SNYDER F, 1972, ETHER LIPIDS CHEM BI, P273; SNYDER F, 1985, BIOCH LIPIDS MEMBRAN, P271; SUZUKI TT, 1985, J BIOL CHEM, V260, P1394; THOMAS SE, 1990, BIOCHIM BIOPHYS ACTA, V1044, P349, DOI 10.1016/0005-2760(90)90079-D; TIJBURG LBM, 1989, BIOCHIM BIOPHYS ACTA, V1004, P1, DOI 10.1016/0005-2760(89)90206-3; TURNER RS, 1985, PHOSPHOLIPIDS CELLUL, V2, P75; VANCE DE, 1985, BIOCH LIPIDS MEMBRAN, P242; VANGOLDE LM, 1974, BIOCHIM BIOPHYS ACTA, V360, P179, DOI 10.1016/0005-2760(74)90168-4; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; VOELKER DR, 1984, P NATL ACAD SCI-BIOL, V81, P2669, DOI 10.1073/pnas.81.9.2669; VOELKER DR, 1985, J BIOL CHEM, V260, P4671; VOELKER DR, 1989, J BIOL CHEM, V264, P8019; YAVIN E, 1977, J BIOL CHEM, V252, P260; YOREK MA, 1985, J BIOL CHEM, V260, P2930; ZOELLER RA, 1988, J BIOL CHEM, V263, P11590	56	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2143	2150						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899236				2022-12-25	WOS:A1991EV51500023
J	FRELINGER, AL; DU, XP; PLOW, EF; GINSBERG, MH				FRELINGER, AL; DU, XP; PLOW, EF; GINSBERG, MH			MONOCLONAL-ANTIBODIES TO LIGAND-OCCUPIED CONFORMERS OF INTEGRIN ALPHA-IIB-BETA-3 (GLYCOPROTEIN-IIB-IIIA) ALTER RECEPTOR AFFINITY, SPECIFICITY, AND FUNCTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED HUMAN-PLATELETS; FIBRONECTIN-BINDING; GLANZMANNS THROMBASTHENIA; SYNTHETIC PEPTIDES; FIBRINOGEN; INHIBITION; COMPLEX; AGGREGATION; ACTIVATION; ADHESION	Occupancy of integrin receptors induces conformational changes in the receptor, resulting in exposure of novel interactive sites termed ligand-induced binding sites (LIBS). We report here that Fab fragments of certain antibodies against LIBS on integrin alpha-IIb-beta-3 (platelet glycoprotein IIb-IIIa) block platelet aggregation. Thus, certain LIBS or the regions surrounding them may participate in events required for platelet aggregation. In addition, certain anti-alpha-IIb-beta-3 LIBS Fab fragments stimulated platelet aggregation. This was due to induction of fg binding to alpha-IIb-beta-3, apparently by shifting a conformational equilibrium between a "resting" and an "activated" state of alpha-IIb-beta-3. Some of the activating anti-LIBS Fab fragments also induced high affinity fibronectin binding to alpha-IIb-beta-3, whereas others did not. Thus, changes in the conformation of this integrin modulate both the specificity and affinity of ligand recognition.	Scripps Res Inst, RES INST, LA JOLLA, CA 92037 USA	Scripps Research Institute				Frelinger, Andrew/0000-0002-6871-7441	NHLBI NIH HHS [HL-28235, HL-31950] Funding Source: Medline; NIAMS NIH HHS [AR-27214] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031950, R01HL028235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR027214, R01AR027214] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENNETT JS, 1979, J CLIN INVEST, V64, P1393, DOI 10.1172/JCI109597; CHARO IF, 1977, J CLIN INVEST, V60, P866, DOI 10.1172/JCI108841; COLLER BS, 1983, J CLIN INVEST, V72, P325, DOI 10.1172/JCI110973; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; FRELINGER AL, 1988, J BIOL CHEM, V263, P12397; FRELINGER AL, 1990, J BIOL CHEM, V265, P6346; FUJIMOTO T, 1982, J CLIN INVEST, V69, P1212, DOI 10.1172/JCI110560; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1977, J CLIN INVEST, V60, P999, DOI 10.1172/JCI108880; GULINO D, 1990, J BIOL CHEM, V265, P9575; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; JENNINGS LK, 1990, J BIOL CHEM, V265, P3815; KOUNS WC, 1990, J BIOL CHEM, V265, P20594; LAHAV J, 1984, EUR J BIOCHEM, V145, P151, DOI 10.1111/j.1432-1033.1984.tb08534.x; LAM SCT, 1987, J BIOL CHEM, V262, P947; MARGUERIE GA, 1979, J BIOL CHEM, V254, P5357; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NEUGEBAUER KM, 1991, NATURE, V350, P68, DOI 10.1038/350068a0; NURDEN AT, 1974, BRIT J HAEMATOL, V28, P253, DOI 10.1111/j.1365-2141.1974.tb06660.x; OTOOLE TE, 1990, CELL REGUL, V1, P883, DOI 10.1091/mbc.1.12.883; PARISE LV, 1985, J BIOL CHEM, V260, P698; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PARISE LV, 1987, J BIOL CHEM, V262, P12597; PEDVIS LG, 1988, THROMB HAEMOSTASIS, V59, P323; PHILLIPS DR, 1977, J CLIN INVEST, V60, P535, DOI 10.1172/JCI108805; PLOW EF, 1986, P NATL ACAD SCI USA, V83, P6002, DOI 10.1073/pnas.83.16.6002; PLOW EF, 1985, BLOOD, V66, P26; PLOW EF, 1985, P NATL ACAD SCI USA, V82, P8057, DOI 10.1073/pnas.82.23.8057; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1981, J BIOL CHEM, V256, P9477; SACHS DH, 1972, P NATL ACAD SCI USA, V69, P3790, DOI 10.1073/pnas.69.12.3790; SHADLE PJ, 1984, J CELL BIOL, V99, P2056, DOI 10.1083/jcb.99.6.2056; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SIMS PJ, 1991, J BIOL CHEM, V266, P7345; VANKOOYK Y, 1991, J CELL BIOL, V112, P345, DOI 10.1083/jcb.112.2.345; WENCELDRAKE JD, 1986, AM J PATHOL, V124, P324; WOODS VL, 1984, BLOOD, V63, P368	37	344	353	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17106	17111						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894607				2022-12-25	WOS:A1991GF44500024
J	KOSHIYAMA, H; LEE, HC; TASHJIAN, AH				KOSHIYAMA, H; LEE, HC; TASHJIAN, AH			NOVEL MECHANISM OF INTRACELLULAR CALCIUM RELEASE IN PITUITARY-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CYTOSOLIC FREE CA-2+; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CYCLIC METABOLITE; HORMONE; GH3; 1,4,5-TRISPHOSPHATE; MITOCHONDRIA; MOBILIZATION; CA2+	In sea urchin eggs an enzymatic metabolite of beta-NAD+, called cyclic ADP-ribose (cADPR), is as potent and powerful a releaser of sequestered intracellular Ca2+ as is inositol 1,4,5-trisphosphate (IP3). The enzyme that synthesizes cADPR is present in several vertebrate animal tissues, but the Ca2+-releasing activity of cADPR has not been described in mammalian cells. We report here that incubation of beta-NAD+ with cell-free extracts of several rat tissues (including pituitary gland) generates a product which releases intracellular Ca2+ stores in permeabilized rat pituitary GH4C1 cells. This product has the biological characteristics of cADPR (it acts after depletion of the IP3 stores and after blockade of the IP3 receptor by heparin). The response is mimicked, in a concentration-dependent manner, by authentic cADPR and is desensitized by prior incubation with cADPR. We conclude that cADPR is not only synthesized by certain mammalian cells but also acts in such cells to release compartmentalized intracellular Ca2+ by a mechanism that differs from that used by IP3. Therefore, cADPR may serve, in addition to IP3, as a second messenger for intracellular Ca2+ mobilization in mammalian cells.	HARVARD UNIV,SCH PUBL HLTH,TOXICOL LAB,665 HUNTINGTON AVE,BOSTON,MA 02115; UNIV MINNESOTA,DEPT PHYSIOL,MINNEAPOLIS,MN 55455; HARVARD UNIV,SCH MED,DEPT BIOL CHEM & MOLEC PHARMACOL,BOSTON,MA 02115	Harvard University; Harvard T.H. Chan School of Public Health; University of Minnesota System; University of Minnesota Twin Cities; Harvard University; Harvard Medical School			Lee, Hon Cheung/C-4329-2009		NIDDK NIH HHS [DK 11011] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK011011] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALBERT PR, 1984, J BIOL CHEM, V259, P5827; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BIDEN TJ, 1986, J BIOL CHEM, V261, P7223; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; GERSHENGORN MC, 1984, J BIOL CHEM, V259, P675; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GILL DL, 1989, CELL CALCIUM, V10, P363, DOI 10.1016/0143-4160(89)90062-6; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; KOSHIYAMA H, 1991, ENDOCRINOLOGY, V128, P2715, DOI 10.1210/endo-128-6-2715; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1989, J BIOL CHEM, V264, P1608; MOLLARD P, 1990, BIOCHEM J, V268, P345, DOI 10.1042/bj2680345; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; RONNING SA, 1982, P NATL ACAD SCI-BIOL, V79, P6294, DOI 10.1073/pnas.79.20.6294; RUSINKO N, 1989, J BIOL CHEM, V264, P11725; SCHLEGEL W, 1984, J CELL BIOL, V99, P83, DOI 10.1083/jcb.99.1.83; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; Tashjian A H Jr, 1979, Methods Enzymol, V58, P527; TASHJIAN AH, 1987, BIOCHEM J, V243, P305, DOI 10.1042/bj2430305; WILSON DB, 1985, J BIOL CHEM, V260, P3496; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	23	130	131	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					16985	16988						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894597				2022-12-25	WOS:A1991GF44500006
J	LIU, DH; CAPERELLI, CA				LIU, DH; CAPERELLI, CA			CARBOCYCLIC SUBSTRATES FOR DENOVO PURINE BIOSYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE; MULTIFUNCTIONAL PROTEIN; ESCHERICHIA-COLI; CHICKEN LIVER; SYNTHETASE; OVERPRODUCTION; CLONING	The carbocyclic analogues of phosphoribosylamine, glycinamide ribonucleotide, and formylglycinamide ribonucleotide have been prepared as the racemates. Carbocyclic phosphoribosylamine was utilized as a substrate by the monofunctional glycinamide ribonucleotide synthetase from Escherichia coli as well as the glycinamide ribonucleotide synthetase activity of the eucaryotic trifunctional enzyme of de novo purine biosynthesis. Furthermore, carbocyclic glycinamide ribonucleotide was processed in the reverse reaction catalyzed by these enzymes. In addition, carbocyclic formylglycinamide ribonucleotide was converted, by E. coli formylglycinamidine ribonucleotide synthetase, to carbocyclic formylglycinamidine ribonucleotide, which was accepted as a substrate by the aminoimidazole ribonucleotide synthetase activity of the trifunctional enzyme. This study has afforded carbocyclic substrate analogues, in particular for the chemically labile phosphoribosyl amine, for the initial steps of de novo purine biosynthesis.	UNIV CINCINNATI,MED CTR,COLL PHARM,DIV PHARMACOL & MED CHEM,3223 EDEN AVE,ML004,CINCINNATI,OH 45267	University of Cincinnati					NIGMS NIH HHS [GM-42024] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM042024] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMES BN, 1960, J BIOL CHEM, V235, P769; BEARDSLEY GP, 1986, PTERIDINES FOLIC ACI, P953; BENKOVIC SJ, 1984, TRENDS BIOCHEM SCI, V9, P320, DOI 10.1016/0968-0004(84)90302-5; CAPERELLI CA, 1989, J BIOL CHEM, V264, P5053; CAPERELLI CA, 1988, ARCH BIOCHEM BIOPHYS, V264, P340, DOI 10.1016/0003-9861(88)90602-9; CARDINI CE, 1957, METHOD ENZYMOL, V3, P835, DOI 10.1016/S0076-6879(57)03458-8; CHETTUR G, 1977, CARBOHYD RES, V56, P75, DOI 10.1016/S0008-6215(00)84238-X; Cleland W W, 1979, Methods Enzymol, V63, P103; DAUBNER SC, 1985, BIOCHEMISTRY-US, V24, P7059, DOI 10.1021/bi00346a006; DAUBNER SC, 1986, BIOCHEMISTRY-US, V25, P2951, DOI 10.1021/bi00358a033; Harwood LM., 1985, ALDRICHIM ACTA, V18, P25; KAM BL, 1981, J ORG CHEM, V46, P3268, DOI 10.1021/jo00329a026; MORODER L, 1976, H-S Z PHYSIOL CHEM, V357, P1651, DOI 10.1515/bchm2.1976.357.2.1651; PATEY CAH, 1973, BIOCHEM J, V135, P543, DOI 10.1042/bj1350543; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; SCHENDEL FJ, 1986, BIOCHEMISTRY-US, V25, P2256, DOI 10.1021/bi00356a061; SCHENDEL FJ, 1989, BIOCHEMISTRY-US, V28, P2459, DOI 10.1021/bi00432a017; SCHRIMSHER JL, 1986, BIOCHEMISTRY-US, V25, P4356, DOI 10.1021/bi00363a027; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; Smith M., 1961, BIOCH PREP, V8, P130; WOLFE MS, 1990, J ORG CHEM, V55, P4712, DOI 10.1021/jo00302a043; Woodward D O, 1978, Methods Enzymol, V51, P202; YOUNG M, 1984, BIOCHEMISTRY-US, V23, P3979, DOI 10.1021/bi00312a027	23	12	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16699	16702						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885598				2022-12-25	WOS:A1991GD63500073
J	POON, PP; STORMS, RK				POON, PP; STORMS, RK			THE PERIODICALLY EXPRESSED TMP1 GENE OF SACCHAROMYCES-CEREVISIAE IS SUBJECT TO START-DEPENDENT AND START-INDEPENDENT REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYMIDYLATE SYNTHASE GENE; CELL-CYCLE; MITOCHONDRIAL-DNA; YEAST; TRANSCRIPTION; SEQUENCES; ELEMENTS; MUTANTS; CLONING; ENCODES	The rate of transcription of the Saccharomyces cerevisiae gene encoding thymidylate synthase (TMP1) fluctuates periodically during the cell cycle. The simplest explanation for this pattern of expression is that transcription occurs during the late G1 and early S phases and does not occur during other stages of the cell cycle. In this report, however, we show that TMP1 is subject to regulation that results in at least three different levels of expression: essentially nondetectable expression during stationary phase (G0), moderate level expression in START-arrested growing cells (START-independent), and a high level of expression in proliferating cells (START-dependent). Our analysis also shows that upstream elements important for START-independent expression and required for START-dependent expression are located within a 37-base region.	CONCORDIA UNIV,DEPT BIOL,MONTREAL H3G 1M8,QUEBEC,CANADA	Concordia University - Canada			Storms, Reginald/B-2405-2013					BAUER GA, 1990, NUCLEIC ACIDS RES, V18, P261, DOI 10.1093/nar/18.2.261; BISSON L, 1977, J BACTERIOL, V132, P44, DOI 10.1128/JB.132.1.44-50.1977; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; FOIANI M, 1989, MOL CELL BIOL, V9, P3081, DOI 10.1128/MCB.9.7.3081; GREENWOOD MT, 1986, J BACTERIOL, V168, P1336, DOI 10.1128/jb.168.3.1336-1342.1986; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; JOHNSTON LH, 1987, NUCLEIC ACIDS RES, V15, P5017, DOI 10.1093/nar/15.13.5017; LORINCZ AT, 1984, NATURE, V307, P183, DOI 10.1038/307183a0; MCINTOSH EM, 1988, MOL CELL BIOL, V8, P4616, DOI 10.1128/MCB.8.11.4616; NASMYTH K, 1983, NATURE, V302, P670, DOI 10.1038/302670a0; NEWLON CS, 1975, CELL, V5, P423; ORD RW, 1988, CURR GENET, V14, P363, DOI 10.1007/BF00419994; PETERSON TA, 1985, MOL CELL BIOL, V5, P226, DOI 10.1128/MCB.5.1.226; PETES TD, 1973, BIOCHEM BIOPH RES CO, V55, P603, DOI 10.1016/0006-291X(73)91186-8; PLEVANI P, 1987, NUCLEIC ACIDS RES, V15, P7975; PRINGLE JR, 1981, MOL BIOL YEAST SACCH, P97; STORMS RK, 1979, J BACTERIOL, V140, P73, DOI 10.1128/JB.140.1.73-82.1979; STORMS RK, 1984, MOL CELL BIOL, V4, P2858, DOI 10.1128/MCB.4.12.2858; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; WHITE JHM, 1987, EXP CELL RES, V171, P223, DOI 10.1016/0014-4827(87)90265-5; WHITE JHM, 1986, EMBO J, V5, P1705, DOI 10.1002/j.1460-2075.1986.tb04414.x	23	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16808	16812						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885607				2022-12-25	WOS:A1991GD63500089
J	WATANABE, H; ABE, K; EMORI, Y; HOSOYAMA, H; ARAI, S				WATANABE, H; ABE, K; EMORI, Y; HOSOYAMA, H; ARAI, S			MOLECULAR-CLONING AND GIBBERELLIN-INDUCED EXPRESSION OF MULTIPLE CYSTEINE PROTEINASES OF RICE SEEDS (ORYZAINS)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; CATHEPSIN-H; ESCHERICHIA-COLI; CDNA; PURIFICATION; ORYZACYSTATIN; INHIBITOR; HOMOLOGY; PAPAIN; NUCLEOTIDE	We screened a cDNA library of germinating rice seeds with a cDNA for aleurain (cysteine proteinase from barley) and obtained three distinct types of cDNA clones encoding three species of cysteine proteinases (oryzains-alpha, beta, and gamma). The deduced amino acid sequences are distinct in part, but, on the whole, are similar to one another. The three sequences all contain the catalytic triad Cys25-His159-Asn175 (papain numbering). The three oryzains are similar to one another and also to other known cysteine proteinases such as papain and cathepsin H with respect to the sequences around the active site residues and the COOH-terminal Trp-rich region. Amino acid sequence comparison revealed that oryzains-alpha and beta are similar not only to each other (70% similarity) but also to actinidin and papain (about 50%), whereas oryzain-gamma was rather similar to aleurain (85%) and cathepsin H (60%). Northern blot analysis revealed that the mRNAs for the three oryzains are expressed only in seeds, not in shoots or roots, and show different expression profiles during germination and when the seeds are treated with gibberellic acid. Oryzains-alpha and gamma are expressed continuously during germination with a maximum expression 5 days from the start of germination, but are present in neither ripening nor ripened seeds. On the other hand, oryzain-beta is expressed not only during germination, but also in ripened seeds before germination. It was noted that the expression of the three oryzain mRNAs is enhanced in different manners by gibberellic acid but is not enhanced by other plant hormones such as auxin. The induction of oryzain-beta mRNA is transient, reaching a maximum in 4 h from the addition of gibberellic acid and diminishing rapidly thereafter, while the induction of oryzain-alpha and gamma mRNAs continues over 5 days. Thus, multiple systems involving cysteine proteinases must be differentially involved in the germination process, probably under hormonal control.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo	WATANABE, H (corresponding author), UNIV TOKYO,FAC AGR,DEPT AGR CHEM,BUNKYO KU,TOKYO 113,JAPAN.							ABE K, 1988, J BIOL CHEM, V263, P7655; ABE K, 1987, AGR BIOL CHEM TOKYO, V51, P2763; ABE K, 1987, J BIOL CHEM, V262, P16793; ABE K, 1985, AGR BIOL CHEM TOKYO, V49, P3349, DOI 10.1080/00021369.1985.10867271; ABE K, 1987, AGR BIOL CHEM TOKYO, V51, P1509, DOI 10.1080/00021369.1987.10868238; ARAI S, 1987, AGR BIOL CHEM TOKYO, V52, P2957; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BRAWERMAN G, 1972, BIOCHEMISTRY-US, V11, P637, DOI 10.1021/bi00754a027; CARNE A, 1978, BIOCHEM J, V173, P73, DOI 10.1042/bj1730073; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; COHEN LW, 1986, GENE, V48, P219, DOI 10.1016/0378-1119(86)90080-6; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; ISHIDOH K, 1987, FEBS LETT, V226, P33, DOI 10.1016/0014-5793(87)80545-8; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; ISHIDOH K, 1989, FEBS LETT, V259, P711; JACQUET A, 1989, BIOL CHEM H-S, V370, P425, DOI 10.1515/bchm3.1989.370.1.425; JOSHI CP, 1987, NUCLEIC ACIDS RES, V15, P6643, DOI 10.1093/nar/15.16.6643; KATSUNUMA N, 1986, CYSTEINE PROTEASES T, P219; KONDO H, 1989, GENE, V81, P259, DOI 10.1016/0378-1119(89)90186-8; KONDO H, 1990, J BIOL CHEM, V265, P15832; LINDWALL G, 1984, J BIOL CHEM, V259, P2241; Maniatis T., 1982, MOL CLONING; MASON RW, 1986, BIOCHEM J, V240, P373, DOI 10.1042/bj2400373; PODIVINSKY E, 1989, NUCLEIC ACIDS RES, V17, P8363, DOI 10.1093/nar/17.20.8363; ROGERS JC, 1985, P NATL ACAD SCI USA, V82, P6512, DOI 10.1073/pnas.82.19.6512; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SUZUKI K, 1985, BIOL ROLE PROTEINASE, P111; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; TSUNASAWA S, 1987, J BIOCHEM, V101, P111, DOI 10.1093/oxfordjournals.jbchem.a121882; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WILLIAMS JG, 1985, EMBO J, V4, P999, DOI 10.1002/j.1460-2075.1985.tb03730.x	33	219	224	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16897	16902						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885617				2022-12-25	WOS:A1991GD63500103
J	WU, DQ; KAN, M; SATO, GH; OKAMOTO, T; SATO, JD				WU, DQ; KAN, M; SATO, GH; OKAMOTO, T; SATO, JD			CHARACTERIZATION AND MOLECULAR-CLONING OF A PUTATIVE BINDING-PROTEIN FOR HEPARIN-BINDING GROWTH-FACTORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-GROWTH; BOVINE BRAIN; EXTRACELLULAR-MATRIX; FACTOR-BETA; ACIDIC FGF; A431 CELLS; FIBROBLAST; SERUM; ANGIOGENESIS; SEQUENCES	A novel M(r) 17,000 heparin-binding protein was purified from culture medium conditioned by A431 human epidermoid carcinoma cells. This protein, designated HBpl7, was found to bind the heparin-binding peptide growth factors HBGF-1 and HBGF-2 in a non-covalent, reversible manner. In addition HBp17 was found to inhibit the biological activities of both HBGF-1 and HBGF-2. Both the binding and inactivation of HBGF-1 and HBGF-2 by HBp17 were abolished by heparin. Full-length 1163-base pair HBp17 cDNA was cloned and sequenced by using the polymerase chain reaction technique. The deduced primary structure of HBp17 consisted of 234 amino acids including each of five partial peptide sequences obtained from proteolytic fragments of purified HBp17. The encoded protein included a 33-residue N-terminal signal sequence for secretion and a single potential N-linked glycosylation site. No homology with any known protein was found for the deduced primary structure of HBp17. The expression of HBp17 mRNA was found to occur preferentially in normal human keratinocytes and in squamous cell carcinomas. This pattern of HBp17 gene expression suggests that this binding protein for HBGFs 1 and 2 has a physiological role in squamous epithelia.	W ALTON JONES CELL SCI CTR INC, 10 OLD BARN RD, LAKE PLACID, NY 12946 USA					NOIRI, Eisei/0000-0002-9515-7582	NCI NIH HHS [CA40294, CA37589] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040294, P01CA037589] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; ADEN DP, 1979, NATURE, V282, P615, DOI 10.1038/282615a0; BAIRD A, 1987, BIOCHEM BIOPH RES CO, V142, P428, DOI 10.1016/0006-291X(87)90292-0; BOHLEN P, 1984, P NATL ACAD SCI-BIOL, V81, P5364, DOI 10.1073/pnas.81.17.5364; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BUSS JE, 1982, P NATL ACAD SCI-BIOL, V79, P2574, DOI 10.1073/pnas.79.8.2574; COHEN KL, 1976, ACTA ENDOCRINOL-COP, V83, P243, DOI 10.1530/acta.0.0830243; CRABB JW, 1988, J BIOL CHEM, V263, P18678; DAMORE PA, 1986, CANCER METASTASIS EX, P269; DENNIS PA, 1989, J BIOL CHEM, V264, P7210; DILLARIO J, 1989, SCIENCE, V244, P688; ESCH F, 1985, P NATL ACAD SCI USA, V82, P6507, DOI 10.1073/pnas.82.19.6507; ESCH F, 1985, BIOCHEM BIOPH RES CO, V133, P554, DOI 10.1016/0006-291X(85)90942-8; FABRICANT RN, 1977, P NATL ACAD SCI USA, V74, P565, DOI 10.1073/pnas.74.2.565; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FOGH J, 1972, HUMAN TUMOR CELL LIN, P115; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GERARD GF, 1986, FOCUS, V8, P3; GIRARD DJ, 1973, JNCI-J NATL CANCER I, V51, P1417; GOSPODAROWICZ D, 1986, MOL CELL ENDOCRINOL, V46, P187, DOI 10.1016/0303-7207(86)90001-8; GOSPODAROWICZ D, 1986, J CELL PHYSIOL, V128, P475, DOI 10.1002/jcp.1041280317; GREENE LA, 1969, BIOCHEMISTRY-US, V8, P3735, DOI 10.1021/bi00837a037; HALABAN R, 1988, J CELL BIOL, V107, P1611, DOI 10.1083/jcb.107.4.1611; HALABAN R, 1987, IN VITRO CELL DEV B, V23, P47; HARPEL PC, 1973, J EXP MED, V138, P508, DOI 10.1084/jem.138.3.508; HINTZ RL, 1977, J CLIN ENDOCR METAB, V45, P988, DOI 10.1210/jcem-45-5-988; HOFFMANN R, 1973, EXP CELL RES, V80, P275, DOI 10.1016/0014-4827(73)90297-8; HOUMARD J, 1972, P NATL ACAD SCI USA, V69, P3506, DOI 10.1073/pnas.69.12.3506; HUANG JS, 1984, P NATL ACAD SCI-BIOL, V81, P342, DOI 10.1073/pnas.81.2.342; HUANG SS, 1988, J BIOL CHEM, V263, P1535; IMBER MJ, 1981, J BIOL CHEM, V256, P8134; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JONES HW, 1971, OBSTET GYNECOL, V38, P945; KAN M, 1989, P NATL ACAD SCI USA, V86, P7432, DOI 10.1073/pnas.86.19.7432; KAN M, 1988, J BIOL CHEM, V263, P11306; KANZAKI T, 1990, CELL, V61, P1051, DOI 10.1016/0092-8674(90)90069-Q; KLAGSBRUN M, 1986, P NATL ACAD SCI USA, V83, P2448, DOI 10.1073/pnas.83.8.2448; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASFARGUES EY, 1958, J NATL CANCER I, V21, P1131; LOBB RR, 1985, BIOCHEMISTRY-US, V24, P4969, DOI 10.1021/bi00340a001; LOMANT AJ, 1976, J MOL BIOL, V104, P243, DOI 10.1016/0022-2836(76)90011-5; MASUDA Y, 1987, CELL BIOL INT REP, V11, P359, DOI 10.1016/0309-1651(87)90002-6; MONTESANO R, 1986, P NATL ACAD SCI USA, V83, P7297, DOI 10.1073/pnas.83.19.7297; MOSES AC, 1976, NATURE, V263, P137, DOI 10.1038/263137a0; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; OCONNORMCCOURT MD, 1987, J BIOL CHEM, V262, P14090; OKAMOTO T, 1987, IN VITRO CELL DEV B, V23, pA41; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RHEINWALD JG, 1981, CANCER RES, V41, P1657; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHREIBER AB, 1985, P NATL ACAD SCI USA, V82, P6138, DOI 10.1073/pnas.82.18.6138; SCHWEIGERER L, 1987, NATURE, V325, P257, DOI 10.1038/325257a0; SHING Y, 1985, J CELL BIOCHEM, V29, P275, DOI 10.1002/jcb.240290402; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SHIPLEY GD, 1989, J CELL PHYSIOL, V138, P511, DOI 10.1002/jcp.1041380310; SMITH AP, 1968, BIOCHEMISTRY-US, V7, P3259, DOI 10.1021/bi00849a032; SOULE HD, 1973, J NATL CANCER I, V51, P1409, DOI 10.1093/jnci/51.5.1409; STONE KR, 1978, INT J CANCER, V21, P274, DOI 10.1002/ijc.2910210305; SYKES JA, 1970, J NATL CANCER I, V45, P107; TAYLOR JM, 1974, J BIOL CHEM, V249, P3198; TAYLOR JM, 1970, P NATL ACAD SCI USA, V67, P164, DOI 10.1073/pnas.67.1.164; THOMAS KA, 1984, P NATL ACAD SCI-BIOL, V81, P357, DOI 10.1073/pnas.81.2.357; THOMAS KA, 1986, TRENDS BIOCHEM SCI, V11, P81, DOI 10.1016/0968-0004(86)90271-9; VLODAVSKY I, 1987, P NATL ACAD SCI USA, V84, P2292, DOI 10.1073/pnas.84.8.2292; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WATSON MEE, 1984, NUCLEIC ACIDS RES, V12, P5145, DOI 10.1093/nar/12.13.5145; WU DG, 1989, J BIOL CHEM, V264, P17469; ZAPF J, 1975, ARCH BIOCHEM BIOPHYS, V168, P638, DOI 10.1016/0003-9861(75)90296-9	75	110	118	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16778	16785						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885605				2022-12-25	WOS:A1991GD63500084
J	CHRISTIE, DL; BATCHELOR, DC; PALMER, DJ				CHRISTIE, DL; BATCHELOR, DC; PALMER, DJ			IDENTIFICATION OF KEX2-RELATED PROTEASES IN CHROMAFFIN GRANULES BY PARTIAL AMINO-ACID-SEQUENCE ANALYSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOBE SECRETORY VESICLES; TWO-DIMENSIONAL GELS; PROCESSING ENZYME; ADRENAL-MEDULLA; CONVERTING ENZYME; MEMBRANE-PROTEINS; PURIFICATION; PROHORMONE; YEAST; ENDOPEPTIDASE	We have characterized glycoprotein H (GpH) from bovine adrenal medullary chromaffin granules. Two-dimensional gel electrophoresis was used to purify GpH from an insoluble fraction obtained following extraction of chromaffin granule membranes with lithium diiodosalicylate. The GpH material was recovered from two-dimensional gel spots by concentration and recovery on a one-dimensional gel followed by electro-blotting to a poly(vinylidene difluoride) membrane. This material was subjected to in situ tryptic digestion. The released peptides were purified by microbore high performance liquid chromatography and sequenced. The peptide sequences revealed extensive similarity to the mammalian kex2/subtilisin-related proteases (PC2 and PC3) which have been characterized recently by molecular cloning and sequence analysis (Smeekens, S. P., and Steiner, D. F. (1990) J. Biol. Chem. 265, 2997-3000; Smeekens, S. P., Avruch, A. S., La-Mendola, J., Chan, S. J., and Steiner, D. F. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 340-344). The sequence similarity included regions that contain residues equivalent to the aspartic acid and histidine residues which are involved in the active site of the subtilisin family of serine proteases. The sequence data revealed the presence of tryptic peptides derived from both PC2 and PC3. NH2-terminal sequence analysis of GpH gave two sequences which were aligned with residues 110-121 of PC2 and PC3. It is likely that these sequences represent the mature form of PC2 and PC3 in chromaffin granules. These forms would be generated by cleavage at a site which is conserved in mammalian kex2-related enzymes and which would result in the release of approximately 80-residue pro-peptides. It was concluded that the spot identified as GpH by two-dimensional gel electrophoresis contains the bovine counterparts of both PC2 and PC3. The direct identification of these components in chromaffin granules supports their role in the processing of protein precursors.			CHRISTIE, DL (corresponding author), UNIV AUCKLAND,DEPT BIOCHEM,PRIVATE BAG,AUCKLAND,NEW ZEALAND.		Christie, David L/C-8065-2009					AEBERSOLD RH, 1987, P NATL ACAD SCI USA, V84, P6970, DOI 10.1073/pnas.84.20.6970; BAUW G, 1989, P NATL ACAD SCI USA, V86, P7701, DOI 10.1073/pnas.86.20.7701; BIRCH NP, 1987, J BIOL CHEM, V262, P3382; BIRCHNP, 1986, J BIOL CHEM, V261, P12213; CHRISTIE DL, 1990, BIOCHEM J, V270, P57, DOI 10.1042/bj2700057; DAVIDSON HW, 1988, NATURE, V333, P93, DOI 10.1038/333093a0; DOCHERTY K, 1982, ANNU REV PHYSIOL, V44, P625, DOI 10.1146/annurev.ph.44.030182.003205; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; HOOK VYH, 1985, J NEUROCHEM, V45, P987, DOI 10.1111/j.1471-4159.1985.tb04094.x; HUNKAPILLER MW, 1983, METHOD ENZYMOL, V91, P227; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; LASLOP A, 1986, NEUROSCI LETT, V72, P300, DOI 10.1016/0304-3940(86)90530-6; LINDBERG I, 1990, ENDOCRINOLOGY, V126, P480, DOI 10.1210/endo-126-1-480; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; LOH YP, 1985, J BIOL CHEM, V260, P7194; MARET GE, 1988, ANAL BIOCHEM, V172, P248, DOI 10.1016/0003-2697(88)90439-3; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MIZUNO K, 1985, BIOCHEM BIOPH RES CO, V128, P884, DOI 10.1016/0006-291X(85)90129-9; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; PALMER DJ, 1990, J BIOL CHEM, V265, P6617; PARISH DC, 1986, J BIOL CHEM, V261, P4392; PRYDE JG, 1986, BIOCHEM J, V233, P525, DOI 10.1042/bj2330525; RHODESCJ, 1989, J BIOL CHEM, V264, P14240; SMEEKENS SP, 1991, P NATL ACAD SCI USA, V88, P340, DOI 10.1073/pnas.88.2.340; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; THIM L, 1986, P NATL ACAD SCI USA, V83, P6766, DOI 10.1073/pnas.83.18.6766; THOMAS G, 1988, SCIENCE, V241, P226, DOI 10.1126/science.3291117; UDENFRIEND S, 1983, ARCH BIOCHEM BIOPHYS, V221, P309, DOI 10.1016/0003-9861(83)90149-2; UDENFRIENDS, 1953, SCIENCE, V117, P663; WALSH MJ, 1988, BIOCHEMISTRY-US, V27, P6867, DOI 10.1021/bi00418a032; WINKLER H, 1990, NEUROCHEM INT, V17, P245, DOI 10.1016/0197-0186(90)90147-L; WINKLER H, 1986, NEUROSCIENCE, V18, P261, DOI 10.1016/0306-4522(86)90154-5	32	93	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15679	15683						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874725				2022-12-25	WOS:A1991GB97700026
J	KUHLMANN, MK; VADGAMA, JV				KUHLMANN, MK; VADGAMA, JV			CHARACTERIZATION OF THREONINE TRANSPORT INTO A KIDNEY EPITHELIAL-CELL LINE (BSC-1) - EVIDENCE FOR THE PRESENCE OF NA+-INDEPENDENT SYSTEM ASC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-TRANSPORT; HORSE ERYTHROCYTES; HARMALINE INHIBITION; RAT HEPATOCYTES; CULTURES; MATURATION; LIVER; SITES; ION	The transport routes for threonine in a primate kidney epithelia cell line (BSC-1) grown as monolayer continuous cell culture were studied. We discovered at least four different transport systems for threonine uptake. The Na+-dependent route shows biphasic kinetics with a low and high affinity parameter. The apparent kinetic constants for K(m1) and K(m2) were 0.3 and 36 mM with apparent V(max) values of 6.3 and 90 nmol/mg protein/min, respectively. The high affinity, low K(m) component resembles system ASC activity, with respect to substrate selectivity. The Na+-independent route also exhibits biphasic kinetics. A high affinity component (apparent K(m) of 1.0 mM, and apparent V(max) of 7.2 nmol/mg protein/min) is sensitive to inhibition by leucine and the aminoendolevo-rotatory isomer of 2-aminobicyclo[2,2,1]heptane-2-carboxylic acid, suggesting participation by system L. The low affinity component (apparent K(m) of 10.2 mM, and apparent V(max) of 71 nmol/mg protein/min) was specifically inhibited by threonine, serine, and alanine and could be assigned to system asc. The discrimination between system L and asc is based upon differences in pH sensitivity, trans stimulation, and K(i) values. In addition, the effects of harmaline, a suspected sodium transport site inhibitor, have been studied. Harmaline noncompetitively inhibited Na+-dependent threonine uptake but had no effect on Na+-independent transport of threonine. This report is the first to present evidence for the presence of system asc in renal epithelial cells. The physiological and biochemical significance of our findings are discussed.	UNIV CALIF LOS ANGELES, LOS ANGELES CTY HARBOR MED CTR,SCH MED,DEPT MED, DIV NEPHROL, TORRANCE, CA 90509 USA; UNIV CALIF LOS ANGELES, LOS ANGELES CTY HARBOR MED CTR,SCH PUBL HLTH, DEPT PEDIAT,DIV MED GENET, TORRANCE, CA 90509 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK039147] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK39147] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1980, AM J PHYSIOL, V238, pF210, DOI 10.1152/ajprenal.1980.238.3.F210; BOERNER P, 1986, J BIOL CHEM, V261, P13957; BOERNER P, 1982, J CELL PHYSIOL, V113, P240, DOI 10.1002/jcp.1041130209; CANESSA M, 1973, J MEMBRANE BIOL, V13, P263, DOI 10.1007/BF01868232; CHRISTENSEN HN, 1984, BIOCHIM BIOPHYS ACTA, V779, P255, DOI 10.1016/0304-4157(84)90012-1; CHRISTENSEN HN, 1967, J BIOL CHEM, V242, P5237; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1981, BIOCHEM BIOPH RES CO, V98, P102, DOI 10.1016/0006-291X(81)91875-1; CHRISTENSEN HN, 1983, J MED CHEM, V26, P1374, DOI 10.1021/jm00364a008; Cleland W W, 1979, Methods Enzymol, V63, P103; DUNN MJ, 1975, J PHARMACOL EXP THER, V193, P903; FINCHAM DA, 1987, J PHYSIOL-LONDON, V389, P385, DOI 10.1113/jphysiol.1987.sp016662; FINCHAM DA, 1985, BIOCHEM J, V227, P13, DOI 10.1042/bj2270013; HOPPS HE, 1963, J IMMUNOL, V91, P416; JENTSCH TJ, 1985, J BIOL CHEM, V260, P5554; JONES DP, 1990, KIDNEY INT, V38, P219, DOI 10.1038/ki.1990.189; KILBERG MS, 1980, J BIOL CHEM, V255, P4011; KILBERG MS, 1981, J BIOL CHEM, V256, P3304; LECAM A, 1977, J BIOL CHEM, V252, P148; LEIGHTON J, 1969, SCIENCE, V163, P472, DOI 10.1126/science.163.3866.472; LOWRY OH, 1951, J BIOL CHEM, V193, P265; OXENDER DL, 1963, J BIOL CHEM, V238, P3686; RABITO CA, 1982, J BIOL CHEM, V257, P6802; ROSENBERG R, 1980, BIOCHIM BIOPHYS ACTA, V598, P374; SEPULVEDA FV, 1982, J CELL PHYSIOL, V112, P182, DOI 10.1002/jcp.1041120205; SHOTWELL MA, 1981, J BIOL CHEM, V256, P5422; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; THOMAS EL, 1970, BIOCHEM BIOPH RES CO, V40, P277, DOI 10.1016/0006-291X(70)91006-5; THOMAS EL, 1971, J BIOL CHEM, V246, P1682; UNGER RH, 1991, SCIENCE, V251, P1200, DOI 10.1126/science.2006409; VADGAMA JV, 1983, J BIOL CHEM, V258, P6422; VADGAMA JV, 1984, J BIOL CHEM, V259, P3648; VADGAMA JV, 1985, ANN NY ACAD SCI, V456, P454, DOI 10.1111/j.1749-6632.1985.tb14900.x; VADGAMA JV, 1987, J BIOL CHEM, V262, P13273; VADGAMA JV, 1985, J BIOL CHEM, V260, P2912; VADGAMA JV, 1989, FASEB J, V3, pA1060; VADGAMA JV, 1984, FED PROC, V43, P1776; VADGAMA JV, 1989, METHOD ENZYMOL, V171, P133; VANWINKLE LJ, 1988, J BIOL CHEM, V263, P3150; WEISSBACH L, 1982, J BIOL CHEM, V257, P2006; WHITE MF, 1982, J BIOL CHEM, V257, P4443; YOUNG JD, 1975, NATURE, V254, P156, DOI 10.1038/254156a0; YOUNG JD, 1988, J BIOL CHEM, V263, P140	43	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15042	15047						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1907970				2022-12-25	WOS:A1991GB09700039
J	FAUSTINELLA, F; CHANG, A; VANBIERVLIET, JP; ROSSENEU, M; VINAIMONT, N; SMITH, LC; CHEN, SH; CHAN, L				FAUSTINELLA, F; CHANG, A; VANBIERVLIET, JP; ROSSENEU, M; VINAIMONT, N; SMITH, LC; CHEN, SH; CHAN, L			CATALYTIC TRIAD RESIDUE MUTATION (ASP156-]GLY) CAUSING FAMILIAL LIPOPROTEIN-LIPASE DEFICIENCY - CO-INHERITANCE WITH A NONSENSE MUTATION (SER447-]TER) IN A TURKISH FAMILY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED IMMUNOSORBENT-ASSAY; PANCREATIC LIPASE; QUANTITATIVE-DETERMINATION; MONOCLONAL-ANTIBODIES; MISSENSE MUTATION; COMPLEMENTARY-DNA; HEPATIC LIPASE; GENE; PLASMA; SITE	We studied the molecular basis of familial Type I hyperlipoproteinemia in two brothers of Turkish descent who had normal plasma apolipoprotein C-II levels and undetectable plasma post-heparin lipoprotein lipase (LPL) activity. We cloned the cDNAs of LPL mRNA from adipose tissue biopsies obtained from these individuals by the polymerase chain reaction and directional cloning into M13 vectors. Direct sequencing of pools of > 2000 cDNA clones indicates that their LPL mRNA contains two mutations: a missense mutation changing codon 156 from GAU to GGU predicting an Asp156 --> Gly substitution and a nonsense mutation changing the codon for Ser447 from UCA to UGA, a stop codon, predicting a truncated LPL protein that contains 446 instead of 448 amino acid residues. Both patients were homozygous for both mutations. Analysis of genomic DNAs of the patients and their family members by the polymerase chain reaction, restriction enzyme digestion (the GAT --> GGT mutation abolishes a TaqI restriction site), and allele-specific oligonucleotide hybridization confirms that the patients were homozygous for these mutations at the chromosomal level, and the clinically unaffected parents and sibling were true obligate heterozygotes for both mutations. In order to examine the functional significance of the mutations in this family, we expressed wild type and mutant LPLs in vitro using a eukaryotic expression vector. Five types of LPL proteins were produced in COS cells by transient transfection: (i) wild type LPL, (ii) Asp156 --> Gly mutant, (iii) Ser447 --> Ter mutant, (iv) Gly448 --> Ter mutant, and (v) Asp156 --> Gly/Ser447 --> Ter double mutant. Both LPL immunoreactive mass and enzyme activity were determined in the culture media and intracellularly. Immunoreactive LPLs were produced in all cases. The mutant LPLs, Asp156 --> Gly and Asp156 --> Gly/Ser447 --> Ter, were devoid of enzyme activity, indicating that the Asp156 --> Gly mutation is the underlying defect for the LPL deficiency in the two patients. The two mutant LPLs missing a single residue (Gly448) or a dipeptide (Ser447-Gly448) from its carboxyl terminus had normal enzyme activity. Thus, despite its conservation among all mammalian LPLs examined to date, the carboxyl terminus of LPL is not essential for enzyme activity. We further screened 224 unrelated normal Caucasians for the Ser447 --> Ter mutation and found 36 individuals who were heterozygous and one individual who was homozygous for this mutation, indicating that it is a sequence polymorphism of no functional significance. Human LPL shows high homology to hepatic triglyceride lipase and pancreatic lipase. The crystal structure of human pancreatic lipase (Winkler, F. K., D'Arcy, A., and Hunziker, W. (1990) Nature 343, 771-774) reveals that the enzyme contains an Asp-His-Ser catalytic triad which is chemically analogous to that in the serine proteases. By sequence alignment to pancreatic lipase, the homologous catalytic triad in human LPL corresponds to Asp156-His241-Ser132. The totally inactive Asp156 --> Gly LPL mutant described in this study is the first naturally occurring mutant reported that involves a catalytic triad residue among the lipases and serine proteases. It gives strong support for the essential role of Asp156 in enzyme catalysis.	BAYLOR UNIV, DEPT CELL BIOL, 1 BAYLOR PLAZA, HOUSTON, TX 77030 USA; METHODIST HOSP, HOUSTON, TX 77030 USA; ALGEMEEN ZICKHUIS ST JAN, DEPT PEDIAT, B-8000 Brugge, BELGIUM; ALGEMEEN ZICKHUIS ST JAN, DEPT CLIN BIOCHEM, B-8000 Brugge, BELGIUM	Baylor College of Medicine; Baylor University; The Methodist Hospital System; The Methodist Hospital - Houston					NHLBI NIH HHS [HL16512, HL15648] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL015648, R37HL016512, R01HL016512] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLAIN CC, 1974, CLIN CHEM, V20, P470; AMEIS D, 1991, J CLIN INVEST, V87, P1165, DOI 10.1172/JCI115114; BEG OU, 1990, P NATL ACAD SCI USA, V87, P3474, DOI 10.1073/pnas.87.9.3474; BLOW D, 1990, NATURE, V343, P694, DOI 10.1038/343694a0; BRADY L, 1990, NATURE, V343, P767, DOI 10.1038/343767a0; Brunzell JD, 1989, METABOLIC BASIS INHE, P1165; BUCOLO G, 1973, CLIN CHEM, V19, P476; BURY J, 1985, J CLIN CHEM CLIN BIO, V23, P63; BURY J, 1986, J CLIN CHEM CLIN BIO, V24, P457; BURY J, 1986, CLIN CHEM, V32, P265; CAI SJ, 1989, BIOCHEMISTRY-US, V28, P8966, DOI 10.1021/bi00449a002; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAIK CS, 1987, SCIENCE, V237, P909, DOI 10.1126/science.3303334; DATTA S, 1988, J BIOL CHEM, V263, P1107; DEEB SS, 1989, BIOCHEMISTRY-US, V28, P4132, DOI 10.1021/bi00436a001; DEVLIN RH, 1990, AM J HUM GENET, V46, P112; DICHEK HL, 1991, J BIOL CHEM, V266, P473; EMI M, 1990, J BIOL CHEM, V265, P5910; EMI M, 1990, AM J HUM GENET, V47, P107; HATA A, 1990, NUCLEIC ACIDS RES, V18, P5407, DOI 10.1093/nar/18.18.5407; HATA A, 1990, AM J HUM GENET, V47, P721; HENDERSON HE, 1990, MOL BIOL MED, V7, P511; KIRCHGESSNER TG, 1989, P NATL ACAD SCI USA, V86, P9647, DOI 10.1073/pnas.86.24.9647; LABEUR C, 1989, CLIN CHEM, V35, P1380; LABEUR C, 1990, CLIN CHEM, V36, P591; LANGLOIS S, 1989, P NATL ACAD SCI USA, V86, P948, DOI 10.1073/pnas.86.3.948; MICHELSON O, 1977, ANAL CHEM, V29, P60; MICKEL FS, 1989, J BIOL CHEM, V264, P12895; MONSALVE MV, 1990, J CLIN INVEST, V86, P728, DOI 10.1172/JCI114769; PERSSON B, 1989, EUR J BIOCHEM, V179, P39, DOI 10.1111/j.1432-1033.1989.tb14518.x; ROSSENEU M, 1984, CLIN CHEM, V30, P234; ROSSENEU M, 1988, CLIN CHEM, V34, P739; ROSSENEU M, 1981, ANAL BIOCHEM, V116, P204, DOI 10.1016/0003-2697(81)90345-6; ROSSENEU M, 1981, CLIN CHEM, V27, P856; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SEMENKOVICH CF, 1989, J BIOL CHEM, V264, P9030; SEMENKOVICH CF, 1989, J LIPID RES, V30, P423; SEMENKOVICH CF, 1990, J BIOL CHEM, V265, P5429; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; VOYTA JC, 1985, J BIOL CHEM, V260, P893; WINKLER FK, 1990, NATURE, V343, P771, DOI 10.1038/343771a0; WION KL, 1987, SCIENCE, V235, P1638, DOI 10.1126/science.3823907; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YANG CY, 1989, J BIOL CHEM, V264, P16822	45	105	107	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14418	14424						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907278				2022-12-25	WOS:A1991FZ35100049
J	NISHIYAMA, M; SHIMADA, K; HORINOUCHI, S; BEPPU, T				NISHIYAMA, M; SHIMADA, K; HORINOUCHI, S; BEPPU, T			ROLE OF THREONINE-190 IN MODULATING THE CATALYTIC FUNCTION OF MALATE-DEHYDROGENASE FROM A THERMOPHILE THERMUS-FLAVUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; SEQUENCE; MITOCHONDRIAL	Random mutagenesis of malate dehydrogenase from a thermophilic bacterium, Thermus flavus AT-62, had revealed that a Thr190 --> Ile replacement near the essential catalytic residue His187 caused marked modulation of the catalytic properties. For further exploration of a role of the residue at this position, this residue was substituted with each of the other amino acids by site-directed mutagenesis. Most of the mutations except for substitution with Ser caused increases in K(m) for oxaloacetate and increases K(i) for oxaloacetate of 2-110 times. Substitution with His or Pro was characterized by the complete loss of substrate inhibition, along with a marked increase in K(m) for oxaloacetate. Kinetic analyses of the native and altered malate dehydrogenases at various pHs revealed that both K(m) and K(i) for oxaloacetate decreased proportionally to the decrease in pH from 8.40 to 5.75, whereas k(cat) was nearly constant within the pH range. Apparent shifts of the optimum pH values toward acidity observed with most of the altered malate dehydrogenases were attributed to the increase in K(i), which facilitated the release from the substrate inhibition at a lower pH. Replacement of Thr310, a possible counterpart with which Thr190 forms a hydrogen bond, by Ile caused changes in the catalytic properties similar to those of the Thr190-substituted enzymes. These results suggest that not only the loss of the hydrogen bond between Thr190 and Thr310 but also properties of the residues introduced at position 190 cause modulation of the catalytic properties, probably through dislocation of the loop structure that contains the catalytic residue His187.			NISHIYAMA, M (corresponding author), UNIV TOKYO,DEPT AGR CHEM,YAYOI 1-1-1,BUNKYO KU,TOKYO 113,JAPAN.			Nishiyama, Makoto/0000-0001-8143-8052				BERNSTEIN LH, 1978, J BIOL CHEM, V253, P8697; BIRKTOFT JJ, 1989, BIOCHEMISTRY-US, V28, P6065, DOI 10.1021/bi00440a051; BIRKTOFT JJ, 1982, P NATL ACAD SCI-BIOL, V79, P6166, DOI 10.1073/pnas.79.20.6166; Cleland W W, 1979, Methods Enzymol, V63, P103; FERSHT AR, 1974, PROC R SOC SER B-BIO, V187, P397, DOI 10.1098/rspb.1974.0084; IIJIMA S, 1980, BIOCHIM BIOPHYS ACTA, V613, P1, DOI 10.1016/0005-2744(80)90185-0; JOH T, 1987, J BIOL CHEM, V262, P15127; Johnson WC., 1939, ANAL LOND, V64, P490, DOI DOI 10.1039/AN9396400490; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; NISHIYAMA M, 1986, J BIOL CHEM, V261, P14178; NORGARD MV, 1978, GENE, V3, P279, DOI 10.1016/0378-1119(78)90038-0; SANGER F, 1981, SCIENCE, V214, P1205, DOI 10.1126/science.7302589; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8749, DOI 10.1093/nar/13.24.8749; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8764	17	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14294	14299						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907277				2022-12-25	WOS:A1991FZ35100030
J	COULIER, F; BATOZ, M; MARICS, I; DELAPEYRIERE, O; BIRNBAUM, D				COULIER, F; BATOZ, M; MARICS, I; DELAPEYRIERE, O; BIRNBAUM, D			PUTATIVE STRUCTURE OF THE FGF6 GENE-PRODUCT AND ROLE OF THE SIGNAL PEPTIDE	ONCOGENE			English	Article							FIBROBLAST GROWTH-FACTOR; FACTOR RECEPTOR GENES; NUCLEOTIDE-SEQUENCE; ACID SEQUENCES; FACTOR FAMILY; CELL-GROWTH; EXPRESSION; MESODERM; INT-2; HST	The human FGF6 gene is an oncogene related by sequence similarities to the fibroblast growth factor (FGF) gene family, which encodes mitogenic peptides implicated in various physiological processes including angiogenesis, morphogenesis, tissue regeneration and survival and oncogenesis. Nucleotide sequence analysis of the FGF6 gene and of cDNA clones revealed an open reading frame able to code for a protein of 208 residues. The FGF6 protein shares 32-70% residues with the other members of the family within the C-terminal two-thirds of the molecule. In vitro, three in-frame ATG codons are able to initiate the translation of three peptides of 175, 198 and 208 residues. These three peptides differ at their amino termini with respect to the relative position of a hydrophobic leader peptide, which extends from residues 16 to 40, and is therefore absent from the shorter (175 amino acids) form. In-vitro analysis indicates that this signal peptide is able to drive the FGF6 protein through the endoplasmic reticulum, where it becomes glycosylated. The presence of this signal peptide sequence appears essential for the in vivo transforming capacity of the FGF6 gene.			COULIER, F (corresponding author), INSERM, UNITE 119, 27 BD LEI ROURE, F-13009 MARSEILLE, FRANCE.		Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773				ABRAHAM JA, 1986, EMBO J, V5, P2523, DOI 10.1002/j.1460-2075.1986.tb04530.x; ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; ANDERSON KJ, 1988, NATURE, V332, P360, DOI 10.1038/332360a0; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BLAM SB, 1988, ONCOGENE, V3, P129; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; BROWDER TM, 1989, MOL CELL BIOL, V9, P204, DOI 10.1128/MCB.9.1.204; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; DELAPEYRIERE O, 1990, ONCOGENE, V5, P823; DICKSON C, 1987, NATURE, V326, P833, DOI 10.1038/326833a0; DIMARIO J, 1989, SCIENCE, V244, P688, DOI 10.1126/science.2717945; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; ENSOLI B, 1989, CANCER CELL-MON REV, V1, P93; FASANO O, 1984, MOL CELL BIOL, V4, P1695, DOI 10.1128/MCB.4.9.1695; FENG DF, 1985, J MOL EVOL, V21, P112, DOI 10.1007/BF02100085; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; GOLDFARB M, 1990, CELL GROWTH DIFFER, V1, P439; GOSPODAROWICZ D, 1987, J CELL PHYSIOL, P15; HANNINK M, 1984, SCIENCE, V226, P1197, DOI 10.1126/science.6095451; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOUSSAINT E, 1990, P NATL ACAD SCI USA, V87, P8180, DOI 10.1073/pnas.87.20.8180; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; KEESEY J, 1987, BIOCH INFORMATION; KIEFER MC, 1990, P NATL ACAD SCI USA, V87, P6985, DOI 10.1073/pnas.87.18.6985; KIMELMAN D, 1988, SCIENCE, V242, P1053, DOI 10.1126/science.3194757; KIMELMAN D, 1987, CELL, V51, P869, DOI 10.1016/0092-8674(87)90110-3; Klagsbrun M, 1990, CURR OPIN CELL BIOL, V2, P857, DOI 10.1016/0955-0674(90)90084-R; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARICS I, 1989, ONCOGENE, V4, P335; MERLO GR, 1990, CELL GROWTH DIFFER, V1, P463; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; PATERNO GD, 1989, DEVELOPMENT, V106, P79; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; QUARTO N, 1989, ONCOGENE RES, V5, P101; ROGELJ S, 1988, NATURE, V331, P173, DOI 10.1038/331173a0; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUTA M, 1988, ONCOGENE, V3, P9; Sambrook J, 1989, MOL CLONING LABORATO; SLACK JMW, 1987, NATURE, V326, P197, DOI 10.1038/326197a0; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; TALARICO D, 1991, MOL CELL BIOL, V11, P1138, DOI 10.1128/MCB.11.2.1138; THEILLET C, 1989, ONCOGENE, V4, P915; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; XERRI L, 1991, AM J PATHOL, V138, P9; YAYON A, 1990, P NATL ACAD SCI USA, V87, P5346, DOI 10.1073/pnas.87.14.5346; YOSHIDA T, 1987, P NATL ACAD SCI USA, V84, P7305, DOI 10.1073/pnas.84.20.7305; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZHOU DJ, 1988, ONCOGENE, V2, P279; ZUKER M, 1981, NUCLEIC ACIDS RES, V9, P133, DOI 10.1093/nar/9.1.133	57	11	18	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	1991	6	8					1437	1444						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886714				2022-12-25	WOS:A1991GX27200021
J	DARLAND, T; SAMUELS, M; EDWARDS, SA; SUKHATME, VP; ADAMSON, ED				DARLAND, T; SAMUELS, M; EDWARDS, SA; SUKHATME, VP; ADAMSON, ED			REGULATION OF EGR-1 (ZFP-6) AND C-FOS EXPRESSION IN DIFFERENTIATING EMBRYONAL CARCINOMA-CELLS	ONCOGENE			English	Article							GENE-EXPRESSION; PROTO-ONCOGENE; 3T3 CELLS; TRANSCRIPTIONAL ACTIVATION; CULTURED-CELLS; GROWTH-FACTORS; ENCODES; SERUM; JUN; PRODUCT	The Egr-1 gene (zfp-6) encodes a 'zinc finger'-type transcription factor that is one of the early growth response genes induced, together with c-fos proto-oncogene, in many cell types. Our earlier work indicated that Egr-1 and c-fos may also play roles in differentiation and we now present data to show some features of their regulation. Transcriptional regulation accounts at least partly for the increased steady-state levels of Egr-1 mRNA in differentiating teratocarcinoma cells; this rate increases threefold over the 7-10 days of differentiation of P]9 embryonal carcinoma cells with both 0.5% DMSO (to give predominantly cardiac muscle) and 1-mu-M retinoic acid (to give nerve and glial cells). The stability of Egr-1 transcripts remains the same (T1/2 = 90 min) in undifferentiated EC and differentiated cell products. In contrast, transcripts for c-fos are barely detectable in EC cells and increase 20-fold during differentiation. The basis for this is a marked increase in stability of c-fos mRNA after differentiation. The protein products of both genes parallel the steady-state levels of their mRNAs, but both proteins become more stable in differentiated cells. This is particularly marked for c-Fos protein, which appears as a distinct 58 kDa species in terminally differentiated P19 cells. Both Egr-1 and c-Fos proteins remain at high constitutive levels in differentiated cells indicating a distinct role for these transcription factors. For instance, it appears that this form of Fos protein may not repress the synthesis of the Egr-1 gene as it does during transient expression of serum-stimulated genes.	LA JOLLA CANC RES FDN,10901 N TORREY PINES RD,LA JOLLA,CA 92037; MEHARRY MED COLL,NASHVILLE,TN 37208; UNIV CHICAGO,HOWARD HUGHES MED INST,CHICAGO,IL 60637	Sanford Burnham Prebys Medical Discovery Institute; Meharry Medical College; Howard Hughes Medical Institute; University of Chicago			Sukhatme, Vikas/W-2776-2019		NCI NIH HHS [P30CA 30199] Funding Source: Medline; NICHD NIH HHS [R01 HD 21957] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD021957] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMSON ED, 1984, DIFFERENTIATION, V27, P152, DOI 10.1111/j.1432-0436.1984.tb01421.x; ANDREWS GK, 1987, MOL CELL BIOL, V7, P3452, DOI 10.1128/MCB.7.10.3452; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAPETANAKI Y, 1990, ONCOGENE, V5, P645; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHAVRIER P, 1990, EMBO J, V9, P1209, DOI 10.1002/j.1460-2075.1990.tb08228.x; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CURRAN T, 1984, CELL, V36, P259; DEGROOT RP, 1990, NUCLEIC ACIDS RES, V18, P3195, DOI 10.1093/nar/18.11.3195; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; DUDOV KP, 1984, CELL, V37, P457, DOI 10.1016/0092-8674(84)90376-3; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; EDWARDS SA, 1986, EXP CELL RES, V165, P473, DOI 10.1016/0014-4827(86)90600-2; EDWARDS SA, 1988, DEV BIOL, V129, P91, DOI 10.1016/0012-1606(88)90164-9; EDWARDS SA, 1991, UNPB DEV BIOL; GIUS D, 1990, MOL CELL BIOL, V10, P4243, DOI 10.1128/MCB.10.8.4243; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KASIK JW, 1987, MOL CELL BIOL, V7, P3349, DOI 10.1128/MCB.7.9.3349; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; Maniatis T., 1982, MOL CLONING; MARX JL, 1987, SCIENCE, V237, P854, DOI 10.1126/science.3039659; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCMAHON AP, 1990, DEVELOPMENT, V108, P281; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; PATWARDHAN S, 1991, ONCOGENE, V6, P917; RAUSCHER FJ, 1988, NATURE, V334, P314; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SMITH SC, 1987, J CELL PHYSIOL, V131, P74, DOI 10.1002/jcp.1041310112; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TAYLOR R, 1990, J NIH RES, V2, P49; VERMA IM, 1987, ADV CANCER RES, V49, P29, DOI 10.1016/S0065-230X(08)60793-9; VOSATKA RJ, 1989, J CELL PHYSIOL, V138, P493, DOI 10.1002/jcp.1041380308; WATERS CM, 1990, ONCOGENE, V5, P669	46	47	47	1	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1367	1376						10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1909429				2022-12-25	WOS:A1991GX27200012
J	LUNDQVIST, T; SCHNEIDER, G				LUNDQVIST, T; SCHNEIDER, G			CRYSTAL-STRUCTURE OF ACTIVATED RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE COMPLEXED WITH ITS SUBSTRATE, RIBULOSE-1,5-BISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBULOSE-BISPHOSPHATE CARBOXYLASE; SITE-DIRECTED MUTAGENESIS; RUBRUM RIBULOSEBISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; 3-DIMENSIONAL STRUCTURE; INTERSUBUNIT INTERACTION; QUATERNARY STRUCTURE; FACTOR REFINEMENT; PLANT RUBISCO; SMALL SUBUNIT	The three-dimensional structure of the complex of ribulose-1,5-bisphosphate carboxylase from Rhodospirillum rubrum, CO2, Mg2+, and ribulose bisphosphate has been determined with x-ray crystallographic methods to 2.6-angstrom resolution. Ribulose- 1,5-bisphosphate binds across the active site with the two phosphate groups in the two phosphate binding sites of the beta/alpha-barrel. The oxygen atoms of the carbamate and the side chain of Asp-193 provide the protein ligands to the bound Mg2+ ion. The C2 and the C3 or C4 oxygen atoms of the substrate are also within the first coordination sphere of the metal ion. At the present resolution of the electron density maps, two slightly different conformations of the substrate, with the C3 hydroxyl group "cis" or "trans" to the C2 oxygen, can be built into the observed electron density. The two different conformations suggest two different mechanisms of proton abstraction in the first step of catalysis, the enolization of the ribulose 1,5-bisphosphate. Two loop regions, which are disordered in the crystals of the nonactivated enzyme, could be built into their respective electron density. A comparison with the structure of the quaternary complex of the spinach enzyme shows that despite the different conformations of loop 6, the positions of the Mg2+, ion, and most atoms of the substrate are very similar when superimposed on each other. There are, however, some significant differences at the active site, especially in the metal coordination sphere.	SWEDISH UNIV AGR SCI,CTR BIOMED,DEPT MOLEC BIOL,BOX 590,S-75124 UPPSALA,SWEDEN	Swedish University of Agricultural Sciences				Schneider, Gunter/0000-0003-0622-5713				ALBER T, 1981, PHILOS T ROY SOC B, V293, P159, DOI 10.1098/rstb.1981.0069; ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHAPMAN MS, 1987, NATURE, V329, P354, DOI 10.1038/329354a0; CLELAND WW, 1990, BIOCHEMISTRY-US, V29, P3194, DOI 10.1021/bi00465a006; DESLONGC.P, 1972, CAN J CHEMISTRY, V50, P3405, DOI 10.1139/v72-549; DURBIN RM, 1986, SCIENCE, V232, P1127, DOI 10.1126/science.3704639; HARTMAN FC, 1987, BIOCHEM BIOPH RES CO, V145, P1158, DOI 10.1016/0006-291X(87)91558-0; HARTMAN FC, 1985, J BIOL CHEM, V260, P3968; HARTMAN FC, 1987, J BIOL CHEM, V262, P3496; HARTMAN FC, 1989, J BIOL CHEM, V264, P11784; JAWOROWSKI A, 1984, J BIOL CHEM, V259, P6783; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1982, COMPUTATIONAL CRYSTA, P303; JONES TA, 1990, MOL MODELLING; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KNIGHT S, 1990, J MOL BIOL, V215, P113, DOI 10.1016/S0022-2836(05)80100-7; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; LARIMER FW, 1987, J BIOL CHEM, V262, P15327; LEE EH, 1987, BIOCHEMISTRY-US, V26, P4599, DOI 10.1021/bi00389a001; LORIMER GH, 1981, BIOCHEMISTRY-US, V20, P1236, DOI 10.1021/bi00508a028; LORIMER GH, 1988, J BIOL CHEM, V263, P6468; LORIMER GH, 1989, J BIOL CHEM, V264, P9873; LORIMER GH, 1987, PLANT MOL BIOL, P21; LUNDQVIST T, 1989, J BIOL CHEM, V264, P3643; LUNDQVIST T, 1989, J BIOL CHEM, V264, P7078; MURAL RJ, 1990, J BIOL CHEM, V265, P6501; PAECH C, 1978, BIOCHEM BIOPH RES CO, V83, P1084, DOI 10.1016/0006-291X(78)91506-1; PERIANA RA, 1980, J AM CHEM SOC, V102, P3923, DOI 10.1021/ja00531a040; PIERCE J, 1985, APPL ENVIRON MICROB, V49, P1094, DOI 10.1128/AEM.49.5.1094-1100.1985; PRIESTLE JP, 1988, J APPL CRYSTALLOGR, V21, P572, DOI 10.1107/S0021889888005746; RICHARDS JP, 1984, J AM CHEM SOC, V106, P949; ROSE IA, 1981, PHILOS T ROY SOC B, V293, P131, DOI 10.1098/rstb.1981.0067; SCHNEIDER G, 1986, J MOL BIOL, V187, P141, DOI 10.1016/0022-2836(86)90415-8; SCHNEIDER G, 1990, EMBO J, V9, P2045, DOI 10.1002/j.1460-2075.1990.tb07371.x; SCHNEIDER G, 1986, EMBO J, V5, P3409, DOI 10.1002/j.1460-2075.1986.tb04662.x; SCHNEIDER G, 1990, J MOL BIOL, V211, P989, DOI 10.1016/0022-2836(90)90088-4; SOMMERVILLE RC, 1984, MOL GEN GENET, V193, P214; SOPER TS, 1988, PROTEIN ENG, V2, P39, DOI 10.1093/protein/2.1.39; STEIGEMANN W, 1974, THESIS TU MUNCHEN; STYRING S, 1985, BIOCHEMISTRY-US, V24, P6011, DOI 10.1021/bi00342a048; TABITA FR, 1974, J BIOL CHEM, V249, P3459	45	86	94	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12604	12611						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905726				2022-12-25	WOS:A1991FV18000079
J	CHATTERJEE, D; BOZIC, CM; MCNEIL, M; BRENNAN, PJ				CHATTERJEE, D; BOZIC, CM; MCNEIL, M; BRENNAN, PJ			STRUCTURAL FEATURES OF THE ARABINAN COMPONENT OF THE LIPOARABINOMANNAN OF MYCOBACTERIUM-TUBERCULOSIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL ARABINOGALACTAN; TUMOR-NECROSIS-FACTOR; LEPRAE; PROLIFERATION; RESIDUES; LIPOPOLYSACCHARIDE; ARABINOMANNAN; SUPPRESSION; MACROPHAGES; SMEGMATIS	The recent availability of pure lipoarabinomannan (LAM) from Mycobacterium spp. has resulted in its implication in host-parasite interaction, which events may be mediated by the presence of a phosphatidylinositol unit at the reducing end of LAM. Herein we address the structure of the antigenic, nonreducing end of the molecule. Through the process of C-13 NMR analysis of the whole molecule and gas chromatography/mass spectrometry of alditol acetates derived from the differential per-O-alkylated lipopolysaccharide, the majority of the arabinosyl residues were recognized as furanosides. Second, through analysis of per-O-alkylated oligoarabinosyl arabinitol fragments of partially hydrolyzed LAM, it was established that the internal segments of the arabinan component consists of branched 3,5-linked alpha-D-arabinofuranosyl (Araf) units with stretches of linear 5-linked alpha-D-Araf residues attached at both branch positions, whereas the nonreducing terminal segments of LAM consist of either of the two arrangements, beta-D-Araf-(1 --> 2)-alpha-D-Araf-(1 --> 5)-alpha-D-Araf --> or [beta-D-Araf-(1 --> 2)-alpha-D-Araf-(1 -->]2 --> (3 and 5)-alpha-D-Araf -->. Since this latter arrangement also characterizes the terminal segments of the peptidoglycan-bound arabinogalactan of Mycobacterium spp., we propose that mycobacteria elaborate unique terminal arabinan motifs in two distinct settings. In the case of the bound arabinogalactan, these motifs provide the nucleus for the esterified mycolic acids, entities which dominate the physicochemical features of mycobacteria and their peculiar pathogenesis. In the case of LAM, these motifs, non-mycolylated, are the dominant B-cell antigens responsible for the majority of the copious antibody response evident in most mycobacterial infections.	COLORADO STATE UNIV,DEPT MICROBIOL,FT COLLINS,CO 80523	Colorado State University			McNeil, Michael/G-3325-2019		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI052582, R22AI018357, R37AI018357, R01AI018357] Funding Source: NIH RePORTER; NIAID NIH HHS [N01 AI-52582, AI-18357] Funding Source: Medline; PHS HHS [I-27288] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AZUMA I, 1962, J BIOCHEM-TOKYO, V52, P200, DOI 10.1093/oxfordjournals.jbchem.a127597; BARNES PF, 1990, J IMMUNOL, V145, P149; BRENNAN PJ, 1990, MICROBIAL DETERMINANTS OF VIRULENCE AND HOST RESPONSE, P55; DAFFE M, 1990, J BIOL CHEM, V265, P6734; DANIEL TM, 1984, MYCOBACTERIA SOURCE, P417; DARVILL AG, 1980, CARBOHYD RES, V86, P309, DOI 10.1016/S0008-6215(00)85910-8; ELLNER JJ, 1979, CLIN EXP IMMUNOL, V35, P250; GAYLORD H, 1987, INFECT IMMUN, V55, P2860, DOI 10.1128/IAI.55.11.2860-2863.1987; Goren M.B., 1979, TUBERCULOSIS, P69; GRUBER PR, 1990, CARBOHYD RES, V203, P79, DOI 10.1016/0008-6215(90)80047-7; HUNTER SW, 1990, J BIOL CHEM, V265, P9272; HUNTER SW, 1986, J BIOL CHEM, V261, P2345; KAPLAN G, 1987, J IMMUNOL, V138, P3028; KOTANI S, 1971, BIKEN J, V14, P379; MARKOVITS J, 1969, BIOCHIM BIOPHYS ACTA, V192, P49, DOI 10.1016/0304-4165(69)90008-7; MCNEIL M, 1987, CARBOHYD RES, V166, P299, DOI 10.1016/0008-6215(87)80065-4; MISAKI A, 1977, J BIOCHEM-TOKYO, V82, P1759, DOI 10.1093/oxfordjournals.jbchem.a131874; MOLLOY A, 1990, P NATL ACAD SCI USA, V87, P973, DOI 10.1073/pnas.87.3.973; MORENO C, 1989, CLIN EXP IMMUNOL, V76, P240; MORENO C, 1988, CLIN EXP IMMUNOL, V74, P206; SETO W, 1974, J BIOCHEM-TOKYO, V76, P15; SIBLEY LD, 1988, INFECT IMMUN, V56, P1232, DOI 10.1128/IAI.56.5.1232-1236.1988; VALENT BS, 1980, CARBOHYD RES, V79, P165, DOI 10.1016/S0008-6215(00)83830-6; VILKAS E, 1973, C R ACAD SCI C, V273, P845; WEBER PL, 1979, CARBOHYD RES, V74, P259, DOI 10.1016/S0008-6215(00)84781-3	25	141	143	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9652	9660						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903393				2022-12-25	WOS:A1991FM45900050
J	FORCE, T; HYMAN, G; HAJJAR, R; SELLMAYER, A; BONVENTRE, JV				FORCE, T; HYMAN, G; HAJJAR, R; SELLMAYER, A; BONVENTRE, JV			NONCYCLOOXYGENASE METABOLITES OF ARACHIDONIC-ACID AMPLIFY THE VASOPRESSIN-INDUCED CA2+SIGNAL IN GLOMERULAR MESANGIAL CELLS BY RELEASING CA2+FROM INTRACELLULAR STORES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATES PHOSPHOLIPASE-C; CALCIUM-CONCENTRATION; INOSITOL PHOSPHATES; CA-2+; LIPOXYGENASE; ACTIVATION; IDENTIFICATION; MOBILIZATION; INHIBITION; CHANNELS	Noncyclooxygenase metabolites of arachidonic acid may be potent modulators of the mitogenic response of renal mesangial cells to the mitogenic vasoactive peptide arginine vasopressin (AVP). Since Ca2+ is a critical second messenger in the response of mesangial cells to AVP, and Ca2+ has been implicated in the regulation of growth, we determined whether noncyclooxygenase metabolites altered the phospholipase C-Ca2+ signalling cascade which is activated by AVP. Pretreatment of mesangial cells for 10 min with lipoxygenase and cytochrome P450 monooxygenase inhibitors, nordihydroguaiaretic acid (NDGA, 10(-5) M) or SKF-525A (2.5 x 10(-5) M), but not the cyclooxygenase inhibitor indomethacin (2 x 10(-5) M), reduced the magnitude of the AVP (10(-8) and 10(-7) M)-induced increase in cytosolic free Ca2+ concentration ([Ca2+]i) without affecting inositol trisphosphate production. With 10(-8) M AVP, [Ca2+]i increased to 250 +/- 47 nM in NDGA-treated cells versus 401 +/- 59 nM in control cells (p < 0.01). [Ca2+]i, measured 2 min after exposure to AVP, was also lower with NDGA (152 +/- 21 nM) when compared with AVP alone (220 +/- 22 nM, p < 0.01). 14,15-epoxyeicosatrienoic acid (EET) (10(-8) M), which had no effect on inositol trisphosphate production, completely reversed the NDGA-induced inhibition of the [Ca2+]i transient, whereas 5-hydroperoxyeicosatetraenoic acid (HPETE) (5 x 10(-7) M) did not. Pretreatment with higher concentrations of 14,15-EET (10(-7)-10(-6) M) markedly potentiated the AVP-induced increase in [Ca2+]i. NDGA-induced inhibition of the AVP-generated [Ca2+]i transient was also observed when cells were incubated in low Ca2+ media ([Ca2+] < 5 x 10(-8) M), suggesting that NDGA pretreatment impaired intracellular release of Ca2+. Since NDGA had no direct effect on inositol 1,4,5-trisphosphate-induced Ca2+ release, we postulated that NDGA blocked production of a metabolite that releases Ca2+ from intracellular stores. 14,15-EET and 15-HPETE, but not 15-hydroxyeicosatetraenoic acid (each at 3 x 10(-7) M), raised [Ca2+]i when added directly to cells in low Ca2+ media. In permeabilized cells 14,15-EET and 15-HPETE (10(-7) M) potently released Ca2+ from intracellular stores. In summary, noncyclooxygenase metabolites of arachidonic acid, and in particular P450 metabolites, are potent endogenous amplifiers of the AVP-induced [Ca2+]i signal by mechanisms not directly involving phospholipase C activation. This effect is mediated, at least in part, by enhanced release of Ca2+ from intracellular storage sites by an inositol 1,4,5-trisphosphate-independent mechanism.	MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	FORCE, T (corresponding author), MASSACHUSETTS GEN HOSP, DEPT PREVENT MED, BOSTON, MA 02114 USA.			Force, Thomas/0000-0002-0450-8659	NIDDK NIH HHS [DK-38452, DK-38165, DK-39773] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039773, R37DK039773, P01DK038452, R01DK038165] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUD L, 1983, J EXP MED, V158, P1836, DOI 10.1084/jem.158.6.1836; BEAUMIER L, 1987, FEBS LETT, V221, P289, DOI 10.1016/0014-5793(87)80942-0; BONVENTRE JV, 1988, J CLIN INVEST, V82, P168, DOI 10.1172/JCI113566; BONVENTRE JV, 1990, J BIOL CHEM, V265, P4934; BONVENTRE JV, 1986, AM J PHYSIOL, V251, pF94, DOI 10.1152/ajprenal.1986.251.1.F94; BONVENTRE JV, 1988, AM J PHYSIOL, V254, pF87, DOI 10.1152/ajprenal.1988.254.1.F87; BORIN ML, 1989, FEBS LETT, V257, P345; BUTTNER N, 1989, NATURE, V342, P553, DOI 10.1038/342553a0; CAPDEVILA J, 1988, ARCH BIOCHEM BIOPHYS, V261, P257, DOI 10.1016/0003-9861(88)90340-2; CHEUNG JY, 1986, AM J PHYSIOL, V251, pF690, DOI 10.1152/ajprenal.1986.251.4.F690; FISCHER TH, 1990, BIOCHIM BIOPHYS ACTA, V1022, P215, DOI 10.1016/0005-2736(90)90117-7; GANZ MB, 1988, AM J PHYSIOL, V255, pF898, DOI 10.1152/ajprenal.1988.255.5.F898; GARRICK R, 1989, BIOCHEM BIOPH RES CO, V162, P626, DOI 10.1016/0006-291X(89)92356-5; GOLIGORSKY MS, 1989, J BIOL CHEM, V264, P16771; GOODWIN JS, 1986, IMMUNOL RES, V5, P233, DOI 10.1007/BF02919204; GRONICH JH, 1988, J BIOL CHEM, V263, P16645; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HIRT DL, 1989, J CLIN INVEST, V84, P1805, DOI 10.1172/JCI114365; HYMAN GA, 1990, J AM SOC NEPHROL, V1, P721; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KIM D, 1989, SCIENCE, V244, P1174, DOI 10.1126/science.2727703; KREISBERG JI, 1982, KIDNEY INT, V22, P355, DOI 10.1038/ki.1982.181; KURACHI Y, 1989, NATURE, V337, P555, DOI 10.1038/337555a0; KUTSKY P, 1983, PROSTAGLANDINS, V26, P13, DOI 10.1016/0090-6980(83)90070-9; MENE P, 1989, AM J PHYSIOL, V256, pF375, DOI 10.1152/ajprenal.1989.256.3.F375; MENE P, 1988, AM J PHYSIOL, V255, pF1059, DOI 10.1152/ajprenal.1988.255.6.F1059; MENE P, 1987, AM J PHYSIOL, V253, pF458, DOI 10.1152/ajprenal.1987.253.3.F458; MONCADA S, 1976, PROSTAGLANDINS, V12, P323, DOI 10.1016/0090-6980(76)90014-9; ONDREY F, 1989, CANCER RES, V49, P1138; PRETUS HA, 1985, PROSTAGLANDINS, V30, P591, DOI 10.1016/0090-6980(85)90023-1; PUTNEY JW, 1989, FASEB J, V3, P1899, DOI 10.1096/fasebj.3.8.2542110; RICHTER C, 1987, BIOCHEM BIOPH RES CO, V143, P609, DOI 10.1016/0006-291X(87)91397-0; SACERDOTI D, 1989, SCIENCE, V243, P388, DOI 10.1126/science.2492116; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pC113, DOI 10.1152/ajpcell.1987.253.1.C113; SCHLONDORFF D, 1987, AM J PHYSIOL, V253, pF464, DOI 10.1152/ajprenal.1987.253.3.F464; SCHWARTZMAN M, 1985, HYPERTENSION, V7, pI136, DOI 10.1161/01.HYP.7.3_Pt_2.I136; SCHWARTZMAN M, 1985, NATURE, V314, P620, DOI 10.1038/314620a0; SCHWARTZMAN ML, 1989, J BIOL CHEM, V264, P11658; SELLMAYER A, 1991, IN PRESS J BIOL CHEM, V266; SETTY BNY, 1987, BIOCHEM BIOPH RES CO, V144, P345; SIMONSON MS, 1989, J CLIN INVEST, V83, P708, DOI 10.1172/JCI113935; SNYDER G, 1986, BIOCHEM BIOPH RES CO, V139, P1188, DOI 10.1016/S0006-291X(86)80303-5; TOHMATSU T, 1989, BIOCHIM BIOPHYS ACTA, V1012, P97, DOI 10.1016/0167-4889(89)90016-5; VACHER P, 1989, AM J PHYSIOL, V257, pE203, DOI 10.1152/ajpendo.1989.257.2.E203; WOLF BA, 1986, J BIOL CHEM, V261, P3501	46	72	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4295	4302						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900289				2022-12-25	WOS:A1991FA69400045
J	WINEGAR, DA; VEDIA, LMY; LAPETINA, EG				WINEGAR, DA; VEDIA, LMY; LAPETINA, EG			ISOPRENYLATION OF RAP2 PROTEINS IN PLATELETS AND HUMAN ERYTHROLEUKEMIA-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; RAS-RELATED PROTEIN; EUKARYOTIC PROTEINS; GENE-PRODUCTS; IDENTIFICATION; P21RAS; ACID	The covalent modification of proteins by isoprenoid derivatives of mevalonic acid was investigated in human platelets, cells that lack the ability to synthesize endogenous cholesterol, and human erythroleukemia (HEL) cells, cholesterol-producing cultured cells derived from megakaryocytes. When washed platelets or HEL cells were incubated with [H-3]mevalonic acid, the radiolabel was incorporated into a distinct group of proteins with molecular masses between 21,000 and 28,000. We have identified one of these proteins as a ras-related rap2 protein based on its immunoreactivity with a polyclonal antiserum raised against purified recombinant rap2b. This anti-rap2 antiserum was used for two-dimensional immunoblotting analysis and immunoprecipitation of mevalonate-labeled rap2 from platelets and HEL cells. These results suggest that rap2 may undergo a series of carboxyl-terminal modifications similar to the p21ras proteins. In addition, it is shown that non-cholesterol-producing cells are capable of incorporating isoprenyl groups into specific proteins.			WINEGAR, DA (corresponding author), BURROUGHS WELLCOME CO,DIV CELL BIOL,RES TRIANGLE PK,NC 27709, USA.							BHULLAR RP, 1990, FEBS LETT, V260, P48, DOI 10.1016/0014-5793(90)80063-O; BOKOCH GM, 1990, BIOCHEM J, V267, P407, DOI 10.1042/bj2670407; BRUENGER E, 1986, BIOCHEM BIOPH RES CO, V139, P209, DOI 10.1016/S0006-291X(86)80100-0; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DERKSEN A, 1973, J BIOL CHEM, V248, P7396; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; ECKLES NE, 1955, J LAB CLIN MED, V46, P359; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FARRELL FX, 1990, NUCLEIC ACIDS RES, V18, P4281, DOI 10.1093/nar/18.14.4281; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GRAND RJA, 1989, BIOCHEM J, V258, P625, DOI 10.1042/bj2580625; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1989, P NATL ACAD SCI USA, V86, P3131, DOI 10.1073/pnas.86.9.3131; LAPETINA EG, 1990, FEBS LETT, V268, P400, DOI 10.1016/0014-5793(90)81293-W; LAZAROWSKI ER, 1990, J BIOL CHEM, V265, P13118; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; MALTESE WA, 1988, J BIOL CHEM, V263, P10104; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; NAGATA K, 1989, J BIOL CHEM, V264, P1700; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; OHMORI T, 1988, BIOCHEM BIOPH RES CO, V157, P670, DOI 10.1016/S0006-291X(88)80302-4; OHMORI T, 1989, J BIOL CHEM, V264, P1877; OHMSTEDE CA, 1990, P NATL ACAD SCI USA, V87, P6527, DOI 10.1073/pnas.87.17.6527; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REPKO EM, 1989, J BIOL CHEM, V264, P9945; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEFTON BM, 1987, J CELL BIOL, V104, P1449, DOI 10.1083/jcb.104.6.1449; SEPPLORENZINO L, 1989, FEBS LETT, V245, P110, DOI 10.1016/0014-5793(89)80202-9; SIESS W, 1990, BIOCHEM BIOPH RES CO, V170, P944, DOI 10.1016/0006-291X(90)92182-Y; VEDIA LMY, 1990, BIOCHEM BIOPH RES CO, V171, P319; WHITE TE, 1990, P NATL ACAD SCI USA, V87, P758, DOI 10.1073/pnas.87.2.758; WINEGAR DA, 1991, IN RESS J BIOLC HEM; ZHANG K, 1990, SCIENCE, V249, P162, DOI 10.1126/science.2115210	46	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4381	4386						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900292				2022-12-25	WOS:A1991FA69400057
J	KAHN, RA; KERN, FG; CLARK, J; GELMANN, EP; RULKA, C				KAHN, RA; KERN, FG; CLARK, J; GELMANN, EP; RULKA, C			HUMAN ADP-RIBOSYLATION FACTORS - A FUNCTIONALLY CONSERVED FAMILY OF GTP-BINDING PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLERA-TOXIN; ADENYLATE-CYCLASE; MAMMALIAN-CELLS; REGULATORY COMPONENT; NUCLEOTIDE-BINDING; STABLE REPLICATION; RNA-POLYMERASE; EXPRESSION; SEQUENCES; COFACTOR	A new member, hARF4, of the ADP-ribosylation factor (ARF) family, a subset of the superfamily of regulatory GTP-binding proteins, has been cloned from a cDNA expression library. Two other human ARF cDNA sequences, designated human ARF1 and ARF3, have been reported previously and are 96% identical in amino acid sequence. A human ARF1 cDNA significantly longer than previously described clones, was obtained, by cross-species hybridization using a bovine ARF1 cDNA probe. Bovine ARF1p and human ARF1p are 100% identical while each is only 80% identical to hARF4p. Thus, hARF4p is the most divergent of the mammalian ARF proteins identified. Northern blot analysis revealed the expression of at least three different ARF messages in human placenta and adrenal carcinoma cells. Both hARF1 and hARF4 encode GTP-binding proteins with predicted molecular masses of 20,000- 21,000 Da. Biochemical analysis of the purified recombinant proteins revealed a high degree of conservation of nucleotide binding properties and in vitro ARF activities. ARF is an essential gene in the yeast, Saccharomyces cerevisiae, and is encoded by two genes. Expression of either hARF1p or hARF4p in yeast was found to rescue the lethal double mutant, arf1- arf2-, thus demonstrating the functional conservation of ARF functions between yeast and man. The combination of in vivo and in vitro assays for ARF function provides a specific and unambiguous means of determining bona fide ARF proteins from divergent species from among the rapidly increasing number of structurally related, small molecular weight GTP-binding proteins.	GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, DIV MED ONCOL, WASHINGTON, DC 20007 USA; GEORGETOWN UNIV, MED CTR, VINCENT T LOMBARDI CANC RES CTR, DEPT BIOCHEM & MOLEC BIOL, WASHINGTON, DC 20007 USA	Georgetown University; Georgetown University	KAHN, RA (corresponding author), NCI, DIV CANC TREATMENT, BIOL CHEM LAB, BETHESDA, MD 20892 USA.		Kahn, Richard/ABD-2666-2020	Kahn, Richard/0000-0002-0259-0601	NATIONAL CANCER INSTITUTE [R01CA050376] Funding Source: NIH RePORTER; NCI NIH HHS [CA-50376] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COLBEREGARAPIN F, 1981, J MOL BIOL, V150, P1, DOI 10.1016/0022-2836(81)90321-1; FARNHAM PJ, 1990, MOL CELL BIOL, V10, P1390, DOI 10.1128/MCB.10.4.1390; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; GUNNING P, 1984, J MOL EVOL, V20, P202, DOI 10.1007/BF02104727; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KAHN RA, 1989, G PROTEINS, P201; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; LEIBOVITZ A, 1973, JNCI-J NATL CANCER I, V51, P691; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; OKAYAMA H, 1983, MOL CELL BIOL, V3, P280, DOI 10.1128/MCB.3.2.280; PENG Z, 1989, Biofactors, V2, P45; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SANGER F, 1975, J MOL BIOL, V94, P441, DOI 10.1016/0022-2836(75)90213-2; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; Sherman F., 1974, METHODS YEAST GENETI; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; STEARNS T, 1990, IN PRFESS MOL CELL B; STERNS T, 1990, P NATL ACAD SCI USA, V87, P1238; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TOWLER DA, 1987, J BIOL CHEM, V262, P1030; WEISS O, 1989, J BIOL CHEM, V264, P21066; WELLSTEIN A, 1990, CELL GROWTH DIFFER, V1, P63; YATES J, 1984, P NATL ACAD SCI-BIOL, V81, P3806, DOI 10.1073/pnas.81.12.3806; YATES JL, 1985, NATURE, V313, P812, DOI 10.1038/313812a0	36	182	187	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2606	2614						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899243				2022-12-25	WOS:A1991EV51500090
J	KONDO, K; INOUYE, M				KONDO, K; INOUYE, M			TIP1, A COLD SHOCK-INDUCIBLE GENE OF SACCHAROMYCES-CEREVISIAE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK; DICTYOSTELIUM-DISCOIDEUM; GEL-ELECTROPHORESIS; ESCHERICHIA-COLI; XENOPUS-LAEVIS; CDNA CLONING; YEAST; PROTEIN; DNA; EXPRESSION	Using differential hybridization, genes whose expression is induced at low temperatures were identified in yeast Saccharomyces cerevisiae. One of these genes that corresponds to an mRNA that is induced 6-8-fold within 2 h after shifting the culture temperature from 30 to 10-degrees-C was further characterized. Surprisingly, its expression was also induced by heat shock, and thus the gene was designated TIP1 (temperature shock-inducible protein gene). Southern hybridization analysis demonstrated that there are several genes homologous to the TIP1 gene on the yeast genome. A TIP1 disruption mutation exerted an observable effect neither on growth nor on viability after being exposed to freezing temperatures. The TIP1 gene encodes a protein of 210 amino acid residues with a molecular weight of 20,727, containing 20.0% alanine and 23.3% serine. The TIP1 protein has a typical signal peptide at the amino-terminal end and an extremely hydrophobic sequence at the carboxyl-terminal end. The TIP1 protein is thus likely to be secreted across the membrane and anchored on the outside surface of the plasma membrane. These results indicate that the TIP1 protein is a new type of stress-inducible protein in yeast.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT BIOCHEM,675 HOES LANE,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center								BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; BOUCHE G, 1984, NUCLEIC ACIDS RES, V12, P3025, DOI 10.1093/nar/12.7.3025; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; BRYAN J, 1989, J BIOL CHEM, V264, P13873; CAIZERGUESFERRER M, 1989, GENE DEV, V3, P324, DOI 10.1101/gad.3.3.324; Cryer D R, 1975, Methods Cell Biol, V12, P39; DUFFAUD GD, 1985, CURR TOP MEMBR TRANS, V24, P65; FOSNAUGH KL, 1989, NUCLEIC ACIDS RES, V17, P9489, DOI 10.1093/nar/17.22.9489; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HEREFORD LM, 1977, CELL, V10, P453, DOI 10.1016/0092-8674(77)90032-0; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; KLEINSCHMIDT J, 1986, EMBO J, V5, P3547, DOI 10.1002/j.1460-2075.1986.tb04681.x; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; MANIAK M, 1988, MOL CELL BIOL, V8, P153, DOI 10.1128/MCB.8.1.153; MARGUET D, 1986, BIOCHEM BIOPH RES CO, V138, P297, DOI 10.1016/0006-291X(86)90279-2; MARGUET D, 1988, J MOL BIOL, V202, P455, DOI 10.1016/0022-2836(88)90278-1; MILLER MJ, 1982, J BACTERIOL, V151, P311, DOI 10.1128/JB.151.1.311-327.1982; MULLERTAUBENBERGER A, 1988, J CELL SCI, V90, P51; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; PELHAM H, 1985, TRENDS GENET, V1, P31, DOI 10.1016/0168-9525(85)90012-5; PRAEKELT UM, 1990, MOL GEN GENET, V223, P97, DOI 10.1007/BF00315801; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SIKORSKI RS, 1989, GENETICS, V122, P19; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; TAKANO E, 1988, BIOCHEMISTRY-US, V27, P1964, DOI 10.1021/bi00406a024; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; VEINOTDREBOT LM, 1989, J BIOL CHEM, V264, P19473; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WERNERWASHBURNE M, 1989, J BACTERIOL, V171, P2680, DOI 10.1128/jb.171.5.2680-2688.1989; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2; [No title captured]	39	100	101	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17537	17544						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894636				2022-12-25	WOS:A1991GF44500083
J	NEMECZ, G; JEFFERSON, JR; SCHROEDER, F				NEMECZ, G; JEFFERSON, JR; SCHROEDER, F			POLYENE FATTY-ACID INTERACTIONS WITH RECOMBINANT INTESTINAL AND LIVER FATTY ACID-BINDING PROTEINS - SPECTROSCOPIC STUDIES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TIME-RESOLVED FLUORESCENCE; PHOSPHATIDYLCHOLINE TRANSFER PROTEIN; ESCHERICHIA-COLI; ENERGY-TRANSFER; BOVINE LIVER; PROBES; EXPRESSION; MEMBRANES; TARGET; PURIFICATION	Binding and proximity relationships of fatty acids with recombinant rat liver fatty acid-binding protein (L-FABP) and intestinal fatty acid-binding protein (I-FABP) were studied with absorption and fluorescence spectroscopy. Protein aromatic amino acids were examined in the absence and presence of bound fatty acid. Second derivative absorbance spectroscopy of the apo- and holoproteins suggested that fatty acid binding altered the conformation of L-FABP, but not of I-FABP. Fatty acid binding also blocked the accessibility of L-FABP tyrosine and I-FABP tryptophan to Stern-Volmer quenching by acrylamide, indicating that these amino acids were present in the fatty acid-binding pocket. Forster energy transfer from I-FABP tryptophan to bound cis-parinaric acid resulted in quenching of tryptophan lifetime and appearance of sensitized lifetime of bound cis-parinaric acid. The calculated donor-acceptor distances were 16.9 +/- 0.6 and 19.2 +/- 0.3 angstrom for I-FABP and L-FABP, respectively. Absorbance spectral shifts and ratios of fluorescence excitation maxima indicated that the parinaric acid microenvironment in the fatty acid-binding site of I-FABP was much less polar than that of L-FABP. Parinaric acids displayed similar rotational correlation time and limiting anisotropy when bound to I-FABP and to L-FABP. These results are consistent with a close proximity of bound fatty acids to the tyrosine and tryptophan residues and with immobilization of the polyene fatty acids in the fatty acid-binding site(s) of L-FABP and I-FABP. The two proteins differ in that only L-FABP has two fatty acid-binding sites and appears to undergo significant conformational change upon fatty acid binding.	UNIV CINCINNATI, MED CTR, DEPT PHARMACOL & CELL BIOPHYS, DIV PHARMACOL & MED CHEM, CINCINNATI, OH 45267 USA	University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007460] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NCRR NIH HHS [RR03155-01] Funding Source: Medline; NHLBI NIH HHS [HL07460] Funding Source: Medline; NIDDK NIH HHS [DK41402] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASSUK JA, 1987, P NATL ACAD SCI USA, V84, P7547, DOI 10.1073/pnas.84.21.7547; BERKHOUT TA, 1984, BIOCHEMISTRY-US, V23, P1505, DOI 10.1021/bi00302a025; BISMUTO E, 1989, BIOCHEMISTRY-US, V28, P1508, DOI 10.1021/bi00430a013; BOHNER FD, 1987, J BIOL CHEM, V262, P15137; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; BRANDT R, 1988, BIOCHEMISTRY-US, V27, P1420, DOI 10.1021/bi00405a005; BURSTEIN EA, 1973, PHOTOCHEM PHOTOBIOL, V18, P263, DOI 10.1111/j.1751-1097.1973.tb06422.x; CANTOR CR, 1980, BIOPHYSICAL CHEM 2, P459; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; CISTOLA DP, 1988, BIOCHEMISTRY-US, V27, P711, DOI 10.1021/bi00402a033; CLARKE SD, 1989, FASEB J, V3, P2480, DOI 10.1096/fasebj.3.13.2680704; CUSTER RP, 1984, P NATL ACAD SCI-BIOL, V81, P6738, DOI 10.1073/pnas.81.21.6738; DALE RE, 1979, BIOPHYS J, V26, P161, DOI 10.1016/S0006-3495(79)85243-1; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; FISCHER RT, 1985, BIOCHEMISTRY-US, V24, P3322, DOI 10.1021/bi00334a037; FORSTER T, 1959, DISCUSS FARADAY SOC, P7; GLATZ JFC, 1985, INT J BIOCHEM, V17, P13, DOI 10.1016/0020-711X(85)90080-1; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; GORDON JI, 1983, J BIOL CHEM, V258, P3356; GORDON JI, 1985, CHEM PHYS LIPIDS, V38, P137, DOI 10.1016/0009-3084(85)90063-5; HAAS E, 1978, BIOCHEMISTRY-US, V17, P5064, DOI 10.1021/bi00616a032; HRESKO RC, 1988, P NATL ACAD SCI USA, V85, P8835, DOI 10.1073/pnas.85.23.8835; JEFFERSON JR, 1990, BIOCHEMISTRY-US, V29, P6687, DOI 10.1021/bi00480a019; KEUPER HJK, 1985, CHEM PHYS LIPIDS, V38, P159, DOI 10.1016/0009-3084(85)90064-7; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; LOWE JB, 1985, J BIOL CHEM, V260, P3413; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LOWE JB, 1984, J BIOL CHEM, V259, P2696; LUDESCHER RD, 1985, BIOCHEMISTRY-US, V24, P7240, DOI 10.1021/bi00346a033; MCINTYRE JC, 1990, BIOCHEMISTRY-US, V29, P2092, DOI 10.1021/bi00460a019; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; NEMECZ G, 1988, BIOCHEMISTRY-US, V27, P7740, DOI 10.1021/bi00420a024; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; Paulussen R J, 1990, Subcell Biochem, V16, P175; RAGONE R, 1984, BIOCHEMISTRY-US, V23, P1871, DOI 10.1021/bi00303a044; ROSS JBA, 1981, BIOCHEMISTRY-US, V20, P4369, DOI 10.1021/bi00518a021; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SACCHETTINI JC, 1989, P NATL ACAD SCI USA, V86, P7736, DOI 10.1073/pnas.86.20.7736; SCHROEDER F, 1989, SER SYMP AD, V1, P29; SCHROEDER F, 1985, J BIOL CHEM, V260, P2904; SCHROEDER F, 1976, J BIOL CHEM, V251, P6739; SKLAR LA, 1977, BIOCHEMISTRY-US, V16, P5100, DOI 10.1021/bi00642a024; SKLAR LA, 1980, BIOCHEMISTRY-US, V19, P1294, DOI 10.1021/bi00548a005; SKLAR LA, 1975, P NATL ACAD SCI USA, V72, P1649, DOI 10.1073/pnas.72.5.1649; SPENER F, 1989, FEBS LETT, V244, P1, DOI 10.1016/0014-5793(89)81149-4; STEINBERG IZ, 1971, ANNU REV BIOCHEM, V40, P83, DOI 10.1146/annurev.bi.40.070171.000503; STRYER L, 1978, ANNU REV BIOCHEM, V47, P819, DOI 10.1146/annurev.bi.47.070178.004131; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; VANLOON D, 1985, CHEM PHYS LIPIDS, V38, P29, DOI 10.1016/0009-3084(85)90055-6; WEINBERGER C, 1990, ANNU REV PHYSIOL, V52, P823; WILTON DC, 1989, BIOCHEM J, V261, P273, DOI 10.1042/bj2610273; WINTER NS, 1990, J BIOL CHEM, V265, P10955; YANG VW, 1989, P NATL ACAD SCI USA, V86, P3629, DOI 10.1073/pnas.86.10.3629; [No title captured]	57	66	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17112	17123						12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894608				2022-12-25	WOS:A1991GF44500025
J	NOVY, RE; LIN, JLC; LIN, JJC				NOVY, RE; LIN, JLC; LIN, JJC			CHARACTERIZATION OF CDNA CLONES ENCODING A HUMAN FIBROBLAST CALDESMON ISOFORM AND ANALYSIS OF CALDESMON EXPRESSION IN NORMAL AND TRANSFORMED-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CALDESMON; 83-KDA NONMUSCLE CALDESMON; CHICKEN-EMBRYO FIBROBLASTS; ACTIN-SEVERING ACTIVITY; GIZZARD CALDESMON; MULTIPLE ISOFORMS; ATPASE ACTIVITY; THIN-FILAMENT; TROPONIN-T; DIFFERENTIAL MODULATION	Overlapping cDNA clones encoding a low M-gamma human nonmuscle caldesmon isoform (HUM 1-CaD) span the entire coding region (538 amino acids) as well as 111 base pairs (bp) of 5'-noncoding and 1249 bp of 3'-noncoding region. Northern blot probes derived from either the coding or 3'-noncoding region hybridized to a 4.3-kilobase mRNA in nonmuscle cells and a 5.2-kilobase mRNA in stomach tissue. Primer extension results indicated that the 5'-noncoding region of the HUM 1-CaD mRNA is approximately 700 bp in length and also suggested that 1-CaD mRNAs with common 5'-noncoding regions are expressed in both liver and fibroblast cells. Comparisons of the human, rat, and chicken 1-CaD amino acids sequences demonstrated that although each isoform has unique characteristics, extensive regions of conservation exist. Amino acids 27-53 and 97-127 are 100% identical in these isoforms while amino acids 297-531 of HUM 1-CaD are 94 and 85% identical to the rat and chicken 1-CaDs, respectively. In addition, the levels of HUM 1-CaD mRNA and protein appeared to be decreased by 2-4 fold in the transformed derivatives of KD and WI38 cell lines as judged by Northern and Western blot analysis. The results suggest that the decrease of 1-CaD protein in these transformed cells is a direct result of decreased 1-CaD mRNA synthesis and/or increased mRNA turnover.	UNIV IOWA,DEPT BIOL,IOWA CITY,IA 52242	University of Iowa					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD018577] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042266] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040580] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42266] Funding Source: Medline; NICHD NIH HHS [HD18577] Funding Source: Medline; NIGMS NIH HHS [GM40580] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAM LP, 1989, J BIOL CHEM, V264, P7698; AUSBEL FM, 1987, CURRENT PROTOCOLS MO; BARTEGI A, 1990, J BIOL CHEM, V265, P15231; BRETSCHER A, 1986, NATURE, V321, P726, DOI 10.1038/321726b0; BRYAN J, 1989, J BIOL CHEM, V264, P13873; BRYAN J, 1990, J MUSCLE RES CELL M, V11, pA434; CHALOVICH JM, 1988, CELL BIOPHYS, V12, P73, DOI 10.1007/BF02918351; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; CRISS WE, 1982, FED PROC, V41, P2289; ERBA HP, 1986, NUCLEIC ACIDS RES, V14, P5275, DOI 10.1093/nar/14.13.5275; FELICE GR, 1990, EUR J CELL BIOL, V52, P47; FUJII T, 1988, J BIOCHEM-TOKYO, V104, P734, DOI 10.1093/oxfordjournals.jbchem.a122542; HATHAWAY DR, 1990, J MUSCLE RES CELL M, V11, pA435; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V164, P503, DOI 10.1016/0006-291X(89)91748-8; HAYASHI K, 1991, J BIOL CHEM, V266, P355; HAYASHI K, 1989, BIOCHEM BIOPH RES CO, V161, P38, DOI 10.1016/0006-291X(89)91556-8; HEGMANN TE, 1991, IN PRESS CELL MOTIL; HEMRIC ME, 1988, J BIOL CHEM, V263, P1878; HENDRICKS M, 1984, MOL CELL BIOL, V4, P1823, DOI 10.1128/MCB.4.9.1823; HORIUCHI KY, 1991, BIOCHEMISTRY-US, V30, P712, DOI 10.1021/bi00217a019; HURRICANE MC, 1990, FEBS LETT, V269, P185; Huynh TV, 1985, DNA CLONING TECHNIQU, V1, P49; IKEBE M, 1988, J BIOL CHEM, V263, P3055; IKEBE M, 1990, J BIOL CHEM, V265, P17607; ISHIKAWA R, 1989, J BIOL CHEM, V264, P16764; ISHIKAWA R, 1989, J BIOL CHEM, V264, P7490; JIN JP, 1989, J BIOL CHEM, V264, P14471; KAKIUCHI S, 1983, TRENDS BIOCHEM SCI, V8, P59, DOI 10.1016/0968-0004(83)90391-2; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LASH JA, 1986, J BIOL CHEM, V261, P6155; LEAVITT J, 1985, NATURE, V316, P840, DOI 10.1038/316840a0; LEONARDI CL, 1982, BIOCHIM BIOPHYS ACTA, V720, P154, DOI 10.1016/0167-4889(82)90007-6; LIN JJC, 1988, HYBRIDOMA, V7, P273, DOI 10.1089/hyb.1988.7.273; LIN JJC, 1985, J CELL BIOL, V100, P692, DOI 10.1083/jcb.100.3.692; LIN JJC, 1991, IN PRESS CELL MOTIL; LITCHFIELD DW, 1987, J BIOL CHEM, V262, P8056; MAK AS, 1981, J MOL BIOL, V149, P541, DOI 10.1016/0022-2836(81)90486-1; MARSTON S, 1988, FEBS LETT, V238, P147, DOI 10.1016/0014-5793(88)80245-X; MATSUMURA F, 1983, J BIOL CHEM, V258, P3954; MATSUMURA F, 1986, J BIOL CHEM, V261, P4655; MORNET D, 1988, BIOCHEM BIOPH RES CO, V154, P564, DOI 10.1016/0006-291X(88)90177-5; MULLAUER L, 1990, BIOCHEM BIOPH RES CO, V171, P852, DOI 10.1016/0006-291X(90)91224-G; NGAI PK, 1987, BIOCHEM J, V244, P417, DOI 10.1042/bj2440417; OWADA MK, 1984, P NATL ACAD SCI-BIOL, V81, P3133, DOI 10.1073/pnas.81.10.3133; PEARLSTONE JR, 1977, CAN J BIOCHEM CELL B, V55, P1032, DOI 10.1139/o77-154; PRITCHARD K, 1989, BIOCHEM J, V257, P839, DOI 10.1042/bj2570839; REDWOOD CS, 1990, FEBS LETT, V270, P53, DOI 10.1016/0014-5793(90)81233-E; RISEMAN VM, 1989, J BIOL CHEM, V264, P2869; SCHOWALTER DB, 1989, ANAL BIOCHEM, V177, P90, DOI 10.1016/0003-2697(89)90019-5; SMITH CWJ, 1987, J BIOL CHEM, V262, P116; SOBUE K, 1982, FEBS LETT, V138, P289, DOI 10.1016/0014-5793(82)80463-8; SOBUE K, 1988, J CELL BIOCHEM, V37, P317, DOI 10.1002/jcb.240370306; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUTHERLAND C, 1989, J BIOL CHEM, V264, P578; SZPACENKO A, 1986, FEBS LETT, V202, P182, DOI 10.1016/0014-5793(86)80683-4; TAKAGI T, 1989, J BIOCHEM-TOKYO, V106, P778, DOI 10.1093/oxfordjournals.jbchem.a122930; TANAKA T, 1990, EUR J BIOCHEM, V188, P495, DOI 10.1111/j.1432-1033.1990.tb15427.x; VANDEKERCKHOVE J, 1990, J CELL BIOL, V111, P95, DOI 10.1083/jcb.111.1.95; VELAZ L, 1990, J BIOL CHEM, V265, P2929; WANG CLA, 1989, BIOCHEM BIOPH RES CO, V162, P746, DOI 10.1016/0006-291X(89)92373-5; YAMAKITA Y, 1990, Journal of Cell Biology, V111, p94A; YAMASHIRO S, 1991, NATURE, V349, P169, DOI 10.1038/349169a0; YAMASHIROMATSUMURA S, 1988, J CELL BIOL, V106, P1973, DOI 10.1083/jcb.106.6.1973; YAZAWA M, 1987, J BIOCHEM-TOKYO, V102, P1065, DOI 10.1093/oxfordjournals.jbchem.a122144	65	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16917	16924						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885618				2022-12-25	WOS:A1991GD63500106
J	BALSINDE, J; DIEZ, E; MOLLINEDO, F				BALSINDE, J; DIEZ, E; MOLLINEDO, F			ARACHIDONIC-ACID RELEASE FROM DIACYLGLYCEROL IN HUMAN NEUTROPHILS - TRANSLOCATION OF DIACYLGLYCEROL-DEACYLATING ENZYME-ACTIVITIES FROM AN INTRACELLULAR POOL TO PLASMA-MEMBRANE UPON CELL ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; MOUSE PERITONEAL-MACROPHAGES; PROTEIN KINASE-C; SN-1,2-DIACYLGLYCEROL 2ND MESSENGERS; STIMULATED HUMAN-NEUTROPHILS; PHOSPHOLIPASE-D; HUMAN-PLATELETS; POLYPHOSPHOINOSITIDE PHOSPHODIESTERASE; SUBCELLULAR-LOCALIZATION; ALKALINE-PHOSPHATASE	We have studied the capacity of human neutrophils to release arachidonic acid from diacylglycerol, employing 1-stearoyl-2-[1-C-14]arachidonoyl-sn-glycerol and 1-[1-C-14]stearoyl-2-arachidonoyl-sn-glycerol as exogenous substrates. We have found that arachidonic acid is removed from diacylglycerol by the sequential action of two enzymes. First, the sn-1 position is split by 1-diacylglycerol lipase activity, and then, arachidonic acid is released from the resulting 2-monoacylglycerol by a 2-monoacylglycerol lipase. The specific activity of the 2-monoacylglycerol lipase, using 2-[1-C-14]arachidonoyl-sn-glycerol as exogenous substrate, was at least 9-fold higher than that of 1-diacylglycerol lipase, indicating that the action of the 1-diacylglycerol lipase is the rate-limiting step in arachidonic acid release from diacylglycerol. Postnuclear supernatants from A23187-treated cells showed a 2.5-fold increase in both lipase activities. The arachidonic acid-releasing diacylglycerol lipase system showed an optimum pH of 4.5 and was not inhibited by EGTA or stimulated by Ca2+, Mg2+, Mn2+, Zn2+, or Co2+. However, arachidonic acid release was inhibited by Hg2+, suggesting the involvement of sulfhydryl groups in catalytic activity. The subcellular distribution of both 1-diacylglycerol lipase and 2-monoacylglycerol lipase activities was examined in resting and A23187-treated human neutrophils by fractionation of postnuclear supernatants on continuous sucrose gradients. Both lipases were localized mainly in the membrane of gelatinase-containing granules, which were resolved from cytosol, plasma membrane, phosphasomes, and specific and azurophilic granules. When neutrophils were stimulated by the calcium ionophore A23187, a drastic shift of the 1-diacylglycerol lipase and 2-monoacylglycerol lipase toward the plasma membrane was detected. This shift was due to fusion of gelatinase-containing granules with the plasma membrane upon neutrophil stimulation. As a result of the membrane fusion process, the capacity to release arachidonic acid from diacylglycerol was increased. This translocation from the membrane of gelatinase-containing granules to the plasma membrane may play an important role in regulating the diacylglycerol level in stimulated human neutrophils.	CSIC, CTR INVEST BIOL, VELAZQUEZ 144, E-28006 MADRID, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consiglio Nazionale delle Ricerche (CNR)			Balsinde, Jesús/C-7833-2018	Balsinde, Jesús/0000-0002-4157-6714				AGWU DE, 1989, J BIOL CHEM, V264, P1405; BALSINDE J, 1990, FEBS LETT, V259, P237, DOI 10.1016/0014-5793(90)80017-D; BALSINDE J, 1988, BIOCHEM BIOPH RES CO, V154, P502, DOI 10.1016/0006-291X(88)90168-4; BALSINDE J, 1990, J IMMUNOL, V144, P4298; BALSINDE J, 1989, EUR J BIOCHEM, V186, P717, DOI 10.1111/j.1432-1033.1989.tb15265.x; BALSINDE J, 1988, J BIOL CHEM, V263, P1929; BELFRAGE P, 1969, J LIPID RES, V10, P341; BELL RL, 1979, P NATL ACAD SCI USA, V76, P3238, DOI 10.1073/pnas.76.7.3238; BELL RM, 1986, CELL, V45, P631, DOI 10.1016/0092-8674(86)90774-9; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BISHOP WR, 1986, J BIOL CHEM, V261, P6993; BISHOP WR, 1986, J BIOL CHEM, V261, P2513; BORREGAARD N, 1990, J CLIN INVEST, V85, P408, DOI 10.1172/JCI114453; CHAU LY, 1981, BIOCHEM BIOPH RES CO, V100, P1688, DOI 10.1016/0006-291X(81)90713-0; CHAU LY, 1988, BIOCHIM BIOPHYS ACTA, V963, P436, DOI 10.1016/0005-2760(88)90312-8; COCKCROFT S, 1984, BIOCHEM J, V221, P477, DOI 10.1042/bj2210477; COCKCROFT S, 1986, BIOCHEM J, V240, P503, DOI 10.1042/bj2400503; DANIEL LW, 1988, BIOCHEM BIOPH RES CO, V151, P291, DOI 10.1016/0006-291X(88)90592-X; DIEZ E, 1987, BIOCHIM BIOPHYS ACTA, V921, P82, DOI 10.1016/0005-2760(87)90173-1; DIEZ E, 1990, BIOCHIM BIOPHYS ACTA, V1047, P83, DOI 10.1016/0005-2760(90)90264-X; EMILSSON A, 1986, BIOCHIM BIOPHYS ACTA, V876, P533, DOI 10.1016/0005-2760(86)90041-X; GELAS P, 1989, FEBS LETT, V251, P213, DOI 10.1016/0014-5793(89)81457-7; HEECHEONG M, 1985, BIOCHIM BIOPHYS ACTA, V833, P59, DOI 10.1016/0005-2760(85)90253-X; HIBBS MS, 1989, J CLIN INVEST, V84, P1395, DOI 10.1172/JCI114312; HONEYCUTT PJ, 1986, J BIOL CHEM, V261, P5900; KORCHAK HM, 1988, J BIOL CHEM, V263, P11090; LACAL P, 1988, BIOCHEM BIOPH RES CO, V154, P641, DOI 10.1016/0006-291X(88)90187-8; LACAL P, 1988, J BIOL CHEM, V263, P9946; LAPETINA EG, 1981, J BIOL CHEM, V256, P5037; MAHADEVAPPA VG, 1986, BIOCHEM BIOPH RES CO, V134, P1327, DOI 10.1016/0006-291X(86)90395-5; MAJERUS PW, 1984, CELL, V37, P701, DOI 10.1016/0092-8674(84)90405-7; MAUCO G, 1984, BIOCHIM BIOPHYS ACTA, V796, P169, DOI 10.1016/0005-2760(84)90345-X; MEADE CJ, 1986, BIOCHEM J, V238, P425, DOI 10.1042/bj2380425; MOLLINEDO F, 1986, BIOCHIM BIOPHYS ACTA, V861, P33, DOI 10.1016/0005-2736(86)90368-8; MOLLINEDO F, 1984, J BIOL CHEM, V259, P7143; MOLLINEDO F, 1987, FEBS LETT, V217, P158, DOI 10.1016/0014-5793(87)80655-5; MOLLINEDO F, 1988, BIOCHEM BIOPH RES CO, V154, P1232, DOI 10.1016/0006-291X(88)90271-9; MOLLINEDO F, 1986, J BIOL CHEM, V261, P1077; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; NAKASHIMA S, 1989, J IMMUNOL, V143, P1295; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; OKAZAKI T, 1981, J BIOL CHEM, V256, P7316; PREISS JE, 1987, J IMMUNOL, V138, P1542; PRESCOTT SM, 1983, J BIOL CHEM, V258, P764; REIBMAN J, 1988, J BIOL CHEM, V263, P6322; RIDER LG, 1987, J BIOL CHEM, V262, P5603; RIDER LG, 1988, J IMMUNOL, V140, P200; RINDLISBACHER B, 1987, BIOCHIM BIOPHYS ACTA, V905, P349, DOI 10.1016/0005-2736(87)90463-9; SAGAWA N, 1982, J BIOL CHEM, V257, P8158; SMITH GP, 1985, J CELL SCI, V76, P167; TAKENAWA T, 1983, J IMMUNOL, V130, P2849; TAO W, 1989, BIOCHEM J, V257, P633, DOI 10.1042/bj2570633; TRUETT AP, 1989, BIOCHEM J, V260, P909, DOI 10.1042/bj2600909; TYAGI SR, 1988, J BIOL CHEM, V263, P13191; WALENGA RW, 1981, J BIOL CHEM, V256, P2523; WALSH CE, 1983, BIOCHIM BIOPHYS ACTA, V750, P32, DOI 10.1016/0005-2760(83)90201-1	56	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15638	15643						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908458				2022-12-25	WOS:A1991GB97700019
J	ROITELMAN, J; BARNUN, S; INOUE, S; SIMONI, RD				ROITELMAN, J; BARNUN, S; INOUE, S; SIMONI, RD			INVOLVEMENT OF CALCIUM IN THE MEVALONATE-ACCELERATED DEGRADATION OF 3-HYDROXY-3-METHYLGLUTARYL-COA REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; HMG-COA REDUCTASE; STEROL-ENHANCED DEGRADATION; ACTIVATED NEUTRAL PROTEASE; MEMBRANE-BOUND DOMAIN; FAST AXONAL-TRANSPORT; ENDOPLASMIC-RETICULUM; RAT-LIVER; REGULATED DEGRADATION; INOSITOL PHOSPHATES	3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase), the rate-limiting enzyme in the biosynthesis of cholesterol and isoprenoids, is subject to rapid degradation which is regulated by mevalonate (MVA)-derived metabolic products. HMG-CoA reductase is an integral membrane protein of the endoplasmic reticulum, the largest nonmitochondrial pool of cellular Ca2+. To assess the possible role of Ca2+ in the regulated degradation of HMG-CoA reductase, we perturbed cellular Ca2+ concentration and followed the fate of HMG-CoA reductase and of HMGal, a fusion protein consisting of the membrane domain of HMG-CoA reductase and the soluble bacterial enzyme beta-galactosidase. The degradation of HMGal mirrors that of HMG-CoA reductase, demonstrating that the membrane domain of HMG-CoA reductase is sufficient to confer regulated degradation (Skalnik, D. G., Narita, H., Kent, C., and Simoni, R. D. (1988) J. Biol. Chem. 263, 6836-6841; Chun, K. T., Bar-Nun, S., and Simoni, R. D. (1990) J. Biol. Chem. 265,22004-22010). In this study we show that the MVA-dependent accelerated rates of degradation of HMG-CoA reductase and HMGal in cells maintained in Ca2+ free medium are 2-3-fold slower than the rate of degradation in cells grown in high (1.8-2 mM) Ca2+ concentration. This effect is reversed upon addition of Ca2+ to the medium. Furthermore, when cells maintained in high Ca2+ are treated with 1-mu-M ionomycin, the MVA-dependent accelerated degradation of HMG-CoA reductase and HMGal is also reduced about 2-3-fold. This inhibition is not due to a Ca2+-dependent uptake or incorporation of MVA into sterols, since these processes are not affected in the absence of external Ca2+. In addition, cobalt, a known antagonist of Ca2+ dependent cellular functions, totally abolishes (IC50 = 520-mu-M in the presence of 1.8 mM extracellular Ca2+) the MVA-accelerated degradation of HMGal. These results suggest that Ca2+ plays a major role in the regulated degradation of HMG-CoA reductase.			ROITELMAN, J (corresponding author), STANFORD UNIV,DEPT BIOL SCI,STANFORD,CA 94305, USA.				NHLBI NIH HHS [HL26502] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026502] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BEG ZH, 1987, METABOLISM, V36, P900, DOI 10.1016/0026-0495(87)90101-6; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; BROWN DA, 1984, P NATL ACAD SCI-BIOL, V81, P1674, DOI 10.1073/pnas.81.6.1674; CAPPEL RE, 1988, J BIOL CHEM, V263, P12204; CHIN DJ, 1985, MOL CELL BIOL, V5, P634, DOI 10.1128/MCB.5.4.634; CHUN KT, 1990, J BIOL CHEM, V265, P22004; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; DAVIS RA, 1990, J BIOL CHEM, V265, P10005; DAWSON AP, 1989, CELL CALCIUM, V10, P343, DOI 10.1016/0143-4160(89)90060-2; EDWARDS PA, 1983, J BIOL CHEM, V258, P219; ELFERINK JGR, 1989, AM J PHYSIOL, V257, pC859, DOI 10.1152/ajpcell.1989.257.5.C859; FAUST J, 1987, J BIOL CHEM, V262, P1996; GARDNER A M, 1990, Journal of Cell Biology, V111, p456A; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GILL DL, 1989, CELL CALCIUM, V10, P363, DOI 10.1016/0143-4160(89)90062-6; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GOMPERTS BD, 1986, TRENDS BIOCHEM SCI, V11, P290, DOI 10.1016/0968-0004(86)90032-0; HAGIWARA S, 1981, ANNU REV NEUROSCI, V4, P69, DOI 10.1146/annurev.ne.04.030181.000441; HAMMERSCHLAG R, 1977, J NEUROBIOL, V8, P439, DOI 10.1002/neu.480080505; HARDIE DG, 1989, TRENDS BIOCHEM SCI, V14, P20; HUGHES BP, 1989, BIOCHIM BIOPHYS ACTA, V1013, P197, DOI 10.1016/0167-4889(89)90135-3; INOUE S, 1991, J BIOL CHEM, V266, P13311; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; JINGAMI H, 1987, J CELL BIOL, V104, P1693, DOI 10.1083/jcb.104.6.1693; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVOIE PA, 1983, NEUROSCIENCE, V8, P351, DOI 10.1016/0306-4522(83)90071-4; LEONARD DA, 1987, J BIOL CHEM, V262, P7914; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LISCUM L, 1983, P NATL ACAD SCI-BIOL, V80, P7165, DOI 10.1073/pnas.80.23.7165; LISCUM L, 1985, J BIOL CHEM, V260, P522; LODISH HF, 1990, J BIOL CHEM, V265, P10893; LUSKEY KL, 1983, J BIOL CHEM, V258, P8462; MURACHI T, 1983, TRENDS BIOCHEM SCI, V8, P167, DOI 10.1016/0968-0004(83)90165-2; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NISHIMOTO I, 1987, J BIOL CHEM, V262, P12120; NOSSEN JO, 1987, BIOCHEM J, V247, P433, DOI 10.1042/bj2470433; ORCI L, 1984, CELL, V36, P335; OSBORNE TF, 1985, CELL, V42, P203, DOI 10.1016/S0092-8674(85)80116-1; PARKER RA, 1989, J BIOL CHEM, V264, P4877; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PONTREMOLI S, 1986, ANNU REV BIOCHEM, V55, P455, DOI 10.1146/annurev.biochem.55.1.455; ROITELMAN J, 1984, J BIOL CHEM, V259, P870; RONNING SA, 1985, BIOCHEM BIOPH RES CO, V130, P524, DOI 10.1016/0006-291X(85)90448-6; ROTHBLAT GH, 1976, IN VITRO CELL DEV B, V12, P554; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; SATO R, 1990, J BIOL CHEM, V265, P11880; SINENSKY M, 1983, J BIOL CHEM, V258, P8547; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SUZUKI K, 1987, TRENDS BIOCHEM SCI, V12, P103, DOI 10.1016/0968-0004(87)90048-X; SUZUKI K, 1987, FEBS LETT, V220, P271, DOI 10.1016/0014-5793(87)80828-1; TANAKA RD, 1983, J BIOL CHEM, V258, P3331; TENAKA RD, 1986, J LIPID RES, V27, P261; TSIEN RW, 1990, ANNU REV CELL BIOL, V6, P715, DOI 10.1146/annurev.cb.06.110190.003435	60	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16085	16091						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908464				2022-12-25	WOS:A1991GB97700084
J	MANNING, AM; WILLIAMS, AC; GAME, SM; PARASKEVA, C				MANNING, AM; WILLIAMS, AC; GAME, SM; PARASKEVA, C			DIFFERENTIAL SENSITIVITY OF HUMAN COLONIC ADENOMA AND CARCINOMA-CELLS TO TRANSFORMING GROWTH-FACTOR-BETA (TGF-BETA) - CONVERSION OF AN ADENOMA CELL-LINE TO A TUMORIGENIC PHENOTYPE IS ACCOMPANIED BY A REDUCED RESPONSE TO THE INHIBITORY EFFECTS OF TGF-BETA	ONCOGENE			English	Article							POLYPOSIS COLI PATIENTS; LIVER EPITHELIAL-CELLS; PROLIFERATION; CANCER; CARCINOGENESIS; PROGRESSION; RESISTANCE; RECEPTORS; ONCOGENE; GENE	The growth of three non-tumorigenic human colonic adenoma cell lines, designated AA/C1, RG/C2 and RR/C1, was inhibited by low concentrations of transforming growth factor-beta (TGF-beta) (0.05-0.5 ng ml-1). However, the growth of five human colon cancer cell lines under identical conditions was resistant to high concentrations of TGF-beta (2-10 ng ml-1). This is the first report of well-characterized premalignant human colonic cells showing sensitivity to TGF-beta. The TGF-beta-sensitive adenoma cell line AA/C1 was derived from a relatively large adenoma with a K-ras gene mutation and represents a relatively late-stage adenoma, indicating that loss of response to TGF-beta occurs at a relatively late stage in colorectal carcinogenesis and that the presence of a ras gene mutation does not necessarily confer resistance to TGF-beta. Of further interest, the RG/CZ cell line has a p53 mutation showing that p53 mutations do not necessarily lead to TGF-B insensitivity. Furthermore, in this paper we show that the conversion of the AA/C1 adenoma cell line to a tumorigenic phenotype [Williams et al., (1990) Cancer Res., 50, 4724] is accompanied by a reduced response to the growth-inhibitory effects of TGF-beta up to 10 ng ml-1. Reduced responsiveness to the inhibitory effects of TGF-beta may be an important event in the loss of growth control in colorectal carcinogenesis.	UNIV BRISTOL,SCH MED SCI,DEPT PATHOL & MICROBIOL,UNIV WALK,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV BRISTOL,DENT SCH & HOSP,DEPT ORAL MED,BRISTOL BS8 1TH,AVON,ENGLAND	University of Bristol; University of Bristol				Williams, Ann/0000-0002-6009-7137				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; BAKER SJ, 1990, CANCER RES, V50, P777; BARNARD JA, 1989, P NATL ACAD SCI USA, V86, P1578, DOI 10.1073/pnas.86.5.1578; COFFEY RJ, 1988, CANCER RES, V48, P1596; COFFEY RJ, 1986, CANCER RES, V46, P1164; FARR CJ, 1988, ONCOGENE, V3, P673; FEARON ER, 1990, SCIENCE, V247, P49, DOI 10.1126/science.2294591; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GAME SM, 1990, CARCINOGENESIS, V11, P965, DOI 10.1093/carcin/11.6.965; HADDOW S, 1991, ONCOGENE, V6, P1467; HOOSEIN NM, 1989, EXP CELL RES, V181, P442, DOI 10.1016/0014-4827(89)90101-8; HOUCK KA, 1989, ONCOGENE, V4, P19; HUBBS AF, 1989, CARCINOGENESIS, V10, P1599, DOI 10.1093/carcin/10.9.1599; IGNOTZ RA, 1987, CELL, V51, P189, DOI 10.1016/0092-8674(87)90146-2; KIMCHI A, 1988, SCIENCE, V240, P196, DOI 10.1126/science.2895499; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; KUROKOWA M, 1987, BIOCHEM BIOPH RES CO, V142, P775, DOI 10.1016/0006-291X(87)91481-1; LAMPRECHT SA, 1989, ANTICANCER RES, V9, P1877; MACIEWICZ RA, 1989, INT J CANCER, V43, P478, DOI 10.1002/ijc.2910430323; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCMAHON JB, 1986, CANCER RES, V46, P4665; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; MOSES HL, 1985, CANCER CELL, V3, P65; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; PARASKEVA C, 1984, INT J CANCER, V34, P49, DOI 10.1002/ijc.2910340109; PARASKEVA C, 1990, BRIT J CANCER, V61, P828, DOI 10.1038/bjc.1990.185; PARASKEVA C, 1989, CANCER RES, V49, P1282; PARKINSON K, 1990, CARCINOGENESIS, V11, P195, DOI 10.1093/carcin/11.2.195; PIGNATELLI M, 1989, INT J CANCER, V44, P518, DOI 10.1002/ijc.2910440324; Reddel R R, 1988, Oncogene Res, V3, P401; ROBERTS AB, 1988, ADV CANCER RES, V51, P107, DOI 10.1016/S0065-230X(08)60221-3; ROBERTS AB, 1985, P NATL ACAD SCI USA, V82, P119, DOI 10.1073/pnas.82.1.119; ROLLINS BJ, 1989, J CELL PHYSIOL, V139, P455, DOI 10.1002/jcp.1041390302; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SONG MKH, 1985, EXP CELL RES, V156, P271, DOI 10.1016/0014-4827(85)90281-2; SPORN MB, 1986, SCIENCE, V233, P532, DOI 10.1126/science.3487831; VALVERIUS EM, 1989, CANCER RES, V49, P6269; WEINBERG RA, 1989, CANCER RES, V49, P3713; WILLIAMS AC, 1990, CANCER RES, V50, P4724	39	183	189	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1471	1476						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886718				2022-12-25	WOS:A1991GX27200026
J	LIN, WJ; TUAZON, PT; TRAUGH, JA				LIN, WJ; TUAZON, PT; TRAUGH, JA			CHARACTERIZATION OF THE CATALYTIC SUBUNIT OF CASEIN KINASE-II EXPRESSED IN ESCHERICHIA-COLI AND REGULATION OF ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-MELANOGASTER; MOLECULAR-CLONING; ALPHA-SUBUNIT; INHIBITION; BETA; 2,3-BISPHOSPHOGLYCERATE; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; CELLS	The catalytic (alpha) subunit of casein kinase II from Drosophila, cloned and expressed in Escherichia coli (Saxena, A., Padmanabha, R., and Glover, C. V. C., (1987) Mol. Cell. Biol. 7, 3409-3417), has been purified and characterized, and the properties have been compared those of the holoenzyme. The catalytic subunit exhibits protein kinase activity with casein as substrate and is autophosphorylated. The specific activity of the purified subunit is 6% of the activity of the holoenzyme from reticulocytes or from Drosophila. The alpha-subunit is a monomer, eluting at M(r) = 40,000 upon gel filtration in high salt, but as part of an aggregate in low salt. The alpha-subunit has been purified to apparent homogeneity by sequential chromatography on DEAE-cellulose, Mono S, and Mono Q. A single band, M(r) = 37,000, is detected by silver staining following polyacrylamide gel electrophoresis. The isolated alpha-subunit displays apparent K(m) values for beta-casein, ATP, and GTP similar to those of the holoenzyme. The activity of the alpha-subunit is inhibited by heparin with an I50 of 0.1-0.3-mu-g/ml, a value similar to that observed for the holoenzyme; autophosphorylation is also inhibited by heparin. Polylysine has no stimulatory effect on the activity of the catalytic subunit, as measured with casein and by autophosphorylation, but stimulates both activities with the holoenzyme. When physiological substrates for casein kinase II are examined, glycogen synthase and eukaryotic initiation factor 3 (eIF-3) (p120) are phosphorylated by the alpha-subunit at a rate equivalent to that of the holoenzyme, while phosphorylation of eIF-3 (p67) is reduced 9-fold and eIF-2-beta is not modified. From these data, it can be concluded that the alpha-subunit of casein kinase II is sufficient for catalysis, is autophosphorylated, and can be directly inhibited by heparin, whereas the beta-subunit mediates the effects of basic stimulatory compounds and is involved in recognition and/or binding to specific physiological substrates.			LIN, WJ (corresponding author), UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA.				NIGMS NIH HHS [GM26738] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026738] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACKERMAN P, 1990, P NATL ACAD SCI USA, V87, P821, DOI 10.1073/pnas.87.2.821; ACKERMAN P, 1989, J BIOL CHEM, V264, P11958; BENNE R, 1978, P NATL ACAD SCI USA, V75, P108, DOI 10.1073/pnas.75.1.108; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHENWU JLP, 1988, MOL CELL BIOL, V8, P4981, DOI 10.1128/MCB.8.11.4981; COCHET C, 1983, MOL CELL ENDOCRINOL, V30, P247, DOI 10.1016/0303-7207(83)90062-X; COCHET C, 1983, J BIOL CHEM, V258, P1403; CRISS WE, 1978, CANCER RES, V38, P3532; FEIGE JJ, 1983, BIOCHEMISTRY-US, V22, P1452, DOI 10.1021/bi00275a020; FEIGE JJ, 1980, FEBS LETT, V121, P139, DOI 10.1016/0014-5793(80)81283-X; GLOVER CVC, 1983, J BIOL CHEM, V258, P3258; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hathaway G M, 1979, Methods Enzymol, V60, P495; HATHAWAY GM, 1984, J BIOL CHEM, V259, P2850; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HATHAWAY GM, 1984, J BIOL CHEM, V259, P7011; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HATHAWAY GM, 1982, CURR TOP CELL REGUL, V21, P101; HATHAWAY GM, 1981, J BIOL CHEM, V256, P1442; JAKOBI R, 1989, EUR J BIOCHEM, V183, P227, DOI 10.1111/j.1432-1033.1989.tb14917.x; MEGGIO F, 1984, EUR J BIOCHEM, V145, P593, DOI 10.1111/j.1432-1033.1984.tb08598.x; MEISNER H, 1989, BIOCHEMISTRY-US, V28, P4072, DOI 10.1021/bi00435a066; PALEN E, 1990, FASEB J, V4, pA2075; SAXENA A, 1987, MOL CELL BIOL, V7, P3409, DOI 10.1128/MCB.7.10.3409; TAKIO K, 1987, P NATL ACAD SCI USA, V84, P4851, DOI 10.1073/pnas.84.14.4851; TRAUGH JA, 1990, ADV 2ND MESSENGER PH, V24, P224; TRAUGH JA, 1981, COLD SPRING HARBOR C, V8, P999; TRAUGH JA, 1989, REGULATION CELL GROW, V1, P173; TUAZON PT, 1991, ADV 2ND MESSENGER PH, V23, P123; WOODGETT JR, 1984, BIOCHIM BIOPHYS ACTA, V788, P339, DOI 10.1016/0167-4838(84)90047-5	30	99	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5664	5669						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1900838				2022-12-25	WOS:A1991FD37000048
J	KOJIMA, N; HAKOMORI, SI				KOJIMA, N; HAKOMORI, SI			MOLECULAR MECHANISMS OF CELL MOTILITY .3. CELL-ADHESION, SPREADING, AND MOTILITY OF GM3-EXPRESSING CELLS BASED ON GLYCOLIPID-GLYCOLIPID INTERACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; BINDING-PROTEIN; MELANOMA-CELLS; ENDOGENOUS LECTINS; RECOGNITION; FIBRONECTIN; MIGRATION; INTEGRIN; TUMOR; DETERMINANTS	Cell lines expressing varying levels of ganglioside G(M3) at the cell surface show different degrees of adhesion and spreading on solid phase coated with such glycosphingolipids (GSLs) as Gg3 (GalNAc-beta-1 --> 4Gal-beta-1 --> 4Glc-beta-1 --> 1Cer), LacCer (Gal-beta-1 --> 4Glc-beta-1 --> 1Cer), or Gb4 (GalNAc-beta-1 --> 3Gal-alpha-1 --> 4Gal-beta-1 --> 4Glc-beta-1 --> 1Cer) (where Cer is ceramide), which may have structures complementary to G(M3), but not on solid phase coated with various other GSLs. The degree of cell adhesion and spreading on Gg3 was correlated with the degree of cell-surface G(M3) expression, as defined by reactivity with anti-G(M3) monoclonal antibody (mAb) DH2. Only cells with high G(M3) expression adhered on solid phase coated with LacCer or Gb4. Adhesion of G(M3)-expressing cells on Gg3-, LacCer-, and Gb4-coated solid phase is based on interaction of G(M3) with G(g3) and, to a lesser extent, with LacCer and Gb4, as demonstrated by: (i) the interaction of the G(M3) liposome with solid phase coated with Gg3, LacCer, and Gb4, respectively; (ii) the abolition of cell adhesion on each GSL-coated solid phase by treatment of cells with mAb DH2 or sialidase; and (iii) the inhibition of cell adhesion by treatment of GSL-coated solid phase with mAb specific to each GSL. Sialosyllactosyl-lysyllysine conjugate was bound to Gg3 adsorbed on a C18 silica gel column in the presence of bivalent cation, suggesting that the carbohydrate moiety of G(M3) is involved in G(M3)-Gg3 interaction. Not only the adhesion and spreading of G(M3)-expressing cells, but also their cell motility was greatly enhanced on Gg3-coated solid phase, as determined by Transwell assay and phagokinetic track assay on a gold sol-coated surface. Spreading and motility of G(M3)-expressing cells on Gg3-coated solid phase were both inhibited by treatment of cells with mAb DH2 or sialidase. These results provide evidence that not only cell adhesion, but also spreading and motility in these cell lines are controlled by complementary GSL-GSL interaction.	UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195	University of Washington; University of Washington Seattle	KOJIMA, N (corresponding author), BIOMEMBRANE INST,SEATTLE,WA 98119, USA.				NATIONAL CANCER INSTITUTE [R35CA042505] Funding Source: NIH RePORTER; NCI NIH HHS [CA42505] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBRECHTBUEHLER G, 1977, CELL, V11, P395, DOI 10.1016/0092-8674(77)90057-5; BARONDES SH, 1981, ANNU REV BIOCHEM, V50, P207, DOI 10.1146/annurev.bi.50.070181.001231; BIRD JM, 1984, DEV BIOL, V104, P449, DOI 10.1016/0012-1606(84)90101-5; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; EGGENS I, 1989, J BIOL CHEM, V264, P9476; FENDERSON BA, 1984, J EXP MED, V160, P1591, DOI 10.1084/jem.160.5.1591; FENDERSON BA, 1990, BIOESSAYS, V12, P173, DOI 10.1002/bies.950120406; FIDLER IJ, 1975, CANCER RES, V35, P218; GABIUS HJ, 1986, ANTICANCER RES, V6, P573; GABIUS HJ, 1985, CANCER RES, V45, P253; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HAKOMORI SI, 1983, SPHINGOLIPID BIOCH, P1; HALTIWANGER RS, 1986, J BIOL CHEM, V261, P7440; HART IR, 1979, AM J PATHOL, V97, P587; HEMLER ME, 1990, ANNU REV IMMUNOL, V8, P365, DOI 10.1146/annurev.iy.08.040190.002053; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; KOBATA A, 1972, METHOD ENZYMOL, V28, P262; KOJIMA N, 1989, J BIOL CHEM, V264, P20159; LEHRMAN MA, 1986, J BIOL CHEM, V261, P712; LIANG JG, 1988, BIOCHEMISTRY-US, V27, P5329; MAKABE T, 1990, J BIOL CHEM, V265, P14270; MARCHASE RB, 1977, J CELL BIOL, V75, P237, DOI 10.1083/jcb.75.1.237; MCCARTHY JB, 1983, J CELL BIOL, V97, P772, DOI 10.1083/jcb.97.3.772; MIYAKE M, 1991, BIOCHEMISTRY-US, V30, P3328, DOI 10.1021/bi00227a023; MOUTSATSOS IK, 1987, P NATL ACAD SCI USA, V84, P6452, DOI 10.1073/pnas.84.18.6452; NAGASAWA T, 1973, B CHEM SOC JPN, V46, P1269, DOI 10.1246/bcsj.46.1269; OBATA K, 1977, NATURE, V266, P369, DOI 10.1038/266369a0; PHILLIPS ML, 1990, SCIENCE, V250, P1130, DOI 10.1126/science.1701274; PIERCE M, 1982, J CELL BIOL, V93, P76, DOI 10.1083/jcb.93.1.76; POLLEY MJ, 1991, P NATL ACAD SCI USA, V88, P6224, DOI 10.1073/pnas.88.14.6224; RAUVALA H, 1981, J CELL BIOL, V88, P127, DOI 10.1083/jcb.88.1.127; RAZ A, 1989, CANCER RES, V49, P3489; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; ROCK P, 1991, BIOCHEMISTRY-US, V30, P19, DOI 10.1021/bi00215a003; ROSEMAN S, 1970, CHEM PHYS LIPIDS, V5, P270, DOI 10.1016/0009-3084(70)90024-1; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; SHARON N, 1984, BIOL CELL, V51, P239, DOI 10.1111/j.1768-322X.1984.tb00304.x; SHUR BD, 1982, J BIOL CHEM, V257, P6871; STRAUS AH, 1989, EXP CELL RES, V183, P126, DOI 10.1016/0014-4827(89)90423-0; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; TILLACK TW, 1983, BIOCHIM BIOPHYS ACTA, V733, P15, DOI 10.1016/0005-2736(83)90086-X; WOO HJ, 1990, J BIOL CHEM, V265, P7097; 1977, LIPIDS, V12, P455	46	196	197	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17552	17558						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894638				2022-12-25	WOS:A1991GF44500085
J	CHAKRAVARTI, D; IBEANU, GC; TANO, K; MITRA, S				CHAKRAVARTI, D; IBEANU, GC; TANO, K; MITRA, S			CLONING AND EXPRESSION IN ESCHERICHIA-COLI OF A HUMAN CDNA-ENCODING THE DNA-REPAIR PROTEIN N-METHYLPURINE-DNA GLYCOSYLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOFUNCTIONAL ALKYLATING-AGENTS; 3-METHYLADENINE-DNA GLYCOSYLASE; ADAPTIVE RESPONSE; ALKA GENE; PURIFICATION; CELLS; RESISTANT; FRAGMENTS; INDUCTION; ACID	A 871-base pair cDNA encoding the human N-methylpurine-DNA glycosylase (MPG) was cloned from a HeLa S3 cDNA expression library in a pUC vector by phenotypic screening of MPG-negative (tag- alkA-) Escherichia coli cells exposed to methylmethane sulfonate. The active MPG is expressed as a 31-kDa fusion protein. The human cDNA-encoded MPG releases 3-methyladenine, 7-methylguanine, and 3-methyl-guanine from DNA and thus has a substrate range similar to that of the indigenous enzyme and the E. coli AlkA protein. The cDNA hybridizes with distinct restriction fragments of mammalian DNAs but not with E. coli or yeast DNA. A search in the GenBank data bank failed to show any other cloned DNA with a similar sequence. Although the human protein has 62% sequence homology with the corresponding rat enzyme, only a few amino acid residues are conserved between the human protein and the E. coli and yeast MPGs. However, a conserved glutamine residue in all MPGs that release 3-alkyladenine and an arginine residue in eukaryotic MPGs and E. coli AlkA that act additionally on N-alkylguanines suggest that these residues are involved in recognition of adenine and guanine adducts in DNA, respectively. Although the 1.1-kilobase mRNAs of MPG from human and rodents are similar in size, liver and cultured cells of rat have much lower levels of MPG mRNA than do human and mouse cells. A hamster cell line variant isolated as being resistant to methylmethane sulfonate does not have a higher level of MPG mRNA than the parent cell line.	OAK RIDGE NATL LAB, DIV BIOL, OAK RIDGE, TN 37831 USA; UNIV TENNESSEE, OAK RIDGE GRAD SCH BIOMED SCI, OAK RIDGE, TN 37830 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory; United States Department of Energy (DOE); Oak Ridge National Laboratory; University of Tennessee System; University of Tennessee Knoxville					NCI NIH HHS [CA31721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA031721] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BERANEK DT, 1990, MUTAT RES, V231, P11, DOI 10.1016/0027-5107(90)90173-2; BERDAL KG, 1990, EMBO J, V9, P4563, DOI 10.1002/j.1460-2075.1990.tb07909.x; BJELLAND S, 1987, NUCLEIC ACIDS RES, V15, P2787, DOI 10.1093/nar/15.7.2787; BODELL WJ, 1988, CANCER RES, V48, P4489; BRADLEY JE, 1988, BIOTECHNIQUES, V6, P114; CHAKRAVARTI D, 1990, FASEB J, V4, pA2291; CHEN J, 1989, P NATL ACAD SCI USA, V86, P7961, DOI 10.1073/pnas.86.20.7961; CHEN J, 1990, EMBO J, V9, P4569, DOI 10.1002/j.1460-2075.1990.tb07910.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRADDOCK VM, 1982, CARCINOGENESIS, V3, P747, DOI 10.1093/carcin/3.7.747; DUNN WC, 1991, CARCINOGENESIS, V12, P83, DOI 10.1093/carcin/12.1.83; EBRIGHT RH, 1986, UCLA S MOL CELL BIOL, V39, P207; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOOTE RS, 1984, CARCINOGENESIS, V5, P277, DOI 10.1093/carcin/5.2.277; GALLAGHER PE, 1984, BIOCHIM BIOPHYS ACTA, V782, P394, DOI 10.1016/0167-4781(84)90045-9; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; HELLAND DE, 1987, J CELL SCI, P139; LINDAHL T, 1988, ANNU REV BIOCHEM, V57, P133, DOI 10.1146/annurev.bi.57.070188.001025; LINDAHL T, 1982, ANNU REV BIOCHEM, V51, P61, DOI 10.1146/annurev.bi.51.070182.000425; MALE R, 1985, J BIOL CHEM, V260, P1623; MALE R, 1981, EUR J BIOCHEM, V121, P243, DOI 10.1111/j.1432-1033.1981.tb06455.x; MANIATIS T, 1982, MOL CLONING LABORATO, P280; MCCARTHY TV, 1984, EMBO J, V3, P545, DOI 10.1002/j.1460-2075.1984.tb01844.x; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3723; NAKABEPPU Y, 1984, J BIOL CHEM, V259, P3730; OCONNOR TR, 1990, EMBO J, V9, P3337, DOI 10.1002/j.1460-2075.1990.tb07534.x; SAKUMI K, 1986, J BIOL CHEM, V261, P5761; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEEMAN NC, 1976, P NATL ACAD SCI USA, V73, P804, DOI 10.1073/pnas.73.3.804; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SONO A, 1988, SOMAT CELL MOLEC GEN, V14, P329, DOI 10.1007/BF01534641; TANO K, 1990, P NATL ACAD SCI USA, V87, P686, DOI 10.1073/pnas.87.2.686; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; VOLKERT MR, 1988, ENVIRON MOL MUTAGEN, V11, P241, DOI 10.1002/em.2850110210; VOLKERT MR, 1986, GENETICS, V112, P11; WASHINGTON WJ, 1988, MUTAT RES, V207, P165, DOI 10.1016/0165-1218(88)90236-4; WASHINGTON WJ, 1989, MECH AGEING DEV, V48, P43, DOI 10.1016/0047-6374(89)90024-9	39	136	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15710	15715						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874728				2022-12-25	WOS:A1991GB97700032
J	CHOI, KW; SMITH, RF; BURATOWSKI, RM; QUINN, WG				CHOI, KW; SMITH, RF; BURATOWSKI, RM; QUINN, WG			DEFICIENT PROTEIN-KINASE-C ACTIVITY IN TURNIP, A DROSOPHILA LEARNING MUTANT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER RECEPTOR; LONG-TERM POTENTIATION; ADENYLATE-CYCLASE; RAT-BRAIN; WILD-TYPE; MELANOGASTER; SENSITIZATION; PURIFICATION; MEMORY; PHOSPHODIESTERASE	The Drosophila mutant turnip was initially isolated based on poor learning performance (Quinn, W. G., Sziber, P. P., and Booker, R. (1979) Nature 277, 212-214). Here we show that turnip is dramatically reduced in protein kinase C (PKC) activity. In addition, turnip flies are deficient in phosphorylation of a 76-kDa head membrane protein (hereafter pp76) which is a major substrate for protein kinase C in homogenates of wild-type flies. Reduced PKC activity, defective pp76 phosphorylation, and most of turnip's learning deficiency co-map genetically to a region on the X-chromosome, I8A5-18D1-2, spanned by the deletion Df(1)JA27. Apparently turnip+ is not a structural gene for PKC because Drosophila PKC genes map elsewhere in the genome. Our results suggest that turnip gene product is required for activation of PKC and that PKC plays a role in associative learning in Drosophila.	MIT,DEPT BRAIN & COGNIT SCI,CAMBRIDGE,MA 02139; MIT,DEPT BIOL,CAMBRIDGE,MA 02139	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)			Choi, Kwang-Wook/C-1707-2011	Choi, Kwang-Wook/0000-0002-8997-3065	NIGMS NIH HHS [GM 07287] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACEVESPINA EO, 1983, COLD SPRING HARB SYM, V48, P831, DOI 10.1101/SQB.1983.048.01.086; ACEVESPINA FO, 1979, SCIENCE, V206, P93, DOI 10.1126/science.206.4414.93; AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; BOOKER R, 1981, P NATL ACAD SCI-BIOL, V78, P3940, DOI 10.1073/pnas.78.6.3940; BRAHA O, 1990, P NATL ACAD SCI USA, V87, P2040, DOI 10.1073/pnas.87.5.2040; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CHEN CN, 1986, P NATL ACAD SCI USA, V83, P9313, DOI 10.1073/pnas.83.24.9313; CHOI KW, 1988, THESIS PRINCETON U P; CRAYMER L, 1980, DROSOPH INF SERV, V55, P200; DUDAI Y, 1976, P NATL ACAD SCI USA, V73, P1684, DOI 10.1073/pnas.73.5.1684; DUERR JS, 1982, P NATL ACAD SCI-BIOL, V79, P3646, DOI 10.1073/pnas.79.11.3646; EDELMAN AM, 1987, ANNU REV BIOCHEM, V56, P567, DOI 10.1146/annurev.biochem.56.1.567; FARLEY J, 1986, NATURE, V319, P220, DOI 10.1038/319220a0; FOLKERS E, 1982, J INSECT PHYSIOL, V28, P535, DOI 10.1016/0022-1910(82)90034-8; GITSCHIER J, 1980, BIOCHIM BIOPHYS ACTA, V595, P291, DOI 10.1016/0005-2736(80)90091-7; HUANG KP, 1986, P NATL ACAD SCI USA, V83, P8535, DOI 10.1073/pnas.83.22.8535; JAKEN S, 1987, P NATL ACAD SCI USA, V84, P4418, DOI 10.1073/pnas.84.13.4418; KALDERON D, 1988, GENE DEV, V2, P1539, DOI 10.1101/gad.2.12a.1539; KANDEL ER, 1983, COLD SPRING HARB SYM, V48, P821, DOI 10.1101/SQB.1983.048.01.085; KATADA T, 1985, EUR J BIOCHEM, V151, P431, DOI 10.1111/j.1432-1033.1985.tb09120.x; KIKKAWA U, 1982, J BIOL CHEM, V257, P13341; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDSLEY DL, 1987, DROS INFORM SERV, V65, P1; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OBRIEN SJ, 1978, GENETICS BIOL DROS A, V2, P395; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PARKER PJ, 1986, SCIENCE, V233, P853, DOI 10.1126/science.3755547; PARKER PJ, 1984, EMBO J, V3, P953, DOI 10.1002/j.1460-2075.1984.tb01913.x; QUINN WG, 1974, P NATL ACAD SCI USA, V71, P708, DOI 10.1073/pnas.71.3.708; QUINN WG, 1979, NATURE, V277, P212, DOI 10.1038/277212a0; ROSENTHAL A, 1987, EMBO J, V6, P433, DOI 10.1002/j.1460-2075.1987.tb04773.x; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SCHWARTZ JH, 1983, COLD SPRING HARB SYM, V48, P811, DOI 10.1101/SQB.1983.048.01.084; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; TEMPEL BL, 1983, P NATL ACAD SCI-BIOL, V80, P1482, DOI 10.1073/pnas.80.5.1482; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; YOSHIMASA T, 1987, NATURE, V327, P67, DOI 10.1038/327067a0	40	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15999	16006						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874743				2022-12-25	WOS:A1991GB97700072
J	HANSPAL, M; KALRAIYA, R; HANSPAL, J; SAHR, KE; PALEK, J				HANSPAL, M; KALRAIYA, R; HANSPAL, J; SAHR, KE; PALEK, J			ERYTHROPOIETIN ENHANCES THE ASSEMBLY OF ALPHA,BETA-SPECTRIN HETERODIMERS ON THE MURINE ERYTHROBLAST MEMBRANES BY INCREASING BETA-SPECTRIN SYNTHESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE MEMBRANE; ALPHA-SPECTRIN; MESSENGER-RNA; UNEQUAL SYNTHESIS; PROTEIN 4.1; PHOSPHATIDYLSERINE; CELLS; DIFFERENTIATION; TRANSCRIPTION; IDENTIFICATION	Previous biosynthetic studies have revealed that in both mammalian and chicken erythroid cells, alpha-spectrin is synthesized in 2-3-fold excess over beta-spectrin. However, in the membrane skeleton, the two polypeptides are assembled in equimolar amounts, suggesting that the association of a spectrin with the membrane skeleton is rate-limited by the amount of beta-spectrin synthesized. Here we have analyzed the synthesis and transcription of alpha and beta-spectrin in Friend virus-infected murine erythroblasts (FVA cells) in vitro during the erythropoietin-dependent period of maturation. Erythropoietin (Epo) increases the synthesis of beta-spectrin but not a spectrin, thereby altering the alpha/beta-spectrin synthetic ratio. When immature FVA cells are exposed for 24 h to a standard dose of 0.2 unit/ml Epo for maximum effect, the mRNA content and the synthesis of beta-spectrin are increased resulting in about 1.3-1.5-fold excess of beta-spectrin over alpha-spectrin in the cytosol. On the membrane, the incorporation of both alpha and beta-spectrins is increased equally by about 30-35%. Furthermore, nuclear run-off transcription measurements indicate that the increased beta-spectrin gene expression is regulated at the level of transcription. We conclude that in cells with strong Epo stimulus, the expression and synthesis of beta-spectrin are increased resulting in an increase in the amount of alpha,beta-spectrin heterodimers available for membrane assembly.			HANSPAL, M (corresponding author), TUFTS UNIV,ST ELIZABETHS HOSP,SCH MED,DEPT BIOMED RES,736 CAMBRIDGE ST,BOSTON,MA 02135, USA.				NHLBI NIH HHS [HL 37462] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL037462] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON RA, 1984, NATURE, V307, P655, DOI 10.1038/307655a0; AXELRAD AA, 1964, VIROLOGY, V24, P513, DOI 10.1016/0042-6822(64)90199-0; BENNETT V, 1979, J BIOL CHEM, V254, P2533; BENNETT V, 1980, J BIOL CHEM, V255, P6424; BITBOL M, 1989, FEBS LETT, V244, P217, DOI 10.1016/0014-5793(89)81196-2; BLIKSTAD I, 1983, CELL, V32, P1081, DOI 10.1016/0092-8674(83)90292-1; BODINE DM, 1984, CELL, V37, P721, DOI 10.1016/0092-8674(84)90408-2; BONDURANT MC, 1985, MOL CELL BIOL, V5, P675, DOI 10.1128/MCB.5.4.675; CIOE L, 1987, BLOOD, V70, P915; COHEN AM, 1986, BLOOD, V68, P920; COHEN AM, 1988, BIOCHEMISTRY-US, V27, P614, DOI 10.1021/bi00402a018; CURTIS PJ, 1985, GENE, V36, P357, DOI 10.1016/0378-1119(85)90191-X; DANDREA AD, 1990, J CLIN INVEST, V86, P681, DOI 10.1172/JCI114763; GRABER SE, 1989, HEMATOL ONCOL CLIN N, V3, P369; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HADCOCK JR, 1989, AM J PHYSIOL, V256, pC457, DOI 10.1152/ajpcell.1989.256.3.C457; HANSPAL M, 1987, J CELL BIOL, V105, P1417, DOI 10.1083/jcb.105.3.1417; HANSPAL M, 1991, BLOOD, V77, P165; KOURY MJ, 1988, J CELL PHYSIOL, V137, P65, DOI 10.1002/jcp.1041370108; KOURY MJ, 1987, J CELL PHYSIOL, V133, P438, DOI 10.1002/jcp.1041330304; KOURY MJ, 1984, J CELL PHYSIOL, V121, P526, DOI 10.1002/jcp.1041210311; LEHNERT ME, 1988, J CELL BIOL, V107, P413, DOI 10.1083/jcb.107.2.413; MAKSYMIW R, 1987, BIOCHEMISTRY-US, V26, P2983, DOI 10.1021/bi00385a005; MANIATIS T, 1989, MOL CLONING LABORATO, P196; MCKNIGHT GS, 1979, J BIOL CHEM, V254, P9050; NIJHOF W, 1987, EXP HEMATOL, V15, P779; PALEK J, 1990, SEMIN HEMATOL, V27, P290; PFEFFER SR, 1986, J CELL BIOL, V103, P103, DOI 10.1083/jcb.103.1.103; RYBICKI AC, 1988, J CLIN INVEST, V81, P255, DOI 10.1172/JCI113303; SAWYER ST, 1987, METHOD ENZYMOL, V147, P340; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; TULLIS RH, 1980, ANAL BIOCHEM, V107, P260, DOI 10.1016/0003-2697(80)90519-9	32	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15626	15630						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874720				2022-12-25	WOS:A1991GB97700017
J	KESSELS, GCR; GERVAIX, A; LEW, PD; VERHOEVEN, AJ				KESSELS, GCR; GERVAIX, A; LEW, PD; VERHOEVEN, AJ			THE CHYMOTRYPSIN INHIBITOR CARBOBENZYLOXY-LEUCINE-TYROSINE-CHLOROMETHYLKETONE INTERFERES WITH PHOSPHOLIPASE-D ACTIVATION INDUCED BY FORMYL-METHIONYL-LEUCYL-PHENYLALANINE IN HUMAN NEUTROPHILS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; DEPENDENT SUPEROXIDE PRODUCTION; RESPIRATORY BURST; SIGNAL TRANSDUCTION; HL-60 GRANULOCYTES; PHOSPHATIDIC-ACID; ARACHIDONIC-ACID; PLASMA-MEMBRANE; NADPH OXIDASE	The effects of carbobenzyloxy-leucine-tyrosine-chloromethylketone (zLYCK), an inhibitor of chymotrypsin-like proteases, on signal transduction in human neutrophils triggered by the chemoattractant formyl-methionyl-leucyl-phenylalanine (fMLP) were investigated. zLYCK (10-mu-M) inhibited the fMLP-induced respiratory burst in neutrophils treated with cytochalasin B. In the presence of zLYCK (10-mu-M), the activation of phospholipase D in response to fMLP addition was inhibited. zLYCK did not inhibit the binding of [H-3]fMLP to its receptor or the enzymic activity of phospholipase D because the response to ionomycin was unaffected. The effect of zLYCK on phospholipase D correlated well with its effects on the accumulation of diglycerides, which was also inhibited in the presence of zLYCK. In electropermeabilized neutrophils, too, zLYCK caused an inhibition of the fMLP-induced respiratory burst and the fMLP-induced activation of phospholipase D. Interestingly, this inhibition could be bypassed by guanosine 5'-O-(thiotriphosphate). We conclude that the inhibition of the respiratory burst in human neutrophils by zLYCK is caused by the selective inhibition of signal transduction leading to activation of phospholipase D and that zLYCK might be a useful probe to study the role of phospholipase D in neutrophil activation.	NETHERLANDS RED CROSS,BLOOD TRANSFUS SERV,CENT LAB,POB 9190,1006 AD AMSTERDAM,NETHERLANDS; UNIV AMSTERDAM,EXPTL & CLIN IMMUNOL LAB,1066 CX AMSTERDAM,NETHERLANDS; UNIV GENEVA,CHILDRENS HOSP,DEPT PEDIAT,CH-1211 GENEVA 4,SWITZERLAND; UNIV GENEVA,DEPT MED,DIV INFECT DIS,CH-1211 GENEVA 4,SWITZERLAND	University of Amsterdam; University of Geneva; University of Geneva								AMBRUSO DR, 1990, J BIOL CHEM, V265, P924; ANTHES JC, 1989, BIOCHEM BIOPH RES CO, V163, P657, DOI 10.1016/0006-291X(89)92187-6; BAGGIOLINI M, 1990, TRENDS BIOCHEM SCI, V15, P69, DOI 10.1016/0968-0004(90)90179-F; BELLAVITE P, 1988, J BIOL CHEM, V263, P8210; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BOLSCHER BGJM, 1990, J BIOL CHEM, V265, P15782; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; COMBADIERE C, 1990, BIOCHEM BIOPH RES CO, V168, P65, DOI 10.1016/0006-291X(90)91675-I; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DEWALD B, 1988, J BIOL CHEM, V263, P16179; FOREHAND JR, 1989, J CLIN INVEST, V83, P74, DOI 10.1172/JCI113887; GABIG TG, 1979, J BIOL CHEM, V254, P9070; GOMEZCAMBRONERO J, 1989, INT ARCH ALLER A IMM, V89, P362, DOI 10.1159/000234976; GRINSTEIN S, 1988, J BIOL CHEM, V263, P1779; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; KOENDERMAN L, 1989, FEBS LETT, V243, P399, DOI 10.1016/0014-5793(89)80170-X; KOENDERMAN L, 1989, J IMMUNOL, V142, P623; KRAMER IM, 1988, J BIOL CHEM, V263, P2352; MCPHAIL LC, 1983, J CLIN INVEST, V72, P192, DOI 10.1172/JCI110957; MULLMANN TJ, 1990, J IMMUNOL, V144, P1901; NACCACHE PH, 1983, J CELL PHYSIOL, V115, P243, DOI 10.1002/jcp.1041150305; PAI JK, 1988, J BIOL CHEM, V263, P12472; PEVERI P, 1990, BLOOD S1, V76; PREISS J, 1986, J BIOL CHEM, V261, P8597; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; ROBINSON JM, 1990, BIOCHIM BIOPHYS ACTA, V1055, P55, DOI 10.1016/0167-4889(90)90090-Z; ROSSI F, 1990, BIOCHEM BIOPH RES CO, V168, P320, DOI 10.1016/0006-291X(90)91711-Z; SAKO T, 1988, CANCER RES, V48, P4646; SEGAL AW, 1985, NATURE, V316, P547, DOI 10.1038/316547a0; SUTER S, 1986, PEDIATR RES, V20, P848, DOI 10.1203/00006450-198609000-00008; TAUBER AI, 1979, BIOCHEMISTRY-US, V18, P5576, DOI 10.1021/bi00592a009; TAUBER AI, 1987, BLOOD, V69, P1711; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; YUKISHIGE K, 1980, FEBS LETT, V124, P19	37	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15870	15875						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874738				2022-12-25	WOS:A1991GB97700054
J	KNUTSON, VP				KNUTSON, VP			PROTEOLYTIC PROCESSING OF THE INSULIN-RECEPTOR BETA-SUBUNIT IS ASSOCIATED WITH INSULIN-INDUCED RECEPTOR DOWN-REGULATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED HUMAN-LYMPHOCYTES; GROWTH-FACTOR RECEPTORS; RAS GENE-PRODUCTS; CELL-SURFACE; CATHEPSIN-L; 3T3-L1 ADIPOCYTES; DEGRADATION; PROTEIN; INACTIVATION; BINDING	This report describes the use of an antibody directed against the carboxyl terminus of the insulin receptor beta-subunit to assess the fate of the insulin receptor protein over the time course of insulin-induced receptor down-regulation. The insulin receptor beta-subunit is lost from the cellular membranes of insulin-treated 3T3-C2 fibroblasts with a time course superimposable with the insulin-induced loss of cellular insulin binding activity. Concomitant with the time-dependent loss of the intact beta-subunit from the membranes, a 61,000-Da fragment of the insulin receptor beta-subunit accumulates in the cytosol of the cells in a time-dependent manner. The insulin-induced loss of the intact beta-subunit from the cellular membranes is inhibited by cycloheximide. Chloroquine and the thiol protease inhibitors leupeptin and E-64 inhibit the insulin-induced loss of the intact beta-subunit from the membranes and induce an accumulation of the intact subunit in the membranes. However, in the presence of leupeptin, E-64, or chloroquine, the insulin-induced loss of insulin binding activity occurs normally. These data indicate that down-regulation results in the loss of the intact beta-subunit from the cellular membranes with the production of a fragment of the beta-subunit in the cytosol. The protease responsible for the generation of the fragment is a thiol protease which requires acidic conditions. Since the insulin-induced proteolysis of the beta-subunit can be totally inhibited under conditions where the insulin-induced loss of insulin binding activity proceeds normally, the proteolysis of the beta-subunit is a process which is separate and distinguishable from the insulin-induced loss of insulin binding activity.			KNUTSON, VP (corresponding author), UNIV TEXAS,SCH MED,DEPT PHARMACOL,6431 FANNIN,POB 20708,HOUSTON,TX 77225, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035397] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK35397] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAR RS, 1976, J CLIN INVEST, V58, P1123, DOI 10.1172/JCI108565; BARICOS WH, 1988, BIOCHEM J, V252, P301, DOI 10.1042/bj2520301; BARRETT AJ, 1982, BIOCHEM J, V201, P189, DOI 10.1042/bj2010189; BARRETT AJ, 1981, PROTEINASES THEIR IN, P103; BERGERON JJM, 1985, ANNU REV PHYSIOL, V47, P383; BEYNON RJ, 1986, AM J PHYSIOL, V251, pC141, DOI 10.1152/ajpcell.1986.251.2.C141; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; DEDUVE C, 1983, EUR J BIOCHEM, V137, P391, DOI 10.1111/j.1432-1033.1983.tb07841.x; ELLIS L, 1987, MOL ENDOCRINOL, V1, P15, DOI 10.1210/mend-1-1-15; HERRERA R, 1986, J BIOL CHEM, V261, P2489; HERRERA R, 1985, P NATL ACAD SCI USA, V82, P7899, DOI 10.1073/pnas.82.23.7899; HIWASA T, 1988, BIOCHEM BIOPH RES CO, V151, P78, DOI 10.1016/0006-291X(88)90561-X; HIWASA T, 1988, FEBS LETT, V233, P367, DOI 10.1016/0014-5793(88)80462-9; KASUGA M, 1981, P NATL ACAD SCI-BIOL, V78, P6917, DOI 10.1073/pnas.78.11.6917; KATHURIA S, 1986, P NATL ACAD SCI USA, V83, P8570, DOI 10.1073/pnas.83.22.8570; KNUTSON VP, 1986, J BIOL CHEM, V261, P306; KNUTSON VP, 1987, J BIOL CHEM, V262, P2374; KNUTSON VP, 1982, P NATL ACAD SCI-BIOL, V79, P2822, DOI 10.1073/pnas.79.9.2822; KNUTSON VP, 1985, J BIOL CHEM, V260, P4180; KNUTSON VP, 1991, J IMMUNOL METHODS, V136, P151, DOI 10.1016/0022-1759(91)90001-V; KNUTSON VP, 1983, J BIOL CHEM, V258, P2139; KNUTSON VP, 1991, ARCH BIOCHEM BIOPHYS, V285, P197, DOI 10.1016/0003-9861(91)90349-N; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEREA KM, 1986, BIOCHEM J, V236, P535, DOI 10.1042/bj2360535; LIPSON KE, 1989, BIOCHEM J, V261, P333, DOI 10.1042/bj2610333; MASSAGUE J, 1981, J BIOL CHEM, V256, P3182; OKABAYASHI Y, 1989, DIABETES, V38, P182, DOI 10.2337/diabetes.38.2.182; POSNER BI, 1985, ADV EXP MED BIOL, V189, P159; RICH DH, 1986, PROTEINASE INHIBITOR, P153; RONNETT GV, 1983, J BIOL CHEM, V258, P283; RONNETT GV, 1982, J BIOL CHEM, V257, P4285; ROTH RA, 1983, J BIOL CHEM, V258, P4456; ROUILLER DG, 1987, P NATL ACAD SCI USA, V84, P126, DOI 10.1073/pnas.84.1.126; ROUILLER DG, 1988, J BIOL CHEM, V263, P13185; SHILA MA, 1983, J BIOL CHEM, V258, P14450; SOLL AH, 1975, J CLIN INVEST, V56, P769, DOI 10.1172/JCI108155; STOSCHECK CM, 1988, J CELL BIOCHEM, V38, P51, DOI 10.1002/jcb.240380106	37	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15656	15662						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874723				2022-12-25	WOS:A1991GB97700022
J	TSUNEYOSHI, T; WESTERHAUSEN, A; CONSTANTINOU, CD; PROCKOP, DJ				TSUNEYOSHI, T; WESTERHAUSEN, A; CONSTANTINOU, CD; PROCKOP, DJ			SUBSTITUTIONS FOR GLYCINE ALPHA-1-637 AND GLYCINE ALPHA-2-694 OF TYPE-I PROCOLLAGEN IN LETHAL OSTEOGENESIS IMPERFECTA - THE CONFORMATIONAL STRAIN ON THE TRIPLE HELIX INTRODUCED BY A GLYCINE SUBSTITUTION CAN BE TRANSMITTED ALONG THE HELIX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN GENE STRUCTURE; LENGTH CDNA CLONE; THERMAL-STABILITY; MUTATIONS; CHAIN; PROTEIN; ISOMERIZATION; CONSERVATION; DISORDERS; SEQUENCES	Two substitutions for glycine in the triple-helical domain were found in type I procollagen synthesized by skin fibroblasts from two probands with lethal osteogenesis imperfecta. One was a substitution of valine for glycine alpha-1-637, and the other was a substitution of arginine for glycine alpha-2-694. The effects of the mutations on the zipper-like folding of the collagen triple helix were similar, since there was post-translational overmodification of the collagenase A fragments (amino acids 1-775) but not of more COOH-terminal fragments of the protein. The mutations differed markedly, however, on their effects on thermal unfolding of the triple helix. The collagenase A fragment from the collagen containing the arginine alpha-2-694 substitution was cleaved at about amino acid 700 when incubated with trypsin at 30-35-degrees-C. Therefore, there was micro-unfolding of the triple helix at a site close to the glycine substitution. Surprisingly, however, the collagenase A fragment with the valine alpha-1-637 substitution was also cleaved at about amino acid 700 under the same conditions. The results, therefore, demonstrated that although most glycine substitutions delay folding of the triple helix in regions that are NH2-terminal to the site of the substitution, the effects on unfolding can be transmitted to regions that are COOH-terminal to the site of the glycine substitution.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,JEFFERSON INST MOLEC MED,DEPT BIOCHEM & MOLEC BIOL,PHILADELPHIA,PA 19107	Jefferson University			Deltas, Constantinos/J-9345-2013	Deltas, Constantinos/0000-0001-5549-9169	NIAMS NIH HHS [AR38188, AR39740] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740, P01AR038188] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BACHINGER HP, 1978, EUR J BIOCHEM, V90, P605, DOI 10.1111/j.1432-1033.1978.tb12641.x; BARSH GS, 1981, COLLAGEN REL RES, V1, P543; BARSH GS, 1984, J BIOL CHEM, V259, P4906; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P1139, DOI 10.1021/bi00274a023; BERNARD MP, 1983, BIOCHEMISTRY-US, V22, P5213, DOI 10.1021/bi00291a023; BRUCKNER P, 1981, ANAL BIOCHEM, V110, P360, DOI 10.1016/0003-2697(81)90204-9; BRUCKNER P, 1978, EUR J BIOCHEM, V90, P595, DOI 10.1111/j.1432-1033.1978.tb12640.x; BYERS PH, 1990, TRENDS GENET, V6, P293, DOI 10.1016/0168-9525(90)90235-X; BYERS PH, 1988, AM J HUM GENET, V42, P237; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; CONSTANTINOU CD, 1987, EUR J BIOCHEM, V163, P247, DOI 10.1111/j.1432-1033.1987.tb10794.x; ENGEL J, 1991, IN PRESS ANN REV BIO; GIBBS RA, 1989, NUCLEIC ACIDS RES, V17, P2437, DOI 10.1093/nar/17.7.2437; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; IJUTA S, 1987, NUCLEIC ACIDS RES, V15, P797; KADLER KE, 1988, J BIOL CHEM, V263, P10517; KUHN K, 1966, BIOCHEM Z, V344, P418; KUIVANIEMI H, 1988, BIOCHEM J, V252, P633, DOI 10.1042/bj2520633; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; Maniatis T., 1982, MOL CLONING; PACK M, 1989, J BIOL CHEM, V264, P19694; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V32, P1; PROCKOP DJ, 1990, J BIOL CHEM, V265, P15349; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; PROCKOP DJ, 1989, AM J MED GENET, V34, P60, DOI 10.1002/ajmg.1320340112; RYHANEN L, 1983, ARCH BIOCHEM BIOPHYS, V233, P562; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SPOTILLA LD, 1991, IN PRESS P NATL ACAD; STRICKLIN GP, 1977, BIOCHEMISTRY-US, V16, P1607, DOI 10.1021/bi00627a013; Traub W, 1971, Adv Protein Chem, V25, P243, DOI 10.1016/S0065-3233(08)60281-8; TROMP G, 1988, BIOCHEM J, V253, P919, DOI 10.1042/bj2530919; TSUNEYOSHI T, 1990, AM J HUM GENET, V47, pA240; WESTERHAUSEN A, 1990, J BIOL CHEM, V265, P13995; WESTERHAUSEN A, 1990, AM J HUM GENET, V47, pA242; YEE RY, 1974, J MOL BIOL, V83, P1, DOI 10.1016/0022-2836(74)90420-3	37	15	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15608	15613						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874719				2022-12-25	WOS:A1991GB97700014
J	FUNK, CD; FITZGERALD, GA				FUNK, CD; FITZGERALD, GA			EICOSANOID FORMING ENZYME MESSENGER-RNA IN HUMAN TISSUES - ANALYSIS BY QUANTITATIVE POLYMERASE CHAIN-REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; AMINO-ACID SEQUENCE; MOLECULAR-CLONING; LEUKOTRIENE-A4 HYDROLASE; HUMAN 5-LIPOXYGENASE; COMPLEMENTARY-DNA; CDNA; GENE; CYCLOOXYGENASE; EXPRESSION	The key enzymes in the formation of eicosanoids, including leukocyte 5-lipoxygenase (5LX), platelet 12-lipoxygenase (12LX), reticulocyte 15-lipoxygenase (15LX), prostaglandin G/H synthase cyclooxygenase, and leukotriene A4 (LTA) hydrolase have been studied extensively in recent years. Little is known, however, about the regulation of these enzymes at the gene level. We have developed a quantitative polymerase chain reaction (PCR) assay to quantify the mRNAs for these five enzymes, as well as for cytoplasmic beta-actin (bACT) mRNA. Human erythroleukemia (HEL) cells, which display megakaryocytic/erythroid characteristics, were selected as a source of RNA to characterize the assay. These cells expressed mRNA for bACT, LTA, cyclooxygenase, and 12LX (in decreasing order). mRNA for 5LX and 15LX was undetectable. Bronchoalveolar lavage fluid cells obtained from asthmatic patients, primarily alveolar macrophages, contained mRNA for bACT, LTA, 5LX, cyclooxygenase, and 15LX (in decreasing order). Treatment of HEL cells with phorbol 12-myristate 13-acetate or steroid administration to asthmatic patients apparently selectively regulated certain of these target genes. The utility of this assay in quantifying mRNA for the various target genes in blood cells, including platelets from patients with chronic myelogenous leukemia, has also been demonstrated. Studies on the regulation of genes for enzymes involved in the leukotriene and prostaglandin biosynthetic pathways, especially when only small tissue samples are available, will be facilitated with this approach.			FUNK, CD (corresponding author), VANDERBILT UNIV,DEPT CLIN PHARMACOL,NASHVILLE,TN 37232, USA.		Funk, Colin D/A-9518-2010; FitzGerald, Garret A/A-4222-2010	Funk, Colin/0000-0001-7029-4233	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030400] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30400] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; DEWITT DL, 1990, ADV PROSTAGLANDIN TH, V21, P65; DIXON RAF, 1988, P NATL ACAD SCI USA, V85, P416, DOI 10.1073/pnas.85.2.416; DWORSKI R, 1989, AM REV RESPIR DIS, V139, P46, DOI 10.1164/ajrccm/139.1.46; FUNK CD, 1989, P NATL ACAD SCI USA, V86, P2587, DOI 10.1073/pnas.86.8.2587; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; FUNK CD, 1991, ADV PROSTAG THROMB L, V21, P33; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; IZUMI T, 1990, P NATL ACAD SCI USA, V87, P7477, DOI 10.1073/pnas.87.19.7477; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P3406; MATSUMOTO T, 1988, P NATL ACAD SCI USA, V85, P26, DOI 10.1073/pnas.85.1.26; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; MINAMI M, 1987, J BIOL CHEM, V262, P13873; MINAMI M, 1990, BIOCHEM BIOPH RES CO, V173, P620, DOI 10.1016/S0006-291X(05)80080-4; MULLIS KB, 1987, METHOD ENZYMOL, V155, P335; MURPHY LD, 1990, BIOCHEMISTRY-US, V29, P10351, DOI 10.1021/bi00497a009; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; OKUMA M, 1977, NEW ENGL J MED, V297, P1351; OPREY J, 1989, GENE, V84, P493, DOI 10.1016/0378-1119(89)90526-X; PASH JM, 1988, FASEB J, V2, P2613, DOI 10.1096/fasebj.2.10.2968288; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; SCHAFER AI, 1982, NEW ENGL J MED, V306, P381, DOI 10.1056/NEJM198202183060701; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; SIGAL E, 1988, BIOCHEM BIOPH RES CO, V157, P457, DOI 10.1016/S0006-291X(88)80271-7; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YOKOYAMA C, 1988, FEBS LETT, V231, P347, DOI 10.1016/0014-5793(88)80847-0; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; YOSHIMOTO T, 1990, P NATL ACAD SCI USA, V87, P2142, DOI 10.1073/pnas.87.6.2142	40	93	95	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12508	12513						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905725				2022-12-25	WOS:A1991FV18000065
J	NAIM, HY; LACEY, SW; SAMBROOK, JF; GETHING, MJH				NAIM, HY; LACEY, SW; SAMBROOK, JF; GETHING, MJH			EXPRESSION OF A FULL-LENGTH CDNA CODING FOR HUMAN INTESTINAL LACTASE-PHLORIZIN HYDROLASE REVEALS AN UNCLEAVED, ENZYMATICALLY ACTIVE, AND TRANSPORT-COMPETENT PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCRASE-ISOMALTASE; MALTASE-GLUCOAMYLASE; INTRACELLULAR-TRANSPORT; MEMBRANE HYDROLASES; LACTOSE DIGESTION; EPITHELIAL-CELLS; HIGH-MANNOSE; BIOSYNTHESIS; RAT; PURIFICATION	Lactase-phlorizin hydrolase (LPH) (EC 3.2.1.23/62) is a major intestinal microvillar membrane glycoprotein that digests lactose, the main carbohydrate of milk. To investigate structure/function relationships of LPH and to assess the impact of intracellular processing on the function of LPH and on its transport to the cell surface, we have expressed a full-length cDNA encoding LPH in mammalian COS-1 cells. Analysis of the expressed protein by immunoprecipitation with monoclonal anti-LPH antibodies and treatments with endo-beta-N-acetylglucosaminidase H and sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed two polypeptides with apparent molecular masses of 215 and 230 kDa, representing the mannose-rich (pro-LPH(h)) and complex (pro-LPH(c)) glycosylated forms of the precursor. By contrast to pro-LPH in human enterocytes, the expressed pro-LPH in COS-1 cells does not undergo intracellular proteolytic cleavage to generate a form similar to the mature enzyme of the brush-border membrane. Intracellular cleavage, however, is not essential for the molecule to acquire its enzymatic activity since pro-LPH in COS-1 cells is enzymatically as active as LPH isolated from intestinal brush-border membranes. Indirect immunofluorescent staining of transfected cells demonstrated that pro-LPH is expressed at the cell surface. This was further corroborated by the sensitivity of the complex glycosylated form (pro-LPH(c)) to trypsin in the medium. Our results provide the first conclusive evidence that pro-LPH is an enzymatically active molecule and that the intracellular proteolysis of pro-LPH is not essential for the generation of transport-competent forms of LPH.	UNIV TEXAS, SW MED CTR, DEPT INTERNAL MED, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001860] Funding Source: NIH RePORTER; NIDDK NIH HHS [K11 DK 01860] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERS DH, 1986, BIOCHEM BIOPH RES CO, V134, P37, DOI 10.1016/0006-291X(86)90523-1; BIRD P, 1987, J CELL BIOL, V105, P2905, DOI 10.1083/jcb.105.6.2905; Brady R. O., 1983, METABOLIC BASIS INHE, P842; BULLER HA, 1989, AM J PHYSIOL, V257, pG616, DOI 10.1152/ajpgi.1989.257.4.G616; BULLER HA, 1987, J BIOL CHEM, V262, P17206; COLOMBO V, 1973, BIOCHIM BIOPHYS ACTA, V327, P412, DOI 10.1016/0005-2744(73)90425-7; DAHLQVIST A, 1968, ANAL BIOCHEM, V22, P99, DOI 10.1016/0003-2697(68)90263-7; DANIELSEN EM, 1984, BIOCHEM BIOPH RES CO, V122, P82; DOELL RG, 1962, BIOCHIM BIOPHYS ACTA, V62, P353, DOI 10.1016/0006-3002(62)90097-5; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREUND JN, 1989, FEBS LETT, V248, P39, DOI 10.1016/0014-5793(89)80427-2; FUHRMANN U, 1984, NATURE, V307, P755, DOI 10.1038/307755a0; GETHING MJ, 1988, CURR TOP MEMBR TRANS, V32, P337; GREEN F, 1987, GENE, V57, P101, DOI 10.1016/0378-1119(87)90181-8; Hauri H P, 1988, Subcell Biochem, V12, P155; HAURI HP, 1979, P NATL ACAD SCI USA, V76, P5183, DOI 10.1073/pnas.76.10.5183; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; HAURI HP, 1982, J BIOL CHEM, V257, P4522; HENNING SJ, 1981, AM J PHYSIOL, V241, pG199, DOI 10.1152/ajpgi.1981.241.3.G199; Johnson LR., 1987, PHYSL GASTROINTESTIN; KENNY AJ, 1982, PHYSIOL REV, V62, P91, DOI 10.1152/physrev.1982.62.1.91; KRETCHMER N, 1971, GASTROENTEROLOGY, V61, P805; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE L, 1984, CAN J BIOCHEM CELL B, V62, P36, DOI 10.1139/o84-006; LEE LMY, 1980, BIOCHEM J, V187, P437, DOI 10.1042/bj1870437; MANTEI N, 1988, EMBO J, V7, P2705, DOI 10.1002/j.1460-2075.1988.tb03124.x; NAIM H Y, 1989, Journal of Cell Biology, V109, p222A; NAIM HY, 1988, J BIOL CHEM, V263, P7242; NAIM HY, 1987, BIOCHEM J, V241, P427, DOI 10.1042/bj2410427; POTTER J, 1985, BIOCHEM GENET, V23, P423, DOI 10.1007/BF00499084; RANSOMEKUTI O, 1975, GASTROENTEROLOGY, V68, P431; SAHI T, 1973, LANCET, V2, P823; Sambrook J, 1989, MOL CLONING LABORATO; SCHLEGEL.S, 1972, BIOCHIM BIOPHYS ACTA, V258, P506, DOI 10.1016/0005-2744(72)90242-2; SEBASTIO G, 1989, AM J HUM GENET, V45, P489; SEMENZA G, 1986, ANNU REV CELL BIOL, V2, P255, DOI 10.1146/annurev.cellbio.2.1.255; SJOSTROM H, 1985, J PEDIATR GASTR NUTR, V4, P980, DOI 10.1097/00005176-198512000-00021; SJOSTROM H, 1980, J BIOL CHEM, V255, P1332; SKOVBJERG H, 1981, EUR J BIOCHEM, V114, P653, DOI 10.1111/j.1432-1033.1981.tb05193.x; SORENSEN SH, 1982, EUR J BIOCHEM, V126, P559, DOI 10.1111/j.1432-1033.1982.tb06817.x; STEINER DF, 1984, J CELL BIOCHEM, V24, P121, DOI 10.1002/jcb.240240204; THOMSEN DR, 1984, P NATL ACAD SCI-BIOL, V81, P659, DOI 10.1073/pnas.81.3.659; [No title captured]	43	91	91	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12313	12320						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905719				2022-12-25	WOS:A1991FV18000035
J	GUTTERIDGE, S				GUTTERIDGE, S			THE RELATIVE CATALYTIC SPECIFICITIES OF THE LARGE SUBUNIT CORE OF SYNECHOCOCCUS RIBULOSE BISPHOSPHATE CARBOXYLASE OXYGENASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; RIBULOSEBISPHOSPHATE CARBOXYLASE; RHODOSPIRILLUM-RUBRUM; PLANT RUBISCO; 1,5-BISPHOSPHATE; ABSENCE	The relative specificities of the carboxylase and oxygenase reactions catalyzed by the recombinant large subunit core (L8) of Synechococcus ribulose 1,5-bisphosphate carboxylase have been determined. The L8 core still retained the ability to catalyze both reactions but at a much reduced turnover rate, about 0.6% of the holoenzyme. The fate of ribulose 1,5-bisphosphate during carboxylation and oxygenation by L8 was compared with the Synechococcus holoenzyme (reconstituted from L8 and recombinant small subunits), the carboxylase from Rhodospirullum rubrum, and that of spinach. The absence of small subunits had no significant effect on the partitioning of the bisphosphate substrate between the two reactions. Thus the course of the two competing reactions is a characteristic of the structural elements that compose the L-subunits, whereas the S-subunits exert their effect on factors common to both reactions such as the specificity of the bisphosphate substrate.			GUTTERIDGE, S (corresponding author), DUPONT CO,CENT RES & DEV DEPT,WILMINGTON,DE 19880, USA.							ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; Andrews T.J., 1987, BIOCH PLANTS, P131, DOI 10.1016/B978-0-12-675410-0.50009-9; ANDREWS TJ, 1984, P NATL ACAD SCI-BIOL, V81, P3660, DOI 10.1073/pnas.81.12.3660; ANDREWS TJ, 1985, J BIOL CHEM, V260, P4632; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; BONGGEUN L, 1990, BIOCHEMISTRY-US, V29, P9352; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHEN ZX, 1989, J BIOL CHEM, V264, P3051; GUTTERIDGE S, 1990, BIOCHIM BIOPHYS ACTA, V1015, P1, DOI 10.1016/0005-2728(90)90210-U; GUTTERIDGE S, 1984, EMBO J, V3, P2737, DOI 10.1002/j.1460-2075.1984.tb02204.x; GUTTERIDGE S, 1989, BIOCHEM J, V260, P711, DOI 10.1042/bj2600711; GUTTERIDGE S, 1989, PERSPECT BIOCH GENET, V10, P225; JORDAN DB, 1981, NATURE, V291, P513, DOI 10.1038/291513a0; KETTLEBOROUGH CA, 1987, EUR J BIOCHEM, V170, P335, DOI 10.1111/j.1432-1033.1987.tb13704.x; LORIMER GH, 1977, ANAL BIOCHEM, V78, P66, DOI 10.1016/0003-2697(77)90009-4; LORIMER GH, 1981, ANNU REV PLANT PHYS, V32, P349, DOI 10.1146/annurev.pp.32.060181.002025; NEWMAN J, 1990, J BIOL CHEM, V265, P15154; PARRY MAJ, 1989, J EXP BOT, V40, P317, DOI 10.1093/jxb/40.3.317; PIERCE J, 1985, APPL ENVIRON MICROB, V49, P1094, DOI 10.1128/AEM.49.5.1094-1100.1985; SCHNEIDER G, 1990, EMBO J, V9, P2045, DOI 10.1002/j.1460-2075.1990.tb07371.x; SCHNEIDER G, 1986, EMBO J, V5, P3409, DOI 10.1002/j.1460-2075.1986.tb04662.x; SMITH HB, 1990, J BIOL CHEM, V265, P1243	22	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7359	7362						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902218				2022-12-25	WOS:A1991FJ34200010
J	LEE, B; BERKA, RM; TABITA, FR				LEE, B; BERKA, RM; TABITA, FR			MUTATIONS IN THE SMALL SUBUNIT OF CYANOBACTERIAL RIBULOSE-BISPHOSPHATE CARBOXYLASE OXYGENASE THAT MODULATE INTERACTIONS WITH LARGE SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; RIBULOSE-1,5-BISPHOSPHATE CARBOXYLASE; ANACYSTIS-NIDULANS; 1,5-BISPHOSPHATE CARBOXYLASE; PHENOTYPIC SELECTION; DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; GENES; DNA; COTRANSCRIPTION	In the cyanobacterium Anacystis nidulans (Synechococcus PCC6301), ribulose 1,5-bisphosphate carboxylase/oxygenase (Rbu-P2 carboxylase) is composed of eight large subunits and eight small subunits. There are three regions of the small subunit that contain amino acids that are conserved throughout evolution, from bacteria to higher plants. Since the function of the small subunit is not fully understood, site-directed mutagenesis was performed on highly conserved residues in the first and second conserved regions. Ser-16, Pro-19, Leu-21, and Tyr-54 were replaced by Asp-16, His-19, Glu-21, and Ser-54, respectively. Crude extracts containing the recombinant His-19 mutant enzyme indicated that there was little effect on either Rbu-P2 carboxylase activity or interactions between large and small subunits. However, the Asp-16, Glu-21, and Ser-54 mutations showed effects on Rbu-P2 carboxylase activity and the interaction between large and small subunits. The large and small subunits of the Asp-16, Glu-21, and Ser-54 enzymes were found to dissociate during nondenaturing gel electrophoresis or sucrose density gradient centrifugation. However, the dissociated small subunits remained functional and were capable of reconstituting Rbu-P2 carboxylase activity when added to large subunits. These results indicated that Ser-16, Leu-21, and Tyr-54 might play an important role in interactions between large and small subunits of the A. nidulans enzyme.	OHIO STATE UNIV,DEPT MICROBIOL,484 W 12TH AVE,COLUMBUS,OH 43210; GENENCOR INC,S SAN FRANCISCO,CA 94080; OHIO STATE UNIV,CTR BIOTECHNOL,COLUMBUS,OH 43210	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 24497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON I, 1989, NATURE, V337, P229, DOI 10.1038/337229a0; ANDREWS TJ, 1983, J BIOL CHEM, V258, P7514; ANDREWS TJ, 1988, J BIOL CHEM, V263, P12213; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAPMAN MS, 1988, SCIENCE, V241, P71, DOI 10.1126/science.3133767; CHRISTELLER JT, 1985, PLANT MOL BIOL, V5, P257, DOI 10.1007/BF00020643; FITCHEN JH, 1990, P NATL ACAD SCI USA, V87, P5768, DOI 10.1073/pnas.87.15.5768; GATENBY AA, 1985, NATURE, V314, P617, DOI 10.1038/314617a0; Horecker B. L., 1958, BIOCHEM PREP, V6, P83; JOUANNEAU Y, 1986, J BACTERIOL, V165, P620, DOI 10.1128/jb.165.2.620-624.1986; KNIGHT S, 1989, SCIENCE, V244, P702, DOI 10.1126/science.244.4905.702; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE B, 1990, BIOCHEMISTRY-US, V29, P9352, DOI 10.1021/bi00492a007; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANIATIS T, 1982, MOL CLONING LABORATO, P440; MCFADDEN BA, 1988, PHOTOSYNTH RES, V18, P245, DOI 10.1007/BF00042987; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; NIERZWICKIBAUER SA, 1984, P NATL ACAD SCI-BIOL, V81, P5961, DOI 10.1073/pnas.81.19.5961; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHNEIDER G, 1990, EMBO J, V9, P2045, DOI 10.1002/j.1460-2075.1990.tb07371.x; SHINOZAKI K, 1985, MOL GEN GENET, V200, P27, DOI 10.1007/BF00383308; SHINOZAKI K, 1983, NUCLEIC ACIDS RES, V11, P6957, DOI 10.1093/nar/11.20.6957; STARNES SM, 1985, FEMS MICROBIOL LETT, V28, P165; TABITA FR, 1988, MICROBIOL REV, V52, P155, DOI 10.1128/MMBR.52.2.155-189.1988; TABITA FR, 1985, P NATL ACAD SCI USA, V82, P6100, DOI 10.1073/pnas.82.18.6100; VALENTIN K, 1990, MOL GEN GENET, V222, P425, DOI 10.1007/BF00633849; VALENTIN K, 1989, CURR GENET, V16, P203, DOI 10.1007/BF00391478; VIALE AM, 1989, J BACTERIOL, V171, P2391, DOI 10.1128/jb.171.5.2391-2400.1989; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; VOORDOUW G, 1987, EUR J BIOCHEM, V163, P591, DOI 10.1111/j.1432-1033.1987.tb10908.x; WHITMAN W, 1976, BIOCHEM BIOPH RES CO, V71, P1034, DOI 10.1016/0006-291X(76)90758-0	33	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7417	7422						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902220				2022-12-25	WOS:A1991FJ34200019
J	DAS, KK; BASU, M; BASU, S; CHOU, DKH; JUNGALWALA, FB				DAS, KK; BASU, M; BASU, S; CHOU, DKH; JUNGALWALA, FB			BIOSYNTHESIS INVITRO OF GLCA-BETA-1-3NLCOSE4CER BY A NOVEL GLUCURONYLTRANSFERASE (GLCAT-1) FROM EMBRYONIC CHICKEN BRAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER UDP-GLUCURONOSYLTRANSFERASE; MYELIN-ASSOCIATED GLYCOPROTEIN; SULFATED GLUCURONIC-ACID; GREEN-BOTTLE FLY; LUCILIA-CAESAR; MONOCLONAL IGM; NERVOUS-SYSTEM; MESSENGER-RNA; NEUROPATHY; GLYCOLIPIDS	A novel glucuronyltransferase (GlcAT-1) has been detected in embryonic chicken brains. This enzyme catalyzes the biosynthesis in vitro of glucuronic acid containing glycolipids starting from neolactotetraosylceramide (nLcOse4Cer) and neolactohexaosylceramide (nLcOse6Cer). The activity is present primarily in the Golgi-rich membrane fraction and can be extracted (60%) from the membrane using a neutral detergent, Nonidet P-40, at pH 7.0. The detergent-solubilized GlcAT-1 is stable (70%) at -20-degrees-C for at least 4 months. Both membrane-bound GlcAT-1 and solubilized GlcAT-1 show similar pH optima, 6.5-7.0, in HEPES buffer. The K(m) values were 15 and 200-mu-M with UDP-[C-14]GlcA and nLcOse4Cer, respectively, when the detergent-solubilized supernatant fraction was used as enzyme source. The purified C-14 radioactive product that comigrated with chemically characterized GlcA-beta-1-3nLcOse4Cer (GlcA-nLc4) also yielded a positive immunostain with monoclonal antibody (human IgM-RI). The anomeric linkage was established as beta-linked GlcA to the terminal galactose of the substrate, as evidenced by 90-99% cleavage of the terminal [C-14]GlcA by purified Helix pomatia and limpet glucuronidases. Permethylation studies of the radioactive product obtained from [6-H-3]Gal-beta-1-4LcOse3Cer and nonradioactive UDP-GlcA showed the presence of 2,4,6-tri-O-methylgalactose in the hydrolyzed enzymatic product. These studies established the structure of the biosynthesized product from nLcOse4Cer as GlcA-beta-1-3Gal-beta-1-4 GlcNAc-beta-1-3Gal-beta-1-4Glc-ceramide.	UNIV NOTRE DAME,DEPT CHEM & BIOCHEM,BIOCHEM BIOPHYS & MOLEC BIOL PROGRAM,NOTRE DAME,IN 46556; EK SHRIVER CTR,DEPT BIOCHEM,WALTHAM,MA 02254	University of Notre Dame					NCI NIH HHS [CA-14764] Funding Source: Medline; NINDS NIH HHS [NS-18005, NS-24405] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014764] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS024405] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARIGA T, 1987, J BIOL CHEM, V262, P848; BASU M, 1972, J BIOL CHEM, V247, P1489; BASU M, 1982, J BIOL CHEM, V257, P2765; BASU M, 1987, METHOD ENZYMOL, V138, P575; BASU M, 1974, THESIS U CALCUTTA; BASU M, 1991, IN PRESS CARBOHYDR R; BASU S, 1970, Federation Proceedings, V29, P410; BASU S, 1984, GANGLIOSIDE STRUCTUR, P249; BASU S, 1976, GLYCOLIPID METHODOLO, P123; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAWDHURY JR, 1985, P NATL ACAD SCI USA, V82, P2990; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU KH, 1985, BIOCHEM BIOPH RES CO, V128, P383, DOI 10.1016/0006-291X(85)91690-0; DAS KK, 1984, ANAL BIOCHEM, V143, P125, DOI 10.1016/0003-2697(84)90566-9; DAS KK, 1988, FASEB J, V2, pA1780; Dutton GJ, 1980, GLUCURONIDATION DRUG, P1; ETO T, 1968, J BIOCHEM, V64, P205, DOI 10.1093/oxfordjournals.jbchem.a128881; FRAIL DE, 1984, MOL IMMUNOL, V21, P721, DOI 10.1016/0161-5890(84)90024-5; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HORI T, 1983, J BIOL CHEM, V258, P2239; ILYAS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1225, DOI 10.1073/pnas.81.4.1225; ILYAS AA, 1984, BIOCHEM BIOPH RES CO, V122, P1206, DOI 10.1016/0006-291X(84)91220-8; JACKSON MR, 1986, BIOCHEM PHARMACOL, V35, P1191, DOI 10.1016/0006-2952(86)90159-0; KASPER CB, 1980, ENZYMATIC BASIS DETO, V2, P3; KELLER M, 1990, HYBRIDOMA, V9, P295, DOI 10.1089/hyb.1990.9.295; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; KYLE J, 1985, THESIS U NOTRE DAME; LEDEEN RW, 1978, J SUPRAMOL STR CELL, V8, P1, DOI 10.1002/jss.400080102; LI YT, 1972, METHOD ENZYMOL, V28, P714; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKENZIE PI, 1984, ARCH BIOCHEM BIOPHYS, V231, P487, DOI 10.1016/0003-9861(84)90412-0; MACKENZIE PI, 1986, J BIOL CHEM, V261, P6119; MACKENZIE PI, 1984, J BIOL CHEM, V259, P2153; MACKENZIE PI, 1980, ANAL BIOCHEM, V109, P362, DOI 10.1016/0003-2697(80)90661-2; NEER EJ, 1974, J BIOL CHEM, V249, P6527; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; STOFFYN P, 1979, CARBOHYD RES, V74, P279, DOI 10.1016/S0008-6215(00)84782-5; SUGITA M, 1989, J BIOL CHEM, V264, P15028; SUGITA M, 1982, J BIOCHEM-TOKYO, V92, P327, DOI 10.1093/oxfordjournals.jbchem.a133938; SUGITA M, 1988, P JPN C BIOCH LIPIDS, V30, P77; SVENNERHOLM L, 1980, BIOCHIM BIOPHYS ACTA, V617, P97, DOI 10.1016/0005-2760(80)90227-1; WEIGANDT H, 1985, NEW COMPREHENSIVE BI, V10, P199; YOKOTA H, 1990, J BIOCHEM, V107, P92, DOI 10.1093/oxfordjournals.jbchem.a123019; YOKOTA H, 1989, J BIOCHEM-TOKYO, V106, P248, DOI 10.1093/oxfordjournals.jbchem.a122839	44	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5238	5243						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1900517				2022-12-25	WOS:A1991FC21700080
J	MALIN, R; ZIELENKIEWICZ, P; SAENGER, W				MALIN, R; ZIELENKIEWICZ, P; SAENGER, W			STRUCTURALLY CONSERVED WATER-MOLECULES IN RIBONUCLEASE-T1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; CRYSTAL-STRUCTURE; RESOLUTION; COMPLEX; BINDING	In the high resolution (1.7-1.9 angstrom) crystal structures of ribonuclease T1 (RNase T1) in complex with guanosine, guanosine 2'-phosphate, guanylyl 2',5'-guanosine, and vanadate, there are 30 water sites in nearly identical (+/- 1 angstrom) positions that are considered conserved. One water is tightly bound to Asp76(O-delta), Thr93(O-gamma), Cys6(O), and Asn9(N); another bridges two loops by hydrogen-bonding to Tyr68(O-eta) and to Ser35(N), Asn36(N); a loop structure is stabilized by two waters coordinated to Gly31(O) and His27(N-delta), and by water bound to cis-Pro39(O). Most notable is a hydrogen-bonded chain of 10 water molecules. Waters 1-5 of this chain are inaccessible to solvent, are anchored at Trp59(N-epsilon), and stitch together the loop formed by segments 60-68; waters 5-8 coordinate to Ca2+, and waters 9 and 10 hydrogen-bond to N-terminal side chains of the alpha-helix. The water chain and two conserved water molecules are bound to amino acids adjacent to the active site residues His40, Glu58, Arg77, and His92; they are probably involved in maintaining their spatial orientation required for catalysis. Water sites must be considered in genetic engineering; the mutation Trp59Tyr, which probably influences the 10-water chain, doubles the catalytic activity of RNase T1.			MALIN, R (corresponding author), FREE UNIV BERLIN,INST KRISTALLOG,TAKUSTR 6,W-1000 BERLIN 33,GERMANY.			Zielenkiewicz, Piotr/0000-0001-8151-6874				ARNI R, 1987, ACTA CRYSTALLOGR B, V43, P548, DOI 10.1107/S0108768187097337; ARNI R, 1988, J BIOL CHEM, V263, P15358; HEINEMANN U, 1989, TOPICS MOL STRUCTURA, V10; JOHNSON CK, 1971, ORNL3794 REP; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KELLER W, 1988, SCHAKAL88; KOEHLER JEH, 1987, J COMPUT CHEM, V8, P1090, DOI 10.1002/jcc.540080804; KOEPKE J, 1989, J MOL BIOL, V206, P475, DOI 10.1016/0022-2836(89)90495-6; KOSTREWA D, 1989, BIOCHEMISTRY-US, V28, P7592, DOI 10.1021/bi00445a014; LESK AM, 1982, SCIENCE, V216, P539, DOI 10.1126/science.7071602; MACKERELL AD, 1989, PROTEINS, V6, P20, DOI 10.1002/prot.340060103; OOBATAKE M, 1979, J BIOCHEM, V86, P55; PACE CN, 1988, BIOCHEMISTRY-US, V27, P3242, DOI 10.1021/bi00409a018; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; SAENGER W, 1979, NATURE, V279, P343, DOI 10.1038/279343a0	15	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					4848	4852						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1900511				2022-12-25	WOS:A1991FC21700029
J	NEYLON, CB; IRVINE, RF				NEYLON, CB; IRVINE, RF			THROMBIN ATTENUATES THE STIMULATORY EFFECT OF HISTAMINE ON CA2+ ENTRY IN CONFLUENT HUMAN UMBILICAL VEIN ENDOTHELIAL-CELL CULTURES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREE CALCIUM-CONCENTRATION; PHORBOL-MYRISTATE ACETATE; BIVALENT-CATION INFLUX; PROTEIN KINASE-C; PROSTACYCLIN PRODUCTION; CA-2+ EFFLUX; INTRACELLULAR CA-2+; CYTOSOLIC CALCIUM; HUMAN-PLATELETS; MOBILIZATION	Human umbilical vein endothelial cells were grown to confluence, as first passage cells, on coverslips. Treatment with ionomycin or histamine caused a sustained rise in intracellular Ca2+ (measured by Fura-2 fluorescence), but after treatment with thrombin, only a transient rise in Ca2+ was observed. Furthermore, the addition of thrombin after ionomycin or histamine lowered the raised Ca2+ back to near control levels. This effect of thrombin was concentration dependent, with increasing concentrations producing increases in both the rate and extent of the lowering of Ca2+. A similar effect of thrombin was seen on video imaging of Fura-2-loaded cell monolayers. The Ca2+-lowering effect of thrombin was not mimicked by phorbol 12-myristate 13-acetate nor blocked by staurosporine, indicating a lack of involvement of protein kinase C; intracellular pH also does not appear to be involved. The mechanism by which thrombin lowers cytoplasmic Ca2+ is due mainly to inhibition of Ca2+ entry since thrombin prevented the stimulated influx of Mn2+ caused by histamine or ionomycin. It may therefore be that in vivo under certain physiological or pathological conditions, thrombin's effects on intracellular Ca2+ are more transient than those of histamine, and thrombin also may induce transience in histamine's actions.	AFRC,INST ANIM PHYSIOL & GENET RES,DEPT BIOCHEM,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute								BARTHA K, 1989, BIOCHEM J, V263, P149, DOI 10.1042/bj2630149; BROCK TA, 1988, J CELL PHYSIOL, V136, P54, DOI 10.1002/jcp.1041360107; CARTER TD, 1989, BIOCHEM J, V262, P431, DOI 10.1042/bj2620431; CHOW SC, 1990, BIOCHEM J, V267, P727, DOI 10.1042/bj2670727; CHOW SC, 1990, J BIOL CHEM, V265, P902; DUDDY SK, 1989, J BIOL CHEM, V264, P20863; GARCIA JGN, 1990, J CELL PHYSIOL, V142, P186, DOI 10.1002/jcp.1041420123; GHIGO D, 1988, J BIOL CHEM, V263, P19437; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HALLAM TJ, 1989, BIOCHEM J, V259, P125, DOI 10.1042/bj2590125; HALLAM TJ, 1988, BIOCHEM J, V251, P243, DOI 10.1042/bj2510243; HALLAM TJ, 1988, BIOCHEM J, V255, P179, DOI 10.1042/bj2550179; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JACOB R, 1988, NATURE, V335, P40, DOI 10.1038/335040a0; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; JAFFE EA, 1987, J BIOL CHEM, V262, P8557; JONES LG, 1989, MOL PHARMACOL, V36, P142; KILLACKEY JJF, 1986, AM J PATHOL, V122, P50; KWAN CY, 1990, J BIOL CHEM, V265, P678; LAGAST H, 1984, J CLIN INVEST, V73, P878, DOI 10.1172/JCI111284; LARSON DM, 1990, CIRC RES, V66, P1074, DOI 10.1161/01.RES.66.4.1074; LO WWY, 1987, BIOCHEM BIOPH RES CO, V148, P47, DOI 10.1016/0006-291X(87)91074-6; MCCARTHY SA, 1989, BIOCHEM J, V264, P357, DOI 10.1042/bj2640357; MITSUI M, 1990, AM J PHYSIOL, V258, pC787, DOI 10.1152/ajpcell.1990.258.5.C787; NEYLON CB, 1990, CIRC RES, V67, P814, DOI 10.1161/01.RES.67.4.814; NEYLON CB, 1990, AM J PHYSIOL, V259, pC675, DOI 10.1152/ajpcell.1990.259.4.C675; NEYLON CB, 1990, LEBS LETT, V275, P173; OETTGEN HC, 1985, CELL, V40, P583, DOI 10.1016/0092-8674(85)90206-5; PERIANIN A, 1989, J BIOL CHEM, V264, P1005; POLLOCK WK, 1988, BIOCHEM J, V256, P371, DOI 10.1042/bj2560371; POLLOCK WK, 1987, FEBS LETT, V210, P132, DOI 10.1016/0014-5793(87)81322-4; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; RESINK TJ, 1987, BIOCHEM BIOPH RES CO, V144, P438, DOI 10.1016/S0006-291X(87)80529-6; RINK TJ, 1987, J PHYSIOL-LONDON, V393, P513, DOI 10.1113/jphysiol.1987.sp016837; SAGE SO, 1986, EUR J PHARMACOL, V128, P99, DOI 10.1016/0014-2999(86)90563-7; SAGE SO, 1989, J BIOL CHEM, V264, P6; SCHILLING WP, 1989, AM J PHYSIOL, V257, pH778, DOI 10.1152/ajpheart.1989.257.3.H778; STAUDERMAN KA, 1989, J BIOL CHEM, V264, P18349; TAKEMURA H, 1990, CELL CALCIUM, V11, P11, DOI 10.1016/0143-4160(90)90044-U	40	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4251	4256						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900287				2022-12-25	WOS:A1991FA69400038
J	ROTENBERG, M; ZAKIM, D				ROTENBERG, M; ZAKIM, D			EFFECTS OF CHOLESTEROL ON THE FUNCTION AND THERMOTROPIC PROPERTIES OF PURE UDP-GLUCURONOSYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRAL MEMBRANE-PROTEINS; MICROSOMAL-ENZYMES; GLUCURONYLTRANSFERASE; PHOSPHOLIPIDS; RECONSTITUTION; STABILITY; TRANSPORT; VESICLES; DYNAMICS; BILAYERS	The effects of cholesterol on the activity and thermal properties of a pure, delipidated isoform of UDP-glucuronosyltransferase were examined after incorporation of enzyme into unilamellar bilayers of distearoylphosphatidylcholine (DSPC) or dioleoylphosphatidylcholine (DOPC). Cholesterol, in bilayers of DSPC, decreased enzyme activity and lowered the temperature (from 37 to 30-degrees-C) for a reversible transition from the active form of the enzyme to a less active form. These effects could be separated from each other in that the effect on reversible inactivation of the enzyme occurred at lower concentrations of cholesterol than the effect on activity of the active form of the enzyme. In addition, cholesterol in bilayers of DSPC stabilized UDP-glucuronosyltransferase against irreversible thermal inactivation. The extent of stabilization increased with increasing concentration of cholesterol in the bilayers. The effects of cholesterol on UDP-glucuronosyltransferase depended, however, on the nature of the bilayer containing cholesterol. Cholesterol had small effects, if any, on the properties of UDP-glucuronosyltransferase in bilayers of DOPC.	CORNELL UNIV,MED CTR,COLL MED,DEPT MED,DIV DIGEST DIS,NEW YORK,NY 10021	Cornell University								BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BRASITUS TA, 1988, J BIOL CHEM, V263, P8592; BRUCKDORFER KR, 1976, BIOLOGICAL MEMBRANES, V3, P103; CASTUMA CE, 1986, BIOCHEMISTRY-US, V25, P4733, DOI 10.1021/bi00365a002; CASTUMA CE, 1986, BIOCHIM BIOPHYS ACTA, V855, P231, DOI 10.1016/0005-2736(86)90169-0; CHENG KH, 1986, J BIOL CHEM, V261, P5081; DANNENBERG A, 1989, J BIOL CHEM, V264, P238; DANNENBERG A, 1990, ARCH BIOCHEM BIOPHYS, V277, P312, DOI 10.1016/0003-9861(90)90585-M; DANNENBERG AJ, 1990, BIOCHEMISTRY-US, V29, P8961; Dutton G.F., 1980, GLUCURONIDATION DRUG; HOCHMAN Y, 1983, J BIOL CHEM, V258, P1758; HOCHMAN Y, 1981, J BIOL CHEM, V256, P4783; HYSLOP PA, 1990, BIOCHEMISTRY-US, V29, P1025, DOI 10.1021/bi00456a027; LEUDERS KK, 1967, ARCH BIOCHEM BIOPHYS, V120, P198, DOI 10.1016/0003-9861(67)90614-5; MAGDALOU J, 1982, J BIOL CHEM, V257, P13624; MANERI LR, 1988, J BIOL CHEM, V263, P16170; ROTENBERG M, 1989, BIOCHEMISTRY-US, V28, P8577, DOI 10.1021/bi00447a046; SAITO Y, 1979, J BIOL CHEM, V254, P1102; SCOTTO AW, 1988, J BIOL CHEM, V263, P18500; SCOTTO AW, 1985, BIOCHEMISTRY-US, V24, P4066, DOI 10.1021/bi00336a040; STOCKTON GW, 1976, CHEM PHYS LIPIDS, V17, P251, DOI 10.1016/0009-3084(76)90070-0; VESSEY DA, 1971, J BIOL CHEM, V246, P4649; WARREN GB, 1975, NATURE, V255, P684, DOI 10.1038/255684a0; YEAGLE PL, 1988, BIOL CHOLESTEROL, P122; ZAKIM D, 1988, J BIOL CHEM, V263, P5164; ZAKIM D, 1973, EUR J BIOCHEM, V38, P59, DOI 10.1111/j.1432-1033.1973.tb03033.x; ZAKIM D, 1975, BIOCHIM BIOPHYS ACTA, V410, P61, DOI 10.1016/0005-2744(75)90207-7	27	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4159	4161						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900286				2022-12-25	WOS:A1991FA69400024
J	SCHMIDT, CJ; NEER, EJ				SCHMIDT, CJ; NEER, EJ			INVITRO SYNTHESIS OF G-PROTEIN BETA-GAMMA-DIMERS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; MUSCARINIC K+-CHANNEL; CIS-TRANS ISOMERASE; ADENYLATE-CYCLASE; BINDING PROTEINS; REGULATORY COMPONENT; LIMITED PROTEOLYSIS; ALPHA-SUBUNITS; MESSENGER-RNAS; FAMILY	The guanine nucleotide-binding proteins (G proteins), which play a central role in coupling membrane-bound receptors to intracellular effectors, are heterotrimers composed of alpha, beta, and gamma-subunits. The beta and gamma-subunits form a functional monomer that does not appear to separate under physiological conditions. This has made it difficult to differentiate the individual roles of beta and gamma-subunits in signal transduction. To characterize the individual subunits, the 36-kDa beta-subunit (beta-1), brain-gamma (gamma-2), and transducin-gamma (gamma-t) were translated in vitro in a rabbit reticulocyte lysate system. Hydrodynamic studies and tryptic proteolysis were used to compare the physical properties of the in vitro translation products with those of beta-gamma-dimers purified from bovine brain. The hydrodynamic studies indicate that, without gamma-subunits, the beta-subunits are not stable but tend to aggregate into high molecular weight complexes. When beta and gamma-subunits were co-translated, stable beta-gamma-dimers formed that bound alpha-0 in a guanine nucleotide-dependent manner. The beta-gamma-dimers were less hydrophobic than those purified from bovine brain. This may reflect a lack of post-translational modification in the reticulocyte lysate or other differences between the in vitro translation products and the purified beta-gamma. When beta and gamma were translated separately and then mixed, beta-gamma-dimers also formed. Analysis of in vitro translated beta-gamma-subunits will provide ways to assess the function of these subunits and to determine the structural requirements for beta-gamma-formation.	HARVARD UNIV,SCH MED,BOSTON,MA 02115	Harvard University; Harvard Medical School	SCHMIDT, CJ (corresponding author), BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115, USA.			Schmidt, Carl/0000-0002-8386-4781	NIGMS NIH HHS [GM36259] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036259, R37GM036259] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CHRISTY KG, 1989, BIOTECHNIQUES, V7, P692; EVANS T, 1987, J BIOL CHEM, V262, P176; FISCHER G, 1989, NATURE, V337, P476, DOI 10.1038/337476a0; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FREISSMUTH M, 1989, FASEB J, V3, P2125, DOI 10.1096/fasebj.3.10.2546847; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1990, P NATL ACAD SCI USA, V87, P7973, DOI 10.1073/pnas.87.20.7973; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HUFF RM, 1985, J BIOL CHEM, V260, P864; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; JELSEMA CL, 1987, P NATL ACAD SCI USA, V84, P3623, DOI 10.1073/pnas.84.11.3623; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KATADA T, 1984, J BIOL CHEM, V259, P3568; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KRIEG PA, 1984, NUCLEIC ACIDS RES, V12, P7057, DOI 10.1093/nar/12.18.7057; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE MA, 1990, P NATL ACAD SCI USA, V87, P2329, DOI 10.1073/pnas.87.6.2329; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; ROOF DJ, 1985, J BIOL CHEM, V260, P6242; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; STRYER L, 1986, ANNU REV NEUROSCI, V9, P87, DOI 10.1146/annurev.ne.09.030186.000511; TAKAHASHI N, 1989, NATURE, V337, P473, DOI 10.1038/337473a0; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	38	88	88	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 5	1991	266	7					4538	4544						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FA694	1900295				2022-12-25	WOS:A1991FA69400080
J	BRIGLE, KE; WESTIN, EH; HOUGHTON, MT; GOLDMAN, ID				BRIGLE, KE; WESTIN, EH; HOUGHTON, MT; GOLDMAN, ID			CHARACTERIZATION OF 2 CDNAS ENCODING FOLATE-BINDING PROTEINS FROM L1210 MURINE LEUKEMIA-CELLS - INCREASED EXPRESSION ASSOCIATED WITH A GENOMIC REARRANGEMENT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; METHOTREXATE TRANSPORT-SYSTEM; CARRIER-MEDIATED TRANSPORT; PLASMA-MEMBRANE VESICLES; GLYCOSYL-PHOSPHATIDYLINOSITOL; ENTRY ROUTES; TUMOR-CELLS; DNA; REQUIREMENTS; INHIBITORS	L1210 murine leukemic cells grown under conditions of continuous low folate concentrations acquire increased levels of a high affinity/low capacity folate-binding protein (FBP). Using an oligonucleotide probe complementary to the human FBP, we have cloned and sequenced two murine FBP cDNAs isolated from a library constructed using a L1210 subline adapted for growth on low levels of 5-formyltetrahydrofolate. The encoding proteins, designated FBP1 and FBP2, have predicted M(r) values of 29,415 and 28,821, respectively. These proteins share significant sequence identity with each other (70%) and with the deduced sequences of the human- and bovine-encoded FBPs (68-79%). Southern blot analysis of the low folate-adapted cell line revealed that, while neither of the two FBP-encoding genes was amplified, the FBP1 genomic locus had undergone rearrangement. On Northern blot analysis, this rearrangement was reflected in the enhanced expression (> 100-fold) of a FBP1-specific transcript which was 200 nucleotides shorter than the corresponding L1210 parental transcript. The increased expression of this transcript coincided with the increased expression of a membrane protein (M(r) = 38,000) which could be affinity-labeled with a N-hydroxysuccinimide ester of [H-3]folate. Accordingly, the FBP1 transcript appears to encode the high affinity/low capacity FBP. Compared to parental L1210 cells, expression of the FBP2-encoding transcript was unchanged in this cell line and, while the exact nature of the protein is unclear, FBP2 may represent a fetal form of the FBP.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT MED,BOX 230 MCV STN,RICHMOND,VA 23298; VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT PHARMACOL,RICHMOND,VA 23298	Virginia Commonwealth University; Virginia Commonwealth University					NCI NIH HHS [CA-39807, CA-09340] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039807] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; DEMBO M, 1984, J MEMBRANE BIOL, V78, P9, DOI 10.1007/BF01872527; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELLWOOD PC, 1989, J BIOL CHEM, V264, P14893; GOLDMAN ID, 1968, J BIOL CHEM, V243, P5007; GOLDMAN ID, 1969, J BIOL CHEM, V244, P3779; GOLDMAN ID, 1971, ANN NY ACAD SCI, V186, P400; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HENDERSON GB, 1990, ANNU REV NUTR, V10, P319, DOI [10.1146/annurev.nutr.10.1.319, 10.1146/annurev.nu.10.070190.001535]; HENDERSON GB, 1988, J MEMBRANE BIOL, V101, P247, DOI 10.1007/BF01872839; HENDERSON GB, 1984, J BIOL CHEM, V259, P4558; HENDERSON GB, 1990, CANCER RES, V50, P1709; HENDERSON GB, 1983, ARCH BIOCHEM BIOPHYS, V221, P438, DOI 10.1016/0003-9861(83)90162-5; HILL BT, 1979, CANCER RES, V39, P2440; JANSEN G, 1989, CANCER RES, V49, P1959; KAMEN BA, 1988, J BIOL CHEM, V263, P13602; KORNELUK RG, 1985, GENE, V40, P317, DOI 10.1016/0378-1119(85)90055-1; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACEY SW, 1989, J CLIN INVEST, V84, P715, DOI 10.1172/JCI114220; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUHRS CA, 1989, J BIOL CHEM, V264, P21446; MATHERLY LH, 1987, J BIOL CHEM, V262, P710; RADER JI, 1974, BIOCHEM PHARMACOL, V23, P2057, DOI 10.1016/0006-2952(74)90264-0; RATNAM M, 1989, BIOCHEMISTRY-US, V28, P8249, DOI 10.1021/bi00446a042; ROTHBERG KG, 1990, J CELL BIOL, V110, P637, DOI 10.1083/jcb.110.3.637; SADASIVAN E, 1989, J BIOL CHEM, V264, P5806; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHUETZ JD, 1988, J BIOL CHEM, V263, P9840; SIROTNAK FM, 1981, CANCER RES, V41, P966; SIROTNAK FM, 1985, CANCER RES, V45, P3992; SIROTNAK FM, 1984, J BIOL CHEM, V259, P3139; SIROTNAK FM, 1987, BIOCHEM PHARMACOL, V36, P1659, DOI 10.1016/0006-2952(87)90051-7; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SVENDSEN IB, 1984, CARLSBERG RES COMMUN, V49, P123, DOI 10.1007/BF02913971; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; YANG CH, 1983, J MEMBRANE BIOL, V75, P11, DOI 10.1007/BF01870795; YANG CH, 1984, J MEMBRANE BIOL, V79, P285, DOI 10.1007/BF01871067; ZHENG DB, 1988, J BIOL CHEM, V263, P11126	41	85	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17243	17249						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894617				2022-12-25	WOS:A1991GF44500043
J	HAHN, CN; HANSEN, AJ; MAY, BK				HAHN, CN; HANSEN, AJ; MAY, BK			TRANSCRIPTIONAL REGULATION OF THE CHICKEN CYP2H1 GENE - LOCALIZATION OF A PHENOBARBITAL-RESPONSIVE ENHANCER DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINATE SYNTHASE; CHEMICALLY DEFINED MEDIUM; MONO-OXYGENASE ACTIVITY; CHLORAMPHENICOL ACETYLTRANSFERASE; BASEMENT-MEMBRANE; P-450C GENE; EXPRESSION; CYTOCHROME-P-450; HEPATOCYTES; INDUCTION	The mechanism by which the drugs phenobarbital and 2-allyl-2-isopropylacetamide induce levels of chicken cytochrome P-450 (CYP) mRNAs has been investigated in primary hepatocyte cultures from 17-day-old chick embryos. It has been demonstrated that three CYP mRNAs of 3.5, 2.5, and 2.2 kilobases (kb) are strongly induced by phenobarbital in primary hepatocytes, as found previously in chick embryo liver in ovo (Hansen, A. J., Elferink, L. A., and May, B. K. (1989) DNA (NY) 8, 179-191), and that, at least for the 3.5-kb mRNA, this is predominantly a result of enhanced transcription of the corresponding gene, CYP2H1. Transient transfection assays were carried out in primary cultures using constructs containing different lengths of CYP2H1 gene 5'-flanking sequence fused to the reporter chloramphenicol acetyl-transferase (CAT) gene. These experiments established that cis-acting elements located in the first 0.5 kb of the CYP2H1 gene 5'-flanking region direct high basal expression of the CAT gene, but do not mediate phenobarbital inducibility. When constructs containing more than 1.1 kb of CYP2H1 gene 5'-flanking sequence were examined, phenobarbital induction of CAT expression was observed, and a drug-responsive domain between positions -5.9 and -1.1 kb was identified. This domain has the properties of an enhancer, since it is able to confer phenobarbital responsiveness to the enhancerless SV40 promoter when tested in either orientation or at different distances from the promoter. The enhancer domain also responds to 2-allyl-2-isopropylacetamide, but whether the action of the two drugs is mediated by a single nuclear receptor interacting with common DNA elements in the domain remains to be established.	UNIV ADELAIDE,DEPT BIOCHEM,GPO BOX 498,ADELAIDE,SA 5001,AUSTRALIA	University of Adelaide			Hahn, Christopher/C-1369-2009	Hahn, Christopher/0000-0001-5105-2554				ALTHAUS FR, 1979, J BIOL CHEM, V254, P2148; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLAYTON DF, 1983, MOL CELL BIOL, V3, P1552, DOI 10.1128/MCB.3.9.1552; DENISON MS, 1988, P NATL ACAD SCI USA, V85, P2528, DOI 10.1073/pnas.85.8.2528; DENISON MS, 1988, J BIOL CHEM, V263, P17221; ELLIOTT WH, 1989, BIOCHEM SOC SYMP, V55, P13; FISHER JM, 1990, J BIOL CHEM, V265, P9676; FONNE R, 1987, PHARMACOL THERAPEUT, V33, P19, DOI 10.1016/0163-7258(87)90022-2; FRAIN M, 1989, CELL, V59, P145, DOI 10.1016/0092-8674(89)90877-5; FROMM M, 1985, P NATL ACAD SCI USA, V82, P5824, DOI 10.1073/pnas.82.17.5824; FUJISAWASEHARA A, 1988, P NATL ACAD SCI USA, V85, P5859, DOI 10.1073/pnas.85.16.5859; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GIGER U, 1981, J BIOL CHEM, V256, P1182; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANSEN AJ, 1989, DNA-J MOLEC CELL BIO, V8, P179, DOI 10.1089/dna.1.1989.8.179; HARDWICK JP, 1983, J BIOL CHEM, V258, P8081; HOBBS AA, 1986, J BIOL CHEM, V261, P9444; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LUND J, 1990, J BIOL CHEM, V265, P3304; Maniatis T., 1982, MOL CLONING; MARZLUFF WF, 1978, METHOD CELL BIOL, V19, P313; MATTSCHOSS LA, 1986, J BIOL CHEM, V261, P9438; NEBERT DW, 1991, DNA CELL BIOL, V10, P1, DOI 10.1089/dna.1991.10.1; ORON L, 1984, BIOCHEM BIOPH RES CO, V125, P1096, DOI 10.1016/0006-291X(84)91396-2; POLAND A, 1981, MOL PHARMACOL, V20, P442; POLAND A, 1980, MOL PHARMACOL, V18, P571; RANGARAJAN PN, 1989, P NATL ACAD SCI USA, V86, P3963, DOI 10.1073/pnas.86.11.3963; SASSA S, 1977, J BIOL CHEM, V252, P2428; SCHUETZ EG, 1990, J BIOL CHEM, V265, P1188; SCHUETZ EG, 1988, J CELL PHYSIOL, V134, P309, DOI 10.1002/jcp.1041340302; SINCLAIR JF, 1989, BIOCHEM PHARMACOL, V38, P657, DOI 10.1016/0006-2952(89)90212-8; SLEIGH MJ, 1986, ANAL BIOCHEM, V156, P251, DOI 10.1016/0003-2697(86)90180-6; TIERNEY B, 1981, ARCH BIOCHEM BIOPHYS, V210, P729, DOI 10.1016/0003-9861(81)90240-X; WAGNER EK, 1967, BIOCHEM BIOPH RES CO, V28, P152, DOI 10.1016/0006-291X(67)90422-6; WEN LP, 1989, J BIOL CHEM, V264, P10996; WHITLOCK JP, 1989, TRENDS PHARMACOL SCI, V10, P285, DOI 10.1016/0165-6147(89)90030-8; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; ZHAO J, 1990, DNA CELL BIOL, V9, P37, DOI 10.1089/dna.1990.9.37	40	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17031	17039						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894600				2022-12-25	WOS:A1991GF44500014
J	MUNOA, FJ; MILLER, KW; BEERS, R; GRAHAM, M; WU, HC				MUNOA, FJ; MILLER, KW; BEERS, R; GRAHAM, M; WU, HC			MEMBRANE TOPOLOGY OF ESCHERICHIA-COLI PROLIPOPROTEIN SIGNAL PEPTIDASE (SIGNAL PEPTIDASE-II)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; ALKALINE-PHOSPHATASE; GENE FUSIONS; LSP GENE; PROTEINS; CLONING; DNA	The lsp gene of Escherichia coli encodes the inner membrane enzyme, signal peptidase II (SPase II). SPase II is comprised of 164 amino acid residues and contains four hydrophobic domains. A series of lsp-phoA and lsp-lacZ gene fusions have been constructed in vitro to determine the topology of SPase II. The fusion junction for each of these gene fusions was determined by DNA sequencing. The lengths of the SPase II fragment in the fusions varied from 12 to 159 amino acid residues. Strains containing SPase II-PhoA fusions to the two predicted periplasmic loops exhibited higher levels of alkaline phosphatase activity than fusions to the predicted cytoplasmic domains. In contrast, SPase II-LacZ fusions at the cytoplasmic and the periplasmic domains of SPase II showed high and low levels of beta-galactosidase activity, respectively, a result opposite to those shown by SPase II-PhoA fusions located at precisely the same amino acid of SPase II. Taken together, these results strongly support the predicted model for SPase II topology, i.e. this enzyme spans the cytoplasmic membrane four times with both the amino and the carboxyl termini facing the cytoplasm.	UNIFORMED SERV UNIV HLTH SCI,DEPT MICROBIOL,BETHESDA,MD 20814	Uniformed Services University of the Health Sciences - USA					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028811] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-28811] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CASADABAN MJ, 1980, J BACTERIOL, V143, P971, DOI 10.1128/JB.143.2.971-980.1980; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; HOFFMAN CS, 1985, P NATL ACAD SCI USA, V82, P5107, DOI 10.1073/pnas.82.15.5107; INNIS MA, 1984, P NATL ACAD SCI-BIOL, V81, P3708, DOI 10.1073/pnas.81.12.3708; ISAKI L, 1990, J BACTERIOL, V172, P469, DOI 10.1128/JB.172.1.469-472.1990; ISAKI L, 1990, J BACTERIOL, V172, P6512, DOI 10.1128/jb.172.11.6512-6517.1990; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; LEWIS MJ, 1990, J BIOL CHEM, V265, P10541; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MANOIL C, 1990, J BACTERIOL, V172, P515, DOI 10.1128/jb.172.2.515-518.1990; MANOIL C, 1990, J BACTERIOL, V172, P1035, DOI 10.1128/jb.172.2.1035-1042.1990; MILLER JH, 1971, EXPT MOL GENETICS, P352; REGUE M, 1984, J BACTERIOL, V158, P632, DOI 10.1128/JB.158.2.632-635.1984; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; TOKUNAGA M, 1985, J BIOL CHEM, V260, P5610; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; YAMAGATA H, 1983, MOL GEN GENET, V192, P10, DOI 10.1007/BF00327640; YU F, 1984, FEBS LETT, V173, P264, DOI 10.1016/0014-5793(84)81060-1	22	48	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17667	17672						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894646				2022-12-25	WOS:A1991GF44500101
J	ORNING, L; KRIVI, G; BILD, G; GIERSE, J; AYKENT, S; FITZPATRICK, FA				ORNING, L; KRIVI, G; BILD, G; GIERSE, J; AYKENT, S; FITZPATRICK, FA			INHIBITION OF LEUKOTRIENE-A4 HYDROLASE AMINOPEPTIDASE BY CAPTOPRIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN CONVERTING ENZYME; AMINO-ACID SEQUENCE; WHOLE-BLOOD; MOLECULAR-CLONING; BIOSYNTHESIS; LEUKOCYTES; RAT; INACTIVATION; NEUTROPHILS; METABOLISM	Captopril ((2S)-1-(3-mercapto-2-methyl-propionyl)-L-proline) inhibited the bifunctional, Zn 2+-containing enzyme leukotriene A4 hydrolase/aminopeptidase reversibly and competitively with K(i) = 6.0-mu-m for leukotriene B4 formation and K(i) = 60 nm for L-lysine-p-nitroanilide hydrolysis at pH 8. Inhibition was independent of pH between pH 7 and 8, the optimum range for each catalytic activity. Half-maximal inhibition of leukotriene B4 formation by intact erythrocytes and neutrophils required 50 and 88-mu-M captopril, respectively. In neutrophils and platelets neither 5(S)-hydroxyeicosatetraenoic acid, 12(S)-hydroxyeicosatetraenoic acid, nor leukotriene C4 formation were reduced, indicating selective inhibition of leukotriene A4 hydrolase/aminopeptidase, not 5-lipoxygenase, 12-lipoxygenase, or leukotriene C4 synthase. In whole blood, captopril inhibited leukotriene B4 formation with an accompanying redistribution of substrate toward formation of cysteinyl leukotrienes. The decrease in leukotriene B4 Was more substantial than the corresponding increase in cysteinyl leukotrienes suggesting that nonenzymatic hydration predominates over transcellular metabolism of leukotriene A4 by platelets during selective inhibition of leukotriene A4 hydrolase. Enalapril dicarboxylic acid and Glu-Trp-Pro-Arg-Pro-GIn-Ile-Pro-Pro which inhibit angiotensin-converting enzyme: angiotensin I, bradykinin, and N-[3-(2-furyl)acryloyl]Phe-Gly-Gly which are substrates; and chloride ions which activate angiotensin-converting enzyme did not modulate leukotriene A4 hydrolase/aminopeptidase, activity. The results indicate that: (i) the sulfhydryl group of captopril is an important determinant for inhibition of leukotriene A4 hydrolase/aminopeptidase, aminopeptidase, probably by binding to an active site Zn2+; (ii) aminopeptidase and leukotriene A4 hydrolase display differential susceptibility to inhibition; (iii) there is minimal functional similarity between angiotensin-converting enzyme (peptidyl dipeptidase) and leukotriene A4 hydrolase/aminopeptidase; (iv) captopril may be a useful prototype to identify more potent and selective leukotriene A4 hydrolase inhibitors.	MONSANTO CO, MONSANTO CORP RES, ST LOUIS, MO 63167 USA	Monsanto	ORNING, L (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL C236, DENVER, CO 80262 USA.				NHLBI NIH HHS [P01 HL34303] Funding Source: Medline; NIAID NIH HHS [R01 AI26730] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026730] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AUGENSTEIN WL, 1988, JAMA-J AM MED ASSOC, V259, P3302, DOI 10.1001/jama.259.22.3302; BEUTLER E, 1976, J LAB CLIN MED, V88, P328; CLAESSON HE, 1985, BIOCHEM BIOPH RES CO, V131, P579, DOI 10.1016/0006-291X(85)91276-8; COOPER RA, 1983, ARCH INTERN MED, V143, P659, DOI 10.1001/archinte.143.4.659; EVANS JF, 1985, J BIOL CHEM, V260, P966; FEINMARK SJ, 1986, J BIOL CHEM, V261, P6466; FRADIN A, 1989, J IMMUNOL, V143, P3680; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; GRAHAM SR, 1989, MED J AUSTRALIA, V151, P111, DOI 10.5694/j.1326-5377.1989.tb101174.x; GRESELE P, 1986, BIOCHEM BIOPH RES CO, V137, P334, DOI 10.1016/0006-291X(86)91215-5; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V173, P431, DOI 10.1016/S0006-291X(05)81076-9; HAEGGSTROM JZ, 1990, BIOCHEM BIOPH RES CO, V172, P965, DOI 10.1016/0006-291X(90)91540-9; JACKSCHIK B, 1983, PROSTAGLANDINS, V25, P767; JONGENEEL CV, 1989, FEBS LETT, V242, P211, DOI 10.1016/0014-5793(89)80471-5; KOSTIS JB, 1988, AM HEART J, V116, P1591, DOI 10.1016/0002-8703(88)90748-X; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; MACLOUF JA, 1988, J BIOL CHEM, V263, P174; MALFROY B, 1989, BIOCHEM BIOPH RES CO, V161, P236, DOI 10.1016/0006-291X(89)91586-6; MARCUS AJ, 1990, BLOOD, V76, P1903; MCGEE JE, 1986, P NATL ACAD SCI USA, V83, P1349, DOI 10.1073/pnas.83.5.1349; MINAMI M, 1990, BIOCHEM BIOPH RES CO, V173, P620, DOI 10.1016/S0006-291X(05)80080-4; OHISHI N, 1987, J BIOL CHEM, V262, P10200; ORNING L, 1990, J BIOL CHEM, V265, P14911; ORNING L, 1991, J BIOL CHEM, V266, P1375; PRADELLES P, 1990, METHOD ENZYMOL, V187, P82; PRESCOTT SM, 1984, J BIOL CHEM, V259, P7615; RADMARK O, 1984, J BIOL CHEM, V259, P2339; RAZ A, 1990, BIOCHEM J, V269, P603, DOI 10.1042/bj2690603; SALENA BJ, 1986, ARCH INTERN MED, V146, P202, DOI 10.1001/archinte.146.1.202; SAMUELSSON B, 1989, J BIOL CHEM, V264, P19469; SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5234, DOI 10.1021/bi00317a022; SHAPIRO R, 1984, BIOCHEMISTRY-US, V23, P5225, DOI 10.1021/bi00317a021; SMITH WL, 1990, ADV PROSTAG THROMB L, V20, P14; STENSON WF, 1984, J BIOL CHEM, V259, P1784; TOH H, 1990, BIOCHEM BIOPH RES CO, V171, P216, DOI 10.1016/0006-291X(90)91379-7; VALLEE BL, 1990, BIOCHEMISTRY-US, V29, P5647, DOI 10.1021/bi00476a001; WESTCOTT JY, 1986, PROSTAGLANDINS, V32, P857, DOI 10.1016/0090-6980(86)90095-X; YONETANI T, 1964, ARCH BIOCHEM BIOPHYS, V106, P243, DOI 10.1016/0003-9861(64)90184-5	38	85	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16507	16511						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885582				2022-12-25	WOS:A1991GD63500045
J	SHAH, RR; KNOTT, TJ; LEGROS, JE; NAVARATNAM, N; GREEVE, JC; SCOTT, J				SHAH, RR; KNOTT, TJ; LEGROS, JE; NAVARATNAM, N; GREEVE, JC; SCOTT, J			SEQUENCE REQUIREMENTS FOR THE EDITING OF APOLIPOPROTEIN-B MESSENGER-RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							STOP CODON; IDENTIFICATION; INITIATION; INTESTINE; PROTEIN	Apolipoprotein (apo) B48 is produced in the mammalian intestine by a tissue-specific RNA-editing mechanism, which mediates a C to U conversion at position 6666 in apoB mRNA. This generates an inframe translation stop codon (UAA) in place of glutamine (CAA) at position 2153. To establish the sequences required for editing we have used an in vitro conversion assay to monitor the editing of synthetic RNAs by rat intestinal extracts. Transcripts containing 55 nucleotides (positions 6649-6703) or more of human apoB mRNA sequence were edited in vitro. Transcripts containing 42 nucleotides (positions 6648-6689) and 26 nucleotides (positions 6662-6687) were edited at 62 and 24% efficiency, respectively, of the 55-nucleotide sequence. To delineate the precise sequence requirements for editing, mutants were generated where 6-nucleotide sections of the 55-base region were changed to anti-sense sequence. Mutation of the 12-nucleotide region immediately downstream of C-6666 abolished editing, and mutation of 6-base sequences immediately 3' and 5' of this 12-nucleotide region significantly reduced editing. Having identified the key region of interest, a panel of 46 mutant RNAs carrying single base substitutions or deletions between nucleotide positions 6657 and 6685 was constructed. Mutagenesis in the sequence 5'-TGATCAGTATA-3' (positions 6671-6681) downstream of C-6666 had the most dramatic effect, since almost all mutations abolished or greatly reduced conversion in vitro. These results suggest that editing is a highly sequence-specific process. We propose that this downstream region is a recognition and/or binding site for the editing enzyme. A search for this sequence in other genes may help to reveal other RNAs that undergo editing.	MRC,CLIN RES CTR,DIV MOLEC MED,WATFORD RD,HARROW HA1 3UJ,MIDDX,ENGLAND	Medical Research Council Clinical Trials Unit								BOSTROM K, 1989, J BIOL CHEM, V264, P15701; BOSTROM K, 1990, J BIOL CHEM, V265, P22446; CHEN SH, 1990, J BIOL CHEM, V265, P6811; CHEN SH, 1987, SCIENCE, V238, P363, DOI 10.1126/science.3659919; DAVIES MS, 1989, J BIOL CHEM, V264, P13395; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOTTO GP, 1984, NATURE, V311, P279, DOI 10.1038/311279a0; DRISCOLL DM, 1989, CELL, V58, P519, DOI 10.1016/0092-8674(89)90432-7; HERMES JD, 1989, GENE, V84, P143, DOI 10.1016/0378-1119(89)90148-0; HODGES PE, 1991, NUCLEIC ACIDS RES, V19, P1197, DOI 10.1093/nar/19.6.1197; HOSPATTANKAR AV, 1987, BIOCHEM BIOPH RES CO, V148, P279, DOI 10.1016/0006-291X(87)91107-7; KANE JP, 1983, ANNU REV PHYSIOL, V45, P637, DOI 10.1146/annurev.ph.45.030183.003225; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; Sambrook J, 1989, MOL CLONING LABORATO; ZUCKER M, 1981, NUCLEIC ACIDS RES, V9, P133	17	125	131	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16301	16304						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885564				2022-12-25	WOS:A1991GD63500012
J	AHN, JY; HONG, SO; KWAK, KB; KANG, SS; TANAKA, K; ICHIHARA, A; HA, DB; CHUNG, CH				AHN, JY; HONG, SO; KWAK, KB; KANG, SS; TANAKA, K; ICHIHARA, A; HA, DB; CHUNG, CH			DEVELOPMENTAL REGULATION OF PROTEOLYTIC ACTIVITIES AND SUBUNIT PATTERN OF 20-S PROTEASOME IN CHICK EMBRYONIC MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; RAT SKELETAL-MUSCLE; POLYACRYLAMIDE GELS; MAMMALIAN-CELLS; INVOLVEMENT; MYOGENESIS; PARTICLE; FUSION; LIVER; LINE	The proteolytic activities of the 20 S proteasome were found to change in their levels during the development of chick embryonic muscle. The peptide-cleaving activities against N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin and N-benzyloxycarbonyl-Ala-Arg-Arg-4-methoxy-beta-naphthylamide gradually decreased with the time of development. On the other hand, the casein-degrading activity in the presence of poly-L-lysine markedly increased from embryonic day 11 and reached a maximal level by day 17. These changes appeared to be tissue-specific because little or no change in any of the proteolytic activities was observed with developing embryonic brain, while dramatic alterations occurred in the extents of the peptide hydrolyses in liver. Furthermore, a number , but not all, of the proteasome subunits in embryonic muscle were changed in their amounts during the development. These results suggest that the alterations in the proteasome activities and subunit pattern are developmentally regulated and may be correlated.	SEOUL NATL UNIV,COLL NAT SCI,DEPT MOLEC BIOL,SEOUL 151742,SOUTH KOREA; KYUNGPOOK NATL UNIV,DEPT BIOL,TAEGU 702701,SOUTH KOREA; SEOUL NATL UNIV,COLL NAT SCI,SRC CELL DIFFERENTIAT,SEOUL 151742,SOUTH KOREA; UNIV TOKUSHIMA,INST ENZYME RES,TOKUSHIMA 770,JAPAN	Seoul National University (SNU); Kyungpook National University; Seoul National University (SNU); Tokushima University								ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; AXEN R, 1967, NATURE, V214, P1302, DOI 10.1038/2141302a0; BISCHOFF R, 1969, J CELL BIOL, V41, P188, DOI 10.1083/jcb.41.1.188; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTANO JG, 1986, CELL, V46, P377, DOI 10.1016/0092-8674(86)90658-6; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; ENDO T, 1987, CELL, V49, P515, DOI 10.1016/0092-8674(87)90454-5; EPPENBERGER HM, 1967, J BIOL CHEM, V242, P204; EYTAN E, 1989, P NATL ACAD SCI USA, V86, P7751, DOI 10.1073/pnas.86.20.7751; FALKENBURG PE, 1988, NATURE, V331, P190, DOI 10.1038/331190a0; FULTON AB, 1981, J CELL BIOL, V91, P103, DOI 10.1083/jcb.91.1.103; HAASS C, 1989, EXP CELL RES, V180, P243, DOI 10.1016/0014-4827(89)90228-0; Herrmann H, 1970, Curr Top Dev Biol, V5, P181, DOI 10.1016/S0070-2153(08)60056-3; HERRMANN H, 1957, J CELL COMPAR PHYSL, V49, P227, DOI 10.1002/jcp.1030490206; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; KLEIN U, 1990, J CELL BIOL, V111, P2275, DOI 10.1083/jcb.111.6.2275; KUEHN L, 1990, FEBS LETT, V264, P279; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; NADALGINARD B, 1978, CELL, V15, P855, DOI 10.1016/0092-8674(78)90270-2; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; ONEILL MC, 1972, J CELL BIOL, V52, P52, DOI 10.1083/jcb.52.1.52; ORLOWSKI M, 1990, BIOCHEMISTRY-US, V29, P10289, DOI 10.1021/bi00497a001; PAUW PG, 1979, DEV BIOL, V70, P27, DOI 10.1016/0012-1606(79)90004-6; RIVETT AJ, 1989, J BIOL CHEM, V264, P12215; SEOL JH, 1989, FEBS LETT, V247, P197, DOI 10.1016/0014-5793(89)81333-X; TAMURA T, 1991, BIOCHIM BIOPHYS ACTA, V1089, P95, DOI 10.1016/0167-4781(91)90090-9; TANAKA K, 1988, FEBS LETT, V236, P159, DOI 10.1016/0014-5793(88)80306-5; TANAKA K, 1988, J MOL BIOL, V203, P985, DOI 10.1016/0022-2836(88)90123-4; TANAKA K, 1986, J BIOL CHEM, V261, P5197; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350	32	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15746	15749						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874733				2022-12-25	WOS:A1991GB97700037
J	FOSANG, AJ; NEAME, PJ; HARDINGHAM, TE; MURPHY, G; HAMILTON, JA				FOSANG, AJ; NEAME, PJ; HARDINGHAM, TE; MURPHY, G; HAMILTON, JA			CLEAVAGE OF CARTILAGE PROTEOGLYCAN BETWEEN G1 AND G2 DOMAINS BY STROMELYSINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BOVINE ARTICULAR-CARTILAGE; GLOBULAR PROTEIN DOMAINS; AMINO-ACID SEQUENCE; LINK-PROTEIN; BINDING REGION; SYNOVIAL FIBROBLASTS; CORE PROTEIN; CDNA CLONES; METALLOPROTEINASE; COLLAGENASE	Normal and pathological turnover of proteoglycans in articular cartilage involves its cleavage close to the N-terminal G1 domain responsible for aggregation. A fragment containing G1 and G2 N-terminal domains of pig cartilage proteoglycans was therefore used as a substrate to investigate its degradation by the metalloproteinase stromelysin and related recombinant stromelysin enzymes. The stromelysins produced an apparent single cleavage yielding a G1 fragment of 56 kDa and a G2 fragment of 110 kDa. Rabbit bone stromelysin was much more active against the G1-G2 fragment and against proteoglycan aggregates than recombinant human stromelysin-1 and stromelysin-2. All metalloproteinase preparations were active against proteoglycan and the G1-G2 fragment at acid (pH 5.5) and neutral pH (7.4). N-terminal sequencing of the G2 fragment derived from the action of recombinant human stromelysin-1 revealed that cleavage between G1 and G2 occurred at the N-terminal end of the interglobular domain, close to the last cysteine in G1. The specific cleavage site was between an asparagine and a pair of phenylalanine residues, where the asparagine corresponds to residue 341 in human and rat mature core protein sequence.	SHRINERS HOSP CRIPPLED CHILDREN, TAMPA, FL 33612 USA; KENNEDY INST, LONDON W6 7DW, ENGLAND; STRANGEWAYS RES LAB, CAMBRIDGE CB1 4RN, ENGLAND	University of Oxford	FOSANG, AJ (corresponding author), UNIV MELBOURNE, ROYAL MELBOURNE HOSP, DEPT MED, MELBOURNE, VIC 3050, AUSTRALIA.			Hamilton, John A/0000-0002-9493-9224; Fosang, Amanda/0000-0002-5523-5427; Hardingham, Timothy/0000-0001-8271-6763				BALDWIN CT, 1989, J BIOL CHEM, V264, P15747; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BIRKEDALHANSEN H, 1989, IMMUNOL INVEST, V18, P211, DOI 10.3109/08820138909112238; BONNET F, 1986, BIOCHIM BIOPHYS ACTA, V873, P152, DOI 10.1016/0167-4838(86)90202-5; BONNET F, 1985, BIOCHEM J, V228, P77, DOI 10.1042/bj2280077; CAMPBELL MA, 1984, ARCH BIOCHEM BIOPHYS, V234, P275, DOI 10.1016/0003-9861(84)90350-3; CAMPBELL MA, 1989, BIOCHEM J, V259, P21, DOI 10.1042/bj2590021; CARNEY SL, 1986, ANAL BIOCHEM, V156, P38, DOI 10.1016/0003-2697(86)90150-8; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CHIN JR, 1985, J BIOL CHEM, V260, P2367; DEAK F, 1986, P NATL ACAD SCI USA, V83, P3766, DOI 10.1073/pnas.83.11.3766; DEBLAS AL, 1983, ANAL BIOCHEM, V133, P214, DOI 10.1016/0003-2697(83)90245-2; DOCHERTY AJP, 1990, ANN RHEUM DIS, P469; DOEGE K, 1987, J BIOL CHEM, V262, P17757; DOEGE KJ, 1991, J BIOL CHEM, V266, P894; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FOSANG AJ, 1989, BIOCHEM J, V261, P801, DOI 10.1042/bj2610801; FOSANG AJ, 1991, BIOCHEM J, V273, P369, DOI 10.1042/bj2730369; FOSANG AJ, 1991, MATRIX, V11, P17, DOI 10.1016/S0934-8832(11)80223-4; GALLOWAY WA, 1983, BIOCHEM J, V209, P741, DOI 10.1042/bj2090741; GOLDS EE, 1983, J RHEUMATOL, V10, P861; HALBERG DF, 1988, J BIOL CHEM, V263, P9486; HARDINGHAM TE, 1986, CIBA F SYMP, V124, P30; HARDINGHAM TE, 1972, BIOCHIM BIOPHYS ACTA, V279, P401, DOI 10.1016/0304-4165(72)90160-2; HARDINGHAM TE, 1979, BIOCHEM J, V177, P237, DOI 10.1042/bj1770237; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; KOKLITIS PA, 1991, BIOCHEM J, V276, P217, DOI 10.1042/bj2760217; MIYAZAKI K, 1990, CANCER RES, V50, P7758; MORALES TI, 1989, CONNECT TISSUE RES, V19, P255, DOI 10.3109/03008208909043900; MORALES TI, 1984, J BIOL CHEM, V259, P6720; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1987, BIOCHEM J, V248, P265, DOI 10.1042/bj2480265; MURPHY G, 1991, BIOCHEM J, V277, P277, DOI 10.1042/bj2770277; NEAME PJ, 1987, J BIOL CHEM, V262, P17768; OKADA Y, 1986, J BIOL CHEM, V261, P14245; OLDBERG A, 1987, BIOCHEM J, V243, P255, DOI 10.1042/bj2430255; PATTHY L, 1987, J MOL BIOL, V198, P567, DOI 10.1016/0022-2836(87)90200-2; PAULSSON M, 1987, BIOCHEM J, V245, P763, DOI 10.1042/bj2450763; PELLETIER JP, 1987, ARTHRITIS RHEUM, V30, P541, DOI 10.1002/art.1780300508; PERKINS SJ, 1989, J MOL BIOL, V206, P737, DOI 10.1016/0022-2836(89)90580-9; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; RATCLIFFE A, 1983, BIOCHEM J, V213, P371, DOI 10.1042/bj2130371; RATCLIFFE A, 1986, BIOCHEM J, V238, P571, DOI 10.1042/bj2380571; SANDY JD, 1978, BIOCHIM BIOPHYS ACTA, V543, P536, DOI 10.1016/0304-4165(78)90308-2; SANDY JD, 1990, J BIOL CHEM, V265, P21108; TYLER JA, 1985, BIOCHEM J, V225, P493, DOI 10.1042/bj2250493; WILHELM SM, 1987, P NATL ACAD SCI USA, V84, P6725, DOI 10.1073/pnas.84.19.6725	48	152	157	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15579	15582						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874716				2022-12-25	WOS:A1991GB97700007
J	KOBREHEL, K; YEE, BC; BUCHANAN, BB				KOBREHEL, K; YEE, BC; BUCHANAN, BB			ROLE OF THE NADP THIOREDOXIN SYSTEM IN THE REDUCTION OF ALPHA-AMYLASE AND TRYPSIN-INHIBITOR PROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEAT; PHOTOSYNTHESIS; PURIFICATION; CHLOROPLASTS; PUROTHIONIN; LEAVES	Thioredoxin, reduced either enzymatically with NADPH and NADP-thioredoxin reductase or chemically with dithiothreitol, reduced alpha-amylase and trypsin inhibitor proteins from several sources. Included were cystine-rich seed representatives from wheat (alpha-amylase inhibitors), soybean (Bowman-Birk trypsin inhibitor), and corn (kernel trypsin inhibitor). This system also reduced other trypsin inhibitors: the soybean Kunitz inhibitor, bovine lung aprotinin, and egg white ovoinhibitor and ovomucoid proteins. The ability of these proteins to undergo reduction by thioredoxin was determined by 1) a coupled enzyme activation assay with chloroplast NADP-malate dehydrogenase or fructose-1,6-bisphosphatase, 2) a dye reduction assay with 5',5'-dithiobis(2-nitrobenzoic acid), and 3) a direct reduction method based on the fluorescent probe, monobromobimane, and sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Reduction experiments with the seed proteins were carried out with thioredoxin from wheat germ (h-type) or Escherichia coli; the corresponding experiments with the animal trypsin inhibitors were carried out with thioredoxin from calf thymus or E. coli. In all cases, thioredoxin appeared to act catalytically; the reduced form of glutathione was without effect. When considered in conjunction with earlier results on purothionin (confirmed and extended in the current study), the new findings suggest that the NADP/thioredoxin system functions in the reduction of protein inhibitors of seeds and animal tissues. These results also raise the question of the occurrence of glutaredoxin in plants, as E. coli glutaredoxin was found to promote the reduction of some but not all of the proteins tested.	UNIV CALIF BERKELEY, DEPT PLANT BIOL, 111 GENET & PLANT BIOL BLDG, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley								BIRK Y, 1985, INT J PEPT PROT RES, V25, P113, DOI 10.1111/j.1399-3011.1985.tb02155.x; Birk Y, 1976, Methods Enzymol, V45, P695; CRAWFORD NA, 1989, ARCH BIOCHEM BIOPHYS, V271, P223, DOI 10.1016/0003-9861(89)90273-7; FLORENCIO FJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P496, DOI 10.1016/0003-9861(88)90282-2; Garcia-Olmedo F., 1987, OXFORD SURVEYS PLANT, V4, P275; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; JACQUOT JPP, 1981, PLANT PHYSIOL, V68, P300, DOI 10.1104/pp.68.2.300; JOHNSON TC, 1987, PLANT PHYSIOL, V85, P446, DOI 10.1104/pp.85.2.446; JONES BL, 1977, CEREAL CHEM, V54, P511; KASSELL B, 1965, BIOCHEM BIOPH RES CO, V20, P463, DOI 10.1016/0006-291X(65)90601-7; KOBREHEL K, 1989, J SCI FOOD AGR, V48, P441, DOI 10.1002/jsfa.2740480406; KOBREHEL K, 1991, IN PRESS CEREAL CHEM; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKOWSKI M, 1980, ANNU REV BIOCHEM, V49, P593, DOI 10.1146/annurev.bi.49.070180.003113; NISHIZAWA AN, 1982, METHODS CHLOROPLAST, P707; TSANG MLS, 1981, PLANT PHYSIOL, V68, P1098, DOI 10.1104/pp.68.5.1098; WADA K, 1981, FEBS LETT, V124, P237, DOI 10.1016/0014-5793(81)80145-7; WESELAKE RJ, 1983, PLANT PHYSIOL, V72, P809, DOI 10.1104/pp.72.3.809; WOLOSIUK RA, 1977, NATURE, V266, P565, DOI 10.1038/266565a0	19	107	121	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16135	16140						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874751				2022-12-25	WOS:A1991GB97700091
J	DEEB, SS; CHEUNG, MC; PENG, R; WOLF, AC; STERN, R; ALBERS, JJ; KNOPP, RH				DEEB, SS; CHEUNG, MC; PENG, R; WOLF, AC; STERN, R; ALBERS, JJ; KNOPP, RH			A MUTATION IN THE HUMAN APOLIPOPROTEIN-A-I GENE - DOMINANT EFFECT ON THE LEVEL AND CHARACTERISTICS OF PLASMA HIGH-DENSITY-LIPOPROTEINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LECITHIN-CHOLESTEROL ACYLTRANSFERASE; CORONARY HEART-DISEASE; TANGIER DISEASE; IMMUNOAFFINITY CHROMATOGRAPHY; PREMATURE ATHEROSCLEROSIS; IMILANO APOPROTEIN; IMMUNOASSAY; ULTRACENTRIFUGATION; CHROMOSOME-11; POLYMORPHISM	Epidemiologic and genetic data suggest an inverse relationship between plasma high density lipoprotein (HDL) cholesterol and the incidence of premature coronary artery disease. Some of the defects leading to low levels of HDL may be a consequence of mutations in the genes coding for HDL apolipoproteins A-I and A-II or for enzymes that modify these particles. A proband with plasma apoA-I and HDL cholesterol that are below 15% of normal levels and with marked bilateral arcus senilis was shown to be heterozygous for a 45-base pair deletion in exon four of the apoA-I gene. This most likely represents a de novo mutation since neither parent carries the mutant allele. The protein product of this allele is predicted to be missing 15 (Glu146-Arg160) of the 22 amino acids comprising the third amphipathic helical domain. The HDL, of the proband and his family were studied. Using anti-A-I and anti-A-11 immunosorbents we found three populations of HDL particles in the proband. One contained both apoA-I and A-II, Lp(A-I w A-II); one contained apoA-I but no A-II, Lp(A-I w/o A-II); and the third (an unusual one) contained apoA-II but no A-I. Only Lp(A-I w A-II) and (A-I w/o A-II) were present in the plasma of the proband's parents and brother. Analysis of the HDL particles of the proband by sodium dodecyl sulfate-polyacrylamide gel electrophoresis revealed two protein bands with a molecular mass differing by 6% in the vicinity of 28 kDa whereas the HDI, particles of the family members exhibited only a single apoA-I band. The largely dominant effect of this mutant allele (designated apoA-I(Seattle)) on HDL levels suggests that HDL particles containing any number of mutant apoA-I polypeptides are catabolized rapidly.	NW LIPID RES LABS,SEATTLE,WA 98195; NW LIPID RES CLIN,SEATTLE,WA 98195		DEEB, SS (corresponding author), UNIV WASHINGTON,SCH MED,DEPT MED,DIV MED GENET,RG-25,SEATTLE,WA 98195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30086] Funding Source: Medline; PHS HHS [35816] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALBERS JJ, 1982, ATHEROSCLEROSIS, V43, P369, DOI 10.1016/0021-9150(82)90036-3; ALBERS JJ, 1989, CLIN LAB MED, V9, P137, DOI 10.1016/S0272-2712(18)30646-2; ALBERS JJ, 1981, J CLIN INVEST, V67, P141, DOI 10.1172/JCI110006; ALBERS JJ, 1976, METABOLISM, V25, P633, DOI 10.1016/0026-0495(76)90060-3; ALBERS JJ, 1975, METABOLISM, V24, P1339, DOI 10.1016/0026-0495(75)90050-5; ALBERS JJ, 1981, ATHEROSCLEROSIS, V39, P395, DOI 10.1016/0021-9150(81)90025-3; ASSMAN G, 1989, METABOLIC BASIS INHE, V1, P1267; ASSMANN G, 1977, J CLIN INVEST, V60, P242, DOI 10.1172/JCI108761; ASSMANN G, 1977, J CLIN INVEST, V59, P565, DOI 10.1172/JCI108672; BALAZS I, 1989, AM J HUM GENET, V44, P182; BOERWINKLE E, 1989, P NATL ACAD SCI USA, V86, P212, DOI 10.1073/pnas.86.1.212; BRESLOW JL, 1989, METABOLIC BASIS INHE, V1, P1251; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Cheung M C, 1986, Methods Enzymol, V129, P130; CHEUNG MC, 1977, J CLIN INVEST, V60, P43, DOI 10.1172/JCI108767; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; CHEUNG MC, 1988, J LIPID RES, V29, P15; CHEUNG MC, 1987, J LIPID RES, V28, P913; CHEUNG MC, 1988, BIOCHIM BIOPHYS ACTA, V960, P73, DOI 10.1016/0005-2760(88)90011-2; CHEUNG MC, 1990, ARTERIOSCLEROSIS, V10, P856; CHEUNG MC, 1987, NIH872646 PUBL, P341; CHEUNG P, 1984, P NATL ACAD SCI-BIOL, V81, P508, DOI 10.1073/pnas.81.2.508; DEEB SS, 1986, COLD SPRING HARB SYM, V51, P405; DELOOF H, 1987, BIOCHIM BIOPHYS ACTA, V911, P45, DOI 10.1016/0167-4838(87)90268-8; FRANCESCHINI G, 1980, J CLIN INVEST, V66, P892, DOI 10.1172/JCI109956; FRANCESCHINI G, 1985, ATHEROSCLEROSIS, V58, P159, DOI 10.1016/0021-9150(85)90063-2; FRIEDL W, 1990, J LIPID RES, V31, P659; GHISELLI G, 1982, J CLIN RES, V30, P393; GLOMSET JA, 1968, J LIPID RES, V9, P155; GUSTAFSON A, 1979, SCAND J CLIN LAB INV, V39, P377, DOI 10.3109/00365517909106122; HAINLINE A, 1982, MANUAL LABORATORY OP; HIGGS DR, 1986, P NATL ACAD SCI USA, V83, P5165, DOI 10.1073/pnas.83.14.5165; HUANG LS, 1987, J BIOL CHEM, V262, P8952; JAMES RW, 1988, J LIPID RES, V29, P1557; KARATHANASIS SK, 1983, P NATL ACAD SCI-BIOL, V80, P6147, DOI 10.1073/pnas.80.20.6147; KARATHANASIS SK, 1987, P NATL ACAD SCI USA, V84, P7198, DOI 10.1073/pnas.84.20.7198; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI CC, 1988, AM J HUM GENET, V43, P197; MANIATIS T., 1982, MOL CLONING LABORATO, P382; MCLACHLAN AD, 1977, NATURE, V267, P465, DOI 10.1038/267465a0; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; NAKAMURA Y, 1987, SCIENCE, V235, P1616, DOI 10.1126/science.3029872; NICHOLS AV, 1983, HDB ELECTROPHORESIS, V3, P29; ORDOVAS JM, 1989, J BIOL CHEM, V264, P16339; RADER DJ, 1989, CIRCULATION, V80, P277; RITTER MC, 1979, J BIOL CHEM, V254, P2517; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; SCHAEFER EJ, 1978, NEW ENGL J MED, V299, P905, DOI 10.1056/NEJM197810262991701; SCHMITZ G, 1989, 8TH P INT S ATH ROM, P399; SEGREST JP, 1977, BIOPOLYMERS, V16, P2053, DOI 10.1002/bip.1977.360160916; SEILHAMER JJ, 1984, DNA-J MOLEC CELL BIO, V3, P309, DOI 10.1089/dna.1.1984.3.309; SHAEFFER EJ, 1985, J LIPID RES, V26, P1089; SWANEY JB, 1978, J BIOL CHEM, V253, P7069; THOMPSON EA, 1986, AM J HUM GENET, V39, P582; VONECKARDSTEIN A, 1989, J CLIN INVEST, V84, P1727; Warnick G R, 1986, Methods Enzymol, V129, P101; YOKOYAMA S, 1985, ARTERIOSCLEROSIS, V5, P613, DOI 10.1161/01.ATV.5.6.613; 1979, CIRCULATION, V60, P427	59	71	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13654	13660						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906882				2022-12-25	WOS:A1991FY02700034
J	KHANANSHVILI, D				KHANANSHVILI, D			VOLTAGE-DEPENDENT MODULATION OF ION BINDING AND TRANSLOCATION IN THE CARDIAC NA+-CA2+ EXCHANGE SYSTEM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; PLASMA-MEMBRANE VESICLES; PIG VENTRICULAR CELLS; GUINEA-PIG; SARCOLEMMAL VESICLES; STOICHIOMETRY; PUMP; SOLUBILIZATION; IDENTIFICATION; HEART	The transport of Na+ and Ca2+ ions in the cardiac Na+-Ca2+ exchanger can be described as separate events (Khananshvili, D. (1990) Biochemistry 29, 2437-2442). Thus, the Na+-Na+ and Ca2+-Ca2+ exchange reactions reflect reversible partial reactions of the transport cycle. The effect of diffusion potentials (K+-valinomycin) on different modes of the Na+-Ca2+ exchanger (Na+-Ca2+, Ca2+-Ca2+, and Na+-Na+ exchanges) were tested in reconstituted proteoliposomes, obtained from the Triton X-100 extracts of the cardiac sarcolemmal membranes. The initial rates of the Na(i)-dependent Ca-45-uptake (t = 1 s) were measured in EGTA-entrapped proteoliposomes at different voltages. At the fixed values of voltage [Ca-45]o was varied from 4 to 122-mu-M, and [Na]i was saturating (150 mM). Upon varying DELTA-PSI from -94 to +91 mV, the V(max) values were increased from 9.5 +/- 0.5 to 26.5 +/- 1.5 nmol.mg-1.s-1 and the K(m) from 17.8 +/- 2.5 to 39.1 +/- 5.2-mu-M, while the V(max)/K(m) values ranged from only 0.53 +/- 0.08 to 0.73 +/- 0.17 nmol.mg-1.s-1.mu-M-1. The equilibrium Ca2+-Ca2+ exchange was voltage sensitive at very long [Ca]o = [Ca]i = 2-mu-M, while at saturating [Ca]o = [Ca]i = 200-mu-M the Ca2+-Ca2+ exchange became voltage-insensitive. The rates of the equilibrium Na+-Na+ exchange appears to be voltage insensitive at saturating [Na]o = [Na]i = 160 mM. Under the saturating ionic conditions, the rates of the Na+-Na+ exchange were at least 2-3-fold slower than the Ca2+-Ca2+ exchange. The following conclusions can be drawn. (a) The near constancy of the V(max)/K(m) for Na+-Ca2+ exchange at different voltages is compatible with the ping-pong model proposed previously. (b) The effects of voltage on V(max) of Na+-Ca2+ exchange are consistent with the existence of a single charge carrying transport step. (c) It is not yet possible to clearly assign this step to the Na+ or Ca2+ transport half of the cycle although it is more likely that 3Na+-transport is a charge carrying step. Thus, the unloaded ion-binding-domain contains either -2 or -3 charges (presumably carboxyl groups). (d) The binding of Na+ and Ca2+ appears to be weakly voltage-sensitive. The Ca2+-binding site may form a small ion-well (< 2-3 angstrom).			KHANANSHVILI, D (corresponding author), WEIZMANN INST SCI, DEPT BIOCHEM, POB 26, IL-76100 REHOVOT, ISRAEL.			Khananshvili, Daniel/0000-0002-4202-9966				BAUER PJ, 1981, ANAL BIOCHEM, V110, P61, DOI 10.1016/0003-2697(81)90112-3; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CHEON J, 1988, J BIOL CHEM, V263, P2309; EGAN TM, 1989, J PHYSIOL-LONDON, V411, P639, DOI 10.1113/jphysiol.1989.sp017596; EHARA T, 1989, J PHYSIOL-LONDON, V410, P227, DOI 10.1113/jphysiol.1989.sp017530; GOLDSHLEGGER R, 1987, J PHYSIOL-LONDON, V387, P331, DOI 10.1113/jphysiol.1987.sp016576; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P304, DOI 10.1016/0003-2697(73)90436-3; KHANANSHVILI D, 1990, BIOCHEMISTRY-US, V29, P2437, DOI 10.1021/bi00462a001; KIMURA J, 1987, J PHYSIOL-LONDON, V384, P199, DOI 10.1113/jphysiol.1987.sp016450; LAGNADO L, 1990, J MEMBRANE BIOL, V113, P177, DOI 10.1007/BF01870070; LANGER GA, 1982, ANNU REV PHYSIOL, V44, P435, DOI 10.1146/annurev.ph.44.030182.002251; LAUGER P, 1984, BIOCHIM BIOPHYS ACTA, V779, P307, DOI 10.1016/0304-4157(84)90015-7; LAUGER P, 1987, J MEMBRANE BIOL, V99, P1, DOI 10.1007/BF01870617; LEDVORA RF, 1983, BIOCHIM BIOPHYS ACTA, V729, P123, DOI 10.1016/0005-2736(83)90463-7; LEGNADO L, 1988, P NATL ACAD SCI USA, V85, P4548; MIYAMOTO H, 1980, J BIOL CHEM, V255, P2656; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; NIGGLI E, 1991, NATURE, V349, P621, DOI 10.1038/349621a0; PHILIPSON KD, 1980, J BIOL CHEM, V255, P6880; PHILIPSON KD, 1985, ANNU REV PHYSIOL, V47, P561; PITTS BJR, 1979, J BIOL CHEM, V254, P6232; RAKOWSKI RF, 1989, J GEN PHYSIOL, V93, P903, DOI 10.1085/jgp.93.5.903; REEVES JP, 1985, CURR TOP MEMBR TRANS, V25, P77; REEVES JP, 1984, J BIOL CHEM, V259, P7733; REEVES JP, 1988, METHOD ENZYMOL, V157, P505; REEVES JP, 1990, CELLUALR CALCIUM PRA; SOLDATI L, 1985, J BIOL CHEM, V260, P3321; Stein W., 2012, TRANSPORT DIFFUSION; VEMURI R, 1988, BIOCHIM BIOPHYS ACTA, V937, P258, DOI 10.1016/0005-2736(88)90248-9	29	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13764	13769						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906884				2022-12-25	WOS:A1991FY02700050
J	MENNITI, FS; BIRD, GS; TAKEMURA, H; THASTRUP, O; POTTER, BVL; PUTNEY, JW				MENNITI, FS; BIRD, GS; TAKEMURA, H; THASTRUP, O; POTTER, BVL; PUTNEY, JW			MOBILIZATION OF CALCIUM BY INOSITOL TRISPHOSPHATES FROM PERMEABILIZED RAT PAROTID ACINAR-CELLS - EVIDENCE FOR TRANSLOCATION OF CALCIUM FROM UPTAKE TO RELEASE SITES WITHIN THE INOSITOL 1,4,5-TRISPHOSPHATE-SENSITIVE AND THAPSIGARGIN-SENSITIVE CALCIUM POOL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG HEPATOCYTES; ADRENAL GLOMERULOSA CELLS; 2ND MESSENGER; CA-2+ RELEASE; ENDOPLASMIC-RETICULUM; INTRACELLULAR CALCIUM; MICROSOMAL FRACTIONS; 3-KINASE ACTIVITY; RECEPTOR-BINDING; TUMOR PROMOTER	D-myo-Inositol (1,4,5)-trisphosphate ((1,4,5)IP3)-induced Ca2+ release and subsequent Ca2+ reuptake were investigated in saponin-permeabilized rat parotid acinar cells. Following the rapid release of Ca2+ by (1,4,5)IP3, Ca2+ was resequestered. The sequential addition of submaximal concentrations of (1,4,5)IP3 resulted in sequential Ca2+ release. However, when the cells were challenged with the poorly metabolized (1,4,5)IP3 analogues, (1,4,5)IPS3 or (2,4,5)IP3, or under conditions where the metabolism of authentic (1,4,5)IP3 was reduced, Ca2+ reuptake again occurred, but sequestered Ca2+ was not released by subsequent additions of (1,4,5)IP3. The sequestered Ca2+ was, however, released by thapsigargin, an agent which inhibits active Ca2+ uptake into the (1,4,5)IP3-sensitive pool. Furthermore, the rate of thapsigargin-induced release was significantly increased in the continued presence of an (1,4.5)IP3 stimulus. Thus, Ca2+ reuptake apparently occurred into the (1,4,5)IP3- and thapsigargin-sensitive Ca2+ store and (1,4,5)IP3 continued to influence the permeability of this pool to Ca2+ during Ca2+ reuptake. In contrast to the findings in permeabilized cells, Ca2+ reuptake did not occur in the sustained presence of (1,4,5)IP3 in intact parotid cells. We conclude that cell permeabilization reveals a kinetic, and presumably structural, separation of Ca2+ uptake and release sites within the (1,4,5)IP3-regulated intracellular organelle.	UNIV COPENHAGEN HOSP, RIGSHOSP, DEPT CLIN CHEM, DK-2100 COPENHAGEN, DENMARK; SYMBION, THROMBOSIS GRP, DK-2100 COPENHAGEN, DENMARK; UNIV BATH, SCH PHARM & PHARMACOL, BATH BA2 7AY, AVON, ENGLAND	Rigshospitalet; University of Copenhagen; University of Bath	MENNITI, FS (corresponding author), NIEHS, CALCIUM REGULAT SECT, CELLULAR & MOLEC PHARMACOL LAB, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Potter, Barry VL/A-1845-2012; Bird, Gary/AAI-8186-2021; Potter, Barry/AAX-4781-2020; Putney, James/F-7247-2019	Bird, Gary/0000-0003-1389-8748; Menniti, Frank/0000-0003-2612-9534; Putney, James/0000-0002-3379-4789				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BIDEN TJ, 1984, BIOCHEM J, V223, P467, DOI 10.1042/bj2230467; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGESS GM, 1984, NATURE, V309, P63, DOI 10.1038/309063a0; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; COOK GA, 1983, BIOCHIM BIOPHYS ACTA, V763, P356, DOI 10.1016/0167-4889(83)90097-6; COOKE AM, 1987, J CHEM SOC CHEM COMM, P1525, DOI 10.1039/c39870001525; CULLEN PJ, 1988, FEBS LETT, V228, P57, DOI 10.1016/0014-5793(88)80584-2; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; DAWSON AP, 1984, BIOCHEM BIOPH RES CO, V120, P858, DOI 10.1016/S0006-291X(84)80186-2; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; FERRIS CD, 1989, NATURE, V342, P87, DOI 10.1038/342087a0; FURUICHI T, 1989, NATURE, V342, P32, DOI 10.1038/342032a0; GHOSH TK, 1988, J BIOL CHEM, V263, P11075; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HILL TD, 1988, SCIENCE, V242, P1176, DOI 10.1126/science.2847317; HIRATA M, 1984, BIOCHEM J, V223, P229, DOI 10.1042/bj2230229; HORSTMAN DA, 1988, J BIOL CHEM, V263, P15297; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IINO M, 1990, J GEN PHYSIOL, V95, P1103, DOI 10.1085/jgp.95.6.1103; IRVINE RF, 1986, NATURE, V320, P631, DOI 10.1038/320631a0; IRVINE RF, 1988, PHILOS T ROY SOC B, V320, P281, DOI 10.1098/rstb.1988.0077; JACOB R, 1990, BIOCHIM BIOPHYS ACTA, V1052, P427, DOI 10.1016/0167-4889(90)90152-4; JEAN T, 1986, J BIOL CHEM, V261, P6414; JOSEPH SK, 1986, J BIOL CHEM, V261, P4658; JOSEPH SK, 1984, J BIOL CHEM, V259, P3077; KOJIMA I, 1987, J BIOL CHEM, V262, P4557; KRAUSE KH, 1990, BIOCHEM J, V270, P545, DOI 10.1042/bj2700545; LESLIE BA, 1988, CELL CALCIUM, V9, P9, DOI 10.1016/0143-4160(88)90033-4; MEYER T, 1990, P NATL ACAD SCI USA, V87, P3841, DOI 10.1073/pnas.87.10.3841; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1989, J BIOL CHEM, V264, P205; MULDOON LL, 1987, J CELL PHYSIOL, V130, P29, DOI 10.1002/jcp.1041300106; MULLANEY JM, 1988, P NATL ACAD SCI USA, V85, P2499, DOI 10.1073/pnas.85.8.2499; NAHORSKI SR, 1989, TRENDS PHARMACOL SCI, V10, P139, DOI 10.1016/0165-6147(89)90165-X; PAYNE R, 1990, NEURON, V4, P547, DOI 10.1016/0896-6273(90)90112-S; POLOKOFF MA, 1988, J BIOL CHEM, V263, P11922; PRENTKI M, 1984, J BIOL CHEM, V259, P3777; PRENTKI M, 1985, J BIOL CHEM, V260, P9185; PUTNEY JW, 1977, J PHYSIOL-LONDON, V268, P139, DOI 10.1113/jphysiol.1977.sp011851; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RASMUSSEN U, 1978, ACTA PHARM SUEC, V15, P133; ROSSIER MF, 1989, J BIOL CHEM, V264, P14078; ROSSIER MF, 1987, J BIOL CHEM, V262, P4053; ROSSIER MF, 1991, BIOCHEM J, V274, P643, DOI 10.1042/bj2740643; SOMLYO AV, 1985, CALCIUM BIOL SYSTEMS, P351; STAUDERMAN KA, 1988, BIOCHEM J, V255, P677; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; SUPATTAPONE S, 1988, P NATL ACAD SCI USA, V85, P8747, DOI 10.1073/pnas.85.22.8747; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAYLOR CW, 1985, BIOCHEM J, V232, P435, DOI 10.1042/bj2320435; TAYLOR CW, 1990, BIOCHEM J, V266, P189, DOI 10.1042/bj2660189; TAYLOR CW, 1989, BIOCHEM J, V259, P645, DOI 10.1042/bj2590645; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THEVENOD F, 1989, J MEMBRANE BIOL, V109, P173, DOI 10.1007/BF01870856; THEVENOD F, 1988, AM J PHYSIOL, V255, pG429, DOI 10.1152/ajpgi.1988.255.4.G429; VOLPE P, 1988, P NATL ACAD SCI USA, V85, P1091, DOI 10.1073/pnas.85.4.1091; WILLCOCKS AL, 1988, EUR J PHARMACOL, V155, P181, DOI 10.1016/0014-2999(88)90420-7; WILLEMS PHGM, 1990, BIOCHEM J, V265, P681, DOI 10.1042/bj2650681; WINEGRAD S, 1970, J GEN PHYSIOL, V55, P77, DOI 10.1085/jgp.55.1.77; WORLEY PF, 1987, J BIOL CHEM, V262, P12132	65	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13646	13653						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906881				2022-12-25	WOS:A1991FY02700033
J	ELLIS, C; LIU, XQ; ANDERSON, D; ABRAHAM, N; VEILLETTE, A; PAWSON, T				ELLIS, C; LIU, XQ; ANDERSON, D; ABRAHAM, N; VEILLETTE, A; PAWSON, T			TYROSINE PHOSPHORYLATION OF GAP AND GAP-ASSOCIATED PROTEINS IN LYMPHOID AND FIBROBLAST CELLS EXPRESSING LCK	ONCOGENE			English	Article							GTPASE ACTIVATING PROTEIN; KINASE P56LCK; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL KINASE; PHOSPHOLIPASE-C; VIRAL ONCOGENE; CD4 RECEPTOR; BINDING; TRANSFORMATION; DOMAINS	The Ras GTPase activating protein (GAP) is a strong candidate for the protein that links protein-tyrosine kinases to the Ras mitogenic pathway. GAP and two associated proteins, p62 and p190, were shown to be phosphorylated on tyrosine in the LSTRA thymoma cell line, in which the p56lck tyrosine kinase is overexpressed as a result of retroviral promoter insertion. In NIH3T3 fibroblasts expressing specific oncogenic and transformation-defective variants of p56lck, we found that the tyrosine phosphorylation of GAP complexes required both enzymatic activation and myristylation of p56lck, and correlated with lck transforming activity. The interaction between p62 and p190 from lck-transformed fibroblasts and GAP could be reconstituted in vitro using bacterial TrpE fusion proteins containing GAP Src homology 2 (SH2) domains. In vitro complex formation was insensitive to the prior denaturation of SH2 ligands, suggesting that SH2-binding sites are formed by linear peptide sequences. These results suggest that the tyrosine phosphorylation of GAP, and its interactions with SH2-binding proteins, may be involved in fibroblast transformation by activated lck, and may participate in signal transduction and cellular transformation in lymphoid cells.	MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA; MCGILL UNIV, MCGILL CANC CTR, MONTREAL H3G 1Y6, QUEBEC, CANADA; MCGILL UNIV, DEPT BIOCHEM, MONTREAL H3G 1Y6, QUEBEC, CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; McGill University; McGill University	PAWSON, T (corresponding author), MT SINAI HOSP, SAMUEL LUNENFELD RES INST, DIV MOLEC & DEV BIOL, 600 UNIV AVE, TORONTO M5G 1X5, ONTARIO, CANADA.		Abraham, Ninan/K-5572-2012; Pawson, Tony J/E-4578-2013	Abraham, Ninan/0000-0002-2747-1246; Liu, X. Johne/0000-0003-3381-5030				ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; AMREIN KE, 1988, P NATL ACAD SCI USA, V85, P4247, DOI 10.1073/pnas.85.12.4247; ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BOLEN JB, 1989, TRENDS BIOCHEM SCI, V14, P404, DOI 10.1016/0968-0004(89)90288-0; COURTNEIDGE SA, 1987, CELL, V50, P1031, DOI 10.1016/0092-8674(87)90169-3; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KAZLAUSKAS A, 1990, SCIENCE, V247, P1578, DOI 10.1126/science.2157284; LEHTO VP, 1988, NATURE, V334, P388, DOI 10.1038/334388a0; MARTH JD, 1988, MOL CELL BIOL, V8, P540, DOI 10.1128/MCB.8.2.540; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; MORAN M, 1990, IN PRESS P NATL ACAD; PAWSON T, 1988, ONCOGENE, V3, P491; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P3951, DOI 10.1128/MCB.9.9.3951; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1989, NATURE, V338, P257, DOI 10.1038/338257a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	32	40	41	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					895	901						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906156				2022-12-25	WOS:A1991GU62200002
J	ANDERSON, KS; MILES, EW; JOHNSON, KA				ANDERSON, KS; MILES, EW; JOHNSON, KA			SERINE MODULATES SUBSTRATE CHANNELING IN TRYPTOPHAN SYNTHASE - A NOVEL INTERSUBUNIT TRIGGERING MECHANISM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALPHA-SUBUNIT; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; TETRAHEDRAL INTERMEDIATE; PHOSPHOGLYCERATE KINASE; SALMONELLA-TYPHIMURIUM; CATALYTIC MECHANISM; BETA-ELIMINATION; ENZYME COMPLEX; B-PROTEIN	Tryptophan synthase, an alpha-2-beta-2 complex, is a classic example of an enzyme that is thought to "channel" a metabolic intermediate (indole) from the active site of the alpha-subunit to the active site of the beta-subunit. We now examine the kinetics of substrate channeling by tryptophan synthase directly by chemical quench-flow and stopped-flow methods. The conversion of indole-3-glycerol phosphate (IGP) to tryptophan at the active site proceeds at a rate of 24 s-1, which is limited by the rate of cleavage of IGP to produce indole (alpha-reaction). In a single turnover experiment monitoring the conversion of radiolabeled IGP to tryptophan, only a trace of indole is detectable (less-than-or-equal-to 1% of the IGP), implying that the reaction of indole to form tryptophan must be quite fast (greater-than-or-equal-to 1000 s-1). The rate of reaction of indole from solution is much too slow (40 s-1 under identical conditions) to account for the negligible accumulation of indole in a single turnover. Therefore, the indole produced at the alpha-site must be rapidly channeled to the beta-site, where it reacts with serine to form tryptophan: channeling and the reaction of indole to form tryptophan must each occur at rates greater-than-or-equal-to 1000 s-1. Steady-state turnover is limited by the slow rate of tryptophan release (8 s-1). In the absence of serine, the cleavage of IGP to indole is limited by a change in protein conformation at a rate of 0.16 s-1. When the alpha-beta-reaction is initiated by mixing enzyme with IGP and serine simultaneously, there is a lag in the cleavage of IGP and formation of tryptophan. The kinetics of the lag correspond to the rate of formation of the aminoacrylate in the reaction of serine with pyridoxal phosphate at the beta-site, measured by stopped-flow methods (45 s-1). There is also a change in protein fluorescence, suggestive of a change in protein conformation, occurring at the same rate. Substitution of cysteine for serine leads to a longer lag in the kinetics of IGP cleavage and a correspondingly slower rate of formation of the aminoacrylate (6 s-1). Thus, the reaction of serine at the beta-site modulates the alpha-reaction such that the formation of the aminoacrylate leads to a change in protein conformation that is transmitted to the alpha-site to enhance the rate of IGP cleavage 150-fold. Analysis of a mutant in the beta-subunit (E109D) shows that the rate of reaction of indole at the beta-site is decreased 300-fold, supporting the postulated role of Glu-109 in deprotonating indole to facilitate its reaction with the aminoacrylate. Kinetic analysis of the conversion of IGP and serine to tryptophan catalyzed by the mutant enzyme demonstrates the formation and decay of a significant fraction of indole in a single turnover due to the slower rate of condensation of indole with the aminoacrylate. Taken together, these data demonstrate directly that efficient channeling of indole is a consequence of three features of the reaction kinetics. 1) The rate of diffusion of indole through the channel is very fast; 2) the reaction of indole to form tryptophan at the beta-site is fast and largely irreversible; and 3) the reaction of serine at the beta-site modulates the formation of indole at the alpha-site or in the tunnel such that indole is not produced until serine has reacted with pyridoxal phosphate to form the highly reactive aminoacrylate. This intersubunit communication keeps the alpha and beta-reactions in phase so that indole does not accumulate at the alpha-site. It is only the combination of these three aspects of the reaction kinetics that leads to efficient channeling of the indole by maintaining a low concentration of indole bound to the enzyme.	NIDDKD, BIOCHEM PHARMACOL LAB, BETHESDA, MD 20892 USA; PENN STATE UNIV, DEPT MOLEC & CELL BIOL, UNIVERSITY PK, PA 16802 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	ANDERSON, KS (corresponding author), YALE UNIV, SCH MED, DEPT PHARMACOL, 333 CEDAR ST, NEW HAVEN, CT 06510 USA.				NIGMS NIH HHS [GM26726] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026726] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMED SA, 1986, BIOCHEMISTRY-US, V25, P4233, DOI 10.1021/bi00363a010; ANDERSON KS, 1988, J AM CHEM SOC, V110, P6577, DOI 10.1021/ja00227a056; ANDERSON KS, 1988, BIOCHEMISTRY-US, V27, P7395, DOI 10.1021/bi00419a034; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; CHOCK PB, 1988, P NATL ACAD SCI USA, V85, P8870, DOI 10.1073/pnas.85.23.8870; CRAWFORD IP, 1964, P NATL ACAD SCI USA, V51, P390, DOI 10.1073/pnas.51.3.390; CREIGHTO.TE, 1970, EUR J BIOCHEM, V13, P1, DOI 10.1111/j.1432-1033.1970.tb00892.x; DEMOSS JA, 1962, BIOCHIM BIOPHYS ACTA, V62, P279, DOI 10.1016/0006-3002(62)90041-0; DONLIN M, 1991, IN PRESS BIOCHEMISTR; DREWE WF, 1985, BIOCHEMISTRY-US, V24, P3977, DOI 10.1021/bi00336a027; DUNN MF, 1990, BIOCHEMISTRY-US, V29, P8598, DOI 10.1021/bi00489a015; FAEDER EL, 1971, BIOCHEMISTRY-US, V10, P4043; HOUBEN KF, 1990, BIOCHEMISTRY-US, V29, P2421, DOI 10.1021/bi00461a028; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KAWASAKI H, 1987, J BIOL CHEM, V262, P10678; KAYASTHA AM, 1990, FASEB J, V4, pA2118; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; KUMAGAI H, 1971, BIOCHEM BIOPH RES CO, V44, P1271, DOI 10.1016/S0006-291X(71)80223-1; KVASSMAN J, 1989, EUR J BIOCHEM, V186, P261, DOI 10.1111/j.1432-1033.1989.tb15204.x; KVASSMAN J, 1989, EUR J BIOCHEM, V186, P265, DOI 10.1111/j.1432-1033.1989.tb15205.x; LANE AN, 1981, EUR J BIOCHEM, V120, P379, DOI 10.1111/j.1432-1033.1981.tb05715.x; LANE AN, 1983, EUR J BIOCHEM, V129, P561; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LANE AN, 1983, EUR J BIOCHEM, V129, P571; MATCHETT WH, 1974, J BIOL CHEM, V249, P4041; Miles E W, 1979, Adv Enzymol Relat Areas Mol Biol, V49, P127; MILES EW, 1970, J BIOL CHEM, V245, P6016; MILES EW, 1989, J BIOL CHEM, V264, P6280; MILES EW, 1991, IN PRESS ADV ENZYMOL, V64; NAGATA S, 1989, J BIOL CHEM, V264, P6288; NICKBARG EB, 1988, BIOCHEMISTRY-US, V27, P5948, DOI 10.1021/bi00416a019; PHILLIPS RS, 1984, BIOCHEMISTRY-US, V23, P6228, DOI 10.1021/bi00320a052; RACKER E, 1959, J BIOL CHEM, V234, P2510; SRIVASTAVA DK, 1989, P NATL ACAD SCI USA, V86, P6464, DOI 10.1073/pnas.86.17.6464; WEBER JP, 1982, BIOCHEMISTRY-US, V21, P4189, DOI 10.1021/bi00260a042; YANOFSKY C, 1958, BIOCHIM BIOPHYS ACTA, V28, P640, DOI 10.1016/0006-3002(58)90533-X; YORK SS, 1972, BIOCHEMISTRY-US, V11, P2733, DOI 10.1021/bi00764a029	38	169	170	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8020	8033						14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1902468				2022-12-25	WOS:A1991FK44100013
J	MCGEE, MP; LI, LC				MCGEE, MP; LI, LC			FUNCTIONAL DIFFERENCE BETWEEN INTRINSIC AND EXTRINSIC COAGULATION PATHWAYS - KINETICS OF FACTOR-X ACTIVATION ON HUMAN MONOCYTES AND ALVEOLAR MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE FACTOR-X; HUMAN FACTOR-VII; TISSUE FACTOR; HUMAN-PLATELETS; DEPENDENT COAGULATION; PROCOAGULANT ACTIVITY; SELECTIVE INCREASES; BLOOD-COAGULATION; POPULATIONS; BINDING	Activation of coagulation factor X via the intrinsic pathway requires the assembly of factors IXa and VIII on lipid membranes. It is known that the platelet expresses membrane sites for assembly of factors IXa/VIII and promotes efficient factor X activation. We now show that human blood monocytes, but not lymphocytes or polymorphonuclear leukocytes, also express appropriate sites for factors IXa/VIII assembly. The maximal rate of factor X activation by factors IXa (0.75 nM) and VIII (1 unit/ml) assembled on monocytes is similar to the maximal rate on platelets. This rate, adjusted per micromole of lipid phosphorus, is 1636 +/- 358 nM factor Xa/min on monocyte, and 1569 +/- 54 nM factor Xa/min on platelets. At physiologic concentrations of factors X and VIII, the activation rate increases with factor IXa concentration asymptotically approaching a maximum. Half-maximal rate is achieved with 1.0 +/- 0.16 nM factor IXa. Monocytes and macrophages, but not platelets, can express membrane tissue factor and thus promote simultaneous assembly of two distinct factor X-activating protease complexes. In these studies, blood monocytes and alveolar macrophages are used as membrane sources in kinetic experiments comparing factor X activation by intrinsic (factor IXa/VIII) versus extrinsic (factor VII/tissue factor) protease complexes. At plasma concentration of factors VIII and VII, apparent K(m) on the monocyte is 14.6 +/- 1.4 nM for intrinsic and 117.0 +/- 10.1 nM for extrinsic activation. The apparent K(m) on alveolar macrophages is 12.1 +/- 1.9 and 90.6 +/- 10.2 nM for intrinsic and extrinsic activation, respectively. Maximal rates on monocytes at saturating concentration of factors IXa, VIII, and VII are 48.0 +/- 11.2 nM factor Xa/min, for intrinsic activation, and 16.5 +/- 5.5 nM factor Xa/min, for extrinsic activation. These data show that the monocyte/macrophage is the only blood-derived cell type with membrane sites for both intrinsic and extrinsic pathway assembly. We have exploited this characteristic of the monocyte/macrophage membrane to demonstrate that factor X activation by the intrinsic pathway protease is more efficient than activation via the extrinsic pathway protease complex.			MCGEE, MP (corresponding author), WAKE FOREST UNIV, BOWMAN GRAY SCH MED, DEPT MED, RHEUMATOL SECT, 300 S HAWTHORNE RD, WINSTON SALEM, NC 27103 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042812] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL42812] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AHMAD SS, 1989, J BIOL CHEM, V264, P20012; BEVERS EM, 1987, PLATELETS BIOL PATHO, V3, P127; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOTTENUS R, 1986, PURIFICATION CHARACT; BRIGG R, 1961, THROMB DIATH HAEMO, V6, P1; BROZE GJ, 1982, J CLIN INVEST, V70, P526, DOI 10.1172/JCI110644; DOELLGAST GJ, 1986, ANAL BIOCHEM, V152, P199, DOI 10.1016/0003-2697(86)90141-7; EDWARDS RL, 1979, BLOOD, V54, P359; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; FORMAN SD, 1986, P NATL ACAD SCI USA, V83, P4675, DOI 10.1073/pnas.83.13.4675; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; HOYER LW, 1987, HEMOSTASIS THROMBOSI, P48; JESTY J, 1979, J BIOL CHEM, V254, P2337; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407, DOI 10.1164/ajrccm/139.2.407; LI CY, 1973, J HISTOCHEM CYTOCHEM, V21, P1; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; MALAR RA, 1982, BLOOD, V60, P1353; MANN KG, 1984, PROG HEMOST THROMB, V7, P1; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; MCGEE MP, 1984, THROMB HAEMOSTASIS, V51, P228; MCGEE MP, 1989, BLOOD, V74, P1583; MCGEE MP, 1985, AM REV RESPIR DIS, V131, P331; MCGEE MP, 1986, J EXP MED, V164, P1902, DOI 10.1084/jem.164.6.1902; NEMERSON Y, 1985, THROMB RES, V40, P351, DOI 10.1016/0049-3848(85)90270-1; NESHEIM ME, 1988, J BIOL CHEM, V263, P16467; NEUENSCHWANDER P, 1988, BLOOD, V72, P1761; OSTERUD B, 1977, P NATL ACAD SCI USA, V74, P5260, DOI 10.1073/pnas.74.12.5260; OSTERUD B, 1983, THROMB HAEMOSTASIS, V49, P5; PITLICK FA, 1970, BIOCHEMISTRY-US, V9, P5105; RAO LVM, 1986, BLOOD, V68, P685; RAWALASHEIKH R, 1990, BIOCHEMISTRY-US, V29, P2606, DOI 10.1021/bi00462a025; ROSING J, 1985, BLOOD, V65, P319; ROTHBERGER H, 1984, J CLIN INVEST, V73, P1524, DOI 10.1172/JCI111358; ROTHBERGER H, 1983, BLOOD, V61, P712; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SCHREIBER AB, 1988, SEMIN HEMATOL, V25, P27; SINHA D, 1984, J CLIN INVEST, V73, P1550, DOI 10.1172/JCI111361; SMITH RL, 1973, J BIOL CHEM, V248, P2418; TRACY PB, 1985, J BIOL CHEM, V260, P2119; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; ZEMBALA M, 1989, HUMAN MONOCYTES, P429; ZIMMERMAN TS, 1988, SEMIN HEMATOL, V25, P25; ZUR M, 1980, J BIOL CHEM, V255, P5703	43	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8079	8085						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1902470				2022-12-25	WOS:A1991FK44100022
J	YADAV, SP; BREW, K				YADAV, SP; BREW, K			STRUCTURE AND FUNCTION IN GALACTOSYLTRANSFERASE - SEQUENCE LOCATIONS OF ALPHA-LACTALBUMIN BINDING-SITE, THIOL-GROUPS, AND DISULFIDE BOND	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE MILK GALACTOSYLTRANSFERASE; LACTOSE SYNTHETASE; GALACTOSYL TRANSFERASE; CDNA; BETA-1,4-GALACTOSYLTRANSFERASE; IDENTIFICATION; ACTIVATION; GOLGI	The region(s) of bovine galactosyltransferase that interacts with the lactose synthase regulatory protein alpha-lactalbumin was investigated using trace H-3 acetylation to probe the effects of alpha-lactalbumin on the reactivities of the individual amino groups of galactosyl-transferase. In the presence of Mn2+, alpha-lactalbumin was found to reduce the reactivities of lysines 93 and 181 and to increase the reactivities of one or more of lysines 230, 237, and 241. The addition of N-acetyl-glucosamine (20 mM), which enhances complex formation between the two proteins, did not significantly alter the pattern of perturbation. These results indicate that the NH2-terminal region of the catalytic domain of galactosyltransferase, and possibly part of the proline-rich "stem" region, is affected by the association with alpha-lactalbumin and is therefore implicated in the binding of acceptor substrates. In a separate study only cysteines 176, 266, and 342 of galactosyltransferase were found to react with [H-3]iodoacetic acid under denaturing conditions. From their lack of reactivity it is deduced that the remaining two cysteines, residues 134 and 247, are joined in a disulfide linkage. From these results and those of a previous study of UDP-galactose binding (Yadav, S., and Brew, K. (1990) J. Biol. Chem. 265, 14163-14169) it appears that the soluble form of galactosyltransferase is composed of two domains, the NH2-terminal 150 residues containing the Cys134-Cys247 disulfide bond, which functions in alpha-lactalbumin and acceptor binding, and the COOH-terminal region, which is involved in UDP-galactose binding.	UNIV MIAMI,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33136	University of Miami			Brew, Keith/W-1643-2019; Brew, Keith/A-6746-2009	Brew, Keith/0000-0003-1306-1032	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021363] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21363] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL JE, 1976, J BIOL CHEM, V251, P3003; BREW K, 1975, J BIOL CHEM, V250, P1434; BREW K, 1979, MIAMI WINTER S, V16, P433; HILL RL, 1975, ADV ENZYMOL RAMB, V43, P411; JACKSON AE, 1986, J BIOL CHEM, V261, P2226; JUZIASSE DH, 1989, J BIOL CHEM, V264, P14290; KHATRA BS, 1974, EUR J BIOCHEM, V44, P537, DOI 10.1111/j.1432-1033.1974.tb03513.x; KITCHEN BJ, 1974, BIOCHEM J, V141, P173, DOI 10.1042/bj1410173; MAGEE SC, 1974, J BIOL CHEM, V249, P6992; MASRI KA, 1988, BIOCHEM BIOPH RES CO, V157, P657, DOI 10.1016/S0006-291X(88)80300-0; NARIMATSU H, 1986, P NATL ACAD SCI USA, V83, P4720, DOI 10.1073/pnas.83.13.4720; NAVARATNAM N, 1988, EUR J BIOCHEM, V171, P623, DOI 10.1111/j.1432-1033.1988.tb13833.x; OKEEFFE ET, 1980, BIOCHEMISTRY-US, V19, P4954, DOI 10.1021/bi00563a003; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POWELL JT, 1976, J BIOL CHEM, V251, P3645; POWELL JT, 1974, EUR J BIOCHEM, V48, P217, DOI 10.1111/j.1432-1033.1974.tb03759.x; POWELL JT, 1976, J BIOL CHEM, V251, P3653; PRIEELS JP, 1975, EUR J BIOCHEM, V60, P525, DOI 10.1111/j.1432-1033.1975.tb21031.x; RAM BP, 1985, CRC CR REV BIOCH MOL, V17, P257, DOI 10.3109/10409238509113606; RICHARDSON RH, 1980, J BIOL CHEM, V255, P3377; SHAPER NL, 1988, J BIOL CHEM, V263, P10420; SHAPER NL, 1986, P NATL ACAD SCI USA, V83, P1573, DOI 10.1073/pnas.83.6.1573; SILVIA JS, 1980, J BIOL CHEM, V255, P12262; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; YADAV S, 1990, J BIOL CHEM, V265, P14163	25	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					698	703						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898734				2022-12-25	WOS:A1991ET17700006
J	DAUGHERTY, A; RATERI, DL				DAUGHERTY, A; RATERI, DL			FAILURE OF THE INTRACELLULAR ITINERARY OF BETA VERY LOW-DENSITY LIPOPROTEINS TO AUGMENT CHOLESTEROL ESTERIFICATION IN MACROPHAGES FROM WATANABE HERITABLE HYPERLIPIDEMIC RABBITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN MONOCYTE-MACROPHAGES; MOUSE PERITONEAL-MACROPHAGES; RECEPTOR-MEDIATED UPTAKE; HMG-COA REDUCTASE; FAMILIAL HYPERCHOLESTEROLEMIA; ANIMAL-MODEL; WHHL-RABBIT; REMNANT LIPOPROTEINS; CONTINUAL HYDROLYSIS; CHYLOMICRON REMNANTS	Beta very low density lipoproteins (beta-VLDL) interact with mouse peritoneal macrophages via specific receptors leading to pronounced stimulation of cholesterol esterification. The present study has defined an alternative pathway for the processing of beta-VLDL in alveolar macrophages from Watanabe heritable hyperlipidemic (WHHL) rabbits. Macrophages from either New Zealand (NZ) or WHHL rabbits degraded I-125-beta-VLDL to an equivalent extent. Degradation was competed to a similar extent in both cell types by either excess unlabeled beta-VLDL or low density lipoprotein, indicative of a specific receptor involvement. Accumulation of intracellular degradation products of beta-VLDL labeled with the residualizing label, dilactitol-I-125-tyramine, was similar in both cell types demonstrating that degradation was not due to secreted proteolytic enzymes. Beta-VLDL promoted the incorporation of [H-3]oleate into cholesteryl-[H-3]oleate and increased the cellular mass of cholesterol in NZ macrophages. In contrast, beta-VLDL did not augment cholesteryl-[H-3]oleate deposition in WHHL macrophages. This lack of cholesterol esterification occurred despite equivalent acyl-CoA: cholesterol acyltransferase activity in microsomal fractions of both cell types, and similar augmentations in cholesteryl-[H-3]oleate during incubation with phospholipase C-treated LDL. Incubation of WHHL macrophages with beta-VLDL increased cellular cholesterol mass, although the response was attenuated compared to NZ cells. To determine whether these disparities in cholesterol esterification were related to the catabolic fate of beta-VLDL-derived cholesterol esters, [H-3]cholesteryl oleate was exchanged into the core of beta-VLDL and incubated with macrophages in medium containing [C-14]oleate. NZ macrophages accumulated both [H-3]cholesterol and [H-3]cholesteryl-[C-14]oleate after 5 h, indicating hydrolysis and re-esterification of cholesterol esters. In contrast, WHHL macrophages only accumulated [H-3]cholesterol esters, suggesting uptake of cholesterol esters without subsequent hydrolysis. These data demonstrate that WHHL macrophages possess a pathway for the intracellular processing of beta-VLDL that permits internalization of the particle without stimulation of cholesterol esterification.			DAUGHERTY, A (corresponding author), WASHINGTON UNIV,SCH MED,DEPT MED,DIV CARDIOVASC,BOX 8086,ST LOUIS,MO 63110, USA.		Daugherty, Alan/C-8282-2009	Daugherty, Alan/0000-0003-2093-3775	NHLBI NIH HHS [HL-17646, HL-36822] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL017646, P60HL017646, R23HL036822] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATTIE AD, 1981, J BIOL CHEM, V256, P9789; BAKER DP, 1984, ARTERIOSCLEROSIS, V4, P248, DOI 10.1161/01.ATV.4.3.248; BATES SR, 1987, J LIPID RES, V28, P787; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J BIOL CHEM, V255, P9344; BROWN MS, 1979, J CELL BIOL, V82, P597, DOI 10.1083/jcb.82.3.597; BUJA LM, 1983, ARTERIOSCLEROSIS, V3, P87, DOI 10.1161/01.ATV.3.1.87; COLE TG, 1984, J LIPID RES, V25, P593; DAUGHERTY A, 1988, J CLIN INVEST, V82, P562, DOI 10.1172/JCI113633; DAUGHERTY A, 1985, J BIOL CHEM, V260, P4564; DAUGHERTY A, 1988, ARTERIOSCLEROSIS, V8, P768, DOI 10.1161/01.ATV.8.6.768; DIAZ R, 1989, J BIOL CHEM, V264, P13171; DIMENT S, 1989, J BIOL CHEM, V264, P13403; DIMENT S, 1985, J BIOL CHEM, V260, P5311; ELLSWORTH JL, 1987, J BIOL CHEM, V262, P2316; FAINARU M, 1982, J LIPID RES, V23, P702; FOGELMAN AM, 1980, P NATL ACAD SCI-BIOL, V77, P2214, DOI 10.1073/pnas.77.4.2214; FOWLER S, 1979, LAB INVEST, V41, P372; GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; GOLDSTEIN JL, 1980, J BIOL CHEM, V255, P1839; HAVEL RJ, 1982, ARTERIOSCLEROSIS, V2, P467, DOI 10.1161/01.ATV.2.6.467; HELGERUD P, 1982, J LIPID RES, V23, P609; HENSON DA, 1989, EXP MOL PATHOL, V51, P243, DOI 10.1016/0014-4800(89)90023-3; HOUGH JL, 1984, BIOCHIM BIOPHYS ACTA, V792, P338, DOI 10.1016/0005-2760(84)90202-9; INNERARITY TL, 1986, ARTERIOSCLEROSIS, V6, P114, DOI 10.1161/01.ATV.6.1.114; ISHII K, 1988, BIOCHIM BIOPHYS ACTA, V962, P387, DOI 10.1016/0005-2760(88)90270-6; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; JURGENS G, 1986, BIOCHIM BIOPHYS ACTA, V875, P103, DOI 10.1016/0005-2760(86)90016-0; KITA T, 1986, J CLIN INVEST, V77, P1460, DOI 10.1172/JCI112458; KNIGHT BL, 1987, ATHEROSCLEROSIS, V64, P131, DOI 10.1016/0021-9150(87)90238-3; KOO C, 1988, J CLIN INVEST, V81, P1332, DOI 10.1172/JCI113460; KOO C, 1986, J BIOL CHEM, V261, P1194; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUSK L, 1982, BIOCHIM BIOPHYS ACTA, V710, P134, DOI 10.1016/0005-2760(82)90143-6; MAHLEY RW, 1980, J LIPID RES, V21, P970; MCLEAN LR, 1989, BIOCHEMISTRY-US, V28, P321, DOI 10.1021/bi00427a043; NATHAN CF, 1987, J CLIN INVEST, V79, P319, DOI 10.1172/JCI112815; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; ROSS AC, 1977, J LIPID RES, V18, P169; SALZMAN NH, 1989, J CELL BIOL, V109, P2097, DOI 10.1083/jcb.109.5.2097; SHIMADA Y, 1981, EUR J BIOCHEM, V118, P557, DOI 10.1111/j.1432-1033.1981.tb05555.x; STROBEL JL, 1985, ARCH BIOCHEM BIOPHYS, V240, P635, DOI 10.1016/0003-9861(85)90071-2; SUCKLING KE, 1985, J LIPID RES, V26, P647; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; THOMPSON KH, 1983, J NUTR, V113, P2002, DOI 10.1093/jn/113.10.2002; TRABER MG, 1984, ATHEROSCLEROSIS, V52, P1, DOI 10.1016/0021-9150(84)90152-7; TSUJITA Y, 1989, CARDIOVASC DRUG REV, V7, P110, DOI 10.1111/j.1527-3466.1989.tb00520.x; VANLENTEN BJ, 1990, J LIPID RES, V31, P1455; VANLENTEN BJ, 1985, J BIOL CHEM, V260, P8783; VANLENTEN BJ, 1983, J BIOL CHEM, V258, P5151; WERNETTEHAMMOND ME, 1989, ARTERIOSCLEROSIS, V9, P501, DOI 10.1161/01.ATV.9.4.501; YAMAMOTO T, 1986, SCIENCE, V232, P1230, DOI 10.1126/science.3010466	56	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17269	17275						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894618				2022-12-25	WOS:A1991GF44500047
J	SMITH, RM; SEELY, BL; SHAH, N; OLEFSKY, JM; JARETT, L				SMITH, RM; SEELY, BL; SHAH, N; OLEFSKY, JM; JARETT, L			TYROSINE KINASE-DEFECTIVE INSULIN-RECEPTORS UNDERGO INSULIN-INDUCED MICROAGGREGATION BUT DO NOT CONCENTRATE IN COATED PITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH FACTOR-I; LIVER PLASMA-MEMBRANES; MEDIATED ENDOCYTOSIS; SIGNAL TRANSDUCTION; LIGAND-BINDING; 3T3-L1 ADIPOCYTES; TRANSFECTED CELLS; RAT ADIPOCYTES; GLUCOSE-UPTAKE; INTACT-CELLS	Biologically active colloid-gold complexes were used to compare ligand-induced microaggregation, redistribution, and internalization of insulin receptors on Rat 1 fibroblasts expressing wild type (HIRc) or tyrosine kinase-defective (HIR A/K1018) human insulin receptors. Insulin-like growth factor I (IGF I) and alpha-2-macroglobulin receptors also were compared. On both cell types, all four unoccupied receptor types occurred predominantly as single receptors. Ligand binding caused receptor microaggregation. Microaggregation of wild type or kinase-defective insulin receptors or IGF I receptors was not different. Alpha-2-Macroglobulin receptors formed larger microaggregates. Compared to wild type insulin or IGF I receptors, accumulation of kinase-defective insulin receptor microaggregates in endocytic structures was decreased, and the size of microaggregates in coated pits was significantly smaller. As a result, receptor-mediated internalization of gold-insulin by HIR A/K1018 cells was less than 6% of the cell-associated particles compared to approximately 60% of the particles in HIRc cells. On HIR A/K1018 cells, alpha-2-macroglobulin and IGF I were internalized via coated pits demonstrating that those structures were functional. These results suggest that: 1) ATP binding, receptor autophosphorylation, and activation of receptor kinase activity are not required for receptor microaggregation; 2) receptor microaggregation per se is not sufficient to cause ligand-induced receptor-mediated internalization or the biological effects of insulin; and 3) autophosphorylation of the beta-subunit or activation of the receptor kinase activity is required for the insulin-induced concentration of occupied receptors in coated pits.	UNIV PENN,SCH MED,DEPT PATHOL & LAB MED,PHILADELPHIA,PA 19104; UNIV CALIF SAN DIEGO,DEPT MED,DIV ENDOCRINOL & METAB,LA JOLLA,CA 92093; VET ADM MED CTR,SAN DIEGO,CA 92161	University of Pennsylvania; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK019525, R37DK033649, R01DK033649, R01DK028143] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 33649, DK 19525, DK 28143] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMAN GA, 1981, J HISTOCHEM CYTOCHEM, V29, P1137, DOI 10.1177/29.10.6271866; BACKER JM, 1990, J BIOL CHEM, V265, P16450; BERNIER M, 1987, P NATL ACAD SCI USA, V84, P1844, DOI 10.1073/pnas.84.7.1844; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BONISCHNETZLER M, 1988, J BIOL CHEM, V263, P6822; CARPENTIER JL, 1978, J CLIN INVEST, V61, P1057, DOI 10.1172/JCI109005; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHEN WS, 1987, NATURE, V328, P8820; CHOU CK, 1987, J BIOL CHEM, V262, P1842; CORVERA S, 1990, J BIOL CHEM, V265, P15963; CORVERA S, 1989, J BIOL CHEM, V264, P10133; CZECH MP, 1988, J BIOL CHEM, V263, P11017; DAVIS RJ, 1986, J BIOL CHEM, V261, P8708; DEBANT A, 1988, P NATL ACAD SCI USA, V85, P8032, DOI 10.1073/pnas.85.21.8032; DEBANT A, 1989, BIOCHEMISTRY-US, V28, P14, DOI 10.1021/bi00427a003; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; EBINA Y, 1987, P NATL ACAD SCI USA, V84, P704, DOI 10.1073/pnas.84.3.704; ELLIS L, 1987, P NATL ACAD SCI USA, V84, P5101, DOI 10.1073/pnas.84.15.5101; FURLANETTO RW, 1988, ENDOCRINOLOGY, V122, P2044, DOI 10.1210/endo-122-5-2044; GERSHON ND, 1981, J MEMBRANE BIOL, V58, P155, DOI 10.1007/BF01870977; GOLDBERG RI, 1988, J CELL PHYSL, V133, P203; HAMMONS GT, 1982, J BIOL CHEM, V257, P1563; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HONEGGER AM, 1990, J CELL BIOL, V110, P1541, DOI 10.1083/jcb.110.5.1541; JARETT L, 1980, SCIENCE, V210, P1127, DOI 10.1126/science.7003710; KADOWAKI T, 1985, BIOCHEM BIOPH RES CO, V127, P493, DOI 10.1016/S0006-291X(85)80187-X; KAHN CR, 1978, P NATL ACAD SCI USA, V75, P4209, DOI 10.1073/pnas.75.9.4209; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KLEIN HH, 1987, J BIOL CHEM, V262, P10557; LYEN KR, 1982, J RECEPTOR RES, V2, P523, DOI 10.3109/107998981809038883; MAEGAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1053, P185, DOI 10.1016/0167-4889(90)90012-3; MAEGAWA H, 1988, J BIOL CHEM, V263, P8912; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; MCCLAIN DA, 1990, J BIOL CHEM, V265, P1678; MOLL UM, 1986, HISTOCHEMISTRY, V86, P83, DOI 10.1007/BF00492349; MOXHAM CP, 1989, J BIOL CHEM, V264, P13238; OKA Y, 1986, J BIOL CHEM, V261, P9090; OLEFSKY JM, 1990, DIABETES, V39, P1009, DOI 10.2337/diabetes.39.9.1009; OPRESKO LK, 1987, J BIOL CHEM, V262, P4116; REESJONES RW, 1985, J BIOL CHEM, V260, P4461; RIEDEL H, 1989, EMBO J, V8, P2943, DOI 10.1002/j.1460-2075.1989.tb08444.x; SAPERSTEIN R, 1989, BIOCHEMISTRY-US, V28, P5694, DOI 10.1021/bi00439a053; SCHLESSINGER J, 1988, TRENDS BIOCHEM SCI, V13, P443, DOI 10.1016/0968-0004(88)90219-8; SCHWEITZER JB, 1980, P NATL ACAD SCI-BIOL, V77, P4692, DOI 10.1073/pnas.77.8.4692; SEELY L, 1990, 2ND P INT IGF I S SA, P100; SEVERINSSON L, 1990, MOL CELL BIOL, V10, P801, DOI 10.1128/MCB.10.2.801; SHECHTER Y, 1979, P NATL ACAD SCI USA, V76, P2720, DOI 10.1073/pnas.76.6.2720; SMITH RM, 1986, LAB INVEST, V55, P593; SMITH RM, 1990, ENDOCRINOLOGY, V126, P1551, DOI 10.1210/endo-126-3-1551; SMITH RM, 1983, J CELL PHYSIOL, V115, P199, DOI 10.1002/jcp.1041150215; SMITH RM, 1988, LAB INVEST, V58, P613; SMITH RM, 1988, J HISTOCHEM CYTOCHEM, V36, P359, DOI 10.1177/36.4.3279110; SMITH RM, 1990, COLLOIDAL GOLD PRINC, V3, P243; SMITH RM, 1981, SERONO S, V41, P197; SOLER AP, 1990, ENDOCRINOLOGY, V127, P595; SOOS MA, 1989, BIOCHEM J, V263, P553, DOI 10.1042/bj2630553; SOOS MA, 1990, BIOCHEM J, V270, P383, DOI 10.1042/bj2700383; THIES RS, 1990, J BIOL CHEM, V265, P10132; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WHITE MF, 1985, NATURE, V318, P183, DOI 10.1038/318183a0; WHITE MF, 1988, CELL, V54, P641, DOI 10.1016/S0092-8674(88)80008-4; WILEY HS, 1981, CELL, V25, P433, DOI 10.1016/0092-8674(81)90061-1; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0	67	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17522	17530						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910046				2022-12-25	WOS:A1991GF44500081
J	ASKEW, GR; WANG, S; LUKENS, LN				ASKEW, GR; WANG, S; LUKENS, LN			DIFFERENT LEVELS OF REGULATION ACCOMPLISH THE SWITCH FROM TYPE-II TO TYPE-I COLLAGEN GENE-EXPRESSION IN 5-BROMO-2'-DEOXYURIDINE-TREATED CHONDROCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIMB CARTILAGE DIFFERENTIATION; ROUS-SARCOMA VIRUS; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; CELLS; STABILIZATION; NUCLEAR; CHONDROGENESIS; TRANSFORMATION; IDENTIFICATION	The shift of chick embryo chondrocytes to a fibroblastic phenotype by 5-bromo-2'-deoxyuridine (BrdUrd) has been used to examine the molecular basis of the switch from type II to type I collagen gene expression. Transcription rates of each of these three collagen genes before and after this shift were measured in nuclear run-on transcription assays with double-stranded 3'-cDNA probes specific for each of these three mRNAs. Degradation rates of each of these RNAs were calculated from the rate of decrease in the concentration of each RNA after the inhibition of synthesis with actinomycin D. The shut-off of the expression of the type II collagen gene during this shift was shown to occur at the transcriptional level, since the transcription rate of this gene decreased dramatically. The decay rate of the type II mRNA (half-life of approximately 15 h) is not significantly faster in BrdUrd-treated cells. The alpha-1(I) gene is transcribed at similar rates in untreated and shifted chondrocytes, but the steady state level of alpha-1(I) RNA in chondrocytes is only 1.5% of that in shifted cells. Although the measured degradation rate of the total alpha-1(I) RNA from untreated chondrocyte cultures is approximately the same as in shifted cells (half-life of approximately 12 h), indirect evidence suggests that this alpha-1(I) RNA is derived from a low level of fibroblast contamination of these chondrocyte cultures. The alpha-1(I) RNA synthesized by untreated chondrocytes is assumed therefore to be broken down very rapidly in the nucleus. The alpha-2(I) gene is also transcribed in untreated chondrocytes at rates similar to shifted cells but, unlike alpha-1(I) RNA, its steady state level in untreated chondrocytes is approximately 30% of its level in shifted chondrocytes. The increased level of alpha-2(I) RNA in shifted cells may be regulated in part by an increase in stability of the alpha-2(I) mRNA, which has half-lives of 5.2 and 10.4 h, respectively, in untreated and shifted chondrocytes. The alpha-2(I) RNA in the untreated chondrocytes was found to have a different 5' end from that present in the BrdUrd-shifted chondrocytes or in chick embryo fibroblasts. The presence of this altered RNA in untreated chondrocytes explains the absence of synthesis of the fibroblastic alpha-2(I) collagen polypeptide chains in these chondrocytes, despite the presence of the alpha-2(I) RNA as measured with 3' probes.	WESLEYAN UNIV, DEPT MOLEC BIOL & BIOCHEM, MIDDLETOWN, CT 06459 USA	Wesleyan University								ABBOTT J, 1968, P NATL ACAD SCI USA, V59, P1144, DOI 10.1073/pnas.59.4.1144; ADAMS SL, 1982, CELL, V30, P373, DOI 10.1016/0092-8674(82)90235-5; ADAMS SL, 1979, J BIOL CHEM, V254, P4935; AHO S, 1983, NUCLEIC ACIDS RES, V11, P5443, DOI 10.1093/nar/11.16.5443; ALLEBACH ES, 1985, MOL CELL BIOL, V5, P1002, DOI 10.1128/MCB.5.5.1002; BENNETT VD, 1989, J BIOL CHEM, V264, P8402; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; CASTAGNOLA P, 1988, J CELL BIOL, V106, P461, DOI 10.1083/jcb.106.2.461; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CONBOY JG, 1988, P NATL ACAD SCI USA, V85, P9062, DOI 10.1073/pnas.85.23.9062; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DOZIN B, 1990, J BIOL CHEM, V265, P7216; FINER MH, 1985, MOL CELL BIOL, V5, P1415, DOI 10.1128/MCB.5.6.1415; FULLER F, 1981, BIOCHEMISTRY-US, V20, P996, DOI 10.1021/bi00507a054; GREENBERG ME, 1987, CURRENT PROTOCOLS; HYUNDUCK N, 1988, COLLAGEN REL RES, V8, P277; KONIECZNY SF, 1985, MOL CELL BIOL, V5, P2423, DOI 10.1128/MCB.5.9.2423; KOSHER RA, 1986, J CELL BIOL, V102, P1151, DOI 10.1083/jcb.102.4.1151; KRAVIS D, 1985, DEV BIOL, V108, P164, DOI 10.1016/0012-1606(85)90018-1; LEYS EJ, 1984, J CELL BIOL, V99, P180, DOI 10.1083/jcb.99.1.180; LIU TJ, 1989, MOL CELL BIOL, V9, P3499, DOI 10.1128/MCB.9.8.3499; LUKENS LN, 1983, NUCLEIC ACIDS RES, V11, P6021, DOI 10.1093/nar/11.17.6021; MAYNE R, 1975, P NATL ACAD SCI USA, V72, P4511, DOI 10.1073/pnas.72.11.4511; Mayne R., 1987, STRUCTURE FUNCTION C; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MEURS E, 1988, EMBO J, V7, P1689, DOI 10.1002/j.1460-2075.1988.tb02997.x; MILLER EJ, 1987, METHOD ENZYMOL, V144, P3; NISHIMURA I, 1989, J BIOL CHEM, V264, P20033; PACIFICI M, 1977, AM J ANAT, V150, P207, DOI 10.1002/aja.1001500116; PACIFICI M, 1977, CELL, V11, P891, DOI 10.1016/0092-8674(77)90300-2; RAVE N, 1979, NUCLEIC ACIDS RES, V6, P3559, DOI 10.1093/nar/6.11.3559; REGINATO A, 1986, J BIOL CHEM, V261, P2897; RUDD T, 1987, SCIENCE, V235, P1486; SANDELL LJ, 1984, J BIOL CHEM, V259, P7826; SAXE SA, 1985, J BIOL CHEM, V260, P3812; Schiltz J., 1973, DIFFERENTIATION, V1, P97; SONG MKH, 1988, J BIOL CHEM, V263, P17970; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; von der Mark K, 1980, Curr Top Dev Biol, V14, P199; WILL CL, 1989, J BIOL CHEM, V264, P21413; ZHANGKECK ZY, 1988, J BIOL CHEM, V263, P3513	41	26	26	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16834	16841						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885609				2022-12-25	WOS:A1991GD63500093
J	FAGAN, RJ; LAZARISKARATZAS, A; SONENBERG, N; ROZEN, R				FAGAN, RJ; LAZARISKARATZAS, A; SONENBERG, N; ROZEN, R			TRANSLATIONAL CONTROL OF ORNITHINE AMINOTRANSFERASE - MODULATION BY INITIATION FACTOR-EIF-4E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; PROTEIN-SYNTHESIS; BETA-GLOBIN; PHOSPHORYLATION; CELLS; FACTOR-4E; REGION; ALPHA; CAP	Ornithine aminotransferase (OAT) is a mitochondrial enzyme expressed at high levels in liver, kidney, and retina. To characterize OAT regulation in retinal lines, we have been studying OAT synthesis in retinoblastomas RB355 and Y79. Our previous data (Fagan, R.J., Sheffield, W.P., and Rozen, R. (1989) J. Biol. Chem. 264, 20513-20517) indicated similar OAT mRNA levels in the two strains with 3-fold greater immunoreactive OAT protein and enzyme activity in Y79. To examine the regulatory mechanisms in these cell lines, we performed nuclear runoff experiments and characterized polysome-associated OAT mRNAs. The nuclear runoff data did not reveal any differences in transcription between the two strains. However, OAT mRNA of the RB355 strain was present in the lighter polysome fractions as compared with Y79. Treatment with cycloheximide, which slows the rate of elongation, indicated that initiation was decreased in RB355. Eukaryotic initiation factor eIF-4E mRNA and protein were reduced in RB355, suggesting that eIF-4E might be rate-limiting for OAT translation. Overexpression of a wild-type eIF-4E in RB355 shifted the OAT mRNA into denser fractions of the gradient and increased the amount of OAT protein to the level observed in Y79; overexpression of a mutant eIF-4E had no such effect. We previously identified an alternatively spliced OAT mRNA (containing exon 2) in these cells. This mRNA appeared in the lightest fractions of the gradient in both strains and was not affected by eIF-4E overexpression.	MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,DEPT PEDIAT,2300 TUPPER ST,MONTREAL H3H 1P3,QUEBEC,CANADA; MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,DEPT BIOL,MONTREAL H3H 1P3,QUEBEC,CANADA; MCGILL UNIV,MONTREAL CHILDRENS HOSP,RES INST,DEPT BIOCHEM,MONTREAL H3H 1P3,QUEBEC,CANADA	McGill University; McGill University; McGill University			Rozen, Rima/AAE-9294-2020					AJTKHOZHIN MA, 1973, FEBS LETT, V31, P104, DOI 10.1016/0014-5793(73)80083-3; Ausubel F. M., 1988, CURRENT PROTOCOLS MO; AZIZ N, 1987, P NATL ACAD SCI USA, V84, P8478, DOI 10.1073/pnas.84.23.8478; DEBENEDETTI A, 1990, P NATL ACAD SCI USA, V87, P8212, DOI 10.1073/pnas.87.21.8212; DUNCAN R, 1987, J BIOL CHEM, V262, P380; FAGAN RJ, 1989, J BIOL CHEM, V264, P20513; FAN H, 1970, J MOL BIOL, V50, P655, DOI 10.1016/0022-2836(70)90091-4; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; HIREMATH LS, 1989, J BIOL CHEM, V264, P1132; KIRSCHMEIER PT, 1988, DNA-J MOLEC CELL BIO, V7, P219, DOI 10.1089/dna.1988.7.219; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; LODISH HF, 1971, J BIOL CHEM, V246, P7131; MARZLUFF WF, 1985, TRANSCRIPTION TRANSL, P89; MATHEWS MB, 1986, TRANSLATIONAL CONTRO; MERRILL MJ, 1985, J BIOL CHEM, V260, P1248; MITCHELL GA, 1988, J BIOL CHEM, V263, P14288; MUECKLER MM, 1984, J BIOL CHEM, V259, P2302; MUECKLER MM, 1983, J BIOL CHEM, V258, P6109; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; PELLETIER J, 1985, CELL, V40, P515, DOI 10.1016/0092-8674(85)90200-4; PERAINO C, 1964, J BIOL CHEM, V239, P4308; RYCHLIK W, 1987, J BIOL CHEM, V262, P10434; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; Sambrook J, 1989, MOL CLONING LABORATO; SONENBERG N, 1988, PROG NUCLEIC ACID RE, V35, P173, DOI 10.1016/S0079-6603(08)60614-5; VALLE D, 1989, METABOLIC BASIS INHE, P599; WATERHOUSE P, 1990, J BIOL CHEM, V265, P5585; YENOFSKY R, 1982, P NATL ACAD SCI-BIOL, V79, P5876, DOI 10.1073/pnas.79.19.5876	28	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16518	16523						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1909329				2022-12-25	WOS:A1991GD63500047
J	PHILIPHOLLINGSWORTH, S; HOLLINGSWORTH, RI; DAZZO, FB				PHILIPHOLLINGSWORTH, S; HOLLINGSWORTH, RI; DAZZO, FB			N-ACETYLGLUTAMIC ACID - AN EXTRACELLULAR NOD SIGNAL OF RHIZOBIUM-TRIFOLII-ANU843 THAT INDUCES ROOT HAIR BRANCHING AND NODULE-LIKE PRIMORDIA IN WHITE CLOVER ROOTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOBIUM-LEGUME SYMBIOSIS; NODULATION GENES; TRIFOLII; MELILOTI; LEGUMINOSARUM; DEFORMATION; EXPRESSION; STIMULATE	An extracellular metabolite purified from Rhizobium trifolii ANU843 was established as N-acetylglutamic acid (GluNAc) by H-1 NMR and Fourier transform IR spectroscopy, gas chromatography/mass spectrometry of its methylated product, and organic synthesis. TLC analyses indicated that extracellular accumulation of GluNAc by R. trifolii ANU843 grown in defined BIII culture medium was dependent on induction of its bacterial nodulation (nod) genes and the positive regulatory gene nodD on its symbiotic plasmid. H-1 NMR analyses showed less GluNAc in fractionated culture supernatants of nodL and nodM mutant derivatives of R. trifolii ANU843. GluNAc induced three morphological responses on axenic roots of white clover seedlings: (i) root hair branching; (ii) tip swelling followed by resumed elongation of root hairs; and (iii) a slight increase in foci of cortical cell divisions, which developed into nodule-like primordia. These biological activities of extracellular GluNAc from R. trifolii ANU843 were confirmed with authentic standards of GluNAc. These results indicate that extracellular accumulation of N-acetylglutamic acid is linked to flavone-dependent metabolism involving nodD, nodL, and nodM in R. trifolii ANU843. This constitutes the first report on the structure of a nod-dependent extracellular signal from R. trifolii that can affect root hair and nodule development in white clover and whose biological activity on this host has been confirmed with authentic standards.	MICHIGAN STATE UNIV, DEPT MICROBIOL, E LANSING, MI 48824 USA; MICHIGAN STATE UNIV, DEPT BIOCHEM & CHEM, E LANSING, MI 48824 USA	Michigan State University; Michigan State University								BANFALVI Z, 1989, PLANT MOL BIOL, V13, P1, DOI 10.1007/BF00027330; BHUVANESWARI TV, 1985, PHYSIOL PLANTARUM, V63, P25, DOI 10.1111/j.1399-3054.1985.tb02813.x; CALVERT HE, 1984, CAN J BOT, V62, P2375, DOI 10.1139/b84-324; CREMERS HCJ, 1986, J PLANT PHYSIOL, V122, P25, DOI 10.1016/S0176-1617(86)80082-7; DAZZO F, 1984, EXPT MICROBIAL ECOLO, P431; DAZZO FB, 1975, APPL MICROBIOL, V30, P1017, DOI 10.1128/AEM.30.6.1017-1033.1975; DAZZO FB, 1989, SYMBIOSIS, V7, P193; DAZZO FB, 1982, NITROGEN FIXATION, V2, P274; DJORDJEVIC MA, 1987, EMBO J, V6, P1173, DOI 10.1002/j.1460-2075.1987.tb02351.x; DOWNIE JA, 1989, MOL MICROBIOL, V3, P1649, DOI 10.1111/j.1365-2958.1989.tb00150.x; DOWNIE JA, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P201; ERVIN SE, 1985, APPL ENVIRON MICROB, V49, P61, DOI 10.1128/AEM.49.1.61-68.1985; FAUCHER C, 1988, J BACTERIOL, V170, P5489, DOI 10.1128/jb.170.12.5489-5499.1988; GLANSDORFF N, 1987, ESCHERICHIA COLI SAL, P321; HOLLINGSWORTH R, 1989, SIGNAL MOL PLANTS PL, P387; HOLLINGSWORTH RI, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P193; INNES RW, 1985, MOL GEN GENET, V201, P426, DOI 10.1007/BF00331334; LEROUGE P, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P177; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; LIBBENGA KR, 1973, PLANTA, V114, P17, DOI 10.1007/BF00390281; Neuhard, 1987, ESCHERICHIA COLI SAL, V1, P445; Puhler A., 1988, Nitrogen fixation: Hundred years after. Proceedings of the 7th International Congress on N-Nitrogen Fixation, Koln (Cologne), F.R.G., March 13-20, 1988., P423; REDMOND JW, 1986, NATURE, V323, P632, DOI 10.1038/323632a0; ROLFE BG, 1988, ANNU REV PLANT PHYS, V39, P297, DOI 10.1146/annurev.pp.39.060188.001501; SARGENT L, 1987, APPL ENVIRON MICROB, V53, P1611, DOI 10.1128/AEM.53.7.1611-1619.1987; SCHMIDT J, 1988, P NATL ACAD SCI USA, V85, P8578, DOI 10.1073/pnas.85.22.8578; SCHOFIELD PR, 1983, MOL GEN GENET, V192, P459, DOI 10.1007/BF00392191; SOLHEIM B, 1973, J GEN MICROBIOL, V77, P241, DOI 10.1099/00221287-77-2-241; SURIN BP, 1988, MOL MICROBIOL, V2, P173, DOI 10.1111/j.1365-2958.1988.tb00019.x; THORNTON H. G., 1936, Nature, London, V137, P494, DOI 10.1038/137494b0; TRUCHET G, 1989, PROTOPLASMA, V149, P82, DOI 10.1007/BF01322980; TRUCHET G, 1989, MOL GEN GENET, V219, P65, DOI 10.1007/BF00261158; VANBRUSSEL AAN, 1986, J BACTERIOL, V165, P517, DOI 10.1128/jb.165.2.517-522.1986; VINING LC, 1990, ANNU REV MICROBIOL, V44, P395, DOI 10.1146/annurev.mi.44.100190.002143; WEINMAN JJ, 1988, MOL GENETICS PLANT M, P33; YAO PY, 1976, PLANT SOIL, V45, P1, DOI 10.1007/BF00011124; YAO PY, 1969, AUST J BIOL SCI, V22, P413	37	21	21	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16854	16858						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885611				2022-12-25	WOS:A1991GD63500096
J	WANG, R; MESCHIA, JF; COTTER, RJ; SISODIA, SS				WANG, R; MESCHIA, JF; COTTER, RJ; SISODIA, SS			SECRETION OF THE BETA-A4 AMYLOID PRECURSOR PROTEIN IDENTIFICATION OF A CLEAVAGE SITE IN CULTURED-MAMMALIAN-CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; NEXIN-II; DOMAIN; LOCALIZATION; BRAIN; RNAS; FORM	Alzheimer's disease, a progressive neurodegenerative disorder, affects > 10% of the population of individuals > 65 years of age. A principal neuropathological feature of this disease is the senile plaque, a fibrillar extracellular deposit primarily composed of a approximately 4-kDa peptide beta/A4, derived from the amyloid precursor protein (APP). Studies in cultured cells have documented that APP matures through a constitutive secretory pathway and is cleaved at or near the cell surface to release a large ectodomain into the extracellular space. To define the APP cleavage site, we constructed a Chinese hamster ovary cell line, which constitutively overexpresses human APP-770, and analyzed the COOH termini of secreted APP-770-related molecules. Using plasma desorption mass spectrometry and chemical microsequencing, we document that an APP cleavage site in Chinese hamster ovary cells leading to secretion occurs immediately COOH-terminal to lysine residue 687, which lies adjacent to the hydrophobic membrane-spanning domain.	JOHNS HOPKINS UNIV,SCH MED,NEUROPATHOL LAB,509 PATHOL BLDG,600 N WOLFE ST,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PHARMACOL & MOLEC SCI,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PATHOL,BALTIMORE,MD 21205	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University			Wang, Rong/A-8721-2009		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS020471, P01NS020471] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P50AG005146] Funding Source: NIH RePORTER; NIA NIH HHS [AG05146] Funding Source: Medline; NINDS NIH HHS [NS 20471] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLESSED G, 1968, BRIT J PSYCHIAT, V114, P797, DOI 10.1192/bjp.114.512.797; COTTER RJ, 1988, ANAL CHEM, V60, pA781, DOI 10.1021/ac00164a002; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KHACHATURIAN ZS, 1985, ARCH NEUROL-CHICAGO, V42, P1097, DOI 10.1001/archneur.1985.04060100083029; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; MASTERS CL, 1985, EMBO J, V4, P2757, DOI 10.1002/j.1460-2075.1985.tb04000.x; OLTERSDORF T, 1989, NATURE, V341, P144, DOI 10.1038/341144a0; PALMERT MR, 1989, P NATL ACAD SCI USA, V86, P6338, DOI 10.1073/pnas.86.16.6338; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; PRICE DL, 1986, ANNU REV NEUROSCI, V9, P489; SISODIA S S, 1990, New Biologist, V2, P66; SISODIA SS, 1987, MOL CELL BIOL, V7, P3602, DOI 10.1128/MCB.7.10.3602; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; VANNOSTRAND WE, 1989, NATURE, V341, P546; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3; WISNIEWSKI HM, 1976, J NEUROL SCI, V27, P173, DOI 10.1016/0022-510X(76)90059-9	23	176	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16960	16964						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1909332				2022-12-25	WOS:A1991GD63500113
J	FEUERSTEIN, N				FEUERSTEIN, N			PHOSPHORYLATION OF NUMATRIN AND OTHER NUCLEAR PROTEINS BY CDC2 CONTAINING CTD KINASE CDC2 P58	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE CONTROL GENE; CELL-DIVISION CYCLE; YEAST SCHIZOSACCHAROMYCES-POMBE; HEPATOMA ASCITES-CELLS; FISSION YEAST; MATRIX PROTEIN; PROMOTING FACTOR; LEUKEMIC-CELLS; PHORBOL ESTER; M-PHASE	Numatrin is a nuclear matrix phosphoprotein whose synthesis and abundance were shown to be regulated during the cell cycle in mitogen-stimulated lymphocytes (Feuerstein, N., and Mond, J. (1987) J. Bio. Chem. 262, 11389-11397). We examined the effect of (a) CTD-kinase, which contains the cdc2 catalytic component (p34) in a complex with a p58 subunit (cdc2/p58) and (b) the M phase-specific histone H-1 kinase, which contains the cdc2 kinase in association with a p62 subunit (cdc2/p62), on phosphorylation of numatrin. We show that both cdc2 kinase complexes can phosphorylate numatrin. However, cdc2/p58 at conditions that caused a similar effect to cdc2/p62 on phosphorylation of histone H-1 (dpm/mu-g of substrate/mu-g of enzyme) was found to have a 5-25-fold higher catalytic activity in the phosphorylation of numatrin. Analysis of the tryptic phosphopeptide map of numatrin phosphorylated by these cdc2 kinase complexes showed that both kinase complexes phosphorylated two major identical peptides, but minor additional peptides were differentially phosphorylated by each of these kinases. This indicates that under certain experimental conditions cdc2/p58 and cdc2/p62 may express some differences in their catalytic activity. In vitro phosphorylation by CTD kinase of a whole nuclear protein extract from murine fibroblasts showed that numatrin is the most prominent substrate for CTD kinase in this nuclear extract. CTD kinase cdc2/p58 was found to induce significantly the phosphorylation of five other discrete nuclear substrates. Particularly, two nuclear proteins at 75 kDa/pI approximately 6.5 and 85 kDa/pI approximately 5.3, which were not Coomassie Blue stainable, were found to be markedly phosphorylated by CTD kinase. The results of this study call for further study of the role of CTD kinase cdc2/p58 in the phosphorylation of numatrin under physiological conditions and to further characterization of the other nuclear substrates for CTD kinase.	UNIV PENN, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA	University of Pennsylvania								ARION D, 1988, CELL, V55, P371, DOI 10.1016/0092-8674(88)90060-8; BOOHER R, 1986, MOL CELL BIOL, V6, P3523, DOI 10.1128/MCB.6.10.3523; BRIZUELA L, 1989, P NATL ACAD SCI USA, V86, P4362, DOI 10.1073/pnas.86.12.4362; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; CHAN PK, 1985, EXP CELL RES, V161, P101, DOI 10.1016/0014-4827(85)90494-X; CHAN PK, 1986, J BIOL CHEM, V261, P1868; CISEK LJ, 1989, NATURE, V339, P679, DOI 10.1038/339679a0; CISEK LJ, 1991, METHOD ENZYMOL, V200, P301; DRAETTA G, 1988, NATURE, V336, P738, DOI 10.1038/336738a0; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DRAETTA G, 1989, CELL, V56, P829, DOI 10.1016/0092-8674(89)90687-9; FEUERSTEIN N, 1985, CANCER RES, V45, P3243; FEUERSTEIN N, 1988, J CELL BIOL, V107, P1629, DOI 10.1083/jcb.107.5.1629; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1987, J BIOL CHEM, V262, P11389; FEUERSTEIN N, 1990, BIOCHIM BIOPHYS ACTA, V1087, P127, DOI 10.1016/0167-4781(90)90196-9; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; FEUERSTEIN N, 1984, J BIOL CHEM, V259, P2782; GAUTIER J, 1989, NATURE, V339, P626, DOI 10.1038/339626a0; GAUTIER J, 1988, CELL, V54, P433, DOI 10.1016/0092-8674(88)90206-1; GIORDANO A, 1989, CELL, V58, P981, DOI 10.1016/0092-8674(89)90949-5; GOEBL M, 1988, CELL, V54, P738; HAYLES J, 1986, J CELL SCI, P155; KANG YJ, 1974, J BIOL CHEM, V249, P5580; KANG YJ, 1975, CANCER RES, V35, P1470; LABBE JC, 1988, NATURE, V335, P251, DOI 10.1038/335251a0; LABBE JC, 1989, CELL, V57, P253, DOI 10.1016/0092-8674(89)90963-X; LOHKA MJ, 1989, J CELL SCI, V92, P131; MORLA AO, 1989, CELL, V58, P193, DOI 10.1016/0092-8674(89)90415-7; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; NURSE P, 1985, TRENDS GENET, V1, P51, DOI 10.1016/0168-9525(85)90023-X; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; WITTENBERG C, 1988, CELL, V54, P1061, DOI 10.1016/0092-8674(88)90121-3; YUNG BYM, 1985, BIOCHIM BIOPHYS ACTA, V826, P167, DOI 10.1016/0167-4781(85)90002-8; YUNG BYM, 1987, BIOCHIM BIOPHYS ACTA, V925, P74, DOI 10.1016/0304-4165(87)90149-8	38	17	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16200	16206						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874752				2022-12-25	WOS:A1991GB97700100
J	BERNARD, O; LECOINTE, N; JONVEAUX, P; SOUYRI, M; MAUCHAUFFE, M; BERGER, R; LARSEN, CJ; MATHIEUMAHUL, D				BERNARD, O; LECOINTE, N; JONVEAUX, P; SOUYRI, M; MAUCHAUFFE, M; BERGER, R; LARSEN, CJ; MATHIEUMAHUL, D			2 SITE-SPECIFIC DELETIONS AND T(1,14) TRANSLOCATION RESTRICTED TO HUMAN T-CELL ACUTE LEUKEMIAS DISRUPT THE 5' PART OF THE TAL-1 GENE	ONCOGENE			English	Article							ACUTE LYMPHOBLASTIC-LEUKEMIA; LOOP-HELIX PROTEIN; DNA-BINDING MOTIF; CHROMOSOMAL TRANSLOCATION; LEUCINE ZIPPER; SCL GENE; COMMON; LINE; ENCODES; RECOMBINATION	Analysis of several cases of t(1:14)(p32;q11) translocation present in 3% of T-cell acute leukemias (T-ALL) has revealed the tal-1 gene. This gene encodes a helix-loop-helix protein. It has been found to be expressed in normal bone marrow and in leukemic T-cell and erythroleukemia cell lines, but not in normal T cells. Recently, a site-specific deletion, tal(d), renamed tal(d1) in this paper, has been detected in a high proportion of pediatric T-ALL, which arose by a site-specific DNA recombination between tal-1 and a new locus termed SIL. In this study we searched for structural rearrangements within tal-1 in a panel of 134 non-selected leukemic patients (including 66 with T-ALL). Only 6% of patients with T-ALL harbored the tal(d1) deletion. A second specific deletion termed tal(d2) was observed in another 6% of T-ALL patients; it involves another site within tal-1 plus the same site as tal(d1) in the SIL locus. Similarly to tal(d1) deletion, tal dl junctions harbor structural characteristics that are reminiscent of aberrant recombinase activity. Moreover, we report a detailed analysis of the tal-1 gene structure. Transcription analysis and in vitro translation data are consistent with the differential expression of several TAL-1 protein species containing the HLH motif but differing in their amino terminus. Taken together, our data indicate that t(1;14) translocations and both tal(d) deletions disrupt the 5' part of the tal-1 gene, placing its entire coding sequences under the control of the regulatory elements of the TCR-delta-gene or the SIL gene, both of which are normally expressed in T-cell lineage.	INST GENET MOLEC,INSERM,U301,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE; HOP COCHIN,INSERM,U148,F-75674 PARIS 14,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Bernard, Olivier A./E-5721-2016; Souyri, Michele/L-5845-2017; Mathieu, Daniele/G-6092-2012	Bernard, Olivier/0000-0002-0463-9747				APLAN PD, 1990, SCIENCE, V250, P1426, DOI 10.1126/science.2255914; APLAN PD, 1990, MOL CELL BIOL, V10, P6426, DOI 10.1128/MCB.10.12.6426; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P2031, DOI 10.1073/pnas.86.6.2031; BEGLEY CG, 1989, P NATL ACAD SCI USA, V86, P10128, DOI 10.1073/pnas.86.24.10128; BERNARD O, 1989, NUCLEIC ACIDS RES, V17, P6427, DOI 10.1093/nar/17.15.6427; BERNARD O, 1990, GENE CHROMOSOME CANC, V1, P194, DOI 10.1002/gcc.2870010303; BLACKWELL TK, 1989, J BIOL CHEM, V264, P10327; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BOEHM T, 1989, FASEB J, V3, P2344, DOI 10.1096/fasebj.3.12.2676678; BROWN L, 1990, EMBO J, V9, P3343, DOI 10.1002/j.1460-2075.1990.tb07535.x; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CARROLL AJ, 1990, BLOOD, V76, P1220; CHEN Q, 1990, EMBO J, V9, P415, DOI 10.1002/j.1460-2075.1990.tb08126.x; CHEN Q, 1990, J EXP MED, V172, P1403, DOI 10.1084/jem.172.5.1403; CROCE CM, 1987, ADV VIRAL ONCOL, V7, P35; DESIDERIO SV, 1984, NATURE, V311, P752, DOI 10.1038/311752a0; FINGER LR, 1986, SCIENCE, V234, P982, DOI 10.1126/science.3490692; FINGER LR, 1989, P NATL ACAD SCI USA, V86, P5039, DOI 10.1073/pnas.86.13.5039; GREENBERG JM, 1990, NATURE, V344, P158, DOI 10.1038/344158a0; GUAZZI S, 1990, EMBO J, V9, P3631, DOI 10.1002/j.1460-2075.1990.tb07574.x; HERSHFIELD MS, 1984, P NATL ACAD SCI-BIOL, V81, P253, DOI 10.1073/pnas.81.1.253; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KURTZBERG J, 1985, J EXP MED, V162, P1561, DOI 10.1084/jem.162.5.1561; LAFAILLE JJ, 1989, CELL, V59, P859, DOI 10.1016/0092-8674(89)90609-0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; MARTIN P, 1982, SCIENCE, V216, P1233, DOI 10.1126/science.6177045; MATHIEUMAHUL D, 1986, CR ACAD SCI III-VIE, V302, P525; MATHIEUMAHUL D, 1985, EMBO J, V4, P3427, DOI 10.1002/j.1460-2075.1985.tb04100.x; MCGUIRE EA, 1989, MOL CELL BIOL, V9, P2124, DOI 10.1128/MCB.9.5.2124; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; SAIKI RK, 1988, SCIENCE, V239, P488	34	147	151	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1477	1488						12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886719				2022-12-25	WOS:A1991GX27200027
J	DENIS, N; KITZIS, A; KRUH, J; DAUTRY, F; CORCOS, D				DENIS, N; KITZIS, A; KRUH, J; DAUTRY, F; CORCOS, D			STIMULATION OF METHOTREXATE RESISTANCE AND DIHYDROFOLATE-REDUCTASE GENE AMPLIFICATION BY C-MYC	ONCOGENE			English	Article							PRIMARY EMBRYO FIBROBLASTS; TUMOR PROMOTERS; MOUSE 3T6-CELLS; GROWTH-FACTOR; CELLS; EXPRESSION; DNA; ONCOGENES; MECHANISMS; RADIATION	We have hypothesized that the c-myc oncogene might promote DNA amplification. Resistance to methotrexate (MTX), a widely used cancer chemotherapeutic agent, often results from amplification of the gene coding for the target enzyme, dihydrofolate reductase (DHFR). We report here that gratuitously induced expression of c-myc in rat fibroblasts grown in the presence of MTX greatly increases the number of colonies resistant to the drug. This effect is not related to an alteration of cell growth, and it can also be observed to a lesser extent when c-myc is induced prior to selection in MTX. The DHFR gene is amplified in nearly half of the colonies cultured under selection conditions. Given the likely role of the c-myc product in DNA replication, these results strongly suggest that expression of c-myc plays a role in methotrexate resistance by promoting DNA amplification.	INST COCHIN GENET MOLEC,CNRS,URA 1147,24 RUE FAUBOURG ST JACQUES,F-75014 PARIS,FRANCE; INST GUSTAVE ROUSSY,CNRS,URA 1158,F-94805 VILLEJUIF,FRANCE; UNIV PARIS 07,INST JACQUES MONOD,CNRS,UNITE 257,F-75251 PARIS 05,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UNICANCER; Gustave Roussy; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Cite			Corcos, Daniel/M-1296-2016	Corcos, Daniel/0000-0002-4572-186X				ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; BARSOUM J, 1983, P NATL ACAD SCI-BIOL, V80, P5330, DOI 10.1073/pnas.80.17.5330; BROWN PC, 1983, MOL CELL BIOL, V3, P1097, DOI 10.1128/MCB.3.6.1097; CERNI C, 1987, EXP CELL RES, V168, P438; CLASSON M, 1987, NATURE, V330, P272, DOI 10.1038/330272a0; COUGHLIN SR, 1985, CELL, V43, P243, DOI 10.1016/0092-8674(85)90029-7; DENIS N, 1988, NUCLEIC ACIDS RES, V16, P2354, DOI 10.1093/nar/16.5.2354; DOTTO GP, 1985, NATURE, V318, P472; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; HANSON C, 1990, CYTOGENET CELL GENET, V53, P23, DOI 10.1159/000132888; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; IGUCHIARIGA SMM, 1987, EMBO J, V6, P2365, DOI 10.1002/j.1460-2075.1987.tb02513.x; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KLEINBERGER T, 1988, MOL CELL BIOL, V8, P1366, DOI 10.1128/MCB.8.3.1366; KLEINBERGER T, 1986, MOL CELL BIOL, V6, P1958, DOI 10.1128/MCB.6.6.1958; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; LUCKEHUHLE C, 1987, INT J CANCER, V39, P94, DOI 10.1002/ijc.2910390117; NICOLAIEW N, 1986, EXP CELL RES, V166, P357, DOI 10.1016/0014-4827(86)90482-9; NOWELL PC, 1986, CANCER RES, V46, P2203; RONAI ZA, 1988, ONCOGENE, V2, P201; SAGER R, 1985, P NATL ACAD SCI USA, V82, P7015, DOI 10.1073/pnas.82.20.7015; Sambrook J, 1989, MOL CLONING LABORATO; SCHIMKE RT, 1984, CANCER RES, V44, P1735; SCHIMKE RT, 1986, P NATL ACAD SCI USA, V83, P2157, DOI 10.1073/pnas.83.7.2157; SHARMA RC, 1989, CANCER RES, V49, P3861; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; STARK GR, 1989, CELL, V57, P901, DOI 10.1016/0092-8674(89)90328-0; SUBRAMANI S, 1981, MOL CELL BIOL, V1, P854, DOI 10.1128/MCB.1.9.854; TLSTY TD, 1984, MOL CELL BIOL, V4, P1050, DOI 10.1128/MCB.4.6.1050; VARSHAVSKY A, 1981, CELL, V25, P561, DOI 10.1016/0092-8674(81)90074-X; WAHL GM, 1989, CANCER RES, V49, P1333; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YOKOTA J, 1986, SCIENCE, V231, P261, DOI 10.1126/science.3941898; [No title captured]	34	56	57	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1453	1457						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886715				2022-12-25	WOS:A1991GX27200023
J	VIEIRA, RP; MULLOY, B; MOURAO, PAS				VIEIRA, RP; MULLOY, B; MOURAO, PAS			STRUCTURE OF A FUCOSE-BRANCHED CHONDROITIN SULFATE FROM SEA-CUCUMBER - EVIDENCE FOR THE PRESENCE OF 3-O-SULFO-BETA-D-GLUCURONOSYL RESIDUES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; EMBRYO EPIPHYSEAL CARTILAGES; MAGNETIC-RESONANCE-SPECTRA; OVARIAN-CYST MUCINS; BODY WALL; GLUCURONIC-ACID; GLYCOSAMINOGLYCANS; POLYSACCHARIDES; GLYCANS; MUCOPOLYSACCHARIDES	The structure of a unique fucose-branched chondroitin sulfate isolated from the body wall of a sea cucumber was examined in detail. This glycosaminoglycan contains side chain disaccharide units of sulfated fucopyranosyl units linked to approximately one-half of the glucuronic acid moieties through the O-3 position of the acid. The intact polysaccharide is totally resistant to chondroitinase degradation, whereas, after defucosylation, it is partially degraded by the enzyme. However, only after an additional step of desulfation, the chondroitin from sea cucumber is almost totally degraded by chondroitinase AC or ABC. This result, together with the methylation and NMR studies of the native and chemically modified polysaccharide, suggest that besides the fucose branches, the sea cucumber chondroitin sulfate contains sulfate esters at position O-3 of the beta-D-glucuronic acid units. Furthermore, the proteoglycan from the sea cucumber chondroitin sulfate is recognized by anti-Leu-7 monoclonal antibody, which specifically recognizes 3-sulfoglucuronic acid residues. In analogy with the fucose branched units, the 3-O-sulfo-beta-D-glucuronosyl residues are resistant to chondroitinase degradation. Regarding the position of the glycosidic linkage and site of sulfation in the fucose branches, our results suggest high heterogeneity. Tentatively, it is possible to suggest the preponderance of disaccharide units formed by 3,4-di-O-sulfo-alpha-L-fucopyranosyl units glycosidically linked through position 1 --> 2 to 4-O-sulfo-alpha-L-fucopyranose. Finally, the presence of unusual 4/6-disulfated disaccharide units, together with the common 6-sulfated and nonsulfated units, was detected in the chondroitin sulfate core of this polysaccharide.	UNIV FED RIO DE JANEIRO,INST CIENCIAS BIOMED,DEPT BIOQUIM,CAIXA POSTAL 68041,BR-21910 RIO DE JANEIRO,BRAZIL; NATL INST BIOL STAND & CONTROLS,POTTERS BAR EN6 3QG,HERTS,ENGLAND	Universidade Federal do Rio de Janeiro; National Institute for Biological Standards & Control			Mourao, Paulo/AAA-5386-2020					ALBANO RM, 1983, BIOCHIM BIOPHYS ACTA, V760, P192, DOI 10.1016/0304-4165(83)90143-5; ALBANO RM, 1986, J BIOL CHEM, V261, P7758; ASPINALL GO, 1982, POLYSACCHARIDES, V1, P19; CAPEK P, 1987, CARBOHYD RES, V164, P443, DOI 10.1016/0008-6215(87)80147-7; CHATURVEDI P, 1990, CARBOHYD RES, V203, P91, DOI 10.1016/0008-6215(90)80048-8; Conrad H.E., 1972, METHODS CARBOHYDR CH, V6, P361; DIETRICH CP, 1977, J CHROMATOGR, V130, P299, DOI 10.1016/S0021-9673(00)89809-X; DIETRICH CP, 1976, ANAL BIOCHEM, V70, P645, DOI 10.1016/0003-2697(76)90496-6; DISCHE Z, 1948, J BIOL CHEM, V175, P595; DISCHE Z, 1947, J BIOL CHEM, V167, P189; DUA VK, 1984, BIOCHIM BIOPHYS ACTA, V802, P29, DOI 10.1016/0304-4165(84)90030-8; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; FARNDALE RW, 1986, BIOCHIM BIOPHYS ACTA, V883, P173, DOI 10.1016/0304-4165(86)90306-5; HABUCHI O, 1977, J BIOL CHEM, V252, P4570; HAKOMORI SI, 1964, J BIOCHEM-TOKYO, V55, P205; HAMER GK, 1976, CARBOHYD RES, V49, P37, DOI 10.1016/S0008-6215(00)83123-7; HILBORN JC, 1969, ANAL BIOCHEM, V31, P51, DOI 10.1016/0003-2697(69)90240-1; HOLME KR, 1989, CARBOHYD RES, V186, P301, DOI 10.1016/0008-6215(89)84044-3; KARIYA Y, 1990, J BIOL CHEM, V265, P5081; KAWAI Y, 1966, J BIOCHEM-TOKYO, V60, P317, DOI 10.1093/oxfordjournals.jbchem.a128438; KIRCHER HW, 1960, ANAL CHEM, V32, P1103, DOI 10.1021/ac60165a016; MARTINI R, 1986, J CELL BIOL, V103, P2439, DOI 10.1083/jcb.103.6.2439; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P431, DOI 10.1111/j.1432-1033.1987.tb13534.x; MOURAO PAS, 1987, EUR J BIOCHEM, V166, P639, DOI 10.1111/j.1432-1033.1987.tb13561.x; MOURAO PAS, 1983, MOL CELL BIOCHEM, V57, P49, DOI 10.1007/BF00223524; PAVAO MSG, 1989, J BIOL CHEM, V264, P9972; RAO BNN, 1985, BIOPOLYMERS, V24, P2207, DOI 10.1002/bip.360241205; RODRIGUEZ ML, 1988, EUR J BIOCHEM, V177, P117, DOI 10.1111/j.1432-1033.1988.tb14351.x; RONDLE CJM, 1955, BIOCHEM J, V61, P586, DOI 10.1042/bj0610586; SAITO H, 1968, J BIOL CHEM, V243, P1536; SALAC MLB, 1984, ARCH BIOCHEM BIOPHYS, V231, P243, DOI 10.1016/0003-9861(84)90384-9; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; SHASHOUA VE, 1986, BIOCHEM BIOPH RES CO, V138, P902, DOI 10.1016/S0006-291X(86)80581-2; Taylor R. L., 1976, METHODS CARBOHYDRATE, V7, P149; VIEIRA RP, 1988, J BIOL CHEM, V263, P18176; WANG YM, 1990, CLIN CHIM ACTA, V188, P193, DOI 10.1016/0009-8981(90)90201-3; WELTI D, 1979, EUR J BIOCHEM, V94, P505, DOI 10.1111/j.1432-1033.1979.tb12919.x; YAMAGATA M, 1987, J BIOL CHEM, V262, P4146; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4	40	208	220	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13530	13536						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906878				2022-12-25	WOS:A1991FY02700014
J	ELING, TE; GLASGOW, WC; CURTIS, JF; HUBBARD, WC; HANDLER, JA				ELING, TE; GLASGOW, WC; CURTIS, JF; HUBBARD, WC; HANDLER, JA			STUDIES ON THE REDUCTION OF ENDOGENOUSLY GENERATED PROSTAGLANDIN-G2 BY PROSTAGLANDIN-H SYNTHASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VESICULAR GLAND MICROSOMES; ELECTRON-PARAMAGNETIC-RES; ENDOPEROXIDE SYNTHETASE; HUMAN-LUNG; POLYMORPHONUCLEAR LEUKOCYTES; ARACHIDONIC-ACID; BIOSYNTHESIS; PEROXIDASE; PURIFICATION; SUBSTRATE	Prostaglandin H synthase oxidizes arachidonic acid to prostaglandin G2 (PGG2) via its cyclooxygenase activity and reduces PGG2 to prostaglandin H-2 by its peroxidase activity. The purpose of this study was to determine if endogenously generated PGG2 is the preferred substrate for the peroxidase compared with exogenous PGG2. Arachidonic acid and varying concentrations of exogenous PGG2 were incubated with ram seminal vesicle microsomes or purified prostaglandin H synthase in the presence of the reducing cosubstrate, aminopyrine. The formation of the aminopyrine cation free radical (AP.+) served as an index of peroxide reduction. The simultaneous addition of PGG2 with arachidonic acid did not alter cyclooxygenase activity of ram seminal vesicle microsomes or the formation of the AP.+. This suggests that the formation of AP.+, catalyzed by the peroxidase, was supported by endogenous endoperoxide formed from arachidonic acid oxidation rather than by the reduction of exogenous PGG2. In addition to the AP.+ assay, the reduction of exogenous versus endogenous PGG2 was studied by using [5,6,8,9,11,12,14,15-H-2]arachidonic acid and unlabeled PGG2 as substrates, with gas chromatography-mass spectrometry techniques to measure the amount of reduction of endogenous versus exogenous PGG2. Two distinct results were observed. With ram seminal vesicle microsomes, little reduction of exogenous PGG2 was observed even under conditions in which all of the endogenous PGG2 was reduced. In contrast, studies with purified prostaglandin H synthase showed complete reduction of both exogenous and endogenous PGG2 using similar experimental conditions. Our findings indicate that PGG2 formed by the oxidation of arachidonic acid by prostaglandin H synthase in microsomal membranes is reduced preferentially by prostaglandin H synthase.	NCI,FREDERICK CANC RES FACIL,DIV CANC TREATMENT,PROGRAM DEV RES GRP,FREDERICK,MD 21701	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	ELING, TE (corresponding author), NIEHS,MOLEC BIOPHYS LAB,RES TRIANGLE PK,NC 27709, USA.							BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; ELING TE, 1985, J BIOL CHEM, V260, P1601; ELING TE, 1986, J BIOL CHEM, V261, P5023; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HENKE DC, 1984, ANAL BIOCHEM, V140, P87, DOI 10.1016/0003-2697(84)90137-4; HUBBARD WC, 1989, CANCER RES, V49, P826; HUBBARD WC, 1988, CANCER RES, V48, P4770; HUBBARD WC, 1988, CANCER RES, V48, P2674; KARTHEIN R, 1987, EUR J BIOCHEM, V166, P173, DOI 10.1111/j.1432-1033.1987.tb13499.x; KARTHEIN R, 1988, EUR J BIOCHEM, V171, P313, DOI 10.1111/j.1432-1033.1988.tb13792.x; LASKER JM, 1981, J BIOL CHEM, V256, P7764; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARKEY CM, 1987, J BIOL CHEM, V262, P6266; MARNETT LJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P222, DOI 10.1016/0005-2760(77)90058-3; MARNETT LJ, 1990, PEROXIDASES CHEM BIO, P293; MARSHALL PJ, 1988, ARCH BIOCHEM BIOPHYS, V266, P162, DOI 10.1016/0003-9861(88)90246-9; MIYAMOTO T, 1976, J BIOL CHEM, V251, P2629; NUGTEREN DH, 1973, BIOCHIM BIOPHYS ACTA, V326, P448, DOI 10.1016/0005-2760(73)90145-8; OGINO N, 1978, J BIOL CHEM, V253, P5061; OHKI S, 1979, J BIOL CHEM, V254, P829; PUUSTINEN T, 1987, FEBS LETT, V217, P265, DOI 10.1016/0014-5793(87)80675-0; VANDEROUDERAA FJ, 1977, BIOCHIM BIOPHYS ACTA, V487, P315, DOI 10.1016/0005-2760(77)90008-X; WELLER PE, 1985, ARCH BIOCHEM BIOPHYS, V243, P633, DOI 10.1016/0003-9861(85)90541-7; WISEMAN JS, 1987, BIOCHEMISTRY-US, V26, P5684, DOI 10.1021/bi00392a016	26	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12348	12355						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905721				2022-12-25	WOS:A1991FV18000040
J	LI, HY; DARWISH, K; POULOS, TL				LI, HY; DARWISH, K; POULOS, TL			CHARACTERIZATION OF RECOMBINANT BACILLUS-MEGATERIUM CYTOCHROME-P-450BM-3 AND ITS 2 FUNCTIONAL DOMAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REDOX EQUILIBRIA; P-450 REDUCTASE; P450; IDENTIFICATION; EXPRESSION; GENES; SPIN	Bacillus megaterium cytochrome P-450BM-3 and its two functional domains, the heme and flavin domains, have been purified and characterized using an Escherichia coli expression system. Recombinant P-450BM-3 behaves both spectrally and enzymatically the same as the enzyme produced from the natural host, B. megaterium, and another E. coli system recently described (Bouddupalli, S. S., Estabrook, R. W., and Peterson, J. A. (1990) J. Biol. Chem. 265, 4233-4239). Reduction of the flavins in P-450BM-3 domain with NADPH appears to be very similar to microsomal P-450 reductases where two reducing equivalents are consumed to fully reduce the FMN while the FAD is converted to the semiquinone in an one electron reduction. NADPH reduction of the heme occurs only in the presence of substrate suggesting, by analogy with the cytochrome P-450CAM system, a possible increase in iron redox potential of the heme upon substrate binding which facilitates electron transfer from the flavins to the heme. The flavin domain retains a high level of cytochrome c reductase activity and also reacts with NADPH to give a 3-electron reduced product. The heme domain retains the ability to bind substrate and generates the characteristic 450-nm absorption band upon reduction in the presence of CO. The heme domain has been crystallized and a preliminary set of x-ray diffraction data obtained.	UNIV MARYLAND,DEPT CHEM BIOCHEM,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park	LI, HY (corresponding author), MARYLAND BIOTECHNOL INST,CTR ADV RES BIOTECHNOL,ROCKVILLE,MD 20850, USA.				PHS HHS [33688, 42614] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BODDUPALLI SS, 1990, J BIOL CHEM, V265, P4233; DEBRUNNER PG, 1978, MET IONS BIOL SYST, V7, P241; FISHER MT, 1985, J AM CHEM SOC, V107, P5018, DOI 10.1021/ja00303a045; Gunsalus I C, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P1; Gunsalus I.C., 1974, MOL MECHANISMS OXYGE, P559; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; MATSON RS, 1977, BIOCHIM BIOPHYS ACTA, V487, P487, DOI 10.1016/0005-2760(77)90218-1; McPherson A, 1982, PREPARATION ANAL PRO; NARHI LO, 1986, J BIOL CHEM, V261, P7160; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NEBERT DW, 1987, ANNU REV BIOCHEM, V56, P945, DOI 10.1146/annurev.biochem.56.1.945; OKEEFFE DH, 1978, METHOD ENZYMOL, V51, P151; PHILLIPS AH, 1962, J BIOL CHEM, V237, P2652; PHILSON SB, 1976, THESIS U ILLINOIS UR; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1991, IN PRESS METHODS ENZ; RUETTINGER RT, 1989, J BIOL CHEM, V264, P10987; SLIGAR SG, 1976, P NATL ACAD SCI USA, V73, P1078, DOI 10.1073/pnas.73.4.1078; SLIGAR SG, 1976, BIOCHEMISTRY-US, V15, P5399, DOI 10.1021/bi00669a029; STUDIER FW, 1990, METHOD ENZYMOL, V185, P69; STURA E A, 1990, Methods (Orlando), V1, P38, DOI 10.1016/S1046-2023(05)80145-8; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Ullrich V, 1979, Top Curr Chem, V83, P67; VERMILION JL, 1978, J BIOL CHEM, V253, P2694; VERMILION JL, 1978, J BIOL CHEM, V253, P8812; WAGNER GC, 1982, BIOL CHEM IRON, P405; WEN LP, 1987, J BIOL CHEM, V262, P6676; WILLIAMS CH, 1962, J BIOL CHEM, V237, P587	28	101	108	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11909	11914						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904873				2022-12-25	WOS:A1991FT76200076
J	FUJII, M; NIKI, T; MORI, T; MATSUDA, T; MATSUI, M; NOMURA, N; SEIKI, M				FUJII, M; NIKI, T; MORI, T; MATSUDA, T; MATSUI, M; NOMURA, N; SEIKI, M			HTLV-1 TAX INDUCES EXPRESSION OF VARIOUS IMMEDIATE EARLY SERUM RESPONSIVE GENES	ONCOGENE			English	Article							T-CELL LEUKEMIA; VIRUS TYPE-I; LONG TERMINAL REPEAT; JUN PROTO-ONCOGENE; LEUCINE ZIPPER STRUCTURE; C-FOS PROTEIN; TRANSCRIPTIONAL ACTIVATOR; TRANS-ACTIVATION; RECEPTOR EXPRESSION; HUMAN INTERLEUKIN-2	Human T-cell leukemia virus type 1 (HTLV-1) is an etiological agent of adult T-cell leukemia (ATL). We showed here by mobility-shift assay that T-cell lines transformed with the virus contained high levels of AP-1 activities. Consistent with this result, these cell lines expressed increased levels of mRNAs encoding the AP-1 proteins, c-Fos, Fra-1, c-Jun, JunB, and JunD. Previously, transcription of the c-fos gene has been reported to be transactivated by the viral transcription factor, Tax1. By using the human T-cell line (JPX-9), in which expression of the Tax1 is inducible, we showed that expression of mRNAs for Fra-1, c-Jun, and JunD was also transactivated by Tax1. Moreover, Tax1 activated expression of two other transcription factors having zinc finger motifs, Egr-1 and Egr-2, in the same cells. The Tax1-inducible transcription factors identified here are encoded by the members of immediate early genes under the control of growth signals. Thus, Tax1 was suggested to replace growth signals, at least in part, by this mechanism.	KANAZAWA UNIV, CANC RES INST, DEPT VIROL, KANAZAWA, ISHIKAWA 920, JAPAN; KANAZAWA UNIV, DEPT INTERNAL MED 3, KANAZAWA, ISHIKAWA 920, JAPAN; NIPPON MED COLL, INST GERONTOL, MOLEC BIOL LAB, KAWASAKI, KANAGAWA 211, JAPAN	Kanazawa University; Kanazawa University; Nippon Medical School	SEIKI, M (corresponding author), KANAZAWA UNIV, CANC RES INST, DEPT VIROL, KANAZAWA, ISHIKAWA 920, JAPAN.		Matsui, Minami/A-5235-2016; Seiki, Motoharu/K-9443-2015	Matsui, Minami/0000-0001-5162-2668; 				ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BENHAM FJ, 1984, EMBO J, V3, P2635, DOI 10.1002/j.1460-2075.1984.tb02186.x; BRADY J, 1987, J VIROL, V61, P2175, DOI 10.1128/JVI.61.7.2175-2181.1987; CHAVRIER P, 1988, EMBO J, V7, P29, DOI 10.1002/j.1460-2075.1988.tb02780.x; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; COHEN DR, 1989, GENE DEV, V3, P173, DOI 10.1101/gad.3.2.173; CROSS SL, 1987, CELL, V49, P47, DOI 10.1016/0092-8674(87)90754-9; DEPPER JM, 1984, J IMMUNOL, V133, P1691; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FALLER DV, 1988, J VIROL, V62, P2942, DOI 10.1128/JVI.62.8.2942-2950.1988; FELBER BK, 1985, SCIENCE, V229, P675, DOI 10.1126/science.2992082; FUJII M, 1988, P NATL ACAD SCI USA, V85, P8526, DOI 10.1073/pnas.85.22.8526; FUJISAWA J, 1985, P NATL ACAD SCI USA, V82, P2277, DOI 10.1073/pnas.82.8.2277; FUJISAWA J, 1986, EMBO J, V5, P713, DOI 10.1002/j.1460-2075.1986.tb04272.x; HATAKEYAMA M, 1985, NATURE, V318, P467, DOI 10.1038/318467a0; HATTORI T, 1981, BLOOD, V58, P645; HIJIKATA M, 1990, J VIROL, V64, P4632, DOI 10.1128/JVI.64.10.4632-4639.1990; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; INOUE J, 1986, EMBO J, V5, P2883, DOI 10.1002/j.1460-2075.1986.tb04583.x; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; JOSEPH LJ, 1988, P NATL ACAD SCI USA, V85, P7164, DOI 10.1073/pnas.85.19.7164; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LEMAIRE P, 1990, MOL CELL BIOL, V10, P3456, DOI 10.1128/MCB.10.7.3456; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MARUYAMA M, 1987, CELL, V48, P343, DOI 10.1016/0092-8674(87)90437-5; MATSUI M, 1990, ONCOGENE, V5, P249; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; MIYATAKE S, 1988, NUCLEIC ACIDS RES, V16, P6547, DOI 10.1093/nar/16.14.6547; MORRIS CHT, 1988, NUCLEIC ACIDS RES, V16, P8835, DOI 10.1093/nar/16.18.8835; NAGATA K, 1989, J VIROL, V63, P3220, DOI 10.1128/JVI.63.8.3220-3226.1989; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NISHINA H, 1990, P NATL ACAD SCI USA, V87, P3619, DOI 10.1073/pnas.87.9.3619; NOMURA N, 1990, NUCLEIC ACIDS RES, V18, P3047, DOI 10.1093/nar/18.10.3047; PASKALIS H, 1986, P NATL ACAD SCI USA, V83, P6558, DOI 10.1073/pnas.83.17.6558; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; RANGNEKAR VM, 1990, NUCLEIC ACIDS RES, V18, P2749, DOI 10.1093/nar/18.9.2749; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RUBEN S, 1988, SCIENCE, V241, P89, DOI 10.1126/science.2838905; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SEIKI M, 1985, SCIENCE, V228, P1532, DOI 10.1126/science.2990031; SEIKI M, 1986, EMBO J, V5, P561, DOI 10.1002/j.1460-2075.1986.tb04247.x; SHIMOTOHNO K, 1986, P NATL ACAD SCI USA, V83, P8112, DOI 10.1073/pnas.83.21.8112; SIEKEVITZ M, 1987, P NATL ACAD SCI USA, V84, P5389, DOI 10.1073/pnas.84.15.5389; SODROSKI JG, 1984, SCIENCE, V225, P381, DOI 10.1126/science.6330891; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; SUVA LJ, 1989, GENE, V77, P95, DOI 10.1016/0378-1119(89)90363-6; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; TENDLER CL, 1990, P NATL ACAD SCI USA, V87, P5218, DOI 10.1073/pnas.87.13.5218; VANSTRAATEN F, 1983, P NATL ACAD SCI-BIOL, V80, P3183; VERMA IM, 1987, CELL, V51, P513, DOI 10.1016/0092-8674(87)90115-2; WANO Y, 1988, P NATL ACAD SCI USA, V63, P3234; WATANABE T, 1990, J EXP MED, V172, P759, DOI 10.1084/jem.172.3.759; WRIGHT JJ, 1990, SCIENCE, V248, P588, DOI 10.1126/science.2110381; YOSHIDA M, 1982, P NATL ACAD SCI-BIOL, V79, P2031, DOI 10.1073/pnas.79.6.2031; YOSHIDA M, 1987, ANNU REV IMMUNOL, V5, P541, DOI 10.1146/annurev.iy.05.040187.002545; YOSHIMURA T, 1990, EMBO J, V9, P2537, DOI 10.1002/j.1460-2075.1990.tb07434.x	66	192	192	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					1023	1029						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906155				2022-12-25	WOS:A1991GU62200018
J	KOBAYASHI, H; SCHMITT, M; GORETZKI, L; CHUCHOLOWSKI, N; CALVETE, J; KRAMER, M; GUNZLER, WA; JANICKE, F; GRAEFF, H				KOBAYASHI, H; SCHMITT, M; GORETZKI, L; CHUCHOLOWSKI, N; CALVETE, J; KRAMER, M; GUNZLER, WA; JANICKE, F; GRAEFF, H			CATHEPSIN-B EFFICIENTLY ACTIVATES THE SOLUBLE AND THE TUMOR-CELL RECEPTOR-BOUND FORM OF THE PROENZYME UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (PRO-UPA)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; CYSTEINE PROTEINASE; U937 MONOCYTES; BINDING SITE; DEGRADATION; PROUROKINASE; INACTIVATION; MODULATION; KALLIKREIN; RELEVANCE	Action of purified human cathepsin B on recombinant single-chain urokinase-type plasminogen activator (pro-uPA) generated enzymatically active two-chain uPA (HMW-uPA), which was indistinguishable by sodium dodecyl sulfate -polyacrylamide gel electrophoresis and Western blot from plasmin-generated HMW-uPA and from elastase- or thrombin-generated inactive two-chain urokinase-type plasminogen activator. Preincubation of cathepsin B with E-64 (trans-epoxysuccinyl-L-leucylamino-(4-guanidino)butane, a potent inhibitor for cathepsin B) prior to the addition of pro-uPA prevented the activation of pro-uPA. The cleavage site within the cathepsin B-treated urokinase-type plasminogen activator (uPA) molecule, determined by N-terminal amino acid sequence analysis, is located between Lys158 and Ile159. Pro-uPA is cleaved by cathepsin B at the same peptide bond that is cleaved by plasmin or kallikrein. Binding of cathepsin B-activated pro-uPA to the uPA receptor on U937 cells did not differ from that of enzymatically inactive pro-uPA, indicating an intact receptor-binding region within the growth factor-like domain of the cathepsin B-treated uPA molecule. Not only soluble but also tumor cell receptor-bound pro-uPA could be efficiently cleaved by cathepsin B to generate enzymatically active two-chain uPA. Thus, cathepsin B can substitute for plasmin in the proteolytic activation of pro-uPA to enzymatically active HMW-uPA. In contrast, no significant activation of pro-uPA by cathepsin D was observed. As tumor cells may produce both pro-uPA and cathepsin B, implications for the activation of tumor cell-derived pro-uPA by cellular proteases may be considered.	TECH UNIV MUNICH, KLINIKUM RECHTS ISAR, FRAUENKLIN, ISMANINGER STR 22, W-8000 MUNICH 80, GERMANY; MAX PLANCK INST BIOCHEM, W-8033 MARTINSRIED, GERMANY; UNIV HEIDELBERG, INST DERMATOL, W-6900 HEIDELBERG, GERMANY; GRUNENTHAL GMBH, W-5190 STOLBERG, GERMANY	Technical University of Munich; Max Planck Society; Ruprecht Karls University Heidelberg; Grunenthal Group			Calvete, Juan/P-2555-2019; Calvete, Juan J/K-9619-2014	Calvete, Juan/0000-0001-5026-3122; Calvete, Juan J/0000-0001-5026-3122				ASSFALGMACHLEIDT I, 1988, BIOL CHEM H-S, V369, P263; BARNATHAN ES, 1990, J BIOL CHEM, V265, P2865; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; CUBELLIS MV, 1986, J BIOL CHEM, V261, P5819; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; DUFFY MJ, 1988, CANCER, V62, P531, DOI 10.1002/1097-0142(19880801)62:3<531::AID-CNCR2820620315>3.0.CO;2-B; EECKHOUT Y, 1977, BIOCHEM J, V166, P21, DOI 10.1042/bj1660021; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ESTREICHER A, 1989, J BIOL CHEM, V264, P1180; GUREWICH V, 1987, BLOOD, V69, P769; HEARING VJ, 1988, CANCER RES, V48, P1270; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; JANICKE F, 1990, FIBRINOLYSIS, V4, P69, DOI 10.1016/0268-9499(90)90001-Z; JANICKE F, 1989, LANCET, V2, P1049; KEPPLER D, 1988, CANCER RES, V48, P6856; KEREN Z, 1988, CANCER RES, V48, P1416; KREPELA E, 1987, J CELL SCI, V87, P145; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAH TT, 1989, CLIN EXP METASTAS, V7, P461, DOI 10.1007/BF01753666; LENARCIC B, 1988, BIOCHEM BIOPH RES CO, V154, P765, DOI 10.1016/0006-291X(88)90206-9; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIOTTA LA, 1983, LAB INVEST, V49, P636; MARKUS G, 1988, ENZYME, V40, P158, DOI 10.1159/000469158; MAUDELONDE T, 1988, CANCER RES, V48, P462; NISHIMURA Y, 1987, BIOCHEM BIOPH RES CO, V148, P254, DOI 10.1016/0006-291X(87)91103-X; OSSOWSKI L, 1988, J CELL BIOL, V107, P2437, DOI 10.1083/jcb.107.6.2437; PLOW EF, 1986, J CELL BIOL, V103, P2411, DOI 10.1083/jcb.103.6.2411; POLLANEN J, 1990, P NATL ACAD SCI USA, V87, P2230, DOI 10.1073/pnas.87.6.2230; ROCHEFORT H, 1989, DEV ONCOL, V58, P171; ROZHIN J, 1987, CANCER RES, V47, P6620; SCHLECHTE W, 1989, CANCER RES, V49, P6064; SCHMITT M, 1989, FEBS LETT, V255, P83, DOI 10.1016/0014-5793(89)81065-8; SCHMITT M, 1990, FIBRINOGEN, V4, P213; SPYRATOS F, 1989, LANCET, V2, P1115; STEPHENS RW, 1989, J CELL BIOL, V108, P1987, DOI 10.1083/jcb.108.5.1987; STOPPELLI MP, 1985, P NATL ACAD SCI USA, V82, P4939, DOI 10.1073/pnas.82.15.4939; TANDON AK, 1990, NEW ENGL J MED, V322, P297, DOI 10.1056/NEJM199002013220504; THORPE SM, 1989, CANCER RES, V49, P6008; VASSALLI JD, 1985, J CELL BIOL, V100, P86, DOI 10.1083/jcb.100.1.86	39	341	349	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5147	5152						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1900515				2022-12-25	WOS:A1991FC21700070
J	MANROW, RE; SBURLATI, AR; HANOVER, JA; BERGER, SL				MANROW, RE; SBURLATI, AR; HANOVER, JA; BERGER, SL			NUCLEAR TARGETING OF PROTHYMOSIN-ALPHA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; MULTIDRUG RESISTANCE; BINDING-PROTEINS; P-GLYCOPROTEIN; CYTOCHALASIN-B; ALPHA GENE; TRANSPORT; LOCATION	Prothymosin-alpha is a highly acidic protein which lacks an amino-terminal signal peptide, yet was once thought to be a precursor for thymosin-alpha-1, a putative peptide hormone secreted by the thymus. Here, two lines of evidence are presented that strongly implicate prothymosin-alpha as a nuclear protein: 1) in COS cells transfected with the human prothymosin-alpha gene copious amounts of prothymosin-alpha were present in sealed nuclei obtained by treating these cells with cytochalasin B and enucleating them centrifugally. 2) Constructs in which human prothymosin-alpha nucleic acid sequences were fused in-frame either near the amino terminus of the beta-galactosidase gene in pCH110 or at the carboxyl terminus, when expressed in COS cells, resulted in nuclear localization of the fusion protein; indirect immunofluorescence in situ was used as the assay. The basic cluster of amino acids at the carboxyl terminus of prothymosin-alpha, TKKQKT, has been identified as part of the nuclear targeting signal, whereas the basic cluster of amino acids situated within the thymosin-alpha-1 sequence at the amino terminus failed to effect nuclear transport.	NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	MANROW, RE (corresponding author), NCI,BIOCHEM LAB,GENES & GEN PROD SECT,BETHESDA,MD 20892, USA.							ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; AUGER C, 1987, J HISTOCHEM CYTOCHEM, V35, P181, DOI 10.1177/35.2.3540103; BOLTON AE, 1973, BIOCHEM J, V133, P529, DOI 10.1042/bj1330529; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; COBIANCHI F, 1987, METHOD ENZYMOL, V152, P94; CONTEAS CN, 1990, P NATL ACAD SCI USA, V87, P3269, DOI 10.1073/pnas.87.9.3269; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; ESCHENFELDT WH, 1989, J BIOL CHEM, V264, P7546; ESCHENFELDT WH, 1986, P NATL ACAD SCI USA, V83, P9403, DOI 10.1073/pnas.83.24.9403; FOLLETT EAC, 1974, EXP CELL RES, V84, P72, DOI 10.1016/0014-4827(74)90381-4; FRANCO FJ, 1989, IMMUNOLOGY, V67, P263; GOLDFARB DS, 1986, NATURE, V322, P641, DOI 10.1038/322641a0; GOMEZMARQUEZ J, 1988, FEBS LETT, V226, P217, DOI 10.1016/0014-5793(88)81425-X; GREENE JR, 1987, METHOD ENZYMOL, V152, P512; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; HALL MN, 1984, CELL, V36, P1057, DOI 10.1016/0092-8674(84)90055-2; HANNAPPEL E, 1982, BIOCHEM BIOPH RES CO, V104, P266, DOI 10.1016/0006-291X(82)91969-6; HANOVER JA, 1988, BIOCHEM BIOPH RES CO, V152, P469, DOI 10.1016/S0006-291X(88)80737-X; HARITOS AA, 1984, P NATL ACAD SCI-BIOL, V81, P1391, DOI 10.1073/pnas.81.5.1391; HARITOS AA, 1985, P NATL ACAD SCI USA, V82, P343, DOI 10.1073/pnas.82.2.343; JACOBSON A, 1983, NUCLEIC ACIDS RES, V11, P6353, DOI 10.1093/nar/11.18.6353; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEONE A, 1989, ANAL BIOCHEM, V183, P64, DOI 10.1016/0003-2697(89)90172-3; LOW TLK, 1985, METHOD ENZYMOL, V116, P213; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACKMAN N, 1986, CURR TOP MICROBIOL, V125, P159; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MELTON DA, 1987, METHOD ENZYMOL, V152, P288; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OPPENHEIM JJ, 1986, IMMUNOL TODAY, V7, P45, DOI 10.1016/0167-5699(86)90124-6; PAN LX, 1986, ARCH BIOCHEM BIOPHYS, V250, P197, DOI 10.1016/0003-9861(86)90717-4; PANNEERSELVAM C, 1987, P NATL ACAD SCI USA, V84, P4465, DOI 10.1073/pnas.84.13.4465; PARK MK, 1987, P NATL ACAD SCI USA, V84, P6462, DOI 10.1073/pnas.84.18.6462; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; SBURLASTI AR, 1991, IN PRESS P NATL ACAD; SHAY JW, 1975, EXP CELL RES, V94, P47, DOI 10.1016/0014-4827(75)90529-7; SHULOF RS, 1985, CRC CRIT R ONCOL HEM, V3, P309; SIGLER PB, 1988, NATURE, V333, P210, DOI 10.1038/333210a0; STARR CM, 1990, J CELL BIOL, V110, P1861, DOI 10.1083/jcb.110.6.1861; TSITSILONI OE, 1989, EXPERIENTIA, V45, P332, DOI 10.1007/BF01957467; TSUNEOKA M, 1986, J BIOL CHEM, V261, P1829; URBANIK E, 1989, ARCH BIOCHEM BIOPHYS, V269, P181, DOI 10.1016/0003-9861(89)90098-2; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; WATTS JD, 1989, FEBS LETT, V245, P17, DOI 10.1016/0014-5793(89)80182-6; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	52	122	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3916	3924						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1899869				2022-12-25	WOS:A1991EY68200085
J	VANDEGRIFF, KD; BENAZZI, L; RIPAMONTI, M; PERRELLA, M; LETELLIER, YC; ZEGNA, A; WINSLOW, RM				VANDEGRIFF, KD; BENAZZI, L; RIPAMONTI, M; PERRELLA, M; LETELLIER, YC; ZEGNA, A; WINSLOW, RM			CARBON-DIOXIDE BINDING TO HUMAN HEMOGLOBIN CROSS-LINKED BETWEEN THE ALPHA-CHAINS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							BLOOD SUBSTITUTE	The binding of carbon dioxide to human hemoglobin cross-linked between Lys-alpha-99 residues with bis(3,5-dibromosalicyl) fumarate was measured using manometric techniques. The binding of CO2 to unmodified hemoglobin can be described by two classes of sites with high and low affinities corresponding to the amino-terminal valines of the beta and alpha-chains, respectively (Perrella, M., Kilmartin, J. V., Fogg, J., and Rossi-Bernardi, L. (1975b) Nature 256, 759-761. The cross-linked hemoglobin bound less CO2 than native hemoglobin at all CO2 concentrations in deoxygenated and liganded conformations, and the ligand-linked effect was reduced. Fitting the data to models of CO2 binding suggests that only half of the expected saturation with CO2 is possible. The remaining binding is described by a single affinity constant that for cross-linked deoxy-hemoglobin is about two-thirds of the high affinity constant for deoxyhemoglobin A and that for cross-linked cyanomethemoglobin is equal to the high affinity constant for unmodified cyanomethemoglobin A or carbonmonoxyhemoglobin A. The low affinity binding constant for cross-linked hemoglobin in both the deoxygenated and liganded conformations is close to zero, which is significantly less than the affinity constants for either subunit binding site in unmodified hemoglobin. Comparing the low affinity sites in this modified hemoglobin to native hemoglobin suggests that cross-linking hemoglobin between Lys-alpha-99 residues prevents CO2 binding at the alpha-subunit NH2 termini.	UNIV MILAN,DIPARTIMENTO SCI & TECNOL BIOMED,I-20122 MILAN,ITALY; CNR,IST TECHNOL BIOMED AVANZATE,I-20133 MILAN,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Milan; Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR)	VANDEGRIFF, KD (corresponding author), LETTERMAN ARMY MED CTR,DIV BLOOD RES,SAN FRANCISCO,CA 94129, USA.		Ripamonti, Marilena/AAY-4013-2020	RIPAMONTI, MARILENA/0000-0001-9403-9915				BALDWIN J, 1979, J MOL BIOL, V129, P175, DOI 10.1016/0022-2836(79)90277-8; CHATTERJEE R, 1986, J BIOL CHEM, V261, P9929; CHRISTENSEN SM, 1988, J BIOCHEM BIOPH METH, V17, P143, DOI 10.1016/0165-022X(88)90045-0; DEDUVE C, 1948, ACTA CHEM SCAND, V2, P264, DOI 10.3891/acta.chem.scand.02-0264; ESTEP TN, 1989, BLOOD SUBSTITUTES, P129; Evelyn KA, 1938, J BIOL CHEM, V126, P655; Imai K, 1981, Methods Enzymol, V76, P438; KILMARTIN JV, 1973, J BIOL CHEM, V248, P7039; LARSEN RW, 1990, J BIOL CHEM, V265, P4449; PARRELLA M, 1981, METHOD ENZYMOL, V76, P487; PERRELLA M, 1990, BIOPHYS CHEM, V35, P97, DOI 10.1016/0301-4622(90)80064-E; PERRELLA M, 1975, NATURE, V256, P759, DOI 10.1038/256759a0; PERRELLA M, 1975, J BIOL CHEM, V250, P5413; PERRELLA M, 1977, FEBS LETT, V76, P287; PERRELLA M, 1972, OXYGEN AFFINITY HEMO, V4, P177; PERRELLA M, 1980, BIOPHYSICS PHYSL CAR, P75; SHAANAN B, 1983, J MOL BIOL, V171, P31, DOI 10.1016/S0022-2836(83)80313-1; SNYDER SR, 1987, P NATL ACAD SCI USA, V84, P7280, DOI 10.1073/pnas.84.20.7280; VANDEGRIFF KD, 1989, J BIOL CHEM, V264, P17824	19	17	17	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2697	2700						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1899662				2022-12-25	WOS:A1991EX60000005
J	ENGHILD, JJ; SALVESEN, G; HEFTA, SA; THOGERSEN, IB; RUTHERFURD, S; PIZZO, SV				ENGHILD, JJ; SALVESEN, G; HEFTA, SA; THOGERSEN, IB; RUTHERFURD, S; PIZZO, SV			CHONDROITIN 4-SULFATE COVALENTLY CROSS-LINKS THE CHAINS OF THE HUMAN BLOOD PROTEIN PRE-ALPHA-INHIBITOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-TRYPSIN INHIBITOR; HUMAN-PLASMA; HYDROLYSIS; COLLAGEN	The human blood protein pre-alpha-inhibitor is composed of one heavy and one light protein chain. The chains are covalently linked to each other by a structure that has not previously been described, which we designate a protein-glycosaminoglycan-protein (PGP) cross-link. A combination of protein and carbohydrate analytical techniques indicates that the interchain linkage is mediated by a chondroitin 4-sulfate glycosaminoglycan that originates from a typical O-glycosidic link to Ser-10 of the light chain. The heavy chain is esterified, via the alpha-carbon of its C-terminal Asp, to C-6 of an internal N-acetylgalactosamine of the glycosaminoglycan chain. This PGP cross-link may be present in other proteins, but could have been overlooked due to the heterogeneous behavior of proteins containing glycosaminoglycan.	CITY HOPE NATL MED CTR, BECKMAN RES INT, DIV IMMUNOL, DUARTE, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	ENGHILD, JJ (corresponding author), DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA.		Rutherfurd, Shane M/D-8254-2011	Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL CANCER INSTITUTE [P30CA033572] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024066, R01HL024066] Funding Source: NIH RePORTER; NCI NIH HHS [CA-33572] Funding Source: Medline; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIERMANN CJ, 1988, ADV CARBOHYD CHEM BI, V46, P251, DOI 10.1016/S0065-2318(08)60168-7; BOURGUIGNON J, 1989, BIOCHEM J, V261, P305, DOI 10.1042/bj2610305; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; Carney S.L., 1986, CARBOHYDRATE ANAL, P97; DIARRAMEHRPOUR M, 1989, EUR J BIOCHEM, V179, P147, DOI 10.1111/j.1432-1033.1989.tb14532.x; DOERING TL, 1990, J BIOL CHEM, V265, P611; ENGHILD JJ, 1989, J BIOL CHEM, V264, P15975; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1407; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; GEBHARD W, 1989, EUR J BIOCHEM, V181, P571, DOI 10.1111/j.1432-1033.1989.tb14762.x; Gebhard W., 1986, PROTEINASE INHIBITOR, P389; HOCHSTRASSER K, 1981, H-S Z PHYSIOL CHEM, V362, P1357, DOI 10.1515/bchm2.1981.362.2.1357; JESSEN TE, 1988, FEBS LETT, V230, P195, DOI 10.1016/0014-5793(88)80670-7; KAUMEYER JF, 1986, NUCLEIC ACIDS RES, V14, P7839, DOI 10.1093/nar/14.20.7839; LINDAHL U, 1978, ANNU REV BIOCHEM, V47, P385, DOI 10.1146/annurev.bi.47.070178.002125; LORAND L, 1983, ANN NY ACAD SCI, V421, P10, DOI 10.1111/j.1749-6632.1983.tb18089.x; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MEANS GE, 1971, CHEM MODIFICATION PR, P139; MELTZER NM, 1987, ANAL BIOCHEM, V160, P356, DOI 10.1016/0003-2697(87)90060-1; PARTRIDGE SM, 1962, ADV PROTEIN CHEM, V17, P227; Salvesen G, 1989, PROTEOLYTIC ENZYMES, P83; SELL DR, 1989, J BIOL CHEM, V264, P21597; TANAKA S, 1988, J BIOL CHEM, V263, P17650; URIEL J, 1968, NATURE, V218, P578, DOI 10.1038/218578b0; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523	26	159	165	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					747	751						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898736				2022-12-25	WOS:A1991ET17700014
J	HSU, TC; BODINE, PV; LITWACK, G				HSU, TC; BODINE, PV; LITWACK, G			ENDOGENOUS MODULATORS OF GLUCOCORTICOID RECEPTOR FUNCTION ALSO REGULATE PURIFIED PROTEIN-KINASE-C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; TYROSINE AMINOTRANSFERASE; ORNITHINE DECARBOXYLASE; ALLOSTERIC REGULATION; KINETIC-ANALYSIS; MIXED MICELLES; ACTIVATION; INHIBITION; DIACYLGLYCEROL; COMPLEX	Modulator-1 and -2, proposed to be novel ether-linked aminophosphoglycerides, were originally identified as regulators of glucocorticoid receptor function (Bodine, P.V., and Litwack, G. (1990) J. Biol. Chem. 265, 9544-9554). We now demonstrate that these modulators are also potent new stimulators of protein kinase C activity in vitro. These endogenous biomolecules regulate purified protein kinase C activity in a biphasic and dose-dependent pattern, as determined by histone phosphorylation. Modulators, at concentrations within their apparent cellular range, stimulate protein kinase C-catalyzed histone phosphorylation 2-4-fold when added separately, or 10-12-fold when added together. This enhancement of kinase activity apparently is specific for protein kinase C, since neither protein kinase M, nor cAMP-dependent protein kinase A are stimulated by the modulators. The stimulation of purified protein kinase C occurs only when the enzyme has been initially activated by calcium, phosphatidylserine, and diacylglycerol, indicating that the modulators do not simply substitute for one of the enzyme cofactors. In addition, the modulators appear to interact directly with protein kinase C, perhaps with the regulatory domain of the enzyme, since these biomolecules inhibit the binding of phorbol ester to purified protein kinase C. Finally, time-course studies of protein kinase C-catalyzed histone phosphorylation indicate that the velocity of the enzyme reaction is increased by the modulators. Taken together, these results suggest that the modulators are a new class of regulators of protein kinase C.	TEMPLE UNIV, HLTH SCI CTR, SCH MED, FELS INST CANC RES & MOLEC BIOL, PHILADELPHIA, PA 19140 USA; TEMPLE UNIV, HLTH SCI CTR, SCH MED, DEPT BIOCHEM, PHILADELPHIA, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University					NIDDK NIH HHS [DK-13531, DK-42353] Funding Source: Medline; NIGMS NIH HHS [GM-41452] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042353, R01DK013531] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041452] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; Bell R M, 1986, Methods Enzymol, V124, P353; Bodine P V, 1991, Receptor, V1, P167; Bodine P V, 1990, Receptor, V1, P83; BODINE PV, 1988, J BIOL CHEM, V263, P3501; BODINE PV, 1988, P NATL ACAD SCI USA, V85, P1462, DOI 10.1073/pnas.85.5.1462; BODINE PV, 1990, J BIOL CHEM, V265, P9544; BODINE PV, 1990, 6TH P INTS CELL END; BODINE PV, 1991, P ENDOCRINE SOC M WA, P98; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; CHARP PA, 1988, BIOCHEMISTRY-US, V27, P4607, DOI 10.1021/bi00413a004; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; ELTOUNY S, 1990, J BIOL CHEM, V265, P16437; FORD DA, 1989, J BIOL CHEM, V264, P13818; GUSTAFSSON JA, 1987, ENDOCR REV, V8, P185, DOI 10.1210/edrv-8-2-185; HANNUN YA, 1987, METHOD ENZYMOL, V141, P287; HANNUN YA, 1986, J BIOL CHEM, V261, P9341; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATUNUMA N, 1988, ADV ENZYME REGUL, V27, P277; KIDO H, 1987, BIOCHEMISTRY-US, V26, P2349, DOI 10.1021/bi00382a041; KIDO H, 1986, BIOCHEM BIOPH RES CO, V138, P275, DOI 10.1016/0006-291X(86)90276-7; KIDO H, 1987, BIOCHEM BIOPH RES CO, V144, P152, DOI 10.1016/S0006-291X(87)80488-6; KIKKAWA U, 1989, ANNU REV BIOCHEM, V58, P31, DOI 10.1146/annurev.bi.58.070189.000335; KISHIMOTO A, 1980, J BIOL CHEM, V255, P2273; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Kitano T, 1986, Methods Enzymol, V124, P349; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MH, 1989, J BIOL CHEM, V264, P14797; LITWACK G, 1988, CANCER RES, V48, P2636; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; MCPHAIL LC, 1984, SCIENCE, V224, P622, DOI 10.1126/science.6231726; MOCHLYROSEN D, 1987, J BIOL CHEM, V262, P2291; MOLLEYRES LP, 1988, J BIOL CHEM, V263, P14832; MOORHOUSE KG, 1989, FEBS LETT, V256, P43, DOI 10.1016/0014-5793(89)81714-4; OISHI K, 1988, J BIOL CHEM, V263, P6865; RANDO RR, 1988, FASEB J, V2, P2348, DOI 10.1096/fasebj.2.8.3282960; REIMANN EM, 1983, METHOD ENZYMOL, V99, P51; ROMANO M, 1990, J BIOL CHEM, V265, P1765; SCHMIDT TJ, 1982, PHYSIOL REV, V62, P1131, DOI 10.1152/physrev.1982.62.4.1131; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; SCHULMAN G, 1990, J AM SOC NEPHROL, V1; SERVIN SEJ, 1988, FEBS LETT, V232, P286; SHARKEY NA, 1984, P NATL ACAD SCI-BIOL, V81, P607, DOI 10.1073/pnas.81.2.607; SHARMA R, 1990, BIOCHEM BIOPH RES CO, V168, P823, DOI 10.1016/0006-291X(90)92395-G; TAKAI Y, 1979, J BIOL CHEM, V254, P3692; UCHIDA T, 1984, J BIOL CHEM, V259, P2311; WALKER JM, 1988, J BIOL CHEM, V263, P4537; WALTON GM, 1987, ANAL BIOCHEM, V161, P425, DOI 10.1016/0003-2697(87)90471-4; WITT JJ, 1975, ANAL BIOCHEM, V66, P253, DOI 10.1016/0003-2697(75)90743-5; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V	54	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17573	17579						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894640				2022-12-25	WOS:A1991GF44500088
J	SHEDBALKAR, VP; IOANNIDES, IM; REBEIZ, CA				SHEDBALKAR, VP; IOANNIDES, IM; REBEIZ, CA			CHLOROPLAST BIOGENESIS - DETECTION OF MONOVINYL PROTOCHLOROPHYLL(IDE)-B IN PLANTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AXIAL LIGAND COORDINATION; CHLOROPHYLL BIOSYNTHESIS; METALATED TETRAPYRROLES; PORPHYRINS	The occurrence of protochlorophyllide b and protochlorophyllide b phytyl ester in green plants is described. The chemical structure of protochlorophyllide b phytyl ester was established by proton nuclear magnetic resonance, fast atom bombardment mass spectroscopic analysis, and chemical derivatization coupled to electronic spectroscopic analysis. The macrocycles of protochlorophyll(ide) b are identical to those of conventional protochlorophyll(ide) except for the presence of a formyl group instead of a methyl group at position 3 of the macrocycles. They differ from chlorophyll(ide) b by the presence of an oxidized double bond at positions 7 and 8 of the macrocycles. The trivial name protochlorophyll(ide) b is proposed to differentiate these two tetrapyrroles from conventional protochlorophyll(ide), which in turn will be referred to as protochlorophyll(ide) a. Protochlorophyll(ide) b appears to be widely distributed in green plants. Its molar extinction coefficients in 80% acetone and diethyl ether are reported. The impact of this discovery on the heterogeneity of the chlorophyll a and b biosynthetic pathways is discussed.	UNIV ILLINOIS,PLANT PIGMENT BIOCHEM & PHOTOBIOL LAB,240A,1201 W GREGORY,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign								BELANGER FC, 1980, BIOCHEMISTRY-US, V19, P4875, DOI 10.1021/bi00562a027; BELANGER FC, 1982, J BIOL CHEM, V257, P1360; BELANGER FC, 1982, J BIOL CHEM, V257, P4849; BELANGER FC, 1984, SPECTROCHIM ACTA A, V40, P807, DOI 10.1016/0584-8539(84)80171-3; BELANGER FC, 1980, J BIOL CHEM, V255, P1266; BENZ J, 1981, Z NATURFORSCH C, V36, P51; COHEN CE, 1978, PLANT PHYSIOL, V61, P824, DOI 10.1104/pp.61.5.824; DUGGAN JX, 1982, BIOCHIM BIOPHYS ACTA, V679, P248, DOI 10.1016/0005-2728(82)90295-X; DUGGAN JX, 1981, PLANT PHYSL BETHESDA, V67, pS267; GURINOVICH GP, 1968, ATOMIC ENERGY TRANSL, P134; IOANNIDES IM, 1989, THESIS U ILLINOIS; KENNER GW, 1974, J CHEM SOC PERK T 1, P527, DOI 10.1039/p19740000527; LEE HJ, 1991, PLANT PHYSIOL, V96, P910, DOI 10.1104/pp.96.3.910; OELZEKAROW H, 1978, PHOTOCHEM PHOTOBIOL, V27, P189, DOI 10.1111/j.1751-1097.1978.tb07586.x; OGAWA T, 1965, PHOTOCHEM PHOTOBIOL, V4, P193; REBEIZ CA, 1984, SPECTROCHIM ACTA A, V40, P793, DOI 10.1016/0584-8539(84)80170-1; REBEIZ CA, 1983, MOL CELL BIOCHEM, V58, P97; SCHEER H, 1975, PORPHYRINS METALLOPO, P395; Seely G. R., 1966, CHLOROPHYLLS, P67; SHYLK AA, 1971, ANN REV PLANT PHYSL, V22, P169; SMITH KM, 1984, ORG MAGN RESONANCE, V22, P779, DOI 10.1002/mrc.1270221210; TRIPATHY BC, 1986, J BIOL CHEM, V261, P3556; WU SM, 1985, J BIOL CHEM, V260, P3632; WU SM, 1984, TETRAHEDRON, V40, P659, DOI 10.1016/S0040-4020(01)91093-2; WU SM, 1987, PHYTOCHEMISTRY OXF, V27, P353	25	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17151	17157						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894610				2022-12-25	WOS:A1991GF44500030
J	ASHIZAWA, K; WILLINGHAM, MC; LIANG, CM; CHENG, SY				ASHIZAWA, K; WILLINGHAM, MC; LIANG, CM; CHENG, SY			INVIVO REGULATION OF MONOMER-TETRAMER CONVERSION OF PYRUVATE-KINASE SUBTYPE-M2 BY GLUCOSE IS MEDIATED VIA FRUCTOSE-1,6-BISPHOSPHATE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3,3',5-TRIIODO-L-THYRONINE BINDING-PROTEIN; THYROID-HORMONE BINDING; MONOCLONAL-ANTIBODIES; RAT	The activity of pyruvate kinase, subtype M2 (PKM2), is known to be increased by fructose 1,6-bisphosphate (Fru-1,6-P2), one of the metabolites in the glycolytic pathway. Recently, we have shown that in vitro, Fru-1,6-P2 activated the association of monomer to form the tetrameric PKM2. To ascertain whether this mode of regulation also occurs in vivo, we prepared monomer-specific monoclonal antibody and quantified the monomer formation in situ in cultured cells by immunocytochemistry. The intracellular Fru-1,6-P2 was manipulated by the glucose concentration in the media. At the physiological concentration of glucose (4-6 mM), 30-35% of PK existed as a monomer. However, PKM2 was dissociated into monomer within minutes after cells were deprived of glucose. The maximal level of monomer was detected after 1 h at 37-degrees-C. Monomer was rapidly (within minutes) converted to tetramer after addition of glucose. Furthermore, when cells cultured in 10 mm of glucose were treated with cytochalasin B, an inhibitor of the glucose transporter, a maximal level of monomer was detected within 20-30 min. Determination of Fru-1,6-P2 indicated that its intracellular concentration decreased concomitantly with the reduction in glucose concentration in the medium. These results indicate that monomer-tetramer interconversion is a major in vivo cellular regulatory mechanism in response to changes in the extracellular glucose concentration via Fru-1,6-P2.	NCI,DIV CANC BIOL DIAG & CTR,MOLEC BIOL LAB,BLDG 37,ROOM 4B09,BETHESDA,MD 20892; US FDA,DIV BLOOD & BLOOD PROD,BETHESDA,MD 20014	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); US Food & Drug Administration (FDA)								ASHIZAWA K, 1990, BIOCHEM BIOPH RES CO, V167, P587, DOI 10.1016/0006-291X(90)92065-8; ASHIZAWA K, 1991, BIOCHEMISTRY-US, V30, P7105, DOI 10.1021/bi00243a010; EIGENBRODT E, 1985, REGULATION CARBOHYDR, V2, P142; HASUMURA S, 1986, BIOCHEMISTRY-US, V25, P7881, DOI 10.1021/bi00372a014; IMAMURA K, 1982, METHOD ENZYMOL, V90, P150; KATO H, 1989, P NATL ACAD SCI USA, V86, P7861, DOI 10.1073/pnas.86.20.7861; KITAGAWA S, 1987, J BIOL CHEM, V262, P3903; LIN KH, 1990, J BIOL CHEM, V265, P5161; MICHAL G, 1974, METHOD ENZYMAT AN, P1314; OBATA T, 1989, BIOCHEMISTRY-US, V28, P617, DOI 10.1021/bi00428a030; OBATA T, 1988, FEBS LETT, V230, P9, DOI 10.1016/0014-5793(88)80630-6; PARKISON C, 1989, NUCLEIC ACIDS RES, V17, P7106, DOI 10.1093/nar/17.17.7106; RICHERT ND, 1982, J GEN VIROL, V62, P385, DOI 10.1099/0022-1317-62-2-385; SIMPSON IA, 1986, ANNU REV BIOCHEM, V55, P1059, DOI 10.1146/annurev.biochem.55.1.1059	14	133	139	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16842	16846						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885610				2022-12-25	WOS:A1991GD63500094
J	COOK, RK; SHEFF, DR; RUBENSTEIN, PA				COOK, RK; SHEFF, DR; RUBENSTEIN, PA			UNUSUAL METABOLISM OF THE YEAST ACTIN AMINO TERMINUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DICTYOSTELIUM-DISCOIDEUM ACTIN; N-ALPHA-ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; NUCLEOTIDE-SEQUENCE; BINDING PROTEINS; ACID SEQUENCE; GENE; IDENTIFICATION; TRANSFORMATION; ACETYLATION	In this paper we have examined the post-translational modifications of the NH2 terminus of actin from the yeast Saccharomyces cerevisiae. Like actins examined previously, this actin contains an acetylated NH2 terminus. Actins in other organisms undergo a unique post-translational processing event in which the initial amino acid(s) are removed by an actin-specific processing enzyme in an acetylation-dependent reaction. This is defined as actin processing. In yeast, actin retains its initiator Met in vivo and is thus not processed even though a rat liver actin processing enzyme can process yeast actin in vitro. This lack of actin processing appears to be a general property of fungi, as the actin from three other species, Aspergillus nidulans, Schizosaccharomyces pombe, and Candida albicans are not NH2 terminally processed either. Yeast actin is a class I actin; its initiator Met directly precedes an acidic residue. We converted yeast actin to a class II species by inserting a Cys codon between the Met-1 and Asp-2 codons. In normal class II actins the Cys residue is removed as acetyl-Cys during processing. Neither the mutant actin nor chick beta-actin (a class I actin) are processed when expressed in yeast. S. cerevisiae thus appears to be also incapable of processing exogenous actins. Further study of the mutant actin containing a Cys at position 2 shows that 30-40% of this actin is stably unacetylated. This unacetylated actin does not have a shorter half-life than the acetylated form. From these studies we conclude that 1) NH2-terminal actin-specific processing is not required for actin function in yeast and three other fungi, 2) yeast are apparently incapable of processing any type of actin precursor, and 3) the stability of a yeast pseudo-class Il actin is not affected by the acetylation state of the NH2 terminus.	UNIV IOWA,COLL MED,DEPT BIOCHEM,IOWA CITY,IA 52242	University of Iowa				Rubenstein, Peter/0000-0003-1225-4414	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033689] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-33689] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; DOI Y, 1987, EUR J BIOCHEM, V164, P89, DOI 10.1111/j.1432-1033.1987.tb10997.x; DRUBIN DG, 1990, CELL MOTIL CYTOSKEL, V15, P7, DOI 10.1002/cm.970150103; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; FIDEL S, 1988, GENE, V70, P283, DOI 10.1016/0378-1119(88)90200-4; FIRTEL RA, 1979, P NATL ACAD SCI USA, V76, P6206, DOI 10.1073/pnas.76.12.6206; FYRBERG EA, 1981, CELL, V24, P107, DOI 10.1016/0092-8674(81)90506-7; GALLWITZ D, 1980, P NATL ACAD SCI-BIOL, V77, P2546, DOI 10.1073/pnas.77.5.2546; HAARER BK, 1990, CELL MOTIL CYTOSKEL, V17, P71, DOI 10.1002/cm.970170202; HAMADA H, 1982, P NATL ACAD SCI-BIOL, V79, P5901, DOI 10.1073/pnas.79.19.5901; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON GG, 1988, J BIOL CHEM, V263, P9079; JORNVALL H, 1975, J THEOR BIOL, V55, P1, DOI 10.1016/S0022-5193(75)80105-6; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KILMARTIN JV, 1984, J CELL BIOL, V98, P922, DOI 10.1083/jcb.98.3.922; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEE FJS, 1990, J BIOL CHEM, V265, P3603; LEE FJS, 1990, J BIOL CHEM, V265, P11576; LIU H, 1989, CELL, V57, P233, DOI 10.1016/0092-8674(89)90961-6; LIU HP, 1989, P NATL ACAD SCI USA, V86, P90, DOI 10.1073/pnas.86.1.90; LOSBERGER C, 1989, NUCLEIC ACIDS RES, V17, P9488, DOI 10.1093/nar/17.22.9488; MA H, 1987, GENE, V58, P201, DOI 10.1016/0378-1119(87)90376-3; MATSUURA S, 1981, P NATL ACAD SCI-BIOL, V78, P4368, DOI 10.1073/pnas.78.7.4368; MERTINS P, 1987, NUCLEIC ACIDS RES, V15, P7369, DOI 10.1093/nar/15.18.7369; MOERSCHELL RP, 1990, J BIOL CHEM, V265, P19638; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; NG R, 1980, P NATL ACAD SCI-BIOL, V77, P3912, DOI 10.1073/pnas.77.7.3912; NOVICK P, 1985, CELL, V40, P405, DOI 10.1016/0092-8674(85)90154-0; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; PELHAM HRB, 1976, EUR J BIOCHEM, V67, P247, DOI 10.1111/j.1432-1033.1976.tb10656.x; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; REDMAN K, 1981, J BIOL CHEM, V256, P3226; REDMAN KL, 1985, J BIOL CHEM, V260, P4857; RUBENSTEIN P, 1981, J BIOL CHEM, V256, P8149; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P3961; RUBENSTEIN PA, 1983, J BIOL CHEM, V258, P1354; RUBENSTEIN PA, 1986, MICROBIOLOGY, P283; SHEFF DR, 1989, J BIOL CHEM, V264, P11491; Sherman F., 1986, METHODS YEAST GENETI; SHORTLE D, 1982, SCIENCE, V217, P371, DOI 10.1126/science.7046050; STRAUCH AR, 1984, J BIOL CHEM, V259, P7224; SUTOH K, 1984, BIOCHEMISTRY-US, V23, P6757, DOI 10.1021/bi00321a073; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P3654, DOI 10.1021/bi00258a020; SUTOH K, 1986, BIOCHEMISTRY-US, V25, P435, DOI 10.1021/bi00350a024; VANDEKERCKHOVE J, 1978, J MOL BIOL, V126, P783, DOI 10.1016/0022-2836(78)90020-7; VANDEKERCKHOVE J, 1981, EUR J BIOCHEM, V113, P595, DOI 10.1111/j.1432-1033.1981.tb05104.x; WARING RB, 1989, GENE, V79, P119, DOI 10.1016/0378-1119(89)90097-8; ZAKUT R, 1982, NATURE, V298, P857, DOI 10.1038/298857a0; ZECHEL K, 1980, EUR J BIOCHEM, V110, P343, DOI 10.1111/j.1432-1033.1980.tb04873.x	49	62	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16825	16833						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885608				2022-12-25	WOS:A1991GD63500092
J	NYGARD, O; NILSSON, A; CARLBERG, U; NILSSON, L; AMONS, R				NYGARD, O; NILSSON, A; CARLBERG, U; NILSSON, L; AMONS, R			PHOSPHORYLATION REGULATES THE ACTIVITY OF THE EEF-2-SPECIFIC CA-2+-DEPENDENT AND CALMODULIN-DEPENDENT PROTEIN KINASE-III	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ELONGATION FACTOR-II; MR 100,000 SUBSTRATE; STEROID-RECEPTORS; ALPHA-SUBUNIT; TRANSPLANTATION ANTIGEN; MAMMALIAN-TISSUES; CASEIN KINASE; RAT-LIVER; BINDING	The activity of the eukaryotic elongation factor 2 (eEF-2)-specific Ca2+- and calmodulin-dependent protein kinase III (CaM PK III) is regulated by phosphorylation. The kinase can be inactivated by treatment with alkaline phosphatase and subsequently reactivated by an endogenous protein kinase. This kinase can be substituted for by the catalytic subunit of cAMP-dependent protein kinase but not by casein kinase II. The purified kinase preparation contains only one protein as judged by gel electrophoresis. This protein has a molecular mass of approximately 90 kDa and an isoelectric point of 5.2. Reactivation of the eEF-2 kinase is associated with the phosphorylation of this protein. The amino acid sequence obtained from the 90-kDa protein reveals substantial homology with that of murine heat shock protein 86 (HSP 86) a member of the HSP 90-family. Conventional preparations of HSP 90 contain an inactive eEF-2 kinase that could be activated after dephosphorylation and phosphorylation by the catalytic subunit of cAMP-dependent protein kinase.	LEIDEN UNIV,DEPT MED BIOCHEM,2300 RA LEIDEN,NETHERLANDS	Leiden University; Leiden University - Excl LUMC	NYGARD, O (corresponding author), UNIV STOCKHOLM,ARRHENIUS LABS E5,DEPT ZOOL CELL BIOL,S-10691 STOCKHOLM,SWEDEN.							BAULIEU EE, 1987, J CELL BIOCHEM, V35, P161, DOI 10.1002/jcb.240350209; BENSAUDE O, 1983, EMBO J, V2, P173, DOI 10.1002/j.1460-2075.1983.tb01401.x; BINART N, 1989, BIOCHEM BIOPH RES CO, V159, P140, DOI 10.1016/0006-291X(89)92415-7; BLACKSHEAR PJ, 1988, FASEB J, V2, P2957, DOI 10.1096/fasebj.2.14.2972578; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAHILL AL, 1988, NEUROSCI LETT, V84, P345, DOI 10.1016/0304-3940(88)90533-2; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DEDMAN JR, 1977, J BIOL CHEM, V252, P8415; DOUGHERTY JJ, 1987, BIOCHIM BIOPHYS ACTA, V927, P74, DOI 10.1016/0167-4889(87)90067-X; GESCHWENDT M, 1989, FEBS LETT, V257, P357; HATHAWAY GM, 1979, J BIOL CHEM, V254, P762; HUNTER T, 1987, CELL, V50, P823, DOI 10.1016/0092-8674(87)90509-5; IWASAKI M, 1989, BIOCHIM BIOPHYS ACTA, V992, P1, DOI 10.1016/0304-4165(89)90043-3; JANSSEN GMC, 1988, J BIOL CHEM, V263, P11063; JOVE R, 1987, CELL, V50, P937, DOI 10.1016/0092-8674(87)90520-4; KOYASU S, 1986, P NATL ACAD SCI USA, V83, P8054, DOI 10.1073/pnas.83.21.8054; KUDLICKI W, 1987, J BIOL CHEM, V262, P9695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI Y, 1986, P NATL ACAD SCI USA, V83, P4253, DOI 10.1073/pnas.83.12.4253; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; LOEWE PN, 1982, BIOORG CHEM, V11, P55; MACKIE KP, 1989, J BIOL CHEM, V264, P1748; MILLER SG, 1986, CELL, V44, P861, DOI 10.1016/0092-8674(86)90008-5; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; NAIRN AC, 1987, J BIOL CHEM, V262, P14265; NILSSON A, 1991, EUR J BIOCHEM, V195, P377, DOI 10.1111/j.1432-1033.1991.tb15716.x; NILSSON L, 1984, BIOCHIM BIOPHYS ACTA, V782, P49, DOI 10.1016/0167-4781(84)90105-2; NISHIDA E, 1986, J BIOL CHEM, V261, P6033; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PAIN VM, 1986, BIOCHEM J, V235, P625, DOI 10.1042/bj2350625; PALFREY HC, 1983, FEBS LETT, V157, P183, DOI 10.1016/0014-5793(83)81142-9; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; ROADES RE, 1988, TRENDS BIOCHEM SCI, V13, P52; ROSE DW, 1987, BIOCHEMISTRY-US, V26, P6583, DOI 10.1021/bi00395a003; ROSE DW, 1989, J BIOL CHEM, V264, P6239; ROSEN OM, 1983, P NATL ACAD SCI-BIOL, V80, P3237, DOI 10.1073/pnas.80.11.3237; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; RYAZANOV AG, 1988, BIOCHIMIE, V70, P619, DOI 10.1016/0300-9084(88)90245-3; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SITIKOV AS, 1988, FEBS LETT, V228, P327, DOI 10.1016/0014-5793(88)80025-5; SZYSZKA R, 1989, BIOCHEMISTRY-US, V28, P1435, DOI 10.1021/bi00430a001; THIEL G, 1988, P NATL ACAD SCI USA, V85, P6337, DOI 10.1073/pnas.85.17.6337; ULLRICH SJ, 1986, P NATL ACAD SCI USA, V83, P3121, DOI 10.1073/pnas.83.10.3121; WALSH DA, 1968, J BIOL CHEM, V243, P3763	50	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16425	16430						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885575				2022-12-25	WOS:A1991GD63500032
J	BORELLINI, F; HE, YF; AQUINO, A; YU, G; JOSEPHS, SF; GLAZER, RI				BORELLINI, F; HE, YF; AQUINO, A; YU, G; JOSEPHS, SF; GLAZER, RI			INCREASED DNA-BINDING AND TRANSCRIPTIONAL ACTIVITY ASSOCIATED WITH TRANSCRIPTION FACTOR-SP1 IN K562 CELLS TRANSFECTED WITH THE MYELOID-SPECIFIC C-FES TYROSINE KINASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HL-60 LEUKEMIA-CELLS; NF-KAPPA-B; DEPENDENT PROTEIN-KINASE; ONCOGENE EXPRESSION; CELLULAR ONCOGENES; GROWTH-FACTORS; MESSENGER-RNA; DIFFERENTIATION; ACTIVATION; IDENTIFICATION	Myeloblast cell line K562, when stably transfected with the human genomic c-fes sequence encoding a proto-oncogene tyrosine-protein kinase, acquires the characteristics of more mature granulocytic cells (WS-1 cells) and the ability to undergo differentiation (Yu, G., Smithgall, T. E., and Glazer, R. I. (1989) J. Biol. Chem. 264, 10276-1028 1). To explore the role of transcription factors in the differentiation process, WS-1 cells were analyzed for the presence of DNA-binding proteins capable of interacting with the 5'-long terminal repeat (LTR) region of human immunodeficiency virus (HIV)-l, that contains the binding sequences for transcription factors Sp1 and NF-kappa-B. Southwestern blotting and mobility shift assays revealed the presence of Sp1 in K562 and WS-1 cells. The DNA-binding activity of Sp1 was significantly greater in WS-1 cells than in K562 cells, despite the detection by immunoblotting of equivalent quantities and degrees of heterogeneity of Spl in both cell lines. DNA footprinting of the HIV-1 5'-LTR demonstrated that two of the three Sp1-binding sites and both NF-kappa-B binding sequences were protected by nuclear extracts from WS-1 cells, while no protection was afforded by nuclear extracts from K562 cells. Analysis of transcription in vitro by primer extension revealed enhanced initiation of transcription from the HIV-1 5'-LTR by nuclear extracts from WS-1 cells, but not from K562 cells. These data indicate that the response evoked by the c-fes tyrosine-protein kinase leads to enhanced DNA binding activity of Sp1 and NFKB, that results in the activation of transcription from the HIV-1 5'-LTR.	NCI,BIOL CHEM LAB,BALTIMORE,MD 21211; NCI,TUMOR CELL BIOL LAB,BALTIMORE,MD 21211; GEORGETOWN UNIV,MED CTR,VINCENT T LOMBARDI CANC RES CTR,WASHINGTON,DC 20007; GEORGETOWN UNIV,MED CTR,DEPT PHARMACOL,WASHINGTON,DC 20007	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University; Georgetown University								ALTON NK, 1979, NATURE, V282, P864, DOI 10.1038/282864a0; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BIRCHENALLROBERTS MC, 1990, MOL CELL BIOL, V10, P4978, DOI 10.1128/MCB.10.9.4978; BISHOP JM, 1985, CELL, V42, P23, DOI 10.1016/S0092-8674(85)80098-2; BODNER M, 1987, CELL, V50, P267, DOI 10.1016/0092-8674(87)90222-4; BORELLINI F, 1990, MOL CELL BIOL, V10, P541; CHAPEKAR MS, 1987, MOL PHARMACOL, V31, P140; COLLINS SJ, 1987, BLOOD, V70, P1233; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; EMILIA G, 1986, BRIT J HAEMATOL, V62, P287, DOI 10.1111/j.1365-2141.1986.tb02931.x; FELDMAN RA, 1985, P NATL ACAD SCI USA, V82, P2379, DOI 10.1073/pnas.82.8.2379; FERRARI S, 1985, BRIT J HAEMATOL, V59, P21, DOI 10.1111/j.1365-2141.1985.tb02959.x; FUJII M, 1989, MOL CELL BIOL, V9, P2493, DOI 10.1128/MCB.9.6.2493; GLAZER RI, 1986, BIOCHEM BIOPH RES CO, V140, P908, DOI 10.1016/0006-291X(86)90721-7; GRIFFIN GE, 1989, NATURE, V339, P70, DOI 10.1038/339070a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Heisig V, 1987, Haematol Blood Transfus, V31, P423; HELDIN CH, 1984, CELL, V37, P9, DOI 10.1016/0092-8674(84)90296-4; HENNIGHAUSEN L, 1987, METHOD ENZYMOL, V152, P721; HORI Y, 1990, ONCOGENE, V5, P1201; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; JONES KA, 1985, CELL, V42, P59; KOEFFLER HP, 1981, CANCER RES, V41, P919; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; MACDONALD I, 1985, MOL CELL BIOL, V5, P2543, DOI 10.1128/MCB.5.10.2543; MAEKAWA T, 1989, J BIOL CHEM, V264, P2826; MAVILIO F, 1986, P NATL ACAD SCI USA, V83, P4394, DOI 10.1073/pnas.83.12.4394; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MULLER R, 1986, TRENDS BIOCHEM SCI, V11, P129, DOI 10.1016/0968-0004(86)90066-6; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; ROEBROEK AJM, 1986, MOL BIOL REP, V11, P117, DOI 10.1007/BF00364823; SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; SLAMON DJ, 1984, SCIENCE, V224, P256, DOI 10.1126/science.6538699; SMITHGALL TE, 1988, J BIOL CHEM, V263, P15050; SMITHGALL TE, 1990, J NATL CANCER I, V83, P42; TRUS MD, 1982, J BIOL CHEM, V257, P2730; YARDEN Y, 1988, BIOCHEMISTRY-US, V27, P3113, DOI 10.1021/bi00409a001; YU G, 1988, MOL PHARMACOL, V33, P384; YU G, 1989, J BIOL CHEM, V264, P10276; YU G, 1987, J BIOL CHEM, V262, P17543	46	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15850	15854						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874737				2022-12-25	WOS:A1991GB97700051
J	GOLDKORN, T; DRESSLER, KA; MUINDI, J; RADIN, NS; MENDELSOHN, J; MENALDINO, D; LIOTTA, D; KOLESNICK, RN				GOLDKORN, T; DRESSLER, KA; MUINDI, J; RADIN, NS; MENDELSOHN, J; MENALDINO, D; LIOTTA, D; KOLESNICK, RN			CERAMIDE STIMULATES EPIDERMAL GROWTH-FACTOR RECEPTOR PHOSPHORYLATION IN A431 HUMAN EPIDERMOID CARCINOMA-CELLS - EVIDENCE THAT CERAMIDE MAY MEDIATE SPHINGOSINE ACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; GH3 PITUITARY-CELLS; PHORBOL ESTERS; HL-60 CELLS; SPHINGOMYELIN; DIFFERENTIATION; PHOSPHOTYROSINE; ANTIBODIES; LIVER	Recent studies suggest the existence of a signal transduction pathway involving sphingomyelin and derivatives (Kolesnick, R. N. (1989) J. Biol. Chem. 264, 7617-7623). The present studies compare effects of ceramide, sphingosine, and N,N-dimethylsphingosine on epidermal growth factor (EGF) receptor phosphorylation in A431 human epidermoid carcinoma cells. To increase ceramide solubility, a ceramide containing octanoic acid at the second position (C8-cer) was synthesized. C8-cer induced time- and concentration-dependent EGF receptor phosphorylation. This event was detectable by 2 min and maximal by 10 min. As little as 0.1-mu-M C8-cer was effective, and 3-mu-M C8-cer induced maximal phosphorylation to 1.9-fold of control. EGF (20 nM) increased phosphorylation to 2.1-fold of control. Sphingosine stimulated receptor phosphorylation over the same concentration range (0.033-mu-M) and to the same extent (1.8-fold of control) as ceramide. The effects of C8-cer and sphingosine were similar by three separate criteria, phosphoamino acid analysis, anti-phosphotyrosine antibody immunoblotting, and phosphopeptide mapping by high performance liquid chromatography. Phosphorylation occurred specifically on threonine residues. N,N'-Dimethylsphingosine, a potential derivative of sphingosine, was less effective. Since sphingosine and ceramide are interconvertible, the level of each compound was measured under conditions sufficient for EGF receptor phosphorylation. C8-cer (0.1-1-mu-M) induced dose-responsive elevation of cellular ceramide from 132 to 232 pmol.10(6) cells-1. In contrast, cellular sphingosine levels did not rise. This suggests that C8-cer acts without conversion to sphingosine. Exogenous sphingosine (0.1-1-mu-M) also increased cellular ceramide levels to 227 pmol.10(6) cells-1, but did not increase its own cellular level of 12 pmol.10(6) cells-1. Higher sphingosine concentrations that induced no further increase in EGF receptor phosphorylation produced very large elevations in cellular sphingosine. Hence, at effective concentrations, both compounds elevated cellular ceramide but not sphingosine levels. Additional studies performed with [H-3]sphingosine demonstrated that cells contain substantially less NN-dimethyl-sphingosine than free sphingosine and, during short term incubation, convert less than 5% of added sphingosine to N,N-dimethylsphingosine. These studies provide evidence that ceramide may have bioeffector properties and suggest sphingosine may act in part by conversion to ceramide.	UNIV MICHIGAN,MENTAL HLTH RES INST,ANN ARBOR,MI 48104; EMORY UNIV,DEPT CHEM,ATLANTA,GA 30322	University of Michigan System; University of Michigan; Emory University	GOLDKORN, T (corresponding author), CORNELL UNIV,MED CTR,COLL MED,SLOAN KETTERING INST,DIV MOLEC PHARMACOL & THERAPEUT,NEW YORK,NY 10021, USA.				NCI NIH HHS [R01-CA-42385] Funding Source: Medline; NICHD NIH HHS [HD 07406] Funding Source: Medline; NINDS NIH HHS [NS 03192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042385] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS003192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS RJ, 1988, J BIOL CHEM, V263, P5373; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; FAUCHER M, 1988, J BIOL CHEM, V263, P5319; HANNUN YA, 1987, SCIENCE, V235, P670, DOI 10.1126/science.3101176; IGARASHI Y, 1990, J BIOL CHEM, V265, P5385; JEFFERSON AB, 1988, J BIOL CHEM, V263, P15241; KALLER H, 1961, BIOCHEM Z, V334, P451; KIM MY, 1991, J BIOL CHEM, V266, P484; KISHIMOTO Y, 1983, ENZYMES, V16, P357; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1987, J BIOL CHEM, V262, P16759; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; KRIS RM, 1985, CELL, V40, P619, DOI 10.1016/0092-8674(85)90210-7; MERRILL AH, 1988, ANAL BIOCHEM, V171, P373, DOI 10.1016/0003-2697(88)90500-3; NIMKAR S, 1988, TETRAHEDRON LETT, V29, P3037, DOI 10.1016/0040-4039(88)85079-2; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NORTHWOOD IC, 1988, J BIOL CHEM, V263, P7540; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; SCHNEIDER EG, 1973, J BIOL CHEM, V248, P3739; SLIFE CW, 1989, J BIOL CHEM, V264, P10371; SUNADA H, 1985, ANAL BIOCHEM, V149, P438, DOI 10.1016/0003-2697(85)90595-0; VUNNAM RR, 1979, BIOCHIM BIOPHYS ACTA, V573, P73, DOI 10.1016/0005-2760(79)90174-7; WILSON E, 1988, J BIOL CHEM, V263, P9304; WINICOV I, 1988, J BIOL CHEM, V263, P12179; ZIPPEL R, 1986, BIOCHIM BIOPHYS ACTA, V881, P54, DOI 10.1016/0304-4165(86)90096-6	26	156	159	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16092	16097						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874747				2022-12-25	WOS:A1991GB97700085
J	HEYDUK, T; MICHALCZYK, R; KOCHMAN, M				HEYDUK, T; MICHALCZYK, R; KOCHMAN, M			LONG-RANGE EFFECTS AND CONFORMATIONAL FLEXIBILITY OF ALDOLASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT-MUSCLE ALDOLASE; FRUCTOSE-1,6-BISPHOSPHATE ALDOLASE; SUBUNIT STRUCTURE; THIOL-GROUPS; REACTIVITY; RESIDUES; DISSOCIATION; RESOLUTION; SITE	The conformational flexibility and long-range interactions in rabbit muscle aldolase induced by active-site ligand binding, cross-linking of the enzyme between Cys72 and Cys338, and removal of the C-terminal tyrosine residue were studied by following the changes in the microenvironments of Cys239 and Cys289 located outside the active site. It was found that substrates induced a conformational change in aldolase, which propagates from the active site to Cys239, which is located close to intersubunit contacts. The response of the enzyme is differential. Ligands having both C-1 and C-6 phosphates or C-1 phosphate only induce the enhancement of Cys239 reactivity, whereas those with C-6 phosphates only decrease Cys239 reactivity. This correlates well with a dramatic difference in kinetic parameters for a cleavage of fructose-1,6-P2 and fructose-1-P. Therefore, these changes can be interpreted as syncatalytic. Cross-linking of the aldolase subunit by an -S-S- bridge between Cys72 and Cys338 inactivates the enzyme, abolishes binding of active-site ligands, and induces a conformational change in the enzyme that can be detected far away (at Cys239 and Cys289) from the site of perturbation. Cys72 and Cys338 are not in the active site. This shows that the region of the active site and the environment of Cys72 and Cys338 are tightly coupled and that residues far away from the active site, through such coupling, can possess properties of active-site residues. Similar, although less dramatic changes are observed upon removal of the C-terminal tyrosine residue. In view of the results obtained in this paper, aldolase seems to be quite a flexible molecule, whose conformation is sensitive to the nature of a substrate bound to the enzyme and is able to transmit the information about a local perturbation over long distances within a molecule.			HEYDUK, T (corresponding author), WROCLAW TECH UNIV,INST ORGAN & PHYS CHEM,DIV BIOCHEM,PL-50370 WROCLAW,POLAND.			Michalczyk, Ryszard/0000-0001-8839-6473				ADELMAN RC, 1968, ARCH BIOCHEM BIOPHYS, V126, P343, DOI 10.1016/0003-9861(68)90590-0; ANDERSON PJ, 1970, BIOCHEM J, V117, P291, DOI 10.1042/bj1170291; BARANOWSKI T, 1949, J BIOL CHEM, V180, P543; Birchmeier W, 1977, Methods Enzymol, V46, P41; BRENNERHOLZACH O, 1982, J BIOL CHEM, V257, P1747; BUCZYLKO J, 1980, COMP BIOCHEM PHYS B, V67, P225, DOI 10.1016/0305-0491(80)90136-4; CROWDER AL, 1973, BIOCHEMISTRY-US, V12, P2078, DOI 10.1021/bi00735a009; DEAL WC, 1963, BIOCHEMISTRY-US, V2, P246, DOI 10.1021/bi00902a007; EAGLES PAM, 1969, J MOL BIOL, V45, P533, DOI 10.1016/0022-2836(69)90310-6; EFTINK MR, 1981, ANAL BIOCHEM, V114, P199, DOI 10.1016/0003-2697(81)90474-7; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GINSBURG A, 1966, BIOCHEMISTRY-US, V5, P2623, DOI 10.1021/bi00872a021; GORYUNOV A I, 1969, Biofizika, V14, P1116; GRAZI E, 1974, BIOCHIM BIOPHYS ACTA, V364, P120, DOI 10.1016/0005-2744(74)90139-9; GUHA A, 1971, ARCH BIOCHEM BIOPHYS, V147, P692, DOI 10.1016/0003-9861(71)90429-2; HEIDNER EG, 1971, SCIENCE, V171, P677, DOI 10.1126/science.171.3972.677; HEYDUK T, 1986, BIOCHIM BIOPHYS ACTA, V874, P337, DOI 10.1016/0167-4838(86)90033-6; HEYDUK T, 1986, BIOCHIM BIOPHYS ACTA, V874, P365, DOI 10.1016/0167-4838(86)90036-1; HEYDUK T, 1985, EUR J BIOCHEM, V151, P337, DOI 10.1111/j.1432-1033.1985.tb09106.x; Horecker B. L, 1972, ENZYMES, P213, DOI DOI 10.1016/S1874-6047(08)60450-3; HUDSON EN, 1973, BIOCHEMISTRY-US, V12, P4154, DOI 10.1021/bi00745a019; JOHNSON ML, 1985, METHOD ENZYMOL, V117, pR301; KASPRZAK AA, 1980, EUR J BIOCHEM, V104, P443, DOI 10.1111/j.1432-1033.1980.tb04446.x; KASPRZAK AA, 1980, THESIS TU WROCLAW; KAWAHARA T, 1966, BIOCHEMISTRY-US, V5, P1578; KENT CD, 1984, BIOCHEMISTRY-US, V23, P5257, DOI 10.1021/bi00317a025; KOBASHI K, 1967, ARCH BIOCHEM BIOPHYS, V121, P178, DOI 10.1016/0003-9861(67)90022-7; KOCHMAN M, 1974, FEBS LETT, V41, P104, DOI 10.1016/0014-5793(74)80964-6; KOPPITZ B, 1986, EUR J BIOCHEM, V161, P421, DOI 10.1111/j.1432-1033.1986.tb10462.x; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LAI CY, 1974, SCIENCE, V183, P1204, DOI 10.1126/science.183.4130.1204; LIEBMAN MN, 1986, ENZYME, V36, P115, DOI 10.1159/000469283; MILLAR DB, 1971, NATURE-NEW BIOL, V230, P117, DOI 10.1038/newbio230117a0; MILLAR JR, 1981, PHILOS T ROY SOC B, V293, P209, DOI 10.1098/rstb.1981.0074; PALCZEWSKI K, 1985, EUR J BIOCHEM, V146, P309, DOI 10.1111/j.1432-1033.1985.tb08654.x; PALCZEWSKI K, 1987, BIOCHEMISTRY-US, V26, P3466, DOI 10.1021/bi00386a033; PALCZEWSKI K, 1983, EUR J BIOCHEM, V137, P429, DOI 10.1111/j.1432-1033.1983.tb07846.x; PENHOET E, 1967, BIOCHEMISTRY-US, V6, P2940, DOI 10.1021/bi00861a039; PENHOET EE, 1969, BIOCHEMISTRY-US, V8, P4391, DOI 10.1021/bi00839a025; PENHOET EE, 1971, J BIOL CHEM, V246, P318; PERIANA RA, 1980, J AM CHEM SOC, V102, P3923, DOI 10.1021/ja00531a040; RUDOLPH R, 1976, EUR J BIOCHEM, V67, P455, DOI 10.1111/j.1432-1033.1976.tb10710.x; SAWYER L, 1972, Journal of Molecular Biology, V71, P503, DOI 10.1016/0022-2836(72)90365-8; STEINMAN HM, 1970, BIOCHEMISTRY-US, V9, P4360; STELLWAGEN E, 1962, BIOCHEMISTRY-US, V1, P1056, DOI 10.1021/bi00912a016; SUSOR WA, 1969, SCIENCE, V165, P1260, DOI 10.1126/science.165.3899.1260; SYGUSCH J, 1987, P NATL ACAD SCI USA, V84, P7846, DOI 10.1073/pnas.84.22.7846; TAKAHASHI I, 1989, J BIOCHEM, V105, P281, DOI 10.1093/oxfordjournals.jbchem.a122654; WESTHEAD EW, 1963, BIOCHEMISTRY-US, V2, P927, DOI 10.1021/bi00905a006; WLSON JM, 1980, J AM CHEM SOC, V102, P359	50	25	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15650	15655						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874722				2022-12-25	WOS:A1991GB97700021
J	KOMALAVILAS, P; ZHU, JK; NOTHNAGEL, EA				KOMALAVILAS, P; ZHU, JK; NOTHNAGEL, EA			ARABINOGALACTAN-PROTEINS FROM THE SUSPENSION-CULTURE MEDIUM AND PLASMA-MEMBRANE OF ROSE CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYPROLINE-RICH GLYCOPROTEIN; PLANT PROTOPLAST AGGLUTINATION; RYEGRASS ENDOSPERM CELLS; PHASEOLUS-VULGARIS L; ACID-CHROMIC ACID; TOBACCO CELLS; LOLIUM-MULTIFLORUM; BETA-LECTINS; CARBOHYDRATE ANTIGENS; NICOTIANA-TABACUM	Arabinogalactan-proteins (AGPs) that bind to beta-glycosyl Yariv antigens have been purified from the culture medium and plasma membrane of "Paul's Scarlet" rose cells. Starting from culture medium or from plasma membrane vesicles prepared by aqueous two-phase partitioning, the purification procedure involved Yariv antigen-induced precipitation and subsequent chromatographic steps. Two fractions, AGP (a) and AGP-(b), were obtained from the culture medium, and one AGP fraction was obtained from the plasma membrane. The glycosyl compositions of all three fractions were dominated by arabinosyl and galactosyl residues and included glucuronosyl and other minor residues. Methylation analysis showed that AGP-(a) and AGP-(b) were both highly branched 3,6-galactans with terminal arabinofuranosyl substituents. The amino acid compositions of all three AGPs were high in alanine, hydroxyproline, and serine and/or threonine. The amino-terminal sequence of AGP-(b) contained an alanine-hydroxyproline repeat. While sharing general structural similarity, the AGPs from the plasma membrane and the culture medium were distinguishable by composition and by size and charge, with the plasma membrane AGPs being larger and more negatively charged than the culture medium AGPs.	UNIV CALIF RIVERSIDE,DEPT BOT & PLANT SCI,RIVERSIDE,CA 92521	University of California System; University of California Riverside			Zhu, Jian-Kang/F-7658-2011	Zhu, Jian-Kang/0000-0001-5134-731X	NATIONAL CENTER FOR RESEARCH RESOURCES [S07RR007010] Funding Source: NIH RePORTER; NCRR NIH HHS [2 S07 RR07010-22] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AKIYAMA Y, 1984, AGR BIOL CHEM TOKYO, V48, P235, DOI 10.1080/00021369.1984.10866126; AKIYAMA Y, 1981, PHYTOCHEMISTRY, V20, P2507, DOI 10.1016/0031-9422(81)83083-X; Albertsson P A, 1982, Methods Biochem Anal, V28, P115, DOI 10.1002/9780470110485.ch2; ANDERSON RL, 1977, AUST J PLANT PHYSIOL, V4, P143, DOI 10.1071/PP9770143; Ashwell G., 1966, METHODS ENZYMOLOGY, V8, P85; ASPINALL GO, 1968, J CHEM SOC C, P2174, DOI 10.1039/j39680002174; ASPINALL GO, 1969, CAN J BIOCHEM CELL B, V47, P1063, DOI 10.1139/o69-170; Bacic A., 1988, BIOCHEM PLANT, V14, P297, DOI [DOI 10.1016/B978-0-08-092615-5.50014-X, 10.1016/B978-0-08-092615-5.50014-X]; BISHOP CT, 1957, CAN J CHEM, V35, P1010, DOI 10.1139/v57-138; BLAKENEY AB, 1983, CARBOHYD RES, V113, P291, DOI 10.1016/0008-6215(83)88244-5; BOSS WF, 1979, PLANT PHYSIOL, V64, P1005, DOI 10.1104/pp.64.6.1005; CARTIER N, 1987, CARBOHYD RES, V168, P275, DOI 10.1016/0008-6215(87)80030-7; CHAPLIN MF, 1982, ANAL BIOCHEM, V123, P336, DOI 10.1016/0003-2697(82)90455-9; CLARKE A, 1979, P NATL ACAD SCI USA, V76, P3358, DOI 10.1073/pnas.76.7.3358; CLARKE AE, 1978, AUST J PLANT PHYSIOL, V5, P707, DOI 10.1071/PP9780707; CLARKE AE, 1979, PHYTOCHEMISTRY, V18, P521, DOI 10.1016/S0031-9422(00)84255-7; CLARKE AE, 1975, J CELL SCI, V19, P157; DUPENHOAT CH, 1987, CARBOHYD RES, V165, P31, DOI 10.1016/0008-6215(87)80075-7; FINCHER GB, 1983, ANNU REV PLANT PHYS, V34, P47, DOI 10.1146/annurev.pp.34.060183.000403; Gallagher JT, 1989, CURR OPIN CELL BIOL, V1, P1201, DOI 10.1016/S0955-0674(89)80072-9; GALLAGHER SR, 1982, PLANT PHYSIOL, V70, P1335, DOI 10.1104/pp.70.5.1335; GLEESON PA, 1989, BIOCHEM J, V264, P857, DOI 10.1042/bj2640857; GRUBER PJ, 1984, PROTOPLASMA, V121, P34, DOI 10.1007/BF01279750; GUIDOTTI G, 1972, ANNU REV BIOCHEM, V41, P731, DOI 10.1146/annurev.bi.41.070172.003503; HAHN MG, 1987, PLANTA, V171, P453, DOI 10.1007/BF00392292; Hames BD., 1990, GEL ELECTROPHORESIS, P1; HORI H, 1977, PHYTOCHEMISTRY, V16, P1485, DOI 10.1016/0031-9422(77)84005-3; HORI H, 1980, PHYTOCHEMISTRY, V19, P2755, DOI 10.1016/S0031-9422(00)83958-8; JERMYN M A, 1975, Australian Journal of Plant Physiology, V2, P501; JERMYN MA, 1978, AUST J PLANT PHYSIOL, V5, P697, DOI 10.1071/PP9780697; JERMYN MA, 1978, AUST J PLANT PHYSIOL, V5, P687; JOSELEAU JP, 1977, CARBOHYD RES, V58, P165, DOI 10.1016/S0008-6215(00)83412-6; KAWASAKI S, 1987, PLANT CELL PHYSIOL, V28, P925, DOI 10.1093/oxfordjournals.pcp.a077375; KAWASAKI S, 1987, PLANT CELL PHYSIOL, V28, P187; KNOX JP, 1989, PROTOPLASMA, V152, P123, DOI 10.1007/BF01323071; KOMALAVILAS P, 1989, CARBOHYD RES, V189, P261, DOI 10.1016/0008-6215(89)84102-3; KVERNHEIM AL, 1987, ACTA CHEM SCAND B, V41, P150, DOI 10.3891/acta.chem.scand.41b-0150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARKIN PJ, 1978, J CELL SCI, V30, P283; LARKIN PJ, 1977, J CELL SCI, V26, P31; LARSSON C, 1987, METHOD ENZYMOL, V148, P558; MARCHESI VT, 1971, SCIENCE, V174, P1247, DOI 10.1126/science.174.4015.1247; MASCARA T, 1982, AUST J PLANT PHYSIOL, V9, P31, DOI 10.1071/PP9820031; MORT AJ, 1983, ANAL BIOCHEM, V133, P380, DOI 10.1016/0003-2697(83)90098-2; NAGAHASHI G, 1978, PLANT PHYSIOL, V61, P993, DOI 10.1104/pp.61.6.993; NESIUS KK, 1972, PLANTA, V106, P173, DOI 10.1007/BF00383997; NORMAN PM, 1990, PLANTA, V181, P365, DOI 10.1007/BF00195889; NOTHNAGEL EA, 1986, PLANT PHYSIOL, V80, P91, DOI 10.1104/pp.80.1.91; PENNELL RI, 1990, NATURE, V344, P547, DOI 10.1038/344547a0; PENNELL RI, 1989, J CELL BIOL, V108, P1967, DOI 10.1083/jcb.108.5.1967; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRESTIDGE RL, 1979, ANAL BIOCHEM, V97, P95, DOI 10.1016/0003-2697(79)90332-4; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RAY PM, 1969, P NATL ACAD SCI USA, V64, P605, DOI 10.1073/pnas.64.2.605; ROLAND JC, 1972, STAIN TECHNOL, V47, P195, DOI 10.3109/10520297209116484; SAMSON MR, 1983, PLANTA, V159, P322, DOI 10.1007/BF00393170; SHOWALTER AM, 1989, BIOCH PLANTS, V15, P485; SNOW LD, 1977, ARCH BIOCHEM BIOPHYS, V179, P690, DOI 10.1016/0003-9861(77)90158-8; SOJAR HT, 1987, METHOD ENZYMOL, V138, P341; SPURR AR, 1969, J ULTRA MOL STRUCT R, V26, P31, DOI 10.1016/S0022-5320(69)90033-1; SWEET DP, 1975, CARBOHYD RES, V40, P217, DOI 10.1016/S0008-6215(00)82604-X; VANHOLST GJ, 1981, PLANT PHYSIOL, V68, P910, DOI 10.1104/pp.68.4.910; VANHOLST GJ, 1986, PLANT PHYSIOL, V80, P786, DOI 10.1104/pp.80.3.786; WALKO RM, 1987, PROTOPLASMA, V141, P33, DOI 10.1007/BF01276786; WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23; YARIV J, 1962, BIOCHEM J, V85, P383, DOI 10.1042/bj0850383; YARIV J, 1967, BIOCHEM J, V105, pC1; ZHU JK, 1991, ANAL BIOCHEM, V195, P101, DOI 10.1016/0003-2697(91)90302-A	68	112	117	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15956	15965						10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874742				2022-12-25	WOS:A1991GB97700066
J	MAY, E; JENKINS, JR; MAY, P				MAY, E; JENKINS, JR; MAY, P			ENDOGENOUS HELA P53 PROTEINS ARE EASILY DETECTED IN HELA-CELLS TRANSFECTED WITH MOUSE DELETION MUTANT P53 GENE	ONCOGENE			English	Article							T-ANTIGEN; ONCOGENE	It has been reported [Matlashewski et al. (1986). Eur. J. Biochem., 154, 665-6721 that HeLa cells contain no detectable p53 protein, although they contain p53 mRNA which is translationally active. Here it is shown that endogenous HeLa p53 proteins were easily detected in HeLa cells transiently expressing mouse deletion mutant p53 gene after transfection with the appropriate recombinant plasmid. This detection was obtained by immunoprecipitation coupled with SDS-PAGE as well as by Western blotting experiments. Our results strongly suggest that HeLa p53 mRNA is actually translated in vivo, generating an extremely unstable p53 protein. Considering that the HeLa cell line is a HPV-18-positive human cervical carcinoma cell line, this high instability of HeLa p53 proteins is in keeping with the finding that E6 oncoprotein encoded by human papillomavirus 16 or 18 promotes the degradation of p53 proteins [Scheffner et al. (1990). Cell, 63, 1129-1136].	MARIE SKLODOWSKA CURIE MEM INST,OXTED RH8 0TL,SURREY,ENGLAND		MAY, E (corresponding author), INST RECH SCI CANC,7 RUE GUY MOQUET,F-94801 VILLEJUIF,FRANCE.							CULLEN BR, 1986, CELL, V46, P973, DOI 10.1016/0092-8674(86)90696-3; DURST M, 1987, P NATL ACAD SCI USA, V84, P1070, DOI 10.1073/pnas.84.4.1070; ELIYAHU D, 1988, ONCOGENE, V3, P313; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GURNEY EG, 1980, J VIROL, V34, P752, DOI 10.1128/JVI.34.3.752-763.1980; JENKINS JR, 1988, J VIROL, V62, P3903, DOI 10.1128/JVI.62.10.3903-3906.1988; MATLASHEWSKI G, 1986, EUR J BIOCHEM, V154, P665, DOI 10.1111/j.1432-1033.1986.tb09449.x; MAY E, 1991, VIROLOGY, V180, P285, DOI 10.1016/0042-6822(91)90033-8; ROMANO JW, 1989, ONCOGENE, V4, P1483; ROVINSKI B, 1988, ONCOGENE, V2, P445; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8	11	37	39	0	3	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1363	1365						3	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886712				2022-12-25	WOS:A1991GX27200011
J	NARINDRASORASAK, S; LOWERY, D; GONZALEZDEWHITT, P; POORMAN, RA; GREENBERG, B; KISILEVSKY, R				NARINDRASORASAK, S; LOWERY, D; GONZALEZDEWHITT, P; POORMAN, RA; GREENBERG, B; KISILEVSKY, R			HIGH-AFFINITY INTERACTIONS BETWEEN THE ALZHEIMERS BETA-AMYLOID PRECURSOR PROTEINS AND THE BASEMENT-MEMBRANE FORM OF HEPARAN-SULFATE PROTEOGLYCAN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRIL PROTEIN; SENILE PLAQUES; SYSTEMIC AMYLOIDOSIS; COMMON CONSTITUENT; MESSENGER-RNAS; DOWNS-SYNDROME; DISEASE; DOMAIN; EXPRESSION; BRAIN	High affinity interactions were studied between the basement membrane form of heparan sulfate proteoglycan (HSPG) and the 695-, 751-, and 770-amino acid Alzheimer amyloid precursor (AAP) proteins. Based on quantitative analyses of binding data, we identified single binding sites for the HSPG on AAP-695 (K(d) = 9 x 10(-10) M), AAP-751 (K(d) = 10 x 10(-9) M), and AAP-770 (K(d) = 9 x 10(-9) M). It is postulated that the "Kunitz" protease inhibitor domain which is present in AAP-751 and -770 reduces the affinity of AAPs for the HSPG through steric hindrance and/or conformational alteration. HSPG binding was inhibited by heparin and dextran sulfate, but not by dermatan or chondroitin sulfate. HSPG protein core, obtained by heparitinase digestion, also bound to the beta-amyloid precursor proteins with high affinity, indicating that the high affinity binding site is constituted by the polypeptide chain rather than the carbohydrate moiety. The effects of various cations on these interactions were also studied. Our results suggest that specific interactions between the AAP proteins and the extracellular matrix may be involved in the nucleation stages of Alzheimer's disease type amyloidogenesis.	UPJOHN CO,KALAMAZOO,MI 49001	Pfizer	NARINDRASORASAK, S (corresponding author), QUEENS UNIV,KINGSTON GEN HOSP,SYL & MOLLY APPS RES CTR,DEPT PATHOL,KINGSTON K7L 3N6,ONTARIO,CANADA.			Lowery, David/0000-0001-5111-4719				ARAI H, 1990, P NATL ACAD SCI USA, V87, P2249, DOI 10.1073/pnas.87.6.2249; BREEN KC, 1991, J NEUROSCI RES, V28, P90, DOI 10.1002/jnr.490280109; BREEN KC, 1990, SOC NEUR ABSTR, V322, P787; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; CORNWELL GG, 1988, BIOCHEM BIOPH RES CO, V154, P648, DOI 10.1016/0006-291X(88)90188-X; ERICSSON LH, 1987, FEBS LETT, V218, P11, DOI 10.1016/0014-5793(87)81008-6; GEJYO F, 1985, BIOCHEM BIOPH RES CO, V129, P701, DOI 10.1016/0006-291X(85)91948-5; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V120, P885, DOI 10.1016/S0006-291X(84)80190-4; GLENNER GG, 1984, BIOCHEM BIOPH RES CO, V122, P1131, DOI 10.1016/0006-291X(84)91209-9; GOLDE TE, 1990, NEURON, V4, P253, DOI 10.1016/0896-6273(90)90100-T; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; GOLDGABER D, 1987, J NEURAL TRANSM, V24, P23; GOREVIC PD, 1985, J CLIN INVEST, V76, P2425, DOI 10.1172/JCI112257; HEREMANS A, 1990, J BIOL CHEM, V265, P8716; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KATO M, 1985, ANAL BIOCHEM, V148, P479, DOI 10.1016/0003-2697(85)90255-6; KISILEVSKY R, 1988, MED HYPOTHESES, V26, P231, DOI 10.1016/0306-9877(88)90125-9; KISILEVSKY R, 1987, CAN J PHYSIOL PHARM, V65, P1805, DOI 10.1139/y87-282; KITAGUCHI N, 1988, NATURE, V331, P530, DOI 10.1038/331530a0; KLIER FG, 1990, BRAIN RES, V515, P336, DOI 10.1016/0006-8993(90)90619-M; LEDBETTER SR, 1987, BIOCHEMISTRY-US, V26, P988, DOI 10.1021/bi00378a003; MCCUBBIN WD, 1988, BIOCHEM J, V256, P775, DOI 10.1042/bj2560775; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; NORLING B, 1988, CLIN EXP IMMUNOL, V73, P333; OHYAGI Y, 1990, BIOCHEM BIOPH RES CO, V167, P54, DOI 10.1016/0006-291X(90)91729-C; PALMERT MR, 1988, BIOCHEM BIOPH RES CO, V156, P432, DOI 10.1016/S0006-291X(88)80859-3; PERRY G, 1988, LANCET, V2, P746; PONTE P, 1988, NATURE, V331, P525, DOI 10.1038/331525a0; ROBAKIS NK, 1987, P NATL ACAD SCI USA, V84, P4190, DOI 10.1073/pnas.84.12.4190; SARAIVA MJM, 1984, J CLIN INVEST, V74, P104, DOI 10.1172/JCI111390; SELKOE DJ, 1989, NEUROBIOL AGING, V10, P387, DOI 10.1016/0197-4580(89)90072-9; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; SNOW AD, 1990, NEUROBIOL AGING, V11, P304; SNOW AD, 1987, LAB INVEST, V56, P120; SNOW AD, 1989, ACTA NEUROPATHOL, V78, P113, DOI 10.1007/BF00688198; SNOW AD, 1987, LAB INVEST, V57, P687; SNOW AD, 1988, AM J PATHOL, V133, P456; SNOW AD, 1990, LAB INVEST, V63, P601; SNOW AD, 1985, LAB INVEST, V53, P37; SNOW AD, 1988, AMYLOID AMYLOIDOSIS, P87; TAGLIAVINI F, 1990, LAB INVEST, V62, P761; TANZI RE, 1987, SCIENCE, V235, P880, DOI 10.1126/science.2949367; TANZI RE, 1988, NATURE, V331, P528, DOI 10.1038/331528a0; TATEOSTROFF B, 1989, P NATL ACAD SCI USA, V86, P745, DOI 10.1073/pnas.86.2.745; YAMAOKA K, 1981, J PHARMACOBIO-DYNAM, V4, P879, DOI 10.1248/bpb1978.4.879; YOUNG I, 1991, AMYLOID AND AMYLOIDOSIS 1990, P334; YOUNG ID, 1989, ACTA NEUROPATHOL, V78, P202, DOI 10.1007/BF00688210	47	211	229	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					12878	12883						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1906461				2022-12-25	WOS:A1991FX13200016
J	EMKEY, R; FREEDMAN, S; FEIG, LA				EMKEY, R; FREEDMAN, S; FEIG, LA			CHARACTERIZATION OF A GTPASE-ACTIVATING PROTEIN FOR THE RAS-RELATED RAL PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHORYLATION; BOVINE BRAIN; GENE-PRODUCT; GAP; P21; DOMAIN; PURIFICATION; STIMULATION; INTERACTS; CELLS	We have demonstrated the presence of a GTPase-activating protein (GAP) for the Ras-related Ral A protein in the cytosolic fraction of brain and testis. This protein, designated Ral-GAP, was distinguished from Ras-GAP by its behavior in two chromatography systems and by the fact that the two GAP proteins did not stimulate the GTPase activity of each others target GTP binding proteins. The lack of effect of Ral-GAP on Ras GTPase activity also distinguished it from the product of the neurofibromatosis gene NF-1. Ral-GAP also differed from Rho-GAP and Rap-GAP by virtue of its elution from a gel filtration column with proteins of M(r) greater than 10(6). This was likely an overestimate of the protein's molecular mass, however, since it sedimented in sucrose gradients between standard proteins of 150 and 443 kDa. Ral-GAP failed to promote the GTPase activity of mutant Ral proteins containing amino acid substitutions that in Ras lead to GAP-insensitive proteins.	TUFTS UNIV,DEPT BIOCHEM,HLTH SCI CAMPUS,BOSTON,MA 02111	Tufts University								ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; ELLIS C, 1990, NATURE, V343, P377, DOI 10.1038/343377a0; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; FRECH M, 1990, J BIOL CHEM, V265, P6353; GARRETT MD, 1989, J BIOL CHEM, V264, P10; GIBBS JB, 1990, J BIOL CHEM, V265, P20437; GIBBS JB, 1988, P NATL ACAD SCI USA, V85, P5026, DOI 10.1073/pnas.85.14.5026; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; KAPLAN DR, 1990, CELL, V61, P125, DOI 10.1016/0092-8674(90)90220-9; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MOLLOY CJ, 1989, NATURE, V342, P711, DOI 10.1038/342711a0; OLOFSSON B, 1988, ONCOGENE, V3, P231; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	26	55	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9703	9706						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903395				2022-12-25	WOS:A1991FM45900057
J	MALIK, RK; ROE, MW; BLACKSHEAR, PJ				MALIK, RK; ROE, MW; BLACKSHEAR, PJ			EPIDERMAL GROWTH-FACTOR AND OTHER MITOGENS INDUCE BINDING OF A PROTEIN COMPLEX TO THE C-FOS SERUM RESPONSE ELEMENT IN HUMAN ASTROCYTOMA AND OTHER CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3T3 CELLS; GEL-ELECTROPHORESIS; ANTISENSE RNA; EXPRESSION; ONCOGENE; TRANSCRIPTION; GENE; SEQUENCES; ACTIVATION; INSULIN	Rapid stimulation of c-fos transcription by many agonists requires the serum response element (SRE), which binds at least two distinct nuclear proteins, p67SRF and p62TCF. Using nuclear protein extracts from 1321-N1 human astrocytoma cells, we investigated ligand-induced changes in binding of these proteins to SRE probes. In these cells c-fos mRNA expression can be induced by epidermal growth factor (EGF) through protein kinase C-independent pathways and by phorbol esters through protein kinase C. We detected two DNA-protein complexes that formed specifically with the SRE (bands 1 and 2). Band 2 formation was increased 4-6 min after stimulation with EGF as well as serum and phorbol esters; this peaked at 10-30 min and returned to basal levels by 60 min. Induction of band 2 formation preceded the onset and peak accumulation of c-fos mRNA (15 and 30 min after EGF stimulation, respectively) and its return to basal levels (by 1-2 h). Band 2 formation was also increased in A431 cells stimulated with EGF and in HeLa and Swiss-3T3 cells stimulated with serum. We found that band 1 contained p67SRF bound to the SRE; band 2 contained p67SRF and a second protein. Gel shift analyses using [S-35]methionine-labeled p67SRF and nonradioactive DNA probes suggested that hormone treatment most likely modified the second protein component of band 2. Transient transfection of 1321-N1 cells with plasmids containing point mutations that prevented band 2 formation in vitro also abolished induction of c-fos transcription in vivo as assayed by RNase protection analysis. Thus, hormone-stimulated formation of the protein-DNA complex represented by band 2 may be involved in the activation of c-fos transcription.	DUKE UNIV,MED CTR,DEPT PEDIAT,DIV PEDIAT HEMATOL ONCOL,BOX 3897,DURHAM,NC 27710; DUKE UNIV,MED CTR,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT MED,DIV ENDOCRINOL METAB & GENET,DIABET & METAB SECT,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University; Duke University; Howard Hughes Medical Institute; Duke University; Duke University			Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529	NIDDK NIH HHS [R01 DK-40408] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040408] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BLACKSHEAR PJ, 1987, J BIOL CHEM, V262, P7774; BRAVO R, 1986, EMBO J, V5, P695, DOI 10.1002/j.1460-2075.1986.tb04269.x; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COCHRAN BH, 1984, SCIENCE, V226, P1080, DOI 10.1126/science.6093261; CURRAN T, 1985, SCIENCE, V229, P1265, DOI 10.1126/science.4035354; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FISCH TM, 1987, MOL CELL BIOL, V7, P3490, DOI 10.1128/MCB.7.10.3490; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GILMAN MZ, 1988, GENE DEV, V2, P394, DOI 10.1101/gad.2.4.394; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GREENBERG ME, 1985, J BIOL CHEM, V260, P4101; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; GREENBERG ME, 1986, MOL CELL BIOL, V6, P1050, DOI 10.1128/MCB.6.4.1050; HAYES TE, 1987, P NATL ACAD SCI USA, V84, P1272, DOI 10.1073/pnas.84.5.1272; HERRERA RE, 1989, NATURE, V340, P68, DOI 10.1038/340068a0; HOLT JT, 1986, P NATL ACAD SCI USA, V83, P4794, DOI 10.1073/pnas.83.13.4794; KRUIJER W, 1985, P NATL ACAD SCI USA, V82, P7330, DOI 10.1073/pnas.82.21.7330; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; KRUIJER W, 1986, J BIOL CHEM, V261, P7929; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MILBRANDT J, 1986, P NATL ACAD SCI USA, V83, P4789, DOI 10.1073/pnas.83.13.4789; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; NISHIKURA K, 1987, MOL CELL BIOL, V7, P639, DOI 10.1128/MCB.7.2.639; NORMAN C, 1988, CELL, V55, P89; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; PRYWES R, 1988, COLD SPRING HARB SYM, V53, P739, DOI 10.1101/SQB.1988.053.01.084; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RYAN WA, 1989, EMBO J, V8, P1785, DOI 10.1002/j.1460-2075.1989.tb03572.x; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; STUMPO DJ, 1988, J BIOL CHEM, V263, P1611; STUMPO DJ, 1986, P NATL ACAD SCI USA, V83, P9453, DOI 10.1073/pnas.83.24.9453; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WHITTAKER J, 1987, P NATL ACAD SCI USA, V84, P5237, DOI 10.1073/pnas.84.15.5237	38	54	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8576	8582						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1902475				2022-12-25	WOS:A1991FK44100092
J	ANDREWS, RK; FOX, JEB				ANDREWS, RK; FOX, JEB			INTERACTION OF PURIFIED ACTIN-BINDING PROTEIN WITH THE PLATELET MEMBRANE GLYCOPROTEIN-IB-IX COMPLEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR-BINDING; VEIN ENDOTHELIAL-CELLS; AMINO-ACID-SEQUENCE; ALPHA-CHAIN; CA-2+-DEPENDENT PROTEASE; IDENTIFICATION; PURIFICATION; SKELETON; MACROPHAGES; THROMBIN	The interaction of platelet membrane glycoprotein (GP) Ib-IX complex with the cytoplasmic membrane skeleton is potentially of major importance in regulating platelet function. Indirect evidence suggested that this interaction is mediated by actin-binding protein, but it is not known whether GP Ib-IX and actin-binding protein associate directly. To examine more closely the nature of this association, purified GP Ib-IX complex was specifically bound and oriented on the surface of impermeable polymer beads via a monoclonal antibody, AK 2, directed against the extracytoplasmic domain of GP Ib-alpha (glycocalicin). Binding was specific since 1) it was abolished by excess unlabeled actin-binding protein; 2) there was no detectable specific binding of radiolabeled actin-binding protein to beads coated with glycocalicin, the major extracytoplasmic proteolytic fragment of GP Ib-alpha; and 3) unlike actin-binding protein, there was no specific binding of bovine serum albumin or human platelet vinculin to the GP Ib-IX complex-coated beads. Binding of actin-binding protein to the GP Ib-IX complex-coated beads, but not to the glycocalicin-coated beads, was saturable and reversible (apparent K(d) = 1 x 10(-7) M). These experiments provide direct evidence that actin-binding protein can bind to the cytoplasmic domain of a membrane glycoprotein. Because actin-binding protein is found submembranously in cells other than the platelet, it is possible that this protein may link actin filaments to the plasma membrane in those cells.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,GLADSTONE FDN LABS CARDIOVASC DIS,POB 40608,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; The J David Gladstone Institutes					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030657, R23HL030657, R01HL030657] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30657] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews RK, 1990, CURR OPIN CELL BIOL, V2, P894, DOI 10.1016/0955-0674(90)90089-W; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8326, DOI 10.1021/bi00447a010; ASCH AS, 1988, J CLIN INVEST, V81, P1600, DOI 10.1172/JCI113494; BERNDT MC, 1985, EUR J BIOCHEM, V151, P637, DOI 10.1111/j.1432-1033.1985.tb09152.x; BERNDT MC, 1988, BIOCHEMISTRY-US, V27, P633, DOI 10.1021/bi00402a021; CARRAWAY KL, 1989, BIOCHIM BIOPHYS ACTA, V988, P147, DOI 10.1016/0304-4157(89)90017-8; DU XP, 1987, BLOOD, V69, P1524; EZZELL RM, 1988, J BIOL CHEM, V263, P13303; FOX JEB, 1987, BLOOD, V69, P537; FOX JEB, 1985, J BIOL CHEM, V260, P1060; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1988, J BIOL CHEM, V263, P4882; FOX JEB, 1985, J CLIN INVEST, V76, P1673, DOI 10.1172/JCI112153; FOX JEB, 1985, J BIOL CHEM, V260, P1970; FOX JEB, 1987, THROMB DIATH HAEMO, P175; GEORGE JN, 1988, BLOOD, V71, P1253; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; KONKLE BA, 1990, J BIOL CHEM, V265, P19833; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; MUSZBEK L, 1989, J BIOL CHEM, V264, P9716; OKITA JR, 1985, J CELL BIOL, V100, P317, DOI 10.1083/jcb.100.1.317; OTEY CA, 1990, J CELL BIOL, V111, P721, DOI 10.1083/jcb.111.2.721; ROSENFELD GC, 1985, J CELL BIOL, V100, P669, DOI 10.1083/jcb.100.3.669; SOLUM NO, 1989, THROMB HAEMOSTASIS, V62, P193; SPRANDIO JD, 1988, BLOOD, V71, P234; STENDAHL OI, 1980, J CELL BIOL, V84, P215, DOI 10.1083/jcb.84.2.215; VICENTE V, 1988, J BIOL CHEM, V263, P18473; WALLACH D, 1978, J BIOL CHEM, V253, P3328; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WEIHING RR, 1983, BIOCHEMISTRY-US, V22, P1839, DOI 10.1021/bi00277a015; WEISGRABER KH, 1981, J BIOL CHEM, V256, P9077; WICKI AN, 1985, EUR J BIOCHEM, V153, P1, DOI 10.1111/j.1432-1033.1985.tb09259.x; WICKI AN, 1987, EUR J BIOCHEM, V163, P43, DOI 10.1111/j.1432-1033.1987.tb10734.x	35	71	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 15	1991	266	11					7144	7147						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FG727	1901862				2022-12-25	WOS:A1991FG72700078
J	TORAYA, T; ISHIDA, A				TORAYA, T; ISHIDA, A			ROLES OF THE D-RIBOSE AND 5,6-DIMETHYLBENZIMIDAZOLE MOIETIES OF THE NUCLEOTIDE LOOP OF ADENOSYLCOBALAMIN IN MANIFESTATION OF COENZYMIC FUNCTION IN THE DIOL DEHYDRASE REACTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON-COBALT BOND; DIOLDEHYDRASE; MECHANISM; ANALOGS; BINDING; CLEAVAGE	Coenzyme analogs in which the D-ribose moiety of the nucleotide loop was replaced by an oligomethylene group and a trimethylene analog containing imidazole instead of 5,6-dimethylbenzimidazole were synthesized. Coordination of the 5,6-dimethylbenzimidazole to the cobalt atom in these analogs was much weaker than that in cobalamins. The replacement of this base with imidazole did not significantly alter the strength of the coordination to the cobalt atom. 5,6-Dimethylbenzimidazolyl trimethylene and tetramethylene and imidazolyl trimethylene analogs were partially active as coenzymes in the diol dehydrase reaction in this order as judged by k(cat), but the others were not active as coenzymes and were weak competitive inhibitors. This indicates that neither the alpha-D-ribofuranose ring nor the functional groups of the ribose moiety are essential for coenzymic function. There was an optimum loop size of the analogs for catalysis and for tight binding to the apoenzyme, which corresponds to the loop size of cobalamins. Therefore, the D-ribose moiety seems important as a spacer to keep the base in the proper position. The reaction with the imidazolyl trimethylene analog as coenzyme was accompanied with concomitant rapid inactivation during catalysis. The inactivation occurred only in the presence of substrate. Upon inactivation with this analog, 5'-deoxyadenosine and a B12r-like species were formed from the adenosyl group and the rest of the analog molecule, respectively, without modification of the apoenzyme. Therefore, it can be concluded that this is a kind of suicide inactivation which occurred from one of the intermediates in the normal catalytic process. The dimethylbenzo moiety of the regular coenzyme thus seems to play an important role in preventing the intermediate complexes from inactivation during catalysis.	OKAYAMA UNIV,FAC ENGN,DEPT BIOTECHNOL,OKAYAMA 700,JAPAN	Okayama University	TORAYA, T (corresponding author), KYOTO UNIV,COLL LIBERAL ARTS & SCI,DEPT CHEM,SAKYO KU,KYOTO 606,JAPAN.							Abeles R. H, 1966, METHODS ENZYMOLOGY, V9, P686; ABELES RH, 1976, ACCOUNTS CHEM RES, V9, P114, DOI 10.1021/ar50099a006; BABIOR BM, 1975, ACCOUNTS CHEM RES, V8, P376, DOI 10.1021/ar50095a003; BARKER HA, 1960, J BIOL CHEM, V235, P181; BRADY RO, 1961, BIOCHEM BIOPH RES CO, V4, P373, DOI 10.1016/0006-291X(61)90221-2; ESSENBERG MK, 1971, J AM CHEM SOC, V93, P1242; FRIEDRICH W, 1954, Z NATURFORSCH B, V9, P685; FRIEDRICH W, 1975, VITAMIN B12 VERWANDT, P289; HAYWARD GC, 1965, J CHEM SOC, P6485, DOI 10.1039/jr9650006485; ICHIKAWA M, 1988, BIOCHIM BIOPHYS ACTA, V952, P191, DOI 10.1016/0167-4838(88)90115-X; LEE HA, 1963, J BIOL CHEM, V238, P2367; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERVYN L., 1964, PROGR IND MICROBIOL, V5, P151; POZNANSKAJA AA, 1979, ARCH BIOCHEM BIOPHYS, V194, P379, DOI 10.1016/0003-9861(79)90630-1; PRATT JM, 1972, INORGANIC CHEM VITAM, P104; TENER GM, 1961, J AM CHEM SOC, V83, P159, DOI 10.1021/ja01462a032; TORAYA T, 1977, J BIOL CHEM, V252, P963; TORAYA T, 1985, ARCH BIOCHEM BIOPHYS, V242, P470, DOI 10.1016/0003-9861(85)90232-2; TORAYA T, 1986, J BIOL CHEM, V261, P9289; TORAYA T, 1983, J BIOL CHEM, V258, P9296; TORAYA T, 1976, BIOCHEM BIOPH RES CO, V69, P475, DOI 10.1016/0006-291X(76)90546-5; TORAYA T, 1980, ARCH BIOCHEM BIOPHYS, V203, P174, DOI 10.1016/0003-9861(80)90166-6; TORAYA T, 1988, BIOCHEMISTRY-US, V27, P7677, DOI 10.1021/bi00420a016; TORAYA T, 1987, J BIOL CHEM, V262, P8544; TORAYA T, 1979, BIOCHEMISTRY-US, V18, P417, DOI 10.1021/bi00570a005; TORAYA T, 1980, ADV CHEM SER, V191, P139; Toraya T., 1982, B12, P233; USHIO K, 1984, BIOCHIM BIOPHYS ACTA, V788, P318, DOI 10.1016/0167-4838(84)90044-X; WAGNER OW, 1966, J BIOL CHEM, V241, P1751	29	49	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 25	1991	266	9					5430	5437						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FD370	1900834				2022-12-25	WOS:A1991FD37000015
J	SANTACOLOMA, TA; REICHERT, LE				SANTACOLOMA, TA; REICHERT, LE			DETERMINATION OF ALPHA-SUBUNIT CONTACT REGIONS OF HUMAN FOLLICLE-STIMULATING-HORMONE BETA-SUBUNIT USING SYNTHETIC PEPTIDES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS PROGRAMS; AMINO-ACID SEQUENCE; GLYCOPROTEIN HORMONES; FOLLITROPIN BINDING; RECEPTOR-BINDING; LUTEINIZING-HORMONE; METHIONINE RESIDUES; LUTROPIN; THYROTROPIN; TESTIS	Follicle-stimulating hormone (FSH) is a glycoprotein hormone composed of two different subunits designated FSH-alpha and FSH-beta. Using synthetic peptides corresponding to the primary structure of human (h) FSH-beta subunit, we previously identified two regions of the beta-subunit, hFSH-(33-53) and hFSH-(81-95), as receptor binding regions. In this report, we tested the ability of synthetic peptides to interact with hFSH-alpha-subunit. Synthetic peptides corresponding to hFSH-beta-(11-25), (41-55), (51-65), and (101-111) were able to bind specifically radioiodinated hFSH-alpha-subunit, suggesting that they represent regions of interaction with the alpha-subunit. These experimental results were in agreement with the location of alpha-subunit contact regions predicted by sequence analysis. Peptides of hFSH-beta-subunit showing maximum specific binding to the alpha-subunit were those possessing minimum interaction with receptor whereas those not binding to alpha-subunit corresponded to regions shown to interact with receptor (hFSH-beta-(33-53) and hFSH-beta-(81-95). The hFSH-beta-subunit, therefore, seems to have two discontinuous receptor binding regions flanked by three alpha-subunit contact regions.			SANTACOLOMA, TA (corresponding author), UNION UNIV,DEPT BIOCHEM,ALBANY,NY 12208, USA.		Santa-Coloma, Tomas/I-1254-2019	Santa-Coloma, Tomas/0000-0002-3266-1095	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013938] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-13938] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDERSEN TT, 1983, MOL CELL ENDOCRINOL, V33, P37, DOI 10.1016/0303-7207(83)90055-2; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BONIFACE JJ, 1990, SCIENCE, V247, P61, DOI 10.1126/science.2104678; BURLEIGH BD, 1976, J BIOL CHEM, V251, P308; CHARLESWORTH MC, 1987, J BIOL CHEM, V262, P13409; CHENG KW, 1976, BIOCHEM J, V159, P79, DOI 10.1042/bj1590079; COLOMA TAS, 1990, J BIOL CHEM, V265, P5037; COLOMA TAS, 1990, BIOCHEMISTRY-US, V29, P1194, DOI 10.1021/bi00457a015; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; GIUDICE LC, 1978, BIOCHEM BIOPH RES CO, V81, P725, DOI 10.1016/0006-291X(78)91412-2; GOVERMAN JM, 1981, J BIOL CHEM, V256, P9431; HAYASHIZAKI Y, 1989, EMBO J, V8, P2291, DOI 10.1002/j.1460-2075.1989.tb08355.x; HOUGHTEN RA, 1985, P NATL ACAD SCI USA, V82, P5131, DOI 10.1073/pnas.82.15.5131; IJSSELMUIDEN OE, 1989, J IMMUNOL METHODS, V119, P35, DOI 10.1016/0022-1759(89)90378-5; JAMESON BA, 1988, COMPUT APPL BIOSCI, V4, P181; KEUTMANN HT, 1987, P NATL ACAD SCI USA, V84, P2038, DOI 10.1073/pnas.84.7.2038; KEUTMANN HT, 1989, MOL ENDOCRINOL, V3, P526, DOI 10.1210/mend-3-3-526; KUROSKY A, 1977, SCIENCE, V195, P299, DOI 10.1126/science.831277; MERRIFIELD RB, 1963, J AM CHEM SOC, V85, P2149, DOI 10.1021/ja00897a025; MORRIS JC, 1988, ENDOCRINOLOGY, V123, P456, DOI 10.1210/endo-123-1-456; PERNOLLET JC, 1976, BIOCHIM BIOPHYS ACTA, V446, P262, DOI 10.1016/0005-2795(76)90117-3; PIERCE JG, 1981, ANNU REV BIOCHEM, V50, P465, DOI 10.1146/annurev.bi.50.070181.002341; REICHERT LE, 1989, BIOL REPROD, V40, P13, DOI 10.1095/biolreprod40.1.13; RYAN RJ, 1987, RECENT PROG HORM RES, V43, P383; RYAN RJ, 1988, FASEB J, V2, P2661, DOI 10.1096/fasebj.2.11.2456242; SALESSE R, 1990, MOL CELL ENDOCRINOL, V68, P113, DOI 10.1016/0303-7207(90)90183-9; SANBORN BB, 1987, BIOCHEMISTRY-US, V26, P8196, DOI 10.1021/bi00399a026; SCHNEYER AL, 1986, ENDOCRINOLOGY, V119, P1446, DOI 10.1210/endo-119-4-1446; SHOME B, 1988, J PROTEIN CHEM, V7, P325, DOI 10.1007/BF01024882; SLUSS PM, 1986, BIOCHEMISTRY-US, V25, P2644, DOI 10.1021/bi00357a053; STENBERG M, 1988, J IMMUNOL METHODS, V113, P3, DOI 10.1016/0022-1759(88)90376-6; STEWART M, 1977, J MOL BIOL, V116, P175, DOI 10.1016/0022-2836(77)90126-7; Ward D.N., 1979, ANIMAL MODELS RES FE, P151; WATKINS PC, 1987, DNA-J MOLEC CELL BIO, V6, P205, DOI 10.1089/dna.1987.6.205; WEARE JA, 1979, J BIOL CHEM, V254, P6972; WOLF H, 1988, COMPUT APPL BIOSCI, V4, P187; WONDISFORD FE, 1988, J BIOL CHEM, V263, P12538	37	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 15	1991	266	5					2759	2762						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EX600	1899663				2022-12-25	WOS:A1991EX60000016
J	NICKLIN, MJH; CASARI, G				NICKLIN, MJH; CASARI, G			A SINGLE SITE MUTATION IN A TRUNCATED FOS PROTEIN ALLOWS IT TO INTERACT WITH THE TRE INVITRO	ONCOGENE			English	Article							DNA-BINDING DOMAIN; LEUCINE ZIPPER; C-JUN; GCN4; TRANSCRIPTION; SPECIFICITY; HETERODIMER; COMMON; C/EBP; AP-1	The Fos and Jun proteins, which are components of the transcription factor AP1, associate through the interaction of their so-called leucine zipper domains and bind strongly and specifically to DNA at phorbol esterresponsive elements. Jun also homodimerizes and binds the same element whereas Fos seems to have no specific affinity for DNA. We show that a single amino-acid change in the leucine zipper of Fos is sufficient to allow a truncated Fos protein to homodimerize and thus form a complex with DNA, even in the absence of Jun. This Fos-derived homodimer recognizes the consensus phorbol-ester responsive element specifically, in vitro. We conclude that the structural requirements for specific DNA binding are present in the Fos protein itself, with the exception of its lack of self-affinity.			NICKLIN, MJH (corresponding author), FORSCHUNGSINST MOLEK PATHOL,DR BOHR GASSE 7,A-1030 VIENNA,AUSTRIA.			Nicklin, Martin/0000-0002-0127-1131				AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; ANGEL P, 1988, NATURE, V332, P166, DOI 10.1038/332166a0; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BENBROOK DM, 1990, ONCOGENE, V5, P295; BOHMANN D, 1989, CELL, V59, P709, DOI 10.1016/0092-8674(89)90017-2; CURRAN T, 1984, CELL, V36, P259; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GLASS CK, 1989, CELL, V59, P697, DOI 10.1016/0092-8674(89)90016-0; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; HALAZONETIS TD, 1988, CELL, V55, P917, DOI 10.1016/0092-8674(88)90147-X; HOPE IA, 1987, EMBO J, V6, P2781, DOI 10.1002/j.1460-2075.1987.tb02573.x; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KOUZARIDES T, 1989, NATURE, V340, P568, DOI 10.1038/340568a0; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LEE W, 1987, CELL, V49, P741, DOI 10.1016/0092-8674(87)90612-X; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NAKABEPPU Y, 1989, EMBO J, V8, P3833, DOI 10.1002/j.1460-2075.1989.tb08561.x; NEUBERG M, 1989, NATURE, V341, P243, DOI 10.1038/341243a0; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V245, P646, DOI 10.1126/science.2503872; PARKS GD, 1986, J VIROL, V60, P376, DOI 10.1128/JVI.60.2.376-384.1986; SMEAL T, 1989, GENE DEV, V3, P2091, DOI 10.1101/gad.3.12b.2091; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VANDERWERF S, 1986, P NATL ACAD SCI USA, V83, P2330; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088	31	26	26	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	JAN	1991	6	1					173	179						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	EY039	1899479				2022-12-25	WOS:A1991EY03900026
J	VINCENT, JB; CROWDER, MW; AVERILL, BA				VINCENT, JB; CROWDER, MW; AVERILL, BA			EVIDENCE FOR A PHOSPHORYL-ENZYME INTERMEDIATE IN PHOSPHATE ESTER HYDROLYSIS BY PURPLE ACID-PHOSPHATASE FROM BOVINE SPLEEN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PHOSPHOTYROSYL-PROTEIN PHOSPHATASE; BEEF SPLEEN; ACTIVE-SITE; PURIFICATION; UTEROFERRIN; BINDING; RESIDUE	The possibility of the existence of a covalent enzyme-phosphoryl intermediate, E-PO3, during catalysis of phosphate ester hydrolysis by the purple acid phosphatase (PAP) from bovine spleen has been examined. Transphosphorylation experiments show that up to 22% of the phosphoryl group from p-nitrophenyl phosphate (PNPP) can be transferred to primary alcohols. Burst experiments at high pH (9.1 or 8.1 for reduced or oxidized PAP, respectively), where hydrolysis of a phosphoenzyme intermediate is expected to be rate-limiting, show clear evidence for stoichiometric bursts of p-nitrophenolate from PNPP. The formation of base-stable, acid-sensitive adducts between PAP and the (PO3)-P-32 group of [gamma-P-32]ATP has been demonstrated. The pH dependence of the kinetics parameters for reduced PAP has been determined over the range pH 3-8; a feature with a pK-alpha of approximately 6.75 that is attributable to the enzyme-substrate complex is observed. Taken together, the present results are consistent with a two-stem pseudo Uni Bi mechanism that utilizes a covalent enzyme-phosphoryl intermediate, possibly a phosphohistidine.	UNIV VIRGINIA,DEPT CHEM,CHARLOTTESVILLE,VA 22901	University of Virginia					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013500, R01GM032117] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 32117, GM 13500] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAZAN JF, 1989, P NATL ACAD SCI USA, V86, P9642, DOI 10.1073/pnas.86.24.9642; BENDER ML, 1967, J CHEM EDUC, V44, P84, DOI 10.1021/ed044p84; BUCHWALD SL, 1984, J BIOL CHEM, V259, P2208; BURMAN S, 1986, BIOCHEM BIOPH RES CO, V136, P490, DOI 10.1016/0006-291X(86)90467-5; CAMPBELL HD, 1978, BIOCHEM BIOPH RES CO, V82, P615, DOI 10.1016/0006-291X(78)90919-1; DAVID SS, 1990, J AM CHEM SOC, V112, P6455, DOI 10.1021/ja00174a001; DAVIS JC, 1981, BIOCHEMISTRY-US, V20, P4062, DOI 10.1021/bi00517a018; Doi K., 1988, STRUCT BONDING BERLI, V70, P1; HULTQUIS.DE, 1968, BIOCHIM BIOPHYS ACTA, V153, P329, DOI 10.1016/0005-2728(68)90078-9; HULTQUIST DE, 1966, BIOCHEMISTRY-US, V5, P322, DOI 10.1021/bi00865a041; HUNT DF, 1987, BIOCHEM BIOPH RES CO, V144, P1154, DOI 10.1016/0006-291X(87)91432-X; IGARASHI M, 1970, BIOCHIM BIOPHYS ACTA, V220, P85, DOI 10.1016/0005-2744(70)90231-7; KOMKOVA AI, 1982, 1ST ALL UN BIOPH C S, V1, P137; LAU KHW, 1987, J BIOL CHEM, V262, P1389; MCTIGUE JJ, 1978, BIOCHIM BIOPHYS ACTA, V523, P407, DOI 10.1016/0005-2744(78)90043-8; OSTROWSKI W, 1973, BIOCHEMISTRY-US, V12, P3893, DOI 10.1021/bi00744a016; REIZER J, 1984, J BACTERIOL, V160, P333, DOI 10.1128/JB.160.1.333-340.1984; REZYAPKIN V I, 1985, Biokhimiya, V50, P1067; VANETTEN RL, 1977, BIOCHIM BIOPHYS ACTA, V484, P386, DOI 10.1016/0005-2744(77)90094-8; VANETTEN RL, 1977, ARCH BIOCHEM BIOPHYS, V183, P250, DOI 10.1016/0003-9861(77)90438-6; VANETTEN RL, 1982, ANN NY ACAD SCI, V390, P27; VINCENT JB, 1991, BIOCHEMISTRY-US, V30, P3025, DOI 10.1021/bi00226a007; VINCENT JB, 1990, FASEB J, V4, P3009, DOI 10.1096/fasebj.4.12.2394317; ZHANG ZY, 1990, ARCH BIOCHEM BIOPHYS, V282, P39, DOI 10.1016/0003-9861(90)90084-C; ZHANG ZY, 1991, J BIOL CHEM, V266, P1516	25	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 25	1991	266	27					17737	17740						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GG553	1917918				2022-12-25	WOS:A1991GG55300005
J	DOUCET, JP; TUANA, BS				DOUCET, JP; TUANA, BS			IDENTIFICATION OF LOW-MOLECULAR-WEIGHT GTP-BINDING PROTEINS AND THEIR SITES OF INTERACTION IN SUBCELLULAR-FRACTIONS FROM SKELETAL-MUSCLE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM CHANNELS; SODIUM DODECYL-SULFATE; JUNCTIONAL FOOT PROTEIN; SARCOPLASMIC-RETICULUM; DIHYDROPYRIDINE RECEPTOR; ENDOPLASMIC-RETICULUM; RAS P21; GLYCOLYTIC-ENZYMES; MUSCARINIC RECEPTORS; GEL-ELECTROPHORESIS	The presence of low molecular weight GTP-binding proteins was investigated in subcellular fractions from skeletal muscle. Skeletal muscle homogenate, transverse tubules, triads, sarcoplasmic reticulum membranes, and cytosol fractions were separated in sodium dodecyl sulfate-gel electrophoresis and blotted onto nitrocellulose. The presence of GTP-binding proteins was explored by incubation of these blots with [alpha-P-32]GTP. GTP labeled two polypeptides of M(r) = 23,000 and 29,000 in all the fractions examined. Binding of [alpha-P-32]GTP was specific and dependent on Mg2+. The 23-kDa polypeptide was labeled to a higher extent with [alpha-P-32]GTP than the 29-kDa polypeptide, although both were enriched in transverse tubule fractions. A GTP-binding polypeptide of 40 kDa was also enriched in transverse tubule preparations and identified as G(i)alpha by immunostaining with anti-G(i)alpha. Using a blot overlay approach and [alpha-P-32]GTP-labeled cytosolic components, several polypeptides were identified that interact with the 23- and 29-kDa GTP-binding proteins. Among these components were polypeptides of M(r) = 60,000, 47,000, 44,000, 42,000, and 38,000, which were mainly of cytosolic origin but also associated with triads and transverse tubule membranes. The 47-, 44-, 42-, and 38-kDa polypeptides were found to be structurally related to the glycolytic enzymes enolase, 3-phosphoglyceric phosphokinase, aldolase, and glyceraldehyde-3-phosphate dehydrogenase, respectively. The purified glycolytic enzymes specifically bound the 23- and 29-kDa GTP-binding proteins under both denaturing and nondenaturing conditions. The association of the GTP-binding proteins with these polypeptides was resistant to detergents such as 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid (CHAPS), Triton X-100, and Tween. A 23-kDa GTP-binding protein purified from chromaffin cells bound to a 157-kDa polypeptide in triads and chromaffin cell membranes. The 157-kDa polypeptide was a minor component in these membranes and not related to the subunits of the dihydropyridine receptor. In view of the proposed function of low molecular weight GTP-binding proteins in processes such as membrane communication and secretion coupling, the association of these proteins with transverse tubules and triads in skeletal muscle is discussed in terms of a role in signal transmission.	UNIV OTTAWA,FAC MED,DEPT PHARMACOL,OTTAWA K1H 8M5,ONTARIO,CANADA	University of Ottawa								BECKERS CJM, 1989, J CELL BIOL, V108, P1245, DOI 10.1083/jcb.108.4.1245; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BIELINSKI DF, 1989, J BIOL CHEM, V264, P18363; BOKOCH GM, 1988, FEBS LETT, V227, P67; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRANDT NR, 1990, J MEMBRANE BIOL, V113, P237, DOI 10.1007/BF01870075; BREITWIESER GE, 1985, NATURE, V317, P538, DOI 10.1038/317538a0; BURGOYNE RD, 1989, FEBS LETT, V245, P122, DOI 10.1016/0014-5793(89)80204-2; CARLIN RK, 1981, J CELL BIOL, V89, P449, DOI 10.1083/jcb.89.3.449; CHANG JP, 1986, J BIOL CHEM, V261, P9105; CLARKE FM, 1980, BIOCHEM J, V186, P105, DOI 10.1042/bj1860105; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CURTIS BM, 1984, BIOCHEMISTRY-US, V23, P3492; DAWSON AP, 1989, CELL CALCIUM, V10, P343, DOI 10.1016/0143-4160(89)90060-2; DIVIRGILIO F, 1986, EMBO J, V5, P259, DOI 10.1002/j.1460-2075.1986.tb04207.x; DOLPHIN A, 1988, TRENDS NEUROSCI, V1, P287; DOUCET JP, 1990, ANAL BIOCHEM, V190, P209, DOI 10.1016/0003-2697(90)90182-9; DOUCET JP, 1988, ANAL BIOCHEM, V168, P265, DOI 10.1016/0003-2697(88)90317-X; DOUCET JP, 1989, FEBS LETT, V247, P127, DOI 10.1016/0014-5793(89)81254-2; DROBAK BK, 1988, BIOCHEM BIOPH RES CO, V150, P899, DOI 10.1016/0006-291X(88)90713-9; DUNN SMJ, 1989, J BIOL CHEM, V264, P11053; EDELSTEIN MG, 1988, BIOCHEMISTRY-US, V27, P1818; FRANZINI.C, 1970, J CELL BIOL, V47, P488, DOI 10.1083/jcb.47.2.488; GERSHONI JM, 1983, ANAL BIOCHEM, V131, P1, DOI 10.1016/0003-2697(83)90128-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAMILTON SL, 1989, BIOCHEMISTRY-US, V28, P7820, DOI 10.1021/bi00445a044; HARTZELL HC, 1986, NATURE, V323, P273, DOI 10.1038/323273a0; HESCHELER J, 1987, NATURE, V325, P445, DOI 10.1038/325445a0; HILDALGO C, 1986, BIOCHIM BIOPHYS ACTA, V855, P89; HOLZ GG, 1986, NATURE, V319, P670, DOI 10.1038/319670a0; HUBBARD MJ, 1987, J BIOL CHEM, V262, P15062; IMAGAWA T, 1987, J BIOL CHEM, V262, P16636; INUI M, 1987, J BIOL CHEM, V262, P1740; KIM KC, 1990, BIOCHEMISTRY-US, V29, P9281, DOI 10.1021/bi00491a025; KOJIMA I, 1986, FEBS LETT, V204, P347, DOI 10.1016/0014-5793(86)80841-9; KOPPITZ B, 1986, EUR J BIOCHEM, V161, P421, DOI 10.1111/j.1432-1033.1986.tb10462.x; KURACHI Y, 1986, AM J PHYSIOL, V251, pH681, DOI 10.1152/ajpheart.1986.251.3.H681; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; LANOIX J, 1989, BIOCHEM J, V262, P497, DOI 10.1042/bj2620497; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0; MEISSNER G, 1984, J BIOL CHEM, V259, P2365; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MITCHELL RD, 1983, J CELL BIOL, V96, P1008, DOI 10.1083/jcb.96.4.1008; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; MURPHY BJ, 1990, MOL PHARMACOL, V37, P173; NAGAHARA H, 1987, BIOCHEM BIOPH RES CO, V149, P686, DOI 10.1016/0006-291X(87)90422-0; NGSEE JK, 1990, J NEUROSCI, V10, P317; PFAFFINGER PJ, 1985, NATURE, V317, P536, DOI 10.1038/317536a0; PIERCE GN, 1985, J BIOL CHEM, V260, P6862; PINES M, 1985, P NATL ACAD SCI USA, V82, P4095, DOI 10.1073/pnas.82.12.4095; POLONIS VR, 1987, ARCH BIOCHEM BIOPHYS, V254, P541, DOI 10.1016/0003-9861(87)90135-4; RIOS E, 1987, NATURE, V325, P717, DOI 10.1038/325717a0; ROBINSON A, 1987, FEBS LETT, V218, P63, DOI 10.1016/0014-5793(87)81019-0; ROSEMBLATT MS, 1989, MOL CELL BIOCHEM, V87, P57, DOI 10.1007/BF00421083; SCOTT RH, 1986, NEUROSCI LETT, V69, P59, DOI 10.1016/0304-3940(86)90414-3; SCOTT RH, 1987, NATURE, V330, P760, DOI 10.1038/330760a0; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; TANABE T, 1987, NATURE, V328, P313, DOI 10.1038/328313a0; TANABE T, 1988, NATURE, V336, P134, DOI 10.1038/336134a0; TANIMOTO T, 1988, FEBS LETT, V226, P291, DOI 10.1016/0014-5793(88)81442-X; TOUTANT M, 1988, BIOCHEM J, V254, P405, DOI 10.1042/bj2540405; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TRIFARO JM, 1980, NEUROSCIENCE, V5, P1533, DOI 10.1016/0306-4522(80)90018-4; TUANA BS, 1988, MOL CELL BIOCHEM, V80, P133; TUANA BS, 1988, FEBS LETT, V235, P219, DOI 10.1016/0014-5793(88)81266-3; VILLAZ M, 1989, CELL SIGNAL, V1, P493, DOI 10.1016/0898-6568(89)90034-X; WAKELAM MJO, 1986, NATURE, V323, P173, DOI 10.1038/323173a0; WALSH TP, 1981, BIOCHIM BIOPHYS ACTA, V675, P29, DOI 10.1016/0304-4165(81)90066-0; YATANI A, 1987, SCIENCE, V238, P1288, DOI 10.1126/science.2446390; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YATANI A, 1989, SCIENCE, V245, P71, DOI 10.1126/science.2544999	78	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17613	17620						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1910047				2022-12-25	WOS:A1991GF44500094
J	JUVONEN, RO; IWASAKI, M; NEGISHI, M				JUVONEN, RO; IWASAKI, M; NEGISHI, M			STRUCTURAL FUNCTION OF RESIDUE-209 IN COUMARIN 7-HYDROXYLASE (P450COH) - ENZYME-KINETIC STUDIES AND SITE-DIRECTED MUTAGENESIS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; STEROID 15-ALPHA-HYDROXYLASE; SUBSTRATE-SPECIFICITY; II P-45015-ALPHA; AMINO-ACID; CYTOCHROME-P-450; CDNA; 7-ETHOXYCOUMARIN; CYTOCHROMES-P450; IDENTIFICATION	Residue-209 plays a critical role in determining the substrate and product specificity of cytochrome P450coh. In order to investigate further the structural function of residue-209 in coumarin 7-hydroxylase reaction, we measured the enzyme-kinetic properties of wild-type P450coh and its mutants in which residue-209 was substituted with various amino acids. In general, the K(m) and V(max) values for coumarin increased as the size of residue-209 became smaller and V(max) values decreased. The size of residue-209, therefore, was a principle factor determining K(m), K(d), and V(max) values of P450coh. Although the polarity and charge also increased the K(m) value consistently, they altered V(max) and K(d) values in an irregular manner. The substitution of serine for residue-209 increased the V(max), while the substitution of lysine decreased it. Coumarin 7-hydroxylase activity was inhibited weakly by indan, but competitively and strongly by 2-coumaranone. Moreover, K(i) values for the inhibitor were similar to K(m) values of the corresponding, mutated P450s. The results indicate, therefore, that residue-209 is localized in a proposed substrate-binding sequence 1 which binds to the 2-keto group of coumarin and directs its 7-position toward the sixth ligand of heme. Consequently, the identity of residue-209 determines not only the binding of coumarin in P450coh, but also the other reaction step(s) of coumarin 7-hydroxylation.	NIEHS,REPROD & DEV TOXICOL LAB,PHARMACOGENET SECT,POB 12233,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Negishi, Masahiko/F-7805-2019	Negishi, Masahiko/0000-0002-2076-8928				AITIO A, 1978, ANAL BIOCHEM, V85, P488, DOI 10.1016/0003-2697(78)90245-2; EDWARDS RJ, 1989, BIOCHEMISTRY-US, V28, P3762, DOI 10.1021/bi00435a021; FUJIIKURIYAMA Y, 1982, P NATL ACAD SCI-BIOL, V79, P2793, DOI 10.1073/pnas.79.9.2793; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; GIBSON GG, 1984, XENOBIOTICA, V14, P27, DOI 10.3109/00498258409151397; IMAI M, 1989, P NATL ACAD SCI USA, V86, P7823, DOI 10.1073/pnas.86.20.7823; IMAI Y, 1989, BIOCHEM BIOPH RES CO, V158, P717, DOI 10.1016/0006-291X(89)92780-0; IWASAKI M, 1991, J BIOL CHEM, V266, P3380; JEFCOATE F, 1978, METHOD ENZYMOL, V52, P255; JUVONEN RO, 1988, EUR J BIOCHEM, V171, P205, DOI 10.1111/j.1432-1033.1988.tb13777.x; LANGE R, 1988, EUR J BIOCHEM, V172, P189, DOI 10.1111/j.1432-1033.1988.tb13872.x; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; NEGISHI M, 1989, BIOCHEMISTRY-US, V28, P4169, DOI 10.1021/bi00436a007; NELSON DR, 1989, BIOCHEMISTRY-US, V28, P656, DOI 10.1021/bi00428a036; OEDA K, 1985, DNA-J MOLEC CELL BIO, V4, P203, DOI 10.1089/dna.1985.4.203; OMURA T, 1964, J BIOL CHEM, V239, P2370; POMPON D, 1989, GENE, V83, P15, DOI 10.1016/0378-1119(89)90399-5; POULOS TL, 1989, NATURE, V339, P580, DOI 10.1038/339580a0; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; RAAG R, 1989, BIOCHEMISTRY-US, V28, P917, DOI 10.1021/bi00428a077; SHIMIZU T, 1991, BIOCHEMISTRY-US, V30, P1490, DOI 10.1021/bi00220a007	22	68	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16431	16435						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885576				2022-12-25	WOS:A1991GD63500033
J	GETTYS, TW; RAMKUMAR, V; UHING, RJ; SEGER, L; TAYLOR, IL				GETTYS, TW; RAMKUMAR, V; UHING, RJ; SEGER, L; TAYLOR, IL			ALTERATIONS IN MESSENGER-RNA LEVELS, EXPRESSION, AND FUNCTION OF GTP-BINDING REGULATORY PROTEINS IN ADIPOCYTES FROM OBESE MICE (C57BL 6J-OB OB)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSINE RECEPTOR AGONIST; ADENYLATE-CYCLASE ACTIVITY; EPIDIDYMAL ADIPOSE-TISSUE; OB/OB MICE; GI-ALPHA; PHOSPHORYLATION STATE; HYPERGLYCEMIC MICE; PLASMA-MEMBRANES; RAT ADIPOCYTES; ZUCKER RATS	Messenger RNA levels for the alpha-subunit of G-proteins expressed in adipocytes of lean and obese (ob/ob) mice were compared with relative levels of the encoded proteins. Using both toxin labeling and Western blots, expression of G(s-alpha), G(i-alpha-1), and G(i-alpha-3) was decreased by approximately 2-fold in adipocytes of obese mice, while levels of G(i-alpha-2) did not differ between the phenotypes. The decreases in G(i-alpha-1) and G(s-alpha) in the obese mouse were attributed to decreased mRNA levels for these proteins. Similar mRNA levels for G(i-alpha-3) were noted in both phenotypes, but G(i-alpha-2) message was increased 2-fold in the obese mouse. Inhibitory regulation of adipocyte adenylylcyclase through G-proteins was evaluated by comparing the ability of R-PIA to inhibit isoproterenol-stimulated responses between the phenotypes. In spite of the decrease in G(i-alpha-1) and G(i-alpha-3) in adipocytes from obese mice, R-PIA inhibited adenylylcyclase, cAMP-dependent protein kinase, and lipolysis in similar fashion in both phenotypes. The GTP analog, Gpp(NH)p also inhibited forskolin-stimulated adenylylcyclase in a comparable manner, but the magnitude of the inhibition was slightly less in adipocyte membranes from obese mice. In contrast, the decrease in expression of G(s-alpha) was translated into substantially poorer activation of isoproterenol-stimulated responses in the obese mouse. The concentration of isoproterenol producing half-maximal activation of adenylylcyclase, protein kinase, and lipolysis did not differ between the phenotypes, but the maximal responses were much lower in cells from obese mice. Similar lipolytic potential in isolated adipocytes from each phenotype and similar total forskolin-stimulated cyclase activity in adipocyte membranes from each phenotype suggest that decreased expression of G(s-alpha) may contribute to the characteristic alteration in mobilization of triglycerides noted in adipocytes from obese mice.	DUKE UNIV, MED CTR, DEPT MED, DIV GASTROENTEROL, POB 3913, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT PATHOL, DURHAM, NC 27710 USA; VET ADM MED CTR, DURHAM, NC 27705 USA	Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Gettys, Thomas W/N-1964-2017	Gettys, Thomas W/0000-0001-7125-7995	NIDDK NIH HHS [DK 38216, DK 42486] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038216, R29DK042486] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEEBE SJ, 1984, J BIOL CHEM, V259, P3359; BEGINHEICK N, 1988, MOL CELL ENDOCRINOL, V59, P187, DOI 10.1016/0303-7207(88)90103-7; BEGINHEICK N, 1987, MOL CELL ENDOCRINOL, V53, P1, DOI 10.1016/0303-7207(87)90185-7; BEGINHEICK N, 1977, CAN J PHYSIOL PHARM, V55, P1320, DOI 10.1139/y77-177; BEGINHEICK N, 1980, CAN J BIOCHEM CELL B, V58, P1033, DOI 10.1139/o80-140; BEGINHEICK N, 1985, J BIOL CHEM, V260, P6187; BEGINHEICK N, 1990, BIOCHEM J, V268, P83, DOI 10.1042/bj2680083; BEGINHEICK N, 1984, CAN J BIOCHEM CELL B, V62, P819, DOI 10.1139/o84-104; BIRNBAUMER L, 1988, COLD SPRING HARB SYM, V53, P229, DOI 10.1101/SQB.1988.053.01.029; BRAY GA, 1971, PHYSIOL REV, V51, P598, DOI 10.1152/physrev.1971.51.3.598; BUSHFIELD M, 1990, BIOCHEM J, V271, P365, DOI 10.1042/bj2710365; BUSHFIELD M, 1990, EUR J BIOCHEM, V192, P537, DOI 10.1111/j.1432-1033.1990.tb19258.x; DEHAYE JP, 1977, DIABETOLOGIA, V13, P553, DOI 10.1007/BF01236307; DEHAYE JP, 1978, DIABETOLOGIA, V15, P45, DOI 10.1007/BF01219328; DEMAZANCOURT P, 1989, BIOCHEM INT, V19, P505; GAWLER D, 1987, NATURE, V327, P229, DOI 10.1038/327229a0; GETTYS TW, 1986, AM J PHYSIOL, V251, pE357, DOI 10.1152/ajpendo.1986.251.3.E357; GETTYS TW, 1987, J BIOL CHEM, V262, P333; GETTYS TW, 1988, J BIOL CHEM, V263, P10359; GETTYS TW, 1990, SEC MESS PHOSPHOPROT, V13, P37; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GREEN A, 1991, DIABETES, V40, P88, DOI 10.2337/diabetes.40.1.88; GREEN A, 1990, J BIOL CHEM, V265, P5206; GREENBERG AS, 1987, J BIOL CHEM, V262, P4564; GRIFFITHS SL, 1990, EUR J BIOCHEM, V193, P367, DOI 10.1111/j.1432-1033.1990.tb19348.x; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; HINSCH KD, 1988, FEBS LETT, V238, P191, DOI 10.1016/0014-5793(88)80254-0; KAHN CR, 1973, J BIOL CHEM, V248, P244; KONO T, 1984, METHODS DIABETES RES, P83; LEVINE MA, 1990, J BIOL CHEM, V265, P3553; LONGABAUGH JP, 1989, MOL PHARMACOL, V36, P681; LYNCH CJ, 1989, J CLIN INVEST, V83, P2050, DOI 10.1172/JCI114116; MALBON CC, 1985, J BIOL CHEM, V260, P2558; MARSHALL NB, 1960, J LIPID RES, V1, P339; MAZANCOURT PD, 1989, ENDOCRINOLOGY, V124, P1131; MILLIGAN G, 1990, BIOCHEM J, V270, P765, DOI 10.1042/bj2700765; MORRE DJ, 1989, BIOTECHNIQUES, V7, P946; MUMBY S, 1988, J BIOL CHEM, V263, P2020; RAMKUMAR V, 1990, ENDOCRINOLOGY, V126, P1295, DOI 10.1210/endo-126-2-1295; RAPIEJKO PJ, 1986, BIOCHEM J, V240, P35, DOI 10.1042/bj2400035; RAPIEJKO PJ, 1987, BIOCHEM J, V241, P765, DOI 10.1042/bj2410765; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROS M, 1989, BIOCHEM J, V257, P737, DOI 10.1042/bj2570737; SMITH CJ, 1989, MOL PHARMACOL, V35, P381; SPYDEVOLD SO, 1978, EUR J BIOCHEM, V89, P329, DOI 10.1111/j.1432-1033.1978.tb12534.x; STRASSHEIM D, 1990, BIOCHEM J, V266, P521, DOI 10.1042/bj2660521; THURLBY PL, 1978, BRIT J NUTR, V39, P397, DOI 10.1079/BJN19780050; TRAYHURN P, 1984, CLIN ENDOCRINOL META, V13, P451, DOI 10.1016/S0300-595X(84)80033-X; UHING RJ, 1987, J BIOL CHEM, V262, P15575; VANNUCCI SJ, 1989, AM J PHYSIOL, V257, pE871, DOI 10.1152/ajpendo.1989.257.6.E871; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	51	59	59	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15949	15955						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908462				2022-12-25	WOS:A1991GB97700065
J	LAWEN, A; TRABER, R; GEYL, D				LAWEN, A; TRABER, R; GEYL, D			INVITRO BIOSYNTHESIS OF [THR2,LEU5,D-HIV8,LEU10]-CYCLOSPORINE, A CYCLOSPORINE-RELATED PEPTOLIDE, WITH IMMUNOSUPPRESSIVE ACTIVITY BY A MULTIENZYME POLYPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							MULTIFUNCTIONAL PEPTIDE SYNTHETASE; PENICILLIN BIOSYNTHESIS; TOLYPOCLADIUM-INFLATUM; ENZYME	A new cyclic peptolide (SDZ 214-103), which is produced by the fungus Cylindrotrichumoligospermum (Corda) BONORDEN (Dreyfuss, M. M., Schreier, M. H., Tscherter, H., and Wenger, R. (June 15, 1988) European Patent Application 0 296 123 A2) and is closely related to cyclosporin A (CyA), has as the main structural difference D-2-hydroxyisovaleric acid in ester linkage at position 8 instead Of D-alanine in the cyclosporins. This peptolide exerts similar biological activities to CyA. We were able to prepare an enzyme fraction of crude extracts of the mycelium, which is capable of synthesizing the peptolide with consumption of the constitutive amino acids, D-2-hydroxyisovaleric acid, ATP, and S-adenosyl-L-methionine. The in vitro product co-chromatographs with authentic peptolide on thin layer chromatography and high performance liquid chromatography and shows similar immunosuppressive activity in vitro. The enzyme does not synthesize CyA, whereas cyclosporin synthetase does not synthesize the peptolide. Peptolide synthetase has a high molecular weight (in the same range as cyclosporin synthetase) and also does not appear to be glycosylated. The enzyme cross-reacts with antibodies directed specifically against cyclosporin synthetase.	SANDOZ PHARM LTD,PRECLIN RES,CH-4002 BASEL,SWITZERLAND	Novartis; Sandoz	LAWEN, A (corresponding author), TECH UNIV BERLIN,INST BIOCHEM & MOLEK BIOL,OE-2,FRANKLINSTR 29,W-1000 BERLIN 10,GERMANY.		Lawen, Alfons/A-6598-2008	Lawen, Alfons/0000-0001-6553-9945				BILLICH A, 1987, J BIOL CHEM, V262, P17258; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DIEZ B, 1990, J BIOL CHEM, V265, P16358; DREYFUSS MM, 1988, Patent No. 296123; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; KAHAN BD, 1984, CYCLOSPORIN BIOL ACT; LAWEN A, 1989, J ANTIBIOT, V42, P1283, DOI 10.7164/antibiotics.42.1283; LAWEN A, 1990, J BIOL CHEM, V265, P11355; PEETERS H, 1988, J ANTIBIOT, V41, P352, DOI 10.7164/antibiotics.41.352; SANGLIER JJ, 1990, J ANTIBIOT, V43, P683; SCHINDLER R, 1985, CYCLOSPORIN AUTOIMMU; SMITH DJ, 1990, EMBO J, V9, P2743, DOI 10.1002/j.1460-2075.1990.tb07461.x; TRABER R, 1987, HELV CHIM ACTA, V70, P13, DOI 10.1002/hlca.19870700103; VANLIEMPT H, 1989, J BIOL CHEM, V264, P3680; ZOCHER R, 1986, BIOCHEMISTRY-US, V25, P550, DOI 10.1021/bi00351a005; ZOCHER R, 1982, BIOCHEMISTRY-US, V21, P43, DOI 10.1021/bi00530a008	16	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15567	15570						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874714				2022-12-25	WOS:A1991GB97700004
J	ROSENTHAL, GA; DAHLMAN, DL				ROSENTHAL, GA; DAHLMAN, DL			STUDIES OF L-CANAVANINE INCORPORATION INTO INSECTAN LYSOZYME	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYALOPHORA-CECROPIA; PROTEIN; ACID	L-Canavanine is incorporated into the lysozyme synthesized, in response to administration of bacterial cell wall materials, by canavanine-treated larvae of the tobacco hornworm Manduca sexta (Sphingidae). Maximum canavanine incorporation into M. sexta lysozyme occurs when the larvae are provided 1 mg of canavanine g-1 fresh body weight. Analysis of canavanine-containing lysozyme purified from these insects reveals that 21% of the arginine residues are replaced by canavanine; this residue substitution results in a loss of 49.5% of the catalytic activity. When the larvae are provided 0.5 mg of canavanine g-1, 16.5% of the arginine residues are substituted by canavanine and 39.5% of the catalytic activity is lost. Canavanine is also incorporated into the lysozyme induced by canavanine-treated pupae of the giant silk moth Hyalophora cecropia (Saturnidae). In contrast, replacement of 17% of the arginine in H. cecropia lysozyme by canavanine fails to affect the catalytic activity. We have determined the primary structure of M. sexta lysozyme and compared it with the primary structure of H. cecropia lysozyme which has been described elsewhere. M. sexta lysozyme has an arginine at positions 23, 42, and 107. H. cecropia contains serine, lysine, and lysine, respectively, at these locations. The ability of incorporated canavanine to inhibit M. sexta lysozyme activity selectively may result from the fact that replacement of any one of the 3 arginine residues at position 23, 42, or 107 by canavanine causes the loss of catalytic activity.	UNIV KENTUCKY,TH MORGAN SCH BIOL SCI,LEXINGTON,KY 40506; UNIV KENTUCKY,DEPT ENTOMOL,LEXINGTON,KY 40506	University of Kentucky; University of Kentucky	ROSENTHAL, GA (corresponding author), UNIV KENTUCKY,GRAD SCH TOXICOL,LEXINGTON,KY 40506, USA.							ALLENDE CC, 1964, J BIOL CHEM, V239, P1102; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; Dickerson R.E., 1969, STRUCTURE ACTION PRO; ENGSTROM A, 1985, EMBO J, V4, P2119, DOI 10.1002/j.1460-2075.1985.tb03901.x; ENGSTROM A, 1984, EMBO J, V3, P2065, DOI 10.1002/j.1460-2075.1984.tb02092.x; Goldberger R.F., 1967, METHOD ENZYMOL, V11, P317; Gray W. R., 1967, METHOD ENZYMOL, V11, P469; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MITRA SK, 1967, J BIOL CHEM, V242, P5490; OZINSKAS AJ, 1986, J ORG CHEM, V51, P5047, DOI 10.1021/jo00376a001; ROSENTHAL GA, 1977, ANAL BIOCHEM, V77, P147, DOI 10.1016/0003-2697(77)90299-8; ROSENTHAL GA, 1989, J BIOL CHEM, V264, P13693; ROSENTHAL GA, 1989, J BIOL CHEM, V264, P9768; ROSENTHAL GA, 1987, EXPERIENTIA, V43, P558, DOI 10.1007/BF02143585; ROSENTHAL GA, 1985, ANAL BIOCHEM, V147, P428, DOI 10.1016/0003-2697(85)90292-1; ROSENTHAL GA, 1991, J FOOD AGR CHEM, V265, P868; YAMAMOTO RT, 1969, J ECON ENTOMOL, V62, P1427, DOI 10.1093/jee/62.6.1427; YARWOOD A, 1989, PROTEIN SEQUENCING P, P119	18	26	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15684	15687						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874726				2022-12-25	WOS:A1991GB97700027
J	MALDEN, LT; CHAIT, A; RAINES, EW; ROSS, R				MALDEN, LT; CHAIT, A; RAINES, EW; ROSS, R			THE INFLUENCE OF OXIDATIVELY MODIFIED LOW-DENSITY LIPOPROTEINS ON EXPRESSION OF PLATELET-DERIVED GROWTH-FACTOR BY HUMAN MONOCYTE-DERIVED MACROPHAGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HERITABLE HYPERLIPIDEMIC RABBIT; SMOOTH-MUSCLE CELLS; FACTOR-LIKE PROTEIN; LOW-LEVEL HYPERCHOLESTEROLEMIA; HUMAN ATHEROSCLEROTIC PLAQUES; FATTY STREAK FORMATION; ENDOTHELIAL-CELLS; NONHUMAN PRIMATE; MESSENGER-RNA; FAMILIAL HYPERCHOLESTEROLEMIA	Platelet-derived growth factor (PDGF) is secreted by several cells that participate in the process of atherogenesis, including arterial wall monocyte-derived macrophages. Macrophages in human and non-human primate lesions have recently been demonstrated to contain PDGF-B chain protein in situ. In developing lesions of atherosclerosis, macrophages take up and metabolize modified lipoproteins, leading to lipid accumulation and foam cell formation. Oxidatively modified low density lipoproteins (LDL) have been implicated in atherogenesis and have been demonstrated in atherosclerotic lesions. The effects of the uptake of various forms of modified LDL on PDGF gene expression, synthesis, and secretion in adherent cultures of human blood monocyte-derived macrophages were examined. LDL oxidized in a cell-free system in the presence of air and copper inhibited the constitutive expression of PDGF-B mRNA and secretion of PDGF in a dose-dependent fashion. Oxidatively modified LDL also attenuated lipopolysaccharide-induced PDGF-B mRNA expression. These changes were unrelated to the mechanism of lipid uptake and the degree of lipid loading and were detectable within 2 h of exposure to oxidized LDL. The degree of inhibition of both basal and lipopolysaccharide-induced PDGF-B-chain expression increased with the extent of LDL oxidation. Monocyte-derived macrophages exposed to acetylated LDL or LDL aggregates accumulated more cholesterol than cells treated with oxidized LDL, but PDGF expression was not consistently altered. Thus, uptake of a product or products of LDL oxidation modulates the expression and secretion of one of the principal macrophage-derived growth factors, PDGF. This modulation may influence chemotaxis and mitogenesis of smooth muscle cells locally in the artery wall during atherogenesis.	UNIV WASHINGTON,DEPT PATHOL,SM-30,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle					NHLBI NIH HHS [HL-03174, HL-18645, HL-30086] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030086, P01HL018645] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARRETT TB, 1987, P NATL ACAD SCI USA, V84, P1099, DOI 10.1073/pnas.84.4.1099; BARRETT TB, 1988, P NATL ACAD SCI USA, V85, P2810, DOI 10.1073/pnas.85.8.2810; BASU SK, 1976, P NATL ACAD SCI USA, V73, P3178, DOI 10.1073/pnas.73.9.3178; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BOWENPOPE DF, 1985, METHOD ENZYMOL, V109, P69; BOYD HC, 1989, AM J PATHOL, V135, P815; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Buege J A, 1978, Methods Enzymol, V52, P302; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; CHAIT A, 1980, P NATL ACAD SCI-BIOL, V77, P4084, DOI 10.1073/pnas.77.7.4084; CHAIT A, 1982, ARTERIOSCLEROSIS, V2, P134, DOI 10.1161/01.ATV.2.2.134; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANI C, 1984, EUR J BIOCHEM, V145, P299, DOI 10.1111/j.1432-1033.1984.tb08552.x; DEGEN JL, 1983, J BIOL CHEM, V258, P2153; DINARELLO CA, 1987, NEW ENGL J MED, V317, P940, DOI 10.1056/NEJM198710083171506; DUGAICZYK A, 1983, BIOCHEMISTRY-US, V22, P1605, DOI 10.1021/bi00276a013; EMESON EE, 1988, AM J PATHOL, V130, P369; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FOX PL, 1988, SCIENCE, V241, P453, DOI 10.1126/science.3393911; FOX PL, 1986, P NATL ACAD SCI USA, V83, P4774, DOI 10.1073/pnas.83.13.4774; FOX PL, 1987, J BIOL CHEM, V262, P6046; GERRITY RG, 1981, AM J PATHOL, V103, P191; GERRITY RG, 1981, AM J PATHOL, V103, P181; GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333; HAMILTON TA, 1990, J IMMUNOL, V144, P2343; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; JIALAL I, 1989, J LIPID RES, V30, P1561; JONASSON L, 1986, ARTERIOSCLEROSIS, V6, P131, DOI 10.1161/01.ATV.6.2.131; JURGENS G, 1987, CHEM PHYS LIPIDS, V45, P315, DOI 10.1016/0009-3084(87)90070-3; KIM RS, 1987, J LIPID RES, V28, P1110; KITA T, 1987, P NATL ACAD SCI USA, V84, P5928, DOI 10.1073/pnas.84.16.5928; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINET Y, 1986, NATURE, V319, P158, DOI 10.1038/319158a0; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P178, DOI 10.1161/01.ATV.10.2.178; MASUDA J, 1990, ARTERIOSCLEROSIS, V10, P164, DOI 10.1161/01.ATV.10.2.164; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; MONRO JM, 1987, HUM PATHOL, V18, P375; MOREL DW, 1983, J LIPID RES, V24, P1070; MORNEX JF, 1986, J CLIN INVEST, V78, P61, DOI 10.1172/JCI112574; OPPENHEIMER MJ, 1987, ARTERIOSCLEROSIS, V7, P325, DOI 10.1161/01.ATV.7.4.325; PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372; Raines E. W., 1990, HDB EXPT PHARM PEPTI, V951, P173; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Roberts AB, 1990, HDB EXPT PHARM, V95, P419; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; ROSS R, 1990, SCIENCE, V248, P1009, DOI 10.1126/science.2343305; SARIBAN E, 1988, CANCER RES, V48, P4498; SHIMOKADO K, 1985, CELL, V43, P277, DOI 10.1016/0092-8674(85)90033-9; SPARROW CP, 1989, J BIOL CHEM, V264, P2599; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SUITS AG, 1989, P NATL ACAD SCI USA, V86, P2713, DOI 10.1073/pnas.86.8.2713; WILCOX JN, 1988, J CLIN INVEST, V82, P1134, DOI 10.1172/JCI113671; 1985, JAMA-J AM MED ASSOC, V253, P2080	58	101	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13901	13907						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906887				2022-12-25	WOS:A1991FY02700070
J	FAWZI, AB; FAY, DS; MURPHY, EA; TAMIR, H; ERDOS, JJ; NORTHUP, JK				FAWZI, AB; FAY, DS; MURPHY, EA; TAMIR, H; ERDOS, JJ; NORTHUP, JK			RHODOPSIN AND THE RETINAL G-PROTEIN DISTINGUISH AMONG G-PROTEIN BETA-GAMMA-SUBUNIT FORMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROD OUTER SEGMENTS; NUCLEOTIDE-BINDING-PROTEINS; MUSCARINIC K+-CHANNEL; STIMULATORY REGULATORY COMPONENT; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; GUANINE-NUCLEOTIDES; ADP-RIBOSYLATION; PERTUSSIS TOXIN; BOVINE BRAIN	The beta-gammma-subunits of G-proteins are composed of closely related beta-35 and beta-36 subunits tightly associated with diverse 6-10-kDa gamma-subunits. We have developed a reconstitution assay using rhodopsin-catalyzed guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S) binding to resolved alpha-subunit of the retinal G-protein transducin (G(t)alpha) to quantitate the activity of beta-gamma-proteins. Rhodopsin facilitates the exchange of GTP-gamma-S for GDP bound to G(t)alpha-beta-gamma with a 60-fold higher apparent affinity than for G(t)alpha alone. At limiting rhodopsin, G-protein-derived beta-gamma-subunits catalytically enhance the rate of GTP-gamma-S binding to resolved G(t)alpha. The isolated beta-gamma-subunit of retinal G-protein (beta-1, gamma-1 genes) facilitates rhodopsin-catalyzed GTP-gamma-S exchange on G(t)alpha in a concentration-dependent manner (K0.5 = 254 +/- 21 nM). Purified human placental beta-35-gamma, composed of beta-2 gene product and gamma-placenta protein (Evans, T., Fawzi, A., Fraser, E. D., Brown, L. M., and Northup, J. K. (1987) J. Biol. Chem. 262, 176-181), substitutes for G(t)beta-gamma-reconstitution of rhodopsin with G(t)alpha. However, human placental beta-35-gamma facilitates rhodopsin-catalyzed GTP-gamma-S exchange on G(t)alpha with a higher apparent affinity than G(t)beta-gamma (K0.5 = 76 +/- 54 nM). As an alternative assay for these interactions, we have examined pertussis toxin-catalyzed ADP-ribosylation of the G(t)alpha-subunit which is markedly enhanced in rate by beta-gamma-subunits. Quantitative analyses of rates of pertussis modification reveal no differences in apparent affinity between G(t)beta-gamma and human placental beta-35-gamma (K0.5 values of 49 +/- 29 and 70 +/- 24 nm, respectively). Thus, the G(t)alpha subunit alone does not distinguish among the beta-gamma-subunit forms. These results clearly show a high degree of functional homology among the beta-35 and beta-36 subunits of G-proteins for interaction with G(t)alpha and rhodopsin, and establish a simple functional assay for the beta-gamma-subunits of G-proteins. Our data also suggest a specificity of recognition of beta-gamma subunit forms which is dependent both on G(t)alpha and rhodopsin. These results may indicate that the recently uncovered diversity in the expression of beta-gamma-subunit forms may complement the diversity of G-alpha-subunits in providing for specific receptor recognition of G-proteins.	YALE UNIV, SCH MED, DEPT PHARMACOL, NEW HAVEN, CT 06510 USA	Yale University					NCRR NIH HHS [RR 05358] Funding Source: Medline; NIGMS NIH HHS [GM40154] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040154] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATRUDA TT, 1988, J BIOL CHEM, V263, P5008; BIRNBAUMER L, 1989, RECENT PROG HORM RES, V45, P121; BOYER JL, 1989, J BIOL CHEM, V264, P13917; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CERIONE RA, 1987, BIOCHEMISTRY-US, V26, P1485, DOI 10.1021/bi00379a041; CERIONE RA, 1986, J BIOL CHEM, V261, P9514; EVANS T, 1987, J BIOL CHEM, V262, P176; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; FLORIO VA, 1989, J BIOL CHEM, V264, P3909; FONG HKW, 1987, P NATL ACAD SCI USA, V84, P3792, DOI 10.1073/pnas.84.11.3792; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUKADA Y, 1989, J BIOL CHEM, V264, P5937; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GAO B, 1987, J BIOL CHEM, V262, P17254; GAO B, 1987, P NATL ACAD SCI USA, V84, P6122, DOI 10.1073/pnas.84.17.6122; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GIERSCHIK P, 1985, P NATL ACAD SCI USA, V82, P727, DOI 10.1073/pnas.82.3.727; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; HEKMAN M, 1987, EUR J BIOCHEM, V169, P431, DOI 10.1111/j.1432-1033.1987.tb13630.x; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P762; HILDEBRANDT JD, 1985, J BIOL CHEM, V260, P4867; HILDEBRANDT JD, 1984, J BIOL CHEM, V259, P2039; HORTHUP JK, 1982, J BIOL CHEM, V257, P11416; HUFF RM, 1986, J BIOL CHEM, V261, P1105; HURLEY JB, 1984, P NATL ACAD SCI-BIOL, V81, P6948, DOI 10.1073/pnas.81.22.6948; KANAHO Y, 1984, J BIOL CHEM, V259, P7378; KATADA T, 1986, J BIOL CHEM, V261, P8182; KATADA T, 1984, J BIOL CHEM, V259, P3568; KATADA T, 1984, J BIOL CHEM, V259, P3578; KIM D, 1989, NATURE, V337, P557, DOI 10.1038/337557a0; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOCHRIE MA, 1988, BIOCHEMISTRY-US, V27, P4957, DOI 10.1021/bi00414a001; LOGOTHETIS DE, 1988, P NATL ACAD SCI USA, V85, P5814, DOI 10.1073/pnas.85.16.5814; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MORIARTY TM, 1988, P NATL ACAD SCI USA, V85, P8865, DOI 10.1073/pnas.85.23.8865; NAVON SE, 1984, J BIOL CHEM, V259, P6686; NEER EJ, 1988, NATURE, V333, P129, DOI 10.1038/333129a0; NEER EJ, 1984, J BIOL CHEM, V259, P4222; NORTHUP JK, 1983, J BIOL CHEM, V258, P1369; NORTHUP JK, 1983, J BIOL CHEM, V258, P1361; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Shaltiel S, 1974, Methods Enzymol, V34, P126; STERNWEIS PC, 1986, J BIOL CHEM, V261, P631; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STRATHMANN M, 1989, P NATL ACAD SCI USA, V86, P7407, DOI 10.1073/pnas.86.19.7407; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; SUGIMOTO K, 1985, FEBS LETT, V191, P235, DOI 10.1016/0014-5793(85)80015-6; TAMIR H, 1991, BIOCHEMISTRY-US, V30, P3929, DOI 10.1021/bi00230a018; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATKINS PA, 1985, J BIOL CHEM, V260, P3478; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; YAMAZAKI A, 1987, J BIOL CHEM, V262, P9316; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P1936, DOI 10.1073/pnas.82.7.1936	57	82	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12194	12200						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905716				2022-12-25	WOS:A1991FV18000017
J	HOFFMANLIEBERMANN, B; LIEBERMANN, DA				HOFFMANLIEBERMANN, B; LIEBERMANN, DA			SUPPRESSION OF C-MYC AND C-MYB IS TIGHTLY LINKED TO TERMINAL DIFFERENTIATION INDUCED BY IL6 OR LIF AND NOT GROWTH-INHIBITION IN MYELOID-LEUKEMIA CELLS	ONCOGENE			English	Article							MESSENGER-RNA; ERYTHROLEUKEMIA-CELLS; ONCOGENE EXPRESSION; GENE-EXPRESSION; PROTO-ONCOGENE; PROTEINS; ARREST; MOUSE; PROLIFERATION; TRANSCRIPTION	Cell proliferation and differentiation are intimately related processes where the proto-oncogenes c-myc and c-myb have been implicated to play a role. Previously, we have shown that both c-myc and c-myb were induced in normal myeloid precursors when the cells were stimulated for growth, were expressed in the autonomously proliferating myeloid leukemic M1 cell line and were rapidly suppressed in both normal and M1 cells following induction of terminal differentiation associated with growth arrest. In order to distinguish molecular events associated with terminal differentiation versus those due to growth inhibition, as well as to increase our understanding of the role of the proto-oncogenes c-myc and c-myb in both of these cellular processes, in this work we have studied the expression of c-myc and c-myb in M1 cells induced for growth inhibition associated with terminal differentiation (via treatment with the physiological inducers IL6 or leukemia inhibitory factor <LIF>), partial differentiation (using IL1 or LPS) or no detectable differentiation properties (using IFN-beta or IFN-gamma). We show that, for all the treatments used in this study, down regulation of the proto-oncogenes c-myc and c-myb occurred only when M1 cells were stimulated to undergo terminal differentiation. In addition, we transfected the M1 cell line with a vector containing the c-myc gene under control of the beta-actin promoter, so that c-myc was no longer down regulated by IL6 or LIF. Previously, we have shown that in the presence of the myeloid differentiation inducers IL6 or LIF, these M1myc cells were blocked at an intermediate stage of myeloid differentiation and continued to proliferate. In sharp contrast to their altered response to IL6 or LIF, M1myc cells were as responsive as the parental M1 cells to growth suppression by the different antiproliferative compounds which do not induce terminal differentiation. Thus, continued expression of c-myc had no effect on growth suppression induced by IL1, IFN-beta, IFN-gamma and LPS. Taken together, these results indicate that c-myc and c-myb down regulation is not necessary for growth suppression, but down regulation of c-myc is, and c-myb may be, essential for terminal differentiation.			HOFFMANLIEBERMANN, B (corresponding author), UNIV PENN, SCH MED, DEPT BIOCHEM & BIOPHYS, PHILADELPHIA, PA 19104 USA.				NATIONAL CANCER INSTITUTE [R01CA043618] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA43618-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BENDER TP, 1987, SCIENCE, V237, P1473, DOI 10.1126/science.3498214; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLARKE MF, 1988, MOL CELL BIOL, V8, P884, DOI 10.1128/MCB.8.2.884; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPPOLA JA, 1986, NATURE, V320, P760, DOI 10.1038/320760a0; DMITROVSKY E, 1986, NATURE, V322, P748, DOI 10.1038/322748a0; EINAT M, 1985, NATURE, V313, P597, DOI 10.1038/313597a0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x; GONDA TJ, 1982, MOL CELL BIOL, V2, P617, DOI 10.1128/MCB.2.6.617; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; HEIKKILA R, 1987, NATURE, V328, P445, DOI 10.1038/328445a0; HOFFMANLIEBERMA.B, 1991, IN PRESS MOL CELL; HOFFMANLIEBERMANN B, 1978, CELL, V14, P825, DOI 10.1016/0092-8674(78)90338-0; HOFFMANLIEBERMANN B, 1981, DEV BIOL, V81, P255, DOI 10.1016/0012-1606(81)90289-X; HOFFMANLIEBERMANN B, 1986, MOL CELL BIOL, V6, P3632, DOI 10.1128/MCB.6.11.3632; IKEGAKI N, 1990, ONCOGENE, V5, P397; KELLY K, 1986, ANNU REV IMMUNOL, V4, P317, DOI 10.1146/annurev.immunol.4.1.317; KUEHL WM, 1988, CURR TOP MICROBIOL, V141, P318; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIEBERMANN D, 1978, CELL, V15, P823, DOI 10.1016/0092-8674(78)90267-2; LIEBERMANN DA, 1989, ONCOGENE, V4, P583; LODMICO P, 1984, NATURE, V312, P458; LORD KA, 1990, ONCOGENE, V5, P387; LOTEM J, 1978, INT J CANCER, V22, P214, DOI 10.1002/ijc.2910220216; LOTEM J, 1989, LEUKEMIA RES, V13, P13, DOI 10.1016/0145-2126(89)90026-X; LOTEM J, 1979, P NATL ACAD SCI USA, V76, P5158, DOI 10.1073/pnas.76.10.5158; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCLINTON D, 1990, MOL CELL BIOL, V10, P705, DOI 10.1128/MCB.10.2.705; ONOZAKI K, 1987, CANCER RES, V47, P2397; ONOZAKI K, 1989, CANCER RES, V49, P3602; ONOZAKI K, 1988, J IMMUNOL, V140, P112; PERSSON H, 1984, SCIENCE, V225, P687, DOI 10.1126/science.6431612; PIETENPOL JA, 1990, P NATL ACAD SCI USA, V87, P3758, DOI 10.1073/pnas.87.10.3758; PROCHOWNIK EV, 1986, NATURE, V322, P848, DOI 10.1038/322848a0; RAMSAY RG, 1986, P NATL ACAD SCI USA, V83, P6849, DOI 10.1073/pnas.83.18.6849; RESNITZKY D, 1986, CELL, V46, P31, DOI 10.1016/0092-8674(86)90857-3; SHABO Y, 1988, BLOOD, V72, P2070; SHENONG GLC, 1987, P NATL ACAD SCI USA, V84, P199, DOI 10.1073/pnas.84.1.199; THIELE CJ, 1988, MOL CELL BIOL, V8, P1677, DOI 10.1128/MCB.8.4.1677; THOMPSON CB, 1986, NATURE, V319, P374, DOI 10.1038/319374a0; THOMPSON CB, 1985, NATURE, V314, P363, DOI 10.1038/314363a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WIESE B, 1978, P NATL ACAD SCI USA, V75, P1374	45	62	62	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN	1991	6	6					903	909						7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GU622	1906157				2022-12-25	WOS:A1991GU62200003
J	RAWAT, M; MORONEY, JV				RAWAT, M; MORONEY, JV			PARTIAL CHARACTERIZATION OF A NEW ISOENZYME OF CARBONIC-ANHYDRASE ISOLATED FROM CHLAMYDOMONAS-REINHARDTII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONCENTRATING MECHANISM; LOW CO2; PROTEINS; MUTANT; BIOSYNTHESIS; ADAPTATION; EXPRESSION; TRANSPORT; DEFICIENT; SEQUENCE	A new isoenzyme of carbonic anhydrase has been isolated and purified from Chlamydomonas reinhardtii. This carbonic anhydrase is composed of two nonidentical subunits with apparent molecular masses of 39 and 4.5 kDa and is located in the periplasmic space. This is the second periplasmic carbonic anhydrase found in C. reinhardtii. Two genes, CAH1 and CAH2, which code for carbonic anhydrase, have been recently described by Fujiwara et al. (Fujiwara, S., Fukuzawa, H., Tachiki, A., and Miyachi, S. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 9779-9783). The CAH1 gene codes for a periplasmic carbonic anhydrase which is induced under low CO2 conditions and is well characterized. The carbonic anhydrase characterized in this report was isolated from a mutant that is unable to synthesize the CAH1 gene product. Amino acid sequencing demonstrates that this newly isolated carbonic anhydrase is the CAH2 gene product. This is the first report of another functional carbonic anhydrase in C. reinhardtii.	LOUISIANA STATE UNIV,DEPT BOT,BATON ROUGE,LA 70803	Louisiana State University System; Louisiana State University								AIZAWA K, 1986, FEMS MICROBIOL LETT, V39, P215, DOI 10.1016/0378-1097(86)90447-7; BADGER MR, 1980, PLANT PHYSIOL, V66, P407, DOI 10.1104/pp.66.3.407; BERRY J, 1976, CARNEGIE I WASHINGTO, V75, P423; Coleman, 1985, INORGANIC CARBON UPT, P339; COLEMAN JR, 1984, PLANT PHYSIOL, V76, P472, DOI 10.1104/pp.76.2.472; COLEMAN JR, 1984, P NATL ACAD SCI-BIOL, V81, P6049, DOI 10.1073/pnas.81.19.6049; FAWCETT TW, 1990, J BIOL CHEM, V265, P5414; FUJIWARA S, 1990, P NATL ACAD SCI USA, V87, P9779, DOI 10.1073/pnas.87.24.9779; FUKUZAWA H, 1990, P NATL ACAD SCI USA, V87, P4383, DOI 10.1073/pnas.87.11.4383; HUSIC HD, 1989, PLANT PHYSIOL, V89, P904, DOI 10.1104/pp.89.3.904; IMAMURA M, 1983, PLANT CELL PHYSIOL, V24, P533; KAMO T, 1990, EUR J BIOCHEM, V192, P557, DOI 10.1111/j.1432-1033.1990.tb19261.x; KATZMAN GL, 1987, PLANT PHYSIOL, V89, P117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANUEL LJ, 1988, PLANT PHYSIOL, V88, P491, DOI 10.1104/pp.88.2.491; MORONEY JV, 1987, PLANT PHYSIOL, V83, P460, DOI 10.1104/pp.83.3.460; MORONEY JV, 1987, PLANT PHYSIOL, V84, P757, DOI 10.1104/pp.84.3.757; MORONEY JV, 1985, PLANT PHYSIOL, V77, P253, DOI 10.1104/pp.77.2.253; MORONEY JV, 1989, PLANT PHYSIOL, V89, P897, DOI 10.1104/pp.89.3.897; MORONEY JV, 1990, CURRENT RES PHOTOSYN, V4, P449; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPALDING MH, 1983, PLANT PHYSIOL, V73, P273, DOI 10.1104/pp.73.2.273; SPALDING MH, 1989, PLANT PHYSIOL, V89, P133, DOI 10.1104/pp.89.1.133; SPALDING MH, 1983, PLANT PHYSIOL, V73, P268, DOI 10.1104/pp.73.2.268; SUEOKA N, 1960, P NATL ACAD SCI USA, V46, P83, DOI 10.1073/pnas.46.1.83; TOGURI T, 1986, EUR J BIOCHEM, V158, P443, DOI 10.1111/j.1432-1033.1986.tb09773.x; YANG SY, 1985, PLANT CELL PHYSIOL, V26, P25	28	53	57	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9719	9723						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903396				2022-12-25	WOS:A1991FM45900060
J	PETTITT, TR; ROWLEY, AF; BARROW, SE; MALLET, AI; SECOMBES, CJ				PETTITT, TR; ROWLEY, AF; BARROW, SE; MALLET, AI; SECOMBES, CJ			SYNTHESIS OF LIPOXINS AND OTHER LIPOXYGENASE PRODUCTS BY MACROPHAGES FROM THE RAINBOW-TROUT, ONCORHYNCHUS-MYKISS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID; HUMAN-LEUKOCYTES; PORCINE LEUKOCYTES; HUMAN-NEUTROPHILS; SALMO-GAIRDNERI; BLOOD-CELLS; EICOSANOIDS; METABOLISM; TRANSFORMATION; LEUKOTRIENE	Rainbow trout macrophages maintained in short term culture when incubated with either calcium ionophore, A23187, or opsonized zymosan synthesize a range of lipoxygenase products including lipoxins and leukotrienes. These cells are unusual in that they generate more lipoxin than leukotriene following such challenge. The main lipoxin synthesized was lipoxin (LX) A4. This compound was identified by cochromatography with authentic standard during reverse-phase high performance liquid chromatography, by ultra violet spectral analysis, radiolabeling following incorporation of [C-14]arachidonic acid substrate into macrophage phospholipids, and gas chromatography electron impact mass spectrometry of the methyl ester, trimethylsilyl ether derivative. Other 4-series lipoxins synthesized by trout macrophages were identified as 11-trans-LXA4, 7-cis-11-trans-LXA4, and 6(S)-LXA4. These cells also produced 5-series lipoxins tentatively identified as LXA5, 11-trans-LXA5 and possibly 6(S)-LXA5. No LXB4 or LXB5 was, however, detected. The dynamics of leukotriene and lipoxin release were also determined. Lipoxin generation was slower then leukotriene generation the latter reaching a maximum after 30 min of exposure to ionophore (5-mu-M, 18-degrees-C) compared with 45 min for the former.	UNIV COLL SWANSEA,SCH BIOL SCI,BIOMED & PHYSIOL RES GRP,SWANSEA SA2 8PP,W GLAM,WALES; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,GUYS HOSP,DEPT CLIN PHARMACOL,LONDON SE1 9RT,ENGLAND; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,ST THOMAS HOSP,INST DERMATOL,LONDON,ENGLAND; UNIV ABERDEEN,DEPT ZOOL,ABERDEEN AB9 2TN,SCOTLAND	Swansea University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; University of Aberdeen								BARROW SE, 1987, PROSTAGLANDINS RELAT, P99; BELCH JJF, 1989, PROSTAG LEUKOTR ESS, V36, P219, DOI 10.1016/0952-3278(89)90135-X; COWELL AM, 1989, PROSTAG LEUKOTR ESS, V36, P235, DOI 10.1016/0952-3278(89)90136-1; EDENIUS C, 1991, ADV PROSTAG THROMB L, V21, P97; EDENIUS C, 1988, FEBS LETT, V228, P167; FISCHER S, 1984, BIOCHEM BIOPH RES CO, V120, P907, DOI 10.1016/S0006-291X(84)80193-X; KIM SJ, 1988, BIOCHEM BIOPH RES CO, V150, P870, DOI 10.1016/0006-291X(88)90473-1; KUHN H, 1987, BIOMED BIOCHIM ACTA, V46, pS156; LAGARDE M, 1989, BIOCHEM J, V257, P313, DOI 10.1042/bj2570313; Lam B K, 1988, Adv Exp Med Biol, V229, P51; LAM BK, 1987, BIOCHIM BIOPHYS ACTA, V917, P398, DOI 10.1016/0005-2760(87)90118-4; LAM BK, 1987, BIOCHEM BIOPH RES CO, V144, P123, DOI 10.1016/S0006-291X(87)80484-9; LINDGREN JA, 1991, ADV PROSTAG THROMB L, V21, P89; LOTE CJ, 1989, PROSTAG LEUKOTR ESS, V36, P203, DOI 10.1016/0952-3278(89)90134-8; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NICOLAOU KC, 1989, BIOCHIM BIOPHYS ACTA, V1003, P44, DOI 10.1016/0005-2760(89)90096-9; PETTITT TR, 1989, FEBS LETT, V259, P168, DOI 10.1016/0014-5793(89)81520-0; PETTITT TR, 1989, BIOCHIM BIOPHYS ACTA, V1003, P1, DOI 10.1016/0005-2760(89)90090-8; PETTITT TR, 1990, BIOCHIM BIOPHYS ACTA, V1042, P62, DOI 10.1016/0005-2760(90)90057-5; PUUSTINEN T, 1986, FEBS LETT, V207, P127, DOI 10.1016/0014-5793(86)80025-4; ROKACH J, 1988, INT J BIOCHEM, V20, P753, DOI 10.1016/0020-711X(88)90060-2; ROWLEY AF, 1991, ADV PROSTAG THROMB L, V21, P557; SECOMBES CJ, 1985, J FISH DIS, V8, P461, DOI 10.1111/j.1365-2761.1985.tb01279.x; SERHAN CN, 1990, J CLIN INVEST, V85, P772, DOI 10.1172/JCI114503; SERHAN CN, 1987, FEBS LETT, V217, P242, DOI 10.1016/0014-5793(87)80671-3; SERHAN CN, 1984, BIOCHEM BIOPH RES CO, V118, P943, DOI 10.1016/0006-291X(84)91486-4; SERHAN CN, 1984, P NATL ACAD SCI-BIOL, V81, P5335, DOI 10.1073/pnas.81.17.5335; SERHAN CN, 1989, BIOCHIM BIOPHYS ACTA, V1004, P158, DOI 10.1016/0005-2760(89)90264-6; SMITH WL, 1989, BIOCHEM J, V259, P315, DOI 10.1042/bj2590315; WALSTRA P, 1988, FEBS LETT, V228, P167, DOI 10.1016/0014-5793(88)80609-4	30	71	80	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					8720	8726						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1902832				2022-12-25	WOS:A1991FM03800016
J	TSAI, SC; ADAMIK, R; TSUCHIYA, M; CHANG, PP; MOSS, J; VAUGHAN, M				TSAI, SC; ADAMIK, R; TSUCHIYA, M; CHANG, PP; MOSS, J; VAUGHAN, M			DIFFERENTIAL EXPRESSION DURING DEVELOPMENT OF ADP-RIBOSYLATION FACTORS, 20-KDA GUANINE NUCLEOTIDE-BINDING PROTEIN ACTIVATORS OF CHOLERA-TOXIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENYLATE-CYCLASE; REGULATORY COMPONENT; RIBOSYLTRANSFERASE ACTIVITY; NUCLEOSIDE TRIPHOSPHATES; MACROMOLECULAR FACTOR; ALPHA-SUBUNIT; BOVINE BRAIN; GTP; PURIFICATION; TRANSDUCIN	Cholera toxin exerts its effects on cells in large part through the ADP-ribosylation of guanine nucleotide-binding proteins. Toxin-catalyzed ADP-ribosylation is enhanced by approximately 20-kDa guanine nucleotide-binding proteins termed ADP-ribosylation factors (ARFs), which are allosteric activators of the toxin catalytic unit. Rabbit antiserum against a purified bovine brain ARF (sARF II) reacted on immunoblots with two approximately 20-kDa ARF-like proteins (sARF I and II) in tissue extracts from bovine, rat, frog, and chicken. Levels of ARF were higher in brain than in non-neural tissues. In rat brain, on the second postnatal day, amounts of sARF I and II were similar. By the 10th postnatal day and thereafter, sARF II predominated. Relative levels of ARF determined by immunoreactivity were in agreement with levels assessed in functional assays of cholera toxin-catalyzed ADP-ribosylation. Based on nucleotide and deduced amino acid sequences of human and bovine cDNAs, there appear to be at least six different ARF-like genes. Northern blots of rat brain poly(A)+ RNA were hybridized with cDNA and oligonucleotide probes specific for each of the human and bovine ARF genes. From the second to the 27th postnatal day, ARF 3 mRNA increased, whereas mRNAs for ARFs 2 and 4 decreased; and those for ARFs 1, 5, and 6 were apparently unchanged. Partial amino acid sequence of sARF II is consistent with it being either the ARF 1 or 3 gene product. The developmental changes in rat brain ARF parallel neuronal maturation and synapse formation.			TSAI, SC (corresponding author), NHLBI, CELLULAR METAB LAB, RM 5N-307, BLDG 10, BETHESDA, MD 20892 USA.							ABOOD ME, 1982, J BIOL CHEM, V257, P540; ALSIP GR, 1986, NUCLEIC ACIDS RES, V14, P2123, DOI 10.1093/nar/14.5.2123; ALTMAN J, 1972, J COMP NEUROL, V145, P399, DOI 10.1002/cne.901450402; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BIRNBAUMER L, 1987, KIDNEY INT, V32, pS14; BOBAK DA, 1989, P NATL ACAD SCI USA, V86, P6101, DOI 10.1073/pnas.86.16.6101; BOBAK DA, 1990, BIOCHEMISTRY-US, V29, P855, DOI 10.1021/bi00456a600; BURNS DL, 1982, J BIOL CHEM, V257, P32; CASEY PJ, 1988, J BIOL CHEM, V263, P2577; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; ENOMOTO K, 1982, BIOMED RES-TOKYO, V3, P122, DOI 10.2220/biomedres.3.122; ENOMOTO K, 1980, J BIOL CHEM, V255, P1252; FUNG BKK, 1983, J BIOL CHEM, V258, P495; GILL DM, 1983, J BIOL CHEM, V258, P1908; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; HAYAISHI O, 1977, ANNU REV BIOCHEM, V46, P95, DOI 10.1146/annurev.bi.46.070177.000523; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1988, J BIOL CHEM, V263, P8282; KAHN RA, 1984, J BIOL CHEM, V259, P6235; KAHN RA, 1986, J BIOL CHEM, V261, P7906; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE H, 1981, BIOCHIM BIOPHYS ACTA, V672, P248, DOI 10.1016/0304-4165(81)90291-9; LIN MC, 1978, J CYCLIC NUCL PROT, V4, P159; MONACO L, 1990, P NATL ACAD SCI USA, V87, P2206, DOI 10.1073/pnas.87.6.2206; MOSS J, 1978, P NATL ACAD SCI USA, V75, P3621, DOI 10.1073/pnas.75.8.3621; MOSS J, 1988, ADV ENZYMOL RAMB, V61, P303; NAKAYA S, 1980, BIOCHEMISTRY-US, V19, P4871, DOI 10.1021/bi00562a026; NODA M, 1989, PREP BIOCHEM, V19, P351, DOI 10.1080/10826068908544923; NODA M, 1990, BIOCHIM BIOPHYS ACTA, V1034, P195, DOI 10.1016/0304-4165(90)90076-9; PENG Z, 1989, Biofactors, V2, P45; PINKETT MO, 1982, BIOCHIM BIOPHYS ACTA, V714, P337, DOI 10.1016/0304-4165(82)90342-7; PRICE SR, 1988, P NATL ACAD SCI USA, V85, P5488, DOI 10.1073/pnas.85.15.5488; PRICE SR, 1990, INSIGHTS SIGNAL TRAN, P397; SCHLEIFER LS, 1982, J BIOL CHEM, V257, P20; SERAFINI T, 1990, J CELL BIOCHEM     S, V14, pH338; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1987, BIOCHEMISTRY-US, V26, P4728, DOI 10.1021/bi00389a020; TSUCHIYA M, 1989, BIOCHEMISTRY-US, V28, P9668, DOI 10.1021/bi00451a019; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; VAITUKAITIS J, 1971, J CLIN ENDOCR METAB, V33, P988, DOI 10.1210/jcem-33-6-988	49	55	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 5	1991	266	13					8213	8219						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FK441	1902473				2022-12-25	WOS:A1991FK44100042
J	SEYDEL, U; GERACE, L				SEYDEL, U; GERACE, L			A 28,000-DA GDP GTP-BINDING PROTEIN-SPECIFIC TO THE NUCLEAR-ENVELOPE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEX LAMINA FRACTION; INITIATION FACTOR-II; PORE COMPLEX; ESCHERICHIA-COLI; ADP-RIBOSYLATION; IDENTIFICATION; POLYPEPTIDE; MEMBRANE; PURIFICATION; ORGANIZATION	Using a photoaffinity labeling approach to characterize GDP/GTP-binding proteins of the nuclear envelope, we found that several polypeptides of isolated rat liver nuclear envelopes were photolabeled with [alpha-P-32]GDP. One of these labeled proteins, which had an apparent molecular mass of 28 kDa (p28), was highly enriched in nuclear envelopes relative to unfractionated nuclei and was not detectable in fractions of mitochondria, cytosol, and endoplasmic reticulum membranes by two-dimensional gel electrophoresis. Thus p28 is specific to the nuclear envelope. Chemical extractions showed that p28 was tightly associated with a subfraction of the nuclear envelope enriched in nuclear pore complexes and lamina. Solubilization of p28 required buffers containing 1% octylglucoside and at least 300 mM KCl. Photolabeling of p28 was specific for GTP and GDP, since no other guanine or adenine nucleotide tested was able to compete efficiently with [alpha-P-32]GDP for photolabeling. Added magnesium or manganese cations were not required for photolabeling of p28, and labeling was substantially inhibited with 10 mM MgCl2, 1 mM MnCl2, and KCl concentrations greater than 150 mM. Sucrose density centrifugation showed that detergent-solubilized p28 had a S value of 2.5. The properties of p28 described in this study suggest that it may have a role in functions of the pore complex or lamina.			SEYDEL, U (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, 10666 N TORREY PINES RD, LA JOLLA, CA 92037 USA.							ADAM SA, 1989, NATURE, V337, P276, DOI 10.1038/337276a0; BANKS GR, 1986, BIOCHEMISTRY-US, V25, P5882, DOI 10.1021/bi00368a007; BERRIOS M, 1983, J BIOL CHEM, V258, P4548; BOKOCH GM, 1988, J BIOL CHEM, V263, P16744; BOSCH L, 1989, GUANINE NUCLEOTIDE B; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; DINGWALL C, 1982, CELL, V30, P449, DOI 10.1016/0092-8674(82)90242-2; DINGWALL C, 1986, ANNU REV CELL BIOL, V2, P367, DOI 10.1146/annurev.cellbio.2.1.367; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GERACE L, 1984, J CELL SCI, P137; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; HALL A, 1986, J BIOL CHEM, V261, P963; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HOWELL KE, 1982, J CELL BIOL, V92, P822, DOI 10.1083/jcb.92.3.822; KAHN RA, 1984, J BIOL CHEM, V259, P6228; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARCH PE, 1985, P NATL ACAD SCI USA, V82, P7500, DOI 10.1073/pnas.82.22.7500; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; NEWPORT JW, 1987, ANNU REV BIOCHEM, V56, P535; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; PANNIERS R, 1988, J BIOL CHEM, V263, P5519; PARMEGGIANI A, 1981, MOL CELL BIOCHEM, V35, P129, DOI 10.1007/BF02357085; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; RABILLOUD T, 1988, ELECTROPHORESIS, V9, P288, DOI 10.1002/elps.1150090608; RUBINS JB, 1990, P NATL ACAD SCI USA, V87, P7080, DOI 10.1073/pnas.87.18.7080; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHEER U, 1988, CELL BIOL INT REP, V12, P669, DOI 10.1016/0309-1651(88)90083-5; Shetlar M.D., 1980, PHOTOCHEMICAL AND PHOTOBIOLOGICAL REVIEWS, V5, P105; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STEIN RB, 1984, J VIROL, V50, P343, DOI 10.1128/JVI.50.2.343-351.1984; YAMASAKI L, 1989, MOL CELL BIOL, V9, P3028, DOI 10.1128/MCB.9.7.3028	36	35	35	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7602	7608						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902223				2022-12-25	WOS:A1991FJ34200046
J	YI, F; DENKER, BM; NEER, EJ				YI, F; DENKER, BM; NEER, EJ			STRUCTURAL AND FUNCTIONAL-STUDIES OF CROSS-LINKED G0 PROTEIN SUBUNITS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING PROTEINS; BOVINE CEREBRAL-CORTEX; ROD OUTER SEGMENTS; ADP-RIBOSYLATION; PERTUSSIS TOXIN; ALPHA-SUBUNITS; CONFORMATIONAL-CHANGES; LIMITED PROTEOLYSIS; MOLECULAR-CLONING; ADENYLATE-CYCLASE	The guanine nucleotide binding proteins (G proteins) that couple hormone and other receptors to a variety of intracellular effector enzymes and ion channels are heterotrimers of alpha, beta, and gamma-subunits. One way to study the interfaces between subunits is to analyze the consequences of chemically cross-linking them. We have used 1,6-bismaleimidohexane (BMH), a homobifunctional cross-linking reagent that reacts with sulfhydryl groups, to cross-link alpha to beta-subunits of G(o) and G(i-1). Two cross-linked products are formed from each G protein with apparent molecular masses of 140 and 122 kDa on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Both bands formed from G(o) reacted with anti-alpha-o and anti-beta antibody. The mobility on sodium dodecyl sulfate-polyacrylamide gel electrophoresis is anomalous since the undenatured, cross-linked proteins have the same Stokes radius as the native, uncross-linked alpha-beta-gamma-heterotrimer. Therefore, each cross-linked product contains one alpha and one beta-subunit. Activation of G(o) by guanosine 5'-3-O-(thio)triphosphate (GTP-gamma-S) does not prevent cross-linking of alpha to beta-gamma, consistent with an equilibrium between associated and dissociated subunits even in the presence of GTP-gamma-S. The same cross-linked products of G(o) are formed in brain membranes reacted with BMH as are formed in solution, indicating that the residues cross-linked by BMH in the pure protein are accessible when G(o) is membrane bound. Analysis of tryptic peptides formed from the cross-linked products indicates that the alpha-subunit is cross-linked to the 26-kDa carboxyl-terminal portion of the beta-subunit. The cross-linked G protein is functional, and its alpha-subunit can change conformation upon binding GTP-gamma-S. GTP-gamma-S stabilizes alpha-o to digestion by trypsin (Winslow, J. W., Van Amsterdam, J. R., and Neer, E. J. (1986) J. Biol. Chem. 261, 7571-7579) and also stabilizes the alpha-subunit in the cross-linked product. Cross-linked G(o) can be ADP-ribosylated by pertussis toxin. This ADP-ribosylation is inhibited by GTP-gamma-S with a concentration dependence that is indistinguishable from that of the control, uncross-linked G(o). These two kinds of experiments indicate that alpha-o is able to change its conformation even though it cannot separate completely from beta-gamma. Thus, although dissociation of the subunits accompanies activation of G(o) in solution, it is not obligatory for a conformational change to occur in the alpha-subunit.	BRIGHAM & WOMENS HOSP, DEPT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM036259, R01GM036259, F32GM012578] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM12578, GM36259] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; FONG HKW, 1986, P NATL ACAD SCI USA, V83, P2162, DOI 10.1073/pnas.83.7.2162; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HALLIDAY KR, 1984, J BIOL CHEM, V259, P516; HINGORANI VN, 1988, J BIOL CHEM, V263, P6916; HUFF RM, 1985, J BIOL CHEM, V260, P864; HUFF RM, 1986, J BIOL CHEM, V261, P1105; HURLEY JB, 1984, SCIENCE, V226, P860, DOI 10.1126/science.6436980; ITOH H, 1986, P NATL ACAD SCI USA, V83, P3776, DOI 10.1073/pnas.83.11.3776; IYENGAR R, 1988, J BIOL CHEM, V263, P15348; JONES DT, 1987, J BIOL CHEM, V262, P14241; KATADA T, 1984, J BIOL CHEM, V259, P3586; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MARBACH I, 1990, J BIOL CHEM, V265, P9999; MATTERA R, 1987, J BIOL CHEM, V262, P11247; NAVON SE, 1987, J BIOL CHEM, V262, P15746; NEER EJ, 1988, J BIOL CHEM, V263, P8996; RANSNAS LA, 1988, J BIOL CHEM, V263, P17239; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TSAI SC, 1984, J BIOL CHEM, V259, P5320; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; WEST RE, 1985, J BIOL CHEM, V260, P4428; WINSLOW JW, 1986, J BIOL CHEM, V261, P7571; WINSLOW JW, 1987, J BIOL CHEM, V262, P4501	26	53	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3900	3906						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1899868				2022-12-25	WOS:A1991EY68200083
J	SOOHOO, CK; HOLLOCHER, TC				SOOHOO, CK; HOLLOCHER, TC			PURIFICATION AND CHARACTERIZATION OF NITROUS-OXIDE REDUCTASE FROM PSEUDOMONAS-AERUGINOSA STRAIN-P2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER SITES; PARACOCCUS-DENITRIFICANS; SPECTROSCOPIC CHARACTERIZATION; DENITRIFYING BACTERIA; ELECTRONIC-STRUCTURES; MULTICOPPER ENZYME; PLASTOCYANIN; STUTZERI; PROTEIN; PERFECTOMARINA	Nitrous oxide reductase, which catalyzes the reduction of N2O to N2, was purified in a largely oxidized form from Pseudomonas aeruginosa strain P2 by a simple anaerobic procedure to yield an enzyme with a peptide purity of 95-98%. For the native (dimeric) enzyme, M(r) = 120,000 and for the denatured subunit, M(r) = 73,000. The enzyme contained four Cu atoms/subunit, was purple in color, and exhibited a broad absorption band at 550 nm with an extinction coefficient of about 11,000 M-1 x cm-1 referenced to the dimer. It was nearly inactive as prepared but could be activated by incubation with 2-(N-cyclohexylamino)ethane sulfonate buffer, pH 10, to specific activities as high as 27-mu-mol of N2O x min-1 x mg-1. K(m) for N2O and benzyl viologen radical cation was about 2 and 4-mu-M, respectively, both before and after enzyme activation. Activation increased the t1/2 for turnover-dependent inactivation from about 30 s to 5-10 min. Reduction of the enzyme by dithionite was kinetically biphasic and resulted in the loss of the 550-nm band and ultimate appearance of a 670-nm band. Isoelectric focusing revealed five components with pI values from 5.2 to 5.7. The pI values did not change following activation. The copper CD spectrum of the enzyme as prepared was different from that for the activated enzyme, whereas those for the enzyme after exposure to air and the activated enzyme were similar. Because the activated enzyme is a mixture of activated and inactive species, the specific activity of the activated species must be substantially greater than the observed value. Molecular heterogeneity may also explain the decreased optical absorbance and CD amplitude that resulted from the activation process. The data overall reinforce the view that the absorption spectrum of nitrous oxide reductase is not a good predictor of absolute activity.	BRANDEIS UNIV, GRAD DEPT BIOCHEM, WALTHAM, MA 02254 USA	Brandeis University								BAZYLINSKI DA, 1986, APPL ENVIRON MICROB, V51, P1239, DOI 10.1128/AEM.51.6.1239-1246.1986; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRYAN BA, 1985, APPL ENVIRON MICROB, V50, P1301, DOI 10.1128/AEM.50.5.1301-1303.1985; CASELLA L, 1988, BIOCHEM J, V251, P441, DOI 10.1042/bj2510441; COYLE CL, 1985, EUR J BIOCHEM, V153, P459, DOI 10.1111/j.1432-1033.1985.tb09324.x; DAWSON JH, 1979, J AM CHEM SOC, V101, P5046, DOI 10.1021/ja00511a040; DOOLEY DM, 1987, J AM CHEM SOC, V109, P6730, DOI 10.1021/ja00256a029; DOOLEY DM, 1979, J AM CHEM SOC, V101, P5038, DOI 10.1021/ja00511a039; DRAHEIM JE, 1985, ARCH BIOCHEM BIOPHYS, V237, P110, DOI 10.1016/0003-9861(85)90259-0; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Habeeb A F, 1972, Methods Enzymol, V25, P457, DOI 10.1016/S0076-6879(72)25041-8; HANNA PM, 1988, BIOCHEM J, V253, P561, DOI 10.1042/bj2530561; HOGLEN J, 1989, J BIOL CHEM, V264, P7556; HULSE CL, 1990, BIOCHEM BIOPH RES CO, V166, P729, DOI 10.1016/0006-291X(90)90870-S; KRISTJANSSON JK, 1981, CURR MICROBIOL, V6, P247, DOI 10.1007/BF01566982; KRISTJANSSON JK, 1980, J BIOL CHEM, V255, P704; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARGOLIASH E, 1959, BIOCHEM J, V71, P570, DOI 10.1042/bj0710570; MCEWAN AG, 1985, J BACTERIOL, V164, P823, DOI 10.1128/JB.164.2.823-830.1985; MICHALSKI WP, 1986, BIOCHIM BIOPHYS ACTA, V872, P50, DOI 10.1016/0167-4838(86)90146-9; RIESTER J, 1989, EUR J BIOCHEM, V178, P751, DOI 10.1111/j.1432-1033.1989.tb14506.x; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SNYDER SW, 1984, BIOCHEM BIOPH RES CO, V119, P588, DOI 10.1016/S0006-291X(84)80289-2; SNYDER SW, 1987, J BIOL CHEM, V262, P6515; SNYDER SW, 1987, APPL ENVIRON MICROB, V53, P2045, DOI 10.1128/AEM.53.9.2045-2049.1987; SOLOMON EI, 1980, J AM CHEM SOC, V102, P168, DOI 10.1021/ja00521a029; SOOHOO CK, 1991, J BIOL CHEM, V266, P2210; SUZUKI S, 1986, BIOCHEM BIOPH RES CO, V136, P610, DOI 10.1016/0006-291X(86)90484-5; TERAGUCHI S, 1989, J BIOL CHEM, V264, P1972; VIEBROCK A, 1988, J BACTERIOL, V170, P4658, DOI 10.1128/jb.170.10.4658-4668.1988; WEBER K, 1969, J BIOL CHEM, V244, P4406	32	39	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 5	1991	266	4					2203	2209						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EV515	1899237				2022-12-25	WOS:A1991EV51500031
J	NAKAMURA, A; FUKUMORI, F; HORINOUCHI, S; MASAKI, H; KUDO, T; UOZUMI, T; HORIKOSHI, K; BEPPU, T				NAKAMURA, A; FUKUMORI, F; HORINOUCHI, S; MASAKI, H; KUDO, T; UOZUMI, T; HORIKOSHI, K; BEPPU, T			CONSTRUCTION AND CHARACTERIZATION OF THE CHIMERIC ENZYMES BETWEEN THE BACILLUS-SUBTILIS CELLULASE AND AN ALKALOPHILIC BACILLUS CELLULASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN N-4; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCES; CATALYTIC RESIDUES; MOLECULAR-CLONING; GENE; EXPRESSION; DNA; MUTAGENESIS; AMYLASE	The amino acid sequences of cellulase from Bacillus subtilis (BSC) and that from an alkalophilic Bacillus sp. N-4 (NK1) show significant homology in most parts except for the C-terminal portions. Despite the high homology, the pH activity profiles of the two enzymes are quite different; BSC has its optimum pH at 6-6.5, whereas NK1 is active over a broad pH range from 6 to 10.5. In order to identify the structural features which determine such pH activity profiles, chimeric cellulases between BSC and NK1 were constructed using four restriction sites commonly present within the homologous coding sequences, and were produced in Escherichia coli. The chimeric cellulases showed various chromatographic behaviors, reflecting the origins of their C-terminal regions. The pH activity profiles of the chimeric enzymes in the alkaline range could be classified into either the BSC or NK1 type mainly depending on the origins of the fifth C-terminal regions. In the acidic range, the profile was determined only by the origin of the fourth enzyme region from the N terminus. Comparison of the kinetic parameters between pH 5 and 6 using p-nitrophenyl cellobioside as a substrate indicated that the fourth region is responsible for the pH-dependent change of the k(cat) value. Only a limited number of amino acids in the fourth region may affect on deprotonation of catalytic residues of the cellulases and modulate the catalytic activity in the acidic pH values.	RIKEN INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN	RIKEN	NAKAMURA, A (corresponding author), UNIV TOKYO,FAC AGR,DEPT BIOTECHNOL,YAYOI 1-1-1,BUNKYO KU,TOKYO 113,JAPAN.			Nakamura, Akira/0000-0001-7250-7175				BLAKE CCF, 1967, PROC R SOC SER B-BIO, V167, P378, DOI 10.1098/rspb.1967.0035; CORNELIS P, 1982, MOL GEN GENET, V186, P507, DOI 10.1007/BF00337957; Dawson R. M. C., 1991, DATA BIOCH RES, V3rd, P363; DESHPANDE MV, 1984, ANAL BIOCHEM, V138, P481, DOI 10.1016/0003-2697(84)90843-1; FUKUMORI F, 1989, GENE, V76, P289, DOI 10.1016/0378-1119(89)90169-8; FUKUMORI F, 1986, J BACTERIOL, V168, P479, DOI 10.1128/jb.168.2.479-485.1986; FUKUMORI F, 1987, FEMS MICROBIOL LETT, V40, P311; HENRISSAT B, 1989, GENE, V81, P83, DOI 10.1016/0378-1119(89)90339-9; Imoto T., 1972, ENZYMES, V7, P665; KOIDE Y, 1986, AGR BIOL CHEM TOKYO, V50, P233, DOI 10.1080/00021369.1986.10867366; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANIATIS T, 1981, MOL CLONING LABORATO, P68; MATSUURA Y, 1984, J BIOCHEM-TOKYO, V95, P697, DOI 10.1093/oxfordjournals.jbchem.a134659; MAYER FC, 1959, J AM CHEM SOC, V81, P188, DOI 10.1021/ja01510a043; NAKAMURA A, 1987, EUR J BIOCHEM, V164, P317, DOI 10.1111/j.1432-1033.1987.tb11060.x; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; ONO S, 1958, B CHEM SOC JPN, V31, P957, DOI 10.1246/bcsj.31.957; PAICE MG, 1979, ADV CHEM SER, V181, P361; RUPLEY JA, 1967, PROC R SOC SER B-BIO, V167, P416, DOI 10.1098/rspb.1967.0038; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASHIHARA N, 1984, J BACTERIOL, V158, P503, DOI 10.1128/JB.158.2.503-506.1984; SUMNER JB, 1944, LABORATORY EXPT BIOL, P34; TOMME P, 1989, FEBS LETT, V243, P239, DOI 10.1016/0014-5793(89)80136-X; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZVELEBIL MJJM, 1988, PROTEIN ENG, V2, P127, DOI 10.1093/protein/2.2.127	28	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1579	1583						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1899090				2022-12-25	WOS:A1991EU49700036
J	HULETT, FM; KIM, EE; BOOKSTEIN, C; KAPP, NV; EDWARDS, CW; WYCKOFF, HW				HULETT, FM; KIM, EE; BOOKSTEIN, C; KAPP, NV; EDWARDS, CW; WYCKOFF, HW			BACILLUS-SUBTILIS ALKALINE PHOSPHATASE-III AND PHOSPHATASE-IV - CLONING, SEQUENCING, AND COMPARISONS OF DEDUCED AMINO-ACID-SEQUENCE WITH ESCHERICHIA-COLI ALKALINE-PHOSPHATASE 3-DIMENSIONAL STRUCTURE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; VONWILLEBRAND-FACTOR; LICHENIFORMIS; MEMBRANE; LOCALIZATION; GENE; DOMAIN; CELLS	Bacillus subtilis has an alkaline phosphatase multigene family. Two members of this gene family, phoAIII and phoAIV, were cloned, taking advantage of in vitro constructed strains containing a plasmid insertion within one or the other of the structural genes. The DNA sequences of the two genes showed approximately 64% identity at the DNA level and 63% identity in the deduced primary amino acid sequences. The phoAIII and phoAIV genes code for predicted proteins of 47,149 and 45,935 Da, respectively. Comparison of the deduced primary amino acid sequence of the mature proteins with other sequenced alkaline phosphatases from Escherichia coli, yeast, and humans shows 25-30% identity. Based on the refined crystal structure of E. coli alkaline phosphatase, it appears that the active site and the core of the structure are retained in both Bacillus alkaline phosphatases. However, both proteins are truncated at the amino terminus compared with other mature alkaline phosphatases, three sizable surface loops of E. coli are deleted, and a minidomain is replaced with a larger domain in the model. Neither Bacillus alkaline phosphatase sequenced contains any cysteine residues, an amino acid implicated in intrachain disulfide bond formation in other alkaline phosphatases.	YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511	Yale University	HULETT, FM (corresponding author), UNIV ILLINOIS,DEPT BIOL SCI,MOLEC BIOL LAB,MC 067,POB 4348,CHICAGO,IL 60680, USA.							ARGRAVES WS, 1987, P NATL ACAD SCI USA, V84, P464, DOI 10.1073/pnas.84.2.464; BERG PE, 1981, J BACTERIOL, V146, P660, DOI 10.1128/JB.146.2.660-667.1981; BOOKSTEIN C, 1990, J BACTERIOL, V172, P3730, DOI 10.1128/jb.172.7.3730-3737.1990; CHANG CN, 1986, GENE, V44, P121; COLEMAN JE, 1983, ADV ENZYMOL RAMB, V55, P381; FERRARI E, 1989, GENETICS, V4, P57; GHOSH R, 1977, J BIOL CHEM, V252, P6813; GLENN AR, 1971, BIOCHEM J, V123, P129, DOI 10.1042/bj1230129; GLYNN JA, 1977, J BACTERIOL, V129, P1010, DOI 10.1128/JB.129.2.1010-1019.1977; Hanahan D., 1985, DNA CLONING PRACTICA, V1, P109; HENTHORN PS, 1988, J BIOL CHEM, V263, P12011; HULETT FM, 1986, J GEN MICROBIOL, V132, P2387; HULETT FM, 1988, J BACTERIOL, V170, P3765, DOI 10.1128/jb.170.8.3765-3768.1988; HULETT FM, 1990, J BACTERIOL, V172, P3765; KANEKO Y, 1987, GENE, V58, P137; KAPP NV, 1990, IN PRESS GENE AMST; KIM EE, 1989, CLIN CHIM ACTA, V186, P379; KLIONSKY DJ, 1989, EMBO J, V8, P2241, DOI 10.1002/j.1460-2075.1989.tb08348.x; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MCNICHOLAS JM, 1977, J BACTERIOL, V129, P501, DOI 10.1128/JB.129.1.501-515.1977; OGATA S, 1988, J BIOL CHEM, V263, P10489; OTVOS JD, 1980, BIOCHEMISTRY-US, V19, P4011, DOI 10.1021/bi00558a019; OTVOS JD, 1980, BIOCHEMISTRY-US, V19, P4031, DOI 10.1021/bi00558a021; OTVOS JD, 1980, BIOCHEMISTRY-US, V19, P4021, DOI 10.1021/bi00558a020; PYTELA R, 1988, EMBO J, V7, P1371, DOI 10.1002/j.1460-2075.1988.tb02953.x; ROBERTS CH, 1984, J BIOL CHEM, V259, P729; SOWADSKI JM, 1985, J MOL BIOL, V186, P417, DOI 10.1016/0022-2836(85)90115-9; SPENCER DB, 1981, J BACTERIOL, V145, P934, DOI 10.1128/JB.145.2.934-945.1981; SPENCER DB, 1982, J BACTERIOL, V150, P826, DOI 10.1128/JB.150.2.826-834.1982; TITANI K, 1986, BIOCHEMISTRY-US, V25, P3171, DOI 10.1021/bi00359a015; TSONIS PA, 1988, BIOCHEM J, V254, P623, DOI 10.1042/bj2540623; TYLERCROSS R, 1989, J BIOL CHEM, V264, P4523; Wyckoff HW, 1987, PHOSPHATE METABOLISM, P118	33	88	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					1077	1084						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898729				2022-12-25	WOS:A1991ET17700064
J	MCNAMARA, PD; REA, CT; SEGAL, S				MCNAMARA, PD; REA, CT; SEGAL, S			EXPRESSION OF RAT JEJUNAL CYSTINE CARRIER IN XENOPUS OOCYTES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER VESICLES; DIBASIC AMINO-ACIDS; BRAIN MESSENGER-RNA; LAEVIS OOCYTES; GLUCOSE-TRANSPORTER; CLONING	Functional interactive cystine-lysine carriers have been expressed in Xenopus oocytes following the injection of RNA extracted from rat intestinal mucosa. Lysine-inhibitable cystine uptake was able to be measured 16 h after oocyte injection with RNA. The longer the oocytes were maintained after injection, the more cystine transport capability was induced. Uninjected or water-injected oocytes showed virtually no lysine-inhibitable cystine uptake, and no system developed after the oocytes had been isolated and maintained in vitro. The cystine uptake expressed after RNA injection was selectively inhibited by dibasic amino acids and phenylalanine but not by other amino acids or alpha-methyl-D-glucoside. Expression of the interactive cystine-lysine system was induced only by RNA isolated from intestinal tissue and not by RNA from rat liver. The K(m) for cystine uptake in RNA-injected oocytes was 0.01 mM and appears identical to the single system found in the RNA source tissue.	UNIV PENN,SCH MED,DEPT PEDIAT & MED,PHILADELPHIA,PA 19104	University of Pennsylvania	MCNAMARA, PD (corresponding author), CHILDRENS HOSP PHILADELPHIA,DIV BIOCHEM DEV & MOLEC DIS,RM 7074,34TH ST & CIVIC CTR BLVD,PHILADELPHIA,PA 19104, USA.				NIDDK NIH HHS [DK40555] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK040555] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AOSHIMA H, 1988, ARCH BIOCHEM BIOPHYS, V265, P73, DOI 10.1016/0003-9861(88)90372-4; BANNON MJ, 1990, J NEUROCHEM, V54, P706, DOI 10.1111/j.1471-4159.1990.tb01929.x; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; BLAKELY RD, 1988, P NATL ACAD SCI USA, V85, P9846, DOI 10.1073/pnas.85.24.9846; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CONTRERAS R, 1981, ANAL BIOCHEM, V113, P185, DOI 10.1016/0003-2697(81)90063-4; DENT CE, 1954, J CLIN INVEST, V33, P1216, DOI 10.1172/JCI102996; DENT CE, 1951, Q J MED, V20, P205; DUMONT JN, 1972, J MORPHOL, V136, P153, DOI 10.1002/jmor.1051360203; FOREMAN JW, 1980, METABOLISM, V29, P53, DOI 10.1016/0026-0495(80)90098-0; HEDIGER MA, 1987, P NATL ACAD SCI USA, V84, P2634, DOI 10.1073/pnas.84.9.2634; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; KELLER K, 1989, J BIOL CHEM, V264, P18884; KWON O, 1989, P SOC EXP BIOL MED, V192, P205; Maniatis T., 1982, MOL CLONING; MCNAMARA PD, 1981, BIOCHEM J, V194, P443, DOI 10.1042/bj1940443; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; OZEGOVIC B, 1982, BIOSCIENCE REP, V2, P913, DOI 10.1007/BF01114898; PALACIN M, 1990, J BIOL CHEM, V265, P7142; SARTHY V, 1986, MOL BRAIN RES, V1, P97, DOI 10.1016/0169-328X(86)90025-2; SEGAL S, 1977, SCIENCE, V197, P169, DOI 10.1126/science.877548; TATE SS, 1989, ARCH BIOCHEM BIOPHYS, V275, P591, DOI 10.1016/0003-9861(89)90405-0; VERA JC, 1990, MOL CELL BIOL, V10, P743, DOI 10.1128/MCB.10.2.743	23	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 15	1991	266	2					986	989						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	ET177	1898741				2022-12-25	WOS:A1991ET17700050
J	LECLERC, S; PALANISWAMI, R; XIE, BX; GOVINDAN, MV				LECLERC, S; PALANISWAMI, R; XIE, BX; GOVINDAN, MV			MOLECULAR-CLONING AND CHARACTERIZATION OF A FACTOR THAT BINDS THE HUMAN GLUCOCORTICOID RECEPTOR GENE AND REPRESSES ITS EXPRESSION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANDROGEN RECEPTOR; MESSENGER-RNA; REGULATORY ELEMENTS; DOWN-REGULATION; DNA; TRANSCRIPTION; CDNA; SEQUENCE; PROMOTER; PROTEINS	The human DNA binding factor GRF-1, which associates with the promoter region of the glucocorticoid receptor gene (hGR gene), is a repressor of glucocorticoid receptor transcription. The GRF-1 cDNA was cloned using polyclonal antibodies against the purified protein. The deduced amino acid sequence from the cDNA sequences show the presence of three sequence motifs characteristic of a zinc finger and one motif suggestive of a leucine zipper in which 1 cysteine is found instead of all leucines. The GRF-1 expressed in COS-1 cells has a molecular weight of 95,000 and enhances the homologous down-regulation of wild-type hGR gene expression. Biochemical analysis suggests that GRF-1 interaction is sequence specific and that transcriptional efficacy of GRF-1 is regulated through its interaction with specific sequence motif, namely 5'-GAAGGAGGTAGCGAGAAAAGAAACTGGAGAAACTCGGT.GG-3'. The GRF-1 mRNA is 6.5 kilobases long in rat liver and human MCF-7 cells, and its level is regulated by glucocorticoids.	CHU LAVAL, RES CTR, MOLEC ENDOCRINOL LAB, QUEBEC CITY G1V 4G2, QUEBEC, CANADA; UNIV LAVAL, QUEBEC CITY G1K 7P4, QUEBEC, CANADA	Laval University; Laval University								AGRE P, 1989, SCIENCE, V246, P922, DOI 10.1126/science.2530632; AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BREATHNACH R, 1983, NUCLEIC ACIDS RES, V11, P7119, DOI 10.1093/nar/11.20.7119; BURNSTEIN KL, 1990, J BIOL CHEM, V265, P7284; CIDLOWSKI JA, 1981, ENDOCRINOLOGY, V109, P1975; DIFFLEY JFX, 1989, SCIENCE, V246, P1034, DOI 10.1126/science.2511628; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOVINDAN MV, 1990, MOL ENDOCRINOL, V4, P417, DOI 10.1210/mend-4-3-417; GOVINDAN MV, 1984, J BIOL CHEM, V259, P2915; GOVINDAN MV, 1985, NUCLEIC ACIDS RES, V13, P8293, DOI 10.1093/nar/13.23.8293; GOVINDAN MV, 1991, IN PRESS J STEROID B, V40; GRANGE T, 1985, J MOL BIOL, V184, P347, DOI 10.1016/0022-2836(85)90386-9; GRUOL DJ, 1986, J BIOL CHEM, V261, P4909; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JONES NC, 1988, GENE DEV, V2, P267, DOI 10.1101/gad.2.3.267; JOST JP, 1984, P NATL ACAD SCI-BIOL, V81, P429, DOI 10.1073/pnas.81.2.429; KADANOGA JT, 1986, P NATL ACAD SCI USA, V83, P5889; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; KAGEYAMA R, 1989, CELL, V59, P815, DOI 10.1016/0092-8674(89)90605-3; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KALINYAK JE, 1987, J BIOL CHEM, V262, P10441; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECLERC S, 1991, J BIOL CHEM, V266, P8711; LEMEUR M, 1981, CELL, V23, P561, DOI 10.1016/0092-8674(81)90152-5; OKRET S, 1986, P NATL ACAD SCI USA, V83, P5899, DOI 10.1073/pnas.83.16.5899; RINGOLD GM, 1985, ANNU REV PHARMACOL, V25, P529, DOI 10.1146/annurev.pa.25.040185.002525; ROSEWICZ S, 1988, J BIOL CHEM, V263, P2581; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAPOLSKY RM, 1984, ENDOCRINOLOGY, V114, P287, DOI 10.1210/endo-114-1-287; SCHEIDEREIT C, 1986, DNA-J MOLEC CELL BIO, V5, P383, DOI 10.1089/dna.1986.5.383; SHINOMIYA T, 1984, P NATL ACAD SCI-BIOL, V81, P1346, DOI 10.1073/pnas.81.5.1346; STRAHLE U, 1987, P NATL ACAD SCI USA, V84, P7871, DOI 10.1073/pnas.84.22.7871; STRUHL K, 1989, TRENDS BIOCHEM SCI, V14, P137, DOI 10.1016/0968-0004(89)90145-X; SVEC F, 1981, J BIOL CHEM, V256, P5984; TEWARI DS, 1989, J BIOL CHEM, V264, P16238; TILLEY WD, 1990, J BIOL CHEM, V265, P13776; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; YAMAMOTO KR, 1985, ANNU REV GENET, V19, P209, DOI 10.1146/annurev.genet.19.1.209	43	47	49	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17333	17340						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894621				2022-12-25	WOS:A1991GF44500056
J	WOLF, WM; BAJORATH, J; MULLER, A; RAGHUNATHAN, S; SINGH, TP; HINRICHS, W; SAENGER, W				WOLF, WM; BAJORATH, J; MULLER, A; RAGHUNATHAN, S; SINGH, TP; HINRICHS, W; SAENGER, W			INHIBITION OF PROTEINASE-K BY METHOXYSUCCINYL-ALA-ALA-PRO-ALA-CHLOROMETHYL KETONE - AN X-RAY STUDY AT 2.2-A RESOLUTION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; SUBTILISIN BPN'; PROGRAM	The crystal structure of the transition state analog complex formed covalently between proteinase K and methoxysuccinyl-Ala-Ala-Pro-Ala-chloromethyl ketone was determined by x-ray diffraction methods at a resolution of 2.2 angstrom and refined by constrained least squares to an R factor of 19.8% for the 11864 structure amplitudes greater than 1-sigma-F. The chloromethyl ketone group is covalently linked with the active site functional groups His69(N-epsilon) and Ser224(O-gamma). The former has substituted for chlorine and the latter has attacked the carbon of the ketone group, thereby forming the tetrahedral carbon atom of the transition state analog. The peptide part of the inhibitor is in an extended conformation and fills subsites S1 to S5 of the substrate recognition site. Its backbone hydrogens bond with strands 100-104 and 132-136 of the substrate recognition site as the central strand of a three-stranded antiparallel beta-pleated sheet. This sheet formation is associated with a movement by approximately 1 angstrom of strand 100-104 which is probably associated with the insertion of the bulky proline side chain. The methoxysuccinyl group is stacked on the phenolic side chain of Tyr104 that is a part of the bottom of the recognition site. Biochemical studies show that shorter inhibitors of this type are less effective than the longer one, because there are fewer hydrogen bonding and van der Waals/stacking interactions.	FREE UNIV BERLIN,INST KRISTALLOG,TAKUSTR 6,W-1000 BERLIN 33,GERMANY	Free University of Berlin				Hinrichs, Winfried/0000-0002-0435-4565; Wolf, Wojciech/0000-0002-9162-9933				BAJORATH J, 1988, EUR J BIOCHEM, V176, P441, DOI 10.1111/j.1432-1033.1988.tb14301.x; BETZEL C, 1988, EUR J BIOCHEM, V178, P155, DOI 10.1111/j.1432-1033.1988.tb14440.x; BETZEL C, 1986, FEBS LETT, V197, P105, DOI 10.1016/0014-5793(86)80307-6; BETZEL C, 1988, PROTEINS, V4, P157, DOI 10.1002/prot.340040302; BETZEL C, 1988, FEBS LETT, V4, P157; BROMME D, 1986, ARCH BIOCHEM BIOPHYS, V244, P439, DOI 10.1016/0003-9861(86)90611-9; CECCARELLI C, 1981, J MOL STRUCT, V70, P255, DOI 10.1016/0022-2860(81)80112-3; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; HENDRICKSON WA, 1981, INT S BIOMOLECULAR S, P43; JONES TA, 1983, COMPUTATIONAL CRYSTA, P303; KELLER E, 1988, SCHAKAL88; MACHIN PA, 1983, DARESBURY LABORATORY, V10, P3; PAHLER A, 1984, EMBO J, V3, P1311, DOI 10.1002/j.1460-2075.1984.tb01968.x; POULOS TL, 1976, J BIOL CHEM, V251, P1097; ROBERTUS JD, 1972, BIOCHEMISTRY-US, V11, P2439, DOI 10.1021/bi00763a009; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124	17	48	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17695	17699						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894649				2022-12-25	WOS:A1991GF44500105
J	BORA, PS; BORA, NS; WU, XL; LANGE, LG				BORA, PS; BORA, NS; WU, XL; LANGE, LG			MOLECULAR-CLONING, SEQUENCING, AND EXPRESSION OF HUMAN MYOCARDIAL FATTY-ACID ETHYL-ESTER SYNTHASE-III CDNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONOXIDATIVE ETHANOL-METABOLISM; GLUTATHIONE S-TRANSFERASES; PROTEINS; GENES	Fatty acid ethyl ester synthase-III (FAEES-III), previously purified to homogeneity from human heart, metabolizes ethanol nonoxidatively. Using a derived partial amino acid sequence and corresponding oligonucleotide probes, the cDNA for this enzyme has been cloned from a human heart lambda-gtII library. Of the five positive clones obtained, one contained a complete coding region (630 base pairs) and the entire 3'-noncoding region (41 base pairs). From this nucleotide sequence the complete 210 amino acid sequence of FAEES-III (M(r) 23, 307) is reported. Comparison of its amino acid sequence with that of glutathione S-transferase pi-1 suggests that they belong to the same gene family since they differ in only six nucleotides and four amino acids. The sequence of FAEES-III was also compared with those of placental glutathione S-transferase and the basic glutathione S-transferase. FAEES-III was 84% homologous with placental glutathione S-transferase but only less than 10% homologous with the basic glutathione S-transferase. Northern blots demonstrate expression of FAEES-III mRNA in normal human liver, placenta, and heart. In all cases, the mRNA for the enzyme is 0.7 kilobase in size. MCF-7 cells transfected with FAEES-III cDNA have a 14-fold increase in synthase activity and a 12-fold increase in glutathione S-transferase (GST) activity compared with control cells. MCF-7 cells transfected with GST-pi-1 cDNA have a 13-fold increase in GST activity compared with control cells but no increase in synthase activity. When the supernatant of COS-7 cells transfected with FAEES-III cDNA were immunoblotted with rabbit FAEES-III antibody, a band at 24 kilodaltons was demonstrated. Thus, we have obtained the first cDNA and amino acid sequence for a human FAEES-III which also has significant GST activity, and we have identified 4 residues potentially responsible for conferring ethanol recognition to GSTs.	WASHINGTON UNIV,JEWISH HOSP ST LOUIS,MED CTR,DEPT MED,DIV CARDIOVASC,4007 STEINBERG,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT PSYCHIAT,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT OPHTHALMOL & VISUAL SCI,ST LOUIS,MO 63110	Barnes-Jewish Hospital; Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)				Bora, Puran/0000-0003-4781-1217	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008247, R01AA006989, R01AA007656] Funding Source: NIH RePORTER; NIAAA NIH HHS [1R01AA08247-01A1, 5R01AA07656-03, 2R01AA06989-05] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BORA PS, 1989, J CLIN INVEST, V84, P1942, DOI 10.1172/JCI114382; BORA PS, 1989, FEBS LETT, V258, P236, DOI 10.1016/0014-5793(89)81662-X; BORA PS, 1989, P NATL ACAD SCI USA, V86, P4470, DOI 10.1073/pnas.86.12.4470; BORA PS, 1991, CLIN RES, V39, P295; BORA PS, 1991, ALCOHOL DRUG ABUSE R, V2, P350; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHANG C, 1987, J BIOL CHEM, V262, P11901; FUHLBRIGGE RC, 1988, P NATL ACAD SCI USA, V85, P5649, DOI 10.1073/pnas.85.15.5649; GILLIGAN SB, 1987, AM J HUM GENET, V41, P255; HANAHAN D, 1980, GENE, V10, P63, DOI 10.1016/0378-1119(80)90144-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGE LG, 1983, J CLIN INVEST, V72, P724, DOI 10.1172/JCI111022; LAPOSATA EA, 1986, SCIENCE, V231, P497, DOI 10.1126/science.3941913; LAPOSATA EA, 1987, J BIOL CHEM, V262, P4653; LAPOSATA EA, 1989, ARCH PATHOL LAB MED, V113, P762; MOSCOW JA, 1989, CANCER RES, V49, P1422; RHOADS DM, 1987, BIOCHEM BIOPH RES CO, V145, P474, DOI 10.1016/0006-291X(87)91345-3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SUGUOKA Y, 1985, NUCLEIC ACIDS RES, V13, P6049, DOI 10.1093/nar/13.17.6049; TU CPD, 1986, BIOCHEM BIOPH RES CO, V141, P229, DOI 10.1016/S0006-291X(86)80358-8; WRIGHT M, 1987, BIOCHEM BIOPH RES CO, V142, P979, DOI 10.1016/0006-291X(87)91510-5	21	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16774	16777						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885604				2022-12-25	WOS:A1991GD63500083
J	DEVITRY, C; DINER, BA; POPOT, JL				DEVITRY, C; DINER, BA; POPOT, JL			PHOTOSYSTEM-II PARTICLES FROM CHLAMYDOMONAS-REINHARDTII - PURIFICATION, MOLECULAR-WEIGHT, SMALL SUBUNIT COMPOSITION, AND PROTEIN-PHOSPHORYLATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYANOBACTERIUM-SYNECHOCYSTIS 6803; THYLAKOID MEMBRANE POLYPEPTIDES; OXYGEN-EVOLVING COMPLEX; OPEN READING FRAMES; PETD GENE-CLUSTER; NUCLEOTIDE-SEQUENCE; CHLOROPLAST DNA; PSBK GENE; REACTION CENTERS; CORE COMPLEX	PSII particles from Chlamydomonas reinhardtii were purified according to the protocol of Diner and Wollman (Diner, B. A., and Wollman, F.-A. (1980) Eur. J. Biochem. 110, 521-526) followed by ion-exchange chromatography. They contained the psbA, psbB, psbC, and psbD gene products in a 1/1/1/1 stoichiometry, cytochrome b559, and several small polypeptides, and exhibited electron transfer from donor Z to acceptor Q(A) (40-50 chlorophylls/reducible Q(A)). Upon ultracentrifugation and molecular sieving in the presence of either lauryl maltoside or octaethylene glycol dodecyl ether (C12E8), they behaved as monomers of 440-510 kDa, including the detergent. C12E8 preparations also contained a small proportion of a partially interconvertible dimeric form. Four small subunits were identified by N-terminal sequencing, namely a 6.1-kDa nuclear-encoded subunit and three chloroplast-encoded subunits homologous to psbE, psbK, and psbM gene products. Cytochrome b559 subunit-alpha (psbE) of C. reinhardtii, but not subunit-beta (psbF), was recognized by an antiserum raised against higher plant cytochrome b559. The products of the psbF, psbI, and psbN genes remained undetected, presumably because of blocked N termini. At least four polypeptides presented both phosphorylated and unphosphorylated forms (psbC, psbD, and psbH gene products, as well as an unidentified 5kDa subunit).	DUPONT CO,EXPTL STN,DEPT CENT RES & DEV,WILMINGTON,DE 19880	DuPont	DEVITRY, C (corresponding author), INST BIOL PHYSICOCHIM,13 RUE PIERRE & MARIE CURIE,F-75005 PARIS,FRANCE.							ABDELMAWGOOD AL, 1990, PLANT MOL BIOL, V14, P445, DOI 10.1007/BF00028780; AKABORI K, 1988, BIOCHIM BIOPHYS ACTA, V932, P345, DOI 10.1016/0005-2728(88)90170-3; BASSI R, 1989, EUR J CELL BIOL, V50, P84; BASSI R, 1990, CURRENT RES PHOTOSYN, V2, P209; BENNOUN P, 1986, PLANT MOL BIOL, V6, P151, DOI 10.1007/BF00021484; BERTHOLD DA, 1981, FEBS LETT, V134, P231, DOI 10.1016/0014-5793(81)80608-4; BRICKER TM, 1990, PHOTOSYNTH RES, V24, P1, DOI 10.1007/BF00032639; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CANTRELL A, 1988, PHOTOSYNTH RES, V16, P65, DOI 10.1007/BF00039486; CHAKHMAKHCHEVA OG, 1989, NUCLEIC ACIDS RES, V17, P2858, DOI 10.1093/nar/17.7.2858; CHUA NH, 1975, P NATL ACAD SCI USA, V72, P2175, DOI 10.1073/pnas.72.6.2175; CRAMER WA, 1977, ANNU REV PLANT PHYS, V28, P133, DOI 10.1146/annurev.pp.28.060177.001025; CUSHMAN JC, 1988, CURR GENET, V13, P173, DOI 10.1007/BF00365652; Dawson R. M. C., 1986, DATA BIOCH RES, P545; de Vitry C, 1987, PROGR PHOTOSYNTHESIS, VII, P105; DEBUS RJ, 1988, BIOCHEMISTRY-US, V27, P9071, DOI 10.1021/bi00426a001; DEDNER N, 1988, FEBS LETT, V236, P77, DOI 10.1016/0014-5793(88)80288-6; DEKKER JP, 1988, BIOCHIM BIOPHYS ACTA, V936, P307, DOI 10.1016/0005-2728(88)90006-0; DELEPELAIRE P, 1983, PHOTOBIOCH PHOTOBIOP, V6, P279; DELEPELAIRE P, 1984, EMBO J, V3, P701, DOI 10.1002/j.1460-2075.1984.tb01872.x; DELEPELAIRE P, 1985, BIOCHIM BIOPHYS ACTA, V809, P277, DOI 10.1016/0005-2728(85)90071-4; DESSEN P, 1990, COMPUT APPL BIOSCI, V6, P355; DEVITRY C, 1989, CR ACAD SCI III-VIE, V309, P709; DEVITRY C, 1989, J CELL BIOL, V109, P991, DOI 10.1083/jcb.109.3.991; DINER BA, 1980, EUR J BIOCHEM, V110, P521, DOI 10.1111/j.1432-1033.1980.tb04894.x; DUNAHAY TG, 1984, BIOCHIM BIOPHYS ACTA, V764, P179, DOI 10.1016/0005-2728(84)90027-6; Einstein A, 1906, ANN PHYS-BERLIN, V19, P289, DOI 10.1002/andp.19063240204; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; ERICKSON JM, 1984, EMBO J, V3, P2753, DOI 10.1002/j.1460-2075.1984.tb02206.x; FUKUDA M, 1989, NUCLEIC ACIDS RES, V17, P7521, DOI 10.1093/nar/17.18.7521; GHANOTAKIS DF, 1990, ANNU REV PLANT PHYS, V41, P255, DOI 10.1146/annurev.pp.41.060190.001351; GHANOTAKIS DF, 1987, BIOCHIM BIOPHYS ACTA, V891, P15, DOI 10.1016/0005-2728(87)90078-8; GOUY M, 1985, COMPUT APPL BIOSCI, V1, P167; HAAG E, 1990, EUR J BIOCHEM, V189, P47, DOI 10.1111/j.1432-1033.1990.tb15458.x; HERRMANN RG, 1984, FEBS LETT, V176, P239, DOI 10.1016/0014-5793(84)80949-7; HIRATSUKA J, 1989, MOL GEN GENET, V217, P185, DOI 10.1007/BF02464880; HIRD SM, 1986, FEBS LETT, V209, P181, DOI 10.1016/0014-5793(86)81107-3; HUNDAL T, 1990, BIOCHIM BIOPHYS ACTA, V1017, P235, DOI 10.1016/0005-2728(90)90190-F; IKEUCHI M, 1989, FEBS LETT, V242, P263, DOI 10.1016/0014-5793(89)80482-X; IKEUCHI M, 1989, FEBS LETT, V251, P155, DOI 10.1016/0014-5793(89)81446-2; IKEUCHI M, 1989, FEBS LETT, V253, P178, DOI 10.1016/0014-5793(89)80954-8; JOLIOT P, 1990, BIOCHEMISTRY-US, V29, P4355, DOI 10.1021/bi00470a014; JOLIOT P, 1989, BIOCHIM BIOPHYS ACTA, V975, P336, DOI 10.1016/S0005-2728(89)80341-X; KOIKE H, 1989, FEBS LETT, V244, P391, DOI 10.1016/0014-5793(89)80570-8; Kuntz I D Jr, 1974, Adv Protein Chem, V28, P239, DOI 10.1016/S0065-3233(08)60232-6; MATTOO AK, 1987, P NATL ACAD SCI USA, V84, P1497, DOI 10.1073/pnas.84.6.1497; MATUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MCEWEN CR, 1967, ANAL BIOCHEM, V20, P114, DOI 10.1016/0003-2697(67)90271-0; METZ JG, 1989, BIOCHEMISTRY-US, V28, P6960, DOI 10.1021/bi00443a028; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MICHEL HP, 1987, FEBS LETT, V212, P103, DOI 10.1016/0014-5793(87)81565-X; MOOS M, 1988, J BIOL CHEM, V263, P6005; MORSCHEL E, 1987, PLANTA, V172, P145, DOI 10.1007/BF00394582; MURATA N, 1990, BIOCHIM BIOPHYS ACTA, V1019, P261, DOI 10.1016/0005-2728(90)90203-G; MURATA N, 1988, FEBS LETT, V235, P283, DOI 10.1016/0014-5793(88)81280-8; NANBA O, 1987, P NATL ACAD SCI USA, V84, P109, DOI 10.1073/pnas.84.1.109; OHYAMA K, 1986, NATURE, V322, P572, DOI 10.1038/322572a0; OLIVE J, 1981, ARCH BIOCHEM BIOPHYS, V208, P456, DOI 10.1016/0003-9861(81)90532-4; PAKRASI HB, 1988, EMBO J, V7, P325, DOI 10.1002/j.1460-2075.1988.tb02816.x; PICCIONI RG, 1981, EUR J BIOCHEM, V117, P93; POPOT JL, 1990, ANNU REV BIOPHYS BIO, V19, P369; POPOT JL, 1990, BIOCHEMISTRY-US, V29, P4031, DOI 10.1021/bi00469a001; REVERDATTO SV, 1989, NUCLEIC ACIDS RES, V17, P2859, DOI 10.1093/nar/17.7.2859; ROCK CD, 1987, CURR GENET, V12, P69, DOI 10.1007/BF00420729; ROGNER M, 1990, J BIOL CHEM, V265, P6189; SCHRODER PW, 1988, FEBS LETT, V235, P289; SEIBERT M, 1987, J CELL BIOL, V105, P2257, DOI 10.1083/jcb.105.5.2257; SHINOZAKI K, 1986, EMBO J, V5, P2043, DOI 10.1002/j.1460-2075.1986.tb04464.x; SILK GW, 1990, NUCLEIC ACIDS RES, V18, P4930, DOI 10.1093/nar/18.16.4930; STAEHELIN LA, 1986, ENCY PLANT PHYSL, V19, P1; STIREWALT VL, 1989, NUCLEIC ACIDS RES, V17, P10096, DOI 10.1093/nar/17.23.10096; SUAREZ MD, 1984, J BIOL CHEM, V259, P3791; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREBST A, 1986, Z NATURFORSCH C, V41, P240; VERNON LP, 1966, J BIOL CHEM, V241, P4101; WEBBER AN, 1989, PLANT MOL BIOL, V12, P141, DOI 10.1007/BF00020499; WESTHOFF P, 1986, CURR GENET, V11, P165, DOI 10.1007/BF00420602; WILLEY DL, 1989, CURR GENET, V15, P213, DOI 10.1007/BF00435508; WOLLMAN FA, 1984, J CELL BIOL, V98, P1, DOI 10.1083/jcb.98.1.1; ZHANG ZH, 1990, NUCLEIC ACIDS RES, V18, P1284, DOI 10.1093/nar/18.5.1284; [No title captured]	82	89	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16614	16621						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885590				2022-12-25	WOS:A1991GD63500061
J	ZHANG, ZY; POORMAN, RA; MAGGIORA, LL; HEINRIKSON, RL; KEZDY, FJ				ZHANG, ZY; POORMAN, RA; MAGGIORA, LL; HEINRIKSON, RL; KEZDY, FJ			DISSOCIATIVE INHIBITION OF DIMERIC ENZYMES - KINETIC CHARACTERIZATION OF THE INHIBITION OF HIV-1 PROTEASE BY ITS COOH-TERMINAL TETRAPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							HERPESVIRUS RIBONUCLEOTIDE REDUCTASE; IMMUNODEFICIENCY-VIRUS PROTEASE; RETROVIRAL PROTEASES	Human immunodeficiency virus 1 (HIV-1) protease is an aspartyl protease composed of two identical protomers linked by a four-stranded antiparallel beta-sheet consisting of the NH2- and COOH-terminal segments (Weber, 1. T. (1990) J. Biol. Chem. 265, 10492-10496). Kinetic analysis of the HIV-1 protease-catalyzed hydrolysis of a fluorogenic substrate demonstrates that the enzyme is an obligatory dimer. At pH = 5.0, 0.1 M sodium acetate, 1 M NaCl, 1 mm EDTA buffer, 37-degrees-C, the equilibrium dissociation constant, K(d) = 3.6 +/- 1.9 nm. We found that the tetrapeptide Ac-Thr-Leu-Asn-Phe-COOH, corresponding to the COOH-terminal segment of the enzyme, is an excellent inhibitor of the enzyme. Kinetic analysis shows that the inhibitor binds to the inactive protomers and prevents their association into the active dimer (dissociative inhibition). The dissociative nature of this inhibition is consistent with the results obtained from sedimentation equilibrium experiments in which the apparent molecular weight of the enzyme was observed to be 20,800 +/- 1,500 and 12,100 +/- 300, in the absence and presence of the COOH-terminal tetrapeptide, respectively. The dissociation constant of the protomer-inhibitor complex is K(i) = 45.1 +/- 1.8-mu-m. This is the first kinetic analysis and direct experimental demonstration of noncovalent dissociative inhibition.	UPJOHN CO,DEPT BIOCHEM,301 HENRIETTA ST,KALAMAZOO,MI 49001	Pfizer								BABE LM, 1991, BIOCHEMISTRY-US, V30, P106, DOI 10.1021/bi00215a016; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; CHERVENKA CH, 1973, MANUAL METHODS ANAL, P55; COHEN EA, 1986, NATURE, V321, P441, DOI 10.1038/321441a0; DUTIA BM, 1986, NATURE, V321, P439, DOI 10.1038/321439a0; KATOH I, 1989, J VIROL, V63, P2226, DOI 10.1128/JVI.63.5.2226-2232.1989; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; MCQUADE TJ, 1990, SCIENCE, V247, P454, DOI 10.1126/science.2405486; MEEK TD, 1990, NATURE, V343, P90, DOI 10.1038/343090a0; SHEN BW, 1975, J AM CHEM SOC, V97, P1205, DOI 10.1021/ja00838a040; TOMASSELLI AG, 1990, BIOCHEMISTRY-US, V29, P264, DOI 10.1021/bi00453a036; TOMASSELLI AG, 1990, J BIOL CHEM, V265, P14675; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279	15	179	180	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15591	15594						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874717				2022-12-25	WOS:A1991GB97700010
J	NEDA, H; WU, CH; WU, GY				NEDA, H; WU, CH; WU, GY			CHEMICAL MODIFICATION OF AN ECOTROPIC MURINE LEUKEMIA-VIRUS RESULTS IN REDIRECTION OF ITS TARGET-CELL SPECIFICITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							ISOLATED RAT HEPATOCYTES; ASIALOGLYCOPROTEIN RECEPTOR; ENDOCYTIC VESICLES; GENE DELIVERY; RETROVIRUS; EXPRESSION; INVITRO	An ecotropic virus was chemically modified in order to determine whether its target cell specificity could be altered. We hypothesized that chemical coupling of galactose residues to a virus might permit specific infection of hepatocytes mediated by asialoglycoprotein receptors unique to these cells. To test this hypothesis, we took advantage of the fact that: 1) artificial asialoglycoproteins can be created by chemical coupling of lactose to proteins; and 2) viruses that are ecotropic have a narrow species specificity. An ecotropic, rodent-specific, replication-defective murine leukemia virus containing the gene for beta-galactosidase was chemically modified with lactose to contain 5.9-mu-mol of lactose per mg of viral RNA. Modified and unmodified viruses were incubated for 5 days with HepG2, a human hepatoma line that possesses asialoglycoprotein receptors, and SK Hep1, a human cell line that does not. As expected from the ecotropism, unmodified virus did not produce beta-galactosidase activity in either cell type. Modified virus did not produce beta-galactosidase activity in SK Hep1 cells. However, modified virus did produce beta-galactosidase activity, 71.2 units/mg of cell protein, in the human receptor (+) HepG2 cells. Interestingly, modification of the virus also resulted in decreased enzyme activity in previously susceptible host rodent cells. Competition with modified virus by an excess of an asialoglycoprotein completely prevented development of enzymatic activity in HepG2 cells. Histochemical treatment of cells with 5-bromo-4-chloro-3-indoyl beta-D-galactoside to detect in situ beta-galactosidase activity demonstrated that only HepG2 cells treated with modified virus were positive and that 36% of these cells were stained after 5 days. These data indicate that chemical modification of a virus can result in a redirection of the infectivity of the virus toward hepatocyte-derived cells mediated by the presence of asialoglycoprotein receptors.	UNIV CONNECTICUT,SCH MED,DEPT MED,DIV GASTROENTEROL HEPATOL,RM AM-044,263 FARMINGTON AVE,FARMINGTON,CT 06030	University of Connecticut					NATIONAL CANCER INSTITUTE [K04CA001110, R01CA046801] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042182] Funding Source: NIH RePORTER; NCI NIH HHS [CA01 110, CA46801] Funding Source: Medline; NIDDK NIH HHS [DK42182] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSEN KB, 1983, VIROLOGY, V125, P85, DOI 10.1016/0042-6822(83)90065-X; ASHWELL G, 1974, ADV ENZYMOL RAMB, V41, P99; BUYNAK EB, 1976, JAMA-J AM MED ASSOC, V235, P2832, DOI 10.1001/jama.235.26.2832; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; DANOS O, 1988, P NATL ACAD SCI USA, V85, P6460, DOI 10.1073/pnas.85.17.6460; GORMAN C, 1986, DNA CLONING, V2, P157; GOUD B, 1988, VIROLOGY, V163, P251, DOI 10.1016/0042-6822(88)90261-9; HELENIUS A, 1984, BIOL CELL, V51, P181, DOI 10.1111/j.1768-322X.1984.tb00297.x; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; NUNRO HN, 1966, METHOD BIOCHEM ANAL, V14, P113; NUSSBAUM O, 1987, FEBS LETT, V221, P61, DOI 10.1016/0014-5793(87)80352-6; OKA JA, 1983, J BIOL CHEM, V258, P253; ROUX P, 1989, P NATL ACAD SCI USA, V86, P9079, DOI 10.1073/pnas.86.23.9079; SANES JR, 1986, EMBO J, V5, P3133, DOI 10.1002/j.1460-2075.1986.tb04620.x; SCHWARTZ AL, 1981, J BIOL CHEM, V256, P8878; SCHWARTZ BA, 1977, ARCH BIOCHEM BIOPHYS, V181, P542, DOI 10.1016/0003-9861(77)90261-2; TOLLESHAUG H, 1979, BIOCHIM BIOPHYS ACTA, V585, P71, DOI 10.1016/0304-4165(79)90326-X; TYCKO B, 1982, CELL, V28, P643, DOI 10.1016/0092-8674(82)90219-7; WATANABE N, 1989, CANCER IMMUNOL IMMUN, V28, P157; WHITEHEAD PH, 1966, BIOCHIM BIOPHYS ACTA, V124, P209, DOI 10.1016/0304-4165(66)90336-9; WILSON G, 1978, J BIOL CHEM, V253, P2070; WILSON JM, 1990, P NATL ACAD SCI USA, V87, P439, DOI 10.1073/pnas.87.1.439; WILSON JM, 1988, P NATL ACAD SCI USA, V85, P3014, DOI 10.1073/pnas.85.9.3014; WU GY, 1988, J BIOL CHEM, V263, P14621; WU GY, 1988, J BIOL CHEM, V263, P4719; WU GY, 1988, BIOCHEMISTRY-US, V27, P887, DOI 10.1021/bi00403a008	27	83	117	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 5	1991	266	22					14143	14146						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FZ351	1907269				2022-12-25	WOS:A1991FZ35100002
J	NEUBERG, M; SCHUERMANN, M; MULLER, R				NEUBERG, M; SCHUERMANN, M; MULLER, R			MUTAGENESIS OF THE DNA CONTACT SITE IN FOS PROTEIN - COMPATIBILITY WITH THE SCISSORS GRIP MODEL AND REQUIREMENT FOR TRANSFORMATION	ONCOGENE			English	Article							HYPOTHETICAL STRUCTURE COMMON; TRANSCRIPTION FACTOR AP-1; LEUCINE ZIPPER MOTIF; ONCOGENE V-JUN; C-FOS; BINDING PROTEINS; GENE-EXPRESSION; AUTO-REGULATION; CELLULAR GENES; NUCLEAR FACTOR	To elucidate the mechanisms involved in the transformation by fos we have initiated a study pertaining to the identification of molecular functions of Fos protein that are crucial for transformation. We have previously reported that the presence of an intact leucine zipper in Fos is an absolute requirement for the induction of transformation, but that the autorepression function of Fos is dispensable. We now show that Fos protein also needs an intact DNA (TRE)-binding site to be able to transform. Amino acid substitutions in this domain of Fos which impair DNA binding also destroy the transforming potential of Fos, suggesting that the interaction of Fos-Jun complexes with TREs may be a crucial part of Fos-induced transformation. This hypothesis is further strengthened by our observation that Fos and Jun can cooperate in the induction of transformation. We show that a Fos protein which contains a Jun leucine zipper and is thus capable of dimerization is still dependent on the presence of exogenous Jun to induce transformation. The critical positions in the Fos DNA-binding site include those which the 'scissors grip' model predicts to be crucial, although the DNA-binding site in Fos seems to extend beyond the basic region into an adjacent cluster of acidic amino acids.	UNIV MARBURG,INST MOLEK BIOL & TUMORFORSCH,EMIL MANNKOPFF STR 2,W-3550 MARBURG,GERMANY	Philipps University Marburg			Müller, Rolf/L-4997-2016	Müller, Rolf/0000-0003-3339-4248				ABATE C, 1990, P NATL ACAD SCI USA, V87, P1032, DOI 10.1073/pnas.87.3.1032; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BARBERIS A, 1987, CELL, V50, P347, DOI 10.1016/0092-8674(87)90489-2; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHIU R, 1988, CELL, V54, P541, DOI 10.1016/0092-8674(88)90076-1; COHEN DR, 1988, MOL CELL BIOL, V8, P2063, DOI 10.1128/MCB.8.5.2063; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DISTEL RJ, 1987, CELL, V49, P835, DOI 10.1016/0092-8674(87)90621-0; FARRELL PJ, 1989, EMBO J, V8, P127, DOI 10.1002/j.1460-2075.1989.tb03356.x; FU TH, 1989, MOL CELL BIOL, V9, P1120; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HALAZONETIS TD, 1988, CELL, V55, P916; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; JENUWEIN T, 1987, CELL, V48, P647, DOI 10.1016/0092-8674(87)90243-1; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KATAGIRI F, 1989, NATURE, V340, P727, DOI 10.1038/340727a0; KONIG H, 1989, EMBO J, V8, P2559, DOI 10.1002/j.1460-2075.1989.tb08394.x; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LUCIBELLO FC, 1988, ONCOGENE, V3, P43; LUCIBELLO FC, 1990, EMBO J, V9, P2827, DOI 10.1002/j.1460-2075.1990.tb07471.x; LUCIBELLO FC, 1989, CELL, V59, P999, DOI 10.1016/0092-8674(89)90756-3; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MATSUI M, 1990, ONCOGENE, V5, P249; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; MILLER AD, 1984, CELL, V36, P51; MOYEROWLEY WS, 1989, GENE DEV, V3, P283, DOI 10.1101/gad.3.3.283; MULLER R, 1984, EMBO J, V3, P1121, DOI 10.1002/j.1460-2075.1984.tb01939.x; Muller R, 1986, Biochim Biophys Acta, V823, P207, DOI 10.1016/0304-419X(86)90003-X; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NEUBERG M, 1989, NATURE, V338, P589, DOI 10.1038/338589a0; NEUBERG M, 1989, NATURE, V341, P2243; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; OSHEA EK, 1989, SCIENCE, V243, P538, DOI 10.1126/science.2911757; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; PERKINS KK, 1990, GENE DEV, V4, P822, DOI 10.1101/gad.4.5.822; RAUSCHER FJ, 1988, GENE DEV, V2, P1687, DOI 10.1101/gad.2.12b.1687; RAUSCHER FJ, 1988, SCIENCE, V240, P1010, DOI 10.1126/science.3130660; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; RISSE G, 1989, EMBO J, V8, P3825, DOI 10.1002/j.1460-2075.1989.tb08560.x; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V334, P314, DOI 10.1038/334314a0; SASSONECORSI P, 1988, CELL, V54, P553, DOI 10.1016/0092-8674(88)90077-3; SCHEURMANN M, 1989, CELL, V56, P507; SCHONTHAL A, 1988, CELL, V54, P325, DOI 10.1016/0092-8674(88)90195-X; SHAW PE, 1989, EMBO J, V8, P2567, DOI 10.1002/j.1460-2075.1989.tb08395.x; SHUMAN JD, 1990, SCIENCE, V249, P771, DOI 10.1126/science.2202050; TABATA T, 1989, SCIENCE, V245, P965, DOI 10.1126/science.2772648; TALANIAN RV, 1990, SCIENCE, V249, P769, DOI 10.1126/science.2389142; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VANBEVEREN C, 1984, VIROLOGY, V135, P229, DOI 10.1016/0042-6822(84)90133-8; VANBEVEREN C, 1983, CELL, V32, P1241, DOI 10.1016/0092-8674(83)90306-9; VINSON CR, 1989, SCIENCE, V246, P911, DOI 10.1126/science.2683088; VOGT PK, 1987, P NATL ACAD SCI USA, V84, P3316, DOI 10.1073/pnas.84.10.3316; ZARBL H, 1987, CELL, V51, P357, DOI 10.1016/0092-8674(87)90632-5; ZERIAL M, 1989, EMBO J, V8, P805, DOI 10.1002/j.1460-2075.1989.tb03441.x	60	29	29	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1325	1333						9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1909428				2022-12-25	WOS:A1991GX27200005
J	NIMMO, ER; SANDERS, PG; PADUA, RA; HUGHES, D; WILLIAMSON, R; JOHNSON, KJ				NIMMO, ER; SANDERS, PG; PADUA, RA; HUGHES, D; WILLIAMSON, R; JOHNSON, KJ			THE MEL GENE - A NEW MEMBER OF THE RAB/YPT CLASS OF RAS-RELATED GENES	ONCOGENE			English	Article							GTP-BINDING-PROTEINS; HUMAN-MALIGNANT MELANOMA; CELL-LINE; MOLECULAR-CLONING; DNA-BINDING; YEAST YPT1; C-MEL; TRANSLOCATION; CHROMOSOME-19; FAMILY	The MEL gene was identified following transfection of NIH3T3 mouse fibroblasts with DNA from a human melanoma cell line. The human MEL gene has been localized to 19cen-p13.2, a region in which translocation breakpoints occur in a number of malignancies. We have identified and sequenced human and mouse MEL cDNA clones which show homology of 92% and 96% at the nucleotide and amino acid levels respectively. The predicted human MEL protein shows only six amino acid differences between it and the recently described dog RAB8 protein. All of these changes occur in the 30 amino acids at the C-terminal of these proteins. MEL is similar to the RAB/YPT proteins in the region corresponding to the putative effector domain, suggesting that they may interact with the same cellular substrates. However, MEL contains a C-terminal CAAX motif in common with the majority of the RAS superfamily, unlike YPT1 and the majority of the RAB proteins.	CHARING CROSS & WESTMINSTER MED SCH,DEPT ANAT,LONDON W6 8RF,ENGLAND; UNIV LONDON IMPERIAL COLL SCI & TECHNOL,ST MARYS HOSP,SCH MED,BIOCHEM & MOLEC GENET,LONDON W2 1PG,ENGLAND; HEATH PK HOSP,DEPT HAEMATOL,LRF PRELEUKAEMIA UNIT,CARDIFF CF4 4XN,WALES; UNIV SURREY,DEPT MICROBIOL,GUILDFORD GU2 5XH,SURREY,ENGLAND	Imperial College London; Imperial College London; University of Surrey			Padua, Rose Ann/GVT-5961-2022; PADUA, Rose Ann/E-8621-2019	PADUA, Rose Ann/0000-0001-9964-7864; johnson, keith/0000-0002-8578-5921				BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; BOS JL, 1988, MUTAT RES, V195, P255, DOI 10.1016/0165-1110(88)90004-8; CAVANNA JS, 1990, GENOMICS, V7, P12, DOI 10.1016/0888-7543(90)90513-T; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1990, MOL CELL BIOL, V10, P6578, DOI 10.1128/MCB.10.12.6578; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1990, CELL, V63, P133, DOI 10.1016/0092-8674(90)90294-O; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HAUBRUCK H, 1987, EMBO J, V6, P4049, DOI 10.1002/j.1460-2075.1987.tb02750.x; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; KOZAK M, 1984, NATURE, V308, P241, DOI 10.1038/308241a0; LOWE DG, 1987, CELL, V48, P137, DOI 10.1016/0092-8674(87)90364-3; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MCGRATH JP, 1983, NATURE, V304, P501, DOI 10.1038/304501a0; MELLENTIN JD, 1989, CELL, V58, P77, DOI 10.1016/0092-8674(89)90404-2; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; NIMMO E, 1989, HUM GENET, V81, P382, DOI 10.1007/BF00283697; PADUA RA, 1984, NATURE, V311, P671, DOI 10.1038/311671a0; PARMITER AH, 1986, CANCER RES, V46, P1526; ROUSSEAUMERCK MF, 1989, GENOMICS, V5, P694, DOI 10.1016/0888-7543(89)90110-9; SALTMAN DL, 1990, GENE CHROMOSOME CANC, V2, P259, DOI 10.1002/gcc.2870020402; SHIMIZU K, 1983, NATURE, V304, P497, DOI 10.1038/304497a0; SPURR NK, 1986, SOMAT CELL MOLEC GEN, V12, P637, DOI 10.1007/BF01671949; TAPAROWSKY E, 1983, CELL, V34, P581, DOI 10.1016/0092-8674(83)90390-2; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WHANGPENG J, 1982, CANCER GENET CYTOGEN, V6, P119, DOI 10.1016/0165-4608(82)90077-2; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394; ZAHRAOUI A, 1988, NUCLEIC ACIDS RES, V16, P1204, DOI 10.1093/nar/16.3.1204	33	24	28	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1347	1351						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886711				2022-12-25	WOS:A1991GX27200009
J	DURONIO, RJ; RUDNICK, DA; ADAMS, SP; TOWLER, DA; GORDON, JI				DURONIO, RJ; RUDNICK, DA; ADAMS, SP; TOWLER, DA; GORDON, JI			ANALYZING THE SUBSTRATE-SPECIFICITY OF SACCHAROMYCES-CEREVISIAE MYRISTOYL-COA-PROTEIN N-MYRISTOYLTRANSFERASE BY CO-EXPRESSING IT WITH MAMMALIAN G-PROTEIN-ALPHA SUBUNITS IN ESCHERICHIA-COLI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; CHAIN FATTY-ACIDS; BINDING PROTEIN; MEMBRANE ASSOCIATION; ADENYLATE-CYCLASE; AMINO-ACID; MYRISTYLATION SIGNAL; PLASMA-MEMBRANE; RAT-LIVER; FADL GENE	A dual plasmid system was used to examine the protein and acyl-CoA specificities of Saccharomyces cerevisiae myristoyl-CoA:protein N-myristoyltransferase (NMT) by co-expressing it in Escherichia coli with each of four homologous alpha-subunits of the signal-transducing, heterotrimeric G proteins. Exogenous [H-3]myristate was incorporated into rat G(i-alpha-1) and rat G(o-alpha) but not into bovine G(s-alpha) or human G(z-alpha). Oxygen for methylene group substitutions in myristate result in analogs with comparable chain length and stereochemistry but marked reductions in hydrophobicity. Metabolic labeling studies with 6-, 11-, or 13-[H-3]oxatetradecanoic acid indicated that they were incorporated into rat G(i-alpha-1) and G(o-alpha) with an efficiency that could be correlated with their accumulation into E. coli and their interactions with purified NMT in vitro. Octapeptides derived from the NH2-terminal sequences of these four G-alpha polypeptides were tested as substrates for purified S. cerevisiae NMT. None were bound by the enzyme. Acidic residues at positions 7 and 8 appear to contribute to this effect; deletion of these two amino acids or addition of the next 9 residues of rat G(o-alpha) produced active substrates. These results imply that productive interactions between NMT and G-alpha protein substrates in vivo require structural features that are not fully represented within their NH2-terminal 8 residues.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,660 5 EUCLID AVE,BOX 8103,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DEPT MED,ST LOUIS,MO 63110; MONSANTO CO,ST LOUIS,MO 63198	Washington University (WUSTL); Washington University (WUSTL); Monsanto				Duronio, Robert/0000-0001-6469-6965; Towler, Dwight/0000-0003-2107-7923	NIAID NIH HHS [AI30188, AI27179] Funding Source: Medline; NIGMS NIH HHS [GM07200] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027179, U01AI030188] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007200] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMANN E, 1983, GENE, V25, P167, DOI 10.1016/0378-1119(83)90222-6; AUDIGIER Y, 1990, J CELL BIOL, V111, P1427, DOI 10.1083/jcb.111.4.1427; BENBASSAT A, 1987, J BACTERIOL, V169, P751, DOI 10.1128/jb.169.2.751-757.1987; BLACK PN, 1987, J BIOL CHEM, V262, P1412; BROT N, 1973, ARCH BIOCHEM BIOPHYS, V155, P475, DOI 10.1016/0003-9861(73)90140-9; BRYANT M, 1990, P NATL ACAD SCI USA, V87, P523, DOI 10.1073/pnas.87.2.523; BRYANT ML, 1989, P NATL ACAD SCI USA, V86, P8655, DOI 10.1073/pnas.86.22.8655; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUSS JE, 1989, SCIENCE, V243, P1600, DOI 10.1126/science.2648572; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COPELAND NG, 1988, J VIROL, V62, P479, DOI 10.1128/JVI.62.2.479-487.1988; CROSS FR, 1984, MOL CELL BIOL, V4, P1834, DOI 10.1128/MCB.4.9.1834; DEBOER HA, 1983, DNA-J MOLEC CELL BIO, V2, P231, DOI 10.1089/dna.1983.2.231; DEICHAITE I, 1988, MOL CELL BIOL, V8, P4295, DOI 10.1128/MCB.8.10.4295; DURONIO RJ, 1989, SCIENCE, V243, P796, DOI 10.1126/science.2644694; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; FEINSTEIN SI, 1983, NUCLEIC ACIDS RES, V11, P2927, DOI 10.1093/nar/11.9.2927; FONG HKW, 1988, P NATL ACAD SCI USA, V85, P3066, DOI 10.1073/pnas.85.9.3066; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOTTLINGER HG, 1989, P NATL ACAD SCI USA, V86, P5781, DOI 10.1073/pnas.86.15.5781; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HEMMINGS BA, 1981, P NATL ACAD SCI-BIOL, V78, P435, DOI 10.1073/pnas.78.1.435; HEUCKEROTH RO, 1989, P NATL ACAD SCI USA, V86, P5262, DOI 10.1073/pnas.86.14.5262; HEUCKEROTH RO, 1988, P NATL ACAD SCI USA, V85, P8795, DOI 10.1073/pnas.85.23.8795; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; HORII T, 1980, P NATL ACAD SCI-BIOL, V77, P313, DOI 10.1073/pnas.77.1.313; HUANG S, 1987, BIOCHEMISTRY-US, V26, P8242, DOI 10.1021/bi00399a033; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; JOHNSON DR, 1990, P NATL ACAD SCI USA, V87, P8511, DOI 10.1073/pnas.87.21.8511; JONES DT, 1987, J BIOL CHEM, V262, P14241; JONES TLZ, 1990, P NATL ACAD SCI USA, V87, P568, DOI 10.1073/pnas.87.2.568; JORGENSENEC, 1988, J VIROL, V62, P3217; KAMEDA K, 1981, J BIOL CHEM, V256, P5702; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KAPLAN JM, 1988, MOL CELL BIOL, V8, P2435, DOI 10.1128/MCB.8.6.2435; KHANDWALA AS, 1971, J BIOL CHEM, V246, P6242; KLEIN K, 1971, EUR J BIOCHEM, V19, P442, DOI 10.1111/j.1432-1033.1971.tb01334.x; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MARC D, 1989, EMBO J, V8, P2661, DOI 10.1002/j.1460-2075.1989.tb08406.x; MEDYNSKI DC, 1985, P NATL ACAD SCI USA, V82, P4311, DOI 10.1073/pnas.82.13.4311; MITCHELL AR, 1976, J AM CHEM SOC, V98, P7357, DOI 10.1021/ja00439a041; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; NAKAFUKU M, 1987, P NATL ACAD SCI USA, V84, P2140, DOI 10.1073/pnas.84.8.2140; NAKAFUKU M, 1988, P NATL ACAD SCI USA, V85, P1374, DOI 10.1073/pnas.85.5.1374; NUNN WD, 1979, J BIOL CHEM, V254, P9130; NUNN WD, 1986, J BIOL CHEM, V261, P167; OLINS PO, 1989, J BIOL CHEM, V264, P16973; PELLMAN D, 1985, NATURE, V314, P374, DOI 10.1038/314374a0; PINE MJ, 1969, BIOCHIM BIOPHYS ACTA, V174, P359, DOI 10.1016/0005-2787(69)90261-5; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; ROCK CO, 1985, J BIOL CHEM, V260, P2720; RUDNICK DA, 1991, J BIOL CHEM, V266, P9732; RUDNICKDA, 1990, J BIOL CHEM, V265, P13370; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SIMONS J, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P158; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; TOWLER D, 1986, P NATL ACAD SCI USA, V83, P2812, DOI 10.1073/pnas.83.9.2812; TOWLER DA, 1987, P NATL ACAD SCI USA, V84, P2708, DOI 10.1073/pnas.84.9.2708; TOWLER DA, 1988, J BIOL CHEM, V263, P1784; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; WILCOX C, 1987, SCIENCE, V238, P1275, DOI 10.1126/science.3685978	65	58	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 5	1991	266	16					10498	10504						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FP086	1903791				2022-12-25	WOS:A1991FP08600076
J	KINSELLA, BT; ERDMAN, RA; MALTESE, WA				KINSELLA, BT; ERDMAN, RA; MALTESE, WA			CARBOXYL-TERMINAL ISOPRENYLATION OF RAS-RELATED GTP-BINDING PROTEINS ENCODED BY RAC1, RAC2, AND RALA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA SUBUNITS CONTAIN; POSTTRANSLATIONAL MODIFICATION; MEVALONIC ACID; LAMIN-B; FARNESYL CYSTEINE; NUCLEAR-ENVELOPE; HUMAN-PLATELETS; CELL-PROTEINS; GENE-PRODUCTS; IDENTIFICATION	Membrane localization of p21ras is dependent upon its posttranslational modification by a 15-carbon farnesyl group. The isoprenoid is linked to a cysteine located within a conserved carboxyl-terminal sequence termed the "CAAX" box (where C is cysteine, A is an aliphatic amino acid, and X is any amino acid). We now show that three GTP-binding proteins encoded by the recently identified rac1, rac2, and ralA genes also undergo isoprenoid modification. cDNAs coding for each protein were transcribed in vitro, and the RNAs were translated in reticulocyte lysates. Incorporation of isoprenoid precursors, [H-3]mevalonate or [H-3]farnesyl pyrophosphate, indicated that the translation products were modified by isoprenyl groups. A protein recognized by an antibody to rac1 also comigrated with a protein metabolically labeled by a product of [H-3]mevalonate in cultured cells. Gel permeation chromatography of radiolabeled hydrocarbons released from the rac1, rac2, and ralA proteins by reaction with Raney nickel catalyst indicated that unlike p21Hras, which was modified by a 15-carbon moiety, the rac and ralA translation products were modified by 20-carbon isoprenyl groups. Site-directed mutagenesis established that the isoprenylated cysteines in the rac1, rac2, and ralA proteins were located in the fourth position from the carboxyl terminus. The three-amino acid extension distal to the cysteine was required for this modification. The isoprenylation of rac1 (CSLL), ralA (CCIL), and the site-directed mutants rac1 (CRLL) and ralA (CSIL), demonstrates that the amino acid adjacent to the cysteine need not be aliphatic. Therefore, proteins with carboxyl-terminal CXXX sequences that depart from the CAAX motif should be considered as potential targets for isoprenoid modification.	WEIS CTR RES,GEISINGER CLIN,26-16,DANVILLE,PA 17822					Kinsella, B. Therese/0000-0003-3072-941X	NCI NIH HHS [CA-34569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDEREGG RJ, 1988, J BIOL CHEM, V263, P18236; BECK LA, 1988, J CELL BIOL, V107, P1307, DOI 10.1083/jcb.107.4.1307; BECK LA, 1990, J CELL BIOL, V110, P1489, DOI 10.1083/jcb.110.5.1489; BHULLAR RP, 1990, FEBS LETT, V260, P48, DOI 10.1016/0014-5793(90)80063-O; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRAKE AJ, 1985, CURRENT COMMUNICATIO, P103; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1986, EMBO J, V5, P2203, DOI 10.1002/j.1460-2075.1986.tb04485.x; CHARDIN P, 1989, NUCLEIC ACIDS RES, V17, P4380, DOI 10.1093/nar/17.11.4380; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GARRELS JI, 1979, J BIOL CHEM, V254, P7961; GAUTAM N, 1989, SCIENCE, V244, P971, DOI 10.1126/science.2499046; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HOLTZ D, 1989, CELL, V59, P969, DOI 10.1016/0092-8674(89)90753-8; JONES TLZ, 1990, J BIOL CHEM, V265, P19389; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KELLER RK, 1986, J BIOL CHEM, V261, P2053; KIM R, 1990, MOL CELL BIOL, V10, P5945, DOI 10.1128/MCB.10.11.5945; KROHNE G, 1989, J CELL BIOL, V109, P2003, DOI 10.1083/jcb.109.5.2003; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LOWE PN, 1990, ONCOGENE, V5, P1045; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MALTESE WA, 1990, J BIOL CHEM, V265, P2148; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; POLAKIS PG, 1989, J BIOL CHEM, V264, P16383; POLLARD KM, 1990, MOL CELL BIOL, V10, P2164, DOI 10.1128/MCB.10.5.2164; REESE JH, 1991, IN PRESS MOL CELL BI; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; REPKO EM, 1989, J BIOL CHEM, V264, P9945; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; ROBISHAW JD, 1989, J BIOL CHEM, V264, P15758; SAGAMI H, 1981, BIOCHEM INT, V3, P669; SAITO A, 1979, J BIOL CHEM, V254, P8511; Sambrook J, 1989, MOL CLONING LABORATO; SANTOS E, 1989, FASEB J, V3, P2151, DOI 10.1096/fasebj.3.10.2666231; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEPPLORENZINO L, 1989, FEBS LETT, V245, P110, DOI 10.1016/0014-5793(89)80202-9; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SHIRSAT NV, 1990, ONCOGENE, V5, P769; SINENSKY M, 1985, P NATL ACAD SCI USA, V82, P3257, DOI 10.1073/pnas.82.10.3257; STEPHENSON RC, 1990, J BIOL CHEM, V265, P16248; SUZUKI H, 1988, ANAL BIOCHEM, V172, P259, DOI 10.1016/0003-2697(88)90440-X; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286	65	140	144	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 25	1991	266	15					9786	9794						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM459	1903399				2022-12-25	WOS:A1991FM45900069
J	COBURN, J; KANE, AV; FEIG, L; GILL, DM				COBURN, J; KANE, AV; FEIG, L; GILL, DM			PSEUDOMONAS-AERUGINOSA EXOENZYME-S REQUIRES A EUKARYOTIC PROTEIN FOR ADP-RIBOSYLTRANSFERASE ACTIVITY	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO GENE-PRODUCT; GTP-BINDING-PROTEIN; ADENYLATE-CYCLASE; CHOLERA-TOXIN; CLOSTRIDIUM-BOTULINUM; RIBOSYLATION; INFECTIONS; ACTIVATION; SITE; PURIFICATION	Pseudomonas aeruginosa exoenzyme S ADP-ribosylates several GTP-binding proteins of apparent M(r) = 23,000-25,000. Exoenzyme S absolutely requires a soluble eukaryotic protein, which we have named FAS (Factor Activating exoenzyme S), in order to ADP-ribosylate all substrates. The rate of ADP-ribosylation of all exoenzyme S substrates increases linearly with time and with the FAS concentration. FAS is widespread in eukaryotes but appears to be absent from prokaryotes. We have estimated the molecular mass of the protein to be approximately 29,000 daltons and its pI to be 4.3-4.5. Several bacterial toxins share this sort of requirement for the presence of a eukaryotic protein for enzymic activity. In particular, FAS resembles ADP-ribosylation factor, a 21,000-dalton GTP-binding protein which performs an analogous function for cholera toxin. However, we can find no evidence that FAS binds GTP. In the presence of FAS, exoenzyme S ADP-ribosylates several proteins in lysates of P. aeruginosa. The requirement for a eukaryotic protein for enzymic activity, which is common to several bacterial toxins, may be a device to identify the eukaryotic environment and to ensure that the enzymes cannot function within and harm the toxin-producing bacteria.	TUFTS UNIV,DEPT BIOCHEM,BOSTON,MA 02111; NEW ENGLAND MED CTR HOSP,CTR GASTROENTEROL RES ABSORPT & SECRETORY PROC,BOSTON,MA 02111	Tufts University; Tufts Medical Center	COBURN, J (corresponding author), TUFTS UNIV,DEPT MOLEC BIOL & MICROBIOL,HLTH SCI CAMPUS,BOSTON,MA 02111, USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI016928, R37AI016928, R22AI016928] Funding Source: NIH RePORTER; NIADDK NIH HHS [AM 39428] Funding Source: Medline; NIAID NIH HHS [AI 16928] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKTORIES K, 1989, BIOCHEM BIOPH RES CO, V158, P209, DOI 10.1016/S0006-291X(89)80199-8; BJORN MJ, 1979, INFECT IMMUN, V24, P837, DOI 10.1128/IAI.24.3.837-842.1979; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; COBURN J, 1989, INFECT IMMUN, V57, P996, DOI 10.1128/IAI.57.3.996-998.1989; COBURN J, 1989, J BIOL CHEM, V264, P9004; FEIG LA, 1987, MOL ENDOCRINOL, V1, P27; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GILL DM, 1983, J BIOL CHEM, V258, P1908; GILL DM, 1987, BIOCHEMISTRY-US, V26, P6364, DOI 10.1021/bi00394a009; GILL DM, 1971, J BIOL CHEM, V246, P1492; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1986, J BIOL CHEM, V261, P7906; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAPETINA EG, 1987, P NATL ACAD SCI USA, V84, P2261, DOI 10.1073/pnas.84.8.2261; LEPPLA SH, 1978, BIOCHEM BIOPH RES CO, V81, P532, DOI 10.1016/0006-291X(78)91567-X; LEPPLA SH, 1985, MICROBIOLOGY 1985, P63; Maniatis T., 1982, MOL CLONING; MOSS J, 1976, P NATL ACAD SCI USA, V73, P4424, DOI 10.1073/pnas.73.12.4424; Nicas T I, 1985, Antibiot Chemother (1971), V36, P40; NICAS TI, 1985, J INFECT DIS, V152, P716, DOI 10.1093/infdis/152.4.716; NICAS TI, 1985, EUR J CLIN MICROBIOL, V4, P175, DOI 10.1007/BF02013593; NICAS TI, 1984, INFECT IMMUN, V45, P470, DOI 10.1128/IAI.45.2.470-474.1984; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SOKOL PA, 1981, INFECT IMMUN, V34, P147, DOI 10.1128/IAI.34.1.147-153.1981; STEARNS T, 1990, P NATL ACAD SCI USA, V87, P1238, DOI 10.1073/pnas.87.3.1238; Sugimura T, 1980, NOVEL ADP RIBOSYLATI, P425; SULTZER BM, 1976, J EXP MED, V144, P821, DOI 10.1084/jem.144.3.821; TSAI SC, 1987, P NATL ACAD SCI USA, V84, P5139, DOI 10.1073/pnas.84.15.5139; VANDOP C, 1984, J BIOL CHEM, V259, P696; VASIL ML, 1977, INFECT IMMUN, V16, P353, DOI 10.1128/IAI.16.1.353-361.1977; WOLFF J, 1980, P NATL ACAD SCI-BIOL, V77, P3841, DOI 10.1073/pnas.77.7.3841; WOODS DE, 1985, EUR J CLIN MICROBIOL, V4, P163, DOI 10.1007/BF02013591	35	72	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6438	6446						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1901061				2022-12-25	WOS:A1991FE37300066
J	CROWELL, PL; CHANG, RR; REN, Z; ELSON, CE; GOULD, MN				CROWELL, PL; CHANG, RR; REN, Z; ELSON, CE; GOULD, MN			SELECTIVE-INHIBITION OF ISOPRENYLATION OF 21-26-KDA PROTEINS BY THE ANTICARCINOGEN D-LIMONENE AND ITS METABOLITES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; GTP-BINDING PROTEIN; GAMMA SUBUNITS CONTAIN; COENZYME-A REDUCTASE; C-TERMINAL CYSTEINE; MEVALONIC ACID; POSTTRANSLATIONAL MODIFICATION; COMPETITIVE INHIBITOR; CARBOXYL-METHYLATION; ISOPRENOID SYNTHESIS	Limonene has chemotherapeutic activity against chemically induced rat mammary carcinomas, many of which contain activated ras genes. Given the recent discovery of the post-translational modification of p21ras and other cell growth-associated proteins by intermediates in the mevalonic acid pathway, and the common biochemical origins of limonene and these isoprene products, we investigated the effect of limonene on protein isoprenylation. NIH3T3 and human mammary epithelial cells were incubated with lovastatin and [2-C-14]mevalonolactone in the absence and presence of limonene. Labeled proteins were then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and fluorography. Limonene inhibited isoprenylation of a class of cellular proteins of 21-26 kDa, including p21ras and possibly other small GTP-binding proteins, in a dose-dependent manner in both cell lines. In contrast, limonene did not affect the isoprenylation of several other proteins, including nuclear lamins. Limonene is metabolized extensively in vivo but not in cultured cells. The two major rat serum metabolites of limonene, perillic acid and dihydroperillic acid, were more potent than limonene in the inhibition of isoprenylation. These results demonstrate that limonene selectively inhibits isoprenylation of 21-26-kDa proteins at a point in the mevalonic acid pathway distal to 3-hydroxy-3-methylglutaryl coenzyme A reductase, and they provide a plausible explanation for its chemotherapeutic activity. Inhibition of isoprenylation of proteins such as p21ras and other small GTP-binding proteins would alter their intracellular localization and, hence, disrupt their biological activity.	UNIV WISCONSIN,DEPT HUMAN ONCOL,600 HIGHLAND AVE,K4-332 CSC,MADISON,WI 53792; UNIV WISCONSIN,DEPT NUTR SCI,MADISON,WI 53792	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison			Gould, Michael N/C-7414-2014		NATIONAL CANCER INSTITUTE [R01CA038128, T32CA009471, R37CA038128] Funding Source: NIH RePORTER; NCI NIH HHS [CA38128, 5T32CA09471] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALBERTS AW, 1980, P NATL ACAD SCI-BIOL, V77, P3957, DOI 10.1073/pnas.77.7.3957; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BROWN MS, 1980, J LIPID RES, V21, P505; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CLARKE S, 1988, P NATL ACAD SCI USA, V85, P4643, DOI 10.1073/pnas.85.13.4643; CLEGG RJ, 1980, BIOCHEM PHARMACOL, V29, P2125, DOI 10.1016/0006-2952(80)90183-5; CLEGG RJ, 1982, J BIOL CHEM, V257, P2294; Croteau R., 1981, BIOSYNTHESIS ISOPREN, V1, P225; CROWELL P L, 1989, Proceedings of the American Association for Cancer Research Annual Meeting, V30, P171; DECLUE JE, 1991, CANCER RES, V51, P712; DIDSBURY JR, 1990, BIOCHEM BIOPH RES CO, V171, P804, DOI 10.1016/0006-291X(90)91217-G; ELDRIDGE SR, 1989, CANCER RES, V49, P4326; ELEGBEDE JA, 1986, J NATL CANCER I, V76, P323; ELEGBEDE JA, 1984, CARCINOGENESIS, V5, P661, DOI 10.1093/carcin/5.5.661; ELSON CE, 1988, CARCINOGENESIS, V9, P331, DOI 10.1093/carcin/9.2.331; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GUMERLOCK PH, 1989, ANAL BIOCHEM, V180, P158, DOI 10.1016/0003-2697(89)90105-X; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; HAAG J D, 1991, Proceedings of the American Association for Cancer Research Annual Meeting, V32, P402; HAMMOND SL, 1984, P NATL ACAD SCI-BIOL, V81, P5435, DOI 10.1073/pnas.81.17.5435; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HART MJ, 1990, J BIOL CHEM, V265, P5990; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAWATA M, 1990, P NATL ACAD SCI USA, V87, P8960, DOI 10.1073/pnas.87.22.8960; KJONAAS R, 1983, ARCH BIOCHEM BIOPHYS, V220, P79, DOI 10.1016/0003-9861(83)90389-2; KODAMA R, 1976, XENOBIOTICA, V6, P377, DOI 10.3109/00498257609151649; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASKEY RA, 1975, EUR J BIOCHEM, V56, P335, DOI 10.1111/j.1432-1033.1975.tb02238.x; LEONARD S, 1990, J BIOL CHEM, V265, P5157; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTESE WA, 1989, J BIOL CHEM, V264, P18168; MALTESE WA, 1987, J CELL PHYSIOL, V133, P471, DOI 10.1002/jcp.1041330307; MALTESE WA, 1990, J BIOL CHEM, V265, P18071; MALTESE WA, 1990, J BIOL CHEM, V265, P17883; MALTESE WA, 1985, J CLIN INVEST, V76, P1748, DOI 10.1172/JCI112165; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MALTESE WA, 1988, J BIOL CHEM, V263, P10104; MALTESE WA, 1990, J BIOL CHEM, V265, P248; MALTZMAN TH, 1989, CARCINOGENESIS, V10, P781, DOI 10.1093/carcin/10.4.781; MANNE V, 1990, P NATL ACAD SCI USA, V87, P7541, DOI 10.1073/pnas.87.19.7541; MAZIERE C, 1987, J BIOCHEM BIOPH METH, V14, P267, DOI 10.1016/0165-022X(87)90052-2; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P5873, DOI 10.1073/pnas.87.15.5873; QURESHI AA, 1988, J AGR FOOD CHEM, V36, P1220, DOI 10.1021/jf00084a023; REGAN JW, 1976, J AGR FOOD CHEM, V24, P377, DOI 10.1021/jf60204a031; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SCHMIDT RA, 1984, J BIOL CHEM, V259, P175; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEPPLORENZINO L, 1989, FEBS LETT, V245, P110, DOI 10.1016/0014-5793(89)80202-9; SHINJO K, 1990, P NATL ACAD SCI USA, V87, P9853, DOI 10.1073/pnas.87.24.9853; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; SINENSKY M, 1991, FASEB J, V5, pA1181; Stampfer M, 1985, J TISSUE CULTURE MET, V9, P107; STAMPFER MR, 1985, P NATL ACAD SCI USA, V82, P2394, DOI 10.1073/pnas.82.8.2394; SUKUMAR S, 1983, NATURE, V306, P658, DOI 10.1038/306658a0; VORBURGER K, 1989, EMBO J, V8, P4007, DOI 10.1002/j.1460-2075.1989.tb08583.x; WATTENBERG LW, 1991, CARCINOGENESIS, V12, P115, DOI 10.1093/carcin/12.1.115; WEBB DR, 1990, FOOD CHEM TOXICOL, V28, P669, DOI 10.1016/0278-6915(90)90142-A; WEBB DR, 1989, FOOD CHEM TOXICOL, V27, P639, DOI 10.1016/0278-6915(89)90118-X; WOLDA SL, 1988, J BIOL CHEM, V263, P5997; YAMANE HK, 1990, P NATL ACAD SCI USA, V87, P5868, DOI 10.1073/pnas.87.15.5868; YAMANE HK, 1991, P NATL ACAD SCI USA, V88, P286, DOI 10.1073/pnas.88.1.286; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M; ZARBL H, 1985, NATURE, V315, P382, DOI 10.1038/315382a0; ZHANG R, 1990, CANCER RES, V50, P4286	74	243	249	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17679	17685						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894647				2022-12-25	WOS:A1991GF44500103
J	TIKKA, L; ELOMAA, O; PIHLAJANIEMI, T; TRYGGVASON, K				TIKKA, L; ELOMAA, O; PIHLAJANIEMI, T; TRYGGVASON, K			HUMAN ALPHA-1(XIII) COLLAGEN GENE - MULTIPLE FORMS OF THE GENE TRANSCRIPTS ARE GENERATED THROUGH COMPLEX ALTERNATIVE SPLICING OF SEVERAL SHORT EXONS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-CHAIN COLLAGEN; MESSENGER-RNA; IV COLLAGEN; XIII COLLAGEN; VI COLLAGEN; IX COLLAGEN; X COLLAGEN; 5' END; EXPRESSION; CONTAINS	The structure of the gene for the human alpha-1(XIII) collagen chain (COL13A1) was determined from genomic clones spanning 140,000 base pairs (bp), including about 3,000 bp of the 5'-end-flanking regioin and 5,000 bp of the 3'-end-flanking region. The gene was shown to contain 39 exons. There were eight exons of 27 bp, five of 36 bp, four of 54 bp, three of 45 bp, and two of 42 bp. The rest of the exons coding for translated sequences had sizes varying between 24 and 153 bp. The genomic clones did not contain exons 3 and 4 whose sizes could, however, be estimated from cDNA clones. S1 nuclease mapping and primer extension analyzes indicated five closely spaced initiation sites of transcription. Sequencing of the 5'-end-flanking region did not reveal a typical TATA box but a four times repeated TATTTAT sequence that may serve as true TATA boxes. Two CCAAT boxes were found starting at positions -13 and -194, and furthermore, the promoter region contains two GC boxes. Previous studies on alpha-1(XIII) collagen cDNA and genomic clones showed that the primary transcript undergoes complex alternative splicing generating at least four different forms of mRNAs. The present work demonstrated that sequences of seven exons are alternatively used. These exons contain sequences coding for pure collagenous regions, pure noncollagenous regions, and an exon coding for a junction of a collagenous and noncollagenous domain.	UNIV OULU,BIOCTR,SF-90570 OULU,FINLAND; UNIV OULU,DEPT BIOCHEM,SF-90570 OULU,FINLAND; UNIV OULU,DEPT MED BIOCHEM,SF-90220 OULU,FINLAND	University of Oulu; Finland National Institute for Health & Welfare; University of Oulu; University of Oulu				Pihlajaniemi, Taina/0000-0002-1664-9045				BENNETT VD, 1989, J BIOL CHEM, V264, P8402; BOEDTKER H, 1985, ANN NY ACAD SCI, V460, P85, DOI 10.1111/j.1749-6632.1985.tb51159.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1984, NATURE, V310, P337, DOI 10.1038/310337a0; CHU ML, 1990, ANN NY ACAD SCI, V580, P55, DOI 10.1111/j.1749-6632.1990.tb17917.x; DLIANA R, 1990, J CELL BIOL, V11, P297; DYNAN WS, 1983, CELL, V32, P669, DOI 10.1016/0092-8674(83)90053-3; Eyre D, 1987, STRUCTURE FUNCTION C, P261; Favaloro J, 1980, Methods Enzymol, V65, P718; FESSLER JH, 1987, STRUCTURE FUNCTION C, P81; GORDON MK, 1989, J BIOL CHEM, V264, P19772; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1987, FEBS LETT, V224, P297, DOI 10.1016/0014-5793(87)80473-8; KUHN K, 1985, ANN NY ACAD SCI, V460, P14, DOI 10.1111/j.1749-6632.1985.tb51153.x; KURKINEN M, 1985, NATURE, V317, P177, DOI 10.1038/317177a0; LAIMINS LA, 1982, P NATL ACAD SCI-BIOL, V79, P6453, DOI 10.1073/pnas.79.21.6453; LAU YF, 1983, P NATL ACAD SCI-BIOL, V80, P5225, DOI 10.1073/pnas.80.17.5225; LOZONO G, 1985, P NATL ACAD SCI USA, V82, P4050; Maniatis T., 1982, MOL CLONING; MILLER EJ, 1985, ANN NY ACAD SCI, V460, P1, DOI 10.1111/j.1749-6632.1985.tb51152.x; NINOMIYA Y, 1986, J BIOL CHEM, V261, P5041; NINOMIYA Y, 1990, EXTRACELLULAR MATRIX, P79; NSHURA I, 1989, J BIOL CHEM, V264, P20033; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; PAJUNEN L, 1989, CYTOGENET CELL GENET, V52, P190, DOI 10.1159/000132875; PIERSCHBACHER MD, 1984, P NATL ACAD SCI-BIOL, V81, P5985, DOI 10.1073/pnas.81.19.5985; PIHLAJANIEMI T, 1990, J BIOL CHEM, V265, P16922; PIHLAJANIEMI T, 1987, P NATL ACAD SCI USA, V84, P940, DOI 10.1073/pnas.84.4.940; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; RYAN MC, 1990, J BIOL CHEM, V265, P10334; SAITTA B, 1990, J BIOL CHEM, V265, P6473; SANDBERG M, 1989, J CELL BIOL, V109, P1371, DOI 10.1083/jcb.109.3.1371; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHOWS TB, 1989, GENOMICS, V5, P128, DOI 10.1016/0888-7543(89)90096-7; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SNINEN R, 1989, J BIOL CHEM, V264, P13565; SOININEN R, 1986, P NATL ACAD SCI USA, V83, P1568, DOI 10.1073/pnas.83.6.1568; TIKKA L, 1988, P NATL ACAD SCI USA, V85, P7491, DOI 10.1073/pnas.85.20.7491; VASIOS G, 1988, J BIOL CHEM, V263, P2324; VAUGHAN L, 1988, J CELL BIOL, V106, P991, DOI 10.1083/jcb.106.3.991; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; YAMADA Y, 1980, CELL, V22, P887, DOI 10.1016/0092-8674(80)90565-6; YAMAGUCHI N, 1989, J BIOL CHEM, V264, P16022	44	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17713	17719						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894651				2022-12-25	WOS:A1991GF44500108
J	CLARKE, CF; WILLIAMS, W; TERUYA, JH				CLARKE, CF; WILLIAMS, W; TERUYA, JH			UBIQUINONE BIOSYNTHESIS IN SACCHAROMYCES-CEREVISIAE - ISOLATION AND SEQUENCE OF COQ3, THE 3,4-DIHYDROXY-5-HEXAPRENYLBENZOATE METHYLTRANSFERASE GENE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; MITOCHONDRIAL-MEMBRANE SYSTEM; ESCHERICHIA-COLI; RAT-LIVER; COENZYME-Q; ENDOPLASMIC-RETICULUM; STRUCTURAL GENE; YEAST; MUTANTS; PROTEIN	Ubiquinone (or coenzyme Q) is a lipid component of the respiratory chain in the inner mitochondrial membrane, in which it functions in electron transport. Recent reports show that ubiquinone and ubiquinone biosynthetic enzymes are present in both mitochondrial and nonmitochondrial membranes of cells (Kalen, A., Appelkvist, E.-L., Chojnacki, T., and Dallner, G. (1990) J. Biol. Chem. 265, 1158-1164) although the functions that ubiquinone may play outside of the mitochondrion are not understood. To study coenzyme Q synthesis and function we cloned the 3,4-dihydroxy-5-hexaprenylbenzoate (DHHB) methyltransferase gene by functional complementation of a yeast coenzyme Q mutant strain, defective in the COQ3 gene (Tzagoloff, A., and Dieckmann, C. L. (1990) Microbiol. Rev. 54, 211-225). This gene restores both coenzyme Q synthesis in the mutant strain and the ability to grow on media containing glycerol, a nonfermentable substrate. A one-step in situ gene replacement with the cloned DHHB methyltransferase DNA directs integration to the yeast COQ3 locus on chromosome XV of Saccharomyces cerevisiae, establishing that the COQ3 locus encodes the DHHB methyltransferase structural gene. The predicted amino acid sequence of the yeast DHHB methyltransferase contains a methyltransferase consensus sequence and shows a 40% identity with an open reading frame of Escherichia coli, the gyrA5' hypothetical protein. This open reading frame is adjacent to the gyrA gene and close to the mapped location of the ubiG gene at 48 min on the E. coli chromosome. These results suggest that the E. coli gyrA5' open reading frame encodes a methyltransferase and may correspond to the ubiG gene, which is required for ubiquinone biosynthesis.	UNIV CALIF LOS ANGELES, SCH MED, DEPT MED, DIV CARDIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL30568] Funding Source: Medline; NIGMS NIH HHS [GM45952] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASHBY MN, 1990, J BIOL CHEM, V265, P13157; BERNSTEIN M, 1985, J CELL BIOL, V101, P2374, DOI 10.1083/jcb.101.6.2374; BERTOCCI B, 1991, P NATL ACAD SCI USA, V88, P1416, DOI 10.1073/pnas.88.4.1416; BEYER RE, 1987, CHEM SCRIPTA, V27, P145; BRAMSON HN, 1984, CRC CR REV BIOCH MOL, V15, P93, DOI 10.3109/10409238409102298; CARLSON J, 1984, P NATL ACAD SCI-BIOL, V81, P4294, DOI 10.1073/pnas.81.14.4294; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CASEY J, 1978, BIOCHIM BIOPHYS ACTA, V530, P487, DOI 10.1016/0005-2760(78)90168-6; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Crane F.L., 1977, BIOMEDICAL CLIN ASPE, P3; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DOOLITTLE RF, 1990, METHOD ENZYMOL, V183, P99; ELMBERGER PG, 1989, LIPIDS, V24, P919, DOI 10.1007/BF02544535; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FREI B, 1990, P NATL ACAD SCI USA, V87, P4879, DOI 10.1073/pnas.87.12.4879; GIBERT I, 1988, J BACTERIOL, V170, P1346, DOI 10.1128/jb.170.3.1346-1349.1988; GIBSON F, 1973, Biochemical Society Transactions, V1, P317; GOEWERT RR, 1981, BIOCHEMISTRY-US, V20, P4217, DOI 10.1021/bi00517a041; GORDON PA, 1969, BIOCHIM BIOPHYS ACTA, V177, P358, DOI 10.1016/0304-4165(69)90150-0; HARTL FU, 1989, BIOCHIM BIOPHYS ACTA, V988, P1, DOI 10.1016/0304-4157(89)90002-6; HENDRICK JP, 1989, P NATL ACAD SCI USA, V86, P4056, DOI 10.1073/pnas.86.11.4056; HUSSAIN K, 1987, MOL MICROBIOL, V1, P259, DOI 10.1111/j.1365-2958.1987.tb01932.x; IKENOYA S, 1981, CHEM PHARM BULL, V29, P158; INGROSSO D, 1989, J BIOL CHEM, V264, P20131; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KALEN A, 1990, J BIOL CHEM, V265, P1158; KALEN A, 1987, BIOCHIM BIOPHYS ACTA, V926, P70, DOI 10.1016/0304-4165(87)90183-8; KREUZER KN, 1978, MOL GEN GENET, V167, P129, DOI 10.1007/BF00266906; LEHRACH H, 1977, BIOCHEMISTRY-US, V16, P4743, DOI 10.1021/bi00640a033; MABUCHI H, 1981, NEW ENGL J MED, V305, P478, DOI 10.1056/NEJM198108273050902; MCEWEN JE, 1986, J BIOL CHEM, V261, P1872; MEDIGUE C, 1990, MOL MICROBIOL, V4, P169, DOI 10.1111/j.1365-2958.1990.tb00585.x; MOMOSE K, 1972, J BIOL CHEM, V247, P3930; OLSON RE, 1983, VITAM HORM, V40, P1, DOI 10.1016/S0083-6729(08)60431-8; PAYNE GS, 1985, SCIENCE, V230, P1009, DOI 10.1126/science.2865811; PINKHAM JL, 1985, MOL CELL BIOL, V5, P3410, DOI 10.1128/MCB.5.12.3410; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SALMINEN M, 1990, GENE, V93, P241, DOI 10.1016/0378-1119(90)90231-F; Sambrook J, 1989, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHERMAN F, 1986, LABORATORY COURSE MA; SIKORSKI RS, 1989, GENETICS, V122, P19; SIPPEL CJ, 1983, J BIOL CHEM, V258, P1057; STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646; STROOBAN.P, 1972, J BACTERIOL, V109, P134, DOI 10.1128/JB.109.1.134-139.1972; SUN IL, 1990, BIOCHEM BIOPH RES CO, V172, P979, DOI 10.1016/0006-291X(90)91542-Z; TAKADA M, 1982, BIOCHIM BIOPHYS ACTA, V679, P308, DOI 10.1016/0005-2728(82)90301-2; TRUMPOWER BL, 1981, J BIOENERG BIOMEMBR, V13, P1, DOI 10.1007/BF00744743; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; TZAGOLOFF A, 1975, J BACTERIOL, V122, P826, DOI 10.1128/JB.122.3.826-831.1975; WRIGHT RM, 1984, J BIOL CHEM, V259, P5401	53	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16636	16644						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885593				2022-12-25	WOS:A1991GD63500065
J	FARKAS, I; HARDY, TA; GOEBL, MG; ROACH, PJ				FARKAS, I; HARDY, TA; GOEBL, MG; ROACH, PJ			2 GLYCOGEN-SYNTHASE ISOFORMS IN SACCHAROMYCES-CEREVISIAE ARE CODED BY DISTINCT GENES THAT ARE DIFFERENTIALLY CONTROLLED	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PHOSPHORYLATION SITES; YEAST; DNA; SEQUENCE; FORMS; PURIFICATION; MUTAGENESIS; SYNTHETASE; METABOLISM	In previous work, we identified a Saccharomyces cerevisiae glycogen synthase gene, GSY1, which codes for an 85-kDa polypeptide present in purified yeast glycogen synthase (Farkas, I., Hardy, T. A., DePaoli-Roach, A. A., and Roach, P. J. (1990) J. Biol. Chem. 265, 20879-20886). We have now cloned another gene, GSY2, which encodes a second S. cerevisiae glycogen synthase. The GSY2 sequence predicts a protein of 704 residues, molecular weight 79,963, with 80% identity to the protein encoded by GSY1. Amino acid sequences obtained from a second polypeptide of 77 kDa present in yeast glycogen synthase preparations matched those predicted by GSY2. GSY1 resides on chromosome VI, and GSY2 is located on chromosome XII. Disruption of the GSY1 gene produced a strain retaining about 85% of wild type glycogen synthase activity at stationary phase, while disruption of the GSY2 gene yielded a strain with only about 10% of wild type enzyme activity. The level of glycogen synthase activity in yeast cells disrupted for GSY1 increased in stationary phase, whereas the activity remained at a constant low level in cells disrupted for GSY2. Disruption of both genes resulted in a viable haploid that totally lacked glycogen synthase activity and was defective in glycogen deposition. In conclusion, yeast expresses two forms of glycogen synthase with activity levels that behave differently in the growth cycle. The GSY2 gene product appears to be the predominant glycogen synthase with activity linked to nutrient depletion.			FARKAS, I (corresponding author), INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA.		Ilona, Farkas/AAX-8344-2021		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK027221, R01DK042576, R01DK027221, P60DK020542] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK27221, DK42576, DK20542] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATTFIELD PV, 1987, FEBS LETT, V225, P259, DOI 10.1016/0014-5793(87)81170-5; BAI G, 1990, J BIOL CHEM, V265, P7843; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; Bergmeyer H.U., 1974, METHOD ENZYMAT AN, VVol. 3., P1196; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1989, P NATL ACAD SCI USA, V86, P1443, DOI 10.1073/pnas.86.5.1443; CAMERON S, 1988, CELL, V53, P555, DOI 10.1016/0092-8674(88)90572-7; CANNON JF, 1987, MOL CELL BIOL, V7, P2653, DOI 10.1128/MCB.7.8.2653; CARABAZA A, 1990, BIOCHEM J, V268, P401, DOI 10.1042/bj2680401; CHU G, 1986, SCIENCE, V234, P1582, DOI 10.1126/science.3538420; Cohen P., 1986, ENZYMES, VXVII, P461; DEPAOLIROACH AA, 1983, J BIOL CHEM, V258, P702; FARKAS I, 1990, J BIOL CHEM, V265, P20879; FRANCOIS J, 1988, EUR J BIOCHEM, V174, P561, DOI 10.1111/j.1432-1033.1988.tb14135.x; FRANCOIS J, 1987, EUR J BIOCHEM, V164, P369, DOI 10.1111/j.1432-1033.1987.tb11067.x; GRBA S, 1976, EUR J APPL MICROBIOL, V2, P29, DOI 10.1007/BF01385443; GUNJA-SMITH Z, 1977, Journal of Bacteriology, V130, P818; HAMILTON R, 1987, NUCLEIC ACIDS RES, V15, P3581, DOI 10.1093/nar/15.8.3581; HUANG KP, 1974, J BIOL CHEM, V249, P3851; HUANG KP, 1972, BIOCHEM BIOPH RES CO, V49, P1610, DOI 10.1016/0006-291X(72)90526-8; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; PENG ZY, 1990, J BIOL CHEM, V265, P13871; PETES TD, 1978, J BACTERIOL, V134, P295, DOI 10.1128/JB.134.1.295-305.1978; ROACH PJ, 1990, FASEB J, V4, P2961, DOI 10.1096/fasebj.4.12.2168324; ROTHMANDENES LB, 1970, P NATL ACAD SCI USA, V66, P967, DOI 10.1073/pnas.66.3.967; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; SNYDER M, 1986, P NATL ACAD SCI USA, V83, P730, DOI 10.1073/pnas.83.3.730; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; TREGER JM, 1990, MOL CELL BIOL, V10, P3174, DOI 10.1128/MCB.10.6.3174; YOCHEM J, 1987, J MOL BIOL, V195, P233, DOI 10.1016/0022-2836(87)90646-2; ZHANG WM, 1989, FASEB J, V3, P2532, DOI 10.1096/fasebj.3.13.2509275	37	128	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15602	15607						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908457				2022-12-25	WOS:A1991GB97700013
J	GOLDSTEIN, JL; BROWN, MS; STRADLEY, SJ; REISS, Y; GIERASCH, LM				GOLDSTEIN, JL; BROWN, MS; STRADLEY, SJ; REISS, Y; GIERASCH, LM			NONFARNESYLATED TETRAPEPTIDE INHIBITORS OF PROTEIN FARNESYLTRANSFERASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							GAMMA-SUBUNIT; RAS PROTEINS; FARNESYL; TRANSFERASE; P21RAS	The protein farnesyltransferase from rat brain was previously shown to be inhibited competitively by tetrapeptides that conform to the consensus Cys-A1-A2-X, where A1 and A2 are aliphatic amino acids and X is methionine, serine, or phenylalanine. In the current studies we use a thin layer chromatography assay to show that most of these tetrapeptides are themselves farnesylated by the purified enzyme. Two classes of tetrapeptides are not farnesylated and therefore act as true inhibitors: 1) those that contain an aromatic residue at the A2 position and 2) those that contain penicillamine (beta,beta-dimethylcysteine) in place of cysteine. The most potent of these pure inhibitors was Cys-Val-Phe-Met, which inhibited farnesyltransferase activity by 50% at < 0.1-mu-M. These data indicate that the inclusion of bulky aromatic or methyl residues in a tetrapeptide can abolish prenyl group transfer without blocking binding to the enzyme. This information should be useful in the design of peptides or peptidomimetics that inhibit farnesylation and thus block the action of p21ras proteins in animal cells.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	GOLDSTEIN, JL (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Gierasch, Lila M/D-1494-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline; NIGMS NIH HHS [GM37616] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHEN WJ, 1991, IN PRESS CELL; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FINEGOLD AA, 1991, P NATL ACAD SCI USA, V88, P4448, DOI 10.1073/pnas.88.10.4448; FUKADA Y, 1990, NATURE, V346, P658, DOI 10.1038/346658a0; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GLOMSET JA, 1990, TRENDS BIOCHEM SCI, V15, P139, DOI 10.1016/0968-0004(90)90213-U; GOODMAN LE, 1988, YEAST, V4, P271, DOI 10.1002/yea.320040405; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; LAI RK, 1990, P NATL ACAD SCI USA, V87, P7673, DOI 10.1073/pnas.87.19.7673; PATAKI G, 1963, J CHROMATOGR, V12, P541, DOI 10.1016/S0021-9673(01)83727-4; REISS Y, 1990, Methods (Orlando), V1, P241, DOI 10.1016/S1046-2023(05)80323-8; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1991, J BIOL CHEM, V266, P10672; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; ROSSI G, 1991, NATURE, V351, P158, DOI 10.1038/351158a0; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SCHAFER WR, 1990, SCIENCE, V249, P1133, DOI 10.1126/science.2204115; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; Stewart JM, 1984, SOLID PHASE PEPTIDE	20	202	254	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15575	15578						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874715				2022-12-25	WOS:A1991GB97700006
J	CLARKLEWIS, I; SANGHERA, JS; PELECH, SL				CLARKLEWIS, I; SANGHERA, JS; PELECH, SL			DEFINITION OF A CONSENSUS SEQUENCE FOR PEPTIDE SUBSTRATE RECOGNITION BY P44MPK, THE MEIOSIS-ACTIVATED MYELIN BASIC-PROTEIN KINASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-ASSOCIATED PROTEIN-2; GROWTH-FACTOR RECEPTOR; PHOSPHORYLATION SITE; SPATIAL REQUIREMENTS; OOCYTE MATURATION; CASEIN KINASE-2; MAP KINASE; S6 KINASE; RESIDUES; INVIVO	Synthetic peptides have been used to define the consensus amino acid sequence for substrate recognition by the meiosis-activated myelin basic protein (MBP) kinase (p44mpk), which was purified from maturing sea star oocytes. This protein kinase shares many properties with the mitogen-activated microtubule-associated protein-2 kinase (p42mapk) in vertebrates. Recently, Thr-97 in the tryptic fragment KNIVTPRTPPPSQGK of bovine MBP was identified as the major site of phosphorylation by p44mpk (Sanghera, J. S., Aebersold, R., Morrison, H. D., Bures, E. J., and Pelech, S. L. (1990) FEBS Lett. 273, 223-226). Synthetic peptides modeled after this sequence revealed that the presence of a proline residue C-terminal (+1 position) to the phosphorylatable threonine (or serine) residue was critical for recognition by p44mpk. Although not essential, a proline residue located at the -2 position enhanced the V(max) of peptide phosphorylation. Basic, acidic, and non-polar residues were equally tolerated at the -1 position. The presence of an amino acid residue at position -3 also increased peptide phosphorylation. Thus, the optimum consensus sequence for phosphorylation by p44mpk was defined as Pro-X-(Ser/Thr)-Pro, where X is a variable amino acid residue, but ideally not a Pro. Peptides that included this sequence were phosphorylated by p44mpk with V(max) values approaching 1-mu-mol.min-1.mg-1 and with apparent K(m) values of approximately 1 mM). Pseudosubstrate peptides in which the phosphorylatable residue was replaced by valine or alanine were weak inhibitors of p44mpk (apparent K(i) values of approximately 3 mM). Over 40 distinct protein kinases contain Pro-X-(Ser/Thr)-Pro sequences including the human receptors for insulin and epidermal growth factor, and kinases encoded by the human proto-oncogenes abl, neu, and raf-1, and Schizosaccharomyces pombe cell cycle control genes ran-1 and wee-1. Multiple putative sites were also identified in rat microtubule-associated protein-2, human retinoblastoma protein, human tau protein, and Drosophila myb protein and RNA polymerase II.	UNIV BRITISH COLUMBIA,BIOMED RES CTR,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT BIOCHEM,VANCOUVER V6T 1Z3,BC,CANADA; UNIV BRITISH COLUMBIA,DEPT MED,VANCOUVER V6T 1Z3,BC,CANADA	University of British Columbia; University of British Columbia; University of British Columbia								ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BAIROCH A, 1982, BIOCHEM J, V203, P527, DOI 10.1042/bj2030527; BALLOU LM, 1991, NATURE, V349, P348, DOI 10.1038/349348a0; BILOFSKY HS, 1988, NUCLEIC ACIDS RES, V16, P1861, DOI 10.1093/nar/16.5.1861; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CICIRELLI MF, 1988, J BIOL CHEM, V263, P2009; CLARKLEWIS I, 1986, SCIENCE, V231, P134, DOI 10.1126/science.3079915; CLARKLEWIS I, 1989, USE HPLC RECEPTOR BI, P43; COUNTAWAY JL, 1989, J BIOL CHEM, V264, P10828; DELANEY AD, 1982, NUCLEIC ACIDS RES, V10, P61, DOI 10.1093/nar/10.1.61; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; FERAMISCO JR, 1980, J BIOL CHEM, V255, P4240; HEISERMANN GJ, 1988, J BIOL CHEM, V263, P13152; HOSHI M, 1989, EUR J BIOCHEM, V184, P477, DOI 10.1111/j.1432-1033.1989.tb15040.x; HOWELL BW, 1991, MOL CELL BIOL, V11, P568, DOI 10.1128/MCB.11.1.568; JONES SW, 1988, P NATL ACAD SCI USA, V85, P3377, DOI 10.1073/pnas.85.10.3377; KEMP BE, 1985, J BIOL CHEM, V260, P3355; KUENZEL EA, 1987, J BIOL CHEM, V262, P9136; LITCHFIELD DW, 1990, FEBS LETT, V261, P117, DOI 10.1016/0014-5793(90)80650-8; MARIN O, 1986, EUR J BIOCHEM, V160, P239, DOI 10.1111/j.1432-1033.1986.tb09962.x; MEGGIO F, 1988, FEBS LETT, V237, P225, DOI 10.1016/0014-5793(88)80206-0; ORCUTT BC, 1983, ANNU REV BIOPHYS BIO, V12, P419, DOI 10.1146/annurev.bb.12.060183.002223; PEARSON RB, 1986, J BIOL CHEM, V261, P25; PELECH SL, 1990, BIOCHEM CELL BIOL, V68, P1297, DOI 10.1139/o90-194; PELECH SL, 1988, DEV BIOL, V130, P28, DOI 10.1016/0012-1606(88)90410-1; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; SANGHERA JS, 1991, J BIOL CHEM, V266, P6700; SANGHERA JS, 1990, J BIOL CHEM, V265, P52; SANGHERA JS, 1990, FEBS LETT, V273, P223, DOI 10.1016/0014-5793(90)81090-B; SILLIMAN CC, 1989, BIOCHEM BIOPH RES CO, V160, P993, DOI 10.1016/S0006-291X(89)80099-3; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; ZHANG J, 1991, J BIOL CHEM, V266, P2290	34	413	418	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 15	1991	266	23					15180	15184						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB097	1907971				2022-12-25	WOS:A1991GB09700057
J	HULL, SR; SUGARMAN, ED; SPIELMAN, J; CARRAWAY, KL				HULL, SR; SUGARMAN, ED; SPIELMAN, J; CARRAWAY, KL			BIOSYNTHETIC MATURATION OF AN ASCITES TUMOR-CELL SURFACE SIALOMUCIN - EVIDENCE FOR O-GLYCOSYLATION OF CELL-SURFACE GLYCOPROTEIN BY THE ADDITION OF NEW OLIGOSACCHARIDES DURING RECYCLING	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT MAMMARY ADENOCARCINOMA; EXPRESSION; PURIFICATION; ASSOCIATION; CARCINOMAS; RECEPTORS; PRECURSOR; COMPLEX; MAT-B1	Previous biosynthetic studies of the ascites 13762 rat mammary adenocarcinoma cell surface sialomucin ASGP-1 (ascites sialoglycoprotein-1) showed that it is synthesized initially as a poorly glycosylated immature form, which is converted to a larger premature form (t1/2 30 min) and more slowly to the mature glycoprotein (t1/2 > 4 h). In the present study O-glycosylation of ASGP-1 polypeptide is shown to occur in two phases: an early phase complete in < 30 min, which corresponds to the synthesis of the premature form, and a later phase that continues for hours and corresponds to the synthesis of the mature form. Pulse-chase labeling studies indicate that 95% of the ASGP-1 has moved to the cell surface in 2 h. Since transit to the cell surface is faster than the slow phase of addition of new oligosaccharides, some new oligosaccharides must be added after ASGP-1 has reached the cell surface. Initiation of new oligosaccharides on cell surface ASGP-1 was demonstrated directly using a biotinylation procedure to identify cell surface molecules. Glucosamine labeling of biotinylated ASGP-1 was shown to occur on galactosamine residues, which are linked to the polypeptide, establishing the addition of new oligosaccharides to the cell surface molecules. Finally, resialylation studies indicate that ASGP-1 rapidly recycles through a sialylating compartment. From these results we propose that ASGP-1 reaches the cell surface in an incompletely glycosylated state and that additional oligosaccharides are added to the glycoprotein in a second process involving recycling.	UNIV MIAMI,SCH MED,DEPT CELL BIOL & ANAT,POB 016960,MIAMI,FL 33101; UNIV MIAMI,SCH MED,DEPT BIOCHEM & MOLEC BIOL,MIAMI,FL 33101	University of Miami; University of Miami					NATIONAL CANCER INSTITUTE [P30CA014395, R01CA031695] Funding Source: NIH RePORTER; NCI NIH HHS [CA 14395, CA 31695] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CARRAWAY K L, 1991, Glycobiology, V1, P131, DOI 10.1093/glycob/1.2.131; CARRAWAY KL, 1976, J BIOL CHEM, V251, P6173; CARRAWAY KL, 1989, BIOESSAYS, V10, P117, DOI 10.1002/bies.950100406; CARRAWAY KL, 1986, MOL CELL BIOCHEM, V72, P108; GENDLER S, 1988, J BIOL CHEM, V263, P12820; GOODLOEHOLLAND CM, 1987, METHOD CELL BIOL, V28, P103; HATHAWAY HJ, 1988, BIOESSAYS, V9, P153, DOI 10.1002/bies.950090504; HULL SR, 1989, J CELL BIOCHEM, V40, P67, DOI 10.1002/jcb.240400108; HULL SR, 1984, J BIOL CHEM, V259, P4866; HULL SR, 1988, FASEB J, V2, P2380, DOI 10.1096/fasebj.2.8.3360239; LAN MS, 1987, INT J CANCER, V39, P68, DOI 10.1002/ijc.2910390112; LEBIVIC A, 1989, P NATL ACAD SCI USA, V86, P9313; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LOHMANDER LS, 1986, ANAL BIOCHEM, V154, P75, DOI 10.1016/0003-2697(86)90498-7; LOHMANDER LS, 1989, J BIOL CHEM, V264, P18775; RITTENHOUSE HG, 1985, LAB MED, V16, P55; SCHLOM J, 1986, CANCER RES, V46, P3225; SHENG Z, 1989, J CELL BIOCHEM, V40, P453, DOI 10.1002/jcb.240400406; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SNIDER MD, 1986, J CELL BIOL, V103, P265, DOI 10.1083/jcb.103.1.265; SPIELMAN J, 1987, J BIOL CHEM, V262, P269; SPIELMAN J, 1988, J BIOL CHEM, V263, P9621; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; VANDERPUYE OA, 1988, EXP CELL RES, V178, P211, DOI 10.1016/0014-4827(88)90392-8; WOODS JW, 1986, J CELL BIOL, V103, P277, DOI 10.1083/jcb.103.1.277	26	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13580	13586						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906879				2022-12-25	WOS:A1991FY02700022
J	FUNK, CD; FUNK, LB; KENNEDY, ME; PONG, AS; FITZGERALD, GA				FUNK, CD; FUNK, LB; KENNEDY, ME; PONG, AS; FITZGERALD, GA			HUMAN PLATELET ERYTHROLEUKEMIA CELL PROSTAGLANDIN G/H SYNTHASE - CDNA CLONING, EXPRESSION, AND GENE CHROMOSOMAL ASSIGNMENT	FASEB JOURNAL			English	Note						CYCLOOXYGENASE; ASPIRIN; PHORBOL ESTER; QUANTITATIVE PCR; CHRONIC MYELOGENOUS LEUKEMIA	HUMAN ENDOTHELIAL-CELLS; MESSENGER-RNA; ENDOPEROXIDE SYNTHASE; COMPLEMENTARY-DNA; MOLECULAR-CLONING; GROWTH-FACTOR; H SYNTHASE; CYCLOOXYGENASE; ASPIRIN; SHEEP	Platelets metabolize arachidonic acid to thromboxane A2, a potent platelet aggregator and vasoconstrictor compound. The first step of this transformation is catalyzed by prostaglandin (PG) G/H synthase, a target site for nonsteroidal antiinflammatory drugs. We have isolated the cDNA for both human platelet and human erythroleukemia cell PGG/H synthase using the polymerase chain reaction and conventional screening procedures. The cDNA encoding the full-length protein was expressed in COS-M6 cells. Microsomal fractions from transfected cells produced prostaglandin endoperoxide-derived products which were inhibited by indomethacin and aspirin. Mutagenesis of the serine residue at position 529, the putative aspirin acetylation site, to an asparagine reduced cyclooxygenase activity to barely detectable levels, an effect observed previously with the expressed sheep vesicular gland enzyme. Platelet-derived growth factor and phorbol ester differentially regulated the expression of PGG/H synthase mRNA levels in the megakaryocytic/platelet-like HEL cell line. The PGG/H synthase gene was assigned to chromosome 9 by analysis of a human-hamster somatic hybrid DNA panel. The availability of platelet PGG/H synthase cDNA should enhance our understanding of the important structure/function domains of this protein and its gene regulation.			FUNK, CD (corresponding author), VANDERBILT UNIV,DIV CLIN PHARMACOL,NASHVILLE,TN 37232, USA.		FitzGerald, Garret A/A-4222-2010; Funk, Colin D/A-9518-2010	Funk, Colin/0000-0001-7029-4233	NHLBI NIH HHS [HL30400] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL030400] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAILEY JM, 1990, PROSTAGLANDINS, V40, P585, DOI 10.1016/0090-6980(90)90003-E; BAILEY JM, 1989, TRENDS LIPID MED RES, V3, P8; BRASS LF, 1991, J BIOL CHEM, V266, P958; CHNG JLC, 1990, SCIENCE, V248, P1003, DOI 10.1126/science.2343304; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; DEWITT D L, 1989, P109; DEWITT DL, 1988, P NATL ACAD SCI USA, V85, P1412, DOI 10.1073/pnas.85.5.1412; DEWITT DL, 1990, J BIOL CHEM, V265, P5192; EGGLESTON DL, 1990, PROSTAGLANDINS, V39, P675, DOI 10.1016/0090-6980(90)90027-S; FITZGERALD GA, 1987, FASEB J, V46, P154; FU JY, 1990, J BIOL CHEM, V265, P16737; FUNK CD, 1987, P NATL ACAD SCI USA, V84, P6677, DOI 10.1073/pnas.84.19.6677; FUNK CD, 1990, P NATL ACAD SCI USA, V87, P5638, DOI 10.1073/pnas.87.15.5638; FUNK CD, 1991, IN PRESS J BIOL CHEM; GOERIG M, 1987, J CLIN INVEST, V79, P903, DOI 10.1172/JCI112900; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HAN JW, 1990, P NATL ACAD SCI USA, V87, P3373, DOI 10.1073/pnas.87.9.3373; HENNEKENS CH, 1989, CIRCULATION, V80, P749, DOI 10.1161/01.CIR.80.4.749; LIN AH, 1989, J BIOL CHEM, V264, P17379; MAIER JAM, 1990, SCIENCE, V249, P1570, DOI 10.1126/science.2218499; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; PASH JM, 1988, FASEB J, V2, P2613, DOI 10.1096/fasebj.2.10.2968288; PATRONO C, 1986, EUR HEART J, V7, P454, DOI 10.1093/oxfordjournals.eurheartj.a062091; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; ROSEN GD, 1989, BIOCHEM BIOPH RES CO, V164, P1358, DOI 10.1016/0006-291X(89)91819-6; ROTH GJ, 1975, J CLIN INVEST, V56, P624, DOI 10.1172/JCI108132; SMITH JB, 1971, NATURE-NEW BIOL, V231, P235, DOI 10.1038/newbio231235a0; SMITH WL, 1990, ADV PROSTAG THROMB L, V20, P14; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; YOKOYAMA C, 1991, ADV PROSTAG THROMB L, V21, P61; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X; 1988, NEW ENGL J MED, V321, P129	36	519	550	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998	0892-6638			FASEB J	Faseb J.	JUN	1991	5	9					2304	2312		10.1096/fasebj.5.9.1907252	http://dx.doi.org/10.1096/fasebj.5.9.1907252			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	FP872	1907252				2022-12-25	WOS:A1991FP87200013
J	LONGO, EA; TORNHEIM, K; DEENEY, JT; VARNUM, BA; TILLOTSON, D; PRENTKI, M; CORKEY, BE				LONGO, EA; TORNHEIM, K; DEENEY, JT; VARNUM, BA; TILLOTSON, D; PRENTKI, M; CORKEY, BE			OSCILLATIONS IN CYTOSOLIC FREE CA2+, OXYGEN-CONSUMPTION, AND INSULIN-SECRETION IN GLUCOSE-STIMULATED RAT PANCREATIC-ISLETS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURINE NUCLEOTIDE CYCLE; SKELETAL-MUSCLE EXTRACTS; ATP ADP RATIO; BETA-CELLS; GLYCOLYTIC OSCILLATIONS; FREE CA-2+; FURA-2-LOADED HEPATOCYTES; INTRACELLULAR CA-2+; PULSATILE SECRETION; CYTOPLASMIC CA-2+	Insulin secretion in the intact organism, and by the perfused pancreas and groups of isolated perifused islets, is pulsatile. We have proposed a metabolic model of glucose-induced insulin secretion in which oscillations in the ATP/ADP ratio drive alterations in metabolic and electrical events that lead to insulin release. A key prediction of our model is that metabolically driven Ca2+ oscillations will also occur. Using the fluorescent Ca2+ probe, fura 2, digital image analysis, and sensitive O2 electrodes, we investigated cytosolic free Ca2+ responses and O2 consumption in perifused rat islets that had been maintained in culture for 1-4 days. We found that elevated ambient glucose increased the average cytosolic free Ca2+ level, the ATP/ADP ratio, and oxygen consumption, as previously found in freshly isolated islets. Oscillatory patterns were obtained for Ca2+, O2 consumption, and insulin secretion in the presence of 10 and 20 mM glucose. Very low amplitude oscillations in cytosolic free Ca2+ were observed at 3 mM nonstimulatory glucose levels. Evaluation of the Ca2+ responses of a large series of individual islets, monitored by digital image analysis and perifused at both 3 and 10 mM glucose, indicated that the rise in glucose concentration caused more than a doubling of the average cytosolic free Ca2+ value and a 4-fold increase in the amplitude of the oscillations with little change in period. The pattern of Ca2+ change within the islets was consistent with recruitment of responding cells. The coexistence of oscillations with similar periods in insulin secretion, oxygen consumption, and cytosolic free Ca2+ is consistent with the model of metabolically driven pulsatile insulin secretion.	BOSTON UNIV,SCH MED,EVANS DEPT MED,DIV DIABET & METAB,E-205,88 E NEWTON ST,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PHYSIOL,BOSTON,MA 02118; UNIV GENEVA,MED CTR,INST BIOCHIM CLIN,CH-1211 GENEVA 4,SWITZERLAND	Boston University; Boston University; Boston University; University of Geneva			Corkey, Barbara/E-7712-2015	Corkey, Barbara/0000-0002-5467-1630; Deeney, Jude/0000-0003-0988-9419; Tornheim, Keith/0000-0002-6235-5128	NIDDK NIH HHS [DK35914, DK40127, DK31559] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035914, R01DK031559, R01DK035914, R01DK040127] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMBLER SK, 1988, J BIOL CHEM, V263, P1952; ANDRES V, 1990, J BIOL CHEM, V265, P21441; ARKHAMMAR P, 1989, BIOCHEM BIOPH RES CO, V159, P223, DOI 10.1016/0006-291X(89)92426-1; ASHCROFT FM, 1984, NATURE, V312, P446, DOI 10.1038/312446a0; BERGSTROM RW, 1989, AM J PHYSIOL, V257, pE479, DOI 10.1152/ajpendo.1989.257.4.E479; BERRIDGE MJ, 1988, PHILOS T ROY SOC B, V320, P325, DOI 10.1098/rstb.1988.0080; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; BETZ A, 1965, ARCH BIOCHEM BIOPHYS, V109, P585, DOI 10.1016/0003-9861(65)90404-2; CHANCE B, 1965, J BIOL CHEM, V240, P3170; CHOU HF, 1990, DIABETES, V39, P112, DOI 10.2337/diabetes.39.1.112; CHOU HF, 1990, DIABETES S1, V39, pA133; COOK DL, 1984, NATURE, V311, P271, DOI 10.1038/311271a0; Corkey B. E., 1988, INTEGRATION MITOCHON, P543; CORKEY BE, 1988, J BIOL CHEM, V263, P4247; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; CORKEY BE, 1988, J BIOL CHEM, V263, P4254; CORKEY BE, 1989, CELL CALCIUM METABOL, P369; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P157, DOI 10.1016/0003-9861(68)90650-4; GERISCH G, 1979, J EXP BIOL, V81, P33; GRAPENGIESSER E, 1989, ARCH BIOCHEM BIOPHYS, V268, P404, DOI 10.1016/0003-9861(89)90602-4; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HELLERSTROM C, 1967, ENDOCRINOLOGY, V81, P105, DOI 10.1210/endo-81-1-105; Hess B, 1969, Adv Enzyme Regul, V7, P149, DOI 10.1016/0065-2571(69)90016-8; HESS B, 1971, ANNU REV BIOCHEM, V40, P237, DOI 10.1146/annurev.bi.40.070171.001321; HUTTON JC, 1980, DIABETOLOGIA, V18, P395; IBSEN KH, 1967, BIOCHIM BIOPHYS ACTA, V131, P407; KAWANISHI T, 1989, J BIOL CHEM, V264, P12859; LACY PE, 1967, DIABETES, V16, P35, DOI 10.2337/diab.16.1.35; LEFEBVRE PJ, 1987, DIABETOLOGIA, V30, P443, DOI 10.1007/BF00279610; MATTHEWS DR, 1983, DIABETOLOGIA, V24, P231; MCCALL AL, 1988, MICROVASC RES, V35, P325, DOI 10.1016/0026-2862(88)90087-8; MCCORMACK JG, 1990, BIOCHEM J, V267, P527, DOI 10.1042/bj2670527; MEGLASSON M D, 1986, Diabetes Metabolism Reviews, V2, P163; MISLER S, 1986, P NATL ACAD SCI USA, V83, P7119, DOI 10.1073/pnas.83.18.7119; ORAHILLY S, 1988, NEW ENGL J MED, V318, P1225, DOI 10.1056/NEJM198805123181902; PRALONG WF, 1990, EMBO J, V9, P53, DOI 10.1002/j.1460-2075.1990.tb08079.x; PRENTKI M, 1988, J BIOL CHEM, V263, P11044; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; PYE EK, 1969, CAN J BOTANY, V47, P271, DOI 10.1139/b69-040; QUINN SJ, 1990, ENDOCRINOLOGY, V127, P541, DOI 10.1210/endo-127-2-541; QUINN SJ, 1988, AM J PHYSIOL, V255, pE488, DOI 10.1152/ajpendo.1988.255.4.E488; QUINN SJ, 1988, P NATL ACAD SCI USA, V85, P5254; RAPP PE, 1987, PROG NEUROBIOL, V29, P261, DOI 10.1016/0301-0082(87)90023-2; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SCHUIT FC, 1988, P NATL ACAD SCI USA, V85, P3865, DOI 10.1073/pnas.85.11.3865; SENER A, 1984, EXPERIENTIA, V40, P1026, DOI 10.1007/BF01971448; STAGNER JI, 1980, J CLIN INVEST, V65, P939, DOI 10.1172/JCI109750; TORNHEIM K, 1974, J BIOL CHEM, V249, P3241; TORNHEIM K, 1979, J THEOR BIOL, V79, P491, DOI 10.1016/0022-5193(79)90240-6; TORNHEIM K, 1988, J BIOL CHEM, V263, P2619; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; TORNHEIM K, 1975, J BIOL CHEM, V250, P6304; TRUS M, 1980, DIABETES, V29, P1, DOI 10.2337/diabetes.29.1.1; TURK J, 1987, PROG LIPID RES, V26, P125, DOI 10.1016/0163-7827(87)90010-5; VALDEOLMILLOS M, 1989, FEBS LETT, V259, P19, DOI 10.1016/0014-5793(89)81484-X; WADDELL ID, 1988, BIOCHEM J, V255, P471, DOI 10.1042/bj2550471; WANG JL, 1990, BIOCHEM BIOPH RES CO, V166, P813, DOI 10.1016/0006-291X(90)90882-N; WEIGLE DS, 1987, DIABETES, V36, P764, DOI 10.2337/diab.36.6.764; WOLLHEIM CB, 1981, PHYSIOL REV, V61, P914, DOI 10.1152/physrev.1981.61.4.914; WOODS NM, 1986, NATURE, V329, P719	61	209	212	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 15	1991	266	14					9314	9319						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FM038	1902835				2022-12-25	WOS:A1991FM03800098
J	KEEN, JH; BECK, KA; KIRCHHAUSEN, T; JARRETT, T				KEEN, JH; BECK, KA; KIRCHHAUSEN, T; JARRETT, T			CLATHRIN DOMAINS INVOLVED IN RECOGNITION BY ASSEMBLY PROTEIN AP-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; LIGHT-CHAINS; PLASMA-MEMBRANE; BOVINE BRAIN; BINDING; PURIFICATION; IDENTIFICATION; TRISKELIONS; RECEPTORS; COMPLEX	The domains on clathrin responsible for interaction with the plasma membrane-associated assembly protein AP-2 have been studied using a novel cage binding assay. AP-2 bound to pure clathrin cages but not to coat structures already containing AP that had been prepared by coassembly. Binding to preassembled cages also occurred in the presence of elevated Tris-HCl concentrations (greater-than-or-equal-to 200 mM) which block AP-2 interactions with free clathrin. AP-2 interactions with assembled cages could also be distinguished from AP-2 binding to clathrin trimers by sodium tripolyphosphate (NaPPP(i)), which binds to the alpha-subunit of AP-2 (Beck, K., and Keen, J. H. (1991) J. Biol. Chem. 266, 4442-4447). At concentrations of 1-5 mM, NaPPP(i) blocked clathrin-triskelion binding; in contrast, interactions with cages persisted in the presence of 25 mM NaPPP(i). To begin to identify the region(s) of the clathrin molecule important in recognition by AP-2, clathrin cages were proteolyzed to remove heavy chain terminal domains and portions of the distal leg as well as all of the light chains. AP-2 bound to these "clipped cages"; however, unlike the interaction with native cages, binding of AP-2 to clipped cages was sensitive to the lower concentrations of both Tris-HCl and NaPPP(i) which disrupt interactions of AP-2 with clathrin trimers. Reconstitution of the clipped cages with clathrin light chains did not restore resistance of AP-2 binding to Tris-HCl. We conclude that one binding site for AP-2 resides on the hub and/or proximal part of the clathrin triskelion whereas a second site is likely to involve the terminal domain and/or distal leg; the second site is manifested only in the assembled lattice structure. We suggest that these two distinct binding interactions may be mediated by the two unique large subunits within the AP-2 complex, acting sequentially during assembly.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,PHILADELPHIA,PA 19140; HARVARD UNIV,SCH MED,DEPT ANAT & CELLULAR BIOL,BOSTON,MA 02115	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Harvard University; Harvard Medical School	KEEN, JH (corresponding author), TEMPLE UNIV,HLTH SCI CTR,SCH MED,FELS INST CANC RES & MOLEC BIOL,PHILADELPHIA,PA 19140, USA.				NIGMS NIH HHS [GM-28526] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028526] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHLE S, 1989, J BIOL CHEM, V264, P20089; AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BECK KA, 1991, J BIOL CHEM, V266, P4442; BECK KA, 1991, J BIOL CHEM, V266, P4437; BRODSKY FM, 1983, J CELL BIOL, V96, P911, DOI 10.1083/jcb.96.3.911; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HANSPAL M, 1984, J BIOL CHEM, V259, P1075; HEUSER J, 1985, J ULTRA MOL STRUCT R, V92, P1, DOI 10.1016/0889-1605(85)90123-5; HEUSER JE, 1988, J CELL BIOL, V107, P877, DOI 10.1083/jcb.107.3.877; JACKSON AP, 1987, NATURE, V326, P154, DOI 10.1038/326154a0; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; KEEN JH, 1989, BIOCHEM BIOPH RES CO, V158, P17, DOI 10.1016/S0006-291X(89)80170-6; KEEN JH, 1987, J CELL BIOL, V105, P1989, DOI 10.1083/jcb.105.5.1989; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; KEEN JH, 1990, ADV CELL BIOL, V3, P153; KEEN JH, 1986, J CELL BIOL, V103, P54; KIRCHHAUSEN T, 1987, SCIENCE, V236, P320, DOI 10.1126/science.3563513; KIRCHHAUSEN T, 1989, P NATL ACAD SCI USA, V86, P2612, DOI 10.1073/pnas.86.8.2612; KIRCHHAUSEN T, 1984, J CELL BIOL, V99, P1725, DOI 10.1083/jcb.99.5.1725; LISANTI MP, 1982, EUR J BIOCHEM, V125, P463, DOI 10.1111/j.1432-1033.1982.tb06706.x; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MOSLEY ST, 1988, EXP CELL RES, V174, P511, DOI 10.1016/0014-4827(88)90320-5; PEARSE BMF, 1984, EMBO J, V3, P1951, DOI 10.1002/j.1460-2075.1984.tb02075.x; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PRASAD K, 1986, BIOCHEMISTRY-US, V25, P6942, DOI 10.1021/bi00370a030; UNANUE ER, 1981, CELL, V26, P439, DOI 10.1016/0092-8674(81)90213-0; UNGEWICKELL E, 1983, EMBO J, V2, P1401, DOI 10.1002/j.1460-2075.1983.tb01598.x; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; VIGERS GPA, 1986, EMBO J, V5, P529, DOI 10.1002/j.1460-2075.1986.tb04242.x; WIEDENMANN B, 1985, J CELL BIOL, V101, P12, DOI 10.1083/jcb.101.1.12; WINKLER FK, 1983, EMBO J, V2, P1393, DOI 10.1002/j.1460-2075.1983.tb01597.x; ZAREMBA S, 1983, J CELL BIOL, V97, P1339, DOI 10.1083/jcb.97.5.1339	33	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 25	1991	266	12					7950	7956						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FJ342	1902233				2022-12-25	WOS:A1991FJ34200097
J	HORI, Y; KIKUCHI, A; ISOMURA, M; KATAYAMA, M; MIURA, Y; FUJIOKA, H; KAIBUCHI, K; TAKAI, Y				HORI, Y; KIKUCHI, A; ISOMURA, M; KATAYAMA, M; MIURA, Y; FUJIOKA, H; KAIBUCHI, K; TAKAI, Y			POSTTRANSLATIONAL MODIFICATIONS OF THE C-TERMINAL REGION OF THE RHO-PROTEIN ARE IMPORTANT FOR ITS INTERACTION WITH MEMBRANES AND THE STIMULATORY AND INHIBITORY GDP/GTP EXCHANGE PROTEINS	ONCOGENE			English	Article							GTP-BINDING PROTEIN; BOVINE BRAIN MEMBRANES; BOTULINUM ADP-RIBOSYLTRANSFERASE; GENE-PRODUCT; MOLECULAR-CLONING; CLOSTRIDIUM-BOTULINUM; PARTIAL-PURIFICATION; SUBSEQUENT BINDING; EFFECTOR DOMAIN; TOXIN TYPE-C1	We have recently found, by use of the rhoA p21 purified from bovine aortic smooth muscle, that it is similarly post-translationally processed as described for ras p21s: it is first geranylgeranylated at the cysteine residue in the C-terminal region followed by removal of the three C-terminal amino acids and the subsequent carboxyl methylation of the revealed C-terminal cysteine residue. In the present study, we investigated the function(s) of these post-translational modifications of the C-terminal region of rhoA p21 by use of the rhoA p21s purified from bovine aortic smooth muscle and rhoA p21-overexpressing Escherichia coli since the bacterial protein was not modified with a geranylgeranyl moiety. Bovine rhoA p21 bound to plasma membranes and phosphatidylserine-linked Affigel, but bacterial rhoA p21 did not bind to them. The inhibitory GDP/GTP exchange protein for rhoA p21, named GDP dissociation inhibitor (GDI), made a complex with the GDP-bound form of bovine rhoA p21 and thereby inhibited the dissociation of GDP from and the subsequent binding of GTP to it. However, rho GDI neither made a complex with the GDP-bound form of bacterial rhoA p21 nor affected these reactions of the bacterial protein. The stimulatory GDP/GTP exchange protein for rhoA p21, named GDP dissociation stimulator (GDS), stimulated the dissociation of GDP from bovine rhoA p21, but was inactive for the bacterial protein. In contrast, the GTPase activating protein for rhoA p21 is active not only for bovine rhoA p21 but also for the bacterial protein. These results suggest that the post-translational modifications of the C-terminal region of bovine rhoA p21, most presumably the geranylgeranylation, which are absent in bacterial rhoA p21, play important roles in its interaction with membranes and the stimulatory and inhibitory GDP/GTP exchange proteins but not with the GAP.	KOBE UNIV,SCH MED,DEPT BIOCHEM,KOBE 650,JAPAN	Kobe University								ADAMVIZI V, 1988, FEBS LETT, V238, P277, DOI 10.1016/0014-5793(88)80496-4; ARAKI S, 1991, IN PRESS MOL CELL BI; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BRAUN U, 1989, FEBS LETT, V243, P70, DOI 10.1016/0014-5793(89)81220-7; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; GARRETT MD, 1989, J BIOL CHEM, V264, P10; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HIROYOSHI M, 1991, IN PRESS J BIOL CHEM; HOSHIJIMA M, 1990, MOL BRAIN RES, V7, P9, DOI 10.1016/0169-328X(90)90067-N; ISOMURA M, 1990, BIOCHEM BIOPH RES CO, V169, P652, DOI 10.1016/0006-291X(90)90380-6; ISOMURA M, 1990, IN PRESS ONCOGENE; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; KAWAHARA Y, 1990, BIOCHEM BIOPH RES CO, V170, P673, DOI 10.1016/0006-291X(90)92144-O; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAWATA M, IN PRESS P NATL ACAD; KIKUCHI A, 1989, J BIOL CHEM, V264, P9133; KIKUCHI A, 1988, J BIOL CHEM, V263, P2897; KIKUCHI A, 1988, J BIOL CHEM, V263, P16303; KIM S, 1989, MOL BRAIN RES, V6, P167, DOI 10.1016/0169-328X(89)90051-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MADAULE P, 1985, CELL, V41, P31, DOI 10.1016/0092-8674(85)90058-3; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1990, MOL CELL BIOL, V10, P4116, DOI 10.1128/MCB.10.8.4116; MATSUI Y, 1988, J BIOL CHEM, V263, P11071; MATSUI Y, 1990, BIOCHEM BIOPH RES CO, V166, P1010, DOI 10.1016/0006-291X(90)90911-6; NARUMIYA S, 1988, J BIOL CHEM, V263, P17255; NISHIKI T, 1990, BIOCHEM BIOPH RES CO, V167, P265, DOI 10.1016/0006-291X(90)91760-P; OHGA N, 1989, BIOCHEM BIOPH RES CO, V163, P1523, DOI 10.1016/0006-291X(89)91153-4; RUBIN EJ, 1988, MOL CELL BIOL, V8, P418, DOI 10.1128/MCB.8.1.418; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SSAKI T, 1990, J BIOL CHEM, V263, P2333; TAKAI Y, 1988, PROGR ENDOCRINOLOGY, V2, P995; UEDA T, 1990, J BIOL CHEM, V265, P9373; Weber K, 1972, Methods Enzymol, V26, P3; YAMAMOTO J, 1990, MOL BRAIN RES, V8, P105, DOI 10.1016/0169-328X(90)90054-H; YAMAMOTO K, 1988, J BIOL CHEM, V263, P9926; YAMAMOTO T, 1990, J BIOL CHEM, V265, P16626; YERAMIAN P, 1987, NUCLEIC ACIDS RES, V15, P1869, DOI 10.1093/nar/15.4.1869	44	202	205	0	5	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	APR	1991	6	4					515	522						8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FR939	1903193				2022-12-25	WOS:A1991FR93900004
J	NARANJO, JR; MELLSTROM, B; ACHAVAL, M; LUCAS, JJ; DELRIO, J; SASSONECORSI, P				NARANJO, JR; MELLSTROM, B; ACHAVAL, M; LUCAS, JJ; DELRIO, J; SASSONECORSI, P			COINDUCTION OF JUN B AND C-FOS IN A SUBSET OF NEURONS IN THE SPINAL-CORD	ONCOGENE			English	Article							DNA-BINDING DOMAINS; GENE-EXPRESSION; PROTO-ONCOGENE; GROWTH-FACTORS; LEUCINE ZIPPERS; RAT; STIMULATION; TRANSCRIPTION; HYBRIDIZATION; HYPERALGESIA	Noxious stimulation in vivo provokes the transcriptional activation of several genes which are though to play an important role in the phenomena of stress and pain. In the rat, the expression of the c-fos proto-oncogene is rapidly induced upon noxious stimulation in defined neurons in the dorsal horn of the spinal cord. Interestingly, expression of the prodynorphin gene, which is thought to be involved in the endogenous mechanisms for pain/stress control, also localizes in the same anatomical area. Fos proteins are known to associate in transcriptional complexes with the products of the jun family constituting nuclear factor AP-1. These considerations prompted us to analyse the expression of the jun gene family members c-jun, jun B and jun D in rats subjected to noxious stimulation. We present data indicating that in unstimulated animals the transcripts of the three genes are differentially expressed and abundant within the various laminas of the lumbar spinal cord. Surprisingly, upon stimulation only the jun B transcript is augmented, being co-localized with Fos in a subset of neurons of the medial dorsal horn.	FAC MED STRASBOURG,CNRS,GENET MOLEC EUCARYOTES LAB,INSERM,U184,11 RUE HUMANN,F-67085 STRASBOURG,FRANCE; CSIC,INST CAJAL NEUROCIENCIA,E-28002 MADRID,SPAIN	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Consejo Superior de Investigaciones Cientificas (CSIC)			NARANJO, Jose R/K-1950-2014; Lucas, Jose J./U-6543-2019; Sassone-Corsi, Paolo/H-6182-2011	NARANJO, Jose R/0000-0002-0270-3469; Lucas, Jose J./0000-0003-1597-3916				ALHO H, 1988, P NATL ACAD SCI USA, V85, P7018, DOI 10.1073/pnas.85.18.7018; ANGERER LM, 1987, IN SITU HYBRIDIZATIO, P42; AUWERX J, 1990, NUCLEIC ACIDS RES, V18, P221, DOI 10.1093/nar/18.2.221; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BULLITT E, 1989, BRAIN RES, V493, P391, DOI 10.1016/0006-8993(89)91177-3; BUSCH SJ, 1990, TRENDS GENET, V6, P36, DOI 10.1016/0168-9525(90)90071-D; CECCATELLI S, 1989, P NATL ACAD SCI USA, V86, P9569, DOI 10.1073/pnas.86.23.9569; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; COMB M, 1988, EUR MOL BIOL ORG J, V7, P3795; CURRAN T, 1985, MOL CELL BIOL, V5, P167, DOI 10.1128/MCB.5.1.167; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DRAISCI G, 1989, MOL BRAIN RES, V6, P31, DOI 10.1016/0169-328X(89)90025-9; DUBNER R, 1984, ADV PAIN RES THER, V6, P151; GENTZ R, 1989, SCIENCE, V243, P1695, DOI 10.1126/science.2494702; GIZANGGINSBERG E, 1990, GENE DEV, V4, P477, DOI 10.1101/gad.4.4.477; GOELET P, 1986, NATURE, V311, P433; HALEZONETIS TD, 1988, CELL, V55, P917; HENGERER B, 1990, P NATL ACAD SCI USA, V87, P3899, DOI 10.1073/pnas.87.10.3899; HERDEGEN T, 1990, 6TH P WORLD C PAIN; HIRAI SI, 1989, EMBO J, V8, P1433, DOI 10.1002/j.1460-2075.1989.tb03525.x; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; IADAROLA MJ, 1988, BRAIN RES, V455, P205, DOI 10.1016/0006-8993(88)90078-9; KOUZARIDES T, 1988, NATURE, V336, P646, DOI 10.1038/336646a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; MENETREY D, 1989, J COMP NEUROL, V285, P177, DOI 10.1002/cne.902850203; MINAMI M, 1989, NEUROSCI LETT, V98, P105, DOI 10.1016/0304-3940(89)90382-0; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; NAKABEPPU Y, 1988, CELL, V55, P907, DOI 10.1016/0092-8674(88)90146-8; NARANJO JR, 1990, NUCLEIC ACIDS RES, V18, P3605, DOI 10.1093/nar/18.12.3605; NOGUCHI K, 1989, MOL BRAIN RES, V5, P227, DOI 10.1016/0169-328X(89)90039-9; QUANTIN B, 1988, NATURE, V334, P538, DOI 10.1038/334538a0; RUDA MA, 1988, P NATL ACAD SCI USA, V85, P622, DOI 10.1073/pnas.85.2.622; RYDER K, 1988, P NATL ACAD SCI USA, V85, P8464, DOI 10.1073/pnas.85.22.8464; RYDER K, 1988, P NATL ACAD SCI USA, V85, P1487, DOI 10.1073/pnas.85.5.1487; RYDER K, 1989, P NATL ACAD SCI USA, V86, P1500, DOI 10.1073/pnas.86.5.1500; RYSECK RP, 1988, NATURE, V334, P535, DOI 10.1038/334535a0; SASSONECORSI P, 1988, NATURE, V336, P692, DOI 10.1038/336692a0; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; SONNENBERG JL, 1989, SCIENCE, V246, P1622, DOI 10.1126/science.2512642; STERNBERGER LA, 1986, IMMUNOCYTOCHEMISTRY; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; VOGT PK, 1989, TRENDS BIOCHEM SCI, V14, P172, DOI 10.1016/0968-0004(89)90268-5; WILKINSON DG, 1989, DEVELOPMENT, V106, P465; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y	44	66	66	0	1	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	FEB	1991	6	2					223	227						5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	FZ134	1900356				2022-12-25	WOS:A1991FZ13400007
J	LOESSBERG, PA; ZHAO, H; MUALLEM, S				LOESSBERG, PA; ZHAO, H; MUALLEM, S			SYNCHRONIZED OSCILLATION OF CA2+ ENTRY AND CA2+ RELEASE IN AGONIST-STIMULATED AR42J CELLS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							PAROTID ACINAR-CELLS; SENSITIVE CALCIUM POOL; CYTOSOLIC FREE CALCIUM; FURA-2-LOADED HUMAN-PLATELETS; INOSITOL TRISPHOSPHATE; PLASMA-MEMBRANE; INFLUX; CA-2+; CHANNELS; 1,3,4,5-TETRAKISPHOSPHATE	Oscillation in [Ca2+]i induced by agonists has been described in many cell types and is thought to reflect Ca2+ release from and uptake into internal stores. We measured [Ca2+]i and Mn2+ entry in single cells of the pancreatic acinar cell line AR42J loaded with Fura 2 to examine the behavior of Ca2+ influx across the plasma membrane (Ca2+ entry) during agonist-evoked [Ca2+]i oscillation. Addition of extracellular Ca2+ (Ca(out)2+) to agonist-stimulated cells bathed in Ca2+-free medium resulted in a marked [Ca2+]i increase blocked by La3+. The use of Mn2+ as a congener of Ca2+ to follow unidirectional Ca2+ movement reveals an oscillatory activation of Ca2+ entry by Ca2+-mobilizing agonists. The frequency at which Ca2+ entry oscillated matched the frequency of Ca2+ release from intracellular stores. Ca2+ entry is activated after completion of Ca2+ release and is inactivated within the time span of each [Ca2+]i spike. These studies reveal a new aspect of [Ca2+]i oscillation in agonist-stimulated cells, that is the oscillatory activation of [Ca2+]i entry during [Ca2+]i oscillation.	UNIV TEXAS, SW MED CTR, DEPT PHYSIOL, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039245] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038938] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 39245] Funding Source: Medline; NIDDK NIH HHS [DK 38938] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BERRIDGE MJ, 1988, FASEB J, V2, P3074, DOI 10.1096/fasebj.2.15.2847949; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.biochem.56.1.395; CASE RM, 1989, CURR OPIN GASTROEN, V5, P665, DOI 10.1097/00001574-198910000-00012; CHUEH SH, 1986, J BIOL CHEM, V261, P13883; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HUGHES AR, 1988, J BIOL CHEM, V263, P10314; IRVINE RF, 1986, BIOCHEM J, V240, P917, DOI 10.1042/bj2400917; JACOB R, 1990, J PHYSIOL-LONDON, V421, P55, DOI 10.1113/jphysiol.1990.sp017933; JEAN T, 1986, J BIOL CHEM, V261, P6414; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; MERRITT JE, 1987, J BIOL CHEM, V262, P14912; MERRITT JE, 1987, J BIOL CHEM, V262, P4958; MERRITT JE, 1989, J BIOL CHEM, V264, P1522; MERRITT JE, 1987, J BIOL CHEM, V262, P17362; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; MUALLEM S, 1988, AM J PHYSIOL, V255, pG229, DOI 10.1152/ajpgi.1988.255.2.G229; MUALLEM S, 1990, J BIOL CHEM, V265, P2011; MUALLEM S, 1989, ANNU REV PHYSIOL, V51, P83; MUALLEM S, 1988, AM J PHYSIOL, V255, pG221, DOI 10.1152/ajpgi.1988.255.2.G221; PANDOL SJ, 1987, J BIOL CHEM, V262, P16963; PARKER I, 1990, P NATL ACAD SCI USA, V87, P260, DOI 10.1073/pnas.87.1.260; PENNER R, 1988, NATURE, V334, P499, DOI 10.1038/334499a0; PETERSEN OH, 1986, AM J PHYSIOL, V251, pG1, DOI 10.1152/ajpgi.1986.251.1.G1; PRALONG WF, 1988, FEBS LETT, V242, P79, DOI 10.1016/0014-5793(88)80989-X; ROONEY TA, 1989, J BIOL CHEM, V264, P17131; SACHS G, 1989, CELL CALCIUM, V10, P265, DOI 10.1016/0143-4160(89)90053-5; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; SAGE SO, 1987, J BIOL CHEM, V262, P16364; SNYDER PM, 1988, J BIOL CHEM, V263, P11048; STUENKEL EL, 1989, BIOCHEM BIOPH RES CO, V158, P863, DOI 10.1016/0006-291X(89)92802-7; SUPATTAPONE S, 1988, J BIOL CHEM, V263, P1530; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TSIEN RW, 1983, ANNU REV PHYSIOL, V45, P341, DOI 10.1146/annurev.ph.45.030183.002013; WOODS NM, 1986, NATURE, V329, P719; YULE DI, 1988, FEBS LETT, V239, P358, DOI 10.1016/0014-5793(88)80951-7	37	71	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 25	1991	266	3					1363	1366						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EU497	1899088				2022-12-25	WOS:A1991EU49700003
J	CAMPAGNE, MMV; FRANKE, J; KESSIN, RH				CAMPAGNE, MMV; FRANKE, J; KESSIN, RH			FUNCTIONAL CLONING OF A DICTYOSTELIUM-DISCOIDEUM CDNA-ENCODING GMP SYNTHETASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCE; GLUTAMINE PHOSPHORIBOSYLPYROPHOSPHATE AMIDOTRANSFERASE; CARBAMOYL-PHOSPHATE SYNTHETASE; ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; RIBONUCLEOTIDE SYNTHETASE; SACCHAROMYCES-CEREVISIAE; ANTHRANILATE SYNTHASE; SERRATIA-MARCESCENS; IMP DEHYDROGENASE	A functional cloning procedure has been used to recover a cDNA coding for the GMP synthetase of Dictyostelium discoideum. The enzyme is encoded by a single gene, which is actively transcribed during growth, but not during development. The open reading frame encodes a protein of 718 amino acids with a predicted molecular mass of 79.6 kDa. The Dictyostelium enzyme has extensive homology with the GMP synthetase of Escherichia coli and regional homology to other glutamine amidotransferases.			CAMPAGNE, MMV (corresponding author), COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, 630 W 168TH ST, NEW YORK, NY 10032 USA.		van Lookeren Campagne, Michiel Maurits/AAX-6436-2021	van Lookeren Campagne, Michiel Maurits/0000-0002-8312-5946	NIAID NIH HHS [AI24240] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024240] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACHLEITNER E, 1985, ADV ENZYME REGUL, V24, P225, DOI 10.1016/0065-2571(85)90078-0; AIMI J, 1990, NUCLEIC ACIDS RES, V18, P6665, DOI 10.1093/nar/18.22.6665; AIMI J, 1990, J BIOL CHEM, V265, P9011; CHEN ZD, 1990, P NATL ACAD SCI USA, V87, P3097, DOI 10.1073/pnas.87.8.3097; FAURE M, 1989, EUR J BIOCHEM, V179, P345, DOI 10.1111/j.1432-1033.1989.tb14560.x; FAURE M, 1988, CELL DIFFER DEV, V22, P159, DOI 10.1016/0045-6039(88)90028-0; FRANKE J, 1977, P NATL ACAD SCI USA, V74, P2157, DOI 10.1073/pnas.74.5.2157; FRANKE J, 1987, DEV BIOL, V124, P504, DOI 10.1016/0012-1606(87)90503-3; FREUND JN, 1987, J MOL BIOL, V193, P1, DOI 10.1016/0022-2836(87)90621-8; FUKUYAMA TT, 1966, J BIOL CHEM, V241, P4745; GRIBSKOV M, 1986, NUCLEIC ACIDS RES, V14, P6745, DOI 10.1093/nar/14.16.6745; HIRAI K, 1987, J BIOCHEM, V102, P893, DOI 10.1093/oxfordjournals.jbchem.a122130; JAYARAM HN, 1975, CANCER CHEMOTH REP 1, V59, P481; KAPLAN JB, 1983, J MOL BIOL, V168, P451, DOI 10.1016/S0022-2836(83)80295-2; KAWAMURA M, 1978, J BIOL CHEM, V253, P4659; KESSIN RH, 1988, MICROBIOL REV, V52, P29, DOI 10.1128/MMBR.52.1.29-49.1988; KHARBANDA SM, 1988, CANCER RES, V48, P5965; KIMMEL AR, 1983, NUCLEIC ACIDS RES, V11, P541, DOI 10.1093/nar/11.2.541; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE HJ, 1985, CANCER RES, V45, P5512; MAKAROFF CA, 1983, J BIOL CHEM, V258, P586; MINET M, 1990, CURR GENET, V18, P287, DOI 10.1007/BF00318209; NEEDLEMAN SB, 1970, J MOL BIOL, V48, P443, DOI 10.1016/0022-2836(70)90057-4; NICHOLS BP, 1980, J MOL BIOL, V142, P503, DOI 10.1016/0022-2836(80)90260-0; NYUNOYA H, 1984, J BIOL CHEM, V259, P9790; PIETTE J, 1984, P NATL ACAD SCI-BIOL, V81, P4134, DOI 10.1073/pnas.81.13.4134; SIDI Y, 1988, BRIT J CANCER, V58, P61, DOI 10.1038/bjc.1988.162; SLECHTA L, 1960, BIOCHEM BIOPH RES CO, V3, P596, DOI 10.1016/0006-291X(60)90068-1; SOUCIET JL, 1987, MOL GEN GENET, V207, P314, DOI 10.1007/BF00331595; TIEDEMAN AA, 1985, J BIOL CHEM, V260, P8676; TIEDEMAN AA, 1985, NUCLEIC ACIDS RES, V13, P1303, DOI 10.1093/nar/13.4.1303; TSO JY, 1982, J BIOL CHEM, V257, P3525; TSO JY, 1980, J BIOL CHEM, V255, P1451; VONDERSAAL W, 1985, BIOCHEMISTRY-US, V24, P5343, DOI 10.1021/bi00341a011; WARRICK HM, 1987, METHOD CELL BIOL, V28, P497; WELKER DL, 1985, MOL CELL BIOL, V5, P273, DOI 10.1128/MCB.5.2.273; WERNER M, 1985, EUR J BIOCHEM, V146, P371, DOI 10.1111/j.1432-1033.1985.tb08663.x; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WRIGHT DG, 1987, BLOOD, V69, P334; ZALKIN H, 1985, J BIOL CHEM, V260, P3350; ZALKIN H, 1984, J BIOL CHEM, V259, P3985; ZALKIN H, 1977, J BIOL CHEM, V252, P5431	42	11	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16448	16452						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885577				2022-12-25	WOS:A1991GD63500036
J	FANJUL, AN; FARIAS, RN				FANJUL, AN; FARIAS, RN			NOVEL COLD-SENSITIVE CYTOSOLIC 3,5,3'-TRIIODO-L-THYRONINE-BINDING PROTEINS IN HUMAN RED-BLOOD-CELL - ISOLATION AND CHARACTERIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER NUCLEI; L-TRIIODOTHYRONINE BINDING; HUMAN-ERYTHROCYTE MEMBRANE; THYROID-HORMONE RECEPTOR; PROGESTERONE-RECEPTOR; MONOCLONAL-ANTIBODIES; (T3)-BINDING PROTEIN; UNOCCUPIED RECEPTORS; KIDNEY CYTOSOL; CHICK OVIDUCT	Four cytosolic 3,5,3'-triiodo-L-thyronine-binding proteins (CTBP) were isolated from hemoglobin-free human erythrocyte on DEAE-cellulose column by linear gradient of NaCl (0-0.4 M). CTBP I, II, and IV underwent rapid loss of their activities at low temperatures, whereas CTBP III was cold-insensitive. Reactivation of cold-inactivated CTBPs by warming was obtained at 20 and 37-degrees-C. CTBP I, II, and IV were not inhibited by thiol-blocking agents, whereas CTBP III was blocked. Scatchard analysis Of L-3,5,3'-triodothyronine binding showed a high affinity site with K(d) on the order of 10-(10) M for CTBP II and K(d) values of about 10(-9) M for CTBP I and IV and of about 10(-8) M for CTBP III. The order of affinity of iodothyronine analogues to CTBPs was similar in CTBP I, II, and IV but different in CTBP III. Chromatography on Sephacryl S-200 HR showed the elution of a single peak for each CTBP. The apparent molecular weights were about 200,000, 200,000, 25,000, and 60,000 for CTBP I, II, III, and IV, respectively. The physiological relevance of these CTBPs is discussed.	UNIV NACL TUCUMAN,CONSEJO INVEST CIENT & TECN,INST SUPER INVEST BIOL,DEPT BIOQUIM NUTR,RA-4000 TUCUMAN,ARGENTINA; INST QUIM BIOL DR BERNABE BLOJ,RA-4000 TUCUMAN,ARGENTINA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Universidad Nacional de Tucuman								ANGEL RC, 1989, J BIOL CHEM, V264, P19143; BALSAM A, 1978, ENDOCRINOLOGY, V102, P1247, DOI 10.1210/endo-102-4-1247; BARSANO CP, 1983, MOL BASIS THYROID HO, P140; BERNAL J, 1978, ENDOCRINOLOGY, V103, P403, DOI 10.1210/endo-103-2-403; BOLGER MB, 1980, J BIOL CHEM, V255, P271; BOTTA JA, 1985, BIOCHEM BIOPH RES CO, V133, P442, DOI 10.1016/0006-291X(85)90926-X; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAVIS PJ, 1974, J BIOL CHEM, V249, P6208; DEGROOT LJ, 1975, ENDOCRINOLOGY, V96, P357, DOI 10.1210/endo-96-2-357; DEGROOT LJ, 1976, ACTA ENDOCRINOL-COP, V83, P293, DOI 10.1530/acta.0.0830293; DILLMAN W, 1974, ENDOCRINOLOGY, V95, P492, DOI 10.1210/endo-95-2-492; GALTON VA, 1980, ENDOCRINOLOGY, V107, P61; GASC JM, 1984, J CELL BIOL, V99, P1193, DOI 10.1083/jcb.99.4.1193; Gorski J, 1968, Recent Prog Horm Res, V24, P45; HAMADA S, 1970, BIOCHIM BIOPHYS ACTA, V201, P479, DOI 10.1016/0304-4165(70)90168-6; HASHIZUME K, 1986, ENDOCRINOLOGY, V119, P710, DOI 10.1210/endo-119-2-710; HASHIZUME K, 1989, J BIOL CHEM, V264, P4857; HASHIZUME K, 1989, J BIOL CHEM, V264, P4864; ICHIKAWA K, 1986, J BIOL CHEM, V261, P6540; JAFFE RC, 1977, ENDOCRINOLOGY, V101, P447, DOI 10.1210/endo-101-2-447; JENSEN EV, 1968, P NATL ACAD SCI USA, V59, P632, DOI 10.1073/pnas.59.2.632; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; KNOPP J, 1981, ACTA ENDOCRINOL-COP, V98, P68, DOI 10.1530/acta.0.0980068; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MICHELOT J, 1979, BIOCHEM BIOPH RES CO, V88, P1368, DOI 10.1016/0006-291X(79)91131-8; MOUDGIL V, 1981, EUR J BIOCHEM, V118, P547, DOI 10.1111/j.1432-1033.1981.tb05554.x; MOUDGIL VK, 1985, ENDOCRINOLOGY, V116, P1267, DOI 10.1210/endo-116-4-1267; MOUDGIL VK, 1987, BIOCHEMISTRY-US, V26, P4993, DOI 10.1021/bi00390a017; MUNCK A, 1979, NATURE, V278, P752, DOI 10.1038/278752a0; NAJAD I, 1975, ENDOCRINOLOGY, V96, P773; OBATA T, 1989, BIOCHEMISTRY-US, V28, P617, DOI 10.1021/bi00428a030; Oppenheimer J., 1983, MOL BASS THYROID HOR, P1; OPPENHEIMER JH, 1974, J CLIN INVEST, V53, P768, DOI 10.1172/JCI107615; REFETOFF S, 1972, ENDOCRINOLOGY, V91, P934, DOI 10.1210/endo-91-4-934; ROBBINS J, 1986, THYROID, P116; SAMUELS HH, 1974, J CLIN INVEST, V53, P656, DOI 10.1172/JCI107601; SAMUELS HH, 1983, MOL BASIS THYROID HO, P35; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; STERLING K, 1979, CLIN RES, V27, pA506; SURKS MI, 1975, J CLIN INVEST, V55, P50, DOI 10.1172/JCI107917; SURKS MI, 1973, J BIOL CHEM, V248, P7066; TATA JR, 1975, NATURE, V257, P18, DOI 10.1038/257018a0; THOMOPOULOS P, 1974, BIOPHYS RES COMMUN, V55, P544; VANDOORN J, 1985, ENDOCRINOLOGY, V117, P1201; WAHL R, 1977, EUR J BIOCHEM, V80, P25, DOI 10.1111/j.1432-1033.1977.tb11851.x; WAHL R, 1989, ENDOCRINOLOGY, V124, P1428, DOI 10.1210/endo-124-3-1428; WEINBERGER C, 1986, NATURE, V324, P641, DOI 10.1038/324641a0; WELSHONS WV, 1984, NATURE, V307, P747, DOI 10.1038/307747a0; WELSHONS WV, 1985, ENDOCRINOLOGY, V117, P2140, DOI 10.1210/endo-117-5-2140; WRAP W, 1981, ANAL BIOCHEM, V118, P197; YOSHIDA K, 1980, ENDOCR RES COMMUN, V7, P177, DOI 10.3109/07435808009065971; YOSHIDA K, 1981, HORM METAB RES, V13, P394, DOI 10.1055/s-2007-1019279	53	7	7	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16415	16419						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885573				2022-12-25	WOS:A1991GD63500030
J	ISHIDOH, K; MUNO, D; SATO, N; KOMINAMI, E				ISHIDOH, K; MUNO, D; SATO, N; KOMINAMI, E			MOLECULAR-CLONING OF CDNA FOR RAT CATHEPSIN-C - CATHEPSIN-C, A CYSTEINE PROTEINASE WITH AN EXTREMELY LONG PROPEPTIDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; LYSOSOMAL-ENZYMES; ESCHERICHIA-COLI; MESSENGER-RNAS; THIOL PROTEASE; HOMOLOGY; PAPAIN	A cDNA for rat cathepsin C (dipeptidylaminopeptidase I) was isolated. The deduced amino acid sequence of cathepsin C comprises 462 amino acid residues: 28 NH2-terminal residues corresponding to the signal peptide, 201 residues corresponding to the propeptide, and 233 COOH-terminal residues corresponding to the mature enzyme region. Four potential glycosylation sites were found, three located in the propeptide region, and one in the mature enzyme region. The amino acid sequence of mature cathepsin C has 39.5% identity to that of cathepsin H, 35.1 % to that of cathepsin L, 30.1% to that of cathepsin B, and 33.3% to that of papain. Cathepsin C, therefore, is a member of the papain family, although its propeptide region is much longer than those of other cysteine proteinases and shows no significant amino acid sequence similarity to any other cysteine proteinase.			ISHIDOH, K (corresponding author), JUNTENDO UNIV,SCH MED,DEPT BIOCHEM,HONGO 2-1-1,BUNKYO KU,TOKYO 113,JAPAN.		Kominami, Eiki/D-3802-2009					BARRETT AJ, 1972, ANAL BIOCHEM, V47, P280, DOI 10.1016/0003-2697(72)90302-8; BARRETT AJ, 1982, BIOCHEM J, V47, P280; BAZAN JF, 1988, P NATL ACAD SCI USA, V85, P7872, DOI 10.1073/pnas.85.21.7872; CHAN SJ, 1986, P NATL ACAD SCI USA, V83, P7721, DOI 10.1073/pnas.83.20.7721; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN LW, 1986, GENE, V48, P219, DOI 10.1016/0378-1119(86)90080-6; CRESTFIELD AM, 1963, J BIOL CHEM, V238, P622; DAGROSA RM, 1988, BIOCHEM BIOPH RES CO, V157, P770, DOI 10.1016/S0006-291X(88)80316-4; DOUGHTY MJ, 1987, BIOCHEM CELL BIOL, V65, P617, DOI 10.1139/o87-082; DUFUR E, 1988, BIOCHIMIE PARIS, V70, P1335; GUAGLIARDI LE, 1990, NATURE, V343, P133, DOI 10.1038/343133a0; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HATTORI M, 1986, ANAL BIOCHEM, V152, P232, DOI 10.1016/0003-2697(86)90403-3; ISHIDOH K, 1987, FEBS LETT, V226, P33, DOI 10.1016/0014-5793(87)80545-8; ISHIDOH K, 1987, FEBS LETT, V223, P69, DOI 10.1016/0014-5793(87)80511-2; IVY GO, 1984, SCIENCE, V226, P985, DOI 10.1126/science.6505679; KANEHISA M, 1982, NUCLEIC ACIDS RES, V10, P183, DOI 10.1093/nar/10.1.183; KLINKERT MQ, 1989, MOL BIOCHEM PARASIT, V33, P113, DOI 10.1016/0166-6851(89)90025-X; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KUTUNUMA N, 1989, INTRACELLULAR PROTEO, P3; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LATHE R, 1985, J MOL BIOL, V183, P1, DOI 10.1016/0022-2836(85)90276-1; LIAO JCR, 1984, BIOCHEM BIOPH RES CO, V124, P909, DOI 10.1016/0006-291X(84)91044-1; LYNTH GW, 1988, THROMB HAEMOSTASIS, V59, P372; Maniatis T, 1982, MOL CLONING LABORATO; MCDONALD JK, 1969, J BIOL CHEM, V244, P2693; MCDONALD JK, 1966, J BIOL CHEM, V241, P1494; MOTTRAM JC, 1989, FEBS LETT, V258, P211, DOI 10.1016/0014-5793(89)81655-2; OHNO S, 1984, NATURE, V312, P566, DOI 10.1038/312566a0; PROUDFOOT NJ, 1976, NATURE, V263, P211, DOI 10.1038/263211a0; RITONJA A, 1988, FEBS LETT, V228, P341, DOI 10.1016/0014-5793(88)80028-0; SCHAFFER MA, 1988, PLANT PHYSIOL, V87, P431, DOI 10.1104/pp.87.2.431; SEBTI SM, 1987, BIOCHEMISTRY-US, V26, P4213, DOI 10.1021/bi00388a006; SLOANE BF, 1984, CANCER METAST REV, V3, P249, DOI 10.1007/BF00048388; SMITH SM, 1989, J BIOL CHEM, V264, P20487; TAKIO K, 1983, P NATL ACAD SCI-BIOL, V80, P3666, DOI 10.1073/pnas.80.12.3666; VONFIGURA K, 1986, ANNU REV BIOCHEM, V55, P167, DOI 10.1146/annurev.biochem.55.1.167; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; WATANABE H, 1991, J BIOL CHEM, V266, P16897	43	78	81	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16312	16317						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885565				2022-12-25	WOS:A1991GD63500014
J	OKUBO, K; HAMASAKI, N; HARA, K; KAGEURA, M				OKUBO, K; HAMASAKI, N; HARA, K; KAGEURA, M			PALMITOYLATION OF CYSTEINE-69 FROM THE COOH-TERMINAL OF BAND-3 PROTEIN THE HUMAN ERYTHROCYTE-MEMBRANE - ACYLATION OCCURS IN THE MIDDLE OF THE CONSENSUS SEQUENCE OF F--I-IICLAVL FOUND IN BAND-3 PROTEIN AND G2-PROTEIN OF RIFT-VALLEY FEVER VIRUS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE BINDING-SITE; ANION-EXCHANGE PROTEIN; FATTY-ACID ACYLATION; PHOSPHOENOLPYRUVATE TRANSPORT; BOVINE RHODOPSIN; CELL-MEMBRANE; ALPHA-SUBUNIT; RESIDUES; FRAGMENT; RECEPTOR	One of the major physiologic functions of erythrocytes is the mediation of chloride-bicarbonate exchange in the transport of carbon dioxide from the tissues to the lungs. The anion exchange is mediated by a typical polytopic transmembrane protein in the cell membrane, designated Band 3. A carboxyl-terminal peptide of Band 3 was affinity-labeled with pyridoxal phosphate, a substrate for the anion transport system, and then sequenced (Kawano, Y., Okubo, K., Tokunaga, F., Miyata, T., Iwanaga, S., and Hamasaki, N. (1988) J. Biol. Chem. 263, 8232-8238). The 10th amino acid residue of the peptide could not be determined, suggesting post-translational modification of the residue. In the present communication, we have investigated the molecular structure of human Band 3 and the COOH-terminal 8500-dalton peptide using gas-liquid chromatography-mass spectrometry. Band 3 was modified covalently by fatty acids and these acids were released from Band 3 by hydroxylamine treatment at either pH 7 or 11, indicating that the linkage between Band 3 and the fatty acid is a thio ester bond. 1 mol of Band 3 interacted with 1 mol of fatty acid at a cysteine residue located 69 residues from the COOH terminus of Band 3. The fatty acids used in the modification were myristate, palmitate, oleate, and stearate, with palmitate being the major component. The esterified site is close to the site affinity-labeled with pyridoxal phosphate (Kawano, Y., Okubo, K., Tokunaga, F., Miyata, T., Iwanaga, S., and Hamasaki, N. (1988) J. Biol. Chem. 263, 8232-8238). The amino acid sequence including the acylation site was Phe-Thr-Gly-Ile-Gln-Ile-Ile-Cys-Leu-Ala-Val-Leu, which is conserved in the G2 protein of Rift Valley fever virus as Phe-Ser-Ser-Ile-Ala-Ile-Ile-Cys-Leu-Ala-Val-Leu. The G2 protein, like Band 3, is a polytopic transmembrane protein. Although acylation of the cysteine residue of G2 protein has not been examined, the Phe-X-X-Ile-X-Ile-Ile-Cys-Leu-Ala-Val-Leu sequence could be a common motif for fatty acylation of certain membrane proteins.	FUKUOKA UNIV, SCH MED, DEPT CLIN CHEM & LAB MED, FUKUOKA 81401, JAPAN; FUKUOKA UNIV, SCH MED, DEPT LEGAL MED, FUKUOKA 81401, JAPAN	Fukuoka University; Fukuoka University								ANDREWS PC, 1987, ANAL BIOCHEM, V161, P524, DOI 10.1016/0003-2697(87)90484-2; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; COCKLE SA, 1980, J BIOL CHEM, V255, P9182; COLLETT MS, 1985, VIROLOGY, V144, P228, DOI 10.1016/0042-6822(85)90320-4; DOLCI ED, 1985, J BIOL CHEM, V260, P728; FINKEL T, 1984, CELL, V37, P151, DOI 10.1016/0092-8674(84)90310-6; FOLCH J, 1951, J BIOL CHEM, V191, P807; GEBHARDT A, 1984, J MOL BIOL, V174, P297, DOI 10.1016/0022-2836(84)90340-1; HAMASAKI N, 1987, TRENDS BIOCHEM SCI, V12, P183, DOI 10.1016/0968-0004(87)90089-2; HAMASAKI N, 1983, EUR J BIOCHEM, V132, P531, DOI 10.1111/j.1432-1033.1983.tb07394.x; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KAWANO Y, 1986, J BIOCHEM-TOKYO, V100, P191, DOI 10.1093/oxfordjournals.jbchem.a121692; KAWANO Y, 1988, J BIOL CHEM, V263, P8232; KEENAN TW, 1982, EUR J CELL BIOL, V26, P270; KOPITO RR, 1985, NATURE, V316, P234, DOI 10.1038/316234a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUX SE, 1989, P NATL ACAD SCI USA, V86, P9089, DOI 10.1073/pnas.86.23.9089; MARETZKI D, 1990, FEBS LETT, V259, P305, DOI 10.1016/0014-5793(90)80033-F; MARINETTI GV, 1982, BIOCHIM BIOPHYS ACTA, V685, P109, DOI 10.1016/0005-2736(82)90086-4; MATSUYAMA H, 1983, J BIOL CHEM, V258, P5376; NANRI H, 1983, J BIOL CHEM, V258, P5985; OBRIEN PJ, 1984, J BIOL CHEM, V259, P5054; OBRIEN PJ, 1987, J BIOL CHEM, V262, P5210; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; OLSON EN, 1988, PROG LIPID RES, V27, P177, DOI 10.1016/0163-7827(88)90012-4; OLSON EN, 1984, J BIOL CHEM, V259, P5364; OMARY MB, 1981, J BIOL CHEM, V256, P4715; OVCHINNIKOV YA, 1988, FEBS LETT, V230, P1, DOI 10.1016/0014-5793(88)80628-8; PASSOW H, 1986, REV PHYSIOL BIOCH P, V103, P61; RAO A, 1979, J BIOL CHEM, V254, P3503; SCHLESINGER MJ, 1981, ANNU REV BIOCHEM, V50, P193, DOI 10.1146/annurev.bi.50.070181.001205; SCHMIDT JW, 1987, J BIOL CHEM, V262, P13713; SCHMIDT MFG, 1979, P NATL ACAD SCI USA, V76, P1687, DOI 10.1073/pnas.76.4.1687; SCHMIDT MFG, 1982, VIROLOGY, V116, P327, DOI 10.1016/0042-6822(82)90424-X; SCHMIDT MFG, 1989, BIOCHIM BIOPHYS ACTA, V988, P411, DOI 10.1016/0304-4157(89)90013-0; SCHULTZ AM, 1988, ANNU REV CELL BIOL, V4, P611, DOI 10.1146/annurev.cb.04.110188.003143; SLOMIANY A, 1984, ARCH BIOCHEM BIOPHYS, V229, P560, DOI 10.1016/0003-9861(84)90188-7; STAUFENBIEL M, 1988, J BIOL CHEM, V263, P13615; STAUFENBIEL M, 1986, P NATL ACAD SCI USA, V83, P318, DOI 10.1073/pnas.83.2.318; STAUFENBIEL M, 1987, MOL CELL BIOL, V7, P2981, DOI 10.1128/MCB.7.8.2981; STOFFEL W, 1983, H-S Z PHYSIOL CHEM, V364, P1455, DOI 10.1515/bchm2.1983.364.2.1455; TANNER MJA, 1988, BIOCHEM J, V256, P703, DOI 10.1042/bj2560703; TOWLER DA, 1988, ANNU REV BIOCHEM, V57, P69, DOI 10.1146/annurev.bi.57.070188.000441; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ZDEBSKA E, 1989, ARCH BIOCHEM BIOPHYS, V273, P223, DOI 10.1016/0003-9861(89)90182-3	48	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16420	16424						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885574				2022-12-25	WOS:A1991GD63500031
J	QARI, SH; GOLDMAN, IF; POVOA, MM; OLIVEIRA, S; ALPERS, MP; LAL, AA				QARI, SH; GOLDMAN, IF; POVOA, MM; OLIVEIRA, S; ALPERS, MP; LAL, AA			WIDE DISTRIBUTION OF THE VARIANT FORM OF THE HUMAN MALARIA PARASITE PLASMODIUM-VIVAX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							T-CELLS RECOGNIZE; CIRCUMSPOROZOITE PROTEIN; IMMUNODOMINANT EPITOPE; CS PROTEIN; FALCIPARUM; GENE; POLYMORPHISM; SEQUENCE; ANTIGEN	We have found polymorphism in the repetitive and nonrepetitive regions of the sporozoite vaccine antigen, the circumsporozoite (CS) protein, in Plasmodium vivax malaria parasites from two geographically distant malaria endemic regions of the world. Like the recently described variant repeat sequence of P. vivax from Thailand, the CS protein repeat sequence of the variant P. vivax parasites from Papua New Guinea and Brazil is ANGA(G/D)(N/D)QPG, which differs from the previously identified CS repeat sequence, GDRA(D/A)GQPA, of P. vivax parasites from South America, Central America, and North Korea. Comparison of the P. vivax CS protein outside the repeat region revealed restricted polymorphism in regions that have exhibited T-cell immune function and sequence heterogeneity in the CS protein of Plasmodium falciparum. Our results show that P. vivax malaria parasites with the variant CS repeat sequences are widespread in nature and that the polymorphism in the CS protein of P. vivax is also present in the nonrepeat region.	CTR DIS CONTROL,CTR INFECT DIS,DIV PARASIT DIS,MALARIA BRANCH,MAIL STOP F-12,1600 CLIFTON RD,ATLANTA,GA 30333; EVANDRO CHAGAS INST,MALARIA PROGRAM,BELEM,PARA,BRAZIL; PAPUA NEW GUINEA INST MED RES,MADANG,PAPUA N GUINEA	Centers for Disease Control & Prevention - USA; Instituto Evandro Chagas; PNG Institute Of Medical Research			Povoa, Marinete Marins/C-7039-2017	Povoa, Marinete Marins/0000-0003-3517-2227; Qari, Shoukat/0000-0002-0016-4414	NIAID NIH HHS [I-Y02-AI-00006-01] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGGARWAL A, 1990, J EXP MED, V172, P1083, DOI 10.1084/jem.172.4.1083; ARNOT DE, 1985, SCIENCE, V230, P815, DOI 10.1126/science.2414847; ARNOT DE, 1988, P NATL ACAD SCI USA, V85, P8102, DOI 10.1073/pnas.85.21.8102; BRUCECHWATT LJ, 1965, B WORLD HEALTH ORGAN, V32, P363; BURKOT TR, 1989, J CLIN MICROBIOL, V27, P1346, DOI 10.1128/JCM.27.6.1346-1351.1989; DAME JB, 1984, SCIENCE, V225, P593, DOI 10.1126/science.6204383; DELACRUZ VF, 1988, J IMMUNOL, V141, P2456; DELACRUZ VF, 1987, J BIOL CHEM, V262, P11935; ENEA V, 1984, SCIENCE, V225, P638; GALINSKI MR, 1987, CELL, V48, P311, DOI 10.1016/0092-8674(87)90434-X; GEORGE FW, 1990, INFECT IMMUN, V58, P575, DOI 10.1128/IAI.58.2.575-578.1990; GOOD MF, 1987, SCIENCE, V235, P1059, DOI 10.1126/science.2434994; LAL AA, 1988, MOL BIOCHEM PARASIT, V30, P291, DOI 10.1016/0166-6851(88)90099-0; LOCKYER MJ, 1987, MOL BIOCHEM PARASIT, V22, P101, DOI 10.1016/0166-6851(87)90073-9; MCCUTCHAN TF, 1989, PARASITOL TODAY, V5, P143, DOI 10.1016/0169-4758(89)90078-1; MCCUTCHAN TF, 1985, SCIENCE, V230, P1381, DOI 10.1126/science.2416057; MILLER LH, 1986, SCIENCE, V234, P1346; NUSSENZWEIG RS, 1990, IMMUNOL LETT, V25, P21, DOI 10.1016/0165-2478(90)90084-4; NUSSENZWEIG V, 1985, CELL, V42, P401, DOI 10.1016/0092-8674(85)90093-5; ROMERO P, 1989, NATURE, V341, P323, DOI 10.1038/341323a0; ROSENBERG R, 1989, SCIENCE, V245, P973, DOI 10.1126/science.2672336; SHARMA S, 1985, SCIENCE, V229, P779, DOI 10.1126/science.4023712; WEISS WR, 1990, J EXP MED, V171, P763, DOI 10.1084/jem.171.3.763	23	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16297	16300						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885563				2022-12-25	WOS:A1991GD63500011
J	HADDOW, S; FOWLIS, DJ; PARKINSON, K; AKHURST, RJ; BALMAIN, A				HADDOW, S; FOWLIS, DJ; PARKINSON, K; AKHURST, RJ; BALMAIN, A			LOSS OF GROWTH-CONTROL BY TGF-BETA OCCURS AT A LATE STAGE OF MOUSE SKIN CARCINOGENESIS AND IS INDEPENDENT OF RAS GENE ACTIVATION	ONCOGENE			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; LIVER EPITHELIAL-CELLS; HA-RAS; TERMINAL DIFFERENTIATION; INHIBITION; PROLIFERATION; ONCOGENE; PROGRESSION; HEPATOCYTES; EXPRESSION	The relationship between the expression of a mutant ras gene in epithelial cells and loss of responsiveness to the negative effects of transforming growth factor-beta (TGF-beta) is presently unclear. We have investigated this question using a series of cell lines derived from benign and malignant mouse skin tumours which express mutant forms of the H-ras gene. Immortalised, non-tumorigenic mouse epidermal cells respond to TGF-beta by cessation of growth, whereas in a series of malignant carcinoma lines the response was substantially reduced. Introduction of a mutant H-ras gene into the immortalised cells did not lead to any appreciable change in TGF-beta responsiveness, suggesting that initiation of carcinogenesis by ras mutation does not directly alter growth control by this pathway. Of two non-tumorigenic papilloma lines tested which had mutant H-ras genes, one retained complete sensitivity to TGF-beta, whereas the other showed a similar response to carcinomas. We conclude that growth control by TGF-beta is lost at a relatively late stage of carinogenesis in this system, and is independent of ras gene activation.	BEATSON INST CANC RES,CRC,BEATSON LABS,GARSCUBE ESTATE,SWITCHBACK RD,BEARSDEN,GLASGOW G61 1BD,SCOTLAND; YORKHILL HOSP,DUNCAN GUTHRIE INST MED GENET,GLASGOW,SCOTLAND	Beatson Institute				AKHURST, ROSEMARY/0000-0002-4474-9668				AKHURST RJ, 1988, NATURE, V331, P363, DOI 10.1038/331363a0; BIANCHI AB, 1990, P NATL ACAD SCI USA, V87, P6902, DOI 10.1073/pnas.87.17.6902; BIZUB D, 1986, P NATL ACAD SCI USA, V83, P6048, DOI 10.1073/pnas.83.16.6048; Boutwell R K, 1974, CRC Crit Rev Toxicol, V2, P419; BOYD JA, 1990, CANCER RES, V50, P3394; BREMNER R, 1990, CELL, V61, P407, DOI 10.1016/0092-8674(90)90523-H; BROWN K, 1986, CELL, V46, P447, DOI 10.1016/0092-8674(86)90665-3; FURSTENBERGER G, 1989, INT J CANCER, V43, P915; FUSENIG N E, 1973, INSERM (Institut National de la Sante et de la Recherche Medicale) Colloque, V19, P219; GLICK AB, 1989, CELL REGUL, V1, P87, DOI 10.1091/mbc.1.1.87; GOUSTIN AS, 1986, CANCER RES, V46, P1015; HOUCK KA, 1989, ONCOGENE, V4, P19; KULESZMARTIN M, 1983, CARCINOGENESIS, V4, P1367, DOI 10.1093/carcin/4.11.1367; KULESZMARTIN M, 1990, CANCER RES, V50, P686; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LIN P, 1987, BIOCHEM BIOPH RES CO, V143, P26, DOI 10.1016/0006-291X(87)90624-3; MADHUKAR BV, 1989, CARCINOGENESIS, V10, P13, DOI 10.1093/carcin/10.1.13; MANNING A, 1991, IN PRESS ONCOGENE; MANSBRIDGE JN, 1988, J INVEST DERMATOL, V90, P336, DOI 10.1111/1523-1747.ep12456286; MASUI T, 1986, P NATL ACAD SCI USA, V83, P2438, DOI 10.1073/pnas.83.8.2438; MCMAHON JB, 1986, CANCER RES, V46, P4665; NAGY P, 1989, MOL CARCINOGEN, V2, P345, DOI 10.1002/mc.2940020609; PARKINSON EK, 1990, CARCINOGENESIS, V11, P195; PERA MF, 1984, CARCINOGENESIS, V5, P671, DOI 10.1093/carcin/5.5.671; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; PITTELKOW MR, 1989, J BIOL CHEM, V264, P5164; QUINTANILLA M, 1986, NATURE, V322, P78, DOI 10.1038/322078a0; Reddel R R, 1988, Oncogene Res, V3, P401; REISS M, 1987, CANCER RES, V47, P6705; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; ROLLINS BJ, 1989, J CELL PHYSIOL, V139, P455, DOI 10.1002/jcp.1041390302; SHIPLEY GD, 1986, CANCER RES, V46, P2068; SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0; TERZAGHIHOWE M, 1989, CARCINOGENESIS, V10, P973, DOI 10.1093/carcin/10.6.973; VALVERIUS EM, 1989, CANCER RES, V49, P6269; WAKEFIELD LM, 1987, J CELL BIOL, V105, P965, DOI 10.1083/jcb.105.2.965; WOLLENBERG GK, 1987, CANCER RES, V47, P6595; YUSPA SH, 1983, CANCER RES, V43, P6021; YUSPA SH, 1981, NATURE, V293, P72, DOI 10.1038/293072a0	39	74	77	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1465	1470						6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886717				2022-12-25	WOS:A1991GX27200025
J	EKLUND, EA; MARSHALL, M; GIBBS, JB; CREAN, CD; GABIG, TG				EKLUND, EA; MARSHALL, M; GIBBS, JB; CREAN, CD; GABIG, TG			RESOLUTION OF A LOW-MOLECULAR-WEIGHT G-PROTEIN IN NEUTROPHIL CYTOSOL REQUIRED FOR NADPH OXIDASE ACTIVATION AND RECONSTITUTION BY RECOMBINANT KREV-1 PROTEIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE SYSTEM; CHRONIC GRANULOMATOUS-DISEASE; DEPENDENT SUPEROXIDE PRODUCTION; GTP-BINDING PROTEIN; RESPIRATORY BURST; ONCOGENIC RAS-P21; ADENYLATE-CYCLASE; CYTOCHROME-B; RAS; IDENTIFICATION	Activation of the membrane-associated NADPH oxidase in intact human neutrophils requires a receptor-associated heterotrimeric GTP-binding protein that is sensitive to pertussis toxin. Activation of this NADPH oxidase by arachidonate in a cell-free system requires an additional downstream pertussis toxin-insensitive G protein (Gabig, T. G., English, D., Akard, L. P., and Schell, M. J. (1987) (J. Biol. Chem. 262, 1685-1690) that is located in the cytosolic fraction of unstimulated cells (Gabig, T. G., Eklund, E. A., Potter, G. B., and Dykes, J. R. (1990) J. Immunol. 145, 945-951). In the present study, immunodepletion of G proteins from the cytosolic fraction of unstimulated neutrophils resulted in a loss of the ability to activate NADPH oxidase in the membrane fraction. The activity in immunodepleted cytosol was fully reconstituted by a partially purified fraction from neutrophil cytosol that contained a 21-kDa GTP-binding protein. Purified human recombinant Krev-1 p21 also completely reconstituted immunodepleted cytosol whereas recombinant human H-ras p21 or yeast RAS GTP-binding proteins had no reconstitutive activity. Rabbit antisera raised against a synthetic peptide corresponding to the effector region of Krev-1 (amino acids 31-43) completely inhibited cell-free NADPH oxidase activation, and this inhibition was blocked by the synthetic 31-43 peptide. An inhibitory monoclonal antibody specific for ras p21 amino acids 60-77 (Yl3-259) had no effect on cell-free NADPH oxidase activation. Activation of the NADPH oxidase in intact neutrophils by stimulation with phorbol myristate acetate caused a marked increase in the amount of membrane-associated antigen recognized by 151 antiserum on Western blot. Thus a G protein in the cytosol of unstimulated neutrophils antigenically and functionally related to Krev-1 may be the downstream effector G protein for NADPH oxidase activation. This system represents a unique model to study molecular interactions of a ras-like G protein.	INDIANA UNIV, SCH MED,DEPT MED,DIV HEMATOL ONCOL, MED RES & LIB BLDG,ROOM 442, 975 W WALNUT ST, INDIANAPOLIS, IN 46202 USA; MERCK SHARP & DOHME LTD, DEPT CANC RES, W POINT, PA 19486 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Merck & Company					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021961] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007519] Funding Source: NIH RePORTER; NIAID NIH HHS [AI21961] Funding Source: Medline; NIDDK NIH HHS [T32DK7519] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BABIOR BM, 1984, J CLIN INVEST, V73, P599, DOI 10.1172/JCI111249; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; BUSS JE, 1991, MOL CELL BIOL, V11, P1523, DOI 10.1128/MCB.11.3.1523; CHESA PG, 1987, P NATL ACAD SCI USA, V84, P3234, DOI 10.1073/pnas.84.10.3234; CURNUTTE JT, 1989, P NATL ACAD SCI USA, V86, P825, DOI 10.1073/pnas.86.3.825; CURNUTTE JT, 1985, J CLIN INVEST, V75, P1740, DOI 10.1172/JCI111885; DINAUER MC, 1987, NATURE, V327, P717, DOI 10.1038/327717a0; EKLUND EA, 1990, J BIOL CHEM, V265, P8426; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GABIG TG, 1987, J BIOL CHEM, V262, P1685; GABIG TG, 1990, J IMMUNOL, V145, P945; GIBBS JB, 1989, P NATL ACAD SCI USA, V86, P6630, DOI 10.1073/pnas.86.17.6630; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704; HEYNEMAN RA, 1984, J LEUKOCYTE BIOL, V36, P751, DOI 10.1002/jlb.36.6.751; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; KIM S, 1990, MOL CELL BIOL, V10, P2645, DOI 10.1128/MCB.10.6.2645; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARSHALL MS, 1988, MOL CELL BIOL, V8, P52, DOI 10.1128/MCB.8.1.52; MCPHAIL LC, 1985, J CLIN INVEST, V75, P1735, DOI 10.1172/JCI111884; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; NAGATA K, 1989, J BIOL CHEM, V264, P17000; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; NUNOI H, 1988, SCIENCE, V242, P1298, DOI 10.1126/science.2848319; QUINN MT, 1989, NATURE, V342, P198, DOI 10.1038/342198a0; SCHNEIDER C, 1982, J BIOL CHEM, V257, P766; SIGAL IS, 1987, ANTI-CANCER DRUG DES, V2, P107; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SMITH CD, 1986, SCIENCE, V232, P97, DOI 10.1126/science.3006254; TIMMONS TM, 1990, METHOD ENZYMOL, V182, P679; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; VOLPP BD, 1988, SCIENCE, V242, P1295, DOI 10.1126/science.2848318	34	72	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	1991	266	21					13964	13970						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FY027	1906890				2022-12-25	WOS:A1991FY02700081
J	MORIMATSU, M; SYUTO, B; SHIMADA, N; FUJINAGA, T; YAMAMOTO, S; SAITO, M; NAIKI, M				MORIMATSU, M; SYUTO, B; SHIMADA, N; FUJINAGA, T; YAMAMOTO, S; SAITO, M; NAIKI, M			ISOLATION AND CHARACTERIZATION OF BOVINE HAPTOGLOBIN FROM ACUTE PHASE SERA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEINS; BINDING; DUPLICATION; EVOLUTION; FAMILIES; GENE	A macromolecular hemoglobin-binding protein, which was not detectable in normal bovine sera but appeared during acute phase inflammation, was purified, characterized, and designated as bovine haptoglobin (Hp). The purified protein had a molecular mass of 1,000-2,000 kDa, and was composed of two kinds of peptides, a 20-kDa peptide (alpha-chain) and a 35-kDa glycopeptide (beta-chain) linked by disulfide bonds. Amino acid composition and N-terminal sequence analyses revealed that both peptides were homologous to each counterpart of human Hp. Studies using some reducing reagents proved that highly polymerized Hp in serum was composed of 2-20 polymerized forms of alpha-2-beta-2 tetramer. Hp could bind one molecule of hemoglobin/alpha-2-beta-2 unit. Hp with smaller sizes obtained from native Hp by partial reduction with cysteine showed almost the same Hb-binding capacity.	HOKKAIDO UNIV,FAC VET MED,DEPT BIOCHEM,SAPPORO,HOKKAIDO 060,JAPAN; HOKKAIDO UNIV,FAC VET MED,DEPT SURG,SAPPORO,HOKKAIDO 060,JAPAN; AZABU COLL VET SCH,DEPT IMMUNOL,SAGAMIHARA 229,JAPAN	Hokkaido University; Hokkaido University; Azabu University			Morimatsu, Masami/A-6698-2012	Morimatsu, Masami/0000-0003-0740-0157				BAILLIE RD, 1976, BIOCHIM BIOPHYS ACTA, V429, P383, DOI 10.1016/0005-2744(76)90286-2; BOWMAN BH, 1982, ADV HUM GENET, V12, P189; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREMNER KC, 1964, AUST J EXP BIOL MED, V42, P643, DOI 10.1038/icb.1964.62; BUSBY JR, 1978, COMP BIOCH PHYSL B, V60, P389; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; FRIEDMAN M, 1970, J BIOL CHEM, V245, P3868; FULLER GM, 1973, BIOCHEMISTRY-US, V12, P253, DOI 10.1021/bi00726a012; HATTORI A, 1989, SEIKAGAKU, V61, P717; KINO K, 1980, J BIOL CHEM, V255, P9616; KUHAJDA FP, 1989, P NATL ACAD SCI USA, V86, P1188, DOI 10.1073/pnas.86.4.1188; KUROSKY A, 1980, P NATL ACAD SCI-BIOL, V77, P3388, DOI 10.1073/pnas.77.6.3388; KUROSKY A, 1976, COMP BIOCHEM PHYS B, V55, P453, DOI 10.1016/0305-0491(76)90320-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUSTBADER JW, 1983, J BIOL CHEM, V258, P1227; MAEDA N, 1985, J BIOL CHEM, V260, P6698; MAEDA N, 1986, ANNU REV GENET, V20, P81; MAEDA N, 1984, NATURE, V309, P131, DOI 10.1038/309131a0; MAKIMURA S, 1982, JPN J VET SCI, V44, P15, DOI 10.1292/jvms1939.44.15; MORIISHI K, 1989, INFECT IMMUN, V57, P2886, DOI 10.1128/IAI.57.9.2886-2891.1989; OSADA J, 1987, ACTA BIOCHIM POL, V34, P337; OSADA J, 1985, ACTA BIOCHIM POL, V32, P225; PUTNAM FW, 1975, PLASMA PROTEIN STRUC, V2, P1; SPOONER RL, 1971, VET REC, V81, P2; SPOONER RL, 1970, BIOCHEM J, V119, P35; TRAVIS JC, 1972, J EXP ZOOL, V180, P141, DOI 10.1002/jez.1401800112; VIRELLA G, 1973, IMMUNOCHEMISTRY, V10, P213, DOI 10.1016/0019-2791(73)90197-3	27	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 25	1991	266	18					11833	11837						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FT762	1904872				2022-12-25	WOS:A1991FT76200064
J	PIRIESHEPHERD, SR; MILLER, HRP; RYLE, A				PIRIESHEPHERD, SR; MILLER, HRP; RYLE, A			DIFFERENTIAL INHIBITION OF RAT MAST-CELL PROTEINASE-I AND PROTEINASE-II BY MEMBERS OF THE ALPHA-1-PROTEINASE INHIBITOR FAMILY OF SERINE PROTEINASE-INHIBITORS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; SYSTEMIC RELEASE; REACTIVE SITE; GENE FAMILY; PRIMED RATS; PROTEASE; PURIFICATION; TRYPTASE; CHYMASE; ALPHA-1-ANTICHYMOTRYPSIN	Rat mast cell proteinase II (RMCP II) from mucosal mast cells was titrated into rat serum, and the resulting serine proteinase inhibitor (serpin)-enzyme complex was purified by affinity chromatography on anti-RMCP II-Sepharose 4B and by Mono-Q anion-exchange. The purified complex was used to raise polyclonal antibodies which, after cross-absorption against RMCP II-Sepharose 4B, were specific for serpin and were used to affinity purify two rat serpin molecules (RSI and RSII) that inhibit RMCP II in rat serum. The kinetic constants characterizing the interaction between RMCP II and RSI and RSII are k(a), 2.2 x 10(5) and 1.65 x 10(5) M-1 s-1, respectively; K(i), 3.6 x 10(-10) and 1.0 x 10(-9) M; and k(d), 7.9 x 10(-5) and 1.65 x 10(-4) s-1. Amino-terminal sequence analysis indicated that RSI and RSII are distinct, differing at the amino-terminal residues, and are products of the rat Spi-1 locus. Rat mast cell proteinase I (RMCP I) from connective tissue mast cells cleaved both RSI and RSII and was not inhibited.	UNIV EDINBURGH, DEPT BIOCHEM, EDINBURGH EH8 9YL, MIDLOTHIAN, SCOTLAND	University of Edinburgh	PIRIESHEPHERD, SR (corresponding author), MOREDUN RES INST, 408 GILMERTON RD, EDINBURGH EH17 7JH, MIDLOTHIAN, SCOTLAND.							BEATTY K, 1980, J BIOL CHEM, V255, P3931; BENDITT EP, 1959, J EXP MED, V110, P451, DOI 10.1084/jem.110.3.451; BENFEY PN, 1987, J BIOL CHEM, V262, P5377; Bieth J., 1974, BAYER S, P463; BORRIELLO F, 1990, NUCLEIC ACIDS RES, V18, P5481, DOI 10.1093/nar/18.18.5481; BOUDIER C, 1989, BIOCHIM BIOPHYS ACTA, V995, P36, DOI 10.1016/0167-4838(89)90230-6; CAUGHEY GH, 1989, AM J PHYSIOL, V257, pL39, DOI 10.1152/ajplung.1989.257.2.L39; CHAO S, 1990, BIOCHEMISTRY-US, V29, P323, DOI 10.1021/bi00454a004; CHASE T, 1970, METHOD ENZYMOL, V19, P20; ENGHILD JJ, 1989, J BIOL CHEM, V264, P11428; GIANAZZA E, 1982, BIOCHEM J, V203, P637, DOI 10.1042/bj2030637; GIBSON S, 1986, IMMUNOLOGY, V58, P101; HILL RE, 1984, NATURE, V311, P175, DOI 10.1038/311175a0; HUNTLEY JF, 1990, PARASITE IMMUNOL, V12, P85, DOI 10.1111/j.1365-3024.1990.tb00938.x; HUNTLEY JF, 1987, PARASITE IMMUNOL, V9, P603, DOI 10.1111/j.1365-3024.1987.tb00533.x; INGLIS JD, 1990, NATO ADV SCI I A-LIF, V191, P137; IRVINE J, 1990, IMMUNOLOGY, V69, P139; KATUNUMA N, 1975, EUR J BIOCHEM, V52, P37, DOI 10.1111/j.1432-1033.1975.tb03970.x; KEZDY FJ, 1970, METHOD ENZYMOL, V19, P3; KIDO H, 1988, BIOL CHEM H-S, V369, P95; KING SJ, 1984, IMMUNOLOGY, V51, P653; KUEHN L, 1984, BIOCHEM J, V218, P953, DOI 10.1042/bj2180953; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGUNOFF D, 1976, ARCH BIOCHEM BIOPHYS, V173, P554, DOI 10.1016/0003-9861(76)90292-7; LETRONG H, 1987, P NATL ACAD SCI USA, V84, P364; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILLER HRP, 1983, IMMUNOLOGY, V49, P471; MORII M, 1983, J BIOL CHEM, V258, P2749; NADEL JA, 1989, DRUGS, V37, P51, DOI 10.2165/00003495-198900371-00011; PATRICK MK, 1988, GASTROENTEROLOGY, V94, P1; REYNOLDS DS, 1990, P NATL ACAD SCI USA, V87, P3230, DOI 10.1073/pnas.87.8.3230; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHECHTER NM, 1989, J BIOL CHEM, V264, P21308; SCHICK B, 1990, IMMUNOLOGY, V69, P423; SOPATA I, 1988, Reumatologia (Warsaw), V26, P8; TAM EK, 1990, AM J RESP CELL MOL, V3, P27, DOI 10.1165/ajrcmb/3.1.27; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; TRONG HL, 1987, BIOCHEMISTRY-US, V26, P6988; VANDERSLICE P, 1990, P NATL ACAD SCI USA, V87, P3811, DOI 10.1073/pnas.87.10.3811; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P4298, DOI 10.1021/bi00613a029; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P811, DOI 10.1021/bi00598a010; YOSHIDA N, 1980, BIOCHEMISTRY-US, V19, P5799, DOI 10.1021/bi00566a021	43	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 15	1991	266	26					17314	17319						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GF445	1894620				2022-12-25	WOS:A1991GF44500053
J	ANTONSSON, P; HEINEGARD, D; OLDBERG, A				ANTONSSON, P; HEINEGARD, D; OLDBERG, A			POSTTRANSLATIONAL MODIFICATIONS OF FIBROMODULIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL PROTEOGLYCAN; KERATAN SULFATE; CELL-SURFACE; PROTEIN; IDENTIFICATION; INHIBITION; DECORIN; ACID	Tyrosine sulfate residues were identified in fibromodulin produced by tracheal chondrocytes, by tendon and sclera fibroblasts in primary culture, as well as in Chinese hamster ovary cells transfected with a construct containing fibromodulin cDNA. The tyrosine sulfate residues were located in the N-terminal part of fibromodulin. Thus, Chinese hamster ovary cells expressing a deleted variant of fibromodulin lacking the N-terminal 52 amino acids following the predicted signal peptide did not contain any tyrosine sulfate residues. The substitution with keratan sulfate chains was not restricted to chondrocytes, but was also identified in fibromodulin synthesized by bovine tendon fibroblasts and sclera fibroblasts, as well as in fibromodulin isolated from tendon. Digestion of fibromodulin with N-glycosidase F reduced the apparent size of fibromodulin to that of the core protein, as predicted from sequence analysis (Oldberg, A., Antonsson, P., Lindblom, K., and Heinegard, D. (1989) EMBO J. 8,2601-2604). Thus fibromodulin from cartilage, tendon, and sclera contains N-glycosidically linked oligosaccharides, some of which are extended to keratan sulfate chains.			ANTONSSON, P (corresponding author), UNIV LUND, DEPT MED & PHYSIOL CHEM, POB 94, S-22100 LUND, SWEDEN.							BOWEN B, 1980, NUCLEIC ACIDS RES, V8, P1, DOI 10.1093/nar/8.1.1; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; CATERSON B, 1983, J BIOL CHEM, V258, P8848; CHAMBERLAIN JP, 1979, ANAL BIOCHEM, V98, P132, DOI 10.1016/0003-2697(79)90716-4; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FRIEDERICH E, 1988, J CELL BIOL, V107, P1655, DOI 10.1083/jcb.107.5.1655; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEINEGARD D, 1986, J BIOL CHEM, V261, P3866; HUTTNER WB, 1984, METHOD ENZYMOL, V107, P200; KINGSTON RE, 1988, CURRENT PROTOCOLS MO; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALMSTROM A, 1975, BIOCHEM J, V151, P477; NIEHRS C, 1990, EMBO J, V9, P35, DOI 10.1002/j.1460-2075.1990.tb08077.x; OLDBERG A, 1988, J BIOL CHEM, V263, P19433; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; PAUWELS S, 1987, GASTROENTEROLOGY, V92, P1220, DOI 10.1016/S0016-5085(87)91081-X; PLAAS AHK, 1990, J BIOL CHEM, V265, P20634; REITZ HC, 1946, J AM CHEM SOC, V68, P1024, DOI 10.1021/ja01210a036; SOMMARIN Y, 1983, BIOCHEM J, V214, P777, DOI 10.1042/bj2140777; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587	23	64	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16859	16861						3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885612				2022-12-25	WOS:A1991GD63500097
J	CHEN, CY; EMIG, FA; SCHRAMM, VL; ASH, DE				CHEN, CY; EMIG, FA; SCHRAMM, VL; ASH, DE			INACTIVATION OF CHICKEN MITOCHONDRIAL PHOSPHOENOLPYRUVATE CARBOXYKINASE BY ORTHO-PHTHALALDEHYDE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; AMINO-ACID-SEQUENCE; ACTIVE-SITE; STEREOCHEMICAL COURSE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; CYTOSOLIC FORM; MESSENGER-RNA; LIVER; GTP	Chicken liver mitochondrial phosphoenolpyruvate carboxykinase is inactivated by omicron-phthalaldehyde. The inactivation followed pseudo first-order kinetics, and the second-order rate constant for the inactivation process was 29 M-1 s-1 at pH 7.5 and 25-degrees-C. The modified enzyme showed maximal fluorescence at 427 nm upon excitation at 337 nm, consistent with the formation of isoindole derivatives by the cross-linking of proximal cysteine and lysine residues. Activities in the physiologic reaction and in the oxaloacetate decarboxylase reaction were lost in parallel upon modification with omicron-phthalaldehyde. Plots of (percent of residual activity) versus (mol of isoindole incorporated/mol of enzyme) were biphasic, with the initial loss of enzymatic activity corresponding to the incorporation of one isoindole derivative/enzyme molecule. Complete inactivation of the enzyme was accompanied by the incorporation of 3 mol of isoindole/mol of enzyme. Beta-sulfopyruvate, an isoelectronic analogue of oxaloacetate, completely protected the enzyme from reacting with omicron-phthalaldehyde. Other substrates provided protection from inactivation, in decreasing order of protection: oxaloacetate > phosphoenolpyruvate > MgGDP, MgGTP > oxalate. Cysteine 31 and lysine 39 have been identified as the rapidly reacting pair in isoindole formation and enzyme inactivation. Lysine 56 and cysteine 60 are also involved in isoindole formation in the completely inactivated enzyme. These reactive cysteine residues do not correspond to the reactive cysteine residue identified in previous iodoacetate labeling studies with the chicken mitochondrial enzyme (Makinen, A. L., and Nowak, T. (1989) J. Biol. Chem. 264, 12148-12157). Protection experiments suggest that the sites of omicron-phthalaldehyde modification become inaccessible when the oxaloacetate/phosphoenolpyruvate binding site is saturated, and sequence analyses indicate that cysteine 31 is located in the putative phosphoenolpyruvate binding site.	TEMPLE UNIV,HLTH SCI CTR,SCH MED,DEPT BIOCHEM,3420 N BROAD ST,PHILADELPHIA,PA 19140; YESHIVA UNIV ALBERT EINSTEIN COLL MED,DEPT BIOCHEM,BRONX,NY 10461	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Yeshiva University; Albert Einstein College of Medicine					NIGMS NIH HHS [GM36604] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036604] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZCOQUE MCG, 1989, ANAL BIOCHEM, V178, P1; ASH DE, 1990, J BIOL CHEM, V265, P7377; BALLARD FJ, 1969, J BIOL CHEM, V244, P5625; BEALE EG, 1985, J BIOL CHEM, V260, P748; BLANER WS, 1979, J BIOL CHEM, V254, P1794; CARLSON GM, 1978, BIOCHEMISTRY-US, V17, P5329, DOI 10.1021/bi00618a002; CHENG KC, 1989, J BIOL CHEM, V264, P3317; CHENG KC, 1989, J BIOL CHEM, V264, P19666; COOK JS, 1986, P NATL ACAD SCI USA, V83, P7583, DOI 10.1073/pnas.83.20.7583; FOSTER DO, 1967, BIOCHEMISTRY-US, V6, P2120, DOI 10.1021/bi00859a033; GRIFFITH OW, 1987, METHOD ENZYMOL, V143, P221; GUNDELFINGER ED, 1987, NUCLEIC ACIDS RES, V15, P6745, DOI 10.1093/nar/15.16.6745; HEBDA CA, 1982, J BIOL CHEM, V257, P5503; HOD Y, 1982, J BIOL CHEM, V257, P13787; HOLTEN DD, 1965, BIOCHEMISTRY-US, V4, P723, DOI 10.1021/bi00880a018; HUYNH QK, 1990, J BIOL CHEM, V265, P6700; KONOPKA JM, 1986, BIOCHEMISTRY-US, V25, P5571, DOI 10.1021/bi00367a034; Lardy H, 1972, ENZYMES, P117; LEWIS CT, 1989, J BIOL CHEM, V264, P27; LEWIS CT, 1989, BIOCHEMISTRY-US, V28, P9248, DOI 10.1021/bi00450a003; MAKINEN AL, 1989, J BIOL CHEM, V264, P12148; MUIRHEAD H, 1986, EMBO J, V5, P475, DOI 10.1002/j.1460-2075.1986.tb04236.x; NOCE PS, 1975, J BIOL CHEM, V250, P9099; PALCZEWSKI K, 1983, EUR J BIOCHEM, V137, P429, DOI 10.1111/j.1432-1033.1983.tb07846.x; PURI RN, 1985, BIOCHEMISTRY-US, V24, P6508, DOI 10.1021/bi00344a030; PURI RN, 1985, BIOCHEMISTRY-US, V24, P6499, DOI 10.1021/bi00344a029; PURI RN, 1988, BIOCHIM BIOPHYS ACTA, V957, P34, DOI 10.1016/0167-4838(88)90154-9; RIDER MH, 1989, BIOCHEM J, V262, P97, DOI 10.1042/bj2620097; SHEU KF, 1984, BIOCHEMISTRY-US, V23, P1779, DOI 10.1021/bi00303a030; SHULTZ J, 1984, J BIOL CHEM, V259, P9655; Simmons Jr SS, 1978, J ORG CHEM, V43, P2886; SIMONS SS, 1979, BIOCHEMISTRY-US, V18, P4915, DOI 10.1021/bi00589a020; STALKER DM, 1985, J BIOL CHEM, V260, P4724; STERNSON LA, 1985, ANAL BIOCHEM, V144, P233, DOI 10.1016/0003-2697(85)90111-3; Utter MF, 1978, BIOCHEM SOC T, V6, P11, DOI 10.1042/bst0060011a; WATFORD M, 1981, J BIOL CHEM, V256, P23; WELDON SL, 1990, J BIOL CHEM, V265, P7308	37	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16645	16652						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885594				2022-12-25	WOS:A1991GD63500066
J	EHRMANN, M; BECKWITH, J				EHRMANN, M; BECKWITH, J			PROPER INSERTION OF A COMPLEX MEMBRANE-PROTEIN IN THE ABSENCE OF ITS AMINO-TERMINAL EXPORT SIGNAL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; TOPOLOGY; DETERMINANTS; LOCALIZATION; TRANSPORT; SEQUENCE; RESIDUES; BINDING; DOMAIN	The MalF protein spans the Escherichia coli cytoplasmic membrane eight times. Deletion of the first transmembrane stretch of MalF, which acts as an export signal, results in a truncated protein that still exhibits high levels of maltose transport activity. These and additional results indicate that the orientation of a membrane protein is not determined by the amino-terminal export signal, topological information is distributed throughout the MalF protein, and insertion of a protein into the cytoplasmic membrane can occur nonsequentially.	HARVARD UNIV,SCH MED,DEPT MICROBIOL & MOLEC GENET,200 LONGWOOD AVE,BOSTON,MA 02115	Harvard University; Harvard Medical School			Ehrmann, Michael/A-7307-2012	Ehrmann, Michael/0000-0002-1927-260X				ADAMS GA, 1985, CELL, V41, P1007, DOI 10.1016/S0092-8674(85)80081-7; AUDIGIER Y, 1987, P NATL ACAD SCI USA, V84, P5783, DOI 10.1073/pnas.84.16.5783; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BOYD D, 1989, P NATL ACAD SCI USA, V86, P9446, DOI 10.1073/pnas.86.23.9446; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; BRASS JM, 1983, J BACTERIOL, V155, P97, DOI 10.1128/JB.155.1.97-106.1983; BROSIUS J, 1984, P NATL ACAD SCI-BIOL, V81, P6929, DOI 10.1073/pnas.81.22.6929; DAVIS NG, 1985, J MOL BIOL, V181, P111, DOI 10.1016/0022-2836(85)90329-8; EHRMANN M, 1990, P NATL ACAD SCI USA, V87, P7574, DOI 10.1073/pnas.87.19.7574; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; ITO K, 1981, CELL, V24, P707, DOI 10.1016/0092-8674(81)90097-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPP J, 1988, J CELL BIOL, V106, P1813, DOI 10.1083/jcb.106.6.1813; MANOIL C, 1986, SCIENCE, V233, P1403, DOI 10.1126/science.3529391; MCGOVERN K, 1991, IN PRESS EMBO J; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Miller J.H., 1972, EXPT MOL GENETICS; RUSSEL M, 1986, GENE, V45, P333, DOI 10.1016/0378-1119(86)90032-6; Schwartz M., 1987, ESCHERICHIA COLI SAL, V2, P1482; SINGER SJ, 1987, P NATL ACAD SCI USA, V84, P1960, DOI 10.1073/pnas.84.7.1960; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2971, DOI 10.1093/nar/10.9.2971; STRAUCH KL, 1988, P NATL ACAD SCI USA, V85, P1576, DOI 10.1073/pnas.85.5.1576; VONHEIJNE G, 1988, BIOCHIM BIOPHYS ACTA, V947, P307, DOI 10.1016/0304-4157(88)90013-5; VONHEIJNE G, 1989, NATURE, V341, P456, DOI 10.1038/341456a0; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; ZAGURSKY RJ, 1984, GENE, V27, P183, DOI 10.1016/0378-1119(84)90139-2; ZERIAL M, 1987, CELL, V48, P147, DOI 10.1016/0092-8674(87)90365-5	28	44	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16530	16533						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885584				2022-12-25	WOS:A1991GD63500049
J	MYATT, EA; STEVENS, FJ; SIGLER, PB				MYATT, EA; STEVENS, FJ; SIGLER, PB			EFFECTS OF PH AND CALCIUM-ION ON SELF-ASSOCIATION PROPERTIES OF 2 DIMERIC PHOSPHOLIPASES-A2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFORMANCE LIQUID-CHROMATOGRAPHY; SIZE-EXCLUSION CHROMATOGRAPHY; PROTEIN PROTEIN-INTERACTION; PANCREATIC PHOSPHOLIPASE-A2; CROTALUS-ATROX; SIMULATION	The monomer-dimer equilibria of the dimeric phospholipases A2 from Crotalus atrox and Agkistrodon piscivorus piscivorus venoms were examined chromatographically as a function of pH and in the presence versus absence of the essential cofactor, calcium ion. At neutral pH without calcium, the subunits of both enzymes reequilibrated sufficiently slowly that dimer and monomer were separated by size exclusion chromatography. At pH 4.2 and lower, the dimers underwent rapid dissociation and reassociation, eluting as single broad peaks whose position as a function of applied protein concentration could be analyzed to determine association constants using an algorithm that estimates these values based on elution positions. Lowering the pH from 7.0 to 4.2 increased the self-association constant of the C. atrox enzyme by 1 order of magnitude and that of the A. p. piscivorus dimer by a factor of 3. Calcium ion, an essential cofactor of phospholipase A2, converted the kinetic behavior of the dimers at neutral pH from slow to virtually instantaneous on the time scale of the chromatography runs, 40 min. Calcium ion also altered the thermodynamic stability of the enzymes; the association constant of A. p. piscivorus phospholipase A2 in neutral pH buffer was reduced by approximately 2 orders of magnitude, whereas that of C. atrox was increased by a factor of 6. The structural basis for the disparate effects of calcium ion on these two acidic, dimeric venom phospholipases A2 is uncertain. This study illustrates the importance of calcium ion and pH on the solution behavior of the dimeric members of this class of enzymes.	UNIV CHICAGO, DEPT BIOCHEM & MOLEC BIOL, CHICAGO, IL 60637 USA	University of Chicago	MYATT, EA (corresponding author), ARGONNE NATL LAB, DIV BIOL & MED RES, 9700 S CASS AVE, ARGONNE, IL 60439 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007237] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM022324] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32HL7237] Funding Source: Medline; NIGMS NIH HHS [GM22324] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOTES DP, 1974, TOXICON, V12, P611, DOI 10.1016/0041-0101(74)90195-0; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; BUKOWSKI T, 1986, BIOCHEMISTRY-US, V25, P8024, DOI 10.1021/bi00372a035; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; HACHIMORI Y, 1971, BIOCHEMISTRY-US, V10, P4084, DOI 10.1021/bi00798a012; HEINRIKSON RL, 1984, ANAL BIOCHEM, V136, P65, DOI 10.1016/0003-2697(84)90307-5; HEINRIKSON RL, 1991, METHOD ENZYMOL, V197, P201; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; MAL'TSEV V G, 1979, Soviet Journal of Bioorganic Chemistry, V5, P1274; RADVANYI F, 1989, ANAL BIOCHEM, V177, P103, DOI 10.1016/0003-2697(89)90022-5; RANDOLPH A, 1980, FRONTIERS PROTEIN CH, P297; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; STEVENS FJ, 1986, BIOCHEMISTRY-US, V25, P981, DOI 10.1021/bi00353a006; STEVENS FJ, 1989, BIOPHYS J, V55, P1155, DOI 10.1016/S0006-3495(89)82912-1; STEVENS FJ, 1986, LCGC, V4, P340; WELLS MA, 1972, BIOCHEMISTRY-US, V11, P1030, DOI 10.1021/bi00756a013	16	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16331	16335						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885568				2022-12-25	WOS:A1991GD63500017
J	SCHWARTZBACH, CJ; SPREMULLI, LL				SCHWARTZBACH, CJ; SPREMULLI, LL			INTERACTION OF ANIMAL MITOCHONDRIAL EF-TU.EF-TS WITH AMINOACYL-TRANSFER RNA, GUANINE-NUCLEOTIDES, AND RIBOSOMES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION-FACTOR-TU; GRACILIS CHLOROPLAST RIBOSOMES; FACTOR SPECIFICITY; PIG LIVER; PROTEIN; COMPLEX; ASSAY; GTP	The mammalian mitochondrial complex consisting of elongation factors EF-Tu and EF-Ts (EF-Tu-Ts(mt)) is capable of efficiently binding aminoacyl-tRNA to the ribosome in the presence and absence of guanine nucleotides. In the presence of GTP the binding reaction is catalytic. In the absence of guanine nucleotides, or in the presence of a non-hydrolyzable GTP analog, only one round of ribosome binding occurs. EF-Tu-Ts(mt) is capable of forming a ternary complex with GTP and Escherichia coli Phe-tRNA as demonstrated by gel filtration chromatography, nitrocellulose filter binding, and by protection of the aminoacyl-tRNA bond from hydrolysis. GDP and the non-hydrolyzable GTP analog guanyl-5'-yl imidodiphosphate are also capable of facilitating ternary complex formation with EF-Tu.Ts(mt), but are less effective. No kinetic advantage results from the formation of this ternary complex prior to ribosome binding, and EF-Tu Ts(mt) may actually bind aminoacyl-tRNA directly to the ribosome prior to binding GTP. These results suggest that a variation of the prokaryotic elongation cycle is occurring in animal mitochondria. N-Ethylmaleimide inhibits the activity of EF-Tu.Ts(mt) in polymerization and in ribosome binding. However, the activity of the EF-Ts(mt) which can be measured independently, is not altered.	UNIV N CAROLINA,DEPT CHEM,CHAPEL HILL,NC 27599	University of North Carolina; University of North Carolina Chapel Hill					NIGMS NIH HHS [GM32734] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032734] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; CARVALHO MDD, 1984, ARCH BIOCHEM BIOPHYS, V234, P603, DOI 10.1016/0003-9861(84)90310-2; CRECHET JB, 1986, EUR J BIOCHEM, V161, P647, DOI 10.1111/j.1432-1033.1986.tb10489.x; EBERLY SL, 1985, J BIOL CHEM, V260, P8721; GRAVES MC, 1983, ARCH BIOCHEM BIOPHYS, V222, P192, DOI 10.1016/0003-9861(83)90516-7; GRAVES MC, 1980, ARCH BIOCHEM BIOPHYS, V204, P444, DOI 10.1016/0003-9861(80)90055-7; Hershey JW., 1987, ESCHERICHIA COLI SAL, P613; JANIAK F, 1990, BIOCHEMISTRY-US, V29, P4268, DOI 10.1021/bi00470a002; MILLER DL, 1977, MOL MECHANISMS PROTE, P324; MOLDAVE K, 1985, ANNU REV BIOCHEM, V54, P1109, DOI 10.1146/annurev.biochem.54.1.1109; MOTOYOSHI K, 1977, J BIOCHEM, V82, P145, DOI 10.1093/oxfordjournals.jbchem.a131663; MUENCH KH, 1966, PROCEDURES NUCLEIC A, P375; NAGATA S, 1978, J BIOCHEM-TOKYO, V83, P423, DOI 10.1093/oxfordjournals.jbchem.a131929; PINGOUD A, 1977, EUR J BIOCHEM, V78, P403, DOI 10.1111/j.1432-1033.1977.tb11752.x; RAVEL JM, 1968, ARCH BIOCHEM BIOPHYS, V125, P514, DOI 10.1016/0003-9861(68)90609-7; RAVEL JM, 1971, METHODS ENZYMOLOGY C, V20, P306; SCHWARTZBACH CJ, 1989, J BIOL CHEM, V264, P19125; SEDMAK JJ, 1977, ANAL BIOCHEM, V79, P544, DOI 10.1016/0003-2697(77)90428-6	18	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16324	16330						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885567				2022-12-25	WOS:A1991GD63500016
J	SHAILUBHAI, K; PUKAZHENTHI, BS; SAXENA, ES; VARMA, GM; VIJAY, IK				SHAILUBHAI, K; PUKAZHENTHI, BS; SAXENA, ES; VARMA, GM; VIJAY, IK			GLUCOSIDASE-I, A TRANSMEMBRANE ENDOPLASMIC RETICULAR GLYCOPROTEIN WITH A LUMINAL CATALYTIC DOMAIN	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPARAGINE-LINKED OLIGOSACCHARIDES; BOVINE MAMMARY-GLAND; GOLGI-APPARATUS; INTRACELLULAR-TRANSPORT; SECRETORY PROTEIN; GLYCOSYLATION; PURIFICATION; ENZYME; TRANSFERASE; MANNOSE	We have analyzed the functional domain structure of rat mammary glucosidase I, an enzyme involved in N-linked glycoprotein processing, using biochemical and immunological approaches. The enzyme contains a high mannose type sugar chain that can be cleaved by endo-beta-N-acetyl-D-glucosaminidase H without significantly affecting the catalytic activity. Based on trypsin digestion pattern and the data on membrane topography, glucosidase I constitutes a single polypeptide chain of 85 kDa with two contiguous domains: a membrane-bound domain that anchors the protein to the endoplasmic reticulum and a luminal domain. A catalytically active 39-kDa domain could be released from membranes by limited proteolysis of saponin-permeabilized membranes with trypsin. This domain appeared to contain the active site of the enzyme and had the ability to bind to glucosidase I-specific affinity gel. Phase partitioning with Triton X-114 indicated the amphiphilic nature of the native enzyme, consistent with its location as an integral membrane protein, whereas the 39-kDa fragment partitioned in the aqueous phase, a characteristic of soluble polypeptide. These results indicate that glucosidase I is a transmembrane protein with a luminally oriented catalytic domain. Such an orientation of the catalytic domain may facilitate the sequential processing of asparagine-linked oligosaccharide, soon after its transfer en bloc by the oligosaccharyl transferase complex in the lumen of endoplasmic reticulum.	UNIV MARYLAND,DEPT ANIM SCI,COLLEGE PK,MD 20742; UNIV MARYLAND,CTR AGR BIOTECHNOL,COLLEGE PK,MD 20742	University System of Maryland; University of Maryland College Park; University System of Maryland; University of Maryland College Park					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019682] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-19682] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABEIJON C, 1990, J BIOL CHEM, V265, P14691; BISCHOFF J, 1983, J BIOL CHEM, V258, P7907; BORDIER C, 1981, J BIOL CHEM, V256, P1604; CAREY DJ, 1980, J BIOL CHEM, V255, P4348; COLLEY KJ, 1989, J BIOL CHEM, V264, P17619; DORDAL MS, 1985, ENDOCRINOLOGY, V116, P2293, DOI 10.1210/endo-116-6-2293; GEETHAHABIB M, 1988, CELL, V54, P1053, DOI 10.1016/0092-8674(88)90120-1; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GREEN SA, 1985, J BIOL CHEM, V260, P9867; HANOVER JA, 1980, J BIOL CHEM, V255, P3600; HANOVER JA, 1978, J BIOL CHEM, V254, P9237; HASELBECK A, 1989, EUR J BIOCHEM, V181, P663, DOI 10.1111/j.1432-1033.1989.tb14774.x; HETTKAMP H, 1984, EUR J BIOCHEM, V142, P85, DOI 10.1111/j.1432-1033.1984.tb08253.x; HIRSCHBERG CB, 1987, ANNU REV BIOCHEM, V56, P63, DOI 10.1146/annurev.bi.56.070187.000431; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENNARZ WJ, 1987, BIOCHEMISTRY-US, V26, P7205, DOI 10.1021/bi00397a001; LINGAPPA VR, 1978, P NATL ACAD SCI USA, V75, P2338, DOI 10.1073/pnas.75.5.2338; LISCHWE MA, 1982, ANAL BIOCHEM, V127, P453, DOI 10.1016/0003-2697(82)90203-2; LISCUM L, 1985, J BIOL CHEM, V260, P522; LUCOCQ JM, 1986, J CELL BIOL, V102, P2137, DOI 10.1083/jcb.102.6.2137; MICHAEL JM, 1980, ARCH BIOCHEM BIOPHYS, V199, P249, DOI 10.1016/0003-9861(80)90278-7; MOREMEN KW, 1986, J BIOL CHEM, V261, P945; NILSSON T, 1989, CELL, V58, P707, DOI 10.1016/0092-8674(89)90105-0; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; ORLEAN P, 1988, J BIOL CHEM, V263, P17499; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; PELHAM HRB, 1988, EMBO J, V7, P913, DOI 10.1002/j.1460-2075.1988.tb02896.x; ROTH J, 1986, J BIOL CHEM, V261, P14307; ROTHMAN JE, 1987, CELL, V50, P521, DOI 10.1016/0092-8674(87)90024-9; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SAXENA S, 1987, BIOCHEM J, V247, P563, DOI 10.1042/bj2470563; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHWEDEN J, 1989, BIOCHEM J, V264, P347, DOI 10.1042/bj2640347; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P9701; SHAILUBHAI K, 1990, J BIOL CHEM, V265, P14105; SHAILUBHAI K, 1988, J BIOL CHEM, V263, P15964; SHAILUBHAI K, 1987, BIOCHEM J, V247, P555, DOI 10.1042/bj2470555; SKALNIK DG, 1988, J BIOL CHEM, V263, P6836; SLIEKER LJ, 1985, J BIOL CHEM, V260, P687; SNIDER MD, 1984, BIOL CARBOHYDRATES, P163; STROUS GJ, 1983, J CELL BIOL, V97, P723, DOI 10.1083/jcb.97.3.723; STROUS GJ, 1987, J BIOL CHEM, V262, P3620; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; ZHU XY, 1990, J BIOL CHEM, V265, P14250	45	43	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16587	16593						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885588				2022-12-25	WOS:A1991GD63500057
J	TANNIN, GM; AGARWAL, AK; MONDER, C; NEW, MI; WHITE, PC				TANNIN, GM; AGARWAL, AK; MONDER, C; NEW, MI; WHITE, PC			THE HUMAN GENE FOR 11-BETA-HYDROXYSTEROID DEHYDROGENASE - STRUCTURE, TISSUE DISTRIBUTION, AND CHROMOSOMAL LOCALIZATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL 17-BETA-HYDROXYSTEROID DEHYDROGENASE; APPARENT MINERALOCORTICOID EXCESS; AMINO-ACID-SEQUENCE; PREP PLASMID DNA; ALCOHOL-DEHYDROGENASE; NUCLEOTIDE-SEQUENCE; CORTICOSTEROID 11-BETA-DEHYDROGENASE; STREPTOMYCES-COELICOLOR; DROSOPHILA-MELANOGASTER; RHIZOBIUM-MELILOTI	The Type I (mineralocorticoid) receptor has identical affinities in vitro for cortisol and aldosterone. It has been suggested that the selective role of aldosterone in regulating sodium homeostasis relies on the microsomal enzyme 11-beta-hydroxysteroid dehydrogenase (11-HSD). This enzyme converts cortisol to its inactive metabolite, cortisone, preventing cortisol from binding to the Type I receptor. We have isolated human cDNA clones encoding ll-HSD from a human testis cDNA library by hybridization with a previously isolated rat 11-HSD cDNA clone. The cDNA contains an open reading frame of 876 bases, which predicts a protein of 292 amino acids. The sequence is 77% identical at the amino acid level to rat 11-HSD cDNA. The mRNA is widely expressed, but the level of expression is highest in the liver. Hybridization of the human 11-HSD cDNA to a human-hamster hybrid cell panel localized the single corresponding HSD11 gene to chromosome 1. This gene was isolated from a chromosome 1 specific library using the cDNA as a probe. HSD11 consists of 6 exons and is at least 9 kilobases long. The data developed in this study should be applicable to the study of patients with hypertension due to apparent mineralocorticoid excess, a deficiency in ll-HSD activity.	CORNELL UNIV, MED CTR,COLL MED,DIV PEDIAT ENDOCRINOL,BOX 42, 1300 YORK AVE, NEW YORK, NY 10021 USA; NATL INST IMMUNOL, NEW DELHI 110067, INDIA; POPULAT COUNCIL, CTR BIOMED RES, NEW YORK, NY 10021 USA	Cornell University; Department of Biotechnology (DBT) India; National Institute of Immunology (NII); Population Council					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD000072, R37HD000072] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042169, R01DK037094] Funding Source: NIH RePORTER; NICHD NIH HHS [HD00072] Funding Source: Medline; NIDDK NIH HHS [DK37094, DK42169] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1989, J BIOL CHEM, V264, P18939; ARRIZA JL, 1987, SCIENCE, V237, P268, DOI 10.1126/science.3037703; BAKER ME, 1989, MOL ENDOCRINOL, V3, P881, DOI 10.1210/mend-3-5-881; BAKER ME, 1990, FASEB J, V4, P222, DOI 10.1096/fasebj.4.2.2153594; BAKER ME, 1990, BIOCHEM J, V267, P839, DOI 10.1042/bj2670839; BENTON WD, 1977, SCIENCE, V196, P180, DOI 10.1126/science.322279; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIS RW, 1980, ADV BACTERIAL GENET, P70; DENHARDT DT, 1966, BIOCHEM BIOPH RES CO, V23, P641, DOI 10.1016/0006-291X(66)90447-5; DIMARTINONARDI J, 1987, CLIN ENDOCRINOL, V27, P49, DOI 10.1111/j.1365-2265.1987.tb00838.x; DOTHIE JM, 1985, BIOCHEM J, V230, P569, DOI 10.1042/bj2300569; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FISHER RF, 1987, GENETICS, V117, P191; FURUKAWA K, 1987, J BACTERIOL, V169, P427, DOI 10.1128/jb.169.1.427-429.1987; HALLAM SE, 1988, GENE, V74, P305, DOI 10.1016/0378-1119(88)90165-5; HOLMES DS, 1981, ANAL BIOCHEM, V114, P193, DOI 10.1016/0003-2697(81)90473-5; INNIS MA, 1988, P NATL ACAD SCI USA, V85, P9436, DOI 10.1073/pnas.85.24.9436; JORNVALL H, 1981, P NATL ACAD SCI-BIOL, V78, P4226, DOI 10.1073/pnas.78.7.4226; KINGSTON RE, 1987, CURRENT PROTOCOLS MO; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KROZOWSKI Z, 1990, ENDOCRINOLOGY, V127, P3009, DOI 10.1210/endo-127-6-3009; LACHANCE Y, 1990, J BIOL CHEM, V265, P20469; LORENCE MC, 1990, MOL ENDOCRINOL, V4, P1850, DOI 10.1210/mend-4-12-1850; LUU-THE V, 1990, Molecular Endocrinology, V4, P268; MAREKOV L, 1990, FEBS LETT, V266, P51, DOI 10.1016/0014-5793(90)81504-H; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; MONDER C, 1990, ANN NY ACAD SCI, V595, P26, DOI 10.1111/j.1749-6632.1990.tb34280.x; MURPHY BEP, 1981, J STEROID BIOCHEM, V14, P811; NAVRE M, 1988, J CELL BIOL, V107, P279, DOI 10.1083/jcb.107.1.279; NEW MI, 1977, J CLIN ENDOCR METAB, V44, P924, DOI 10.1210/jcem-44-5-924; PELTOKETO H, 1988, FEBS LETT, V239, P73, DOI 10.1016/0014-5793(88)80548-9; STEGGLES AW, 1989, BIOTECHNIQUES, V7, P241; STEWART PM, 1987, LANCET, V2, P821; STUDENCKI AB, 1984, DNA-J MOLEC CELL BIO, V3, P7, DOI 10.1089/dna.1.1984.3.7; THATCHER DR, 1980, BIOCHEM J, V187, P875, DOI 10.1042/bj1870875; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; THOMAS PS, 1980, P NATL ACAD SCI-BIOL, V77, P5201, DOI 10.1073/pnas.77.9.5201; ULICK S, 1979, J CLIN ENDOCR METAB, V49, P757, DOI 10.1210/jcem-49-5-757; ULICK S, 1977, J CLIN ENDOCR METAB, V44, P799, DOI 10.1210/jcem-44-4-799; VOGELSTEIN B, 1979, P NATL ACAD SCI USA, V76, P615, DOI 10.1073/pnas.76.2.615; WHITE PC, 1988, P NATL ACAD SCI USA, V85, P4436, DOI 10.1073/pnas.85.12.4436; WYMAN AR, 1980, P NATL ACAD SCI-BIOL, V77, P6754, DOI 10.1073/pnas.77.11.6754	45	430	434	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16653	16658						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885595				2022-12-25	WOS:A1991GD63500067
J	VENDITTI, S; WELLS, RD				VENDITTI, S; WELLS, RD			A DNA CONFORMATIONAL ALTERATION INDUCED BY A NEIGHBORING OLIGOPURINE TRACT ON GAATTA ENABLES NICKING BY ECORI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTION ENDONUCLEASE RSRI; C-MYC GENE; RI ENDONUCLEASE; H-DNA; TRIPLE-HELIX; B-DNA; SUPERCOILED PLASMIDS; CRYSTAL-STRUCTURE; RECOGNITION SITE; TELOMERIC DNA	The pseudo EcoRI site GAATTA in the U3 region of the long terminal repeat of human immunodeficiency virus, which is flanked by a 26-base pair oligopurine tract, is readily nicked by either EcoRI or RsrI. The strand-specific nick occurs predominantly between the G and A residues and is independent of negative supercoiling. Other GAATTA sites surrounded by random (non-oligopurine) sequences are not nicked by these restriction endonucleases. However, other types and lengths of oligopurine tracts are effective in inducing the nicking in neighboring GAATTA sites. Hence, we propose that the flanking oligopurine tracts induce an altered DNA conformation on the GAATTA target site which may be similar to the transition state induced by EcoRI when binding to its canonical recognition site. Gel retardation analyses on restriction fragments containing the oligopurine-GAATTA-oligopurine sequences suggest the presence of helical axis distortions which are consistent with this interpretation.	UNIV ALABAMA,SCH DENT,BIRMINGHAM,AL 35294	University of Alabama System; University of Alabama Birmingham	VENDITTI, S (corresponding author), UNIV ALABAMA,SCH MED,DEPT BIOCHEM,BIRMINGHAM,AL 35294, USA.				NCI NIH HHS [CA13148] Funding Source: Medline; NIGMS NIH HHS [GM30822] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA013148] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030822] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AIKEN C, 1988, NUCLEIC ACIDS RES, V16, P7901, DOI 10.1093/nar/16.16.7901; ALVES J, 1984, EUR J BIOCHEM, V140, P83, DOI 10.1111/j.1432-1033.1984.tb08069.x; BISHOP JO, 1979, J MOL BIOL, V128, P545, DOI 10.1016/0022-2836(79)90292-4; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; COLLIER DA, 1988, J BIOL CHEM, V263, P7397; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DIEKMANN S, 1988, J MOL BIOL, V202, P823, DOI 10.1016/0022-2836(88)90561-X; DREW HR, 1985, NUCLEIC ACIDS RES, V13, P4445, DOI 10.1093/nar/13.12.4445; FREDERICK CA, 1984, NATURE, V309, P327, DOI 10.1038/309327a0; GARDNER RC, 1982, DNA-J MOLEC CELL BIO, V1, P109, DOI 10.1089/dna.1.1982.1.109; GAYNOR R, 1989, P NATL ACAD SCI USA, V86, P4858, DOI 10.1073/pnas.86.13.4858; GERMANN MW, 1990, NUCLEIC ACIDS RES, V18, P1489, DOI 10.1093/nar/18.6.1489; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLOVER JNM, 1990, J MOL BIOL, V215, P653, DOI 10.1016/S0022-2836(05)80175-5; GREENE PJ, 1988, GENE, V68, P43, DOI 10.1016/0378-1119(88)90597-5; HANVEY JC, 1990, NUCLEIC ACIDS RES, V18, P157, DOI 10.1093/nar/18.1.157; HANVEY JC, 1988, J BIOL CHEM, V263, P7386; HANVEY JC, 1988, P NATL ACAD SCI USA, V85, P6292, DOI 10.1073/pnas.85.17.6292; HENDERSON E, 1987, CELL, V51, P899, DOI 10.1016/0092-8674(87)90577-0; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JENJACOBSON L, 1983, J BIOL CHEM, V258, P4638; JENJACOBSON L, 1986, CELL, V45, P619, DOI 10.1016/0092-8674(86)90294-1; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KIM R, 1984, NUCLEIC ACIDS RES, V12, P7285, DOI 10.1093/nar/12.19.7285; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KOHWI Y, 1988, P NATL ACAD SCI USA, V85, P3781, DOI 10.1073/pnas.85.11.3781; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LILLEY DMJ, 1983, EMBO J, V2, P527, DOI 10.1002/j.1460-2075.1983.tb01458.x; MAHER LJ, 1989, SCIENCE, V245, P725, DOI 10.1126/science.2549631; MARINI JC, 1984, J BIOL CHEM, V259, P8974; Maxam A M, 1980, Methods Enzymol, V65, P499; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MCLEAN MJ, 1986, P NATL ACAD SCI USA, V83, P5884, DOI 10.1073/pnas.83.16.5884; MIRKIN SM, 1987, NATURE, V330, P495, DOI 10.1038/330495a0; OKAMOTO T, 1986, CELL, V47, P29, DOI 10.1016/0092-8674(86)90363-6; POLISKY B, 1975, P NATL ACAD SCI USA, V72, P3310, DOI 10.1073/pnas.72.9.3310; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; SHIMIZU M, 1989, J BIOL CHEM, V264, P5944; SHIMIZU M, 1990, BIOCHEMISTRY-US, V29, P4704, DOI 10.1021/bi00471a027; THOMAS M, 1975, J MOL BIOL, V91, P315, DOI 10.1016/0022-2836(75)90383-6; VARDIMON L, 1984, P NATL ACAD SCI-BIOL, V81, P3268, DOI 10.1073/pnas.81.11.3268; VOLOSHIN ON, 1988, NATURE, V333, P475, DOI 10.1038/333475a0; WEINREB A, 1990, J BIOL CHEM, V265, P1352; WELLS RD, 1988, FASEB J, V2, P2939, DOI 10.1096/fasebj.2.14.3053307; WILLIAMSON JR, 1989, CELL, V59, P871, DOI 10.1016/0092-8674(89)90610-7; WING R, 1980, NATURE, V287, P755, DOI 10.1038/287755a0; WOHLRAB F, 1989, J BIOL CHEM, V264, P8207; WOODBURY CP, 1980, J BIOL CHEM, V255, P1534; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; ZACHARIAS W, 1984, NUCLEIC ACIDS RES, V12, P7677, DOI 10.1093/nar/12.20.7677	54	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	1991	266	25					16786	16790						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GD635	1885606				2022-12-25	WOS:A1991GD63500085
J	COATS, WS; BROWNER, MF; FLETTERICK, RJ; NEWGARD, CB				COATS, WS; BROWNER, MF; FLETTERICK, RJ; NEWGARD, CB			AN ENGINEERED LIVER-GLYCOGEN PHOSPHORYLASE WITH AMP ALLOSTERIC ACTIVATION	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-ANALYSIS; RAT-LIVER; RABBIT; PURIFICATION; PROTEINS; QUANTITATION; EXPRESSION; ISOZYMES; CDNAS; FORM	Liver and muscle glycogen phosphorylases, which are products of distinct genes, are both activated by covalent phosphorylation, but in the unphosphorylated (b) state, only the muscle isozyme is efficiently activated by the allosteric activator AMP. The different responsiveness of the phosphorylase isozymes to allosteric ligands is important for the maintenance of tissue and whole body glucose homeostasis. In an attempt to understand the structural determinants of differential sensitivity of the muscle and liver isozymes to AMP, we have developed a bacterial expression system for the liver enzyme, allowing native and engineered proteins to be expressed and characterized. Engineering of the single amino acid substitutions Thr48Pro, Met197Thr and the double mutant Thr48Pro, Met197Thr in liver phosphorylase, and Pro48Thr in muscle phosphorylase, did not qualitatively change the response of the two isozymes to AMP. These sites had previously been implicated in the configuration of the AMP binding site. However, when nine amino acids among the first 48 in liver phosphorylase were replaced with the corresponding muscle phosphorylase residues (L1M2-48L49-846), the engineered liver enzyme was activated by AMP to a higher maximal activity than native liver phosphorylase. Interestingly, the homotropic cooperativity of AMP binding was unchanged in the engineered phosphorylase b protein, and heterotropic cooperativity between the glucose-1-phosphate and AMP sites was only slightly enhanced. The native liver, native muscle and L1M2-48L49-846 phosphorylases were converted to the a form by treatment with purified phosphorylase kinase; the maximal activity of the chimeric alpha-enzyme was greater than the native liver alpha-enzyme and approached that of muscle phosphorylase-alpha From these results we suggest that tissue-specific phosphorylase isozymes have evolved a complex mechanism in which the N-terminal 48 amino acids modulate intrinsic activity (V(max)), probably by affecting subunit interactions, and other, as yet undefined regions specify the allosteric interactions with ligands and substrates.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,5323 HARRY HINES BLVD,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,CTR DIABET RES,GIFFORD LABS,DALLAS,TX 75235; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Diabetes & Endocrine Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK032822, R29DK040734, R01DK026081] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK32822-07, R29-DK40734, DK26081-12] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; APPLEMAN MM, 1966, BIOCHEMISTRY-US, V5, P2101, DOI 10.1021/bi00870a043; BARFORD D, 1991, J MOL BIOL, V218, P233, DOI 10.1016/0022-2836(91)90887-C; BLACK WJ, 1968, J BIOL CHEM, V243, P5892; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNER MF, 1991, PROTEIN ENG, V4, P351, DOI 10.1093/protein/4.3.351; BURKE J, 1987, PROTEINS, V2, P177, DOI 10.1002/prot.340020303; CARSON M, 1986, J MOL GRAPHICS, V4, P121, DOI 10.1016/0263-7855(86)80010-8; CRAIK CS, 1985, BIOTECHNIQUES    JAN, P12; DAVID ES, 1986, BIOCHIM BIOPHYS ACTA, V880, P78, DOI 10.1016/0304-4165(86)90122-4; EREL Z, 1972, BIOCHEM BIOPH RES CO, V49, P383, DOI 10.1016/0006-291X(72)90422-6; FLETTERICK RJ, 1983, P RA WELCH F C CHEM, V27, P173; GUENARD D, 1977, EUR J BIOCHEM, V76, P447, DOI 10.1111/j.1432-1033.1977.tb11614.x; HWANG PK, 1985, EUR J BIOCHEM, V152, P267, DOI 10.1111/j.1432-1033.1985.tb09193.x; HWANG PK, 1987, PROTEIN STRUCTURE FO, P247; JANSKI AM, 1979, J BIOL CHEM, V254, P1644; JOHNSON LN, 1990, J MOL BIOL, V211, P645, DOI 10.1016/0022-2836(90)90271-M; KOBAYASHI M, 1982, J BIOL CHEM, V257, P4041; KOBAYASHI M, 1982, ANAL BIOCHEM, V122, P94, DOI 10.1016/0003-2697(82)90256-1; LEBO RV, 1984, SCIENCE, V225, P57, DOI 10.1126/science.6587566; LIVANOVA NB, 1976, FEBS LETT, V69, P95, DOI 10.1016/0014-5793(76)80661-8; MADSEN NB, 1964, BIOCHEM BIOPH RES CO, V15, P390, DOI 10.1016/0006-291X(64)90179-2; NAKANO K, 1986, FEBS LETT, V204, P283, DOI 10.1016/0014-5793(86)80829-8; NEWGARD CB, 1988, J BIOL CHEM, V263, P3850; NEWGARD CB, 1987, AM J HUM GENET, V40, P351; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; NEWGARD CB, 1989, CRIT REV BIOCHEM MOL, V24, P69, DOI 10.3109/10409238909082552; OSAWA S, 1986, FEBS LETT, V202, P282, DOI 10.1016/0014-5793(86)80702-5; PERUTZ MF, 1989, Q REV BIOPHYS, V22, P139, DOI 10.1017/S0033583500003826; PICKETTGIES CA, 1985, J BIOL CHEM, V260, P2046; QUAADE C, 1991, FEBS LETT, V280, P47, DOI 10.1016/0014-5793(91)80201-D; RATH VL, 1987, PROTEINS, V2, P225, DOI 10.1002/prot.340020307; SPRANG S, 1987, SCIENCE, V237, P1012, DOI 10.1126/science.3616621; SPRANG S, 1980, BIOPHYS J, V32, P175, DOI 10.1016/S0006-3495(80)84932-0; SPRANG SR, 1988, NATURE, V336, P215, DOI 10.1038/336215a0; STALMANS W, 1975, EUR J BIOCHEM, V54, P341, DOI 10.1111/j.1432-1033.1975.tb04144.x; SUTHERLAND EW, 1956, J BIOL CHEM, V218, P459; TAN AWH, 1975, BIOCHIM BIOPHYS ACTA, V410, P45, DOI 10.1016/0005-2744(75)90206-5; TITANI K, 1977, P NATL ACAD SCI USA, V74, P4762, DOI 10.1073/pnas.74.11.4762; Wang J. H, 1972, ENZYMES, V7, P435; ZOLLER MJ, 1984, DNA-J MOLEC CELL BIO, V3, P479, DOI 10.1089/dna.1.1984.3.479	41	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					16113	16119						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1874749				2022-12-25	WOS:A1991GB97700088
J	SHIBAHARA, S; TAGUCHI, H; MULLER, RM; SHIBATA, K; COHEN, T; TOMITA, Y; TAGAMI, H				SHIBAHARA, S; TAGUCHI, H; MULLER, RM; SHIBATA, K; COHEN, T; TOMITA, Y; TAGAMI, H			STRUCTURAL ORGANIZATION OF THE PIGMENT CELL-SPECIFIC GENE LOCATED AT THE BROWN LOCUS IN MOUSE - ITS PROMOTER ACTIVITY AND ALTERNATIVELY SPLICED TRANSCRIPTS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT HEME OXYGENASE; TYROSINASE GENE; MOLECULAR-BASIS; MELANIN BIOSYNTHESIS; MAMMALIAN TYROSINASE; FUNCTIONAL-ANALYSIS; WILD-TYPE; CDNA; EXPRESSION; MELANOCYTES	The pigment cell-specific gene, located at the brown (b) locus in mouse, has been cloned and characterized. Its gene product is required for the formation of black melanin rather than brown, although its exact function remains to be elucidated. We thus tentatively named it b-locus protein in this report. The b-locus protein gene is about 18 kilobase pairs long and organized into 8 exons and 7 introns. Functional analysis of its promoter region suggests that the nucleotide residues -38/154 is sufficient to direct the pigment cell-specific transcription in melanoma whole cell extracts. On the other hand, we were unable to detect its transcripts in HeLa whole cell extracts. Sequence comparison with the promoter region of the tyrosinase gene, another pigment cell-specific gene, reveals that two elements of the b-locus protein gene (-33/-24 and 18/28) are also conserved in the tyrosinase gene at equivalent positions, suggesting that these two elements may be involved in their pigment cell-specific transcription. Furthermore, we have cloned a cDNA, pMT3, coding for an isoform of b-locus protein from a cDNA library of mouse B16 melanoma cells. Sequence analysis of pMT3 reveals a deletion of 103 base pairs, which corresponds to the 5'-end of the exon 8 of the b-locus protein gene, indicating that pMT3 represents a mRNA species generated by alternative splicing. Since this deletion changes the reading frame and eliminates the transmembrane domain of b-locus protein, the pMT3-type mRNA may code for a soluble isoform. Such an isoform, consisting of 553 amino acids, differs only in its carboxyl terminus and is larger than b-locus protein by 16 amino acids. Using transient expression assays, we confirmed that such an isoform is able to react with anti-b-locus protein monoclonal antibody, TMH-1, suggesting that a b-locus protein isoform may have some function in pigmentation.	TOHOKU UNIV,SCH MED,DEPT DERMATOL,SENDAI,MIYAGI 980,JAPAN; FRIEDRICH MIESCHER INST,CH-4002 BASEL,SWITZERLAND	Tohoku University; Friedrich Miescher Institute for Biomedical Research	SHIBAHARA, S (corresponding author), TOHOKU UNIV,SCH MED,DEPT APPL PHYSIOL & MOLEC BIOL,SENDAI,MIYAGI 980,JAPAN.		Shibahara, Shigeki/M-3644-2014	Taguchi, Hayao/0000-0001-5270-581X				BENNETT DC, 1990, DEVELOPMENT, V110, P471; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FRISCHAUF AM, 1983, J MOL BIOL, V170, P827, DOI 10.1016/S0022-2836(83)80190-9; HALABAN R, 1990, P NATL ACAD SCI USA, V87, P4809, DOI 10.1073/pnas.87.12.4809; JACKSON IJ, 1988, P NATL ACAD SCI USA, V85, P4392, DOI 10.1073/pnas.85.12.4392; JIMENEZ M, 1989, J BIOL CHEM, V264, P3397; KORNER A, 1982, SCIENCE, V217, P1163, DOI 10.1126/science.6810464; KORNER AM, 1980, J INVEST DERMATOL, V75, P192, DOI 10.1111/1523-1747.ep12522650; KWON BS, 1989, J INVEST DERMATOL, V93, P589, DOI 10.1111/1523-1747.ep12319693; KWON BS, 1987, P NATL ACAD SCI USA, V84, P7473, DOI 10.1073/pnas.84.21.7473; LERNER AB, 1950, J BIOL CHEM, V187, P793; MANLEY JL, 1980, P NATL ACAD SCI-BIOL, V77, P3855, DOI 10.1073/pnas.77.7.3855; Maxam A M, 1980, Methods Enzymol, V65, P499; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; MULLER RM, 1987, J BIOL CHEM, V262, P6795; NAKATANI Y, 1990, NATURE, V348, P86, DOI 10.1038/348086a0; OKAYAMA H, 1982, MOL CELL BIOL, V2, P161, DOI 10.1128/MCB.2.2.161; PAWELEK J, 1980, NATURE, V286, P617, DOI 10.1038/286617a0; RUPPERT S, 1988, EMBO J, V7, P2715, DOI 10.1002/j.1460-2075.1988.tb03125.x; SHIBAHARA S, 1986, NUCLEIC ACIDS RES, V14, P2413, DOI 10.1093/nar/14.6.2413; SHIBAHARA S, 1988, TOHOKU J EXP MED, V156, P403, DOI 10.1620/tjem.156.403; SHIBAHARA S, 1990, EUR J BIOCHEM, V189, P455, DOI 10.1111/j.1432-1033.1990.tb15510.x; SHIBAHARA S, 1985, P NATL ACAD SCI USA, V82, P7865, DOI 10.1073/pnas.82.23.7865; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; TAKEDA A, 1989, BIOCHEM BIOPH RES CO, V162, P984, DOI 10.1016/0006-291X(89)90770-5; TAKEDA A, 1990, J BIOL CHEM, V265, P17792; TOMITA Y, 1991, J INVEST DERMATOL, V96, P500, DOI 10.1111/1523-1747.ep12470204; TOMITA Y, 1985, J INVEST DERMATOL, V85, P426, DOI 10.1111/1523-1747.ep12277121; VIJAYASARADHI S, 1990, J EXP MED, V171, P1375, DOI 10.1084/jem.171.4.1375; YAMAMOTO H, 1989, JPN J GENET, V64, P121, DOI 10.1266/jjg.64.121; ZDARSKY E, 1990, GENETICS, V126, P443	32	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 25	1991	266	24					15895	15901						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	GB977	1908461				2022-12-25	WOS:A1991GB97700058
J	FURUKAWA, Y; DECAPRIO, JA; BELVIN, M; GRIFFIN, JD				FURUKAWA, Y; DECAPRIO, JA; BELVIN, M; GRIFFIN, JD			HETEROGENEOUS EXPRESSION OF THE PRODUCT OF THE RETINOBLASTOMA SUSCEPTIBILITY GENE IN PRIMARY HUMAN LEUKEMIA-CELLS	ONCOGENE			English	Article							SV40 LARGE-T; OSTEO-SARCOMA; RB GENE; CYCLE; PHOSPHORYLATION; PROTEIN; BINDING; ABNORMALITIES; INACTIVATION; ANTIONCOGENE	To investigate the possible role of the product of the retinoblastoma susceptibility gene, pRB, in leukemogenesis, we examined fresh leukemia cells from 56 cases of primary leukemia (AML, 32; ALL, 12; CML-BC, 9; CLL, 3) for expression of pRB by using an immunoblotting assay with anti-pRB monoclonal antibodies PMG 3-245 or 3-340. Expression of the 70 kDa heat shock protein (Hsp70) was examined simultaneously as an internal control. pRB was found to be absent or expressed at an abnormally low level in 13 of 56 cases. Abnormal expression of pRB was most common in AML (8/32) and CML-BC (4/9), and less common in ALL (1/12). Expression of pRB was not induced in two cases of pRB- AML cultured for 24 h with GM-CSF, indicating that pRB expression could not be induced by increasing the rate of proliferation. The eight cases of AML lacking pRB protein were examined for RB1 mRNA by Northern blot. Two lacked RBI mRNA and six had a normal-sized mRNA (approximately 4.7 kb), although the amount of RB mRNA was very low in some cases. RB1 gene structure was normal by Southern blot in all eight cases lacking pRB protein which were studied. These results show that lack of pRB expression is relatively common in human myeloid leukemias, and suggests that loss of pRB expression could contribute to the altered growth control of these cells.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV TUMOR IMMUNOL,44 BINNEY ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School			Furukawa, Yusuke/Y-1342-2018	Furukawa, Yusuke/0000-0002-7249-6418				BUCHKOVICH K, 1989, CELL, V58, P1097, DOI 10.1016/0092-8674(89)90508-4; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; CHEN PL, 1989, CELL, V58, P1193, DOI 10.1016/0092-8674(89)90517-5; CHENG J, 1990, BLOOD, V75, P730; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; Dryja T P, 1986, Symp Fundam Cancer Res, V39, P115; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; FITCHETT M, 1987, CANCER GENET CYTOGEN, V24, P143, DOI 10.1016/0165-4608(87)90091-4; FRIEND SH, 1987, P NATL ACAD SCI USA, V84, P9059, DOI 10.1073/pnas.84.24.9059; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; FUNG YKT, 1987, SCIENCE, V236, P1657, DOI 10.1126/science.2885916; FURUKAWA Y, 1990, P NATL ACAD SCI USA, V87, P2770, DOI 10.1073/pnas.87.7.2770; HARBOUR JW, 1988, SCIENCE, V241, P353, DOI 10.1126/science.2838909; HOROWITZ JM, 1989, SCIENCE, V243, P937, DOI 10.1126/science.2521957; HOROWITZ JM, 1990, P NATL ACAD SCI USA, V87, P2775, DOI 10.1073/pnas.87.7.2775; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KNUDSON AG, 1989, CANCER, V63, P1888, DOI 10.1002/1097-0142(19890515)63:10<1888::AID-CNCR2820631004>3.0.CO;2-L; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LEE EYHP, 1988, SCIENCE, V241, P218, DOI 10.1126/science.3388033; LEE WH, 1987, SCIENCE, V235, P1394, DOI 10.1126/science.3823889; LEE WH, 1987, NATURE, V329, P642, DOI 10.1038/329642a0; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; NADLER LM, 1981, PROG HEMATOL, V12, P187; PIETENPOL JA, 1990, CELL, V61, P777, DOI 10.1016/0092-8674(90)90188-K; ROBBINS PD, 1990, NATURE, V346, P668, DOI 10.1038/346668a0; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; TANG A, 1988, SCIENCE, V242, P263, DOI 10.1126/science.3175651; TOGUCHIDA J, 1989, NATURE, V338, P156, DOI 10.1038/338156a0; WEICHSELBAUM RR, 1988, P NATL ACAD SCI USA, V85, P2106, DOI 10.1073/pnas.85.7.2106; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7	32	36	36	0	0	STOCKTON PRESS	BASINGSTOKE	HOUNDMILLS, BASINGSTOKE, HAMPSHIRE, ENGLAND RG21 6XS	0950-9232			ONCOGENE	Oncogene	AUG	1991	6	8					1343	1346						4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	GX272	1886710				2022-12-25	WOS:A1991GX27200008
J	NOVOKHATNY, VV; INGHAM, KC; MEDVED, LV				NOVOKHATNY, VV; INGHAM, KC; MEDVED, LV			DOMAIN-STRUCTURE AND DOMAIN-DOMAIN INTERACTIONS OF RECOMBINANT TISSUE PLASMINOGEN-ACTIVATOR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; SINGLE-CHAIN; T-PA; KRINGLE-2 DOMAIN; FIBRIN; VARIANTS; BINDING; FINGER; PROTEINS; DELETION	The melting of recombinant tissue plasminogen activator (rtPA) has been investigated by differential scanning calorimetry and fluorescence spectroscopy. At neutral pH, rtPA melts with only partial reversibility in a single sharp peak that can be deconvoluted into four transitions. By contrast, at acidic pH the melting process is spread over a broad range of temperature and is highly reversible. Under these conditions five transitions are resolved by deconvolution analysis. Additional measurements in 6 M guanidinium chloride reveal a sixth transition representing an extremely stable domain. Comparison of the melting curves of several fragments with those of the parent protein allowed all of the transitions to be assigned. The results indicate that rtPA is comprised of six independently folded domains. Two of these domains correspond to the two kringle modules whose thermodynamic properties are similar to those of the kringles in plasminogen. Two additional domains are formed by the epidermal growth factor (EGF)-like and finger modules, the latter of which is extremely stable, requiring the presence of a chemical denaturant for its melting to be observed. The serine protease module contains two more domains which at neutral pH melt cooperatively in a single transition but at low pH melt independently, accounting for the greater number of transitions observed there. Measurements with a 50-kDa fragment lacking the C-terminal half of the serine protease module and with a variant lacking the finger and EGF domains indicate that the serine protease domains interact strongly with and are stabilized by the finger and/or EGF domains in the intact protein. This interaction between domains located at opposite ends of the rtPA molecule produces a more compact structure. A better understanding of such interactions may enhance efforts to engineer plasminogen activators with improved thrombolytic properties.	AMER RED CROSS, BIOMED RES & DEV, BIOCHEM LAB, 15601 CRABBS BRANCH WAY, ROCKVILLE, MD 20855 USA	American Red Cross				Medved, Leonid/0000-0002-3665-9849	NHLBI NIH HHS [HL21791] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL021791] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARON M, 1990, NATURE, V345, P642, DOI 10.1038/345642a0; BOGUSKY MJ, 1989, BIOCHEMISTRY-US, V28, P6728, DOI 10.1021/bi00442a028; BURCK PJ, 1990, J BIOL CHEM, V265, P5170; CASTELLINO FJ, 1981, J BIOL CHEM, V256, P4778; COLLEN D, 1986, PROG HEMOST THROMB, V8, P1; DEMUNK GAW, 1989, BIOCHEMISTRY-US, V28, P7318, DOI 10.1021/bi00444a026; DEVRIES C, 1988, BIOCHEMISTRY-US, V27, P2565, DOI 10.1021/bi00407a044; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; FEARS R, 1989, BIOCHEM J, V261, P313, DOI 10.1042/bj2610313; FREIRE E, 1978, BIOPOLYMERS, V17, P463, DOI 10.1002/bip.1978.360170212; GETHING MJ, 1988, EMBO J, V7, P2731, DOI 10.1002/j.1460-2075.1988.tb03127.x; HIGAKI JN, 1986, J BIOL CHEM, V261, P606; HOLLADAY LA, 1976, BIOCHEMISTRY-US, V15, P2624, DOI 10.1021/bi00657a023; HUBER R, 1978, ACCOUNTS CHEM RES, V11, P114, DOI 10.1021/ar50123a006; KALYAN NK, 1988, J BIOL CHEM, V263, P3971; KELLEY RF, 1989, BIOCHEMISTRY-US, V28, P4047, DOI 10.1021/bi00435a062; LARSEN GR, 1988, J BIOL CHEM, V263, P1023; LAZDUNSKI M, 1967, BIOCHIM BIOPHYS ACTA, V140, P417, DOI 10.1016/0005-2795(67)90516-8; LIJNEN HR, 1988, J BIOL CHEM, V263, P19083; LIJNEN HR, 1990, J BIOL CHEM, V265, P5677; LITVINOVICH SV, 1991, J MOL BIOL, V217, P563, DOI 10.1016/0022-2836(91)90758-X; LOSCALZO J, 1988, J CLIN INVEST, V82, P1391, DOI 10.1172/JCI113743; MARKLAND W, 1989, PROTEIN ENG, V3, P111, DOI 10.1093/protein/3.2.111; NELLES L, 1990, THROMB HAEMOSTASIS, V64, P53; NOVOKHATNY VV, 1984, J MOL BIOL, V179, P215, DOI 10.1016/0022-2836(84)90466-2; PATTHY L, 1990, SEMIN THROMB HEMOST, V16, P245, DOI 10.1055/s-2007-1002677; PRIVALOV PL, 1982, ADV PROTEIN CHEM, V35, P1, DOI 10.1016/S0065-3233(08)60468-4; RADEK JT, 1988, ARCH BIOCHEM BIOPHYS, V267, P776, DOI 10.1016/0003-9861(88)90087-2; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; TRILL JJ, 1990, FIBRINOLYSIS, V4, P131, DOI 10.1016/S0268-9499(05)80044-X; VANZONNEVELD AJ, 1986, P NATL ACAD SCI USA, V83, P4670; VANZONNEVELD AJ, 1986, J BIOL CHEM, V261, P14214; VEHAR GA, 1986, COLD SPRING HARB SYM, V51, P551, DOI 10.1101/SQB.1986.051.01.067; WILCZYNSKA M, 1990, THROMB HAEMOSTASIS, V63, P246	34	49	54	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 15	1991	266	20					12994	13002						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FX132	1906462				2022-12-25	WOS:A1991FX13200034
J	LOLLAR, P; PARKER, ET				LOLLAR, P; PARKER, ET			STRUCTURAL BASIS FOR THE DECREASED PROCOAGULANT ACTIVITY OF HUMAN FACTOR-VIII COMPARED TO THE PORCINE HOMOLOG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODIES; FACTOR XA; THROMBIN; CONCENTRATE; ACTIVATION; PROTEIN; PURIFICATION; INACTIVATION; COAGULANT	The stability of activated human and porcine factor VIII (fVIII) differ, but a direct comparison of their structural and functional properties has not been made. Highly purified, heterodimeric human recombinant and porcine plasma-derived fVIII were exchanged into a common buffer and some minor contaminants were removed by anion-exchange chromatography. The activations of human and porcine fVIII by thrombin were studied by a two-stage coagulation assay using human citrated plasma as the standard. The peak activation of porcine FVIII was 10-fold greater than human fVIII (1.1 x 10(6) unit/mg versus 1.1 x 10(5) unit/mg). The proteolytic fragmentation of fVIII by thrombin was evaluated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and was not different between human and porcine fVIII, yielding previously identified bands corresponding to fragments A1, A2, A3-C1-C2, and the B domain. Following activation by thrombin, human fVIII was subjected to cation-exchange (Mono S) high performance liquid chromatography at pH 6.0 under conditions that yields stable, heterotrimeric (A1/A2/A3-C1-C2) porcine fVIIIa(IIa) (Lollar, P., and Parker, C. G. (1990) Biochemistry 28, 666-674). Coagulant activity was recovered in a single peak that was less than 0.5% that of porcine fVIIIa(IIa) (1.2 x 10(4) unit/mg versus 2.6 x 1O(6) unit/mg). Sodium dodecyl sulfate-polyacrylamide gel electrophoresis of the peak fraction revealed bands corresponding to the A3-C1-C2 and A1 fragments but only trace levels of the A2 fragment. In contrast, activation of human fVIII by thrombin followed by Mono S HPLC at pH 5.0 produced a peak with 10-fold greater activity (1.2 x 10(5) unit/mg) than at pH 6.0 and which contained significant amounts of the A2 fragment. We conclude that human fVIII(IIa), like porcine fVIII(IIa), is a heterotrimer and propose that its apparent decreased coagulant activity is due to weaker association of the A2 subunit.			LOLLAR, P (corresponding author), EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,DRAWER AR,ATLANTA,GA 30322, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040921] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL40921] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1986, P NATL ACAD SCI USA, V83, P2979, DOI 10.1073/pnas.83.9.2979; BOWIE EJW, 1984, DISORDERS HEMOSTASIS, P43; BRINKHOUS KM, 1985, P NATL ACAD SCI USA, V82, P8752, DOI 10.1073/pnas.82.24.8752; BURKE RL, 1986, J BIOL CHEM, V261, P2574; COOPER HA, 1975, J CLIN INVEST, V56, P751, DOI 10.1172/JCI108146; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; EATON DL, 1987, J BIOL CHEM, V262, P3285; FASS DN, 1982, BLOOD, V59, P594; FAY PJ, 1986, BIOCHIM BIOPHYS ACTA, V871, P268, DOI 10.1016/0167-4838(86)90208-6; FAY PJ, 1988, ARCH BIOCHEM BIOPHYS, V262, P525, DOI 10.1016/0003-9861(88)90404-3; FAY PJ, 1991, IN PRESS J BIOL CHEM; FAY PJ, 1987, BIOCHIM BIOPHYS ACTA, V952, P181; FULCHER CA, 1983, BLOOD, V61, P807; HAMER RJ, 1987, EUR J BIOCHEM, V167, P253, DOI 10.1111/j.1432-1033.1987.tb13331.x; HAMER RJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P356, DOI 10.1016/0167-4838(86)90084-1; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HULTIN MB, 1981, BLOOD, V57, P476; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOLLAR P, 1990, J BIOL CHEM, V265, P1688; LOLLAR P, 1985, BIOCHEMISTRY-US, V24, P8056, DOI 10.1021/bi00348a033; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1988, BLOOD, V71, P137; LOLLAR P, 1987, J BIOL CHEM, V262, P17572; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; Mosesson MW, 1990, J CLIN INVEST, V145, P1310, DOI [10.1172/JCI114662, DOI 10.1172/JCI114662]; OWEN WG, 1975, BIOCHIM BIOPHYS ACTA, V405, P380, DOI 10.1016/0005-2795(75)90103-8; PIETERS J, 1989, BLOOD, V74, P1021; ROTBLAT F, 1985, BIOCHEMISTRY-US, V24, P4294, DOI 10.1021/bi00337a007; TOOLE JJ, 1984, NATURE, V312, P342, DOI 10.1038/312342a0; TUDDENHAM EGD, 1982, BRIT J HAEMATOL, V52, P259, DOI 10.1111/j.1365-2141.1982.tb03888.x; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0	32	113	130	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1991	266	19					12481	12486						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FV180	1905722				2022-12-25	WOS:A1991FV18000061
J	BECKINGHAM, K				BECKINGHAM, K			USE OF SITE-DIRECTED MUTATIONS IN THE INDIVIDUAL CA2+-BINDING SITES OF CALMODULIN TO EXAMINE CA2+- INDUCED CONFORMATIONAL-CHANGES	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							CALCIUM-BINDING; TROPONIN-C; SEQUENCE; MUSCLE; SCALLOP; BRAIN; GENE	Mutant versions of the calmodulin of Drosophila melanogaster have been prepared for use in the study of Ca2+ binding and Ca2+-induced conformational changes. In each mutant, a conserved glutamic acid residue indicated to play a critical role in Ca2+ binding has been mutated to glutamine in one of the Ca2+-binding sites. Thus a series of four proteins, each with an analogous mutation in one of the four binding sites, has been generated. Here the Ca2+-induced conformational changes in these proteins have been examined by use of the fluorescent hydrophobic reporter molecule, 9-anthroyl choline. These studies confirm earlier work which indicates that the carboxyl-terminal pair of Ca2+-binding sites shows cooperative Ca2+ binding to produce a major conformational change in the protein. However, these studies provide evidence that the sites of the amino-terminal pair are more independent in their Ca2+ binding properties and contribute individually to the conformational changes associated with Ca2+ binding in the amino-terminal half of the protein. This work also indicates that mutation of either of the amino-terminal Ca2+-binding sites can influence the conformational change produced by Ca2+ binding to the carboxyl-terminal sites.			BECKINGHAM, K (corresponding author), RICE UNIV,DEPT BIOCHEM & CELL BIOL,HOUSTON,TX 77251, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037214] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM37214] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BURGER D, 1984, BIOCHEMISTRY-US, V23, P1966, DOI 10.1021/bi00304a013; COX JA, 1988, BIOCHEM J, V249, P621, DOI 10.1042/bj2490621; FABIATO A, 1975, J PHYSIOL-LONDON, V249, P497, DOI 10.1113/jphysiol.1975.sp011027; FORSEN S, 1986, CALCIUM CELL FUNCTIO, V6, P113; GARIEPY J, 1983, FEBS LETT, V160, P1, DOI 10.1016/0014-5793(83)80924-7; INAGAKI M, 1983, PHARMACOLOGY, V27, P125, DOI 10.1159/000137861; KELLER CH, 1982, CALCIUM CELL FUNCTIO, V3, P103; KLEE CB, 1988, CALMODULIN MOL ASPEC, V5, P35; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; LAPORTE DC, 1980, BIOCHEMISTRY-US, V19, P3814, DOI 10.1021/bi00557a025; PUTKEY JA, 1985, J BIOL CHEM, V260, P4704; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; REID RE, 1987, BIOCHEMISTRY-US, V26, P6070, DOI 10.1021/bi00393a019; Schulz G.E., 1979, PRINCIPLES PROTEIN S, P108, DOI 10.1007/978-1-4612-6137-7_6; SHAW GS, 1990, SCIENCE, V249, P280, DOI 10.1126/science.2374927; SMITH VL, 1987, J MOL BIOL, V196, P471, DOI 10.1016/0022-2836(87)90025-8; TANAKA T, 1980, J BIOL CHEM, V255, P1078; TODA H, 1981, J BIOCHEM-TOKYO, V90, P1493, DOI 10.1093/oxfordjournals.jbchem.a133616; YAMANAKA MK, 1987, NUCLEIC ACIDS RES, V8, P3335; YAZAWA M, 1980, J BIOCHEM, V87, P1313, DOI 10.1093/oxfordjournals.jbchem.a132869	22	67	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 5	1991	266	10					6027	6030						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FE373	1901056				2022-12-25	WOS:A1991FE37300006
J	YAMAGUCHI, T; CARRETERO, OA; SCICLI, AG				YAMAGUCHI, T; CARRETERO, OA; SCICLI, AG			A NOVEL SERINE PROTEASE WITH VASOCONSTRICTOR ACTIVITY CODED BY THE KALLIKREIN GENE S3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-SUBMAXILLARY-GLAND; TISSUE-SPECIFIC EXPRESSION; NUCLEOTIDE-SEQUENCES; FAMILY-MEMBERS; ANGIOTENSIN-II; TONIN; PURIFICATION; LOCALIZATION; QUANTITIES; ENZYME	A fraction separated from rat submandibular gland homogenates was found to contain a potent vasoconstrictor when tested on isolated rabbit aortic rings. The vasoconstrictor was purified by a series of chromatographic steps. The purified compound (2.77 X 10(-9) M) induced 40% of the maximum contractile response to 60 mM KCl. Constriction was slow in onset, long-lasting, rinse-resistant, and unchanged by de-endothelialization; in addition, it was dose-related and inhibited by both EGTA and verapamil, but it was not affected by DUP753, an angiotensin II receptor antagonist. The compound was found to be a protein having a pI of 7.36 and a molecular weight of approximately 29,000 and exhibiting partial immunologic identity to rat glandular kallikrein and rat tonin. After 2-mercaptoethanol treatment, it separated into heavy (approximately 19,900) and light (approximately 10,700) chains having amino-terminal sequences of AY(X)HNNDLMLL and VVGGYN(X)ETNSQ, respectively. We found that they correspond to the amino-terminal and internal sequence of a previously unidentified kallikrein-like serine protease whose mRNA, named S3, has been found in the rat submandibular gland and prostate. The vasoconstrictor is able to hydrolyze t-butoxycarbonyl-valine-proline-arginine-methylcoumarin amide (a thrombin substrate), although its K(cat)/K(m) was only 0.02% that of rat thrombin. Both vasoconstrictor and enzymatic activity on t-butoxycarbonyl-valine-proline-arginine-methylcoumarin amide were completely suppressed by amidinophenylmethylsulfonyl fluoride and soybean trypsin inhibitor; however, they were unaffected by hirudin, a thrombin inhibitor. At pH 6.5, it released angiotensin II when incubated with sheep angiotensinogen, although it had approximately one-tenth the activity of tonin. The submandibular enzymatic vasoconstrictor is a kallikrein-like enzyme, having some properties of both tonin and thrombin. It directly contracts vascular smooth muscle, acting via a mechanism that requires intact enzymatic activity.	HENRY FORD HOSP, DIV HYPERTENS RES,2799 W GRAND BLVD, DETROIT, MI 48202 USA	Henry Ford Health System; Henry Ford Hospital					PHS HHS [28982] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4512, DOI 10.1021/bi00338a005; ASHLEY PL, 1985, BIOCHEMISTRY-US, V24, P4520, DOI 10.1021/bi00338a006; BERG T, 1987, BIOL CHEM H-S, V368, P1455, DOI 10.1515/bchm3.1987.368.2.1455; BOUCHER R, 1977, CIRC RES, V41, P26, DOI 10.1161/01.RES.41.4.26; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADY JM, 1989, BIOCHEMISTRY-US, V28, P5203, DOI 10.1021/bi00438a043; CARRETERO OA, 1989, ENDOCRINE MECHANISMS, P219; CLEMENTS JA, 1988, J BIOL CHEM, V263, P16132; CLEMENTS JA, 1989, ENDOCR REV, V10, P393, DOI 10.1210/edrv-10-4-393; FIEDLER F, 1979, HDB EXPT PHARMACOLOG, V25, P103; GARCIA R, 1981, HYPERTENSION, V3, P101; GERALD WL, 1986, BIOCHIM BIOPHYS ACTA, V866, P1, DOI 10.1016/0167-4781(86)90093-X; GRICE C, 1981, CAN J BIOCHEM, V59, P250; GUTMAN N, 1988, EUR J BIOCHEM, V171, P577, DOI 10.1111/j.1432-1033.1988.tb13827.x; HAVER VM, 1984, BLOOD VESSELS, V21, P53; HAYAKAWA K, 1978, J MOL BIOL, V123, P107, DOI 10.1016/0022-2836(78)90379-0; IKENO K, 1986, J BIOCHEM, V99, P1219, DOI 10.1093/oxfordjournals.jbchem.a135585; JUNQUEIRA LCU, 1965, COMP ASPECTS VERTEBR, P36; KATO H, 1987, J BIOCHEM, V102, P1389, DOI 10.1093/oxfordjournals.jbchem.a122185; KHULLAR M, 1986, BIOCHEMISTRY-US, V25, P1851, DOI 10.1021/bi00356a002; LAURA R, 1980, BIOCHEMISTRY-US, V19, P4859, DOI 10.1021/bi00562a024; LAZURE C, 1984, NATURE, V307, P555, DOI 10.1038/307555a0; LAZURE C, 1981, 7TH P AM PEPT S, P517; MACDONALD RJ, 1988, BIOCHEM J, V253, P313, DOI 10.1042/bj2530313; MACDONALD RJ, 1982, J BIOL CHEM, V257, P9724; MANN KG, 1981, METHOD ENZYMOL, V80, P286; Markwardt F., 1970, METHOD ENZYMOL, V19, P924, DOI [10.1016/0076-6879(70)19082-3, DOI 10.1016/0076-6879(70)19082-3]; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MINATO A, 1967, CHEM PHARM BULL, V15, P1356; MURRAY SR, 1990, J CARDIOVASC PHARM, V15, pS7, DOI 10.1097/00005344-199000156-00003; NUSSBERGER J, 1986, HYPERTENSION, V8, P476, DOI 10.1161/01.HYP.8.6.476; ORSTAVIK TB, 1982, J HISTOCHEM CYTOCHEM, V30, P1123, DOI 10.1177/30.11.6292285; OZA NB, 1976, BIOCHEM PHARMACOL, V25, P1607, DOI 10.1016/0006-2952(76)90471-8; RIEKKINEN PJ, 1965, ANN MED EXP BIOL FEN, V43, P6; SAED GM, 1990, CIRC RES, V67, P510, DOI 10.1161/01.RES.67.2.510; SCHILLER PW, 1976, CIRC RES, V39, P629, DOI 10.1161/01.RES.39.5.629; SETO S, 1984, CIRC RES, V55, P580, DOI 10.1161/01.RES.55.5.580; SHARPLESS NS, 1965, HENRY FORD HOSP MED, V13, P55; SKINNER SL, 1975, AUST J EXP BIOL MED, V53, P77, DOI 10.1038/icb.1975.8; THIBAULT G, 1981, BIOCHIM BIOPHYS ACTA, V660, P23, DOI 10.1016/0005-2744(81)90103-0; THOMPSON LP, 1989, J VASC MED BIOL, V1, P347; WALZ DA, 1986, ANN NY ACAD SCI, V485, P323, DOI 10.1111/j.1749-6632.1986.tb34594.x; WALZ DA, 1985, P SOC EXP BIOL MED, V180, P518; WINES DR, 1989, J BIOL CHEM, V264, P7653; YAMAGUCHI T, 1990, J HYPERTENS       S3, V8, pS97	45	27	29	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 15	1991	266	8					5011	5017						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	FC217	1900513				2022-12-25	WOS:A1991FC21700052
J	HIGASHIJIMA, T; GRAZIANO, MP; SUGA, H; KAINOSHO, M; GILMAN, AG				HIGASHIJIMA, T; GRAZIANO, MP; SUGA, H; KAINOSHO, M; GILMAN, AG			F-19 AND P-31 NMR-SPECTROSCOPY OF G-PROTEIN ALPHA-SUBUNITS - MECHANISM OF ACTIVATION BY AL3+ AND F-	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-BINDING; ELONGATION-FACTOR TU; ADENYLATE-CYCLASE; REGULATORY COMPONENT; ESCHERICHIA-COLI; GAMMA-PHOSPHATE; GTPASE ACTIVITY; EF-TU; COMPLEXES; GDP	F-19 and P-31 NMR spectroscopy was used to study the mechanism of activation of the alpha-subunits of guanine nucleotide-binding regulatory proteins (G proteins) by Al3+, Mg2+, and F-. F-19 NMR spectra of solutions containing Al3+, Mg2+, and F- showed a characteristic F- peak at -10 ppm. Addition of the GDP-bound form of either of two G protein alpha-subunits (G-alpha) resulted in the appearance of an additional peak at -29 or -30 ppm. This peak was not observed with guanosine 5'-3-O-(thio)triphosphate-G-alpha) or with GDP alone. Titration of Al3+, Mg2+, and F- indicated that each molecule of G-alpha binds 3-5 molecules of F- (K(d) = 0.47 mM), a single molecule of Al3+ (K(d) << 0.1 mM), and a single Mg2+ ion (K(d) about 0.1 mM). Replacement of Mg2+ with Mn2+ caused a dramatic broadening of the NMR signal, indicating that the metal ion binds in proximity to the protein-bound F- (< 1 nm). P-31 NMR of GDP-G-alpha showed peaks at -2 and -8.6 ppm, corresponding to the beta- and alpha-phosphoryl groups of GDP, respectively. Binding of Al3+, Mg2+, and F- caused an upfield shift of 6 ppm for the beta-phosphoryl signal with no change in the alpha-phosphoryl signal. These observations indicate that Mg2+.GDP.AlF3-5 mimics Mg2+.GTP in its capacity to activate G protein alpha-subunits.	UNIV TOKYO,FAC SCI,DEPT BIOPHYS & BIOCHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO METROPOLITAN UNIV,FAC SCI,DEPT CHEM,TOKYO 158,JAPAN	University of Tokyo; Tokyo Metropolitan University	HIGASHIJIMA, T (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235, USA.		SUGA, Hinako/I-8095-2014	SUGA, Hinako/0000-0002-9158-6224	NIGMS NIH HHS [GM34497, GM40676] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497, R01GM040676] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKITT JW, 1989, PROG NUCL MAG RES SP, V21, P1, DOI 10.1016/0079-6565(89)80001-9; ARAI KI, 1974, J BIOCHEM-TOKYO, V76, P293, DOI 10.1093/oxfordjournals.jbchem.a130571; BIGAY J, 1987, EMBO J, V6, P2907, DOI 10.1002/j.1460-2075.1987.tb02594.x; BIGAY J, 1985, FEBS LETT, V191, P181, DOI 10.1016/0014-5793(85)80004-1; CHABRE M, 1990, TRENDS BIOCHEM SCI, V15, P6, DOI 10.1016/0968-0004(90)90117-T; DEVENDITTIS E, 1986, EUR J BIOCHEM, V161, P473; DWEK RA, 1973, NUCL MAGN RESON, P174; ECKSTEIN F, 1979, J BIOL CHEM, V254, P9829; FASANO O, 1982, J BIOL CHEM, V257, P3145; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GOLDSTEIN G, 1964, ANAL CHEM, V36, P243, DOI 10.1021/ac60207a074; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; HAZLETT TL, 1990, BIOPHYS J, V57, pA289; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; HOWLETT AC, 1978, ADV PHARMACOL THER, V1, P159; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAHN RA, 1986, J BIOL CHEM, V261, P7906; NAKANO A, 1980, FEBS LETT, V116, P72, DOI 10.1016/0014-5793(80)80531-X; Navon G, 1970, CHEM PHYS LETT, V7, P390, DOI 10.1016/0009-2614(70)80191-9; NECHAY BR, 1984, ANNU REV PHARMACOL, V24, P501; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; REED GH, 1970, J BIOL CHEM, V245, P662; ROSCH P, 1986, BIOCHEM BIOPH RES CO, V135, P549, DOI 10.1016/0006-291X(86)90029-X; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Segel I.H., 1975, ENZYME KINETICS BEHA, P161; STERNWEIS PC, 1982, P NATL ACAD SCI-BIOL, V79, P4888, DOI 10.1073/pnas.79.16.4888; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; STERNWEIS PC, 1981, J BIOL CHEM, V256, P1517; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624	33	82	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3396	3401						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1899863				2022-12-25	WOS:A1991EY68200010
J	SHIMIZU, T; TATEISHI, T; HATANO, M; FUJIIKURIYAMA, Y				SHIMIZU, T; TATEISHI, T; HATANO, M; FUJIIKURIYAMA, Y			PROBING THE ROLE OF LYSINES AND ARGININES IN THE CATALYTIC FUNCTION OF CYTOCHROME-P450D BY SITE-DIRECTED MUTAGENESIS - INTERACTION WITH NADPH-CYTOCHROME-P450 REDUCTASE	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Note							LIVER MICROSOMAL CYTOCHROME-P-450; CHEMICAL MODIFICATION; ADRENODOXIN-BINDING; ELECTRON-TRANSFER; P-450 REDUCTASE; ENZYME SYSTEM; LM2; PUTIDAREDOXIN; ASSOCIATION; SUBSTRATE	To identify amino acids of cytochrome P450d (P450d) which participate in the interaction with NADPH-cytochrome P450 reductase, we changed conserved ionic amino acids of P450d to others by site-directed mutagenesis. Turnover numbers (0.032-0.008 min-1) of purified mutants Lys94-Glu, Lys99-Glu, Lys105-Glu, Lys440-Glu, Lys453-Glu, Arg455-Glu, and Lys463-Glu toward 7-ethoxycoumarin were much lower than that (0.380 min-1) of the wild type at 25-degrees-C. Reduction rates (less than 0.054 s-1) of the heme of all mutants (0.1-mu-M) in the presence of NADPH and the reductase (0.3-mu-M) were much lower than that (5.9 s-1) of the wild type. Furthermore, a turnover number (0.042 min-1) of a microsomal triple mutant (Arg135-Leu + Arg136-Leu + Arg137-Leu) of a conserved Arg cluster was much lower than that (0.674 min-1) of the wild type at 37-degrees-C. Thus, we suggest that Lys94, Lys99, Lys105, Lys440, Lys453, Arg455, Lys463, and perhaps the Arg cluster Arg135-Arg136-Arg137 of P450d will participate in the intermolecular electron transfer process by forming ionic bridges between the two proteins and/or by orienting appropriate geometry for electron transfer on the interfacial surface between the two proteins.	TOHOKU UNIV,FAC SCI,DEPT CHEM,SENDAI,MIYAGI 980,JAPAN	Tohoku University	SHIMIZU, T (corresponding author), TOHOKU UNIV,CHEM RES INST NONAQUEOUS SOLUT,SENDAI,MIYAGI 980,JAPAN.							BACKES WL, 1989, J BIOL CHEM, V264, P6252; BACKES WL, 1988, J BIOL CHEM, V263, P247; BERNHARDT R, 1984, BIOCHIM BIOPHYS ACTA, V785, P186, DOI 10.1016/0167-4838(84)90143-2; BERNHARDT R, 1988, BIOMED BIOCHIM ACTA, V7, P581; BREWER CB, 1988, J BIOL CHEM, V263, P791; CHIOU SH, 1990, J BIOL CHEM, V265, P3549; FRENCH JS, 1980, J BIOL CHEM, V255, P4112; FURUYA H, 1989, BIOCHEM BIOPH RES CO, V160, P669, DOI 10.1016/0006-291X(89)92485-6; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; Gotoh O., 1989, FRONTIERS BIOTRANSFO, V1, P195; GUENGERICH FP, 1975, J BIOL CHEM, V250, P7405; KAMINSKY LS, 1987, BIOCHEMISTRY-US, V26, P1276, DOI 10.1021/bi00379a012; KOMINAMI S, 1984, J BIOL CHEM, V259, P2991; KUNZ BC, 1983, FEBS LETT, V161, P311, DOI 10.1016/0014-5793(83)81031-X; LAMBETH JD, 1980, J BIOL CHEM, V255, P4667; MULLERENOCH D, 1984, J BIOL CHEM, V259, P8174; NELSON DR, 1988, J BIOL CHEM, V263, P6038; OPRIAN DD, 1979, J BIOL CHEM, V254, P8895; Ortiz de Montellano P.R., 2015, CYTOCHROME P450 STRU, P912; PETERSON JA, 1976, J BIOL CHEM, V251, P4010; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RYAN DE, 1980, J BIOL CHEM, V255, P7941; SHIMIZU T, 1986, FEBS LETT, V207, P217, DOI 10.1016/0014-5793(86)81491-0; SHIMIZU T, 1988, BIOCHEMISTRY-US, V27, P4138, DOI 10.1021/bi00411a035; SOTOKAWA H, 1990, BIOCHIM BIOPHYS ACTA, V1037, P122, DOI 10.1016/0167-4838(90)90110-2; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STAYTON PS, 1990, BIOCHEMISTRY-US, V29, P7381, DOI 10.1021/bi00484a005; TANIGUCHI H, 1987, BIOCHEMISTRY-US, V26, P7084, DOI 10.1021/bi00396a033; TSUBAKI M, 1989, BIOCHEMISTRY-US, V28, P6899, DOI 10.1021/bi00443a019; TULS J, 1989, J BIOL CHEM, V264, P16421; WAGNER SL, 1987, BIOCHEMISTRY-US, V26, P2343, DOI 10.1021/bi00382a040	31	129	131	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	FEB 25	1991	266	6					3372	3375						4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EY682	1899862				2022-12-25	WOS:A1991EY68200005
J	WERA, S; BOLLEN, M; STALMANS, W				WERA, S; BOLLEN, M; STALMANS, W			PURIFICATION AND CHARACTERIZATION OF THE GLYCOGEN-BOUND PROTEIN PHOSPHATASE FROM RAT-LIVER	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT SKELETAL-MUSCLE; SYNTHASE PHOSPHATASE; PHOSPHORYLASE-PHOSPHATASE; CELLULAR-REGULATION; MODULATOR PROTEIN; ACTIVATION; SUBSTRATE; BINDING; SUBUNIT; FRACTIONS	Glycogen-bound protein phosphatase G from rat liver was transferred from glycogen to beta-cyclodextrin (cycloheptaamylose) linked to Sepharose 6B. After removal of the catalytic subunit and of contaminating proteins with 2 M naCl, elution with beta-cyclodextrin yielded a single protein on native polyacrylamide gel electrophoresis and two polypeptides (161 and 54 kDa) on sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Several lines of evidence indicate that the latter polypeptides are subunits of the protein phosphatase G holoenzyme. First, these polypeptides were also present, together with the catalytic subunit, in the extensively purified holoenzyme. Also, polyclonal antibodies against these polypeptides were able to bind the holoenzyme. Further, while bound to cyclodextrin-Sepharose, the polypeptides were able to recombine with separately purified type-1 (AMD) catalytic subunit, but not with type-2A (PCS) catalytic subunit. The characteristics of the reconstituted enzyme resembled those of the nonpurified protein phosphatase G. At low dilutions, the spontaneous phosphorylase phosphatase activity of the reconstituted enzyme was about 10 times lower than that of the catalytic subunit, but it was about 1000-fold more resistant to inhibition by the modulator protein (inhibitor-2). In contrast with the free catalytic subunit, the reconstituted enzyme cosedimented with glycogen, and it was able to activate purified liver glycogen synthase b. Also, the synthase phosphatase activity was synergistically increased by a cytosolic phosphatase and inhibited by physiological concentrations of phosphorylase a and of Ca2+.	CATHOLIC UNIV LEUVEN,FAC GENEESKUNDE,AFDELING BIOCHEM,B-3000 LOUVAIN,BELGIUM	KU Leuven								ALEMANY S, 1986, EUR J BIOCHEM, V156, P101, DOI 10.1111/j.1432-1033.1986.tb09554.x; ALEMANY S, 1986, FEBS LETT, V198, P194, DOI 10.1016/0014-5793(86)80404-5; ANTONIW JF, 1977, BIOCHEM J, V162, P423, DOI 10.1042/bj1620423; BALLOU LM, 1986, ENZYMES, V17, P311; BOLLEN M, 1986, BIOCHEM BIOPH RES CO, V139, P1033, DOI 10.1016/S0006-291X(86)80281-9; BOLLEN M, 1988, BIOCHEM J, V250, P659, DOI 10.1042/bj2500659; BOLLEN M, 1988, BIOCHIM BIOPHYS ACTA, V969, P66, DOI 10.1016/0167-4889(88)90089-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; COHEN PTW, 1989, BIOCHIM BIOPHYS ACTA, V1008, P125, DOI 10.1016/0167-4781(89)90181-4; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DENT P, 1990, FEBS LETT, V259, P281, DOI 10.1016/0014-5793(90)80027-G; DOPERE F, 1982, BIOCHEM BIOPH RES CO, V104, P443, DOI 10.1016/0006-291X(82)90657-X; DOPERE F, 1980, EUR J BIOCHEM, V104, P137, DOI 10.1111/j.1432-1033.1980.tb04409.x; FISCHER EDMOND H., 1958, JOUR BIOL CHEM, V231, P65; HUBBARD MJ, 1989, EUR J BIOCHEM, V180, P457, DOI 10.1111/j.1432-1033.1989.tb14668.x; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MERLEVEDE W, 1985, ADV PROTEIN PHOSPHAT, V1, P1; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MVUMBI L, 1985, BIOCHEM J, V232, P697, DOI 10.1042/bj2320697; MVUMBI L, 1983, BIOCHEM J, V212, P407, DOI 10.1042/bj2120407; MVUMBI L, 1987, BIOCHEM J, V246, P367, DOI 10.1042/bj2460367; NELSON TE, 1970, ANAL BIOCHEM, V33, P87, DOI 10.1016/0003-2697(70)90442-2; RAMACHANDRAN C, 1987, J BIOL CHEM, V262, P3210; SCHELLING DL, 1988, BIOCHIM BIOPHYS ACTA, V927, P221; STALMANS W, 1987, Diabetes Metabolism Reviews, V3, P127; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; VANDEBROECK A, 1985, EUR J BIOCHEM, V153, P621, DOI 10.1111/j.1432-1033.1985.tb09345.x; VANDENABEELE C, 1988, FEBS LETT, V232, P167; YANG SD, 1981, FEBS LETT, V132, P293, DOI 10.1016/0014-5793(81)81182-9	31	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 5	1991	266	1					339	345						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	EQ339	1898724				2022-12-25	WOS:A1991EQ33900050
